Exhibit 10.24 ***Text Omitted and Filed Separatelywith the Securities and Exchange Commission.Confidential Treatment RequestedUnder 17 C.F.R. Sections 200.80(b)(4)and Rule 406 of theSecurities Act of 1933,as amended. 
  
Collaboration Agreement, BII/ XENCOR
 
 
 
Confidential
 
 COLLABORATION AGREEMENT This Collaboration Agreement (“Agreement”) is made by and among  Xencor, Inc. 111 W. Lemon Ave.Monrovia,CA 91016USA
(hereinafter called “XENCOR”), and Boehringer Ingelheim International GmbH  Binger Straße 17355216 IngelheimGermany (hereinafter called “BII”) (hereinafter BII an XENCOR each shall also be called “Party” and collectively “Parties” as the case may be).  EFFECTIVE DATE: February 10, 2012  1TABLE OF CONTENTS 
                                                   1
 
Definitions
 
5
 1.1
 
“Acceptance Criteria”
 
5
 1.2
 
“Affiliated Companies”
 
5
 1.3
 
“Batch”
 
5
 1.4
 
“BII Confidential Information and Know­How”
 
5
 1.5
 
“BII Facility”
 
6
 1.6
 
“BII Intellectual Property”
 
6
 1.7
 
“BII Technology”
 
6
 1.8
 
“Business Partner”
 
6
 1.9
 
“Certificate of Analysis”
 
6
 1.10
 
“Claim”
 
6
 1.11
 
“CMO”
 
6
 1.12
 
“Confidential Information­and Know­How”
 
6
 1.13
 
“Confirmation of Compliance”
 
6
 1.14
 
“Controlled Technology”
 
6
 1.15
 
“cGMP”
 
6
 1.16
 
“Deliverables”
 
7
 1.17
 
“Due Date”
 
7
 1.18
 
“Effective Date”
 
7
 1.19
 
“FTE”
 
7
 1.20
 
“Improvements”
 
7
 1.21
 
“Knowledge”
 
7
 1.22
 
“Latent Defects”
 
7
 1.23
 
“Licensing Revenue”
 
7
 1.24
 
“Losses”
 
7
 1.25
 
“Major Territories”
 
7
 1.26
 
“Material”
 
7
 1.27
 
“MTA”
 
7
 1.28
 
“Obvious Defects”
 
8
 1.29
 
“Other Improvements”
 
8
 1.30
 
“Principal Supplier”
 
8
 1.31
 
“Process”
 
81.32
 
“Process Description”
 
8
 1.33
 
“Product”
 
8
 1.34
 
“Project”
 
8
 1.35
 
“Project Fees”
 
8
 1.36
 
“Project Manager”
 
8
 1.37
 
“Project Plan”
 
8
 1.38
 
“Project Team”
 
8
 1.39
 
“QAA”
 
9
 1.40
 
“Representatives”
 
9
 1.41
 
“Service(s)”
 
9
 1.42
 
“Specification(s)”
 
9
 1.43
 
“Steering Committee”
 
9
 1.44
 
“Technology”
 
9
 1.45
 
“Technology Access Fee”
 
9
 1.46
 
“Total Amount”
 
9
 1.47
 
“XENCOR Confidential Information and Know­How”
 
9
 1.48
 
“XENCOR Intellectual Property”
 
9
 1.49
 
“XENCOR Technology”
 
9
  22
 
Cooperation between the Parties in the Course of a Project
 
10
 2.1
 
General
 
10
 
 
 2.1.1
 
General
 
10
  
 
 
 
 
 
 
 
 
 2.1.2
 
Priority
 
10
  
 
 
 
 
 
 
 2.2
 
Personnel
 
10
 
 
 2.2.1
 
Designation of Project Manager
 
10
  
 
 
 
 
 
 
 
 
 2.2.2
 
Project Team
 
10
  
 
 
 
 
 
 
 
 
 2.2.3
 
Steering Committee
 
11
  
 
 
 
 
 
 
 2.3
 
Conduct of the Project and BII’s Work and Tasks
 
11
 2.4
 
Deliverables
 
12
 2.5
 
Nature of the Project
 
12
 2.6
 
Additional Work
 
12
 2.7
 
XENCOR Confidential Information and Know-How and Material
 
12
 2.8
 
Further Obligations of XENCOR
 
13
 
 
 2.8.1
 
General
 
13
  
 
 
 
 
 
 
 
 
 2.8.2
 
Obligations of XENCOR
 
13
  
 
 
 
 
 
 
 
 
 2.8.3
 
Timelines and Information
 
13
  
 
 
 
 
 
 
 3
 
Payments
 
14
 3.1
 
Project Fee
 
14
 
 
 3.1.1
 
Consideration for Services
 
14
  
 
 
 
 
 
 
 
 
 3.1.2
 
Payment of the Project Fees
 
14
  
 
 
 
 
 
 
 
 
 3.1.3
 
Invoicing
 
153.2
 
Technology Access Fee
 
15
 3.3
 
VAT
 
15
  
 
 
 
 
 4
 
Delivery Terms of Product
 
16
 4.1
 
Delivery Terms
 
16
 4.2
 
Cancellation of Order
 
17
  
 
 
 
 
 5
 
Ownership and Use of Project Data
 
17
 5.1
 
Project Data
 
17
 5.2
 
Use of the Process; Right of Negotiation
 
18
 
 
 5.2.1
 
Use of the Process outside this Agreement
 
18
  
 
 
 
 
 
 
 
 
 5.2.2
 
Right of First Negotiation to Manufacture
 
18
  
 
 
 
 
 
 
 
 
 5.2.3
 
Technology Access Fee and Technology Transfer
 
20
  
 
 
 
 
 
 
 
 
 5.2.4
 
Payment Terms
 
21
  
 
 
 
 
 
 
 
 
 5.2.5
 
License
 
21
  
 
 
 
 
 
 
 5.3
 
Acknowledgement
 
21
  
 
 
 
 
 6
 
Representations, Warranties and Indemnification
 
22
 6.1
 
Mutual Representations, Warranties and Covenants
 
22
 6.2
 
XENCOR Warranties
 
22
 6.3
 
BII Warranties
 
22
 6.4
 
Process for Defense of Infringement of Third Party Intellectual Property
 
23
 6.5
 
Disclaimer of Warranties
 
24
  37
 
Liability, Indemnification, Limitations and Insurance
 
24
 7.1
 
General
 
24
 7.2
 
Liability
 
24
 7.3
 
Indemnification
 
25
 7.4
 
Limitation of Liability and Indemnification Obligations
 
25
 7.5
 
Insurance
 
26
  
 
 
 
 
 8
 
Intellectual Property
 
26
 8.1
 
Existing Intellectual Property Rights
 
26
 8.2
 
New Intellectual Property, Project Results and Licenses
 
26
 
 
 8.2.1
 
XENCOR
 
26
  
 
 
 
 
 
 
 
 
 8.2.2
 
BII
 
27
  
 
 
 
 
 
 
 
 
 8.2.3
 
Other Improvements
 
27
  
 
 
 
 
 
 
 
 
 8.2.4
 
Licenses to Xencor
 
27
  
 
 
 
 
 
 
 
 
 8.2.5
 
Licenses to BII
 
27
  
 
 
 
 
 
 
 9
 
Confidentiality
 
28
 9.1
 
General
 
28
 9.2
 
MTA Superseded
 
30
 9.3
 
Controlled Technology
 
30
  
 
 
 
 
 10
 
Term and Termination
 
30
 10.1
 
Term
 
30
 10.2
 
Termination of this Agreement
 
30
 
 
 10.2.1
 
 
 30
  
 
 
 
 
 
 
 
 
 10.2.2
 
 
 30
  
 
 
 
 
 
 
 10.3
  
Effects of Termination of this Agreement
  
3110.3.2
 
 
 31
  
 
 
 
 
 
 
 
 
 10.3.3
 
 
 32
  
 
 
 
 
 
 
 10.4
 
Surviving Provisions
 
32
  
 
 
 
 
 11
 
Miscellaneous
 
32
 11.1
 
Force Majeure
 
32
 11.2
 
Conflict with Improvements under the MTA
 
33
 11.3
 
Secrecy Agreement between the Parties
 
33
 11.4
 
Publicity
 
33
 11.5
 
Notices
 
33
 11.6
 
Applicable Law and Arbitration
 
34
 11.7
 
Entire Agreement
 
34
 11.8
 
Waiver; Amendment
 
34
 11.9
 
Severability
 
35
 11.10
 
Dispute Resolution
 
35
 11.11
 
Assignment
 
35
 11.12
 
Independent Contractors
 
35
 11.13
 
Counterparts
 
35
  4
 Preamble WHEREAS, XENCOR and an Affiliated Company (as defined below) of BII, the Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65,88397 Biberach, Germany (“BI Pharma”) entered into a Material Transfer and Initial Service Agreement dated as of June 28, 2011 relating toXENCOR’s proprietary product, a monoclonal antibody directed against TNF­
 known as “Xtend­TNF” or “XmAb6755”; and WHEREAS, XENCOR is a company engaged in the design and development of biopharmaceutical drugs and is owner of a cell line expressing theProduct (as defined below); WHEREAS, BII has know-how and expertise to develop production processes for biopharmaceuticals towards commercial scale volumes andwithin international regulatory requirements; WHEREAS, XENCOR and BII herewith agreed on a business collaboration for the mutual benefit of both Parties by having XENCOR providing theMaterial (as defined below) and the description of the Product and by having BII developing a fed­batch production process to have XENCOR’sProduct expressed from the Material in the quantity suitable for preclinical and completion of Phase 1 clinical testing; and WHEREAS, as BII finances the Project in advance and receives a first right to negotiate to manufacture and payments at a later point in the future,XENCOR agrees, in order to make both Parties benefit from their collaboration, to use its commercially reasonable efforts to complete Phase 1clinical testing of the Product and to find a business partner for the further development of the Product into a successful medicinal product; NOW THEREFORE and in consideration of the mutual covenants set forth in this Agreement, BII and XENCOR hereby agree as follows: 1 Definitions 1.1 “Acceptance Criteria”shall mean either, (as the case may be) the following criteria with respect to a Batch of Product; (i) the preliminary specifications as agreedupon by the Parties with respect to the three (3) initial manufacturing runs as described in Section 2.5, or (ii) except as provided in clause(i), the Specifications accompanied by a Confirmation of Compliance and Certificate of Analysis. 1.2 “Affiliated Companies” shall mean any company or business entity which controls, is controlled by, or is under common control with, either XENCOR or BII. Forpurposes of this definition, “control” shall mean the possession, directly or indirectly of the power to direct or cause the direction of themanagement and policies of an entity (other than a natural person), whether through the majority ownership of voting capital stock, bycontract or otherwise. 1.3 “Batch” shall mean Product from one fermentation run using the Process. 1.4 “BII Confidential Information and Know­How” shall mean all existing or future technical or other information relating specifically to (a) the BII Facility, (b) the Process, (c) BII IntellectualProperty, and/or (d) know-how for the development and manufacture of biopharmaceuticals generally, in each case (a)-(d) whether 5patented or not patented, including, without limitation, trade secrets, know-how, processes, concepts, experimental methods and resultsand business and scientific plans that are disclosed or supplied directly or indirectly to XENCOR or used in connection with the Project,but always excluding all confidential technical or other information of XENCOR specifically relating to XENCOR Technology. 1.5 “BII Facility” shall mean the biotech buildings and all other buildings used by BII and/or its Affiliated Companies in performance of the Project inFremont, CA, USA (it being understood that certain aspects of the Services may be performed in Germany, and, with respect thereto, suchbuildings in Germany used by BII and/or its Affiliated Companies in performance of the Project, shall also be deemed “BII Facility”). 1.6 “BII Intellectual Property” shall have the meaning set forth in Section 8.2.2 hereof. 1.7 “BII Technology” shall mean the Technology developed or obtained by or on behalf of BII or any of its Affiliated Companies without the use of the ofXENCOR Confidential Information and Know-How or the Material, including without limitation, the Process. 1.8 “Business Partner” shall have the meaning set forth in Section 2.8.2 hereof. 1.9 “Certificate of Analysis” shall mean, with respect to a Batch, that complete and accurate document setting forth the conformance with the Specifications set forth inthe QAA. 1.10 “Claim” shall have the meaning set forth in section 6.4.(a)a) hereof. 1.11 “CMO” shall mean Contract Manufacturing Organization. 1.12 “Confidential Information­and Know­How” shall mean either or both Xencor Confidential Information and Know-How (as defined herein) or BII Confidential Information and Know-How (as defined herein), as applicable. 1.13 “Confirmation of Compliance” shall mean BII’s complete and accurate certificate, executed and delivered to XENCOR in connection with each Batch of Product,confirming that such Batch of Product was manufactured according to cGMP, the Process and applicable laws at the BI Facility, andsetting forth any deviations therefrom and the results of final investigations performed by BII according to the QAA. 1.14 “Controlled Technology” shall have the meaning specified in Section 9.3 hereof. 1.15 “cGMP” shall mean current Good Manufacturing Practice regulations as codified in: The Rules Governing Medicinal products supplied in the European Union: Volume 4 -Medicinal products supplied for Human andVeterinary Use: Good Manufacturing Practice, as amended from time to time; the United States Code of Federal Regulations, title 21, parts 6210, 211, 600 and 610, as amended from time to time; and the International Committee on Harmonisation and other comparable guidelines,directives or standards required by governmental authorities in the Major Territories or in any other country or countries agreed in writingby the Parties. 1.16 “Deliverables” shall have the meaning specified in Section 2.4 hereof. 1.17 “Due Date” shall have the meaning specified in Section 3.1.2 hereof. 1.18 “Effective Date” shall mean the date of commencement of this Agreement as mentioned on the cover page above. 1.19 “FTE” shall mean a fully allocated employee or consultant of BII and working on the Technology transfer with such time and effort to constitutethe equivalent of one (1) employee on a full time basis consistent with normal business and scientific practice […***…]. 1.20 “Improvements” shall mean all discoveries and inventions, and all modifications, derivatives and improvements to Technology or new uses thereof(whether or not protectable under patent, trademark, copyright or similar laws) that are discovered, developed or reduced to practice by oron behalf of BII or any of its Affiliated Companies (alone or jointly with XENCOR) in the performance of this Agreement. 1.21 “Knowledge” shall mean that which a Party knows or should have known following that inquiry a reasonable person would have made in light of thefacts and circumstances. 1.22 “Latent Defects” shall mean non-conformance of the Product with this Agreement other than Obvious Defects. 1.23 “Licensing Revenue” shall have the meaning set forth in Section 3.1.2 hereof. 1.24 “Losses” shall have the meaning set forth in Section 7.2.a hereof. 1.25 “Major Territories” shall mean the United States, the European Union and/or Japan. 1.26 “Material” shall mean the respective XENCOR proprietary cell line as laid down in detail in Appendix 1 and any know-how or data relating directlythereto and provided together with such cell line to BII by or on behalf of XENCOR (including any progeny or derivative thereof). 1.27 “MTA” shall mean the Material Transfer and Initial Service Agreement entered into by XENCOR and BI Pharma on June 28, 2011 attached to thisAgreement as Appendix 4. 
***Confidential Treatment Requested 71.28 “Obvious Defects” shall mean any non-conformance of the Product with this Agreement, which is visible or easily detectable without any analysis in alaboratory, such as noticeable damages of the Product caused by the transport of Product. 1.29 “Other Improvements” shall have the meaning set forth in Section 8.2.3 hereof. 1.30 “Principal Supplier” shall mean the right to manufacture and supply commercial Product in the amount per annum of at least […***…] of the worldwide annualdemand of commercial Product calculated based on XENCOR’s reasonably forecasted request for commercial Product for the respectivecalendar year.  1.31 “Process” shall mean all the respective steps involved in the process developed and performed by BII pursuant to this Agreement to produce therespective Product from the Material or having the Product expressed from the Material, including, without limitation, the manufacture,testing and packaging thereof. 1.32 “Process Description” shall mean a controlled document, approved by authorized technical and quality representatives of both Parties, that documents thegeneral outline of the respective Process. It includes all relevant Process parameters to be met and equipment and raw materials to be used. 1.33 “Product” shall mean XENCOR’s proprietary biopharmaceutical product, a monoclonal antibody directed against TNF­
 known as “Xtend­INF” or“XmAb6755”, as further laid down in detail in Appendix 1, expressed from the Material disclosed by XENCOR to BII and formulated eitheras bulk drug substance or in final dosage form as drug product, as the context requires. 1.34 “Project” shall mean the performance of the Services, including without limitation the Process development program for the Product. 1.35 “Project Fees” shall have the meaning specified in Section 3.1 hereof. 1.36 “Project Manager” shall have the meaning specified in Section 2.2.1 hereof. 1.37 “Project Plan” shall mean the plan describing the Services to be performed by BII under the Project, including the Project timeline and the Project Fees,attached to this Agreement as Appendix 2. 1.38 “Project Team” shall have the meaning specified in Section 2.2.2 hereof and at the Effective Date shall consist of the persons listed in Appendix 3. 1.39 “QAA” 
***Confidential Treatment Requested 8shall mean the Quality (Assurance) Agreement entered into between the Parties simultaneously with this Agreement and attached heretoas Appendix 5. 1.40 “Representatives” shall have the meaning specified in Section 7.3 a hereof. 1.41 “Service(s)” shall mean those certain services performed by BII under this Agreement. 1.42 “Specification(s)” shall mean all the tests, analytical methods and/or limits, and the results thereof, as applicable, agreed by the Parties, within which theProduct has to conform to be considered acceptable by XENCOR for clinical use set forth in Appendix 6. The Parties are in agreement, thatin the first instance they will agree on preliminary specifications which shall then be fixed to final Specifications in accordance with Section2.5. 1.43 “Steering Committee” shall have the meaning specified in Section 2.2.3 hereof. 1.44 “Technology” shall mean all cDNA, cell lines, cell banks, master cell banks, constructs, reagents, antibodies and/or other tangible materials, methods,techniques, processes, trade secrets, copyrights, know-how, data, documentation, regulatory submissions, specifications and otherintellectual property of any kind (whether or not protectable under patent, trademark, copyright or similar laws). 1.45 “Technology Access Fee” is defined in Section 5.2.3. 1.46 “Total Amount” shall have the meaning specified in Section 3.1.2 hereof. 1.47 “XENCOR Confidential Information and Know­How” shall mean all existing or future technical or other information relating specifically to (a) the Material, (b) the Product (and any modification,derivative or fragment thereof), and/or (c) the XENCOR Technology, in each case (a), (b) and (c) whether patented or not patented, andincluding, without limitation, all know-how, trade secrets, inventions, patent applications, processes, concepts, experimental methods andany other information concerning XENCOR’s financial situation, business plans, and its research and product designs, that are disclosedor supplied to BII in connection with the Project, but always excluding BII Confidential Information and Know-How. 1.48 “XENCOR Intellectual Property” shall have the meaning specified in Section 8.2.1 hereof. 1.49 “XENCOR Technology” shall mean (i) the Material, (ii) the Product, and any modifications, derivatives, or fragments thereof, and (iii) the Technology of XENCORdeveloped or obtained by or on behalf of XENCOR independent of and without the use of technical or other information disclosed orsupplied by BII or its Affiliated Companies to XENCOR relating specifically to the BII Facility, the Process, BII Intellectual Property and/orknow-how for the development and manufacturer of biopharmaceuticals generally, and which was introduced by XENCOR to the Project. 92 Cooperation between the Parties in the Course of a Project 2.1 General 2.1.1 General This Agreement sets forth the terms and conditions under which BII and XENCOR will perform their tasks regarding the Project. BII shall(by itself or by its Affiliated Companies) perform for XENCOR the Services as specified in this Agreement and the Project Plan and BII andXENCOR shall adhere to their obligations under this Agreement and the Project Plan. 2.1.2 Priority In the event of a conflict or ambiguity between any term of this Agreement and an Appendix, the terms of this Agreement shall prevail. Incase the Parties mutually agree that a specific Section of this Agreement shall be modified by the terms of a Project Plan (and that suchterm of the Project Plan shall prevail) for a specific Service, they may only do so by explicit reference to the Section of this Agreement thatshall be modified. 2.2 Personnel 2.2.1 Designation of Project Manager Upon commencement of the Project, BII and XFNCOR will each appoint a Project Manager, who will coordinate and supervise the Projectincluding communication of all instructions and information concerning the Project to the other Party. The Project Manager will serve asthe primary contact person for the other Party. Each Project Manager will be available on an agreed basis for consultation at prearrangedtimes during the course of the Project. The Project Managers shall be copied on all correspondence by other Project Team members and allcorrespondence between the Parties. In the absence of the Project Manager, a substitute shall be appointed. Additional modes or methodsof communication and decision making may be implemented with the mutual written consent of each Party. Each Party will use reasonableefforts to provide the other Party with […***…] prior written notice of any change in such Party’s Project Manager. 2.2.2 Project Team The Parties shall establish a Project Team consisting of representatives of each Party from the necessary disciplines and their respectiveProject Managers to (a) ensure the progress of the Project, (b) coordinate the performance of the Project, and (c) facilitate communicationamong the Parties. Each Project Team member shall have knowledge and ongoing familiarity with the Project and will possess the authorityto make decisions on matters likely to be raised in the Project Team. Each Party shall have the right to substitute its members of the ProjectTeam as needed from time to time by giving written notice to the other Party due time in advance. The Project Team shall meet in person or by means of a video conference or teleconference on a periodic basis (a) as agreed by the ProjectManagers within [...***...] after written request for such meeting by either Party, or (b) as specified in the Project Plan (Appendix 2, asamended from time to time), but in any event, unless otherwise agreed in writing by the Parties, the Project Team shall meet at least one (1)time per calendar quarter (by means of a video conference or teleconference or in person, provided, however, that at least two (2) of thesemeetings per calendar year are held in person on an alternating basis between XENCOR’s facilities and BII’s facilities in Fremont, CA,USA). The Project Team shall oversee the Project. Prior to each meeting of the Project Team the Parties will distribute to each other written copiesof all materials, data and information arising out of the conduct of their activities hereunder. 
***Confidential Treatment Requested 10Each Party shall bear its own costs associated with such meetings and communications. It is the right of each Party to call for a ProjectTeam meeting according to the covenants of this Section 2.2 upon written request at any time. The Parties shall alternate responsibility for preparing minutes of the meeting which shall be circulated promptly following the meeting. The initial members of the Project Team and the Project Managers are set forth in Appendix 3 attached hereto which may be updated fromtime to time to reflect changes in the Project Team and/or Project Managers as provided in this Section 2.2. 2.2.3 Steering Committee The Parties shall form a Steering Committee, to which each Party will appoint three (3) executive employees, including the ProjectManagers, all of whom shall be familiar with the Project. The Steering Committee shall have general oversight and review of the activitiesof the Project Team and shall resolve any issues referred to the Steering Committee by the Project Team. Each Party shall have the right tosubstitute its members of the Steering Committee as needed from time to time by giving written notice to the other Party due time inadvance. The Steering Committee shall meet within [...***...] after receipt of a written request by one Party to the other Party. The request shalldescribe the matter in dispute and the solution which the requesting Party proposes to be decided. Each Party shall bear its own costsassociated with meetings and communications of the Steering Committee.  The Steering Committee will take action by unanimous consent of the Parties, with the representatives of BII collectively having a singlevote and the representatives of XENCOR collectively having a single vote, or by a written resolution signed by all of the representatives.If the Steering Committee is unable to reach unanimous consent on a particular matter, then the matter will be referred to the chiefexecutive officers of the Parties, who will use good faith efforts to resolve such matter, and the decision reached by mutual agreement ofthe chief executive officers of the Parties shall be final and binding on the Parties. If, (i) after good faith efforts, the chief executive officersof the Parties are unable to resolve such matter by mutual agreement, and (ii) such matter concerns the Product or the Process, but doesnot concern the BI Facility or the management of manufacturing slots, then the chief executive officer of XENCOR shall make the finaldecision about how to resolve such dispute, after good faith consideration of BII’s position, which decision shall be final and binding onthe Parties; provided, however, that, in resolving such matter, XENCOR’s chief executive officer shall not have any authority to require BIIor its Affiliated Companies to incur additional expenses or obligations not contemplated by this Agreement. In no event will the SteeringCommittee, or the executive officers of the Parties in resolving any Steering Committee matter, have any authority to amend or modify thisAgreement; any such amendment or modification of this Agreement must be in accordance with Section 11.8. For the avoidance of doubt,nothing in this Section shall prevent any Party from seeking arbitration proceedings pursuant to Section 11.6 hereof with regard to anymatters other than matters resolved by mutual agreement of the chief executive officers in accordance with this Section 2.2.3. The members of the Steering Committee are set forth in Appendix 3 attached hereto, which may be updated from time to time to reflectchanges in the Steering Committee as provided in this Section 2.2.3. 2.3 Conduct of the Project and BII’s Work and Tasks The Parties shall engage in the Project upon the terms and conditions set forth in this Agreement. In the course of this Agreement theParties shall perform the Project as laid down and detailed in the Project Plan. Each Party shall fully and reasonably cooperate with the other Party to provide appropriate information and assistance to the other Partyin connection with the Project, responding in a 
***Confidential Treatment Requested 11reasonable and timely manner with respect to all reasonable requests for information and approval. Neither Party shall be liable for anydelays in its performance of the Project to the extent caused solely by the other Party’s failure to provide in a reasonably timely mannerany information or approval reasonably requested by the other Party. The Parties shall assign a sufficient number of professionally qualified personnel to perform the Project and shall perform its tasks underthis Agreement according to the generally acceptable professional and then current industry standards and subject to terms andconditions as set forth herein, at all times in compliance in all material respects with all requirements of applicable laws and regulations.The Parties will use commercially reasonable efforts to achieve the estimated timelines as laid down in the Project Plan. Changes to the Project Plan, if any, shall require the written consent of both Parties. 2.4 Deliverables BII will deliver such deliverables expressly laid down in detail in the Project Plan, including but not limited to the Product (the“Deliverables”) within the timelines laid down in the Project Plan to XENCOR. Following the completion of the activities required under theProject, BII will provide to XENCOR then available Product (if any), Batch records and a summary containing manufacturing and analyticaltesting, including without limitation, the information and the results of the development phase according to the workscope as furtherdescribed in the Project Plan. 2.5 Nature of the Project As the Product has never been produced by BII or on behalf of BII by its Affiliated Companies at the BI Facility, XENCOR acknowledgesthat the Project is experimental in nature and that no favorable or useful results can be assured by BII. However, after […***…], theParties shall in good faith agree on a revision (if necessary) to the preliminary specifications for the Product (that have been mutuallyagreed upon by the Parties) that shall then be the Specifications for subsequent runs in subsequent campaigns that shall form a basis forrejection or acceptance of the respective Product produced in any additional runs at such scale under the provisions of Section 4.1, and,provided that the Process has not been materially changed (i.e. a change that is subject to the Change Control procedures of the QAA),the Project shall no longer be considered experimental in nature and the obligation to meet the respective Specification shall apply to allfuture runs at such scale.  2.6 Additional Work In case the Parties mutually agree on additional work for the benefit of the Project by changing the Project Plan by written agreement ofthe Parties, BII shall perform such additional work to sustain the progress of the Project on conditions in terms of money, time and scopeto be subject to agreement of the Parties hereto as set forth in the then amended Project plan. 2.7 XENCOR Confidential Information and Know-How and Material To the extent not already transferred by XENCOR, XENCOR shall transfer the Material for the Project to BII to the BII Facility subject tothe terms of this Section 2.7, and BII shall use or have used by its Affiliated Companies such Material solely to conduct the Project inaccordance with the Project Plan, this Agreement, or as otherwise may be agreed to by the Parties in writing. The Material will not be usedin connection with any animal studies or diagnosis, treatment or any activity in humans or for any use not directly related to the Project.BII’s use of the Material will be in compliance with all applicable laws in the state or country where the Services are performed. BII acceptsthe Material with the knowledge that it is experimental. The Material may not be transferred or otherwise made available, in whole or inpart, by BII to any other individual, entity or institution other than any Affiliated Companies 
***Confidential Treatment Requested 12of BII without the prior written consent of XENCOR, which may be withheld by XENCOR for any reason. Such consent is hereby given forBII or its Affiliated Companies to transfer the Material for quality control testing performed by a third party on a blinded basis. For theavoidance of doubt, in the event of a transfer of Material to an Affiliated Company of BII or to any third party with the consent ofXENCOR, BII shall ensure that the respective Affiliated Company or third party shall use such Material solely to conduct the Project inaccordance with the Project Plan, this Agreement, or as otherwise may be agreed to by the Parties in writing and shall not transfer orotherwise make available, in whole or in part, the Material to any other individual, entity or institution. The Material is the property of XENCOR. It is agreed that the transfer of the Material hereunder shall not constitute a sale of Material or agrant, option or license of any patent or other rights except to allow BII to perform the Project. XENCOR shall retain and have all right, titleand interest in and to the Material. XENCOR will inform BII in a timely manner about any safety issues of which XENCOR becomes aware relating to the handling of theMaterial and the Product after the date of the execution of this Agreement. BII shall at all times take reasonable measures to protect the Material from loss or damage and in no event measures less than employed byBII in the protection of its own proprietary materials, and shall promptly notify XENCOR, if at any time it believes the Material has beendamaged, lost or stolen. XENCOR and BII hereby acknowledge and agree that XENCOR is providing XENCOR Confidential Information and Know-How to BII forits use by BII for the purposes of this Agreement, and BII will make use thereof solely for such purposes and XENCOR hereby consentsto such use. 2.8 Further Obligations of XENCOR 2.8.1 General The Parties acknowledge and agree, that. subject to the terms and conditions of this Agreement, BII substantially finances the Project atthe costs and fees outlined in Appendix 2 in advance and receives payments at a later point in the future. Accordingly, XENCOR agrees,in order to make both Parties benefit from their collaboration, that the success of the collaboration between the Parties depends stronglyon the fact whether or not XENCOR is able to find a suitable business partner for the further development of the Product into a successfulmedicinal product with one or more marketing authorisations worldwide. 2.8.2 Obligations of XENCOR Therefore, XENCOR shall use commercially reasonable efforts to conduct and complete at its own cost and risk a Phase 1 clinical trial withthe Product as described in Section 2.8.3 within the timelines set forth herein (subject to Section 2.8.3); and find one or more suitable thirdparty/parties as business partner(s) for the further development of the Product into a medicinal product (“Business Partner”). For the avoidance of doubt, XENCOR bears the sole responsibility for the conduct and completion of the clinical trials of the Product andthe search for the Business Partner and shall bear all costs and expenses in connection therewith. In no event will it be a breach of thisAgreement by XENCOR if the Phase 1 clinical trial or other clinical trials of the Product are not completed or an agreement is not enteredinto with a Business Partner so long as XENCOR uses commercially reasonable efforts to do so. 2.8.3 Timelines and Information XENCOR shall use commercially reasonable efforts to conduct and complete a Phase 1 clinical trial of the Product in a timely fashion andto search for the Business Partner. A summary of the preliminary plan for the Phase 1 clinical trial of the Product to be conducted byXENCOR is attached as Appendix 7, it being understood that timing of such clinical trial 13may be delayed to the extent (i) caused primarily by BII’s failure to provide Product conforming to the Specifications; or (ii) by safetyissues relating to the Product; or (iii) by regulatory delays; or (iv) other causes outside the control of XENCOR. XENCOR shall promptly provide BII notice of the completion and a summary overview of the outcome/observations of the Phase 1 clinicaltrial regarding the Product and a summary overview of any negotiations with a possible Business Partner regarding the furtherdevelopment of the Product. Moreover, XENCOR shall inform BII on an annual basis or, if there is good cause, upon request of BII(whichever is the case) about the actual status of such Phase 1 clinical trial or such negotiations, such request not to be more often thantwice per year. 3 Payments 3.1 Project Fee 3.1.1 Consideration for Services As consideration for the performance of BII’s Services, XENCOR shall pay BII all fees to be paid to BII as set forth in the Project Plan (the“Project Fees”) according to the terms and conditions set forth in the following subsections of this Section 3.1. The Project Fees as set forth in the Project Plan include BII’s internal and out­of­pocket cost and expenses for its performance of theProject, including without limitation, ordinary and standard raw materials, components and consumables, and XENCOR shall not beobligated to make any payments with respect to any Services except the Project Fees or payments for additional work agreed uponaccording to Section 2.6 (which shall then be considered “Project Fees”). 3.1.2 Payment of the Project Fees The Project Fees referred to in Section 3.1.1 above, together with interest at a […***…] percent ([...***...]%) annual interest rate on anyunpaid Project Fees accruing from the earlier of (i) the date of completion of the clinical summary report for the Phase 1 clinical trials of theProduct as planned according to Appendix 7 unless delayed as described in Section 2.8.3 or (ii) the date that is five (5) calendar years afterthe Effective Date (each of the alternatives above, the “Due Date”) until paid in full (the Project Fees together with any such interest,referred to as the “Total Amount”), shall become duly payable in accordance with the following schedule: a. In case XENCOR has entered into an agreement with at least one Business Partner, then, beginning from the later of (i) the effective dateof such agreement or (ii) the Due Date, XENCOR will pay BII the Total Amount in [...***...] installments of [...***...] of the[...***...] (defined below) that [...***...]; provided, however, that in no event will [...***...] of the annual Licensing Revenue[...***...]; provided that, for the avoidance of doubt, [...***...] shall be excluded from [...***...]. 
***Confidential Treatment Requested 14
 b. In case XENCOR decides to proceed with the further development of the Product without a Business Partner, XENCOR will pay BII theTotal Amount in one or more lump sum payments within five (5) calendar years from the Due Date. c. As long as XENCOR, notwithstanding its commercially reasonable efforts after the completion of the Phase 1 clinical trial either (i) is notable to further develop the Product for technical and/or scientific reasons or (ii) does not decide to proceed with the furtherdevelopment of the Product without a Business Partner and does not enter into an agreement with a Business Partner within two(2) calendar years from the Due Date, then XENCOR shall have no obligation to pay BII any or all of the Total Amount. For theavoidance of doubt, such obligations will become due as described in this Section 3.1.2, at any time XENCOR enters into anagreement with at least one Business Partner or further develops the Product within ten (10) calendar years following theEffective Date, as provided in Section 10.3. 3.1.3 Invoicing XENCOR shall notify BII in writing of any of the circumstances listed in Section 3.1.2.a to 3.1.2.c. BII shall issue an invoice for thepayments of the Total Amount agreed upon with XENCOR according to the payment schedule in Section 3.1.2 and payment of theTechnology Access Fee, as applicable. The amount of the Project Fees and the interest (if any) will be shown separately in the invoice. XENCOR shall make payments of all invoiced amounts for the payments of the Total Amount and of the Technology Access Fee due andpayable in accordance with Section 5.2.3 and 5.2.4, as applicable [...***...] from the date of receipt of BII’s invoice. If XENCOR fails tomake timely payment of the invoiced amount, interest shall accrue on the amount of the Project Fees shown in the invoice at a fixed annualrate equal to the highest rate of interest quoted as the “prime rate” in The Wall Street Journal on the day that payment was due. Allpayments due under this Agreement shall be paid in US dollars by wire transfer or by such other means agreed to in writing by the Parties.XENCOR will provide at least twenty-four (24) hours advance notice to BII of each wire transfer to the bank account identified below orsuch other bank accounts as BII shall designate in writing. 
      
Account Name:
 
[...***...]
 
Account Number:
 
[...***...]Bank:
 
[...***...]
 
BIC (SWIFT-CODE):
 
[...***...]
 
IBAN:
 
[...***...]
 
 3.2 Technology Access Fee The Technology Access Fee (if any) is due according to Section 5.2.3 and 5.2.4 below. Section 3.1.3 shall apply accordingly. 3.3 VAT All payments under this Agreement (including the Technology Access Fee) shall be understood as net payments without value added tax(“VAT”). VAT, if applicable, shall be added to the respective payment. The Parties will reasonably cooperate in completing and filingdocuments required under applicable law in connection with any refund of or credit for any such payment of VAT. 
***Confidential Treatment Requested 154 Delivery Terms of Product 4.1 Delivery Terms BII shall (a) deliver to XENCOR or, (b) at the request of XENCOR, store, the agreed amounts of the Product produced according to theProject Plan in accordance with agreed upon schedule, at the price set forth in the Project Plan. Delivery of Product by BII shall be made[...***...] BII Facility (Incoterms 2010). BII shall package and arrange for shipment of Product to the delivery address specified by XENCOR, all in accordance with theinstructions of XENCOR provided that BII shall not be responsible for any damages with respect to Product or third party claims arisingout of such arrangements for shipment of Product after delivery of such Product to the shipper in accordance with such instructions inaccordance with XENCOR’s instructions. Each shipment of cGMP Product will include a Certificate of Analysis, a Confirmation ofCompliance and such other documentation as reasonably required to meet all applicable statutory and regulatory requirements. Delivery ofthe Product shall be subject to quality and other provisions set forth in the QAA. The Parties shall cooperate reasonably to obtain allcustoms licenses or permits necessary to ship the Product (the evaluation of which customs licenses or permits required shall beperformed by XENCOR), and no shipment shall be made until such licenses or permits, if any, have been obtained. XENCOR shall diligently examine all Product delivered under this Agreement as soon as practicable after receipt. Notice of all claimsarising out of or relating to Obvious Defects shall be given in writing to BII within [...***...] after the date of XENCOR’s receipt of Product,otherwise, such Product shall be considered free of any Obvious Defects as between BII and XENCOR. XENCOR shall make a damagedProduct available for inspection and shall comply with the requirements of any insurance policy covering the Product, and BII shall offerXENCOR all reasonable assistance, at the cost and expense of XENCOR, in pursuing any claims arising out of the transportation of theProduct. Except as otherwise provided herein and as set forth in Section 2.5, XENCOR shall have [...***...] after the date of XENCOR’s receipt ofProduct, for all claims arising out of or relating to any Latent Defects and to reject such delivered Product for Latent Defects; provided,however that XENCOR shall only be permitted to reject the Product if the Acceptance Criteria are not met. If XENCOR determines after reviewing the relevant documentation and performing reasonable testing that any Batch does not meet theAcceptance Criteria, or if Product is determined by BII to be unsuitable for release, then the Parties will mutually agree, as promptly asreasonably possible, whether (a) to produce a new Batch at BII’s cost and expense, including the costs of materials used in themanufacture of such Batch, or (b) to rework or reprocess the Batch, at BII’s cost and expense, so that the Batch can be deemed to havebeen manufactured in compliance with cGMP and the agreed Process Description, and to conform to the Acceptance Criteria (providedthat the Parties have mutually agreed in writing on any procedures for reworking or reprocessing a Batch). If the remedy set forth in either(a) or (b) is agreed to be performed by BII, then BII shall start the applicable work as soon as reasonably practicable, such that the nextreasonably available (taking into consideration BII’s entire contract manufacturing business) manufacturing slot shall be used by BII toproduce Product, and BII will use commercially reasonable efforts to resupply within [...***...] but in any event no later than [...***...] fromtime of rejection by XENCOR. For the avoidance of doubt, if Product is not accepted by XENCOR as provided above, then BII’sobligations set forth above shall apply both to the drug product and the bulk drug substance contained therein. In the event XENCOR rejects the Product for Obvious Defects or Latent Defects as provided above, BII shall have the right to sample andretest the Product, which shall be done as soon as 
***Confidential Treatment Requested 16practicable, provided that, if BII does not notify XENCOR in writing of its election to retest the Product within [...***...] after notice ofrejection from XENCOR, BII shall be deemed to agree with XENCOR’s rejection of the Product. In the event of a discrepancy betweenXENCOR’s and BII’ s test results such that one Party’s results fall within the Acceptance Criteria and the other Party’s test results falloutside the Acceptance Criteria, or there exists a dispute over whether such failure is due (in whole or in part) to acts or omissions ofXENCOR or any third party after delivery, the Parties shall cause a testing laboratory agreeable to both Parties to perform comparativetests and/or analyses on samples of the alleged defective Product. The testing laboratory’s results shall be in writing and shall be final andbinding save for manifest error on the face of its report. Unless otherwise agreed to by the Parties in writing, the costs associated withsuch testing and review shall be borne by the Party against whom the testing laboratory result finally rules. The testing laboratory shall berequired to enter into written undertakings of confidentiality no less burdensome than set forth or referred to by this Agreement. 4.2 Cancellation of Order If XENCOR at any time cancels or postpones any campaign set forth in the Project Plan for the manufacture of Product for non-technicalreasons later than [...***...] prior to the date on which inoculation of the respective production fermenter is to take place, XENCOR shallnevertheless be obliged to pay [...***...] percent ([...***...]%) of the Project Fees for such campaign to the extent that BII is not able toadequately use the respective capacity for such campaign alternatively (e.g. for production of any other material for any third party oritself) provided always that BII shall use its commercially reasonable efforts to use such capacity and mitigate any losses that may incurarising from such cancellation or postponement, including, for the avoidance of doubt, the reapplication of raw materials, if possible. 5 Ownership and Use of Project Data 5.1 Project Data In consideration of the Project Fees: a. BII shall carry out the Project by itself or by its Affiliated Companies) and provide XENCOR with a summary of the results from theProject, including manufacturing and analytical release and also shall provide XENCOR with a summary report about the resultson the various stages of Process development; b. BII shall supply XENCOR with data, results and information required to comply with any mandatory request of any applicable regulatorybody in the Major Territories to comply with such regulatory body’s requirements. BII shall provide complete Batch records forall cGMP runs and will provide to XENCOR all data reasonably necessary from all process development and manufacturingactivities to enable XENCOR’s preparation of any regulatory filings; and shall not unreasonably reject supplying data results andinformation required to comply with any requirement of any applicable regulatory body outside the Major Territories orcooperating with XENCOR’s preparation of the chemistry, manufacturing and controls section of any regulatory filing supportingthe clinical development of the Product in and outside the Major Territories. BII shall bear the cost of such supply and cooperation by BII, provided that, if there are specific requirements of a given countrythat are significant and in addition to requirements of the Major Territories, the Parties will enter into good faith discussionswhether additional resources and costs are required, with the intent of minimizing any additional cost to XENCOR. 
***Confidential Treatment Requested 17c. Certain trade secret information may be provided by BII via DMF or similar filing (e.g. to a notified body) directly to the respectiveauthorities. d. For the avoidance of doubt, all summaries and/or reports generated as a result of the BII’s performance under this Agreement anddelivered to XENCOR by BII will be part of the Process and the sole and exclusive property of BII. Subject to XENCOR’sconfidentiality and non-use obligations hereunder and without affecting the ownership of Improvements as set forth in Section 8,BII hereby grants to XENCOR a non-exclusive, worldwide license to use and reproduce all such summaries and/or reports for alluses in connection with development activities relating to Product that do not involve manufacturing of Product (e.g.,formulation work, toxicology studies or the development of a manufacturing process), regulatory activities relating to the Productand, to the extent necessary, any commercial activities relating to the Product, which XENCOR may sublicense in connection withany license of rights to the Product. 5.2 Use of the Process; Right of Negotiation 5.2.1 Use of the Process outside this Agreement Except as set forth in this Agreement, the Process shall not be used by XENCOR or any third party outside the scope of this Agreementwithout the prior written consent of BII. 5.2.2 Right of First Negotiation to Manufacture a. XENCOR hereby grants and will make an eventual Business Partner do so, BII a first right to negotiate to manufacture and supplyProduct for use in Phase 2 and 3 clinical trials. XENCOR shall provide BII written notice (i) of the completion of the Phase 1clinical trials of the Product, which notice shall include reasonable documentation of the results of such Phase 1 clinical trials ofthe Product or (ii) that XENCOR has entered into an agreement with at least one Business Partner, whichever of (i) and (ii) occursearlier. If BII provides XENCOR written notice of its exercise of the first right to negotiate within [...***...] after receipt of suchwritten notice from XENCOR, then for a period of [...***...] following such written notice from BII or such longer period as agreedin writing by BII and XENCOR (or its Business Partner) (the “Clinical Negotiation Period”), XENCOR (or its Business Partner) andBII will negotiate in good faith an agreement for the manufacture and supply of Product for use in Phase 2 and 3 clinical trials, atmarket rate terms and conditions common for the contract manufacture of monoclonal antibodies within the contractmanufacturing industry, to be mutually agreed in writing by the Parties. If BII does not provide written notice of its exercise of thefirst right to negotiate within such [...***...] period, XENCOR and any Business Partner shall be free to enter into one or moreagreements with third parties for the manufacture and supply of Product for use in Phase 2 and 3 clinical trials. If BII provideswritten notice of its exercise of the first right to negotiate within such [...***...] period but BII and XENCOR (or its BusinessPartner) do not enter into such a contract manufacturing agreement within the Clinical Negotiation Period, XENCOR and anyBusiness Partner shall be free to enter into one or more agreements with third parties for the manufacture and supply of Productfor use in Phase 2 and 3 clinical trials (which may include an agreement for any Business Partner or its affiliate to manufacture andsupply Product for clinical trials), provided that the supply price for Product is no more than [...***...] percent ([...***...]%) of theclinical supply price of Product last proposed by BII during the negotiations between the Parties (or BII and the BusinessPartner). If the supply price for Product proposed by a third party (which may include a Business Partner or its affiliate) is morethan [...***...] percent ([...***...]%) of the clinical supply price of Product last proposed by BII during the negotiations betweenthe Parties (or BII and the Business Partner) , XENCOR (or its Business Partner) shall provide written notice to BII that XENCOR(and its Business Partner) will accept the clinical supply price last proposed by BII, and BII and XENCOR (or its BusinessPartner) will enter into a contract manufacturing agreement reflecting such clinical supply price; provided that, if BII does notagree to enter into such contract 
***Confidential Treatment Requested 18manufacturing agreement within [...***...] after such written notice, XENCOR (or its Business Partner) shall be free to enter intoan agreement with a third party (or an agreement for the Business Partner or its affiliate to manufacture and supply Product). b. In addition, if BI has exercised its first right of negotiation in Section 5.2.2.a, XENCOR hereby grants and will make an eventual BusinessPartner do so, BII a first right to negotiate to manufacture and supply commercial Product as Principal Supplier for a period up tothe [...***...], starting with the first commercial launch of the Product. XENCOR shall provide BII written notice (i) of the decisionto have the Product manufactured at a commercial scale and to launch the Product commercially or (ii) that XENCOR has enteredinto an agreement with at least one Business Partner, whichever of (i) and (ii) occurs earlier. If BII provides XENCOR writtennotice of its exercise of the first right to negotiate within [...***...] after receipt of such written notice from XENCOR, then for aperiod of [...***...] following such written notice, or such longer period as agreed in writing by BII and XENCOR (or its BusinessPartner) (the “Commercial Negotiation Period”), XENCOR (or its Business Partner) and BII will negotiate in good faith anagreement for the manufacture and supply of commercial Product as Principal Supplier, at market rate terms and conditionscommon for the contract manufacture of monoclonal antibodies within the contract manufacturing industry to be mutually agreedin writing by the Parties. If BII does not provide written notice of its exercise of the first right to negotiate within such [...***...]period, XENCOR and any Business Partner shall be free to enter into one or more agreements with third parties for themanufacture and supply of commercial Product (which may include an agreement for any Business Partner or its affiliate tomanufacture and supply commercial Product). If BII provides written notice of its exercise of the first right to negotiate withinsuch [...***...] period but BII and XENCOR (or its Business Partner) do not enter into such a contract manufacturing agreementwithin the Commercial Negotiation Period, XENCOR and any Business Partner shall be free to enter into one or more agreementswith third parties for the manufacture and supply, of commercial Product (which may include an agreement for any BusinessPartner or its affiliate to manufacture and supply commercial Product); provided that the supply price for Product is no more than[...***...] percent ([...***...]%) of the commercial supply price of Product last proposed by BII during the negotiations betweenthe Parties (or BII and the Business Partner). If the supply price for Product proposed by a third party (which may include aBusiness Partner or its affiliate) is more than [...***...] percent ([...***...]%) of the commercial supply price of Product lastproposed by BII during the negotiations between the Parties (or BII and the Business Partner), XENCOR (or its Business Partner)shall provide written notice to BII that XENCOR (and its Business Partner) will accept the commercial supply price last proposedby BII, and BII and XENCOR (or its Business Partner) will enter into a contract manufacturing agreement reflecting suchcommercial supply price; provided that, if BII does not agree to enter into such contract manufacturing agreement within[...***...] after such written notice, XENCOR (or its Business Partner) shall be free to enter into an agreement with a third party(which may include an agreement for any Business Partner or its affiliate to manufacture and supply Product). c. The right set forth in Section 5.2.2.b shall automatically terminate if BII does not exercise the first right of negotiation set forth in Section5.2.2.a. The rights set forth in Section 5.2.2.a and b shall automatically terminate if BII does not produce a viable Process formanufacture of Product as evidenced by failure to produce cGMP Product within a timeframe reasonably and customary in thebiopharmaceutical industry for companies of comparable size and the respective activities. d. In both cases set forth above, in Section 5.2.2.a. and b., if BII exercises its first right of negotiation, BII and XENCOR (and/or itsBusiness Partner, as applicable) will negotiate in good faith a respective contract manufacturing agreement based on the marketrate 
***Confidential Treatment Requested 19terms and conditions common for the contract manufacture of monoclonal antibodies within the contract manufacturing industry,it being understood that any such contract manufacturing agreement would provide for Technology transfer, payment of theTechnology Access Fee (if applicable), and other terms set forth in Sections 5.2.3, 5.2.4 and 5.2.5 below. e. Any use of the Process by XENCOR or any third party outside the terms and conditions set forth in such contract manufacturingagreement is always subject to the provisions set forth in Section 5.2.3 below. f. In the event that BII elects not to exercise its first right of negotiation described in Section 5.2.2.a or 5.2.2.b, or, despite their commerciallyreasonably efforts and good faith negotiations the Parties (or BII and the Business Partner) are unable to agree upon amanufacturing agreement within the Clinical Negotiation Period or, Commercial Negotiation Period, as applicable; and/orXENCOR (and/or XENCOR’s Business Partner) wishes to use the Process outside the terms and conditions set forth in a contractmanufacturing agreement with BII, BII shall transfer the Process in accordance with Section 5.2.3 below. g. All of BII’s rights of negotiation set forth in this Secti6n 5.2.2 shall terminate upon payment of the Technology Access Fee by XENCOR. 5.2.3 Technology Access Fee and Technology Transfer In the event that XENCOR wishes to use or have used (e.g. by a Business Partner) the Process outside this Agreement or the terms andconditions set forth in a contract manufacturing agreement with BII, except as provided below, XENCOR shall pay BII a technology accessfee of three million five hundred thousand (3,500,000.00) US dollars (the “Technology Access Fee”). In the event that XENCOR pays the Technology Access Fee set forth above, XENCOR shall have the right to use or have used (e.g. by aBusiness Partner) the Process worldwide for the manufacture of Product in accordance with the terms and conditions of this Agreement,without entering into a contract manufacturing agreement with BII. Notwithstanding the foregoing, no Technology Access Fee shall be due or payable if BII does not produce a viable Process formanufacture of Product as evidenced by failure to produce cGMP Product within the timeframe agreed in the Project Plan or, if factorsoutside of the reasonable control of BII (such as e.g. a cell-line not suitable for production, delay in the growth of the cell line; shortage ofraw materials and supplies, delay or non­performance of BII’s suppliers, requests or orders of governments or regulatory authorities, etc.)require the timeframe in the Project Plan to be extended, the extended timeframe agreed upon in writing between BII and XENCOR that isreasonable and customary for paying customers in the biopharmaceutical industry for companies of comparable size and the respectiveactivities. In addition, no Technology Access Fee shall be due or payable in connection with XENCOR’s election to use or have used (e.g.by a Business Partner) the Process if (i) BII does not exercise its first right to negotiate under either Section 5.2.2.a or 5.2.2.b, (ii) BIIexercises its first right to negotiate but demands a supply price for clinical/commercial supply of Product that exceeds the bid price for theclinical/ commercial supply of Product of a comparable quantity and quality by a third party biopharmaceutical CMO of comparable sizeand respective activities to BII and with registered headquarters in the Major Territories, or (iii) XENCOR (or its Business Partner) hasentered into a contract manufacturing agreement with BII, but BII is not able to supply XENCOR and its Business Partners [...***...] of theProduct required. For the avoidance of doubt, nothing in this Section 5.2.3 (ii) shall affect such contract manufacturing agreement or BII’sposition as Principal Supplier, but XENCOR may solely request the Technology Transfer pursuant to the following sentences of thisSection without paying the Technology Access Fee in order to have manufactured the amount of Product missing to satisfy XENCOR’sand its Business Partners’ demand. 
***Confidential Treatment Requested 20For the avoidance of doubt, the Technology Access Fee is only due one time, and if XENCOR pays the Technology Access Fee, exceptfor the Project Fees, no additional amount will be payable for use or having used the Process worldwide. The Technology Access Fee includes Technology transfer support of [...***...] FTEs of BII for a period of [...***...] for each of the[...***...] FTEs in a time frame of [...***...] beginning with XENCOR’s written request to use or have used (e.g. by a Business Partner) theProcess outside the terms and conditions set forth in a contract manufacturing agreement with BII. Further support of BII requested byXENCOR shall be reimbursed at an hourly rate of [...***...] US dollars. The Parties will agree upon the times when to render suchTechnology transfer support in good faith. Promptly following XENCOR’s election to use the Process, BII shall start to transfer the Process and all reasonably necessary related BIIConfidential Information and Know-How) to XENCOR or such designee experienced in the biopharmaceutical production and shall usecommercially reasonable efforts, taking into consideration BII’s entire contract manufacturing business and other contract manufacturingcontracts, to transfer the Process as quickly as possible (and in any event within [...***...] from receipt of XENCOR’s written electionnotice). Both Parties agree and XENCOR will make its Business Partner agree that BII may, however, select the way how to render suchsupport of any Technology transfer at its own discretion, in particular but not only any support of such Technology transfer to acompany whose primary business is providing biopharmaceutical CMO services (including e.g. a Technology transfer outside the BIFacility), provided, however, that BII’s exercise of such discretion is not unreasonable. XENCOR and/or any third party may not use the Process outside the terms and conditions set forth in a contract manufacturing agreementwith BII except as set forth in Section 5.2.2 and this Section 5.2.3 and provided that XENCOR or it Business Partner strictly adhere to thelicense conditions set forth in Sect ion 5.2.5 herein. 5.2.4 Payment Terms The Technology Access Fee, as applicable, shall be paid to BII upon completion of the Technology transfer described in Section 5.2.3 andshall be payable in accordance with the provisions set forth under Sections 3.2 and 3.3 above. Parties agree that the Technology transfershall be completed upon the transfer of Process and all reasonably necessary related BII Confidential Information and Know-How. 5.2.5 License Subject to XENCOR’s adherence to the obligations under this Agreement, BII hereby grants XENCOR a worldwide, irrevocable, exclusive,sublicensable and royalty free license to use the Process and all reasonably necessary related BII Confidential Information and Know-How, BII Technology and BII Intellectual Property for the sole purpose of making and having made the Product; provided that suchlicense shall become effective only upon complete payment of the Technology Access Fee, as applicable. 5.3 Acknowledgement The Parties acknowledge that nothing in this Agreement shall limit or restrict XENCOR, itself or with or through any third party, fromdeveloping and using any process (except for the Process) for the manufacture of any of its products, including the Product, provided thatno BII Confidential Information and Know-How is used and XENCOR adheres to its confidentiality and non-use obligations hereunderand complies with the ownership of intellectual property and Improvements as set forth in Section 8 below. 
***Confidential Treatment Requested 216 Representations, Warranties and Indemnification 6.1 Mutual Representations, Warranties and Covenants Each Party hereby represents, warrants and covenants to the other Party as follows as of the Effective Date: a. it is a corporation duly organized and validly existing under the laws of the state or other jurisdiction of incorporation or formation; and b. the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite corporate action; and c. it has full corporate authority to execute and deliver this Agreement and to perform its obligations hereunder, and the Agreement isbinding upon it in accordance with it terms; and d. it has the right, without restriction, to grant the licenses granted under this Agreement. 6.2 XENCOR Warranties XENCOR hereby warrants that: a. XENCOR has the right to provide the Material, the XENCOR Technology, the XENCOR Intellectual Property and all XENCORConfidential. Information and Know-How under this Agreement and to the best of its Knowledge at the Effective Date that thereare no third party rights that will limit or restrict use thereof by BII in accordance with this Agreement; and b. to the best of its Knowledge at the Effective Date XENCOR is not aware of any special or unusual hazards involved in handling theMaterials and/or Product of which it has failed to inform BII; and that it will inform BII immediately of any changes related theretoafter the date of execution of this Agreement; and c. at the Effective Date, no third party has asserted any claim or lawsuit against XENCOR claiming that use of the Material, XENCORTechnology, the XENCOR Intellectual Property and the XENCOR Confidential Information and Know-How infringes anyintellectual property owned by a third party, and it will promptly notify BII in writing should it become aware of any claims by athird party asserting that use of such infringes any third part intellectual property rights owned by such third party. d. it will use commercially reasonable efforts to conduct and complete a clinical trial phase 1 regarding the Product; and e. it will use commercially reasonable efforts to find and enter into an agreement with a suitable Business Partner. For avoidance of doubt, all XENCOR liability or indemnification obligations that might result from representations and the warrantiesunder this Section 6 are always subject to the limitations set forth in Section 7.4 of this Agreement. 6.3 BII Warranties BII hereby warrants that: a. BI is entitled to use the BI Facility and BII Confidential Information and Know-How, for the purposes set forth in this Agreement; and b. BII at the Effective Date, it is not aware of any special or unusual hazards that would arise as a result of its carrying out of the Projectsas planned; and c. at the Effective Date, it has not been debarred, nor is it subject to a pending debarment, and that it will not, to the best of its Knowledge,use in any capacity in connection with 22the Services under this Agreement any person, who has been debarred pursuant to section 306 of the FDCA, 21 U.S.C. § 335a, orwho is the subject of a conviction described in such section. BII agrees to notify XENCOR in writing immediately if it hasKnowledge that BII or any person who is performing Services is debarred or is the subject of a conviction described in section306, or if any action, suit, claim, investigation, or proceeding is pending, or to BII’s Knowledge, is threatened, relating to thedebarment or conviction of BII or any person performing Services under this Agreement; and d. to the best of its Knowledge at the Effective Date its performance under this Agreement including, but not limited to, the BIITechnology and its use in the Process, by BII, XENCOR or a third party manufacturer of XENCOR does not infringe theintellectual property rights of any third party and it will promptly notify XENCOR in writing should it become aware of any claimsasserting such infringement or of any third party intellectual property rights, that would be infringed by the BII Technology andits use in the Process. For the avoidance of doubt, the currently pending Cabilly dispute is excluded and will be addressed/compensated by XENCOR once applicable: and e. as of the Effective Date no third party has asserted any claim or lawsuit against BII claiming infringement of any intellectual propertyowned by a third party with relation to BII Technology and/or the Process, or any part or component thereof. For avoidance of doubt, all BII liability or indemnification obligation that might result from representations and the warranties under thisSection 6 are always subject to the limitations set forth in Section 7.4 of this Agreement. 6.4 Process for Defense of Infringement of Third Party Intellectual Property Subject to each Party’s indemnification obligations, in the event that there occurs a Claim (as defined below), the Parties shall follow thefollowing procedures with respect to the defense of the Claim: a. BII agrees that if a third party threatens or asserts any claim or files any lawsuit, claiming that BII Intellectual Property utilized under thisAgreement and necessary for manufacture and production of the Product in accordance with this Agreement, including, withoutlimitation, the BII Technology or the Process, or the use thereof, constitutes infringement of any intellectual property owned by athird party (each, a “Claim”), BII will promptly and timely inform XENCOR of such Claim, and BII shall have the first right tonegotiate, litigate and/or settle any such Claim, and shall defend any such Claim unless it would not be commercially reasonablefor BII to bear the reasonably anticipated losses, damages, costs and expenses arising from any settlement or judgment resultingfrom such Claim. For the avoidance of doubt, the term “commercially reasonable”, as used in this paragraph a. shall be determined(i) in the context of BII’s entire business related to the intellectual property that is the subject to the Claim, where the Claimasserts infringement that impacts aspects of BII’s business beyond the XENCOR relationship, and (ii) if the Claim assertsinfringement that is limited only to activities performed for XENCOR, in the context of the entire relationship between XENCORand BII. b. BII will keep XENCOR reasonably informed about such negotiation or litigation at all times, including all material events related thereto,and in the event that the amounts paid or to be paid by BII in settlement of any such Claim or group of related or unrelated Claimsappear reasonably likely to exceed, individually or in the aggregate, BII’s indemnification obligations, or any contemplatedsettlement would place any obligations or restrictions upon XENCOR or the Product, then BII shall immediately inform XENCOR. c. XENCOR shall not be responsible to pay for any costs of any settlement by BII of any Claim(s) (including, without limitation, anypayments resulting of such settlement) that 23exceed BII’s indemnification obligations or be bound by any obligations or restrictions agreed to by BII in any such settlement,in case such settlement is made without the prior written consent of XENCOR, which may be granted or withheld in its solediscretion. d. In the case that BII decides not to negotiate, litigate or settle any Claim, XENCOR shall have the right to negotiate, litigate and settle anysuch Claim, and, provided that XENCOR decides to pursue such negotiation, litigation or settlement, BII will provide allcommercially reasonable cooperation to XENCOR such that XENCOR may appropriately defend such Claims. 6.5 Disclaimer of Warranties EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY OF ANYKIND, EXPRESS OR IMPLIED, WITH RESPECT TO ANY INTELLECTUAL PROPERTY, TECHNOLOGY, RIGHTS, RESULTS OF THEPROJECTS, MATERIAL, THE DELIVERABLES OR OTHER SUBJECT MATTER OF THIS AGREEMENT OR THAT THE PROJECTSWILL RESULT IN A COMMERCIALLY-VIABLE PROCESS, INCLUDING, WITHOUT LIMITATION, WARRANTIES OFMERCHANTABIIITY AND FITNESS FOR A PARTICULAR PURPOSE. 7 Liability, Indemnification, Limitations and Insurance 7.1 General BII has no control over the manner in which XENCOR intends to use the results of the Project, the Product or the Deliverables, if any,obtained in the Project and in particular does not know or control how XENCOR intends to use such Product or results in clinical studies. 7.2 Liability a. Of BII Always subject Section 7.4, in consideration of the aspects set forth in Section 7.1, BII shall only be liable for any losses,damages, costs or expenses including, without limitation, reasonable attorneys’ fees of any nature (“Losses”) incurred orsuffered by XENCOR or its Affiliated Companies or any third party (including but not limited to Business Partners) to the extentsuch Losses are arising from either (i) BII’s non­compliance with the warranties given under Sections 6.1 and 6.3 of thisAgreement, or (ii) gross negligence or willful acts or omissions of BII or its Affiliated Companies in performing its obligationsunder this Agreement. BII shall not be liable to XENCOR or be obligated to indemnify XENCOR or its Representatives under Section 7.3 for any Lossesincurred or suffered by XENCOR, its Affiliated Companies or by any third party, arising out of any dispute or other claims orproceedings made by or brought against XENCOR and/or its Affiliated Companies with respect to XENCOR’s use of any resultsof the Project, the Deliverables (including but not limited to the Product, if any), the Process, the BII Technology and/or the BIIConfidential Information and Know-How, obtained (including but not limited to the use under a license that may be grantedunder this Agreement) under this Agreement including, without limitation, product liability claims, except to the extent suchLosses are caused by the gross negligence or wilful acts or omissions of BII or its Affiliated Companies in performing itsobligations under this Agreement, nor shall BII be responsible in any way for dealing with any such disputes, claims orproceedings. 24
 b. Of XENCOR Always subject to Section 7.4, XENCOR shall be liable for any Losses incurred or suffered by BII, its Affiliated Companies or byany third party arising from either (i) XENCOR’s non­compliance with the warranties given under Sections 6.1 and/or 6.2 of thisAgreement, or (ii) BII’s or XENCOR’s use of XENCOR Confidential Information and Know­How, the Material, the XENCORIntellectual Property and/or the XENCOR Technology in accordance with this Agreement, or (iii) XENCOR’s use of theDeliverables (including but not limited to the Product, if any), or (iv) XENCOR’ s use of the Process, the BII Technology, the BIIConfidential Information and Know-How, and/or any other results of the Project or this Agreement, not in accordance with thisAgreement. XENCOR shall not be liable to BII or its Affiliated Companies or be ob1igated to indemnify BII or its Representatives underSection 7.3 for any Losses incurred or suffered by BII or its Affiliated Companies or any third party arising out of any dispute orother claims or proceedings made by or brought against BII or its Affiliated Companies with respect to BII’s use of the BIIConfidential Information and Know-How, the Material, the XENCOR Intellectual Property, and/or the XENCOR Technology orBII’s use of the license granted to BII under Section 8.2.5.a outside the scope of this Agreement, in each case except to the extentsuch liability is caused by the gross negligence or wilful acts or omissions of XENCOR, or its Affiliated Companies in performingits obligations under this Agreement, nor shall XENCOR be responsible in any way for dealing with any such disputes, claims orproceedings. 7.3 Indemnification a. BII’s Indemnification Obligations Always subject to Section 7.4, BII shall indemnify, defend and hold XENCOR, its Affiliated Companies and their respectiveofficers, employees and agents (the “Representatives”) harmless from and against all Losses incurred by them as a result of thirdparty claims based on or resulting from (i) BII’s non­compliance with the warranties given under Sections 6.1 and 6.3 of thisAgreement, or (ii) any gross negligence or wilful acts or omissions of BII or any of its Affiliated Companies in performing itsobligations under this Agreement. b. XENCOR’s Indemnification Obligations Always subject to Section 7.4, XENCOR shall indemnify, defend and hold BII and its Representatives harmless from and againstall Losses incurred by them as a result of third party claims based on or resulting from (i) BII’s use of the XENCOR ConfidentialInformation and Know-How, the Material, the XENCOR Intellectual Property and/or the XENCOR Technology in accordance withthis Agreement; or (ii) XENCOR’s non­compliance with the warranties given under Sections 6.1 and 6.2 of this Agreement, or (iii)XENCOR’s use of the Deliverables (including but not limited to the Product, if any), or (iv) XENCOR’ s use of the Process, the BIITechnology, the BII Confidential Information and Know-How, and/or any other results of the Project or this Agreement, not inaccordance with this Agreement. 7.4 Limitation of Liability and Indemnification Obligations With the exception of wilful misconduct by a Party, and such cases where a limitation of liability and/or indemnification is not possibleunder applicable law, for which cases there shall be no limitation, any and all liability and/or indemnification obligations of each of BII andXENCOR under this Agreement shall be: a. excluded for incidental, indirect, consequential, punitive or special damages (provided that the foregoing shall not exclude a Party’s rightto consequential or incidental  25damages for any negligent or intentional breach of confidentiality and non-use obligations under Section 9); and b. each Party’s aggregate liability and/or indemnification obligations towards the other Party under this Agreement shall not exceed anamount equal to the average annual aggregate amount paid or to be paid by XENCOR to BII hereunder; provided, however, thatin the case of a Party’s negligent or intentional breach of confidentiality and non­use obligations pursuant to Section 9, thislimitation of liability shall be increased to twice the average annual aggregate amount paid or to be paid by XENCOR to BIIhereunder; provided however that the foregoing Subsections a. and b. of this Section 7.4 shall not limit XENCOR’ s liability and indemnificationobligation towards BII with respect to any third party claims according to clause (iii) and (iv) of Section 7.3 b. regarding any use of theDeliverables (in particular the Product) in humans and/or with respect to any third party claim that BII’s use of the Material to manufacturethe Product infringes any issued patent owed by such third party (excluding any such claim based specifically on use of the Process butnot on the use of the Material). 7.5 Insurance XENCOR and BII shall obtain and/or maintain during the term of this Agreement and for a period of [...***...] thereafter, liability insurancein amounts which are reasonable and customary in the biopharmaceutical industry for companies of comparable size and the respectiveactivities (i.e. BII as CMO and XENCOR as sponsor/pharmaceutical company) at the respective place of business and such liabilityinsurance shall insure against all mandatory liability, including liability for personal injury, physical injury and property damage. BII shallhave the right to reasonably self insure. 8 Intellectual Property 8.1 Existing Intellectual Property Rights BII hereby acknowledges that XENCOR is the owner of XENCOR Confidential Information and Know-How and the XENCOR Technologyand BII shall acquire no rights, title or interest whatsoever in or to any of XENCOR Confidential Information and Know-How and/orXENCOR Technology, except as specifically provided for in this Agreement. XENCOR hereby acknowledges that BII is the owner of BII Confidential Information and Know-How and the BII Technology andXENCOR shall acquire no rights, title or interest whatsoever in or to any of BII Confidential Information and Know-How and/or the BIITechnology, except as specifically provided for in this Agreement. 8.2 New Intellectual Property, Project Results and Licenses 8.2.1 XENCOR Improvements that (i) relate specifically to XENCOR Confidential Information and Know-How and/or the Product (or any modification,derivative or fragment thereof), and (ii) do not relate to BII Confidential Information and Know­How (collectively, “XENCOR IntellectualProperty”), will be exclusively owned by XENCOR and XENCOR shall control patent prosecution and maintenance thereof. BII (on behalfof itself and its Affiliated Companies) agrees to assign and hereby assigns to XENCOR all right title and interest it may have in anyXENCOR Intellectual Property. BII shall provide reasonable assistance to XENCOR for any action which may be necessary to assign orotherwise transfer any rights to XENCOR Intellectual Property contemplated by this Section 8.2.1. BII shall notify XENCOR within[...***...] of becoming aware of such XENCOR Intellectual Property. 
***Confidential Treatment Requested 268.2.2 BII Improvements that (i) relate specifically to BII Confidential Information and Know-How, and (ii) do not relate to XENCOR ConfidentialInformation and Know­How (collectively, “BII Intellectual Property”) will be exclusively owned by BII, and BII shall control patentprosecution and maintenance thereof. XENCOR agrees to assign and hereby assigns to BII all right title and interest it may have in any BIIIntellectual Property. XENCOR shall provide reasonable assistance to BII for any action which may be necessary to assign or otherwisetransfer such rights to BII Intellectual Property contemplated by this Section 8.2.2. 8.2.3 Other Improvements Any Improvements that are neither XENCOR Intellectual Property nor BII Intellectual Property shall be defined as “Other Improvements”and shall be jointly owned by BII and XENCOR, with the Parties entitled to practice the same as joint owners, without duty of accountingto the other Party and with the right to license to others without consent of the other Party. BII shall notify XENCOR within [...***...] daysof becoming aware of such Other Improvements. Each Party agrees to assign and hereby assigns to the other Party such right title andinterest it may have in any Other Improvements as necessary to effect joint ownership of the Other Improvements by BII and XENCOR.Each Party shall provide reasonable assistance for any action which may be necessary to assign or otherwise transfer such rights to OtherImprovements to Parties as joint owners. BII shall have the first right to prosecute and maintain patent rights within the OtherImprovements, at its expense, provided that if BII elects not to prosecute or maintain an Other Improvement it shall provide written noticeto XENCOR, and XENCOR may elect to take over responsibility for prosecution and maintenance of such Other Improvement, at its ownexpense, by providing written notice to BII, in which case all rights to such Other Improvement shall be assigned to XENCOR. For theavoidance of doubt, except as expressly stated otherwise in Section 10.3, Parties agree that XENCOR’s use of the Process is alwayssubject to Section 5.2.3, 5.2.4 and 5.2.5. For the avoidance of doubt, (i) know-how pertaining to manufacturing of biopharmaceuticals generally and gained during the course ofperforming this Agreement may be freely used by BII in its biopharmaceutical business without any restrictions, provided, that,notwithstanding the foregoing, BII may not use any Other Improvement that relates specifically to the Product. a. Each Party shall ensure that all of such Party’s (or its Affiliated Company’s) employees or contractors acting on its behalf pursuant tothis Agreement are and will be obligated under a binding written agreement or by law to assign to such Party all inventions andrights on the inventions made under this Agreement so that such Party can comply with the terms of this Agreement. b. Subject to the terms and conditions contained in this Agreement, BII shall be responsible for filing, prosecution and maintenance ofpatent applications and patents granted or generated under this Agreement and owned by BR. XENCOR shall be responsible forfiling, prosecution and maintenance of patent applications and patents granted or generated under this Agreement and owned byXENCOR. c. BII shall keep XENCOR and XENCOR shall keep BII reasonably informed about prosecution of any patent applications and maintenanceof any patents generated under this Agreement. 8.2.4 Licenses to Xencor BII grants to XENCOR the license set forth in Section 5.2.5 as provided therein. 8.2.5 Licenses to BII a. Freedom to operate XENCOR hereby grants to BII and BII herewith accepts a non exclusive, worldwide, irrevocable, sublicensable (inseveral cascades), perpetual, royalty-free/fully paid up license under the XENCOR Intellectual Property to the extent it isgenerally applicable to the manufacturing of biopharmaceutical products, handling 27of cell lines and/or development of manufacturing processes, to use such XENCOR Intellectual Property in for the manufacture ofbiopharmaceutical products, handling of cell lines and/or development of manufacturing processes, but excluding any use withrespect to the Product (or any modification, derivative or fragment thereof). BII expressly agrees not to practice any XENCORIntellectual Property specific to the Product or for any purpose other than as expressly provided in this Section 8.2.5. b. Performance of Project: During the term of this Agreement, XENCOR hereby grants to BII and BII hereby accepts for the purpose ofpursuing the Project a non-exclusive, non-sub-licensable (except to Affiliated Companies), royalty-free, license to use theXENCOR Confidential Information and Know-How, the Material, the XENCOR Intellectual Property and/or any part of the OtherImprovements for the sole purpose to develop the Process, and for the manufacturing of the Product for clinical purposes inaccordance with this Agreement. BII expressly agrees not to use or practice any XENCOR Confidential Information and Know-How, the Material, and/or the XENCOR Intellectual Property for any purpose other than performance or the Services inaccordance with this Agreement, except if otherwise expressly permitted in this Agreement. 9 Confidentiality 9.1 General The Parties agree, for the duration of this Agreement and a term of [...***...] after the Effective Date: (a) to hold in strict confidence allConfidential Information and Know­How of a Party (“Disclosing Party”) or its Affiliated Companies which has been or will be madeavailable to the other Party (“Receiving Party”) or its Affiliated Companies, and not to disclose such Confidential Information and Know­How of the Disclosing Party to any third party whatsoever, (b) not to use such Confidential Information and Know-How of the DisclosingParty for any purpose other than those set forth herein. For clarification, all XENCOR Confidential Information and Know-How, XENCORTechnology and XENCOR Intellectual Property shall be Confidential Information and Know-How of XENCOR and XENCOR shall be theDisclosing Party and BII shall be the Receiving Party with respect thereto, and all BII Confidential Information and Know-How, BIITechnology and BII Intellectual Property shall be Confidential Information and Know-How of BII and BII shall be the Disclosing Party andXENCOR shall be the Receiving Party with respect thereto.  The Receiving Party undertakes to protect the Disclosing Party’s Confidential Information and Know ­How against unauthorized accessby third parties using all commercially reasonable efforts. If Confidential Information and Know-How is disclosed by Disclosing Party or its Affiliated Companies other than in written or electronicform, then Receiving Parties’ obligations of confidentiality and non­use shall only apply if the Confidential Information and Know­How isindicated upon disclosure as being confidential and is then summarised electronically or in writing and provided to Receiving Party within[...***...] after initial disclosure. Notwithstanding the foregoing, in no event shall a failure to provide such an electronic or writtensummary preclude either Party from asserting that such information is Confidential Information and Know-How. The obligations to keep secret, not to disclose and not to use the Disclosing Party’s Confidential Information and Know­How or partsthereof shall not apply in the event that the respective Confidential Information or and Know-How such parts thereof: 
***Confidential Treatment Requested 28a. can be shown by written documentation to have been known to Receiving Party or its Affiliated Companies prior to disclosure by theDisclosing Party or its Affiliated Companies hereunder or under the MTA (in no event will Confidential Information and Know-How of the Disclosing Party that is generated by the Receiving Party or its Affiliated Companies (e.g., Improvements that areXENCOR Intellectual Property) be considered to be known by the Receiving Party or its Affiliated Companies prior to disclosureby the Disclosing Party or its Affiliated Companies), b. is or comes into the public domain by publication or otherwise through no breach of this Agreement or the MTA, or c. can be shown by written documentation to have been made known to Receiving Party or its Affiliated Companies from another sourcefree from any obligation of confidentiality and was not obtained either directly or indirectly from Disclosing Party or its AffiliatedCompanies, or d. can be shown by written documentation to have been independently developed or created by Receiving Party or its AffiliatedCompanies without access to the other Party’s Confidential Information and Know­How (in no event will ConfidentialInformation and Know-How of the Disclosing Party that is generated by the Receiving Party or its Affiliated Companies (e.g.,Improvements that are XENCOR Intellectual Property) be considered to be independently developed by the Receiving Party or itsAffiliated Companies). Confidential Information and Know-How not be deemed to be in the public domain merely because they may be derived from one or moreitems which are publicly known. Receiving Party shall not disclose Disclosing Party Confidential Information and Know-How to any third party without the prior writtenconsent of Disclosing Party, except to such of the Receiving Party’s or its Affiliated Companies’ responsible employees and/or advisorsto whom it is necessary to disclose such Confidential Information and Know-How for purpose set forth herein. Before such ConfidentialInformation and Know-How is disclosed to such employees and/or advisors, Receiving Party shall first impose on such employees and/oradvisors confidentiality and non-use obligations not less stringent than those set forth herein, however, the imposition of suchobligations shall not relieve Receiving Party of its obligations hereunder. In the event that Receiving Party or its Affiliated Companies are required by law, regulation, rule, act or order of any governmentalauthority or agency to disclose the Disclosing Party’s Confidential Information and Know­How, the Receiving Party or its AffiliatedCompanies shall be entitled to do so provided that Receiving Party shall first notify Disclosing Party forthwith of any such requireddisclosure and limit such disclosure as far as is possible under applicable law. Such disclosure shall, however, not relieve Receiving Partyof its other obligations contained herein. Furthermore, a Receiving Party may make such disclosures of the Disclosing Party’s Confidential Information and Know­How togovernmental entities to the extent reasonably necessary in connection with pursuit of intellectual property protection, development andcommercialization activities related to the Product as contemplated by this Agreement, and approvals to use and sell the Product.Moreover, XENCOR may disclose BII Confidential Information and Know-How to entities (i) with whom XENCOR has (or may have) amarketing and/or development collaboration for the Product (including an actual or potential Business Partner) or (ii) that are actual orpotential investors in or acquirers of XENCOR, to the extent reasonably necessary for the pursuit of such actual/ potential collaboration orrelationship pursuant to (i) or (ii), and, in both cases, who have a specific need to know such information and who are bound byobligations of confidentiality and restrictions on use similar to those set forth in this Agreement, provided always that XENCOR may notdisclose any BII  29Confidential Information and Know-How to any company whose primary business is providing biopharmaceutical CMO services exceptwith BII’s prior written consent. 9.2 MTA Superseded The confidentiality and non-use obligations under the MTA shall be superseded hereby and all information disclosed pursuant to theMTA shall be Confidential Information and Know-How subject to this Agreement. 9.3 Controlled Technology XENCOR hereby agrees and covenants that if it or its Affiliated Companies intend to provide Confidential Information and Know-How toBII or its Affiliated Companies that XENCOR has Knowledge may be listed on the Commerce Control List or the Chemical WeaponsConvention Schedules of Chemicals, both contained within the U.S. Export Administration Regulations (hereinafter “ControlledTechnology”), then XENCOR shall notify promptly BII of such Knowledge as soon as possible prior to such intended disclosure. In orderfor BII to take any appropriate precautionary actions before receipt of such Controlled Technology and to ensure compliance with U.S.export laws, XENCOR shall, before providing the Controlled Technology: a. identify all Confidential Information and Know-How of XENCOR that may be Controlled Technology; and b. inform BII, to the extent known to XENCOR, where the Controlled Technology is listed on the Commerce Control List or the ChemicalWeapons Convention Schedules of Chemicals and what restrictions apply to the export or disclosure of the ControlledTechnology under U.S. law. XENCOR further agrees to cooperate with BII by providing upon request information and other assistance necessary for the exportclassification, export documentation and export licensing, if required, for the Controlled Technology under U.S. export laws. In any event, XENCOR hereby agrees that it will not disclose Controlled Technology to BII or its Affiliated Companies without the expressprior consent of BII. 10 Term and Termination 10.1 Term This Agreement shall take effect as of the Effective Date and shall expire upon completion of the Project as set forth in the Project Plan andafter payment of all payments due and payable according to this Agreement, unless terminated earlier in accordance with this Agreement. 10.2 Termination of this Agreement 10.2.1 If it is apparent to either Party at any stage of the Project that it will not be possible to carry out the Project for scientific, technical or businessreasons, such Party may terminate this Agreement upon one hundred eighty (180) days prior written notice to the other Party. 10.2.2 Termination for Material Breach: This Agreement may be terminated at once by written notice by either Party, if the other Party breaches thisAgreement in any material manner and shall have failed to remedy such default within thirty (30) days after written notice thereof from theterminating Party. 10.3 Effects of Termination of this Agreement 3010.3.1 Effect of Termination prior to completion of the Phase 1 clinical trial with the Product as described in Section 2.8.3. a. In the event of termination by XENCOR according to Section 10.2.1 prior to completion of the Phase 1 clinical trial with the Product asdescribed in Section 2.8.3 for technical and/or scientific reasons, XENCOR shall have no obligation to pay BII any or all of theTotal Amount. For the avoidance of doubt, in such case, XENCOR may not use the Process outside BII, except as otherwiseagreed in writing by XENCOR and BII. b. In the event of termination by XENCOR according to Section 10.2.1 prior to completion of the Phase 1 clinical trial with the Product asdescribed in Section 2.8.3. for any other reason than the reasons set forth under Section 10.3.1.a the Total Amount shall be limitedto all non-cancellable expenses reasonably incurred by BII in accordance with the Project Plan prior to such termination in respectof the purchase of supplies or raw materials, and reasonable wind-down costs not to exceed sixty (60) days. BII shall mitigate allwind-down costs and non-cancellable expenses to the extent possible. Campaigns cancelled shall be paid as provided for inSection 4.2 above. For the avoidance of doubt, in such case, XENCOR many not use the Process outside BII, except as otherwiseagreed in writing by XENCOR and BII. c. In the event of termination by BII according to Section 10.2.1 prior to completion of the Phase 1 clinical trial with the Product, XENCORshall have no obligation to pay BII any or all of the Total Amount. The use of the Process is subject to Section 5.2.3, 5.2.4 and5.2.5. d. In all of the foregoing cases a.-c., at the request of XENCOR and to the extent available at BII, BII shall destroy the Material or deliverthe Material to XENCOR at XENCOR’s cost and shall promptly return all XENCOR Confidential Information and Know­How toXENCOR; except for a copy and/or sample of each material for documentation purposes only, which shall remain to theconfidentiality and non­use provisions in Section 9, and shall refrain from using the Material. Except for the foregoing, BII’sresponsibility to keep and store the Material and any other materials shall terminate one hundred eighty (180) days afterexpiration or termination of the respective Project or this Agreement. In the foregoing cases a.-c., XENCOR shall promptly return all BII Confidential Information and Know-How to BII, except for asingle copy and/or sample for documentation purposes only, which shall remain to the confidentiality and non-use provisions inSection 9, and shall refrain from using the Process, except as contemplated in Section 10.3.1.c or 10.3.1.d. For the a voidance of doubt, in the event of a termination by XENCOR as contemplated in clause b of this Section 10.3.1, Section3.1.2.c shall continue in effect, but Section 3.1.2 shall not survive in the event of any termination described in clause a. and c. 10.3.2 Effect of Termination after completion of the Phase 1 clinical trial with the Product as described in Section 2.8.3. a. In the event of termination by XENCOR according to Section 10.2.1 after completion of the Phase 1 clinical trial with the Product asdescribed in Section 2.8.3 for technical and/or scientific reasons, XENCOR shall have no obligation to pay BII any or all of theTotal Amount. For the avoidance of doubt, in such case, XENCOR may not use the Process outside BII, except as otherwiseagreed in writing by XENCOR and BII. For the avoidance of doubt, in the event of a termination as contemplated in this Section10.3.2a, Section 3.1.2 c shall survive. b. In the event of termination by XENCOR according to Section 10.2.1 after completion of the Phase 1 clinical trial with the Product asdescribed in Section 2.8.3 for a reason not listed in Section 10.3.2.a, the Total Amount shall be limited to all non-cancellableexpenses reasonably incurred by BII in accordance with the Project Plan prior to such 31termination in respect of the purchase of supplies or raw materials, and reasonable wind-down costs not to exceed sixty (60) days.BII shall mitigate all wind-down costs and non-cancellable expenses to the extent possible. Campaigns cancelled shall be paid asprovided for in Section 4.2 above. For the avoidance of doubt, in the event of a termination as contemplated in this Section10.3.2b, Section 3.1.2.c shall continue in effect. The use of the Process is subject to Sections 5.2.3, 5.2.4 and 5.2.5. c. In the event of termination by BII according to Section 10.2.1 after completion of the Phase 1 clinical trial with the Product, XENCORshall have no obligation to pay BII any or all of the Total Amount. The use of the Process is subject to Sections 5.2.3, 5.2.4 and5.2.5. For the avoidance of doubt, in the event of a termination as contemplated in this Section 10.3.2c, Section 3.1.2 shall notsurvive. 10.3.3 Effect of Termination due to Material Breach a. In case of a termination by BII according to Section 10.2.2, the Total Amount shall become immediately due and BII shall be free to claimfor damages according to the applicable law and, subject to Section 7.4 above. All licenses granted by either Party to the otherParty hereunder shall be null and void. For the avoidance of doubt, XENCOR may not use the Process outside BII, except asotherwise agreed in writing by XENCOR and BII; except that, if XENCOR has already exercised its rights under Sections 5.2.3,5.2.4 and 5.2.5, all such rights granted prior to termination shall remain in effect. b. In case of a termination by XENCOR according to Section 10.2.2, XENCOR shall have no obligation to pay BII any or all of the TotalAmount, and subject to Section 7.4 above, XENCOR shall be free to claim for damages according to the applicable law. Alllicenses granted by XENCOR to BII hereunder shall be null and void. For the avoidance of doubt, Section 3.1.2 shall not survivein the event of termination as described in this Section 10.3.3.b. The use of the Process is subject to Sections 5.2.3, 5.2.4 and 5.2.5. 10.4 Surviving Provisions Upon any expiration or termination of this Agreement by either Party pursuant to Section 10.2, all rights and obligations of the Partiesunder this Agreement shall terminate and be of no further force or effect, except as otherwise expressly set forth below in this Section 10.4and in Section 10.3. The expiration or termination of this Agreement for any reason shall not release either Party from any liability that, atthe time of such expiration or termination, has already accrued to the other Party or that is attributable to a period prior to such expirationor termination. The following provisions of this Agreement shall survive expiration or termination of this Agreement for any reason:Section 1 (Definitions), Section 3 (Payments) except as expressly set forth in Section 10.3; Section 5 (Ownership and Use of Project Data),Section 6.4 (Process for Defense of Infringement of Third Party Intellectual Property); Section 6.5 (Disclaimer of Warranties); Section 7(Liability, Indemnification, Limitations and Insurance); Section 8 (Intellectual Property), but excluding the last sentence of the firstparagraph of Section 8.2.3 (Other Improvements) referring to Sections 5.2.3, 5.2.4 and 5.2.4 except to the extent that those sections areexpressly stated to survive termination as set forth in Section 10.3, and excluding Section 8.2.5b; Section 9 (Confidentiality); Section 10.3(Effects of Termination of this Agreement), including the provisions referenced in Section 10.3 as continuing after termination, asapplicable; Section 10.4 (Surviving Provisions); and Section 11 (Miscellaneous). 11 Miscellaneous 11.1 Force Majeure Neither Party shall be in breach of this Agreement if there is any failure of performance under this Agreement (except for payment of anyamounts due hereunder) occasioned by any reason 32beyond the control of either Party, including, without limitation, any act of God, fire, act of government or state, war, civil commotion,insurrection, embargo, prevention from or hindrance in obtaining energy or other utilities, or labour disputes of whatever nature. 11.2 Conflict with Improvements under the MTA The Parties agree that with respect to the ownership of intellectual property rights and/or ownership of Improvements, this Agreementshall prevail over the terms and conditions of the MTA and shall also cover the term of the MTA. 11.3 Secrecy Agreement between the Parties The Parties agree that all information exchanged pursuant to the Secrecy Agreement between the Parties with effectiveness as of June 28,2011 shall be Confidential Information and Know-How protected in accordance with this Agreement, and such Secrecy Agreement shall besuperseded by the terms of this Agreement and shall have no further force or effect. 11.4 Publicity XENCOR or BII may issue the mutually agreed press release attached as Appendix 8 announcing the execution of this Agreement. Exceptas provided in the preceding sentence, no press release or other form of publicity regarding a Project or this Agreement shall be permittedby either Party to be published unless both Parties have indicated their consent to the form of the release in writing. The same applies, toany changes in the press release attached as Appendix 8. Nothing in this Section shall prevent the Parties from disclosing this Agreement,if and as far as required by applicable laws, rules or regulations. However, the disclosing Party shall inform the other Party well in advancewhenever reasonably possible and shall provide the opportunity to comment on such required disclosure (e.g. under SEC rules). Inaddition, subject to XENCOR’s compliance with Section 9.1, nothing in this Section shall prevent XENCOR from disclosing the status ofdevelopment, regulatory approval or commercialization of the Product. 11.5 Notices Any notice required or permitted to be given hereunder by either Party shall be in writing and shall be (i) delivered personally, (ii) sent byregistered mail, return receipt requested, postage prepaid or (iii) delivered by facsimile with immediate confirmation of receipt, to theaddresses or facsimile numbers set forth below: If to BII: Boehringer Ingelheim International GmbHBinger Straße 17355216 IngelheimFederal Republic of GermanyAttention: Mr. Alois Konrad (Global Dept. Biopharma Contract Manufacturing Business)Fax: 0049- 7351/54 - 4845Phone: 0049- 7351/54 - 96145  33If to XENCOR: 111 West Lemon AvenueMonrovia, CA 91016Attention: Chief Executive OfficerPhone: (626) 305-5900Fax: (626) 305-0350 11.6 Applicable Law and Arbitration This Agreement shall be exclusively governed by and construed in accordance with the laws of the State of New York, USA withoutregard to its conflict of laws provisions. The application of the UN Convention on Contracts for the International Sale of Goods is excluded. The Parties agree that all disputes, claims or controversies arising out of, relating to, or in connection with this Agreement, including anyquestion regarding its formation, existence, validity, enforceability, performance, interpretation, breach or termination, shall be finallysettled under the Rules of Arbitration of the International Chamber of Commerce (“ICC”) by one arbitrator appointed in accordance withsaid rules. The exclusive place of arbitration shall be New York State of New York, USA and the proceedings shall be conducted in English language. The award for arbitration shall be final and binding and may be enforced in any court of competent jurisdiction against BII or XENCOR.Nothing in this Section shall prevent any Party, before an arbitration has commenced hereunder or any time thereafter during sucharbitration proceedings, from seeking conservatory and interim measures, including, but not limited to temporary restraining orders orpreliminary injunctions, or their equivalent, from any court of competent jurisdiction. The Parties further agree that a. except as may be otherwise required by applicable laws, rules or regulations, neither Party, its witnesses, or the arbitrator may disclosethe existence, content, results of the arbitration hereunder without prior written consent of both Parties; and b. neither Party shall be required to give general discovery of documents, but may be required only to produce specific, identifieddocuments, or narrow and specific categories of documents, which are relevant to the case and material to its outcome andreasonably believed to be in the custody, possession or control of the other Party; and c. decisions ex aequo et bono or in equity are not permissible. 11.7 Entire Agreement This Agreement (including the Exhibits and Schedules attached hereto) constitutes the entire agreement between the Parties relating to itssubject matter and supersedes all prior or contemporaneous agreements, understandings or representations, either written or oral, betweenXENCOR and BII with respect to such subject matter (including the Secrecy Agreement effective as of June 28, 2011). 11.8 Waiver; Amendment No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise in any one or more instances shall bedeemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other term, provision or 34
 condition of this Agreement. No amendment or modification of any provision of this Agreement shall be effective unless in writing signedby a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oralagreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorizedrepresentative of each Party. 11.9 Severability If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction all other provisions shallcontinue in full force and effect. The Parties hereby agree to attempt to substitute for any invalid or unenforceable provision a valid andenforceable provision which achieves to the greatest extent possible the economic legal and commercial objectives of the invalid orunenforceable provision. 11.10 Dispute Resolution Any dispute relating to the Project shall first be submitted for resolution to the Steering Committee. 11.11 Assignment This Agreement shall be binding upon the successors and assigns of the Parties and the name of a Party appearing herein shall be deemedto include, the names of its successors and assigns. This Agreement shall not be assignable by either Party, except with the writtenconsent of the other Party hereto; provided, however, that either Party may assign this Agreement without the other Party’s consent to anacquiring party in connection with the transfer or sale of all or substantially all of the business of such Party to which this Agreementrelates to such acquiring party, whether by merger, sale of stock, sale of assets or otherwise, provided that in the event of such a sale ortransfer (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g,. in the context of areverse triangular merger)). 11.12 Independent Contractors Nothing in this Agreement is intended, or shall be deemed, to establish a joint venture or partnership (or any fiduciary duty) betweenXENCOR and BII. Neither Party to this Agreement shall have any express or implied right or authority to assume or create any obligationson behalf of, or in the name of, the other Party, or to bind the other Party to any contract, agreement or undertaking with any third party. 11.13 Counterparts This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shallconstitute one and the same instrument.  35IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the Effective Date. 
              
 
 
 Monrovia, February 16 2012
 
Biberach, February 13, 2012
  
 
 
  
 
 
 XENCOR, Inc.
 
Boehringer Ingelheim International GmbH
  
 
 
  
 
 
 
 
 ppa.
 
ppa.
  
 
 
 
 
 /s/ Bassil Dahiyat
 
 
 /s/ Alois Konrad
 
 
 /s/ Dr. Andreas Felder
 
Bassil Dahiyat
 
 
 Alois Konrad
 
 
 Dr. Andreas Felder
 President and CEO
 
 
 
 
 
 
 
 
 
 36List of Appendices: Appendix 1: Material and Product Appendix 2: Project Plan Appendix 3: Members of the Project Team, Steering Committee and Chief Executive Officers Appendix 4: MTA Appendix 5: Quality Agreement Appendix 6: Specifications, incl. shipping and packing instructions agreed by the Parties (to be attached upon agreement of the Parties) Appendix 7: Summary Plan for Phase 1 Clinical Trials Appendix 8: Press Release  37Appendix 1: XmAb®6755 : Anti­TNF_Adalimumab_lgG1/2_M428L/N434S_XtendHeavy Chain ORF (Protein)[...***...][...***...] [...***...] [...***...][...***...] [...***...] 
***Confidential Treatment Requested 38[...***...] [...***...] [...***...] 
     [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]]
 [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
  
***Confidential Treatment Requested 39[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
  
***Confidential Treatment Requested 40[...***...] 
    [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
  [...***...] 
     [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
  
***Confidential Treatment Requested 41[...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
  
 
 
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
  [...***...] [...***...] 
             [...***...]
 
[...***...]
 
[...***...]
 [...***...]
 
[...***...]
 
[...***...]
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 [...***...]
 
[...***...]
 
[...***...]
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
 
 
 [...***...]
 
 
  
***Confidential Treatment Requested 42[...***...] […***…] 
                      […***…]
 
[…***…]
 
[…***…]
 […***…]
 
[…***…]
 
[…***…]
 […***…]
 
[…***…]
 
[…***…]
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
  
***Confidential Treatment Requested 43Appendix 2: Appendix 2.1: Project Plan and PriceProject PlanXtend-TNFProcess DevelopmentManufacturing of Clinical Grade Material  44
 
 Appendix 2.1: Project Plan and PriceProject PlanXtend-TNFProcess DevelopmentManufacturing of Clinical Grade Material Version of December 19, 2011  45[...***...]  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 46[...***...] […***…] […***…]  
***Confidential Treatment Requested 47[...***...]  […***…] […***…] […***…] […***…] […***…][…***…][…***…] […***…]  
   […***…]
 
[…***…]
 […***…]
 
[…***…]
   […***…] […***…] 
***Confidential Treatment Requested 48[...***...] […***…] […***…] […***…] […***…]  […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 49[...***...]
 
[…***…]
 […***…]
 
[…***…]
  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…]  
   […***…]
 
[…***…]
 […***…]
 
[…***…]
  […***…] […***…] […***…] 
***Confidential Treatment Requested 50[...***...]  […***…] […***…] […***…] […***…] 
   […***…]
 
[…***…]
 […***…]
 
[…***…]
  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 51[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
   […***…]
 
[…***…]
 […***…]
 
[…***…]
  […***…] […***…] 
***Confidential Treatment Requested 52[...***...]
 
[…***…]
 […***…]
 
[…***…]
  […***…] […***…] […***…] […***…] 
   […***…]
 
[…***…]
 […***…]
 
[…***…]
  […***…]  […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 53[...***...]  […***…] […***…] […***…] 
   […***…]
 
[…***…]
 […***…]
 
[…***…]
  […***…] […***…] 
   […***…]
 
[…***…]
 […***…]
 
[…***…]
  […***…] […***…] 
***Confidential Treatment Requested 54
 [...***...] 
   […***…]
 
[…***…]
 […***…]
 
[…***…]
  […***…] […***…] […***…] […***…] […***…] […***…] […***…]
   […***…]
 
[…***…]
 […***…]
 
[…***…]
  […***…] […***…] 
***Confidential Treatment Requested 55[...***...]  
     […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
  
    […***…]
 
 
 
[…***…]
 […***…][…***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
[…***…]
  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…]  
***Confidential Treatment Requested 56[...***...]  […***…] […***…] […***…] […***…] 
   […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 57[...***...]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
 […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
   […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
  
***Confidential Treatment Requested 58[...***...]  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
    […***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
 […***…] […***…] […***…] […***…] 
   […***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
 
***Confidential Treatment Requested 59[...***...]  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
   […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
  
***Confidential Treatment Requested 60[...***...]  […***…] […***…] 
     […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
  
    […***…]
 
 
 
[…***…]
 […***…][…***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
[…***…]
  […***…] […***…] […***…] 
      […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
 
 
[…***…]
 
 
 
[…***…]
 […***…]
 
 
 
 
 
 
   […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
  
***Confidential Treatment Requested 61[...***...]
 
 
 […***…]
 […***…]
 
 
 […***…]
  […***…] […***…] […***…] 
   [...***...]
 
 
 […***…]
 [...***...]
 
 
 […***…]
  […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 62[...***...] 
                           […***…]
 
 
 
[…***…]
 […***…]
 
 
 
 
 
[…***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
 […***…]
 
 
 
[…***…]
  
***Confidential Treatment Requested 63[...***...]  […***…] […***…] […***…] 
***Confidential Treatment Requested 64
 Appendix 3: Members of the Project Team and Steering Committee […***…] […***…] […***…] […***…]  […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 65Appendix 4: MTA […***…]  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 66[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…]  […***…] 
***Confidential Treatment Requested 67[...***...]  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…]  […***…] 
***Confidential Treatment Requested 68[...***...] […***…] […***…] […***…] […***…] […***…] […***…]  […***…] 
***Confidential Treatment Requested 69[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…]  […***…] 
***Confidential Treatment Requested 70[...***...] […***…] […***…] […***…] […***…] […***…] […***…]  […***…] 
***Confidential Treatment Requested 71[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…]  […***…] 
***Confidential Treatment Requested 72[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…]  […***…] 
***Confidential Treatment Requested 73[...***...] […***…] […***…] […***…]  […***…] […***…][…***…] […***…]  […***…][…***…]  […***…] […***…]  […***…]  […***…] […***…]  […***…] 
***Confidential Treatment Requested 74
 [...***...] […***…]  […***…] […***…]  […***…] 
***Confidential Treatment Requested 75Appendix 5 Quality Agreement  […***…] […***…] […***…]  […***…]  […***…] […***…] […***…] […***…] […***…]  […***…]  […***…]  […***…] […***…] […***…]  […***…] 
***Confidential Treatment Requested 76[...***...] […***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…][…***…] 
***Confidential Treatment Requested 77[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 78[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 79[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 80[...***...]  […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 81[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 82[...***...] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 83[...***...] […***…]  […***…] […***…]  […***…] […***…] […***…] 
***Confidential Treatment Requested 84
 [...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 85[...***...] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] […***…] 
***Confidential Treatment Requested 86[...***...] […***…] […***…]  […***…][…***…]  […***…][…***…]  […***…]  […***…][…***…]  […***…][…***…] 
***Confidential Treatment Requested 87Exhibit 1  [...***...]  
       
[...***...]
 
 
 
[...***...]
 
 
 
[...***...]
 
 
 [...***...]
 
 
 
[...***...]
 
 
 
 
 
 
 
[...***...][...***...]
 
 
 [...***...][...***...][...***...]
 
 
 [...***...]
 
 
 [...***...]
 
 
 [...***...][...***...]
 
 
 [...***...][...***...][...***...]
 
 
 [...***...]
 
 
 [...***...]
 
 
 [...***...][...***...]
 
 
 [...***...][...***...][...***...]
 
 
 [...***...]
 
 
 [...***...]
 
 
 [...***...][...***...]
 
 
 [...***...][...***...][...***...]
 
 
 [...***...]
 
 
 
 
 
 
 [...***...][...***...]
 
 
 [...***...][...***...][...***...]
 
 
  
***Confidential Treatment Requested 88Exhibit 2  [...***...]  
         […***…]
 
 
  
 
 
 […***…]
 
 
 
[…***…]
 
[…***…][…***…]
 […***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
  
      […***…]
  
 […***…]
 […***…]
 […***…]
   
***Confidential Treatment Requested 89Exhibit 3  [...***...] […***…] […***…]  
     
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  […***…] […***…]  
     
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
***Confidential Treatment Requested 90Exhibit 3  [...***...]  […***…] […***…]  
     
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
***Confidential Treatment Requested 91Exhibit 4  [...***...]  
                
 
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 […***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***Confidential Treatment Requested 92Exhibit 5  [...***...]  
             […***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…][…***…][…***…]
 
 
 […***…][…***…]
 
[…***…]
 
[…***…]
 
 
 […***…][…***…][…***…]
 
 
 
[…***…]
 
 
 […***…][…***…][…***…][…***…]
 
 
 
[…***…][…***…]
 
 […***…] 
 
 
  […***…][…***…]
 […***…]
 
[…***…]
 
 
 […***…]
  […***…]
 
 […***…]
 
 
  […***…]
  […***…]
 
 […***…]
 
 
  […***…]
 […***…][…***…]
 
 
 […***…][…***…][…***…][…***…][…***…]
 
 
 
[…***…]
 
 
 […***…][…***…][…***…]
 
 
 
[…***…] 
 
 
 
 
 
 
 
 
***Confidential Treatment Requested 93[...***...]
 […***…]
   Exhibit 5  […***…]  
      […***…]
  
  […***…][…***…]
 […***…][…***…]
  […***…][…***…]  […***…][…***…] […***…]
  
***Confidential Treatment Requested 94
 Exhibit 6 […***…] […***…] 
                                
 
 
 
 
[…***…]
 
 
 
 
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 […***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…][…***…]
   […***…]
    
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
***Confidential Treatment Requested 95[…***…] 
                                    
 
 
 
 
[…***…]
 
 
 
 
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
 
 [...***...]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…][…***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
***Confidential Treatment Requested 96[…***…] 
                                              
 
 
 
 
[…***…]
 
 
 
 
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
 
 [...***...]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…][…***…]
     […***…]
  
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
***Confidential Treatment Requested 97[…***…] 
                            
 
 
 
 
[…***…]
 
 
 
 
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[...***...]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
 […***…]
 
 
 
[…***…]
 
[…***…]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 […***…]
 
 
 
 
 […***…]
 
 
 
 
 
 
 
 
***Confidential Treatment Requested 98Appendix 6: Specifications, incl. shipping and packing instructions agreed by the Parties (to be attached upon agreement of the Parties) […***…] 
***Confidential Treatment Requested 99Appendix 7: Summary Plan for Phase I Clinical Trials […***…] 
       […***…]
 
[…***…]
 […***…]
 
[…***…]
 […***…]
 
[…***…]
 […***…]
 
[…***…]
 […***…]
 
[…***…]
 […***…]
 
[…***…]
  […***…] 
       […***…]
 
[…***…]
 […***…]
 
[…***…]
 […***…]
 
[…***…]
 […***…]
 
[…***…]
 […***…]
 
[…***…]
 […***…]
 
[…***…]
  
***Confidential Treatment Requested 100Appendix 8: Press Release February 8th, 2012 Boehringer Ingelheim GmbHCorporate Communications:Heidrun Thoma+49/6132 77 3966Heidrun.Thoma@boehringer-ingelheim.comTwitter: www.twitter.com/boehringer Xencor Media ContactHeidi Chokeir, Ph.D.Canale CommunicationsTel: 619-849-5377heidi@canalecomm.com Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half­life MONROVIA, Calif., USA and INGELHEIM, Germany — February 14, 2012 — Xencor, Inc., a company using its proprietary ProteinDesign Automation® (PDA) platform technology to engineer next­generation antibodies, and Boehringer Ingelheim announced today acollaboration agreement for certain Xencor biosuperior monoclonal antibodies. Under the terms of the agreement, Boehringer Ingelheim will provideall manufacturing and product supply from preclinical through Phase I development. Xencor is responsible for preclinical and clinical studies andretains all development and commercial rights to products under the agreement. Upon successful advancement of clinical programs beyond Phase 1development, Boehringer Ingelheim has certain manufacturing rights to supply clinical and commercial material to Xencor. “Xencor has developeddeep portfolio of biosuperior antibodies with the potential for superior clinical and commercial performance, and this collaboration agreement withBoehringer Ingelheim allows us to establish an important relationship with the leading global contract manufacturer of biologics,” said BassilDahiyat, Ph.D., president and CEO of Xencor. “Xencor and Boehringer Ingelheim will share the financial risk in early preclinical and clinicaldevelopment with the incentive of sharing in future success of the programs.” “We are delighted to start this collaboration with Xencor. It reflects one of our new business models in the contract manufacturing in which bothparties are enabled to focus on their core competencies”, stated Corporate Senior Vice President Simon Sturge at Boehringer IngelheimBiopharmaceuticals. “We are convinced that this creates a win­win situation for both parties.” Xencor’s lead biosuperior compound is an anti­TNFantibody engineered using the company’s proprietary Xtend™ antibody engineering technology for increasing antibody half­life. Xencor expectsto initiate a Phase 1 trial in 2013 potentially resulting in key human pharmacokinetic data validating Xtend technology. 101
thAbout Xencor, Inc. Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader inthe field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancingmultiple XmAb® antibody drug candidates in the clinic, including XmAb®5871 targeting CD32b and CD19 for autoimmune diseases, and an anti­CD30 candidate XmAb®2513 for the treatment of Hodgkin’s lymphoma. Xencor is also advancing a portfolio of biosuperior versions of blockbusterantibody drugs engineered for superior half-life and dosing schedule. Xencor has entered into multiple partnerships with industry leaders such asAmgen, Pfizer, Centocor, MorphoSys, Boehringer Ingelheim, CSL Ltd. and Human Genome Sciences. In these partnerships Xencor is applying itssuite of proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and/or potency. For moreinformation, please visit www.xencor.com. About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, itoperates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company hasbeen committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human andveterinary medicine. Today, Boehringer Ingelheim is one of the world’s leading companies for contract development and manufacture of biopharmaceuticals.All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shopconcept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customersat its global manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 19 molecules to marketand has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusionmolecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins andantibody fragments are available for the manufacture of customer products. www.biopharma-cmo.com. For more information, please contact: Xencor Inc.Heidi Chokeir, Ph.D.Canale Communications for XencorTel: 619-849-5377heidi@canalecomm.com Boehringer Ingelheim GmbHHeidrun ThomaCorporate communicationsBoehringer Ingelheim GmbH55216 Ingelheim/GermanyPhone: +49/6132 77 3966 Twitter: www.twitter.com/boehringerMore information:bio-cmo@boehringer-ingelheim.com  102Exhibit 99(d)(2)
COOPERATION AGREEMENT
This Cooperation Agreement, dated as of 02 June, 2015, between Otkritie Investments Cyprus Limited, a company incorporated under the laws of
the Republic of Cyprus with registration number HE 301373, whose registered address is at Angelou Vlachou, 4A, 6052, Larnaca, Cyprus (“ OICL”
and together with its Affiliates, “ Otkritie”) and QIWI plc, a public company limited by shares incorporated under the laws of the Republic of Cyprus
with registration number HE 193010, whose registered office is at Kennedy 12, Kennedy Business Centre, 2nd floor, P.C. 1087, Nicosia, Cyprus
(“QIWI”, and, together with its Affiliates, “ QIWI Group”).
RECITALS
 
(A) On 14 May 2015, OICL, Otkritie Holding JSC and QIWI entered into a deed of subscription (the “Deed of Subscription ”), pursuant to which
OICL will acquire 5,593,041 class B ordinary shares in QIWI (the “Subscription Shares ”).
 
(B) Under the terms of the Deed of Subscription, QIWI will acquire a one hundred (100) percent ownership interest in the charter capital of
CIHRUS Limited Liability Company 
  
  (“CIHRUS”), a limited liability
company duly existing and incorporated under the laws of the Russian Federation.
 
(C) CIHRUS is the parent company of Rapida Ltd 
  
  , a
company duly existing and incorporated under the laws of the Russian Federation under registration number 1037700111679, which QIWI will
acquire as part of the transactions contemplated under the Deed of Subscription (“NKO Rapida” and, together with its Affiliates that are also
being acquired pursuant to the transactions contemplated by the Subscription Agreement, “Rapida”).
 
(D) Following the acquisition of CIHRUS by QIWI and in order to promote their mutual interests, the parties wish to cooperate for their mutual
benefit in the fields of their business, including digital payments, and establish a steering committee in order to analyse and develop potential
areas of cooperation between the Parties.
NOW THEREFORE, in consideration of the mutual agreements and covenants set forth herein, the parties hereto agree as follows:
 
1. Definitions and Interpretation .
 
1.1 Definitions
“Affiliate” means, with respect to any person, any other person directly or indirectly, through one or more intermediaries, Controlling,
Controlled by or under common Control with such person and, in the case of a trust, any trustee or beneficiary (actual or potential) of that
trust and, in the case of an individual, any person connected with him; provided that, for the purposes of this Agreement, neither QIWI nor
any of its subsidiaries is to be regarded as an Affiliate of Otkritie;“Applicable Law(s)” means all laws, regulations, directives, statutes, subordinate legislation, common law and civil codes of any jurisdiction,
all judgments, orders, notices, instructions, decisions and awards of any court or competent authority having jurisdiction over Otkritie or
QIWI, as applicable, or tribunal or in an administrative, regulatory or similar proceeding;
“Business Day ” means a day other than Saturday, Sunday or public holiday in Moscow (Russia); New York (United States) and Nicosia
(Cyprus);
“Committee Member” has the meaning given to it in Clause 3.2;
“Completion 1” has the meaning given to it in the Deed of Subscription;
“Confidential Information” means the existence and contents of this Agreement, the arrangements contemplated by this Agreement and:
 
 (a) any information of whatever nature concerning the business, finance, assets, liabilities, dealings, transactions, know-how, customers,
suppliers, processes or affairs of the other parties and any of their group undertakings from time to time;
 
 (b) any information which is expressly indicated to be confidential in relation to the party disclosing it (or in relation to any of its group
undertakings) from time to time,
which any party may from time to time receive or obtain (verbally or in writing or in disk or electronic form or by any other means) from any
other party as a result of negotiating, entering into, or performing its obligations pursuant to this Agreement;
in each case except to the extent that such information is, has or does become available:
 
 (i) to a party through the public domain other than pursuant to a breach of an obligation of confidentiality in respect thereof by
such party or its Representatives; or
 
 (ii) pursuant to disclosure, in a non-confidential manner, to a party by a source which to the knowledge of such party is not
prohibited to disclose the information by reason of any legal, contractual or fiduciary obligation;
 
2“Control” in relation to an undertaking means the direct or indirect holding or control of: (a) a majority of the voting rights exercisable at
general meetings of the members of that undertaking on all, or substantially all, matters; (b) the right to appoint or remove directors having a
majority of the voting rights exercisable at meetings of the board of directors of that undertaking on all, or substantially all, matters; or (c) the
right (whether pursuant to a contract, understanding or other arrangement) to direct or cause to be directed directly or indirectly a dominant
influence over such other undertaking, and (i) where an undertaking is not a company, references above to directors, general meetings and
members shall be deemed to refer to the equivalent bodies in such undertaking; and (ii) “Controlled” and “Controlling” shall have a
corresponding meaning;
“Dispute” has the meaning given to it in Clause 9.2;
“Effective Time” has the meaning given to it in Clause 6.1;
“LCIA” has the meaning given to it in Clause 9.2;
“LCIA Rules” has the meaning given to it in Clause 9.2;
“NKO Rapida” has the meaning given to it in the Recitals;
“Parties” shall mean OICL and QIWI, together, and each of them a “Party”;
“Representatives ” has the meaning given to it in Clause 5.2;
“Steering Committee” has the meaning given to it in Clause 3.1;
 
1.2 In this Agreement unless the context otherwise requires:
 
 (a) references to a “party” mean a party to this Agreement and includes the successors in title to substantially the whole of its
undertaking;
 
 (b) references to a “person” include a body corporate, an unincorporated association, a trust and a partnership;
 
 
(c) references to any statutory provision, rule or law shall include references to such statutory provision, rule or law as it may, after the date
of this Agreement, from time to time be amended, supplemented or re-enacted and any subordinate legislation made under such
statutory provision;
 
3(d) references to “Clauses” are to clauses of this Agreement; and
 
 (e) words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders.
 
1.3 The headings in this Agreement are inserted for convenience only and shall not affect its interpretation or construction.
 
2. Joint Cooperation to Further Business .
 
2.1 Subject to Applicable Law, fiduciary duties and obligations, the best interests of their respective customers, existing contractual agreements,
business and market conditions, the protection of confidential or competitively sensitive information and commercial determinations as to
appropriate business, product and marketing efforts, each of Otkritie and QIWI Group agree to strategically cooperate with each other in
order to carry out certain joint projects related to certain areas of their respective businesses, including by virtue of establishing the Steering
Committee described further herein.
 
3. Steering Committee.
 
3.1 The Parties shall form a steering committee (the “Steering Committee”), which shall analyse and develop potential areas of strategic
cooperation between the Parties and oversee the Parties’ cooperation in these areas.
 
3.2 The Steering Committee shall consist of three representatives of QIWI Group and three representatives of Otkritie (each, a “ Committee
Member”). The representatives shall include:
 
 (a) at least one representative from Otkritie occupying the position of Chief Executive Officer or the Chairman of the Management Board or
similar within Otkritie Holding JSC, PJSC Khanty-Mansiysk Bank Otkritie or JSC Bank Otkritie Financial Corporation; and
 
 (b) QIWI’s Chief Executive Officer.
Each of Otkritie and QIWI Group shall have the exclusive right to remove and replace any of its designees to the Steering Committee at any
time by notice to the other party.
 
3.3 The Steering Committee shall meet at least once in each month and as otherwise agreed between Committee Member. Such meetings shall take
place in Moscow, in a location agreed by Otkritie and QIWI Group or by telephone.
 
43.4 The presence of four Committee Members, including two representatives of Otkritie and two representatives of QIWI Group, shall constitute
a quorum.
 
3.5 The Steering Committee shall validly act only at a duly convened meeting with the approval of at least four (4) of the Committee Members
present at such meeting. Upon the approval of a proposal by the Steering Committee, the Steering Committee shall present such proposal to
the respective governing body of each Otkritie and of QIWI for approval. For the avoidance of doubt, no decision of the Steering Committee
shall be binding on the Parties unless, and the Parties are only required to act upon any decision of the Steering Committee if and to the
extent that, such decision is properly approved/ratified by the relevant governing bodies of both Otkritie and QIWI.
 
3.6 The Parties agree that the following items are potential areas of joint cooperation to be discussed, among other matters, at Steering Committee
meetings:
 
 (a) Participation of Otkritie as a privileged party in banking projects established by QIWI where QIWI seeks a banking partner;
 
 (b) Subject to Applicable Law, commercial terms for QIWI to provide consumer scoring data it has collected to Otkritie;
 
 (c) Commercial terms for Otkritie to act as settlement bank of NKO Rapida in accordance with Clause 4.1;
 
 (d) Commercial terms relating to the amounts of deposits to be placed by NKO Rapida in Otkritie;
 
 (e) Separation of NKO Rapida’s digital wallet business from the core business of NKO Rapida;
 
 (f) Commercial terms of cooperation of the parties in the areas of pre-paid cards and loyalty programs;
 
 (g) Commercial terms of the use by Otkritie of the NKO Rapida brands owned by QIWI Group; and
 
 (h) Commercial terms of the potential sale of the NKO Rapida’s banking license to Otkritie.
 
3.7 The Parties agree and acknowledge that no agreement has been reached between the Parties with respect to any of the matters referenced in
Clause 3.6, the matters in Clause 3.6 merely reflects potential areas of discussion for the Steering Committee.
 
53.8 Notwithstanding anything to the contrary, nothing in this Agreement shall be deemed or construed as QIWI and Otkritie having reached a
binding agreement in respect of any items listed in Clause 3.6.
 
3.9 The Parties agree and acknowledge that the Steering Committee shall not represent an exclusive forum through which any of the matters set
forth in Clause 3.6 may be discussed between the Parties and that the Parties may reach agreement with respect to any of the matters set forth
in Clause 3.6 or any other matter without Steering Committee approval or action.
 
4. Bank Services.
 
4.1 For two (2) years following the Effective Time, QIWI covenants that at least one half of the total transactions processed by the Contact
money transfer system during such two-year period shall be settled through PJSC Khanty-Mansiysk Bank Otkritie,  provided that  QIWI may
terminate its obligation under this Clause 4.1 at any time, in which case it shall pay to Otkritie a fee equal to the demonstrated costs incurred
by Otkritie for such period starting from 1 September 2014, until the date of termination of QIWI’s obligations under this Clause 4.1 in
connection with (i) the transfer of settlement bank function to PJSC Khanty-Mansiysk Bank Otkritie ; and (ii) supporting the settlement bank
functionality for the Contact money transfer system, provided further that  such fee shall in no event exceed RUB 50 000 000 (fifty million
roubles).
 
5. Confidential Information.
 
5.1 Except as provided in clause 5.2, no party shall, and each party shall procure that their Representatives shall not, disclose to any third party,
or use or exploit commercially for its or their own purposes, any Confidential Information. The obligations of the parties under this clause 5.1
shall remain in force until the relevant information enters the public domain otherwise than by the default of a party.
 
5.2 The obligations of confidentiality in clause 5.1 do not apply in respect of the disclosing of Confidential Information in the following
circumstances:
 
 (a) in connection with the performance of each party’s obligations hereunder or the enforcement of its rights hereunder;
 
 (b) to its Affiliates and the directors, officers, employees, agents, and professional advisers or its and/or their Affiliates (the
“Representatives ”) on a need to know basis to the extent reasonably required for purposes connected with this Agreement;
 
6(c) pursuant to any listing agreement with or the rules and regulations of any recognised security exchange on which securities of such
Party or any of its Affiliates are listed and/or traded;
 
 (d) as required by Applicable Law,
provided in each case set out in Clauses 5.2(a) and 5.2(b) above, the Party disclosing the same shall take all reasonable steps to preserve the
confidentiality thereof and to ensure that such information shall be used only for the purposes for which it has been disclosed.
 
5.3 If a Party becomes required, in circumstances contemplated by Clauses 5.2(c) or 5.2(d), to disclose any information, such party shall (save to
the extent prohibited by such rules and regulations or Applicable Law) give to the other party such notice as is practical in the circumstances
of such disclosure and shall co-operate with the other party, having due regard to the other party’s views, and take such steps as the other
party may reasonably require in order to enable it to mitigate the effects of, or avoid the requirements for, any such disclosure.
 
5.4 In the event that any Affiliate of any party who has received Confidential Information is requested in any Litigation to disclose Confidential
Information, that party shall give each other party prompt written notice of such request (if permitted by Applicable Law) so that each other
party may seek an appropriate protective order. If in the absence of a protective order a party’s Affiliate is compelled to disclose Confidential
Information, such Representative may disclose such portion of the Confidential Information that in the opinion of the disclosing party’s
counsel such Affiliate is compelled to disclose without liability under this Agreement; provided, however, that the disclosing party shall give
the other party written notice of the Confidential Information to be disclosed as far in advance of its disclosure as is practicable (if permitted
by Applicable Law) and shall use reasonable efforts to obtain assurances that confidential treatment will be accorded to such Confidential
Information.
In this Clause 5.4, “Litigation” means any action, cause of action, claim, demand, suit, proceeding, citation, summons, subpoena, inquiry or
investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or threatened, by or before any court, tribunal,
arbitrator, expert or other governmental authority.
 
6. Effectiveness and Termination.
 
6.1 This Clause 6 and Clauses 1, 5, 7 through 9 (inclusive) come into force and effect upon the execution of this Agreement by the Parties. The
remaining provisions of this Agreement shall be effective only upon Completion 1 (the “ Effective Time”).
 
76.2 Unless otherwise mutual agreed between the Parties, this Agreement shall remain in effect until the earlier of the below events occur:
 
 (a) The fifth (5th ) anniversary of this Agreement; and
 
 (b) Otkritie ceasing to own more than 2,237,216 class B shares or American depositary shares of QIWI.
 
6.3 Notwithstanding Clause 6.2, this Clause 6 and Clauses 1, 5, 7 through 9 (inclusive) shall survive any termination of this Agreement.
 
7. Miscellaneous .
 
7.1 Nothing in this Agreement or in any document referred to in it shall constitute any of the Parties a partner of any other, nor shall the
execution, completion and implementation of this Agreement confer on any Party any power to bind or impose any obligations to any third
parties on any other Party or to pledge the credit of any other Party.
 
7.2 If any provision or part of this Agreement is void or unenforceable due to any Applicable Law, it shall be deemed to be deleted and the
remaining provisions of this Agreement shall continue in full force and effect. Each party shall use its reasonable endeavours to replace the
invalid provision in that respect with a valid and enforceable substitute provision the effect of which is as close (commercially and legally) to
its intended effect as possible.
 
7.3 No variation of this Agreement (or any of the documents referred to in it) shall be valid unless it is in writing (which, for this purpose, does
not include email) and signed by or on behalf of each of the parties. The expression “variation” includes any variation, supplement, deletion
or replacement however effected.
 
7.4 This Agreement may be executed in any number of counterparts and by the parties to it on separate counterparts, each of which when
executed and delivered shall be an original, but all the counterparts together constitute one instrument.
 
7.5 No Party shall assign (whether absolutely or by way of security and whether in whole or in part), transfer, mortgage, charge or otherwise
dispose in any manner whatsoever of the benefit of this Agreement or sub-contract or delegate in any manner whatsoever its performance
under this Agreement.
 
7.6 No term of this Agreement is enforceable under the Contracts (Rights of Third Parties) Act 1999 or otherwise by a person who is not a Party
to this Agreement.
 
88. Notices.
 
8.1 A notice (including any approval, consent or other communication) in connection with this Agreement and the documents referred to in it or
with any arbitration under this Agreement:
 
 (a) must be in writing in English;
 
 (b) for the avoidance of doubt, must not be sent by electronic mail;
 
 
(c) must be delivered by hand, fax or courier using an internationally recognised courier company to the address specified below in relation
to the Party to whom the notice is addressed, and marked for the attention of the person so specified, or to such other address or fax
number or marked for the attention of such other person, as the relevant party may from time to time specify by notice given in
accordance with this clause.
The relevant details of each party at the date of this Agreement are:
 
OICL
Address: 2\4 Letnikovskaya street, 115114, Moscow, Russia
Fax number:  
Attention: Evgeny Dankevich
Ruben Aganbegyan\Konstantin Olefir
 
and
QIWI
Address: Kennedy 12, Kennedy Business Centre, 2nd floor, P.C. 1087, Nicosia, Cyprus
Fax number:  
Attention: Mr. Philios Yiangou / Mr. Sergey Solonin
 
8.2 In the absence of evidence of earlier receipt, any notice shall take effect from the time that it is deemed to be received in accordance with
Clause 8.3.
 
98.3 A notice is deemed to be received:
 
 (a) in the case of a notice delivered by hand or courier at the address of the addressee given above, upon delivery at that address; and
 
 (b) in the case of a notice delivered by fax, at the time of transmission (provided that a transmission report from the machine from which the
fax was sent is received by the sender which indicates that the fax was sent in its entirety to the fax number of the recipient).
 
8.4 A notice received, or deemed to be received, on a day which is not a business day in the place of receipt, or after 5pm on any business day in
the place of receipt, shall be deemed to have been received on the next following business day in the place of receipt (and for the purposes of
this clause, a business day in the place of receipt shall mean a day (other than a Saturday or Sunday) on which banks are open for general
business in that place).
 
8.5 The parties agree that the provisions of this clause shall not apply to the service of any writ, summons, order, judgment or other document
relating to or in connection with any legal proceedings and service of any request for arbitration or other document in arbitral proceedings
commenced pursuant to this Agreement shall be at the address given in Clause 9.
 
9. Governing Law and Dispute Resolution .
 
9.1 This Agreement and any dispute, controversy or claim arising out of or in connection with it or its subject matter, existence, negotiation,
validity, termination, breach or enforceability (including non-contractual disputes or claims) shall be governed by and construed in
accordance with the laws of England and Wales.
 
9.2 Any dispute, controversy or claim arising out of or in connection with this Agreement or its subject matter, including any question regarding
its existence, negotiation, termination, breach, validity or enforceability (including any non-contractual disputes or claims) (“ Dispute”) shall
be referred to, and finally resolved by, arbitration under the Rules of Arbitration (the “ LCIA Rules”) of the London Court of International
Arbitration (the “ LCIA”) which rules are deemed to be incorporated by reference into this Clause 9.2.
 
9.3 There shall be three (3) arbitrators appointed in accordance with the LCIA Rules. The claimant party and the respondent party shall each
nominate one (1) arbitrator. Where either party fails to nominate an arbitrator within the time provided by the LCIA Rules, that arbitrator shall
be appointed by the LCIA. The third arbitrator, who shall act as the chairman of the tribunal, shall be nominated by agreement of the first two
(2) party-appointed arbitrators within fifteen (15) Business Days of the confirmation of the appointment of the second arbitrator, or
 
10in default of such agreement, appointed by the LCIA. Notwithstanding anything to the contrary in the LCIA Rules, in agreeing upon a third
arbitrator, the two arbitrators may communicate directly with each other and their respective appointing parties. Each party expressly agrees
and consents to this process for nominating and appointing the arbitrators and, in the event that this Clause 9.3 operates to exclude a party’s
right to choose its own arbitrator, irrevocably and unconditionally waives any right to do so.
 
9.4 The seat, or legal place, of arbitration shall be London, England.
 
9.5 The language of the arbitration proceedings shall be English.
 
9.6 The award of the arbitrators shall be final and binding on the parties, their successors and assigns.
 
9.7 Nothing in Clauses 9.2 to 9.6 shall limit the rights of the parties to bring proceedings against another party in any court of competent
jurisdiction in order to:
 
 (a) enforce an arbitration award rendered in accordance with Clauses 9.2 to 9.6; or
 
 (b) make a claim for interim or injunctive relief.
 
9.8 Each party agrees that if more than one arbitration is commenced under this Agreement or any document related to this Agreement, and any
party contends that two or more arbitrations are substantially related and that the issues should be heard in one proceeding, the arbitral
tribunal appointed in such proceedings as have been filed with the LCIA first in time shall have the discretion to determine whether, in the
interests of justice and efficiency and taking into account the stage of the proceedings and all other relevant circumstances, the proceedings
should be consolidated before that arbitral tribunal and any party should be joined to such proceedings.
 
9.9 Each party agrees that it may be joined as an additional party to an arbitration involving other parties under this Agreement or any document
related to this Agreement. Any joined party (even if it chooses not to participate in the arbitral proceedings) shall be bound by any award
rendered by the arbitral tribunal.
 
9.10 The law of this arbitration agreement shall be the law of England and Wales.
 
9.11 QIWI and OICL hereby irrevocably undertake to at all times maintain an agent with an address in England and Wales for service of process
and any other documents in proceedings in England or any other proceedings in connection with
 
11this Agreement, and to keep the other party advised of the identity and address of such agent, for so long as it has any obligations under this
Agreement. Any claim form, request for arbitration, judgement or any other notice of legal process whatsoever shall be sufficiently served on:
 
 (a) QIWI, if delivered to:
 
 (i) QIWI plc
c/o Law Debenture Corporate Services Limited
Fifth Floor
100 Wood Street
London EC2V 7EX
United Kingdom
or
 
 (ii) if delivered to the last address notified to OICL as an address for service under this Clause 9.
 
 (b) OICL, if delivered to:
 
 (i) Otkritie Capital International Limited
12 Floor,
88 Wood Street
London EC2V 7RS
United Kingdom
(or to any other registered office in England and Wales of Otkritie Capital International Limited from time to time); or
 
 (ii) if delivered to the last address notified to QIWI as an address for service under this Clause 9.
This Agreement has been duly executed by the parties (or their duly authorised representatives) on the date specified at the beginning of this
Agreement.
[Signature page follows ] 
 
12EXECUTED and DELIVERED )
as a DEED for and on behalf of )
QIWI PLC )
 
Signed in the presence of:
 
Witness Signature
 
Witness Name
 
Witness Occupation
 
Witness Address
 
13EXECUTED and DELIVERED )
as a DEED for and on behalf of )
OTKRITIE INVESTMENTS CYPRUS LIMITED )
 
 
Signed in the presence of:
 
Witness Signature
 
Witness Name
 
Witness Occupation
 
Witness Address
 
14Exhibit 10.1
Redactions with respect to certain portions hereof denoted with “***”
COLLABORATION AGREEMENT
This Collaboration Agreement (the “Agreement ”) is made as of April 14 th, 2020 (the “Effective Date ”) by and between
Anixa Biosciences, Inc., a Delaware corporation, located at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118, U.S.A.
(“Anixa”), and OntoChem GmbH, a German limited liability company, located at Blücherstr. 24, D-06120 Halle (Saale), Germany
(“OntoChem”). Anixa and OntoChem are referred to herein individually as a “Party” and collectively as the “Parties.”
WHEREAS, the Parties wish to collaborate in the discovery and development of novel drug candidates for the treatment of
COVID-19 in accordance with the terms and conditions of this Agreement.
NOW, THEREFORE, in consideration of the premises and the mutual promises set forth in this Agreement, and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
1. Defined Terms.
1.1 “Affiliate” means, with respect to a Party, any entity directly or indirectly controlled by, controlling or under
common control with such Party. For purposes of this definition, “control” means (a) ownership of fifty percent (50%) (or such lesser
percentage which is the maximum allowed to be owned by a foreign entity or investor in a particular jurisdiction) or more of the
outstanding voting stock or other ownership interest of an entity, or (b) possession of the power to (i) elect, appoint, direct or remove
fifty percent (50%) or more of the members of the board of directors or other governing body of an entity or (ii) otherwise direct or
cause the direction of the management or policies of an entity by contract or otherwise.
1.2 “Hit Compound” means any chemical entity that is determined in performing the Research Plan to meet the Hit
Criteria.
1.3 “Hit Criteria” means the criteria identified as “Hit Criteria” as set forth in the Research Plan.
1.4 “Invention” means any invention, know-how, data, discovery or proprietary information, whether or not
patentable, that is made or generated solely by the Representatives of Anixa or OntoChem or jointly by the Representatives of Anixa
and OntoChem in performing the Research Plan, including all intellectual property rights in the foregoing.
1.5 “Representative ” means, with respect to a Party, an officer, director, employee, agent or permitted
subcontractor of such Party.
1.6 “Research Plan ” means the research plan attached hereto as Exhibit A.
11.7 “SAR” means the relationship between the chemical or three-dimensional structure of a compound and its
biological activity, and includes the determination of the chemical groups responsible for evoking a target biological effect.
1.8 “Target” means: (a) any protease of any coronavirus, including Mpro; (b) the Nsp15-pRB ribonuclease protein-
protein interaction; (c) all mutants and variants of any molecule or component referenced in clauses (a) or (b); and (d) all truncated
forms (including fragments) of any molecule or component referenced in clauses (a) or (b) or mutant or variant referenced in clause
(c).
1.9 “Variant” means, with respect to any Hit Compound: (a) all compounds within the genus of compounds to which
such Hit Compound would belong under United States patent laws as referenced in the Selection Notice (as defined below); and (b)
any base form, metabolite, ester, salt form, racemate, stereoisomer, polymorph, hydrate, anhydride or solvate of such Hit Compound or
any other compound described in clause (a) (in the case of this clause (b), without regard to whether such compound is referenced in
the Selection Notice).
2. Research Program.
2.1 Performance. The Parties will diligently perform their respective activities set forth in the Research Plan (such
activities, collectively, the “Research Program”) in accordance with the timelines set forth therein, with the objective of identifying
Hit Compounds and Lead Scaffolds that modulate the applicable Target. Without limiting the foregoing, OntoChem will (a) provide all
deliverables set forth in the Research Plan (each, a “Deliverable ”) and (b) obtain any authorizations, approvals and licenses required
for performance of the Research Plan. If any terms set forth in the Research Plan conflict with the terms set forth in this Agreement,
the terms of this Agreement will control unless expressly indicated to the contrary in the Research Plan. The Research Plan may not
be amended without the prior written consent of both Parties. If, from time to time, the Parties desire to expand the scope of the
Research Program, then they will negotiate in good faith a potential amendment of the Research Plan in regard to such expanded
scope, on commercially reasonable terms, but neither Party will be obligated to enter into any such amendment.
2.2 Weekly Updates. OntoChem will provide Anixa with weekly (or more frequently as requested) updates regarding
its progress under the Research Program via teleconference, videoconference or e-mail, and the Parties will make appropriate
personnel available in a timely manner to discuss and provide feedback in regard to such updates.
2.3 Delivery of Data . In conjunction with each weekly update described in Section  2.2, OntoChem will deliver to
Anixa all data generated under the Research Plan since the preceding update. In addition, Anixa will have the right to reasonably
request additional information relating to such data, and OntoChem will respond to such requests promptly with any such additional
information in its possession or control, provided that, for clarity, OntoChem will not be required to perform any new or additional
research in order to generate any such additional information.
22.4 Selection of Lead Scaffolds. Within one year following completion of all activities under the Research Plan (the
“Selection Deadline ”), Anixa, in good faith consultation with OntoChem, will have the right to select up to two hundred (200) Hit
Compounds (each, a “Selected Hit Compound ”), by providing OntoChem with written notice of such Selected Hit Compound(s)
(the “Selection Notice ”), and each Selected Hit Compound, along with all Variants of such Selected Hit Compound referenced in
the Selection Notice, is hereby designated as a “Lead Scaffold” under this Agreement. Commencing upon selection of a Selected Hit
Compound, Anixa (itself and through its Affiliates and designees) will have sole authority over and control of the further development,
manufacture, and commercialization of the corresponding Lead Scaffold and any product candidate or product incorporating a
compound from such Lead Scaffold. Following the Selection Deadline, Anixa will have no further rights with respect to any Hit
Compound that is not a Selected Hit Compound or included within a Lead Scaffold (each, a “Rejected Hit Compound ”), provided
that, during the period of two (2) years following the Selection Deadline, neither OntoChem nor any of its Affiliates will use or
disclose to any third party any Rejected Hit Compound or any Variant thereof, including the identity, structure or SAR information of
any such compound, for application as anti-viral agents or protease inhibitors, for purposes of modulating any Target or for treatment
of virus-related conditions. In case OntoChem finds a novel and unexpected antiviral use of those Rejected Hit Compounds during this
2-years period, it will notify Anixa about these findings and Anixa has the right of first negotiation during a period of 6 months after
this notification. If Anixa decides to not license those uses or compounds for this novel antiviral use, OntoChem is free to develop
those molecules further as its own intellectual property without any further restrictions.
2.5 Subcontractors. OntoChem may engage one or more subcontractors to perform its activities under the Research
Plan with the prior written approval of Anixa and provided that, with respect to any such subcontractor, OntoChem will (a) be
responsible and liable for the performance of such subcontractor and (b) enter into a written agreement (i) consistent with terms and
conditions of this Agreement, including with respect to confidentiality and intellectual property, and (ii) prohibiting such subcontractor
from further subcontracting. For clarity, vendors where commercial building blocks or compounds will be purchased are nor regarded
as subcontractors.
2.6 Target Exclusivity. During the term of this Agreement, except in the performance of its obligations or exercise of
its rights under this Agreement, neither OntoChem nor any of its Affiliates will discover, research, develop, manufacture or
commercialize any compound or product directed to any Target, either independently or for or in collaboration with a third party
(including the grant of a license to any third party), or have any of the foregoing activities performed on behalf of OntoChem or any of
its Affiliates by a third party. For clarity, the foregoing includes the screening (including via computational methods) of any compound
library or virtual compound library against any Target.
2.7 Records. Each Party will maintain complete and accurate records of all activities performed by or on behalf of
such Party under the Research Program and all Inventions made or generated by or on behalf of such Party in the performance of
the Research Program. Such records will be in sufficient detail and in good scientific manner appropriate for patent and regulatory
purposes. Each Party will provide the other Party with the right to inspect such records, and upon request will provide copies of all
such records, to the extent reasonably required for the exercise or performance of such other Party’s rights or obligations under this
Agreement, provided that any information disclosed under this Section 2.7 will be subject to the terms and conditions of Section 5.
Each Party will retain such records for at least three (3) years following expiration or termination of this Agreement or such longer
period as may be required by applicable law or regulation.
32.8 Debarment. Each Party hereby represents and warrants to the other Party that neither it nor any of its Affiliates
or personnel has been debarred under any health care laws or regulations and that, to its knowledge, no investigations, claims or
proceedings with respect to debarment are pending or threatened against such Party or any of its Affiliates or personnel. Neither
Party nor any of its Affiliates will use in any capacity, in connection with the Research Program, any person or entity who has been
debarred. Each Party agrees and undertakes to promptly notify the other Party if such Party or any of its Affiliates or personnel
becomes debarred or proceedings have been initiated against any of them with respect to debarment, whether such debarment or
initiation of proceedings occurs during or after the term of this Agreement.
3. Financial Terms.
3.1 Research Program Payments. In consideration for OntoChem’s performance of its activities under the Research
Plan, Anixa will:
(a) pay OntoChem 100,002 Euros in six (6) equal installments as follows: (i) 16,667 Euros within five (5) days
after the Effective Date; and (ii) five (5) installments in the amount of 16,667 Euros on each one-month anniversary of the Effective
Date, except that the last such payment will be due within thirty (30) days after completion of all activities under the Research Plan;
and
(b) reimburse OntoChem for its out-of-pocket expenses incurred in performing the Research Plan on a pass-
through basis without mark-up, within thirty (30) days after delivery of an invoice therefore (including reasonable supporting
documentation), provided that Anixa has approved such expenses in advance and in writing (including in regard to the selection of
specific Hit Compounds to be synthesized and analyzed in biological assays). It is estimated that OntoChem’s out-of-pocket expenses
under the Research Plan will include 110,000 Euros payable to Tube Pharmaceuticals GmbH as a subcontractor of OntoChem ,
subject to Section 2.5.
(c) High-throughput screening compounds
OntoChem will forward a commercial proposal to acquire these compounds at the sole discretion of Anixa.
Both parties will agree on payment conditions.
(d) Extra custom synthesis
OntoChem will forward a commercial proposal to have synthesized these compounds at the sole discretion of
Anixa. Both parties will agree on payment conditions.
(e) Biological testing
OntoChem will forward a commercial proposal to have biologically test these compounds at the sole
discretion of Anixa. Both parties will agree on payment conditions.
3.2 Lead Scaffold Payments. For each Lead Scaffold selected by Anixa, Anixa will pay OntoChem an annual fee of
10,000 U.S. Dollars, payable within thirty (30) days following each anniversary of the date of the Selection Notice, until five (5) years
after the first commercial sale of the first product incorporating a compound from such Lead Scaffold, subject to Section 4.3 with
respect to any Terminated Scaffold (as defined below).
3.3 Milestone Payment. Anixa will pay OntoChem a one-time milestone payment of 300,000 U.S. Dollars within thirty
(30) days following the dosing of the first patient in the first human clinical trial for the first product incorporating a compound from a
Lead Scaffold.
43.4 Payment Terms. Payments to OntoChem will be made by check or by wire transfer of immediately available
funds to such bank account as designated in writing by OntoChem from time to time. Taxes (and any penalties and interest thereon)
imposed on any payment made by Anixa to OntoChem will be the responsibility of OntoChem. The fees for the respective bank
transfers will be borne by Anixa.
3.5 Financial Records. OntoChem will maintain complete and accurate books and accounting records related to all
out-of-pocket expenses incurred in performing the Research Plan. These records will be available for inspection during regular
business hours upon reasonable notice by Anixa, or its duly authorized representative, at Anixa’s expense, for three (3) years
following the end of the calendar year in which such expenses are invoiced. If it is determined that Anixa has overpaid for any
expenses passed through by OntoChem under this Agreement, OntoChem will promptly reimburse Anixa for the amount of such
overpayment and, if such overpayment represents more than five percent (5%) of the corresponding amount due, OntoChem will pay
Anixa’s reasonable fees and expenses incurred in connection with such inspection.
4. Term and Termination.
4.1 Term. Unless earlier terminated in accordance with Section 4.2 or 4.3, this Agreement will be in effect from the
Effective Date until completion of the Research Program.
4.2 Termination by Anixa. This Agreement may be terminated by Anixa, without cause, upon at least thirty (30) days
written notice to OntoChem.
4.3 Termination of Lead Scaffolds. For each Lead Scaffold, if (a) neither Anixa nor any of its Affiliates, licensees or
assignees has dosed the first patient in a human clinical trial for a product incorporating a compound from such Lead Scaffold by the
fifth (5th) anniversary of the date of the Selection Notice, or (b) Anixa earlier provides written notice of termination of such Lead
Scaffold referencing this Section 4.3, then such Lead Scaffold (each, a “Terminated Scaffold”) will thereupon cease to be a Lead
Scaffold under this Agreement and thereafter, notwithstanding anything to the contrary in this Agreement: (i) Anixa will promptly
assign to OntoChem all right, title and interest in and to any patents and patent applications owned by Anixa that claim such
Terminated Scaffold (including the composition, use or manufacture thereof) and, following such assignment, OntoChem will
exclusively control the filing, prosecution, maintenance and enforcement of such patents and patent applications; (ii) the identity,
structure and SAR information of such Terminated Scaffold will be deemed to be the Confidential Information of OntoChem; (iii)
Anixa will not owe any further annual fees under Section 3.2 for such Terminated Scaffold; and (iv) this Agreement will otherwise
remain in full force and effect.
4.4 Termination for Cause. This Agreement may be terminated by either Party for material breach by the other Party,
provided that the terminating Party has given the breaching Party written notice of the breach and at least sixty (60) days to cure the
breach prior to the effective date of termination.
4.5 Effects of Termination. Promptly following expiration or termination of this Agreement, OntoChem will provide
Anixa with an invoice (including reasonable supporting documentation) for any pre-approved out-of-pocket expenses (including non-
cancellable commitments) incurred by OntoChem in performing the Research Plan and not yet reimbursed by Anixa, and Anixa will
pay such invoice within thirty (30) days after receipt thereof. In addition, if this Agreement is terminated prior to completion of the
Research Program, OntoChem will promptly furnish to Anixa any Deliverable or other work product generated to date and not
previously provided to Anixa, including work in process.
54.6 Survival. Expiration or termination of this Agreement will not affect the rights and obligations of the Parties that
accrued prior to the effective date of such expiration or termination. The following provisions will remain in effect following expiration
or termination of this Agreement and the Parties will continue to be bound thereby: Sections 2.4 (last three sentences), 2.7, 2.8 (last
sentence only), 3.2, 3.3, 3.4, 3.5, 4.5, 4.6, 5, 6, 8 and 9.
5. Confidentiality.
5.1 Definition. “Confidential Information” means any information disclosed (directly or indirectly) by a Party (in
such capacity, “Discloser ”) to the other Party (in such capacity, “Recipient ”) in connection with this Agreement whether in written,
graphic, electronic, tangible or any other form. Confidential Information will not, however, include any information that: (a) was
publicly known or generally available to the public prior to the time of disclosure by Discloser to Recipient; (b) becomes publicly
known or generally available to the public after disclosure by Discloser to Recipient through no wrongful action or inaction of
Recipient; (c) is in the rightful possession of Recipient without confidentiality obligations at the time of disclosure by Discloser to
Recipient as shown by Recipient’s then-contemporaneous written files and records kept in the ordinary course of business; (d) is
obtained by Recipient from a third party without an accompanying duty of confidentiality and without (to Recipient’s knowledge) a
breach of such third party’s obligations of confidentiality; or (e) is independently developed by Recipient without use of or reference to
Discloser’s Confidential Information. Notwithstanding anything to the contrary in this Agreement, except as expressly provided in
Section 4.3 with respect to a Terminated Scaffold, the identity, structure and SAR information of: (i) the Hit Compounds will be
deemed to be the Confidential Information of both Parties until the Selection Deadline, provided that, during such period, Anixa (itself
or through one or more third party service providers on its behalf under a written agreement consistent with terms and conditions of
this Agreement, including with respect to confidentiality and intellectual property) may perform biological assays and other analyses to
evaluate the Hit Compounds solely for purposes of selecting Lead Scaffolds pursuant to Section 2.4; (ii) the Lead Scaffolds will be
deemed to be Anixa’s Confidential Information commencing upon the date of the Selection Notice; (iii) the Rejected Hit Compounds
will be deemed to be OntoChem’s Confidential Information commencing upon the date of the Selection Notice, subject to the last
sentence of Section 2.4.
5.2 Non-Use and Non-Disclosure. Neither Party will use any Confidential Information of the other Party for any
purpose except as reasonably necessary to fulfill its obligations or exercise its rights under this Agreement. Neither Party will disclose
any Confidential Information of the other Party nor permit any such Confidential Information to be disclosed, either directly or
indirectly, to any third party or its personnel without the other Party’s prior written consent, except as expressly permitted hereunder.
Each Party may disclose Confidential Information of the other Party to its Representatives who are required to have the information
in order for such Party to fulfill its obligations or exercise its rights under this Agreement, provided that such Representatives are
subject to legally binding non-use and non-disclosure obligations consistent with this Agreement, prior to any disclosure of Confidential
Information to such Representatives. If Recipient becomes legally compelled to disclose any Confidential Information of Discloser,
Recipient will provide Discloser prompt written notice of such disclosure obligation, if legally permissible, and upon request will
reasonably assist Discloser in seeking a protective order or other appropriate remedy. If Discloser waives Recipient’s compliance
with this Agreement or fails to obtain a protective order or other appropriate remedy, Recipient will furnish only that portion of the
Confidential Information that is legally required to be disclosed, provided that any Confidential Information so disclosed will maintain
its confidentiality protection for all purposes other than such legally compelled disclosure.
65.3 Maintenance of Confidentiality. Recipient will take commercially reasonable measures to protect the secrecy of
and avoid disclosure and unauthorized use of the Confidential Information of Discloser. Without limiting the foregoing, Recipient will
take at least those measures that it employs to protect its own confidential information of a similar nature. Recipient will promptly
notify Discloser in writing of any unauthorized use or disclosure, or suspected unauthorized use or disclosure, of Discloser’s
Confidential Information of which Recipient becomes aware.
5.4 Confidential Terms. Except as otherwise required by applicable law or regulation, neither Party will disclose the
existence or terms of this Agreement to any third party without the prior written consent of the other Party, except that (a) each Party
may disclose this Agreement or its terms to its advisors and to existing and potential investors, acquirers, lenders and, in the case of
Anixa, licensees on a reasonable need-to-know basis under circumstances that reasonably ensure the confidentiality thereof, and (b)
Anixa may issue press releases, make investor and other public presentations and post content on its website from time to time
regarding the existence and terms of this Agreement and progress regarding the development, manufacture and commercialization of
Lead Scaffolds (including the identity of any permitted subcontractors under this Agreement), to the extent deemed appropriate for
purposes of investor relations in its capacity as a publicly traded company and compliance with securities laws and regulations.
5.5 Equitable Relief. Recipient agrees that any violation or threatened violation of this Article 5 may cause irreparable
injury to Discloser, entitling Discloser to seek to obtain injunctive relief in addition to all legal remedies without showing or proving any
actual damage and without any bond required to be posted.
5.6 Return of Confidential Information. Upon expiration or termination of this Agreement, or upon written request,
each Party will promptly return to the other Party, or upon written request of such other Party destroy, all materials containing such
other Party’s Confidential Information, provided, however, that the Recipient may retain in confidence (a) one archival copy of the
Confidential Information of the Discloser in its legal files solely to permit the Recipient to determine compliance with this Agreement
and (b) any portion of the Confidential Information of the Discloser which the Recipient is required by applicable law or regulation to
retain. Notwithstanding the return or destruction of the materials described above, the Parties will continue to be subject to the terms
of this Section 5.
6. Intellectual Property.
6.1 Background Intellectual Property . All inventions, know-how, data, discoveries and proprietary information,
including all intellectual property rights in the foregoing, owned or controlled by a Party as of immediately prior to the Effective Date
are and will remain the sole property of such Party.
6.2 Inventions Owned by OntoChem. OntoChem will own, and Anixa hereby assigns to OntoChem, all right, title and
interest in and to all Inventions directed to (a) any methods of generating or screening compound libraries and (b) the Rejected Hit
Compounds (including the composition, use or manufacture thereof), in the case of this clause (b), effective as of the Selection
Deadline (collectively (clauses (a) and (b)), “OntoChem Inventions ”). As between the Parties, OntoChem will exclusively control
the filing, prosecution, maintenance and enforcement of any patents and patent applications claiming OntoChem Inventions.
76.3 Inventions Owned by Anixa. Anixa will own, and OntoChem hereby assigns to Anixa, all right, title and interest in
and to all Inventions other than OntoChem Inventions, including, for clarity, Inventions directed to the Lead Scaffold(s) (including the
composition, use or manufacture thereof) (collectively, “Anixa Inventions ”). As between the Parties, Anixa will exclusively control
the filing, prosecution, maintenance and enforcement of any patents and patent applications claiming Anixa Inventions.
6.4 License Grant . OntoChem hereby grants to Anixa a non-exclusive, fully paid-up, royalty-free, perpetual,
irrevocable, transferable, worldwide license (with the right to grant and authorize sublicenses through multiple tiers) under any patents
which OntoChem or any of its Affiliates own or control during the term of this Agreement, to make, have made, use, sell, offer for
sale and import the Lead Scaffold(s) and products that incorporate compounds from the Lead Scaffold(s). OntoChem will not
incorporate any invention, discovery or other proprietary information owned by any third party into any Anixa Inventions or
Deliverables without Anixa’s prior written consent.
6.5 Invention Disclosure and Implementation. Each Party will notify the other Party promptly in writing of each
Invention made or generated by such Party. The determination of inventorship with respect to all Inventions will be made in
accordance with United States patent law. Each Party will assign, and does hereby assign, to the other Party rights with respect to the
applicable Inventions as necessary to achieve ownership as provided in Sections 6.2 and 6.3. Each assigning Party will execute and
deliver all documents and instruments reasonably requested by the other Party to evidence or record such assignment or to file for,
perfect or enforce the assigned rights. Each assigning Party will make its relevant Representatives (and their assignments and
signatures on such documents and instruments) reasonably available to the other Party for assistance in accordance with this Section
6.5 at no charge. However, out of pocket expenses such as travel or communication costs shall be reimbursed. Each Party will have
the sole right to file and prosecute patent applications claiming any Inventions of which such Party is the sole owner pursuant to this
Agreement without the consent of the other Party, and such other Party will provide, and will cause its Representatives to provide,
reasonable cooperation and assistance with such filing and prosecution upon request. To the extent OntoChem is obligated by reason
of mandatory provisions of the Gesetz über Arbeitnehmererfindungen (ArbNErfG) (German law covering employee inventions) to
make payments to its employees, OntoChem will be solely responsible, and indemnify Anixa, for any and all such payments to
OntoChem’s employees.
6.6 No Implied Rights. Except as otherwise expressly provided herein, nothing in this Agreement is intended to grant
to either Party any rights under any intellectual property right of the other Party.
7. Representations and Warranties.
7.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party that: (a) it
is duly organized, validly existing, and in good standing under the laws and regulations of the jurisdiction in which it is organized; (b) it
has the requisite power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder; (c) it
has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its
obligations hereunder; (d) this Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and
binding obligation of such Party, enforceable against such Party in accordance with its terms; and (e) the execution, delivery and
performance of this Agreement by it do not conflict with any agreement, instrument or understanding, oral or written, to which it is a
party, or to which it is bound, and it will not enter into any agreement, instrument or understanding, oral or written, that conflicts with
the rights and obligations of this Agreement during the term of this Agreement.
87.2 Additional Representations and Warranties of OntoChem. OntoChem hereby further represents and warrants to
Anixa that: (a) to OntoChem’s knowledge, OntoChem’s performance of its activities under the Research Plan does not infringe or
constitute misappropriation of the intellectual property rights of any third party; (b) no licenses, permissions or releases from any third
party are necessary for OntoChem’s performance of its activities under the Research Plan; (c) OntoChem has obtained rights to use
any third-party compound libraries and software referenced in the Research Plan under terms and conditions consistent with this
Agreement; and (d) OntoChem’s performance of its activities under the Research Plan will not result in any third party acquiring any
right, title or interest in or to any Anixa Invention or Deliverable.
7.3 Mutual Covenants. Each Party hereby covenants that: (a) all Representatives of such Party who participate in the
performance of the activities contemplated by this Agreement will be subject to written obligations regarding the treatment of
Confidential Information and the assignment of Inventions that are consistent with such Party’s obligations under this Agreement, as
of the commencement of such activities by such Representatives; and (b) such Party will comply with applicable laws and regulations
in connection its performance of this Agreement.
8. Indemnification and Insurance.
8.1 Indemnification by Anixa. Anixa will indemnify, defend and hold harmless OntoChem, its Affiliates and their
respective Representatives from and against any liability, demand, damage, cost or expense (including reasonable attorney’s fees)
arising from any third-party claim, action or proceeding arising from (a) Anixa’s breach of this Agreement or (b) Anixa’s negligence
or willful misconduct in connection with this Agreement, except with respect to any matter for which OntoChem is obligated to
provide indemnification under Section 8.2.
8.2 Indemnification by OntoChem. OntoChem will indemnify, defend and hold harmless Anixa, its Affiliates and their
respective Representatives from and against any liability, demand, damage, cost or expense (including reasonable attorney’s fees)
arising from any third-party claim, action or proceeding arising from (a) OntoChem’s breach of this Agreement or (b) OntoChem’s
negligence or willful misconduct in connection with this Agreement, except with respect to any matter for which Anixa is obligated to
provide indemnification under Section 8.1. Financial reimbursements claimed according to such indemnification shall not exceed
payments received by OntoChem under this contract.
8.3 Indemnification Procedure. A Party (the “Indemnitee ”) that intends to claim indemnification under this Section 8
will promptly notify the other Party (the “ Indemnitor”) in writing of any claim, action or proceeding in respect of which the
Indemnitee intends to claim such indemnification (each a “ Claim”), and the Indemnitor will have the right to control the defense
and/or settlement of such Claim, provided that the Indemnitee will have the right to participate, at its own expense, with counsel of its
own choosing in the defense and/or settlement of such Claim. The Indemnitor will not, without the prior written consent of the
Indemnitee, enter into any settlement or agree to any disposition of the applicable Claim that imposes any conditions or obligations on
the Indemnitee. The failure to deliver written notice to the Indemnitor within a reasonable period of time after the commencement of
any such Claim will not relieve such Indemnitor of any liability to the Indemnitee under this Section 8 except to the extent such failure
is prejudicial to the Indemnitor’s ability to defend such Claim. The Indemnitee and its Representatives, at the Indemnitor’s request and
expense, will provide full information and reasonable assistance to the Indemnitor and its legal representatives with respect to the
applicable Claim subject to indemnification. It is understood that only a Party may claim indemnification under this Section 8 (on its
own behalf or on behalf of its Affiliates or their respective Representatives), and such Party’s Affiliates and their respective
Representatives may not directly claim indemnification hereunder.
98.4 Insurance. Each Party will maintain liability insurance, with reputable and financially secure insurance carriers, at
levels consistent with industry standards based upon such Party’s respective activities and indemnification obligations under this
Agreement. Upon request, each Party will furnish to the other Party certificates issued by the applicable insurance company(ies)
evidencing such insurance.
9. Miscellaneous.
9.1 Relationship of the Parties. The Parties are independent contractors and nothing contained in this Agreement will
be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venturer. Neither Party will
have the power or right to bind or obligate the other Party, nor will either Party hold itself out as having such authority.
9.2 Use of Name . Neither Party will use the name, logo or trademark of the other Party in any advertising, publicity
or other promotional activities without such other Party’s prior written consent, unless such use is reasonably necessary to comply
with applicable laws or regulations and subject to clause (b) of Section 5.4.
9.3 Notices. Any notice required or permitted to be given under this Agreement by either Party will be in writing (in
English) and will be delivered to the applicable Party at its respective address set forth below by personal delivery, e-mail, reputable
international courier or registered or certified mail. Notices will be deemed given on the date received if delivered personally, on the
next business day if sent by e-mail or international courier, or five (5) days after the date postmarked if sent by registered or certified
mail, return receipt requested, postage prepaid.
If to OntoChem: OntoChem GmbH
Blücherstr. 24, D-06120 Halle (Saale)
Germany
Attention: Chief Executive Officer
E-mail: lutz.weber@ontochem.com
If to Anixa: Anixa Biosciences, Inc.
3150 Almaden Expressway, Suite 250
San Jose, CA 95118
U.S.A.
Attention: Chief Executive Officer
E-mail: ak@anixa.com
109.4 Governing Law. This Agreement and the rights and obligations of the Parties hereunder will be governed by the
laws of the State of Delaware without regard to the conflict of laws provisions of any jurisdiction. The Parties agree that the 1980
United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.
9.5 Arbitration. The Parties agree that any dispute arising out of, or in connection with, this Agreement, which cannot
be amicably resolved between the Parties, will be finally settled by binding arbitration under the then current rules of the International
Chamber of Commerce (“ ICC”) by one (1) arbitrator appointed in accordance with ICC rules. Any such arbitration will be
conducted in English in the State of Delaware. The arbitrator may grant injunctive or other relief in such dispute or controversy. The
decision of the arbitrator will be final, conclusive and binding on the Parties. Judgment may be entered on the arbitrator’s decision in
any court of competent jurisdiction. The costs of the arbitration, including administrative and arbitrator’s fees, will be shared equally
by the Parties. Each Party will bear the cost of its own attorneys’ fees and expert witness fees. Notwithstanding anything to the
contrary in this Agreement, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent
jurisdiction in order to prevent immediate and irreparable injury, loss or damage on a provisional basis, pending the selection of the
arbitrator or pending the arbitrator’s determination of the merits of any dispute pursuant to this Section 9.5.
9.6 Severability. If any one or more provisions of this Agreement will be found to be invalid or unenforceable in any
respect, the Parties will negotiate in good faith a valid and enforceable substitute provision that most nearly reflects the original intent
of the Parties, and the validity and enforceability of the remaining provisions of this Agreement will not in any way be affected or
impaired thereby.
9.7 Amendment; Waiver. This Agreement may be amended or modified, and any of the terms of this Agreement may
be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance.
The delay or failure of either Party at any time or times to require performance of any provision will in no manner affect its rights at a
later time to enforce the same. No waiver by either Party of any condition or of the breach of any term contained in this Agreement,
in any one or more instances, will be deemed to be, or considered as, a further or continuing waiver of any such condition or of the
breach of such term or any other term of this Agreement.
9.8 Assignment. Neither Party may assign or otherwise transfer this Agreement (or any of its rights or obligations
hereunder) without the prior written consent of the other Party, except that either Party may assign this Agreement without such
consent to an entity that acquires all or substantially all of the business or assets of such Party to which this Agreement relates,
whether by merger, consolidation, sale of assets or otherwise. Any assignment or transfer of this Agreement in violation of this
Section 9.8 will be null and void. This Agreement will bind and inure to the benefit of the Parties and their respective successors and
permitted assigns.
9.9 Entire Agreement. This Agreement represents the complete and entire understanding between the Parties
regarding the subject matter hereof and supersedes all prior negotiations, representations or agreements, either written or oral,
regarding such subject matter.
9.10 Counterparts. The Parties may execute this Agreement in multiple counterparts, all of which together will
constitute one instrument. Signatures to this Agreement delivered by facsimile or other electronic transmission (e.g., portable
document format (PDF)) will be deemed to be binding as original signatures.
(The remainder of this page is intentionally left blank. The signature page follows.)11IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.ANIXA BIOSCIENCES, INC. ONTOCHEM GMBH
By: /s/ Amit Kumar By: /s/ Lutz Weber
Amit Kumar, Ph.D. Name: Dr. Lutz Weber
President and Chief Executive Officer Title: CEO
12Exhibit A: Research Plan
***
13Exhibit 10.47 Cooperation Agreement of 50MWp Photovoltaic Grid-connected Power Generation Project in Yangqiao of Fenyi County Party A: People’s Government of Fenyi CountyParty B: Xinyu Xinwei New Energy Co., Ltd. Party A welcomes and supports Party B to invest and develop new energy project in Fenyi County, and Party B is willing to invest and build50MWp photovoltaic grid-connected power generation project in Fenyi County; both parties, in the principle of equality, mutual benefits, win-wincooperation and solid progress, reach the following cooperation agreement as for relevant matters of the project: I. Party A supports and guarantees the project construction and development of Party B, and will provide the most preferential policies and all-round service in the aspects of preliminary work, construction and grid-connected of the project, and actively coordinate relevant departments andunits to help Party B accelerate project construction progress. Party B will give full play to the advantages in funds, talents, technologies, and etc.to accelerate the preliminary work progress of the project, ensure the early commencement of the project and produce benefits upon earlycompletion. II. As required by Party B building PV grid-connected power station project, Party A accepts the Cooperation Agreement of 50MWp PhotovoltaicGrid-connected Power Generation Project in Yangqiao Town of Fenyi County signed by Party B and Yangqiao Town of Fenyi County, and activelycoordinates Yangqiao Town to perform relevant responsibilities. III. In the principle of win-win cooperation, based on 50MWp photovoltaic grid-connected power generation project in Yangqiao Town, Party Bwill vigorously promote the application of PV products, improve local energy-saving and emission reduction benefits, increase local fiscal levy,enhance villagers’ income and increase villagers’ employment. IV. Party B promises that land nature will not be changed for building large-scale PV grid-connected power generation project in the plot;comprehensive development will be carried out according to relevant national stipulations, such commercial crops will be interplanted asagriculture and forestry as well as medicinal materials; local employees will enjoy the priority to be employed; local building materials will beadopted and relevant expenses will be paid on schedule. V. Party B will register a foreign-funded company in Fenyi County before implementing the project; Party A will offer all the preferential policies tothe company as per local investment promotion policies for foreign investment introduction. Party A: People’s Government of Fenyi County (seal)Rao Cheng (signature)June 25, 2014 Party B: Xinyu Xinwei New Energy Co., Ltd. (seal)Xiahou Min (signature)June 25, 2014[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
 
Exhibit 10.11
   
COLLABORATION AGREEMENT
BY AND BETWEEN
ASTELLAS PHARMA INC.
AND
FIBROGEN, INC.
   
June 1, 2005CONFIDENTIAL   EXECUTION COPY
 
TABLE OF CONTENTS
 
ARTICLE 1 DEFINITIONS     1 
1.1   “Actions”     1 
1.2   “Affiliate”     1 
1.3   “Astellas Indemnitees”     1 
1.4   “Astellas Territory”     1 
1.5   “Authorized Designee”     1 
1.6   “Bridging Strategy”     1 
1.7   “Bulk Product”     2 
1.8   “Commercialize”     2 
1.9   “Completion”     2 
1.10   “Confidential Information”     2 
1.11   “Control” or “Controlled”     2 
1.12   “Controlling Party”     2 
1.13   “Data”     2 
1.14   “Delivery” or “Delivered”     2 
1.15   “Development Plan”     2 
1.16   “Development Program”     2 
1.17   “Enforcement Action”     2 
1.18   “Event”     2 
1.19   “Expanded Field”     2 
1.20   “Expenses”     2 
1.21   “FDA”     2 
1.22   “FG Acquired Patents”     3 
1.23   “FG Development Program”     3 
1.24   “FG Indemnitees”     3 
1.25   “FG Technology”     3 
1.26   “FG Patents”     3 
1.27   “FG Technical Information”     3 
1.28   “FG Territory”     3 
1.29   “Field”     4 
1.30   “First Commercial Sale”     4 
1.31   “Force Majeure Event”     4 
1.32   “Fully Burdened Costs”     4 
1.33   “Future Third Party Intellectual Property”     4 
1.34   “GMP Guidelines”     4 
1.35   “[ * ]”     4 
1.36   “[ * ] Percentage”     5 
1.37   “HIF”     5 
 
-i-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.TABLE OF CONTENTS
(continued)
 
        Page  
1.38  “IND”     5 
1.39  “Indemnitee”     5 
1.40  “Indemnitor”     5 
1.41  “Indications”     5 
1.42  “Initial Development Plan”     5 
1.43  “Initiate” or Initiation”     5 
1.44  “Inspected Party” and “Inspecting Party”     5 
1.45  “Joint Development Committee” or “JDC”     5 
1.46  “Lead Compound”     5 
1.47  “Listed Price”     5 
1.48  “Litigation Agreement”     5 
1.49  “Major Indication”     6 
1.50  “Marketing Approval”     6 
1.51  “Marketing Approval Application” or “MAA”     6 
1.52  “Net Sales”     6 
1.53  “Phase I”     6 
1.54  “Phase II”     6 
1.55  “Phase III”     6 
1.56  “Product Specification”     7 
1.57  “Preexisting Third Party Intellectual Property”     7 
1.58  “Proof of Concept”     7 
1.59  “Prosecution and Interference Activities”     7 
1.60  “Protected Field”     7 
1.61  “Reference Materials”     7 
1.62  “Relevant Standards”     7 
1.63  “Sales Price”     7 
1.64  “Standard Materials”     7 
1.65  “Sublicensee”     8 
1.66  “Technical Product Failure”     8 
1.67  “Third Party Agreements”     8 
1.68  “Third Party Licensor”     8 
ARTICLE 2 JOINT DEVELOPMENT COMMITTEE     8 
2.1   Joint Development Committee     8 
2.2   Membership     8 
2.3   JDC Meetings     8 
2.4   Decisions     9 
ARTICLE 3 DEVELOPMENT PLANS     9 
3.1   General     9 
3.2   Annual Review     9 
3.3   Periodic Reviews     9 
ARTICLE 4 DEVELOPMENT PROGRAM     10 
4.1   Development Program for the Astellas Territory     10 
 
-ii-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.TABLE OF CONTENTS
(continued)
 
        Page 
4.2   Global Harmonization     10 
4.3   Selection of Lead Compounds     10 
4.4   Regulatory Matters     11 
ARTICLE 5 RECORDKEEPING; PUBLICATION     13 
5.1   Reports and Records     13 
5.2   Review of Publications     14 
ARTICLE 6 DEVELOPMENT PROGRAM FUNDING     15 
6.1   Payments for Reimbursement; Net Payments     15 
ARTICLE 7 USE OF PRECLINICAL AND CLINICAL DATA     17 
7.1   Exchange     17 
7.2   Disclosure     18 
7.3   Regulatory Requirements     18 
7.4   Review of Protocols     18 
ARTICLE 8 MARKETING RIGHTS     19 
8.1   Astellas     19 
8.2   FibroGen     19 
8.3   Covenants     19 
ARTICLE 9 TRANSFER PRICING     20 
9.1   Transfer for Non-Commercial Purpose     20 
9.2   Transfer for Commercial Purpose     21 
9.3   Payment     22 
9.4   Reference Materials; Standard Materials     22 
ARTICLE 10 ADDITIONAL PAYMENTS; BOOKS AND RECORDS     22 
10.1   Quarterly Reports     22 
10.2   Payment Method     22 
10.3   Currency Conversion     23 
10.4   Taxes     23 
10.5   Records; Inspections     24 
ARTICLE 11 DUE DILIGENCE     24 
11.1   Astellas’ Due Diligence     24 
11.2   FG’s Due Diligence     24 
11.3   Development Diligence     25 
ARTICLE 12 MANUFACTURING RIGHTS     26 
12.1   Procedures     26 
12.2   FG Right     27 
12.3   Manufacture and Supply     27 
12.4   Product Specifications     27 
12.5   Orders Forecast     27 
 
-iii-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.TABLE OF CONTENTS
(continued)
 
        Page  
12.6   Shipment     28 
12.7   Inspection of Shipment/Right to Reject     28 
12.8   Inspection of Facilities     28 
12.9   Recall     29 
12.10  Warranty     29 
12.11  Interruption in Supply     29 
12.12  Reference and Standard Materials     29 
ARTICLE 13 LICENSE GRANTS     29 
13.1   Grant to Astellas     29 
13.2   Sublicenses     29 
13.3   No Rights Beyond Lead Compounds     30 
13.4   Expanded Field Negotiation     30 
ARTICLE 14 INTELLECTUAL PROPERTY     30 
14.1   Ownership of Inventions     30 
14.2   Patent Prosecution     31 
14.3   Defense of Third Party Infringement Claims     31 
14.4   Enforcement     32 
14.5   Third Party Agreements     33 
ARTICLE 15 REPRESENTATIONS AND WARRANTIES     34 
15.1   FG Warranties     34 
15.2   Astellas Warranties     34 
15.3   Disclaimer of Warranties     34 
ARTICLE 16 CONFIDENTIALITY     35 
16.1   Confidential Information     35 
16.2   Permitted Disclosures     35 
16.3   Clinical Data     36 
16.4   Press Releases     36 
ARTICLE 17 INSURANCE; INDEMNIFICATION     36 
17.1   Insurance     36 
17.2   Indemnification of FG     36 
17.3   Indemnification of Astellas     37 
17.4   Procedure     37 
ARTICLE 18 TERM AND TERMINATION     37 
18.1   Term     37 
18.2   Termination for Cause or Technical Product Failure     37 
18.3   Termination in case of Generic Competition     38 
18.4   Negative Advice from Authorities     39 
18.5   Admission of Invalidity or Unenforceability of FG Patent     39 
18.6   Termination upon Notice     39 
 
-iv-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.TABLE OF CONTENTS
(continued)
 
        Page  
18.7   Effect of Termination     39 
ARTICLE 19 DISPUTE RESOLUTION     40 
19.1   Disputes     40 
19.2   Full Arbitration     40 
ARTICLE 20 MISCELLANEOUS     41 
20.1   Confidential Terms     41 
20.2   Governing Law     41 
20.3   Force Majeure     41 
20.4   No Implied Waivers; Rights Cumulative     42 
20.5   Independent Contractors     42 
20.6   Notices     42 
20.7   Assignment     43 
20.8   Modification     43 
20.9   Severability     43 
20.10  Counterparts     43 
20.11  Headings     43 
20.12  Export Laws     43 
20.13  Language     43 
20.14  Entire Agreement     43 
EXHIBIT A LIST OF PATENTS     45 
EXHIBIT B INDICATIONS     46 
EXHIBIT C INITIAL DEVELOPMENT PLAN     47 
 
-v-
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
COLLABORATION AGREEMENT
This COLLABORATION AGREEMENT (“Agreement”), effective as of June 1, 2005 (the “Effective Date”), is made by and between FibroGen,
Inc., a Delaware corporation having offices at 225 Gateway Boulevard, South San Francisco, California 94080 (“FG” or “FibroGen”), and Astellas
Pharma Inc., a Japanese corporation having offices at 3-11 Nihonbashi-Honcho, 2-Chome, Chuo-ku, Tokyo, 103-8411 Japan (“Astellas”).
BACKGROUND
A. FG has a research and development program focused on the development of small molecule prolyl hydroxylase inhibitors which stabilize
hypoxia inducible factor (“HIF”), for the treatment of anemia.
B. Astellas desires to collaborate with FG on the development and commercialization of, and license the rights to use as therapeutics, certain
small molecule prolyl hydroxylase inhibitors on the terms and conditions set forth below for use in the Astellas Territory (as defined below).
NOW THEREFORE, for and in consideration of the covenants, conditions, and undertakings hereinafter set forth, it is agreed by and between
the parties as follows:
ARTICLE 1
DEFINITIONS
1.1 “Actions” shall have the meaning as set forth in Section 14.3 below.
1.2 “Affiliate” shall mean any entity which controls, is controlled by or is under common control with Astellas or FG. For purposes of
this definition only, “control” shall mean beneficial ownership (direct or indirect) of at least fifty percent (50%) of the shares of the subject entity
entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing
authority).
1.3 “Astellas Indemnitees”  shall have the meaning as set forth in Section 17.3 below.
1.4 “Astellas Territory” shall mean the country of Japan.
1.5 “Authorized Designee”  shall mean an officer of FG or Astellas, as the case may be, designated by the Chief Executive Officer of the
respective corporation, that has been granted full authority to resolve a dispute arising between FG and Astellas as required under Section 2.4 or
Section 19.1 hereof.
1.6 “Bridging Strategy” shall mean the decision by Astellas to file an MAA in the Astellas Territory by submitting the data from the
Phase III clinical trial of FG or its Affiliate or Sublicensee.
 
-1-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
1.7 “Bulk Product” shall mean a Lead Compound supplied by FG to Astellas as a bulk formulated drug (such as in a form, including, but
not limited, to a capsule, tablet or caplet formulation) without packaging.
1.8 “Commercialize” shall mean directly or indirectly develop, manufacture, sell, market or distribute.
1.9 “Completion” shall be deemed to occur, with respect to a particular clinical trial for a Lead Compound, upon clinical database lock for
such trial.
1.10 “Confidential Information” shall have the meaning as set forth in Section 16.1 below.
1.11 “Control” or “Controlled” shall mean possession of the ability to grant a license or sublicense as provided for herein without
violating the terms of an agreement with a third party.
1.12 “Controlling Party” shall have the meaning as set forth in Section 14.3 below.
1.13 “Data” shall have the meaning as set forth in Section 7.1 below.
1.14 “Delivery” or “Delivered” shall mean when Lead Compound is made available by FG to Astellas at the Ex Works location.
1.15 “Development Plan” shall mean the plan for the Development Program in effect from time to time, as established in accordance with
Article 3 below.
1.16 “Development Program” shall mean all Astellas activities with respect to the development and commercialization of Lead
Compounds for applications within the Field in the Astellas Territory, in accordance with the Development Plan in effect at that time.
1.17 “Enforcement Action” shall have the meaning as set forth in Section 14.4 below.
1.18 “Event” shall have the meaning as set forth in Article 6 below.
1.19 “Expanded Field” shall mean the treatment of any indications in which therapeutic utility is derived from  [ * ], including, without
limitation, [ * ]. The Expanded Field shall not include the Field.
1.20 “Expenses” shall have the meaning as set forth in Section 14.3 below.
1.21 “FDA” shall mean the U.S. Food and Drug Administration, or any successor agency.
 
-2-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
1.22 “FG Acquired Patents” shall mean those FG Patents that are in-licensed or otherwise acquired by FG.
1.23 “FG Development Program” shall mean those activities by or on behalf of FG directly related to the development and
commercialization of Lead Compounds for applications within the Field in the FG Territory that are directly useful or necessary for
Commercialization in the Astellas Territory.
1.24 “FG Indemnitees” shall have the meaning as set forth in Section 17.2 below.
1.25 “FG Technology” shall mean FG Patents and FG Technical Information.
1.26 “FG Patents” shall mean all patents including all reissues, renewals, re-examinations and extensions thereof, and any patent
applications therefor, including all divisionals or continuations, in whole or in part, thereof, which claim or otherwise cover the composition,
manufacture, sale or use of a Lead Compound and that are Controlled by FG or its Affiliates during the term of this Agreement, subject to Section
14.5.1. For purposes of this definition, a patent or patent application shall be deemed to “cover” a Lead Compound if the manufacture, use or sale of
such Lead Compound would, but for the license granted herein, infringe, contributorily infringe or constitute inducement to infringement of such
patent or patent application, if issued or granted as pending. All patents and patent applications listed on Exhibit A, as revised from time to time to
remove patents and/or patent applications by mutual agreement or to add patents and/or patent applications by FG, shall be within the scope of
definition of the FG Patents, provided, however, that in the event FG designates any additional Lead Compounds, FG shall add to the list on Exhibit
A patents and patent applications which claim or otherwise cover the composition, or manufacture, sale or use of the additional Lead Compounds
within the Field and the Astellas Territory, and upon the cessation of the designation as any compound as Lead Compound and Astellas’ cessation
of development of such Lead Compound, FG shall remove at its sole discretion the related patent or patent application from Exhibit A.
1.27 “FG Technical Information” shall mean confidential information, tangible and intangible, and materials, including, but not limited to:
trade secrets and know how, pharmaceutical, chemical, biological and biochemical compositions; and technical and non-technical data and
information, and/or the results of tests, assays, methods and processes; and plans, specifications and/or other documents containing said
information and data; in each case that is possessed by FG as of the Effective Date or discovered, developed or Controlled by FG or its Affiliates
during the term of this Agreement, to the extent such relates to the development, manufacture, sale or use of a Lead Compound subject to Section
14.5.1, and such information related to a candidate for use as a Lead Compound provided by FG to Astellas in connection with the Lead Compound
selection decision consultation process described in Section 4.3.
1.28 “FG Territory” shall mean all areas of the world outside of the Astellas Territory.
 
-3-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
1.29 “Field” shall mean the treatment of anemia solely in the Indications, by means of the stabilization of HIF causing the stimulation of
erythropoiesis (including an increase in endogenous erythropoietin production) and/or a subsequent increase in hematocrit through modulation of
prolyl hydroxylase and/or asparaginyl hydroxylase. For purposes of clarity, FG and Astellas agree and acknowledge that the Field and the
Indications exclude [ * ].
1.30 “First Commercial Sale” shall mean, with respect to each Lead Compound, the first bona fide commercial sale of such Lead
Compound to a non-Affiliate third party by or under authority of Astellas or FG, or their Affiliates or Sublicensees, as the case may be, in the FG
Territory or the Astellas Territory, respectively.
1.31 “Force Majeure Event” shall mean the occurrence of any event causing a failure to perform where failure to perform is beyond the
reasonable control of the non-performing party, as described in Section 20.3.
1.32 “Fully Burdened Costs” with respect to a Lead Compound shall mean all costs to produce, package and distribute the product to
Astellas or its carrier at the Ex Works location (in compliance with Section 12.6) and any royalties or other consideration (not reimbursed by
Astellas) paid to third parties related to the acquisition or sale of product, with costs to produce and package the product to include the direct
material, labor and indirect costs that are incurred by FG or its Affiliate(s) associated with the manufacture, filling, packaging, labeling, preparation
of product for shipment and/or other preparation of such Lead Compound, as applicable, including, but not limited to taxes, fees, and customs
incurred, as applicable. Costs will be determined in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP) and will include
but not be limited to the costs of facilities, labor, purchasing, depreciation of equipment, materials, payments to third parties for any necessary
contract work related to the manufacture or testing of the product, the validation studies, quality assurance, quality control and other testing,
storage, shipping (if requested by Astellas), costs related to distribution and a reasonable allocation of general and administrative overhead. Costs
related to distribution include the labor, materials and overhead necessary to prepare and package the final product for shipment to the Ex Works
location.
1.33 “Future Third Party Intellectual Property” shall mean any intellectual property rights, including without limitation all patents,
trademarks, or copyrights, and any applications therefor, including any applications for registration, issuance, or grant thereof, owned or Controlled
by a third party that are necessary for the practice of the license granted hereunder that were not owned or Controlled by FG as of the Effective
Date and that do not qualify as Pre-existing Third Party Intellectual Property under Section 1.56.
1.34 “GMP Guidelines” shall mean then-current applicable Good Manufacturing Practices guidelines and regulations of the FDA.
1.35 “[ * ]” shall have the meaning as set forth in Section 1.36 below.
 
-4-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
1.36 “[ * ] Percentage” shall be determined, for any Lead Compound, (i) by dividing (a) the [ * ], which shall be defined as the difference
between (x) the [ * ], and (y) the [ * ], by (b) the [ * ]; and (ii) multiplying the result of (i) above by 100.
1.37 “HIF” shall mean hypoxia inducible factor.
1.38 “IND” shall mean an Investigational New Drug application, as defined in the U.S. Federal Food, Drug and Cosmetic Act and the
regulations promulgated thereunder, or comparable filing in a foreign jurisdiction, in each case with respect to a Lead Compound for use within the
Field.
1.39 “Indemnitee” shall have the meaning as set forth in Section 17.4 below.
1.40 “Indemnitor” shall have the meaning as set forth in Section 17.4 below.
1.41 “Indications” shall mean those indications listed on Exhibit B and any other indications to be agreed upon hereafter between FG
and Astellas, each of which shall be referred to as an Indication.
1.42 “Initial Development Plan” shall mean the Initial Development Plan as described in Section 3.2.1 hereof.
1.43 “Initiate” or Initiation” shall mean with respect to a particular clinical trial for a Lead Compound, the initial dosing of the first patient
in such trial in accordance with the protocol therefor.
1.44 “Inspected Party” and “Inspecting Party”  shall have the meanings as set forth in Section 10.5 below.
1.45 “Joint Development Committee” or “JDC” shall have the meaning as set forth in Section 2.1 below.
1.46 “Lead Compound” shall mean any compound Controlled by FG that is designated by FG as a lead compound for clinical
development in an Indication in accordance with Section 4.3 for the duration of such designation. Any Lead Compound which receives a Marketing
Approval in the Astellas Territory shall remain a Lead Compound for the duration of such Marketing Approval. As of the Effective Date, FG-2216
shall be deemed to be a Lead Compound.
1.47 “Listed Price” shall have the meaning as set forth in Section 9.2.
1.48 “Litigation Agreement” shall have the meaning as set forth in Section 14.4 below.
 
-5-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
1.49 “Major Indication” shall have the meaning set forth in Section 11.3.1 below.
1.50 “Marketing Approval” shall mean, with respect to each Lead Compound, approval in the Astellas Territory by the Japanese
Ministry of Health, Labour and Welfare, or in the FG Territory by U.S. or European regulatory authorities, as the case may be, to market such Lead
Compound for an indication within the Field. It is understood that pricing or reimbursement approval shall constitute a part of the Marketing
Approval. In any event, Marketing Approval shall be deemed to have occurred with respect to a Lead Compound no later than the date of the First
Commercial Sale of such Lead Compound in the FG Territory or the Astellas Territory as the case may be, by or under authority of FG or Astellas
respectively, or their Affiliate or Sublicensee, as the case may be, whether or not formal approval by the relevant health regulatory authority is
required for the First Commercial Sale of such Lead Compound.
1.51 “Marketing Approval Application” or “MAA”  shall mean, within the FG Territory, a New Drug Application or similar application as
required under the U.S. Federal Food, Drug and Cosmetics Act and the regulations promulgated thereunder, or such similar filing in Europe, or a
comparable filing for Marketing Approval in the Astellas Territory, in each case with respect to a Lead Compound for use within the Field.
1.52 “Net Sales” shall mean the gross amount billed or invoiced by Astellas, its Affiliates and its Sublicensees to unaffiliated third
parties for the Lead Compound(s) in bona fide arm’s length transaction, less the following deductions:
 
  i) credits or allowances, if any, given or made on account of rejection or return of the Lead Compound(s);
 
  ii) trade and quantity discounts actually allowed and taken in such amounts as are customary in the trade;
 
  iii) duties, sales taxes, excise taxes, insurance and transportation charges actually paid; and
 
  iv) charge back payments or rebates actually paid to wholesalers.
1.53 “Phase I” shall mean human clinical trials, the principal purpose of which is preliminary determination of safety in healthy
individuals or patients as required in 21 C.F.R. §312.21, or similar clinical study in a country other than the United States, and for which there are no
primary endpoints relating to efficacy included in the protocol.
1.54 “Phase II” shall mean human clinical trials, for which the primary endpoints include a determination of dose ranges and/or a
preliminary determination of efficacy in patients with the Indication being studied as required in 21 C.F.R. §312.21, or similar clinical study in a
country other than the United States.
1.55 “Phase III” shall mean human clinical trials, the principal purpose of which is to establish safety and efficacy of one or more
particular doses in patients with the Indication being studied as required in 21 C.F.R. §312.21, or similar clinical study in a country
 
-6-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
other than the United States. For purposes of this Section 1.55, and Sections 1.53 and 1.54 above, a particular trial that (i) is intended to overlap two
phases of trials, (ii) combines the elements of two phases of trials, or (iii) is treated by the FDA or comparable foreign agency as two phases of
trials, such as a Phase I/II trial or a Phase II/III trial, shall be deemed a trial of the later, as well as the earlier, phase (i.e., a Phase II and a Phase III,
respectively).
1.56 “Product Specification” shall mean, with respect to a Bulk Product, the written document describing, the testing procedures and
results required to determine compliance with release specifications, including, and quality control testing procedures to be determined, and be
amended from time to time, by mutual agreement of both parties. The release specifications of such Product Specifications shall be determined
taking into account and shall be designed to meet the shelf life requirements of the Japanese Ministry of Health, Labor and Welfare for the Lead
Compound, provided, that the Product Specifications shall not require compliance with such shelf life requirements.
1.57 “Preexisting Third Party Intellectual Property” shall mean any intellectual property rights, including without limitation all patents,
trademarks, copyrights, and any applications therefor, including any applications for registration, issuance, or grant thereof, owned or Controlled
by a third party that are necessary for the practice of the license granted hereunder and that the existence of which was discoverable or otherwise
could have been known on or prior to the Effective Date and were not owned or Controlled by FG as of the Effective Date.
1.58 “Proof of Concept” shall mean for any Indication, a demonstration of correction of anemia in relevant patients in a human clinical
study.
1.59 “Prosecution and Interference Activities”  shall mean the preparation, filing, prosecution and maintenance of patent applications
and patents and any continuing applications thereof, and any re-examinations, reissues, renewals and requests for patent term extensions therefor,
and any U.S., international or foreign counterparts of any of the foregoing, together with the conduct of any interference, opposition or other
similar proceeding pertaining to patent applications or patents.
1.60 “Protected Field” shall have the meaning as set forth in Section 14.1.
1.61 “Reference Materials” shall have the meaning as set forth in Section 12.12 below.
1.62 “Relevant Standards”  shall have the meaning as set forth in Section 12.8 below.
1.63 “Sales Price” shall mean the price per unit obtained by dividing the Net Sales during the relevant calendar quarter by the number of
units sold during the same period.
1.64 “Standard Materials” shall have the meaning as set forth in Section 12.12 below.
 
-7-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
1.65 “Sublicensee” shall mean a third party to whom FG or Astellas has directly or indirectly granted the right in its respective territory
to make, use and sell a Lead Compound or a third party to whom FG or Astellas has directly or indirectly granted the right to distribute a Lead
Compound supplied by FG or Astellas (respectively). For purposes of this Agreement, FG and Astellas shall not be deemed Sublicensees of the
other.
1.66 “Technical Product Failure” shall mean as a [ * ], which is not attributed to Astellas’ failure to fulfill its obligations hereunder.
1.67 “Third Party Agreements” shall mean collectively those agreements between FG and a third party existing as of the Effective Date,
pursuant to which FG obtained rights applicable to the development, manufacture, sale or use of Lead Compounds hereunder (but excluding
options or similar agreements to acquire such rights). If, after the Effective Date, FG enters into an agreement to license or acquire rights from a third
party with respect to subject matter to be utilized in connection with Lead Compounds in accordance with Section 14.5 below, such agreements
shall also be deemed Third Party Agreements for purposes of this Agreement.
1.68 “Third Party Licensor” shall have the meaning as set forth in Section 14.5.1 below.
ARTICLE 2
JOINT DEVELOPMENT COMMITTEE
2.1 Joint Development Committee. Astellas and FG shall establish a joint development committee to oversee, review and coordinate the
research and development of Lead Compounds for applications within the Field pursuant to the Development Program (“Joint Development
Committee” or “JDC”). From time to time, the JDC may establish subcommittees or project teams to oversee particular projects or activities, and
such subcommittees or project teams will be constituted as the JDC agrees ( e.g., for oversight of the development or other day-to-day matters).
2.2 Membership. The JDC shall be comprised of an equal number of representatives from each of Astellas and FG, selected by such
party. The exact number of such representatives shall be  [ * ] for each of Astellas and FG, or such other number as the parties may agree. Subject to
the foregoing provisions of this Section 2.2, FG and Astellas may replace its respective JDC representatives at any time, upon prior written notice to
the other party.
2.3 JDC Meetings. The JDC shall meet no fewer than [ * ] times each calendar year, or as otherwise agreed by the parties, with the
understanding that  [ * ] meetings are to be held at mutually agreed locations alternating among Japan, California, Hawaii, or at such other locations
as the parties agree, and the other  [ * ] meetings are to be held by means of telecommunication, videoconference or correspondence as deemed
appropriate. The parties shall conduct team meetings at the same time and location as the JDC meetings. At its meetings, the JDC will, as applicable,
(i) formulate and review the Development Program objectives, including approval of all proposed pre-clinical and clinical studies to be performed,
(ii) monitor the progress of the Development Program toward those objectives, (iii) review and approve the
 
-8-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
Development Plan, pursuant to Section 3.3 of this Agreement, including review, approve and monitor the progress of the clinical and regulatory
plans, (iv) resolve issues surrounding the marketing of the Lead Compounds, (v) discuss the selection of Lead Compounds, (vi) coordinate
manufacturing issues, including the development of standards, scheduling of batch production, and qualification with regulatory requirements for
the Astellas Territory, (vii) resolve issues arising out of the Development Program or this Agreement, and (viii) undertake and/or approve such
other matters as are specifically provided for the JDC under this Agreement. One meeting each year will be focused specifically on setting
Development Program goals and strategy. Other representatives of FG or Astellas may attend JDC or subcommittee meetings as non-voting
observers. Astellas’ lead representative shall chair the meetings and shall be responsible for preparing the agenda and minutes for such meetings,
and shall provide such minutes to FG in English. Such minutes as approved by the JDC shall constitute the official record of the actions of the JDC.
The JDC may also convene or be polled or consulted from time to time by means of telecommunications, videoconferences or correspondence, as
deemed necessary or appropriate. Each party shall bear its own personnel, travel and lodging expenses relating to JDC meetings.
2.4 Decisions. Decisions of the JDC shall be made by unanimous agreement of the members present in person or by other means ( e.g.,
teleconference) at any meeting; provided that at least two (2) representatives of each party is present at such meeting. In the event that the JDC is
unable to reach unanimous agreement on an issue, the issue shall be referred for resolution in accordance with Article 19 hereof.
ARTICLE 3
DEVELOPMENT PLANS
3.1 General. Subject to Section 3.2 below, Astellas shall prepare and propose to the JDC a detailed Development Plan pursuant to which
the Development Program will be performed. The Development Plan shall specify the objectives and work plan activities by Astellas with respect to
the Development Program.
3.2 Annual Review 
3.2.1 Initial Development Plan. The initial Development Plan is attached hereto as Exhibit C (the “Initial Development Plan”), and
shall be fixed for the period from the Effective Date through March 31, 2006, unless otherwise agreed by the JDC.
3.2.2 Other. Beginning upon the date of signing of this Agreement and by December 31 of each year thereafter until expiration or
termination of this Agreement, Astellas shall submit to the JDC the proposed plan required under Section 3.1 above for the following fiscal year,
including for regulatory activities within the Astellas Territory. The JDC shall review such proposals as soon as possible and shall approve the
Development Plan for such following fiscal year, with such changes as the JDC may agree to the plan proposed by Astellas, no later than March 15
of the current fiscal year.
3.3 Periodic Reviews. The JDC shall review the Development Plan on an ongoing basis and may make changes thereto including
variances to the Development Plan in effect.
 
-9-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
ARTICLE 4
DEVELOPMENT PROGRAM
4.1 Development Program for the Astellas Territory. Astellas shall follow FG’s development activities for the Lead Compounds, (i.e.,
Astellas shall develop, and shall have the right and obligation to develop, only those compounds that FG has designated as Lead Compounds, for
the duration of such designation and for which FG or its Sublicensee is pursuing clinical development in the FG Territory), for those Indications
being developed by FG or its sublicensee, and such Astellas development shall comply with, without limitation the procedures set forth in Section
11.3.1. In fulfillment thereof, Astellas shall conduct, directly or through third parties, the Development Program for the Astellas Territory, all in
accordance with the Development Plan then in effect, and shall be responsible for all costs related to the Astellas Territory. Astellas agrees to keep
the JDC informed as to the progress of its activities under the Development Program for Lead Compounds hereunder. FG shall, subject to Section
4.2.2, provide reasonable assistance to Astellas regarding Astellas’ performance of its development activities within the scope of the Development
Program hereunder and provide updates to Astellas as to the FG Development Program. It is understood and agreed that the Development Program
for the Astellas Territory shall include all clinical trials and other development activities necessary to obtain Marketing Approvals for Lead
Compounds for the Astellas Territory.
4.2 Global Harmonization 
4.2.1 Reporting; Redundant Activities . FG shall provide to Astellas regular reports with respect to the FG Development Program
with respect to the Lead Compounds. Such reports may be provided at the JDC meetings provided for in Section 2.3. Recognizing that the Lead
Compounds may be developed on a global basis and that regulatory and budget efficiencies can be achieved through the worldwide use of
appropriate data and files, the parties will seek to design pre-clinical and clinical development activities included in the Development Plan in a
manner to maximize global clinical and regulatory harmonization.
4.2.2 Additional Activities. Without limiting the obligations set forth in 4.2.1, the costs of any non-clinical or clinical
developmental work, whether performed by Astellas or FG, to support needs specific to the Astellas Territory and not required to be performed for
the FG Territory, or at the request of Astellas, shall be borne by Astellas.
4.3 Selection of Lead Compounds. FG shall consult with Astellas with respect to Lead Compound selection, and shall provide to
Astellas information as reasonably necessary to evaluate Lead Compound candidates in connection with the Lead Compound selection process,
including without limitation the information relating to patent situations in the Astellas Territory. For the avoidance of doubt, such Lead Compound
candidates shall potentially include any and all compounds Controlled by FG during the term hereof for use in the Field. Notwithstanding anything
contained in this Agreement, FG shall designate, at its sole discretion but in line with the basic policy that the same Lead Compound shall be
Commercialized both in Astellas Territory and FG Territory for the same Indication(s), Lead Compound(s) in accordance with the terms of this
Section 4.3, and shall notify the JDC of such designations. At any one time, FG may designate up to two (2) Lead Compounds for Commercialization
in any Indication; provided, that in the event that FG designates two (2) Lead
 
-10-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
Compounds for Commercialization in an Indication, it shall designate one (1) as the primary Lead Compound and one (1) as the secondary Lead
Compound. In the event FG determines to cease development of a primary Lead Compound in an Indication, FG may designate the secondary Lead
Compound as the primary Lead Compound for such Indication. In the event, prior to Marketing Approval in the Astellas Territory, FG determines to
stop development of a Lead Compound, FG shall notify the JDC, and upon such notification, such compound shall no longer be considered a Lead
Compound; provided, however, that Astellas may complete those development activities on-going at the time of such notification for such Lead
Compound for a reasonable period of time, unless such notification is based on safety concerns. In the event FG determines to  [ * ], FG shall [ * ]
within [ * ] days of such  [ * ]. In the event that FG [ * ], Astellas may, subject to the [ * ], [ * ], provided, however, that the [ * ] shall apply upon the
[ * ] set forth in such Sections, rather than the  [ * ].
4.4 Regulatory Matters  
4.4.1 Regulatory Filing. FG shall be responsible, directly or through third parties, for the preparation, filing and maintenance of all
regulatory documents in the FG Territory with respect to the Lead Compound(s), which shall be filed in the name of FG or its designee. Astellas
shall be responsible for all preparation, filing and maintenance of all regulatory documents in the Astellas Territory with respect to the Lead
Compound(s), which shall be filed in the name of Astellas. Astellas shall select and own the trademark(s) to be used to identify any Lead
Compound in the Astellas Territory.
4.4.2 Reporting Adverse Experiences 
(a) With respect to adverse drug experiences relating to any Lead Compound, the parties shall promptly report such
experiences to the appropriate regulatory authorities in the countries in which such Lead Compound is being developed or commercialized, in
accordance with the appropriate laws and regulations of the relevant countries and authorities, and each party shall ensure that its Affiliates and
Sublicensees comply with such reporting obligations. In addition, in order that each party may be fully informed of these experiences, each party
shall report to the other party all “adverse events” involving such Lead Compound. “Serious adverse events” for all fatal and life-threatening
adverse events shall be reported to the designated safety contact person of the other party by e-mail within five (5) calendar days of a party’s
and/or its agent’s becoming aware of such an event (a “reporting party”), and all other serious adverse events shall be forwarded to the other party
within seven (7) calendar days of the reporting party’s and/or its agent’s becoming aware of such an event. To the extent legally possible, FG and
Astellas shall report to the other all serious adverse events with respect to a Lead Compound in the Field at least twenty-four (24) hours prior to
reporting the same to a regulatory authority, and shall report adverse events which may constitute a dose limiting toxicity in a reasonably prompt
time after the occurrence of such event. The reporting party shall report all non-serious adverse events on a monthly basis; provided that, non-
serious adverse event data arising from a clinical trial will be included in the clinical trial report which
 
-11-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
shall be prepared and sent to the other party as soon as practicable following completion of the final clinical report.
(b) An “adverse event” is any negative symptom experienced at the time of or after the taking of a medicinal
(investigational) product, whether or not considered a medicinal (investigational) product related, including any side effects, injury, toxicity or
sensitivity reaction, or significant failure of expected pharmacological action. Also included are instances of symptomatic overdose, abuse or
withdrawal reactions.
(c) A “serious adverse event” includes any of the following outcomes: death, a life-threatening event; that is, an adverse
event that puts the patient at risk of dying, requires hospitalization, prolongs existing hospitalization or results in persistent or significant
incapacity or disability, congenital anomaly/birth defect. Other important medical events that may otherwise jeopardize a patient or may require
intervention to prevent one of the statuses of patients listed in the preceding sentence shall also be considered serious.
(d) The parties also agree to develop and implement such other procedures as may be necessary or appropriate to ensure
that each party remains in compliance with all reporting requirements imposed by any regulatory authority in the Astellas Territory, and in the FG
Territory. Upon the Initiation of Phase III, FG shall implement and be responsible for the maintenance of a complete global safety database. FG will
be responsible for preparing, with Astellas’ cooperation set forth below in this Section 4.4.2(d), Periodic Safety Reports for clinical studies
requested by European and U.S. authorities, and Periodic Safety Update Reports (PSURs). FG shall send a draft PSUR for review to Astellas in the
beginning of week 5 after database lock point. Astellas has one week for review. FG shall provide copies of the final PSURs to Astellas in the same
timing as they are submitted to the authorities. Astellas will provide FG with the data needed for making the PSURs. Maintenance of Company Core
Safety Information (CCSI) is under the responsibility of FG who will communicate all revisions to Astellas. FG shall prepare the periodic safety
reports for clinical studies requested by European and U.S. authorities and provide Astellas with the copy of such reports at the time of submission
to the regulatory authorities in the FG Territory. Astellas will provide FG with the data needed for making such periodic safety reports.
(e) Each party shall immediately inform the other party of measures taken in order not to jeopardize public health or
hygiene including but not limited to, discontinuation of manufacture, import and marketing, clinical trial suspension, recall and disposal of the Lead
Compound or the product or the prescription product, irrespective of whether it is due to regulatory actions or voluntary actions.
 
-12-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
(f) Both parties hereby nominate the safety contact persons as follows:
Medical Affairs Department
FibroGen, Inc.
225 Gateway Boulevard
San Francisco, California 94080
Attn: Vice President, Medical Affairs
Tel: 1-650-866-7875
Fax: 1-650-866-7360
E-mail:dyeowell@fibrogen.com
With a copy to:
Chief Executive Officer
FibroGen, Inc.
225 Gateway Boulevard
San Francisco, California 94080
Tel: 1-650-866-7200
Fax: 1-650-866-7201
E-mail:tneff@fibrogen.com
Pharmacovigilance Department, QA, RA, and
Pharmacovigilance Division
Astellas Pharma Inc.
[ * ] 
The safety contact persons for each party hereto may be updated from time to time as necessary upon notice to the other party.
ARTICLE 5
RECORDKEEPING; PUBLICATION
5.1 Reports and Records . Each of Astellas and FG shall use best efforts to maintain (or cause such records to be maintained) records of
the Development Program and FG Development Program, respectively, in sufficient detail and in good scientific manner as will properly reflect all
work done and results achieved in the performance of the Development Program or FG Development Program, as the case may be. Upon  [ * ] days
advance notice or such shorter time period as may be required in order to meet any regulatory requirements, each party shall allow the other party
to have access to all records, materials and data generated by or on behalf of such party with respect to each Lead Compound for applications
within the Field at reasonable times, in a reasonable manner and, upon request, to the extent required under Article 7 hereof.
 
-13-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
5.1.1 Retention. Each of Astellas and FG shall retain its records for the minimum period of time required by applicable law in all
cases, and for not less than  [ * ] following the expiration or termination of this Agreement.
5.1.2 Reports. Not less than [ * ] prior to each JDC meeting under Section 2.3 above, each of Astellas and FG shall provide the
JDC with a written report in English; Astellas’ report summarizing the progress of the Development Program, including the developmental, clinical
and other activities performed by Astellas, its Affiliates and/or Sublicensees with respect to each Lead Compound during the preceding period; and
FG’s report summarizing the progress of the FG Development Program.
5.1.3 Activities Outside the Field. The parties understand and acknowledge that FG is engaged in other research and
development activities directed to prolyl hydroxylase inhibition and/or the stabilization of HIF, and that the focus of this collaboration and the
Development Program is directed to the Field. Accordingly, it is understood that, notwithstanding any other provision of this Agreement, the
obligations of FG specified herein to make available and disclose to Astellas data, technical information, scientific results and findings and other
subject matter is limited in each case to subject matter directed to Lead Compounds within the Field.
5.2 Review of Publications. As soon as is practicable prior to the oral public disclosure, and prior to the submission to any outside
person for publication of scientific data resulting from the Development Program, in each case to the extent the contents of the oral disclosure or
publication have not been previously disclosed pursuant to this Section 5.2 before such proposed disclosure, FG or Astellas, as the case may be,
shall provide to the other party a copy of the publication, or a written summary of any oral disclosure, to be made or submitted, and shall allow the
other party at least  [ * ], to determine whether such disclosure or publication contains subject matter for which patent protection should be sought
prior to publication or which either party believes should be modified to avoid disclosure of Confidential Information or regulatory or other issues.
With respect to publications by investigators or other third parties of scientific data resulting from the Development Program, such disclosures and
publications shall also be subject to review by the reviewing party under this Section 5.2.
5.2.1 Publication Rights. Subject to the provisions of Articles 7 and 16, after the expiration of  [ * ] from the date of receipt of
such disclosure or publication, unless the authoring party has received the written notice specified below, the authoring party shall be free to
submit such publication or to orally disclose or publish the disclosed research results in any manner consistent with academic standards.
5.2.2 Disapproval of Publication. Prior to the expiration of the [ * ] period specified in Section 5.2.1 above, the reviewing party
may notify in writing the submitting party of its determination that such oral presentation or publication contains Confidential Information of the
reviewing party or objectionable material or material that consists of patentable subject matter of the reviewing party for which patent protection
should be sought. In such event, and unless otherwise mutually agreed, the submitting party shall withhold publication of its disclosure.
 
-14-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
ARTICLE 6
DEVELOPMENT PROGRAM FUNDING
6.1 Payments for Reimbursement; Net Payments. FG hereby acknowledges receipt of U.S. $[ * ] on February 13, 2004, U.S. $[ * ] on
January 28, 2005, and U.S. $[ * ] on March 22, 2005 as initial payments for reimbursement of historical research and development expenditures for
the Lead Compounds. Astellas agrees to pay to FG the amounts set forth in Section 6.1.1 below. The parties hereto acknowledge that the
Development Program hereunder involves a high degree of risk and uncertainty; accordingly, both parties hereto expressly disclaim any implied
warranty as to the results of the Development Program.
6.1.1 Reimbursement Payments. As reimbursement and payment for FG’s historical research and development expenditures with
respect to pre-clinical and clinical development of Lead Compounds, Astellas agrees to make the following non-refundable, non-creditable (except
as set forth in Section 14.3 below) reimbursement payments to FG upon the first occurrence of each event specified below (each, an “Event”):
 
    EVENT   AMOUNT
1.
 
Upon [ * ], provided, that U.S. $[ * ] million of such amount shall be paid no later than [ * ] irrespective of whether
the [ * ] has occurred.  
U.S. $[ * ]
2.  Upon each of [ * ], for a total of U.S. $[ * ]   U.S. $[ * ]
3.
 
Upon [ * ] or in the event that Astellas chooses to utilize the Bridging Strategy, the payment shall be made
concurrent with the payment required in paragraph 4 of this Section 6.1.1 below.  
U.S. $[ * ]
4.  Upon the first [ * ].   U.S. $[ * ]
6.1.2 Product Approval Payments . As reimbursement and payment for FG’s historical and ongoing research and development
expenditures with respect to pre-clinical and clinical development of Lead Compounds and as payment for the successful marketing and sales of
Lead Compound(s), Astellas agrees to make the following non-refundable, non-creditable (except as set forth in Section 14.3 below) reimbursement
payments to FG upon the first occurrence of each Event (other than paragraph 5 of this Section 6.1.2 below) specified below. Notwithstanding the
foregoing, in the event that Astellas decides not to pursue Commercialization in  [ * ] set forth in paragraph 3 or 4 of this Section 6.1.2, the milestone
payment associated with the  [ * ] set forth in paragraph 3
 
-15-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
shall be due and payable upon the first  [ * ] of either [ * ], and the milestone payment associated with the  [ * ] set forth in paragraph 4 shall be due
and payable upon the second  [ * ] for a [ * ]; and in the event Astellas decides to pursue only  [ * ] set forth in paragraph 3 or 4 of this Section 6.1.2,
and pursues Commercialization of either of the [ * ], the milestone payment for associated with the  [ * ] for the [ * ] shall be due and payable upon
the first [ * ] for a [ * ]; and in the event that Astellas decides to pursue  [ * ] set forth in paragraphs 3 and 4 of this Section 6.1.2 and also does not
pursue [ * ], the parties shall a [ * ] for which the milestone payments associated with the  [ * ] set forth in paragraph(s) 3 and/or 4 of this Section
6.1.2, as the case may be, shall be due, as negotiated in good faith by the parties hereto.
 
    EVENT   AMOUNT
1.
 
Upon the first [ * ] for the [ * ]; provided, that in the event Astellas chooses the Bridging Strategy, such payment
shall be increased by an additional U.S. $[ * ] for a total of U.S. $[ * ]  
U.S. $[ * ]
2.
 
Upon the first [ * ] in the Astellas Territory for the [ * ]; provided, that in the event Astellas chooses the Bridging
Strategy, such payment shall be increased by an additional U.S. $ [ * ] for a total of U.S. $[ * ].  
U.S. $[ * ]
3.
 
Upon the first [ * ] in the Astellas Territory for the [ * ]; provided, that in the event Astellas chooses the Bridging
Strategy, such payment shall be increased by an additional U.S. $ [ * ] for a total of U.S. $[ * ].  
U.S. $[ * ]
4.
 
Upon the first [ * ] in the Astellas Territory for the first indication within [ * ] (see Exhibit B); provided, that in the
event Astellas chooses the Bridging Strategy, such payment shall be increased by an additional U.S. $ [ * ] for a
total of U.S. $[ * ].  
U.S. $[ * ]
 
-16-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
5.
 
Upon [ * ] in the Astellas Territory for each of up to [ * ] indications listed on Exhibit B, including separate
indications within [ * ] up to a total of U.S. $[ * ].  
U.S. $[ * ]
6.1.3 Sales Success Payments . As reimbursement and payment for FG’s historical and ongoing research and development
expenditures with respect to pre-clinical and clinical development of Lead Compounds and as payment for the successful marketing and sales of the
Lead Compound(s), Astellas agrees to make the following non-refundable, non-creditable (except as set forth in Section 14.3 below) reimbursement
payments to FG upon the first occurrence of the Event specified below.
 
EVENT   AMOUNT
Upon receipt of [ * ] aggregate annual Net Sales achieved for the first time in the Astellas Territory for all indications and
Lead Compounds by Astellas and its Affiliates and Sublicensees.  
U.S. [ * ]
If at the occurrence of an Event (except for Event 2) as set forth in Section 6.1.1 above with respect to a particular Lead Compound the
payment corresponding to the occurrence of any preceding Event (except for Event 2) ( i.e., “previous” as contemplated by the Event number
sequence specified above) has not been made, then the corresponding payment(s) for such preceding Event (except for Event 2) shall then be due.
The payments set forth in Sections 6.1.1, 6.1.2 and 6.1.3 hereof shall each be due and payable within  [ * ] after occurrence of the
corresponding Event. Astellas agrees to promptly notify FG in writing of its achievement of any Event under Sections 6.1.1, 6.1.2 and 6.1.3.
ARTICLE 7
USE OF PRECLINICAL AND CLINICAL DATA
7.1 Exchange. Subject to the provisions of this Article 7 and Article 16 below, the parties shall have access to the underlying preclinical
and clinical data (including raw data thereof), analysis, reports, protocols and correspondence (collectively with such filings, “Data”), at reasonable
times, upon fifteen (15) days advance notice or such shorter notice as may be required in order to meet any regulatory requirements and (upon
request) in English, (it being understood and agreed that Astellas shall provide in English without cost to FG summaries of all final reports and all
documents necessary to comply with regulatory and legal requirements, and
 
-17-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
shall provide all other documents in English with reasonable costs shared equally between the parties) of the other party in accordance with the
following:
(a) FG shall have access to and the right to use for any purpose, any Data developed by or on behalf of Astellas or its
Affiliates or Sublicensees in the course of the Development Program with respect to indications within the Field for Lead Compounds. Astellas
shall obtain from such Sublicensees access to all Data prepared by or for such Sublicensee with respect to a Lead Compound, with the right to
provide such Data and/or access to FG and its Sublicensees, and any sublicense failing to provide such obligation on the part of the Sublicensee
shall be voidable at the option of FG.
(b) Astellas shall have access to and the right to use solely for the purpose of this Agreement, any Data developed by or
on behalf of FG or its Affiliates or Sublicensees with respect to Lead Compounds in connection with the Field (i) to the extent necessary to support
the application to the regulatory authority in the Astellas Territory or to fulfill other Japanese Ministry of Health, Labor and Welfare regulatory
requirements, or (ii) if not necessary to support such application or to fulfill such Japanese Ministry of Health, Labor and Welfare regulatory
requirements, to the extent FG is permitted subject to FG’s third party obligations; provided that FG shall  [ * ] negotiate the availability of such Data
to Astellas from such Sublicensee, and provided, further, that Astellas agrees not to use or disclose to third parties any such data for purposes
outside the Field except as authorized under this Agreement.
7.2 Disclosure. Subject to the provisions of this Section 7.2, FG and Astellas may each provide copies or summaries of Data to its
Affiliates and/or its permitted Sublicensees to the extent reasonably necessary for the development and commercialization of Lead Compounds in
accordance with this Agreement, or in the case of FG of products other than Lead Compounds. It is understood that the foregoing shall include the
right to disclose Data to third parties with whom Astellas or FG are discussing entering into agreements for such permitted purposes, subject to
reasonable conditions of confidentiality, provided, that Astellas may not disclose any Data to any third party competitor of FG within the Field
worldwide without the prior written consent of FG.
7.3 Regulatory Requirements. Notwithstanding the provisions of Section 7.2, in all agreements with third parties or Affiliates involving
the development of Data, FG and Astellas, respectively, shall require that such third parties and Affiliates provide the other party with all such
Data, to the extent such Data is required in order for each party to meet its obligations to the other party under Section 4.4.2 above.
7.4 Review of Protocols. Astellas agrees that all final protocol summaries for all clinical trials and GLP toxicology studies to be
conducted by or under authority of Astellas will be subject to the review and approval of the JDC, in accordance with the following procedures set
forth in this Section 7.4. Astellas shall submit to FG and the JDC the original draft protocol summary in English for any clinical trial or GLP
toxicology study it proposes to conduct, and such protocol summary shall be reviewed and approved by the JDC. The protocol summary shall
contain all information as may be requested by the JDC. Upon Astellas’ completion of the final protocol for the proposed clinical trial or GLP
toxicology study, in the
 
-18-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
event that such protocol deviates from the original protocol summary, Astellas shall resubmit to FG and the JDC for review and approval a revised,
final protocol summary that indicates all changes from the original protocol summary. Notwithstanding the foregoing, FG reserves the right to
request and Astellas shall provide any portion of full text of the protocols in English for review by the JDC, which portion is at issue. In the event
FG requests such a full text protocol, it shall review and provide comments to the JDC as soon as practicable, and within five (5) business days of
receipt.
ARTICLE 8
MARKETING RIGHTS
8.1 Astellas. Astellas shall have the exclusive right to market, sell and distribute the Lead Compounds supplied by FG for use in the
Astellas Territory within the Field under the license granted in Article 13. Astellas may exercise its rights under this Section 8.1 through one or more
Sublicensees; provided, that any such Sublicensee agrees to terms identical in all material respects to those contained in this Agreement, and,
provided, further, that any arrangement between Astellas and an Astellas Sublicensee with respect to a Lead Compound shall be subject to the
requirements of Section 13.2.
8.2 FibroGen. FG shall have the exclusive right, including the right to authorize others, to market, sell and distribute the Lead
Compounds for any use in the FG Territory. Subject to the restrictions contained in Section 8.3.4 hereof, FG retains the exclusive right, including the
right to authorize others, to market, sell and distribute worldwide the Lead Compounds for use outside the Field.
8.3 Covenants 
8.3.1 General. It is understood that, with respect to any particular Lead Compound, whether or not the use and sale of such Lead
Compound by FG and/or Astellas in any country requires a license under intellectual property rights of the other, neither FG nor Astellas shall
market, sell or distribute a Lead Compound anywhere in the world except in accordance with this Agreement, including this Article 8.
8.3.2 Independent Activities by Astellas . During the term of this Agreement, in the event Astellas seeks to Commercialize any
molecules for the Field or the Expanded Field, except for actions taken within the Field in the course of the exercise of the license granted under
Section 13.1 hereof and expressly authorized under this Agreement, Astellas shall notify FG immediately upon the commencement of any such
activities, and provided that  [ * ] such activities are and will be in the future conducted completely independently of any of FG Technology and/or
any other FG materials, confidential information, intellectual property or other related information provided by or on behalf of FG to Astellas under
this Agreement or any other agreement between FG and Astellas relating to the subject matter hereof, Astellas may proceed with such
Commercialization, subject at all times to the obligations contained in this Agreement with respect to any intellectual property in connection with or
related to such activities and FG’s right to terminate this Agreement pursuant to Section 18.2.1 hereof.
 
-19-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
8.3.3 Use of FG Technology by Astellas. Astellas shall use the FG Technology only to exercise the rights granted under Section
13.1 of this Agreement and as expressly authorized under the Development Program, and shall not under any circumstances use or apply any FG
Technology, including without limitation any FG know-how and/or any other FG materials, confidential information, intellectual property or other
related information provided by FG to Astellas under this Agreement or any other agreement between FG and Astellas relating to the subject matter
hereof, for any use outside the Field at any time or within the Field after the expiration or termination of this Agreement.
8.3.4 Activities Outside Field by Astellas . Without limiting the foregoing, Astellas agrees that during the term of this Agreement
it will not (and will not authorize any third party, including, without limitation, any Affiliates or Sublicensees, to) (i) Commercialize any Lead
Compound within the Field in the Astellas Territory, except a Lead Compound that has been designated a Lead Compound by the JDC and that has
received Marketing Approval in the Astellas Territory for use in the Field, (ii) Commercialize any Lead Compound for use outside the Field or
outside the Astellas Territory, (iii) provide any supplies of any Lead Compound to any third party, including, without limitation, any Affiliates or
Sublicensees, which Astellas knows or has reason to know is being marketed, sold or distributed for use outside the Field or outside the Astellas
Territory, (iv) conduct or sponsor, or provide any supplies of any Lead Compound for use in, any clinical trial designed to demonstrate that a Lead
Compound can be used outside the Field, or (v) seek regulatory approval of, or use labeling for a Lead Compound stating that such Lead
Compound is for use outside the Field.
8.3.5 Activities in Astellas Territory by FG During the term of this Agreement, FG shall not Commercialize by itself or through its
Sublicensee any Lead Compound or other compound, whether or not designated as a Lead Compound, within the Field in the Astellas Territory, or
any Lead Compound outside the Field in the Astellas Territory, provided, however, that FG may develop a Lead Compound or other compound in
the Astellas Territory in those Indications for which Astellas has determined not to pursue Commercialization or for which Astellas has lost the
right to pursue Commercialization due to failure to meet diligence obligations hereunder; and provided, further, that FG may Commercialize
compounds other than Lead Compounds outside the Field in the Astellas Territory, irrespective of whether such compound has the effect of
stabilizing HIF causing the stimulation of erythropoiesis (including an increase in endogenous erythropoietin production) and/or a subsequent
increase in hematocrit through modulation of prolyl hydroxylase and/or asparaginyl hydroxylase.
ARTICLE 9
TRANSFER PRICING
9.1 Transfer for Non-Commercial Purpose. In exchange for the transfer of any Lead Compound to Astellas for a non-commercial
purpose, Astellas shall pay FG the total amount of the Fully Burdened Costs for such Lead Compound as reasonably determined by FG. Lead
Compound transferred to Astellas for a non-commercial purpose shall not be used for a commercial purpose.
 
-20-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
9.2 Transfer for Commercial Purpose. For any Lead Compound transferred to Astellas to be used for any commercial purpose, in
exchange for the transfer of such Lead Compound to Astellas, Astellas shall pay FG the amounts set forth in this Section 9.2. All transfers of Lead
Compound for use following Marketing Approval shall be deemed transfers for a commercial purpose, except transfers under Section 9.2(c), and
transfers for the purpose of conducting clinical trials, which shall be considered transfers for a non-commercial purpose.
(a) For any quantities of Lead Compound shipped by FG to Astellas prior to the issuance of the national health insurance
price as determined by the Japanese Ministry of Health, Labour and Welfare (the “Listed Price”), Astellas shall pay for such quantities at a price
equal to [ * ] of the estimate of the Listed Price as determined in good faith by FG and Astellas, subject to adjustment upon the issuance of the
actual Listed Price. Upon the issuance of such Listed Price by the Japanese Ministry of Health, Labour and Welfare, Astellas shall pay to FG, or FG
shall reimburse Astellas, as the case may be, the amount of any difference between the payment made for such Lead Compound at the estimated
Listed Price and the payment required based upon the actual Listed Price.
(b) For all other transfers of Lead Compound, except as set forth in subparagraphs (c) or (d) below, Astellas shall pay for
such quantities at a price equal to  [ * ] of the Listed Price. In the event that a new Listed Price has been notified to Astellas by the Japanese
Ministry of Health, Labour and Welfare before implementation of the new Listed Price, then such new Listed Price shall be used for calculation of
the price of Lead Compound to be shipped on and after the later to occur of (i)  [ * ] before implementation of the new Listed Price, and (ii) the date
upon which Astellas has amended the price of Lead Compound to wholesalers in response to such notification by the Japanese Ministry of Health,
Labour and Welfare, even before implementation of the new Listed Price.
(c) With respect to Lead Compound to be distributed as samples to medical providers and for which Astellas shall not
receive any payment or other consideration, Astellas shall pay to FG the sum of its Fully Burdened Costs for amounts of Lead Compound shipped
to Astellas; provided, however, that the parties shall mutually agree upon the amount of such samples for distribution without consideration in the
Astellas Territory.
(d) Upon the later of (i) the initial retail sale of a generic equivalent (as defined by the Japanese Ministry of Health, Labour
and Welfare) of such Lead Compound in the Territory, and (ii) and the expiration of the last to expire of the FG Patents with respect to such Lead
Compound effectively precluding third parties from selling said generic equivalent, for any quantities shipped by FG to Astellas, Astellas shall pay
FG for such quantities [ * ] of the Sales Price; provided, however, that in the event that the payment of the  [ * ] of the Sales Price would result in
FG’s [ * ] Percentage falling below [ * ], FG shall have the option to initiate a renegotiation of the transfer price upon notice to Astellas, in which
case the parties shall use best efforts in good faith to renegotiate reasonable terms for the transfer price; provided, further, that in the event the
transfer price is not renegotiated to FG’s satisfaction or FG elects not to initiate a renegotiation, FG may elect to terminate its manufacturing
obligations by written notice to Astellas, and FG and Astellas shall negotiate reasonable terms for transfer of manufacturing. During such period of
renegotiation, FG shall transfer the Lead Compound to Astellas at a price
 
-21-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
equal to the greater of [ * ] of the Sales Price and the price resulting if FG’s [ * ] Percentage for such Lead Compound is equal to  [ * ].
9.3 Payment. Any payments to be made with respect to the transfer of any Lead Compound in accordance with Section 9.1 or 9.2 above
shall be immediately due to FG upon shipment, which shall be paid by Astellas to FG no later than  [ * ] of the date of invoice, which invoice FG
shall deliver to Astellas upon Delivery of Lead Compound to Astellas pursuant to Section 9.2(a), (b) or (c), and shall be made in U.S. dollars. For
transfer of any Lead Compound in accordance with Section 9.1 or 9.2(c) above, FG shall deliver to Astellas, within ten (10) days of receipt of a firm
commitment order from Astellas, an invoice for the estimated Fully Burdened Costs of the Lead Compound to be transferred to Astellas. Within  [ * ]
after the transfer of the Lead Compound to Astellas, FG shall provide a revised final invoice to Astellas that shall indicate the actual Fully Burdened
Costs of the Lead Compound. If the actual Fully Burdened Costs are less than the estimated Fully Burdened Costs, FG shall include a
reimbursement payment to Astellas for the difference between the initial estimated Fully Burdened Costs and the actual Fully Burdened Costs. If
the actual Fully Burdened Costs are greater than the estimated Fully Burdened Costs, Astellas shall pay such difference within  [ * ] of receipt of an
invoice from FG for such amounts. For payments for the transfer of Lead Compound under Section 9.2(d) hereof, FG’s invoice to Astellas shall be
calculated based on the current Listed Price as set by the Japanese Ministry of Health, Labour and Welfare. Upon calculation of the Sales Price,
Astellas shall submit, for any amounts actually sold, the Sales Price to FG, and FG shall credit Astellas for the difference between the invoice cost,
cost calculated based on the Listed Price and the cost calculated based on the Sales Price.
9.4 Reference Materials; Standard Materials . In exchange for the transfer by FG of any Reference Materials or Standard Materials for the
purposes of conducting analytical, release, stability and other studies authorized under the Development Program, Astellas shall pay to FG, FG’s
Fully Burdened Costs of such materials as reasonably determined by FG.
ARTICLE 10
ADDITIONAL PAYMENTS; BOOKS AND RECORDS
10.1 Quarterly Reports. Astellas shall make quarterly reports to FG within sixty (60) days after the end of each calendar quarter (April 1
though June 30, July 1 through September 30, October 1 though December 31, January 1 through March 31), which reports shall include, (a) the Net
Sales, unit shipments and other distributions, including samples, by Astellas, and its Affiliates and Sublicensees, in such calendar quarter and (b)
such other information as may be reasonably requested by FG to ensure either proper payment by Astellas of amounts required under this
Agreement or to calculate payments with respect to FG’s Third Party Agreements. Concurrently with making such report, Astellas shall remit
payment to FG for any payments due under this Agreement.
10.2 Payment Method. All payments under this Agreement shall be made by bank wire transfer in immediately available funds to an
account designated by the payee. All
 
-22-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
such payments made by or on behalf of Astellas hereunder shall be made by a Japanese entity. All dollar amounts specified in this Agreement, and,
except as specifically authorized under Section 10.3 hereof, all payments made hereunder, are and shall be made in U.S. dollars. Any payments due
under this Agreement which are not paid by the date such payments are due under this Agreement shall bear interest to the extent permitted by
applicable law at the U.S. prime rate per annum quoted in the “Money Rates” column of  The Wall Street Journal (U.S., Western Edition) on the first
business day after such payment is due, plus an additional  [ * ], calculated on the number of days such payment is delinquent. This Section 10.2
shall in no way limit any other remedies available to either party.
10.3 Currency Conversion. In the event that the amount of an Astellas payment obligation in U.S. dollars must be determined by the
calculation of an underlying amount received by Astellas in Japanese Yen utilizing the U.S. dollar-Japanese Yen exchange rate (i.e., a transfer
payment under Section 9.2(a), (b) or (d) hereof), currency conversion from Japanese Yen to U.S. dollars shall be made using the closing exchange
rate reported in the Wall Street Journal (U.S. Western Edition) for the date on which the Lead Compound is Delivered to Astellas. If any such
payment is not made by the due date, the exchange rate utilized for determination of such payment obligation shall be the exchange rate  [ * ]
reported in the Wall Street Journal (U.S. Western Edition) during the period from the date of invoice through the due date, not including any
additional amounts owed under Section 10.2 hereof.
10.4 Taxes 
10.4.1 Generally. Each party shall bear and, except as otherwise expressly provided in this Section 10.4, pay any and all taxes,
duties, levies, and other similar charges (and any related interest and penalties), however designated, imposed on that party as a result of the
existence or operation of this Agreement. If laws or regulations require that taxes be withheld, the paying party will (i) timely pay the taxes to the
proper taxing authority, and (ii) send proof of payment to the other party within  [ * ] following that payment.
10.4.2 Certain Payments. Notwithstanding Section 10.4.1, all payments by Astellas required under this Agreement above,
including under Section 6.1.1 are expressed as net amounts and shall be made free and clear of, and without reduction for, any withholding taxes,
provided, however, that in the event that any withholding taxes are due on the payments Astellas shall make to FG under Sections 6.1.2 and 6.1.3,
Astellas shall make such payments directly to the Japanese Tax Authority and shall be entitled to reduce the amount paid to FG by  [ * ] of the
amount of the withholding taxes paid to Japanese Tax Authority in respect of such payment, unless the amount of such withholding taxes is
reduced by a decision of the Japanese tax authority, or is subsequently adjusted downward as result of appeal, in which event the next payment
due hereunder, including, without limitation, a transfer payment or a payment upon termination, shall be increased by such amount. Any such taxes
which are otherwise imposed on payments to FG shall be the sole responsibility of Astellas. Astellas shall provide FG with official receipts issued
by the appropriate taxing authority or such other evidence as is reasonably requested by FG to establish that such taxes have been paid. Astellas
and FG shall cooperate to minimize the withholding taxes due on the amounts payable by Astellas to FG hereunder to the extent permissible under
law, including, but not limited to,
 
-23-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
making appropriate application(s) to the tax authorities within the Astellas Territory. If possible, FG shall use its reasonable efforts to apply for the
tax refund from U.S. tax authorities for the withholding taxes paid to the Japanese Tax Authority on the payment U.S. $ [ * ] payment made by
Astellas to FG on January 13, 2004 as set forth in Section 6.1 when such application for the tax refund becomes possible, and if FG has received any
such tax refund, FG shall reimburse to Astellas for the amounts corresponding to the withholding taxes paid in Astellas’ accounts as set forth
above.
10.5 Records; Inspections . Astellas shall keep, and require its Affiliates and Sublicensees to keep, complete, true and accurate books of
accounts and records for the purpose of determining payments due pursuant to this Agreement. Such books and records shall be kept for at least  [
* ] following the end of the calendar quarter to which they pertain. FG shall keep, and require its Sublicensee(s) to keep, complete, true and accurate
books of accounts and records for the purpose of verifying the accuracy of the  [ * ] Percentage and Fully Burdened Costs. Such records will be
open for inspection at the principal place of business of each party (the “Inspected Party”) during such  [ * ] period by an independent auditor
chosen by the other party (the “Inspecting Party”) and reasonably acceptable to the Inspected Party for the purpose of verifying the amounts
payable by Astellas to FG hereunder or the accuracy of the  [ * ] Percentage and/or Fully Burdened Costs. Such inspections may be made no more
than once each calendar year, at reasonable times and on reasonable notice. Any books of accounts or records shall not be inspected more than
once. The independent auditor retained by the Inspecting Party shall be obligated to execute a reasonable confidentiality agreement with the
Inspected Party prior to commencing any such inspection, which, among other customary clauses, contains the provisions to the effect that such
auditor shall not disclose to the Inspecting Party any information other than as necessary to accomplish the purpose of the inspection. Inspections
conducted under this Section 10.5 shall be at the expense of the Inspecting Party. Any underpaid or overcharged amounts that are discovered will
be paid by the Inspected Party, and with interest on such underpaid or overcharged amounts at the rate set forth in Section 10.2 above. The parties
will endeavor to minimize disruption of the Inspected Party’s normal business activities to the extent reasonably practicable.
ARTICLE 11
DUE DILIGENCE
11.1 Astellas’ Due Diligence. Astellas shall use its commercially reasonable efforts (i) to conduct any development work undertaken
under the Development Program, and any and all clinical trials (including without limitation Phase III) required to obtain, and thereafter to take such
other actions as are necessary to obtain, Marketing Approvals for any Lead Compound in the Astellas Territory as soon as practicable, and (ii) to
launch each such Lead Compound in the Astellas Territory as soon as practicable after receiving Marketing Approval in the Astellas Territory for
such Lead Compound.
11.2 FG’s Due Diligence. FG shall use its commercially reasonable efforts to conduct, and to the extent possible taking into account
safety and other applicable issues, complete a Phase II clinical trial with FG-2216 or another Lead Compound in the FG Territory.
 
-24-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
11.3 Development Diligence 
11.3.1 Astellas shall pursue development of Indications according to the following terms: (i) Astellas shall pursue
Commercialization in “Treatment of anemia in patients with chronic kidney disease undergoing dialysis” and “Treatment of anemia in patients with
chronic kidney disease not undergoing dialysis”; (ii) Astellas shall notify FG within six (6) months of the execution of this Agreement whether it
shall pursue Commercialization in [ * ]; (iii) Astellas shall notify FG within six (6) months of the date FG notifies Astellas that it has demonstrated
Proof of Concept whether it will pursue Commercialization in [ * ]; (iv) Astellas shall notify FG within six (6) months of the date FG notifies Astellas
that it has demonstrated Proof of Concept whether it will pursue Commercialization in [ * ]; and (v) Astellas shall notify FG, upon Marketing
Approval for any Lead Compound in each of the following Indications, whether it will pursue Commercialization of such Indication:  [ * ], and any
other indications to be added hereafter to the definition of the Indication by mutual agreement; and (vi) if FG is pursuing Commercialization of  [ * ],
Astellas shall notify FG after Marketing Approval whether it shall pursue Commercialization of such Indication. Should Astellas inform FG that it
does not wish to pursue Commercialization of any Indication, or should Astellas fail to meet the due diligence obligations under Section 11.3.2 for
any Indication as set forth in Section 11.3.1(iv) or under Section 11.3.3 for any Indication as set forth in Section 11.3.1(v), such Indication shall no
longer be considered an Indication for the purposes of this Agreement, and Astellas shall have no right or shall lose any right with respect to such
Indication under this Agreement including, without limitation, the licenses granted under Sections 8.1 and 13.1 hereof. Each Indication for which
Astellas is obligated to pursue Commercialization under Section 11.3.1(i) or for which it decides to pursue Commercialization under Sections
11.3.1(ii), (iii) or (iv) shall be a “Major Indication”.
11.3.2 In addition to the obligations set forth in Section 11.1 and 11.3, for each Major Indication, until such time as Astellas
obtains Marketing Approval in the Astellas Territory for such Major Indication, with respect to each Lead Compound for each Major Indication,
Astellas shall:
(a) If required for development of a Lead Compound in an Indication, Initiate Phase I clinical trials within [ * ] after the later
of (i) the Effective Date, for Indications for which FG has commenced clinical trials prior to the execution of this Agreement, and (ii) FG’s or its
Sublicensees Initiation of a Phase I clinical trial for other such Indications.
 
-25-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
(b) Initiate Phase II clinical trials within the later of (i) [ * ] after FG’s, or its Sublicensee’s, Initiation of Phase II, (ii) [ * ]
after Astellas’ Completion of its Phase I clinical trial(s), (iii) if Astellas’ obligations under this Subsection 11.3.2(b) are triggered upon FG’s
notification of demonstration of Proof of Concept in an Indication,  [ * ] after the date Astellas notifies FG that it will pursue Commercialization in
such Indication, and (iv) in the event Astellas’ obligations under this Section 11.3.2(b) are triggered by the designation of a secondary Lead
Compound as a primary Lead Compound, [ * ] after such designation.
(c) Either notify FG of its intent to employ the Bridging Strategy, if applicable, or Initiate Phase III clinical trials within [ * ]
of the later of (i) FG’s, or its Sublicensee’s Initiation of a Phase III clinical trial and (ii) Astellas’ Completion of its Phase II clinical trial(s).
11.3.3 For each of the Indications set forth in Section 11.3.1(v), Astellas shall Initiate Phase II clinical studies within [ * ] of its
notification to FG that it will pursue Commercialization in such Indication.
11.3.4 Astellas’ diligence obligations set forth in Section 11.3.2 shall apply to all Lead Compounds designated by FG, provided,
that for each Indication for which such diligence obligations apply, the diligence obligations shall only apply to the primary Lead Compound
designated by FG, and for the secondary Lead Compound, Astellas’ diligence obligations shall be limited to those set forth in Section 11.3.2(a) until
the designation of the secondary Lead Compound as the primary Lead Compound, provided, further, upon such designation, that such diligence
obligation shall be expanded to include the requirement that Astellas complete the Phase I clinical studies required to Initiate Phase II clinical
studies in the Indication with such secondary Lead Compound.
ARTICLE 12
MANUFACTURING RIGHTS
12.1 Procedures. FG shall have the exclusive right to determine the methods and procedures for the manufacture of all Lead
Compounds. If FG intends to make any change in the methods or procedures, including, without limitation, manufacturing process, analyzing
process and/or site change for manufacture of the Lead Compounds, FG shall notify Astellas in writing of such intended change; provided, that if
in Astellas’ reasonable opinion, such change may lead to any amendment to the relevant Marketing Approval or Marketing Approval Application,
Astellas shall use best efforts to (i) as soon as possible petition the Japanese Ministry of Health, Labor and Welfare to make the change without an
amendment to the Marketing Approval or MAA and shall concurrently prepare an application for amendment to the Marketing Approval or MAA,
and (ii) if the Japanese Ministry of Health, Labor and Welfare determines such an amendment is required, shall notify FG and submit the application
for amendment immediately following notice of such requirement, and FG shall not make the intended change without a prior written consent from
Astellas, such consent not to be unreasonably withheld or delayed, provided, further, that consent shall be deemed granted upon notice that an
amendment is not required or approval of an amendment from the Japanese
 
-26-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
Ministry of Health, Labor and Welfare. FG shall provide Astellas with all the data and information necessary for Astellas to amend the Marketing
Approval or MAA in Astellas Territory and shall continue to supply Astellas with the Lead Compound as manufactured with the manufacturing
methods and procedures or at the manufacturing site described in Astellas’ (or its Affiliate’s or Sublicensee’s) then current Marketing Approval or
MAA until Astellas will have finished the necessary amendment to the relevant Marketing Approval or MAA or received notice that an amendment
is not required.
12.2 FG Right. FG shall have the worldwide exclusive right (itself or through third party vendors) to manufacture (or have manufactured)
Lead Compounds. Astellas and its Affiliates and Sublicensees shall not directly or indirectly make, produce or manufacture any Lead Compounds.
12.3 Manufacture and Supply . FG shall have the exclusive right and obligation to supply the Lead Compounds to Astellas and its
Affiliates and Sublicensees for all development and commercial purposes, and Astellas and its Affiliates and Sublicensees shall purchase such
Lead Compounds exclusively from FG. It is understood that FG may engage subcontractors with respect to the manufacture of such Lead
Compounds to fulfill its supply obligations to Astellas hereunder. In all cases, supply by FG of Lead Compounds hereunder shall be Ex Works
(Incoterms 2000) the manufacturing facility. Subject to Section 8.3.5 hereof, nothing herein is intended to preclude FG from granting rights to supply
or supplying (a) any Lead Compound outside of the Astellas Territory to any third party for use within or outside the Field, or (b) any compound
Controlled by FG within the Astellas Territory except for a Lead Compound for the duration of its designation in compliance with the terms and
conditions of this Agreement.
12.4 Product Specifications. The Lead Compounds to be supplied by FG hereunder shall meet the Product Specifications. In addition to,
but not in limitation of, the foregoing, FG and Astellas agree that upon Marketing Approval for any Lead Compound, FG’s obligation to supply
Astellas with Lead Compound shall be limited to, and all payment obligations set forth in Section 9.2 shall be based on, the supply of Bulk Product,
unless otherwise agreed by the parties. The packaging for the Lead Compound to be distributed commercially by Astellas shall contain a clearly
visible acknowledgment that the Lead Compound was manufactured by FG, and shall contain a registered trademark of the FG logo or other
trademark approved by FG.
12.5 Orders Forecast 
12.5.1 Orders for Non-Commercial Use. In connection with the supply of any Lead Compound for non-commercial use in the
Territory, Astellas shall provide FG with a firm purchase order as early as possible prior to its requirements, and in no event less than  [ * ] prior to
the shipment or other release date(s) requested by Astellas for such Lead Compound. FG shall provide such Lead Compound to Astellas as soon
as practicable within such time period, subject, prior to Marketing Approval, to the reasonable lead time requirements of third party contract
manufacturers. All forecasts shall be prepared in good faith in order to facilitate FG’s manufacture and shipment of the Lead Compound in
compliance with this Agreement.
 
-27-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
12.5.2 Forecast and Order for Commercial Use. In connection with the supply of any Lead Compound for commercial use in the
Astellas Territory upon FG’s request, Astellas and FG shall negotiate in good faith appropriate forecasting and firm purchase order lead times,
taking into consideration the reasonable notice requirements of FG and its third party manufacturers. All forecasts shall be prepared in good faith in
order to facilitate FG’s manufacture and shipment of the Lead Compound in compliance with this Agreement.
12.6 Shipment. Astellas, or FG at Astellas’ request if specified in a purchase order by Astellas, shall arrange for shipment of the Lead
Compound as specified in each purchase order by Astellas, Ex Works (Incoterms 2000) the manufacturing facility. For purposes of this Agreement,
and notwithstanding anything to the contrary contained within the term “Ex Works”, it is hereby acknowledged and agreed that title and risk of
loss shall transfer to Astellas from receipt by Astellas at the manufacturing facility. Astellas shall bear the costs of such carrier, including the costs
of insurance of the shipment, and all customs, duties, sales taxes and other governmental charges related to the importation and sales of the Lead
Compound.
12.7 Inspection of Shipment/Right to Reject . Each shipment of Lead Compound from FG to Astellas shall contain such laboratory and
quality control certificate as are necessary to show that the Lead Compound is in conformity with the Product Specifications. Astellas shall
promptly inspect each shipment. In the event that any portion of the shipment fails to conform to the Product Specifications, Astellas shall notify
FG within [ * ] of Astellas’ receipt of such shipment. Such notice shall specify the manner in which the Lead Compound fails to meet the Product
Specifications. In the absence of such notification, Astellas shall be deemed to have accepted the shipment. FG and Astellas agree to consult with
each other to resolve any discrepancy between each other’s determinations regarding any possible nonconformity of the Lead Compound. If such
consultation does not resolve the discrepancy, the parties agree to nominate a reputable independent laboratory or other independent third party,
in each case acceptable to both parties, to carry out tests on representative samples taken from such shipment, and the results of such tests shall
be binding on both parties. If the results of such tests demonstrate that the Lead Compound does not meet the Product Specifications, then FG
shall pay the costs of such tests; otherwise, Astellas shall pay for the costs of such tests. FG shall, at its expense, promptly replace any Lead
Compound to the extent that, in accordance with this Section 12.7, it is determined that it does not conform to the Product Specifications. Unless
otherwise instructed by FG, all non-conforming Lead Compound shall be returned to FG at the place of manufacture at FG’s direction and at FG’s
expense. If Astellas detects at any time any defect in the Lead Compound which has not been found through Astellas’ inspection, it shall notify FG
to that effect within [ * ] of the discovery of such defect, and the procedures set forth above in this Section 12.7 shall be applied to such defective
Lead Compound, provided, that FG shall only be responsible to pay for costs of defects that are the result of FG’s gross negligence or willful
misconduct.
12.8 Inspection of Facilities. Astellas shall have the right, upon reasonable advance notice and during regular business hours, to
inspect and audit, either by itself or through its Affiliates or consultants, the facilities (including any facilities of sub-contractors) being used by FG
for production of the Lead Compound to assure compliance with applicable laws, rules and regulations, including, without limitation, Japanese
regulatory standards and FG quality control procedures (“Relevant Standards”). FG shall also reasonably comply with inspection
 
-28-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
requests of the Japanese Ministry of Health, Labor & Welfare. Such inspection and audit shall be conducted at Astellas’ sole cost and expense in a
manner so as to minimize disruption of FG’s, or its subcontractor’s or Sublicensee’s, business operations. FG shall, within  [ * ] after FG’s receipt of
written notice from Astellas detailing any deficiencies which may be noted in any such audit which relate to the Relevant Standards use good faith
efforts to remedy such deficiencies, and submit a plan to the Astellas outlining steps proposed to be taken.
12.9 Recall. In the event that Astellas deems it necessary to recall any Lead Compound from the market, it may do so in its sole
discretion, after notification to the FG. The costs and expenses for such recall shall be borne by Astellas unless caused by a failure for which FG is
required to indemnify Astellas pursuant to Section 17.3, or by FG’s gross negligence or willful misconduct, in which event it shall be borne by FG.
12.10 Warranty. FG represents and warrants that the Lead Compounds to be supplied to Astellas under this Agreement shall conform to
the Product Specifications and shall, as appropriate, be manufactured in compliance with GMP Guidelines. Subject to Sections 12.9 and 17.3 hereof,
FG’s sole obligation and Astellas’ sole remedy with respect to Lead Compound which does not
meet the warranty contained herein is limited to replacement of such Lead Compound and reimbursement of Astellas’ out of pocket expenses for
shipping to FG at the address designated by FG.
12.11 Interruption in Supply. For any particular Lead Compound, in order to minimize any interruptions in supply hereunder, FG and
Astellas agree that within  [ * ], FG shall maintain two separate, validated manufacturing sites (which may either be its own manufacturing facilities
or facilities of a contract manufacturer) for such Lead Compound.
12.12 Reference and Standard Materials . For any Lead Compound provided to Astellas hereunder, upon Astellas’ request and pursuant
to Section 9.4 hereof, FG shall provide to Astellas reasonable quantities of reference materials, including analogs, metabolites, impurities,
degradates and radio-labeled compounds (“Reference Materials”) and standard materials, i.e. defined, highly purified Lead Compound (“Standard
Materials”) for such Lead Compound for the purposes of conducting analytical, release, stability and other studies as may be authorized by the
JDC under the Development Program.
ARTICLE 13
LICENSE GRANTS
13.1 Grant to Astellas. Subject to the terms and conditions of this Agreement including Article 12 above, FG hereby grants to Astellas
an exclusive license under the FG Technology to: use, package, sell, have sold, import, market and otherwise distribute the Lead Compounds for
use solely in the Field in the Astellas Territory
13.2 Sublicenses. The licenses granted under Section 13.1 above include the right to grant and authorize sublicenses, subject to the
requirements of this Agreement and Section 7.2. Notwithstanding the foregoing, Astellas shall not have the right to authorize a Sublicensee to
market, sell or distribute Lead Compounds without FG’s prior written consent
 
-29-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
(which consent shall not be unreasonably withheld). For the purposes of the foregoing, and without limitation, it shall be deemed reasonable for FG
to withhold consent for competitive concerns.
13.3 No Rights Beyond Lead Compounds . Except as expressly provided herein, nothing in this Agreement shall be deemed to grant to
Astellas rights in FG Technology other than the rights granted hereunder to the Lead Compounds, or for applications outside the Field or outside
the Astellas Territory, or to manufacture Lead Compounds; nor shall any provision of this Agreement be deemed to restrict FG’s right to exploit any
FG Technology and/or the Lead Compounds outside the Astellas Territory.
13.4 Expanded Field Negotiation. Following the signing of this Agreement, FG agrees to negotiate in good faith with Astellas for a
license to develop compounds for the Expanded Field in the Astellas Territory, exclusively for a period of  [ * ] following such date, and non-
exclusively thereafter until the execution of a license agreement with a third party to develop compounds for the Expanded Field. FG and Astellas
hereby agree that FG’s obligation to negotiate non-exclusively for the Expanded Field shall not constitute a right of first offer, right of first refusal,
right of first negotiation or any obligation to enter into any agreement with Astellas at any time, and the failure of such negotiations to result in an
agreement between FG and Astellas with respect to the Expanded Field shall not constitute a breach of this Agreement.
ARTICLE 14
INTELLECTUAL PROPERTY
14.1 Ownership of Inventions . Subject to Section 14.1.1, title to all inventions and other intellectual property made related to (i) the
Development Program, (ii) the Lead Compounds, (iii) FG Technology or FG Confidential Information, (iv) the Field, or (v) the Expanded Field
(subsections 14.1(i)-(v), collectively, the “Protected Field”) shall be owned by or is hereby assigned to FG; provided, however that Astellas shall
own inventions of general applicability relating solely to drug delivery systems created exclusively by Astellas under subsection 14.1(i), excluding
inventions related to or based on subsections 14.1(ii), (iii), (iv), or (v), and provided, further, that Astellas hereby grants to FG a worldwide, fully
paid non-exclusive license with the right to sublicense to practice such inventions with respect to the FG Technology. Astellas agrees to execute
any and all assignments and other documents necessary to effectuate the foregoing.
14.1.1 Notwithstanding Section 14.1, in the event that Astellas develops, completely independently from any FG Technology
and/or any other FG materials, confidential information, intellectual property or other related information provided by or on behalf of FG to Astellas
under this Agreement or any other agreement between FG and Astellas relating to the subject matter hereof, any inventions or intellectual property
rights related to the Field or the Expanded Field, [ * ], Astellas shall own such intellectual property and hereby grants to FG and its Sublicensees a
non-exclusive, royalty-free, irrevocable license to such intellectual property for the FG Territory. Astellas agrees to execute any and all assignments
and other documents necessary to effectuate the foregoing.
 
-30-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
14.2 Patent Prosecution  
14.2.1 FG Inventions. FG shall control all Prosecution and Interference Activities pertaining to FG Patents and patent
applications and patents related to its, its Affiliate’s or its Sublicensee’s inventions in the Protected Field worldwide using counsel of its choice and
shall bear the costs of such Prosecution and Interference Activities, provided, however, that; and Astellas shall reimburse to FG, within  [ * ] of
receipt by Astellas of invoice therefor, any such costs to the extent incurred in connection with or reasonably allocable to the FG Patents registered
and/or to be registered in the Astellas Territory and related to the Field and the Lead Compounds, provided, further, that, with respect to patents or
patent applications excluding those covering composition of matter claims and all patents listed on Exhibit A hereto as of the Effective Date,
Astellas may postpone such reimbursement until the respective FG Patent will have been registered in the Astellas Territory if  [ * ], on condition
that once the respective FG Patent has been registered in the Astellas Territory, Astellas shall pay to FG such costs, plus interest to the extent
permitted by applicable law at the U.S. prime rate per annum quoted in the “Money Rates” column of  The Wall Street Journal (U.S., Western
Edition), calculated in each case from the date such costs were incurred, plus an additional  [ * ] thereof.
14.2.2 Astellas Inventions . Astellas shall not file for or otherwise seek to obtain (directly or indirectly) patent or other intellectual
property protection for inventions that are related to the Protected Field, without the prior written consent of FG, which may be withheld at FG’s
sole discretion, subject to Section 14.1.1, and provided also that Astellas may file for or otherwise seek to obtain patent protection for inventions
related to drug delivery systems as described in Section 14.1. To the extent that FG consents to the filing of any patent application or other
intellectual property protection related to the foregoing, such patent application or other intellectual property protection shall be subject to Section
14.1, unless otherwise agreed in writing.
14.2.3 Cooperation. Astellas shall cooperate with and assist FG in connection with Prosecution and Interference Activities and
shall use best efforts to consult with FG regarding the prosecution and maintenance of the FG Patents for the FG Territory and the Astellas
Territory for those FG Patents for which Astellas or its Affiliates, Sublicensees or investigators are inventors, except solely for inventions (i) of
general applicability relating solely to drug delivery systems created by Astellas under subsection 14.1(i), or (ii) created in compliance with Section
14.1.1 as determined solely by FG in good faith.
14.3 Defense of Third Party Infringement Claims. If the development, manufacture, sale or use of any Lead Compound pursuant to this
Agreement results in a claim, suit or proceeding (collectively, “Actions”) alleging patent infringement against FG or Astellas (or their respective
Affiliates or Sublicensees), such party shall promptly notify the other party hereto in writing. The party subject to such Action (for purposes of this
Section 14.3, the “Controlling Party”) shall have the exclusive right to defend and control the defense of any such Action using counsel of its own
choice; provided, however, that if such Action is directed to the subject matter of a patent of the other party ( i.e., for Astellas, a FG Patent), such
other party may participate in the defense and/or settlement thereof at its own expense with counsel of its choice.
 
-31-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
Except as agreed in writing by Astellas and FG, Astellas shall not enter into any settlement relating to a Lead Compound, if such settlement admits
the invalidity or unenforceability, or limits any claim, of any patent within the FG Technology. The Controlling Party agrees to keep the other party
hereto reasonably informed of all material developments in connection with any such Action. Any cost, liability or expense associated with such
action (including amounts paid in settlement) (together, “Expenses”) shall be borne by the Controlling Party; provided, that if Astellas is the
Controlling Party, and the Action is related to Future Third Party Intellectual Property, with respect to Expenses related solely to such Future Third
Party Intellectual Property, it shall be entitled to deduct up to  [ * ] of the Expenses incurred on an annual basis from  [ * ] in such year under this
Agreement, provided, however, that (i) the total amount deducted shall not exceed  [ * ] thereunder, and (ii) notwithstanding (i) above, Astellas’
right to deduct Expenses incurred shall be further limited such that in no event shall the sum of (a) the Expenses deducted by Astellas under this
Section 14.3, and (b) the consideration FG contributes for the acquisition of intellectual property from Third Party Licensors for the Astellas
Territory as set forth in Section 14.5, exceed [ * ] hereunder, and, provided further, that if FG is the Controlling Party, it shall be entitled to
reimbursement by Astellas of [ * ] of such Expenses, as incurred. Notwithstanding the foregoing, Astellas shall be solely responsible (without right
of deduction) for all Expenses related to any Action relating to Preexisting Third Party Intellectual Property.
14.4 Enforcement. Subject to the provisions of this Section 14.4, in the event that FG or Astellas reasonably believes that any FG
Technology necessary for the development, manufacture, use or sale of a Lead Compound is infringed or misappropriated by a third party or is
subject to a declaratory judgment action arising from such infringement, in each case with respect to the development, manufacture, sale or use of a
product within the Field and within the Astellas Territory, Astellas or FG (respectively) shall promptly notify the other party hereto. Promptly after
such notice the parties shall meet to discuss the course of action to be taken with respect to an Enforcement Action (as defined below) with respect
to such infringement or misappropriation, including the control thereof and sharing of costs and expenses related thereto, for the purposes of
entering into a litigation agreement setting forth the same (“Litigation Agreement”). If the parties do not enter such Litigation Agreement, FG shall
have the initial right (but not the obligation) to enforce the intellectual property rights with respect to the FG Technology, or defend any declaratory
judgment action with respect thereto (such action, for purposes of this Section 14.4, an “Enforcement Action”).
14.4.1 Information. Absent a Litigation Agreement, the party initiating or defending any such Enforcement Action within the
Field shall keep the other party hereto reasonably informed of the progress of any such Enforcement Action, and such other party shall have the
right to participate with counsel of its own choice at its own expense.
14.4.2 Enforcement Costs; Recoveries . Absent a Litigation Agreement, FG shall have the initial right to initiate such an
Enforcement Action, and shall notify Astellas within a reasonable time whether it elects to exercise such right. In the event that FG elects to initiate
or defend such Enforcement Action, FG shall be responsible for  [ * ] of the costs and expenses while Astellas shall be responsible for  [ * ] of the
costs and expenses, and all amounts recovered shall first be applied to reimbursement of each
 
-32-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
party’s costs and expenses with the remainder to be allocated to FG and Astellas at the ratio of  [ * ] and [ * ]. In the event that FG elects not to
initiate or defend such Enforcement Action, Astellas shall have the right to initiate or defend such Enforcement Action in its own name, and to the
extent permitted under Third Party Agreements, in the name of FG or in the names of both FG and Astellas, in which case, Astellas shall be
responsible for [ * ] of the costs and expenses while FG shall be responsible for  [ * ] of the costs and expenses, and all amounts recovered shall first
be applied to reimbursement of each party’s costs and expenses with the remainder to be allocated to Astellas and FG at the ratio of  [ * ] and [ * ].
14.4.3 Cooperation in Enforcement Action. Absent a Litigation Agreement, at the request of the party which has the right to
initiate or defend an Enforcement Action, the other party shall reasonably cooperate in the Enforcement Action, such cooperation to include,
without limitation, furnishing records, information and testimony, and attending conferences, discovery proceedings, hearings, trials and appeals;
provided, that the requesting party shall reimburse to the cooperating party for the out-of-pocket expenses incurred for such cooperation pursuant
to the reimbursement regime set forth in Section 14.4.2.
14.5 Third Party Agreements 
14.5.1 Future Agreements. It is understood that FG may find it necessary to utilize in connection with a Lead Compound
intellectual property that is controlled by a non-Affiliate third party (such party, a “Third Party Licensor”), in addition to or in lieu of the FG
Technology existing as of the Effective Date. FG shall have the right to obtain (by purchase, license, or otherwise) rights to such intellectual
property with the right to sublicense to Astellas. In the event that FG determines that it must obtain such rights, it shall provide notice and submit a
description of such rights to Astellas, and shall discuss with Astellas the need to obtain such rights. Astellas shall inform FG within  [ * ] of receipt
of such notice whether it believes it is necessary to obtain such rights for the Astellas Territory and wishes to obtain such rights. In the event
Astellas determines to obtain such rights, FG shall obtain a worldwide license for the rights under such terms and conditions as are  [ * ], and such
intellectual property of the Third Party Licensor shall be deemed to be the part of FG Technology, provided, however, that, notwithstanding
anything contained in this Agreement (i) for Preexisting Third Party Intellectual Property,  [ * ] shall pay [ * ] of all consideration due in connection
with the acquisition of such rights for the Astellas Territory, and (ii) for Future Third Party Intellectual Property,  [ * ] shall [ * ] pay [ * ] of all
consideration due in connection with the acquisition of such rights for the Astellas Territory, provided, however, notwithstanding FG’s obligation
to contribute to the consideration due for Future Third Party Intellectual Property under (ii) above, FG’s obligation to contribute shall be limited
such that in no event shall the sum of (a) the consideration FG contributes for the acquisition of intellectual property from Third Party Licensors for
the Astellas Territory, and (b) the Expenses for which Astellas has the right to deduct under Section 14.3 exceed  [ * ] hereunder, and Astellas shall
be responsible for all consideration related to the acquisition of rights from Third Party Licensors in excess of such amount. In the event Astellas
determines not to obtain such rights for the Astellas Territory, FG shall obtain a license for the FG Territory but not the Astellas Territory, and
Astellas shall be solely responsible for the defense of any infringement
 
-33-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
Action, for all Expenses related to any such Action, and any right of Astellas to deduct Expenses under this Agreement against payments required
to be made to FG hereunder shall not apply to any action brought with respect to such rights.
14.5.2 Payment; Reports. If FG is obligated to pay amounts to a Third Party Licensor, FG shall notify Astellas [ * ] in advance of
the due date of such payment obligation (or such later date as FG may determine), and Astellas shall reimburse its share of such payments within  [
* ] after receipt of notice therefor.
14.5.3 Limitation. To the extent that FG Patents includes any intellectual property licensed under FG’s License Agreement with
Imigen, Inc. relating to HIF stabilization technology dated as of October 30, 2003, and amended as from time to time of which a redacted copy shall
have been provided to Astellas prior to the Effective Date, Astellas shall be considered a sublicensee and be subject to the applicable requirements
thereunder.
14.5.4 Compliance with Third Party Agreements. Notwithstanding anything to the contrary contained herein, Astellas agrees to
comply with the requirements (upon sublicensees or otherwise) of FG’s License Agreement with Imigen, Inc. relating to HIF stabilization
technology dated as of October 30, 2003. In addition, Astellas agrees to comply with the requirements (upon sublicensees or otherwise) of any
future Third Party Agreements for which Astellas obtains rights through an FG license pursuant to Section 14.5.1 hereof.
ARTICLE 15
REPRESENTATIONS AND WARRANTIES
15.1 FG Warranties. FG warrants and represents to Astellas, as of the execution of this Agreement, that (i) it is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware; (ii) the execution, delivery and performance of this
Agreement have been duly authorized by all necessary corporate action on the part of FG; (iii) there is no pending litigation which alleges or any
communication alleging that Commercialization of any Lead Compound or any compound Controlled by FG for use in the Field has infringed or
misappropriated the intellectual property rights of any Third Party or has been obtained by misappropriating any Third Party’s intellectual property
right; and (iv) subject to the terms and conditions of the agreements for the FG Acquired Patents, FG has complete title to and ownership of the FG
Patents, free and clear from any mortgages, pledges, liens, security interests, conditional and installment sale agreements, encumbrances, charges
or claims of any kind.
15.2 Astellas Warranties. Astellas warrants and represents to FG, as of the execution of this Agreement, that (i) it is a corporation duly
organized, validly existing and in good standing under the laws of Japan; and (ii) the execution, delivery and performance of this Agreement have
been duly authorized by all necessary corporate action on the part of Astellas.
15.3 Disclaimer of Warranties. EXCEPT AS OTHERWISE SET FORTH HEREIN, FG AND ASTELLAS EXPRESSLY DISCLAIM ANY
WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO
 
-34-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
THE DEVELOPMENT PROGRAM, OR THE FG TECHNOLOGY OR LEAD COMPOUNDS, INCLUDING, WITHOUT LIMITATION, ANY
WARRANTY OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF FG TECHNOLOGY, PATENTED OR
UNPATENTED, AND NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.
ARTICLE 16
CONFIDENTIALITY
16.1 Confidential Information. Except as expressly provided herein, the parties agree that the receiving party shall not publish or
otherwise disclose and shall not use for any purpose other than this Agreement any information furnished to it by the other party hereto pursuant
to this Agreement which if disclosed in tangible form is marked “Confidential” or with other similar designation to indicate its confidential or
proprietary nature or if disclosed orally is indicated orally to be confidential or proprietary by the party disclosing such information at the time of
such disclosure and is confirmed in writing as confidential or proprietary by the disclosing party within a reasonable time after such disclosure
(collectively, “Confidential Information”). Notwithstanding the foregoing, Confidential Information shall not include information that, in each case
is demonstrated by written documentation:
(a) was already known to the receiving party, other than under an obligation of confidentiality directly or indirectly to the
disclosing party at the time of disclosure hereunder;
(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving
party hereunder;
(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than
through any act or omission of the receiving party in breach of this Agreement; or
(d) was subsequently lawfully disclosed to the receiving party by any third party without any confidentiality obligation
directly or indirectly to the disclosing party or developed by the receiving party without reference to any information or materials disclosed by the
disclosing party.
It is agreed and understood that all matters discussed and presented at the meetings of the JDC shall be considered Confidential Information
hereunder, subject to the terms and conditions of this Agreement.
16.2 Permitted Disclosures. Notwithstanding the provisions of Section 16.1 above, each party hereto may disclose the other party’s
Confidential Information to the extent such disclosure is reasonably necessary to exercise the rights granted to it, or reserved by it, under this
Agreement (including, without limitation, entering into and/or performing business or scientific relationships with respect to products outside the
Field as permitted hereunder), in filing or prosecuting patent applications, prosecuting or defending litigation, complying with applicable
governmental regulations, submitting information to tax or other governmental
 
-35-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
authorities (including regulatory authorities), or conducting clinical trials hereunder with respect to Lead Compounds, provided that if a party is
required by law to make any such disclosure of the other party’s Confidential Information, to the extent it may legally do so, it will give reasonable
advance notice to the latter party of such disclosure and, save to the extent inappropriate in the case of patent applications or otherwise, will use its
reasonable efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or
otherwise).
16.3 Clinical Data. Except as expressly permitted under Sections 7.2 and 16.2, and for publications or disclosures in accordance with
Section 5.2, neither party shall disclose to third parties pre-clinical data, clinical data or regulatory filings, comprising Confidential Information of the
other party.
16.4 Press Releases. Except as may already be, or is agreed to be, publicly disclosed, in the event that either party proposes to release a
press release with respect to this Agreement or the Development Program, such party shall obtain the prior written consent of the other party,
which shall not be unreasonably withheld.
ARTICLE 17
INSURANCE; INDEMNIFICATION
17.1 Insurance. Each party shall secure and maintain in effect during the term of this Agreement and for a period of five (5) years
thereafter insurance policy(ies) underwritten by a reputable insurance company and in a form and having limits standard and customary for entities
in the biopharmaceutical industry for exposures related to the Lead Compounds. Such insurance shall include general liability, clinical trial liability
and products liability coverage with respect to such party’s performance of the Development Program and commercialization of Lead Compounds
hereunder. Upon request by the other party hereto, certificates of insurance evidencing the coverage required above shall be provided to the other
party.
17.2 Indemnification of FG. Astellas shall indemnify each of FG and its Affiliates and the directors, officers, and employees of FG and
such Affiliates and the successors and assigns of any of the foregoing (the “FG Indemnitees”), and hold each FG Indemnitee harmless from and
against any and all liabilities, damages, settlements, claims, actions, suits, penalties, fines, costs or expenses (including, without limitation,
reasonable attorneys’ fees and other expenses of litigation) incurred by any FG Indemnitee to the extent not otherwise covered by insurance,
arising from or occurring as a result of any claim, action, suit, or other proceeding brought by third parties against a FG Indemnitee arising from or
occurring as a result of any development, testing, manufacture, importation, use, offer for sale, sale or other distribution of any Lead Compound by
or for the benefit of Astellas or its Affiliates or Sublicensees, distributors or agents (including, without limitation, product liability and infringement
claims) except to the extent caused by failure of the Lead Compound supplied by FG to meet the Product Specifications in effect at the time of
manufacture, or material deviation by FG or its sub-contractor from GMP Guidelines in manufacturing the Lead Compound, or FG’s breach of this
Agreement or willful misconduct.
 
-36-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
17.3 Indemnification of Astellas. FG shall indemnify each of Astellas and its Affiliates and the directors, officers, and employees of
Astellas and such Affiliates and the successors and assigns of any of the foregoing (the “Astellas Indemnitees”), and hold each Astellas
Indemnitee harmless from and against any and all liabilities, damages, settlements, claims, actions, suits, penalties, fines, costs or expenses
(including, without limitation, reasonable attorneys’ fees and other expenses of litigation) incurred by any Astellas Indemnitee to the extent not
otherwise covered by insurance, arising from or occurring as a result of any claim, action, suit, or other proceeding brought by third parties against
an Astellas Indemnitee to the extent caused by failure of the Lead Compound supplied by FG to meet the Product Specifications in effect at the time
of manufacture, or material deviation by FG or its sub-contractor from GMP Guidelines in manufacturing the Lead Compound, except in each case in
this Section 17.3 to the extent caused by Astellas’ breach of this Agreement or willful misconduct.
17.4 Procedure. A party (for purposes of this Section 17.4, the “Indemnitee”) that intends to claim indemnification under any provision
of this Agreement shall promptly notify the indemnifying party (the “Indemnitor”) in writing of any claim, action, suit, or other proceeding brought
by third parties in respect of which the Indemnitee or any of its Affiliates, or their directors, officers, employees, successors or assigns intend to
claim such indemnification hereunder. As between the parties hereto the Indemnitor shall have the right to control the defense and settlement of
such claim, action, suit, or other proceeding; provided, that the Indemnitee shall have the right to participate in such defense or settlement with
counsel of its own choosing at its expense. The Indemnitee shall not make any settlement of any loss, claim, damage, liability or action without the
consent of the Indemnitor, to the extent such consent is not withheld unreasonably or delayed. The failure to deliver written notice to the
Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such
Indemnitor of any liability to the Indemnitee under this Article 17 but the omission so to deliver written notice to the Indemnitor shall not relieve the
Indemnitor of any liability that it may have to any Indemnitee otherwise than under this Article 17. Without limiting the foregoing, the Indemnitee
shall keep the Indemnitor fully informed of the progress of any claim, action, suit, or other proceeding for which it intends to claim indemnification
under this Article 17.
ARTICLE 18
TERM AND TERMINATION
18.1 Term. This Agreement shall become effective as of the Effective Date and, shall continue in full force and effect until terminated
pursuant to this Article 18.
18.2 Termination for Cause or Technical Product Failure 
18.2.1 Material Breaches. FG may forthwith terminate this Agreement in the event Astellas fails to make any payment due under
Articles 6, 9 or 14, within [ * ] following receipt of written notice of such default, or materially breaches its obligations under Articles 8 or 14, and
fails to cure such breach within [ * ] following receipt of written notice of such default. Astellas may forthwith terminate this Agreement in the
 
-37-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
event FG materially breaches its obligations under Article 7 or Article 12, and fails to cure such breach within  [ * ] following receipt of written notice
of such default. Any termination shall become effective at the end of such  [ * ] or [ * ] period unless the defaulting or breaching party (or any other
party on its behalf) has cured any such default prior to the expiration of the  [ * ] or [ * ] period, as the case may be.
18.2.2 Independent Activities . Notwithstanding anything contained in Section 8.3.2 or Section 14.1.1, in the event that Astellas
Commercializes any molecules for the Field or the Expanded Field, except for actions taken within the Field in the course of the exercise of the
licenses granted under Sections 8.1 and 13.1 hereof and expressly authorized under this Agreement, even if FG determines that Astellas’ activities
are completely independent of any FG Technology and/or any other FG materials, confidential information, intellectual property or other related
information provided by FG to Astellas under this Agreement or any other agreement between FG and Astellas relating to the subject matter hereof,
FG shall have the right at its sole discretion to terminate this Agreement upon  [ * ] notice to Astellas.
18.2.3 Technical Product Failure. Astellas may terminate this Agreement upon  [ * ] notice to FG upon Technical Product Failure.
18.2.4 Development Diligence Failure. FG may terminate this Agreement upon thirty (30) days notice to Astellas in the event
Astellas fails to meet any of its development diligence requirements as set forth in Article 11 hereof, provided, however, that with respect to the
development diligence obligations set forth in Section 11.3.2, such termination right on behalf of FG shall be triggered only upon Astellas’ failure to
meet such development diligence obligations for a Major Indication (except those Major Indications set forth in Section 11.3.1(iv)), and Astellas
may terminate this Agreement upon thirty (30) days notice to FG in the event FG fails to meet the development diligence requirement as set forth in
Section 11.2 hereof.
18.2.5 Other Material Non-Performance/Misrepresentation . Other than a breach giving rise to a termination right as set forth in
Sections 18.2.1 or 18.2.4, or a termination pursuant to a Technical Product Failure as set forth in Section 18.2.3 in the event of (i) a party’s breach or
default in any other material respect in the performance or observance of any other material term, covenant or provision of this Agreement, or (ii) if
any representation by a party contained in this Agreement shall prove to have been incorrect in any material respect when made, resulting in
material adverse consequences for the other party, (any such default or material incorrect representation a “Material Non-Performance”), such
Material Non-Performance shall be remedied only as provided in Section 18.7.4 below.
18.3 Termination in case of Generic Competition. In the event generic equivalents has captured the  [ * ] of the quantity of Lead
Compound sold by Astellas during the  [ * ] preceding such termination calculated on a annual basis; or in the event, after the entry into the market
of generic equivalents, that Astellas’ annual sales fall below $ [ * ] for all Lead Compounds, Astellas may terminate this Agreement upon  [ * ]
written notice to FG; provided, that Astellas does not Commercialize any Lead Compound after such termination until the expiration of the last to
expire FG Patents applicable to such Lead Compound.
 
-38-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
18.4 Negative Advice from Authorities. Astellas may terminate this Agreement upon  [ * ] notice to FG in the event Astellas has
commenced Phase III clinical studies in those of the following Indications that FG is developing: “Treatment of anemia in patients with chronic
kidney disease undergoing dialysis”, “Treatment of anemia in patients with chronic kidney disease not undergoing dialysis” and  [ * ], and the
Japanese Ministry of Health, Labor & Welfare has provided written notification that it will not approve the Lead Compounds in such Indications or
the JDC determines, after the submission by Astellas of Marketing Approval Applications for such Indications, and the receipt of a response or
request of the Japanese Ministry of Health, Labor & Welfare that contains development demands that are so onerous that it is not reasonable to
continue with Development of the Lead Compounds in such Indications.
18.5 Admission of Invalidity or Unenforceability of FG Patent. Astellas may terminate this Agreement upon  [ * ] notice to FG in the
event that FG enters into a settlement under Section 14.3 that admits the invalidity or unenforceability of all patents within the FG Technology,
including patents covering Lead Compounds.
18.6 Termination upon Notice. Subject to Section 18.7.2, Astellas may terminate this Agreement upon six (6) months notice to FG for any
reason or no reason.
18.7 Effect of Termination 
18.7.1 Accrued Obligations. Termination of this Agreement for any reason shall not release either party hereto from any liability
which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination nor
preclude either party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this
Agreement.
18.7.2 Termination. In the event of (a) a termination by Astellas under Section 18.6 during the period from the execution of this
Agreement until the last to expire of the FG Patents, or (b) by FG under Section 18.2.1, 18.2.2, 18.2.4 or 18.2.5 hereof, Astellas shall, upon the
effective date of such termination, pay to FG (i) a termination fee of $[ * ] U.S. dollars and (ii) any payments to which FG is otherwise entitled to
receive hereunder in the period from the date of such termination notice until the  [ * ].
18.7.3 Survival. Articles 1, 5, 14, 16, 17, 18, 19 and 20, and Sections 8.3.3 and 10.5, shall survive any termination of this
Agreement, along with FG’s rights and Astellas’ obligations (but not Astellas’ rights or FG’s obligations, except to the extent required by the
Japanese Ministry of Health, Labor and Welfare) under Section 5.1.1 and Article 7. In addition, the following provisions shall survive termination of
this Agreement for any reason: Astellas shall assign or cause to be assigned to FG (or if not so assignable, Astellas shall take all reasonable
actions to make available to FG) all regulatory filings and registrations (including MAAs and Marketing Approvals) with respect to the Lead
Compounds that have been filed or made by or under authority of Astellas, and the rights in trademark with respect to each Lead Compound as
provided for in Section 4.4.1, in each case such assignment (or availability)
 
-39-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
shall be made within [ * ] after the notice of termination. From and after the date of a notice of termination, FG shall have no further obligations
under this Agreement beyond those obligations that survive termination in such events as specified in this Section 18.7.3.
18.7.4 Material Non-Performance. In the event of any Material Non-Performance by a party, the other party shall, without
reasonable delay following discovery of such Material Non-Performance notify the defaulting party in writing, and the parties shall consult with
each other in good faith to endeavor to agree upon the most effective means to cure such Material Non-Performance and, if necessary, to effect a
remedy in favor of the non-defaulting party for the consequences of such Material Non-Performance by the defaulting party (collectively, the
“Resolution”). In the event (i) the parties are unable to agree upon Resolution, or (ii) the defaulting party, in the exercise of reasonable diligence
shall have been unable to remedy such Material Non-Performance, then in either such event the remedy of the non-defaulting party with respect to
the Material Non-Performance by the defaulting party shall be determined by arbitration pursuant to Section 19.2 hereof, and the arbitrators shall be
authorized to fashion such remedy, including equitable relief, which may include termination of this Agreement in whole or in part, as the arbitrators
shall determine appropriate, except that termination of this Agreement in whole shall only be the remedy of last resort.
18.7.5 License Upon Termination. In the event of a termination of this Agreement, FG shall have an irrevocable, exclusive,
license, with the right to grant and authorize sublicenses, to any trademarks used by Astellas in association with the Lead Compounds hereunder
to make, use, sell, import and otherwise exploit products within the Field in the Astellas Territory. Such license shall be royalty-free, provided,
however, if such trademark is not a global trademark (i.e. materially different from the trademark used in the FG Territory) and either (i) if Astellas
terminates this Agreement under Section 18.2.1 or 18.2.4, or (ii) if this Agreement is terminated in accordance with the procedure as provided for in
Section 18.2.5 as a result of FG’s Material Non-Performance, in which event FG and Astellas shall negotiate in good faith a reasonable fee for such
license.
ARTICLE 19
DISPUTE RESOLUTION
19.1 Disputes. If the parties are unable to resolve any dispute between them regarding the breach, interpretation or enforcement of this
Agreement, either party may, by written notice to the other, have such dispute referred to their Authorized Designees, provided that such
individuals are not directly involved in the dispute (i.e., the dispute occurs at the JDC, such individuals shall not be members of the JDC), for good
faith negotiations. If after [ * ] such executives are unable to resolve the issue, each of Astellas and FG shall have the right to refer the matter to
mediation upon notice to the other party, and the parties shall choose a mediator within  [ * ] of the receipt of such notice, and shall negotiate in
good faith to resolve such matter through the mediator within  [ * ] thereafter.
19.2 Full Arbitration. Any dispute, controversy or claim arising out of or relating to the breach, interpretation or enforcement of this
Agreement, including disputes relating to termination of this Agreement, shall be settled by binding arbitration in the manner
 
-40-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
described in this Section 19.2. The arbitration shall be conducted pursuant to the rules of Arbitration of the International Chamber of Commerce
then in effect. Notwithstanding those rules, the following provisions shall apply to the arbitration hereunder:
19.2.1 Arbitrators. The arbitration shall be conducted by a panel of three (3) arbitrators, with one (1) arbitrator chosen by each of
FG and Astellas and the third appointed by the other two (2) arbitrators. If the parties are unable to agree upon a single arbitrator, or the third
arbitrator in case of a panel of three (3), such third arbitrator (as the case may be) shall be appointed in accordance with the rules of the Arbitration
of the International Chamber of Commerce.
19.2.2 Proceedings. Except as otherwise provided herein, the parties shall use their best efforts to complete the arbitration within
[ * ] after the appointment of the Panel under Section 19.2.1 above, unless a party can demonstrate to the Panel that the complexity of the issues or
other reasons warrant the extension of one or more of the time tables. In such case, the Panel may extend such time table as reasonably required.
The Panel shall, in rendering its decision, apply the substantive law of the State of California, without regard to its conflicts of laws provisions,
except that the interpretation of and enforcement of this Article 19 shall be governed by the U.S. Federal Arbitration Act. The proceeding shall be
conducted in English and shall take place in the city of Vancouver, British Columbia, Canada. The judgment of the Panel shall be binding upon the
parties and enforceable in any court of competent jurisdiction.
19.2.3 Interim Relief. Notwithstanding anything in this Article 19 to the contrary, FG and Astellas shall each have the right to
apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction, or other similar interim or conservatory relief,
as necessary, pending resolution under the above described arbitration procedures. Nothing in the preceding sentence shall be interpreted as
limiting the powers of the arbitrators with respect to any dispute subject to arbitration under this Agreement.
ARTICLE 20
MISCELLANEOUS
20.1 Confidential Terms. Except as expressly provided herein, each party agrees not to disclose any terms of this Agreement to any third
party without the consent of the other party, except (i) as required by securities or other applicable laws or (ii) to prospective and other investors
and such party’s accountants, attorneys and other professional advisors, or (iii) to others under reasonable conditions of confidentiality.
20.2 Governing Law. This Agreement and any dispute arising from the performance or breach hereof shall be governed by and
construed and enforced in accordance with, the laws of the State of California, without reference to conflicts of laws principles.
20.3 Force Majeure. Nonperformance of any party (except for payment of amounts due hereunder) shall be excused to the extent that
performance is rendered impossible by strike, fire, earthquake, flood, governmental acts or orders or restrictions, failure of suppliers, or any other
reason where failure to perform is beyond the reasonable control of the non-
 
-41-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
performing party. In such event FG or Astellas, as the case may be, shall promptly notify the other party of such inability and of the period for
which such inability is anticipated to continue. Without limiting the foregoing, the party subject to such inability shall use reasonable efforts to
minimize the duration of any force majeure event.
20.4 No Implied Waivers; Rights Cumulative. No failure on the part of FG or Astellas to exercise and no delay in exercising any right
under this Agreement, or provided by statute or at law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, nor
shall any partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right.
20.5 Independent Contractors . Nothing contained in this Agreement is intended implicitly, or is to be construed, to constitute FG or
Astellas as partners in the legal sense. No party hereto shall have any express or implied right or authority to assume or create any obligations on
behalf of or in the name of any other party or to bind any other party to any contract, agreement or undertaking with any third party.
20.6 Notices. All notices, requests and other communications hereunder shall be in writing and shall be personally delivered or sent by
registered or certified mail, return receipt requested, postage prepaid; facsimile transmission (receipt verified); or express courier service (signature
required), in each case to the respective address specified below, or such other address or fax number as may be specified in writing to the other
party hereto:
 
Astellas:   Astellas Pharma Inc.
  Attn: Director of Legal Department
  [ * ]
with copy to:   Astellas Pharma Inc.
  Attn: Licensing, Corporate Strategy
  [ * ]
FG:   FibroGen, Inc.
  Attn: Chief Executive Officer
  225 Gateway Boulevard
  San Francisco, California 94080
  Fax: 1-650-866-7202
with a copy
to:  
FibroGen, Inc.
  Attn: Legal Department
  225 Gateway Boulevard
  San Francisco, California 94080
  Fax: 1-650-866-7343
 
-42-
 
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
20.7 Assignment. This Agreement shall not be assignable by either party to any third party without the written consent of the other
party hereto; except that either party may assign this Agreement without the other party’s consent to an entity that acquires substantially all of the
business or assets of the assigning party within the Field, in each case whether by merger, transfer of assets, or otherwise. Upon a permitted
assignment of this Agreement, all references herein to the assigning party shall be deemed references to the party to whom the Agreement is so
assigned.
20.8 Modification. No amendment or modification of any provision of this Agreement shall be effective unless in writing signed by all
parties hereto. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or
any other matter not set forth in an agreement in writing and signed by all parties.
20.9 Severability. If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the parties shall negotiate in
good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the parties and all other provisions
hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the parties
hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such
provision in any other jurisdiction.
20.10 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of
which together, shall constitute one and the same instrument.
20.11 Headings. Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into
consideration in interpreting this Agreement.
20.12 Export Laws. Notwithstanding anything to the contrary contained herein, all obligations of FG and Astellas are subject to prior
compliance with United States and foreign export regulations and such other United States and foreign laws and regulations as may be applicable,
and to obtaining all necessary approvals required by the applicable agencies of the governments of the United States and foreign jurisdictions. FG
and Astellas shall cooperate with each other and shall provide assistance to the other as reasonably necessary to obtain any required approvals.
20.13 Language. This Agreement is in the English language only, which language shall be controlling in all respects, and all versions
hereof in any other language shall not be binding on the parties hereto. All communications and notices to be made or given pursuant to this
Agreement shall be in the English language.
20.14 Entire Agreement. This Agreement (including the Exhibits hereto) constitutes the entire agreement, both written or oral, with
respect to the subject matter hereof, and supersedes all prior or contemporaneous understandings or agreements, including the Binding Term
Sheet, dated as of February 9, 2004 by and between FG and Astellas, as amended
 
-43-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
on January 25, 2005, whether written or oral, between FG and Astellas with respect to such subject matter.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered in duplicate originals as of the
date first above written.
 
ASTELLAS PHARMA INC.   FIBROGEN, INC.
By:   /s/ Toichi Takenaka   By:   /s/ Thomas B. Neff
 
Toichi Takenaka
President and Chief Executive Officer    
Thomas Neff
President and Chief Executive Officer
Date:   1.September.05   Date:   23 August 05
 
-44-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
EXHIBIT A 
LIST OF PATENTS
[ * ]
 
-45-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
EXHIBIT B 
INDICATIONS
Included indications:
 
  •   Treatment of anemia in patients with chronic kidney disease undergoing dialysis
 
  •   Treatment of anemia in patients with chronic kidney disease not undergoing dialysis
 
  •   [ * ] 
 
-46-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.CONFIDENTIAL   EXECUTION COPY
 
EXHIBIT C 
INITIAL DEVELOPMENT PLAN
[ * ] 
 
-47-
 
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.Exhibit 10.17
Confidential Materials omitted and filed separately with the Securities and Exchange Commission.
Triple asterisks denote omissions.
COLLABORATION AGREEMENT
This Collaboration Agreement (“Agreement”), effective as of June , 2010 (the “Effective Date”), is entered into by and between MacroGenics,Inc., a Delaware corporation with a place of business at 1500 East Gude Drive, Rockville, MD 20850 (“MacroGenics”), and Green Cross Corp., aKorean company with a place of business at 303 Bojeong­Dong, Giheung­Gu, Yongin, 446­770, Korea (“Green Cross”). MacroGenics and GreenCross may be referred to herein individually as a “Party” or collectively as the “Parties.”
Recitals:
A. MacroGenics has expertise in, and platforms for, the discovery and development of products for the treatment of patients with cancer,inflammatory and infectious diseases.
B. Green Cross conducts research and development with respect to, and sells, pharmaceutical products.
C. Green Cross and MacroGenics desire to enter into collaboration for the development of MacroGenics’ anti­HER2 Antibody known asMGAH22, and if approved for commercialization, the commercialization of a Product in South Korea, all upon the terms and conditions set forth inthis Agreement.
D. MacroGenics desires to grant to Green Cross, and Green Cross desires to receive, an exclusive license for all Indications for allpharmaceutical forms of MGAH22 for South Korea, upon the terms and conditions set forth in this Agreement.
In consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as follows:
Agreement:
1. DEFINITIONS. Unless specifically set forth to the contrary herein, the following capitalized terms, whether used in the singular or plural, shallhave the respective meanings set forth below:
1.1 “Affiliate” means with respect to any Party, any person or entity controlling, controlled by or under common control with such Party. Forpurposes of this Section 1.1, “control” means (a) in the case of a corporate entity, direct or indirectownership of at least fifty percent (50%) or more of the stock or shares having the right to vote for the election of directors of such corporate entityand (b) in the case of an entity that is not a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the direction of,the management or policies of such entity, whether through the ownership of voting securities, by contract or otherwise.
1.2 “Allocable Overhead” means costs incurred by each Party that are attributable to that Party’s *** reasonably allocated to the Party’sdepartments or functions, or used to support activities under the Collaboration based on space occupied or headcount or other activity-basedmethods consistently applied by each Party. The Allocable Overhead shall not include any costs attributable to *** 
1.3 “Antibody” means a molecule comprising or containing: (a) one or more immunoglobulin variable domains; (b) fragments, variants,modifications or derivatives of such immunoglobulin variable domains; and (c) the nucleic acid consisting of a sequence of nucleotides encoding(or complementary to a nucleic acid encoding) the foregoing molecules in (a) or (b). The term “Antibody” shall include any monospecificantibodies; less than full­length antibody forms such as Fv, Fab, and F(ab’); single­chain antibodies; and an antibody bound to a drug, label orother moiety and any antibody that is conjugated or fused to any other composition, including for example, a toxin, radionucleotide, small molecule,polypeptide or polypeptide fragment. The term Antibody also includes, without limitation to its source or method of manufacture, any human,humanized, primatized, chimeric or other antibody.
1.4 “Applicable Laws and Regulations” means all international, national, federal, state, regional, provincial and local government laws, rules,and regulations that apply to either Party or to the conduct of the Collaboration under this Agreement including without limitation cGMP, GCP,GBPS, and the laws, rules and regulations of the ICH, that may be in effect, as applicable and amended from time to time.
1.5 “Arbitral Tribunal” has the meaning set forth in Section 17.7(a).
1.6 “BLA” means (a) a Biologics License Application or New Drug Application (“NDA”) filed with the FDA for marketing approval of aProduct or any successor applications or procedures, and all supplements and amendments that may be filed with respect to the foregoing, orsimilar filings outside the Territory with applicable Regulatory Authorities, for approval to commercially market and sell a Product, or (b) similarfilings in the Territory with applicable Regulatory Authorities, including the KFDA, for approval to commercially market and sell a Product. Theterm BLA shall exclude pricing and reimbursement approvals.
1.7 “Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30and December 31.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
21.8 “Calendar Year” means the respective periods of twelve (12) months commencing on January 1 and ending on December 31.
1.9 “cGMP” means current good manufacturing practices and general biologics products standards as promulgated under the FDCA orApplicable Law and Regulations in the Territory, as applicable.
1.10 “Change in Control” means the occurrence of any of the following:
(a) Either Party to this Agreement enters into a merger, consolidation, stock sale or sale or transfer of all or substantially all of its assets,or other similar transaction or series of transactions with another Person unless, following such transaction or transactions, (i) the individuals andentities who were the beneficial owners of the outstanding voting securities of the subject Party immediately prior to such transaction beneficiallyown, directly or indirectly, at least fifty percent (50%) of the combined voting power of the then outstanding voting securities entitled to votegenerally in the election of directors or similar governing persons of the corporation or other entity resulting from such transaction (“Successor”)in substantially the same proportions as their ownership immediately prior to such transaction of such outstanding voting securities, (ii) at leastfifty percent (50%) of the members of the Board of Directors or similar governing body of the Successor were members of the Board of Directors ofthe subject Party at the time of the execution of the initial agreement, or the action of the Board of Directors of the subject Party, providing for suchtransaction; (iii) the subject Party retains title ownership after the transaction or transactions to properties and assets (x) representing more thanfifty percent (50%) of such Person’s consolidated total assets or (y) from which more than fifty percent (50%) of such Person’s consolidatedoperating income for its most recent fiscal was derived, and (iv) the subject Party is the surviving entity in such transaction or transactions;
(b) any transaction or series of related transactions in which any Person or group of Persons acquires beneficial ownership of securitiesof the subject Party representing more than fifty percent (50%) of the combined voting power of the then outstanding securities of the subjectParty.
1.11 “Clinical Data” means all data generated or arising from the conduct of a clinical trial or other Development efforts under thisAgreement.
1.12 “Clinical Material(s)” means MGAH22 and Product formulated in accordance with the specifications as adopted by the JSC and UnitedStates and Korean laws, rules and regulations (a) for preclinical activities, and (b) for administration to subjects in clinical trials.
1.13 “CMC” means Chemistry Manufacturing and Controls.
1.14 “Collaboration” means the program established under this Agreement, which includes collaborative development of Products. 
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
31.15 “Commencement” means the first dosing of a human subject with the applicable Product in the applicable human clinical trial.
1.16 “Commercial Supply Costs” shall mean the costs paid by Green Cross to MacroGenics for the commercial supply of Product pursuant toSection 6.2(d), provided that Commercial Supply Costs for a Product shall not be deemed incurred by Green Cross for purposes of this Agreementuntil the Calendar Quarter in which such Product is sold by Green Cross or any of its Related Parties.
1.17 “Commercialization” or “Commercialize” means activities taken before and after obtaining Regulatory Approval relating specifically tothe pre-launch, launch, promotion, marketing, sales force recruitment, sale and distribution of a pharmaceutical product and post-launch medicalactivities, including without limitation: (a) distribution for commercial sale; (b) strategic marketing, sales force Detailing, advertising, and market andproduct support; (c) medical education and liaison and any Phase IV Clinical Trials, to the extent permitted by this Agreement; (d) all customersupport and product distribution, invoicing and sales activities; and (e) all post-approval regulatory activities, including those necessary tomaintain Regulatory Approvals.
1.18 “Commercially Reasonable Efforts” means with respect to the efforts to be expended by a Party with respect to any objective under thisAgreement, reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective of suchParty under similar circumstances, it being understood and agreed that with respect to the Development or Commercialization of MGAH22 andProducts, such efforts shall be similar to those efforts and resources commonly used by a Party for a similar biological or pharmaceutical productowned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential takinginto account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietaryposition of the product, and the likelihood of regulatory approval given the regulatory structure involved.
1.19 “Competing Product” means any Antibody that binds to the protein termed “HER2/Neu”, other than a Product.
1.20 “Completion” or “Completed” for a clinical trial means the later of the following dates: (a) the date on which all patients have completedprotocol-defined study drug administration, and (b) *** 
1.21 “Confidential Information” means any and all non­public scientific, pre­clinical, clinical, regulatory, manufacturing, marketing, financialand commercial information and data, in any tangible or intangible form, including all Know-how subject to Section 12.
1.22 “Control,” “Controls” or “Controlled by” means (except as used in Section 1.1), with respect to any item of or right under Patents orKnow-how, the ability
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
4of a Party (whether through ownership or license, other than pursuant to this Agreement) to grant access to, or a license or sublicense of, such itemor right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time suchParty would be required hereunder to grant the other Party such access or license or sublicense.
1.23 “CRO” means a clinical research organization.
1.24 “CTA” means a Clinical Trial Application or its equivalent used to obtain approval to conduct human clinical investigations filed with orsubmitted to the KFDA in order to establish the clinical safety and/or efficacy of one or more investigational products in conformance with therequirements of the KFDA.
1.25 “Data Exclusivity Period” means the period during which the FDA or KFDA (or, in countries other than the United States or SouthKorea, an equivalent regulatory agency) prohibits reference, without the consent of the owner of a BLA, to the clinical and other data that iscontained in such BLA, and that is not published or publicly available outside of such BLA.
1.26 “Details” or “Detailing” means face­to­face sales presentations made to physicians, nurses, pharmacists, and other individuals whoprovide healthcare services to patients, in their capacity as such.
1.27 “Develop” or “Development” or “Developing” means research, discovery, process development, manufacturing for preclinical and clinicaluses, and preclinical and clinical drug or biological development activities, including, without limitation, test method development and stabilitytesting, toxicology, formulation, quality assurance/quality control development, statistical analysis, preclinical and clinical studies and regulatoryaffairs, approval and registration, in each case, of MGAH22 or a Product for therapy of human diseases.
1.28 “Development Costs” means all costs incurred in connection with any Development activities.
1.29 “FDA” means the United States Food and Drug Administration, or any successor agency thereto.
1.30 “FDCA” means the Federal Food, Drug and Cosmetic Act, as amended.
1.31 “Field” means all oncology therapies; provided, however, that in the case of any Products covered by a Patent or other intellectualproperty right licensed in one or more Upstream Licenses, “Field” shall be limited to the minimum extent necessary to comply with the terms of suchUpstream License for so long as such limitation is necessary to avoid breach of the Upstream License.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
51.32 “Filing of a BLA” means the acceptance by a Regulatory Authority of such BLA for filing.
1.33 “First Commercial Sale” means, with respect to any Product, the first sale to a Third Party for end use or consumption of such Productin the Territory after Regulatory Approval has been granted by the Regulatory Agency for the Product in the Territory. 
1.34 “Fully Burdened Manufacturing Cost” or “FBMC” means one hundred percent (100%) of MacroGenics’ actual manufacturing cost ofgoods produced, as determined for each stage of the manufacturing process, in accordance with GAAP, including product qualityassurance/control costs, failed lots, plus applicable Allocable Overhead. Such Fully Burdened Manufacturing Cost shall include, without limitation:(i) ***
1.35 “GAAP” means U.S. Generally Accepted Accounting Principles as the same may be in effect from time to time.
1.36 “GBPS” means the General Biological Products Standards as set forth in 21 C.F.R. Part 610, to the extent applicable to the Collaboration.
1.37 cGMP” or “current Good Manufacturing Practices” means current Good Manufacturing Practices as set forth in the FDCA and thePublic Health Service Act (the “PHS Act”), and in regulations at 21 C.F.R. Parts 210, 211 and 600, as in effect at the time when any clinical trialregarding a Product is being conducted, provided, and to the extent applicable to such clinical trial, as such regulations are interpreted andenforced by the FDA, including as set forth in applicable guidance documents issued by the FDA, and in accordance with applicable, generallyaccepted industry standards.
1.38 “GCP” or “Good Clinical Practices” means current Good Clinical Practices as set forth in the Applicable Laws and Regulations, such asFDCA and the PHS Act and regulations set forth at 21 C.F.R. Part 312, as well as (but not limited to) the requirements set forth in Directive2001/20/EC of the European Parliament and of the Council of 4 April 2001 and Commission Directive 2005/28/EC of 8 April 2005, to the extentapplicable to a clinical trial regarding any Product, as such obligations are interpreted and enforced by the applicable Regulatory Authority (e.g.,FDA and Member States of the European Union), and as interpreted under prevailing industry standards, including standards of medical ethics,applicable guidance documents issued by the FDA and any other Regulatory Authority, including ICH GCP, the informed consent requirements setforth in 21 C.F.R. Part 50 and the equivalent legal requirements in other applicable jurisdictions, the requirements relating to Institutional ReviewBoards set forth in 21 C.F.R. Part 56 and the equivalent legal requirements in other applicable jurisdictions, all as the same may be amended fromtime to time.
1.39 “GLP” or “Good Laboratory Practices” means the recognized rules governing the conduct of non­clinical safety studies and ensuringthe quality, integrity and reliability of study data as set forth in Applicable Laws and Regulations, such as 21 C.F.R. Part 58.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
61.40 “Green Cross Indemnitees” has the meaning set forth in Section 14.2.
1.41 “Green Cross Licensed Know-how” means all Know-how (excluding any Patent) Controlled by Green Cross as of the Effective Date or atany time during the Term that is: (a) related to MGAH22 and (b) necessary for MacroGenics to exercise the rights licensed to it under thisAgreement or perform its obligations under this Agreement. “Green Cross Licensed Know­how” shall also include Green Cross’ interest in anyKnow-how deemed jointly owned pursuant to Section 15.1(c).
1.42 “Green Cross Licensed Patents” means any and all Patents Controlled by Green Cross at any time during the Term that: (a) are related toany data, result or invention conceived or reduced to practice in the course of conducting the Collaboration solely by Green Cross specifically inrelation to MGAH22 and (b) Green Cross’ interest in any Patent deemed jointly owned pursuant to Section 15.1(c).
1.43 “Health Insurance Portability and Accountability Act” or “HIPAA” means the act enacted by the U.S. Congress in 1996 and took effectin 2003 that strictly dictates the parameters that identifiable private health information (PHI) can be shared outside of the research environment, asamended.
1.44 *** 
1.45 “ICH” means the International Conference on Harmonisation.
1.46 “IND” means an Investigational New Drug application, or similar application or submission for approval to conduct human clinicalinvestigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.
1.47 “Indemnifying Party” means the Party that is obligated to indemnify the Indemnitee under Section 14.
1.48 “Indemnitee” means either the Green Cross Indemnitee or the MacroGenics Indemnitee, as applicable.
1.49 “Independent Ethics Committee” or “IEC” means an independent body (a review board or a committee, institutional, regional, national, orsupranational), constituted of medical professionals and non-medical members, whose responsibility it is to ensure the protection of the rights,safety and well-being of human subjects involved in a trial and to provide public assurance of that protection, by, among other things, reviewingand approving / providing favorable opinion on, the trial protocol, the suitability of the investigator(s), facilities, and the methods and material to beused in obtaining and documenting informed consent of the trial subjects. The legal status,
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
7composition, function, operations and regulatory requirements pertaining to IEC may differ among countries, but should allow the IndependentEthics Committee to act in agreement with GCP as described in this guideline.
1.50 “Indication” means a separate and distinct disease, disorder or medical condition in humans or non­human animals which a product isintended to treat, prevent, diagnose, monitor or ameliorate and which, for a Product, is intended to be reflected in the labeling for such Product asan approved Indication, and which, for an approved Product, is reflected in the labeling for such Product.
1.51 “Informed Assent Form” or “IAF” means an agreement to participate by subjects who are not able to give consent, either because theyare minors or because they are legally incompetent.
1.52 “Informed Consent Form” or “ICF” means a document that outlines a patient’s rights during participation in a clinical trial. It alsodiscusses the potential risks and benefits associated with participation, including all available data on previous studies. The ICF must be signed bythe patient or authorized caregiver before entrance is granted into a study.
1.53 “Initial Public Offering” means the first completed offering of capital stock of MacroGenics registered under the Securities Act of 1933,as amended.
1.54 “Investigational Review Board” or “IRB” means in accordance with 45 C.F.R. 46, Protection of Human Subjects (Revised November 13,2001) and 21 C.F.R. 45, Subpart C, IRB Functions and Operations, (as amended June 18, 1991 and other applicable regulations), an independentbody comprising medical, scientific, and nonscientific members, whose responsibility is to ensure the protection of the rights, safety, and well-being of the subjects involved in a clinical trial. It may also be referred to as an IEC in accordance with ICH E6, Section 1.27.
1.55 “Jointly Owned IP” has the meaning set forth in Section 15.1(c).
1.56 “Jointly Owned Patents” has the meaning set forth in Section 15.2(b)(i).
1.57 “Joint Development Committee” or “JDC” has the meaning set forth in Section 2.2.
1.58 “Joint Steering Committee” or “JSC” has the meaning set forth in Section 2.1.
1.59 “KFDA” means Korean Food and Drug Administration, or any successor agency thereto.
1.60 “Know-how” means (a) any proprietary scientific or technical information, results and data of any type whatsoever, in any tangible orintangible form whatsoever, including databases, practices, methods, techniques, specifications,
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
8formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical,biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and manufacturingprocess and development information, results and data and (b) any proprietary biological, chemical or physical materials.
1.61 “Licensing Transaction” has the meaning set forth in Section 12.3(d)(ii)(C).
1.62 “Losses” has the meaning set forth in Section 14.1.
1.63 “MacroGenics Indemnitee” has the meaning set forth in Section 14.1.
1.64 “MacroGenics Licensed Know-how” means the Know-how (excluding any Patents) that is Controlled by MacroGenics as of the EffectiveDate or at any time during the Term, that is: (a) related to MGAH22 and (b) necessary for Green Cross to exercise the rights licensed to it pursuantto this Agreement or to perform its obligations under this Agreement.
1.65 “MacroGenics Licensed Patents” means the Patents Controlled by MacroGenics as of the Effective Date or at any time during the Termthat: (a) claim the composition of matter of MGAH22 or a Product, (b) would be infringed but for the license granted hereunder by making, havingmade, selling, using, offering for sale or importing MGAH22 or any Product, or (c) are otherwise necessary for Green Cross to exercise the rightslicensed to it under this Agreement, or to perform its obligations under this Agreement, as listed in Exhibit A attached hereto. “MacroGenicsLicensed Patents” shall include MacroGenics’ interest in any Patents deemed jointly owned pursuant to Section 15.1(c).
1.66 “MacroGenics Licensed Technology” means the MacroGenics Licensed Patents and the MacroGenics Licensed Know-how. 
1.67 “MacroGenics Licensed Trademarks” means any and all Trademarks Controlled by MacroGenics as of the Effective Date or at any timeduring the Term, that are registered for or apply to a Product, as listed on Exhibit B.
1.68 “MGAH22” means the therapeutic Antibody which binds to the HER2/Neu receptor described in IND # 107768.
1.69 “Net Sales” means the gross amount invoiced for Products (or, as the case may be, a Competing Product) sold by Green Cross or itsRelated Parties in the Territory initially and directly to Third Parties which are not Related Parties after deducting, if not previously deducted, fromthe amount invoiced, the following, in each case to the extent included in the gross invoice price:
(a) reasonable trade, quantity and cash discounts and rebates (including, but not limited to, wholesaler inventory management fees),chargebacks, and retroactive price reductions or allowances actually allowed or granted from the billed amount;
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
9(b) credits or allowances actually granted upon claims, rejections or returns of such sales of Products, including recalls and amountscredited or repaid because of retroactive price reductions specifically identifiable to the Product;
(c) taxes imposed on the production, sale, import, delivery or use of the Product (including, without limitation, sales, use, excise or valueadded taxes but excluding income taxes), duties or other governmental charges (including, without limitation, charges for product testing requiredfor importation) levied on or measured by the billing amount when included in billing, as adjusted for rebates and refunds; and
(d) costs incurred for importing (including, but not limited to, transportation, freight and insurance, and warehousing in the Territory).
Such amounts shall be determined from the books and records of Green Cross or its Related Party, maintained in accordance withInternational Financial Reporting Standards (IFRS) or such similar accounting principles, consistently applied. Green Cross further agrees, indetermining such amounts, it will use Green Cross’ then­current standard procedures and methodology, including Green Cross’ then­currentstandard exchange rate methodology for the translation of foreign currency sales into U.S. Dollars or, in the case of Sublicensees, such similarmethodology, consistently applied.
1.70 “Patent(s)” means (a) all patents and patent applications in any country or supranational jurisdiction and (b) any provisionals,substitutions, divisions, continuations, continuations in part, reissues, renewals, registrations, confirmations, reexaminations, extensions,supplementary protection certificates and the like, of any such patents or patent applications.
1.71 “Patent Prosecution” means the responsibility for (a) preparing, filing, prosecuting, and pursuing registration of, applications (of alltypes) for any Patent (b) for maintaining any Patent, and (c) for managing any interference or opposition proceeding relating to the foregoing.
1.72 “Permitted Subcontractors” has the meaning set forth in Section 3.5.
1.73 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limitedliability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization,including a government or political subdivision, department or agency of a government. 
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
101.74 “Phase I Clinical Development Plan” means the plan set forth on Exhibit C.
1.75 “Phase I Clinical Trial” means a human clinical trial of a Product in patients in any country that would satisfy the requirements ofApplicable Laws and Regulations for such country, such as 21 C.F.R. § 312.21(a), relating to human clinical trials conducted in the United States.
1.76 “Phase II Clinical Development Plan” means the plan set forth on Exhibit D, as amended pursuant to Section 4.
1.77 “Phase II Clinical Trial” means a human clinical trial conducted in patients with a Product in accordance with GCP and intended todemonstrate efficacy and a level of safety in the particular Indication tested, as well as to obtain a preliminary Indication of the unit and/or dailydosage regimen required, or that would otherwise satisfy the requirements of Applicable Laws and Regulations of the country in which suchhuman clinical trial is conducted, such as 21 C.F.R. § 312.21(b), relating to human clinical trials conducted in the United States, or any successorregulation thereto or foreign equivalents.
1.78 “Phase III Clinical Trial” means a human clinical trial in any country that is conducted in accordance with GCPs and the results of whichare intended to be used as a pivotal study to establish both safety and efficacy of a Product as a basis for a BLA submitted to the FDA, KFDA orthe appropriate Regulatory Authority of such other country, or that would otherwise satisfy the requirements of 21 C.F.R. § 312.21(c), or anysuccessor regulation thereto or foreign equivalents.
1.79 “Phase IV Clinical Trial” means a human clinical trial conducted after the Regulatory Approval of a Product, which trial is conducted (a)voluntarily to enhance scientific knowledge of such Product (e.g., for expansion of product labeling or dose optimization); or (b) conducted due toa request or requirement of a Regulatory Authority.
1.80 “Personal Information Protection and Electronic Documents Act” or “PIPEDA” or “PIPED Act” means the Canadian law relating todata privacy.
1.81 “Product” means a product that incorporates a pharmaceutical form of MGAH22 as an active ingredient.
1.82 “Product Brand” has the meaning set forth in Section 5.2.
1.83 “Regulatory Approval” means all approvals from the relevant Regulatory Authority to market and sell a Product in any country(including all applicable pricing and reimbursement approvals), including a BLA.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
111.84 “Regulatory Authority” means any applicable government regulatory authority involved in granting approvals for the conduct of clinicaltrials or the manufacturing, marketing, reimbursement or pricing, as applicable, of a Product, including in the United States the FDA and in SouthKorea the KFDA, and any successor governmental authority having substantially the same function.
1.85 “Related Party” means, with respect to a Party, its Affiliates and Sublicensees.
1.86 “Requesting Party” has the meaning set forth in Section 9.2.
1.87 “Royalty Term” means, with respect to sales of a Product in the Territory, the time period beginning on the First Commercial Sale of suchProduct in the Territory and expiring on the latest of the following dates:
(a) ***
(b) *** 
(c) *** 
1.88 “Securities Act” has the meaning set forth in Section 8.2(b).
1.89 “Site Regulatory Package” or “SRP” means a set of investigational site specific regulatory documents requiring review and approval bythe JDC. The SRP typically consists of the following documents: Form FDA 1572, principal investigator curriculum vitae, signed protocol signaturepage, site-specific ICF/IAF (back-translated into English if the local language is other than English), privacy requirements (e.g., HIPAA, PIPEDA),IRB/IEC membership, and country-specific requirements.
1.90 “Sublicensee” means a Third Party that is granted a sublicense under the licenses granted to a Party under this Agreement, as permittedunder this Agreement.
1.91 “Successor” has the meaning set forth in Section 1.10.
1.92 “Term” has the meaning set forth in Section 16.1.
1.93 “Territory” means South Korea.
1.94 “Third Party” means an entity other than (a) Green Cross and its Affiliates, and (b) MacroGenics and its Affiliates.
1.95 “Third Party Royalties” means royalties (other than Upstream Royalties) paid by Green Cross to a Third Party to acquire any Third Partyrights which would be infringed by the Development, manufacturing, importation, or Commercialization of any Product in the Territory.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
121.96 “Total Evaluable Patients” means, on a worldwide basis, those patients who have completed protocol­defined procedures and can beassessed for the primary endpoint of the trial.
1.97 “Trademark(s)” means all trade names, logos, common law trademarks and service marks, trademark and service mark registrations andapplications throughout the world.
1.98 “Trademark Prosecution” means the responsibility for (a) preparing, filing, and seeking registration of, trademark applications (of alltypes) for any Trademark, (b) for maintaining any Trademark, and (c) for managing any interference or opposition proceeding relating to theforegoing.
1.99 “United States” or “US” means the United States of America and its territories and possessions, including without limitation theCommonwealth of Puerto Rico and the U.S. Virgin Islands.
1.100 “Upstream Agreements” means the license agreements with MacroGenics’ Third Party licensors listed in Exhibit E or otherwiseidentified in writing by MacroGenics to Green Cross as such.
1.101 “Upstream Licensors” means MacroGenics’ Third Party licensors under the Upstream Agreements.
1.102 “Upstream Royalties” has the meaning set forth in Section 8.6.
1.103 “Valid Claim” means a claim of: (a) an issued and unexpired Patent included within the MacroGenics Licensed Patents in a countrywhich has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction,unappealable or unappealed within the time allowed for appeal, and has not been abandoned, disclaimed or admitted to be invalid or unenforceablethrough reissue, disclaimer or otherwise; or (b) ***
2. GOVERNANCE 
2.1 Joint Steering Committee 
(a) Membership. The Parties hereby establish a Joint Steering Committee, or JSC, to coordinate and oversee activities on which theParties collaborate under this Agreement. The Parties agree that participation in the JSC and any subcommittee of the JSC is a right, rather than anobligation of each Party under this Agreement. The JSC shall consist of three (3) representatives from each Party. MacroGenics shall designate one(1) of its representatives as the initial chairperson of the JSC. Thereafter, the role of chairperson will alternate between MacroGenics and GreenCross representatives on a yearly basis. Each Party may replace its appointed JSC representatives at any time upon reasonable written notice to theother Party. The initial
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
13representatives and chair of the JSC are set forth in Exhibit F attached hereto. The chair shall have the responsibility to call meetings, circulatemeeting agendas at least ten (10) days prior to each regular JSC meeting, draft minutes for each JSC meeting and circulate such minutes for bothParties’ written approval. The chair shall have no other authority or special voting power.
(b) Responsibilities. The responsibilities of the JSC shall be:
(i) to provide a vehicle by which the Parties may share information regarding the overall strategy for the Collaboration;
(ii) to approve changes to the Phase I Clinical Development Plan and Phase II Clinical Development Plan;
(iii) to facilitate the exchange of information between the Parties with respect to the activities hereunder and to establishprocedures for the efficient sharing of information necessary for the Parties to fulfill their respective responsibilities with respect theCollaboration;
(iv) to establish an overall regulatory strategy for Products in the Territory that is compatible with and complements theworldwide regulatory strategy being implemented by MacroGenics for the Products and to allocate the responsibility for regulatoryactivities between the Parties;
(v) to oversee the activities of subcommittees created under this Agreement, and to seek to resolve any issues that suchsubcommittees cannot resolve;
(vi) to perform such other functions as appropriate to further the purposes of this Agreement, as determined by the Parties; and
(vii) to establish such subcommittees in addition to the JDC, as are agreed upon in writing by the Parties.
(viii) to discuss any additional studies, including a Phase III Clinical Trial, in which Green Cross may desire to participate;
(c) Decision-Making. The JSC shall make decisions unanimously, with each Party’s representatives collectively having one (1) voteand at least one (1) representative from each Party present.
(d) Disputes. In the event the JSC cannot reach an agreement regarding any matter within the JSC’s authority for a period of ***, thenthe dispute shall be promptly submitted to the ***. If the dispute remains unresolved for *** after submission to such persons, then the ***;provided, however, that the *** shall have the ***; and provided further that the foregoing shall not be deemed to limit or otherwise alter anyobligation of Green Cross or MacroGenics under this Agreement.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
14(e) JSC Meetings. JSC meetings shall be held semi-annually, or on any other schedule agreed by the Parties. With the consent of therepresentatives of each Party serving on the JSC, other representatives of each Party may attend meetings as nonvoting observers (provided suchnon-voting observers have confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement). A JSCmeeting may be held by audio, video or internet teleconference with the consent of each Party, but at least half (1/2) of the minimum number ofmeetings shall be held in person. Meetings of the JSC shall be effective only if at least one (1) representative of each Party is present orparticipating. Each Party shall be responsible for all of its own expenses of participating in the JSC meetings. The Parties will alternate hosting thein-person meeting, and the Party hosting is responsible for preparing and circulating the minutes of the JSC meetings.
(f) Duration of JSC. The JSC shall continue to exist until the first to occur of (a) the Parties mutually agreeing to disband the JSC or (b)termination of this Agreement.
(g) Limitations. The JSC shall have no authority other than that expressly set forth in this Section 2.1 and, specifically, shall have noauthority (a) to amend or interpret this Agreement, or (b) to determine whether or not a breach of this Agreement has occurred.
2.2 Joint Development Committee 
(a) Membership. Within thirty (30) days after the Effective Date, the Parties shall establish a Joint Development Committee, or JDC, as asubcommittee of the JSC, to coordinate the Development of Products as set forth in Section 2.2(b). The JDC shall consist of three (3)representatives from each Party. Each Party may replace its appointed JDC representatives at any time upon reasonable written notice to the otherParty. The Parties shall alternate in designating a representative on the JDC as the chair of the JDC on an annual basis, with MacroGenicsdesignating the first chair. The chair shall have the responsibility to call meetings, circulate meeting agendas at least ten (10) days prior to eachregular JDC meeting, draft minutes for each JDC meeting and circulate such minutes for both Parties’ written approval. The chair shall have no otherspecial authority or voting power.
(b) Responsibilities. The responsibilities of the JDC shall be:
(i) to share and discuss the Parties’ performance under the Phase I Clinical Development Plan and Phase II Clinical DevelopmentPlan, on a quarterly basis;
(ii) to share and discuss the data generated by or on behalf of the Parties in the course of performance towards the goals set forthin the Phase I Clinical Development Plan and Phase II Clinical Development Plan;
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
15(iii) to coordinate Development strategies, allocate resources and set timelines, in each case to facilitate the activities under thePhase I Clinical Development Plan and Phase II Clinical Development Plan;
(iv) to review and approve proposed clinical trial sites;
(v) to facilitate the exchange of information between the Parties with respect to the activities under the Phase I ClinicalDevelopment Plan and Phase II Clinical Development Plan; and
(vi) to perform such other functions as appropriate to further the purposes of this Agreement, as determined by the Parties.
(c) Decision Making. The JDC shall make decisions unanimously, with each Party’s representatives collectively having one (1) voteand at least one (1) representative from each Party present.
(d) Disputes. In the event the JDC cannot reach an agreement regarding any matter within the JDC’s authority for a period of ***, thenat the option of either Party the matter shall be referred to the JSC for resolution pursuant to Section 2.1(c) and 2.1(d) above.
(e) JDC Meetings. JDC meetings shall be held quarterly, or on any other schedule agreed by the Parties. With the consent of therepresentatives of each Party serving on the JDC, other representatives of each Party may attend meetings as nonvoting observers (provided suchnon-voting observers have confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement). A JDCmeeting may be held by audio, video or internet teleconference with the consent of each Party, but at least half (1/2) of the minimum number ofmeetings shall be held in person. Meetings of the JDC shall be effective only if at least one (1) representative of each Party is present orparticipating. Each Party shall be responsible for all of its own expenses for participating in the JDC meetings. The Parties will alternate hosting thein-person meeting, and the Party hosting is responsible for preparing and circulating the minutes of the JDC meetings.
(f) Duration of JDC. The JDC shall continue to exist until the first to occur of (a) the Parties mutually agreeing to disband the JDC or (b)termination of this Agreement.
(g) Limitations. The JDC shall have no authority other than that expressly set forth in this Section 2.2 and, specifically, shall have noauthority (a) to amend or interpret this Agreement, or (b) to determine whether or not a breach of this Agreement has occurred.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
163. DEVELOPMENT 
3.1 Overview. The Parties shall use Commercially Reasonable Efforts to Develop Products in the Territory in accordance with the Phase IClinical Development Plan and Phase II Clinical Development Plan, as set forth below, with the goal of achieving regulatory approval for themarketing of Products.
(a) MacroGenics Responsibilities. MacroGenics shall perform those activities for which it is identified as the responsible party in thePhase I Clinical Development Plan (unless such responsibility is transferred to Green Cross or a Third Party by MacroGenics), including, withoutlimitation, ***, as appropriate, ***.
(b) Green Cross Responsibilities 
(i) Green Cross shall perform those activities for which it is identified as the responsible party in the Phase I Clinical DevelopmentPlan (and such other activities for which responsibility is transferred to Green Cross), and shall conduct all activities described in thePhase II Clinical Development Plan. Without limiting the foregoing, in the Territory:
(ii) Green Cross shall (A) support clinical trial site and CRO-related activities ***, (B) ***; (C) support clinical trial site and CRO-related activities for the ***, under a CTA filed by Green Cross in the Territory, and (D) support other additional Development activitiesresponsive to unique regulatory or commercial requirements in Territory; and
(iii) Green Cross’ responsibilities shall include the submission of all CTAs; interaction with the KFDA; ***; provided, however,that with respect to the provision of data, information and materials, such obligation to assist shall require Green Cross to useCommercially Reasonable Efforts, and shall not require Green Cross to generate any data not within its possession.
(c) Joint and Additional Responsibilities. For activities specified in the Phase I Clinical Development Plan for which both Parties areidentified as the responsible Party, the Parties’ respective obligations shall be as determined by the JSC. If it is determined that the performance ofactivities not identified in the Phase I Development Plan are required for Completion of the Phase I Clinical Trial, then the responsibility for suchactivities shall be determined by the JSC.
3.2 Development Plans 
(a) Clinical Development Plans. The JDC shall review the progress of the conduct of the Phase I Clinical Development Plan and PhaseII Clinical Development Plan at each meeting of the JDC.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
17(b) Review of the Clinical Development Plans. On no less than an annual basis, the JDC shall review the Phase I Clinical DevelopmentPlan and Phase II Clinical Development Plan, as appropriate, and recommend any amendment, and any changes to such plans shall be subject tothe approval by the JDC and, subsequently, by the JSC.
3.3 Conduct of Development 
(a) General Obligation. Each Party shall use Commercially Reasonable Efforts to conduct the Development activities for which it isresponsible, as described in the Phase I Clinical Development Plan and Phase II Clinical Development Plan, in compliance with: (a) the terms andconditions of this Agreement; (b) the Phase I Clinical Development Plan and Phase II Clinical Development Plan, as updated from time to time; (c)all applicable GLP, GCP and applicable cGMP requirements, including, without limitation those specified by the ICH; and (d) all Applicable Lawsand Regulations.
(b) Green Cross Diligence. Without limiting Section 3.3(a):
(i) Green Cross shall ***; provided, however, that if all necessary documents required for Regulatory Approval of suchCommencement in the Territory, if any, are not received within a reasonable period prior to such date, other than as a result of GreenCross’ acts or omissions, then such period shall be equitably extended to account for such delay for a period mutually agreed upon inwriting by the Parties;
(ii) Green Cross shall ***; and
(iii) Green Cross shall use ***; provided, however, that if all necessary documents required for Regulatory Approval of suchCompletion or filing in the Territory, if any, are not received within a reasonable period prior to such date, other than as a result of GreenCross’ acts or omissions, then such period shall be equitably extended to account for such delay for a period mutually agreed upon inwriting by the Parties.
(c) Green Cross Rights. Green Cross shall have the option to participate in any additional studies, including a Phase III Clinical Trial,with respect MGAH22 to the extent that such studies are required by a Regulatory Authority in the Territory.
3.4 Development Costs 
(a) Phase I Clinical Development Plan. Green Cross shall be responsible for all Development Costs incurred by Green Cross inconnection with the conduct of the Phase I Clinical Development Plan, including, without limitation, Third Party costs for CRO-related activities forthe Phase I Clinical Trial in the Territory.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
18MacroGenics shall be responsible for all Development Costs incurred by MacroGenics in connection with the conduct of the Phase I ClinicalDevelopment Plan, including without limitation, Third Party costs for CRO-related activities for the Phase I Clinical Trial outside of the Territory,except as follows:
(i) Clinical Materials. MacroGenics shall be responsible for the cost of the supply of all Clinical Materials for the initial Phase IClinical Trial;
(ii) Labor Costs. Each Party shall be responsible for its direct labor costs (e.g., salaries, wages, employee benefits, overtime costs,and shirt premiums) for the conduct of its obligations under the Phase I Clinical Development Plan;
(iii) *** MacroGenics will invoice Green Cross at the end of the applicable Calendar Quarter for the amounts due hereunder, andall such amounts shall be paid to MacroGenics by Green Cross in US Dollars not later than sixty (60) days following the receipt of theapplicable invoice.
(iv) Data Management Costs. Each Calendar Quarter, Green Cross shall reimburse MacroGenics for *** of the costs incurred byMacroGenics in connection with the management of Clinical Data from the Phase I Clinical Trials during such Calendar Quarter.MacroGenics will invoice Green Cross at the end of the applicable Calendar Quarter for the amounts due hereunder, and all suchamounts shall be paid to MacroGenics by Green Cross in US Dollars not later than *** following the receipt of the applicable invoice.
(v) Insurance Costs. Each Calendar Quarter, Green Cross shall reimburse MacroGenics for all costs incurred by MacroGenics inconnection with all insurance policies required for the conduct of the Phase I Clinical Trials in the Territory during such CalendarQuarter. MacroGenics will invoice Green Cross at the end of the applicable Calendar Quarter for the amounts due hereunder, and allsuch amounts shall be paid to MacroGenics by Green Cross in US Dollars not later than *** following the receipt of the applicableinvoice. MacroGenics shall include Green Cross as a named insured on each such policy acquired by MacroGenics.
(vi) Limitation on Reimbursement of ***. Notwithstanding anything to contrary set forth in Section 3.4(a)(iv) or 3.4(a)(v), in noevent shall Green Cross be obligated to reimburse MacroGenics for any costs in connection with the *** 
(b) Phase II Clinical Development Plan. Green Cross shall be responsible for all Development Costs incurred in the Territory by eitherParty under the Phase II Clinical Development Plan, except for the cost of the supply of Clinical Materials, which shall be the responsibility ofMacroGenics.
3.5 Subcontractors. MacroGenics shall have the right to engage Third Party contractors to perform any portion of its obligations under thisAgreement (provided that
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
19MacroGenics shall use Commercially Reasonable Efforts to require such Third Party contractors to cooperate with Green Cross, so as to permitGreen Cross to comply with any of its development or commercial diligence obligations, and its reporting and payment obligations under any of theUpstream Agreements insofar as they relate to MGAH22 or any Product), and Green Cross shall have the right to engage a CRO in the Territory tosupport the conduct of the Phase I Clinical Trial *** (each such subcontractor, a “Permitted Subcontractor”). Any such Permitted Subcontractorused in the provision of services shall be required to agree in writing to be bound by terms regarding maintaining the confidentiality of proprietaryinformation that are no less stringent than those contained in this Agreement and regarding ownership of intellectual property that are consistentwith those contained in this Agreement. Either Party’s use of Permitted Subcontractors shall not relieve such Party of any of its obligationspursuant to this Agreement.
3.6 Clinical Trial Data. Except to the extent prohibited by any Applicable Law or Regulation, each Party shall provide all Clinical Data to theother on a schedule reasonably requested by the other.
3.7 Information and Cooperation. In addition to the obligations under Section 3.6, each Party shall use Commercially Reasonable Efforts tokeep the other Party informed of its research, Development and Commercialization (including promotional) activities hereunder, and shall provide tothe other Party, as appropriate, regular summary updates. If reasonably necessary for a Party to perform its work under this Agreement or toexercise its rights under this Agreement, that Party may request that the other Party provide more detailed information and data regarding theupdates it earlier provided, and the other Party shall promptly provide the requesting Party with information and data as is reasonably available andreasonably related to the work under this Agreement. Neither Party is required to generate additional data or prepare additional reports to complywith the foregoing obligation. All such reports, information and data provided shall be subject to Section 12.1. Prior to commencing themanufacture of Products or conduct of studies for the Product outside of the scope of this Agreement in the Territory, MacroGenics shall notifyGreen Cross of any such activity and consult with Green Cross with respect thereto; provided, however, that MacroGenics shall not undertake anysuch activity if and to the extent such activity would have a material adverse affect on Green Cross.
4. ADJUSTMENT OF PHASE II CLINICAL DEVELOPMENT PLAN. If the Parties agree to add additional patients or Indications to the Phase II ClinicalDevelopment Plan, or replace the Indication specified therein as of the Effective Date with a new Indication, then the Parties shall negotiate in goodfaith to agree upon the terms applicable to such expansion or change.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
205. COMMERCIALIZATION 
5.1 Overview. Green Cross shall have full responsibility and authority for all aspects of the Commercialization of Products in the Territory atits sole expense, including, without limitation, developing and executing a plan for commercial launch, obtaining all required approvals fromRegulatory Authorities for Commercialization (including, without limitation, reimbursement activities), marketing and promotion, booking sales anddistribution and performance of related services, providing customer support, including handling medical queries, and performing other relatedfunctions. Green Cross shall use Commercially Reasonable Efforts to Commercialize the Products. Green Cross shall update MacroGenics regardingits Commercialization activities at regular meetings of the JSC as contemplated by Section 2.1.(e). As between Green Cross and MacroGenics, ***.Green Cross shall bear all of the costs and expenses incurred in connection with all such Commercialization activities in the Territory. Green Crossshall timely notify MacroGenics as to the occurrence of the First Commercial Sale in the Territory.
5.2 Product Labeling; Promotional Materials. Green Cross shall Commercialize the Products in the Territory under the worldwide brandspecified by MacroGenics (“Product Brand”), except to the extent such branding is not permitted by any applicable Regulatory Authority, ordeemed culturally inappropriate, in the Territory, in which case MacroGenics shall specify an alternate Product Brand. Except for the depiction oftrademarks, logos and other symbols that are intended to identify MacroGenics’ as a company or the manufacturer or owner of a Product, GreenCross shall be responsible for designing and supplying the printable artworks of product labeling in electronic version and promotional materialsfor the Products for the Territory. Green Cross shall be responsible for how and the manner in which Products shall be presented and described inthe Territory to the medical community in any promotional materials for a Product intended to be disseminated in the Territory, and the placement ofthe name and logos of Green Cross therein, in each case as permitted by applicable law and consistent with the Product Brand and labeling for theProducts approved by the applicable Regulatory Authority.
5.3 Sales and Distribution 
(a) Orders and Sales. Green Cross shall be solely responsible for handling all returns, order processing, invoicing and collection,distribution, and inventory and receivables for the Products throughout the Territory. Green Cross shall have the right and sole responsibility forestablishing and modifying the terms and conditions with respect to the sale of the Products in the Territory, including any terms and conditionsrelating to or affecting the price at which the Products shall be sold, discounts available to any Third Party payers (including, without limitation,managed care providers, indemnity plans, unions, self insured entities, and government payer, insurance or contracting programs), any discountattributable to payments on receivables, distribution of the Products, and credits, price adjustments, or other discounts and allowances to begranted or refused; provided, however, that Green Cross shall act in good faith when doing the foregoing.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
21(b) Pricing. Green Cross shall have the sole right to determine all pricing of the Products in the Territory. Notwithstanding anything inthis Agreement express or implied to the contrary, MacroGenics shall not have any right to direct, control, or approve Green Cross’ pricing ofProducts for the Territory. The provision to MacroGenics of any pricing data is for informational purposes only. Green Cross shall be responsiblefor preparing and implementing the reimbursement strategy for the Products in the Territory. However, except to the extent prohibited byApplicable Laws and Regulations, MacroGenics shall use Commercially Reasonable Efforts to provide all the necessary data so that Green Crosscan file for the medical reimbursement price in the Territory; provided, however, that MacroGenics shall not be obligated to generate any data notwithin its possession.
5.4 Compliance. Each Party shall comply with the terms of this Agreement and all Applicable Laws and Regulations relating to activitiesperformed or to be performed by such Party (or its Affiliates, contractor(s) or Sublicensee(s)) under or in relation to the Commercialization of theProducts pursuant to this Agreement.
5.5 Commercialization Diligence 
(a) Prior to Submission of First BLA. For each Product under Development, prior to the submission of the first BLA to the firstRegulatory Authority in the Territory, Green Cross shall submit to the JSC a written summary plan for the Commercialization for each such Productunder Development. Thereafter, Green Cross shall regularly report on its Commercialization activities at meetings of the JSC or, if formed, the JointCommercialization Committee. Such reports shall cover subject matter at a level of detail similar to that which Green Cross affords to its seniorexecutives with respect to similar Green Cross products. All such plans and information shall be presented for discussion purposes, and GreenCross agrees to consider in good faith any comments or suggestions MacroGenics may make with respect to Commercialization of Products.
(b) Launch. Green Cross shall launch each Product in the Territory ***, provided that MacroGenics has supplied Product ordered byGreen Cross in accordance with Section 6.2(c) for such launch within a reasonable period prior to the planned launch date.
(c) Following Regulatory Approval. Green Cross shall use Commercially Reasonable Efforts to Commercialize each Product in theTerritory after obtaining Regulatory Approval for such Product.
5.6 Upstream Agreements. Green Cross agrees to provide to MacroGenics such information as it reasonably requires, or otherwise cooperatewith MacroGenics, so as to permit MacroGenics to comply with any of its development or commercial diligence obligations, and reporting andpayment obligations under any of the Upstream Agreements insofar as they relate to MGAH22 or any Product. 
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
226. MANUFACTURE AND SUPPLY 
6.1 Clinical Supply of Products. MacroGenics shall be responsible for the manufacture of all Product required for the clinical trials describedin the Phase I Clinical Development Plan, Phase II Clinical Development Plan and, if any, additional development plans, including any plan for aPhase III Clinical Trial, agreed upon in writing by the Parties for additional studies under this Agreement, either by itself or through one or moreThird Parties, including all costs of such manufacture, as set forth in Section 3.4.
6.2 Commercial Supply of Products 
(a) Responsibility. MacroGenics shall be responsible for the manufacture of all commercial supplies of Product required by Green Crossfor the Commercialization of Products in the Territory, in accordance with this Section 6.2, except as the Parties may otherwise agree pursuant toSection 6.4.
(b) Forecasts. For so long as MacroGenics is providing Product, Green Cross, through the JDC, shall furnish to MacroGenics ***forecast of probable quarterly orders for supplies of Product, to be updated quarterly based on Green Cross’ good faith estimate of its need forProduct.
(c) Orders. Green Cross agrees to buy, and MacroGenics agrees to sell, such quantities of Product as may be set forth on purchaseorders placed by Green Cross in accordance with the provisions of this Section 6.2. The Parties shall mutually agree upon an appropriate purchaseagreement. Any purchase orders for Product will reference this Agreement and will be consistent with the terms contained herein. Each purchaseorder shall set forth a delivery date for the quantities of Product ordered, which date will in no event be less than *** from the date of the purchaseorder. MacroGenics will use Commercially Reasonable Efforts to deliver each order on or before the applicable deliver date. If a purchase ordercannot be fulfilled or delivered as requested by Green Cross, then MacroGenics shall immediately inform Green Cross of such fact. If MacroGenicsis unable to manufacture sufficient quantities of Products to deliver to Green Cross hereunder, then MacroGenics shall allocate any shortagesamong its customers, including, without limitation, Green Cross, on a pro-rata basis based on the comparative order volumes of all customers at thetime of such shortage. MacroGenics shall use Commercially Reasonable Efforts to promptly resume production of Commercial Supply.
(d) Price; Payment. The price of Product ordered by Green Cross under this Section 6.2 will be equal to *** of MacroGenics’ FullyBurdened Manufacturing Costs for such material. All payments due hereunder to MacroGenics shall be paid to MacroGenics in US Dollars not laterthan *** following the receipt of the applicable invoice.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
236.3 Delivery. Unless otherwise agreed by the parties in writing, all shipments will be shipped F.O.B. MacroGenics’ or its contractmanufacturer’s facility.
6.4 Technology Transfer. If Green Cross requests, the Parties shall enter into good faith discussions regarding the possibility of a transfer toGreen Cross of technology that is sufficient to enable Green Cross to manufacture commercial supplies of Product in accordance with theApplicable Laws and Regulations of the Territory, provided that nothing herein shall be deemed to obligate MacroGenics to enter into anyagreement to transfer to Green Cross any such technology.
6.5 Manufacturing Specifications. All Clinical Materials and commercial supplies of Product shall be manufactured in accordance with thespecifications determined by MacroGenics and all Applicable Laws and Regulations.
6.6 Change of Manufacturing Process. MacroGenics shall reasonably inform Green Cross of developments in matters of processdevelopment and manufacturing of Products, and shall consult with Green Cross with respect to the development and manufacturing processes ofProducts adopted by MacroGenics to the extent necessary to obtain Regulatory Approval(s) of the same in the Territory. Green Cross shallpromptly notify MacroGenics of any information that will impact approvability of Products in the Territory.
7. REGULATORY 
7.1 Overview. The JSC shall establish an overall regulatory strategy for obtaining Regulatory Approval of the Product in the Territory, andshall allocate regulatory responsibilities between the Parties in a manner consistent with the provisions contained herein. Green Cross shallparticipate in regulatory matters as determined by the JSC, including CMC and other manufacturing-related matters, nonclinical matters, and clinicalmatters. In addition, Green Cross will have access to adverse event and other safety related data.
7.2 Regulatory Filings for Phase I Clinical Trial. MacroGenics shall hold the INDs in the Territory and be responsible for the filing of theINDs and all additional regulatory documents for the initial Phase I Clinical Trial with Regulatory Authorities in the Territory (such as INDs, andIND amendments), including, without limitation, all associated submissions (e.g., safety reports, protocol submissions, CMC updates), forresponding to inquiries and correspondences from the Regulatory Authorities, and the submission of all required reports for the Phase I ClinicalTrial until the Completion of the Phase I Clinical Trial. MacroGenics shall continue to hold INDs filed as of the Effective Date. MacroGenics willtransfer its responsibilities for preparing the Korean IND and IND amendments to Green Cross, but Green Cross shall provide ***, Green
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
24Cross may submit such filing, submission or response to the KFDA at the same time as Green Cross submits the same to MacroGenics; providedthat Green Cross uses Commercially Reasonable Efforts to obtain additional time. MacroGenics will transfer its responsibilities for interacting withthe KFDA to Green Cross, but Green Cross shall attempt to include MacroGenics on any face-to-face meetings or teleconferences, if deemednecessary by Green Cross, and shall not commit to making any revisions to the Phase I Clinical Trial unless for an immediate safety issues, withoutprior agreement with MacroGenics. Green Cross shall allow MacroGenics to review any written correspondence to the KFDA before it is sent to theKFDA.
7.3 Regulatory Filings Following Phase I Clinical Trial. Except as set forth in Section 7.2, Green Cross shall be responsible for the filing of allregulatory documents for MGAH22 and all Products with Regulatory Authorities in the Territory (such as INDs, NDAs and amended INDs andNDAs), including without limitation all associated submissions (e.g., safety alerts, protocol submissions), for responding to inquiries andcorrespondence from the Regulatory Authorities responsible for regulatory matters in the Territory, and the monitoring of all clinical experiencesand submission of all required reports throughout clinical Development and Commercialization, in each case in compliance with all laws andregulations. MacroGenics shall be responsible for providing to Green Cross any revisions to the investigator’s brochure and CMC informationrequired for KFDA submissions. Green Cross may request MacroGenics to participate in meetings with the KFDA if it is foreseeable that there maybe discussions about the Product beyond the scope of Green Cross’ development of the Product in the Territory (e.g., CMC matters, data fromclinical trials MacroGenics conducted). Each Party shall provide information to the other Party as necessary and reasonably consult with the otherParty regarding any filings, and regarding significant or material notices, actions or requests from or by Regulatory Authorities. Each Party shall, atthe other Party’s request, review and comment on filings, submissions, and responses to Regulatory Authorities related to any Product. GreenCross shall hold and maintain all Regulatory Approvals for the Commercialization of the Product in the Territory, as set forth in Section 10.1(c).
7.4 Records of Correspondence with KFDA. Following each communication (whether by phone or in person) with the KFDA regardingmatters arising under this Agreement, Green Cross shall prepare a record of such meeting in accordance with its standard business practices (e.g.,written minutes) and provide to MacroGenics a copy of such record.
7.5 Safety Data Exchange Agreement. The Parties shall conduct in good faith and agree upon a safety data exchange agreement, theagreement setting forth the safety information required to be shared by each Party and the schedule for the sharing of such safety information andother appropriate procedures and matters, as detailed in Exhibit G.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
258. PAYMENTS 
8.1 Upfront Payment. Within thirty (30) days after the Effective Date, Green Cross shall pay to MacroGenics One Million Dollars ($1,000,000),which shall be non-refundable and non-creditable against any other payments due under this Agreement.
8.2 Purchase of MacroGenics Stock Upon Initial Public Offering 
(a) If during the first three (3) years of the Term there is an Initial Public Offering which raises a ***, and if the underwriter(s) in suchInitial Public Offering permit it, Green Cross is obligated to purchase a number of shares of the same class of capital stock, simultaneously with theclosing(s) of, and at the same purchase price as the shares sold in, the Initial Public Offering that is equal to the number of shares that could bepurchased for ***.
(b) Green Cross acknowledges that any securities purchased in accordance with Section 8.2(a) shall not be registered under theSecurities Act of 1933, as amended (“Securities Act”), and may not be sold, assigned, pledged, hypothecated, encumbered or an any other mannertransferred or disposed of in the absence of an effective registration statement or an exemption from registration under the Securities Act. Inconnection with any Initial Public Offering, Green Cross agrees to enter into a lock-up agreement with the underwriter(s) if the managingunderwriter(s) demands or requests such an agreement; provided, however, that such provisions will not be less favorable to Green Cross than theprovisions of any lock-up agreements entered into by the managing underwriter(s) with other holders of securities issued by MacroGenics.
8.3 Clinical Development Milestone Payments. Green Cross shall pay to MacroGenics the milestone payments listed below, which shall benon-refundable, and non-creditable (unless otherwise stipulated under this Agreement). Any such milestone payments are subject to any credits,offsets and waivers specified by this Agreement.
(a) For the Commencement of the first Phase II Clinical Trial: ***; provided, however, that this milestone payment shall not be payableto MacroGenics if *** 
(b) For the Commencement of the first Phase III Clinical Trial: ***; provided, however, that this milestone payment shall not be payableto MacroGenics *** If all necessary documents required for Regulatory Approval of Completion of the Phase II Clinical Trial by Green Cross, ifany, are not received within a reasonable period prior to the agreed upon projected Completion date, other than as a result of Green Cross’ acts oromissions, then such *** period shall be equitably extended to account for such delay for a period mutually agreed upon in writing by the Parties.
(c) Approval of BLA for first Indication for a Product by KFDA in the Territory: *** 
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
268.4 Commercial Milestone Payments. Green Cross shall pay to MacroGenics the Net Sales milestone payments set forth below, which shallbe due and payable within *** after the end of the first Calendar Year during which such milestone is triggered.
(a) First occurrence of aggregate Net Sales for a period of *** of all Products in the Territory *** ***.
(b) First occurrence of aggregate Net Sales for a period of *** of all Products in the Territory exceeding *** 
8.5 Product Royalties.
(a) Green Cross shall pay to MacroGenics a royalty at the rate determined in accordance with the royalty chart included in Exhibit Hattached hereto on Net Sales of Products for the Royalty Term.
(b) Green Cross shall pay to MacroGenics a royalty of *** on Net Sales of Competing Products for the Royalty Term.
8.6 Upstream License Royalties. In addition to the other royalty payments set forth in this Section 8, Green Cross shall reimburseMacroGenics for royalty payments payable by MacroGenics as a result of the Collaboration pursuant to: (a) the Upstream Agreements identified onExhibit E as of the Effective Date and (b) any additional Upstream Agreements identified by MacroGenics after the Effective Date that include alicense to any patent(s) that has any claim(s) that would otherwise prevent MacroGenics from fulfilling its obligations under this Agreement or fromsupplying MGAH22 or any Product in the Territory (the “Upstream Royalties”). Green Cross’ obligation under this Section 8.6 with respect to thepayment of Upstream Royalties under an Upstream Agreement shall terminate upon termination of MacroGenics’ obligation to pay royalties underthe terms of such Upstream Agreement.
8.7 Third Party Agreements. Green Cross (or its Affiliate or Sublicensee) shall be responsible, at its sole expense and discretion, forobtaining any agreements with Third Parties (other than the Upstream Agreements) for any Third Party rights which would be infringed by theDevelopment, manufacturing, importation, or Commercialization of any Product in the Territory.
8.8 Payment of Milestones. All milestone payments shall be due and payable within *** after the event for which the payment is due.
8.9 Reports; Payments 
(a) Net Sales Quarterly Reports. During the Term, following the First Commercial Sale of a Product in the Territory, Green Cross shallfurnish to MacroGenics:
(i) a quarterly written report for the Calendar Quarter showing the Net Sales of all Products (and Competing Products) subject toroyalty payments sold by Green Cross and its Related Parties in the Territory during the reporting period and the royalties payableunder this Agreement; and
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
27(ii) a quarterly report for the Calendar Quarter showing Green Cross’ Commercial Supply Costs, Third Party Royalties andUpstream Royalties for such Calendar Quarter, with such detail as shall reasonably allow MacroGenics to determine the basis for suchquarterly costs.
(b) Submission and Payment Schedule 
(i) Reports. Reports under this Section 8.9 shall be due on the ninetieth (90) day following the close of each Calendar Quarter.
(ii) Royalties. Royalties shown to have accrued by each report shall, unless otherwise specified under this Agreement, be due andpayable on the date such report is due.
8.10 Payment Exchange Rate. All payments to be made by Green Cross to MacroGenics under this Agreement shall be made in United Statesdollars by bank wire transfer in immediately available funds to a bank account in the United States designated in writing by MacroGenics. Forinvoices that Green Cross shall forward to MacroGenics, Green Cross shall use an exchange rate equal to the Telegraphic Transfer (T/T) selling rateas published by Korean Exchange Bank as of the close of business on the last business day of the preceding month.
8.11 Tax Withholding. If laws, rules or regulations require Green Cross to withhold income taxes or other taxes imposed upon payments setforth in this Section 8, Green Cross shall make such withholding payments as required and subtract such withholding payments from the paymentsset forth in this Section 8. Green Cross shall submit original receipts or other appropriate proof of payment of the withholding taxes to MacroGenicswithin a reasonable period of time to allow MacroGenics to document such tax withholdings for purposes of claiming foreign tax credits and similarbenefits, and shall cooperate with reasonable requests of MacroGenics (without acting to the detriment of Green Cross) related to MacroGenicsobtaining such credits and benefits.
9. Record Keeping and Inspections and Audits 
9.1 Records
(a) Collaboration Activities. Each Party shall maintain appropriate records of: (i) all significant research, Development, manufacturingand Commercialization events and activities conducted by it or on its behalf related to a Product, and all costs in connection therewith, asapplicable; and (ii) all significant information generated by it or on its behalf in connection with research and development
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
28
thof MGAH22 and Products under this Agreement, in each case in accordance with such Party’s usual documentation and record retention practices.Such records shall be in sufficient detail to properly reflect, in good scientific manner, all significant work done and results of studies and trialsundertaken, and further shall be at a level of detail appropriate for patent and regulatory purposes.
(b) Green Cross Royalties. Green Cross shall keep complete and accurate records in sufficient detail to enable the royalties payableunder Section 8 and its Commercial Supply Costs, Third Party Royalties and Upstream Royalties to be determined.
(c) MacroGenics’ Royalties. MacroGenics shall keep complete and accurate records of royalty payments due under the UpstreamAgreements in sufficient detail to enable the Upstream Royalties payable by Green Cross under Section 8.6 to be determined. At the request ofGreen Cross, MacroGenics shall make such records available to Green Cross.
(d) MacroGenics’ FBMC. MacroGenics shall keep complete and accurate records with such detail as shall reasonably allow GreenCross to determine the basis for such FBMC. At the request of Green Cross, MacroGenics shall make such records available to Green Cross.
9.2 Audit Rights. Upon the written request of a Party (“Requesting Party”) with reasonable advance notice and not more than once in eachCalendar Year, the other Party shall permit an independent certified public accounting firm of nationally recognized standing selected byRequesting Party and reasonably acceptable to the other Party, at its own expense, to have access during normal business hours to such of therecords as may be reasonably necessary to verify the accuracy of the reports under Section 8 for any Calendar Year ending not more than thirty-six(36) months prior to the date of such request. The accounting firm shall disclose to the Requesting Party only whether the reports are correct orincorrect and the specific details concerning any discrepancies. No other information shall be provided to Requesting Party in connection with thisaudit right. This right to audit shall remain in effect throughout the life of this Agreement and for a period of three (3) years after the termination ofthis Agreement.
9.3 Discrepancies. If such accounting firm identifies a discrepancy, the other Party shall pay Requesting Party the amount of the discrepancywithin thirty (30) days of the date Requesting Party delivers to the other Party such accounting firm’s written report so concluding, or as otherwiseagreed upon by the Parties. The fees charged by such accounting firm shall be paid by Requesting Party unless the underpayment by the otherParty exceeded five percent (5%) of the amount owed for such Calendar Year, in which case the other Party shall pay to Requesting Party thereasonable fees charged by such accounting firm.
9.4 Confidentiality. Each Party shall treat all information of the other Party subject to review under this Section 9 in accordance with theconfidentiality and non-use
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
29provisions of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with the audited Party andany applicable Related Parties, obligating it or them to retain all such information in confidence pursuant to such confidentiality agreement.
10. LICENSES 
10.1 License to Green Cross 
(a) License. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Green Cross an exclusive, royalty-bearing (i) license, with the right to grant sublicenses (subject to Section 10.1(b)), under the MacroGenics Licensed Technology and theMacroGenics Licensed Trademarks; and (ii) to the extent needed under this Section 10.1(a), sublicense under the MacroGenics LicensedTechnology licensed pursuant to the Upstream Agreements, in the case of each of (i) and (ii), to conduct the Phase I Clinical Development Plan andPhase II Clinical Development Plan, and to distribute, sell, offer for sale and import Products in the Field in the Territory during the Term.
(b) Sublicensees. Green Cross may grant sublicensees solely for purposes of performing its Development obligations under thisAgreement. In no event shall Green Cross grant any sublicense to any of the rights granted to it pursuant to Section 10.1(a) for any other purposewithout MacroGenics’ prior written consent. Each sublicense granted by Green Cross shall be consistent with this Agreement and subordinatethereto, and Green Cross shall remain responsible to MacroGenics for the compliance of each such Sublicensee with the financial and otherobligations due under this Agreement. Green Cross shall provide a copy of each such sublicense to MacroGenics so that MacroGenics can confirmGreen Cross’ compliance with the foregoing. Each sublicense granted by Green Cross under this Agreement shall permit the conversion of suchsublicense to a direct license with MacroGenics at MacroGenics’ sole option in the event this Agreement is terminated and, upon such conversion,MacroGenics shall be responsible for all former obligations of Green Cross under such sublicense. Green Cross shall use Commercially ReasonableEfforts to include in each such sublicense a requirement obligating such sublicensees to cooperate with MacroGenics.
(c) Regulatory Approvals. Green Cross shall hold and maintain all Regulatory Approvals for the Commercialization of the Product in theTerritory.
(d) MacroGenics Retained Rights. MacroGenics shall retain the following: (i) the right to conduct its obligations under the Phase IClinical Development Plan and Phase II Clinical Development Plan in the Territory, including, without limitation, data management, monitoring,regulatory compliance and support and shipping requirements and all other requirements in connection with this Agreement; (ii) the right tomanufacture or have manufactured MGAH22 and Products for uses pursuant to this Agreement as provided in Section 6 in the Territory; and (iii)all rights not otherwise granted to Green Cross inside and outside the Territory.
(e) Opportunity ***. In the event that during the period between the ***, MacroGenics wishes to ***, MacroGenics shall provideGreen Cross *** 
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
3010.2 Upstream Agreements. Certain MacroGenics Licensed Know-how and MacroGenics Licensed Patents sublicensed under Section 10.1(a)above and identified on Exhibit A are licensed (or sublicensed, in some instances) to MacroGenics by certain Third Parties pursuant to theUpstream Agreements. Green Cross acknowledges and agrees that its sublicense to and any warranties and/or representations made byMacroGenics under this Agreement regarding such MacroGenics Licensed Technology granted under Section 10.1(a) are at all times subject to theapplicable terms of the Upstream Agreements, current copies of which, for those in effect as of the Effective Date, have been provided to GreenCross as of the Effective Date, including restrictions on the type and nature of the antibodies licensed as Products thereunder, diligencerequirements, and termination provisions thereof, and that MacroGenics is in no way licensing or purporting to license or sublicense to GreenCross rights under the Upstream Agreements that if sublicensed to Green Cross would be a violation of any Upstream Agreement. Green Crosscovenants not to take or fail to take any action that violates the terms of such Upstream Agreements applicable to Sublicensees, or that wouldcause MacroGenics to be in breach of any of the terms of the Upstream Agreements.
10.3 License to MacroGenics. Green Cross hereby grants to MacroGenics a royalty-free, worldwide license during the Term, with the right togrant sublicenses, under the Green Cross Licensed Patents and Green Cross Know-how that is incorporated into any Product, and all otherintellectual property Controlled by Green Cross that is specifically related to MGAH22 to the extent needed by MacroGenics to research, identify,develop, make, have made, use, sell, offer for sale and import Products, including, without limitation, as contemplated by Section 10.1(c) above, inall cases without any obligation to obtain Green Cross’ prior consent. The license granted pursuant to this Section 10.3 shall be non­exclusive inthe Territory and exclusive in the rest of the world outside the Territory. After the Term, the Parties shall discuss in good faith whether futurelicenses are necessary for MacroGenics to continue to use Green Cross Licensed Patents or Green Cross Licensed Know-how, and determinereasonable terms and conditions for such license at MacroGenics’ request.
10.4 Clinical Data Licenses. Subject to the terms and conditions of this Agreement, Green Cross hereby grants to MacroGenics a non-exclusive, royalty-free, perpetual license, with the right to grant and authorize the grant of sublicenses, to use all Clinical Data and any datagenerated by Green Cross or any of its representatives or independent contractors pursuant to its performing its responsibilities under thisAgreement for the research, Development, manufacture Commercialization and sales of MGAH22 and Products by MacroGenics outside theTerritory and for MacroGenics to exercise its rights and fulfill its obligations under this Agreement. Subject to the terms and conditions of thisAgreement, MacroGenics hereby grants to Green Cross a non-exclusive,
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
31royalty-free, license, with the right to grant sublicenses, during the Term to use all Clinical Data and other data generated by MacroGenics pursuantto its performing its responsibilities under this Agreement for Green Cross to fulfill its obligations under this Agreement.
10.5 Negative Covenant. Each Party covenants that, except to the extent Third Parties generally are lawfully permitted to do so, it will not useor practice any of the other Party’s intellectual property rights licensed to it under this Section 10 except for the purposes expressly permitted in theapplicable license grant.
10.6 No Implied Licenses. Except as explicitly set forth in this Agreement, neither Party grants any license, express or implied, under itsintellectual property rights to the other Party.
10.7 Diversion 
(a) Green Cross hereby covenants and agrees that it will not, either directly or indirectly, promote, market, distribute, import, sell or havesold Products, including via the Internet or mail order, to any Third Party, address or Internet Protocol address outside of the Territory.
(b) If any of Green Cross’ Products are diverted for use outside the Territory, the following shall apply: (i) if such Products werediverted by an identifiable customer, distributor, employee, consultant or agent of Green Cross then, upon the request of MacroGenics, GreenCross shall not sell such Products to, or allow the sale of such Products by, any such customer, distributor, employee, consultant or agent for theremaining Term and shall use Commercially Reasonable Efforts to buy back all such Products from such customer, distributor, employee, consultantor agent within *** of such request from MacroGenics; or (ii) Green Cross shall use Commercially Reasonable Efforts to investigate the location ofsuch diverted Products and buy it back; but, if and to the extent that, Green Cross elects not to, or is unable to, buy back the applicable divertedProducts, then MacroGenics may, in its sole discretion, buy back the applicable diverted Products, and Green Cross shall reimburse MacroGenicsfor all reasonable costs incurred by MacroGenics in connection with the buy-back or lost sales of any such diverted Products.
11. EXCLUSIVITY. During the Term, Green Cross shall not (either by itself, or with or through a Related Party or Third Party) Develop orCommercialize any (i) Product outside of the scope of this Agreement or (ii) Competing Product.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
3212. CONFIDENTIALITY; PUBLICATION 
12.1 Nondisclosure Obligation 
(a) Definition and Restrictions. All Confidential Information disclosed by one Party to the other Party at any time, including, withoutlimitation, before the Effective Date or after the expiration or termination of this Agreement, shall be maintained in confidence by the receiving Partyand shall not be disclosed by the receiving Party to any Third Party or used by the receiving Party for any purpose except as set forth hereinwithout the prior written consent of the disclosing Party, *** The following shall not be deemed Confidential Information for purposes of therestrictions set forth in this Section 12.3(a):
(i) Information that is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosingParty, as documented by the receiving Party’s business records;
(ii) Information that is or becomes part of the public domain through no fault of the receiving Party;
(iii) Information that is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under anobligation of confidentiality to the disclosing Party; and
(iv) Information that is developed by the receiving Party independently of Confidential Information received from the disclosingParty, as documented by the receiving Party’s business records.
(b) Combinations. Any combination of features or disclosures shall not be deemed to fall within the exclusions set forth in Section12.1(a) merely because individual features are published or available to the general public or in the rightful possession of the receiving Party unlessthe combination itself and principle of operation are published or available to the general public or in the rightful possession of the receiving Party.
(c) Exceptions. Notwithstanding the restrictions set forth in Section 12.1(a), the receiving Party may disclose Confidential Information ofthe other Party to:
(i) governmental or other regulatory agencies in order to obtain Patents or to gain or maintain approval to conduct clinical trials orto market Products, but such disclosure may be only to the extent reasonably necessary to obtain Patents or authorizations; or
(ii) as the receiving Party deems necessary to be disclosed, to its Affiliates, agents, consultants, or other Third Parties for theDevelopment or
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
33Commercialization of Product(s), or in connection with a licensing transaction related to such Product(s) or loan, financing orinvestment or acquisition, merger, consolidation or similar transaction (or for such entities to determine their interest in performing suchactivities) or in order to perform its obligations under this Agreement, in each case on the condition that any Third Parties, other thanRegulatory Authorities, to whom such disclosures are made agree to be bound by confidentiality and non-use obligations substantiallysimilar to those contained in this Agreement; provided that the term of confidentiality and non-use applicable to such Third Partiesshall be no less than *** from the date of disclosure to them.
(d) Disclosure Required by Judicial or Administrative Process. If a Party is required by judicial or administrative process to discloseConfidential Information of the other Party that is subject to the non-disclosure provisions of this Section 12.1, such Party shall promptly inform theother Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations.Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-useprovisions of this Section 12.1, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonablynecessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such ConfidentialInformation.
(e) Obligations Upon Termination. Upon the termination or expiration of this Agreement, or upon the earlier request of either Party, thereceiving Party shall return to the disclosing Party, all of the disclosing Party’s Confidential Information, including all copies thereof, provided thatthe receiving Party may retain one copy for archival purposes.
12.2 Publication
(a) Publication of Results. Green Cross and MacroGenics each acknowledge the other Party’s interest in publishing the results of itsactivities under the Collaboration in order to obtain recognition within the scientific community and to advance the state of scientific knowledge.Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting business interests and trade secret information.Consequently, the JSC shall establish procedures for review of publications related to the Collaboration, ensuring that, except for disclosurespermitted pursuant to Section 12.1, either Party and its employees wishing to make a publication related to work performed under this Agreementshall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least *** prior to submission forpublication or for presentation.
(b) Review of Publications and Presentations
(i) The reviewing Party shall have the right (a) to propose modifications to the publication or presentation for patent reasons,trade secret reasons,
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
34or for purposes of removing the Confidential Information of the reviewing Party, or (b) to request a reasonable delay in publication orsubmission for presentation in order to protect trade secret or patentable information.
(ii) If the reviewing Party requests the removal of the reviewing Party’s Confidential Information or a delay, the publishing Partyshall remove such Confidential Information and delay submission for publication or submission for presentation for a period of *** toenable patent applications protecting each Party’s rights in such Confidential Information to be filed in accordance with Section 15below.
(iii) Upon expiration of such *** and satisfaction of any other conditions imposed by the JSC, the publishing Party shall be free toproceed with the publication or submission for presentation.
(iv) Upon request of the Party seeking publication, the reviewing Party shall consider expediting the time frames set forth in thisSection 12.2.
(v) If the reviewing Party requests modifications to the publication or submission for presentation, the publishing Party shall editsuch publication to prevent disclosure of the Confidential Information of the reviewing Party or trade secret or proprietary businessinformation prior to submission for publication or for presentation.
12.3 Publicity; Use of Names 
(a) Press Releases. The Parties shall issue a mutually acceptable press release announcing the execution of this Agreement. A Partymay issue any subsequent press release relating to this Agreement or activities conducted hereunder upon prior written approval of the otherParty, such approval not to be unreasonably withheld or delayed; provided, however, that no approval of the other Party shall be required if asubsequent press release or SEC filing solely discloses the information that (1) a milestone under this Agreement has been achieved and/or anypayments associated therewith have been received; (2) the filing and/or approval of a BLA generally has occurred (provided, however, that specificdates of filing shall not be disclosed); (3) initiation of any Phase II Clinical Trial or later clinical trial; and (4) commercial launch of a Product or anyinformation that has previously been approved and disclosed as permitted by this Section 12.3(a). In the case of items (1)-(4) of the precedingsentence, the disclosing Party shall provide the other Party a copy of such proposed disclosures at least *** prior to the proposed release andconsider in good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such disclosing Partyunder applicable laws, rules or regulations, including without limitation the rules and regulations promulgated by the United States Securities andExchange Commission or any other governmental agency.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
35(b) No Other Use of Company Names. Except as otherwise provided in this Section 12.3(b), neither Party shall use the name, trademark,trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without theprior express written permission of the other Party.
(c) Approved Press Releases. In addition and notwithstanding anything to the contrary herein, (a) if the relevant text of a proposedpress release has already previously been reviewed and approved for disclosure by the other Party then such text may be disclosed or republishedin such proposed press release provided that the Party issuing such press release provides notice to the other Party of such press release at leastfour (4) business days prior to the issuance of such press release, where practicable, and (b) if the relevant text of a proposed public announcementsuch as a corporate presentation or comments to analysts or investors has already previously been reviewed and approved for disclosure by theother Party (whether in the form of an approved press release or prior approved presentation materials, Q&A script or the like) then such text maybe included in such proposed public announcement (but not a press release) without resubmission and review by the other Party.
(d) Existence of Agreement 
(i) No Disclosure. Neither Party shall disclose the existence or terms of this Agreement pursuant to a press release or otherwiseexcept as provided in this Section 12.3(d).
(ii) Permitted Disclosures 
(A) Notwithstanding the terms of this Section 12, either Party shall be permitted to disclose the existence and terms of thisAgreement and the conduct of the Collaboration under this Agreement, to the extent required, in the reasonable opinion of such Party’s legalcounsel, to comply with applicable laws, rules or regulations, including without limitation the rules and regulations promulgated by the UnitedStates Securities and Exchange Commission or any other governmental agency. The disclosing Party shall take reasonable and lawful actions toavoid and/or minimize the degree of such disclosure.
(B) Either Party may also disclose the existence and terms of this Agreement to its attorneys and advisors, and to potentialacquirors, in connection with a potential acquisition or other change of control transaction and to existing and potential investors or lenders ofsuch Party, as a part of their due diligence investigations, or to potential licensees or to permitted assignees in each case under an agreement tokeep the terms of this Agreement confidential under terms of confidentiality and non-use substantially similar to the terms contained in thisAgreement and to use such confidential information solely for the purpose of the contemplated transaction.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
36(C) MacroGenics may also disclose the existence and terms of this Agreement pursuant to transactions related to theCommercialization or Development of MGAH22 or any Product (“Licensing Transactions”), in each case under an agreement to keep the terms ofthis Agreement confidential under terms of confidentiality and non-use substantially similar to the terms contained in this Agreement and to usesuch confidential information solely for the purpose of the contemplated transaction, provided that prior to the disclosure of the terms of thisAgreement in connection with any Licensing Transaction, MacroGenics shall redact in any written summary or copy of this Agreement, all financialterms of this Agreement, in a manner substantially consistent with a form provided to Green Cross by MacroGenics on or before the Effective Date.The transactions described in Section 12.3(d)(ii)(B) shall not be deemed Licensing Transactions for purposes of this Section 12.3(d)(ii)(C).
13. REPRESENTATIONS AND WARRANTIES 
13.1 Representations and Warranties of MacroGenics. MacroGenics represents and warrants to Green Cross that, as of the Effective Date:
(a) it has the full right, power and authority to enter into this Agreement, to perform the Collaboration, and to grant the licensescontemplated under Section 10, and the fulfillment of its obligations and performance of its activities hereunder do not materially conflict with,violate, or breach or constitute a default under any contractual obligation or court or administrative order by which MacroGenics is bound;
(b) all necessary consents, approvals and authorizations of all government authorities and other persons required to be obtained byMacroGenics as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained;
(c) it is the exclusive licensee of or otherwise Controls the right, title and interest in and to the MacroGenics Licensed Technology andMacroGenics Licensed Trademarks, and has the right to grant to Green Cross the licenses that it purports to grant hereunder and has not grantedany Third Party rights that would interfere or be inconsistent with Green Cross’ rights hereunder;
(d) to its knowledge, except for those licensed or sublicensed under the Upstream Agreements, the MacroGenics Licensed Patents andMacroGenics Licensed Know-how are not subject to any existing royalty or other payment obligations to any Third Party; and
(e) as of the Effective Date, to its knowledge, the issued Patents in the MacroGenics Licensed Patents are valid and enforceable and it isnot aware of any action, suit, inquiry, investigation or other proceeding threatened, pending, or ongoing brought by any Third Party thatchallenges or threatens the validity or enforceability of
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
37any of the MacroGenics Licensed Patents or that alleges the use of the MacroGenics Licensed Patents or the MacroGenics Licensed Know-how orthe development, manufacture commercialization and use of the Products would infringe or misappropriate the intellectual property or intellectualproperty rights of any Third Party (and it has not received any notice alleging such an infringement or misappropriation). In the event thatMacroGenics becomes aware of any such action or proceeding, it shall immediately notify Green Cross in writing.
13.2 Representations and Warranties of Green Cross. Green Cross represents and warrants to MacroGenics that as of the Effective Date:
(a) it has the full right, power and authority to enter into this Agreement, to perform the Collaboration, to grant the licenses grantedhereunder, and the fulfillment of its obligations and performance of its activities hereunder do not materially conflict with, violate, or breach orconstitute a default under any contractual obligation or court or administrative order by which Green Cross is bound;
(b) all necessary consents, approvals and authorizations of all government authorities and other persons required to be obtained byGreen Cross as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained.
(c) it is the exclusive licensee of or otherwise Controls the right, title and interest in and to the Green Cross Licensed Patents and GreenCross Licensed Know-how, and has the right to grant to MacroGenics the licenses that it purports to grant hereunder and has not granted anyThird Party rights that would interfere or be inconsistent with MacroGenics’ rights hereunder;
(d) to its knowledge, the Green Cross Licensed Patents and Green Cross Licensed Know-how are not subject to any existing royalty orother payment obligations to any Third Party; and
(e) as of the Effective Date, to its knowledge, the issued Patents in the Green Cross Licensed Patents are valid and enforceable and it isnot aware of any action, suit, inquiry, investigation or other proceeding threatened, pending, or ongoing brought by any Third Party thatchallenges or threatens the validity or enforceability of any of the Green Cross Licensed Patents or that alleges the use of the Green Cross LicensedPatents or the Green Cross Licensed Know-how or the development, manufacture commercialization and use of the Products would infringe ormisappropriate the intellectual property or intellectual property rights of any Third Party (and it has not received any notice alleging such aninfringement or misappropriation). In the event that Green Cross becomes aware of any such action or proceeding, it shall immediately notifyMacroGenics in writing.
13.3 Upstream Agreements. MacroGenics represents, warrants and covenants to Green Cross that:
(a) Exhibit E lists all of the Upstream Agreements in existence as of the Effective Date. True and correct copies of the existing UpstreamAgreements have previously been provided to Green Cross by MacroGenics, and copies of any additional Upstream Agreement entered followingthe Effective Date will be provided to Green Cross by MacroGenics. Notwithstanding the foregoing, prior to entering into additional UpstreamAgreements, MacroGenics shall inform Green Cross to allow Green Cross to review the same.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
38(b) The Upstream Agreements identified on Exhibit E are, to MacroGenics’ knowledge, in full force and effect as of the Effective Date,and MacroGenics is not aware of any that it has committed any material breach of any of the provisions of any of such Upstream Agreements, nordoes there exist any condition that, to the knowledge of MacroGenics, with passage of time or sending of notice would constitute a material breachby MacroGenics of any of the provisions of such Upstream Agreements, nor is MacroGenics aware of any material breach of such UpstreamAgreements by any other party thereto.
(c) To the extent required to grant the licenses in this Agreement, MacroGenics has the right under the Upstream Agreements listed onExhibit E to enter into this Agreement and grant the licenses contemplated hereby.
(d) MacroGenics will fulfill all of its material obligations under the Upstream Agreements and otherwise comply with the terms thereof.MacroGenics shall furnish to Green Cross copies of all notices received by MacroGenics relating to alleged breaches or defaults by MacroGenics ofits obligations under the Upstream Agreements within five (5) business days of MacroGenics receipt thereof.
(e) To the extent MacroGenics is permitted or required under the terms of the Upstream Agreements to participate in the prosecution,maintenance, or enforcement or defense of any Patent or other intellectual property right sublicensed to Green Cross under this Agreement,MacroGenics shall do so after consultation with Green Cross and, as and to the extent permitted by the Upstream Agreements, Green Cross shallhave the same rights with respect thereto as set forth in Section 15 hereof.
13.4 No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS ORWARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OFMERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTYINTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES,WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
3914. INDEMNIFICATION 
14.1 By Green Cross. Green Cross agrees to indemnify and hold harmless MacroGenics, its Affiliates, and their directors, officers, employeesand agents (individually and collectively, the “MacroGenics Indemnitee(s)”) from and against all losses, liabilities, damages and expenses(including reasonable attorneys’ fees and costs) incurred in connection with any claims, demands, actions or other proceedings by any Third Party(individually and collectively, “Losses”) first arising after the Effective Date to the extent arising from (a) activities performed by Green Cross or anyof its Affiliates or Permitted Subcontractors with respect to the research, Development, manufacture, use, Commercialization or sale of MGAH22 orProducts or any other exercise of their rights or performance of their obligations hereunder, (b) the use by Green Cross or any of its Related Partiesor Permitted Subcontractors of the MacroGenics Licensed Patents or MacroGenics Licensed Know-how except as permitted in this Agreement, (c)the negligence, illegal conduct or willful misconduct of Green Cross, or (d) Green Cross’ material breach of this Agreement, except to the extentsuch Losses arise out of any of MacroGenics Indemnitee’s negligence, illegal conduct or willful misconduct, or breach of this Agreement.
14.2 By MacroGenics. MacroGenics agrees to indemnify and hold harmless Green Cross, its Affiliates, and their directors, officers, employeesand agents (individually and collectively, the “Green Cross Indemnitee(s)”) from and against all Losses to the extent arising from (a) activitiesperformed by MacroGenics or any of its Affiliates or Permitted Subcontractors with respect to the research, Development, manufacture, use,Commercialization or sale of Products, (b) any latent or hidden defect in a Product that is not caused by any act or omission of Green Cross, (c) theuse by Green Cross or any of its Related Parties or Permitted Subcontractors of the MacroGenics Licensed Patents or MacroGenics LicensedKnow-how or any intellectual property rights under Upstream Agreements as permitted under this Agreement, (d) the negligence, illegal conduct orwillful misconduct of MacroGenics, or (e) MacroGenics’ material breach of this Agreement, except to the extent such Losses arise out of any ofGreen Cross Indemnitee’s negligence, illegal conduct or willful misconduct, or breach of this Agreement.
14.3 Defense. If any such claims or actions are made, the Indemnitee shall be defended at the Indemnifying Party’s sole expense by counselselected by the Indemnifying Party and reasonably acceptable to the Indemnitee, provided that the Indemnitee may, at its own expense, also berepresented by counsel of its own choosing. The Indemnifying Party shall have the sole right to control the defense of any such claim or action,subject to the terms of this Section 14.
14.4 Settlement. The Indemnifying Party may settle any such claim, demand, action or other proceeding or otherwise consent to an adversejudgment (a) with prior written notice to the Indemnitee but without the consent of the Indemnitee where the only liability to the Indemnitee is thepayment of money and the Indemnifying Party makes such payment, or (b) in all other cases, only with the prior written consent of the Indemnitee,such consent not to be unreasonably withheld.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
4014.5 Notice. The Indemnitee shall notify the Indemnifying Party promptly of any claim, demand, action or other proceeding under Section 14.1or Section 14.2 and shall reasonably cooperate with all reasonable requests of the Indemnifying Party with respect thereto.
14.6 Permission by Indemnifying Party. The Indemnitee may not settle any such claim, demand, action or other proceeding or otherwiseconsent to an adverse judgment in any such action or other proceeding or make any admission as to liability or fault without the express writtenpermission of the Indemnifying Party. Provided, however, that such permission shall not be required if such settlement does not involve (a) anyadmission of legal wrongdoing by the other Party’s Indemnitee(s), or (b) the imposition of any equitable relief against the other Party’sIndemnitee(s).
14.7 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL,PUNITIVE, OR INDIRECT DAMAGES OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT,REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THISSECTION 14.7 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTYUNDER ARTICLE 14, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 12.
15. INVENTIONS; PATENT PROVISIONS 
15.1 Ownership of Intellectual Property 
(a) Ownership of MacroGenics IP. As between MacroGenics and Green Cross, MacroGenics shall remain the sole and exclusive ownerof all MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and MacroGenics Licensed Know-how that exist as of the Effective Date.
(b) Ownership of Green Cross IP. As between Green Cross and MacroGenics, Green Cross shall remain the sole and exclusive owner ofall Green Cross Licensed know-how that exists as of the Effective Date.
(c) Ownership of Jointly Owned IP. MacroGenics shall own all data, results and inventions, whether patentable or not, conceived orreduced to practice in the course of conducting the Collaboration solely by MacroGenics or its consultants or subcontractors, together with allintellectual property rights therein. Green Cross shall own all data, results and inventions, whether patentable or not, conceived or reduced topractice in the course of conducting the Collaboration solely by Green Cross or its
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
41consultants or subcontractors, together with all intellectual property rights therein. MacroGenics and Green Cross shall jointly own all data, resultsand inventions, whether patentable or not, conceived or reduced to practice by MacroGenics and Green Cross jointly (“Jointly Owned IP”),together with all intellectual property rights therein, with each Party owning an undivided half interest and the right to exploit without the duty ofaccounting or seeking consent from the other Party to the extent to be permitted under Applicable Laws and Regulations.
15.2 Patent and Trademark Filing, Prosecution and Maintenance 
(a) Overall Strategy. The JSC shall establish an overall strategy for the filing, prosecution and maintenance of MacroGenics LicensedPatents, MacroGenics Licensed Trademarks and Green Cross Licensed Patents in the Territory.
(b) Prosecution 
(i) The responsibility for Patent Prosecution and Trademark Prosecution related to a Patent or Trademark that is within theMacroGenics Licensed Patents and MacroGenics Licensed Trademarks or the Green Cross Licensed Patents that is owned solely by aParty shall be the responsibility of such Party. Such Party shall keep the JSC and the other Party informed of the status of all suchPatent Prosecution and Trademark Prosecution activities. MacroGenics shall be responsible for undertaking the Patent Prosecution withrespect to Patents jointly owned by the Parties (the “Jointly Owned Patents”), and shall do as directed by the JSC.
(ii) MacroGenics shall keep the JSC and Green Cross informed of the status of all matters affecting Patent Prosecution andTrademark Prosecution of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and Jointly Owned Patents in theTerritory, including providing a copy of any correspondence from any governmental authorities to the JSC and Green Cross uponrequest, and consulting on the strategy and content of submissions to such governmental authorities in advance of any submissions.
(iii) Any dispute regarding Patent Prosecution and Trademark Prosecution of MacroGenics Licensed Patents, MacroGenicsLicensed Trademarks, or Jointly Owned Patents, shall be resolved by the JSC.
(iv) Without limiting the generality of the foregoing, MacroGenics shall prosecute and maintain Jointly Owned Patents usingoutside counsel acceptable to Green Cross, and shall instruct such counsel to provide copies of correspondence and filings directly toGreen Cross and otherwise permit Green Cross to participate with MacroGenics in any of the activities of such counsel with respect tothe Patent and Trademark Prosecution of such Jointly Owned Patents. Before taking any material step in the Patent Prosecution orJointly Owned Patents, MacroGenics and its counsel shall allow Green Cross a reasonable opportunity to comment on the actionproposed to be taken, and agrees to incorporate in such filings all reasonable comments of Green Cross.
(v) Green Cross acknowledges and understands that its rights and obligations under this Section 15.2 are secondary to and shallbe subject to any Third Party rights and obligations under the Upstream Agreements.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
42(c) Patent and Trademark Oppositions. The JSC will decide whether and how to participate in Patent and Trademark oppositions andundertake activities intended to invalidate Third Party Patents.
15.3 Costs of Patent and Trademark Prosecution 
(a) Costs. All out­of­pocket costs for Patent Prosecution and Trademark Prosecution of a Party’s solely owned Patent or Trademark andfor maintaining a Party’s solely owned Patent or Trademark shall be solely incurred by and the sole responsibility of that Party. All out­of­pocketcosts for Patent Prosecution of Jointly Owned Patents and for maintaining Jointly Owned Patents in the Territory shall be shared equally by theParties. The out­of­pocket costs of MacroGenics’ participation in Patent and Trademark oppositions, interferences and similar actions, andactivities intended to invalidate Third Party Patents and Trademarks in the Territory shall be borne solely by Green Cross.
15.4 Patent and Trademark Prosecution Cooperation. With respect to all Patent Prosecution and Trademark Prosecution related to Patentsand Trademarks included in MacroGenics Licensed Patents, MacroGenics Licensed Trademarks or Green Cross Licensed Patents, each Party shall:
(a) execute all further instruments to document their respective ownership consistent with this Agreement as reasonably requested bythe other Party;
(b) make its employees, agents and consultants reasonably available to the other Party (or to the other Party’s authorized attorneys,agents or representatives), to the extent reasonably necessary to enable the appropriate Party hereunder to undertake its Patent Prosecution andTrademark Prosecution responsibilities;
(c) cooperate, if necessary and appropriate, with the other Party in gaining Patent and Trademark term extensions; provided, however,that any dispute regarding the same shall be submitted to the JSC for resolution; and
(d) endeavor in good faith to coordinate its efforts under this Agreement with the other Party to minimize or avoid interference with thePatent Prosecution and Trademark Prosecution of the other Party’s Patents and Trademarks.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
4315.5 Enforcement 
(a) Notice. Each Party shall promptly provide, but in no event later than ***, the other with written notice reasonably detailing anyknown or alleged infringement of any Patent or Trademark owned by the other Party and subject to a license under this Agreement.
(b) Enforcement of Intellectual Property Rights 
(i) The sole owner of a Patent, Trademark, Know-how or Confidential Information shall have the exclusive right to institute anddirect legal proceedings against any Third Party believed to be infringing such Patent or Trademark or misappropriating or otherwiseviolating such Know-how or Confidential Information. Green Cross shall have the initial right to institute and direct legal proceedingsagainst any Third Party believed to be infringing Jointly Owned Patents that claims or covers a Product sold in the Territory. If GreenCross has the right to direct legal proceedings pursuant to this Section 15.5(b)(i) and does not abate such violation of Jointly OwnedPatents, including by commencement of a lawsuit against the accused person if necessary, within *** after receiving notice of suchinfringement of Jointly Owned Patents and immediately after notice of other violation of such Jointly Owned Patents, then MacroGenicsshall be entitled (but shall not be obligated) to take all actions reasonably necessary to abate such violation in the Territory, includingcommencement of a lawsuit against the accused Third Party if necessary.
(ii) MacroGenics shall have the initial right to institute and direct legal proceedings against any Third Party believed to beinfringing Jointly Owned Patents that claims or covers a Product sold outside the Territory. If MacroGenics does not abate suchviolation of Jointly Owned Patents, including by commencement of a lawsuit against the accused person if necessary, within *** afterreceiving notice of such infringement of Jointly Owned Patents and immediately after notice of other violation of such Jointly OwnedPatents, then Green Cross shall be entitled (but shall not be obligated) to take all actions reasonably necessary to abate such violationin the Territory, including commencement of a lawsuit against the accused Third Party if necessary.
(iii) All amounts recovered from enforcement of any such rights by either Party in the Territory relating to the intellectual propertylicensed under this Agreement shall be first used to reimburse each Party’s costs and expenses incurred in connection with such action,and any remainder of such recovery, other than amounts recovered as lost profits, shall be retained by the Party instituting the action,provided that any remainder retained by Green Cross shall be treated as Net Sales and shall be subject to Green Cross’ royalty paymentobligations at the applicable rate specified in Section 8.5. For amounts recovered as lost profits the amount of Net Sales represented bysuch lost profits and Green Cross shall be obligated to pay MacroGenics any amounts due under this Agreement if such projected NetSales were actually made by Green Cross. All amounts recovered from
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
44enforcement of any such rights by either Party outside the Territory relating to Jointly Owned Patents shall be first used to reimburseeach Party’s costs and expenses incurred in connection with such action, and any remainder of such recovery, shall be retained by theParty instituting the action.
(c) Cooperation in Enforcement Proceedings. For any action by a Party pursuant to subsection (b) above, in the event that such Partyis unable to initiate or prosecute such action solely in its own name, the other Party will join such action voluntarily and will execute all documentsnecessary for such Party to initiate, prosecute and maintain such action. If either Green Cross or MacroGenics initiates an enforcement actionpursuant to Section 15.5(b), then the other Party shall cooperate to the extent reasonably necessary and at the first Parties’ sole expense (except forthe expenses of the non­controlling Party’s counsel, if any). Upon the reasonable request of the Party instituting any such action, such other Partyshall join the suit and can be represented in any such legal proceedings using counsel of its own choice. Each Party shall assert and not waive thejoint defense privilege with respect to all communications between the Parties reasonably the subject thereof.
(d) Status; Settlement. The Parties shall keep each other informed of the status of and of their respective activities regarding anyenforcement action pursuant to Section 15.5(b). Neither Party shall settle any litigation or legal proceeding in the Territory to enforce MacroGenicsLicensed Patents or MacroGenics Licensed Trademarks without the other Party’s written authorization.
15.6 Defense 
(a) Notice of Allegations. Each Party shall notify the other in writing of any allegations it receives from a Third Party that themanufacture, production, use, development, sale or distribution of any Product or any technology or intellectual property licensed by a Party underthis Agreement infringes the intellectual property rights of such Third Party. Such notice shall be provided promptly, but in no event after morethan fifteen (15) business days, following receipt of such allegations.
(b) Notice of Suit. In the event that a Party receives notice that it or any of its Affiliates have been individually named as a defendant ina legal proceeding by a Third Party alleging infringement of a Third Party’s Patents or other intellectual property right as a result of themanufacture, production, use, development, sale or distribution of Products or any technology or intellectual property licensed by a Party underthis Agreement, such Party shall immediately notify the other Party in writing and in no event notify such other Party later than *** after the receiptof such notice. Such written notice shall include a copy of any summons or complaint (or the equivalent thereof) received regarding the foregoing.Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably the subjectthereof. In such event, the Parties shall agree how best to mitigate or control the defense of any such legal proceeding; provided however, that ifeither Party or any of its Affiliates have been individually named as a defendant in a legal proceeding relating to
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
45the alleged infringement of a Third Party’s Patents or other intellectual property right as a result of the manufacture, production, use, development,sale or distribution of Products, the other Party shall be allowed to join in such action, at its own expense.
(c) Status; Settlement. The Parties shall keep each other informed of the status of and of their respective activities regarding anylitigation or settlement thereof initiated by a Third Party in the Territory concerning a Party’s manufacture, production, use, development, sale ordistribution of Products or any technology or intellectual property licensed by a Party under this Agreement; provided, however, that no settlementor consent judgment or other voluntary final disposition of a suit under this Section 15.6(c) may be undertaken by a Party without the consent ofthe other Party which consent shall not be unreasonably withheld or delayed.
16. TERMS AND TERMINATION 
16.1 Term. Unless earlier terminated, this Agreement shall continue in effect until the expiration of the Royalty Term as defined in Section 1.87(“Term”), and thereafter Green Cross has no remaining payment obligations with respect to the Products pursuant to Section 8.5 above andMacroGenics shall have no further obligations hereunder.
16.2 Termination for Change in Control of Green Cross. In the event of a Change in Control involving Green Cross, Green Cross shallprovide prompt written notice to MacroGenics following such Change in Control, and MacroGenics may, in its sole discretion, terminate thisAgreement by providing written notice to Green Cross within *** of MacroGenics’ receipt of such written notice of the Change in Control.
16.3 Termination for Change in Control of MacroGenics. In the event of a Change in Control involving MacroGenics, MacroGenics shallprovide prompt written notice to Green Cross following such Change in Control, and Green Cross may, in its sole discretion, terminate thisAgreement by providing written notice to MacroGenics within *** of Green Cross’ receipt of such written notice of the Change in Control.
16.4 Termination for Challenge to Patent Validity. MacroGenics may terminate this Agreement immediately upon written notice to GreenCross in the event Green Cross or any of its Affiliates:
(a) directly or indirectly oppose, or assist any Third Party to oppose, in any patent office proceeding, the grant of any patent or patentapplication within the MacroGenics Licensed Patents, or, in any patent office proceeding, dispute or directly or indirectly assist any Third Party todispute, the validity of any patent within the MacroGenics Licensed Patents or any of the claims thereof, including opposing any application foramendment thereto;
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
46(b) directly or indirectly oppose, or assist any Third Party to oppose, in any court proceeding, the grant of any patent or patentapplication within the MacroGenics Licensed Patents, or, in any court proceeding, dispute or directly or indirectly assist any Third Party to dispute,the validity of any patent within the MacroGenics Licensed Patents or any of the claims thereof; or
(c) bring any claim or proceedings of whatever nature in relation to the MacroGenics Licensed Patents against MacroGenics and/or anyof MacroGenics’ Affiliates (or in respect of the foregoing their directors and officers) in respect of any activities carried out by them under anyMacroGenics Licensed Patents which may be the subject of a Valid Claim of the MacroGenics Licensed Patents.
16.5 Termination for Cause. This Agreement may be terminated at any time during the Term upon written notice by either Party if the otherParty is in material breach of its other obligations under this Agreement and, in each case, has not cured such breach within *** after noticerequesting cure of the breach (other than for non-payment which shall be cured within ***).
16.6 Effect of Termination 
(a) If MacroGenics terminates this Agreement pursuant to Section 16.2, 16.4, or pursuant to Section 16.5 for cause based on materialbreach by Green Cross:
(i) Green Cross shall pay any amounts due pursuant to Section 8 prior to the date of termination;
(ii) For the avoidance of doubt, the licenses and sublicenses granted to Green Cross under Sections 10.1(a) and 10.4 shallterminate;
(iii) Green Cross shall return to MacroGenics all Products (including, without limitation, all MGAH22) within its possession orcontrol and arrange for the Green Cross Sublicensees to return to MacroGenics all Products (including, without limitation, all MGAH22)within such Green Cross Sublicensees’ possession or control;
(iv) Green Cross shall cease to research, develop, market and sell any Product that infringes a Valid Claim in a MacroGenicsLicensed Patent;
(v) for the Products (including, without limitation, MGAH22), Green Cross shall assign and promptly transfer to MacroGenics, atno expense to MacroGenics, all of Green Cross’ right, title and interest in and to (A) all regulatory filings (such as INDs, CTAs and drugmaster files), Regulatory Approvals, and clinical trial agreements (to the extent assignable and not cancelled) for such Products(s), tothe extent that MacroGenics elects to continue development of such Product(s); (B) all data, including clinical data, materials andinformation of any kind
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
47or nature whatsoever, in Green Cross’ possession or in the possession of its Affiliates or its or their respective agents related to suchProduct(s); (C) all trademarks related to such Products (if such termination occurs after approval of such trademark by a RegulatoryAuthority); and (D) all material information, and any other information reasonably requested and required by MacroGenics, relating tothe manufacture of such Products;
(vi) all sublicenses under the rights granted pursuant to Section 10.1(b) shall terminate; and
(vii) MacroGenics shall revoke (and Green Cross shall allow revocation of) any powers of attorney for any MacroGenics LicensedPatents that Green Cross holds as of the time of such termination; and
(b) If Green Cross terminates this Agreement pursuant to Section 16.3:
(i) The provisions of Section 16.6(a) shall apply;
(ii) Notwithstanding anything to the contrary, MacroGenics shall continue to provide Green Cross, for up to ***, the Products(including, without limitation, all MGAH22), at the request of Green Cross in accordance with the terms of Section 6.2; and
(c) If Green Cross terminates this Agreement pursuant to Section 16.5 for cause based on material breach by MacroGenics:
(i) As full satisfaction of any claims Green Cross may have based upon such material breach and termination, ***:
(1) Such material breach by MacroGenics results in a substantial reduction in the profit Green Cross would have receivedif such material breach and termination had not occurred;
(2) MacroGenics committed such material breach other than as a result of a material breach committed by Green Cross; and
(3) Both Parties agree in writing not to undertake arbitration in accordance with Section 17.7 to determine whetherMacroGenics committed a material breach.
(ii) For the avoidance of doubt, the license granted under Section 10.3 shall terminate;
(iii) The provisions of Section 16.6(a) shall apply;
(iv) Notwithstanding anything to the contrary, MacroGenics shall continue to provide Green Cross, for up to***, the Products(including, without limitation, all MGAH22), at the request of Green Cross in accordance with the terms of Section 6.2; and
(v) Green Cross shall revoke (and MacroGenics shall allow revocation of) any powers of attorney for any Green Cross LicensedPatents that MacroGenics holds as of the time of such termination.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
48(d) Return of Confidential Information. Upon expiration or termination of this Agreement, the Parties shall comply with Section 12.1(e).
16.7 Survival. The following provisions shall survive the termination or expiration of this Agreement for any reason: Sections 1, 8.9, 8.11, 9,10.4 (with respect to the license granted to MacroGenics), 12 (to the extent provided therein), 13, 14, 15.1, 16 and 17.
17. MISCELLANEOUS 
17.1 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached thisAgreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results fromcauses beyond the reasonable control of the affected Party including, but not limited to, embargoes, war, acts of war (whether war be declared ornot), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions ordelays in acting by any governmental authority or the other Party (“Force Majeure”). The affected Party shall notify the other Party of such forcemajeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeurecircumstances. In the event a Party is unable to perform its obligations under this Agreement due to Force Majeure for a period of ***, the otherParty shall have the option of unilaterally terminating this Agreement upon providing *** written notice.
17.2 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement are,and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” asdefined under Section 101(35A) of the U.S. Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights andelections under the U.S. Bankruptcy Code. The Parties agree that a Party that is a licensee of such rights under this Agreement shall retain and mayfully exercise all of its rights and elections under the U.S. Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by oragainst the licensing Party (such Party, the “Involved Party”) under the U.S. Bankruptcy Code, the other Party (such Party, the “NoninvolvedParty”) shall be entitled to a complete duplicate of or complete access to (as such Noninvolved Party deems appropriate), any such intellectualproperty and all embodiments of such intellectual property, provided the Noninvolved Party continues to fulfill its payment or royalty obligationsas specified herein in full. Such intellectual property and all
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
49embodiments thereof shall be promptly delivered to the Noninvolved Party (a) upon any such commencement of a bankruptcy proceeding uponwritten request therefor by the Noninvolved Party, unless the Involved Party elects to continue to perform all of its obligations under thisAgreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Involved Party upon written requesttherefor by Noninvolved Party. The foregoing is without prejudice to any rights the Noninvolved Party may have arising under the U.S.Bankruptcy Code or other applicable law.
17.3 Assignment. Neither Party may assign its rights and obligations under this Agreement without the prior written consent of the otherParty, provided that either Party may assign its rights and obligations under this Agreement, without such consent from the other Party, to itsAffiliate or any successor in interest in connection with the sale of all or substantially all of its assets or a sale of all or substantially of the businessrelated to MGAH22 or a Product, or a merger, acquisition or other similar transactions. For the avoidance of doubt, the terms and conditions of thisAgreement shall be binding on the permitted successors and assignees of each Party.
17.4 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, thevalidity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless theabsence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their bestefforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical,implement the purposes of this Agreement.
17.5 Notices. All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile(and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier orsent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 
if to MacroGenics, to:
 
1500 East Gude DriveRockville, MD 20850Attention: Chief Executive OfficerFacsimile: ***
with copy to:(which shall not constitutenotice)
 
Arnold & Porter, LLP1600 Tysons BoulevardSuite 900McLean, VA 22102Attention: ***Facsimile: ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
50if to Green Cross, to:
 
Green Cross Corporation303 Bojeong-dong, Giheung-guYongin, 446-770, KoreaAttn: PresidentFacsimile: ***
with copy to:
 
Green Cross Corporation303 Bojeong-dong, Giheung-guYongin, 446-770, KoreaAttn: ***Facsimile: ***
or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Anysuch notice shall be deemed to have been given upon receipt.
17.6 Applicable Law. All questions of inventorship will be determined in accordance with ***. In respect to all other Patent issues related tothe enforceability or validity of a Patent, the laws of the jurisdiction in which the applicable Patent is filed or granted shall govern. Except asotherwise indicated, in all other respects, the right and obligations of the Parties under this Agreement shall be governed by and construed inaccordance with the laws of the ***.
17.7 Arbitration 
(a) All disputes arising out of or in connection with the Agreement shall be finally settled under the Rules of Arbitration of the *** bythree (3) arbitrators (“Arbitral Tribunal”).
(b) Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the Request for Arbitration within ***days of being requested to do so, or if the respondent should fail to appoint an arbitrator in its Answer to the Request for Arbitration within ***days of being requested to do so, the other party shall request the *** to make such appointment.
(c) The arbitrators nominated by the parties shall, within *** from the appointment of the arbitrator nominated in the Answer to theRequest for Arbitration, and after consultation with the parties, agree and appoint a third arbitrator, who will act as a chairman of the ArbitralTribunal. Should such procedure not result in an appointment within the *** time limit, either party shall be free to request the *** to appoint thethird arbitrator.
(d) *** shall be the seat of the arbitration.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
51(e) The language of the arbitration shall be English. Documents submitted in the arbitration (the originals of which are not in English)shall be submitted together with an English translation.
(f) This arbitration agreement does not preclude either party seeking conservatory or interim measures from any court of competentjurisdiction including, without limitation, the courts having jurisdiction by reason of either party’s domicile. Conservatory or interim measuressought by either party in any one or more jurisdictions shall not preclude the Arbitral Tribunal granting conservatory or interim measures.Conservatory or interim measures sought by either party before the Arbitral Tribunal shall not preclude any court of competent jurisdictiongranting conservatory or interim measures.
(g) In the event that any issue shall arise which is not clearly provided for in this arbitration agreement the matter shall be resolved inaccordance with the *** Arbitration Rules.
17.8 Entire Agreement; Amendments. The Agreement contains the entire understanding of the Parties with respect to the Collaboration andlicenses granted hereunder. All express or implied agreements and understandings, either oral or written, with regard to the Collaboration and thelicenses granted hereunder are superseded by the terms of this Agreement. The Agreement may be amended, or any term hereof modified, only bya written instrument duly executed by authorized representatives of both Parties hereto.
17.9 Headings. The captions to the several Sections hereof are not a part of the Agreement, but are merely for convenience to assist inlocating and reading the several Sections and Sections of this Agreement.
17.10 Independent Contractors. It is expressly agreed that MacroGenics and Green Cross shall be independent contractors and that therelationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither MacroGenics nor Green Cross shall havethe authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party,without the prior written consent of the other Party.
17.11 Waiver. The waiver by either Party of any right hereunder, or the failure of the other Party to perform, or a breach by the other Party,shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature orotherwise.
17.12 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in additionto any other remedy referred to in this Agreement or otherwise available under law.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
5217.13 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, draftingand negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against thedrafting Party shall not apply.
17.14 Counterparts. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of whichtogether shall constitute one and the same instrument.
17.15 Further Assurances. Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments anddo and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may benecessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions andpurposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.
17.16 Construction. Except where the context otherwise requires, wherever used, the singular will include the plural, the plural the singular,the use of any gender will be applicable to all genders, and the word “or” is used in the inclusive sense (and/or). The captions of this Agreementare for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of anyprovision contained in this Agreement. The term “including” as used herein means including, without limiting the generality of any descriptionpreceding such term. References to “Section” or “Sections” are references to the numbered sections of this Agreement, unless expressly statedotherwise. All dollars are United States Dollars.
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
53The Parties have executed this Agreement as of the Effective Date. 
Green Cross Corporation   MacroGenics, Inc.
By:  /s/ B. G. Rhee   By:  /s/ Scott Koenig
Name: B. G. Rhee   Name: Scott Koenig
Title: President   Title: President and CEO
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
54Exhibit A
MacroGenics Licensed Patents 
***  ***  ******  ***  ******  ***  ******  ***  ******  ***  ******  ***  ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
55Exhibit B
MacroGenics Licensed Trademarks
***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
56Exhibit C
Phase I Clinical Development Plan
****** 
***  ***  ***
A.***   
1. ***   
***  ***  ***2. ***  ***  ***3. ***   ******  ***  ***4. ***   ***5. ***   ***6. ***   ***7. ***   ******   ******  ***  ***8. ***   
***   ******  ***  ******  ***  ***9. ***   
***   ******  ***  ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
57***  ***  ***
***  ***  ***10. ***   
***   ******  ***  ******  ***  ***11. ***   ***12. ***   ***13. ***   ***14. ***   ***15. ***   
***   ******  ***  ***B. ***   
1. ***  ***  
2. ***  ***  
3. ***  ***  ***4. ***   ***5. ***  ***  
6. ***   ***C. ***   
1. ***  ***  
2. ***  ***  ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
58***  ***  ***
3. ***  ***  
4. ***  ***  
5. ***  ***  
6. ***  ***  
7. ***  ***  
***  ***  
***  ***  
8. ***  ***  
D. ***   
1. ***  ***  ***2. ***  ***  ***3. ***  ***  ***4. ***  ***  ***5. ***  ***  
6. ***   ***E. ***   
1. ***   ***2. ***   ***3. ***   ***4. ***  ***  ***5. ***  ***  ***6. ***  ***  ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
59***  ***  ***
7. ***   ***8. ***   ***9. ***  ***  ***10. ***  ***  
11. ***  ***  
12. ***  ***  ***13. ***  ***  
14. ***   ***15. ***  ***  ***16. ***  ***  ***17. ***  ***  ***F. ***   
1. ***   
***  ***  ******  ***  ******  ***  ***2. ***2. ***   
***   ******   ***3. ***   
***  ***  
***  ***  
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
60***  ***  ***
***  ***  
***  ***  
G. ***   
1. ***  ***  
2. ***  ***  
3. ***   ***4. ***  ***  
5. ***  ***  
6. ***  ***  
H. ***   
1. ***  ***  
2. ***  ***  
3. ***  ***  
4. ***  ***  ***5. ***   ***6. ***   ***7. ***  ***  
8. ***   ***9. ***  ***  
10. ***   ***11. ***   ***12. ***   ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
61***  ***  ***
13. ***   ***14. ***   ***I. ***   
1. ***  ***  ***2. ***   ***3. ***  ***  ***J. ***   
1. ***  ***  
2. ***   ***3. ***  ***  
4. ***  ***  
5. ***  ***  
6. ***  ***  
7. ***  ***  
8. ***  ***  
9. ***  ***  
10. ***  ***  
11. ***  ***  
12. ***   ***13. ***  ***  ***14. ***  ***  
15. ***  ***  ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
62***  ***  ***
16. ***   ***17. ***   ***K. ***   
1. ***   ***2. ***   ***3. ***   ***4. ***   ***5. ***   ***6. ***  ***  
7. ***   ******   ***8. ***   ***9. ***   ***10. ***  ***  ***11. ***   ***12. ***   ***L. ***   
1. ***  ***  ***2. ***  ***  
3. ***  ***  ***4. ***   ***5. ***  ***  ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
63***  ***  ***
6. ***   ***M. ***   
1. ***   ***2. ***   ***3. ***  ***  
N. ***   
1. ***   ***2. ***   ***3. ***   ***4. ***  ***  
5. ***  ***  
6. ***  ***  
7. ***  ***  
8. ***   ***O. ***   
1. ***  ***  
2. ***  ***  
3. ***  ***  
4. ***  ***  
5. ***  ***  
6. ***  ***  
7. ***  ***  ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
64***  ***  ***
8. ***  ***  
9. ***  ***  
10. ***  ***  
11. ***  ***  ***12. ***  ***  
13. ***  ***  
***  ***  
***  ***  
14. ***  ***  
15. ***  ***  
16. ***  ***  
17. ***  ***  
18. ***  ***  
19. ***  ***  
20. ***  ***  
21. ***  ***  
22. ***  ***  
23. ***  ***  ***24. ***  ***  
25. ***  ***  
26. ***  ***  
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
65***  ***  ***
27. ***  ***  
28. ***  ***  
29. ***  ***  
30. ***  ***  
P. ***   
1. ***  ***  
2. ***  ***  
3. ***  ***  
4. ***  ***  
5. ***  ***  
6. ***  ***  
7. ***  ***  
8. ***  ***  
9. ***  ***  
10. ***  ***  
11. ***  ***  
12. ***  ***  
13. ***  ***  
Q. ***   
1. ***  ***  
2. ***  ***  
3. ***  ***  
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
66***  ***  ***
4. ***  ***  
***  ***  
5. ***  ***  
R. ***   
1. ***  ***  
2. ***  ***  
3. ***  ***  
4. ***  ***  
5. ***  ***  ***6. ***  ***  ***7. ***  ***  
8. ***  ***  
9. ***  ***  
***  ***  
***  ***  
10. ***  ***  
11. ***  ***  
12. ***  ***  
13. ***  ***  
14. ***  ***  
15. ***  ***  
16. ***  ***  
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
67***  ***  ***
***  ***  
17. ***  ***  
18. ***  ***  
19. ***  ***  
20. ***  ***  ***21. ***  ***  
22. ***  ***  
a. ***   ***S. ***   
1. ***  ***  
2. ***  ***  
3. ***  ***  
4. ***  ***  
5. ***  ***  
6. ***  ***  
7. ***  ***  
8. ***  ***  ***9. ***  ***  
10. ***  ***  
11. ***  ***  
12. ***  ***  
T. ***   
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
68***  ***  ***
1. ***  ***  
2. ***  ***  
3. ***  ***  
4. ***  ***  
5. ***  ***  
6. ***  ***  
7. ***  ***  
8. ***  ***  
9. ***  ***  
10. ***  ***  
11. ***  ***  
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
69Exhibit D
Phase II Clinical Development Plan
****** 
***  • ***
***  ******  ******  • ***
***  ******  • ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
70Exhibit E
Upstream Agreements
***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
71Exhibit F
Joint Steering Committee
MacroGenics:
 
 1) *** 
 
 2) *** 
 
 3) ***  
Green Cross:
 
 1) *** 
 
 2) *** 
 
 3) *** 
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
72Exhibit G
SAFETY DATA EXCHANGE AGREEMENT COMPONENTS
***
***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
73Exhibit HProduct Royalty Rates 
***  ***
***  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
74***  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ******  ***
***
***
***
***
 
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has beenfiled separately with the Commission.
 
75Exhibit 10.4
COOPERATION AGREEMENT
(2014 Amendment)
This Cooperation Agreement (2014 Amendment) (this “Agreement”) is entered into on January 24, 2014 in Beijing by and between:
 
(1) Nanjing Tuniu Technology Co., Ltd., with its registered address at 3-5/F Building No.6, Southeast University Science Park, 6 ChangjianghouStreet, Xuanwu District, Nanjing and its legal representative being Yu Dunde (“Party A”);
 
(2) Beijing Tuniu Technology Co., Ltd., with its registered address at R1006 10/F Building No.4, Yard No.1 of Shangdishi Street, Haidian District,Beijing and its legal representative being Yu Dunde (“Party B”).
WHEREAS
 
1. Party A is a company with exclusively domestic capital incorporated under the laws of the People’s Republic of China, mainly engaged in theinternet-based sale, promotion of tour products, room reservation and conference affairs services.
 
2. Party B is a limited liability company incorporated under the laws of the People’s Republic of China, mainly engaged in research anddevelopment of computer software technology, technology transfer, technical consultancy and technical services, computer technologytraining, technical services and business consultancy services in relation to the internet-based sale and promotion of tour products.
 
3. Party A intends to authorize Party B to provide to Party A and its subsidiaries the technical services and business consultancy services inrelation to the internet-based sale and promotion of tour products, including but not limited to development, operation, maintenance ofinternet technology platform as well as consultancy services relating to sale and promotion of tour products or cooperation provided byParty B in other forms as required under this Agreement, and Party B agrees to accept such authorization.
 
4. After an amiable consideration, the Parties unanimously agree that the establishment of a long-term and close cooperation relationship is inthe best interests of the Parties and their beneficiaries.
 
5. The Parties have entered into the Cooperation Agreement on September 17, 2008 in respect of the aforementioned cooperative matters (the“Original Cooperation Agreement”).The Parties unanimously agree to amend and restate the Original Cooperation Agreement through friendly negotiation and the OriginalCooperation Agreement is amended and restated as follows:
 
1. Business Cooperation 
Party A and Party B unanimously agree that the proposed cooperation shall be the internet-based sale and promotion of tour productsconducted by Party A and its subsidiaries or other value-added business carried out by Party A. Party B shall provide the businessconsultancy and technical services as well as the technical consultancy as set forth in Article 3 hereinafter to Party A and its subsidiaries tofacilitate them to conduct the aforementioned business and supply relevant products and services.
 
2. Exclusive Cooperation 
 
 
2.1 Party A irrevocably undertakes that Party A will take Party B as its exclusive and sole partner to provide the business consultancy andtechnical services as well as technical consultancy to Party A and its subsidiaries. Party A shall not establish any same or similarcooperative relationship with any third party in respect of such businesses nor shall it make any same or similar arrangement, unlesswith the prior written consent of Party B.
 
  2.2 Party A irrevocably undertakes that it will make best efforts to assist and endeavor to achieve the exclusive operation of thecooperative business to the extent permitted by laws.
 
 
2.3 Party A irrevocably undertakes that, without Party B’s consent, Party A shall not conduct any other business or make any commercialarrangement, including without limitation being engaged in or otherwise participating in any commercial activities and businessesindependently or together with any other person or entity, nor shall it carry out any activities that may be competitive with or causeadverse effect to Party B’s business.
 
3. Party B’s Services 
Party B undertakes to provide the following technical consultancy and services to Party A and its subsidiaries in respect of the cooperativebusiness (collectively referred to as “Party B’s Services”):
 
  3.1 Research, development, production, test, operation and maintenance, upgrade and other services of relevant technology;
 
  3.2 Development, construction, operation and maintenance, upgrade and other services of relevant internet platform and system;
 
  3.3 Design the relevant tour products plan, and provide relevant training, implementation and upgrade and other services;3.4 Consultancy services related to sale and promotion of tour products;
 
  3.5 Other services as agreed by the Parties.
Party A agrees that Party B may, at its own discretion, provide the aforementioned Party B’s Services to Party A and its subsidiaries, orpurchase the required services from any third party and provide the services to Party A and its subsidiaries.
Party A shall cause its subsidiaries to accept Party B’s Services. The Parties agree that the subsidiaries of Party A may otherwise enter intoan agreement with Party B in respect of Party B’s Services in accordance with this Agreement.
 
4. Cooperation Remuneration 
 
  4.1 Party A and Party B unanimously agree that they will allocate the proceeds generated from cooperation in accordance with thefollowing provisions:
Party B shall have the right to charge, on a quarterly basis, the service fee (“Service Fee”) from Party A or its subsidiaries who haveaccepted Party B’s Services, or designate another person to charge Service Fee from Party A or its subsidiaries who have acceptedParty B’s Services. The total sum of Service Fee shall be equal to the amount of profits gained by Party A or its subsidiaries who haveaccepted Party B’s Services. Party B shall have the right to adjust the amount of Service Fee at its own discretion, without the priorconsent of Party A or its subsidiaries.
Party A shall cause its subsidiaries to pay the Service Fee in respect of Party B’s Services provided to such subsidiaries.
 
  4.2 The Service Fee of the last quarter shall be paid prior to the seventh business day following the commencement of the next quarter.Such Service Fee shall be paid to the bank account designated by Party B in writing. If Party B intends to change its bank account, itshall send a written notice to Party A seven business days in advance.
 
  4.3 Except as otherwise agreed hereunder, if Party A or its subsidiaries fail to pay the Service Fee in full on schedule according toprovisions of Article 4.1 and Article 4.2, then Party A or its subsidiaries shall, in addition to the continuance of the payment of ServiceFee in full, it shall pay Party B the liquidated damages at a daily interest rate of 0.03% in respect of the outstanding Service Fee.
 
5. Term of Cooperation 
Party A and Party B agree and confirm that the term of cooperation under this Agreement shall commence from the execution date hereof andend on the expiration date of the operation term of Party B (“Term of Cooperation”).6. Termination 
 
  6.1 Prior to the expiration of the Term of Cooperation , this Agreement shall only be terminated upon occurrence of the followingcircumstances:
 
  6.1.1 Party B shall have the right to terminate this Agreement in advance without the prior written consent from Party A, bysending a written notice to Party A but Party A may not terminate or rescind this Agreement;
 
  6.1.2 One Party requests to terminate this Agreement when the other Party is declared bankrupt in accordance with the laws;
 
  6.1.3 Party B fails to provide Party B’s Services to Party A for more than three consecutive years due to the force majeure event.
 
  6.2 Rights and Obligations of the Parties upon Termination
 
  6.2.1 If this Agreement is terminated according to the aforementioned Article 6.1.1, neither Party shall assume any obligations orliabilities to the other Party as of the termination hereof, unless as otherwise agreed by the Parties, provided that the liabilitiesfor breach occurring prior to the termination shall not be exempted;
 
  6.2.2 If this Agreement is terminated according to the aforementioned Article 6.1.2, the rights and obligations of the Parties at thetime of termination hereof shall be subject to the relevant bankruptcy laws;
 
  6.2.3 If this Agreement is terminated according to the aforementioned Article 6.1.3, neither Party shall assume any obligations orliabilities to the other Party as of the termination hereof, provided that the liabilities for breach that occured prior to the forcemajeure event shall not be exempted.
 
  6.3 Each Party hereby irrevocably waives other rights to terminate this Agreement it may have under any applicable laws, except for therights of the Parties agreed under this Article 6.
 
 
6.4 Party A hereby expressly undertakes that it waives the right to request amendment and revocation of any term of this Agreement on theground of material misunderstanding or unconscionability, regardless of whether such request is based on the percentage and amountof payment specified hereunder or the quantity and quality of any service provided by Party B, or is raised against the provisions underwhich Party A is prohibited from having any cooperation with a third party and conducting any businesses other than those agreedhereunder.7. Representations and Warranties 
 
  7.1 Each Party hereby represents and warrants to the other Party that:
 
  7.1.1 It has sufficient capacity for action, power and authorization (including necessary government approval and internal permit ofcorporation) to execute and perform this Agreement;
 
  7.1.2 This Agreement shall be legally binding on the Parties as of the execution date hereof; and
 
  7.1.3 There is no outstanding litigation, arbitration or other legal or governmental proceedings, or to the knowledge of that Party,there is no litigation, arbitration or other legal or governmental proceedings threatening or affecting the performance ofobligations of that Party hereunder.
 
  7.2 Each Party shall be responsible for and hold the other Party harmless from any loss, damages and claim arising out of violation of anyrepresentations and warranties hereunder.
 
8. Breach 
The Parties agree and acknowledge that:
 
 
8.1 If any Party commits any act in violation of this Agreement, such Party shall assume the liabilities for breach according to thisAgreement and applicable laws. If both Parties breach this Agreement, they shall each assume their own liabilities for breachrespectively. Notwithstanding the foregoing provisions, neither Party shall be responsible to the other Party in respect of any indirectloss or damage caused hereunder.
 
  8.2 The demand for liquidated damages and specific performance in respect of any breach during the Term of Cooperation are all remediesthat the non-breaching Party shall have under this Agreement. The non-breaching Party shall waive the right to request termination ofthis Agreement it may have according to any applicable laws as a result of the violation acts committed by the breaching Party.
 
9. Governing Law 
This Agreement shall be governed by and interpreted pursuant to the laws of the People’s Republic of China that are promulgated and arepublicly available, provided that the general international business practices shall apply if the laws of the People’s Republic of China that arepromulgated and are publicly available do not involve any matter in relation to this Agreement.10. Force Majeure 
The force majeure hereunder shall mean the natural disaster, war, political event, and adjustment of laws, regulations and state policies. If theperformance of this Agreement by one Party or the Parties according to provisions agreed hereunder is directly affected by the force majeureevent, the affected Party shall immediately notify the other Party or its attorney-in-fact of the situation of the force majeure event, and shall,within fifteen (15) days, provide the detailed information of the force majeure event or the reason for non-performance or partial performanceor delay of performance of this Agreement as well as valid evidence thereof (which shall be issued by the notarization authority at the placewhere the force majeure event occurs). The Parties shall negotiate to decide the performance of this Agreement depending on to what degreethe performance of this Agreement is influenced by the force majeure, and decide on whether the affected Party may partially perform orpostpone the performance of its obligations hereunder. Except as provided for under Article 6.1.3 hereof, neither Party shall exercise the rightto termination this Agreement that it may have under any applicable laws on the ground of occurrence of force majeure event.
 
11. Dispute Resolution 
 
  11.1Any dispute arising out of performance of this Agreement or in connection with this Agreement shall be resolved by the Partiesthrough friendly negotiation.
 
  11.2If the dispute cannot be resolved through negotiation within thirty (30) days after a Party sends the written notice to the other Partystating its opinions on this dispute, either Party may submit the dispute to China International Economic and Trade Commission forarbitration in Beijing according to its arbitration rules then in effect. The arbitration award shall be final and binding on each Party.
 
12. Miscellaneous 
 
 
12.1This Agreement shall take effect as of the date when the authorized representatives of the Parties sign hereon. The Parties agree andconfirm that this Agreement shall constitute all understanding, interpretation and intentions of the Parties in respect of the cooperativebusiness. This Agreement shall be taken as an amendment and restatement of the Original Cooperation Agreement and supersede theOriginal Cooperation Agreement in all respects.
 
  12.2The rights and obligations of each Party under this Agreement shall not be transferred, except for the transfer by Party B to its affiliates.12.3The Parties agree that any and all intellectual property researched and developed, created and invented by the Parties (including theiremployees) in the course of performance of this Agreement shall be owned by Party B. For the purpose of this Article 12.3, “IntellectualProperty” means the patent, patent application right, trademark, service mark, logo, image, trade name, internet domain name, designright, copyright (including copyright of computer software) and moral rights, database right, right of semiconductor design drawing,utility model, proprietary technology and other intellectual property that are registered and unregistered including those that haveapplied for registration, as well as all other rights or protection methods with same or similar effect on a global scope.
 
  12.4To the extent permitted under the laws of the People’s Republic of China, the failure or delay of performance of any right under thisAgreement by any Party shall not be deemed as a waive of such right, and any single or partial exercise of any right shall not precludethe further exercise of such right in the future.
 
  12.5This Agreement shall constitute an entire agreement between the Parties in respect of the subject matter of this Agreement andsupersede any and all prior expression of intention or understanding reached by the Parties in relation to this Agreement. ThisAgreement shall not be amended or modified unless the authorized representatives of the Parties sign a written agreement thereof.
 
  12.6This Agreement shall be executed in two (2) copies, each of which shall have the same legal effect.
 
 
12.7Any notice or written communication sent by a Party to the other Party under this Agreement shall be made in writing and delivered bycourier service or by facsimile accompanied with a confirmation hard copy delivered by courier service. The notice, communication orletter sent under this Agreement shall be deemed as effectively received on the seventh (7) day after sending to the courier service, orshall be deemed as effectively received on the first (1) day after delivered by facsimile, which shall be evidenced by the transmissionconfirmation. All notice and communication shall be sent to the following addresses until a Party notify the other Party in writing tochange such addresses:
Party A: Nanjing Tuniu Technology Co., Ltd. Address: Tuiniu Building, 699-32Xuanwu Avenue, Xuanwu District, NanjingFax No.: (86 25) 86853999Attention: General Manager
Party B: Beijing Tuniu Technology Co., Ltd. Address: Tuiniu Building, 699-32Xuanwu Avenue, Xuanwu District, NanjingFax No.: (86 25) 86853999Attention: General Manager12.8Confidentiality Obligations
 
  12.8.1Neither Party shall disclose the financial and technical information obtained in the course of conclusion of this Agreement toany third party nor use such information for matters irrelevant to this Agreement, regardless of written or oral information,unless the other Party gives a prior written consent thereto.
 
  12.8.2The Parties shall be obligated to take measures (including without limitation preparing the confidentiality rules, entering intothe confidentiality agreement, establishing the archive management system and etc.) to ensure their respective employees willobserve the confidentiality obligations specified hereunder.
(The remaining of this page is intentionally left blank)In witness whereof, this Agreement has been executed by the duly authorized representatives of the Parties on the date first mentioned above.
 
Party A: Nanjing Tuniu Technology Co., Ltd.   
By: /s/ Yu Dunde    
Name: Yu Dunde    
Title: Chairman    
Party B: Beijing Tuniu Technology Co., Ltd.   
By: /s/ Yu Dunde    
Name: Yu Dunde    
Title: ChairmanExhibit 99.1
COOPERATION AGREEMENT
This Cooperation Agreement (this “ Agreement”) dated December 12, 2014, is by and among the persons and entities listed on  Schedule A
(collectively, the “ValueAct Group”, and individually a “member” of the ValueAct Group), Allison Transmission Holdings, Inc. (the “Company”)
and Gregory P. Spivy, in his individual capacity and as a member of the ValueAct Group (the “ValueAct Designee”).
WHEREAS, the ValueAct Group currently beneficially owns 19,125,204 shares of the common stock, par value $0.01 per share, of the
Company (the “Common Stock”), which represents approximately 10.77% of the issued and outstanding shares of Common Stock.
WHEREAS, the Nominating and Governance Committee of the Board (the “Nominating Committee ”) and the Company’s Board of Directors
(the “Board”) have considered the qualifications of the ValueAct Designee and conducted such review as they have deemed appropriate.
WHEREAS, the Board has determined that it is in the best interests of the Company to appoint the ValueAct Designee on the terms set forth
in this Agreement.
NOW, THEREFORE, In consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
1. Board Nomination.
(a) Subject to the satisfactory completion of the Company’s customary background check, the Board shall appoint the ValueAct
Designee to serve as a director beginning within ten (10) calendar days following receipt of the ValueAct Group’s written request to the Company to
have the ValueAct Designee appointed to the Board; provided that, at such time, the Board does not conclude in good faith and based on the
written opinion of outside legal counsel that such appointment would constitute a breach of the directors’ fiduciary duties. If the ValueAct
Designee is appointed to the Board pursuant to this Section 1(a), the Company shall include the ValueAct Designee as a Class I Director, which
term expires at the Company’s 2016 annual meeting of stockholders.
(b) As a condition to the ValueAct Designee’s appointment to the Board, the ValueAct Group, including the ValueAct Designee, agrees
to provide to the Company information required to be or customarily disclosed for directors, candidates for directors, and their affiliates and
representatives in a proxy statement or other filings under applicable law or stock exchange rules or listing standards, information in connection
with assessing eligibility, independence and other criteria applicable to directors or satisfying compliance and legal obligations, and such other
information as reasonably requested by the Company from time to time with respect to the ValueAct Group and the ValueAct Designee.
(c) The ValueAct Designee agrees that, at all times while serving as a member of the Board, he will (i) meet all director independence and
other standards of the Company, the New York Stock Exchange and the Securities and Exchange Commission (“SEC”) and applicable provisions of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including Rule 10A-
3; and (ii) be qualified to serve as a director under the Delaware General Corporation Law (the “DGCL”) (clauses (i) and (ii), the “Conditions”). The
ValueAct Designee will promptly advise the Nominating Committee if he ceases to satisfy any of the Conditions.
(d) At all times while serving as a member of the Board, the ValueAct Designee shall comply with all policies, procedures, processes,
codes, rules, standards and guidelines applicable to Board members, including the Company’s Code of Business Conduct, Insider Trading Policy,
Executive Stock Ownership Policy as in effect on the date hereof, and Corporate Governance Guidelines, and (except as permitted by the
Confidentiality Agreement (as defined in Section 7 below)) preserve the confidentiality of Company business and information, including
discussions or matters considered in meetings of the Board or Board committees to the extent not disclosed publicly by the Company.
 
1(e) So long as the ValueAct Group collectively beneficially owns, in the aggregate, at least 7.5% of the outstanding Common Stock, if,
during the Covered Period, a vacancy on the Board is created as a result of the ValueAct Designee’s death, resignation, disqualification or removal,
then the ValueAct Group and the Company (acting through the Board) shall work together in good faith to fill such vacancy or replace such
nominee with an individual who (A) meets the Conditions, (B) meets the historical standards and criteria applied by the Company in nominating and
appointing directors, and (C) is otherwise mutually acceptable (in each of their sole discretion) to the ValueAct Group and the Company, and
thereafter such individual shall serve and/or be nominated as the “ValueAct Designee” under this Agreement.
(f) The Company’s obligations hereunder shall terminate immediately, and the ValueAct Designee shall promptly offer to resign from the
Board, and any committee of the Board on which he then sits (and, if requested by the Company, promptly deliver his written resignation to the
Board (which shall provide for his immediate resignation) it being understood that it shall be in the Board’s sole discretion whether to accept or
reject such resignation) if: (i) members of the ValueAct Group, collectively, cease to beneficially own at least 7.5% of the Company’s outstanding
Common Stock; (ii) the ValueAct Designee ceases to satisfy the conditions set forth in clauses (c)-(d) above; (iii) a member of the ValueAct Group,
including the ValueAct Designee, otherwise ceases to comply or breaches any of the terms of this Agreement or the Confidentiality Agreement; or
(iv) the employment of the ValueAct Designee with the ValueAct Group is terminated for any reason. The ValueAct Group agrees to cause the
ValueAct Designee to resign from the Board if the ValueAct Designee fails to resign if and when requested pursuant to this Section 1(f).
Notwithstanding the foregoing, in the event of the occurrence of an event set forth in subsection (ii) or (iv) above, the provisions of Section 1(e)
must be complied with before the Company’s obligations hereunder may terminate.
(g) The percentage thresholds set forth in clauses (e) and (f) above shall not be deemed unsatisfied to the extent a failure to maintain
the specified ownership thresholds is the result of share issuances or similar Company actions that increase the number of outstanding shares of
Common Stock.
2. Standstill.
(a) Each member of the ValueAct Group agrees that, during the Covered Period, (unless specifically requested in writing by the
Company, acting through a resolution of a majority of the Company’s directors not including the ValueAct Designee), it shall not, and shall cause
each of its Affiliates or Associates (as such terms are defined in Rule 12b-2 promulgated by the SEC under the Exchange Act) (collectively and
individually, the “ValueAct Affiliates,” provided that no portfolio company of the ValueAct Group shall be deemed a “ ValueAct Affiliate” so long
as such portfolio company (A) has not discussed any of the actions set forth in this subsection (a) with the ValueAct Group or the ValueAct
Designee, (B) has not received from the ValueAct Group or the ValueAct Designee information concerning the Company or its business, and (C) is
not acting at the request of, in coordination with or on behalf of the ValueAct Group or the ValueAct Designee), not to, directly or indirectly, in any
manner, alone or in concert with others:
(i) make, engage in, or in any way participate in, directly or indirectly, any “solicitation” of proxies (as such terms are used in the
proxy rules of the SEC but without regard to the exclusion set forth in Rule 14a-1(l)(2)(iv) of the Exchange Act) or consents to vote, or seek to
advise, encourage or influence any person with respect to the voting of any securities of the Company or any securities convertible or
exchangeable into or exercisable for any such securities (collectively, “ securities of the Company”) for the election of individuals to the Board or to
approve stockholder proposals, or become a “participant” in any contested “solicitation” for the election of directors with respect to the Company
(as such terms are defined or used under the Exchange Act) (other than a “solicitation” or acting as a “participant” in support of all of the nominees
of the Board at any stockholder meeting) or make or be the proponent of any stockholder proposal (pursuant to Rule 14a-8 under the Exchange Act
or otherwise);
(ii) form, join, encourage, influence, advise or in any way participate in any Group (as such term is defined in Section 13(d)(3) of
the Exchange Act) with any persons who are not ValueAct Affiliates
 
2with respect to any securities of the Company or otherwise in any manner agree, attempt, seek or propose to deposit any securities of the Company
in any voting trust or similar arrangement, or subject any securities of the Company to any arrangement or agreement with respect to the voting
thereof, except as expressly set forth in this Agreement;
(iii) acquire, offer or propose to acquire, or agree to acquire, directly or indirectly, whether by purchase, tender or exchange offer,
through the acquisition of control of another person, by joining a partnership, limited partnership, syndicate or other group (including any group of
persons that would be treated as a single “person” under Section 13(d) of the Exchange Act), through swap or hedging transactions or otherwise,
any securities of the Company or any rights decoupled from the underlying securities of the Company that would result in the ValueAct Group
(together with the ValueAct Affiliates) owning, controlling or otherwise having any beneficial or other ownership interest in more than 12% in the
aggregate of the shares of Common Stock outstanding at such time;  provided, that, nothing herein will require Common Stock to be sold to the
extent the ValueAct Group and the ValueAct Affiliates, collectively, exceed the ownership limit under this paragraph as the result of a share
repurchase or similar Company actions that reduces the number of outstanding shares of Common Stock;
(iv) sell, offer or agree to sell directly or indirectly, through swap or hedging transactions or otherwise, the securities of the
Company or any rights decoupled from the underlying securities of the Company held by the ValueAct Group or any ValueAct Affiliate to any
person or entity not a (A) party to this Agreement, (B) member of the Board, (C) officer of the Company or (D) ValueAct Affiliate (any person or
entity not set forth in clauses (A)-(D) shall be referred to as a “ Third Party”), that would knowingly result in such Third Party, together with its
affiliates and associates, owning, controlling or otherwise having any beneficial or other ownership interest in the aggregate of more than 4.9% of
the shares of Common Stock outstanding at such time, except in a transaction approved by the Board;
(v) effect or seek to effect, offer or propose to effect, cause or participate in, or in any way assist or facilitate any other person to
effect or seek, offer or propose to effect or participate in, any tender or exchange offer, merger, consolidation, acquisition, scheme, arrangement,
business combination, recapitalization, reorganization, sale or acquisition of material assets, liquidation, dissolution or other extraordinary
transaction involving the Company or any of its subsidiaries or joint ventures or any of their respective securities (each, an “ Extraordinary
Transaction”), or make any public statement with respect to an Extraordinary Transaction;  provided, however, that this clause shall not preclude
the tender by the ValueAct Group or a ValueAct Affiliate of any securities of the Company into any tender or exchange offer or vote by the
ValueAct Group or a ValueAct Affiliate of any securities of the Company with respect to any Extraordinary Transaction;
(vi) engage in any short sale or any purchase, sale or grant of any option, warrant, convertible security, stock appreciation right,
or other similar right (including, without limitation, any put or call option or “swap” transaction) with respect to any security (other than a broad-
based market basket or index) that includes, relates to or derives any significant part of its value from a decline in the market price or value of the
securities of the Company;
(vii) (A) call or seek to call any meeting of stockholders, including by written consent, (B) seek representation, on or nominate
any candidate to, the Board, except as set forth herein, (C) seek the removal of any member of the Board, (D) solicit consents from stockholders or
otherwise act or seek to act by written consent, (E) conduct a referendum of stockholders, or (F) make a request for any stockholder list or other
Company books and records, whether pursuant to Section 220 of the DGCL or otherwise;
(viii) take any action in support of or make any proposal or request that constitutes: (A) advising, controlling, changing or
influencing the Board or management of the Company, including any plans or proposals to change the number or term of directors or to fill any
vacancies on the Board; (B) any material change in the capitalization, stock repurchase programs and practices or dividend policy of the Company;
(C) any other material change in the Company’s management, business or corporate structure; (D) seeking to have the Company waive or make
amendments or modifications to the Company’s Certificate of Incorporation or Bylaws, or other actions that may impede or facilitate the acquisition
of control of the Company by any person; (E) causing a class of securities of the Company to be delisted from, or to cease to be authorized to be
quoted on, any securities exchange; or (F) causing a class of securities of the Company to become eligible for termination of registration pursuant
to Section 12(g)(4) of the Exchange Act;
 
3(ix) disparage or cause to be disparaged the Company or Affiliates thereof, any of its current or former officers, or directors;
(x) make any public disclosure, announcement or statement regarding any intent, purpose, plan or proposal with respect to the
Board, the Company, its management, policies or affairs, any of its securities or assets or this Agreement that is inconsistent with the provisions of
this Agreement;
(xi) enter into any substantive discussions, negotiations, agreements, or understandings with any Third Party with respect to
any of the foregoing, or advise, assist, knowingly encourage or seek to persuade any Third Party to take any action or make any statement with
respect to any of the foregoing, or otherwise take or cause any action or make any statement inconsistent with any of the foregoing; or
(xii) request, directly or indirectly, any amendment or waiver of the foregoing.
The foregoing provisions of this Section 2(a) shall not be deemed to prohibit the ValueAct Group or its directors, officers, partners, employees,
members or agents (acting in such capacity) (“ Representatives ”) from communicating privately with the Company’s directors, officers or advisors
so long as such communications are not intended to, and would not reasonably be expected to, require any public disclosure of such
communications.
(b) Each member of the ValueAct Group shall cause all shares of Common Stock beneficially owned, directly or indirectly, by it, or by
any ValueAct Affiliate, to be present for quorum purposes and to be voted, at the Company’s annual and special stockholder meetings and at any
adjournments or postponements thereof, and further agrees that at the 2015 annual stockholder meeting they shall vote in favor of (i) all directors
nominated by the Board for election at such meeting and (ii) in accordance with the Board’s recommendation with respect to any proposals for the
election of directors that may be the subject of stockholder action at such meeting.
(c) The ValueAct Group acknowledges that the ValueAct Designee shall have all of the rights and obligations, including fiduciary duties
to the Company and its stockholders, of a director under applicable law and the Company’s organizational documents while the ValueAct Designee
is serving on the Board. Notwithstanding the foregoing, nothing in this Section 2 shall limit any actions that may be taken by the ValueAct
Designee acting solely as a director of the Company consistent with his fiduciary duties as a director of the Company (it being understood and
agreed that the ValueAct Group and the ValueAct Affiliates shall not seek to do indirectly through the ValueAct Designee anything that would be
prohibited if done by the ValueAct Group or the ValueAct Affiliates).
For purposes of this Agreement the terms “ person” or “persons” shall mean any individual, corporation (including not-for-profit), general or limited
partnership, limited liability or unlimited liability company, joint venture, estate, trust, association, organization or other entity of any kind or nature.
3. Representations of the Company . The Company represents and warrants as follows: (a) the Company has the power and authority to
execute, deliver and carry out the terms and provisions of this Agreement and to consummate the transactions contemplated hereby; and (b) this
Agreement has been duly and validly authorized, executed and delivered by the Company, constitutes a valid and binding obligation and
agreement of the Company and is enforceable against the Company in accordance with its terms.
4. Representations of the ValueAct Group. The ValueAct Group, jointly and severally, represent and warrant as follows: (a) the ValueAct
Group has the power and authority to execute, deliver and carry out the terms and provisions of this Agreement and to consummate the
transactions contemplated hereby; (b) this Agreement has been duly and validly authorized, executed and delivered by the ValueAct Group,
constitutes a valid and binding obligation and agreement of the ValueAct Group and is enforceable against the ValueAct Group in accordance with
its terms; and (c) the ValueAct Group, together with the ValueAct Affiliates, beneficially owns, directly or indirectly, an aggregate of 19,125,204
shares of Common Stock and such shares of Common Stock constitute all of the Common Stock beneficially owned by the ValueAct Group and the
ValueAct Affiliates or in which the ValueAct Group or the ValueAct Affiliates have any interest or right to acquire, whether through derivative
securities, voting agreements or otherwise; and (d) as of the date of this Agreement, the ValueAct Designee satisfies all of the Conditions.
 
45. Termination. 
(a) This Agreement is effective as of the date hereof and shall remain in full force and effect for the period (the “ Covered Period ”)
commencing on the date hereof and ending on the date that is the earliest of: (i) the Company’s failure to appoint the ValueAct Designee to the
Board following the ValueAct Group’s written request to the Company to have the ValueAct Designee appointed to the Board pursuant to Section
1(a) of this Agreement; (ii) the failure of the Company to comply in good faith with Section 1(e) of this Agreement; or (iii) the date which is the 60th
day prior to the Company’s 2016 annual meeting of stockholders.
(b) The provisions of Section 1(d) this Section 5, Section 7 through Section 16 (and, for the avoidance of doubt, the Confidentiality
Agreement) shall survive the termination of this Agreement. No termination pursuant to  Section 5(a) shall relieve any party hereto from liability for
any breach of this Agreement prior to such termination.
6. Public Announcement and SEC Filing.
(a) The Company shall file promptly a Form 8-K reporting entry into this Agreement (the “Form 8-K”) and appending or incorporating
by reference this Agreement as an exhibit thereto.
(b) The ValueAct Group shall promptly, but in no case prior to the date of filing of the Form 8-K by the Company pursuant to Section
6(a) hereof, file an amendment to its Schedule 13D with respect to the Company filed with the SEC on November 13, 2013 (the “ValueAct Schedule
13D”), reporting the entry into this Agreement and amending applicable items to conform to its obligations hereunder. None of the ValueAct Group,
the ValueAct Affiliates or the ValueAct Designee shall (i) issue a press release in connection with this Agreement or the actions contemplated
hereby or (ii) otherwise make any public statement, disclosure or announcement with respect to this Agreement or the actions contemplated hereby,
other than as mutually agreed to by the Company and the ValueAct Group.
(c) The Company shall promptly issue a press release in connection with this Agreement and in the form attached hereto as  Exhibit A
(the “Press Release”), which is expressly agreed to by the ValueAct Group.
7. Confidentiality Agreement. The Company hereby agrees that, notwithstanding any other provision of this Agreement to the contrary, the
ValueAct Group may be provided confidential information in accordance with and subject to the terms of a Confidentiality Agreement in the form
attached hereto as  Exhibit B (the “Confidentiality Agreement ”), after the Confidentiality Agreement has been mutually executed and delivered
concurrently with the appointment of the ValueAct Designee to the Board pursuant to the terms of this Agreement.
8. Compensation. The ValueAct Designee shall participate in all director compensation and benefit programs in which the Company’s other
non-employee directors participate. The Company acknowledges that pursuant to the ValueAct Group’s policies, cash, equity awards and other
property received by the ValueAct Designee are held by such person for the benefit of certain members of the ValueAct Group. The Company
agrees that it will seek board or appropriate committee approval of all stock-based awards made to the ValueAct Designee so that the grant of such
awards shall be exempt from Section 16(b) of the Exchange Act by virtue of Rule 16b-3 thereunder. Without limiting the foregoing, the Company
also acknowledges that as a result of the ValueAct Designee’s service on the Board, members of the ValueAct Group may be considered directors of
the Company by deputization under applicable interpretations of Section 16 of the Exchange Act. The Company agrees that it will seek board or
appropriate committee approval for purposes of Rule 16b-3 for all transactions in classes of Company securities subject to Section 16 and involving
the ValueAct Designee or any member of the ValueAct Group who may be considered a “director by deputization” or who may be deemed to have
an indirect interest in the transaction in question.
9. Miscellaneous. The parties agree that irreparable damage would occur in the event any of the provisions of this Agreement were not
performed in accordance with the terms hereof and that such damage would not be adequately compensable in monetary damages. Accordingly,
the parties hereto shall be entitled to an injunction or injunctions to prevent breaches of this Agreement, to enforce specifically the terms and
provisions of this Agreement exclusively in the Court of Chancery or other federal or state courts of the State of Delaware and to
 
5require the resignation of the ValueAct Designee from the Board commencing on the date that is 10 days following the date that the ValueAct
Designee and/or the ValueAct Group materially breaches its obligations under this Agreement,  provided, that, such breach has not been cured prior
to the expiration of such 10-day period, in addition to any other remedies at law or in equity, and each party agrees it will not take any action,
directly or indirectly, in opposition to another party seeking relief. Each of the parties hereto agrees to waive any bonding requirement under any
applicable law, in the case any other party seeks to enforce the terms by way of equitable relief. Furthermore, each of the parties hereto (a) consents
to submit itself to the personal jurisdiction of the Court of Chancery or other federal or state courts of the State of Delaware in the event any
dispute arises out of this Agreement or the transactions contemplated by this Agreement, (b) agrees that it shall not attempt to deny or defeat such
personal jurisdiction by motion or other request for leave from any such court, (c) agrees that it shall not bring any action relating to this
Agreement or the transactions contemplated by this Agreement in any court other than the Court of Chancery or other federal or state courts of the
State of Delaware, and each of the parties irrevocably waives the right to trial by jury, and (d) each of the parties irrevocably consents to service of
process by a reputable overnight mail delivery service, signature requested, to the address set forth in Section 11 of this Agreement or as otherwise
provided by applicable law. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS, INCLUDING WITHOUT LIMITATION VALIDITY,
INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF DELAWARE APPLICABLE TO CONTRACTS EXECUTED AND TO BE
PERFORMED WHOLLY WITHIN SUCH STATE WITHOUT GIVING EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE.
10. Expenses. All attorneys’ fees, costs and expenses incurred in connection with this Agreement and all matters related hereto will be paid by
the party incurring such fees, costs or expenses.
11. Entire Agreement; Amendment. This Agreement and the Confidentiality Agreement contain the entire agreement and understanding of
the parties with respect to the subject matter hereof and supersede any and all prior and contemporaneous agreements, memoranda, arrangements
and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter hereof. This Agreement may be
amended only by an agreement in writing executed by the parties hereto, and no waiver of compliance with any provision or condition of this
Agreement and no consent provided for in this Agreement shall be effective unless evidenced by a written instrument executed by the party
against whom such waiver or consent is to be effective. No failure or delay by a party in exercising any right, power or privilege hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right,
power or privilege hereunder.
12. Notices. All notices, consents, requests, instructions, approvals and other communications provided for herein and all legal process in
regard hereto shall be in writing and shall be deemed validly given, made or served, when delivered in person or sent by overnight courier, when
actually received during normal business hours at the address specified in this subsection:
 
If to the Company:   Allison Transmission Holdings, Inc.
  Mail Code L-25
  One Allison Way
  Indianapolis, IN 46222-3271
  Attention: General Counsel
If to the ValueAct Group:  ValueAct Capital Management, L.P.
  One Letterman Drive
  Building D, 4th Floor
  San Francisco, CA 94129
  Attention: General Counsel
13. Severability. If at any time subsequent to the date hereof, any provision of this Agreement shall be held by any court of competent
jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality or unenforceability of such
provision shall have no effect upon the legality or enforceability of any other provision of this Agreement.
 
614. Counterparts. This Agreement may be executed in two or more counterparts either manually or by electronic or digital signature (including
by facsimile or electronic mail transmission), each of which shall be deemed to be an original and all of which together shall constitute a single
binding agreement on the parties, notwithstanding that not all parties are signatories to the same counterpart.
15. No Third Party Beneficiaries; Assignment. This Agreement is solely for the benefit of the parties hereto and is not binding upon or
enforceable by any other persons. No party to this Agreement may assign its rights or delegate its obligations under this Agreement, whether by
operation of law or otherwise, and any assignment in contravention hereof shall be null and void. Nothing in this Agreement, whether express or
implied, is intended to or shall confer any rights, benefits or remedies under or by reason of this Agreement on any persons other than the parties
hereto, nor is anything in this Agreement intended to relieve or discharge the obligation or liability of any third persons to any party.
16. Interpretation and Construction . When a reference is made in this Agreement to a Section, such reference shall be to a Section of this
Agreement, unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement. Whenever the words “include,” “includes” and “including” are used in this Agreement, they shall
be deemed to be followed by the words “without limitation.” The words “hereof, “herein” and “hereunder” and words of similar import when used
in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word “will” shall be
construed to have the same meaning as the word “shall.” The words “dates hereof” will refer to the date of this Agreement. The word “or” is not
exclusive. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms. Any agreement,
instrument, law, rule or statute defined or referred to herein means, unless otherwise indicated, such agreement, instrument, law, rule or statute as
from time to time amended, modified or supplemented. Each of the parties hereto acknowledges that it has been represented by counsel of its
choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said
independent counsel. Each party cooperated and participated in the drafting and preparation of this Agreement and the documents referred to
herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be
construed against any party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require
interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is hereby expressly waived
by each of the parties hereto, and any controversy over interpretations of this Agreement shall be decided without regards to events of drafting or
preparation.
[Signature Pages Follow]
 
7IN WITNESS WHEREOF, each of the parties hereto has executed this COOPERATION AGREEMENT or caused the same to be executed by
its duly authorized representative as of the date first above written.
 
Allison Transmission Holdings, Inc.
By:  /s/ Eric C. Scroggins
Name:  Eric C. Scroggins
Title:  Vice President, General Counsel & Secretary
 
[Signature Page to Cooperation Agreement]IN WITNESS WHEREOF, each of the parties hereto has executed this COOPERATION AGREEMENT or caused the same to be executed by
its duly authorized representative as of the date first above written.
VA Partners I, LLC 
 
By:  /s/ George F. Hamel, Jr.
Name:  George F. Hamel, Jr.
Title:  Chief Operating Officer
ValueAct Capital Master Fund, L.P. 
 
By:  /s/ George F. Hamel, Jr.
Name:  George F. Hamel, Jr.
Title:  Chief Operating Officer
ValueAct Capital Management, L.P. 
 
By:  /s/ George F. Hamel, Jr.
Name:  George F. Hamel, Jr.
Title:  Chief Operating Officer
ValueAct Capital Management, LLC 
 
By:  /s/ George F. Hamel, Jr.
Name:  George F. Hamel, Jr.
Title:  Chief Operating Officer
ValueAct Holdings, L.P. 
 
By:  /s/ George F. Hamel, Jr.
Name:  George F. Hamel, Jr.
Title:  Chief Operating Officer
ValueAct Holdings GP, LLC 
 
By:  /s/ George F. Hamel, Jr.
Name:  George F. Hamel, Jr.
Title:  Chief Operating Officer
 
/s/ Gregory P. Spivy
Gregory P. Spivy
 
[Signature Page to Cooperation Agreement]Schedule A
Members of ValueAct Group
VA Partners I, LLC
ValueAct Capital Master Fund, L.P.
ValueAct Capital Management, L.P.
ValueAct Capital Management, LLC
ValueAct Holdings, L.P.
ValueAct Holdings GP, LLC
Gregory P. SpivyExhibit 10.1 COLLABORATION AGREEMENT by and between THERAVANCE, INC. and GLAXO GROUP LIMITED Dated: November 14, 2002TABLE OF CONTENTS 
                                            
ARTICLE 1 DEFINITIONS
 
1
 
 
 
 
 
ARTICLE 2 RIGHTS AND OBLIGATIONS
 
11
 
2.1 License Grants from Theravance to GSK
 
11
 
2.1.1 Development License
 
11
 
2.1.2 Commercialization License
 
11
 
2.1.3 Manufacturing License
 
11
 
2.2 Sublicensing and Subcontracting
 
11
 
2.3 Trademarks and Housemarks
 
12
 
2.3.1 Trademarks
 
12
 
2.3.2 Housemarks
 
12
 
2.3.3 Ownership of Inventions
 
12
 
 
 
 
 
ARTICLE 3 GOVERNANCE OF DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS
 
13
 
3.1 Joint Steering Committee
 
13
 
3.1.1 Purpose
 
13
 
3.1.2 Members; Officers
 
13
 
3.1.3 Responsibilities
 
13
 
3.1.4 Meetings
 
14
 
3.1.5 Decision-Making
 
14
 
3.2 Joint Project Committee
 
15
 
3.2.1 Purpose
 
15
 
3.2.2 Members; Officers
 
15
 
3.2.3 Responsibilities
 
15
 
3.2.4 Meetings
 
16
 
3.2.5 Decision-Making
 
16
 
3.3 Minutes of Committee Meetings
 
16
 
3.3.1 Distribution of Minutes
 
16
 
3.3.2 Review of Minutes
 
16
 
3.3.3 Discussion of Comments
 
16
 
3.4 Expenses
 
173.5 General Guidelines and Initial Coordination Efforts
 
17
 
 
 
 
 
ARTICLE 4 DEVELOPMENT OF PRODUCTS
 
17
 
4.1 Pooling of Compounds
 
17
 
4.2 Obligations for Development
 
17
 
4.2.1 General; GSK
 
17
 
4.2.2 GSK’s Funding Responsibility
 
18
 
4.2.3 Decisions with Respect to Products
 
18
 
4.2.4 Development Timelines
 
18
 
4.3 Replacement Compounds
 
19
 
4.4 Transfer of Data
 
19
 
4.5 LABA Activity Inside and Outside of the Collaboration
 
19
 
 iARTICLE 5 COMMERCIALIZATION
 
20
 
5.1 Global Marketing Plans
 
20
 
5.1.1 General
 
20
 
5.1.2 Contents of Each Marketing Plan
 
20
 
5.2 Obligations for Commercialization
 
20
 
5.3 Commercialization
 
20
 
5.3.1 GSK Responsibility
 
20
 
5.3.2 Semi-Annual Reports
 
21
 
5.3.3 Exports to the United States
 
21
 
 
 
 
 
ARTICLE 6 FINANCIAL PROVISIONS
 
21
 
6.1 Signing Payment; Equity Investment; One-Time Fee
 
21
 
6.1.1 Signing Payment
 
21
 
6.1.2 Stock Purchase
 
21
 
6.1.3 One-Time Fee for AMI-15471
 
21
 
6.1.4 One-Time Fee for Each Theravance New Compound
 
22
 
6.2 Milestone Payments
 
22
 
6.2.1 General
 
22
 
6.2.2 GSK to Theravance
 
22
 
6.2.3 Theravance to GSK
 
23
 
6.2.4 Notification and Payment
 
24
 
6.3 Payment of Royalties on Net Sales
 
24
 
6.3.1 Royalty on Single-Agent Collaboration Products and LABA/ICS Combination Products
 
24
 
6.3.2 Royalty Adjustment
 
25
 
6.3.3 Royalties on Other Collaboration Products Launched After the LABA/ICS Combination Product
 
25
 
6.4 Royalty Responsibilities; Net Sales Reports
 
26
 
6.4.1 Payments to Third Parties
 
26
 
6.4.2 Net Sales Report
 
26
 
6.5 GAAP
 
26
 
6.6 Currencies
 
26
 
6.7 Manner of Payments
 
26
 
6.8 Interest on Late Payments 276.9 Tax Withholding
 
27
 
6.10 Financial Records; Audits
 
27
 
 
 
 
 
ARTICLE 7 PROMOTIONAL MATERIALS AND SAMPLES
 
28
 
7.1 Promotional Materials
 
28
 
7.1.1 Review of Core Promotional Materials
 
28
 
7.1.2 Markings of Promotional Materials
 
28
 
7.2 Samples
 
28
 
7.3 Statements Consistent with Labeling
 
28
 
7.4 Implications of Change in Control in Theravance
 
28
 
 iiARTICLE 8 REGULATORY MATTERS
 
29
 
8.1 Governmental Authorities
 
29
 
8.2 Filings
 
29
 
8.3 Exchange of Drug Safety Information
 
29
 
8.4 Recalls or Other Corrective Action
 
29
 
8.5 Events Affecting Integrity or Reputation
 
29
 
 
 
 
 
ARTICLE 9 ORDERS; SUPPLY AND RETURNS
 
30
 
9.1 Orders and Terms of Sale
 
30
 
9.2 Supply of API Compound and Formulated Collaboration Product for Development
 
30
 
9.2.1 Supply of API Compound for Development
 
30
 
9.2.2 Supply of Formulated Collaboration Products for Development
 
30
 
9.3 Supply of API Compound for Commercial Requirements
 
30
 
9.4 Supply of Collaboration Products for Commercialization
 
30
 
9.5 Inventories
 
31
 
 
 
 
 
ARTICLE 10 CONFIDENTIAL INFORMATION
 
31
 
10.1 Confidential Information
 
31
 
10.2 Permitted Disclosure and Use
 
31
 
10.3 Publications
 
31
 
10.4 Public Announcements
 
32
 
10.5 Confidentiality of This Agreement
 
32
 
10.6 Termination of Prior Confidentiality Agreements
 
32
 
10.7 Survival
 
32
 
 
 
 
 
ARTICLE 11 REPRESENTATIONS AND WARRANTIES; COVENANTS
 
33
 
11.1 Mutual Representations and Warranties
 
33
 
11.2 Additional GSK Representations and Warranties
 
34
 
11.3 Additional Theravance Representations and Warranties
 
34
 
11.4 Covenants
 
35
 
11.5 Disclaimer of Warranty
 
35ARTICLE 12 INDEMNIFICATION
 
35
 
12.1 Indemnification by GSK
 
35
 
12.2 Indemnification by Theravance
 
35
 
12.3 Procedure for Indemnification
 
36
 
12.3.1 Notice
 
36
 
12.3.2 Defense of Claim
 
36
 
12.4 Assumption of Defense
 
37
 
12.5 Insurance
 
37
 
 iiiARTICLE 13 PATENTS
 
37
 
13.1 Prosecution and Maintenance of Patents
 
37
 
13.1.1 Prosecution and Maintenance of Theravance Patents
 
37
 
13.1.2 Prosecution and Maintenance of Patents Covering Joint Inventions
 
38
 
13.1.3 Prosecution and Maintenance of GSK Patents
 
39
 
13.1.4 GSK Step-In Rights
 
39
 
13.1.5 Theravance Step-In Rights
 
40
 
13.1.6 Execution of Documents by Agents
 
40
 
13.1.7 Patent Term Extensions
 
40
 
13.2 Patent Infringement
 
40
 
13.2.1 Infringement Claims
 
40
 
13.2.2 Infringement of Theravance Patents
 
40
 
13.2.3 Infringement of GSK Patents
 
41
 
13.3 Notice of Certification
 
41
 
13.3.1 Notice
 
41
 
13.3.2 Option
 
41
 
13.3.3 Name of Party
 
41
 
13.4 Assistance
 
41
 
13.5 Settlement
 
41
 
 
 
 
 
ARTICLE 14 TERM AND TERMINATION
 
42
 
14.1 Term and Expiration of Term
 
42
 
14.2 Termination for Material Breach
 
42
 
14.3 GSK Right to Terminate Development of a Collaboration Product
 
42
 
14.4 GSK Right to Terminate Commercialization of a Collaboration Product Following First Commercial Sale
 
42
 
14.5 Termination of the Agreement Due to Discontinuation of Development of All Collaboration Products and All PooledCompounds
 
43
 
14.6 Effects of Termination
 
43
 
14.6.1 Effect of Termination for Material Breach
 
43
 
14.6.2 Effect of Termination by GSK of Certain Terminated Development Collaboration Product(s)
 
44
 
14.6.3 Effect of Termination by GSK of a Terminated Commercialized Collaboration Product
 
45
 
14.6.4 Effect of Termination of the Agreement Due to Discontinuation of Development Prior to First Commercial Sale of AllCollaboration Products and All Pooled Compounds
 
4614.7 License Rights
 
47
 
14.8 Milestone Payments
 
47
 
14.9 Subsequent Royalties
 
47
 
14.10 Accrued Rights; Surviving Obligations
 
47
 
 
 
 
 
ARTICLE 15 LIMITATIONS RELATING TO THERAVANCE EQUITY SECURITIES
 
48
 
15.1 Purchases of Equity Securities
 
48
 
15.2 Exceptions for Purchasing Securities of Theravance
 
48
 
15.3 Voting
 
49
 
15.4 Theravance Voting Securities Transfer Restrictions
 
50
 
15.5 Termination of Purchase Restrictions
 
50
 
 ivARTICLE 16 MISCELLANEOUS
 
50
 
16.1 Relationship of the Parties
 
50
 
16.2 Registration and Filing of This Agreement
 
51
 
16.3 Force Majeure
 
51
 
16.4 Governing Law
 
51
 
16.5 Attorneys’ Fees and Related Costs
 
51
 
16.6 Assignment
 
52
 
16.7 Notices
 
52
 
16.8 Severability
 
52
 
16.9 Headings
 
53
 
16.10 Waiver
 
53
 
16.11 Entire Agreement
 
53
 
16.12 No License
 
53
 
16.13 Third Party Beneficiaries
 
53
 
16.14 Counterparts
 
53
 
16.15 Single Closing Condition
 
54
 
 Schedules 1.19 Criteria for Theravance New Compounds and Replacement Compounds 6.1.2 Preferred Stock Purchase Agreement  vCOLLABORATION AGREEMENT This COLLABORATION AGREEMENT (“Agreement”) dated November 14, 2002, is made by and between THERAVANCE, INC., aDelaware corporation, and having its principal office at 901 Gateway Boulevard, South San Francisco, California 94080 (“Theravance”), and GLAXOGROUP LIMITED, a United Kingdom corporation, and having its principal office at Glaxo Wellcome House, Berkeley Avenue, Greenford,Middlesex, UB6 0NN, United Kingdom (“GSK”). Theravance and GSK may be referred to as a “Party” or together, the “Parties”.  RECITALS WHEREAS, Theravance is currently developing Long-Acting β2 Adrenoceptor Agonists such as but not limited to TD-3327 and AMI-15471 for the treatment and/or prophylaxis of asthma and other respiratory diseases;  WHEREAS, GSK is also currently developing Long-Acting β2 Adrenoceptor Agonists such as but not limited to GW 597901, GW 678007,GW 642444 and GW 774419, as well as other anti-inflammatory compounds, for the treatment and/or prophylaxis of respiratory disease;  WHEREAS, GSK and Theravance desire to pool certain of their respective development compounds on an exclusive, worldwide basis tocommercialize at least one Long-Acting β2 Adrenoceptor Agonist that can be used as a single agent and/or in combination with a Long-ActingInhaled Corticosteroid and potentially other compounds for treatment and/or prophylaxis of respiratory disease;  WHEREAS, GSK and Theravance are willing to undertake research and development activities and investment and to coordinate suchactivities and investment as provided by this Agreement with respect to the Collaboration Products; and  WHEREAS, GSK and Theravance believe that a collaboration pursuant to this Agreement for the development and commercialization ofCollaboration Products would be desirable and compatible with their respective business objectives.  NOW, THEREFORE, in consideration of the foregoing premises and the representations, covenants and agreements contained herein,Theravance and GSK, intending to be legally bound, hereby agree as follows:  ARTICLE 1DEFINITIONS For purposes of this Agreement, the following initially capitalized terms, whether used in the singular or plural, shall have the followingmeanings:  11.1 “AMI-15471” means the Long-Acting β2 Adrenoceptor Agonist designated as such by Theravance and all pharmaceuticallyacceptable salts and solvates thereof.  1.2 “Adverse Drug Experience” means any of: an “adverse drug experience,” a “life-threatening adverse drug experience,” a “seriousadverse drug experience,” or an “unexpected adverse drug experience,” as those terms are defined at either 21 C.F.R.(S)312.32 or 21 C.F.R.(S)314.80.  1.3 “Affiliate” of a Party means any Person, whether de jure or de facto, which directly or indirectly controls, is controlled by, or is undercommon control with such Person for so long as such control exists, where “control” means the decision-making authority as to such Person and,further, where such control shall be presumed to exist where a Person owns more than fifty percent (50%) of the equity (or such lesser percentagewhich is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) having the power to vote on or direct the affairs ofthe entity.  1.4 “API Compound” means bulk quantities of active pharmaceutical ingredient compound prior to the commencement of secondarymanufacturing resulting in a Collaboration Product.  1.5 “Breaching Party” shall have the meaning set forth in Section 14.2.  1.6 “Business Day” means any day on which banking institutions in both New York City, New York, United States and London, Englandare open for business.  1.7 “Calendar Month” means for each Calendar Year, each of the one-month periods.  1.8 “Calendar Quarter” means for each Calendar Year, each of the three month periods ending March 31, June 30, September 30 andDecember 31; provided, however, that the first calendar quarter for the first Calendar Year shall extend from the Effective Date to the end of the firstcomplete calendar quarter thereafter.  1.9 “Calendar Year” means, for the first calendar year, the period commencing on the Effective Date and ending on December 31 of thecalendar year during which the Effective Date occurs, and each successive period beginning on January 1 and ending twelve (12) consecutivecalendar months later on December 31.  1.10 “Change in Control” means, with respect to a Party, any transaction or series of related transactions following which continuingstockholders of such Party hold less than 50% of the outstanding voting securities of either such Party or the entity surviving such transaction.  1.11 “Claim” means all charges, complaints, actions, suits, proceedings, hearings, investigations, claims and demands.  1.12 “Collaboration Product” means any of the Long-Acting β2 Adrenoceptor Agonists identified in Section 4.1 as Pooled Compounds(including any Theravance New Compounds and Replacement Compounds, as applicable) which may become Developed and Commercializedsubject to and in accordance with the terms of this Agreement, which such Collaboration Product can be used as a single agent and/or incombination with other therapeutically active components, including but not limited to a Long-Acting Inhaled Corticosteroid, for the treatment andprophylaxis of respiratory diseases. The term  2“Collaboration Product” shall also include any formulation of excipients, stabilizers, propellants, or other components necessary to prepare anddeliver a pharmaceutically effective dose of the Pooled Compound and any other therapeutically active component together with any deliverydevice.  1.13 “Commercial Conflict” means a situation where Theravance determines that GSK’s decision related to Development orCommercialization of a Collaboration Product is likely to result in a materially reduced financial return to Theravance from such CollaborationProduct, and that such decision is not based on the technical profile of the Collaboration Product but primarily on commercial factors whereby GSKis likely to achieve an increased financial return from a Competing Product owned by GSK.  1.14 “Commercial Failure” means failure of a Collaboration Product for reasons other than Technical Failure, based on the determinationthat such product will result in a net present value that is materially worse than the net present value for GSK’s other prescription pharmaceuticalproducts, based on GSK’s normal and customary procedures for determining net present value for its own portfolio products. The net presentvalue of a Collaboration Product will be based on forecasted cash flow from such product not taking into account the cannibalization of sales orprofit from any other GSK product. 1.15 “Commercialization” means any and all activities directed to marketing, promoting, distributing, offering for sale and selling aCollaboration Product, importing a Collaboration Product (to the extent applicable) and conducting Phase IV Studies. When used as a verb,“Commercialize” means to engage in Commercialization.  1.16 “Competing Product” means a product that is intended for the treatment and/or prophylaxis of respiratory diseases.  1.17 “Confidential Information” means all secret, confidential or proprietary information, data or Know-How (including GSK Know-Howand Theravance Know-How) whether provided in written, oral, graphic, video, computer or other form, provided by one Party (the “DisclosingParty”) to the other Party (the “Receiving Party”) pursuant to this Agreement or generated pursuant to this Agreement, including but not limited to,information relating to the Disclosing Party’s existing or proposed research, development efforts, patent applications, business or products, theterms of this Agreement and any other materials that have not been made available by the Disclosing Party to the general public. ConfidentialInformation shall not include any information or materials that the Receiving Party can document with competent written proof:  1.17.1 were already known to the Receiving Party (other than under an obligation of confidentiality), at the time of disclosure bythe Disclosing Party;  1.17.2 were generally available to the public or otherwise part of the public domain at the time of its disclosure to the ReceivingParty;  1.17.3 became generally available to the public or otherwise part of the public domain after its disclosure or development, as thecase may be, and other than through any act or omission of a Party in breach of such Party’s confidentiality obligations under this Agreement; 31.17.4 were disclosed to a Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to theDisclosing Party not to disclose such information to others; or  1.17.5 were independently discovered or developed by or on behalf of the Receiving Party without the use of the ConfidentialInformation belonging to the other Party.  1.18 “Country” means any generally recognized sovereign entity. 1.19 “Criteria” means the requirements set forth in Schedule 1.19 that the Replacement Compounds and Theravance New Compounds mustmeet to become a Pooled Compound. These requirements may be amended after the Effective Date by written agreement of the Parties (suchagreement not to be unreasonably withheld by either Party) to take account of any newly established data or knowledge that has or have arisensince the Effective Date that affect or is likely to affect same.  1.20 “Designated Foreign Filing” shall have the meaning set forth in Section 13.1.2(b).  1.21 “Development” or “Develop” means preclinical and clinical drug development activities, including, among other things: test methoddevelopment and stability testing, toxicology, formulation, process development, manufacturing scale-up, development-stage manufacturing,current Good Manufacturing Practices audits, current Good Clinical Practices audits, current Good Laboratory Practices audits, analytical methodvalidation, manufacturing process validation, cleaning validation, scale-up and post approval changes, quality assurance/quality controldevelopment, statistical analysis and report writing, preclinical and clinical studies, regulatory filing submission and approval, and regulatory affairsrelated to the foregoing. When used as a verb, “Develop” means to engage in Development.  1.22 “Development Expenses” means the cost of all studies or activities performed by or on behalf of GSK or any of its Affiliates pursuantto this Agreement.  1.23 “Development Milestone” shall have the meaning set forth in Section 6.2.1.  1.24 “Development Plan” means the outline plan for each Collaboration Product designed to achieve the Development for suchCollaboration Product, including, without limitation, the nature, number and schedule of Development activities as well as the estimated resourcesnecessary to implement such activities as such may be amended in accordance with the terms of this Agreement.  1.25 “Diligent Efforts” means the carrying out of obligations in a sustained manner consistent with the efforts a Party devotes to a productof similar market potential, profit potential or strategic value resulting from its own research efforts, based on conditions then prevailing and as ifthere were no Competing Product owned by such Party, with the objective of launching a single agent Collaboration Product and a combinationagent Collaboration Product in accordance with the Development principles more specifically outlined in Section 4.2.4. Diligent Efforts requires that:(i) each Party promptly assign responsibility for such obligations to specific employee(s) who are held accountable for progress and monitor suchprogress on an on-going basis, (ii) each Party set and consistently seek to achieve specific and meaningful objectives for carrying out suchobligations, and (iii) each Party consistently make and implement decisions and allocate resources designed to advance progress with respect tosuch objectives.  41.26 “Disclosing Party” shall have the meaning set forth in Section 1.17.  1.27 “Effective Date” means the first business day following the date on which the last of the conditions contained in Section 16.15 of thisAgreement has been satisfied.  1.28 “Exchange Act” shall have the meaning set forth in Section 15.1.1.  1.29 “FDA” means the United States Food and Drug Administration and any successor agency thereto.  1.30 “Field” means human pharmaceutical use of Long-Acting β2 Adrenoceptor Agonists for the treatment and/or prophylaxis ofrespiratory diseases.  1.31 “First Commercial Sale” means the first shipment of commercial quantities of any Collaboration Product sold to a Third Party by aParty or its sublicensees in any Country after receipt of Marketing Authorization Approval for such Collaboration Product in such Country. Salesfor test marketing, sampling and promotional uses, clinical trial purposes or compassionate or similar uses shall not be considered to constitute aFirst Commercial Sale.  1.32 “Force Majeure Event” shall have the meaning set forth in Section 16.3.  1.33 “Governmental Authority” means any court, tribunal, arbitrator, agency, legislative body, commission, official or other instrumentalityof (i) any government of any Country, (ii) a federal, state, province, county, city or other political subdivision thereof or (iii) any supranationalbody, including without limitation the European Agency for the Evaluation of Medicinal Products.  1.34 “GSK Compound” means a GSK Initially Pooled Compound, any Replacement Compound offered up to the collaboration by GSK or aGSK non-LABA Compound utilised by GSK for Development purposes in relation to combination product activity under this Agreement currentlyowned or subsequently discovered by GSK and/or its predecessors in title or in-licensed from a Third Party by GSK and/or its predecessors in title.  1.35 “GSK Initially Pooled Compound” shall mean the chemical entities individually identified as GW 597901, GW 678007, GW 642444 andGW 774419 and all pharmaceutically acceptable salts and solvates thereof.  1.36 “GSK Invention” means an Invention that is invented by an employee or agent of GSK solely or jointly with a Third Party.  1.37 “GSK Know-How” means all present and future information directly relating to the Collaboration Products, a GSK Compound or theGSK Inventions, including without limitation all data, records, and regulatory filings relating to Collaboration Products, that is required forTheravance to perform its obligations or exercise it rights under this Agreement, and which during the Term are in GSK’s or any of its Affiliates’possession or control and are or become owned by, or otherwise may be licensed to (provided there is no restriction on GSK thereof), GSK. GSKKnow-How does not include any GSK Patents. 51.38 “GSK non-LABA Compound” means any other compound contributed to the collaboration by GSK pursuant to Section 4.2.1 for thepurpose of developing a combination product.  1.39 “GSK Patents” means all present and future patents and patent applications including United States provisional applications and anycontinuations, continuations-in-part, divisionals, registrations, confirmations, revalidations, reissues, Patent Cooperation Treaty applications,certificates of addition, utility models, design patents, petty patents as well as all other intellectual property related to the application or patentincluding extensions or restorations of terms thereof, pediatric use extensions, supplementary protection certificates or any other such rightcovering the Pooled Compounds, Collaboration Products, a GSK Compound or the GSK Inventions which are or become owned by GSK or GSK’sAffiliates, or as to which GSK or GSK’s Affiliates otherwise are or become licensed, now or in the future, where GSK has the right to grant thesublicense rights granted to Theravance under this Agreement, which such patent rights cover the making, having made, use, offer for sale, sale orimportation of the Collaboration Products.  1.40 “Hatch-Waxman Certification” shall have the meaning set forth in Section 13.3.  1.41 “Hostile Tender Offer” shall have the meaning set forth in Section 15.2.6.  1.42 “Indemnified Party” shall have the meaning set forth in Section 12.3.1.  1.43 “Indemnifying Party” shall have the meaning set forth in Section 12.3.1.  1.44 “Invention” means any discovery (whether patentable or not) invented during the Term as a result of research, Development ormanufacturing activities and specifically related to a Pooled Compound or Collaboration Product hereunder.  1.45 “Investigational Authorization” means, with respect to a Country, the regulatory authorization required to investigate a CollaborationProduct in such Country as granted by the relevant Governmental Authority.  1.46 “Joint Invention” means an Invention that is invented jointly by employees and/or agents of both Theravance and GSK hereunderand the patent rights in such Invention.  1.47 “Joint Project Committee” shall have the meaning set forth in Section 3.2.  1.48 “Joint Steering Committee” shall have the meaning set forth in Section 3.1.  1.49 “LABA/ICS Combination Product” means a product that contains a Pooled Compound and a Long-Acting Inhaled Corticosteroid forthe treatment and/or prophylaxis of respiratory diseases. A LABA/ICS Combination Product shall also be considered a Collaboration Product.  1.50 “Laws” means all laws, statutes, rules, regulations (including, without limitation, current Good Manufacturing Practice Regulations asspecified in 21 C.F.R. (S)(S) 210 and 211; Investigational New Drug Application regulations at 21 C.F.R. (S) 312; NDA regulations at 21 C.F.R. (S)314, relevant provisions of the Federal Food, Drug and Cosmetic Act, and other laws and regulations enforced by the FDA), ordinances and otherpronouncements having the binding effect of law of any Governmental Authority. 61.51 “Litigation Condition” shall have the meaning set forth in Section 12.3.2.  1.52 “Long-Acting βAdrenoceptor Agonist” or “LABA” means a chemical entity that (i) selectively binds to human βadrenoceptors andactivates human βadrenoceptors at concentrations less than 100 nanomolar and (ii) has significantly longer activity than salmeterol afterinhalation dosing as determined in a guinea pig acetylcholine bronchoprotection model or similar animal model.  1.53 “Long-Acting Inhaled Corticosteroid” or “ICS” means a corticosteroid that has duration of action of at least 24 hours demonstrated inclinical testing.  1.54 “Losses” means any and all damages (including all incidental, consequential, statutory an treble damages), awards, deficiencies,settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and expenses(including without limitation court costs, interest and reasonable fees of attorneys, accountants and other experts) incurred by or awarded to ThirdParties and required to be paid to Third Parties with respect to a Claim by reason of any judgment, order, decree, stipulation or injunction, or anysettlement entered into in accordance with the provisions of this Agreement, together with all documented out-of-pocket costs and expensesincurred in complying with any judgments, orders, decrees, stipulations and injunctions that arise from or relate to a Claim of a Third Party.  1.55 “Major Market Country” means each of the United States, Canada, Japan, France, United Kingdom, Italy, Germany and Spain.  1.56 “Marketing Authorization” means, with respect to a Country, the regulatory authorization required to market and sell a CollaborationProduct in such Country as granted by the relevant Governmental Authority.  1.57 “Marketing Authorization Approval” shall mean approval by a Governmental Authority for sale of a Collaboration Product, includingany applicable pricing, final labeling or reimbursement approvals.  1.58 “Marketing Plan” means for each relevant Collaboration Product the global plan prepared by GSK identifying the core strategic,commercial and promotional claims and objectives for the specific Collaboration Product as reviewed and approved under Section 5.1.1.  1.59 “NDA” means a new drug application or supplemental new drug application or any amendments thereto submitted to the FDA in theUnited States.  1.60 “NDA Acceptance” shall mean the written notification by the FDA that the NDA has met all the criteria for filing acceptance pursuantto 21 C.F.R.(S)314.101.  1.61 “Net Sales” means the gross sales price of a Collaboration Product sold by GSK, its Affiliates or their licensees (or such licensees’Affiliates) to a Third Party, less the following to the extent borne by the seller and not taken into account in determining gross sales price: (a)deduction of cash, trade and quantity discounts actually given; (b) discounts, refunds, rebates, chargebacks, retroactive price adjustments, andany other allowances actually given which effectively reduce the net selling price, including institutional rebate or discount such as Medicare orMedicaid provided in the United States or any similar organization elsewhere in the world; and 7
2  2 
2(c) credits and allowances for product returns actually made. Net Sales shall exclude Samples distributed in the usual course of business. 1.62 “Net Sales Report” shall have the meaning set forth in Section 6.4.2.  1.63 “Officers” shall have the meaning set forth in Section 3.1.5(b).  1.64 “Other Combination Product” means any product developed pursuant to this Agreement for the treatment and/or prophylaxis ofrespiratory disease that contains a Long-Acting βAdrenoceptor Agonist and another active agent which is a GSK Compound other than a Long-Acting Inhaled Corticosteroid.  1.65 “Patent Infringement Claim” shall have the meaning set forth in Section 13.2.1.  1.66 “Patent Infringement Notice” shall have the meaning set forth in Section 13.2.2.  1.67 “Person” means any natural person, corporation, general partnership, limited partnership, limited liability company, joint venture,proprietorship or other business organization.  1.68 “Phase I Studies” means that portion of the Development Plan or Development relating to each Collaboration Product which providesfor the first introduction into humans of such Collaboration Product including small scale clinical studies conducted in normal volunteers to obtaininformation on such Collaboration Product’s safety, tolerability, pharmacological activity, pharmacokinetics, drug metabolism and mechanism ofaction, as well as early evidence of effectiveness, as more fully defined in 21 C.F.R. (S) 312.21(a).  1.69 “Phase II Studies” means, subject to Section 6.2.2, that portion of the Development Plan or Development relating to eachCollaboration Product which provides for well controlled clinical trials of such Collaboration Product in patients, including clinical studiesconducted in patients with the condition, and designed to evaluate clinical efficacy and safety for such Collaboration Product for one or moreindications, as well as to obtain an indication of the dosage regimen required, as more fully defined in 21 C.F.R. (S) 312.21(b).  1.70 “Phase III Studies” means that portion of the Development Plan or Development relating to each Collaboration Product whichprovides for large scale, pivotal, clinical studies conducted in a sufficient number of patients and whose primary objective is to obtain a definitiveevaluation of the therapeutic efficacy and safety of the Collaboration Product in patients for the particular indication in question that is needed toevaluate the overall risk-benefit profile of the Collaboration Product and to provide adequate basis for obtaining requisite regulatory approval(s)and product labeling, as more fully defined in 21 C.F.R. (S) 312.21(c).  1.71 “Phase IV Studies” means a study for a Collaboration Product that is initiated after receipt of a Marketing Authorization for aCollaboration Product and is principally intended to support the marketing and Commercialization of such Collaboration Product, including withoutlimitation investigator initiated trials, clinical experience trials and studies conducted to fulfill local commitments made as a condition of anyMarketing Authorization.  1.72 “Pooled Compounds” means (i) the four Long-Acting Beta-2 Adrenoceptor Agonists provided by GSK as of the Effective Date(identified as GW 597901, GW 678007, GW 642444 and GW 774419), (ii) the two Long-Acting Beta-2 Adrenoceptor Agonists provided by 8
2Theravance as of the Effective Date (identified as TD-3327 and AMI-15471), (iii) the Theravance New Compounds provided by Theravancepursuant to Section 4.1, and any Replacement Compounds provided by Theravance or GSK. 1.73 “Product Supplier” means any manufacturer, packager or processor of a Collaboration Product for development, marketing and sale.  1.74 “Promotional Materials” means the core written, printed, video or graphic advertising, promotional, educational and communicationmaterials (other than Collaboration Product labeling) for marketing, advertising and promotion of the Collaboration Products.  1.75 “Receiving Party” shall have the meaning set forth in Section 1.17. 1.76 “Replacement Compound” means a Long-Acting β2 Adrenoceptor Agonist that meets the Criteria and is provided by Theravance orGSK, as applicable, (and “GSK Replacement Compound” and “Theravance Replacement Compound” shall be interpreted accordingly) after theEffective Date to replace a Pooled Compound for which Development has been discontinued due to Technical Failure.  1.77 “ROW” means Countries other than the Major Market Countries.  1.78 “Samples” means Collaboration Product packaged and distributed as a complimentary trial for use by patients in the Territory.  1.79 “SEC” shall have the meaning set forth in Section 15.1.2.  1.80 “Selectively” means the chemical entity binds human βadrenoceptors (a) with more than 100 fold greater affinity than it binds otherprotein targets in the human body as determined by receptor binding, radioligand displacement or functional in vitro assays, and (b) more than 5fold greater than the other human β adrenoceptor subtypes.  1.81 “TD-3327” means the Long-Acting β2 Adrenoceptor Agonist so designated by Theravance and all pharmaceutically acceptable saltsand solvates thereof contributed to the collaboration by Theravance.  1.82 “Taxes” shall have the meaning set forth in Section 6.9.1.  1.83 “Technical Failure” means the discontinuation of Development of a Collaboration Product for technical, scientific, medical orregulatory reasons, such as but not limited to unacceptable preclinical toxicity, or the inability to demonstrate sufficient Long-Acting βAdrenoceptor Agonist effect in humans, or demonstration of a side effect profile significantly worse than currently marketed products, or inabilityto manufacture API in an acceptable purity or crystalline form, or inability to produce a metered dose inhaler or dry powder inhaler formulation withacceptable aerosol performance and stability.  1.84 “Term” means, on a Country-by-Country and Collaboration Product-by-Collaboration Product basis, the period from the EffectiveDate until the later of (a) the expiration or termination of the last Valid Claim of a Patent Right covering the Pooled Compound in such CollaborationProduct in such Country, and (b) fifteen (15) years from First Commercial Sale in such Country, unless this Agreement is terminated earlier inaccordance with Article 14.  9
2 
21.85 “Terminated Collaboration Product” shall mean a Terminated Development Collaboration Product or a Terminated CommercializedCollaboration Product.  1.86 “Terminated Commercialized Collaboration Product” shall have the meaning set forth in Section 14.4.  1.87 “Terminated Development Collaboration Product” shall have the meaning set forth in Section 14.3.  1.88 “Territory” means worldwide.  1.89 “Theravance Compound” means TD-3327 and AMI-15471, (together the “Theravance Initially Pooled Compounds”), the twoTheravance New Compounds and any Replacement Compound that is offered up to the collaboration by Theravance.  1.90 “Theravance New Compound” means each of the two chemical entities meeting the Criteria and provided by Theravance to thecollaboration as Pooled Compounds after the Effective Date pursuant to Section 4.1.  1.91 “Housemark” means the name and logo of GSK or Theravance or any of their respective Affiliates as identified by one Party to theother from time to time.  1.92 “Theravance Invention” means an Invention that is invented by an employee or agent of Theravance solely or jointly with a ThirdParty.  1.93 “Theravance Know-How” means all present and future information directly relating to the Collaboration Products, a TheravanceCompound or the Theravance Inventions that is required for GSK to perform its obligations or exercise its rights under this Agreement, and whichduring the Term are in Theravance’s or any of its Affiliates’ possession or control and are or become owned by, or otherwise may be licensed(provided there are no restrictions on Theravance thereof) by, Theravance. Theravance Know-How does not include any Theravance Patents.  1.94 “Theravance Patents” means all present and future patents and patent applications including United States provisional applicationsand any continuations, continuations-in-part, divisionals, registrations, confirmations, revalidations, reissues, Patent Cooperation Treatyapplications, certificates of addition, utility models, design patents, petty patents as well as all other intellectual property related to the applicationor patent including extensions or restorations of terms thereof, pediatric use extensions, supplementary protection certificates or any other suchright covering the Pooled Compounds, the Collaboration Products, a Theravance Compound or the Theravance Inventions which are or becomeowned by Theravance or Theravance’s Affiliates, or as to which Theravance or Theravance’s Affiliates are or become licensed, now or in thefuture, with the right to grant the sublicense rights granted to GSK under this Agreement, which patent rights cover the making, having made, use,offer for sale, sale or importation of Collaboration Products.  1.95 “Third Party” means a Person who is not a Party or an Affiliate of a Party.  1.96 “Third Party Claim” shall have the meaning set forth in Section 12.3.1.  1.97 “United States” means the United States, its territories and possessions. 101.98 “Valid Claim” means any claim(s) pending in a patent application or in an unexpired patent which has not been held unenforceable,unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within thetime allowed for appeal, and which has not has been admitted to be invalid or unenforceable through reissue or disclaimer. If in any country thereshould be two or more such decisions conflicting with respect to the validity of the same claim, the decision of the higher or highest tribunal shallthereafter control; however, should the tribunals be of equal rank, then the decision or decisions upholding the claim shall prevail when thedecisions are equal in number, and the majority of decisions shall prevail when the conflicting decisions are unequal in number.  1.99 “Withholding Party” shall have the meaning set forth in Section 6.9.1.  ARTICLE 2RIGHTS AND OBLIGATIONS 2.1 License Grants from Theravance to GSK.  2.1.1 Development License. Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grants toGSK, and GSK accepts, an exclusive (except as to Theravance and its Affiliates) license in the Field under the Theravance Patents, TheravanceKnow-How and Theravance’s rights in the Joint Inventions to make, have made, use and Develop Collaboration Products for Commercialization inthe Territory.  2.1.2 Commercialization License. Subject to the terms of this Agreement, including without limitation Section 2.2, Theravancehereby grants to GSK, and GSK accepts, an exclusive license in the Field under the Theravance Patents, Theravance Know-How and Theravance’srights in the Joint Inventions to make, have made use, sell, offer for sale and import Collaboration Products in the Territory.  2.1.3 Manufacturing License. Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grantsto GSK an exclusive license in the Field under the Theravance Patents, Theravance Know-How and Theravance’s rights in the Joint Inventions tomake and have made API Compound or formulated Collaboration Product in the Territory.  2.2 Sublicensing and Subcontracting. GSK may sublicense or subcontract its rights to Develop, Manufacture or Commercialize theCollaboration Products in whole or in part to one or more of its Affiliates, provided that the rights sublicensed or subcontracted to such Affiliateshall automatically terminate upon a change of control of such Affiliate in connection with which such Affiliate ceases to be an Affiliate of GSK.GSK may also sublicense or subcontract any of GSK’s rights to Develop or Manufacture the Collaboration Products, in whole or in part, to one ormore Third Parties. In the event GSK wishes to sublicense or subcontract any of GSK’s rights to Commercialize the Collaboration Products, inwhole or in part, to one or more Third Parties, GSK shall obtain the prior written consent of Theravance, such consent not to be unreasonablywithheld, provided always that no such restriction shall apply in respect of those countries of the Territory wherein GSK is or has been requiredunder applicable local laws to appoint a Third Party as its distributor or marketing partner. GSK shall secure all appropriate covenants, obligationsand rights from any such sublicensee or subcontractor granted by it under this Agreement, including, but not limited to, intellectual property rightsand confidentiality obligations in any such agreement or other relationship, to ensure that such sublicensee can 11comply with all of GSK’s covenants and obligations to Theravance under this Agreement. GSK’s rights to sublicense, subcontract or otherwisetransfer its rights granted under Section 2.1 are limited to those expressly set forth in this Section 2.2.  2.3 Trademarks and Housemarks.  2.3.1 Trademarks. The Collaboration Products shall be Commercialized under trademarks (the “Trademarks”) and trade dressselected by the Joint Project Committee and approved by the Joint Steering Committee. Prior to any such proposed Trademark(s) being submittedto the Joint Project Committee, GSK shall be responsible for undertaking their preliminary selection. GSK shall exclusively own all Trademarks, andshall be responsible for the procurement, filing and maintenance of trademark registrations for such Trademarks and all costs and expenses relatedthereto. GSK shall also exclusively own all trade dress and copyrights associated with the Collaboration Products. Nothing herein shall create anyownership rights of Theravance in and to the Trademarks or the copyrights and trade dress associated with the Collaboration Products.  2.3.2 Housemarks. Each Party acknowledges the goodwill and reputation that has been associated with the other Party’sHousemarks over the years, and shall use such Housemarks in a manner that maintains and promotes such goodwill and reputation and isconsistent with trademark guidelines. Each Party shall take all reasonable precautions and actions to protect the goodwill and reputation that hasinured to the other Party’s Housemarks, shall refrain from doing any act that is reasonably likely to impair the reputation of such Housemarks, andshall cooperate fully to protect such Housemarks.  2.3.3 Ownership of Inventions. Each Party shall promptly disclose to the other Party all Inventions made by it during the Term;provided that GSK will be allowed a reasonable time to file patent applications covering GSK Inventions prior to disclosing the GSK Invention toTheravance, and Theravance will be allowed a reasonable time to file patent applications covering Theravance Inventions prior to disclosing theTheravance Invention to GSK. Theravance shall own all Theravance Inventions and GSK shall own all GSK Inventions. All Joint Inventions shallbe owned jointly by Theravance and GSK, and each Party hereby consents to the assignment or license or other disposition by the other Party ofits joint interests in Joint Inventions without the need to seek the consent of the other Party to such assignment or license or other disposition;provided that any such assignment, license or other disposition shall at all times be subject to the grant of rights and accompanying conditionsunder Sections 2.1 and 2.2 and Article 14. The determination of inventorship for Inventions shall be made in accordance with applicable lawsrelating to inventorship set forth in the patent laws of the United States (Title 35, United States Code). 12ARTICLE 3GOVERNANCE OF DEVELOPMENT ANDCOMMERCIALIZATION OF PRODUCTS 3.1 Joint Steering Committee.  3.1.1 Purpose. The purposes of the Joint Steering Committee shall be (i) to determine the overall strategy for this collaborationbetween the Parties and (ii) to coordinate the Parties’ activities hereunder. The Parties intend that their respective organizations will work togetherand will use Diligent Efforts to assure success of the collaboration.  3.1.2 Members; Officers. Within thirty (30) days after the Effective Date, the Parties shall establish a joint steering committee (the“Joint Steering Committee”), which shall consist of four (4) members, two (2) of whom shall be designated by each of GSK and Theravance andshall have appropriate expertise, with at least one (1) member from each Party being at least at a vice president level or higher. Each of GSK andTheravance may replace any or all of its representatives on the Joint Steering Committee at any time upon written notice to the other Party. A Partymay designate a substitute to temporarily attend and perform the functions of such Party’s designee at any meeting of the Joint SteeringCommittee. GSK and Theravance each may, on advance written notice to the other Party, invite non-member representatives of such Party to attendmeetings of the Joint Steering Committee. The Joint Steering Committee shall be chaired on an annual rotating basis by a representative of eitherTheravance or GSK, as applicable, on the Joint Steering Committee, with Theravance providing the first such chairperson. The chairperson shallappoint a secretary of the Joint Steering Committee, who shall be a representative of the other Party and who shall serve for the same annual termas such chairperson.  3.1.3 Responsibilities. The Joint Steering Committee shall perform the following functions:  (a) Manage and oversee the Development and Commercialization of the Collaboration Products pursuant to the terms of thisAgreement;  (b) Review and approve the Development Plans and the Marketing Plans for Collaboration Products and any materialamendments to the Development Plans and Marketing Plans;  (c) At each meeting of the Joint Steering Committee, review Net Sales for the year-to-date as available;  (d) Review and approve the progress of the Joint Project Committee;  (e) Review and approve the Trademarks selected under Section 2.3;  (f) Review and approve “go/no-go” decisions and other matters referred to the Joint Steering Committee, including, withoutlimitation, the continued Development of a particular Collaboration Product or the inclusion of Replacement Compounds;  (g) Life cycle management of, and intellectual property protection for, the Collaboration Products; 13(h) In accordance with the procedures established in Section 3.1.5, resolve disputes, disagreements and deadlocks unresolved bythe Joint Project Committee; and  (i) Have such other responsibilities as may be assigned to the Joint Steering Committee pursuant to this Agreement or as may bemutually agreed upon by the Parties from time to time.  3.1.4 Meetings. The Joint Steering Committee shall meet in person at least once during every Calendar Year, and more frequently(i) as mutually agreed by the Parties or (ii) as required to resolve disputes, disagreements or deadlocks in the Joint Project Committee, on suchdates, and at such places and times, as such Parties shall agree; provided that the Parties shall endeavor to have the first meeting of the JointSteering Committee within thirty (30) days after the establishment of the Joint Steering Committee. The Joint Steering Committee shall arrange tomeet in person or convene otherwise to assess and approve any Development Plans or Marketing Plans, if any, submitted to the Joint SteeringCommittee in each Calendar Year so that such plans will be reviewed and approved within thirty (30) days following submission to the JointSteering Committee. To the extent any such Development Plans or Marketing Plans are not approved and need to be reformulated by the JointProject Committee, such plans shall be reviewed by the Joint Steering Committee as soon as reasonably practicable after resubmission of same.Meetings of the Joint Steering Committee that are held in person shall alternate between offices of GSK and Theravance, or such other place as theParties may agree. In addition to the annual face to face meetings the Joint Steering Committee may also be held by means of telecommunicationsor, video conferences as deemed appropriate by the Parties.  3.1.5 Decision-Making.  (a) The Joint Steering Committee may make decisions with respect to any subject matter that is subject to the Joint SteeringCommittee’s decision-making authority and functions as set forth in Section 3.1.3. Except as specified in Section 3.1.5(b), all decisions of the JointSteering Committee shall be made by consensus, with the representatives from each Party presenting a unified position on behalf of such Party.The Joint Steering Committee shall use Diligent Efforts to resolve the matters within its roles and functions or otherwise referred to it.  (b) With respect to any issue, if the Joint Steering Committee cannot reach consensus within ten (10) Business Days after thematter has been brought to the Joint Steering Committee’s attention, then such issue shall be referred to the Chief Executive Officer of Theravanceand the Chairman of R&D of GSK (collectively, the “Officers”) for resolution. The Parties accept that the use of the Officers for resolution of anyunresolved issues will be on an exceptional basis. In the event that the use of the Officers occurs on more than two occasions in any consecutivetwelve (12) month period and such disputes are not related to Commercial Conflict issues, then GSK will from then on retain the final vote within theJoint Steering Committee for all issues other than Commercial Conflict. If the Officers are unable to reach consensus within thirty (30) days after thematter has been referred to them, the final decision on such disputed issue will reside with GSK; provided, however, that if the disputed issueinvolves a Commercial Conflict, then the final decision will be made by a mutually acceptable Third Party mediator. Either Party can initiate suchmediation on 30 days written notice to the other Party. The Parties will use best efforts to agree on a mediator within such 30-day period. Suchmediation will occur as promptly as practicable following selection of the mediator and will be held in New York, New York. The decision of themediator will be final and binding on the Parties; provided that either party shall retain all rights to bring an action against the other for damagesand other monetary relief related to or arising out of the issue decided by the mediator. 143.2 Joint Project Committee.  3.2.1 Purpose. The purposes of the Joint Project Committee shall be to manage the Parties’ day-to-day activities hereunder.  3.2.2 Members; Officers. Within thirty (30) days after the Effective Date, the Parties shall establish a Project Committee (the “JointProject Committee”), and GSK and Theravance shall designate an equal number of representatives, up to a maximum total of eight (8) members onsuch Joint Project Committee, with a maximum of four (4) from each Party. Each of GSK and Theravance may replace any or all of its representativeson the Joint Project Committee at any time upon written notice to the other Party. Such representatives shall include individuals who have therelevant experience and expertise for the next twelve months as included in the Development Plan for the Collaboration Products. A Party maydesignate a substitute to temporarily attend and perform the functions of such Party’s designee at any meeting of the Joint Project Committee. GSKand Theravance each may, on advance written notice to the other Party, invite non-member representatives of such Party to attend meetings of theJoint Project Committee. The Joint Project Committee shall be chaired by a representative of GSK. The chairperson shall appoint a secretary of theJoint Project Committee, who shall be a representative of Theravance.  3.2.3 Responsibilities. The Joint Project Committee shall perform the following functions:  (a) Review the Development Plans as prepared by GSK;  (b) On an annual rolling basis beginning within six months of the Effective Date, update and amend any initial Development Planand review the Development Plan for each Collaboration Product for the following Calendar Year so that it can immediately thereafter submit suchproposed Development Plan to the Joint Steering Committee for review and approval;  (c) At each meeting of the Joint Project Committee, review the Development strategy for the Collaboration Products in theTerritory;  (d) At each meeting of the Joint Project Committee, review and recommend to the Joint Steering Committee any materialamendments or modifications to the Development Plans;  (e) Coordinate and monitor regulatory strategy and activities for the Collaboration Products in accordance with Article 8;  (f) Review and recommend to the Joint Steering Committee “go/no-go” decisions for the Development of Collaboration Products;  (g) Review the Marketing Plans where appropriate;  (h) Review and recommend to the Joint Steering Committee any material amendments or modifications to the Marketing Plans; 15(j) Discuss the state of the markets for Collaboration Products and opportunities and issues concerning the Commercialization ofthe Collaboration Products, including consideration of marketing and promotional strategy, marketing research plans, labeling, CollaborationProduct positioning and Collaboration Product profile issues;  (k) At each meeting of the Joint Project Committee, review the status of all Studies conducted on Collaboration Products and anyresults therefrom;  (l) At each meeting of the Joint Project Committee, review Net Sales for the year-to-date, as available; and  (m) Have such other responsibilities as may be assigned to the Joint Project Committee pursuant to this Agreement or as may bemutually agreed upon by the Parties through the Joint Steering Committee from time to time.  3.2.4 Meetings. The Joint Project Committee shall meet at least once during every Calendar Quarter, and more frequently as GSKand Theravance mutually agree on such dates, and at such places and times, as such Parties shall agree; provided that the Parties shall endeavor tohave the first meeting of the Joint Project Committee as a face to face meeting within thirty (30) days after the establishment of the Joint ProjectCommittee. Meetings of the Joint Project Committee that are held in person shall alternate between the offices of GSK and Theravance, or suchother place as the Parties may agree and such face to face meetings shall occur no less than twice a year. The remaining meetings may be held bymeans of telecommunications or video conferences as deemed appropriate. Following Commercialization of a Collaboration Product in the firstMajor Market, the Joint Project Committee shall meet twice a year with only one annual face to face meeting required.  3.2.5 Decision-Making. The Joint Project Committee may make decisions with respect to any subject matter that is subject to theJoint Project Committee’s decision-making authority and functions as set forth in Section 3.2.3. All decisions of the Joint Project Committee shall bemade by consensus, with the representatives from each Party presenting a unified position on behalf of such Party. If the Joint Project Committeecannot reach consensus within ten (10) Business Days after it has first met and attempted to reach such consensus, the matter shall be referred onthe eleventh (11) Business Day to the Joint Steering Committee for resolution.  3.3 Minutes of Committee Meetings. Definitive minutes of all committee meetings shall be finalized no later than thirty (30) days after themeeting to which the minutes pertain as follows:  3.3.1 Distribution of Minutes. Within ten (10) days after a committee meeting, the secretary of such committee shall prepare anddistribute to all members of such committee draft minutes of the meeting. Such minutes shall provide a list of any issues yet to be resolved, eitherwithin such committee or through the relevant resolution process.  3.3.2 Review of Minutes. The Party members of each committee shall have ten (10) days after receiving such draft minutes tocollect comments thereon and provide them to the secretary of such committee.  3.3.3 Discussion of Comments. Upon the expiration of such second ten (10) day period, the Parties shall have an additional ten(10) days to discuss each other’s comments and finalize the minutes. The secretary and chairperson(s) of such committee shall each sign and date 16
ththe final minutes. The signature of such chairperson(s) and secretary upon the final minutes shall indicate each Party’s assent to the minutes.  3.4 Expenses. Each Party shall be responsible for all travel and related costs and expenses for its members and other representatives toattend meetings of, and otherwise participate on, a committee.  3.5 General Guidelines and Initial Coordination Efforts. In all matters related to the collaboration established by this Agreement, the Partiesshall strive to balance as best they can the legitimate interests and concerns of the Parties and to realize the economic potential of CollaborationProducts. In all matters relating to this Agreement, the Parties shall seek to comply with good pharmaceutical and environmental practices. TheParties intend, following the Effective Date, to organize meetings of internal staff to communicate and explain the provisions of this Agreement toensure the efficient and timely Development and Commercialization of the Collaboration Products.  ARTICLE 4DEVELOPMENT OF PRODUCTS 4.1. Pooling of Compounds. Subject to and consistent with the further Development principles outlined herein, each Party will offer aminimum of four (4) identified LABA compounds to this collaboration, with the intention of commercializing at least one Long-Acting β2Adrenoceptor Agonist as a single agent and/or as a LABA/ICS Combination Product. Upon commencement of the collaboration pursuant to thisAgreement, GSK and Theravance will contribute the following LABA compounds as Pooled Compounds to the collaboration:  GSK Compounds GW 597901, GW 678007, GW 642444 and GW 774419 and Theravance Compounds TD-3327 and AMI-15471. For the avoidance of doubt, it is agreed and hereby acknowledged by both Parties that the compounds GW 597901, GW 678007, GW 642444 andGW 774419, TD-3327 and AMI-15471 are hereby accepted as Pooled Compounds. Theravance will provide two (2) Theravance New Compounds to the collaboration within eighteen (18) months of the Effective Date in order tomeet the requirement that Theravance contribute a total of four (4) LABA compounds to the Pooled Compounds. Without prejudice to theforegoing, GSK will endeavor to provide Theravance, upon Theravance’s request and at GSK’s expense and discretion, such assistance as may bereasonably required by Theravance to achieve this objective, including providing directly or through GSK’s vendors, assistance in (i) chemicalprocess development, (ii) salt selection, (iii) pharmaceutical formulation, (iv) toxicological evaluation, and (v) API preparation.  4.2 Obligations for Development.  4.2.1 General; GSK. Under the direction of the Joint Project Committee, specific Pooled Compounds will be identified from time totime and, as applicable, selected for Development as a Collaboration Product. The Joint Project Committee will determine the number and extent ofDevelopment of the Pooled Compounds and the criteria to be used for selecting among the eight Pooled Compounds and, subject to the otherterms of this Agreement, will endeavor to move one or more such Collaboration Products forward in Development. In 17relation to the foregoing, GSK shall have the overall responsibility for, and use Diligent Efforts in, the performance of all such Developmentactivities which shall include, where applicable, relevant regulatory filings (as contemplated under Article 8) for any such Collaboration Productmoved forward in Development. Further, GSK shall use Diligent Efforts to advance such Collaboration Product through Development in accordancewith the Go/No-Go checkpoints identified in the then current Development Plan for such Collaboration Product. GSK shall also use Diligent Effortsto contribute at least one ICS and/or other non-LABA compound to the collaboration for the purpose of developing a combination product andDiligent Efforts to develop an optimal inhaled formulation of Collaboration Product in a device which may be either/or a dry powder inhalerformulation and/or a metered dose inhaler formulation of the Collaboration Compound and Development activities of such may continue in parallel.  4.2.2 GSK Funding Responsibility. GSK shall bear all costs and expenses associated with the Development of CollaborationProducts for Commercialization including those incurred by Theravance (or to which it has become obligated) after the signature date of thisAgreement and which previously have been discussed with and agreed to by GSK and, so far as the aforementioned Theravance costs areconcerned, for the avoidance of doubt, the maximum amount shall not exceed U.S. $2,940,000.  4.2.3 Decisions with Respect to Products.  (a) GSK shall have the sole discretion with respect to Development decisions for Collaboration Products subject to and inaccordance with Sections 3.1.5, 3.2.5, and 4.3 .  (b) Notwithstanding the foregoing, the Parties acknowledge that Theravance is about to initiate a Phase I Study in two parts, onTD-3327. The initiation of this study will be approved via the Joint Project Committee in accordance with all other Development activities.Theravance shall be responsible for the routine monitoring of this study and will transfer remaining clinical development responsibility for TD-3327to the Joint Project Committee on completion of the TD-3327 Phase Ia and Phase Ib Studies.  (c) GSK shall provide the Joint Project Committee with an update report within thirty days of (i) the initiation (i.e., first persondosed) of any Study involving a Collaboration Product, and (ii) the last person dosed/last visit in any Study relating to a Collaboration Product.GSK will provide the Joint Project Committee with a reasonably detailed “top line results” report within sixty days following the last persondosed/last visit in any Study involving a Collaboration Product.  4.2.4 Development Timelines. It is hereby acknowledged that GSK’s strategic objective is to move one or more of theCollaboration Products into Development at the earliest opportunity. GSK will consult with the Joint Project Committee and will share, modify andfurther develop all applicable Development Plans and timelines in that forum. It is recognised that success can be optimised by pursuing a numberof Collaboration Products through various phases of clinical Development up to the point of Technical or Commercial Failure, and/or until the firstCollaboration Product for both single agent and combination therapy achieves regulatory agency approval. At a strategic level, GSK is committedto this objective. However, at an operational level it is recognised that internal and external resources will be constrained from time to time, resultingin the need to prioritise individual studies and activities relating to Collaboration Products. GSK will use Diligent Efforts to secure the necessaryresource and will keep the Joint Project Committee informed on the progress of individual studies and activities relating to Collaboration Productsas part of any changes to Development Plans and timelines. 18The current objective of the Collaboration is to achieve Marketing Authorization Approval in the US and other Major Markets for a CollaborationProduct from one of the eight Pooled Compounds which can be used as a single agent and/or in combination with other therapeutically activecomponents (including but not limited to a Long Acting Inhaled Corticosteroid) for the treatment and/or prophylaxis of one or more respiratorydiseases by end 2009 for the single agent and 2010 for the first combination product and Development Plans and timelines will be developed and/orrefined in an effort to achieve this objective.  4.3 Replacement Compounds. If within two years after the Effective Date, the Development of Collaboration Products containing any twoof the Pooled Compounds contributed by a Party is discontinued due to Technical Failure, it will be the option of the Party who contributed thediscontinued compounds to discover and offer up to the collaboration two Replacement Compounds as replacements for the discontinuedcompounds within twelve months following the discontinuation of the second failed compound. For the avoidance of doubt, any such newcompound that satisfies the Criteria will automatically be accepted as a Pooled Compound in place of the relevant Party’s discontinued compound,subject to Joint Steering Committee approval pursuant to Section 3.1.3(f). Nothing in the foregoing shall preclude either Party from having theoption of offering up a Replacement Compound for a Pooled Compound at any time during the period referred to in Section 14.5 (subject to theCriteria being met and Joint Steering Committee approval pursuant to Section 3.1.3(f)).  4.4 Transfer of Data. As soon as practicable but in no event more than thirty (30) days after the Effective Date, the Parties shall determinewhat data and materials relating to TD-3327 and AMI-15471 are necessary for GSK’s Development obligations pursuant to this Article 4, includingany technology transfer required for API Compound manufacturing activities contemplated by Article 9, and establish a process for transferringcopies of such data and material to GSK (including, to the extent available, in appropriate electronic format) or provide means of access theretoreasonably acceptable to GSK.  4.5 LABA Activity Inside and Outside of the Collaboration. 4.5.1 The intent of the Parties in respect of the Pooled Compounds is that such Pooled Compounds remain exclusive to this Collaborationand, subject to Sections 4.5.2 — 4.5.4 and Article 14 below, no activity in respect of such Pooled Compounds shall be permitted outside of thisAgreement. 4.5.2 Subject to Article 14 and to Section 4.5.4, if prior to First Commercial Sale of a GSK Initially Pooled Compound or a GSK ReplacementCompound, Development of such compound is discontinued under this Agreement (“GSK Discontinued Compound”), all rights in respect of suchGSK Discontinued Compound shall revert in full to GSK and such GSK Discontinued Compound shall automatically fall outside of this Agreementexcept that (i) GSK shall thereafter be prohibited from carrying out any further clinical Development work or clinical activity in respect of such GSKDiscontinued Compound inside the Field for at least four (4) years after the termination of this Agreement, and (ii) for the avoidance of doubt, GSKshall pay to Theravance a royalty on Net Sales of any such GSK Discontinued Compound in accordance with Section 14.9. 4.5.3 Subject to Article 14 and Section 4.5.4, if prior to First Commercial Sale of a Theravance Compound, Development of such compoundis discontinued under this Agreement (“Theravance Discontinued Compound”), all rights in respect of such Theravance Discontinued Compoundshall revert in full to Theravance and such Theravance Discontinued Compound shall 19automatically fall outside of this Agreement except that (i) Theravance thereafter shall be prohibited from carrying out any further clinicalDevelopment work or clinical activity in respect of such Theravance Discontinued Compound inside the Field until after the termination of thisAgreement, and (ii) for the avoidance of doubt, Theravance shall pay to GSK a royalty on Net Sales of any such Theravance DiscontinuedCompound in accordance with Section 14.9.  4.5.4 Notwithstanding Sections 4.5.2 and 4.5.3, for so long as there is one Collaboration Product being Developed under this Agreement,neither Party shall carry out clinical Development inside the Field with any Long Acting B2 Adrenoceptor Agonist that is not a Pooled Compoundunder this Agreement; provided, however, that this restriction shall not apply to any compound or product (including new product line extensionsand/or re-formulation work) where the original compound or product is, as of the date of signature of this Agreement, already Commercialized.  ARTICLE 5COMMERCIALIZATION 5.1 Global Marketing Plans.  5.1.1 General. The Joint Project Committee shall be responsible for reviewing and approving a Global Marketing Plan for eachCollaboration Product (“Marketing Plan”). Each Marketing Plan shall define the goals and objectives for Commercializing the CollaborationProducts in the pertinent Calendar Year consistent with the applicable Development Plan.  5.1.2 Contents of Each Marketing Plan. The Marketing Plan for each Collaboration Product shall be prepared during the CalendarYear wherein, and where applicable, Phase III Studies for such Collaboration Product have commenced and shall be a rolling, three year plan,updated annually and shall contain at a minimum and as appropriate to current knowledge:  (a) Results of market research and strategy, including market size, dynamics, growth, customer segmentation, customer targeting,competitive analysis and global Collaboration Product positioning;  (b) Annual sales forecasts for Major Market Countries;  (c) For each major Market Country (as available): sales plans which will include target number of sales representatives, detailorder and target number of details  (d) Core, global advertising and promotion programs and strategies, including literature, media plans, symposia and speakerprograms; and  (e) Core Phase III/Phase IV Studies to be conducted  5.2 Obligations for Commercialization. GSK shall use Diligent Efforts to Commercialize the Collaboration Products.  5.3 Commercialization.  5.3.1 GSK Responsibility. GSK shall have the sole right and responsibility for Commercialization of Collaboration Products fordistribution and sale. GSK shall bear all costs  20and expenses associated with the Commercialization of Collaboration Products for sale or distribution.  (a) GSK shall have the sole right and responsibility to distribute, sell, record sales and collect payments for CollaborationProducts.  (b) GSK shall have the sole right and responsibility for establishing and modifying the terms and conditions with respect to thesale of Collaboration Products, including, without limitation, the price or prices at which the Collaboration Products will be sold, any discountapplicable to payments or receivables, and similar matters.  (c) GSK will be responsible for storage, order receipt, order fulfillment, shipping and invoicing of Collaboration Products.  5.3.2 Semi-Annual Reports.  GSK shall provide the Joint Project Committee reports semi-annually. Such reports shall set forth in summary form the results ofGSK’s Commercialization activities performed during such semi-annual period in the Major Markets.  5.3.3 Exports to the United States. To the extent permitted by Law, the Parties shall use Diligent Efforts to prevent theCollaboration Products distributed for sale in a particular Country other than the United States from being exported to the United States for sale.  ARTICLE 6FINANCIAL PROVISIONS 6.1 Signing Payment; Equity Investment; One-Time Fee.  6.1.1 Signing Payment. In partial consideration for the acquisition of license rights under the Theravance Patents and theTheravance Know-How by GSK under this Agreement, GSK shall on the Effective Date, pay to Theravance a non-creditable, non-refundableamount of Ten Million United States Dollars (U.S. $10,000,000).  6.1.2 Stock Purchase. On the Effective Date, GSK will purchase 4,000,000 shares of Theravance Series E Preferred Stock at a priceof U.S.$10.00 per share for total consideration of Forty Million United States Dollars (U.S. $40,000,000). Such purchase will be made pursuant to thePreferred Stock Purchase Agreement attached hereto as Schedule 6.1.2.  6.1.3 One-Time Fee for AMI-15471. Within thirty days following receipt by GSK of Theravance’s written notification of thedecision by Theravance to nominate AMI-15471 as a “development candidate,” and in further partial consideration for the acquisition of licenserights under the Theravance Patents and the Theravance Know-How by GSK under this Agreement, GSK shall pay to Theravance a non-creditable,non-refundable amount of Five Million United States Dollars (U.S.$5,000,000). AMI-15471 will be declared a development candidate whenTheravance (a) completes a study demonstrating lack of activity in the hERG assay (as per the Criteria in Schedule 1.19), and (b) establishes AMI-15471 in a stable crystalline form.  216.1.4 One-Time Fee for Each Theravance New Compound. Within thirty days following the acceptance by the Joint ProjectCommittee or the Joint Steering Committee of each of the two Theravance New Compounds to be contributed to the collaboration pursuant toSection 4.1, and in further partial consideration for the acquisition of license rights under the Theravance Patents and the Theravance Know-Howby GSK under this Agreement, GSK shall pay to Theravance a non-creditable, non-refundable amount of Five Million United States Dollars(U.S.$5,000,000) for each such Theravance New Compound.  6.2 Milestone Payments.  6.2.1 General. In further consideration of the covenants and agreements contained herein, the Parties shall also pay to each otherthe payments set forth below for each such Development milestone referred to therein (each, a “Development Milestone”); provided always thateach such payment shall be made only one time for each Collaboration Product regardless of how many times such Development Milestones areachieved for such Collaboration Product, and no payment shall be owed for a Development Milestone which is not reached (except that, uponachievement of a Development Milestone for a particular Collaboration Product, any previous Development Milestone for that CollaborationProduct for which payment was not made shall be deemed achieved and payment therefore shall be made); provided further that, in the event thatmore than one Development Milestone is achieved with respect to the same Collaboration Product at one time, then all applicable payments underSection 6.2 shall be made. For example, if TD-3327 as a single-agent Collaboration Product and a LABA/ICS Combination Product that contains TD-3327 are approved in the same Marketing Authorization Approval, then in addition to the relevant milestone for the single-agent TD-3327Collaboration Product, the relevant milestone for the LABA/ICS Combination Product shall be paid simultaneously. In the event of termination ofdevelopment of a particular Collaboration Product and an alternative Collaboration Product replaces such Terminated Collaboration Product thenmilestone payments for such replacement compound shall not be paid in respect of milestones already achieved by the Terminated CollaborationProduct. For example, if development of TD-3327 is terminated and TD-3327 is replaced by a another Collaboration Product which contains aTheravance compound, milestone payments for such replacement compound will only commence for milestones achieved that have not alreadybeen achieved by TD-3327.  6.2.2 GSK to Theravance. GSK shall make the following milestone payments to Theravance upon the achievement of the indicatedDevelopment Milestone for the first Collaboration Product in which the Long-Acting β2 Adrenoceptor Agonist is a Theravance Compound, and forthe first LABA/ICS Combination Product in which the Long-Acting β2 Adrenoceptor Agonist is a Theravance Compound: 
        
Milestone
 
 
 
Amount
 
 
 
 
 
 
 
Initiation of Phase I *
 
 
 
U.S.$10 Million
 
Initiation of Phase IIa**
 
 
 
U.S.$10 Million
 
Initiation of Phase IIb**
 
 
 
U.S.$5 Million
 
 
 
 
 
 
 
Initiation of Phase III
 
 
 
U.S.$25 Million
 
 22Milestone
 
 
 
Amount
 
 
 
 
 
 
 
Registration
 
 
 
 
 
U.S.
 
 
 
U.S.$30 Million
 
Europe
 
 
 
U.S.$15 Million
 
Japan
 
 
 
U.S.$10 Million
 
 
 
 
 
 
 
Launch
 
 
 
 
 
U.S.
 
 
 
U.S.$30 Million
 
Europe
 
 
 
U.S.$15 Million
 
Japan
 
 
 
U.S.$10 Million
 
 
 
 
 
 
 
Annual Worldwide Net Sales overU.S.$500 Million for single agentCollaboration Product
 
 
 
U.S.$10 Million per year for first five years for single agentCollaboration Product
 
 
 
 
 
 
 
Annual Worldwide Net Sales overU.S.$500 Million for LABA/ICSCombination Product
 
 
 
U.S.$20 Million per year for first five years for LABA/ICSCombination Product
 
 
* GSK will make a Phase I milestone payment for both TD-3327 and AMI-15471. The Phase I milestone for TD-3327 is defined as initiationof the methacholine challenge portion of the Phase I Study in normal volunteers and will trigger a payment of U.S. $10 Million. The Phase Imilestone for AMI-15471 is defined as initiation of the first Phase I Study in normal volunteers and will trigger a payment of U.S. $10Million. **Phase IIa is defined as initiation of the first single dose study in patients where such study is statistically powered for efficacy based onFEV. Phase IIb is defined as initiation of the first four (4) week dosing, safety and efficacy study in patients. Other Combination Products that contain a Long-Acting β2 Adrenoceptor Agonist that is a Theravance Compound are not subject to milestonepayments by GSK only if all milestone payments through launch have otherwise been made to Theravance from any Collaboration Product as botha single-agent and as a combination product. The Parties intend that if the collaboration is successful in launching at least two CollaborationProducts that contain a Theravance Compound, Theravance be paid the applicable milestones through launch for two products. If GSK, either individually or as a member of the Joint Steering Committee or Joint Project Committee, discontinues the Development of a singleagent Collaboration Product that is a Theravance Compound for reasons other than Technical Failure, and such compound is the LABA in aLABA/ICS Combination Product or in an Other Combination Product, it will compensate Theravance for the unpaid milestone payments otherwisedue to Theravance under Section 6.2.2 by adding the unpaid milestone amounts for such discontinued single agent product onto thecorresponding milestone payments for the relevant Combination Product.  6.2.3 Theravance to GSK. Theravance shall make the following milestone payments to GSK upon the achievement of the indicatedDevelopment Milestone for the first Collaboration Product in which the Long-Acting β2 Adrenoceptor Agonist is a GSK Compound 23
1and for the first LABA/ICS Combination Product in which the Long-Acting β2 Adrenoceptor Agonist is a GSK Compound: 
            
Milestone
 
 
 
Amount
 
 
 
 
 
 
 
Registration
 
 
 
 
 
US
 
 
 
U.S.$30 Million
 
Europe
 
 
 
U.S.$15 Million
 
Japan
 
 
 
U.S.$10 Million
 
 
 
 
 
 
 
Launch
 
 
 
 
 
US
 
 
 
U.S.$30 Million
 
Europe
 
 
 
U.S.$15 Million
 
Japan
 
 
 
U.S.$10 Million
 
 Other Combination Products that contain a Long-Acting β2 Adrenoceptor Agonist that is a GSK Compound are not subject to milestonepayments by Theravance only if all milestone payments through launch have otherwise been made to GSK from any Collaboration Product as botha single-agent and as a combination product. The Parties intend that if the collaboration is successful in launching at least two CollaborationProducts that contain a GSK Compound, GSK be paid the applicable milestones through launch for two products.  6.2.4 Notification and Payment. In the event a Party achieves a Development Milestone, such Party shall promptly, but in noevent more than ten (10) days after the achievement of each such Development Milestone, notify the other Party in writing of the achievement ofsame. For all Development Milestones achieved, each Party shall promptly, but in no event more than thirty (30) days after notification of theachievement of each such Development Milestone, remit payment to the other Party for such Development Milestone.  6.3 Payment of Royalties on Net Sales.  6.3.1 Royalty on Single-Agent Collaboration Products and LABA/ICS Combination Products. Within twenty (20) days after the end of each Calendar Quarter , GSK shall pay Theravance royalty payments based on Net Sales in such CalendarQuarter during the Term as follows: 
    
On total Annual Worldwide Net Sales up to and including U.S. $3 Billion:
 
 
 
15
 
%
 
 
 
 
 
 
 
 
 
On total Annual Worldwide Net Sales greater than U.S. $3 Billion:
 
 
 
5
 
%
 
 it being understood that Net Sales of a single agent Collaboration Product will be combined with Net Sales of a LABA/ICS Combination Product forpurposes of the foregoing royalty calculation. The quarterly royalty payments made under this Section 6.3.1 may be based on estimated Net Sales. Within thirty (30) days after the end of eachCalendar Quarter, GSK shall calculate the actual amount of Net Sales for the previous Calendar Quarter and either credit or debit the differencebetween such actual and projected amount on the succeeding Calendar Quarter’s royalty payment to Theravance. As soon as practical followingthe end of each Calendar Month, but in no event later than the 10business day of the following month, GSK will provide Theravance with anestimate of Net Sales for such Calendar Month. 24
thThe royalties payable under this Section 6.3 shall be paid on a Country-by-Country basis from the date of first commercial sale of eachCollaboration Product in a particular Country for the Term of the Collaboration.  6.3.2 Royalty Adjustment. The 15% royalty payable on the first U.S. $3 Billion of total annual worldwide Net Sales under thisSection 6.3 shall be reduced to 12% if all of the following occur: (i) all Theravance Compounds are discontinued by the collaboration for TechnicalFailure; (ii) Theravance only contributes one Theravance New Compound to the collaboration within 18 months following the Effective Date; and(iii) the Collaboration Product upon which the royalty is payable contains a LABA that is one of the GSK Initially Pooled Compounds. The 15%royalty payable on the first U.S. $3 Billion of total annual worldwide Net Sales under this Section 6.3 shall be reduced to 10% if all of the followingoccur: (i) all Theravance Compounds are discontinued by the collaboration for Technical Failure; (ii) Theravance fails to contribute any TheravanceNew Compound to the collaboration within 18 months following the Effective Date; and (iii) the Collaboration Product upon which the royalty ispayable contains a LABA that is one of the GSK Initially Pooled Compounds. Nothing in the foregoing shall affect other royalties owed under thisAgreement.  6.3.3 Royalties on Other Collaboration Products Launched After the LABA/ICS Combination Product. For any OtherCollaboration Product launched after the LABA/ICS Combination Product, GSK shall within twenty (20) days after the end of each CalendarQuarter, pay Theravance royalty payments based on Net Sales in such Calendar Quarter during the Term as follows: 
          
Annual Net Sales
 
 
 
PercentageRoyalty
 
 
 
 
 
 
 
 
 
 
 
Up to U.S.$750 Million
 
 
 
6.5
 
%
 
 
 
 
 
 
 
 
 
Additional Net Sales up to U.S.$1.25 Billion
 
 
 
8.0
 
%
 
 
 
 
 
 
 
 
 
Additional Net Sales up to U.S.$2.25 Billion
 
 
 
9.0
 
%
 
 
 
 
 
 
 
 
 
Net Sales exceeding U.S.$2.25 Billion
 
 
 
10.0
 
%
 
 For the avoidance of doubt, the Parties agree that the royalty set forth in this Section 6.3.3 shall only be effective if GSK has launched and is sellinga LABA/ICS Combination Product that is subject to the royalties under Section 6.3.1. If GSK is not selling a LABA/ICS Combination Product, thenthe royalty set forth in Section 6.3.1 shall apply to the first Other Combination Product launched by GSK, provided such Other CombinationProduct does not contain a product in-licensed by GSK; if such Other Combination Product contains a product in-licensed by GSK, then theroyalty payable to Theravance will be reduced by 50% of any running royalties paid to a Third Party, provided that in no case will the royaltypayable to Theravance be less than set forth in this Section 6.3.3. 256.4 Royalty Responsibilities; Net Sales Reports.  6.4.1 Payments to Third Parties.  (a) If, as a result of a settlement approved by both Parties or as a result of a final non-appealable judgment, GSK is required to payany amounts to a Third Party directly because using or selling a Theravance Compound is found to infringe the rights of such Third Party, GSKshall deduct fifty percent (50%) of any such amount paid to such Third Party from the royalties otherwise due Theravance for the CollaborationProduct containing such Theravance Compound, provided in no event shall such reduction reduce the royalties otherwise payable to Theravanceduring any Calendar Year by more than fifty percent (50%); provided, further, that any excess deduction shall be carried over into subsequent yearsof this Agreement until the full deduction is taken.  (b) GSK shall pay any amounts owed to a Third Party as a result of the use of GSK Patents or GSK Know-How with respect tosales of Collaboration Products and shall not deduct any of such amounts from the royalties due Theravance. The foregoing is subject to Section6.3.3.  6.4.2 Net Sales Report. Within thirty (30) days after the end of each Calendar Quarter, GSK shall submit to Theravance a writtenreport setting forth Net Sales in the Territory on a Country-by-Country and Collaboration Product-by-Collaboration Product basis during suchCalendar Quarter, total royalty payments due Theravance, relevant market share data and any payments made to any Third Party pursuant toSection 6.4.1(a) (each a “Net Sales Report”).  6.5 GAAP. All financial terms and standards defined or used in this Agreement for sales or activities occurring in the United States shall begoverned by and determined in accordance with United States generally accepted accounting principles, consistently applied. Except as otherwiseset forth herein, all financial terms and standards defined or used in this Agreement for sales or activities occurring outside the United States shallbe governed by and determined in accordance with United Kingdom generally accepted accounting principles, consistently applied.  6.6 Currencies. Monetary conversion from the currency of a foreign country in which Collaboration Product is sold into US Dollars shall becalculated in accordance with either (a) the methodology referred to in GSK’s then current Corporate Finance Reporting Policy or (b) as otherwisemay be mutually agreed by the Parties. The following summarizes GSK’s current methodology applied in accordance with its current CorporateFinance Reporting System: the cumulative year-to-date Average Rates are calculated by determining the average of (i) the preceding 31st DecemberSpot Rate plus (ii) the Closing Spot Rates of the relevant months to date using the exact figures provided by the Reuters 2000 download. (By wayof example, the Average Rate for the five months from January, 2002 to May, 2002 would be computed by taking the sum of the Spot Rates for thepreceding 31st December, 2001, plus the month-end Spot Rates for the five months to May, 2002, divided by six). 6.7 Manner of Payments. All sums due to either Party under this Section 6 shall be payable in United States Dollars by bank wire transfer inimmediately available funds to such bank account(s) as each of GSK and Theravance shall designate. GSK shall notify Theravance as to the dateand amount of any such wire transfer to Theravance at least five (5) Business Days prior to such transfer. Theravance shall notify GSK as to thedate and amount of any such wire transfer to GSK at least five (5) Business Days prior to such transfer. 266.8 Interest on Late Payments. If either Theravance or GSK shall fail to make a timely payment pursuant to this Article 6, any such paymentthat is not paid on or before the date such payment is due under this Agreement shall bear interest, to the extent permitted by applicable law, at theaverage one-month London Inter-Bank Offering Rate (LIBOR) for the United States Dollar as reported from time to time in The Wall Street Journal,effective for the first date on which payment was delinquent and calculated on the number of days such payment is overdue or, if such rate is notregularly published, as published in such source as the Joint Steering Committee agrees.  6.9 Tax Withholding.  6.9.1 Any taxes, levies or other duties (“Taxes”) paid or required to be withheld under the appropriate local tax laws by one of theParties (“Withholding Party”) on account of monies payable to the other Party under this Agreement shall, subject to Sections 6.9.2 and 6.9.3, bededucted from the amount of monies otherwise payable to the other Party under this Agreement. The Withholding Party shall secure and send tothe other Party within a reasonable period of time proof of any such Taxes paid or required to be withheld by Withholding Party for the benefit ofthe other Party.  6.9.2 If GSK or any GSK Affiliate is or becomes liable to withhold any taxes from payments made to Theravance under Sections6.1 and 6.2 of this Agreement, then GSK shall pay to Theravance an amount equal to the amount GSK or the applicable GSK Affiliate owes to therelevant tax authority provided always that if Theravance is able to obtain credit for any taxes withheld (“Creditable Taxes”) against any liability totax either in the year in which the receipt is taxable or any preceding years, Theravance shall reimburse to GSK an amount equivalent to theCreditable Taxes. Theravance shall provide GSK with such reasonable evidence as GSK may reasonably request to determine whether the taxes arecreditable against taxes payable by Theravance.  6.9.3 If GSK or any GSK Affiliate is or becomes liable to withhold any taxes from payments made to Theravance under Section 6.3,then such taxes may be withheld by GSK or the applicable GSK Affiliate up to a limit of five percent (5%) of the relevant payment. GSK shall pay toTheravance an amount equal to the amount GSK owes to the relevant tax authority in excess of such five percent (5%) provided always that ifTheravance is able to obtain credit for any taxes withheld (“Creditable Taxes”) against any liability to tax either in the year in which the receipt istaxable or any preceding years, Theravance shall reimburse to GSK an amount equivalent to the Creditable Taxes. Theravance shall provide GSKwith such reasonable evidence as GSK may reasonably request to determine whether the taxes are creditable against taxes payable by Theravance.  6.10 Financial Records; Audits. GSK shall keep, and shall cause its Affiliates and sublicensees to keep, such accurate and completerecords of Net Sales as are necessary to determine the amounts due to Theravance under this Agreement and such records shall be retained byGSK or any of its Affiliates or sublicensees (in such capacity, the “Recording Party”) for at least the three preceding Calendar Years to which theNet Sales relate. During normal business hours and with reasonable advance notice to the Recording Party, such records shall be made available forinspection, review and audit, at the request and expense of Theravance, by an independent certified public accountant, or the local equivalent,appointed by Theravance and reasonably acceptable to the Recording Party for the sole purpose of verifying the accuracy of the Recording Party’saccounting reports and payments made or to be made pursuant to this 27Agreement; provided, however that such audits may not be performed by Theravance more than once per Calendar Year. Such accountants shallbe instructed not to reveal to Theravance the details of its review, except for (i) such information as is required to be disclosed under thisAgreement and (ii) such information presented in a summary fashion as is necessary to report the accountants’ conclusions to Theravance, and allsuch information shall be deemed Confidential Information of the Recording Party; provided, however, that in any event such information may bepresented to Theravance in a summary fashion as is necessary to report the accountants’ conclusions. All costs and expenses incurred inconnection with performing any such audit shall be paid by Theravance unless the audit discloses at least a five percent (5%) shortfall, in whichcase the Recording Party will bear the full cost of the audit for such Calendar Year. Theravance will be entitled to recover any shortfall in paymentsdue to it as determined by such audit, plus interest thereon calculated in accordance with Section 6.8, or alternatively shall have the right to offsetand deduct any such shortfall in payments due to it against payments Theravance is otherwise required to make to the Reporting Party under thisAgreement. The documents from which were calculated the sums due under this Article 6 shall be retained by the relevant Party during the Term.  ARTICLE 7PROMOTIONAL MATERIALS AND SAMPLES 7.1 Promotional Materials.  7.1.1 Review of Core Promotional Materials. Subject to applicable Law, in accordance with the direction of the Joint ProjectCommittee, the Parties will jointly, through consultation and with the assistance of each other, review the core Promotional Materials. The relevantlegal or regulatory personnel of each Party shall have the opportunity to review and comment on all such core Promotional Materials prior to useand such comments shall be considered by the Joint Project Committee in the review of such core Promotional Materials.  7.1.2 Markings of Promotional Materials. To the extent required by applicable Law, and further to the extent reasonablypracticable, all Promotional Materials will indicate the contribution of the license from Theravance for the Collaboration Products. Subject to theforegoing, the Theravance Housemark and the GSK Housemark shall both be given exposure and prominence on all promotional materials, labelling,package inserts or outserts and packaging for the Collaboration Products.  7.2 Samples. Packaging, package inserts and outserts, Sample labels and labeling shall each contain reference to Theravance and GSKindicating, in the case of Theravance, the contribution of the license from Theravance for the Collaboration Products, if appropriate, and as may berequired under applicable FDA rules and regulations.  7.3 Statements Consistent with Labeling. GSK shall ensure that its sales representatives detail the Collaboration Products in a fair andbalanced manner and consistent with the requirements of the Federal Food, Drug and Cosmetic Act of the United States, as amended, including,but not limited to, the regulations at 21 C.F.R. (S) 202 in the United States.  7.4 Implications of Change in Control in Theravance. In the event that there is a Change in Control of Theravance and the referencescontemplated in Sections 7.1.2 and 7.2 are no longer made to “Theravance,”, then other than to the extent required by applicable Law, GSK 28shall have the right, not to be unreasonably exercised, to terminate its obligations under Sections 7.1 and 7.2. ARTICLE 8REGULATORY MATTERS 8.1 Governmental Authorities. GSK shall be solely responsible for communicating with Governmental Authorities and will keep Theravanceinformed, through the Joint Project Committee and Joint Steering Committee, of any significant issue or issues arising therefrom. 8.2 Filings. GSK shall also be solely responsible for filing drug approval applications for Collaboration Products and will use DiligentEfforts in seeking appropriate approvals in those Countries of the Territory for Collaboration Products as GSK reasonably determines and sees fit.Such regulatory documents for each filing shall be centralized and held at the offices of GSK. Theravance shall provide such reasonable assistanceas may be required by GSK where liaison between the Parties is, or may be, necessary to enable GSK to fulfill its responsibilities hereunder. GSKshall be responsible for maintaining the Approvals obtained under this Section and shall solely own all such Approvals in the Territory. GSK shallbe fully responsible for bearing all costs and expense associated with undertaking and completing said registration activities in the Territory,including but not limited to the costs of preparing and prosecuting applications for such Approvals and fees payable to regulatory agencies inobtaining and maintaining same. 8.3 Exchange of Drug Safety Information. Subject to the second sentence of this Section 8.3, GSK shall be responsible for recording,investigating, summarizing, notifying, reporting and reviewing all Adverse Drug Experiences in accordance with Law and shall require that itsAffiliates (i) adhere to all requirements of applicable Laws which relate to the reporting and investigation of Adverse Drug Experiences, and (ii) keepthe Joint Project Committee apprised on a regular basis of such matters arising therefrom. The foregoing shall be subject to any of Theravance’sown clinical safety obligations mandated by Law as a result of its ongoing Development activity related to TD-3327 (as such activity is morespecifically referred to in Article 4) and, in acknowledgement of this, it is thereby contemplated that the Parties’ respective clinical safety groupsmay need to discuss and agree, at the appropriate time after the Effective Date, appropriate safety data exchange procedures related to same.  8.4 Recalls or Other Corrective Action. Each Party shall, as soon as practicable, notify the other Party of any recall information received byit in sufficient detail to allow the Parties to comply with any and all applicable Laws. GSK shall promptly notify Theravance of any material actionsto be taken by GSK with respect to any recall or market withdrawal or other corrective action related to a Collaboration Product prior to such actionto permit Theravance a reasonable opportunity to consult with GSK with respect thereto. All costs and expenses with respect to a recall, marketwithdrawal or other corrective action shall be borne by GSK unless such recall, market withdrawal or other corrective action was due solely to thenegligence, willful misconduct or breach of this Agreement by Theravance. GSK shall have sole responsibility for and shall make all decisions withrespect to any recall, market withdrawals or any other corrective action related to the Collaboration Products.  8.5 Events Affecting Integrity or Reputation. During the Term, the Parties shall notify each other immediately of any circumstances ofwhich they are aware and which could impair the integrity and reputation of the Collaboration Products or if a Party is threatened by the 29unlawful activity of any Third Party in relation to the Collaboration Products, which circumstances shall include, by way of illustration, deliberatetampering with or contamination of the Collaboration Products by any Third Party as a means of extorting payment from the Parties or anotherThird Party. In any such circumstances, the Parties shall use Diligent Efforts to limit any damage to the Parties and/or to the Collaboration Products.The Parties shall promptly call a Joint Steering Committee meeting to discuss and resolve such circumstances. ARTICLE 9ORDERS; SUPPLY AND RETURNS 9.1 Orders and Terms of Sale. Except as otherwise expressly stated in this Agreement, GSK shall have the sole right to (i) receive, acceptand fill orders for the Collaboration Products, (ii) control invoicing, order processing and collection of accounts receivable for the CollaborationProducts sales, (iii) record the Collaboration Products sales in its books of account, and (iv) establish and modify the commercial terms andconditions with respect to the sale and distribution of the Collaboration Products, including without limitation matters such as the price at whichthe Collaboration Products will be sold and whether any discounts, rebates or other deductions should be made, paid or allowed.  9.2 Supply of API Compound and Formulated Collaboration Product for Development.  9.2.1 Supply of API Compound for Development. Subject to the terms and conditions of this Agreement, GSK shall conduct orhave conducted any chemical process development required to develop a commercially acceptable process for making API Compound and obtainsupply for worldwide requirements of API Compound. Notwithstanding the foregoing, Theravance may transfer to GSK, at cost, whatever supply ithas on hand of TD-3327 API and/or AMI-15471 API and/or intermediate materials for API manufacture, within specification as of the Effective Date,such cost not to exceed U.S. $1,230,000. API Compound requirements for Development activities shall be set forth in the relevant Development Planand shall be periodically updated by the Joint Project Committee.  9.2.2 Supply of Formulated Collaboration Products for Development. Subject to the terms and conditions of this Agreement, GSKshall obtain supply for worldwide requirements of formulated Collaboration Products. Notwithstanding the foregoing, Theravance agrees totransfer to GSK whatever supply it has on hand of formulated TD-3327, within specification, at cost as of the Effective Date, such cost not toexceed U.S. $175,000. Formulated Collaboration Product requirements for Development activities shall be set forth in the relevant Development Planand shall be periodically updated by the Joint Project Committee.  9.3 Supply of API Compound for Commercial Requirements. Subject to the terms and conditions of this Agreement, GSK shall obtainsupply of API Compound. A forecast for API Compound requirements for Commercialization of the Collaboration Products shall be prepared andperiodically updated by the Joint Project Committee and coordinated with the applicable Marketing Plans for Collaboration Products.  9.4 Supply of Collaboration Products for Commercialization. Subject to the terms and conditions of this Agreement, GSK shall obtainsupply of the commercial requirements of formulated, packaged and labeled Collaboration Products. Such formulated, packaged and labeledCollaboration Products shall be manufactured and supplied in accordance with all 30applicable Laws and current Good Manufacturing Practices. GSK shall be solely responsible for secondary manufacture, packaging and labeling ofthe Collaboration Product.  9.5 Inventories. GSK and its Product Suppliers shall maintain an inventory of API Compound and Collaboration Products in accordancewith their normal practices and so as to ensure fulfillment of its respective supply obligations herein.  ARTICLE 10CONFIDENTIAL INFORMATION 10.1 Confidential Information. Each of GSK and Theravance shall keep all Confidential Information received from the other Party with thesame degree of care it maintains the confidentiality of its own Confidential Information. Neither Party shall use such Confidential Information forany purpose other than in performance of this Agreement or disclose the same to any other Person other than to such of its agents who have aneed to know such Confidential Information to implement the terms of this Agreement or enforce its rights under this Agreement. A ReceivingParty shall advise any agent who receives such Confidential Information of the confidential nature thereof and of the obligations contained in thisAgreement relating thereto, and the Receiving Party shall ensure that all such agents comply with such obligations as if they had been a Partyhereto. Upon termination of this Agreement, the Receiving Party shall return or destroy all documents, tapes or other media containing ConfidentialInformation of the Disclosing Party that remain in the Receiving Party’s or its agents’ possession, except that the Receiving Party may keep onecopy of the Confidential Information in the legal department files of the Receiving Party, solely for archival purposes. Such archival copy shall bedeemed to be the property of the Disclosing Party, and shall continue to be subject to the provisions of this Article 10. Notwithstanding anythingto the contrary in this Agreement, the Receiving Party shall have the right to disclose this Agreement or Confidential Information providedhereunder if, in the reasonable opinion of the Receiving Party’s legal counsel, such disclosure is necessary to comply with the terms of thisAgreement, or the requirements of any Law. Where possible, the Receiving Party shall notify the Disclosing Party of the Receiving Party’s intent tomake such disclosure pursuant to the provision of the preceding sentence sufficiently prior to making such disclosure so as to allow the DisclosingParty adequate time to take whatever action the Disclosing Party may deem to be appropriate to protect the confidentiality of the information. TheReceiving Party will cooperate reasonably with the Disclosing Party’s efforts to protect the confidentiality of the information. Each Party will beliable for breach of this Article 10 by any of its Affiliates.  10.2 Permitted Disclosure and Use. Notwithstanding Section 10.1, a Party may disclose Confidential Information belonging to the otherParty only to the extent such disclosure is reasonably necessary to: (a) obtain Marketing Authorization of a Collaboration Product; (b) enforce theprovisions of this Agreement; or (c) comply with Laws. If a Party deems it necessary to disclose Confidential Information of the other Partypursuant to this Section 10.2, such Party shall give reasonable advance notice of such disclosure to the other Party to permit such other Partysufficient opportunity to object to such disclosure or to take measures to ensure confidential treatment of such information. The Receiving Partywill cooperate reasonably with the Disclosing Party’s efforts to protect the confidentiality of the information.  10.3 Publications. Subject to any Third Party rights existing as of the Effective Date, each Party shall submit to the Joint Project Committeefor review and approval all proposed academic, scientific and medical publications and public presentations relating to a Collaboration Product orany research or Development activities under this Agreement for review in connection 31with preservation of Patent Rights, and trade secrets and/or to determine whether Confidential Information should be modified or deleted from theproposed publication or public presentation. Written copies of such proposed publications and presentations shall be submitted to the JointProject Committee no later than sixty (60) days before submission for publication or presentation and the Joint Project Committee shall provide itscomments with respect to such publications and presentations within ten (10) Business Days of its receipt of such written copy. The review periodmay be extended for an additional sixty (60) days if a representative of the non-publishing Party on the Joint Project Committee can demonstrate areasonable need for such extension including, but not limited to, the preparation and filing of patent applications. By mutual agreement of theParties, this period may be further extended. The Parties will each comply with standard academic practice regarding authorship of scientificpublications and recognition of contribution of other parties in any publications relating to the Collaboration Products or any research orDevelopment activities under this Agreement.  10.4 Public Announcements. Except as may be expressly permitted under Section 10.3 or required by applicable Laws and subject to thefinal two sentences of this Section 10.4, neither Party will make any public announcement of any information regarding this Agreement, theCollaboration Products or any research or Development activities under this Agreement without the prior written approval of the other Party, whichapproval shall not be withheld unreasonably. Once any statement is approved for disclosure by the Parties or information is otherwise made publicin accordance with the preceding sentence, either Party may make a subsequent public disclosure of the contents of such statement without furtherapproval of the other Party. Notwithstanding the foregoing, within sixty (60) days following the Effective Date, appropriate representatives of theParties will meet and agree upon a process and principles for reaching timely consensus on how the Parties will make public disclosure concerningthis Agreement, the Collaboration Products or any research and Development activities under this Agreement.  10.5 Confidentiality of This Agreement. The terms of this Agreement shall be Confidential Information of each Party and, as such, shall besubject to the provisions of this Article 10. Either party may disclose the terms of this Agreement if, in the opinion of its counsel, such disclosure isrequired by Law. In such event, the disclosing Party will seek appropriate confidentiality of those portions of the Agreement for which confidentialtreatment is typically permitted by the relevant Governmental Authority.  10.6 Termination of Prior Confidentiality Agreements. Except as expressly provided in this Section 10.6, this Agreement supercedes theMutual Confidential Disclosure Agreement (the “MCDA”) between the Parties dated April 10, 2002. Except as expressly provided in this Section10.6 and in Paragraph 8 of the Confidentiality Agreement between the Parties dated October 2, 2002 (the “Patent CDA”), this Agreementsupersedes the Patent CDA. Except as set forth in Paragraph 8 of the Patent CDA, all information disclosed pursuant to the MCDA and the PatentCDA shall be subject to the provisions of this Article 10.  10.7 Survival. The obligations and prohibitions contained in this Article 10 shall survive the expiration or termination of this Agreement fora period of ten (10) years.  32ARTICLE 11REPRESENTATIONS AND WARRANTIES; COVENANTS 11.1 Mutual Representations and Warranties. Theravance and GSK each represents and warrants to the other as of the Effective Date that:  11.1.1 Such Party (a) is a company duly organized, validly existing, and in good standing under the Laws of its incorporation; (b)is duly qualified as a corporation and in good standing under the Laws of each jurisdiction where its ownership or lease of property or the conductof its business requires such qualification, where the failure to be so qualified would have a material adverse effect on its financial condition or itsability to perform its obligations hereunder; (c) has the requisite corporate power and authority and the legal right to conduct its business as nowconducted and hereafter contemplated to be conducted; (d) has or will obtain all necessary licenses, permits, consents, or approvals from or by,and has made or will make all necessary notices to, all Governmental Authorities having jurisdiction over such Party, to the extent required for theownership and operation of its business, where the failure to obtain such licenses, permits, consents or approvals, or to make such notices, wouldhave a material adverse effect on its financial condition or its ability to perform its obligations hereunder; and (e) is in compliance with its charterdocuments;  11.1.2 The execution, delivery and performance of this Agreement by such Party and all instruments and documents to bedelivered by such Party hereunder (a) are within the corporate power of such Party; (b) have been duly authorized by all necessary or propercorporate action; (c) do not conflict with any provision of the charter documents of such Party; (d) will not, to the best of such Party’s knowledge,violate any law or regulation or any order or decree of any court of governmental instrumentality; (e) will not violate or conflict with any terms ofany indenture, mortgage, deed of trust, lease, agreement, or other instrument to which such Party is a party, or by which such Party or any of itsproperty is bound, which violation would have a material adverse effect on its financial condition or on its ability to perform its obligationshereunder;  11.1.3 This Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and binding obligationof such Party, enforceable against such Party in accordance with its terms, except as such enforceability may be limited by applicable insolvencyand other Laws affecting creditors’ rights generally, or by the availability of equitable remedies; and  11.1.4 All of its employees, officers, and consultants have executed agreements or have existing obligations under law requiringassignment to such Party of all Inventions made by such individuals during the course of and as the result of their association with such Party, andobligating such individuals to maintain as confidential such Party’s Confidential Information.  11.1.5 Nothing contained in this Agreement shall give a Party the right to use the Confidential Information received from the otherParty in connection with any activity other than Development and Commercialization of a Pooled Compound or Collaboration Product consistentwith this Agreement.  11.1.6 As soon as practicably possible after the Effective Date, the Parties will each deliver to each other a schedule listing (i) inthe case of GSK, GSK Patents as of the date of signature of this Agreement and (ii) in the case of Theravance, Theravance Patents as of the date ofsignature of this Agreement.  3311.2 Additional GSK Representations and Warranties. GSK further represents, warrants and covenants to Theravance that:  11.2.1 It has utilized its own scientific, marketing and distribution expertise and experience to analyze and evaluate both thescientific and commercial value of this collaboration and has solely relied on such analysis and evaluations in deciding to enter into thisAgreement;  11.2.2 Neither GSK nor any of its Affiliates is a party to or otherwise bound by any oral or written contract or agreement that willresult in any Person obtaining any interest in, or that would give to any Person any right to assert any claim in or with respect to, any of GSK’srights granted under this Agreement;  11.2.3 There is no claim or demand of any person or entity pertaining to, or any proceeding which is pending or, to the knowledgeof GSK, threatened, that challenges the rights of Theravance in respect of any GSK Know-How or GSK Patents, or that claims that any defaultexists under any license with respect to any GSK Know-How or GSK Patents to which GSK is a party, except where such claim, demand orproceeding would not materially and adversely affect the ability of GSK to carry out its obligations under this Agreement; and  11.2.4 Having carried out and completed diligent searches in relation to the GSK Patents, and other than as disclosed toTheravance’s counsel by GSK’s counsel, GSK is not aware, nor has been made aware, of any conflict or likely future conflict with the intellectualproperty rights of any Third Party with respect to GSK Patents.  11.3 Additional Theravance Representations and Warranties. Theravance further represents and warrants to GSK as of the Effective Datethat:  11.3.1 Having carried out and completed diligent searches in relation to the Theravance Patents, and other than as disclosed toGSK’s counsel by Theravance’s counsel, Theravance is not aware, nor has been made aware, of any conflict or likely future conflict with theintellectual property rights of any Third Party with respect to Theravance Patents.  Theravance has not received notice from any Third Party of a claim that an issued patent of such Third Party would be infringedby the manufacture, distribution, marketing or sale of the Collaboration Products under this Agreement;  11.3.2 To Theravance’s knowledge, the Theravance Patents are not subject to any pending or any threatened re-examination,opposition, interference or litigation proceedings;  11.3.3 Theravance has not received notice from any Third Party of a claim asserting the invalidity, misuse, unregisterability orunenforceability of any of the Theravance Patents, or challenging its right to use or ownership of any of the Theravance Patents or the TheravanceKnow-How, or making any adverse claim of ownership thereof;  11.3.4 Theravance has not received notice from any Third Party that any trade secrets or other intellectual property rights of suchThird Party would be misappropriated by the development and reduction to practice of the Theravance Patents and Theravance Know-How; and 3411.3.5 Theravance has, up to and including the Effective Date, furnished GSK with all material information requested by GSKconcerning the quality, toxicity, safety and/or efficacy concerns that may materially impair the utility and/or safety of the Compound orCollaboration Products.  11.4 Covenants. Each Party hereby covenants and agrees during the Term that it shall carry out its obligations or activities hereunder inaccordance with (i) the terms of this Agreement and (ii) all applicable Laws.  11.5 Disclaimer of Warranty. Subject to the specific warranties and representations given under Sections 11.1 through and including 11.3,nothing in this Agreement shall be construed as a warranty or representation by either Party (i) that any Collaboration Product made, used, sold orotherwise disposed of under this Agreement is or will be free from infringement of patents, copyrights, trademarks, industrial design or otherintellectual property rights of any Third Party, (ii) regarding the effectiveness, value, safety, non-toxicity, patentability, or non-infringement of anypatent technology, the Collaboration Products or any information or results provided by either Party pursuant to this Agreement or (iii) that anyCollaboration Product will obtain Marketing Authorization or appropriate pricing approval. Each Party explicitly accepts all of the same asexperimental and for development purposes, and without any express or implied warranty from the other Party. EXCEPT AS OTHERWISEEXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES, AND RENOUNCES ANYWARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FORA PARTICULAR PURPOSE.   ARTICLE 12INDEMNIFICATION 12.1 Indemnification by GSK. Subject to Sections 12.4 and 13.2, GSK shall defend, indemnify and hold harmless Theravance and itsAffiliates and each of their officers, directors, shareholders, employees, successors and assigns from and against all Claims of Third Parties, and allassociated Losses, to the extent arising out of (a) GSK’s negligence or willful misconduct in performing any of its obligations under thisAgreement, (b) a breach by GSK of any of its representations, warranties, covenants or agreements under this Agreement, or (c) the manufacture,use, handling, storage, marketing, sale, distribution or other disposition of Collaboration Products by GSK, its Affiliates, agents or sublicensees,except to the extent such losses result from the negligence or willful misconduct of Theravance.  12.2 Indemnification by Theravance. Subject to Sections 12.4 and 13.2, Theravance shall defend, indemnify and hold harmless GSK and itsAffiliates and each of their officers, directors, shareholders, employees, successors and assigns from and against all Claims of Third Parties, and allassociated Losses, to the extent arising out of (a) Theravance’s negligence or willful misconduct in performing any of its obligations under thisAgreement, or (b) a breach by Theravance of any of its representations, warranties, covenants or agreements under this Agreement. 3512.3 Procedure for Indemnification.  12.3.1 Notice. Each Party will notify promptly the other in writing if it becomes aware of a Claim (actual or potential) by any ThirdParty (a “Third Party Claim”) for which indemnification may be sought by that Party and will give such information with respect thereto as the otherParty shall reasonably request. If any proceeding (including any governmental investigation) is instituted involving any Party for which such Partymay seek an indemnity under Section 12.1 or 12.2, as the case may be (the “Indemnified Party”), the Indemnified Party shall not make any admissionor statement concerning such Third Party Claim, but shall promptly notify the other Party (the “Indemnifying Party”) orally and in writing and theIndemnifying Party and Indemnified Party shall meet to discuss how to respond to any Third Party Claims that are the subject matter of suchproceeding. The Indemnifying Party shall not be obligated to indemnify the Indemnified Party to the extent any admission or statement made by theIndemnified Party or any failure by such Party to notify the Indemnifying Party of the claim materially prejudices the defense of such claim.  12.3.2 Defense of Claim. If the Indemnifying Party elects to defend or, if local procedural rules or laws do not permit the same,elects to control the defense of a Third Party Claim, it shall be entitled to do so provided it gives notice to the Indemnified Party of its intention todo so within forty-five (45) days after the receipt of the written notice from the Indemnified Party of the potentially indemnifiable Third Party Claim(the “Litigation Condition”). The Indemnifying Party expressly agrees the Indemnifying Party shall be responsible for satisfying and dischargingany award made to or settlement reached with the Third Party pursuant to the terms of this Agreement without prejudice to any provision in thisAgreement or right at law which will allow the Indemnifying Party subsequently to recover any amount from the Indemnified Party to the extent theliability under such settlement or award was attributable to the Indemnified Party. Subject to compliance with the Litigation Condition, theIndemnifying Party shall retain counsel reasonably acceptable to the Indemnified Party (such acceptance not to be unreasonably withheld, refused,conditioned or delayed) to represent the Indemnified Party and shall pay the reasonable fees and expenses of such counsel related to suchproceeding. In any such proceeding, the Indemnified Party shall have the right to retain its own counsel, but the fees and expenses of such counselshall be at the expense of the Indemnified Party. The Indemnified Party shall not settle any claim for which it is seeking indemnification without theprior written consent of the Indemnifying Party which consent shall not be unreasonably withheld, refused, conditioned or delayed. TheIndemnified Party shall, if requested by the Indemnifying Party, cooperate in all reasonable respects in the defense of such claim that is beingmanaged and/or controlled by the Indemnifying Party. The Indemnifying Party shall not, without the written consent of the Indemnified Party(which consent shall not be unreasonably withheld, refused, conditioned or delayed), effect any settlement of any pending or threatenedproceeding in which the Indemnified Party is, or based on the same set of facts could have been, a party and indemnity could have been soughthereunder by the Indemnified Party, unless such settlement includes an unconditional release of the Indemnified Party from all liability on claimsthat are the subject matter of such proceeding. If the Litigation Condition is not met, then neither Party shall have the right to control the defense ofsuch Third Party Claim and the Parties shall cooperate in and be consulted on the material aspects of such defense at each Party’s own expense;provided that if the Indemnifying Party does not satisfy the Litigation Condition, the Indemnifying Party may at any subsequent time during thependency of the relevant Third Party Claim irrevocably elect, if permitted by local procedural rules or laws, to defend and/or to control the defenseof the relevant Third Party Claim so long as the Indemnifying Party also agrees to pay the reasonable fees and costs incurred by the IndemnifiedParty in relation to the defense of such Third Party Claim from 36the inception of the Third Party Claim until the date the Indemnifying Party assumes the defense or control thereof.  12.4 Assumption of Defense. Notwithstanding anything to the contrary contained herein, an Indemnified Party shall be entitled to assumethe defense of any Third Party Claim with respect to the Indemnified Party, upon written notice to the Indemnifying Party pursuant to this Section12.4, in which case the Indemnifying Party shall be relieved of liability under Section 12.1 or 12.2, as applicable, solely for such Third Party Claimand related Losses.  12.5 Insurance. During the Term of this Agreement and for a period of one (1) year after the termination or expiration of this Agreement,GSK shall obtain and/or maintain at its sole cost and expense, product liability insurance (including any self-insured arrangements) in amountswhich are reasonable and customary in the U.S. pharmaceutical industry for companies of comparable size and activities. Such product liabilityinsurance or self-insured arrangements shall insure against all liability, including without limitation personal injury, physical injury, or propertydamage arising out of the manufacture, sale, distribution, or marketing of the Collaboration Products. GSK shall provide written proof of theexistence of such insurance to Theravance upon request.  ARTICLE 13PATENTS 13.1 Prosecution and Maintenance of Patents.  13.1.1 Prosecution and Maintenance of Theravance Patents. Theravance shall have the exclusive right and the obligation to(subject to Theravance’s election not to file, prosecute, or maintain pursuant to Section 13.1.4) or to cause its licensors to, prepare, file, prosecute ina diligent manner (including without limitation by conducting interferences, oppositions and reexaminations or other similar proceedings), maintain(by timely paying all maintenance fees, renewal fees, and other such fees and costs required under applicable Laws) and extend all TheravancePatents and related applications. Theravance shall consult with GSK prior to abandoning any Theravance Patents or related applications that arematerial to the matters contemplated in this Agreement. Theravance shall regularly advise GSK of the status of all pending applications, includingwith respect to any hearings or other proceedings before any Governmental Authority, and, at GSK’s request, shall provide GSK with copies of alldocumentation concerning such applications, including all correspondence to and from any Governmental Authority. Subject to Section 2.3.3,Theravance shall solicit GSK’s advice and review of the nature and text of such patent applications and important prosecution matters relatedthereto in reasonably sufficient time prior to filing thereof, and Theravance shall take into account GSK’s reasonable comments related thereto;provided, however, Theravance shall have the final decision authority with respect to any action relating to any Theravance Patent. Within thepriority period, Theravance shall agree with GSK regarding the countries outside the United States in which corresponding applications should befiled (“OUS Filings”). It is presumed that a corresponding Patent Cooperation Treaty (“PCT”) application will be filed unless otherwise agreed bythe Parties. Theravance shall effect filing of all such applications within the priority period.  Subject to Section 13.1.4, Theravance shall be responsible for all costs incurred in the United States in connection with procuringTheravance Patents, including applications preparation, filing fees, prosecution, maintenance and all costs associated with reexamination and 37interference proceedings in the United States Patent and Trademark Office and United States Courts. GSK shall be responsible for all out-of-pocketcosts and expenses incurred by Theravance after the Effective Date that are associated with procuring corresponding OUS patents, includingwithout limitation PCT and individual country filing fees, translations, maintenance, annuities, and protest proceedings. For all such OUS patentapplications, Theravance will invoice GSK on a quarterly basis beginning April 1, 2003, setting forth all such expenses incurred. Reimbursement willbe made to Theravance in United States Dollars within thirty (30) days of receipt of the invoice by GSK. GSK will within thirty (30) days followingthe Effective Date identify the GSK representative that should receive such invoices from Theravance. GSK’s obligations hereunder are in additionto any obligations of GSK under Section 13.1.2(b)  13.1.2 Prosecution and Maintenance of Patents Covering Joint Inventions.  (a) For Patents covering Joint Inventions, the Parties shall agree, without prejudice to ownership, which Party shall have the rightto prepare and file a priority patent application, and prosecute such application(s) and maintain any patents derived therefrom, with the Partiesequally sharing the reasonable out-of-pocket costs for the preparation, filing, prosecution and maintenance of such priority patent application. TheParties will reasonably cooperate to obtain any export licenses that might be required for such activities. Should the agreed upon Party elect not toprepare and/or file any such priority patent application, it shall (i) provide the other Party with written notice as soon as reasonably possible aftermaking such election but in any event no later than sixty (60) days before the other Party would be faced with a possible loss of rights, (ii) give theother Party the right, at the other Party’s discretion and sole expense, to prepare and file the priority application(s), and (iii) offer reasonableassistance in connection with such preparation and filing at no cost to the other Party except for reimbursement of reasonable out-of-pocketexpenses incurred by the agreed upon Party in rendering such assistance. The other Party, at its discretion and cost, shall prosecute suchapplication(s) and maintain sole ownership of any patents derived therefrom.  (b) Within nine (9) months after the filing date of a priority application directed to an Invention, the Party filing the priorityapplication shall request that the other Party identify those non-priority, non-PCT (“foreign”) Countries in which the other Party desires that theParty filing the priority application file corresponding patent applications. Within thirty (30) days after receipt by the other Party of such requestfrom the Party filing the priority application, the other Party shall provide to the Party filing the priority application a written list of such foreigncountries in which the other Party wishes to effect corresponding foreign patent applications filings. The Parties will then attempt to agree on theparticular countries in which such applications will be filed, provided that in the event agreement is not reached, the application will be filed in thedisputed as well as the non-disputed countries (all such filings referred to hereinafter as “Designated Foreign Filings”). Thereafter, within twelve(12) months after the filing date of the priority application, the Party filing the priority application shall effect all such Designated Foreign Filings. Itis presumed unless otherwise agreed in writing by the Parties, that a corresponding PCT application will be filed designating all PCT membercountries. As to each Designated Foreign Filing and PCT application, GSK shall bear the costs for the filing and prosecutions of such DesignatedForeign Filing and PCT application (including entering national phase in all agreed countries). Should the Party filing the priority application notagree to file or cause to be filed a Designated Foreign Filing, the other Party will have the right to effect such Designated Foreign Filing in its name. 38(c) Should the filing Party pursuant to Section 13.1.2(a) or 13.1.2(b) no longer wish to prosecute and/or maintain any patentapplication or patent resulting from such application, the filing Party shall (i) provide the non-filing Party with written notice of its wish no later thansixty (60) days before the patent or patent applications would otherwise become abandoned, (ii) give the non-filing Party the right, at the non-filingParty’s election and sole expense, to prosecute and/or maintain such patent or patent application, and (iii) offer reasonable assistance to the non-filing Party in connection with such prosecution and/or maintenance at no cost to the non-filing Party except for reimbursement of the filing Party’sreasonable out-of-pocket expenses incurred by the filing Party in rendering such assistance.  (d) Should the non-filing Party pursuant to Section 13.1.2(c) not wish to incur its share of preparation, filing, prosecution and/ormaintenance costs for a patent application filed pursuant to Section 13.1.2(a) or 13.1.2(b) or patents derived therefrom, it shall (i) provide the filingParty with written notice of its wish, and (ii) continue to offer reasonable assistance to the filing Party in connection with such prosecution ormaintenance at no cost to the filing Party except for reimbursement of the non-filing Party’s reasonable out-of-pocket expenses incurred by thenon-filing Party in rendering such assistance.  (e) The Parties agree to cooperate in the preparation and prosecution of all patent applications filed under Section 13.1.2(a) and13.1.2(b), including obtaining and executing necessary powers of attorney and assignments by the named inventors, providing relevant technicalreports to the filing Party concerning the invention disclosed in such patent application, obtaining execution of such other documents which shallbe needed in the filing and prosecution of such patent applications, and, as requested, updating each other regarding the status of such patentapplications.  13.1.3 Prosecution and Maintenance of GSK Patents. GSK shall have the exclusive right and obligation to (subject to GSK’selection not to file, prosecute or maintain pursuant to Section 13.1.5) or to cause its licensors to, prepare, file and prosecute in a diligent manner(including without limitation by conducting interferences, oppositions and reexaminations or other similar proceedings), maintain (by timely payingall maintenance fees, renewal fees, and other such fees and costs required under applicable Laws) and extend all GSK Patents and relatedapplications. Consistent with Section 2.3.3, GSK will consult with Theravance within the priority period for any patent application that is material tothis Agreement concerning Countries in which corresponding applications will be filed. In the event the Parties can not agree, GSK shall make thefinal decision. GSK shall consult with Theravance prior to abandoning any GSK Patents or related applications that are material to the matterscontemplated in this Agreement. GSK shall regularly advise Theravance of the status of all pending applications, including with respect to anyhearings or other proceedings before any Governmental Authority, and, at Theravance’s request, shall provide Theravance with copies ofdocumentation relating to such applications, including all correspondence to and from any Governmental Authority. Subject to Section 2.3.3, GSKshall solicit Theravance’s advice and review of the nature and text of such patent applications and important prosecution matters related thereto inreasonably sufficient time prior to filing thereof, and GSK shall take into account Theravance’s reasonable comments relating thereto; provided thatGSK shall have the final decision authority with respect to any action relating to a GSK Patent.  13.1.4 GSK Step-In Rights. If Theravance elects not to file, prosecute or maintain the Theravance Patents or claims encompassedby such Theravance Patents necessary for GSK to exercise its rights hereunder in any Country, Theravance shall give GSK notice thereof within areasonable period prior to allowing such Theravance Patents, or such claims encompassed by 39such Theravance Patents, to lapse or become abandoned or unenforceable, and GSK shall thereafter have the right, at its sole expense, to prepare,file, prosecute and maintain such Theravance Patents in such Country.  13.1.5 Theravance Step-In Rights. If GSK elects not to file, prosecute or maintain the GSK Patents or claims encompassed by suchGSK Patents necessary for Theravance to exercise its license rights hereunder in any Country, GSK shall give Theravance notice thereof within areasonable period prior to allowing such GSK Patents, or such claims encompassed by such GSK Patents, to lapse or become abandoned orunenforceable, and Theravance shall thereafter have the right, at its sole expense, to prepare, file, prosecute and maintain such GSK Patents in suchCountry. In the event that GSK elects not to file, prosecute or maintain GSK Patents or claims that would affect the royalty owed Theravancepursuant to Section 6.3, GSK shall reimburse Theravance for all out-of-pocket expenses incurred by Theravance in connection with Theravanceexercising its Step-In Rights under this Section.  13.1.6 Execution of Documents by Agents. Each of the Parties shall execute or have executed by its appropriate agents suchdocuments as may be necessary to obtain, perfect or maintain any Patent Rights filed or to be filed pursuant to this Agreement, and shall cooperatewith the other Party so far as reasonably necessary with respect to furnishing all information and data in its possession reasonably necessary toobtain or maintain such Patent Rights.  13.1.7 Patent Term Extensions. The Parties shall cooperate with each other in gaining patent term extension where applicable toCollaboration Products. The Joint Steering Committee shall determine which patents the Parties shall endeavor to have extended. All filings forsuch extension will be made by the Party to whom the patent is assigned after consultation with the other Party. In the event the Joint SteeringCommittee can not agree, the Party who is assigned the compound patent covering the LABA in the Collaboration Product will make the decision.  13.2 Patent Infringement.  13.2.1 Infringement Claims. With respect to any and all Claims instituted by Third Parties against Theravance or GSK or any oftheir respective Affiliates for patent infringement involving the manufacture, use, license, marketing or sale of a Collaboration Product in the UnitedStates during the Term (each, a “Patent Infringement Claim”) as applicable, Theravance and GSK will assist one another and cooperate in thedefense and settlement of such Patent Infringement Claims at the other Party’s request.  13.2.2 Infringement of Theravance Patents. In the event that Theravance or GSK becomes aware of actual or threatenedinfringement of a Theravance Patent during the Term, that Party will promptly notify the other Party in writing (a “Patent Infringement Notice”).Theravance will have the right but not the obligation to bring an infringement action against any Third Party. If Theravance elects to pursue suchinfringement action, Theravance shall be solely responsible for the costs and expenses associated with such action and retain all recoveries. Duringthe Term, in the event that Theravance does not undertake such an infringement action, upon Theravance’s written consent, which shall not beunreasonably withheld, refused, conditioned or delayed, GSK shall be permitted to do so in Theravance’s or the relevant Theravance Affiliate’sname and on Theravance’s or the relevant Theravance Affiliate’s behalf. If Theravance has consented to an infringement action but GSK is notrecognized by the applicable court or other relevant body as having the requisite standing to pursue such action, then GSK may join Theravance asparty-plaintiff. If GSK elects to pursue such infringement action, Theravance may be represented in 40such action by attorneys of its own choice and its own expense with GSK taking the lead in such action. 13.2.3 Infringement of GSK Patents. In the event that GSK or Theravance becomes aware of actual or threatened infringement of aGSK Patent during the Term, that Party will promptly notify the other Party in writing. GSK will have the right but not the obligation to bring aninfringement action against any Third Party. If GSK elects to pursue such infringement action, GSK shall be solely responsible for the costs andexpenses associated with such action and retain all recoveries. During the Term, in the event that GSK does not undertake such an infringementaction, upon GSK’s written consent, which shall not be unreasonably withheld, refused, conditioned or delayed, Theravance shall be permitted todo so in GSK’s or the relevant GSK Affiliate’s name and on GSK’s or the relevant GSK Affiliate’s behalf. If GSK has consented to an infringementaction but Theravance is not recognized by the applicable court or other relevant body as having the requisite standing to pursue such action, thenTheravance may join GSK as a party-plaintiff. If Theravance elects to pursue such infringement action, GSK may be represented in such action byattorneys of its own choice and at its own expense, with Theravance taking the lead in such action.  13.3 Notice of Certification. GSK and Theravance each shall immediately give notice to the other of any certification filed under the “U.S.Drug Price Competition and Patent Term Restoration Act of 1984” (or its foreign equivalent) claiming that a GSK Patent or a Theravance Patent isinvalid or that infringement will not arise from the manufacture, use or sale of any Collaboration Product by a Third Party (“Hatch-WaxmanCertification”).  13.3.1 Notice. If a Party decides not to bring infringement proceedings against the entity making such a certification, such Partyshall give notice to the other Party of its decision not to bring suit within twenty-one (21) days after receipt of notice of such certification.  13.3.2 Option. Such other Party then may, but is not required to, bring suit against the entity that filed the certification.  13.3.3 Name of Party. Any suit by Theravance or GSK shall either be in the name of Theravance or in the name of GSK, (or anyAffiliate) or jointly in the name of Theravance and GSK (or any Affiliate) , as may be required by law.  13.4 Assistance. For purposes of this Article 13, the Party not bringing suit shall execute such legal papers necessary for the prosecutionof such suit as may be reasonably requested by the Party bringing suit. The out-of-pocket costs and expenses of the Party bringing suit shall bereimbursed first out of any damages or other monetary awards recovered in favor of GSK or Theravance. The documented out-of-pocket costs andexpenses of the other Party shall then be reimbursed out of any remaining damages or other monetary awards. The Party initiating and prosecutingthe action to completion will retain any remaining damages or other monetary awards following such reimbursements.  13.5 Settlement. No settlement or consent judgment or other voluntary final disposition of a suit under this Article may be entered intowithout the joint written consent of GSK and Theravance (which consent will not be withheld unreasonably). 41ARTICLE 14TERM AND TERMINATION 14.1 Term and Expiration of Term. Unless otherwise mutually agreed to by the Parties, this Agreement shall commence on the EffectiveDate and shall end upon expiration of the Term, unless terminated early as contemplated hereunder. Unless terminated early under this Article 14,the licenses granted by Theravance to GSK pursuant to Section 2.1 with respect to the Collaboration Products shall be considered fully-paid andshall become non-exclusive upon expiration of the Term.  14.2 Termination for Material Breach. Either Party may, without prejudice to any other remedies available to it at law or in equity, terminatethis Agreement subject to Section 14.10 in the event that the other Party (as used in this subsection, the “Breaching Party”) shall have materiallybreached or defaulted in the performance of any of its obligations. The Breaching Party shall, if such breach can be cured, have sixty (60) days afterwritten notice thereof was provided to the Breaching Party by the non-breaching Party to remedy such default (or, if such default cannot be curedwithin such 60-day period, the Breaching Party must commence and diligently continue actions to cure such default during such 60-day period).Any such termination shall become effective at the end of such 60-day period unless the Breaching Party has cured any such breach or defaultprior to the expiration of such 60-day period (or, if such default is capable of being cured but cannot be cured within such 60-day period, theBreaching Party has commenced and diligently continued actions to cure such default provided always that, in such instance, such cure must haveoccurred within one hundred twenty (120) days after written notice thereof was provided to the Breaching Party by the non-breaching Party toremedy such default).  14.3 GSK Right to Terminate Development of a Collaboration Product. On a Collaboration Product-by-Collaboration Product basis, and atany time during Development and prior to First Commercial Sale of the applicable Collaboration Product, GSK shall have the right to terminateDevelopment of such Collaboration Product (upon the provision of ninety (90) days written notice) for reasons of Technical Failure or CommercialFailure following communication to, and assessment of such proposed termination by, the Joint Project Committee and Joint Steering Committee (inwhich case such Collaboration Product shall be referred to as a “Terminated Development Collaboration Product”). For the avoidance of doubt, a“Terminated Development Collaboration Product” can be any of the following: (i) a Pooled Compound and/or (ii) a Replacement Compound and/or(iii) a single agent LABA Collaboration Product and/or (iv) a LABA/ICS Combination Product and/or (v) an Other Combination Product.  14.4 GSK Right to Terminate Commercialization of a Collaboration Product Following First Commercial Sale. On a Collaboration Product-by-Collaboration Product basis, and on a Country-by-Country basis, at any time after First Commercial Sale of the applicable Collaboration Product insuch country, GSK shall have the right to terminate Commercialization of such Collaboration Product (upon the provision of one hundred andeighty (180) days written notice) for reasons of Commercial Failure or Technical Failure and following communication to, and assessment of suchproposed termination by, the Joint Project Committee and Joint Steering Committee (in which case, such Collaboration Product shall be referred toas a “Terminated Commercialized Collaboration Product”). For the avoidance of doubt, a Terminated Commercialized Collaboration Product can beany of the following: (i) a single agent LABA Collaboration Product and/or (ii) a LABA/ICS Combination Product and/or (iii) an Other CombinationProduct.  4214.5 Termination of the Agreement Due to Discontinuation of Development of All Collaboration Products and All Pooled Compounds .Any time following the third anniversary of the Effective Date, either Party may terminate this Agreement, subject to Section 14.10, upon theprovision of ninety (90) days written notice if Development of all Collaboration Products and all Pooled Compounds have been discontinued forTechnical Failure and/or Commercial Failure. Notwithstanding the foregoing, in the event that (i) Development of all Collaboration Products and allPooled Compounds (including any Replacement Compounds) has ceased for at least three (3) months, (ii) all such termination and/ordiscontinuance decisions have been validly approved by the Joint Steering Committee, and (iii) both parties have provided written notice to theother that such party does not intend to contribute any additional Replacement Compounds to the collaboration, then either Party shall be entitledto terminate this Agreement, subject to Section 14.10, upon the provision of ninety (90) days written notice.  14.6 Effects of Termination.  14.6.1 Effect of Termination for Material Breach. (a) Material Breach by Theravance. In the event this Agreement is terminated by GSK pursuant to Section 14.2 for material breachby Theravance, all licenses granted by Theravance to GSK under this Agreement shall survive, subject to GSK’s continued obligation to paymilestones and royalties to Theravance hereunder. In such event, GSK shall retain all of its rights to bring an action against Theravance fordamages and any other available remedies in law or equity, and shall be entitled to set-off against any monies payable to Theravance hereunder allamounts GSK reasonably believes constitute its damages incurred by such breach, subject to final judicial resolution or settlement. Also,Theravance shall, at its sole expense, promptly transfer to GSK copies of all data, reports, records and materials in its possession or control thatrelate to the Collaboration Products that contain a GSK Compound and return to GSK, or destroy at GSK’s request, all relevant records andmaterials in its possession or control containing Confidential Information of GSK (provided that Theravance may keep one copy of suchConfidential Information of GSK for archival purposes only in accordance with Section 10.1).  (b) Material Breach By GSK. In the event that this Agreement is terminated by Theravance pursuant to Section 14.2 for materialbreach by GSK:  (i) GSK shall, at its sole expense, promptly transfer to Theravance copies of all data, reports, records and materials in itspossession or control that relate to the Theravance Compounds and return to Theravance, or destroy at Theravance’srequest, all relevant records and materials in its possession or control containing Confidential Information of Theravance(provided that GSK may keep one copy of such Confidential Information of Theravance for archival purposes only inaccordance with Section 10.1).(ii) GSK shall, at its sole expense, transfer to Theravance, or shall cause its designee(s) to transfer to Theravance, ownership of allregulatory filings made or filed for any Collaboration Product that contains a LABA as a single agent (to the extent thatany are held in GSK’s or such designee(s)’s name), and such transfer to be as permitted by applicable Laws andregulations; otherwise GSK shall cooperate as necessary to permit Theravance to exercise its rights hereunder.(iii) Theravance shall have the non-exclusive right to access, use and cite in any regulatory filing any data relating to formulationof a LABA/ICS Combination Product or Other Combination Product. 43(iv) All of the provisions of Section 14.6.2 shall apply for the benefit of Theravance for any Collaboration Product for which thefirst Phase III Study has been initiated at the effective date of such termination, subject to the limitations set forth inSection 14.6.2.(v) All the provisions of Section 14.6.3 shall apply for any Collaboration Product that has been Commercialized at the effectivedate of such termination.(vi) All licenses granted by Theravance to GSK with respect to the applicable Theravance Compounds under this Agreementshall terminate.(vii) Theravance shall retain all of its rights to bring an action against GSK for damages and any other available remedies in law orequity, and shall be entitled to set-off against any monies payable to GSK hereunder all amounts Theravance reasonablybelieves constitute its damages incurred by such breach, subject to final judicial resolution or settlement.  14.6.2 Effect of Termination by GSK of Certain Terminated Development Collaboration Product(s). If GSK terminates aCollaboration Product at any time after initiation of the first Phase III Study concerning such Collaboration Product, and Development of all otherCollaboration Products and Pooled Compounds have been discontinued for Technical Failure and/or Commercial Failure, then at the sole electionof Theravance, the following shall apply:  (a) GSK shall, at its sole expense, promptly transfer to Theravance copies of all data, reports, records and materials in itspossession or control that relate to the Theravance Compounds and return to Theravance, or destroy at Theravance’srequest, all relevant records and materials in its possession or control containing Confidential Information of Theravance(provided that GSK may keep one copy of such Confidential Information of Theravance for archival purposes only inaccordance with Section 10.1). (b) GSK shall, at its sole expense, transfer to Theravance, or shall cause its designee(s) to transfer to Theravance, ownership of allregulatory filings made or filed for the Terminated Development Collaboration Product that contains a LABA as a singleagent (to the extent that any are held in GSK’s or such designee(s)’s name), such transfer to be as permitted by any ThirdParty licenses or other such prior rights and applicable Laws and regulations, otherwise GSK shall cooperate as necessary topermit Theravance to exercise its rights hereunder. (c) Theravance shall have the non-exclusive right to access, use and cite in any regulatory filing any data relating to formulationof a LABA/ICS Combination Product or Other Combination Product. (d) For such Terminated Development Collaboration Product (excluding the non-LABA component of a LABA/ICS CombinationProduct and/or Other Combination Product and GSK’s Diskus delivery device and any information directed thereto), GSKshall grant to Theravance the appropriate licenses in the Territory under the GSK Patents, GSK Inventions and GSK Know-How related to the LABA compound, dry powder inhaler formulation, metered dose inhaler formulation, and metered doseinhaler device, as applicable, to enable Theravance to Develop and Commercialize the Terminated DevelopmentCollaboration Product in the Field. 44(e) In the event of a Change in Control of Theravance prior to termination by GSK under Section 14.3, none of the provisionsunder this Section 14.6.2 shall survive as they pertain to any Collaboration Product other than a Theravance compound as asingle agent LABA. 14.6.3 Effect of Termination by GSK of a Terminated Commercialized Collaboration Product. The provisions of this Section 14.6.3shall apply only where a Terminated Commercialised Collaboration Product is not being or has not been replaced by an alternative CollaborationProduct under this Agreement and provided that, in GSK’s reasonable good faith judgment, exercise by Theravance alone or with a Third Party ofany of the rights or activities contemplated by this Section 14.6.3 (which such rights or activities shall include access to a GSK compound and/orGSK proprietary formulations or devices including Diskus, (collectively “GSK Property”)) will not materially damage GSK’s continued development,regulatory or commercial use of such GSK Property. GSK will use reasonable efforts to assist Theravance in locating a mutually acceptable ThirdParty to carry out the rights and activities contemplated by this Section 14.6.3. Subject to the foregoing: (a) If GSK terminates a Collaboration Product after First Commercial Sale of such Collaboration Product in one or more of theMajor Market Countries, Theravance shall have the right in its sole discretion and at its sole expense, for its own benefit ortogether with a Third Party, to commercialize such Terminated Commercialized Collaboration Product in any of such MajorMarket Countries where it has been terminated. (b) If GSK terminates Commercialization of a Collaboration Product in all Countries of the Territory following the first commercialsale in any Country of the Territory, Theravance shall have the right in its sole discretion and at it sole expense, for its ownbenefit or together with a Third Party, to Commercialise such Terminated Commercialized Collaboration Product in theTerritory. (c) Subject to Section 14.6.3(a), GSK shall grant to Theravance the appropriate licenses in the Territory (or in the case of aCountry-by-Country termination, in the relevant Countries) under the GSK Patents, GSK Inventions and GSK Know-How toenable Theravance by itself and/or through one or more Third Party sublicensees, to Commercialize the TerminatedCommercialized Collaboration Product. GSK shall also provide Theravance with all such information and data which GSK, orits sublicensees reasonably have available in such Country, for example access to drug master file, clinical data and the like,and shall execute such instruments as Theravance reasonably requests, to enable Theravance to obtain the appropriateregulatory approvals to market such Terminated Commercialized Collaboration Product in such Country and for any otherlawful purpose related to Commercialization of such Terminated Commercialized Collaboration Product in such Country. (d) In the event Theravance exercises its rights under Section 14.6.3(a) and (b) above, the Parties shall negotiate in good faith aseparate commercialization and supply agreement for such Terminated Commercialized Collaboration Product which shallensure that, based on commercially reasonable terms 45(recognizing the Commercialized status of the Terminated Commercialized Collaboration Product), Theravance has acontinuous and uninterrupted supply of such Terminated Commercialized Collaboration Product, for a suitable period of timeto enable Theravance to secure Third Party supply.  (e) In the event of a Change in Control of Theravance, prior to termination by GSK under Section 14.4, none of the provisionsunder this Section 14.6.3 shall survive as they pertain to any Collaboration Product other than to a single agent LABA, itsdry powder inhaler formulation, metered dose inhaler formulation, and metered dose inhaler device, as applicable; and theParties will meet in good faith to explore other potential commercial options e.g. use of one or more Third Parties for possiblecontinued Commercialisation of such Terminated Commercialised Collaboration Product if it is a LABA/ICS CombinationProduct or Other Combination Product. (f) If GSK, in the exercise of its reasonable good faith judgment, determines that exercise by Theravance alone or with a ThirdParty of any of the rights or activities contemplated by this Section 14.6.3 will materially damage GSK’s continueddevelopment, regulatory or commercial use of GSK Property, then GSK shall grant to Theravance, for such TerminatedCommercialized Collaboration Product (excluding the non-LABA component of a Combination Product and/or OtherCombination Product and GSK’s Diskus delivery device and any information directed thereto), the appropriate licenses in theTerritory under the GSK Patents, GSK Inventions and GSK Know-How related to the LABA compound, dry powder inhalerformulation, metered dose inhaler formulation, and metered dose inhaler device, as applicable, to enable Theravance toCommercialize a product containing the LABA Compound in the Field. 14.6.4 Effect of Termination of the Agreement Due to Discontinuation of Development Prior to First Commercial Sale of All CollaborationProducts and All Pooled Compounds. In the event that the Agreement is terminated pursuant to Section 14.5, the following shall occur:  (i) Return of Materials. GSK shall, at its sole expense, promptly transfer to Theravance copies of all data, reports, records andmaterials in its possession or control that relate to the Theravance Compounds and return to Theravance, or destroy at Theravance’s request, allrelevant records and materials in its possession or control containing Confidential Information of Theravance (provided that GSK may keep onecopy of such Confidential Information of Theravance for archival purposes only in accordance with Section 10.1). Theravance shall, at its soleexpense, promptly transfer to GSK copies of all data, reports, records and materials in its possession or control that relate to the GSK Compoundsand return to GSK, or destroy at GSK’s request, all relevant records and materials in its possession or control containing Confidential Informationof GSK (provided that Theravance may keep one copy of such Confidential Information of GSK for archival purposes only in accordance withSection 10.1).  (ii) Transfer of Regulatory Filings. GSK shall, at its sole expense, transfer to Theravance, or shall cause its designee(s) totransfer to Theravance, ownership of all regulatory filings made or filed for any Terminated Development Collaboration Product (to the extent thatany are held in GSK’s or such designee(s)’s name), but only where the Terminated Collaboration Product contains a Theravance Compound as asingle agent and such transfer to be as permitted 46by applicable Laws and regulations. GSK, at its sole discretion, shall also give due consideration to transferring to Theravance any additionalregulatory filings for a Terminated Development Collaboration Product which contains a Theravance Compound as a Combination Product.  (iii) License Rights. All licenses granted by Theravance to GSK with respect to the Collaboration Products under thisAgreement shall terminate.  (iv) Stock Return. GSK shall return to Theravance all available formulated and API stocks that contain a TheravanceCompound and which are then held by GSK or cause such API stocks to be provided to Theravance if held by a vendor or other Third Party onbehalf of GSK.  (v) Limitations on Further Development by GSK. GSK shall not be permitted to continue or re-initiate clinical Development ofany GSK Compound that is both a Terminated Collaboration Product and a LABA in the Field for a period of four (4) years after the date of suchtermination.  14.7 License Rights. Except as otherwise provided herein in, all licenses granted hereunder relating to Terminated Collaboration Productsshall terminate. Also the Parties accept that nothing provided for in this Article 14 or elsewhere in this Agreement, grants any licenses (whetherexclusive, semi-exclusive or otherwise) from GSK to Theravance for any (i) GSK Compound (ii) GSK Invention (ii) GSK Know How and (iv) GSKPatents, except for those rights essential and specific to enable Theravance to exercise those rights and carry out those activities contemplatedunder Section 14.6 above. 14.8 Milestone Payments. Neither Party shall be obligated to make a Development Milestone payment under Section 6.2 which is triggeredby an event occurring after the effective date of termination of this Agreement with respect to a Collaboration Product.  14.9 Subsequent Royalties. If after termination of this Agreement either Party subsequently Develops and Commercializes any Long-Acting β2 Adrenoceptor Agonist for the treatment / prophylaxis of respiratory diseases which (i) was never a Pooled Compound or CollaborationProduct or (ii) was a GSK Discontinued Compound or a Theravance Discontinued Compound, it will pay to the other Party a royalty on Net Sales ofany such products at the rate of 3% for a single-agent product and 2% for the first combination product for a period of 15 years from the date oflaunch on a Country-by-Country basis; provided, however, that this royalty shall not apply to any compound or product (including new productline extensions and/or re-formulation work) where the original compound or product is, as of the date of signature of this Agreement, alreadyCommercialized.  14.10 Accrued Rights; Surviving Obligations. Termination, relinquishment or expiration of this Agreement for any reason shall be withoutprejudice to any rights that shall have accrued to the benefit of any Party prior to such termination, relinquishment or expiration. Such termination,relinquishment or expiration shall not relieve any Party from obligations which are expressly or by implication intended to survive termination,relinquishment or expiration of this Agreement, including without limitation Article 10, and shall not affect or prejudice any provision of thisAgreement which is expressly or by implication provided to come into effect on, or continue in effect after, such termination, relinquishment orexpiration.  47ARTICLE 15LIMITATIONS RELATING TO THERAVANCE EQUITY SECURITIES 15.1 Purchases of Equity Securities. So long as this Agreement remains in effect and for a period of one (1) year thereafter, except aspermitted by Section 15.2, or as otherwise agreed in writing by Theravance, GSK and its Affiliates will not (and will not assist or encourage othersto) directly or indirectly in any manner:  15.1.1 acquire, or agree to acquire, directly or indirectly, alone or in concert with others, by purchase, gift or otherwise, any director indirect beneficial ownership (within the meaning of Rule l3d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) orinterest in any securities or direct or indirect rights, warrants or options to acquire, or securities convertible into or exchangeable for, any securitiesof Theravance;  15.1.2 make, or in any way participate in, directly or indirectly, alone or in concert with others, any “solicitation” of “proxies” tovote (as such terms are used in the proxy rules of the Securities and Exchange Commission (the “SEC”) promulgated pursuant to Section 14 of theExchange Act); provided, however, that the prohibition in this Section 15.1.2 shall not apply to solicitations exempted from the proxy solicitationrules by Rule 14a-2 under the Exchange Act as such Rule 14a-2 is in effect as of the date hereof;  15.1.3 form, join or in any way participate in a “group” within the meaning of Section 13(d)(3) of the Exchange Act with respect toany voting securities of Theravance;  15.1.4 acquire or agree to acquire, directly or indirectly, alone or in concert with others, by purchase, exchange or otherwise, (i)any of the assets, tangible or intangible, of Theravance or (ii) direct or indirect rights, warrants or options to acquire any assets of Theravance,except for such assets as are then being offered for sale by Theravance;  15.1.5 enter into any arrangement or understanding with others to do any of the actions restricted or prohibited under Sections15.1.1, 15.1.2, 15.1.3, or 15.1.4.  15.1.6 otherwise act in concert with others, to seek to offer to Theravance or any of its stockholders any business combination,restructuring, recapitalization or similar transaction to or with Theravance or otherwise seek in concert with others, to control, change or influencethe management, board of directors or policies of Theravance or nominate any person as a director of Theravance who is not nominated by thethen incumbent directors, or propose any matter to be voted upon by the stockholders of Theravance.  15.2 Exceptions for Purchasing Securities of Theravance. Nothing herein shall prevent GSK or its Affiliates (or in the case of Section 15.2.4,their employees) from:  15.2.1 purchasing the Series E Preferred Stock of Theravance on the Effective Date as contemplated herein.  15.2.2 purchasing additional equity securities of Theravance after the Effective Date if after such purchase GSK and its Affiliateswould own in the aggregate no greater percent of the total voting power of all voting securities of Theravance then outstanding than GSK togetherwith its Affiliates owned immediately after purchase of the Series E Preferred Stock on the Effective Date. 4815.2.3 acquiring securities of Theravance issued in connection with stock splits or recapitalizations or on exercise of pre-emptiverights afforded to Theravance stockholders generally.  15.2.4 purchasing securities of Theravance pursuant to (i) a pension plan established for the benefit of GSK’s employees, (ii) anyemployee benefit plan of GSK, (iii) any stock portfolios not controlled by GSK or any of its Affiliates that invest in Theravance among othercompanies, or (iv) following an initial public offering of Theravance common stock, for the account of a GSK employee in such employee’s personalcapacity.  15.2.5 acquiring securities of another biotechnology or pharmaceutical company that beneficially owns any of Theravance’ssecurities.  15.2.6 acquiring equity securities of Theravance without any limitation following initiation by a third party of an unsolicitedtender offer to purchase twenty percent (20%) or more of any class or service of Theravance’s publicly traded voting securities (a “Hostile TenderOffer”); provided that the exception provided by this Section 15.2.6 shall be limited to the classes or series of Theravance’s securities that are thesubject of the Hostile Tender Offer; provided, further, that, in the event that either (a) such Hostile Tender Offer is terminated or expires without thepurchase of at least ten percent (10%) of any class or series of Theravance’s publicly traded voting securities by such third party, or (b) theTheravance Board of Directors subsequently recommends that such offer be accepted, then following the date of such termination, expiration orrecommendation the acquisitions by GSK and/or its Affiliates under this Section 15.2.6 prior to the events described in clauses (a) and (b) aboveshall not be considered a breach by GSK of the provisions of Section 15.2 as long as GSK, at its option, either: (i) divests (or cause to be divested) in one or more open-market transactions such number of shares of Theravance’s securitiesacquired by it and its Affiliates pursuant to this Section 15.2.6 such that after such divestiture GSK and its Affiliates would own in the aggregate nogreater percent of the total voting power of all voting securities of Theravance then outstanding than GSK together with its Affiliates ownedimmediately prior to the commencement of such Hostile Tender Offer, any such divestiture to be completed as expeditiously as possible consistentwith applicable securities laws and regulations and in a manner intended to shield GSK and its Affiliates from liability for recovery of short swingprofits under Section 16 of the Exchange Act and the rules promulgated thereunder; or (ii) enters into a voting agreement, proxy or similar arrangement pursuant to which (A) all Theravance voting securities acquiredpursuant to this Section 15.2.6 are voted on all matters to be voted on by holders of Theravance voting securities, including, but not limited to, infavor of any transaction involving a proposed Change in Control (as defined below) of Theravance in the same proportion as the outstandingTheravance voting securities not held by GSK or any GSK Affiliate are voted, (B) no Theravance voting securities beneficially owned by GSKand/or any Affiliate abstain from such a vote, and (C) no dissenter or appraisal or similar rights are exercised with respect to any vote relating to aChange in Control of Theravance. 15.3 Voting. Until the date of an initial public offering of Theravance common stock, GSK shall ensure that all outstanding Theravancevoting securities beneficially owned by GSK and/or any GSK Affiliate are voted for management’s nominees to the Board of Directors ofTheravance to the extent not inconsistent with Section 2.8 of the Investors’ Rights Agreement. 4915.4 Theravance Voting Securities Transfer Restrictions.  15.4.1 So long as this Agreement remains in effect and for a period of one (1) year thereafter, neither GSK nor any of its Affiliatesshall dispose of beneficial ownership of Theravance voting securities except (i) pursuant to a bona fide public offering registered under theSecurities Act of either Theravance voting securities or securities exchangeable or exercisable for Theravance voting securities (in which thesecurities are broadly distributed and GSK does not select the purchasers); or (ii) pursuant to Rule 144 under the Securities Act (provided that ifRule 144(k) is available, such transfer nevertheless is within the volume limits and manner of sale requirements applicable to non-144(k) transfersunder Rule 144); or (iii) in transactions that to the knowledge of GSK do not, directly or indirectly, result in any person or group owning or havingthe right to acquire or intent to acquire beneficial ownership of Theravance voting securities with aggregate voting power of five percent or more ofthe aggregate voting power of all outstanding Theravance voting securities. 15.4.2 Notwithstanding the foregoing, the restrictions on disposition under Section 15.4.1 shall not apply if, as a result of suchdisposition, (A) no filing by any Person (including, but not limited to GSK or any of its Affiliates) shall be required under any Law (including butnot limited to the Exchange Act) that would identify GSK or any of its Affiliates as the seller of the securities, and (B) neither GSK nor any of itsAffiliates (or any transferee thereof) would be required by Law (including without limitation the disclosure requirements of the Securities Act of1933, as amended (the “Securities Act”), and the Exchange Act) to make any public announcement of the transfer or disposition. 15.4.3 So long as this Agreement remains in effect and for a period of one (1) year thereafter, neither GSK nor any of its Affiliatesmay make any public disclosure of any holdings of or disposition of beneficial ownership of Theravance voting securities unless such disclosure isapproved in advance in writing by Theravance, such approval not to be unreasonably withheld or delayed. Notwithstanding the foregoing, noconsent of Theravance shall be required for any filing that GSK or any of its Affiliates is required to make under applicable Law in any jurisdiction,including without limitation any Form 144 under the Securities Act, any Form 4 under the Exchange Act, or any Schedule 13D or 13G or anyamendments thereto under the Exchange Act; provided that, prior to making any such filings, GSK shall use reasonable efforts to (i) to provideTheravance notice and a copy of such proposed filings and (ii) consult with Theravance on the content of such filings. 15.5 Termination of Purchase Restrictions. The limitations on purchase of equity securities set forth in Section 15.1 shall terminateimmediately upon a transaction or series of related transactions following a Change in Control of Theravance.  ARTICLE 16MISCELLANEOUS 16.1 Relationship of the Parties. Each Party shall bear its own costs incurred in the performance of its obligations hereunder without chargeor expense to the other except as expressly provided in this Agreement. Neither Party shall have any responsibility for the hiring, termination orcompensation of the other Party’s employees or for any employee benefits of such employee. No employee or representative of a Party shall haveany authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever, or to create or impose any contractualor other liability on the other Party without said Party’s approval. For all purposes, and notwithstanding any other provision of this Agreement tothe contrary, GSK’s legal  50relationship under this Agreement to Theravance shall be that of independent contractor. This Agreement is not a partnership agreement andnothing in this Agreement shall be construed to establish a relationship of co-partners or joint venturers between the Parties.  16.2 Registration and Filing of This Agreement. To the extent, if any, that either Party concludes in good faith that it or the other Party isrequired to file or register this Agreement or a notification thereof with any Governmental Authority, including without limitation the U.S. Securitiesand Exchange Commission, the Competition Directorate of the Commission of the European Communities or the U.S. Federal Trade Commission, inaccordance with Law, such Party shall inform the other Party thereof. Should both Parties jointly agree that either of them is required to submit orobtain any such filing, registration or notification, they shall cooperate, each at its own expense, in such filing, registration or notification and shallexecute all documents reasonably required in connection therewith. In such filing, registration or notification, the Parties shall request confidentialtreatment of sensitive provisions of this Agreement, to the extent permitted by Law. The Parties shall promptly inform each other as to the activitiesor inquiries of any such Governmental Authority relating to this Agreement, and shall reasonably cooperate to respond to any request for furtherinformation there from on a timely basis.  16.3 Force Majeure. The occurrence of an event which materially interferes with the ability of a Party to perform its obligations or dutieshereunder which is not within the reasonable control of the Party affected or any of its Affiliates, not due to malfeasance by such Party or itsAffiliates, and which could not with the exercise of due diligence have been avoided (each, a “Force Majeure Event”), including, but not limited to,an injunction, order or action by a Governmental Authority, fire, accident, labor difficulty, strike, riot, civil commotion, act of God, inability to obtainraw materials, delay or errors by shipping companies or change in law, shall not excuse such Party from the performance of its obligations or dutiesunder this Agreement, but shall merely suspend such performance during the continuation of the Force Majeure. The Party prevented fromperforming its obligations or duties because of a Force Majeure Event shall promptly notify the other Party of the occurrence and particulars ofsuch Force Majeure and shall provide the other Party, from time to time, with its best estimate of the duration of such Force Majeure Event and withnotice of the termination thereof. The Party so affected shall use Diligent Efforts to avoid or remove such causes of nonperformance as soon as isreasonably practicable. Upon termination of the Force Majeure Event, the performance of any suspended obligation or duty shall promptlyrecommence. The Party subject to the Force Majeure Event shall not be liable to the other Party for any direct, indirect, consequential, incidental,special, punitive, exemplary or other damages arising out of or relating to the suspension or termination of any of its obligations or duties underthis Agreement by reason of the occurrence of a Force Majeure Event, provided such Party complies in all material respects with its obligationsunder this Section 16.3.  16.4 Governing Law. This Agreement shall be construed, and the respective rights of the Parties determined, according to the substantivelaw of the State of Delaware notwithstanding the provisions governing conflict of laws under such Delaware law to the contrary, except matters ofintellectual property law which shall be determined in accordance with the intellectual property laws relevant to the intellectual property inquestion.  16.5 Attorneys’ Fees and Related Costs. In the event that any legal proceeding is brought to enforce or interpret any of the provisions ofthis Agreement, the prevailing party shall be entitled to recover its reasonable attorneys’ fees, court costs and expenses of litigation whether or notthe action or proceeding proceeds to final judgment. 5116.6 Assignment. This Agreement may not be assigned by either Party without the prior written consent of the other Party; provided,however that either Party may assign this Agreement, in whole or in part, to any of its Affiliates if such Party guarantees the performance of thisAgreement by such Affiliate; and provided further that either Party may assign this Agreement to a successor to all or substantially all of theassets of such Party whether by merger, sale of stock, sale of assets or other similar transaction. This Agreement shall be binding upon, andsubject to the terms of the foregoing sentence, inure to the benefit of the Parties hereto, their permitted successors, legal representatives andassigns.  16.7 Notices. All demands, notices, consents, approvals, reports, requests and other communications hereunder must be in writing and willbe deemed to have been duly given only if delivered personally, by facsimile with confirmation of receipt, by mail (first class, postage prepaid), orby overnight delivery using a globally-recognized carrier, to the Parties at the following addresses: Theravance: Theravance, Inc.901 Gateway BoulevardSouth San Francisco, CA 94080Facsimile: 650-827-8683Attn: Senior Vice President, Commercial Development GSK: Glaxo Group LimitedGlaxo Wellcome HouseBerkeley AvenueGreenfordMiddlesex UB6 0NNUnited KingdomAttn: Company SecretaryFacsimile: 011 44 208-047-6912 With a copy to: GlaxoSmithKline plc980 Great West RoadBrentfordMiddlesexTW8 9GSUnited KingdomAttn: Corporate LawFacsimile: 011 44 208-047-6912 and with a copy to: BrentfordMiddlesexTW8 9GSUnited KingdomAttn: Vice President, Worldwide Business DevelopmentFacsimile: 011 44 208-990-8142 or to such other address as the addressee shall have last furnished in writing in accord with this provision to the addressor. All notices shall bedeemed effective upon receipt by the addressee.  16.8 Severability. In the event of the invalidity of any provisions of this Agreement or if this Agreement contains any gaps, the Partiesagree that such invalidity or gap shall not affect 52the validity of the remaining provisions of this Agreement. The Parties will replace an invalid provision or fill any gap with valid provisions whichmost closely approximate the purpose and economic effect of the invalid provision or, in case of a gap, the Parties’ presumed intentions. In theevent that the terms and conditions of this Agreement are materially altered as a result of the preceding sentences, the Parties shall renegotiate theterms and conditions of this Agreement in order to resolve any inequities. Nothing in this Agreement shall be interpreted so as to require eitherParty to violate any applicable laws, rules or regulations.  16.9 Headings. The headings used in this Agreement have been inserted for convenience of reference only and do not define or limit theprovisions hereof.  16.10 Waiver. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but nosuch waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. Nowaiver by any Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of thesame or any other term or condition of this Agreement on any future occasion. Except as expressly set forth in this Agreement, all rights andremedies available to a Party, whether under this Agreement or afforded by law or otherwise, will be cumulative and not in the alternative to anyother rights or remedies that may be available to such Party.  16.11 Entire Agreement. This Agreement (including the exhibits and schedules hereto) constitutes the entire agreement between the Partieshereto with respect to the within subject matter and supersedes all previous agreements and understandings between the Parties, whether writtenor oral. This Agreement may be altered, amended or changed only by a writing making specific reference to this Agreement and signed by dulyauthorized representatives of Theravance and GSK.  16.12 No License. Nothing in this Agreement shall be deemed to constitute the grant of any license or other right in either Party, to or inrespect of any Collaboration Product, patent, trademark, Confidential Information, trade secret or other data or any other intellectual property of theother Party, except as expressly set forth herein.  16.13 Third Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party,including without limitation any creditor of either Party hereto. No such Third Party shall obtain any right under any provision of this Agreement orshall by reasons of any such provision make any Claim in respect of any debt, liability or obligation (or otherwise) against either Party hereto.  16.14 Counterparts. This Agreement may be executed in any two counterparts, each of which, when executed, shall be deemed to be anoriginal and both of which together shall constitute one and the same document. 5316.15 Single Closing Condition. The obligation of each Party to consummate the transaction contemplated hereby is subject to thesatisfaction of the following condition (the “Closing Condition”): All filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 andany other similar competition or merger control laws that are necessary in any jurisdiction with respect to the transaction contemplated hereby shallhave been made and any required waiting period under such laws shall have expired or been terminated and any Governmental Authority that haspower under or authority to enforce such laws shall have, if applicable, approved, cleared or decided neither to initiate proceedings or otherwiseintervene in respect of the transaction contemplated hereby nor to refer the transaction to any other competent Governmental Authority. EachParty shall use good faith efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the otherparty in doing, all things necessary, proper or advisable to consummate and make effective the transaction contemplated by this Agreement,including, but not limited to satisfaction of the Closing Condition and each Party shall keep the other Party reasonably apprised of the status ofmatters relating to the completion of same. In connection with the foregoing, the Parties hereby agree to negotiate in good faith to make as soon aspracticable any modification or amendment to this Agreement or any agreement related hereto that is required by the United States Federal TradeCommission, Department of Justice or equivalent Governmental Authority, provided that no Party shall be required to agree to any modification oramendment that, in the reasonable opinion of such Party’s external legal or financial counsel, would be adverse to such Party. This Agreement maybe terminated by either Party upon written notice any time after June 1, 2003 if the transactions contemplated by this Agreement shall not havebeen consummated by June 1, 2003 due to failure to satisfy the Closing Condition; provided, however, that the terminating Party shall not havebreached in any material respect its obligations under this Agreement in any manner that shall have been the proximate cause of, or resulted in, thefailure to satisfy the Closing Condition or otherwise to consummate the transactions contemplated by this Agreement by such date. 54IN WITNESS WHEREOF, Theravance and GSK, by their duly authorized officers, have executed this Agreement on November 14, 2002. 
       
THERAVANCE, INC.
 
 
  GLAXO GROUP LIMITED
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By:
 
/s/ Rick E Winningham
 
 
 
 
  By:
 
/s/ Jean-Pierre Garnier
 
 
  Rick E Winningham
 
 
 
 
 
 
  Jean-Pierre Garnier
 
 
  Chief Executive Officer
 
 
 
 
 
 
  Chief Executive Officer
 
 55Schedule 1.19 Criteria for Theravance New Compounds and Replacement Compounds 1. Single optical isomer, which is patentable.2. Potency in vitro and in vivo compatible with potential to develop in a DPI device.3. Intrinsic agonist activity not less than that of salmeterol.4. Selectivity at βadrenoceptors, relative to βand β adrenoceptors, similar or superior to that of formoterol, assessed in assays determining equi-potent molar ratios relative to that of isoprenaline (isoproterenol).5. Selectivity at non-βadrenoceptors >100.6. No significant inhibition of the hERG potassium channel at a concentration at least 30 fold greater than the anticipated therapeutic maximumconcentration in plasma.7. Duration of agonist activity in vivo to be clearly longer than that of salmeterol. This would be at least 72 hours in the Theravance model. Theexact duration criterion for either the GSK or the Theravance model might be modified in the light of forthcoming clinical data from theprogram.8. Stable compound suitable for formulation to pursue FTIM studies, with crystalline form identified.9. Oral bioavailability to be less than 10% in the rat and less than 25% in the dog.10. No significant generation of markedly active metabolite(s) in vitro.11. Irritation to the respiratory tract no worse than salmeterol in a non-GLP 7-day inhaled rat study.  56
2  1  3
2Exhibit 10.13
COLLABORATION AGREEMENT
THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of November 2, 2012 (the “Effective Date”)by and between BIOCEPT, INC., a California corporation having an address of 5810 Nancy Ridge Drive, Suite 150, San Diego,CA 92121 (“Biocept”), and LIFE TECHNOLOGIES CORPORATION, a Delaware corporation having an address of 5791 VanAllen Way, Carlsbad, California 92008 (“Life Technologies”).
WHEREAS, Life Technologies, through its Medical Sciences Division, is engaged in the development and commercializationof diagnostic systems, tests and laboratory services, including in oncology;
WHEREAS, Biocept has developed expertise and proprietary technology in enrichment, extraction and analysis of circulatingtumor cells (CTCs) for use in laboratory developed tests used for the non-invasive and early stage detection and characterizationof primary, metastatic or recurrent cancers; and
WHEREAS, Life Technologies and Biocept desire to collaborate so that Biocept will develop and commercialize one ormore Tests, as defined herein, for Non-Small Cell Lung Cancer (NSCLC), using their respective technologies and expertise, onthe terms and subject to the conditions set forth herein. Life Technologies and Biocept will both promote the test and performdifferent components of the test, and Life Technologies will provide test results in the form of reports to physicians.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, and intending tobe legally bound, the parties hereby agree as follows:
 
1. DEFINITIONS 
1.1 “Affiliate” shall mean any company or entity controlled by, controlling, or under common control with a party heretoand shall include any company more than 50% of whose voting stock or participating profit interest is owned or controlled, directlyor indirectly, by a party, and any company which owns or controls, directly or indirectly, more than 50% of the voting stock of aparty.
1.2 “Assay” shall mean Biocept’s OncoCEE-LU™ (and OncoCEE-LU™ with Mutation Analysis) laboratory developedassay for characterization and profiling of CTCs from NSCLC patients, which shall incorporate, as Phase 1, CTC enumeration bycytokeratin and CD45 (and CEE-Enhanced™ when available), EML4/Alk1 fusions and EGFR amplification by fluorescence insitu hybridization (determined by Biocept); and as Phase 2, the additional detection of mutations for relevant genes, e.g., K-RAS,EGFR and B-RAF, as agreed by the parties, on captured CTCs and/or cell-free circulating DNA, as agreed by the parties, andemploying technologies that potentially may include Biocept’s Selector technology, and any improvements or enhancementsthereto, exclusive of new analytes (which are discussed in Section 3.5(f) under Collaboration Assays) or applications to primaryscreening.1.3 “Biocept Trademarks” shall mean Biocept, Inc., “OncoCEE-LU”, “OncoCEE™”, “CEE-Sure”, CEE-Enhanced™”, and/or such other trademarks and trade names owned or licensed, and used, by Biocept and/or its Affiliates in theTerritory to identify the Tests, in each case, whether or not registered.
1.4 “Life Technologies Trademarks,” shall mean Life Technologies, Life Technologies Medical Sciences and/or suchother trademarks and trade names owned or licensed and used by Life Technologies to identify the Tests, in each case, whether ornot registered.
1.5 “CLIA” shall mean the Clinical Laboratory Improvement Amendments of 1988, as it may be amended from time totime.
1.6 “Collaboration” shall have the meaning provided Section 3.1.
1.7 “Collaboration Assay(s)” shall have the meaning provided in Section 3.5(e).
1.8 “CPT Code” shall mean the American Medical Association’s (“AMA”) “Current Procedural Terminology” as publishedin the AMA’s CPT Process Manual, Fourth Edition and any such future editions, for procedures used in performance of theAssay, and amounts reimbursed by Medicare for such procedures for location 99, as modified annually.
1.9 “Designated Executive Officer” shall mean the executive officers of each party designated in writing be each party asbeing responsible for resolving disputes related to the Collaboration, which shall initially be David Hale on behalf of Biocept andRonnie Andrews on behalf of Life Technologies.
1.10 “FDA” shall mean the United States Food and Drug Administration, or any successor federal agency thereto.
1.11 “HIPAA” shall mean, collectively, the Health Insurance Portability and Accountability Act of 1996, as amended, andall regulations promulgated thereunder at 45 C.F.R. parts 160 through 164, and the Health Information Technology for Economicand Clinical Health Act of 2009 and related regulations and guidelines.
1.12 “Intellectual Property Rights” means all now or hereafter existing patents, patent applications, copyrights,trademarks (including service marks), trade secrets, know-how, mask work rights and design rights, whether registered orunregistered, and all rights or forms of protection of a similar nature having equivalent or similar effect to any of the foregoing,which may subsist anywhere in the world.
1.13 “Launch” shall mean formal commercial availability and offering to physicians of a Test, as mutually agreed upon bythe parties.
1.14 “Laws” shall mean all federal, state and local laws and regulations that apply to this Agreement including, withoutlimitation, (i) the Bayh-Dole Act (ii) the
 
2
TM TM
TMFederal Food, Drug, and Cosmetic Act (21 U.S.C § 321 et seq.) (iii) the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)) (iv) the Stark Law (42 U.S.C. § 1395nn) (v) the Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)) (vi) the civil FalseClaims Act (31 U.S.C. §§ 3729 et seq.) (vii) the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)) (viii) the HealthInsurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), (ix) the exclusion laws (x) SSA § 1128 (42U.S.C. § 1320a-7) (xi) Medicare (Title XVIII of the Social Security Act), (xii) Medicaid (Title XIX of the Social Security Act);(xiii) the Clinical Laboratory Improvements Act of 1988 (CLIA); and (xiv) data security, protection and privacy laws in theapplicable jurisdictions.
1.15 “Professional Component” shall mean the performance of the professional component of the steps of the Assay,which is the interpretation of results (generated in the Technical Component) of an Assay by a pathologist, and is covered by CPTcodes from the Professional Fee Schedule with the modifier “26”.
1.16 “Technical Component” shall mean the performance of the technical component of the steps of the Assay, which isthe physical performance of the Assay procedure up to the interpretation of results, and is covered by CPT codes from theProfessional Fee Schedule without the modifier “26”, and typically with a modifier “TC”.
1.17 “Term” shall have the meaning provided in Section 11.1.
1.18 “Test(s)” shall mean the Assay, which is a laboratory developed test, and/or any Collaboration Assay which is addedto this Agreement pursuant to Section 3.5(e), performed as a clinical reference laboratory test.
1.19 “Territory” shall mean the United States of America, and other countries of the world, contingent in the latter case onthe parties agreeing in writing on an appropriate strategy to access them in accordance with Section 3.2.
1.20 “Third Party(ies)” shall mean any entity other than Biocept or Life Technologies or an Affiliate of Biocept or LifeTechnologies.
 
2. APPOINTMENT; LICENSES 
2.1 Appointment. Upon the terms and conditions set forth in this Agreement, Biocept hereby grants Life Technologiesduring the Term the non-exclusive right, as further defined in Section 2.3, to promote the Tests in the Territory and to perform theProfessional Component of the Tests sold by the parties in the Territory, in accordance with the terms of this Agreement.
2.2 Trademark Licenses. The parties hereby grant to each other non-exclusive, fully-paid, royalty-free licenses to utilizethe other party’s trademarks, as follows:
(a) Biocept Trademarks. To facilitate the promotion and performance of Tests, during the Term Biocept herebygrants Life Technologies a non-exclusive, royalty-free, non-transferable license to use the Biocept Trademarks solely for
 
3use in connection with the promotion and performance of the Tests in the Territory. All materials associated with the Tests andused by Life Technologies in connection with the promotion of the Tests, including web-based, shall be co-branded with suchBiocept Trademarks as approved by Biocept prior to distribution. All use of Biocept Trademarks by Life Technologies hereunder(including all goodwill arising as a result of such use) shall inure to the benefit of Biocept, and these rights, whether registered or notregistered, at all times shall remain the sole property of Biocept. Biocept shall provide Life Technologies with copies of the BioceptTrademarks in an appropriate form for the uses contemplated in this Agreement. Life Technologies shall provide Biocept withsamples of all proposed use of the Biocept Trademarks in advance of such proposed use and Biocept shall have the right toapprove the appearance and placement of Biocept Trademarks by Life Technologies for the purpose of protecting and maintainingthe standards of quality maintained by Biocept for products sold under the Biocept Trademarks and for use of the BioceptTrademarks. If Biocept at any time finds that Life Technologies is not in compliance with this Section, then Biocept may notify LifeTechnologies in writing of such deficiencies, and if Life Technologies fails to correct such deficiencies within thirty (30) days afterreceipt of such notice, Biocept may, at its election and in addition to any other remedies, terminate the license granted to LifeTechnologies with respect to the Biocept Trademarks. Life Technologies shall display the ™ or  symbol, as directed by Biocept,in connection with Life Technologies’ use of the Biocept Trademarks.
(b) Life Technologies Trademarks. To facilitate the promotion and performance of Tests, during the Term LifeTechnologies hereby grants Biocept a non-exclusive, royalty-free, non-transferable license to use the Life TechnologiesTrademarks solely for use in connection with the promotion and performance of the Tests in the Territory. Materials associatedwith the Tests and used by Biocept in connection with the promotion of Tests, including web-based materials, may be co-brandedwith such Life Technologies Trademarks as approved by the parties prior to distribution. All use of Life Technologies Trademarksby Biocept hereunder including all goodwill arising as a result of such use) shall inure to the benefit of Life Technologies, and theserights, whether registered or not registered, at all times shall remain the sole property of Life Technologies. Life Technologies shallprovide Biocept with copies of the Life Technologies Trademarks in an appropriate form for the uses contemplated in thisAgreement. Biocept shall provide Life Technologies with samples of all proposed use of the Life Technologies Trademarks inadvance of such proposed use and Life Technologies shall have the right to approve the appearance and placement of LifeTechnologies Trademarks by Biocept for the purpose of protecting and maintaining the standards of quality maintained by LifeTechnologies for products sold under the Life Technologies Trademarks and for use of the Life Technologies Trademarks. If LifeTechnologies at any time finds that Biocept is not in compliance with this Section, then Life Technologies may notify Biocept inwriting of such deficiencies, and if Biocept fails to correct such deficiencies within thirty (30) days after receipt of such notice, LifeTechnologies may, at its election and in addition to any other remedies, terminate the license granted to Biocept with respect to theLife Technologies Trademarks. Biocept shall display the ™ or  symbol, as directed by Life Technologies, in connection withBiocept’s use of the Life Technologies Trademarks.
 
4
®
®2.3 Exclusivity. During the Term, the parties will promote and perform Tests for the clinical testing market on a non-exclusive basis in the Territory, except as otherwise provided for below. Biocept will have sole responsibility for performing theTechnical Component of all Tests sold by the parties, until and unless Life Technologies obtains the right from Biocept toindependently develop its own Tests in accordance with all applicable FDA regulatory requirements, as provided for in Section7.1. Life Technologies will be authorized to perform the Professional Component of all Tests sold by the parties, although Bioceptmay engage other groups in promotion, marketing and performance arrangements for the Tests, at the discretion of Biocept.Biocept shall provide thirty (30) days written notice to Life Technologies before entering into any such promotion, marketing andperformance arrangement.
 
3. COLLABORATION 
3.1 Purpose. During the Term, the parties agree to cooperate and collaborate to develop, promote and commercialize theTests for the clinical testing market in the Territory and in accordance with the terms of this Agreement (the “Collaboration”).The principal objective of the parties hereunder is to maximize the commercialization of the Tests in the Territory. The parties shalldeploy each of their respective sales forces in accordance with the terms of this Agreement in an effort to promote the Tests in theTerritory in the manner as agreed to by the parties, under the direction of the Joint Steering Committee.
3.2 Commercialization of Tests Outside the USA. At any time for up to two (2) years after the Effective Date, shouldLife Technologies desire to offer for sale any Test outside the USA, it shall first discuss with Biocept an appropriate strategy andplan for such effort. Such strategy and plan may involve the development of, and obtaining all applicable regulatory authorizationsfor, an in vitro diagnostic kit, instruments or similar systems, in collaboration with Biocept (with funding support, and more fullydescribed in Section 7.2), such strategy and plan to be reduced to writing and approved by the parties. If such written plan is notapproved by the parties within two (2) years of the Effective Date, the Territory shall revert to only the USA, unless otherwiseagreed to by the parties.
3.3 Life Technologies Responsibilities. Life Technologies shall use commercially reasonable efforts to promote the Testsin the Territory, in accordance with Section 3.2, using sales channels and methods, and adhering to substantially similar standardsthat it generally employs with respect to its laboratory developed tests. Without limiting the foregoing, Life Technologies’responsibilities with respect to marketing and promotion of the Tests in the Territory during the Term shall include the following:
(a) Life Technologies Customers. Life Technologies shall use commercially reasonable efforts to promote theTests to the appropriate healthcare professionals.
 
5(b) Test Performance. Life Technologies shall have the responsibility, subject to its capacity to support in itsreasonable discretion (of which capacity Life Technologies shall notify Biocept in writing at least sixty (60) days before launch ofthe Assay, and use diligent efforts to notify Biocept at least thirty (30) days before discovery of any decreases or increases in suchcapacity), for performing the Professional Component of the Assays sold by either party in the Territory. In particular, thelaboratory director of the Life Technologies CLIA laboratory will be responsible for issuing and signing off on the report.
(c) Sales, Marketing and Customer Service.
(i) Life Technologies shall, at its sole expense and in accordance with Section 2.2, develop and deliver tocustomers marketing materials for the Tests. Life Technologies shall use, as appropriate, Biocept’s “OncoCEE-LU”,OncoCEE™”, “CEE-Enhanced™” and “CEE-Sure” brand and the Biocept corporate name and logo, together with any LifeTechnologies branding, as part of the marketing materials for the marketing of the Tests and, where appropriate, in its other publicpresentations and disclosures concerning the Assay or Tests. Biocept shall have the right to review all such materials prior to theirinitial use.
(ii) Life Technologies shall cause its sales force to use commercially reasonable efforts to promote the Tests.
(iii) Life Technologies shall use commercially reasonable efforts to promote the sale of the Tests by includingthe Tests in its menu of services and by incorporating marketing materials regarding the Tests into its own marketing materials.
(iv) Life Technologies shall keep Biocept reasonably informed of its planned marketing activities with respect tothe Tests to allow Biocept to forecast its needs for reagents, equipment, laboratory space, personnel, computing, and testingreporting capabilities, including at each Joint Steering Committee meeting as indicated in Section 4, and will discuss and consider ingood faith Biocept’s suggestions for marketing the Tests.
(v) Life Technologies will provide customer service and support for the Professional Component of the Testsusing substantially similar methods and adhering to substantially similar standards that it generally employs with respect to its otherproducts and tests.
(d) Samples and Logistics.
(i) Life Technologies will be responsible for the logistics associated with its marketing efforts and performanceof the Professional Components of the Tests; provided, however, that Biocept will send the sample collection systems directly tocustomers identified by Life Technologies who order the Test, at Life Technologies’ expense. Biocept will further work with LifeTechnologies to facilitate transport of collected samples from the customer to Biocept’s CLIA laboratory. Life
 
6
TM
TMTechnologies will work collaboratively with Biocept on patient referral, billing and collections in accordance with Section 3.5(c)(iii), reporting of results and reporting quality control, and insurance or patient reimbursement.
(e) Demand Forecast. Within sixty (60) days of the Effective Date, Life Technologies will prepare a draft one-yearrolling forecast of Life Technologies’ expectation for physician requests for the Assay (the “Demand Forecast”), broken downinto quarterly demand for the Assay (with respect to each quarter, the “Quarterly Forecast”) which will be attached hereto asExhibit A, and will be finalized three (3) months before Launch. Beginning on the first day of the second (2) full calendar quarterfollowing the date of Launch, the Demand Forecast shall be updated on a quarterly basis. The Demand Forecast and QuarterlyForecasts shall be a good faith but non-binding forecast. In the event the parties develop a Collaboration Assay under the terms ofthis Agreement, demand for such Collaboration Assay shall be included in the Demand Forecast at all times following the Launchof such Collaboration Assay. A Performance Standard, mutually agreed to in accordance with Section 3.5(i), shall take effectbeginning with the second (2) full calendar quarter after the launch of any Test.
(f) Technical Developments. Life Technologies shall keep Biocept fully informed as to all discoveries and technicaldevelopments (including, without limitations, any inventions) made by Life Technologies during the Term related to the Assay orTests.
(g) Billing, Reporting, Auditing. 
(i) In all cases where Life Technologies performs the Professional Component of the Assay, Life Technologiesshall be responsible for billing the patient, the provider and/or the payer for the Test, including both the Technical Component andthe Professional Component of the Assay, and the collection of such amounts with respect to each Test performed. Biocept shallbill Life Technologies directly once a month for the Technical Component of each Assay (including the cost for sample collection inaccordance with Section 3.5(b)), based on pricing and reimbursement as agreed by the parties through the Joint SteeringCommittee within sixty (60) days of the Effective Date, generally based on each applicable CPT Code actually used in theperformance of such Technical Component, employing the Medicare rates for the applicable year as described on Exhibit B forthe initial one (1) year period, and Life Technologies shall pay Biocept within sixty (60) days following the invoice date. The partiesshall disclose actual reimbursement for each Test, and shall reconcile or “true-up” any differences between the amounts actuallyreceived by Life Technologies for each billing item or code and amounts paid to Biocept on a quarterly basis. If the allocation ofreimbursement is ambiguous with respect to billing codes or a Technical Component/Professional Component split, amountsreceived by Life Technologies that differ from the amounts agreed by the parties, or Medicare rates, shall be shared by the partieson the same ratio as the Technical Component/Professional Component ratio for Medicare. The Medicare rates used by theparties as the basis for determining the amount Life Technologies will pay Biocept for the Technical Component of the Assaybefore the quarterly true-up will be adjusted annually at the beginning of the calendar year to reflect
 
7
nd
ndchanges to such Medicare rates. Should Medicare change the basis for reimbursement of the Assay, the parties shall agree tonegotiate a structure for revenue sharing that generally accomplishes the result achieved above. Both parties agree to strictly adhereto all applicable Laws with respect to billing practices.
(ii) This Section 3.3(g) shall survive any termination or expiration of this Agreement for at least twelve (12)months following the effective date of such termination or expiration.
3.4 Biocept Responsibilities. Biocept shall use commercially reasonable efforts to promote the sale of the Tests in theTerritory, using at least the same sales channels and methods and adhering to at least the same standards that it generally employswith respect to its other clinical tests. Without limiting the foregoing, Biocept’s responsibilities during the Term shall include thefollowing:
(a) Biocept Customers. Biocept shall use commercially reasonable efforts to promote the Tests to appropriatehealthcare professionals.
(b) Assay Performance. Biocept shall be responsible for performing all Technical Components of all Assays sold byeither party unless and until the parties agree to enable Life Technologies to independently develop, validate and perform the Testat Life Technologies’ CLIA laboratory, in accordance with all applicable FDA regulatory requirements and Section 7.1. Until suchpoint of transfer, Biocept shall comply with all CLIA requirements, including validation of the Assay.
(c) Sales, Marketing and Customer Service. 
(i) Biocept shall cause its sales force to promote the Assay.
(ii) Biocept shall keep Life Technologies reasonably informed of its planned marketing activities with respect tothe Assay to allow Life Technologies to forecast its needs for equipment, space, personnel, computing, and test reportingcapabilities, including at each Joint Steering Committee meeting as indicated in Section 4, and will discuss and consider in goodfaith Life Technologies’ suggestions for marketing the Assay.
(iii) Biocept will provide customer service and support for the Assay using substantially similar methods andadhering to substantially similar standards that it generally employs with respect to its other tests.
(d) Samples and Logistics. Biocept will be responsible for the logistics associated with its own marketing effortsand performance of the Technical Component of the Assay, including distribution of shipping materials and sample collectionsystems by its sales representatives, patient referral and customer service.
 
8(e) Training and Education.
(i) Biocept shall provide sales and technical training and technical support, including assistance with customereducation and customer consultations, to Life Technologies’ personnel, with the frequency and content of the training to bedetermined by agreement between Biocept and Life Technologies.
(ii) Biocept will share its service educational materials and scientific publications to utilize in patient educationwith Life Technologies, and hereby grants Life Technologies rights to use such materials as are reasonably necessary for LifeTechnologies to carry out its obligations under this Agreement. Life Technologies may not alter or revise these materials without theprior written consent of Biocept.
(f) Regulatory Approval. Biocept has licenses enabling it to perform and obtain reimbursement for the Assay in allstates in the Territory except New York, where it is currently seeking such license. Biocept will maintain all such licenses which arereasonably required to perform the Assay during the Term. For any Collaboration Assay, Biocept will use commerciallyreasonable efforts to obtain or maintain licenses enabling it to perform such Collaboration Assay and obtain reimbursementtherefore, in accordance with each amendment to this Agreement entered in accordance with Section 3.5(f). Life Technologies willcooperate with Biocept so that Life Technologies’ marketing and sales efforts are conducted only in those states or regions of theTerritory in which Biocept has obtained any necessary regulatory licenses to provide Tests.
(g) Technical Developments. Biocept shall keep Life Technologies fully informed as to all discoveries and technicaldevelopments (including, without limitations, any inventions) made by Biocept during the Term related to the Tests.
3.5 Joint Responsibilities. The parties shall use commercially reasonable efforts to cooperate and collaborate to developthe market for the Tests in the Territory. Without limiting the generality of the foregoing, the parties shall collaborate to provide thefollowing:
(a) Test Development. The parties shall mutually agree on the content and composition of Phase II of the Assay,and any Collaboration Assays as defined in Section 3.5(f), including specific analytes to be included in the Assay. Considerationfor selection of analytes shall include medical need, clinical utility, technical feasibility, costs, reimbursement, and intellectualproperty status, e.g., the need for Third Party licenses to specific analytes. The parties shall agree on the Phase II Assay content atleast six (6) months before anticipated Launch.
(b) Test Materials and Shipping. Subject to Section 3.3(c)(i), Life Technologies shall design and order all testmaterials, including test requisition forms, test reports and collateral sales and marketing (advertising and promotional) materials tobe used by Life Technologies, which shall be approved by Biocept prior to use. Biocept shall design, order and provide to LifeTechnologies the collection systems to be used by Life Technologies, and Life Technologies shall pay for such collection systemsused by
 
9its sales representatives under this Agreement at cost (direct materials and direct labor) plus ten percent (10%), as well as shippingcosts of collection systems from ordering physicians to Biocept.
(c) Performance of Tests. 
(i) The parties will work together to develop a plan to implement detailed operation protocols for the Testwithin ninety (90) days of the Effective Date for each aspect of sample logistics, including ordering, shipping, accessioning, samplehandling, testing, data generation, data evaluation and reporting. These sample logistics shall be agreed upon by the parties throughthe Joint Steering Committee and, once agreed upon by the parties in writing, deemed to be attached hereto as Exhibit C withoutany additional action required on the part of either party. Information, data and images shall be transferred between the parties asindicated for this purpose, and the parties will seek to make their respective laboratory information management systems and datatransfer capabilities compatible. Life Technologies’ lab director at the CLIA lab will sign off on the reports for Tests.
(ii) If Life Technologies desires to utilize the Tests in support of any clinical trial or research program for apharmaceutical or biotechnology company(ies) in the Territory, Life Technologies shall notify Biocept in writing of such desireduse. The terms and conditions (including pricing and revenue sharing) of each such use shall be covered by a separate writtenagreement which the parties agree to negotiate in good faith.
(iii) Each party will use commercially reasonable efforts to support the other in the account to best meet theneeds and expectations of each customer.
(d) Communication Plan. Life Technologies and Biocept shall develop a communications plan through the JointSteering Committee for the announcement and ongoing promotion of the Tests to customers, with all communication plan materials,including test requisition forms, being co-branded with Biocept and Life Technologies corporate names and logos in accordancewith Sections 2.2 and 3.3(c)(i).
(e) Data Sharing. Life Technologies and Biocept have entered into this Agreement to, among other things, establishindividual databases of results from the Tests performed, which databases will include patient information such as demographic,disease characterization, treatment and outcome information. To that end, to the extent permitted by applicable law and as mutuallyagreed by the parties, where available each party will share all patient data, Test data and results, and corresponding tissue datawith the other party, as well as any follow up or outcome data that may become available or provided by the physician or patientfor Tests performed and will cooperate in good faith with the other party to agree upon procedures for sharing such information.Such information may be used only for longitudinal reporting, outcomes correlation and related research, shall be handled inaccordance with all applicable Laws, including, without limitation, HIPAA, and applicable institutional review board guidelines, andshall not be used for the purpose of obtaining information about the other party’s clients or customers. To the extent feasible, allsuch information will be properly de-identified.
 
10(f) Collaboration Assays. During the Term, Biocept shall keep Life Technologies reasonably apprised of its plans toadd analytes to the Assay. In addition, Life Technologies may desire for Biocept to develop a specific new analytes for the Assay(for example, the inclusion of additional mutations to the mutation analysis component of the Assay), to be offered by the parties asan additional Test under this Agreement. In either case, the parties shall negotiate in good faith an amendment to this Agreementthat will govern the development (as needed) and commercialization of such Tests with new analytes (each a “CollaborationAssay”), which amendment may include financial support, contributions of and access to each party’s technology and/or clinicalsamples, milestones, timing of the development effort, exclusivity and ownership rights. Any such agreed upon Collaboration Assaydevelopment shall be performed by Biocept or jointly as the parties may agree. Once the parties have agreed upon a plan relatingto the development of a particular Collaboration Assay, if development is needed (each, a “Project”), the parties shall reduce suchagreement to writing, which shall include a project plan which will set forth each party’s obligations with respect to the Project(each, a “Project Plan”) and thereafter, such Collaboration Assay shall be deemed a Test for all purposes under this Agreementand shall be subject to the terms of this Agreement as amended. Each such Project Plan shall be attached as a part of Exhibit D tothis Agreement following written acceptance thereof by both parties without any additional action required on the part of eitherparty. Any amendments or revisions to a Project Plan shall be mutually agreed upon by the parties in writing.
(g) Costs and Expenses. Unless otherwise specified herein or in a Project Plan attached hereto, each party shallperform its activities under this Agreement at its sole cost and expense.
(h) Training and Education.
(i) The parties shall work together to develop and implement a training program for client services and the salesand marketing representatives of each party to ensure that a clear and consistent message is delivered to all prospective customers.Following such implementation, each party agrees to train its client services and sales and marketing representatives in accordancewith such training program.
(ii) Representatives of each party, where deployed, shall each educate physicians, clinical and supportpersonnel on the Tests, their applications and benefits, and the procedures for providing samples for the Tests. The Joint SteeringCommittee will approve all presentation and meeting materials. In addition, the parties will each be responsible for providingcustomer support related to test logistics, billing and reimbursement, and for establishing a call center to handle inquiries related tothe Tests. For purposes of clarity, the parties acknowledge and agree that Life Technologies will not be required to establish adedicated web portal, but all results of Tests will be made available through an existing Life Technologies portal solution, oncecommercially available for use, as determined by Life Technologies at its sole discretion. Technical or
 
11process questions regarding the Tests received by Life Technologies can be referred to Biocept. Each party will cover its owncosts related to physician education, customer support, and any travel related thereto and comply with all federal and stateregulations regarding the same.
(i) Performance Standards. Each party shall conduct its activities under this Agreement and any Project Plan in aprofessional and workmanlike manner, and in compliance in all material respects with the requirements of applicable Laws andregulations, to attempt to achieve the objectives of this Agreement efficiently and expeditiously. Each party shall contribute suchpersonnel and resources, and shall maintain such laboratories and other facilities, as are reasonably necessary to carry out theactivities to be performed under this Agreement, including any Project Plans. In conformity with standard industry practices and theterms and conditions of this Agreement, each party shall prepare and maintain, or shall cause to be prepared and maintained,complete and accurate written records, accounts, notes, reports and data with respect to activities conducted by such party underthis Agreement, including any Project Plans. In addition, the parties shall work together to establish minimum agreed uponperformance standards with respect to the promotion, sales and performance of the Tests, including the Demand Forecast, and thetimely supply, accuracy, reliability and reporting of the Tests, as well as responsiveness to customer inquiries related to the Teststhroughout the Territory (collectively, “Performance Standards”). In the event that one or more Performance Standards are notmet by a party, the parties will work quickly and efficiently to (i) identify the cause of the failure, (ii) develop a plan to remediatethe issue, and (iii) implement the remediation plan. If the parties are unable to successfully resolve a Performance Standards issueby this procedure, such failure to maintain Performance Standards shall constitute a material breach by the party failing to maintainsuch Performance Standards, and the other party may terminate this Agreement in accordance with Section 11.2.
(j) Bundling. Neither party shall bundle its assays (including the Tests) with any assays of the other party, without theprior written approval of that party.
 
4. JOINT STEERING COMMITTEE 
4.1 Purpose and Membership. Promptly following the Effective Date, Biocept and Life Technologies will create a JointSteering Committee for the purpose of facilitating communications between the parties regarding, and providing direction andleadership to, the Collaboration. The Joint Steering Committee shall be composed of six (6) representatives, three (3) each fromBiocept and Life Technologies, each of whom shall have appropriate experience, knowledge and authority within such party’sorganization to carry out the duties and obligations of the Joint Steering Committee. Each party will designate one of itsrepresentatives as the primary contact for that party with respect to Joint Steering Committee-related matters, and suchrepresentatives shall serve as co-chairpersons of the Joint Steering Committee. Each party may change its representatives to theJoint Steering Committee or its primary contact from time to time in its sole discretion, effective upon notice to the other party ofsuch change. These representatives shall have appropriate technical credentials, experience and knowledge. A reasonable numberof additional representatives of a party may attend meetings of the Joint Steering Committee in a non-voting capacity.
 
124.2 Duties. The Joint Steering Committee shall meet in person or by teleconference or videoconference no less thanmonthly during the Term or as otherwise mutually agreed by the parties from time to time, with attendees other than Joint SteeringCommittee members permitted to participate in or observe the meetings. The Joint Steering Committee shall be responsible for (a)monitoring the progress of the Collaboration, including discussions relating to Collaboration Assays, (b) physician education withrespect to the Tests, (c) marketing, sales and account coordination, (d) any regulatory inquiries or requirements and other issuesthat affect the availability of the Tests, and (e) reimbursement issues (including annual review of relevant CPT Codes and changesthereto), logistical considerations, and other topics as necessary. The Joint Steering Committee shall serve as the principal forumfor each party to (i) keep the other party informed of the results of its Collaboration activities; (ii) to discuss Test commercializationstrategies, and (iii) generally to encourage and facilitate ongoing cooperation between the parties with respect to the Collaboration,including the business relationship and/or any other matter relating to the Collaboration and resolving disputes between the partieswith respect to Intellectual Property Rights; provided, however, that (A) nothing in this Agreement shall limit either party’s right toseek immediate equitable or injunctive relief where appropriate without any obligation to first submit the dispute to the JointSteering Committee; and (B) any decision concerning medical necessity and patient care with respect to Test sold by or performedon behalf of the parties shall be the responsibility of each party’s Medical Director, with the two Medical Directors workingtogether to coordinate efforts and address concerns.
4.3 Decisions; Disputes. Decisions of the Joint Steering Committee shall be made by unanimous vote, with each party’srepresentatives on the Joint Steering Committee collectively having one vote. In the event that the Joint Steering Committee cannotor does not, after good faith efforts, reach agreement on an issue, such issue shall first be referred to the Designated ExecutiveOfficers, who shall meet promptly thereafter and shall attempt in good faith to resolve such issue. In the event that the DesignatedExecutive Officers cannot or do not, after good faith efforts, reach agreement on an issue, the issue shall be submitted to voluntarymediation. The Designated Executive Officers of each party shall select a mediator who is an expert with no less than seven yearsof experience in the subject matter to which the dispute relates. In the event that the Designated Executive Officers of the partiesare unable to agree upon a mediator within twenty (20) days, then the Designated Executive Officers shall contact the San DiegoCounty office of JAMS to select a mediator from the JAMS panel. If they are unable to agree, JAMS shall provide a list of threeavailable mediators and each party may strike one. The remaining one will serve as the mediator. The mediation shall be conductedunder JAMS rules. The parties agree that they shall share equally the cost of the mediation filing and hearing fees, and the cost ofthe mediators that constitute the panel. Each party shall bear its own attorneys’ and expert fees and all associated costs andexpenses.  
 
135. REGULATORY COMPLIANCE 
5.1 Compliance with Laws. Biocept and Life Technologies and their respective Affiliates each agree to perform theirrespective obligations under this Agreement in compliance with all applicable Laws, in the Territory, including but not limited toapplicable regulations, rules, and policies of third party payers that pay for the Assay.
5.2 Privacy. Biocept and Life Technologies and their respective Affiliates agree to protect the privacy and provide for thesecurity of any information that relates to a patient’s past, present, or future physical or mental health or condition in accordancewith HIPAA, and any other applicable federal and state privacy laws and regulations in the Territory. Each party agrees to executeone or more Business Associate Agreements (as defined under HIPAA) as the other party, or its providers or payers, may fromtime to time request.
5.3 Licenses and Certifications. Biocept and, to the extent applicable, Life Technologies shall have at all times during theTerm, all necessary federal, state and local licenses, qualifications and certifications to operate a laboratory and perform theirrespective components of the Test(s), including, but not limited to, state laboratory licenses, CLIA certification, CAP (College ofAmerican Pathologists) certification, FDA registration, and any other licenses or certification required by state and/or federal law.All Assays performed by Biocept, and, to the extent applicable, Life Technologies, shall be in accordance with applicable stateand federal testing requirements for clinical reference laboratories.
 
6. MATERIALS TRANSFER 
In order to facilitate the Collaboration, either party may provide to the other party certain biological materials or chemicalcompounds including, but not limited to, samples (collectively, “Materials”) for use by the other party in furtherance of theCollaboration. Except as expressly provided under this Agreement, all such Materials delivered to the other party will remain thesole property of the supplying party, will be used only in furtherance of the Collaboration and solely under the control of the otherparty, will not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying party,and will not be used in research or testing involving human subjects except as permitted by applicable law. The Materials suppliedhereunder must be used with prudence and appropriate caution in any experimental work and in accordance with all applicablelaws.
 
7. OPTIONS AND FUTURE DISCUSSIONS 
7.1 Option to License Assay. If Biocept does not obtain at least ten million dollars ($10,000,000) in equity financing byDecember 31, 2012, then Life Technologies shall have the non-exclusive option, exercisable by written notice to Biocept given nolater than January 15, 2013, to negotiate with Biocept for a license (unless the parties mutually agree to a different transactionstructure) to all necessary Intellectual Property
 
14Rights and know-how to independently commercialize the Assay in accordance with applicable Laws. Biocept will provide noticeto Life Technologies on December 31, 2012 if the conditions for the option apply, and if Life Technologies delivers written noticeof exercise of such right of negotiation to Biocept on or before January 15, 2013, the parties will negotiate in good faith toconclude a license agreement no later than February 28, 2013. If such license has not been entered into by the parties by February28, 2013, there are no further obligations for either party under this Section 7.1.
7.2 Option for System Development. The parties have discussed potential adaptation of the Assay to an in vitrodiagnostic format, based on a “system” concept that could include specially manufactured equipment, consumables and reagentsthat would be sold to physicians and laboratories, and linked to the “informatics engine” that Life Technologies is developing. Suchsystems may be used to commercialize the Assay outside the USA. Biocept grants to Life Technologies a non-exclusive option,exercisable during the two (2) year period beginning on the Effective Date, to develop plans, and negotiate with Biocept, for theco-development with Biocept of such systems for the Assay, employing or based on Biocept technologies. Such agreement isexpected to include some or all of the following components: an upfront license fee, R&D funding, development and commercialmilestone payments, royalties and/or revenue sharing, and supply/sale to Life Technologies by Biocept of proprietary componentsand consumables.
 
8. INTELLECTUAL PROPERTY 
8.1 Existing Technology. Each party acknowledges that the other party owns certain technology and Intellectual PropertyRights which have been independently developed by, or at the request of, such other party, whether prior to, during or subsequentto the Term. Except as expressly provided in this Agreement, neither this Agreement nor the activities performed hereunder, shallgive either party any rights or interest in or to the technology or Intellectual Property Rights of the other party (or of any Materialsprovided by such party). Each party owns, and shall continue to own, all right, title and interest in and to its respective technology,including, without limitation, all Intellectual Property Rights relating thereto. Without limiting the generality of the foregoing, at alltimes during and after the Term, Biocept shall own all rights to its CEE™ technology, Selector technology (if utilized) and anyimprovements related thereto, generated during the performance of this Agreement. Biocept and Life Technologies shall promptlynotify the other in writing upon becoming aware of any alleged or threatened third party infringement of any Intellectual PropertyRights related to the Tests. Biocept shall have the right to bring and control any action or proceeding with respect to any suchinfringement at its own expense and by counsel of its own choice. If Biocept elects not to bring any such action or proceeding withrespect to such infringement, it shall promptly notify Life Technologies of the same and agrees to consider, in good faith a requestby Life Technologies to bring any such action or proceeding. Any agreement allowing Life Technologies to bring such action orproceeding on behalf of Biocept shall be set forth in a separate written agreement between the parties. Except as expresslyprovided above, the parties shall be under no obligation to enforce any of their Intellectual Property Rights against any actual orthreatened Third Party infringements.
 
158.2 Biocept Technology. Without limiting the generality of the foregoing, Biocept owns, and Life Technologiesacknowledges Biocept’s ownership of, (i) the Assay and the Selector technology, and (ii) all Intellectual Property Rights in theAssay and the Selector technology, and Life Technologies agrees that it shall not do or suffer to be done any act or thing orundertake any action anywhere that in any manner might infringe, or impair the validity, scope, or title of Biocept in the Assay, theSelector technology or Intellectual Property Rights owned by Biocept. Nothing herein shall limit Life Technologies’ ability toprosecute fully any and all Intellectual Property Rights owned by Life Technologies with any patent office or related governmentagency or to respond fully to any government agency inquiry with respect to its Intellectual Property Rights, products, and services.
8.3 New Technology. In the course of the activities conducted by the parties, Biocept and/or Life Technologies mayconceive of inventions or discoveries or create works that constitute intellectual property and may be patentable or registerable asa copyright or other intellectual property right (all of the foregoing, including such intellectual property rights therein, collectively,“Developments”). Inventorship of all inventions and discoveries, whether or not patentable, will be determined in accordancewith United States patent laws. Authorship of all copyrightable works will be determined in accordance with United Statescopyright laws. Subject to Section 8.2, as between the parties, Developments will be owned consistent with such determination ofinventorship or authorship. To the extent any Development owned by Life Technologies relates directly to the practice of, orconstitutes an improvement to, the Assay, Life Technologies hereby grants to Biocept, during the Term of this Agreement, and,except in the case of termination of this Agreement by Life Technologies for Biocept’s uncured material breach, after expiration ortermination of this Agreement, a non-exclusive, worldwide, royalty-free, fully-paid license, including the right to sublicense, underLife Technologies’ Intellectual Property Rights in such Developments, solely to develop, make, have made, use, sell, have sold,offer for sale, import, perform and provide the Assay. To the extent any Development owned by Biocept relates directly to thepractice of, or constitutes an improvement to, the Assay, Biocept hereby grants to Life Technologies, during the Term of thisAgreement, a non-exclusive license under Biocept’s Intellectual Property Rights in such Development, solely to promote the Assayin the Territory and to perform the Professional Component of the Assay sold by the parties in the Territory, in accordance withthe terms of this Agreement.
8.4 Technology Licenses. To the extent that any Third Party Intellectual Property Rights related to the capture anddetection of CTCs must be licensed to perform the Assay, such royalty shall be paid by Biocept. To the extent that either partyowns Intellectual Property Rights to specific biomarkers, targets, kits, dyes or technology utilized in the Assay other than for thecapture and detection of CTCs, it will, to the extent it is able, grant during the Term of the Agreement, a non-exclusive license tothe other party to practice these Intellectual Property Rights for the Assay. To the extent that either party has licensed or willlicense Intellectual Property Rights from Third Parties related to specific biomarkers, targets, kits, dyes or technology utilized in theAssay other than for the capture and detection of CTCs, it will, to the extent it is able, grant, during the Term of the Agreement, anon-exclusive license to the other party, or ensure that the
 
16other party is covered under its license, to practice these Intellectual Property Rights for the Assay. In the event of the foregoing,then, subject to Section 8.5, the parties agree to negotiate in good faith an allocation of expenses for such Third Party licensesdirectly associated with the Assay.
8.5 Infringement. If any Third Party claims or brings an action alleging that performance of the Assay or Test by Bioceptor Life Technologies or their Affiliates under this Agreement infringe (directly or indirectly) any of such Third Party’s patent rights,Biocept shall use commercially reasonable efforts to address such claims. If Biocept determines to seek a license or otherwiseobtain the right to use such Third Party intellectual property rights on behalf of Biocept and Life Technologies, then (i) if the ThirdParty intellectual property rights relate to the capture and detection of CTCs or the Phase I Assay analytes, then Biocept shall bearthe costs of such licenses, including the payment of licensing fees, royalties or other payments, or (ii) if the Third Party intellectualproperty rights relate to specific biomarkers, targets, kits, dyes or technologies for the Phase II Assay, then the parties agree tonegotiate in good faith an allocation of costs for such licenses, including payment of licensing fees, royalties or other payments thatmay be due to such Third Party, unless the parties agree otherwise in writing. If Biocept and Life Technologies determine to seek alicense or otherwise obtain rights to use Third Party intellectual property rights for any Collaboration Assay(s), the parties similarlyagree to negotiate in good faith an allocation of costs for such licenses, including payment of licensing fees, royalties or otherpayments that may be due to such Third Party, unless the parties agree otherwise in writing. 
8.6 Data and Results. All data and results from performance of a Test on samples provided by Life Technologies shall beused by the parties solely to the extent necessary to perform its obligations under this Agreement and in accordance with Section3.5(d).
8.7 Trademarks. 
(a) Biocept shall be responsible for and bear the expense of any filing, prosecution, maintenance and enforcement ofthe Biocept Trademarks as it may determine in its sole discretion, without obligation. Life Technologies shall not, during the Termor thereafter, use or seek to register the trademarks or any trademark or trade name similar to or confusing with the BioceptTrademarks, or any translation thereof, in any jurisdiction. Life Technologies agrees that, if Life Technologies at any time obtains, inany jurisdiction, any right, title or interest in any mark, symbol or phrase which shall be identical to, similar to or likely to beconfused with any Biocept Trademark or any translation thereof, then Life Technologies shall have acted or shall act as an agentand for the benefit of Biocept for the limited purpose of obtaining such registrations and assigning such registration (and all right,title and interest in such mark, symbol or phrase) to Biocept.
(b) Life Technologies shall be responsible for and bear the expense of any filing, prosecution, maintenance andenforcement of the Life Technologies Trademarks as it may determine in its sole discretion, without obligation. Biocept shall
 
17not, during the Term or thereafter, use or seek to register the trademarks or any trademark or trade name similar to or confusingwith the Life Technologies Trademarks, or any translation thereof, in any jurisdiction. Biocept agrees that, if Biocept at any timeobtains, in any jurisdiction, any right, title or interest in any mark, symbol or phrase which shall be identical to, similar to or likely tobe confused with any Life Technologies Trademark or any translation thereof, then Biocept shall have acted or shall act as an agentand for the benefit of Life Technologies for the limited purpose of obtaining such registrations and assigning such registration (andall right, title and interest in such mark, symbol or phrase) to Life Technologies.
 
9. REPRESENTATIONS AND WARRANTIES 
9.1 Mutual Representations and Warranties. Each party represents and warrants to the other that: (a) it is dulyorganized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate power andauthority to enter into this Agreement and to carry out the provisions hereof; (b) it is duly authorized to execute and deliver thisAgreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has beenduly authorized to do so by all requisite corporate action; (c) this Agreement is legally binding upon it, enforceable in accordancewith its terms; and (d) the execution, delivery and performance of this Agreement by it does not conflict with any agreement,instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law orregulation of any court, governmental body or administrative or other agency having jurisdiction over it.
9.2 Biocept Warranties on Assay.
(a) As of the Effective Date, the Assay employs Biocept’s most current CTC-based technology, and will be validatedfor performing CTC enumeration and the detection of the indicated analytes in the Assay on a timeline as agreed by the partieswithin sixty (60) days of the Effective Date.
(b) Biocept represents and warrants to Life Technologies that: (1) the Assay constitutes an original work of Biocept;and (2) except as previously disclosed to Life Technologies, Biocept is the lawful owner or licensee of all materials used inconnection with the development of the Assay, and Biocept has the rights to make, use and sell the Assay, and to allow LifeTechnologies to use the results of the Technical Component of the Assay to perform the Professional Component of the Assay,and to sell the Assay.
(c) Biocept has full power and authority and has obtained all Third Party consents, approvals, assignments and/orother authorizations required to enter into this Agreement and to carry out its obligations hereunder.
(d) There are no existing contracts, agreements, commitments, proposals, offers, or rights with, to, or in any person toacquire any of the rights under the Assay which would prevent or materially and adversely alter the performance of the obligationshereunder.
 
189.3 Third Party Infringement. In the event that the Tests, or any part thereof becomes the subject of any claim, suit orproceeding for infringement of the Intellectual Property Rights of any Third Party, or if the Test, or any part thereof, is held orotherwise determined to infringe any Intellectual Property Rights of any Third Party such that Biocept can no longer perform itsobligations under this Agreement, Biocept shall in its sole discretion either: (1) secure for itself and Life Technologies the right tocontinue using the Test in accordance with Section 8.4; (2) replace or modify the Test to make it non-infringing without degradingits performance or utility; or (3) notify Life Technologies that it will perform neither (1) nor (2), in which case either party shallthereafter have the right to terminate this Agreement immediately upon written notice to the other party. Notwithstanding theforegoing, and subject to Section 8.5, the indemnification rights of Life Technologies with respect to the Tests as set forth inSection 12.2 shall survive such termination.
9.4 Disclaimer. Except as expressly set forth herein, THE TECHNOLOGY, MATERIALS AND INTELLECTUALPROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED “AS IS,” AND EACH PARTYEXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDINGTHE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM ACOURSE OF DEALING, USAGE OR TRADE PRACTICES.
9.5 Limitation of Liability. NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTYANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THISAGREEMENT OR ANY LICENSE GRANTED HEREUNDER; provided, however, that this Section shall neither (a) apply toany liability for damages arising from breach of any obligations of confidentiality under Article 10, nor (b) limit the indemnificationobligations of the parties arising under Article 12 of this Agreement.
 
10. CONFIDENTIALITY 
10.1 Confidential Information. Except to the extent expressly authorized by this Agreement or otherwise agreed in writingby the parties, each party agrees that, during the Term and for five (5) years thereafter, such party (the “Receiving Party”) shallkeep confidential and shall not publish or otherwise disclose and shall not use for any purpose, other than as expressly provided forin this Agreement, any information furnished to it by or on behalf of the other party (the “Disclosing Party”) pursuant to thisAgreement (collectively, “Confidential Information”). The Receiving Party may use such Confidential Information only to theextent required to accomplish the purposes of this Agreement. The Receiving Party will use at least the same standard of care as ituses to protect proprietary or confidential information of its own to ensure that its, and its Affiliates’, employees, agents,consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information. The ReceivingParty will promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Disclosing Party’sConfidential Information.
 
1910.2 Exceptions. Confidential Information shall not include any information which the Receiving Party can prove bycompetent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, generallyknown or available; (b) is known by the Receiving Party at the time of receiving such information, as evidenced by its writtenrecords; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure;or (d) is independently discovered or developed by the Receiving Party, without the use of Confidential Information of theDisclosing Party, as evidenced by the Receiving Party’s written records maintained in the ordinary course of business.
10.3 Authorized Disclosure. Each party may disclose Confidential Information of the other party as expressly permittedby this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances:
(a) enforcing such party’s rights under this Agreement;
(b) prosecuting or defending litigation as permitted by this Agreement;
(c) complying with applicable court orders or governmental regulations;
(d) disclosure to Affiliates, contractors, employees and consultants who need to know such information for thedevelopment and commercialization of the Test in accordance with this Agreement, on the condition that any such Third Partiesagree to be bound by confidentiality and non-use obligations that are no less stringent than the terms of this Agreement; and
(e) disclosure to Third Parties in connection with due diligence or similar investigations by such Third Parties, anddisclosure to potential Third Party investors in confidential financing documents, provided, in each case, that any such Third Partyagrees to be bound by reasonable obligations of confidentiality and non-use.
Notwithstanding the foregoing, in the event a party is required to make a disclosure of the other party’s ConfidentialInformation pursuant to Section 10.3(b) or Section 10.3(c), it will, except where impracticable, give reasonable advance notice tothe other party of such disclosure and use efforts to secure confidential treatment of such information at least as diligent as suchparty would use to protect its own confidential information, but in no event less than reasonable efforts. In any event, the partiesagree to take all reasonable action to avoid disclosure of Confidential Information hereunder.
10.4 Confidentiality of this Agreement. Except as otherwise provided in this Section 10, each party agrees not todisclose to any Third Party the terms of this Agreement without the prior written consent of the other party hereto, except that eachparty may disclose the terms of this Agreement that are otherwise made public prior to the date of such disclosure or to the extentsuch disclosure is permitted under Section 10.3.
 
2010.5 Press Releases; Public Announcements. Neither party shall make a press release or public announcement thatincludes information relating to the Collaboration without the approval of the other party. At least five (5) days prior to any suchpress release or public announcement the party proposing to make such press release or public announcement (the “ReleasingParty”) shall provide to the other party a draft copy thereof for its review and approval. The Releasing Party may not distributesuch press release or public announcement without obtaining the other party’s prior written approval. In addition, the ReleasingParty shall, at the other party’s request, remove therefrom any Confidential Information of such other party. The contribution ofeach party shall be noted in all scientific publications or presentations by acknowledgment or co-authorship, whichever isappropriate.
 
11. TERM AND TERMINATION 
11.1 Term. The term of this Agreement will commence on the Effective Date and continue for a period of three (3) yearsafter the Effective Date (the “Initial Term”). Thereafter, this Agreement can be renewed by mutual written agreement of theparties for successive one (1) year periods (each, a “Renewal Term” and together with the Initial Term, the “Term”).
11.2 Termination.  
(a) Material Breach. Either party shall have the right to terminate this Agreement before the end of the Term uponwritten notice to the other party if such other party is in material breach of this Agreement and has not cured such breach withinsixty (60) days (the “Cure Period”) after notice from the terminating party requesting cure of the breach. Any such terminationshall become effective at the end of such Cure Period unless the breaching party has cured such breach prior to the end of suchCure Period. Any right to terminate under this Section 11.2(a) shall be stayed and the Cure Period tolled in the event that, duringany Cure Period, the party alleged to have been in material breach shall have initiated dispute resolution in accordance with Article13 with respect to the alleged breach, which stay and tolling shall continue until such dispute resolution procedures have beencompleted in accordance with Article 13. Nothing herein is intended to prevent either party from seeking immediate equitable orinjunctive relief.
(b) Termination for Convenience. Both parties shall have the right to terminate this Agreement at any time, for anyor for no reason, upon one hundred twenty (120) days written notice to the other party. In the event a party undergoes a Changeof Control Event as defined in Section 14.5, the other party may terminate the Agreement upon thirty (30) days written notice tothe party undergoing the Change of Control.
 
2111.3 Effect of Termination; Surviving Obligations. 
(a) Upon any termination or expiration of this Agreement, all licenses granted hereunder shall automatically terminateand revert to the granting party and all other rights and obligations of the parties under this Agreement shall terminate, except asprovided in Sections 11.3(b) and 11.4.
(b) Upon termination or expiration of this Agreement, each party will use their best efforts to return to the other partyor destroy all tangible copies of the other party’s Confidential Information in such party’s possession or control and will erase fromits computer systems all electronic copies thereof; provided, however, that each party may retain one archival copy of the otherparty’s Confidential Information solely for purposes of monitoring compliance with its obligations under Article 10 hereof.
11.4 Survival. Expiration or early termination of this Agreement shall not relieve either party of any obligation accruing priorto such expiration or termination. In addition, Sections 3.3(g), 4.3, 5.1, 5.2 (to the extent required by law) 9.1, 9.2, 9.3, 9.5, 11.3and 11.4, and Articles 1, 8, 10, 12, 13 and 14 will survive any expiration or termination of this Agreement.
 
12. INDEMNIFICATION 
12.1 Indemnification by Life Technologies. Life Technologies hereby agrees to defend, indemnify and hold harmlessBiocept, its Affiliates and their respective officers, directors, employees, consultants and agents (the “Biocept Indemnitees”),from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and attorneys’ feesresulting from any threat, claim, demand, action or other proceeding by any Third Party (“Losses”) to the extent such Losses arisedirectly or indirectly out of: (a) the gross negligence or willful misconduct of any Life Technologies Indemnitee (defined below); (b)the material breach by Life Technologies of any warranty, representation, covenant or agreement made by it in this Agreement; or(c) the performance by Life Technologies of the Professional Component; except, in each case, to the extent such Losses resultfrom the gross negligence or willful misconduct of any Biocept Indemnitee or the material breach by Biocept of any warranty,representation, covenant or agreement made by it in this Agreement.
12.2 Indemnification by Biocept. Biocept hereby agrees to defend, indemnify and hold harmless Life Technologies, itsAffiliates and their respective officers, directors, employees, consultants and agents (the “Life Technologies Indemnitees”),from and against any and all Losses to the extent such Losses arise directly or indirectly out of: (a) the gross negligence or willfulmisconduct of any Biocept Indemnitee; (b) the material breach by Biocept of any warranty, representation, covenant or agreementmade by it in this Agreement; or (c) the performance by Biocept of the Technical Component of the Assay or Test; except, in eachcase, to the extent such Losses result from the gross negligence or willful misconduct of any Life Technologies Indemnitee or thematerial breach by Life Technologies of any warranty, representation, covenant or agreement made by it in this Agreement.
 
2212.3 Procedure. In the event a party seeks indemnification under Section 12.1 or 12.2, it shall inform the other party (the“Indemnifying Party”) of a claim as soon as reasonably practicable after such party (the “Indemnified Party”) receives noticeof the claim (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a claim as providedin this Section 12.3 shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only tothe extent that such Indemnifying Party is actually damaged as a result of such failure to give notice), shall permit the IndemnifyingParty to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetaryconsideration), and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. TheIndemnified Party shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of theIndemnifying Party. The Indemnifying Party shall not agree to any settlement of such action, suit, proceeding or claim or consent toany judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liabilitywith respect thereto, that imposes any liability or obligation on the Indemnified Party or that acknowledges fault by the IndemnifiedParty; in each case, without the prior written consent of the Indemnified Party.
12.4 Insurance. Each party, at its own expense, shall maintain product liability and other appropriate insurance (or self-insure) in an amount consistent with industry standards during the Term and shall name the other party as an additional insured withrespect to such insurance. Each party shall provide a certificate of insurance (or evidence of self-insurance) evidencing suchcoverage to the other party upon request.
 
13. DISPUTE RESOLUTION 
13.1 Dispute Resolution. The parties recognize that disputes as to certain matters may arise from time to time during theTerm. The parties shall first submit the dispute to the Joint Steering Committee for resolution in accordance with Section 4.3hereof. In the event that the Joint Steering Committee is unable to resolve the dispute, the parties shall be entitled to seek relief in acourt of competent jurisdiction. Notwithstanding the foregoing, to the full extent allowed by law, either party may bring an action inany court of competent jurisdiction for injunctive relief (or any other provisional remedy) to protect the parties’ rights or enforcethe parties’ obligations under this Agreement pending resolution of any claims related thereto by the Joint Steering Committee.
 
14. GENERAL PROVISIONS 
14.1 Governing Law. This Agreement and any disputes, claims, or actions related thereto shall be governed by andconstrued in accordance with the laws of the State of California, USA, without regard to the conflicts of law provisions thereof.
14.2 Entire Agreement; Modification. This Agreement, including the Exhibits hereto, is both a final expression of theparties’ agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior
 
23and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all matterscontained herein. This Agreement may only be amended, modified or supplemented in a writing expressly stated for such purposeand signed by the parties to this Agreement.
14.3 Relationship Between the Parties. The parties’ relationship, as established by this Agreement, is solely that ofindependent contractors. This Agreement does not create any partnership, joint venture or similar business relationship betweenthe parties. Neither party is a legal representative of the other party, and neither party can assume or create any obligation,representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever.
14.4 Non-Waiver. The failure of a party to insist upon strict performance of any provision of this Agreement or to exerciseany right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, inwhole or in part, in that instance or in any other instance. Any waiver by a party of a particular provision or right shall be in writing,shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party.
14.5 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereundermay be assigned or otherwise transferred by either party without the prior written consent of the other party (which consent shallnot be unreasonably withheld); provided, however, that either party may assign this Agreement and its rights and obligationshereunder without the other party’s consent in connection with the transfer or sale of all or substantially all of the business of suchparty to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise (a “Changeof Control Event”). The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefitof the successors and permitted assigns of the parties. Any assignment not in accordance with this Agreement shall be void.
14.6 No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the benefit of any partyother than those executing it.
14.7 Severability. If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a courtof competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality ofany remaining portions of this Agreement. All remaining portions shall remain in full force and effect as if the original Agreement hadbeen executed without the invalidated, unenforceable or illegal part.
14.8 Notices. Any notice to be given under this Agreement must be in writing and delivered either in person, by any methodof mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing,to the party to be notified at its address(es) given below, or at any address such party has previously designated by prior writtennotice to the other. Notice shall be deemed sufficiently given for all purposes upon the earlier of: (a) the date of actual receipt; or(b) if mailed, five calendar days after the date of postmark.
 
24If to Biocept, notices must be addressed to:
Biocept, Inc.5810 Nancy Ridge Drive, Suite 150San Diego, CA 92121Attention: David HaleExecutive ChairmanTelephone: (858) 320-8200Facsimile: (858) 320-8225
If to Life Technologies, notices must be addressed to:
Life Technologies Corp.5791 Van Allen WayCarlsbad, CA 92008Attention: David DalyHead of OncologyTelephone: (760) 268-5556
14.9 Force Majeure. Each party shall be excused from liability for the failure or delay in performance of any obligationunder this Agreement by reason of any event beyond such party’s reasonable control, including but not limited to, Acts of God,fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, any strike or labor disturbance. Such excuse fromliability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and providedthat the party has not caused such event(s) to occur. Notice of a party’s failure or delay in performance due to force majeure mustbe given to the other party within five (5) calendar days after its occurrence. All delivery dates under this Agreement that havebeen affected by force majeure shall be tolled for the duration of such force majeure. In no event shall any party be required toprevent or settle any labor disturbance or dispute. In the event of a force majeure that persists for thirty (30) days or more, theneither party may terminate this Agreement upon written notice to the other party.
14.10 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an originaldocument, and all of which, together with this writing, shall be deemed one and the same instrument.
 
25IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorizedrepresentatives as of the date first set forth above.
 
BIOCEPT, INC.   LIFE TECHNOLOGIES CORPORATION
By: /s/ Michael J. Dunn   By: /s/ David J. Daly
Name: Michael Dunn   Name: David J. Daly
Title: Senior Vice President, Corp. Dev.  Title: Head of Oncology
 
26Exhibit 10.1 COLLABORATION AGREEMENT 
THIS COLLABORATION AGREEMENT (“Agreement”) is made as of this 18th day of August 2014 (the “Effective Date”), by and betweenCapsugel US, LLC and its Affiliates with an address at 412 Mt. Kemble Ave, Suite 200C, Morristown, NJ 07960 (“CAPSUGEL”) and Cardax, Inc.,and its Affiliates, with a corporate address at 2800 Woodlawn Dr., Suite 129, Honolulu, HI 96822 (“CARDAX”). CARDAX and CAPSUGEL are eacha “Party” and together constitute the “Parties”  RECITALS WHEREAS, CAPSUGEL is experienced in formulating, developing, manufacturing, testing and packaging of health and nutrition products; and WHEREAS, CARDAX is experienced in developing products that are based on its astaxanthin technologies; and WHEREAS, CAPSUGEL and CARDAX desire to enter into an arrangement under which the Product (as defined below) will be formulated anddeveloped for the purpose of identifying a marketing partner(s) (“Marketer”) for Marketer’s onward sale of the Product in the Territory. NOW, THEREFORE, the Parties hereto agree to the following:  SECTION 1 DEFINITIONS The following terms for the purpose of this Agreement shall have the following respective meanings: 1.1 “Active Ingredient” shall mean the synthetic Astaxanthin and/or esters thereof that will be formulated in the Product as the active ingredient ofthe Product. 1.2 “Adjusted Net Sales” shall mean [***]. 1.3 “Administrative Cost” shall mean [***]. 1.4 “Affiliate” shall mean, with respect to either Party, all entities which, directly or indirectly, are controlled by, control or are under commoncontrol with such Party. For purposes of this Agreement, the word “control” shall mean the possession, directly or indirectly, of the power to director cause the direction of the management and policies of an entity, including through ownership of more than fifty percent (50%) of the votingshares or interest of an entity; provided, however, with respect to CAPSUGEL, the term “Affiliate” shall be limited to entities who directly orindirectly through one or more intermediaries are controlled by the parent of CAPSUGEL’s direct parent entity and with respect to CARDAX theterm “Affiliate” shall not include Cardax Pharmaceuticals, Inc.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.11.5 “Applicable Laws” shall mean all applicable laws, statutes, ordinances, codes, rules and regulations applicable to the formulation, developmentand/or manufacture, marketing, distribution sale, and disposal of the Product or any aspect thereof and the obligations of CAPSUGEL or CARDAX,as the context requires under this Agreement. 1.6 “Annual Period” shall mean the twelve (12) month period beginning on the first day in which the Launch Date occurs and each twelve (12)month period beginning on the anniversary of such day thereafter. 1.7 “Commercially Reasonable Efforts” means a Party’s reasonable efforts and diligence, consistent with professional business standardsgenerally practiced in the health and nutrition industry, applied in accordance with the Party’s commercially reasonable business, legal, medical andscientific judgment, including the efforts and resources the Party would use for a product owned by it or to which it has rights, which is of similarmarket potential at a similar stage in its product life, taking into account the competitiveness of the marketplace, the proprietary position of thecompound, the Applicable Laws, the profitability of the applicable products, and other relevant factors including, without limitation, technical,legal, scientific or medical factors. 1.8 “Development Plan” shall have the meaning set forth in Section 2.1. 1.9 “Disclosing Party” shall have the meaning set forth in the Confidentiality Agreement. 1.10 “Formulation” means a specific combination of excipient(s) that can formulate the Active Ingredient, as well as compounds other than theActive Ingredient, developed as a result of the work conducted under the Development Plan. 1.11 “Force Majeure” shall have the meaning set forth in Section 10.5. 1.12 “Indemnified Party” shall have the meaning set forth in Section 8.3. 1.13 “Indemnifying Party” shall have the meaning set forth in Section 8.3. 1.14 “Intellectual Property Rights” means a composition of matter, formula, process, method of use, invention, improvement, business name,domain name or database right to the extent any of the foregoing is protected in a utility model, trademark, service mark, trade name or businessname, copyright, registered design, design right, patent, know-how, trade secret, rights in or to confidential information all goodwill related theretoand any other intellectual property right of any nature whatsoever throughout the world (whether registered or unregistered and including allapplications and rights to apply for the same).  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.21.15 “Launch Date” shall mean the date [***]. 1.16 “Loss or Losses” shall mean any and all damages, fines, fees, settlements, payments, obligations, penalties, deficiencies, losses, costs andexpenses, including, without limitation, environmental losses, interest, court costs, reasonable fees of attorneys, accountants and other experts andother reasonable expenses of litigation or other proceedings or of any claim, default or assessment. 1.17 “Manufacturing Facility” shall mean those areas of CAPSUGEL or CAPSUGEL’s subcontractors manufacturing, packaging, laboratory andwarehousing facilities utilized in the formulation, manufacture, packaging, storage, testing, shipping or receiving of the Product. 1.18 “Materials” mean all excipient(s) and inactive raw materials used in the formulation of the Product. For the avoidance of doubt, “Materials”does not include any Active Ingredient or work in process or finished goods inventory. 1.19 “Net Sales” means [***]. 1.20 “Product” shall mean Active Ingredient Formulated in CAPSUGEL’s proprietary Lipid Multi-Particulate Technology, including anyimprovements or derivatives of such technology. 1.21 “Receiving Party” shall have the meaning set forth in the Confidentiality Agreement. 1.22 “Regulatory Approvals” means any and all approvals, licenses, registrations, or authorizations of the relevant Regulatory Authority, necessaryfor the development, manufacture, use, storage, import, transport, export or commercialization of the Product in a particular country or jurisdiction. 1.23 “Regulatory Authority (ies)” means any governmental regulatory authority within a Territory involved in regulating any aspect of thedevelopment, manufacture, testing, market approval, sale, distribution, packaging or use of the Product. 1.24 “Regulatory Filings” shall mean the registrations, permits, licenses, authorizations, presentations, notifications, filings and/or approvals(together with all applications therefore and all related documents required by the FDA and all other laws for the development, manufacture, use,importation, export, marketing, sale and distribution of the Product within the Territory.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.31.25 “Royalty Payment” shall have the meaning set forth in Section 5.1. 1.26 “Specifications” shall mean the Product description and attributes agreed upon between the Parties upon conclusion of the Development Planand appended to this Agreement as Exhibit B that will be attached hereto and, when attached, will be a part hereof, prior to commercialization of theProduct. 1.27 “Territory” shall mean worldwide.  Section 2 Product Development, Manufacture and Commercialization 2.1Governance Process Among the Parties. Both CARDAX and CAPSUGEL will agree upon a development plan, which shall be in writing andattached hereto as Exhibit A (the “Development Plan”), which shall describe various parameters including each Party’s duties, obligations, timeschedule and deliverables schedule. The activities performed under the Development Plan (the “Development Activities”) shall beadministered by a joint project team (“JPT”), which shall review/update/amend the Development Plan for the Product in the Territory andcoordinate the Formulation, development, manufacturing and commercialization of the Product, including identifying and selecting one or moreMarketers as contemplated under Section 2.4. Each Party shall appoint a project manager to oversee that Party’s performance of its obligationsunder this Agreement and shall notify the other Party of the name and full contact details of its appointed project manager. The JPT shallcomply with this Agreement for decisions specifically assigned to a Party pursuant to this Agreement. Meetings shall take place by telephoneor in person and the JPT will operate by consensus. If consensus cannot be reached, the matter will be submitted to the Head of Dosage FormSolutions of CAPSUGEL and the President and CEO of CARDAX for resolution. If such matter is not resolved, then the Parties may attempt tomediate such issue under the JAMS mediation rules. No member or any Affiliate of any member of the JPT shall have any liability under thisAgreement and shall be exculpated to the fullest extent not prohibited by law from any liability to any Party that such member is not anemployee, officer, consultant or acting in any similar capacity.   2.2CAPSUGEL Responsibilities. With respect to the Product, CAPSUGEL, [***] shall [***] perform the development work necessary toformulate, analytically develop and take all other developmental actions necessary or required to develop the Product and manufacture pre-clinical and clinical batches (collectively, the “CAPSUGEL Development Activities”). For purposes of further clarification, CAPSUGELDevelopment Activities shall include, without limitation, each of the following performed with all due diligence, care and skill and in accordancewith all other Applicable Laws:    
CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.4(a)Formulation Development. Formulation shall mean a specific combination of Materials that formulate the Active Ingredient, as well ascompounds other than the Active Ingredient, developed as a result of the work conducted under the Development Plan. Thedevelopment of the Formulation of the Product, includes without limitation, all stability tests and other studies as applicable,providing CARDAX reports of such stability tests, using Commercially Reasonable Efforts to modify the Formulation as necessaryand develop processes capable of scale-up and commercialization in accordance with Applicable Laws.       (b)Analytical Methods. Developing and validating analytical methods including but not limited to dissolution, assay, and stability asagreed upon by the Parties.       (c)Manufacture of Study Batches. The manufacture [***] of batches of Product in amounts specified on or about the dates determinedas reasonably necessary for conducting all required for CAPSUGEL/CARDAX funded studies. Any other batches required orreasonably required by the Marketer for applying for and all actions related to additional Regulatory Approvals and RegulatoryFilings of the Product and any related communications, studies or support for the FDA or any other Regulatory Authority (ies), whichmay include human and animal studies, shall be paid for by the Marketer, unless the Parties agree otherwise.       (d)Manufacturing Development. Development of manufacturing processes and systems in conformance with cGMP requirements ofFDA to manufacture pilot batches, exhibit batches and commercial batches of Product.       (e)Reporting. CAPSUGEL shall, throughout the performance of the Development Plan studies, consult with CARDAX on mattersincluding technical, intellectual property and regulatory aspects and keep the other apprised of all developments.       (f)Commercial Manufacturing. CAPSUGEL shall manufacture the Product for each Marketer unless otherwise agreed by the Parties andthe applicable Marketer.
2.3CARDAX Responsibilities.
  (a)CARDAX shall be responsible for [***] the Active Ingredient [***], subject to reasonable notice and delivery schedules andreasonable amounts required by CAPSUGEL for it to perform its obligations under this Agreement or as otherwise agreed byCARDAX.       (b)[***]  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.52.4Joint Responsibilities.
[***] The marketing of the Product shall be carried out by one or more mutually identified Marketer(s) by the JPT or otherwise in accordance with Section2.1. CAPSUGEL and CARDAX will jointly control identification, decision rights, and terms for a Marketer as determined by the JPT or otherwise inaccordance with Section 2.1. If a Marketer is not identified, or the terms are not determined, by the JPT or otherwise in accordance with Section 2.1,then the Marketer (and such terms) may be designated by either Party, subject to the reasonable approval of the other Party.  Any additional costs/activities required from a Marketer will be subject to agreement of the JPT or otherwise as provided in Section 2.1, includingbut not limited to pre-launch out-of-pocket expenses and the funding of such costs and expenses. These costs will be shared [***]. 2.5Ownership of Application. CARDAX shall own and control all information and rights in, to and under all Regulatory Approvals in the Territory(including all associated contents and correspondences) and applications therefore related to the Product and any other marketingauthorizations within the Territory, unless otherwise mutually agreed upon by the Parties.
Section 3 Intellectual Property Matters 3.1 Background IP. This Agreement shall not change, modify or otherwise affect any rights to any confidential information, inventions, patents,patent applications or other Intellectual Property Rights owned or developed by either Party before the Effective Date or developed by a Party afterthe Effective Date other than under the terms of this Agreement (“Background IP”). This Agreement shall not confer on either Party any rights inand/or to any Background IP of the other party, except as otherwise provided in this Agreement. 3.2 CAPSUGEL Property. CARDAX acknowledges that CAPSUGEL possesses certain inventions, processes, know-how, trade secrets,improvements, other intellectual properties and other assets, including but not limited to formulation recipes, processing details, laboratoryanalyses, analytical methods, procedures and techniques, computer technical expertise and software, which have been independently developedby CAPSUGEL, including but not limited to, the Background IP of CAPSUGEL (collectively “Capsugel Property”). CARDAX and CAPSUGEL agreethat any Capsugel Property or improvements thereto which are used, improved, modified or developed by CAPSUGEL under or during the term ofthis Agreement are the product of CAPSGUEL’s technical expertise possessed and developed by CAPSUGEL prior to the Effective Date and are thesole and exclusive property of CAPSUGEL.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.63.3 CARDAX Property. CAPSUGEL acknowledges that CARDAX possesses certain inventions, processes, know-how, trade secrets,improvements, other intellectual properties and other assets, which have been independently developed by CARDAX, including but not limited to,the Background IP of CARDAX (collectively “CARDAX Property”). CAPSUGEL and CARDAX agree that any CARDAX Property orimprovements thereto which are used, improved, modified or developed by CARDAX under or during the term of this Agreement are the product ofCARDAX’s technical expertise possessed and developed by CARDAX prior to the Effective Date and are the sole and exclusive property ofCARDAX. 3.4 Use of Confidential Information. CARDAX may use the confidential information of CAPSUGEL generated under this Agreement, except forCAPSUGEL’s internal technical protocols and Background IP, to the extent necessary (i) in connection with seeking regulatory approval for aCompound Formulation or the Product and/or (ii) filing a patent application. “Compound Formulation” means any specific combination ofexcipient(s) and the Active Ingredient developed as a result of the work conducted under this Agreement. CARDAX may use and discloseCAPSUGEL’s internal technical protocols and Background IP, to the extent necessary for Regulatory Approvals as contemplated by Section 2.3(b)to the extent reasonably determined by CAPSUGEL after notice and consultation with CAPSUGEL by CARDAX. 3.5 Inventions. Each Party will own all of its inventions and other Intellectual Property Rights made under this Agreement, including any patents,patent applications and other Intellectual Property Rights related to such inventions, if any, made solely by its employees or independentcontractors or employees or independent contractors of its Affiliates, unless otherwise expressly set forth herein. 3.6 Joint Inventions. The Parties will jointly own all inventions and other Intellectual Property Rights jointly made under this Agreement that aredirectly resulting from work conducted under this Agreement in accordance with the Development Plan and related specifically to the Product orthe Compound Formulation, including any patents, patent applications and other Intellectual Property Rights related to such inventions, if any,unless otherwise expressly set forth herein. During the Term, each Party hereby provides a worldwide, exclusive, royalty free, perpetual license ofsuch Intellectual Property Rights for use by each licensee in its business in connection with the development and marketing and commercializationof the Product. For avoidance of doubt, no Party or any of its Affiliates shall have any rights to the Background IP of the other Party nor shall anyParty have rights to any trademarks, service marks, trade names, business names or product names developed by the other Party. All decisionsregarding the protection and exploitation of joint investments and other Intellectual Property Rights shall be determined by the JPT or otherwise inaccordance with Section 2.1. 3.7 [reserved]  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.73.8 Freedom to Operate. CARDAX acknowledges that it shall be solely and fully responsible to use its Commercially Reasonable Efforts for doingany and all freedom to operate assessments regarding possible infringement of third party intellectual property rights for the Product in the part ofthe Territory that the Parties reasonably determine require such protection; provided, however, each Party shall be solely and fully responsible fordoing any and all freedom to operate assessments regarding possible infringement of third party intellectual property rights for any and all of itsIntellectual Property Rights.  Section 4 Exclusivity [***] Section 5 Consideration 5.1 Royalty Payments. CAPSUGEL shall pay to CARDAX a royalty equal to [***] of the Adjusted Net Sales (“Royalty Payment”) within [***]after the end of [***]. 5.2 Mode of Payment. CAPSUGEL will endeavor to contract with Marketer to receive profit sharing payments in U.S. dollars and CAPSUGEL will inturn pay CARDAX its share in U.S. dollars. Should Marketer require that local currency based payments be made to CAPSUGEL then CAPSUGELwill pay CARDAX its share in such local currency unless otherwise agreed. For instances in which Marketer sells the product in a local currencyother than U.S. dollars but agrees to pay CAPSUGEL in U.S. dollars, the conversion of local currency to USD will be a mutually agreeablemethodology with such Marketer (e.g., using the Marketer’s standard accounting methodology such as its average daily rate for its accountingmonth). 5.3 Taxes. All federal, national, regional, district, local or other governmental income tax or similar tax that is imposed on either Party as a result ofincome, shall be the responsibility of such Party. All amounts payable by CAPSUGEL to CARDAX under this Agreement shall be paid free andclear of all deductions or withholdings whatsoever, except as may be required by law. If any deductions or withholdings are required by law to bemade from any of the amounts payable by CAPSUGEL to CARDAX, the amount of any such withholding may be treated as part of the RoyaltyPayment, depending on the timing and the applicable legal requirements and CAPSUGEL shall provide CARDAX a receipt of any suchwithholdings.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.8Section 6 Regulatory Requirements 6.1 Regulatory Contacts. [***] CAPSUGEL shall notify CARDAX immediately, and in no event, no later than three (3) business day(s), after itreceives any contact or communication from any governmental or regulatory authority, including without limitation the FDA, that in any wayrelates to or may have an impact on a Product or the CAPSUGEL Development Activities. 6.2 Regulatory Inspections. Throughout the Term of this Agreement, CAPSUGEL agrees to cooperate with any governmental or regulatory body,particularly the FDA, which requests a general GMP inspection or audit or any inspection or audit relative to the manufacture, storage, handling, orshipment of Product manufactured, stored, handled, or shipped by CAPSUGEL. In addition, CAPSUGEL shall use its Commercially ReasonableEfforts to meet all reasonable U.S. FDA and other appropriate regulatory demands. 6.3 CARDAX Inspection. CARDAX shall have the right to audit CAPSUGEL’s facilities, quality systems and records from time to time uponreasonable notice and CARDAX shall have the right to have a third party accounting firm, subject to a non-disclosure agreement, auditCAPSUGEL’s financials as they relate to Net Sales and Adjusted Net Sales. In the event that the amount of the Royalty Payment for any quarter is10% or more than the amount reported by CAPSUGEL, then CAPSUGEL will pay the costs and expenses of the audit or investigation. 6.4 Regulatory Notices. CAPSUGEL shall provide prompt written notice to CARDAX of the occurrence of, and the results of any regulatorynotices including inspections as referenced in this Section 6 relating to the manufacture of Product. 6.5 Recordkeeping. CAPSUGEL shall keep true, accurate, and complete books, records, reports, and accounts (hereinafter “Records”) of allbusiness or activities in connection with or relating to the manufacture, storage, handling, and shipment, including all validations, qualification, andvalidation protocols, of Product and this Agreement. CARDAX has the right, upon reasonable prior notice and during normal business hours, toinspect and examine such Records. CAPSUGEL agrees to retain all such Records for a period of five (5) years after the expiration of the Term orafter termination of this Agreement.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.96.6 Recall. In the event that either Party believes it may be necessary to conduct a recall, field correction, market withdrawal, stock recovery, orother similar action with respect to any Product which was sold under this Agreement (a “Recall”), CARDAX and CAPSUGEL shall promptlyconsult with each other in good faith as to how best to proceed, it being understood and agreed that the final decision as to any Recall of anyProduct sold by Marketer(s) shall be made jointly; provided, however, that neither Party shall be prohibited hereunder from taking any action that itis required to take by Applicable Law or taking Commercially Reasonable Efforts to mitigate the loss from any Recall or seizure or to protect thepublic. Each of CAPSUGEL and CARDAX shall make a permanent, complete and accurate record of all costs incurred by it in connection with anyProduct Recall or seizure. With respect to any Recall or seizure of any Product caused by the negligence, mistake or omission of CAPSUGEL,CAPSUGEL shall (i) reimburse CARDAX for all out-of-pocket costs and expenses reasonably incurred by CARDAX in connection with the Recallor seizure, including, without limitation, replacing the Product subject to the Recall or seizure in accordance with this Agreement; and (ii) asprovided in Section 8.1, indemnify and save CARDAX and its Affiliates harmless from and against any and all damages to or claims by third partiesassociated (or Affiliated) with or resulting from any such Recall or seizure. With respect to any Recall or seizure caused by the negligence, mistakeor omission of CARDAX (including but not limited to failure of the Active Ingredient to meet the Specifications), CARDAX shall: (i) reimburseCAPSUGEL for all out-of-pocket costs and expenses reasonably incurred by CAPSUGEL in connection with the Recall or seizure; and (ii) asprovided in Section 8.2, indemnify and save CAPSUGEL and its Affiliates harmless from and against any and all damages to or claims by thirdparties associated with or resulting from any such Recall or seizure. With respect to any Recall or seizure of a Product not caused by the negligence, mistake or omission of either Party, each Party shall bear [***] ofthe aggregate costs of any and all out-of-pocket costs, expenses and losses reasonably incurred by either Party in connection with the Recall orseizure. If CAPSUGEL and CARDAX cannot agree which party is at fault or whether a Recall or seizure was reasonably beyond the control of the Parties,then an independent technical expert, acceptable to both Parties, shall be designated to make such determination. The designated technical expertshall not be an employee, consultant, officer, director or shareholder of, or otherwise associated with, CAPSUGEL, CARDAX or their respectiveAffiliates. The technical expert’s determination will be, in the absence of fraud or manifest error, binding and conclusive upon the Parties. Each Party shall keep the other fully informed of any notification or other information, whether received directly or indirectly, which might affect themarketability, safety or effectiveness of a Product, or which might result in liability issues or otherwise necessitate action on the part of either party,or which might result in Recall or seizure of the Product. Prior to any reimbursement pursuant to this Section 6 the Party claiming reimbursement shall provide the other Party with all availabledocumentation of all reimbursable costs and expenses.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.10Section 7 Representations and Warranties 7.1 Representations and Warranties of CAPSUGEL. CAPSUGEL hereby represents and warrants to CARDAX as follows:   (a)CAPSUGEL is a corporation in good standing under the laws of the jurisdiction of its organization and authorized to do businesswherever necessary to fulfill the terms and conditions of this Agreement;       (b)CAPSUGEL has the full power and authority to execute and deliver this Agreement and perform its covenants, duties and obligationsdescribed in this Agreement;       (c)This Agreement is the valid, legal and binding obligation of CAPSUGEL, enforceable in accordance with its terms;       (d)Neither the execution and delivery of this Agreement nor the performance of CAPSUGEL’s covenants, duties and obligationsdescribed in this Agreement constitute or will constitute a default under or conflict with any judgment, decree or order of any court orother governmental body to which CAPSUGEL is subject and will not conflict or be inconsistent with or result in the termination,modification, breach or default under the terms of any contract, commitment, covenant, agreement, instrument, document orunderstanding to which CAPSUGEL is a party;       (e)CAPSUGEL is not a party to, nor to CAPSUGEL’s knowledge is CAPSUGEL as of the Effective Date threatened with, any legal orequitable action or proceeding before any court, arbitrator, administrative agency or other tribunal which is reasonably likely toadversely affect its ability to execute and deliver this Agreement or fully and timely perform its covenants, duties and obligationsdescribed in this Agreement;       (f)CAPSUGEL has obtained and continuously maintained all permits, authorizations and licenses issued by all federal, state and localgovernmental agencies and authorities necessary for the conduct of CAPSUGEL’s businesses as of the Effective Date;       (g)CAPSUGEL has and shall continue to follow, comply with and adhere to all Applicable Laws necessary for the conduct ofCAPSUGEL’s businesses;
CAPSUGEL shall during the performance of the CAPSUGEL Development Activities ensure that, at all times, its employees, contractors,consultants, sub-contractors carry out their duties with all reasonable skill and care customary for the type of scientific research and developmentwork covered by this Agreement and shall at all times comply with all applicable laws and regulations; record experimental data and all othermaterial information relating to the CAPSUGEL Development Activities in individual notebooks or other appropriate formats and treat the same asConfidential Information; ensure that, at all times, its employees, contractors, consultants and sub-contractors are fully aware of and comply withthe confidentiality provisions of their respective contracts which, for the avoidance of doubt, are comparable to the confidentiality provisions setout in this Agreement; keep CARDAX informed of the progress of the CAPSUGEL Development Activities by providing bi-weekly written reportsand such other interim reports or updates as CARDAX may reasonably request.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.117.2 Representations and Warranties of CARDAX. CARDAX hereby represents and warrants to CAPSUGEL as follows:   (a)CARDAX is a corporation in good standing under the laws of the jurisdiction of its organization and authorized to do businesswherever necessary to fulfill the terms and conditions of this Agreement;       (b)CARDAX has the full power and authority to execute and deliver this Agreement and perform its covenants, duties and obligationsdescribed in this Agreement;       (c)This Agreement is the valid, legal and binding obligation of CARDAX, enforceable in accordance with its terms;       (d)Neither the execution and delivery of this Agreement nor the performance of CARDAX’s covenants, duties and obligations describedin this Agreement constitute or will constitute a default under or conflict with any judgment, decree or order of any court or othergovernmental body to which CARDAX is subject and will not conflict or be inconsistent with or result in the termination,modification, breach or default under the terms of any contract, commitment, covenant, agreement, instrument, document orunderstanding to which CARDAX is a party;       (e)CARDAX is not a party to, nor to CARDAX’s knowledge is CARDAX as of the Effective Date threatened with, any legal or equitableaction or proceeding before any court, arbitrator, administrative agency or other tribunal which is reasonably likely to adversely affectits ability to execute and deliver this Agreement or fully and timely perform its covenants, duties and obligations described in thisAgreement; and       (f)CARDAX has obtained and continuously maintains all permits, authorizations and licenses issued by all federal, state and localgovernmental agencies and authorities necessary for the conduct of CARDAX’s businesses as of the Effective Date.
Disclaimer. THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS AGREEMENT ARE THE PARTIES’ ONLY WARRANTIESAND NO OTHER WARRANTY, EXPRESS, IMPLIED OR STATUTORY, WILL APPLY. EACH PARTY EXPRESSLY DISCLAIMS ALL OTHERWARRANTIES, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESSFOR A PARTICULAR PURPOSE. FOR THE AVOIDANCE OF DOUBT, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALLWARRANTIES OF NON-INFRINGEMENT THAT ARE NOT EXPRESSLY SET FORTH IN THIS AGREEMENT.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.12Section 8 Indemnification 8.1 CAPSUGEL’s Indemnification of CARDAX. CAPSUGEL shall indemnify, defend and hold CARDAX, its Affiliates and their respective officers,directors, employees and agents harmless from and against any and all third party Losses suffered, incurred or sustained by CARDAX or to whichCARDAX becomes subject at any time, to the extent arising out of or resulting, directly or indirectly, from: (a) any breach of CAPSUGEL’srepresentations, warranties or obligations under this Agreement; (b) any personal injury, death or property damage caused by the possession, use,or consumption by any person of any Product that does not comply with the Specification in any way or is the result of actions or inactions ofCAPSUGEL in its manufacturing or is alleged to result from any inherent risk of the Formulation or a defect in the Formulation; and (c) any othernegligent act or omission on the part of CAPSUGEL, its Affiliates or their respective employees or agents except, in each case, to the extent suchclaims are attributable to the gross negligence or willful misconduct of CARDAX. 8.2 CARDAX’s Indemnification of CAPSUGEL. CARDAX shall indemnify, defend and hold CAPSUGEL, its Affiliates and their respective officers,directors, employees and agents harmless from and against any and all third party Losses suffered, incurred or sustained by CAPSUGEL or towhich CAPSUGEL becomes subject at any time, to the extent arising out of or resulting, directly or indirectly, from (a) any breach of CARDAX’srepresentations, warranties or obligations under this Agreement; (b) any personal injury, death or property damage caused by the possession, useor consumption by any person of any Product supplied by CAPSUGEL under this Agreement that does not comply with the Specifications as aresult of actions or inactions of CARDAX or is alleged to result from any inherent risk of the Product or a defect in the Active Ingredient; and (c)any other negligent act or omission on the part of CARDAX, its Affiliates or their respective employees or agents except, in each case, to the extentsuch claims are attributable to the gross negligence or willful misconduct of CAPSUGEL.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.138.3 Indemnification Process. If CARDAX, Affiliates or their respective employees, servants or agents, or CAPSUGEL, its Affiliates or theirrespective employees, servants or agents (in each case an “Indemnified Party”), receive any written claim which such Indemnified Party believes isthe subject of indemnity hereunder by the other Party hereto (an “Indemnifying Party”), the Indemnified Party shall, as soon as reasonablypracticable after forming such belief, give notice thereof to the Indemnifying Party, provided that the failure to give timely notice to theIndemnifying Party as contemplated hereby shall not release the Indemnifying Party from any liability to the Indemnified Party unless theIndemnifying Party demonstrates that the defense of such claim is prejudiced by such failure. The Indemnifying Party shall have the right, byprompt notice to the Indemnified Party to assume the defense of such claim at its cost, with counsel reasonably satisfactory to the IndemnifiedParty. If the Indemnifying Party does not so assume the defense of such claim or, having done so, does not diligently pursue such defense, theIndemnified Party may assume the defense, with counsel of its choice, but at the cost of the Indemnifying Party. If the Indemnifying Party soassumes the defense, it shall have absolute control of the litigation; the Indemnified Party may, nevertheless, participate therein through counsel ofits choice and at its cost. The Party not assuming the defense of any such claim shall render all reasonable assistance to the Party assuming suchdefense, and out-of-pocket costs of such assistance shall be for the account of the Indemnifying Party. No such claim shall be settled other than bythe Party defending the same, and then only with the consent of the other Party, which consent shall not be unreasonably withheld; provided thatthe Indemnified Party shall have no obligation to consent to any settlement of any such claim which (i) imposes on the Indemnified Party anyliability or obligation which cannot be assumed or performed in full by the Indemnifying Party, (ii) does not unconditionally release the IndemnifiedParty, (iii) does require a statement as to or an admission of fault, culpability or failure to act by or on behalf of Indemnified Party or any of itsAffiliates or (iv) does impose any restrictions on the conduct of business by the Indemnified Party or its Affiliates. 8.4 Limitation of Damages. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY CONSEQUENTIAL, SPECIAL OR PUNITIVEDAMAGES OR LOST PROFITS ARISING UNDER OR RELATING TO THIS AGREEMENT. Except in the event of (i) a Party’s gross negligence orwillful misconduct and/or (ii) a Party’s breach of its confidentiality obligation, the total liability of one Party to the other Party (and its Affiliates)arising out of or in connection with this Agreement or the Products, whether in contract, tort (including negligence), statute or otherwise, shall, tothe maximum extent permitted by Applicable Law, be limited to the amount of revenues it receives under this Agreement. 8.5 Insurance. During the Term and for a period of two (2) years after the termination of the Agreement or the expiry date of the last batchmanufactured whichever is later, thereafter, each Party shall obtain and maintain, at its sole expense adequate product liability insurance for theProduct as it reasonably deems necessary and appropriate. Evidence of coverage, in the form of certificates of insurance, shall be providedpromptly upon registration of the Product in given countries and as reasonably requested thereafter.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.14Section 9 Confidentiality and Publicity Confidentiality. The Parties agree that the terms of the Confidentiality Agreement entered into between the parties dated Nov 19, 2013 shall governthis Agreement.  Section 10 Term and Termination 10.1 Term and Renewal. [***] In addition, any contract entered into by the Parties with a Marketer for the Product shall survive termination of thisAgreement in accordance with its terms, including any renewal rights provided therein. 10.2 Termination for Breach. A material breach that is subject to cure that is not cured within [***] of written notice of breach shall be cause fortermination, provided that if the breaching party is diligently pursuing in good faith the remedy of the breach at the expiration of such [***] cureperiod, then such [***] cure period shall be extended for a reasonable period to effect the cure. Upon any breach by CAPSUGEL, CARDAX shallbe permitted to use all Intellectual Property of CAPSUGEL used in the Formulation and the Product to the extent necessary for the development andmarketing of the Product. Upon any breach by CARDAX, CAPSUGEL shall be permitted to use all Intellectual Property of CARDAX used in theActive Ingredient and the Product to the extent necessary for the development and marketing of the Product in accordance with the terms of thisAgreement as of the date of such termination. 10.3 Termination for Bankruptcy. This Agreement may be terminated by either Party, forthwith, or at any time thereafter by notice to the other ifthe other becomes bankrupt or insolvent, or enters into liquidation whether compulsorily or voluntarily, or convenes a meeting of its creditors, orhas a receiver appointed over all or part of its assets, or ceases for any reason to carry on business. 10.4 Development or Commercial Non-Viability. In the event that CAPSUGEL reasonably determines that the development of the Compound Formulation is not feasible with CommerciallyReasonable Efforts in accordance with the Development Plan, with such changes as reasonably requested by CAPSUGEL, then CAPSUGEL maydiscontinue the development of the Compound Formulation and Product and terminate this Agreement, in which case, CARDAX shall have theright to license the Intellectual Property Rights as provided in Section 4.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.15In the event that CARDAX reasonably determines that, with Commercially Reasonable Efforts by the Parties, the development of a Product is notfeasible due to any legal, or technical developments with respect to the Product, including but not limited to conflicts of Intellectual PropertyRights; withdrawal of a Product by a major regulatory agency for safety or efficacy reasons; or inability of the Parties to produce a Product thatpasses FDA required biostudies, in which such developments make the Product nonviable or that the Product is not acceptable to any applicableMarketer, then, CARDAX may elect to discontinue the development of the Product and terminate this Agreement. 10.5 Termination for Force Majeure. Neither Party shall be liable to the other for default or delay in the performance of any of its obligations underthis Agreement if such default or delay shall be caused directly or indirectly by accident, fire, flood, riot, war, terrorism, act of God, embargo, strike,failure or delay of normal source of supply of materials, or delay of carriers, equipment failure or complete or partial shutdown of plant by any of theforegoing causes or other causes beyond its reasonable control, including FDA action (“Force Majeure”). 10.6 No Waiver. The failure of either Party to terminate this Agreement by reason of the breach of any of its provisions by the other Party shall notbe construed as a waiver of the rights or remedies available for any subsequent breach of the terms and provisions of this Agreement. 10.7 Property. In the event of termination of this Agreement for whatever cause, in addition to the other obligations of the Parties hereunder, eachParty shall return to the other Party or to the other Party’s designee no later than thirty (30) days after the effective date of termination all of suchother Party’s property, including all proprietary information, in its possession, except to the extent required to be retained by law or to comply withsuch Party’s continuing obligations hereunder. 10.8 Survival. The provisions of Sections 3.6, 4, 6, 8, 9 and 11 shall survive any termination of this Agreement.  Section 11 Miscellaneous 11.1 Dispute Resolution. This Agreement shall be governed by and interpreted in accordance under the laws of the State of New York. Anydispute, controversy or claim arising out of this Agreement, or the breach, termination or invalidity thereof, shall be discussed between the seniormanagement of the Parties who will attempt to resolve the matter amicably. Any disputes which cannot be resolved in this way within sixty (60)days of one Party notifying the other of the existence of a dispute shall be finally settled before JAMS in accordance with the expedited arbitrationprocedures of JAMS. The arbitration shall be conducted in English in New York, New York, USA. The costs of the arbitration payable to JAMSshall be funded equally by the parties, provided that the prevailing party shall be reimbursed for such costs and expenses and its own actual out ofpocket costs  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.1611.2 Integration and Amendment. This Agreement, the Exhibits hereto contain the complete agreement between the Parties with respect to thesubject matter hereof. All previous and collateral agreements, representations, warranties, promises and conditions relating to the subject matter ofthis Agreement are superseded by this Agreement. This Agreement may only be amended by a written instrument duly executed by the Partieshereto. 11.3 Assignment. Neither Party may assign this Agreement without the prior written consent of the other Party; provided, however that eitherParty may assign in connection with a merger or sale of all or substantially all of its stock or assets, provided the assignee agrees to be bound by allof the terms and conditions of this Agreement. 11.4 Waiver. No waiver of any default by either Party shall be deemed to constitute a waiver of any subsequent default with respect to the same orany other provision hereof. No waiver shall be effective unless made in writing with specific reference to this Agreement and signed by a dulyauthorized representative of the Party granting the waiver. 11.5 Notice. Any notice or request expressly provided for or permitted under this Agreement shall be in writing, delivered manually or by mail, e-mail, or facsimile and shall be deemed sufficiently given if and when received by the Party to be notified at its address first set forth below, or if andwhen mailed by registered mail or certified mail, postage prepaid, addressed to such Party at such address, or upon delivery confirmation. EitherParty, by notice to the other, may change its address for receiving such notices.  If to CAPSUGEL: CAPSUGEL US, LLC  412 Mt. Kemble Ave. Suite 200C  Morristown, NJ 07960 USA  Attn: President, Dosage Form SolutionsTelephone: [***]Facsimile: [***]E-mail: [***]   With a copy to CAPSUGEL US, LLC  412 Mt. Kemble Ave. Suite 200C  Morristown, NJ 07960 USA  Attn: General CounselTelephone: [***]Facsimile: [***]E-mail: [***]  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.17If to CARDAX: CARDAX, Inc.  2800 Woodlawn Dr., Suite 129  Honolulu, HI 96822  Attn: President and CEOTelephone: [***]Facsimile: [***]E-mail: [***]   With a copy to  Herrick, Feinstein LLP  2 Park Avenue  New York, NY 10016  Attn: Richard M. MorrisTelephone: [***]Facsimile: [***]E-mail: [***] 11.6 Severability of Provisions. Each provision of this Agreement shall be treated as a separate and independent clause, and the unenforceabilityof any one clause shall in no way impair the enforceability of any of the other clauses herein. Moreover, if one or more of the provisions containedin this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law,such provision or provisions shall be construed by the appropriate judicial body or arbitration panel by limiting or reducing such provision orprovisions, so as to be enforceable to the maximum extent allowable under the applicable law as such law shall then be. 11.7 Independent Contractors. Each Party hereto shall be an independent contractor of the other. Neither Party shall be the legal agent of the otherfor any purpose whatsoever and therefore has no right or authority to make or underwrite any promise, warranty or representation, to execute anycontract or otherwise to assume any obligation or responsibility in the name of or on behalf of the other Party, except to the extent specificallyauthorized in writing by the other Party. Neither Party shall be bound by or liable to any third persons for acts or obligations or debts incurred bythe other toward such third party, except to the extent specifically agreed to in writing by the Party to be so bound. This Agreement shall not createa partnership or other similar arrangement. 11.8 Announcement. The Parties agree to coordinate external communications (e.g. joint press release) regarding this collaboration.  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.1811.9 Headings; Interpretation. The section headings contained in this Agreement are for convenience of reference only, do not form a part of thisAgreement and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the context may require, any pronoun shallinclude the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and “including” shall be deemed to be followedby the phrase “but not limited to.” All references herein to Sections, Sections and Exhibits shall be deemed references to Sections and Sections of,and Exhibits to, this Agreement unless the context shall otherwise require. All Exhibits attached to this Agreement shall be deemed incorporatedherein by reference as if fully set forth herein. Words such as “herein,” “hereof,” “hereto,” “hereby” and “hereunder” refer to this Agreement andto the Exhibits, taken as a whole. Except as otherwise expressly provided herein: (a) any reference in this Agreement to any agreement shall meansuch agreement as amended, restated, supplemented or otherwise modified from time to time; (b) any reference in this Agreement to any law shallinclude corresponding provisions of any successor law and any regulations and rules promulgated pursuant to such law or such successor law;and (c) all terms of an accounting or financial nature shall be construed in accordance with generally accepted accounting principles, as in effect inthe United States from time to time. 11.10 Counterparts. This Agreement may be executed by the Parties hereto in separate counterparts, each of which when so executed anddelivered shall be deemed an original and all of which counterparts taken together shall constitute but one and the same instrument. * * * Signature Page Follows * * * CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.19IN WITNESS WHEREOF, the Parties have caused this this Agreement to be executed by their respective duly authorized representatives as of theday and year first above written. CAPSUGEL US, LLC By: /s/ Amit Patel  
Name:Amit Patel  
Title:President, Dosage Form Solutions   CARDAX, INC. By: /s/ David G. Watumull  
Name:David G. Watumull  
Title:President and CEO    CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.20EXHIBIT A DEVELOPMENT PLAN [***] CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.21EXHIBIT B SPECIFICATIONS As provided in Section 1.26, to be provided upon conclusion of the Development Plan  CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.22EXHIBIT C [***] CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.23EXHIBIT D MASS MARKET CHANNELS [***] CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FORCONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEENFILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.24Exhibit 10.43
This is a translation of the original Chinese text
Contract No.: 151315UD0081
Cooperation Agreement
Party A: Beike Internet (Beijing) Security Technology Co., Ltd. 
Party B: Baidu Online Network Technology (Beijing) Co., Ltd. 
April 2013
 
1This Cooperation Agreement is executed by and between the parties below in Haidian District, Beijing, the People’s Republic of China (hereinafterreferred to as “PRC”):
Party A: Beike Internet Security Technology Co., Ltd.
Address: Room 2101, 12/F, Fuxing International Center, No.237, North Chaoyang Road, Chaoyang District, Beijing.
Attention:
Tel:
E-mail:
Postcode:
Bank account:
Account No.:
Party B: Baidu Online Network Technology (Beijing) Co., Ltd.  
Address: No.10, Shangdi Shi Jie, Haidian District, Beijing
Attention:
Tel:
E-mail:
Postcode:
Whereas,
 
1. Party A owns the Kingsoft internet site navigation website and the Cheetah Brower software (hereinafter referred to as Party A’s Product).Website: 123.duba.net and www.duba.com. Party A has opened an account with Baidu Union website (http://union.baidu.com) and theaccount name is 
 (translation: “Kingsoft Cheetah”) and ksbrowser and is willing to comply with the terms of Baidu UnionMembership Registration Agreement (http://union.baidu.com/regAgreement.html).
 
2. Party B is a leading network technology company in the field of search engine.
 
3. The parties wish to collaborate with each other leveraging their respective strengths.
Therefore, the parties agree:
 
2Chapter 1 Definitions and Interpretations
 
1.1 Definitions 
Except as otherwise defined in the context hereof, the terms shall have the following designated meanings:
 
  1.1.1 PRC Laws: means any present and future promulgated laws, regulations, decrees and binding policies in PRC.
 
  1.1.2 Trade Secrets: means any technology, financial, business or any other information owned by either party and / or its subsidiary oraffiliate and protected as trade secrets.
 
  1.1.3 Effective Date: means the date on which this agreement is executed.
 
 
1.1.4 Force Majeure: means any event which is not reasonably controllable, foreseeable or avoidable even if foreseeable by the parties,which makes it impossible for either party to perform the whole or part of its obligations pursuant to this Agreement. Such eventincludes without limitation governmental actions, earthquakes, typhoon, flood, fire or any other natural disaster, wars or any othersimilar event. In respect of the special nature of the internet, Force Majeure also includes the following events which influence thenormal operation of the internet: 1) hacker attacks; 2) material influence of the technical adjustments of the telecommunicationsdepartment except for losses of one party resulting from its own mismanagement; 3) temporary suspension caused bygovernmental control, except for the governmental control on one party resulting from its own misconduct; 4) virus attacks.
 
  1.1.5 Baidu website: means www.baidu.com.
 
  1.1.6 Cooperation Term: means the term set forth in Chapter 3 hereof.
 
  1.1.7 Actual revenues: means the revenues payable by Party B to Party A based on the amount of search traffic generated by Party A’swebsite for Party B, less Party B’s related costs and legal taxes and charges. The search traffic generated by Party A for Party B,which forms the basis for calculating the actual revenues, shall be determined by Party B based on its statistical data.
 
1.2 Interpretations 
1.2.1 The date hereof shall mean the calendar day, the business day hereof shall mean the work day other than public holidays in PRC, andthe month hereof shall mean the calendar month.
 
31.2.2 The headings hereof is for inference only and shall not otherwise affect the meaning and construction of any other part of thisAgreement.
1.2.3 If needed in the context, use of plurals shall include its singulars, and vice versa.
1.2.4 All references to chapters, provisions and paragraphs shall mean the chapters, provisions and paragraphs herein.
Chapter 2 Representations and Warranties
 
2.1 Legal Status 
Either party represents and warrants from the date hereof:
2.1.1 It has the qualification to conduct the transaction hereunder and such transaction is in compliance with the business scope;
2.1.2 It is eligible to enter into this Agreement and perform the obligations hereunder.
2.1.3 Its authorized representative has adequate authorization to execute this Agreement on its behalf (a copy of the authorization letter shallbe delivered to the other party for record).
2.1.4 To its knowledge, it has disclosed all documents which may have a material adverse impact on its performance of obligationshereunder which are issued by the governmental agencies in the registered place or business place and known to it; and it is not the subjectof any insolvency, dissolution or bankruptcy procedures.
 
2.2 Legal Effect
2.2.1 From the Effective Date, this Agreement is legally binding on each party.
2.2.2 Either Party warrants that the execution and performance hereof as well as the business transactions contemplated hereof will notviolate any PRC Laws in any respects.
Chapter 3 Cooperation Term
 
3.1 Cooperation Term 
The Cooperation Term of the parties shall be two years from May 1, 2013 to April 30, 2015. One month prior to the expiry of the CooperationTerm, the parties may further negotiate the cooperation forms, if fails, this Agreement will be terminated upon expiry.
 
  3.1.1 This Agreement is effective on the day of May 1, 2013 and the effective term is the same as the Cooperation Term. The contractsof which the Parry A contract No. are KIS-Y-BJ120195 and KIS-Y-BJ120196 (Party B contract No. are 151215UD0118,151215UD0119) are terminated on April 30, 2013.
 
4Chapter 4 Liabilities of the Parties
 
4.1 Details of Cooperation 
The parties use their respective strengths to cooperate on internet searches, and during the effective Cooperation Term, the parties arecollaborative partners. The parties have complementary advantages in the aspects of information usage, promotion, marketing, technicalsupport and services, and now form a strategic alliance to develop their respective businesses.
 
4.2 Party A’s Obligations  
 
 
4.2.1 Party A imports the search results provided by Party B to the search function in the Party A’s Product by connecting its Productto the technical port provided by Party B. Party A shall also cooperate with Party B to market Baidu promotion services throughthe use of search engine. In other words, it is a technical service in which Party B displays the website of Party B’s clients on therelevant page of Baidu website and/or on the pages and / or interfaces of any other Baidu union members.
 
 
4.2.2 Party A will display Party B’s “search engine box” in the first screen of the homepage of “Kingsoft Navigation” website, andimports the search results provided by Party B to the search function in the Party A’s Product by connecting its Product to thetechnical port provided by Party B. Party A shall also cooperate with Party B to market Baidu promotion services through the useof search engine. In other words, it is a technical service in which Party B displays the website of Party B’s clients on the relevantpage of Baidu website and/or on the pages and/or interfaces of any other Baidu union members. The form of “search engine box”is attached as Annex 2. Without Party B’s confirmation in writing or via email, Party A shall not change the form, or otherwiseParty A will be deemed to breach this Agreement.
 
 
4.2.3 Party A shall not put the Party B’s search engine service on any other website, or change the codes which are used to import thesearch engine service of Party B. Party A’s website(s) that correspond to Party B’s codes are set forth in Annex 2. If Party Aneeds to add any website(s) or change the codes, it shall obtain the confirmation from Party B in writing or via email, or otherwiseParty A will be deemed to breach this Agreement.
 
  4.2.4 When Party A promotes websites by means of software installation, Party A needs to determine the homepage of the softwareusers’ browsers. In the event that the homepage of the software users’ browsers is *.baidu.com or *.hao123.com, Party A shallnot change the homepage of the users’ browsers by means of the software being installed.
 
54.2.5 During the cooperation between the parties, Party A agrees not to enter into any form of cooperation with Qihoo 360, unless PartyA needs such cooperation with Qihoo 360 for business or technology and Party B has provided its prior consent.
 
 
4.2.6 Party A covenants that during the Cooperation Term, it will list Party B’s search engine service as one of its search engineservices, of which “Cheetah Browser” will list Party B’s search engine service as the default search engine service. In the eventthat Party A breaches this covenant, Party B shall have the right to terminate this Agreement at any time and shall not pay anyshare of profits to Party A.
 
  4.2.7 During the cooperation, Party A shall form a team composed of specialized personnel to carry out the related work so as to ensurethe smooth cooperation between the parties.
 
  4.2.8 Party A shall not change the related functions and contents inherent to Party B’s search engine box. If a change is necessray,consent shall first be obtained from Party B.
 
  4.2.9 Party A shall not assign to any third party the functions and contents used in the website column(s) that are made the subjectmatter of this cooperation agreement. In addition, Party A shall not use the functions and information provided by Party B tocarry out any commercial activities.
 
 
4.2.10Party A undertakes to comply with the Business Cooperation Standard of Baidu Union published inhttp://union.baidu.com/regAgreement.html (see Annex 3), or otherwise Party A will be deemed to breach this Agreement. Party Aalso agrees to participate in the “Blue Sky 365” Action Plan and comply with Blue Sky 365 Action Plan Regulations (see Annex4).
 
 
4.2.11Party A warrants that it legally owns or otherwise holds the valid license to the intellectual property relating to the services orproducts provided pursuant to this agreement. Any disputes resulting from the Party A’s technology or intellectual property shallbe handled by Party A; any losses and costs of Party B resulting from the deficiency of Party A’s services or products shall beborne by Party A. Party B has the discretion to terminate this Agreement from time to time in the event that (i) Party A has nolegal right in respect of the services or products provided or, (ii) the services or products provided by Party A lead to any legaldispute or proceedings with third parties.
 
64.3 Party B’s Obligations  
 
  4.3.1 Upon the effectiveness of this Agreement, Party B shall form a team composed of specialized personnel to carry out for the relatedwork so as to ensure the smooth cooperation between the parties.
 
  4.3.2 Party B shall not publish any contents other than agreed hereof in the Party A’s website column(s) that are made the subjectmatter of this cooperation agreement. In the event that Party B breaches this covenant, Party A has the right to terminate thisAgreement at any time and require Party B to pay 30% of Party A’s share of revenues as liquidated damages.
 
 
4.3.3 Party B will provide to Party A an account which will timely return the visiting traffic data for Party A’s easy inquiry. At the sametime, Party B ensures the completion, accuracy and truth of the visiting traffic data. If Party A finds the visiting traffic dataabnormal, Party B shall issue a written explanation, and the actual revenues generated from the questionable traffic shall not besettled until there was a final confirmation.
 
 
4.3.4 Party B warrants that it legally owns or otherwise holds a valid license to the intellectual property relating to the services orproducts provided pursuant to this agreement. Any disputes resulting from the Party B’s technology or intellectual property shallbe handled by Party B; any losses and costs of Party A resulting from the deficiency of Party B’s services or products shall beborne by Party B.
 
 
4.3.5 Party B has the right to penalize any acts of Party A , in whatever form, carried out in contravention with Party B’s unioncooperation policies. The penalties may include =the immediate suspension of Party A’s account, termination of this Agreement,and taking any applicable civil or criminal remedial actions against fraud and any other legal causes. Party B shall have the right tofinal interpretation of this provision.
 
 
4.3.6 Party B retains the right to adjust the public price of the service and the service content, including but not limited to adding orreducing the service items, and raising or lowering the prices. In the event that Party B wishes to carry on such adjustment, it shallnotify Party A in writing two weeks in advance. If Party A objects to such adjustment, it has the right to notify Party B toterminate this Agreement in writing within 2 weeks upon receipt of the notification. Within 3 working days upon termination ofthis Agreement, Party B shall settle with Party A. Failure to exercise such termination right is deemed that Party A agrees theadjustment of Party B.
 
  4.3.7 With respect to the cooperation hereof, Party B has the discretion to assign to its affiliates all or part of its obligations hereunderwithout breaching this agreement. Party B’s affiliates mean Party B’s parent companies at different levels as well as thecompanies, owned or controlled, directly or indirectly, by the Party B’s parent companies at different levels.
 
74.4 Exemption of Liabilities With Respect to the Search Engine (by Party B) 
See Annex 1. The Parties agree that the exemption of liabilities in the annex is applicable to the transactions hereunder. Within the scope ofexemption clause, Party B and its affiliates are not liable for any compensation or any other liabilities.
Chapter 5 Information Content Cooperation
 
5.1 The parties shall arrange an employee to be responsible for the coordination work so as to ensure the regular update and maintenance.
 
5.2 Fees 
 
  5.2.1 The parties will not charge each other any fees for the shared information content. Unless otherwise agreed hereof, the feesincurred shall be borne by each party respectively.
 
  5.2.2 The Actual Revenues of the parties arising from the Baidu promotion services in the search results pages shall be dividedproportionately, and Party A shall bear the taxes payable on its own share of revenues:
 
  (1) The address bar, search bar, homepage/blank page of Cheetah Browser shall use Baidu Search as default search engineservice;
 
  (2) The default traffic shall mean the default traffic of the website address site and the traffic of the Cheetah Browser;
 
  (3) The monthly average daily non-default traffic shall not exceed the default traffic. If it does, then the traffic in excess willnot form part of the basis for calculating the share of revenues;
 
  (4) If the default traffic is lower than ***, the share of revenues for the non-default traffic is ***%, and the share of revenuesfor the default traffic is ***%;
 
  (5) If the default traffic is more than ***, the share of revenues for the non-default traffic is ***%, and the share of revenuesfor the default traffic is ***%;
 
  (6) If the default traffic is more than ***, the share of revenues for the non-default traffic is ***%, and the share of revenuesfor the default traffic is ***%;
 
8(7) If the default traffic is more than ***, the share of revenues for the non-default traffic is ***%, and the share of revenuesfor the default traffic is ***%;
 
  (8) If the default traffic is more than ***, the share of revenues for the non-default traffic is ***%, and the share of revenuesfor the default traffic is ***%; and
 
  (9) If the default traffic is more than ***, the share of revenues for the non-default traffic is ***%, and the share of revenuesfor the default traffic is ***%.
If Party A objects to the Party B’s revenue-sharing policy, it may terminate this Agreement. In the event that Party Acontinues to receive its share of revenues, it shall be deemed that Party A agrees with Party B’s revenue-sharing. Party Ashall bear the taxes payable on its own share of revenues.
 
 
5.2.3 Party B confirms the share of revenues of the preceding month payable to Party A on the first day of each calendar month(hereinafter referred to as (the “Reference Date,” and postponed in the event of public holidays) according to the above Article5.2.2. Upon the confirmation of the share of revenues of such month, it shall not be adjusted, unless there is sufficient proofevidencing the statistics is not correct.
 
  5.2.4 The financial settlement between the parties will be carried out monthly.
Party A provides the invoice of the share of revenues in the preceding month within the first 5 working days in each month inadvance, Party B warrants to pay the share of revenues to Party A prior to the 20th day of each month (postponed in the event ofpublic holidays) according to Article 4.1 hereof. In the event that Party A objects the payment from Party B, it shall proposewithin the first 5 working days in each month in writing, or it will be deemed as no objection. Party B shall review within threeworking days upon receipt of Party A’s written objection and notify the results thereof to Party A.
 
  5.2.5 After the effectiveness of this Agreement, in the event that the share of revenues payable to Party A in the preceding month isless than RMB 100, then it will be carried forward to the next month automatically and settled together according to the precedingprovisions.
Chapter 6 License
 
6.1 The search results provided by Party B and the intellectual property of any related technology shall be owned by Party B, withoutauthorization, Party A shall not amend, deduct, split or reverse Party B’s technologies and programs. Party A shall not obtain the sourcecodes of the programs of Party B with any methods. Without authorization, Party A shall not apply the service provided by Party B forother usage.
 
6.2
  “baidu” and 
  are all registered trademarks of Party B. During the cooperation, if Party A has to use Party B’s trademarks,it shall obtain Party B’s prior written consent. Nevertheless, if this Agreement is terminated or either party rescinds this Agreement, Party Ashall no longer use 
 “baidu”, 
  and any other registered trademarks of Party B in its product page and promotions of allkinds.
 
9Chapter 7 Confidentiality
 
7.1 Any and all information acquired by the parties and their employees due to the execution or performance of this Agreement, includingwithout limitation the scientific, business or internal information relating to technology, finance, marketing or management shall be theconfidential information of the parties and their proprietary properties.
 
7.2 The parties mutually covenant that they will keep each other’s confidential information in strict confidence, and will use only for thepurpose of this Agreement, shall not use or permit others to use the confidential information or disclose such to any third parties except thefollowing events:
 
  7.2.1 Upon the written consent of the other party;
 
  7.2.2 As according to the orders or requirements of the competent courts, any governmental agencies or administrative agencies;
 
  7.2.3 Such information becomes known to the public not for any deliberation, recklessness or negligence of either party or its agents,officers or employees;
 
7.3 The parties are obliged to disclose the confidential information only to the employees necessary to know it and instruct such employees tobe responsible for the confidential liability hereunder and be liable to the violation of the confidential liability of the employees.
Chapter 8 Breach
 
8.1 General Breach 
In the event either party breaches its obligations hereunder, the breach party shall immediately suspend its breach upon the receipt of thenon-breach party’s written notice requiring it to rectify its breach, and pay all the losses to the non-breaching party arising from suchbreach within ten (10) days. If the breach party continue to carry on the breaching conduct or does not perform its obligations, the non-breaching party shall have the right to terminate this Agreement in addition to the compensation for the breach.
 
108.2 Breach Liabilities 
If fault on both parties, they shall bear their respective liabilities according to their actual degree of fault.
Chapter 9 Termination
 
9.1 Termination Events 
This Agreement will be terminated upon any of the following events:
 
  9.1.1The Cooperation Term is expired and the parties determine not to renew;
 
  9.1.2The non-breaching party terminates this Agreement according to Article 8.1 hereof;
 
  9.1.3Either party is under bankruptcy or enters into liquidation or dissolution procedures;
 
  9.1.4If the Force Majeure lasts consecutively for thirty (30) days and above, either party may terminate this Agreement by awritten notice according to Article 11.7 and terminate this Agreement on the receipt date as defined herein.
 
9.2 Matters after the Termination 
 
  9.2.1 Within fifteen (15) days upon the termination of this Agreement, the parties shall delete the links between their websites.
 
  9.2.2 The termination of this Agreement shall not affect the unsettled payment hereunder or either party’s payment obligation andother obligations or rights incurred before the termination.
 
  9.2.3 Notwithstanding the termination of this Agreement, the obligations set forth in Chapter 7 and Chapter 10 are binding to bothparties.
Chapter 10 Governing Laws and Dispute Resolution
 
10.1Governing Laws 
The execution, validity, construction, enforcement and the settlement of any disputes herefrom shall be governed by PRC Laws.
 
10.2Negotiation and Proceedings 
 
  10.2.1Any dispute arising from the construction and enforcement of this Agreement shall be settled through friendly consultation ormediation by a neutral third party first.
 
  10.2.2If the dispute fails to be resolved within thirty (30) days by such method set forth above, either party shall submit to the court inthe location of Party B.
 
11Chapter 11 Miscellaneous
 
11.1Waiver 
If either party fails to exercise or timely exercise its rights, power or preemptive rights hereunder, it shall not be deemed as a waiver;otherwise, any individual exercise or partially exercise any of its rights, power or preemptive rights shall not prejudice its exercise of suchrights, power or preemptive rights thereafter.
 
11.2Amendment 
This Agreement may only be amended by mutual written agreement by the parties.
 
11.3Marketing Supports 
On the basis of the parties’ acknowledgment, the parties will make and carry on necessary marketing measures to expand the reputation andinfluence of the parties cooperation.
 
11.4Entire Agreement 
This Agreement constitutes the entire agreement between the parties and supersedes all previous discussions, negotiations andagreements.
 
11.5Notice 
 
  11.5.1Any material notices or written letters between the parties shall be in Chinese and delivered by facsimile, in person(includingcourier) or by registered mail.
 
  11.5.2All the notices and letters shall be sent to the address in the preamble hereof unless otherwise notified in writing in advance;
 
 
11.5.3If the notices and letters are sent by facsimile, then the delivery time shall be subject to the actual time displayed in the facsimilerecord, except that the sending time is after 17:00 pm of such date, or the time of the receiver’s location is not a Business Day,then the delivery time shall be the following Business Day of the receiver’s time; if sent via e-mail, the delivery time shall besubject to the time when the email enters into the email system designated by the receiver; if sent in person (including courier), itshall be subject to date the receiver’s signing for receipt; if sent by registered letter, it shall be subject to the receipt issued by thepost office and five (5) Business Days from the date of sending.
 
1211.6Successor 
This Agreement is made for the benefit of and equally binding upon the parties and their respective successors and assignees.
 
11.7Force Majeure 
 
  11.7.1In the event of Force Majeure, the affected party shall notify the other party in respect of the nature, incurring date, anticipatedlasting time and related details as fastest as reasonably possible and the degree of such event hindering the performance of itsobligations of the notifying party hereunder.
 
  11.7.2During the consecutive period of the Force Majeure, the affected party shall regularly and timely keep the other party informed ofthe current status of the Force Majeure, in the event that the Force Majeure ends, it shall notify the other party in writing timelyand continue to perform the obligations hereunder.
 
  11.7.3The party affected by the Force Majeure may temporarily suspend the performance hereunder until the influence of the ForceMajeure is removed after it performs its obligations pursuant to Item 1 and 2 of this Article and need not to bear any breachliabilities; however, it shall use best efforts to conquer such event and minimize its adverse influence.
 
11.8Language 
This Agreement is made in Chinese and there are two originals which have the same legal effect and each party has one original.
 
11.9Unmentioned Matters 
Any other matters unmentioned hereof shall be subject to PRC Laws.
 
11.10Other Matters 
This Agreement is effective from the date of its date of signature and chop, and any other agreement between the parties regarding tomatters which are similar to the cooperation contents hereunder shall be terminated automatically. Annexes are integral parts of thisAgreement and have the same legal effect as the text hereof.
 
13Party A: Beike Internet (Beijing) Security Technology Co., Ltd.
Authorized signatory: /s/ common seal
Title:
Date:
Party B: Baidu Online Network Technology (Beijing) Co., Ltd.
Authorized signatory: /s/ Guolin Ma /s/ common seal
Title:
Date:
 
14Annex 1
Search Engine Exemption Clause
1. In addition to service clause indicated by Baidu, Baidu is not responsible for any other accident, negligence, breach, defamation, infringement tocopyright or other intellectual property right and the loss occurred thereby (including by virus through download) arising from using search engineand will not undertake any legal liability.
2. Baidu is not responsible for the legality of link and information, product and service obtained from webpages through search engine which aresearched automatically in accordance with users’ search order, and will not undertake any legal liability.
3. All content of search engine does not represent Baidu’s opinion.
4. User shall undertake the risk of using search engine by itself and Baidu will not guarantee in any form, including the result meeting users’requirement, service continuity, safety, accuracy, timeliness and legality of search result. Baidu will not undertake any legal liability for user’sfailure to normally use Baidu for technology reason such as internet status, communication line and etc.
5. Baidu respects and protects all search service users’ personal privacy and their personal information such as registered user name and emailaddress, etc., which will not be disclosed to the third party without user’s consent or compulsorily required by law. The keywords used by users insearch engine will not be regarded as personal privacy information.
6. Any website shall report to service website or Baidu, or add refusal mark to the webpage in accordance with the Robots Exclusion Protocol, if itdoes not want to be included by Baidu, otherwise it will be deemed as willing to be included.
7. Any unit or person shall report to Baidu or service website in written timely and provide ID card, ownership certificate and detailed violationevidence if it considers the content through Baidu search service or search link may be suspected of violating its legal right. Baidu will remove suchsuspected search service or search link as soon as possible after its receipt of legal documents above.
 
15Annex 2
1. Display Format
 
2. Table of Fee-charging Code and Corresponding Website
 
Fee-charging item  Channel  Display location
   Search box on the first page
 
16Annex 3
Business Cooperation Standard of Baidu Union
In order to standardize the business cooperation of Baidu Union (hereinafter “Union”) and maintain the fair and honest order, it is provided for thebusiness cooperation of Union as follows and member of the Union shall comply with this standard strictly to maintain the smooth and healthydevelopment of business cooperation.
[General Rules]
All act which may damage the right of user of Baidu promotion, damage user experience, disturb market cooperation order of the Union, adverselyaffect Baidu product and business reputation of Baidu, constitute unfair competition against Baidu or violate legal right of Baidu are forbidden bythe Union, including but not limited to:
1. Click by itself
Repeat manual search, click by itself, incite others to search or click.
2. Compel to click
Compel user to click to get resource in return; or pop-up window of search result endlessly.
3. Program click
Simulate user’s click through program or script, automatically click and search tool, the third party’s click or search (such as paid click, auto-browse, clicker, IP click by agent servicer, fault IP click, mutual click and auto-refresh).
4. Illegal promotion
Promote by irregular means such as virus, compulsory first page, compulsory kidnap address bar, search engine cheating, exaggerate times.
 
175. Breach of exclusivity clause
Breach the exclusivity agreement with Baidu to engage in competing business.
6. Mix of competing business
Amend the pattern of the Union product or competing business to mislead users.
7. Other breach
Other act Baidu thought has damaged or may damage the right of user of Baidu, user experience, Baidu brand or business reputation of Baidu,constitutes unfair competition against Baidu or violates other legal right of Baidu.
[Search Promotion Cooperation]
8. Determine keyword
Determine keyword in search frame or direct link to search result page.
9. Amend search result page
9.1 Edit, amend or filtrate any promotion content or information contained in search result or amend the order by any means, or delete, hide orminimize any promotion content or search result, or add any other content to Baidu search result page of browser through software.
9.2 Re-direct the final user from any promotion page or search result page to others, or the promotion page or search result page provided is not thesame version with that got by final user through directly visited.
9.3 Beyond the range permitted by this standard, directly or indirectly visit, launch and/or start promotion content or search result through anysoftware, other website or any form other than member website, or combine promotion content or search result into it by other means.
9.4 Store or cache any or part of, copy of, derivative of information of search result through “capture”, “spider”, index or any other non-temporaryways.
 
1810. Directly use of search result
Directly use any webpage of search result of final user through frame linked or other ways.
11. Breach of release page
11.1 Present business code on any wrong page, register page or “thanks” page (such as thanks page after user registers on relevant website) orany email, or any webpage or website with any pornographic content, hate mongering content or violence content.
11.2 Release code in non-configured domain name.
12. Induce to click
12.1 Introduce the search result with word such as “excellent recommendation”, “relevant link” or “welcome to click”.
12.2 Put graph of arrow, download instruction or other leading graph to the search result.
12.3 Award user’s click.
13. Breach of release number
Release more than three search frames per page.
14. Flow kidnap
14.1 Falsify the charge index by software, plug-in or other ways, kidnap Baidu, hao123 and other Union member’s flow.
14.2 Falsify other Union member’s first page through any promotion way damaging user experience and other unfair competition.
 
1914.3 Amend the first page of Baidu (www.baidu.com) or hao123 (www.hao123.com) set by user in any ways.
14.4 Amend the page of Baidu or hao123 in any ways.
15. Breach of binding with Baidu software
Binding with Baidu software without any indication, install compulsory; add functions other than that of Baidu software or delete original function,re-bind other software without any indication, misleading the act of other software as that of Baidu; set obstacle for user installed Baidu softwarethrough member website to uninstall.
[Union Promotion Cooperation]
16. Determine keyword
Stack keywords in webpage content, source code to affect normal theme matching.
17. Amend promotion content
17.1 Re-direct the promotion page clicked by user to others, which is not the same with that got by final user through directly visited.
17.2 Store or cache any part of, copy of, derivative of promotion content through “capture”, “spider”, index or any other non-temporary ways.
18. Breach of release page
18.1 Present promotion content on any wrong page, register page or “thanks” page (such as thanks page after user registers on relevant website) orany email, or popup window, or webpage or website with any pornographic content, hate mongering content or violence content.
18.2 Release theme promotion business on rubbish page with no essence for the purpose of presenting theme.
18.3 Release promotion content in non-configured domain name or software.
 
2019. Induce to click
19.1 Introduce the promotion content with word such as “excellent recommendation”, “relevant link” or “welcome to click”.
19.2 Put graph of arrow, download instruction or other or misleading graph to the promotion content.
19.3 Award user’s click of promotion content.
19.4 Promotion content is too close to the text or click zone (such as turn-page button, navigation button, video window and etc.) causing voidclick (recommending not to put the promotion content above or below the turn-page button).
19.5 Pretend the promotion content as the text of page which mix the promotion content with page content.
19.6 Hide or auto-block the window through js or other ways, causing user’s failure to see the promotion after click.
19.7 Release code of special zone besides “patch promotion”, amend code without authorization or patch through special ways.
19.8 Cover, hide any part of theme promotion zone or overlap page content with promotion content.
19.9 Float the promotion content or present in other ways.
20. Breach of release number
20.1 Release more than three product codes of “theme description” and “theme link” accumulatively per page. (not include the “patch promotion”)
20.2 Release more than one code of “theme suspension” per page besides “theme description” and “theme link”, release more than one form of“theme suspension” (side bar/button/window) per page.
20.3 Release more than one code of “patch promotion” per playing window, several playing windows on one webpage, more than three codes of“patch promotion” available.
 
2121. Breach of using iframe
Use through amending code or other ways without authorization.
21.1 Use Union’s “theme suspension” product through iframe.
21.2 Use “theme description”, “theme link” and “patch promotion” product through iframe in illegal ways:
21.2.1 Release code of Union promotion business to more than two (including) layers of iframe;
21.2.2 Use more than two (include) business codes through iframe for one time;
21.2.3 Inset more than one iframe unit in one page;
21.2.4 Module presented by iframe is smaller than that used through iframe;
21.2.5 Present promotion content on charged website through non-charged website iframe.
[New Business Cooperation]
22. Breach of release page
Present promotion content on any wrong page, register page or “thanks” page (such as thanks page after user registers on relevant website) or anyemail, or webpage or website with any pornographic content, hate mongering content or violence content.
23. Induce
23.1 Introduce the cooperation promotion content with word such as “excellent recommendation”, “relevant link” or “welcome to click”.
 
2223.2 Put graph of arrow, download instruction or other leading graph to the cooperation promotion content.
23.3 Put pornographic picture close to cooperation promotion content.
23.4 Award use’s install, register, purchase and other act.
23.5 Simulate official website of cooperation promotion client.
24. Breach of release number
Present or release more than three cooperation promotion units per page.
25. Self-lead
Repeat manual install, register, purchase and etc., incite others to install, register, purchase and etc.
If any Union member does any illegal act above, Baidu has the power to punish. Baidu’s data for investigating and punishing the Union member’sillegal act shall prevail, including but not limited to void click data and flow kidnap data.
Appendix: Process method
Baidu may take one or more measures as follows to process the illegal act:
1. Deduct credit index
2. Deduct accumulated credit
3. Deduct share of revenues
4. Block illegal business
5. Stop sub-account authority
6. Limit register information
7. Expose illegal case
 
23Baidu has the right of final explanation for this Business Cooperation Standard of Baidu Union. Baidu may update this Business CooperationStandard of Baidu Union from time to time and all Baidu Union members are urged to pay continued attention to relevant content to learn and timelycomply with the latest regulation.
 
24Annex 4
Rules of “Blue Sky 365” Plan
Honesty is the basis for long-standing business. We could only make more profit, grow faster with stronger cooperation based on honesty.
Honesty is not only a promise but also an act. Hereby, Baidu Alliance, together with partner, build an alliance circle of honesty and health, acooperation environment of self-discipline, fairness and honesty and comply with rules as follows strictly:
1. Agree that honesty is the base of alliance development;
2. Cooperate in line with the Business Cooperation Standard of Baidu Alliance strictly;
3. Dose not launch or engage in any illegal act such as click fraud, flow kidnap;
4. Report the illegal information actively and protect honesty;
5. Accept supervision and willing to undertake liability and result of illegal act.
The rules above shall be reflected every day. Let us build the “Blue Sky 365” of alliance circle together.
 
25Exhibit 10.1
COOPERATION AGREEMENT
This Cooperation Agreement (“ Agreement”) is entered into as of July 1, 2020, by and between e.l.f. Beauty, Inc., a Delaware corporation (the
“Company ”), and Marathon Partners Equity Management, LLC (“ Marathon Partners ”), Marathon Partners L.P., Marathon Focus Fund L.P.,
Marathon Partners LUX Fund, L.P., Cibelli Research & Management, LLC and Mario Cibelli (collectively, the “ Marathon Parties ”) (each of the
Company, on the one hand, and the Marathon Parties, on the other hand, a “ Party” to this Agreement, and collectively, the “ Parties”).
RECITALS
WHEREAS, the Marathon Parties have voting power or sole dispositive power or otherwise have beneficial ownership of 2,585,000 shares of the
common stock, par value $0.01 per share, of the Company (the “ Common Stock ”) as of the date of this Agreement;
WHEREAS, Marathon Partners submitted a letter to the Company on May 28, 2020 (the “ Nomination Notice ”) nominating a slate of director
candidates to be elected to the Board of Directors of the Company (the “ Board ”) at the Company’s 2020 Annual Meeting of Shareholders (the
“2020 Annual Meeting ”); and
WHEREAS, as of the date of this Agreement, the Company and the Marathon Parties have determined to come to an agreement with respect to
certain matters set forth below.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other good
and valuable consideration, the receipt and sufficiency of which are acknowledged, the Parties to this Agreement, intending to be legally bound,
agree as follows:
1.Board Nomination; Certain Information; Other Board and Company Actions .
(a) Lori Keith (the “New Director”) has provided the Company with (i) fully completed and executed copies of the Company’s standard director &
officer questionnaire, representation and agreement letter, and other reasonable and customary director onboarding documentation, including (A)
all information reasonably requested by the Company that is required to be disclosed for directors, candidates for directors, and their affiliates and
representatives in a proxy statement or other filings under applicable law or regulation or stock exchange rules or listing standards, in each case,
relating to their appointment, nomination or election as a director of the Company and (B) information reasonably requested by the Company in
connection with assessing eligibility, independence and other criteria applicable to directors or satisfying compliance and legal or regulatory
obligations, in each case, relating to their appointment, nomination or election as a director of the Company and required by the Company in
connection with the appointment or election of new members of the Board, (ii) an executed consent of the New Director to be named in any proxy
statement or other filings under applicable law or stock exchange rules or listing standards and to serve as a Class III Director and (iii) a written
representation that the New Director, if elected as a director of the Company, would be in compliance, and will comply with, all applicable
confidentiality, corporate governance, conflict of interest, Regulation FD, code of conduct and ethics, stock ownership and trading policies and
guidelines, and other policies of the Company applicable to members of the Board (collectively, the “ Information”), and has cooperated with a
background check.
(b) Based on the Information, the Nominating and Corporate Governance Committee (the “ Nominating Committee ”) of the Board and the Board
have determined that the New Director may serve as an “independent” director of the Company in accordance with the rules and listing standards
of the New York Stock Exchange (“NYSE”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “ SEC”).
(c) As promptly as practicable, but in no event later than two business days following the execution of this Agreement, the Nominating Committee
and the Board shall take all necessary action to (i) increase the size of the Board from eight to nine directors, with such new Board seat to be in
Class III, (ii) appoint the New Director as a Class III director on the Board and (iii) appoint the New Director to the Nominating Committee.(d) Immediately following the execution of this Agreement by the Parties, the Marathon Parties shall send a letter to the Secretary of the Company
irrevocably withdrawing (i) the Nomination Notice, and, accordingly, (ii) their nomination of Mario Cibelli, Dhiren Fonseca and Beth Birnbaum (the
“Nominations ”) for election to the Board as Class I directors at the 2020 Annual Meeting and (iii) the Marathon Parties’ demand letter pursuant to
Section 220 of the Delaware General Corporation Law, dated April 12, 2019.
(e) The Board shall take all necessary action to include in the proposals to be voted on at the 2020 Annual Meeting (i) a “say-on-pay” proposal of
the Company and (ii) a vote as to the frequency at which “say-on-pay” proposals will be presented to and voted on by the stockholders at future
annual meetings of the Company, which shall include a recommendation by the Board that stockholders vote “ FOR” annual “say-on-pay”
proposals.
(f) The Board shall take all necessary action to amend Section 3.1(a) of the 2016 Equity Incentive Award Plan of the Company (the “ 2016 Incentive
Plan”) to reduce the maximum automatic annual percentage increase of shares of Common Stock reserved for issuance under the 2016 Incentive
Plan from 4% to 2%. During the Support Period (as defined below), the Board shall not (i) adopt a new equity incentive award plan or otherwise
seek to amend the 2016 Incentive Plan to increase the Share Limit (as defined in the 2016 Incentive Plan) or (ii) issue Awards (as defined in the 2016
Incentive Plan) in excess of the Share Limit (as defined in the 2016 Incentive Plan).
(g) The New Director (or any Replacement (as defined below)), in addition to all current directors, will (A) comply with all policies, procedures,
codes, rules, standards and guidelines applicable to members of the Board and (B) keep confidential all Company confidential information and not
disclose to any third parties (including the Marathon Parties) discussions or matters considered in meetings of the Board or Board committees.
(h) Annual grants of equity awards to executive officers of the Company in 2021 will take place during the open trading window following the
Company’s fourth quarter earnings call in 2021. The proxy statement for the 2020 Annual Meeting shall include language describing the obligation
of the Company set forth in this Section 1(h).
(i) Nothing in this Agreement shall be deemed to abridge or limit the fiduciary duties of any member of the Board under Delaware law.
(j) The New Director (or any Replacement (as defined below)) may attend as a non-voting observer any meeting(s) of the Compensation Committee
of the Board (the “ Compensation Committee ”) held following the date of this Agreement and during the Support Period, and shall receive a copy
of any materials disseminated to Compensation Committee members in connection with such meeting(s).
2. Representations of the Marathon Parties . The Marathon Parties represent and warrant to the Company as of the date hereof as follows:
(a) The Marathon Parties are the beneficial owners of 2,585,000 shares of Common Stock, such shares of Common Stock constitute all of the
Common Stock beneficially owned by the Marathon Parties, and (i) the Marathon Parties’ interests in the Common Stock and debt or other
securities of the Company is as set forth on Exhibit A, (ii) except as set forth on Exhibit A, the Marathon Parties do not currently have, and do not
currently have any right to acquire, any interest in any other securities of the Company (or any rights, options or other securities convertible into or
exercisable or exchangeable (whether or not convertible, exercisable or exchangeable immediately or only after the passage of time or the occurrence
of a specified event) for such securities or any obligations measured by the price or value of any securities of the Company or any of its controlled
Affiliates, including any swaps, puts, calls, appreciation rights or other derivative arrangements designed to produce economic benefits and risks
that correspond to the ownership of Common Stock, whether or not any of the foregoing would give rise to beneficial ownership, and whether or
not to be settled by delivery of Common Stock, payment of cash or by other consideration, and without regard to any short position under any
such contract or arrangement) (collectively, “ Securities of the Company ”) and (iii) the Marathon Parties will not, directly or indirectly, compensate
or agree to compensate the New Director for her service as a director of the Company with any cash, securities (including any rights or options
convertible into or exercisable for or exchangeable into securities or any profit sharing agreement or arrangement), or other form of compensation.
The terms
2“beneficially owns” and “beneficial ownership” for all purposes under this Agreement shall have the meanings set forth in Rule 13d-3 promulgated
by the SEC under the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”). As used in this Agreement, the terms “ Affiliate ” and
“Associate ” shall have the respective meanings set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act.
(b) The Marathon Parties have no agreements, understandings or undertakings with any third party to share or delegate disposition or voting
control over any of the securities set forth on Exhibit A, or to transfer, hypothecate or lend any of the securities set forth on Exhibit A.
(c) Each of the Marathon Parties represents and warrants to the Company as of the date hereof that it has the power and authority to execute and
deliver this Agreement. This Agreement (i) has been duly and validly authorized by each of the Marathon Parties, and constitutes a legal, valid and
binding obligation of each of the Marathon Parties, enforceable against each of the Marathon Parties in accordance with its terms except as may be
limited by bankruptcy, insolvency or similar laws affecting creditors’ rights and general equitable principles, (ii) does not require the approval of any
investor in or member of the Marathon Parties and (iii) does not violate any law, order of any court or any governmental agency or regulation or the
charter or any organizational document of the Marathon Parties, or conflict with, result in a breach of or constitute a default under any agreement or
instrument by which the Marathon Parties or any of their respective assets is bound.
3. Representations of the Company . The Company represents and warrants to the Marathon Parties as of the date hereof that it has the corporate
power and authority to execute and deliver this Agreement. This Agreement (i) has been duly and validly authorized by the Company and
constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms except as may be
limited by bankruptcy, insolvency or similar laws affecting creditors’ rights and general equitable principles and (ii) does not violate any law, order
of any court or any agency or regulation or the Company’s Certificate of Incorporation or the Amended and Restated Bylaws of the Company (the
“Bylaws ”), or conflict with, result in a breach of or constitute a default under any agreement or instrument by which the Company or any of its
assets or the assets of its subsidiaries are bound. The Company further represents and warrants to the Marathon Parties as of the date hereof that
since March 2, 2019 it has not granted any performance equity awards to any named executive officers other than those disclosed or referenced by
the Company in its Forms 4 filed with the SEC in June 2020.
4. Support Period Covenants .
(a) During the period commencing on the date hereof and ending at 11:59 pm New York Time on the date that is thirty (30) days prior to expiration of
the advance notice period for the submission by stockholders of director nominations for consideration at the Company’s 2021 Annual Meeting of
Stockholders (the “ 2021 Annual Meeting ”) as determined by applicable law and set forth in the Bylaws (such period, as modified, if applicable, in
Section 4(b) below, the “ Support Period ”), the Marathon Parties shall appear in person or by proxy for quorum purposes at the 2020 Annual
Meeting and any other meeting of stockholders of the Company, including any adjournment or postponement thereof, to vote all of the shares of
Common Stock beneficially owned by the Marathon Parties on the record date for such meeting (i) in favor of all persons nominated by the Board
to serve as directors of the Company and against any stockholder nominated candidate not endorsed by the Board, (ii) to ratify the appointment of
the Company’s independent registered public accounting firm, (iii) in accordance with the Board’s recommendation with respect to the Company’s
“say-on-pay” proposal and compensation plans and any amendments thereto and (iv) in favor of any other proposals recommended by the Board,
provided, that with respect to any extraordinary matter, including any merger, acquisition, recapitalization, restructuring, financing, disposition,
distribution, spin-off, asset sale, joint venture or other business combination involving the Company or its subsidiaries which requires a vote of the
Company’s stockholders, the Marathon Parties shall have the right to vote the shares of Common Stock beneficially owned by the Marathon
Parties in their sole discretion. The Marathon Parties shall provide written evidence of such vote to the Company no later than ten (10) business
days prior to the 2020 Annual Meeting.
(b) Notwithstanding the foregoing, if either:
3(i) at any time between the date of this Agreement and the date that is thirty (30) days prior to the expiration of the advance notice period for the
submission by stockholders of director nominations for consideration at the 2021 Annual Meeting as determined by applicable law and set forth in
the Bylaws (such date, the “ 2021 Annual Meeting Nomination Window Date ”), the Marathon Parties do not meet the Minimum Ownership
Threshold (as defined below), or
(ii) as of the 2021 Annual Meeting Nomination Window Date, all of the following conditions have been met:
a. if the New Director or her Replacement is a director on the Board as of the 2021 Annual Meeting Nomination
Window Date, the New Director or her Replacement (as applicable) is a member of the Nominating Committee as
of such date,
b. between the date of this Agreement and the 2021 Annual Meeting Nomination Window Date, Tarang Amin has
not entered into a voting agreement or similar agreement that would subject any Securities of the Company
beneficially owned by Mr. Amin to any arrangement or agreement with respect to the voting thereof with any
other person that is a holder of any Securities of the Company and that is not affiliated with Mr. Amin or his
estate planning, or that would give Mr. Amin the power to vote or direct the voting of any Securities of the
Company beneficially owned by any other person that is not affiliated with Mr. Amin or his estate planning,
c. between the date of this Agreement and the 2021 Annual Meeting Nomination Window Date, the Company has
not issued shares of Common Stock (and/or Securities of the Company convertible into, or exercisable for,
shares of Common Stock) in any transaction that represents more than 20% of the issued and outstanding
shares of Common Stock (including any Securities of the Company convertible into, or exercisable for, shares of
Common Stock) immediately prior to such issuance,
d. the Company has confirmed that the proxy statement for the 2021 Annual Meeting shall include language
describing the obligation of the Company set forth in Section 1(h) above as relates to annual grants of equity
awards to executive officers of the Company in 2022, and
e. the Company has confirmed that any director(s) or officer(s) of the Company who beneficially owned 3% or
more of the issued and outstanding shares of Common Stock as of the record date for the 2020 Annual Meeting
voted all such shares at the 2020 Annual Meeting in favor of annual “say-on-pay” proposal frequency at future
annual meetings of the Company,
then, for all purposes under this Agreement, the Support Period shall not expire on the 2021 Annual Meeting Nomination Window Date, and
instead the Support Period shall automatically be extended until 11:59 pm New York Time on the date that is thirty (30) days prior to expiration of the
advance notice period for the submission by stockholders of director nominations for consideration at the Company’s 2022 Annual Meeting of
Stockholders as determined by applicable law and set forth in the Bylaws for all purposes under this Agreement, and the Marathon Parties shall be
required to (x) appear in person or by proxy at the 2021 Annual Meeting or any other meeting of stockholders of the Company held on or after the
2021 Annual Meeting Nomination Window Date and prior to the end of the Support Period, (y) vote any of the shares of Common Stock
beneficially owned by the Marathon Parties in accordance with Section 4(a)(i), (ii), (iii) and (iv) at any meeting of stockholders of the Company held
on or after the 2021 Annual Meeting Nomination Window Date and prior to the end of the Support Period, provided, however, that in the event that
Institutional Shareholder Services Inc. (“ ISS”) recommends otherwise with respect to the Company’s “say-on-pay” proposal or any proposal
relating to any compensation plan submitted for shareholder approval at the 2021 Annual Meeting, including any amendments thereto, each of the
Marathon Parties will be permitted to vote in accordance with the ISS
4recommendation in its discretion, and (z) provide written evidence of such vote by the Marathon Parties at any meeting of stockholders of the
Company held on or after the 2021 Annual Meeting Nomination Window Date and prior to the end of the Support Period (including the 2021
Annual Meeting) no later than ten (10) business days prior to any such meeting (including the 2021 Annual Meeting). As used herein, the
“Minimum Ownership Threshold ” shall mean beneficial ownership equal to or greater than 2.0% of the issued and outstanding shares of Common
Stock. The Marathon Parties shall provide notice to the Company within two business days following the date on which the Marathon Parties no
longer meet the Minimum Ownership Threshold.
(c) If at any time during the Support Period (x) the New Director is unable to serve out her term as a Class III Director on the Board for any reason,
and (y) as of such time, the Marathon Parties have maintained since the date of this Agreement the Minimum Ownership Threshold and the
Marathon Parties have provided evidence of such ownership, together with a certification of such ownership, to the Company, then the Marathon
Parties and the Company shall negotiate in good faith to propose a mutually-agreed upon replacement director (the “ Replacement ”) to be
appointed to the Board to serve as her successor for the remainder of her current term as a Class III Director in accordance with the Bylaws,
provided such Replacement (i) qualifies as “independent” pursuant to the rules and listing standards of the NYSE and applicable SEC rules and
regulations, (ii) has provided the Company with the Information, (iii) has cooperated with a background check and (iv) has executed all documents
required to be executed by directors of the Company. The Replacement shall be promptly appointed to the Board and at least one standing
committee of the Board, subject to the approval by each of the Nominating Committee and the Board, after conducting a good faith customary due
diligence process and consistent with the Board’s fiduciary duties.
5. Standstill Covenants .
(a) Except as otherwise contemplated in Section 4 of this Agreement, at all times during the Support Period, the Marathon Parties shall not, and
shall cause their Affiliates and Associates and their and such Affiliates’ and Associates’ respective equity owners (including members and limited
partners), directors, officers, managers and employees not to, and will direct their consultants, agents, representatives, attorneys and advisors (to
the extent directly or indirectly acting on behalf of the Marathon Parties) (collectively, the “ Marathon Party Representatives ”) not to, directly or
indirectly, in any manner, alone or in concert with others:
(i) make, engage, solicit, or in any way participate in any “solicitation” of proxies (as such term under the Exchange Act) or consents to vote, or
knowingly advise, encourage or influence any person or entity with respect to the voting of any Securities of the Company or become a
“participant” in any contested “solicitation” for the election of directors with respect to the Company (as such terms are defined or used under the
Exchange Act) (other than a “solicitation” or acting as a “participant” in support of all of the nominees recommended by the Board at any
stockholder meeting);
(ii) propose or otherwise solicit stockholders of the Company for the approval of one or more stockholder proposals (whether made pursuant to
Rule 14a-8 under the Exchange Act or otherwise) or call, attempt to call or solicit consents to call a special meeting of stockholders of the Company;
(iii) agree or propose to grant any proxies with respect to, or deposit any Securities of the Company in a voting trust or similar arrangement or
subject any Securities of the Company to any arrangement or agreement with respect to the voting thereof, except as expressly set forth in Section
4 of this Agreement;
(iv) take any action to form, join, encourage, influence or in any way participate in any partnership, limited partnership, syndicate or other group (as
such term is contemplated in Rule 13d-5 promulgated under the Exchange Act) with respect to the Securities of the Company (other than a group
formed with an Affiliate of the Marathon Parties) or otherwise act in concert with any person or entity for the purpose of circumventing the
provisions or purposes of this Agreement;
(v) purchase or otherwise acquire, or offer, seek, propose or agree to acquire, ownership (including beneficial ownership) of the Securities of the
Company, any direct or indirect rights or options to
5acquire any such Securities of the Company, any derivative securities or contracts or instruments in any way related to the price of shares or value
of Common Stock, any other securities of the Company, or any assets or liabilities of the Company, provided that the Marathon Parties and their
Affiliates, in the aggregate, may acquire beneficial ownership of up to 12.5% of the Company’s outstanding shares of Common Stock;
(vi) other than in open-market transactions where the identity of the purchaser is not known and in underwritten widely dispersed public offerings,
sell, offer or agree to sell, directly or indirectly, through swap or hedging transactions or otherwise, the Securities of the Company or any rights
decoupled from the underlying Securities of the Company held by the Marathon Parties or any of their Affiliates or Associates to any person or
entity not (A) a party to this Agreement, (B) a member of the Board or (C) an officer of the Company (any person or entity not set forth in clauses
(A)-(C) shall be referred to as a “ Third Party ”), that would knowingly result in such Third Party, together with its Affiliates and Associates,
owning, controlling or otherwise having any beneficial or other ownership interest in the aggregate of more than 4.9% of the shares of Common
Stock outstanding at such time, other than Schedule 13G filers that are mutual funds, pension funds, index funds or investment fund managers with
no known history of activism or known plans to engage in activism, except in a transaction approved in advance by the Board;
(vii) effect or seek to effect, offer or propose to effect, cause or participate in, or knowingly assist or facilitate any other person or entity to effect or
seek, offer or propose to effect or participate in, any tender or exchange offer, merger, consolidation, division, acquisition, scheme, arrangement,
business combination, recapitalization, reorganization, sale or acquisition of material assets, liquidation, dissolution or other extraordinary
transaction involving the Company or any of its subsidiaries or joint ventures or any of their respective securities (each, an “ Extraordinary
Transaction”), or make any public statement with respect to an Extraordinary Transaction; provided, however, that nothing in this Agreement shall
prevent the Marathon Parties from making a public statement about how they intend to vote and the reasons therefor with respect to any
Extraordinary Transaction to which any executive officer or director of the Company is a party (other than customary support agreements) and that
requires a vote of the Company’s stockholders; provided further, that this clause shall not preclude the tender by the Marathon Parties or any of
their Affiliates or Associates of any Securities of the Company into any tender or exchange offer which has been approved and recommended to
stockholders of the Company by the Board;
(viii) (A) seek or solicit support for (whether publicly or privately) any written consent of stockholders of the Company, (B) seek representation on,
or nominate any candidate to, the Board, except as set forth in Section 1 of this Agreement, (C) seek the removal of any member of the Board, (D)
conduct a referendum of stockholders, (E) institute any litigation against the Company, its directors or its officers other than to (1) enforce the
provisions of this Agreement and (2) make counterclaims with respect to any proceeding initiated by, or on behalf of, the Company against the
Marathon Parties, or (F) make a request for any stockholder list or other Company books and records, whether pursuant to Section 220 of the
Delaware General Corporation Law or otherwise;
(ix) knowingly encourage, advise or influence any other person or assist any Third Party in so encouraging, assisting or influencing any person or
entity with respect to the giving or withholding of any proxy vote at the 2020 Annual Meeting or the 2021 Annual Meeting (including any “vote
no” or “withhold vote” or similar campaign);
(x) take any action in support of or make any proposal or request that constitutes: (A) advising, controlling, changing or influencing the Board or
management of the Company, including any plans or proposals to change the number or term of directors or to fill any vacancies on the Board or
unfilled newly-created directorships; (B) any material change in the capitalization, stock repurchase programs and practices or dividend policy of
the Company; (C) any other material change in the Company’s management, business or corporate structure, including, without limitation, its
capital allocation, expense structure, business operations or strategies or its management or other personnel; (D) seeking to have the Company
waive or make amendments or modifications to the Company’s Certificate of Incorporation or the Bylaws, or other actions that may impede or
facilitate the acquisition of control of the Company by any person or entity;
6(E) causing a class of Securities of the Company to be delisted from, or to cease to be authorized to be quoted on, any securities exchange; or (F)
causing a class of Securities of the Company to become eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act;
(xi) otherwise act in concert with any person or entity to seek to control or direct the management, Board (or any individual members thereof),
stockholders or policies of the Company;
(xii) take any action that would require the Marathon Parties or any of their Affiliates or Associates to file a statement of beneficial ownership report
on Schedule 13D or any amendment thereto with the SEC, other than solely as a result of the purchase or sale by the Marathon Parties of Securities
of the Company set forth on Exhibit A;
(xiii) make any public disclosure, announcement or statement regarding any intent, purpose, plan or proposal with respect to the Board, the
Company, its management, policies or affairs, any Securities of the Company or assets of the Company or this Agreement;
(xiv) enter into substantive discussions, negotiations, agreements or understandings with any Third Party with respect to the foregoing, or solicit,
assist, prompt, induce or attempt to induce any Third Party to take any action or make any statement with respect to any of the foregoing, or
otherwise take or cause any action or make any statement inconsistent with any of the foregoing; or
(xv) request, directly or indirectly, any amendment or waiver of this Section 5(a).
(b) Notwithstanding anything contained in this Agreement to the contrary:
(i) Nothing in this Section 5(a) shall prohibit or restrict the Marathon Parties from taking any action necessary to comply with any law, rule or
regulation or any action required by any governmental or regulatory authority or stock exchange that has jurisdiction over the Marathon Parties or
any of their Affiliates or Associates. The provisions of this Section 5(a) shall also not prevent the Marathon Parties from freely voting their Shares
(except as otherwise provided in this Agreement) or taking any actions except as specifically contemplated in this Agreement.
(ii) The Marathon Parties shall be responsible for any breach of this Section 5(a) by any of their Affiliates or Associates or any Marathon Party
Representatives.
6. Mutual Non-Disparagement; No Public Statements .
(a) Subject to applicable law, the Company, on the one hand, and each of the Marathon Parties on the other hand, covenants and agrees that,
during the Support Period or if earlier, until such time as the other Party or any of its or her officers, directors, employees, subsidiaries, Affiliates,
Associates, agents, attorneys or other representatives (collectively, the “ Representatives ”) shall have breached this section, neither it nor any of
its respective Representatives acting, directly or indirectly, at its direction or on its behalf, shall in any way publicly (including by any
communication with other investors or prospective investors in the Company where such communications could reasonably be expected to be
made public or trigger a public disclosure obligation, with securities analysts or any member of traditional or digital media) criticize, disparage, call
into disrepute or otherwise defame or slander the other Party or such other Party’s Representatives (including any current officer or director of a
Party or a Party’s subsidiaries who no longer serves in such capacity at any time following the execution of this Agreement), or any of their
businesses, products or services, in any manner that would reasonably be expected to damage the business or reputation of such other Party.
(b) During the Support Period and except for the filing or amendment of a statement of beneficial ownership report on Schedule 13D in relation to
the purchase or sale of Common Stock, neither the Marathon Parties nor any of their Representatives, acting at the direction of, or on behalf of, the
Marathon Parties shall make any public statement relating to the Company nor take any action which would reasonably be expected to require any
public filing
7related to the Company without prior written approval from the Company; provided, however, that nothing in this Agreement shall prevent the
Marathon Parties from making a public statement about how they intend to vote and the reasons therefor with respect to any Extraordinary
Transaction to which any executive officer or director of the Company is a party (other than customary support agreements) and that requires a
vote of the Company’s stockholders.
(c) Each Party shall be responsible for any breach of this Section 6 by any of their respective Representatives.
(d) During the Support Period, so long as the Marathon Parties have maintained since the date of this Agreement the Minimum Ownership
Threshold, (i) management of the Company (together with the Company’s Lead Independent Director, should such director elect to participate) will
hold a customary investor conference call, for up to 45 minutes, with Mr. Cibelli and other representatives of the Marathon Parties following each of
the Company’s quarterly and annual earnings calls, and (ii) promptly following such call, the Lead Independent Director of the Company (together
with any other independent directors of the Company selected by the Lead Independent Director to attend such meeting) will participate in a call
with Mr. Cibelli and other representatives of the Marathon Parties without management of the Company present for up to 15 minutes (the calls in (i)
and (ii), “Quarterly Investor Conference Calls ”). The Marathon Parties shall provide the Company with a detailed agenda of discussion topics for
the portion of the Quarterly Investor Conference Call with the Lead Independent Director no later than three business days prior to the date of such
Quarterly Investor Conference Call. Should the Marathon Parties forgo a Quarterly Investor Conference Call, any unused minutes from such
relinquished Quarterly Investor Conference Call shall carry over to the Quarterly Investor Conference Call being held the following quarter;
provided, however, for the avoidance of doubt, any unused minutes from a Quarterly Investor Conference Call shall not carry over more than one
successive quarter.
(e) Between the date of this Agreement and the 2021 Annual Meeting Nomination Window Date, no Marathon Party or any of their Representatives
will contact or communicate with the Company or any of its Representatives (including any member of the Board) in any way or through any media
other than at a Quarterly Investor Conference Call, in connection with arranging any such Quarterly Investor Conference Call or in connection with
the Marathon Party’s specific rights and obligations under this Agreement. Any communications from any Marathon Party or any of their
Representatives in connection with arranging any such Quarterly Investor Conference Call or in connection with the Marathon Party’s rights and
obligations under this Agreement must be directed to the Parties in accordance with the notice provisions in Section 8(l), and no Marathon Party or
any of their Representatives will contact or communicate with the Company or any of its Representatives (including any member of the Board) in
any other manner unless agreed to in writing by the Company.
(f) In the event that the Support Period is automatically extended pursuant to Section 4(b), then, following the 2021 Annual Meeting Nomination
Window Date, the Marathon Parties agree that any and all contacts and communications regarding the Company, as well as any request by any of
the Marathon Parties or any of the Marathon Party Representatives to contact, communicate or meet with the Company or any of its
Representatives (including any member of the Board), shall be directed solely to the Company’s General Counsel. Any such communications from
any of the Marathon Parties or any of the Marathon Party Representatives in connection with arranging any Quarterly Investor Conference Call or
in connection with the Marathon Parties’ rights and obligations under this Agreement shall be directed solely to the Company’s General Counsel.
7. Press Release . The Parties agree that the Company shall issue a press release (the “ Press Release ”) in substantially the form attached hereto as
Exhibit B promptly following the execution and delivery of this Agreement by the Parties.
8. Miscellaneous .
(a) Specific Enforcement; Special Remedy . Each of the Parties agrees that the other Party would be irreparably injured in the event that any
provision of the Agreement is breached or not performed. Accordingly, it is agreed that each Party shall be entitled to temporary and permanent
injunctive relief with respect to each and any breach or purported repudiation of this Agreement by the other and to specifically enforce strict
adherence to this Agreement and the terms and provisions hereof against the other in any action instituted in a court of competent
8jurisdiction, in addition to any other remedy which such aggrieved Party may be entitled to obtain. Moreover, in the event of the breach of any of
the provisions of this Agreement, timeliness in obtaining relief is of the essence.
(b) Amendments; Waiver . Neither this Agreement nor any term hereof may be changed, waived, discharged or terminated orally or in writing, except
that any term of this Agreement may be amended by a writing signed by the Parties, and the observance of any such term may be waived (either
generally or in a particular instance and either retroactively or prospectively) solely in a writing signed by the Party against whom such waiver is to
be asserted. No delay on the part of either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any
waiver on the part of either Party of any right, power or privilege hereunder operate as a waiver of any other right, power or privilege hereunder, nor
shall any single or partial exercise of any right, power or privilege hereunder, preclude any other or further exercise thereof or the exercise of any
other right, power or privilege hereunder.
(c) Successors and Assigns . This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties.
This Agreement may not be assigned without the prior written consent of the other Party hereto.
(d) No Third-Party Beneficiaries. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person or entity,
other than the Parties and their respective successors and assigns, any legal or equitable right, remedy or claim under or in respect of this
Agreement and any conditions and provisions hereof being intended to be and being for the sole and exclusive benefit of the parties hereto and
their respective successors and assigns, and for the benefit of no other person or entity.
(e) Counterparts . This Agreement may be executed in any number of counterparts and by the Parties in separate counterparts (including by
facsimile signature, Docusign or other form of electronic signature), each of which when so executed shall be deemed to be an original and all of
which taken together shall constitute one and the same agreement. This Agreement may be executed and delivered by the Parties electronically,
including by electronic mail, .pdf, Docusign, or other means of electronic delivery.
(f) Headings . The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.
(g) Governing Law; Choice of Venue.
(i) This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware applicable to agreements made
and to be performed within that state, without giving effect to any law or principals of law that would result in the application of the laws of any
other jurisdiction.
(ii) Each Party (A) consents to submit itself to the personal jurisdiction of the Court of Chancery or other federal or state courts of the State of
Delaware in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (B) agrees that it shall not
attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, (C) agrees that it shall not bring any
action relating to this Agreement or the transactions contemplated by this Agreement in any court other than the Court of Chancery or other
federal or state courts of the State of Delaware, and each Party irrevocably waives the right to trial by jury and (D) irrevocably consents to service
of process by a reputable overnight mail delivery service, signature requested, to the address of such Party’s principal place of business or as
otherwise provided by applicable law.
(h) Reimbursement. The Company shall reimburse the Marathon Parties for their reasonable out-of-pocket expenses, including the reasonable fees
and expenses of counsel, incurred in connection with their engagement with the Company, the Nominations and the negotiation of, and all matters
arising under this Agreement; provided , however , that such reimbursement shall not exceed $250,000.
9(i) Severability. If at any time subsequent to the date hereof, any provision of this Agreement shall be held by any court of competent jurisdiction
to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality or unenforceability of such provision shall have
no effect upon the legality or enforceability of any other provision in this Agreement.
(j) Interpretation and Construction . Each of the Parties acknowledges that it has been represented by counsel of its choice throughout all
negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said independent counsel.
Each Party and its counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referred to herein, and
any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed
against any Party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any
ambiguities in this Agreement against any Party that drafted or prepared it is of no application and is hereby expressly waived by each Party, and
any controversy over interpretations of this Agreement shall be decided without regards to events of drafting or preparation. For purposes of this
Agreement, the term “including” shall be deemed to be followed by the words “without limitation.”
(k) Entire Agreement. This Agreement contains the entire understanding of the Parties with respect to the subject matter hereof.
(l) Notices. Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this
Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by e-mail to the e-mail address for a Party set forth below; and (iii) one (1) business day after deposit with a nationally recognized overnight
delivery service, in each case properly addressed to the Party to receive the same. The addresses for such communications shall be:
If to the Company or the Board:
e.l.f. Beauty, Inc.
570 10th Street
Oakland, CA 94607
Attention: General Counsel
Email: ***
with a copy (which shall not constitute notice) to:
Latham & Watkins LLP
140 Scott Drive
Menlo Park, CA 94025
Attention: Tad Freese and Josh Dubofsky
E-mail: Tad.Freese@lw.com and Josh.Dubofsky@lw.com
If to the Marathon Parties:
Marathon Partners Equity Management, LLC
Attention: Mario Cibelli
Email: ***
with a copy (which shall not constitute notice) to:
Olshan Frome Wolosky LLP
1325 Avenue of the Americas
New York, NY 10019
Attention: Andrew Freedman
E-mail: AFreedman@olshanlaw.com
10(m) Termination. Unless earlier terminated as provided in this Agreement, upon the expiration of the Support Period, this Agreement shall
immediately and automatically terminate in its entirety and no Party shall have any further rights or obligations under this Agreement; provided,
however, (i) that this Section 8 shall survive any such termination and (ii) no Party shall be released from any breach of this Agreement that
occurred prior to the termination of this Agreement.
[Signature Pages Follow]
11IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement, or caused the same to be executed by its duly authorized
representative as of the date first above written.
E.L.F. BEAUTY, INC.
By: /s/ Scott Milsten
Name: Scott Milsten
Title: General Counsel
[Signature Page to Cooperation Agreement ]Marathon Partners Equity Management, LLC
By: /s/ Mario D. Cibell
Name: Mario D. Cibelli
Title: Managing Member
Marathon Partners L.P.
By: Marathon Partners Equity Management, LLC, its General Partner
By: /s/ Mario D. Cibell
Name: Mario D. Cibelli
Title: Managing Member
Marathon Focus Fund L.P.
By: Cibelli Research & Management, LLC,
its General Partner
By: /s/ Mario D. Cibell
Name: Mario D. Cibelli
Title: Managing Member
Marathon Partners LUX Fund, L.P.
By: Cibelli Research & Management, LLC,
its General Partner
By: /s/ Mario D. Cibell
Name: Mario D. Cibelli
Title: Managing Member
Cibelli Research & Management, LLC
By: /s/ Mario D. Cibell
Name: Mario D. Cibelli
Title: Managing Member
By: /s/ Mario D. Cibell
Name: Mario D. Cibelli
[Signature Page to Cooperation Agreement ]Exhibit 10.20  
Pages where confidential treatment has been requested are stamped ‘Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,’ and the confidential section has been marked as follows: [***].  
Collaboration Agreement  
between  
Institute of Grassland and Environmental Research  
and  
Ceres, Inc.       CERES-IGER Collaboration Agreement    Page 1 of 75TABLE OF CONTENTS           1. RESEARCH PROJECTS     3  2. MANAGEMENT COMMITTEE     7  3. EXCLUSIVITY     8  4. INTELLECTUAL PROPERTY     11  5. USE AND COMMERCIALIZATION RIGHTS     14  6. ENFORCEMENT OF JOINT INTELLECTUAL PROPERTY RIGHTS     16  7. CONFIDENTIALITY     16  8. PUBLICATIONS     18  9. PUBLICITY     18  10. RECORDS AND AUDITS     19  11. INDEPENDENT CONTRACTOR     19  12. CONVENTION ON BIOLOGICAL DIVERSITY     19  13. WARRANTIES     20  14. TERM AND TERMINATION     23  15. DISPUTE RESOLUTION AND APPLICABLE LAW     25  16. NOTICES     26  17. GENERAL     27  18. SPECIAL CONDITIONS IN CONNECTION WITH DEFRA AGREEMENT NF 0426     28  EXHIBIT A     30 DEFINITION OF COLLABORATION CROPS     30 EXHIBIT B     31 PREFERRED FORM OF RECEIPT FORM     31 EXHIBIT C     32 PREFERRED FORMS OF VARIETY EVALUATION AGREEMENT     32 EXHIBIT D     50 EXTERNAL FUNDING  EXHIBIT E     5051 
EXISTING AGREEMENTS     51 EXHIBIT F     56  PRODUCTION AND COMMERCIALIZATION ACTIVITIES     56  EXHIBIT G     57 MODEL LICENSE AGREEMENT FOR NON-TRANSGENIC VARIETIES / NON-UK     57 EXHIBIT H     74 CERTAIN REMUNERATION PRINCIPLES     74      CERES-IGER Collaboration Agreement    Page 2 of 75COLLABORATION AGREEMENT  
THIS AGREEMENT is made this 1st day of April, 2007 (“Effective Date”), by and between INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH (“IGER”), a company limited by guarantee, registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom and CERES, INC. (“CERES”), a Delaware corporation, having an office at 1535 Rancho Conejo Blvd., Thousand Oaks, California 91320, United States of America.  
WHEREAS, the Parties wish to establish a research program for undertaking specific, collaborative projects after the Effective Date, to further the scientific research and commercial objectives of CERES as well as the scientific research objectives of IGER;  
WHEREAS, the research programs contemplated by this Agreement and its schedules are consistent with and in furtherance of IGER research programs;  
WHEREAS, CERES and IGER recognize that rights to intellectual property conceived or reduced to practice in the performance of the Parties’ collaboration can be a strong incentive for CERES to risk money and other resources needed to develop proprietary products for wide commercialization;  
NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements contained herein and of other good and valuable consideration, the Parties have agreed and do hereby agree as follows:  
1.1 CERES and IGER anticipate that from time to time they may undertake and conduct certain joint and collaborative research projects (individually a “RESEARCH PROJECT” and collectively “RESEARCH PROJECTS”). The Parties acknowledge and agree that the RESEARCH PROJECTS will involve the contributions, whether financial or otherwise, of both Parties. The specific terms and respective obligations of the Parties for each RESEARCH PROJECT will be negotiated by the Parties and reflected in a schedule (“SCHEDULE”) signed by authorized representatives of both Parties. Any such fully executed SCHEDULE shall become a part of this Agreement and subject to the terms of this Agreement. Each Party shall diligently perform its activities in any given RESEARCH PROJECT.  
1.2 All rights in property, tangible or intangible, used in the RESEARCH PROJECTS shall remain with the Party providing such property, unless otherwise agreed between the Parties in this Agreement, a SCHEDULE or a separate agreement.  
1.3 RESEARCH PROJECTS will relate to crop species defined in EXHIBIT A to this Agreement (“COLLABORATION CROPS”).  
1.4 Each SCHEDULE will at least contain the following:  
1. RESEARCH PROJECTS.
  •  research activities to be performed by each Party in detail     CERES-IGER Collaboration Agreement    Page 3 of 751.5 Unless a SCHEDULE provides for more frequent formal reporting, each Party shall provide to the other Party a detailed, written annual report on its activities in each RESEARCH PROJECT, as described in each SCHEDULE. In addition, upon the request of either Party at any time, the Parties will discuss the RESEARCH PROJECTS, their status, the progress and results achieved, and they will make available each RESEARCH PROJECT principal investigator (and other employees as needed, in the discretion of the respective RESEARCH PROJECT principal investigators) at mutually agreeable times, as needed, for such discussions; provided however, such contacts and discussions shall be reasonable in frequency and duration so as not to be disruptive to the respective research activities of each Party or the research activities of the RESEARCH PROJECTS. Each Party will also voluntarily provide data, information and material generated in the RESEARCH PROJECT to the other Party as required to further the Parties’ mutual goals defined in each RESEARCH PROJECT or in any other agreement between the Parties. Each Party will have the right, upon reasonable notice to the other Party, to visit any location where RESEARCH PROJECT activities are conducted for the purposes of evaluating RESEARCH PROJECT progress and outcomes, and particularly to make observations of any plants in growth chambers, greenhouses or fields that are a part of a RESEARCH  
  •  timelines of such activities
 
  •  goals, expected results and deliverables
 
  •  milestones and “go” and “no-go” decision points
 
  •  all reports to be delivered to the MANAGEMENT COMMITTEE (Article 2) and the required delivery dates for the same
 
  •  additional information on RESEARCH PROJECT activities: breeding records and biological or other material generated in such activities to be provided to the other Party, including delivery method and time
 
  •  location of activities
 
  •  identity of RESEARCH PROJECT principal investigators for CERES and IGER
 
  •  identity and location of any SUBCONTRACTORS (Article 1.13) to be used for the RESEARCH PROJECT activities
 
  •  number of FTE’s made available by each Party for the RESEARCH PROJECT, including names of any IGER PhD-level employees
 
  •  other inputs and resources made available by each Party for the RESEARCH PROJECT
 
  •  financial contributions of each Party to the RESEARCH PROJECT
 
  •  provisions on intellectual property, including lists of BACKGROUND INTELLECTUAL PROPERTY and any provisions which are different from those set forth in this Agreement
 
  •  provisions on use and commercialization rights which are different from those set forth in this Agreement
 
  •  provisions on expiration and early termination
     CERES-IGER Collaboration Agreement    Page 4 of 75PROJECT. Each Party will comply with any reasonable safety and security measures which may be imposed by the other Party when visiting such other Party’s location.  
1.6 Any transfer of information or material pursuant to this Agreement or any SCHEDULE will be governed by the provisions of this Agreement on CONFIDENTIALITY (Article 7) and PUBLICATIONS (Article 8). Any transfer of material shall be accompanied by a receipt form in the preferred format attached as EXHIBIT B to this Agreement. Such receipt forms shall be signed by representatives of both the sending and receiving Parties.  
1.7 Unless otherwise specified in a SCHEDULE, each Party shall bear its own costs and pay its own SUBCONTRACTORS, with respect to its RESEARCH PROJECT activities.  
1.8 Where a SCHEDULE provides that CERES will make a financial contribution to certain RESEARCH PROJECT activities performed by IGER, unless agreed otherwise in the appropriate SCHEDULE, IGER will submit invoices after the end of each calendar quarter for the work performed during that quarter. Each such invoice shall reflect only those costs that have been incurred in performance of the RESEARCH PROJECT and shall provide a breakdown of costs similar to the detail set forth in the budget of the related SCHEDULE. CERES will pay all such invoices within thirty (30) days after the invoice date. Payments shall be remitted to:  
Institute Secretary  Institute of Grassland and Environmental Research  Plas Gogerddan  Aberystwyth  Ceredigion  SY23 3EB  United Kingdom  
1.9 Each Party will conduct RESEARCH PROJECT activities exclusively in laboratories, greenhouses or fields under full control of that Party or of its SUBCONTRACTORS authorized by this Agreement. Each Party will take all reasonable precautions to prevent damage to, or unintentional destruction of or release of any germplasm created in the RESEARCH ACTIVITIES.  
1.10 Each Party shall be responsible for its compliance with all applicable laws, rules and regulations, including, without limitation, those relating to genetically modified organisms (to the extent RESEARCH PROJECTS involve such organisms). Each Party shall obtain any and all permits or authorizations or proceed to any notifications which may be required by such laws, rules and regulations.  
1.11 Each Party will require any and all of its employees or students who will perform activities in RESEARCH PROJECTS to be bound by a written agreement(s) that commits their inventions, discoveries and other intellectual property to the Party-employer and requires confidential treatment of Party and third-party confidential information.  
1.12 The RESEARCH PROJECT principal investigators named in each SCHEDULE shall be charged with leading the RESEARCH PROJECT described therein.       CERES-IGER Collaboration Agreement    Page 5 of 751.12.1 RESEARCH PROJECT principal investigators may not vary the SCHEDULE of delivery, amount, method of payment or any provision of a SCHEDULE. No such change shall be effective unless and until it is reduced to writing in the form of an amendment to such SCHEDULE in accordance with Article 17.1.  
1.12.2 Substitution by IGER of a RESEARCH PROJECT (a) principal investigator or (b) a CERES-funded, PhD-level, IGER employee named or filling a defined position listed in a SCHEDULE shall be subject to CERES’ prior written approval, which will not unreasonably be withheld or delayed. IGER will notify CERES, in writing, of any substitution by IGER of a non-CERES-funded, PhD-level employee named or who filled a defined position listed in a SCHEDULE. CERES will notify IGER, in writing, of any substitution by CERES of a RESEARCH PROJECT principal investigator or a PhD-level CERES employee named or who filled a defined position listed in a SCHEDULE.  
1.13 Each Party may subcontract certain parts of its RESEARCH PROJECT activities to third parties, or use third party consultants in connection with RESEARCH PROJECT activities, but only if the subcontract or consultancy agreement is in writing and complies with the terms and conditions set forth hereinafter. Such third parties with whom such a subcontract or consultancy agreement is executed will be referred to as “SUBCONTRACTORS”.  
1.13.1 Any intended agreement with a SUBCONTRACTOR shall be identified in a SCHEDULE if known at the time the SCHEDULE is executed by the Parties. IGER will obtain CERES’ prior written consent before entering into any agreement with a SUBCONTRACTOR which is not listed in a SCHEDULE.  
1.13.2 The following terms and conditions shall apply to IGER’s SUBCONTRACTORS: (a) the SUBCONTRACTOR shall perform defined activities on behalf and for the benefit of IGER in exchange for a fee or other tangible consideration; (b) the SUBCONTRACTOR shall deliver all the results of the SUBCONTRACTOR’S activities under the subcontract to IGER only, and assign ownership of or exclusively license any inventions made during the performance of the subcontracting activities to IGER, without any further remuneration and (c) the SUBCONTRACTOR shall not have the right to use any results, whether information or material, for any purpose whatsoever other than the performance of the subcontract; provided however, not-for-profit research institution SUBCONTRACTORS may be granted the right to use certain information generated pursuant to the subcontract for their internal academic research and educational purposes (i.e., not in collaboration with or for the benefit of any third party). IGER will provide to CERES a draft copy of any subcontract IGER is planning to conclude at least fifteen (15) days before the scheduled signature date and will provide a true copy of any subcontract to CERES within thirty (30) days of its execution.  
1.13.3 It is anticipated that any agreements with commercial SUBCONTRACTORS will be entered into by CERES. At CERES’ request, IGER will assist CERES in identifying SUBCONTRACTORS for any field activities. The following conditions shall apply to CERES SUBCONTRACTORS: CERES will inform IGER, in writing, of any SUBCONTRACTORS used by CERES for the performance of RESEARCH PROJECT activities.       CERES-IGER Collaboration Agreement    Page 6 of 751.13.4 All SUBCONTRACTORS shall be bound by confidentiality obligations consistent with the terms and obligations of this Agreement. All SUBCONTRACTORS shall be responsible for their respective compliance with all laws, rules and regulations that govern their activities.  
1.13.5 For variety evaluation and performance testing using not-for-profit research institution SUBCONTRACTORS, the Parties agree that each transfer of plant material shall be governed by a written agreement consistent with the preferred forms set forth in EXHIBIT C to this Agreement.  
1.14 The Parties mutually agree that any applications for extramural funding for a RESEARCH PROJECT, from governmental authorities or other public sources, will be subject to the prior, written agreement, neither unreasonably withheld or delayed, by both Parties; provided however, the Parties acknowledge that CERES and/or IGER has or has applied for certain government, extramural funding prior to the Effective Date (EXHIBIT D to this Agreement), and such funding (or possible funding, if awarded) shall not be construed as a breach of the obligations of this Article.  
1.15 IGER agrees not to accept research funding from for-profit entities to perform any RESEARCH PROJECT, whether in whole or in part, initiated under this Agreement without the prior written consent of CERES.  
1.16 The Parties acknowledge and agree that certain RESEARCH PROJECT activities may be covered by government funding set forth in EXHIBIT D and corresponding agreements set forth in EXHIBIT E, as indicated in the relevant SCHEDULE(S). In particular, the Parties acknowledge and agree that IGER will comply with its obligations under the DEFRA project NF 0426 “The generic improvement of miscanthus for biomass” (“DEFRA agreement NF 0426”), including without limitation its obligation to meet the objectives set forth in such project and to report to DEFRA on its results relating to such activities. The Parties further agree that such compliance will not affect any provisions of this Agreement nor of any SCHEDULE, except if explicitly provided otherwise, including without limitation the provisions on INTELLECTUAL PROPERTY in Article 4 and on USE AND COMMERCIALIZATION RIGHTS in Article 5.  
2.1 The Parties will establish a MANAGEMENT COMMITTEE to supervise the implementation, execution and progress of this Agreement and its RESEARCH PROJECTS. The MANAGEMENT COMMITTEE will consist of four (4) members, two (2) to be appointed by each Party and will meet at least once every calendar quarter, in person or by telephone, on dates and at locations to be mutually agreed. The representatives of each Party may invite other employees of that Party to meeting on an as-needed basis, subject to prior notification of the other Party.  
2.2 Decisions of the MANAGEMENT COMMITTEE shall be made by unanimous agreement and recorded in a manner prescribed by the MANAGEMENT COMMITTEE as a true record of the decisions. If the MANAGEMENT COMMITTEE cannot come to a unanimous agreement on any matter then the status quo shall apply.  
2.3 The responsibilities of the MANAGEMENT COMMITTEE shall be as follows:  
2. MANAGEMENT COMMITTEE.
     CERES-IGER Collaboration Agreement    Page 7 of 753.1 In consideration of CERES’ development of new markets for the COLLABORATION CROPS and the significant activities associated with the development of this market, IGER agrees to grant CERES exclusive access to IGER’s plant improvement activities specifically involving the COLLABORATION CROPS, whether through plant breeding, transformation, propagation methods or otherwise, subject however to the exceptions expressly set forth in this Agreement.  
3.2 During the term of this Agreement, subject to the provisions of this Agreement on subcontracting (Article 1.13 and its related subsections) and subject to the agreements entered into by IGER prior to the Effective Date and defined in EXHIBIT E to this Agreement, as such agreements exist on the Effective Date (“EXISTING AGREEMENTS”), IGER agrees to comply with the obligations set forth hereinafter:  
3.2.1 for-profit third parties.  
IGER will not collaborate with or perform any activities for the benefit of or grant any rights to any for-profit third party in the field of the COLLABORATION CROPS without the prior written consent of CERES.  
  –  supervise and review the implementation of the RESEARCH PROJECTS;
 
  –  approve principal investigators and project teams for RESEARCH PROJECTS;
 
  –  determine the resources necessary to achieve the goals of each RESEARCH PROJECT, within the limits of the RESEARCH PROJECT budget provided in the relevant SCHEDULE;
  –  adjust the research activities defined in a RESEARCH PROJECT, subject to the overall budget for that RESEARCH PROJECT in a given year;
  –  review achievement of goals and timelines; propose adjustments of goals or timelines to the Parties;
  –  review achievement of agreed annual milestones for overhead payment purposes and make recommendations relating to milestones to the Parties;
  –  review proposed publications and formulate recommendations to the Parties on publications;
  –  review intellectual property matters relating to the implementation of this Agreement and formulate recommendations to the Parties regarding such matters;
  –  review subcontracting matters and formulate recommendations to the Parties regarding such matters;
  –  review reports to be provided pursuant to SCHEDULES;
  –  such other responsibilities as the Parties jointly may explicitly grant to the MANAGEMENT COMMITTEE.
3. EXCLUSIVITY.
     CERES-IGER Collaboration Agreement    Page 8 of 75a. CERES will not unreasonably withhold its consent for collaborations with small companies (less than fifty (50) employees including world-wide affiliates) established in the United Kingdom (“UK COMPANIES”), with respect to research programs involving COLLABORATION CROPS in the field of environmental impact, carbon sequestration, climate change mitigation, agronomy, or compositional or conversion analysis, provided that (i) IGER will receive the exclusive right (subject to Articles 5.1.2(a) and 5.2) to use and exploit commercially the results of such research programs for GERMPLASM IMPROVEMENT (as defined hereinafter) of the COLLABORATION CROPS, (ii) CERES will have access to the results of such research programs to the extent allowed by the relevant agreement between IGER and the third party and IGER will use reasonable efforts to obtain such right for CERES, and (iii) there is no conflict with CERES’ commercial interests.  
b. CERES recognizes that IGER may receive requests from third parties to make available germplasm of CERTAIN MISCANTHUS ACCESSIONS. IGER will have the right to make available germplasm of CERTAIN MISCANTHUS ACCESSIONS to third parties for research purposes (including breeding), subject to the terms and conditions under which IGER holds such accessions. “CERTAIN MISCANTHUS ACCESSIONS” shall mean the Miscanthus accessions collected by IGER in 2006 from China, Taiwan and Japan, as originally collected by IGER.  
3.2.2 not-for-profit third parties.  
a. “GERMPLASM IMPROVEMENT” shall mean any activities to improve a crop, including without limitation selection, breeding, transgenic improvement, markers, propagation systems:  
IGER will not collaborate with or perform any activities for the benefit of or grant any rights to any not-for-profit third party with respect to GERMPLASM IMPROVEMENT of COLLABORATION CROPS without the prior written consent of CERES. CERES will not unreasonably withhold its consent for research programs with respect to GERMPLASM IMPROVEMENT of COLLABORATION CROPS with academic institutions in the European Union under United Kingdom government or European Union funding, provided that (i) IGER will have the exclusive right to use and exploit commercially the results of such research programs obtained by IGER, (ii) no COLLABORATION CROP germplasm will be made available by IGER to any third party for selection, breeding or propagation work, or for genetic transformation of such germplasm, except that IGER may make available germplasm of CERTAIN MISCANTHUS ACCESSIONS for research purposes (including breeding), subject to the terms and conditions under which IGER holds such accessions, and (iii) if requested by CERES, IGER will use reasonable efforts to obtain commercialization rights for CERES on results       CERES-IGER Collaboration Agreement    Page 9 of 75obtained by third parties in such collaborative research programs or breeding activities.  
b. environmental impact, carbon sequestration, climate change or agronomy studies, and compositional or conversion analysis:  
if IGER would enter into any agreement (or amendment of an existing agreement including without limitation EXISTING AGREEMENTS) after the Effective Date with a not-for-profit third party with respect to research in the field of environmental impact, carbon sequestration, climate change mitigation, agronomy, or compositional or conversion analysis relating to COLLABORATION CROPS, such agreement must provide that (i) IGER will receive the exclusive right (subject to Articles 5.1.2(a) and 5.2) to use and exploit commercially the results obtained pursuant to such agreement for GERMPLASM IMPROVEMENT of COLLABORATION CROPS and (ii) CERES will have access to the results of such research programs to the extent allowed by the relevant agreement between IGER and the third party and IGER will use reasonable efforts to obtain such right for CERES.  
3.2.3 IGER will provide a draft of any agreement intended to cover an activity referred to in Article 3.2.1 a. or b. or 3.2.2 a. or b. to CERES, together with its written request for consent where such consent needs to be obtained. CERES will respond in writing within thirty (30) days or such other period of time as the Parties may agree in writing. In exceptional urgent cases, when asked by IGER, CERES will respond as soon as reasonably possible. Further, where Articles 3.2.1 or 3.2.2 refer to Ceres’ access to results or right to use and commercially exploit such results, IGER will report such results to CERES in compliance with the terms hereof.  
3.2.4 Whenever rights are granted to IGER pursuant to agreements referred to in Articles 3.2.1 or 3.2.2 (“Third Party Agreement Rights”), the provisions of this Agreement about the grant of rights by IGER to CERES will apply and such Third Party Agreement Rights shall be treated as IGER INTELLECTUAL PROPERTY (unless they qualify as JOINT INTELLECTUAL PROPERTY under the circumstances).  
3.3 During the term of this Agreement, IGER will notify CERES, in writing, of any contemplated internal (i.e. not involving third parties but including government-funded) research activities (i.e., non-RESEARCH PROJECTS) that specifically involve the COLLABORATION CROPS, except research activities that relate solely to environmental impact, carbon sequestration, climate change or agronomy studies. If CERES so requests, the Parties will negotiate in good faith to agree on a new RESEARCH PROJECT and accompanying SCHEDULE or an amendment to an existing SCHEDULE on the basis of such research proposal. If CERES does not request such negotiations, or if the Parties fail to reach agreement on a new SCHEDULE (or amendment to an existing SCHEDULE) within thirty (30) days (or such other time period as the Parties may agree) from IGER’s notice, IGER will have the right, subject to Articles 3.2 and 5.3, to proceed to such internal research, and IGER will provide a written report to CERES on the results of such research. CERES is hereby granted a first option, to be exercised by written notice within thirty (30) days from       CERES-IGER Collaboration Agreement    Page 10 of 75IGER’s aforementioned written report or such other time period as the Parties may agree to be granted the same right as set forth in Article 5.3 to commercialize any results of such activities.  
3.3.1 If CERES exercises its option to commercialize under Article 3.3, CERES and IGER shall negotiate the terms of a commercialization agreement that covers the reported result with reference to any commercialization agreement then in existence between the Parties or the model license agreement or remuneration principles included herein (as applicable). If, despite the Parties’ good faith efforts, CERES and IGER are unable to agree upon the terms and conditions of such agreement within one hundred and eighty (180) days after commencing good faith negotiations, CERES shall have the right to start the dispute resolution procedure in Article 15 for any outstanding unresolved issues.  
3.3.2 If CERES declines to exercise the option under Article 3.3 or fails to respond within thirty (30) days of IGER’s notice under Article 3.3, then IGER shall then be free to commercially exploit the results or offer rights in such results to third parties in any and all crops.  
3.3.3 IGER will have no restrictions to undertake internal (i.e. not involving third parties but including government-funded) research activities that involve COLLABORATION CROPS but relate solely to environmental impact, carbon sequestration, climate change or agronomy studies. IGER will use all reasonable efforts to inform CERES of the results of any such activities.  
4.1 “JOINT INTELLECTUAL PROPERTY” shall mean (a) all patentable inventions conceived, discovered, developed and/or reduced to practice (i) jointly by one or more employees, agents, or students of CERES and by one or more employees, agents, or students of IGER in the performance of any RESEARCH PROJECT(S) or (ii) by one or more employees, agents or students of IGER in the performance of any RESEARCH PROJECT(S) to the extent CERES provides a financial contribution for such RESEARCH PROJECT, which is not less than twenty-five percent (25%) of either the overall cost of such RESEARCH PROJECT or of the activity during which the invention was made, unless expressly provided otherwise in a SCHEDULE; (b) patents, patent applications, plant variety rights, plant variety right applications, reissues, continuations, continuations-in-part and divisionals claiming such patentable inventions in any country of the world; (c) all trade secrets and copyrighted works created jointly by one or more employees, agents, or students of CERES and by one or more employees, agents, or students of IGER in the performance of any RESEARCH PROJECT(S); and (d) all germplasm and plant varieties created in the performance of plant breeding activities in the performance of any RESEARCH PROJECT(S).  
4.2 “CERES INTELLECTUAL PROPERTY” shall mean (a) all patentable inventions conceived, discovered, developed, and/or reduced to practice by one or more employees, agents, or students of CERES in the performance of any RESEARCH PROJECT(S), except as set forth in Article 4.1; (b) patents, patent applications, plant variety rights, plant variety right applications, reissues, continuations, continuations-in-part, and divisionals claiming such patentable inventions in any country of the world; and (c) all trade secrets and copyrighted works created by one or more employees, agents, or students of CERES in the performance of any RESEARCH PROJECT(S) .  
4. INTELLECTUAL PROPERTY.
     CERES-IGER Collaboration Agreement    Page 11 of 754.3 “IGER INTELLECTUAL PROPERTY” shall mean (a) all patentable inventions conceived, discovered, developed, and/or reduced to practice by one or more employees, agents, or students of IGER in the performance of RESEARCH PROJECT(S), except as set forth in Article 4.1; (b) patents, patent applications, plant variety rights, plant variety right applications, reissues, continuations, continuations-in-part, and divisionals claiming such patentable inventions in any country of the world; and (c) all trade secrets and copyrighted works created by one or more employees, agents, or students of IGER in the performance of RESEARCH PROJECT(S).  
4.4 “OTHER RESEARCH RESULTS” shall mean all data, information, procedures, techniques and know-how generated in the performance of RESEARCH PROJECT(S), but expressly excludes JOINT INTELLECTUAL PROPERTY, CERES INTELLECTUAL PROPERTY, and IGER INTELLECTUAL PROPERTY.  
4.5 “BACKGROUND INTELLECTUAL PROPERTY” shall mean (i) inventions, discoveries, materials, data and information, whether patentable or not; including related know-how; (ii) patents, patent applications, plant variety rights, plant variety right applications, reissues, continuations, continuations-in-part and divisionals in any country of the world; and (iii) trade secrets or copyrighted works, which are individually or collectively created, developed, made, acquired or licensed in by CERES or IGER independent of the activities performed pursuant to this Agreement, including its SCHEDULES.  
4.5.1 Any Party asserting that certain intellectual property is BACKGROUND INTELLECTUAL PROPERTY shall have the burden of substantiating such claim, if necessary, with tangible evidence, including but not limited to paper or electronic records.  
4.5.2 The Parties acknowledge and agree that all relevant BACKGROUND INTELLECTUAL PROPERTY for a RESEARCH PROJECT should be set forth within the corresponding SCHEDULE. With respect to each element of BACKGROUND INTELLECTUAL PROPERTY listed in a SCHEDULE, the listing Party shall include the following: ownership or licensed rights (exclusive or non-exclusive) held by the listing Party (if no ownership) with respect to the COLLABORATION CROPS. Notwithstanding, subject to Article 4.5.1, failure to specifically set forth such BACKGROUND INTELLECTUAL PROPERTY in a SCHEDULE will not foreclose a later claim that certain intellectual property is BACKGROUND INTELLECTUAL PROPERTY.  
4.6 CERES and IGER shall have an undivided interest in JOINT INTELLECTUAL PROPERTY. Consequently, any and all patent applications or plant variety rights applications that cover JOINT INTELLECTUAL PROPERTY shall be assigned jointly to CERES and IGER as soon as practicable.  
4.6.1 All rights and title to CERES INTELLECTUAL PROPERTY and CERES BACKGROUND INTELLECTUAL PROPERTY shall belong to CERES, and IGER shall not acquire any interest in the same by its performance under this Agreement.  
4.6.2 All rights and title to IGER INTELLECTUAL PROPERTY and IGER BACKGROUND INTELLECTUAL PROPERTY shall belong to IGER, and CERES shall not       CERES-IGER Collaboration Agreement    Page 12 of 75acquire any interest in the same by its performance under this Agreement, except as expressly provided in this Agreement.  
4.7 Each Party will notify the other Party, in writing (“INVENTION NOTICE”), within thirty (30) days of reduction to practice or knowledge of conception or discovery of JOINT INTELLECTUAL PROPERTY, and each INVENTION NOTICE will describe the JOINT INTELLECTUAL PROPERTY with sufficient specificity to allow assessment by the other Party.  
4.8 The Parties shall consult as soon as possible but in any case within twenty (20) days of receiving an INVENTION NOTICE whether to proceed to obtain intellectual property protection on the disclosed JOINT INTELLECTUAL PROPERTY or whether to protect the same through other methods. CERES shall have the first option to pursue such protection in its best judgment in the joint names of both Parties. If CERES so elects by written notice within sixty (60) days of such initial consultation, CERES shall be the “ADMINISTERING PARTY” for the purposes of this Agreement.  
4.8.1 The ADMINISTERING PARTY shall be responsible for retaining counsel, overseeing the process of securing intellectual property protection (i.e., the preparation, filing and prosecution of patent or plant variety rights application(s)) and maintaining intellectual property protection for the mutual benefit of the Parties, in its best judgment, for that which it has prosecution responsibility. In addition to other reporting responsibilities provided below, the ADMINISTERING PARTY shall promptly notify the other Party following retention of counsel. The Parties will provide, and cause their respective employees, agents and students to provide, all reasonable assistance which may be required in connection with the filing and prosecution of such intellectual property rights, including without limitation the signing of documents.  
4.8.2 The ADMINISTERING PARTY shall keep the non-administering Party advised as to all developments with respect to all patent and plant variety rights application(s) and issued patents and plant variety rights covering jointly owned JOINT INTELLECTUAL PROPERTY, which includes supplying copies of all papers received and filed in connection with such applications and patents in sufficient time for the non-administering Party to comment thereon.  
4.9 CERES agrees to bear all legal expenses incurred by CERES as an ADMINISTERING PARTY in obtaining and maintaining patents and plant variety rights, U.S. and other, covering JOINT INTELLECTUAL PROPERTY.  
4.10 If CERES does not elect to file an application for a patent or plant variety rights or continue maintenance of a patent or plant variety rights in a particular country, consistent with the consultation of Article 4.8, IGER may file such application, continue such prosecution, or maintain such patent or plant variety rights at its own expense; provided however, that prior to filing any such application IGER will not take any action or proceed to any filing which would lead to the possible disclosure of information which CERES wishes to keep confidential, as notified by CERES to IGER in writing. For any such application, patent or plant variety rights, IGER shall serve as the ADMINISTERING PARTY. CERES shall have non-exclusive rights under the specific patent application(s), plant variety right application(s), patent(s) and/or plant variety right(s) in the country(ies) in which CERES declined to initiate or continue its participation, subject to paying IGER       CERES-IGER Collaboration Agreement    Page 13 of 75reasonable remuneration (whether as a royalty or in some other form as the Parties may agree) to be negotiated in good faith, and in any case CERES shall remain free to use and practice the JOINT INTELLECTUAL PROPERTY covered by such specific patent application(s)/patent(s) or plant variety rights application(s)/plant variety right(s) for research and evaluation purposes.  
4.11 At each quarterly meeting of the MANAGEMENT COMMITTEE, CERES will report CERES INTELLECTUAL PROPERTY on which patent applications were filed in the preceding quarter and the general subject matter of patent applications reasonably anticipated to be filed in the near term, and IGER will report IGER INTELLECTUAL PROPERTY on which patent applications were filed in the preceding quarter and the general subject matter of patent applications reasonably anticipated to be filed in the near term. In addition, the Parties may exchange information regarding their respective INTELLECTUAL PROPERTY at other times as they deem fit.  
4.12 The provisions of this Article 4 and specifically but without limitation the definitions in Articles 4.1 through 4.4 and Articles 4.6 and 4.7 shall apply to any results obtained in RESEARCH PROJECTS, including results of activities covered by EXISTING AGREEMENTS, except if expressly provided otherwise in a SCHEDULE or in Article 18.  
5.1.1 Through the express grant of such rights in any SCHEDULE, CERES may grant IGER the right to use CERES INTELLECTUAL PROPERTY to the extent required for, and for the sole purpose of, the performance by IGER (or its SUBCONTRACTORS) of RESEARCH PROJECTS. SCHEDULES may specify that similar rights are granted with respect to defined elements of CERES BACKGROUND INTELLECTUAL PROPERTY.  
5.1.2 IGER shall have the right to use JOINT INTELLECTUAL PROPERTY and OTHER RESEARCH RESULTS (a) for the purpose of the implementation of RESEARCH PROJECTS; (b) subject to Article 3 and CERES’ prior written approval, for internal research purposes and research under United Kingdom government or European Union funding in collaboration with academic institutions in the European Union, provided that CERES’ approval may be conditional upon (i) CERES receiving the exclusive right (subject to Articles 5.1.2(a) and 5.2) to use and exploit commercially the results of such research in COLLABORATION CROPS, (ii) adequate safeguards to prevent unauthorized use or disclosure of JOINT INTELLECTUAL PROPERTY, OTHER RESEARCH RESULTS or results directly or indirectly based on any of the foregoing and (iii) CERES reviewing and approving the terms and conditions of any agreement governing such research activities.  
5.2.1 “RELEASED VARIETY” shall mean any variety of a COLLABORATION CROP which constitutes JOINT INTELLECTUAL PROPERTY and which is released for commercialization pursuant to a SCHEDULE. IGER shall have the non-exclusive right to exploit commercially RELEASED VARIETIES in the United Kingdom.  
5. USE AND COMMERCIALIZATION RIGHTS.
  5.1 IGER Research Rights.
  5.2 Commercialization Rights of IGER in the United Kingdom.
     CERES-IGER Collaboration Agreement    Page 14 of 755.2.2 If the commercial exploitation of a RELEASED VARIETY in the United Kingdom by IGER requires a license on CERES INTELLECTUAL PROPERTY or BACKGROUND INTELLECTUAL PROPERTY of CERES, CERES shall negotiate in good faith with IGER or a designee of IGER about the grant of such a license, provided however that CERES shall have no obligation to grant any license on transgenes or transgenic technologies.  
5.2.3 Unless otherwise agreed by the Parties, IGER shall pay royalties to CERES under its non-exclusive right set forth in Article 5.2.1 at a rate equal to one half of the royalty rate in CERES’ exclusive license agreement for the same RELEASED VARIETY, and CERES shall pay royalties at the same rate to IGER for sales by CERES, its AFFILIATED COMPANIES or licensees in the United Kingdom.  
5.3.1 Subject to Articles 5.1 and 5.2, the Parties acknowledge and agree that CERES shall have the exclusive right, with the right to grant sublicenses to this right, to use and commercially exploit JOINT INTELLECTUAL PROPERTY (including but not limited to RELEASED VARIETIES) and OTHER RESEARCH RESULTS for any and all uses and fields, including, but not limited to, use in the COLLABORATION CROPS and crops other than the COLLABORATION CROPS. Any commercialization (including, but not limited to, the grant of commercialization licenses) of JOINT INTELLECTUAL PROPERTY and/or OTHER RESEARCH RESULTS shall result in CERES paying IGER a reasonable remuneration (whether as a royalty or in some other form as the Parties may agree) to be negotiated in good faith. The terms for remuneration will be specified, with respect to specific RESEARCH PROJECTS, JOINT INTELLECTUAL PROPERTY and/or OTHER RESEARCH RESULTS, either in the respective SCHEDULES or in other agreements to be executed by the Parties.  
5.3.2 Subject to Articles 5.1 and 5.2, IGER grants CERES an exclusive, world-wide license, with the right to grant sublicenses, to use and exploit commercially (a) IGER’s interest in any JOINT INTELLECTUAL PROPERTY (including but not limited to RELEASED VARIETIES) and OTHER RESEARCH RESULTS; (b) IGER INTELLECTUAL PROPERTY and (c) when and only to the extent necessary for the commercialization or use of JOINT INTELLECTUAL PROPERTY and/or OTHER RESEARCH RESULTS and/or IGER INTELLECTUAL PROPERTY for the COLLABORATION CROPS, IGER BACKGROUND INTELLECTUAL PROPERTY, subject to paying IGER reasonable remuneration (whether as a royalty or in some other form as the Parties may agree) to be negotiated in good faith. Such license grants will be further specified in SCHEDULES to this Agreement and/or other agreements to be executed by the Parties. Unless otherwise agreed by both Parties, license agreements for non-transgenic RELEASED VARIETIES will be based on the Model License Agreement for Non-transgenic Varieties in EXHIBIT G or such other model license agreements as the Parties may agree upon. Certain remuneration principles to be included in other license agreements, unless the Parties agree otherwise, are set forth in EXHIBIT H.  
  5.3 Commercialization Rights — Other.
     CERES-IGER Collaboration Agreement    Page 15 of 756.1 CERES will have the right, at its own discretion and expense, to take any action to enforce and to initiate and prosecute suits for infringement of jointly owned intellectual property rights covering JOINT INTELLECTUAL PROPERTY. CERES and IGER will consult with each other upon a course of action and enforcement strategy. CERES will be responsible for the conduct of any such enforcement action, and IGER will reasonably cooperate with CERES to effect the enforcement action, and if appropriate, determine a settlement position. CERES shall be responsible for retaining counsel and shall promptly notify IGER following retention of counsel, and IGER agrees to be represented by such counsel as may be required for any enforcement action or settlement. For purposes of settlement, CERES shall be the contact with the Parties’ counsel as well as the opposing Party(ies) and shall have the right to enter into settlements. CERES shall keep IGER advised as to all developments with respect to the enforcement action and settlement discussions, which includes supplying to IGER copies of all papers received and filed in sufficient time for IGER to comment thereon. IGER may attend any and all meetings with the Parties’ counsel and the opposing side for settlement purposes. IGER agrees to join voluntarily in any action brought by CERES as a Party plaintiff/defendant, if necessary, at the expense of CERES. If necessary, IGER agrees to enter into a joint defense agreement.  
6.2 In situations where a substantial commercial interest of IGER in the United Kingdom is harmed by infringement, and CERES elects not to pursue any action to enforce and to initiate and prosecute suits for infringement, IGER shall have the right to pursue any such action and CERES will reasonably cooperate with IGER, if necessary, to permit IGER to properly enforce its rights. IGER will be responsible for the conduct of any such enforcement action. IGER shall be responsible for retaining counsel and shall promptly notify CERES following retention of counsel, and CERES agrees to be represented by such counsel as may be required for any enforcement action or settlement. For purposes of settlement, IGER shall be the contact with the Parties’ counsel as well as the opposing Party(ies) and shall have the right to enter into settlements. IGER shall keep CERES advised as to all developments with respect to the enforcement action and settlement discussions, which includes supplying to CERES copies of all papers received and filed in sufficient time for CERES to comment thereon. CERES may attend any and all meetings with the Parties’ counsel and the opposing side for settlement purposes. CERES agrees to join voluntarily in any action brought by IGER as a Party plaintiff/defendant, if necessary, at the expense of IGER. If necessary, CERES agrees to enter into a joint defense agreement.  
6.3 Any damages received by a Party as a result of an enforcement action of rights to JOINT INTELLECTUAL PROPERTY, after deduction of all enforcement related costs incurred by such Party, shall be considered as revenues for the purpose of remuneration payments to the other Party, as set forth in any applicable license/commercialization agreement between the Parties. In the absence of any such license/commercialization agreement, the Parties will share such damages after deduction of all enforcement related costs incurred by the Party receiving the damages, in proportion to their relative financial contributions to the creation (i.e., research and development) of such JOINT INTELLECTUAL PROPERTY.  
7.1 As used in this Agreement, the term “Confidential Information” shall mean (a) all non-public information and material received by one Party from the other in furtherance of the  
6. ENFORCEMENT OF JOINT INTELLECTUAL PROPERTY RIGHTS.
7. CONFIDENTIALITY.
     CERES-IGER Collaboration Agreement    Page 16 of 75collaboration contemplated by this Agreement and (b) any and all information, results including material and observations generated in the performance of any RESEARCH PROJECT including, without limitation, CERES INTELLECTUAL PROPERTY, IGER INTELLECTUAL PROPERTY, JOINT INTELLECTUAL PROPERTY and OTHER RESEARCH RESULTS. Confidential Information can include, but is not limited to, information concerning the disclosing Party’s operations, research, processes, techniques, data and non-public materials.  
7.2 Subject to Article 7.3, for a period of five (5) years after the termination of the related RESEARCH PROJECT, the receiving Party shall not use, except (a) for the benefit of the Parties’ collaboration or (b) such use as is expressly allowed by this Agreement and/or disclose any Confidential Information to any third party (i) without the prior written consent of the disclosing Party if the Confidential Information was received from the other Party, or (ii) the prior written consent of both Parties if the Confidential Information was generated during a RESEARCH PROJECT, provided however that CERES shall have no restrictions regarding CERES INTELLECTUAL PROPERTY or regarding any information of material resulting from RESEARCH PROJECT activities in which IGER does not participate. Confidential Information shall only be made accessible to each Party’s employees or students on a need-to-know basis and not to any third party, subject to Articles 7.3 and 7.4. Manuscripts and papers published in scientific journals and presentations made at public meetings that include Confidential Information are exempt from the confidentiality obligations of this Article, provided the Parties followed the procedure set forth in Article 8.  
7.3 The receiving Party shall have no obligations of confidentiality for information that: can be established through written evidence to be in the possession of the receiving Party prior to the disclosure by the disclosing Party; is or becomes public knowledge through no fault of the disclosing Party; and/or is acquired from others not under an obligation of confidentiality to the disclosing Party. In addition, the Parties, pursuant to the express terms of this Agreement or any SCHEDULE or other agreement between the Parties, shall have the right to proceed to disclosures of Confidential Information (a) as required to file for intellectual property protection or registration or deregulation or approval of genetically modified organisms; (b) as required to exercise commercialization rights granted in or on the basis of this Agreement and for related marketing activities; (c) as required by laws, rules or regulation or court ordering such as, without limitation, SEC regulations and IRS regulations; or (d) in CERES’ reasonable judgment for the limited purpose of (potential) investors and business partners, but only with respect to the Confidential Information defined in Article 7.1 (b) and not other Confidential Information of IGER.  
7.4 The Parties acknowledge and agree that IGER will comply with its reporting obligations to DEFRA as required by the DEFRA agreement NF 0426 referred to in EXHIBIT E, provided that IGER shall (i) not disclose any CERES BACKGROUND INTELLECTUAL PROPERTY, CERES INTELLECTUAL PROPERTY or OTHER RESEARCH RESULTS obtained by CERES, (ii) use all reasonable efforts to ensure that the confidentiality of all other results of RESEARCH PROJECTS is maintained to the extent allowed by the applicable regulations, and (iii) provide a draft of any such report to CERES at least thirty (30) days before the submission date and take CERES’ comments, if any, into account.       CERES-IGER Collaboration Agreement    Page 17 of 758. PUBLICATIONS.  
8.1 The Parties agree that the researchers involved in the RESEARCH PROJECTS are permitted to present methods and/or results of the RESEARCH PROJECTS at symposia and professional meetings and to publish the same in journals or the like; provided however, the disclosing Party must furnish copies of any proposed publication, presentation or disclosure (collectively “Disclosure”) to the other Party at least thirty (30) days in advance of the specific submission, presentation or other disclosure.  
8.2 The non-disclosing Party shall have the thirty (30) day notice period to object, in writing, to such proposed Disclosure because it contains (a) potentially patentable subject matter that needs protection or (b) BACKGROUND INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY or INTELLECTUAL PROPERTY of the non-disclosing Party or OTHER RESEARCH RESULTS which need to be kept confidential for compelling business reasons in the non-disclosing Party’s reasonable judgment. In the event that the non-disclosing Party makes such objection, the disclosing Party will (x) if applicable, elect to cooperate with the non-disclosing Party to obtain proper protection in accordance with the provisions of Article 4 herein or (y) remove the objectionable subject matter from the Disclosure. No delay caused by the non-disclosing Party under this Article shall extend beyond three (3) months, wherein upon such delay, the disclosing Party shall be permitted to proceed without being in breach of this Article.  
8.3 CERES and IGER shall use reasonable efforts to avoid any action that might jeopardize the ability of the Parties, individually or jointly as the case may be, to obtain or retain valid/enforceable intellectual rights in JOINT INTELLECTUAL PROPERTY, IGER INTELLECTUAL PROPERTY or CERES INTELLECTUAL PROPERTY.  
8.4 Nothing in this Article 8 shall restrict disclosures that are allowed under Article 7.  
8.5 Upon recommendation of the MANAGEMENT COMMITTEE, the Parties may adopt alternative review processes, in particular for information to be presented at symposia or professional meetings or for activities directed towards legislative and regulatory bodies.  
9.1 CERES will not identify IGER in any products, publicity, promotion, promotional advertising or other promotional materials to be disseminated to the public, or use any trademark, service mark, trade name, logo or symbol that is representative of IGER or its entities, whether registered or not, or use the name, title, likeness or statement of any IGER faculty member, employee or student, without IGER’s prior written consent. Any use of IGER’s name shall be limited to statements of fact and shall not imply endorsement by IGER of CERES’ research, products or services.  
9.2 IGER will not identify CERES in any products, publicity, promotion, promotional advertising or other promotional materials to be disseminated to the public, or use any trademark, service mark, trade name, logo or symbol that is representative of CERES or its entities, whether registered or not, or use the name, title, likeness or statement of any CERES employee or student, without CERES’ prior written consent. Any use of CERES’ name shall be limited to statements of fact and shall not imply endorsement by CERES of IGER’s research, products or services.  
9. PUBLICITY.
     CERES-IGER Collaboration Agreement    Page 18 of 759.3 Notwithstanding any provision of this Article, either of the Parties can disclose or otherwise acknowledge, without restriction, the existence of this Agreement as well as the collaborative relationship between the Parties without the prior consent of the other Party. Notwithstanding the unilateral disclosure rights provided for in this Article, if the disclosure or acknowledgement takes the form of a written release by the disclosing Party, the disclosing Party shall provide the other Party a copy of any such unilateral disclosure prior to its release so as to allow the other Party to comment and shall take such comments reasonably into account. However, no advance copy needs to be provided of any releases referred to in Article 9.4(a) or 9.4(b) or of any releases which are identical to previous releases.  
9.4 The Parties intend to issue joint press releases regarding their collaboration. Any such press release and any press release by either Party will be subject to the prior written approval of both Parties; provided however, that (a) CERES shall have the right to otherwise disclose information as may be required in CERES’ judgment to comply with SEC or IRS regulations or other laws, rules or regulations governing disclosure of information and (b) IGER shall have the right to otherwise disclose information as may be required in IGER’s judgment to comply with laws, rules or regulations governing disclosure of information. Notwithstanding the unilateral disclosure rights provided for in this Article, the disclosing Party shall provide the other Party a copy of any such unilateral disclosure preferably prior to its release.  
10. RECORDS AND AUDITS.  
IGER shall keep accurate and detailed records in accordance with good accounting practices of all expenses and extramural income, if any, relating to the RESEARCH PROJECTS. All such records shall be subject to inspection by an independent auditor designated by CERES and reasonably acceptable to IGER within normal business hours with at least fourteen (14) days notice. Such inspection rights shall terminate, with respect to each RESEARCH PROJECT, on the third anniversary of the expiration or termination of such RESEARCH PROJECT.  
11. INDEPENDENT CONTRACTOR.  
The relationship of the Parties is that of independent contractors. Nothing herein is intended or will be construed to establish any agency, partnerships or joint ventures. Neither Party is authorized or empowered to act as an agent for the other Party for any purpose, nor shall either Party be bound by the acts or conduct of the other Party.  
12. CONVENTION ON BIOLOGICAL DIVERSITY.  
12.1 The Parties agree that they shall at all times comply with the Convention on Biological Diversity signed in 1992 at the Rio Earth Summit (“CBD”) in the implementation of this Agreement, to the extent the CBD is applicable.  
12.2 Any germplasm of COLLABORATION CROPS made available by IGER for a RESEARCH PROJECT will be identified in detail in the relevant SCHEDULE. The origin of the material, date of collection and references to any agreements governing such material and/or the collection thereof will be included. Reference to any such agreements existing on the Effective Date is included in EXHIBIT E or in Article 13.2.1.8.       CERES-IGER Collaboration Agreement    Page 19 of 7512.3 With respect to any germplasm made available by IGER for a RESEARCH PROJECT which is covered by the CBD, CERES, in collaboration with IGER who will provide all required assistance, will use reasonable efforts to obtain commercialization rights from the relevant competent authorities in the countries where the germplasm was collected, allowing the grant of rights to CERES as provided in this Agreement.  
13. WARRANTIES.  
13.1 Representations and Warranties of CERES.  
“To the Knowledge of CERES” as used in this Article 13.1 shall mean: to the actual knowledge, as of the Effective Date, of any member of the Board of Directors or any officer of CERES or any employee of CERES who has actively participated in the negotiation of the transactions contemplated by this Agreement.  
13.1.1 CERES represents and warrants to IGER that:  
13.1.1.1 CERES (a) is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware; (b) has all requisite power and authority to conduct the business in which it is currently, or is currently proposed to be, engaged; (c) has the corporate power and authority to execute and deliver this Agreement; and (d) has the corporate power and authority to perform its obligations under this Agreement;  
13.1.1.2 the execution, delivery, and performance by CERES of this Agreement have been duly authorized by all necessary corporate action of CERES;  
13.1.1.3 this Agreement has been duly executed and delivered by CERES, and constitutes the legal, valid and binding obligations of CERES enforceable against CERES in accordance with its terms;  
13.1.1.4 as of the Effective Date, CERES has not received notice of, and is not in default under, or with respect to, any contractual obligation, which, individually or together with all such defaults, would have a material adverse effect on the ability of CERES to perform its obligations under this Agreement;  
13.1.1.5 to the Knowledge of CERES, no approval, consent, compliance, exemption, authorization or other action by, or notice to, or filing with, any governmental agency or other person and no lapse of a waiting period is necessary or required in connection with the execution, delivery or performance by, or enforcement against, CERES of this Agreement or the transactions contemplated hereby;  
13.1.1.6 to the Knowledge of CERES, CERES has the right to make the conveyances and grants in accordance with the Articles hereof, including, without limitation, the license grants in this Agreement, and no such conveyance or grant violates or constitutes an event that is or would be with the passage of time, in any       CERES-IGER Collaboration Agreement    Page 20 of 75material way, a violation, breach or default of, any material agreement or material obligation to which CERES is a party or by which it is bound; and  
13.1.1.7 all former and current employees of CERES have executed written agreements with CERES that assign to CERES all rights to any inventions, improvements, discoveries or information relating to CERES’ business, subject however to Section 2870 of the California Labor Code. To the Knowledge of CERES, no employee of CERES has entered into any agreement with a former employer that would be violated by his or her employment with CERES.  
13.2 Representations and Warranties of IGER.  
“To the Knowledge of IGER” as used in this Article 13.2 shall mean: to the actual knowledge, as of the Effective Date, of any member of the Executive Committee of IGER or of any employee of IGER who has actively participated in the negotiation of the transactions contemplated by this Agreement.  
13.2.1 IGER represents and warrants to CERES that:  
13.2.1.1 IGER (a) is a company limited by guarantee, registered in England No. 473456 and a registered Charity No. 272150, duly incorporated, validly existing and in good standing under the laws of England and Wales; (b) has all requisite power and authority to conduct the business in which it is currently, or is currently proposed to be, engaged; (c) has the corporate power and authority to execute and deliver this Agreement; and (d) has the corporate power and authority to perform its obligations under this Agreement;  
13.2.1.2 the execution, delivery, and performance by IGER of this Agreement have been duly authorized by all necessary corporate action of IGER;  
13.2.1.3 this Agreement has been duly executed and delivered by IGER, and constitutes the legal, valid and binding obligations of IGER enforceable against IGER in accordance with its terms;  
13.2.1.4 as of the Effective Date, IGER has not received notice of, and is not in default under, or with respect to, any contractual obligation, which, individually or together with all such defaults, would have a material adverse effect on the ability of IGER to perform its obligations under this Agreement;  
13.2.1.5 to the Knowledge of IGER, no approval, consent, compliance, exemption, authorization or other action by, or notice to, or filing with, any governmental agency or other person and no lapse of a waiting period is necessary or required in connection with the execution, delivery or performance by, or enforcement against, IGER of this Agreement or the transactions contemplated hereby;  
13.2.1.6 to the Knowledge of IGER, and subject to the Assignment/License referred to in Article 14.1 (e) (v), IGER has the right to make the conveyances and grants in accordance with the Articles hereof, including, without       CERES-IGER Collaboration Agreement    Page 21 of 75limitation, the license grants, and no such conveyance or grant violates or constitutes an event that is or would be with the passage of time, in any material way, a violation, breach or default of, any material agreement or material obligation to which IGER or any such Affiliate of IGER is a party or by which it is bound;  
13.2.1.7 all former and current employees of IGER have executed written agreements with IGER that assign to IGER all rights to any inventions, improvements, discoveries or information relating to IGER’s business. To the Knowledge of IGER, no employee of IGER has entered into any agreement with a former employer that would be violated by his or her employment with IGER; and  
13.2.1.8 EXHIBIT E sets forth an exhaustive list of all agreements and commitments in existence on the Effective Date to which IGER is a party, or that contain obligations or restrictions affecting IGER, in connection with the COLLABORATION CROPS, except for the following agreements which are not included in EXHIBIT E:  
13.3 EXCEPT AS PROVIDED IN ARTICLES 13.1 AND 13.2, THE PARTIES ACKNOWLEDGE AND AGREE THAT NEITHER PARTY HAS MADE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL EITHER PARTY BE HELD RESPONSIBLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOSS OF PROFIT ARISING OUT OF THE USE OF ANY JOINT INTELLECTUAL PROPERTY, CERES INTELLECTUAL PROPERTY, IGER INTELLECTUAL PROPERTY, OTHER RESEARCH RESULTS OR BACKGROUND INTELLECTUAL PROPERTY COVERED BY THIS AGREEMENT OR ANY SCHEDULE OR ARISING OUT OF THE IMPLEMENTATION OF THIS AGREEMENT, EVEN IF SUCH PARTY IS ADVISED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES.  
13.4 Nothing in this Agreement is or shall be construed as:  
(a) a warranty or representation by either Party as to the validity or scope of any patent rights or plant variety rights;  
(b) a warranty or representation by either Party that anything made, used, sold or otherwise disposed of pursuant to any license granted under this Agreement is or will be free from infringement of patents, copyrights or other rights of third parties;  
(c) any obligations by either Party to bring or prosecute actions or suits against third  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
  1.  Agreement of July 12, 2004 between Bio-Renewables Limited, IGER and Plant Research International B.V.;
  2.  Agreement dated the 23rd of June 2005 between [***] and IGER; and
  3.  Agreement dated October 18, 2006 between [***] and IGER.
     CERES-IGER Collaboration Agreement    Page 22 of 75parties for patent infringement; or parties for patent infringement, or  
a grant by implication, estoppel or otherwise of any licenses under patent applications, patents, plant variety rights applications and/or plant variety rights of CERES and/or IGER or other person other than as provided in the express provisions of this Agreement or a SCHEDULE on this Agreement.  
14.1 The term of this Agreement shall be fifteen (15) years from the Effective Date, unless sooner terminated in accordance with the following provisions of this Article:  
(a) mutual, written agreement of the Parties;  
(b) failure of one Party to satisfy its material obligations under this Agreement, and such Party subsequently fails to cure such failure(s) within (i) thirty (30) days for failures to remit payment for amounts due under this Agreement and (ii) ninety (90) days for all other obligations in each case after receipt of written notice from the non-breaching Party specifying such failure(s);  
(c) one (1) year’s written notice of termination by either CERES or IGER to the other Party in case either the terminating Party or the other Party ceases substantially all activities in the COLLABORATION CROPS;  
(d) IGER will have the right to terminate this Agreement unilaterally with thirty (30) days’ written notice to CERES, (i) if CERES seeks protection under any bankruptcy, insolvency, receivership, trust, deed, creditors arrangement or comparable proceeding or if any such proceeding is instituted against CERES (and not dismissed within one hundred twenty (120) days); (ii) in case of dissolution or winding up of CERES (excluding any situation where all or substantially all of CERES’ assets, stock or business to which this Agreement relates are acquired by a third party (whether by sale, acquisition, merger, operation of law or otherwise)); or (iii) with written notice to CERES, if CERES has failed in a substantial manner, three (3) years after either Party or the Parties jointly have developed a propagation method for Miscanthus that results in the crop being commercially competitive in the United States or in Europe as compared to other energy crops being grown at that time in the relevant geography, to implement the activities set forth in EXHIBIT F, and does not remedy such failure or offer a remediation plan which is reasonably acceptable to IGER within ninety (90) days after receipt of a written notice from IGER specifying such failure;  
(e) CERES will have the right to terminate this Agreement unilaterally: (i) with thirty (30) days’ written notice to IGER if John Clifton-Brown or Iain Donnison cease(s) to be associated with IGER and the RESEARCH PROJECTS contemplated by this Agreement, and IGER has not replaced such person(s) within one hundred twenty (120) days by (a) person(s) reasonably acceptable to CERES; (ii) with ninety (90) days’ written notice to IGER, if the institutional mission, purpose, structure or funding of IGER would change substantially and adversely affect IGER’s ability to satisfy its obligations hereunder; (iii) with one (1) years’ written notice to IGER, if CERES has a documented compelling business reason to cease the collaboration, (for example, without limitation, lack of sufficient processing capacity for COLLABORATION CROPS within the expected timeframe in the United States; COLLABORATION CROPS are non-competitive with other biomass sources); (iv) with three (3) months’ prior written notice to IGER, such notice to be given no earlier than eighteen (18)  
14. TERM AND TERMINATION.
     CERES-IGER Collaboration Agreement    Page 23 of 75months after the Effective Date, if no rights to commercialize (including determination of the compensation due upon commercialization) COLLABORATION CROPS germplasm provided by IGER which is included in a RESEARCH PROJECT have been secured to CERES’ reasonable satisfaction in compliance with the CBD; or (v) with thirty (30) days’ written notice to IGER if Defra has not assigned to IGER, or granted to IGER an exclusive license reasonably satisfactory to CERES on, the Intellectual Property vested in Defra or the Crown or the Secretary of State pursuant to the DEFRA agreement NF 0426 within sixty (60) days from the Effective Date (the “Assignment/License”).  
(f) either Party will have the right to terminate this Agreement if no active RESEARCH PROJECTS exist for more than two (2) years, provided that on or after the second anniversary of the expiration or termination of the last SCHEDULE to expire or terminate, the Parties have not agreed on any new SCHEDULE despite (i) negotiations in good faith by both Parties or (ii) diligent, documented attempts by the terminating Party to conduct negotiations in good faith with respect to one or more new SCHEDULES, to which attempts the other Party has not been responsive.  
14.2 Promptly upon the delivery of a notice of termination of this Agreement, the Parties will meet to discuss the ongoing RESEARCH PROJECTS, and each Party will provide to the other Party any data, information and germplasm that constitutes or is covered by JOINT INTELLECTUAL PROPERTY and which has not been provided prior to the notice of termination, without prejudice to additional on-going delivery obligations set forth in any SCHEDULES.  
14.3 Termination of this Agreement shall not affect the rights and obligations of the Parties accrued prior to termination hereof nor any license grants then in existence, nor either Party’s non-exclusive rights to commercialize then existing RELEASED VARIETIES in the United Kingdom, subject to payment of remuneration as set forth in any relevant license/commercialization agreements. Further, the provisions set forth hereinafter shall apply.  
14.3.1 In case of termination on the basis of Article 14.1 (b) if CERES is the breaching Party, Article 14.1 (c) if CERES ceases substantially all activities in the COLLABORATION CROPS, Article 14.1 (d) (i), (ii) or (iii) or Article 14.1. (e) (iii), at or about the effective date of termination, the Parties will negotiate in good faith to reach agreement as to the rights to use and commercially exploit JOINT INTELLECTUAL PROPERTY not covered by any relevant license/commercialization agreement between the Parties, which rights will be addressed in one or more written agreements. If the Parties fail to reach agreement within ninety (90) days after the start of such negotiations, which shall be evidenced by written notice from one Party to the other initiating such negotiations, each Party shall have the non-exclusive right to use and commercially exploit JOINT INTELLECTUAL PROPERTY for any and all purposes, with the right to grant sublicenses, subject to the obligations of the first sentence of Article 14.3, provided that no licenses on any transgenes or transgenic technologies of the other Party shall be included or implied.  
14.3.2 In case of termination on the basis of Article 14.1 (b) if IGER is the breaching Party, Article 14.1 (c) if IGER ceases substantially all activities in the COLLABORATION CROPS, Article 14.1 (e) (i) or (ii) or Article 14.1 (f), subject to the obligations of the first sentence of Article 14.3, CERES shall have the exclusive right to use and commercially exploit any JOINT INTELLECTUAL PROPERTY to the extent such JOINT       CERES-IGER Collaboration Agreement    Page 24 of 75INTELLECTUAL PROPERTY is not covered by any relevant license/commercialization agreement between the Parties. At or about the effective date of termination, the Parties will negotiate in good faith to reach agreement as to reasonable remuneration (whether as a royalty or in some other form as the Parties may agree), which will be addressed in one or more written agreements. If the Parties fail to reach agreement within ninety (90) days after the start of such negotiations, which shall be evidenced by written notice from one Party to the other initiating such negotiations, the remuneration shall be settled in accordance with the dispute resolution procedure in Article 15.  
14.4 Termination of this Agreement for any reason will not relieve either Party of any obligation or liability accrued under this Agreement before termination or rescind any payments made or due before termination. Articles 4, 5 (subject to Article 14.3), 6, 7, 8, 9.1, 9.2, 10, 12.3, 13, 14.2, 14.3, 14.4, 14.5, 15, 16 and 18 will survive any termination of this Agreement.  
14.5 Termination of this Agreement shall not automatically terminate any existing RESEARCH PROJECT, which can only be terminated according to the specific terms of the related SCHEDULE. The terms and provisions of this Agreement shall continue to apply to the activities and outcomes of any such RESEARCH PROJECTS, notwithstanding the termination of this Agreement, unless provided otherwise in the relevant SCHEDULE or by written agreement of the Parties upon termination.  
15.1 All disputes, differences or questions arising out of or in connection with this Agreement or its SCHEDULES, or related to the alleged breach, termination, validity, interpretation or violation thereof, shall be submitted to the MANAGEMENT COMMITTEE for resolution, which shall convene, whether in person or otherwise, to resolve such dispute in a timely manner. Either Party may initiate a resolution procedure by providing written notice (“Dispute Notice”) to the other Party, and any such Dispute Notice must set forth the subject matter of the dispute, difference or question. If after sixty (60) days the dispute remains unresolved, the Chief Scientific Officer of CERES and the Director of IGER shall seek to resolve the dispute through negotiation. The Parties agree that at least eight (8) cumulative hours of negotiations will be undertaken. If the dispute still remains unresolved ninety (90) days after the Dispute Notice, either Party may initiate proceedings pursuant to Article 15.2.  
15.2 Dispute Resolution and Arbitration.  
In the event of any dispute arising out of or in connection with this Agreement, the Parties agree to submit the matter to settlement proceedings under the ICC ADR Rules. If the dispute has not been settled pursuant to the said Rules within forty-five (45) days following the filing of a Request for ADR or within such other period as the Parties may agree in writing, such dispute shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by three (3) arbitrators appointed in accordance with the said Rules of Arbitration. The provisions set forth hereinafter shall apply to the arbitration procedures, without prejudice to the ICC Rules of Arbitration.  
15.2.1 Qualifications of Arbitrators.  
15. DISPUTE RESOLUTION AND APPLICABLE LAW.
     CERES-IGER Collaboration Agreement    Page 25 of 75Each arbitrator appointed shall have a reputation as being experienced in the legal and technical matters related to the dispute, shall be required to disclose, among other disclosures, any prior involvement with the legal and technical matters related to the dispute and any involvement with a competitor of any Party, and shall not be presently nor in the past have been affiliated with any Party or a competitor of any Party. Notwithstanding the method of their appointment, each arbitrator shall be required to meet the standards contained in the Rules with respect to independence.  
15.2.2 Location of the Arbitration.  
The seat of arbitration shall be Paris, France. The arbitrators may hold hearings at such other locations as the arbitrators shall determine, after consultation with the Parties.  
15.2.3 Language of Arbitration.  
The arbitral proceedings and all pleadings and written evidence shall be in the English language. Any written evidence originally in a language other than English shall be submitted in English translation accompanied by the original or true copy thereof  
15.2.4 Limitation on Remedies.  
The arbitrators are precluded from awarding punitive or exemplary damages. In no event shall the arbitrators have the powers of an amiable compositeur.  
15.3 Applicable law.  
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York, United States of America, without regard to the principles of conflicts of law thereof.  
Any notices required to be given or which shall be given under this Agreement shall be in writing and delivered by overnight (trackable) courier addressed to the Parties as follows:  
Vice President of Product Development cc: Legal Department Ceres, Inc. 1535 Ranch Conejo Blvd. Thousand Oaks, California 91320 United States of America  
Institute Business Manager OR for legal or financial notices: Institute Secretary Institute of Grassland and Environmental Research  
16. NOTICES.
     CERES-IGER Collaboration Agreement    Page 26 of 75Plas Gogerddan Aberystwyth Ceredigion SY23 3EB United Kingdom  
Notices under this Agreement sent by overnight courier by one Party to the other Party at its above address, shall be deemed to have been given or made as of the date following the date so mailed.  
17. GENERAL.  
17.1 Entire Agreement/Modifications.  
This Agreement constitutes the entire agreement between the Parties hereto with respect to the subject matter hereof, and there are no representations, warranties, covenants or obligations except as set forth herein. This Agreement supersedes all prior and contemporaneous agreements, understandings, negotiations and discussions, written or oral, of the Parties hereto relating to the subject matter hereof. This Agreement and its SCHEDULES may only be amended, modified or superseded by a writing executed by the authorized representatives of the Parties hereto. It is anticipated that SCHEDULES will be attached to and become part of this Agreement as new RESEARCH PROJECTS are undertaken, as described in Article 1.1.  
17.2 Severability.  
This Agreement, to the greatest extent possible, shall be construed so as to give validity to all of the provisions hereof. If any provision of this Agreement is or becomes invalid, is ruled illegal by a court of competent jurisdiction or is deemed unenforceable under the current applicable law from time to time in effect during the term of this Agreement, the remainder of this Agreement will not be affected or impaired thereby and will continue to be construed to the maximum extent permitted by law. In lieu of each provision which is invalid, illegal or unenforceable, there will be substituted or added as part of this Agreement by mutual written agreement of the Parties, a provision which will be as similar as possible, in economic and business objectives as intended by the Parties to such invalid, illegal or unenforceable provision, but will be valid, legal and enforceable.  
17.3 Waiver.  
No failure or delay by either Party in exercising any right or remedy under this Agreement will waive any provision of this Agreement. Nor will any single or partial exercise by either Party of any right or remedy under this Agreement preclude it from otherwise or further exercising any rights or remedies which it may have, or any other rights or remedies granted by any law or any related document.  
17.4 Enforcement.  
In the event an action is commenced by either Party against the other to enforce any of the provisions of this Agreement, the prevailing Party shall be entitled to recover from the other Party reasonable attorneys’ fees, court costs and necessary disbursements incurred in connection with such action.       CERES-IGER Collaboration Agreement    Page 27 of 7517.5 Assignablility.  
This Agreement binds and enures to the benefit of the Parties, their successor or assigns, but may not be assigned by either Party without the prior written consent of the other Party; provided however, CERES shall have the right to assign its rights and obligations under this Agreement to any Affiliated Company without such prior consent. Each Party shall have the right to assign its rights and obligations under this Agreement to a third party in conjunction with the transfer to such third party of substantially all of the assets of such Party associated with performance under this Agreement without such prior consent. “Affiliated Company” defined as any company owned or controlled by, under common control with or controlling CERES, “control” meaning in this context the direct or indirect ownership of fifty percent (50%) or more of the voting stock/shares of a company, or the power to nominate at least half of the directors.  
17.6 Force Majeure.  
No Party shall be responsible to the other Party for delay or failure in performance of any the obligations imposed by this Agreement, provided such failure shall be occasioned by fire, flood, explosion, lightning, wind storm, hailstorm, earthquake, subsidence of soil, failure of machinery or equipment or supply of materials, discontinuity in the supply of power, court order or governmental interference, terrorist attacks, civil commotion, riot, war, strikes, labor disturbances, transportation difficulties, labor shortage, natural genetic variation of any living matter or by any other cause of like or unlike nature beyond the reasonable control and without fault or negligence of such Party.  
18. SPECIAL CONDITIONS IN CONNECTION WITH DEFRA AGREEMENT NF 0426.  
The Parties acknowledge that Defra is expected to assign or license exclusively to IGER any rights in Intellectual Property which would vest in Defra or the Crown or the Secretary of State pursuant to the DEFRA agreement NF 0426. If IGER receives an exclusive license from Defra rather than an assignment of rights, the following will apply.  
18.1 To the extent the license grant to CERES on IGER BACKGROUND INTELLECTUAL PROPERTY in Article 5.3.2 relates to IGER BACKGROUND INTELLECTUAL PROPERTY that constitutes Intellectual Property to which rights vest in Defra or the Crown or the Secretary of State, the word “license” will be read as “sublicense” and all other terms of such Article will remain unchanged.  
18.2 To the extent that IGER INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY created in a RESEARCH PROJECT constitutes or includes Intellectual Property to which rights vest in Defra or the Crown or the Secretary of State, any conveyance or grant of rights or licenses by IGER to CERES in this Agreement with respect to such IGER INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY, will be read as the grant of an exclusive sublicense under IGER’s exclusive license from Defra.       CERES-IGER Collaboration Agreement    Page 28 of 75IN WITNESS WHEREOF, IGER and CERES have caused this Agreement to be duly executed as indicated below.                   INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH   CERES, INC.   
              By:   /s/ MERVYN HUMPHREYS   By:  /s/ RICHARD FLAVELL   Name: 
   
Professor Mervyn Humphreys   Name: 
   
Richard Flavell, CBE, FRS   
Title:  Director   Title:  Chief Scientific Officer                      By:  /s/ RICHARD HAMILTON   
     Name: 
   
Richard Hamilton   
     Title:  President and Chief Executive Officer        CERES-IGER Collaboration Agreement    Page 29 of 75EXHIBIT A  
to the Collaboration Agreement between IGER and CERES  
DEFINITION OF COLLABORATION CROPS  
Miscanthus and interbreeding species, including without limitation Saccharum and Erianthus species.       CERES-IGER Collaboration Agreement    Page 30 of 75EXHIBIT B  
to the Collaboration Agreement between IGER and CERES  
PREFERRED FORM OF RECEIPT FORM  
Packing Slip and Receipt Form for material transferred pursuant to the Collaboration Agreement dated [x] between INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH and CERES, INC. and SCHEDULES to such Agreement.  
Material transferred pursuant to SCHEDULE [x] dated [...]  
The undersigned [IGER/CERES] signatory certifies that the material and related information set forth hereinafter are included in the shipment with which this form is enclosed.  
The undersigned [IGER/CERES] signatory acknowledges having received in good order the material and related information set forth hereinafter. The signature does not constitute an acceptance of the receiving party’s qualification of the intellectual property (IP) status of the material transferred, such IP status being defined in the Parties’ Collaboration Agreement.  
[Include description of material and related information with indication of IP status (e.g. Background, Joint IP) and any restrictions on transfer to subcontractors.]  
THIS MATERIAL AND RELATED INFORMATION ARE TRANSFERRED ONLY FOR USE IN COMPLIANCE WITH THE ABOVE MENTIONED COLLABORATION AGREEMENT AND SCHEDULE. CONFIDENTIALITY OBLIGATIONS APPLY.                   For sending/receipt,   For receipt/sending,                 Signature:     Signature:      
   
     
   
  Date:       Date:      
             
              Name: Walter E. Nelson   Name:           
   
                Title: Product Development Manager CERES, INC.
 
Title: INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH  
 
     CERES-IGER Collaboration Agreement    Page 31 of 75EXHIBIT C  
to the Collaboration Agreement between IGER and CERES  
PREFERRED FORMS OF VARIETY EVALUATION AGREEMENT  
(to be used for field evaluation)  
FIELD TRIAL AGREEMENT (Non transgenic. Fee for service. Academic.)  
and  
FIELD TRIAL AGREEMENT (Non transgenic. No payment. Academic.)  
PREFERRED FORM OF MATERIAL TRANSFER AGREEMENT (to be used for transfer of material for other purposes than field evaluation)       CERES-IGER Collaboration Agreement    Page 32 of 75FIELD TRIAL AGREEMENT (Non transgenic. Fee for service. Academic.)  
1.  THE PARTIES
 
   This Agreement is made effective on [date] (“Effective Date”) by and between [Ceres, Inc., a Delaware corporation with principal offices at 1535 Rancho Conejo Blvd., Thousand Oaks, CA 91320, United States of America] or [Institute of Grassland and Environmental Research, a company limited by guarantee, registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom] hereinafter “[CERES/IGER],” and [Party information to be completed], hereinafter “[Party].”
 
   THE PARTIES HERETO COVENANT AND AGREE AS FOLLOWS:
 
2.  FIELD TRIAL PROGRAM
  2.1 [CERES/IGER] will deliver to [Party] seeds or other propagating material as described in ANNEX I and related information (jointly referred to as the “CERES/IGER Plant Material”). The delivery conditions are set forth in ANNEX I. Promptly upon receipt of the CERES/IGER Plant Material, Party will sign and return the Receipt Form, in the preferred format attached as ANNEX II to this Agreement, to [CERES/IGER] (attn: [responsible person at CERES/IGER]).
 
  2.2 [Party] agrees to perform the activities defined in ANNEX I which shall be referred to hereinafter as the “Program.” With reasonable notice [CERES/IGER] may change the activities to be performed in the Program. If such changes do not result in additional work to be performed by [Party], but consist for example of changes in experimental design or in observations to be made or in information to be included in reports, they shall be set forth in a written document provided by [CERES/IGER] to [Party] which will be attached to ANNEX I and form part of it. If such changes result in additional work to be performed by [Party] and require an adaptation of the remuneration, they shall be set forth in an amendment to this Agreement signed by both Parties. [CERES/IGER] will consider any suggestions for changes in the Program which [Party] may suggest.
 
  2.3 In performing the Program activities [Party] undertakes to comply with the work plan and time schedule set forth in ANNEX I.
 
  2.4 [Party] undertakes only to use the CERES/IGER Plant Material or any part, progeny or seeds thereof for performing the Program activities to be carried out under the Program and not for any other purpose. Specifically, but without limitation, [Party] shall not use the Plant Material or any progeny, plants, parts of plants, plant material, seeds or products derived therefrom in any form of reselection, breeding, sexual crossing, seed production, back crossing, tissue culturing, mutagenesis, genetic transformation or any biotechnological process, except as specifically approved in this Agreement.     CERES-IGER Collaboration Agreement    Page 33 of 752.5 The CERES/IGER Plant Material will be used only on fields and at premises under the control of [Party] and identified in ANNEX I.
 
  2.6 Upon termination of the Program, [Party] will, at the option of [CERES/IGER], (i) allow [CERES/IGER] to remove any Plant Material and any progeny, plants, plant material, seeds or products obtained in the Program or (ii) destroy any remaining CERES/IGER Plant Material and any plants, plant material and seeds obtained under the Program within fifteen (15) days from [CERES/IGER]‘s request to destroy, and will send [CERES/IGER] forthwith an attestation of such destruction.
 
  2.7 Subject to giving at least one day’s prior written notice in writing or by email to [Party], [CERES/IGER] and [CERES/IGER] invitees will have the right to visit the fields where Program activities are being conducted at any time, to make observations and to collect samples.
3.  REPORTS
  3.1 [Party] shall send [CERES/IGER] detailed written reports on the implementation of the Program activities and the observations made and results obtained during the implementation of the Program. The frequency of the reports and the type of information to be included in same is set forth in ANNEX I.
 
  3.2 During the entire Program, [Party] will promptly communicate to [CERES/IGER] any information on the Program activities or the results obtained or observed that [CERES/IGER] may ask. Between reports, [Party] will also spontaneously communicate to [CERES/IGER] any unexpected observations or results.
4.  REMUNERATION. PAYMENT
  4.1 [CERES/IGER] will pay [Party] a remuneration as set forth in ANNEX I for the implementation of the Program, in accordance with the payment schedule set forth in such annex. Overhead costs included in the remuneration shall not exceed [x] percent (x%).
 
  4.2 The payments will be made on the dates set forth in the payment schedule in ANNEX I provided that [CERES/IGER] has received a corresponding invoice from [Party] at least thirty (30) days in advance, by bank transfer to [Party’s] account mentioned in its invoice.
5.  OWNERSHIP. INTELLECTUAL PROPERTY RIGHTS. EXPLOITATION
  5.1 This Agreement does not bring any change to the ownership and intellectual property rights relating to the CERES/IGER Plant Material. [Party] acknowledges that the CERES/IGER Plant Material may be covered by patents or patent applications of [CERES/IGER].
 
  5.2 [CERES/IGER] will exclusively own any plants, parts of plants, plant material, seeds, information, data, technology, or other findings or inventions resulting from the     CERES-IGER Collaboration Agreement    Page 34 of 75Program that relate to the CERES/IGER Plant Material (hereinafter “Results”). [CERES/IGER] will have the exclusive rights to protect any of the Results through patents or plant variety protection rights or similar protection, and any intellectual property rights arising therefrom will belong exclusively to [CERES/IGER]. In case [Party] has made or contributed to any invention forming part of the Results, [Party] shall promptly inform [CERES/IGER] thereof in writing and shall assign its rights and cause its employees and staff members to assign their rights in any such invention to [CERES/IGER]. [Party] shall render such assistance as may be required for assigning any rights [Party] inventors may have in such invention to [CERES/IGER] or [CERES/IGER]’s designee and for protecting such invention, including but not limited to the signing of documents. Any inventor of [Party] will be recognized in patent applications on an invention which is part of the Results in accordance with [U.S./U.K. patent law].
 
  5.3 [CERES/IGER] will have the exclusive right to commercialize any of the Results.
6.  CONFIDENTIALITY. PUBLICATIONS.
  6.1 [Party] will treat any and all information and material communicated or transferred to it by [CERES/IGER] pursuant to this Agreement (including but not limited to the CERES/IGER Plant Material) and any Results (including without limitation any progeny, plants, seeds, parts of plants, plant material, or products obtained directly or indirectly from the Plant Material) as strictly confidential and will not use the same for any purpose other than as expressly allowed by this Agreement nor disclose or transfer the same to any third party other than its employees or staff members necessary to carry out the Program and bound by appropriate secrecy and non-use undertakings consistent with [Party’s] obligations under this Agreement.
 
  6.2 [Party] shall take all precautions to prevent theft or pilferage of the Plant Material and any progeny, plants, seeds, parts of plants or plant material obtained directly or indirectly from the Plant Material.
 
  6.3 [Party] will not grant access to any field where Plant Material or any progeny, plants, seeds, parts of plants or plant material obtained directly or indirectly from the Plant Material can be viewed to any third party except with the prior written permission of [CERES/IGER].
 
  6.4 “Publication” and “Publish” shall include any discussion with or presentation to a third party, other than parties referred to in Article 6.1. Examples of Publications include, without limitation: presentation at a conference, submission for publication to a journal, submission of joint proposals, posting information on a website, posters, abstracts, Ph.D. dissertations, and informal oral discussions. Subject to [CERES/IGER]’s prior written approval, which will not unreasonably be withheld, [Party] may proceed to Publication of selected Results provided that: (i) no confidential information of [CERES/IGER] is revealed thereby, (ii) [Party] shall take into account any suggestions which may be formulated by [CERES/IGER], and (iii) at least thirty (30) days prior to the submission to a publisher or presentation to any third party, [Party]     CERES-IGER Collaboration Agreement    Page 35 of 75delivers copies of the proposed Publication to [CERES/IGER] for review. At [CERES/IGER]’s request, [Party] shall, for a reasonable period up to ninety (90) days from initial delivery to [CERES/IGER], delay revealing any patentable subject matter in the disclosure in order to permit the filing of patent applications. In any Publication, the Parties shall consider joint authorship and acknowledge the contributions and publications of the other as scientifically appropriate.
7.  WARRANTIES. LIMITED LIABILITY
  7.1 [Party] acknowledges that the CERES/IGER Plant Material is of an experimental nature and will take all reasonable precautions to prevent any damage or injury by the CERES/IGER Plant Material and any progeny, plants, parts of plants, plant material, seeds or products derived therefrom.
 
  7.2 [Party] warrants that the CERES/IGER Plant Material will exclusively and restrictedly be used under suitable containment conditions, and in accordance with all applicable regulations, and it will not be used on human subjects. In addition, [Party] will strictly comply with any planting distance, isolation and similar requirements set forth in ANNEX I. [Party] will obtain any authorizations or permits or proceed to any notifications which may be required for the Program activities, [Party] will inform [CERES/IGER] in writing, within thirty (30) days from the Effective Date, of any such requirements and certify its compliance with same.
 
  7.3 [CERES/IGER] declines any liability for any damage which may be caused by the CERES/IGER Plant Material or the Program activities or Results to [Party] or any third party.
 
  7.4 Neither Party shall be liable for indirect, special, remote, incidental or consequential damages or loss of profit in connection with this Agreement or its implementation.
8.  GENERAL CONDITIONS
  8.1 Amendments: This Agreement, including its annexes, may only be amended by a written document signed by duly authorized representatives of the Parties.
 
  8.2 Ambiguities: In case of ambiguity between this Agreement and its annexes, the contents of the agreement shall prevail.
 
  8.3 Number of copies: This Agreement including its annexes is being made in two (2) copies, one for each Party.
 
  8.4 Assignment / Subcontracts: [CERES/IGER] has concluded this Agreement with [Party] in view of [Party]’s specific qualifications and [Party] shall not have the right to assign any of its rights or obligations under this Agreement nor to sub-contract any part of the Program activities to any third party, except with the prior written approval of [CERES/IGER]. [CERES/IGER] has the right to assign itsrights and obligations under this Agreement to any third party. Further, [CERES/IGER] has the right to     CERES-IGER Collaboration Agreement   Page 36 of 75Made in two (2) copies.  
     entrust the implementation of all or part of its obligations under this Agreement to any of its affiliates.
 
  8.5 Equitable Remedies: It is understood and agreed that money damages would not be a sufficient remedy for any breach of this Agreement by [Party] and that [CERES/IGER] is entitled to equitable relief, including injunction and specific performance, as a remedy for any such breach. Such remedies shall not be deemed to be the exclusive remedies for a breach by [Party] of this Agreement but shall be in addition to all other remedies available at law or equity to [CERES/IGER].
 
  8.6 Governing Law / Jurisdiction: [to be completed]
9.  DURATION
  9.1 This Agreement will enter into force on the Effective Date and will remain in full force and effect until the latest of the following dates: (i) the [third] anniversary of the Effective Date, (ii) the date of delivery by [Party] of the last report provided for in this Agreement, or (iii) the dates on which the last payment due by [CERES/IGER] pursuant to this Agreement is made.
 
  9.2 Notwithstanding Article 9.3., [CERES/IGER] will have the right to terminate this Agreement including the Program at any time with [three (3)] months’ prior written notice. In case of such early termination, [CERES/IGER] will pay the remuneration provided in this Agreement up to the effective date of termination, and all costs relating to the implementation of this Agreement which [Party] irrevocably committed to prior to receipt of the notice of termination.
 
  9.3 Either Party will have the rights to terminate this Agreement unilaterally by registered letter addressed to the other Party in case such other Party has committed a breach of any of its obligations under this Agreement and has failed to remedy such breach within thirty (30) days from the receipt of a registered letter specifying the breach.
 
  9.4 The provisions of Articles 2.6, 5, 6, 7.3, 7.4, 8.5 and 8.6 will survive the expiration or termination of this Agreement.
             [Party]     [Institute of Grassland and Environmental Research] or [Ceres, Inc.]           By:       By:   
         
Name:      Name:  
         
Title:       Title:  
         
           By:       By:   
         
Name:      Name:  
         
Title:       Title:  
         
     CERES-IGER Collaboration Agreement   Page 37 of 75ANNEX I 
to the Field Trial Agreement between [CERES/IGER] and [Party]  
PLANTING / MANAGEMENT PLAN FOR [CERES/IGER] MISCANTHUS EVALUATION TRIAL — [Party]  
Trial Scope and Purpose:  
1. Planting Material  
2. Program Activities  
3. Content and timing of reports       CERES-IGER Collaboration Agreement   Page 38 of 75ANNEX II  
to the Field Trial Agreement between [CERES/IGER] and [Party]  
FORM OF RECEIPT FORM  
Packing Slip and Receipt Form for material transferred pursuant to the Field Trial Agreement dated [x] between [CERES/IGER] and [Party].  
The undersigned [Party/[CERES/IGER]] signatory certifies that the material and related information set forth hereinafter are included in the shipment with which this form is enclosed.  
The undersigned [Party/[CERES/IGER]] signatory acknowledges having received in good order the material and related information set forth hereinafter.  
[Include description of material and related information.]  
THIS MATERIAL AND RELATED INFORMATION ARE TRANSFERRED ONLY FOR USE IN COMPLIANCE WITH THE ABOVE MENTIONED FIELD TRIAL AGREEMENT. CONFIDENTIALITY OBLIGATIONS APPLY.               For sending/receipt,   For receipt/sending,           Signature:     Signature:  
         
           Date:       Date:   
         
           Name:       Name:             Title:       Title:   [CERES/IGER]   [Party]       CERES-IGER Collaboration Agreement   Page 39 of 75FIELD TRIAL AGREEMENT (Non transgenic. No payment. Academic.)  
1.  THE PARTIES
 
   This Agreement is made effective on [date] (“Effective Date”) by and between [Ceres, Inc., a Delaware corporation with principal offices at 1535 Rancho Conejo Blvd., Thousand Oaks, CA 91320, United States of America] or [Institute of Grassland and Environmental Research, a company limited by guarantee, registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom] hereinafter “[CERES/IGER],” and [Party information to be completed], hereinafter “[Party].”
 
   WHEREAS, [CERES/IGER] wishes to obtain information from field trialing certain CERES/IGER plant material;
 
   WHEREAS, [Party] wishes to include CERES/IGER’s plant material in field trials in consideration of its scientific interest in the observations to be made in such trials and the right to publish certain observations, all subject to the terms and conditions of this Agreement;
 
   [or other introduction as appropriate]
 
   NOW THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, [CERES/IGER] and [Party] hereby agree as follows:
 
2.  FIELD TRIAL PROGRAM
  2.1 [CERES/IGER] will deliver to [Party] seeds or other propagating material as described in ANNEX I and related information (jointly referred to as the “CERES/IGER Plant Material”). The delivery conditions are set forth in ANNEX I. Promptly upon receipt of the CERES/IGER Plant Material, Party will sign and return the Receipt Form, in the preferred format attached as ANNEX II to this Agreement, to [CERES/IGER] (attn: [responsible person at CERES/IGER]).
 
  2.2 [Party] agrees to perform the activities defined in ANNEX I which shall be referred to hereinafter as the “Program.” With reasonable notice [CERES/IGER] may change the activities to be performed in the Program. If such changes do not result in additional work to be performed by [Party], but consist for example of changes in experimental design or in observations to be made or in information to be included in reports, they shall be set forth in a written document provided by [CERES/IGER] to [Party] which will be attached to ANNEX I and form part of it. If such changes result in additional work to be performed by [Party], they shall be set forth in an amendment to this Agreement signed by both Parties. [CERES/IGER] will consider any suggestions for changes in the Program which [Party] may suggest.
 
  2.3 In performing the Program activities [Party] undertakes to comply with the work plan and time schedule set forth in ANNEX I.     CERES-IGER Collaboration Agreement   Page 40 of 752.4 [Party] undertakes only to use the CERES/IGER Plant Material or any part, progeny or seeds thereof for performing the Program activities to be carried out under the Program and not for any other purpose. Specifically, but without limitation, [Party] shall not use the Plant Material or any progeny, plants, parts of plants, plant material, seeds or products derived therefrom in any form of reselection, breeding, sexual crossing, seed production, back crossing, tissue culturing, mutagenesis, genetic transformation or any biotechnological process, except as specifically approved in this Agreement.
 
  2.5 The CERES/IGER Plant Material will be used only on fields and at premises under the control of [Party] and identified in ANNEX I.
 
  2.6 Upon termination of the Program, [Party] will, at the option of [CERES/IGER], (i) allow [CERES/IGER] to remove any Plant Material and any progeny, plants, plant material, seeds or products obtained in the Program or (ii) destroy any remaining CERES/IGER Plant Material and any plants, plant material and seeds obtained under the Program within fifteen (15) days from [CERES/IGER]‘s request to destroy, and will send [CERES/IGER] forthwith an attestation of such destruction.
 
  2.7 Subject to giving at least one day’s prior written notice in writing or by email to [Party], [CERES/IGER] and [CERES/IGER] invitees will have the right to visit the fields where Program activities are being conducted at any time, to make observations and to collect samples.
3.  REPORTS
  3.1 [Party] shall send [CERES/IGER] detailed written reports on the implementation of the Program activities and the observations made and results obtained during the implementation of the Program. The frequency of the reports and the type of information to be included in same is set forth in ANNEX I.
 
  3.2 During the entire Program, [Party] will promptly communicate to [CERES/IGER] any information on the Program activities or the results obtained or observed that [CERES/IGER] may ask. Between reports, [Party] will also spontaneously communicate to [CERES/IGER] any unexpected observations or results.
4.  REMUNERATION. PAYMENT
 
   No remuneration will be due.
5.  OWNERSHIP. INTELLECTUAL PROPERTY RIGHTS. EXPLOITATION
  5.1 This Agreement does not bring any change to the ownership and intellectual property rights relating to the CERES/IGER Plant Material. [Party] acknowledges that the CERES/IGER Plant Material may be covered by patents or patent applications of [CERES/IGER].
 
  5.2 [CERES/IGER] will exclusively own any plants, parts of plants, plant material, seeds, information, data, technology, or other findings or inventions resulting from the     CERES-IGER Collaboration Agreement   Page 41 of 75Program that relate to the CERES/IGER Plant Material (hereinafter “Results”). [CERES/IGER] will have the exclusive rights to protect any of the Results through patents or plant variety protection rights or similar protection, and any intellectual property rights arising therefrom will belong exclusively to [CERES/IGER]. In case [Party] has made or contributed to any invention forming part of the Results, [Party] shall promptly inform [CERES/IGER] thereof in writing and shall assign its rights and cause its employees and staff members to assign their rights in any such invention to [CERES/IGER]. [Party] shall render such assistance as may be required for assigning any rights [Party] inventors may have in such invention to [CERES/IGER] or [CERES/IGER]‘s designee and for protecting such invention, including but not limited to the signing of documents. Any inventor of [Party] will be recognized in patent applications on an invention which is part of the Results in accordance with [U.S./U.K. patent law].
 
  5.3 [CERES/IGER] will have the exclusive right to commercialize any of the Results.
6.  CONFIDENTIALITY. PUBLICATIONS.
  6.1 [Party] will treat any and all information and material communicated or transferred to it by [CERES/IGER] pursuant to this Agreement (including but not limited to the CERES/IGER Plant Material) and any Results (including without limitation any progeny, plants, seeds, parts of plants, plant material, or products obtained directly or indirectly from the Plant Material) as strictly confidential and will not use the same for any purpose other than as expressly allowed by this Agreement nor disclose or transfer the same to any third party other than its employees or staff members necessary to carry out the Program and bound by appropriate secrecy and non-use undertakings consistent with [Party’s] obligations under this Agreement.
 
  6.2 [Party] shall take all precautions to prevent theft or pilferage of the Plant Material and any progeny, plants, seeds, parts of plants or plant material obtained directly or indirectly from the Plant Material.
 
  6.3 [Party] will not grant access to any field where Plant Material or any progeny, plants, seeds, parts of plants or plant material obtained directly or indirectly from the Plant Material can be viewed to any third party except with the prior written permission of [CERES/IGER].
 
  6.4 “Publication” and “Publish” shall include any discussion with or presentation to a third party, other than parties referred to in Article 6.1. Examples of Publications include, without limitation: presentation at a conference, submission for publication to a journal, submission of joint proposals, posting information on a website, posters, abstracts, Ph.D. dissertations, and informal oral discussions. Subject to [CERES/IGER]‘s prior written approval, which will not unreasonably be withheld, [Party] may proceed to Publication of selected Results provided that: (i) no confidential information of [CERES/IGER] is revealed thereby, (ii) [Party] shall take into account any suggestions which may be formulated by [CERES/IGER], and (iii) at least thirty (30) days prior to the submission to a publisher or presentation to any third party, [Party]     CERES-IGER Collaboration Agreement   Page 42 of 75delivers copies of the proposed Publication to [CERES/IGER] for review. At [CERES/IGER]‘s request, [Party] shall, for a reasonable period up to ninety (90) days from initial delivery to [CERES/IGER], delay revealing any patentable subject matter in the disclosure in order to permit the filing of patent applications. In any Publication, the Parties shall consider joint authorship and acknowledge the contributions and publications of the other as scientifically appropriate.
7.  WARRANTIES. LIMITED LIABILITY
  7.1 [Party] acknowledges that the CERES/IGER Plant Material is of an experimental nature and will take all reasonable precautions to prevent any damage or injury by the CERES/IGER Plant Material and any progeny, plants, parts of plants, plant material, seeds or products derived therefrom.
 
  7.2 [Party] warrants that the CERES/IGER Plant Material will exclusively and restrictedly be used under suitable containment conditions, and in accordance with all applicable regulations, and it will not be used on human subjects. In addition, [Party] will strictly comply with any planting distance, isolation and similar requirements set forth in ANNEX I. [Party] will obtain any authorizations or permits or proceed to any notifications which may be required for the Program activities, [Party] will inform [CERES/IGER] in writing, within thirty (30) days from the Effective Date, of any such requirements and certify its compliance with same.
 
  7.3 [CERES/IGER] declines any liability for any damage which may be caused by the CERES/IGER Plant Material or the Program activities or Results to [Party] or any third party.
 
  7.4 Neither Party shall be liable for indirect, special, remote, incidental or consequential damages or loss of profit in connection with this Agreement or its implementation.
8.  GENERAL CONDITIONS
  8.1 Amendments: This Agreement, including its annexes, may only be amended by a written document signed by duly authorized representatives of the Parties.
 
  8.2 Ambiguities: In case of ambiguity between this Agreement and its annexes, the contents of the agreement shall prevail.
 
  8.3 Number of copies: This Agreement including its annexes is being made in two (2) copies, one for each Party.
 
  8.4 Assignment / Subcontracts: [CERES/IGER] has concluded this Agreement with [Party] in view of [Party]‘s specific qualifications and [Party] shall not have the right to assign any of its rights or obligations under this Agreement nor to sub-contract any part of the Program activities to any third party, except with the prior written approval of [CERES/IGER]. [CERES/IGER] has the right to assign itsrights and obligations under this Agreement to any third party. Further, [CERES/IGER] has the right to     CERES-IGER Collaboration Agreement   Page 43 of 75Made in two (2) copies.  
     entrust the implementation of all or part of its obligations under this Agreement to any of its affiliates.
 
  8.5 Equitable Remedies: It is understood and agreed that money damages would not be a sufficient remedy for any breach of this Agreement by [Party] and that [CERES/IGER] is entitled to equitable relief, including injunction and specific performance, as a remedy for any such breach. Such remedies shall not be deemed to be the exclusive remedies for a breach by [Party] of this Agreement but shall be in addition to all other remedies available at law or equity to [CERES/IGER].
 
  8.6 Governing Law / Jurisdiction: [to be completed]
9.  DURATION
  9.1 This Agreement will enter into force on the Effective Date and will remain in full force and effect until the latest of the following dates: (i) the [third] anniversary of the Effective Date, (ii) the date of delivery by [Party] of the last report provided for in this Agreement, or (iii) the dates on which the last payment due by [CERES/IGER] pursuant to this Agreement is made.
 
  9.2 Notwithstanding Article 9.3., [CERES/IGER] will have the right to terminate this Agreement including the Program at any time with [three (3)] months’ prior written notice.
 
  9.3 Either Party will have the rights to terminate this Agreement unilaterally by registered letter addressed to the other Party in case such other Party has committed a breach of any of its obligations under this Agreement and has failed to remedy such breach within thirty (30) days from the receipt of a registered letter specifying the breach.
 
  9.4 The provisions of Articles 2.6, 5, 6, 7.3, 7.4, 8.5 and 8.6 will survive the expiration or termination of this Agreement.
             [Party]     [Institute of Grassland and Environmental Research] or [Ceres, Inc.]           By:       By:   
         
Name:      Name:  
         
Title:       Title:  
         
           By:       By:   
         
Name:      Name:  
         
Title:       Title:  
         
     CERES-IGER Collaboration Agreement   Page 44 of 75ANNEX I  
to the Field Trial Agreement between [CERES/IGER] and [Party]  
PLANTING / MANAGEMENT PLAN FOR [CERES/IGER] MISCANTHUS EVALUATION TRIAL — [Party]  
Trial Scope and Purpose:  
1. Planting Material  
2. Program Activities  
3. Content and timing of reports       CERES-IGER Collaboration Agreement   Page 45 of 75ANNEX II 
to the Field Trial Agreement between [CERES/IGER] and [Party]  
FORM OF RECEIPT FORM  
Packing Slip and Receipt Form for material transferred pursuant to the Field Trial Agreement dated [x] between [CERES/IGER] and [Party].  
The undersigned [Party/[CERES/IGER]] signatory certifies that the material and related information set forth hereinafter are included in the shipment with which this form is enclosed.  
The undersigned [Party/[CERES/IGER]] signatory acknowledges having received in good order the material and related information set forth hereinafter.  
[Include description of material and related information.]  
THIS MATERIAL AND RELATED INFORMATION ARE TRANSFERRED ONLY FOR USE IN COMPLIANCE WITH THE ABOVE MENTIONED FIELD TRIAL AGREEMENT. CONFIDENTIALITY OBLIGATIONS APPLY.               For sending/receipt,   For receipt/sending,           Signature:     Signature:  
         
           Date:       Date:   
         
           Name:       Name:             Title:       Title:   [CERES/IGER]   [Party]       CERES-IGER Collaboration Agreement   Page 46 of 75Material Transfer Agreement — Biological Material for Research Purposes  
You have requested that the Institute of Grassland & Environmental Research (IGER) provides you with the Biological Material listed in the Schedule. In consideration of providing the Biological Material, IGER asks you, and you agree, to observe the following conditions, for a period of ten years from the date hereof:  
         To: Name:  (the “Recipient”)        Organisation:  (“the Recipient Institution”)        Address:   
1.  To use the Biological Material only for the purpose of academic research at the laboratories of the Recipient and not in any collaboration with a third party. More specifically the Biological Material will only be used for the following purpose:
 
   [to be completed]
 
   The Recipient will specifically but without limitation not use the Biological Material for the following purposes:
 
   Generation of plants for use in seed production to increase the volume of seed available; generation of plants for use in any breeding or back crossing experiments; any tissue culture, mutagenesis, genetic transformation or any biotechnological process, except if expressly defined as the purpose of this Agreement.
 
   The Biological Material will not be used for production of a commercial product, or for patent purposes or for applications for plant variety rights.
 
2.  Not to provide samples of the Biological Material or samples of material extracted from or derived from the Biological Material or any technical information relating thereto, to third parties without specific written permission from IGER. Samples may only be provided to members of your immediate research team, who undertake to respect these conditions.
 
3.  Not without IGER’s prior written permission (which shall not be unreasonably refused) to disclose to any third party or publish details of the Biological Material, its manufacture or use, or details of any other material that could not have been made but for the Biological Material, or information on results obtained through the use of the Biological Material and to acknowledge the source of the Biological Material in any such publication for which permission is granted. The Recipient must provide IGER any proposed publication at least thirty (30) days prior to submission. IGER will review such proposed publication for the need of intellectual property protection and/or to identify any inadvertent disclosure of proprietary information. If necessary, the Recipient agrees to (i) delay publication by no more than sixty (60) days to enable the filing of an application for intellectual property protection and/or (ii) remove any proprietary information identified by IGER.     CERES-IGER Collaboration Agreement   Page 47 of 75The Schedule  
[to be completed]  
4.  The Recipient acknowledges that the Biological Material and any material or information obtained through the use thereof shall always remain the property of IGER. Upon completion of the research activities defined herein, the Recipient shall, at the option of IGER, (i) return to IGER all unused Biological Material supplied by IGER and all materials, regardless of type, produced from the Biological Material or (ii) destroy all unused Biological Material supplied by IGER and all materials, regardless of type, produced from the Biological Material.
 
5.  The Recipient will not obtain, and will not attempt to obtain patent coverage on the Biological Material or on any use of the Biological Material or on any other material or information that could not have been made or obtained but for the Biological Material.
 
6.  The Recipient agrees promptly to disclose to IGER all information relating to research performed using the Biological Material and all information relating to any modifications or improvements of the Biological Material or any material derived from the Biological Material. [specific reporting obligations to be included]
 
7.  The Recipient and Recipient Institution will use the Biological Material in compliance with all applicable laws and regulations including current health and safety guidelines for work with recombinant DNA (if applicable) and for transport of materials and protection of the environment. The Recipient and Recipient Institution agree to waive all claims against IGER and to defend and Indemnify IGER from all claims and damages asserted by third parties arising from the use, storage, handling and disposal of the Biological material by the Recipient.
 
8.  The Biological Material is experimental in nature and is provided without any warranties express or implied, including any warranties of merchantability or fitness for any purpose.
 
9.  IGER makes no representation that the use of the Biological Material will not infringe any patent or other intellectual property right and the Recipient hereby indemnifies IGER from and against all actions, claims, proceedings or demands which may be brought against IGER by third parties in respect of the infringement of any intellectual property right arising out of the Recipient’s’ exercising of its rights under this Agreement.
 
10. The Recipient shall ensure that its employees, officers and agents comply with the obligations imposed upon the Recipient by this Agreement as if personally bound by such obligations.
     CERES-IGER Collaboration Agreement   Page 48 of 75Signed for and on behalf of IGER:  
Signature:  
Name: P.A. Fentem  
Title: Institute Business Manager  
Date:  
     
 
 
Recipient Institution:    Recipient:
 
Signature:    Signature:
 
Name:    Name:
 
Position:    Date:
 
Date:    
 
     CERES-IGER Collaboration Agreement   Page 49 of 75EXHIBIT D  
to the Collaboration Agreement between IGER and CERES  
EXTERNAL FUNDING  
•  Defra project NF0426 The genetic improvement of miscanthus for Biomass
 
   1 April 2004 — 31 March 2009 — see EXHIBIT E
 
•  Energy crops in the Atlantic space: Possibilities for large scale implementation Interreg IIIB Atlantic Area
 
   1 January 2004 — 31 December 2007 — see EXHIBIT E
 
•  Supergen — Biomass, Biofuels and Energy Crops Consortium
 
   1 April 2003 — 31 March 2007 — see EXHIBIT E
 
•  BBSRC project: Optimising the development of the energy grass Miscanthus through manipulation of flowering time
 
   1 April 2007 — 31 March 2011 — see EXHIBIT E     CERES-IGER Collaboration Agreement   Page 50 of 75EXHIBIT E  
to the Collaboration Agreement between IGER and CERES  
EXISTING AGREEMENTS  
Title: Defra project NF 0426 ‘The genetic improvement of miscanthus for biomass’  
Duration: 1/4/04 — 31/3/09  
Partners: PRI  
Scope and roles of partners  
Material and information provided and to be provided by IGER: Provision of reports on results to Defra.  
Rights of IGER and PRI on results: IP owned by Defra but now being assigned to IGER. Rights to use of results by PRI not specified in contract.  
Rights of third parties on any IGER background material/information  
IGER materials from China subject to rights of GAGE in royalty sharing and in access for research purposes.  
Any exclusivity/non competition  
No  
Any rights of third parties on results obtained by IGER  
Rights of Tinplant with respect to materials developed using their germplasm. NOTE: any future use of Tinplant germplasm for breeding purposes will be subject to mutual agreement of IGER and CERES.  
  1.  Assessment of genetic resources available in UK and elsewhere for yield, canopy development, flowering time (IGER) overwintering and combustion quality (PRI)
 
  2.  Hybridisation and selection based on general and specific combining ability of diploid accessions (IGER, PRI)
 
  3.  Hybridisation of diploid and tetraploid accessions to produce new sterile triploid hybrids (IGER)
 
  4.  Improvement of breeding efficiency based on early morpho-physiological prediction of productivity and persistence and indirect measurement of chemical composition (IGER)
 
  5.  The production of large trait mapping populations and identification of a realistic cost effective road map to more efficient breeding through the development of marker-assisted selection (IGER,PRI)
 
  6.  Identification with Defra of the exploitation route in UK and Europe taking into account expertise in large scale production and marketing (IGER,PRI)
     CERES-IGER Collaboration Agreement    Page 51 of 75Title: Energy crops in the Atlantic space: Possibilities for large scale implementation Interreg IIIB Atlantic Area  
Duration: 1/1/04 — 31/12/07  
Partners and roles:  
Instituto Superior de Agronomia (Portugal) Agronomy and harvesting of Cynara, Arundo, Sorghum  
Associacao de Prudutores Florestias (Portugal) Agronomy, harvesting and conversion of Cynara, Arundo and Sorghum  
Universidade de Evora (Portugal) Agronomy, harvesting of Cynara, Sorghum  
Instituto Nacional de Engenharia, Tecnologia e Invacao (Portugal) Gasification and combustion of Cynara, Arunda, Sorghum  
Associacao Florestal da Galizia (Spain) Agronomy, combustion analysis and alcohol production from Cynara, Arunda, Sorghum  
Mid-South Roscommon Rural Development Company Ltd (Ireland) Identify and monitor farm performance of biomass crops including miscanthus, reed canary grass, and willow.  
IGER (UK) Agronomy and chemical composition analysis of miscanthus. Hybrid miscanthus trials.  
Scope: Analysis of technical and economic aspects of installation of Cynara cardunculus, Arundo donax, Sorghum bicolor and miscanthus in different regions. Conversion of biomass by burning and through conversion to alcohol  
Material and information provided and to be provided by IGER  
Agronomy data, hybrid trial data, chemical composition data.  
Rights of parties to results  
All project results to be left ‘free of all rights’  
Rights of third parties on any Background  
None  
Any exclusivity/non competition  
None  
Rights of third parties on results obtained by IGR outside of agreement activities  
None       CERES-IGER Collaboration Agreement    Page 52 of 75Title: Supergen — Biomass, Biofuels and Energy Crops Consortium  
Duration: 1/4/03 — 31.3.07  
Scope: Feedstock options and meeting criteria of fuel quality for willow, miscanthus, reed canary grass and switch grass.  
Conversion and energy generation — pyrrolysis and combustion Economics and market issues  Integration of fuel production, conversion and end use Environmental issues  
Partners and roles  
University of Leeds Combustion behaviour of buiomass  
Aston University Mass pyrrolysis for biooil  
University of Sheffield Modelling combustion processes  
University of Ulster Techno-economics of combustion and pyrrolysis  
Cranfield University Corrosion in combustion  
University of Manchester Socio-economic analysis  
Rothamsted Research Agronomy (fertilizer requirements) of reed canary grass, switch grass and miscanthus  
Alston Power Ltd Combustion  
Bical Ltd Miscanthus agronomy  
E.ON UK Ltd Combustion  
Rural Regeneration Ltd Environmental impact       CERES-IGER Collaboration Agreement    Page 53 of 75IGER  
Materials and information provided by IGER  
Lolium, Dactylis and Festuca material. NIRS calibrations for lignin, ADF and NDF for miscanthus (material sourced from European Miscanthus Initiative)  
Rights of IGER and other parties on results  
All parties own their own Resulting IP. Partners must make their Resulting IP available to other partners for research purposes  Subject to agreement on commercial terms partners grant each other non-exclusive license to use their IP for commercial purposes  A partner can not unreasonably refuse access on reasonable terms to a second partner to its IP if access is necessary for that second partner to commercialise its own IP  
Rights to IGER Background  
Partners may use IGER’s Background for purposes of project and for internal research purposes  IGER’s Background may be made available to another partner for commercial purposes subject to commercial terms  IGER’s Background to be licensed on fair and reasonable terms when necessary for another partner to commercially exploit its own Resulting IP.  
Exclusivity/non competition  
Should partners wish to exploit their own resulting IP with a third party (outside consortium) during the duration of the project, that party must notify the other partners.  
Ay rights of third parties/partners on results obtained outside of agreement activities  
None       CERES-IGER Collaboration Agreement    Page 54 of 75Title: BBSRC project: Optimising the development of the energy grass Miscanthus through manipulation of flowering time  
Duration: 1/4/07 — 31/3/11  
Scope: Identification of genes involved in flowering time of the two parents of Miscanthus X giganteus  
Roles of partners:  
Materials and information provided and to be provided by IGER:  
A range of miscanthus genotypes from Japan, China and Taiwan to be characterised at field sites at IGER and Rothamsted. M siniensis mapping family will also be assessed at IGER and Rothamsted. IGER mapping data will be made publicly available through a database which is part of the BBSRC cross institute programme on monocot genetics.  
Rights of parties to results  
Each party owns the IP on the results it produces  
Rights of third parties to any background  
Rights of GAGE to collection covered in GAGE agreement  
Exclusivity/non competition  
None  
Rights of third parties on IGER results outside of agreement activities  
None  
   IGER — Assessment of flowering time of miscanthus populations in the Field. Association of flowering time and senescence QTL with miscanthus Genes. Identify miscanthus genes which are homologues of Arabidopsis, maize and rice flowering genes. Build genetic maps around these genes and map flowering time QTL  
 
Rothamsted — Assessment of flowering times of miscanthus populations in the field
     CERES-IGER Collaboration Agreement    Page 55 of 75EXHIBIT F  
to the Collaboration Agreement between IGER and CERES  
PRODUCTION AND COMMERCIALIZATION ACTIVITIES  
CERES will:  
CERES shall provide to IGER a detailed, written annual report on its activities in furtherance of the obligations of this EXHIBIT, such report shall be due at or about March 31 of each year. In addition, upon the request of IGER at any time, CERES will discuss the progress and results achieved in regard to such activities; provided however, such contacts and discussions shall be reasonable in frequency and duration so as not to be disruptive to the respective operations of either Party.  
  1.  Identify growers and establish grower contracts
 
  2.  Lease, build or buy production facility
 
  3.  Establish quality testing capability
 
  4.  Establish a sales force and distribution network and/or distribution through existing distribution systems and/or establish any other commercialization system.
     CERES-IGER Collaboration Agreement    Page 56 of 75EXHIBIT G  
to the Collaboration Agreement between IGER and CERES  
MODEL LICENSE AGREEMENT FOR NON-TRANSGENIC VARIETIES / NON-UK  
EXCLUSIVE LICENSE AGREEMENT FOR [VARIETY X]  
THIS AGREEMENT is made this ___ day of _________, 20— (“Effective Date”), by and between INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH (“IGER”), a company limited by guarantee, registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom and CERES, INC. (“CERES”), a Delaware corporation, having an office at 1535 Rancho Conejo Blvd., Thousand Oaks, California 91320, United States of America.  
WHEREAS, CERES and IGER entered into a COLLABORATION AGREEMENT, (“CA”), that contemplates a long-term research relationship by and between the Parties for the enhancement and improvement of COLLABORATION CROPS (as defined in the CA) for biomass crops;  
WHEREAS, CERES and IGER have jointly developed and jointly own a new MISCANTHUS variety [X] pursuant to SCHEDULE [1] to the CA;  
WHEREAS, CERES wishes to commercialize MISCANTHUS variety [X];  
WHEREAS, CERES has the ability to assume production of and to commercialize MISCANTHUS variety [X] and wishes to receive an exclusive, world-wide license (except in the United Kingdom) to produce, use, sell and commercially exploit MISCANTHUS variety [X];  
WHEREAS, in accordance with the provisions of the CA concerning the commercialization of MISCANTHUS varieties jointly developed and jointly owned by the Parties under the CA, the Parties have developed this Agreement and its terms in accordance with the terms and obligations set forth in the CA;  
WHEREAS, CERES and IGER recognize that the rights intended to be granted hereunder can be a strong incentive for CERES to risk money and other resources needed to produce, use, sell and commercially exploit MISCANTHUS for wide public enjoyment;  
NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements contained herein and of other good and valuable consideration, the Parties have agreed and do hereby agree as follows:  
1.1 “MISCANTHUS” is defined as “COLLABORATION CROPS” in the CA, and such definition is incorporated by reference herein.  
1. DEFINITIONS.
     CERES-IGER Collaboration Agreement    Page 57 of 751.2 “LICENSED VARIETY” shall mean the [NAME] MISCANTHUS variety jointly developed by the Parties pursuant to SCHEDULE [1] to the CA and released, jointly by IGER and CERES, pursuant to the terms of SCHEDULE [1].  
1.3 “VARIETY RELEASE DATE” shall mean the date the LICENSED VARIETY was released pursuant to the terms of SCHEDULE [1].  
1.4 “TERRITORY” shall mean all countries of the world except the United Kingdom.  
1.5 “COMMERCIAL PROPAGULE” shall mean [propagules — seed — reproductive material] of MISCANTHUS that is sold for purposes other than the production of propagating material.  
1.6 “INTELLECTUAL PROPERTY RIGHTS” shall mean all rights in any plant variety, patent, plant breeders rights, registration or equivalent intellectual property protection, or any applications thereof, for the LICENSED VARIETY, which may be filed in any jurisdiction in the TERRITORY, with the exception of TRADEMARKS. INTELLECTUAL PROPERTY RIGHTS, when applied for or granted, will be set forth in ANNEX I.  
1.7 “JOINT INTELLECTUAL PROPERTY” is defined in the CA, and such definition is incorporated by reference herein. Any and all JOINT INTELLECTUAL PROPERTY licensed under this Agreement shall be set forth in ANNEX I.  
1.8 “IGER INTELLECTUAL PROPERTY” is defined in the CA, and such definition is incorporated by reference herein. Any and all IGER INTELLECTUAL PROPERTY licensed under this Agreement shall be set forth in ANNEX I.  
1.9 “OTHER RESEARCH RESULTS” is defined in the CA, and such definition is incorporated by reference herein.  
1.10 “BACKGROUND INTELLECTUAL PROPERTY” is defined in the CA, and such definition is incorporated by reference herein. Any and all IGER BACKGROUND INTELLECTUAL PROPERTY licensed under this Agreement shall be set forth in ANNEX I.  
1.11 “TRADEMARK” shall mean any trademark, trade name or logo owned by CERES and intended for use with a LICENSED VARIETY.  
1.12 “COMMERCIAL NAME” shall mean the complete, preferred name of a LICENSED VARIETY under which a specific LICENSED VARIETY will be marketed and sold.  
1.13 “NET SALES” shall mean the actual wholesale price for COMMERCIAL PROPAGULES of the LICENSED VARIETY received by CERES or any AFFILIATED COMPANY for the sale of such propagules, excluding propagating material for further production of propagating material, less any (a) customary trade, quantity, or cash discounts; (b) amounts repaid or credited by reason of rejection or return; (c) any sales, use, tariff, customs duties, V.A.T. and/or other taxes, duties and similar governmental assessments (except taxes based on income); (d) outbound transportation, shipping, packing, costs of insurance in transit paid by CERES or an AFFILIATED COMPANY; and (e) cost of any coating materials that may have been applied to the COMMERCIAL PROPAGULES.       CERES-IGER Collaboration Agreement    Page 58 of 75Where there is no identifiable sale price or when a LICENSED VARIETY is sold to other than bona fide, arms length customers of CERES or any AFFILIATED COMPANY, CERES or the AFFILIATED COMPANY shall be deemed to have received an amount of NET SALES calculated based on the final sale of the COMMERCIAL PROPAGULES (wholesale level) to an independent third party, usually referred to as net wholesale price payable by dealers. If no such current price is available, a hypothetical fair market value price will be determined by the Parties jointly in good faith for the purpose of calculating NET SALES. Further, TRAIT FEES, if any, shall be added to NET SALES.  
1.14 “TRAIT FEE” shall mean any upfront or annual fee collected by CERES or any AFFILIATED COMPANY in conjunction with NET SALES as 1.14 “TRAIT FEE” shall mean any upfront or annual fee collected by CERES or any AFFILIATED COMPANY in conjunction with NET SALES as an additional remuneration for the sale of COMMERCIAL PROPAGULES that have a particular valuable non-transgenic trait or characteristic.  
1.15 “LICENSE INCOME” shall mean the amount actually received by either CERES or any AFFILIATED COMPANY in consideration for the grant of SUBLICENSES to SUBLICENSEES that are not AFFILIATED COMPANIES to produce and sell COMMERCIAL PROPAGULES of the LICENSED VARIETY, including up-front fees, lump sum payments and any running royalties on a product-by-product and jurisdiction-by-jurisdiction basis.  
*NOTE: definitions of NET SALES and LICENSE INCOME may vary in function of the business models that may be developed  
1.16 “AFFILIATED COMPANY” shall mean any company owned or controlled by, under common control with or controlling CERES, “control” meaning in this context the direct or indirect ownership of more than fifty percent (50%) of the voting stock/shares of a company, or the power to nominate at least half of the directors.  
1.17 “SUBLICENSE” shall mean any sublicense granted (a) by CERES to an AFFILIATED COMPANY or (b) by CERES or an AFFILIATED COMPANY to any third party (“SUBLICENSEE”), as authorized by this Agreement, to produce and sell a LICENSED VARIETY (or LICENSED VARIETIES).  
1.18 “MARKETING PLAN” shall mean a detailed written plan for production, distribution, sale and promotion of the LICENSED VARIETY prepared by or on behalf of CERES and submitted to IGER. Each MARKETING PLAN shall include at least the information outlined in ANNEX II. Actual, adopted MARKETING PLANS shall be attached as further annexes to this Agreement as adopted.  
2.1 IGER hereby grants CERES under IGER’S interest in any JOINT INTELLECTUAL PROPERTY and OTHER RESEARCH RESULTS, the IGER INTELLECTUAL PROPERTY set forth in ANNEX I, and the IGER BACKGROUND INTELLECTUAL PROPERTY set forth in ANNEX I:  
2. GRANT OF LICENSE.
  (a) the exclusive right and license to produce COMMERCIAL PROPAGULES of the LICENSED VARIETY in the TERRITORY, including intermediate propagation material; and     CERES-IGER Collaboration Agreement    Page 59 of 752.2 Sublicenses. CERES shall have the right to grant SUBLICENSES within the TERRITORY provided that:  
2.3 Nothing in this Agreement shall be construed as conferring by implication, estoppel, or otherwise any license or rights under any INTELLECTUAL PROPERTY RIGHTS, whether owned by IGER or licensed to IGER, other than the one(s) expressly set forth in this Agreement.  
3.1 CERES will prepare and file, in accordance with its best judgment, any and all applications for plant variety rights or other forms of intellectual property protection or variety registration for the LICENSED VARIETY in the United States and/or Europe. Applications for plant variety rights shall be filed in the joint names of CERES and IGER. At CERES’ discretion, plant variety rights and/or other forms of intellectual property protection may be filed in any other jurisdiction in the TERRITORY.  
3.2 If CERES intends to abandon any plant variety rights, pending or granted in any jurisdiction, CERES shall first give sufficient written notice to IGER to permit IGER the opportunity to assume such filing, examination and/or maintenance.  
3.3 CERES and IGER will consult with regard to INTELLECTUAL PROPERTY RIGHTS.  
3.4 The obligations of this Article 3.4 shall not apply to any jurisdictions in which CERES has elected not to apply for intellectual property protection. CERES and IGER shall avoid carrying out any act that would prejudice the grant of INTELLECTUAL PROPERTY RIGHTS. Without limitation, neither Party shall make available reproductive material of the LICENSED VARIETY at a date or in a manner that might jeopardize the right to seek INTELLECTUAL PROPERTY RIGHTS protection for the LICENSED VARIETY. CERES, whether directly or through any SUBLICENSEE, shall not sell any propagules of the LICENSED VARIETY until such time as the requirements for INTELLECTUAL PROPERTY RIGHTS have been established.  
  (b) the exclusive right and license to use, sell and commercially exploit the COMMERCIAL PROPAGULES of the LICENSED VARIETY in the TERRITORY.
  (a) The terms and obligations of any such SUBLICENSE shall be consistent with the terms and obligations of this Agreement;
  (b) CERES shall deliver to IGER (under an obligation of confidentiality) a written summary of each SUBLICENSE agreement, which shall include the name and address of the SUBLICENSEE, scope of the SUBLICENSE, exclusive/non-exclusive status, territory, remuneration, reporting and diligence obligations, if any. This summary shall be provided within thirty (30) days after execution, modification or termination of the summarized agreement; and
  (c) CERES will use commercially reasonable efforts to collect any and all amounts due to CERES under any SUBLICENSE for the sale of COMMERCIAL PROPAGULES of the LICENSED VARIETY.
3. INTELLECTUAL PROPERTY RIGHTS.
     CERES-IGER Collaboration Agreement    Page 60 of 753.5 CERES shall use all reasonable endeavors to ensure in any sales jurisdiction of the TERRITORY in which INTELLECTUAL PROPERTY RIGHTS exist that all bags or containers supplied by CERES and any SUBLICENSEE containing only propagules of such LICENSED VARIETY are clearly labeled to show that the LICENSED VARIETY is protected by INTELLECTUAL PROPERTY RIGHTS.  
4.1 In partial consideration for the rights granted in this Agreement, CERES shall be responsible for any and all fees and expenses incurred in filing, examining, certifying and maintaining any INTELLECTUAL PROPERTY RIGHTS for the LICENSED VARIETY, subject to the provisions of Article 3.  
4.2 In partial consideration for the rights granted in this Agreement, CERES agrees to pay to IGER, on behalf of CERES and any AFFILIATED COMPANY, for the LICENSED VARIETY, a royalty of:  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
4. LICENSED VARIETY CONSIDERATION.
  4.2.1 on NET SALES
  (a) [***] percent ([***]%) of NET SALES if the LICENSED VARIETY constitutes IGER INTELLECTUAL PROPERTY, where the genotype exists before the Effective Date of the CA, no further breeding or selection is required after the Effective Date of the CA, and the LICENSED VARIETY is propagated by rhizomes;
  (b) [***] percent ([***]%) of NET SALES if the LICENSED VARIETY constitutes IGER INTELLECTUAL PROPERTY, in all cases not included in Article 4.2.1 (a); or
  (c) [***] percent ([***]%) of NET SALES if the LICENSED VARIETY constitutes JOINT INTELLECTUAL PROPERTY.
  4.2.2 on LICENSE INCOME
  (a) [x percentage to be determined in function of the business model] of LICENSE INCOME if the LICENSED VARIETY constitutes IGER INTELLECTUAL PROPERTY, where the genotype exists before the Effective Date of the CA, no further breeding or selection is required after the Effective Date of the CA, and the LICENSED VARIETY is propagated by rhizomes;
  (b) [[***] x%] of LICENSE INCOME if the LICENSED VARIETY constitutes IGER INTELLECTUAL PROPERTY, in all cases not included in Article 4.2.2 (a); or
 
  (c) [[***] x%] of LICENSE INCOME if the LICENSED VARIETY constitutes JOINT INTELLECTUAL PROPERTY.     CERES-IGER Collaboration Agreement    Page 61 of 754.3 In addition to the royalty provided in Article 4.2, CERES agrees to pay a royalty on NET SALES of the LICENSED VARIETY equal to the royalty due, on the basis of the Convention on Biological Diversity, by IGER to the country or countries where the material on which the LICENSED VARIETY is based has been collected, up to a maximum of [***] percent ([***]%) of NET SALES, and an equivalent additional royalty on LICENSE INCOME to be determined.  
4.4 Where any royalty payments are subject to a withholding tax, CERES shall pay the net royalty and shall provide to IGER proper certificates for such withholding tax.  
4.5 All sums payable by CERES to IGER under this Agreement shall be payable in United States dollars. Royalties shall be payable by March 31 of each year with respect to the NET SALES and LICENSE INCOME received by CERES and any AFFILIATED COMPANIES in the preceding calendar year. Payments shall be made by check to the following address:  
Institute Secretary Institute of Grassland and Environmental Research Plas Gogerddan Aberystwyth Ceredigion SY23 3EB United Kingdom  
Such payments shall be accompanied by a written report setting forth the production volumes and sales by CERES, and each SUBLICENSEE, of COMMERCIAL PROPAGULES during the calendar year, permitted exclusions, NET SALES, LICENSE INCOME and the royalties due.  
4.6 Payments required under this Agreement shall, if overdue, bear interest at a per annum rate of one percent (1%) above the prime interest rate in effect on the due date, as reported in the Wall Street Journal, from the date the payment is due until it is received.  
5.1 The Parties acknowledge that the denomination for the subject variety is established as: [X].  
5.2 CERES shall use the denomination of the LICENSED VARIETY to identify that variety.  
5.3 CERES will determine a COMMERCIAL NAME for the LICENSED VARIETY under which the COMMERCIAL PROPAGULES of the LICENSED VARIETY will be marketed and sold.  
5.4 CERES may determine TRADEMARK(s) associated or intended for use with a LICENSED VARIETY. CERES shall be the owner of all rights in any such TRADEMARK, chosen, applied to, used or registered in association with the LICENSED VARIETY.  
Confidential Treatment Requested and the Redacted Material has been filed separately field with the Commission  
5. DENOMINATIONS, VARIETY NAMES, TRADE MARKS.
     CERES-IGER Collaboration Agreement    Page 62 of 756.1 CERES shall be responsible for multiplying propagating material of the LICENSED VARIETY within the TERRITORY and using commercially reasonable efforts to produce, market and sell the resultant COMMERCIAL PROPAGULES so as to ensure that COMMERCIAL PROPAGULES of the LICENSED VARIETY are commercially available in the United States and/or Europe in reasonable quantities and at a reasonable price no later than [X years — depends on propagation] from the Effective Date.  
6.2 CERES shall meet its own cost of promotion, trials and listing of the LICENSED VARIETY in the TERRITORY.  
6.3 CERES shall use reasonable endeavors to ensure that all COMMERCIAL PROPAGULES of the LICENSED VARIETY offered for sale by CERES, any AFFILIATED COMPANY or SUBLICENSEE shall meet the normally accepted standards of the propagule trade or certifying authorities relating to propagule quality within the relevant jurisdiction of the TERRITORY.  
6.4 CERES shall at all times comply with and abide by any governing law, rules, regulations, plant variety rights legislation or the like and/or requirements relating to the quality and sale of COMMERCIAL PROPAGULES of the LICENSED VARIETY in the relevant jurisdictions of the TERRITORY and shall use all reasonable commercial endeavors to obtain any necessary regulatory approvals for the LICENSED VARIETY.  
7.1 CERES will use commercially reasonable efforts to actively market the LICENSED VARIETY in the United States, and in CERES’ discretion, in other jurisdictions in the TERRITORY, wherein such efforts shall be appropriately reflected in the MARKETING PLAN.  
7.2 This provision shall apply after the third (3rd) anniversary of the market introduction of the LICENSED VARIETY in the United States propagated by a method that results in the LICENSED VARIETY being commercially competitive as compared to other energy crops being grown at that time in the United States. If IGER identifies a bona fide third party who presents a sound commercialization plan for the LICENSED VARIETY in a country or countries of the TERRITORY where the LICENSED VARIETY is not commercially developed by or through CERES, or an AFFILIATED COMPANY (“COUNTRY”), IGER will refer such opportunity to CERES by written notification and CERES will diligently investigate such opportunity. No later than one (1) year after the aforementioned notification from IGER, CERES will inform IGER in writing whether or not CERES wishes to commercialize the LICENSED VARIETY, directly or indirectly, in the COUNTRY. If CERES declines the opportunity entirely, without REASONABLE GROUNDS, IGER will be granted a non-exclusive license with the right to grant sublicenses to test, produce and sell the LICENSED VARIETY in the COUNTRY. If CERES informs IGER in writing that CERES is planning to commercialize the LICENSED VARIETY in all or part of the COUNTRY, directly or indirectly (whether or not through the third party identified by IGER), and CERES has not taken reasonable steps towards the implementation of such commercialization within two (2) years after so informing IGER, unless CERES informs IGER of REASONABLE GROUNDS for its failure or delay  
6. QUALITY AND PERFORMANCE REGULATIONS.
7. DILIGENCE.
     CERES-IGER Collaboration Agreement    Page 63 of 75to implement commercialization plans, IGER will be granted a non-exclusive license with the right to grant sublicenses to test, produce and sell the LICENSED VARIETY in the COUNTRY.  
“REASONABLE GROUNDS” shall mean any factors that a reasonable business person would view as too negative to justify the market opportunity in the light of usual legal business practices in the United States or Europe, including without limitation factors such as the risk that products will be sold below a normal market price, the risk that dumping will occur, the risk of cannibalization of other markets for the LICENSED VARIETY or of other products sold directly or indirectly by CERES, poor intellectual property protection or enforcement, no propagation method which allows the LICENSED VARIETY to be commercially competitive in that country, etc.  
7.3 CERES shall submit to IGER with its annual report under Article 4.5 a report of progress made by CERES (and any AFFILIATED COMPANY), directly or through its SUBLICENSEES, in achieving marketing goals of previous years and meeting the objectives of the MARKETING PLAN submitted and agreed upon for the TERRITORY. From time to time, but at least annually, CERES shall submit an amended and updated MARKETING PLAN.  
8.1 CERES shall keep and shall cause any SUBLICENSEE to keep accurate records of all production and sales of COMMERCIAL PROPAGULES of the LICENSED VARIETY in each country of the TERRITORY where such sales are made. These records will include, at least, the number of acres of LICENSED VARIETY COMMERCIAL PROPAGULES under production, the physical location of the LICENSED VARIETY production field owned or controlled by CERES, any AFFILIATED COMPANY or any SUBLICENSEE, the total amount of LICENSED VARIETY COMMERCIAL PROPAGULES produced, the total amount of LICENSED VARIETY COMMERCIAL PROPAGULES sold and all invoices or shipping documents relating to such sales.  
8.2 CERES shall allow an independent auditor, reasonably acceptable to CERES, appointed by and paid for by IGER to inspect the records of CERES and any AFFILIATED COMPANY pertaining to the LICENSED VARIETY for the exclusive purpose of verifying the accuracy of the reports provided. Any such audit shall occur no more frequently than annually. Any such inspection shall occur during normal business hours and after IGER has provided written notice at least ten business days prior to the date of the intended inspection. IGER agrees that it and its representatives will hold the information obtained from the inspection in confidence, and not use it for any purpose other than verification of the royalties required to be paid hereunder.  
9.1 Each Party shall notify the other of any suspected infringement of any INTELLECTUAL PROPERTY RIGHTS covering the LICENSED VARIETY. CERES will have the exclusive right, but no obligation, at its own discretion and expense, to take any action to enforce and to initiate and prosecute suits for infringement of the INTELLECTUAL PROPERTY RIGHTS. CERES and IGER will consult with each other upon a course of action and enforcement strategy. CERES will be responsible for the conduct of any such enforcement action, and IGER will reasonably cooperate with CERES to effect the enforcement action, and if appropriate, determine a settlement position. CERES shall be responsible for retaining counsel and shall promptly notify IGER following  
8. BOOKS, RECORDS AND RIGHT OF AUDIT.
9. ABATEMENT OF INFRINGEMENT.
     CERES-IGER Collaboration Agreement    Page 64 of 75retention of counsel, and IGER agrees to be represented by such counsel as may be required for any enforcement action or settlement. For purposes of settlement, CERES shall be the contact with the parties’ counsel as well as the opposing party(ies) and shall have the right to enter into settlements. CERES shall keep IGER advised as to all developments with respect to the enforcement action and settlement discussions, which includes supplying to IGER copies of all papers received and filed in sufficient time for IGER to comment thereon. IGER may attend any and all meetings with the parties’ counsel and the opposing side for settlement purposes. IGER agrees to voluntarily join in any action brought by CERES as a party plaintiff/defendant, if necessary, at the expense of CERES. If necessary, IGER agrees to enter into a joint defense agreement.  
9.2 Any damages received by the CERES as a result of an enforcement action of the INTELLECTUAL PROPERTY RIGHTS, after deduction of all enforcement related costs incurred by CERES, shall be considered as either NET SALES or LICENSE INCOME for the purpose of remuneration payments to IGER, to whichever the damages are reasonably deemed equivalent.  
10.1 As used in this Agreement, the term “Confidential Information” shall mean all non-public-information received by one Party from the other in the framework of this Agreement. Confidential Information can include, but is not limited to, information concerning the disclosing Party’s operations, research, processes, techniques, data, sales, marketing, promotion and other activities.  
10.2 From receipt to five (5) years after the disclosure of the relevant CONFIDENTIAL INFORMATION, the receiving Party shall not use, except (a) for the benefit of the Parties’ collaboration, or (b) such use as is expressly allowed by this Agreement, and/or disclose any Confidential Information to any third party without the prior written consent of the disclosing Party if the Confidential Information was received from the other Party, or the prior written consent of both Parties if the Confidential Information was generated during the performance of this Agreement, excepting that information described in Article 10.3. Confidential Information shall only be made accessible to each Party’s employees on a need-to-know basis.  
10.3 The receiving Party shall have no obligations of confidentiality for information that: can be established through written evidence to be in the possession of the receiving Party prior to the disclosure by the disclosing Party; is or becomes public knowledge through no fault of the disclosing Party; is acquired from others not under an obligation of confidentiality to the disclosing Party. In addition, CERES shall have the right to proceed to disclosures of Confidential Information (a) as required to file for INTELLECTUAL PROPERTY RIGHTS or registration, (b) as required to exercise its commercialization rights granted in or on the basis of this Agreement and for related marketing activities, (c) as required by laws, rules or regulation or court ordering such as, without limitation, SEC regulations, or (d) in CERES’ reasonable judgment, to (potential) investors and business partners.  
Any notices required to be given or which shall be given under this Agreement shall be in writing and delivered by overnight (trackable) courier addressed to the Parties as follows:  
10. CONFIDENTIALITY.
11. NOTICES.
     CERES-IGER Collaboration Agreement    Page 65 of 75Vice President of Product Development cc: Legal Department Ceres, Inc. 1535 Ranch Conejo Blvd. Thousand Oaks, California 91320 United States of America  
Institute Business Manager OR for legal or financial notices: Institute Secretary Institute of Grassland and Environmental Research Plas Gogerddan Aberystwyth Ceredigion SY23 3EB United Kingdom  
Notices under this Agreement sent by overnight courier by one Party to the other Party at its above address shall be deemed to have been given or made as of the date following the date so mailed.  
12.1 THE PARTIES ACKNOWLEDGE AND AGREE THAT NEITHER PARTY HAS MADE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.  
12.2 IN NO EVENT SHALL EITHER PARTY BE HELD RESPONSIBLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOSS OF PROFIT ARISING OUT OF THE USE OF ANY INTELLECTUAL PROPERTY RIGHTS COVERED BY THIS AGREEMENT, OR THE IMPLEMENTATION OF THIS AGREEMENT, EVEN IF SUCH PARTY IS ADVISED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES.  
12.3 Nothing in this Agreement shall be construed as:  
12. DISCLAIMERS.
  (a) a warranty or representation by either Party as to the validity or scope of any INTELLECTUAL PROPERTY RIGHTS, patent rights or plant variety rights;
  (b) a warranty or representation by either Party that anything made, used, sold or otherwise disposed of pursuant to any license granted under this Agreement is or will be free from infringement of patents of third parties;
  (c) any obligations by either Party to bring or prosecute actions or suits against third parties for patent infringement; and
  (d) a grant by implication, estoppel, or otherwise of any licenses under any intellectual property rights of IGER or other persons other than as provided in Article 2.1 hereof.     CERES-IGER Collaboration Agreement    Page 66 of 75Excluding those acts directly attributable to the negligence or willful misconduct of IGER, CERES agrees to indemnify, hold harmless and defend IGER, its trustees, officers, employees and agents and the breeders (as named in the INTELLECTUAL PROPERTY RIGHTS, if any) against any and all liability and/or damages with respect to any claims, suits, demands, judgments or causes arising out of (a) the production, development, storage, sale or any other use of the LICENSED VARIETY propagules and/or exercise of rights granted hereunder by CERES, its SUBLICENSEES, distributors, agents, representatives or AFFILIATED COMPANIES; (b) the use by end-users and other third parties of LICENSED VARIETY propagules; and/or (c) any representation, warranty or statement by CERES, its SUBLICENSEES, distributors, agents, representatives or AFFILIATED COMPANIES, concerning IGER, LICENSED VARIETY propagules or any INTELLECTUAL PROPERTY RIGHTS. In the event any such claims, demands or actions are made, CERES shall defend IGER at CERES’ sole expense by counsel selected by CERES and reasonably acceptable to IGER. IGER shall promptly notify CERES, in writing, of any such claims, suits or demands upon discovery and shall cooperate with CERES in the defense, provided that CERES shall have the right to lead the defense including entering into any settlement. CERES will keep IGER informed about the conduct of the defense and consult IGER regarding any settlement proposals.  
14.1 Neither Party shall publicize or disclose the terms of this Agreement without the prior written approval of the other Party, subject to the same exceptions as set forth in Article 10.3(a) through (d).  
14.2 The Parties intend to issue joint press releases regarding this collaboration. Any such press release and any press release by either Party will be subject to the prior written approval of both Parties; provided however, that (i) CERES shall have the right to otherwise disclose information as may be required in CERES’ judgment to comply with SEC regulations or other laws, rules or regulations governing disclosure of information and (ii) IGER shall have the right to otherwise disclose information as may be required in IGER’s judgment to comply with applicable regulations or other laws, rules or regulations governing disclosure of information. Notwithstanding the unilateral disclosure rights provided for in this article, the disclosing Party shall provide the other Party a copy of any such unilateral disclosure preferably prior to its release.  
15.1 All disputes, differences or questions arising out of or in connection with this Agreement, or related to the alleged breach, termination, validity, interpretation or violation thereof, shall be submitted for resolution to the Chief Executive Officer of CERES and the Director of IGER, who shall convene, whether in person or otherwise, to resolve such dispute through negotiation in a timely manner. Either Party may initiate a resolution procedure by providing written notice (“Dispute Notice”) to the other Party, and any such Dispute Notice must set forth the subject matter of the dispute, difference or question. If the dispute remains unresolved sixty (60) days after the Dispute Notice, either Party may initiate proceedings pursuant to Article 15.2.  
13. INDEMNIFICATION.
14. PUBLICITY AND USE OF NAMES.
15. DISPUTE RESOLUTION AND APPLICABLE LAW.
     CERES-IGER Collaboration Agreement    Page 67 of 7515.2 Dispute Resolution and Arbitration. In the event of any dispute arising out of or in connection with this Agreement, the Parties agree to submit the matter to settlement proceedings under the ICC ADR Rules. If the dispute has not been settled pursuant to the said Rules within forty-five (45) days following the filing of a Request for ADR or within such other period as the Parties may agree in writing, such dispute shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by three (3) arbitrators appointed in accordance with the said Rules of Arbitration. The provisions set forth hereinafter shall apply to the arbitration procedures, without prejudice to the ICC Rules of Arbitration.  
15.2.1 Qualifications of Arbitrators. Each arbitrator appointed shall have a reputation as being experienced in the legal and technical matters related to the dispute, shall be required to disclose, among other disclosures, any prior involvement with the legal and technical matters related to the dispute and any involvement with a competitor of any Party, and shall not be presently nor in the past have been affiliated with any Party or a competitor of any Party. Notwithstanding the method of their appointment, each arbitrator shall be required to meet the standards contained in the Rules with respect to independence.  
15.2.2 Location of the Arbitration. The seat of arbitration shall be Paris, France. The arbitrators may hold hearings at such other locations as the arbitrators shall determine, after consultation with the Parties.  
15.2.3 Language of Arbitration. The arbitral proceedings and all pleadings and written evidence shall be in the English language. Any written evidence originally in a language other than English shall be submitted in English translation accompanied by the original or true copy thereof  
15.2.4 Limitation on Remedies. The arbitrators are precluded from awarding punitive or exemplary damages. In no event shall the arbitrators have the powers of an amiable compositeur.  
15.3 Applicable law. This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York without regard to the principles of conflicts of law thereof.  
16.1 Subject to any other rights of termination under this Article, this Agreement shall remain in full force and effect until:  
16. TERM AND TERMINATION.
  (a) on a jurisdiction-by-jurisdiction basis, the expiration of the INTELLECTUAL PROPERTY RIGHTS in the respective jurisdiction covering the LICENSED VARIETY; or
  (b) in those jurisdictions in which the LICENSED VARIETY is sold but no INTELLECTUAL PROPERTY RIGHTS are obtained, the tenth (10th) anniversary of the date of the first sale of a LICENSED VARIETY in such jurisdiction.     CERES-IGER Collaboration Agreement    Page 68 of 7516.2 Each Party shall have the right to terminate this Agreement unilaterally by giving written notice of termination to the other Party if such other Party fails to satisfy its material obligations, which shall include but are not limited to, making required reports and making required payments, under this Agreement, and such Party subsequently fails to cure such failure(s) within (a) thirty (30) days for failures to remit payment for amounts due under this Agreement and (b) ninety (90) days for all other obligations after receipt of written notice from the non-breaching Party specifying such failure.  
16.3 IGER will have the right to terminate this Agreement unilaterally with thirty (30) days’ written notice to CERES, (a) if CERES seeks protection under any bankruptcy, insolvency, receivership, trust, deed, creditors arrangement or comparable proceeding or if any such proceeding is instituted against CERES (and not dismissed within one hundred twenty (120) days) or (b) in case of dissolution or winding up of CERES (excluding any situation where all or substantially all of CERES’ assets, stock or business to which this Agreement relates are acquired by a third party (whether by sale, acquisition, merger, operation of law or otherwise)).  
16.4 CERES may after consultation with IGER terminate this Agreement by written notice if in the commercially reasonable opinion of CERES the markets for the LICENSED VARIETY change or do not develop as anticipated, so as to render the production, promotion and sale of the LICENSED VARIETY uneconomical or impractical or if CERES decides to cease substantially all activities in MISCANTHUS.  
16.5 The Parties may terminate this Agreement at any time by mutual, written agreement.  
16.6 Termination of this Agreement for any reason will not relieve either Party of any obligation or liability accrued under this Agreement before termination or rescind any payments made or due before termination. Articles 8, 10, 11, 12, 13, 14, 15, and 17 will survive any termination of this Agreement.  
16.7 Termination of this Agreement shall not affect the rights and obligations of the Parties accrued prior to termination hereof.  
16.8 Upon termination of this Agreement, no existing SUBLICENSES granted by CERES or AFFILIATED COMPANIES to third parties shall be affected by such termination, and all such sublicenses shall remain in effect according to their terms, pursuant to the election of each SUBLICENSEE. IGER shall continue to be entitled to payments relating to such SUBLICENSES pursuant to this Agreement and such SUBLICENSES.  
16.9 Termination of this Agreement shall not prevent:  
  (a) IGER from recovering any royalties due as of termination; and
  (b) either Party from obtaining a remedy for any breach of the provisions of this Agreement.     CERES-IGER Collaboration Agreement    Page 69 of 7517.1 Entire Agreement/Modifications. This Agreement constitutes the entire agreement between the Parties hereto with respect to the subject matter hereof, and there are no representations, warranties, covenants or obligations except as set forth herein. This Agreement supersedes all prior and contemporaneous agreements, understandings, negotiations and discussions, written or oral, of the Parties hereto relating to the subject matter hereof. This Agreement may only be amended, modified or superseded by a writing executed by the authorized representative of the Parties hereto.  
17.2 Severability. This Agreement, to the greatest extent possible, shall be construed so as to give validity to all of the provisions hereof. If any provision of this Agreement is or becomes invalid, is ruled illegal by a court of competent jurisdiction or is deemed unenforceable under the current applicable law from time to time in effect during the term of this Agreement, the remainder of this Agreement will not be affected or impaired thereby and will continue to be construed to the maximum extent permitted by law. In lieu of each provision which is invalid, illegal or unenforceable, there will be substituted or added as part of this Agreement by mutual written agreement of the Parties, a provision which will be as similar as possible, in economic and business objectives as intended by the Parties to such invalid, illegal or unenforceable provision, but will be valid, legal and enforceable.  
17.3 Waiver. No failure or delay by either Party in exercising any right or remedy under this Agreement will waive any provision of this Agreement. Nor will any single or partial exercise by either Party of any right or remedy under this Agreement preclude it from otherwise or further exercising any rights or remedies which it may have, or any other rights or remedies granted by any law or any related document.  
17.4 Enforcement. In the event an action is commenced by either Party against the other to enforce any of the provisions of this Agreement, the prevailing Party shall be entitled to recover from the other Party reasonable attorneys’ fees, court costs and necessary disbursements incurred in connection with such action.  
17.5 Licensor-Licensee Relationship. The relationship of the Parties is that of independent contractors and licensor-licensee. Nothing herein is intended or will be construed to establish any agency, partnerships, or joint ventures. Neither Party has any authority to act for and/or to bind the other Party in any way or to represent that either is in any way responsible for the acts of the other, except as may be explicitly provided for herein or authorized by the non-acting Party in writing. Neither Party is authorized or empowered to act as an agent for the other Party for any purpose, nor shall either Party be bound by the acts or conduct of the other Party.  
17.6 Assignablility. This Agreement binds and enures to the benefit of the Parties, their successor or assigns, but may not be assigned by either Party without the prior written consent of the other Party; provided however, CERES shall have the right to assign its rights and obligations under this Agreement to any AFFILIATED COMPANY without such prior consent. Each Party shall have the right to assign its rights and obligations under this Agreement to a third party in conjunction with the transfer to such third party of substantially all of the assets of such Party associated with performance under this Agreement without such prior consent.  
17. GENERAL.
     CERES-IGER Collaboration Agreement    Page 70 of 7517.7 Force Majeure. No Party shall be responsible to the other Party for delay or failure in performance of any the obligations imposed by this Agreement, provided such failure shall be occasioned by fire, flood, explosion, lightning, wind storm, hailstorm, earthquake, subsidence of soil, failure of machinery or equipment or supply of materials, discontinuity in the supply of power, court order or governmental interference, terrorist attacks, civil commotion, riot, war, strikes, labor disturbances, transportation difficulties, labor shortage, natural genetic variation of any living matter or by any other cause of like or unlike nature beyond the reasonable control and without fault or negligence of such Party.  
IN WITNESS WHEREOF, IGER and CERES have caused this Agreement to be duly executed as indicated below.               INSTITUTE OF GRASSLAND  AND ENVIRONMENTAL RESEARCH   CERES, INC.
           By:       By:   
         
Name:     Name:  
         
Title:      Title:  
         
Date:      Date:  
         
           By:       By:   
         
Name:     Name:  
         
Title:      Title:  
         
Date:      Date:  
         
     CERES-IGER Collaboration Agreement    Page 71 of 75ANNEX I  INTELLECTUAL PROPERTY  
INTELLECTUAL PROPERTY RIGHTS for the LICENSED VARIETY  
JOINT INTELLECTUAL PROPERTY  
IGER INTELLECTUAL PROPERTY  
IGER BACKGROUND INTELLECTUAL PROPERTY       CERES-IGER Collaboration Agreement    Page 72 of 75ANNEX II MARKETING PLAN (Article 1.18)  
1.  TIMING
 
   The MARKETING PLAN is to cover a five year period and shall be reviewed annually with adjustments made for further five year periods in line with market conditions (or projections of the same) and the agronomic performance of the LICENSED VARIETY.
 
2.  POSITIONING
 
   An assessment of the potential of the LICENSED VARIETY in an identified market.
 
3.  PROMOTION
 
   Details of all project promotional activities, plus anticipated, related expenditures, that are intended to the LICENSED VARIETY achieves its maximum market potential.
 
4.  DISTRIBUTION
 
   Details of the proposed distribution network and activities for supporting the distributor or retailer plus anticipated promotion activities of the distributor/retailer. NOTE: If the anticipated distribution network includes the creation of a new COMMERCIAL PROPAGULES company, details regarding this important component should be included here.
 
5.  EVALUATION
 
   Details of planned evaluation and demonstration, if any.
 
6.  PROTECTION
 
   Anticipated intellectual property protection requirements.
 
7.  COMMERCIAL PROPAGULES SALES
 
   Estimated sales including grade of COMMERCIAL PROPAGULES, volume and price and country of destination.
 
8.  ROYALTY INCOME
  a.  Estimated royalty payments; and
 
  b.  Commencement date of payment.
9.  COMMERCIAL PROPAGULES PRODUCTION
 
   Estimated production, including grade of COMMERCIAL PROPAGULES, land area to be sown, estimated production and harvest date.     CERES-IGER Collaboration Agreement    Page 73 of 75EXHIBIT H  
to the Collaboration Agreement between IGER and CERES  
CERTAIN REMUNERATION PRINCIPLES  
1. If CERES uses germplasm that is IGER INTELLECTUAL PROPERTY or IGER BACKGROUND INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY to develop varieties of the COLLABORATION CROP outside the RESEARCH PROJECTS, the following guiding principles will apply to determine the remuneration due to IGER by CERES upon commercialization of such varieties:  
1.1 Royalty on NET SALES (defined as in EXHIBIT H) of varieties resulting from crosses of IGER INTELLECTUAL PROPERTY or IGER BACKGROUND INTELLECTUAL PROPERTY germplasm with CERES or third party or public germplasm:  
1.1.1 if the variety contains equal to or less than one hundred percent (100%) but more than seventy-five percent (75%) of IGER INTELLECTUAL PROPERTY or IGER BACKGROUND INTELLECTUAL PROPERTY germplasm where said germplasm’s genotype exists before the Effective Date of the CA, no further breeding or selection is done in any RESEARCH PROJECT and the variety is commercialized by rhizomes: [***] percent ([***]%)  
1.1.2 if the variety contains equal to or less than one hundred percent (100%) but more than seventy-five percent (75%) of IGER INTELLECTUAL PROPERTY or IGER BACKGROUND INTELLECTUAL PROPERTY germplasm in all cases not included in 1.1.1: [***] percent ([***]%)  
1.1.3 if the variety contains equal to or less than one hundred percent (100%) but more than seventy-five percent (75%) of JOINT INTELLECTUAL PROPERTY germplasm: [***] percent ([***]%)  
1.1.4 if the variety contains equal to or less than seventy-five percent (75%) but more than twenty-five percent (25%) of IGER INTELLECTUAL PROPERTY or IGER BACKGROUND INTELLECTUAL PROPERTY germplasm: [***] percent ([***]%)  
1.1.5 if the variety contains equal to or less than seventy-five percent (75%) but more than twenty-five percent (25%) of JOINT INTELLECTUAL PROPERTY germplasm: [***] percent ([***]%)  
1.1.6 if the variety contains twenty-five percent (25%) or less IGER INTELLECTUAL PROPERTY or IGER BACKGROUND INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY germplasm, but contains one (1) TRAIT that has been introduced through crossing from such germplasm: [***] percent ([***]%); if two (2) or more TRAITS introduced through crossing from such germplasm: [***] percent ([***]%)  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     CERES-IGER Collaboration Agreement    Page 74 of 751.1.7 in cases other than 1.1.1 through 1.1.6 no remuneration will be due (except if clause 2 hereinafter applies).  
2. If CERES uses IGER INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY other than germplasm to develop a product, a fair and reasonable remuneration will be due by CERES to IGER, taking into account the relative contributions of the Parties to the research, development, production, marketing and sales of the product. Upon CERES’ request, the Parties will negotiate diligently and in good faith to determine such remuneration for one or more particular inventions or products.  
3. Duration of royalty payments will be similar to what is provided in the model license agreement for non-transgenic varieties (non-UK) in EXHIBIT G.  
  “TRAIT” shall mean a valuable characteristic of a plant selected by CERES (e.g. drought tolerance, specific flowering time) where at least seventy percent (70%) of such characteristic is associated with no more than two (2) identified markers.
 
  1.2 Royalty on LICENSE INCOME (defined as in EXHIBIT H) — to be determined in function of business model.
     CERES-IGER Collaboration Agreement    Page 75 of 75AMENDMENT I  
to the Collaboration Agreement effective as of April 1, 2007 between Institute of Grassland and Environmental Research (“IGER”) and Ceres, Inc. (“CERES”) (the “Agreement”).  
Made in two (2) copies.  
Page 1 of 1  
  1.  The Parties agree to replace “sixty (60) days” by “two hundred ten (210) days” in Article 14.1 (e) (v) of the Agreement.
 
  2.  The Parties agree that this Amendment I is effective as of June 1, 2007.
 
  3.  For the remainder, the Agreement remains unchanged and this Amendment I shall form an integral part thereof.
                     INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH     CERES, INC.    By:   /s/ MERVYN HUMPHREYS     By:  /s/ RICHARD FLAVELL   Name: 
   
Professor Mervyn Humphreys    Name: 
   
Richard Flavell, CBE, FRS   
Title:  Director     Title:  Chief Scientific Officer                          By:  /s/ RICHARD HAMILTON   
       Name: 
   
Richard Hamilton   
       Title:  President and Chief Executive OfficerAMENDMENT II  
to the Collaboration Agreement effective as of April 1, 2007 between the Institute of Grassland and Environmental Research (“IGER”) and Ceres, Inc. (“CERES”), as amended (the “Agreement”) and to SCHEDULE 1 between the Institute of Grassland and Environmental Research (“IGER”) and Ceres, Inc. (“CERES”) and dated April 1, 2007, as amended (“Schedule 1”).  
WHEREAS, the Institute of Grassland and Environmental Research (“IGER”) and CERES entered into the Agreement and Schedule 1 on April 1, 2007;  
WHEREAS, on April 1, 2008 IGER merged with Aberystwyth University Institutes of Biological Sciences and Rural Sciences to form the new Institute of Biological, Environmental and Rural Sciences of Aberystwyth University (“AU”);  
WHEREAS, as a consequence of such merger, the Parties wish to substitute AU in place of IGER as a contract party to the Agreement;  
WHEREAS, AU and CERES wish to amend the Agreement, as set forth hereinafter.  
NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements contained herein and of other good and valuable consideration, the Parties have agreed and do hereby agree as follows:  
Page 1 of 2  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
  1.  The Parties agree that Aberystwyth University, a Higher Education Establishment registered in the United Kingdom No. RC000641, having an office at Old College, King Street, Aberystwyth SY23 2AX (“AU”) should be substituted as a contract party to the Agreement in place of IGER.
 
  2.  The Parties agree to amend Article 14.1 (e) (v) of the Agreement so as to read as follows:
 
     “(v) with thirty (30) days’ written notice to AU if Defra has not assigned to AU, or granted to AU a license reasonably satisfactory to CERES on, the Intellectual Property vested in Defra or the Crown or the Secretary of State pursuant to the DEFRA agreement NF 0426 within three (3) years from the Effective Date (the “Assignment/License”); provided however that Ceres will not unreasonably refuse to extend such three (3) year term by six (6) months if so requested by AU by December 31, 2009.”
 
  3.  The Parties agree to add the following clause in Article 6 of Schedule 1:
 
     “As long as the assignment or license grant by Defra to AU, and the corresponding grant of a license or sublicense to CERES in compliance with the Agreement, has not occurred, CERES will have the right to withhold [***]Made in two (2) copies.  
Page 2 of 2  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     percent ([***]%) of the funding payable by CERES to AU pursuant to Attachment B — Budget, attached to Schedule 1 (as this may be amended from time to time). CERES’ rights to withhold such payments will terminate:
  (i)  with respect to [***] percent ([***]%) of the funding, as of the date CERES effectively receives a license or sublicense satisfactory to CERES on CERTAIN MISCANTHUS ACCESSIONS (defined in Article 3.2.1 b. of the Agreement) and related information.
 
  (ii) with respect to [***] percent ([***]%) of the funding as of the date CERES effectively receives a license or sublicense satisfactory to CERES on the Intellectual Property vested in Defra or the Crown or the Secretary of State pursuant to the Defra agreement NF0426.”
  4.  The Parties agree that this Amendment II is deemed to have become effective as of May 1, 2008.
 
  5.  For the remainder, the Agreement and Schedule 1 remain unchanged and this Amendment II shall form an integral part thereof.
                     ABERYSTWYTH UNIVERSITY      CERES, INC.    By:  Name: 
/s/ S.G.A. DURBIN 
   
S.G.A. Durbin    
By: Name: 
/s/ RICHARD FLAVELL 
   
Richard Flavell, CBE, FRS  
 
Title:  Director, Risk & Research Finance     Title:  Chief Scientific Officer                   
 
 
 
 
 
By: Name: 
/s/ RICHARD HAMILTON 
   
Richard Hamilton  
 
       Title:  President and Chief Executive OfficerPages where confidential treatment has been requested are stamped ‘Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,’ and the confidential section has been marked as follows: [***].  
SCHEDULE 1—Plant Breeding, Markers, Composition, Agronomy and Propagation  
THIS SCHEDULE is made this 1st day of April, 2007.  
WHEREAS, CERES and IGER have entered into a Collaboration Agreement (“CA”), dated April 1, 2007, which allows for the undertaking of RESEARCH PROJECTS pursuant to SCHEDULES, these terms being defined in the CA; and  
THEREFORE, the Parties have agreed to undertake the following RESEARCH PROJECT as defined herein on the following terms and conditions:  
GENERAL  
RESEARCH PROJECT TITLE: Developing Miscanthus Cultivars for Use in Bioenergy Production  
Development of Miscanthus Species for Energy Crops — Scientific Overview  
Miscanthus species are capable of producing large quantities of biomass with minimal inputs over a wide geographic range. CERES and IGER aim to develop commercial biomass crops from leading Miscanthus lines via a collaboration with 2 major foci: I) propagation; and II) breeding. These are described in turn below.  
I. Propagation.  
The major barrier to profitable Miscanthus cropping is efficient and inexpensive propagation. In the UK, subsidy support makes [***] of Miscanthus x giganteus an economically viable planting method. This is not the case in [***], where there is no government support for the crop and initial [***] from which to generate planting material is extremely limited.  
It is not commercially feasible to produce Miscanthus on a large scale in [***] from traditional [***] schemes. Success of Miscanthus crops for large markets will be determined by development of  
CERES-IGER SCHEDULE 1  
Page 1 of 10  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     BETWEEN CERES, INC. (“CERES”), a Delaware corporation, having its principal place of business at 1535 Rancho Conejo Blvd., Thousand Oaks, CA 91320, United States of America, and    
 
INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH (“IGER”), a company limited by guarantee, registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom
A. Unless otherwise specified herein, the terms of the CA shall apply to this SCHEDULE.
 
B. In the event of any difference between the terms of this SCHEDULE and the CA, then the terms of this SCHEDULE shall prevail.
I.A. Rationale:cost-effective propagation technology, and the magnitude of success depends on the speed with which this technology can be developed.  
All other lines of crop development research in this collaboration will be dependent on success with propagation.  
To be successful, Miscanthus must be planted from small, homogenous propagules that can be cheaply and rapidly produced, flow-ably transported, stored for months and consistently emerge after planting. In theory, the best propagule for Miscanthus production is seed. However, propagation of Miscanthus from seed is complicated and difficult. Development of [***] Miscanthus varieties will be a [***] of the [***] of this collaboration.  
An alternative approach to seed in the short term is to [***] Miscanthus from [***] as is common in [***]. [***] is more feasible with decreasing [***] and has not been thoroughly explored in Europe. The potential of [***] should be investigated from both an applied and basic perspective. It was agreed that while the approach is more likely to work in [***], it should also include x [***] and at least initially [***].  
Development of [***] and [***] techniques for [***] Miscanthus cropping systems will utilize a combination of theoretical and applied methods in the lab, glasshouse and field.  
CERES-IGER SCHEDULE 1  
Page 2 of 10  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
I.B. Goal: Applied methods for effective [***] of Miscanthus hybrids.
    I.B.i. Objective 1: Identify [***] techniques and optimize them with existing hybrids.
 
    Methods: Screen [***], x [***] and other species at least initially for [***] ability with multiple techniques in a broad range of factorial field and glasshouse experiments. Glasshouse experiments can be conducted year-round at IGER and at CERES in Thousand Oaks, CA. Additional experiments may be conducted at other CERES locations added at a later date. Field experiments will be conducted [***] at IGER and begin in multiple locations in [***] during the three (3) year period of this SCHEDULE.
 
    I.B.ii. Objective 2: More basic genetic and physiological work aimed at characterising and understanding [***].
 
    Methods: A series of experiments into the [***] of [***] with a focus on inducing plant growth from [***] ([***] and [***]) [***]. Work should explore [***] cues ([***], [***], [***]) as well as [***] ([***]). Explore [***] and score in [***] if possible, to locate [***]. Evaluate candidate [***] (from Arabidopsis, [***] if possible and other species) promoting [***] frequency.
I.C. Goal: Applied methods for effective [***] of Miscanthus hybrids.
    I.C.i. Objective 1: Demonstrate potential of [***] and create protocols.
 
    Methods: Check [***] of [***] and [***] of a wide range of [***] in response to [***] and [***] with a combination of [***], glasshouse and finally field experiments. Interpret results in context of [***] range, genotype and [***] conditions under which the [***] was [***]. Produce guidelines for effective [***] and [***].
I.D. Goal: [***] based systems for rapid [***] of germplasm and plants to be used in [***].II. Breeding  
Miscanthus is an unimproved plant species with great potential as an energy crop. [***] has not yet been fully collected and characterized. Miscanthus species are capable of crossing with [***] — a characteristic that has long been exploited in [***] where Miscanthus germplasm is used to [***]. The use of Miscanthus for biomass is a relatively new area, thus initial collection and evaluation of germplasm may discover lines already suited to the commercial market, and will certainly provide the base for the breeding needed to develop [***] into dedicated bioenergy crops. This breeding programme will employ traditional methodology to [***] and [***] for traits of interest. Molecular markers will be developed to assist identification of traits and expedite development of elite lines. Major traits of interest include increased biomass production, altered composition for improved conversion to fuel, [***] tolerance and seed suitable to produce [***] ([***]) [***].  
As lines with commercial potential are identified they will be selected for direct field trialing at IGER and/or at CERES locations in [***] to speed up commercial variety development.  
CERES-IGER SCHEDULE 1  
Page 3 of 10  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
    I.D.i. Objective 1: Provide plants for [***] based [***].
 
    Methods: [***] plants using clean systems for shipment to [***] in accordance with international regulations.
 
    I.D.ii. Objective 2: Investigate [***] in [***] of lines potentially useful in breeding, including hybrids.
 
    Methods: Evaluate the [***] capacity of breeding line candidates in response to standard or improved [***] techniques.
 
    I.D.iii. Objective 3: Develop estimates of time and cost required to [***] plants in [***] based systems.
 
    Methods: Conduct a desk study to compare the costs/benefits and barriers associated with large scale [***] methodology including [***].
I.E. Goal: Proof of Concept field trials of research findings in target locations.
    I.E.i. Objective 1: Evaluate and optimize propagation techniques under commercially relevant conditions.
 
    Methods: Use IGER and CERES infrastructure for field trialing methods in the UK and at multiple locations in [***] and elsewhere. These should expand on research performed at IGER and test genotype by environment interactions, with a focus on potentially commercial genotypes.
 
    I.E.ii. Objective 2: Evaluate and optimize germplasm performance in the UK and in multiple [***].
 
    Methods: Use IGER and CERES infrastructure for field trialing at multiple locations in the UK, [***] and elsewhere. These should expand on research performed at IGER and test genotype by environment interactions with a focus on potentially commercial genotypes.
II.A. Rationale:
II. B. Goal: A complete and documented Miscanthus [***].CERES-IGER SCHEDULE 1  
Page 4 of 10  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
    II.B.i. Objective 1: [***] to [***] in [***].
 
    Methods: In accordance with international conventions, e.g., the Convention on Biodiversity (CBD), [***] Miscanthus [***] from the [***] of [***]. Document the phenotype and growing [***], using [***] to accurately record the [***]. [***] to [***] for [***] and subsequent phenotype documentation.
 
    II B.ii. Objective 2: Characterize full [***].
 
    Methods: Document the morphological, physiological and [***] of interest in the [***] using consistent phenotyping nomenclature and [***] compositional analysis. Develop molecular markers associated with phenotypic traits.
 
    II.B.iii. Objective 3: Assess relatedness of plants identified as useful parents for hybrids.
 
    Methods: Use molecular markers developed for traits of interest in combination with germplasm characterization data, particularly [***], to select parents with desired traits that are also likely to present [***].
 
    II.B.iv. Objective 4: Develop a dynamic warehouse to store data and develop systems to analyse data and support multidisciplinary collaborative research.
 
    Methods: IGER and CERES to consider best options for developing the database. Populate the database with the [***] and [***] information [***]. As germplasm is characterized, integrate phenotype and marker data and use to facilitate choice of promising [***] lines as well as inform the preparation needed to ensure [***] (e.g. [***]). As data become available from other components of the collaborative research, such as field trialing and conversion analysis, it will be added to the database to allow PIs to synergistically design next step experiments.
II.C. Goal: Improved Miscanthus hybrids for commercial use.
    II.C.i. Objective: Select improved parents.
 
    Methods: [***] within [***] using information from molecular markers and composition analysis to shorten and streamline the selection of parents. Cross between [***] and evaluate hybrids to identify improved parents.
 
    II.C.ii. Objective: Make crosses of selected [***] lines.
 
    Methods: Appropriate germplasm will be selected for crossing using the database decision tool. Plants will be [***] to [***] in glasshouses and [***] made both in the glasshouse and outdoors at IGER, depending on time of year. Improve efficiency of [***] and, for [***], [***]. Determine [***] — and [***]. Send seed of [***] candidates and [***] to CERES locations for trialing.
 
    II.C. iii Objective: Selection of superior [***].
 
    Methods: [***] will be transplanted to field. Important morpho-physiological traits will be recorded over [***] years after which the best genotypes will be selected, [***] and [***] into rhizomes. The value of early prediction of traits will be assessed. A mass selection reservoir (MSR) will be maintained as a safety net and to contain interesting genotypes that do not justify commercial development.CERES-IGER SCHEDULE 1  
Page 5 of 10  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
    II.C.iv. Objective: Field evaluation of hybrids.
 
    Methods: From rhizomes taken in iii, replicated trials will be established. After [***] (or [***]) years, the best genotypes will be provided to CERES to test at diverse locations for commercially relevant evaluation.
    II D. Goal: Improved Miscanthus Varieties.
 
    II.D.i. Objective: Explore new methods of breeding.
 
    Methods: Set up and test [***] in terms of [***] and [***]. Set up and test [***] in terms of [***] and [***] to determine whether [***] will be acceptable. The results will guide applications for the setting up of Plant Breeders’ Rights schemes.
3. RESEARCH AND DEVELOPMENT PLAN
   The RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE) contains:
  •  Research and evaluation activities to be performed by each Party in detail, including locations for such activities
 
  •  Timelines of such activities
 
  •  Goals, expected results and deliverables
 
  •  Milestones and go/no-go decision points, if applicable
 
  •  FTEs
4. LOCATION OF WORK:
   IGER Work:
 
   IGER laboratory and glasshouse facilities and properties at its Welsh location and potential subcontractor locations.
 
   CERES Work:
 
   Thousand Oaks, CA and potential subcontractor locations.
 
5. PHD LEVEL SCIENTIFIC STAFF:
 
   Dr. John Clifton-Brown (IGER) Dr. Iain Donnison (IGER)
 
   Dr. Richard Flavell (CERES) Dr. Bonnie Hames (CERES) Dr. Emily Heaton (CERES) Dr. Peter Mascia (CERES) Dr. Steve Thomas (CERES)
 
   The Parties agree to complete this list within three (3) months from the commencement date of this SCHEDULE.CERES-IGER SCHEDULE 1  
Page 6 of 10  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
6. FUNDING APPROVED:
 
   See attached Budget (Attachment B).
 
7. REPORTS:
 
   All reports shall be delivered to the MANAGEMENT COMMITTEE on or before the required delivery dates for the same.
 
   IGER and CERES will deliver at each quarterly MANAGEMENT COMMITTEE meeting (or annual meeting, as the case may be):
  •  Quarterly status update and FTE breakout based on attached planning document.
 
  •  Actual spending relative to budget.
 
  •  INTELLECTUAL PROPERTY generated during the period.
 
  •  Copies of slide presentations summarizing research progress (template attached as Attachment C to this SCHEDULE).
 
  •  Annual Report (compilation of slide presentations and quarterly minutes) (annual meeting).
   Additional information, if not specifically included in the delivered information (above), shall be delivered (or later provided, wherein the delivering Party shall indicate the delivery method and time) as supporting information at the related quarterly meeting, if available:
  •  Breeding records.
 
  •  Copies of field or glasshouse books and records.
 
  •  Copies of raw field trial data.
 
  •  Biological material, including [***] lines from crosses and/or [***].
8. REPORT DATES:
 
   Annual report: Due at annual meeting in January.
 
   Quarterly reports and information: Due at quarterly meetings of the MANAGEMENT COMMITTEE per the CA (e.g., April, July, October, January).
 
9. SUBCONTRACTORS AND LOCATIONS:
 
   Actual locations and work at the locations will be decided by the MANAGEMENT COMMITTEE at the quarterly meetings.
 
10. MAJOR CONSUMABLES TO BE PURCHASED:
 
   None designated at the commencement date of this SCHEDULE.
 
11. ASSETS:CERES-IGER SCHEDULE 1  
Page 7 of 10  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
   Not applicable.
 
12. INSURANCE:
 
   Not applicable.
 
13. INTELLECTUAL PROPERTY RIGHTS:
13.1 IGER Background Intellectual Property:
   See Attachment D. The Parties agree that Attachment D will be worked out in more detail and completed within thirty (30) days of the commencement date of this SCHEDULE.
  13.2. CERES Background Intellectual Property:
  •  Molecular markers
 
  •  Genome sequence information
 
  •  [***]
 
  •  [***] information
 
  •  Proprietary software
14. USE AND COMMERCIALIZATION RIGHTS:
 
   Controlled by CA. License agreements for non-transgenic varieties developed pursuant to this SCHEDULE 1 will be based on the Model License Agreement for Non-transgenic Varieties in EXHIBIT G to the CA.
 
15. CONFIDENTIALITY/PUBLICATION:
 
   Controlled by CA.
 
16. COMMENCEMENT/TERM:
 
   Commencement: April 1, 2007
 
   Term: Three (3) years provided however, at least one (1) year before the end of the term of this SCHEDULE, the Parties shall decide whether to extend it for one (1) or more years, with appropriate updates to the RESEARCH AND DEVELOPMENT PLAN (Attachment A), and FUNDING (Article 6 of this SCHEDULE).
 
17. PROVISIONS FOR EARLY TERMINATION:
 
   This SCHEDULE does not terminate automatically upon termination of the CA.CERES-IGER SCHEDULE 1  
Page 8 of 10  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
   This SCHEDULE shall expire pursuant to the terms set forth in this SCHEDULE, unless extended by the mutual agreement of the Parties, or unless sooner terminated in accordance with the following provisions of this Article:
   (a) mutual, written agreement of the Parties;
   (b) failure of one Party to satisfy its material obligations under this SCHEDULE, and such Party subsequently fails to cure such failure(s) within (i) thirty (30) days for failures to remit payment for amounts due under this SCHEDULE and (ii) ninety (90) days for all other obligations in each case after receipt of written notice from the non-breaching Party specifying such failure(s);
 
   (c) one (1) year’s written notice of termination by either CERES or IGER to the other Party in case either the terminating Party or the other Party ceases substantially all activities in the COLLABORATION CROPS;
 
   (d) IGER will have the right to terminate this SCHEDULE unilaterally with thirty (30) days’ written notice to CERES, (i) if CERES seeks protection under any bankruptcy, insolvency, receivership, trust, deed, creditors arrangement or comparable proceeding or if any such proceeding is instituted against CERES (and not dismissed within one hundred twenty (120) days); (ii) in case of dissolution or winding up of CERES (excluding any situation where all or substantially all of CERES’ assets, stock or business to which the CA relates are acquired by a third party (whether by sale, acquisition, merger, operation of law or otherwise)); (iii) with written notice to CERES, if CERES has failed in a substantial manner, three (3) years after either Party or the Parties jointly have developed a [***] method for Miscanthus that results in the crop being commercially competitive in the United States or in Europe as compared to other energy crops being grown at that time in the relevant geography, to implement the activities set forth in EXHIBIT F to the CA, and does not remedy such failure or offer a remediation plan which is reasonably acceptable to IGER within ninety (90) days after receipt of a written notice from IGER specifying such failure;
 
   (e) CERES will have the right to terminate this SCHEDULE unilaterally: (i) with thirty (30) days’ written notice to IGER if John Clifton-Brown or Iain Donnison cease(s) to be associated with IGER and the research activities associated with this SCHEDULE, and IGER has not replaced such person(s) within one hundred twenty (120) days by (a) person(s) reasonably acceptable to CERES; (ii) with ninety (90) days’ written notice to IGER, if the institutional mission, purpose, structure or funding of IGER would change substantially and adversely affect IGER’s ability to satisfy its obligations hereunder; (iii) with one (1) years’ written notice to IGER, if CERES has a documented compelling business reason to cease the collaboration, (for example, without limitation, lack of sufficient processing capacity for COLLABORATION CROPS within the expected timeframe in the United States; COLLABORATION CROPS are non-competitive with other biomass sources); (iv) with three (3) months’ prior written notice to IGER, such notice to be given no earlier than eighteen (18) months after the Effective Date of the CA, if no rights to commercialize (including determination of the compensation due upon commercialization) COLLABORATION CROPS germplasm provided by IGER which is included in the RESEARCH PROJECT covered by this SCHEDULE have beenCERES-IGER SCHEDULE 1  
Page 9 of 10  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
    secured to CERES’ reasonable satisfaction in compliance with the CBD; or (v) with thirty (30) days’ written notice to IGER if Defra has not assigned to IGER, or granted to IGER an exclusive license reasonably satisfactory to CERES on, the Intellectual Property vested in Defra or the Crown or the Secretary of State pursuant to the DEFRA agreement NF 0426 within sixty (60) days from the Effective Date (the “Assignment/License”), provided however that such termination may be for the entirety of this SCHEDULE or only for certain parts of the RESEARCH PROJECT covered by this SCHEDULE.
18. SPECIAL CONDITIONS:
  18.1 VARIETY RELEASE
   18.1.1 “RELEASE DATE” shall mean the date that CERES determines that a variety developed, tested and evaluated pursuant to the terms of this SCHEDULE is ready for release, wherein upon such decision, such variety will be formally released by IGER and CERES jointly (if the variety constitutes JOINT INTELLECTUAL PROPERTY) or by IGER (if the variety constitutes IGER INTELLECTUAL PROPERTY) or by CERES (if the variety constitutes CERES INTELLECTUAL PROPERTY).
 
    18.1.2 For the purposes of this SCHEDULE, CERES, on advice of the breeder(s) of each variety via the MANAGEMENT COMMITTEE, shall establish, in its sole discretion, an appropriate RELEASE DATE for such varieties.
 
   18.1.3 At or about the RELEASE DATE for a variety, CERES will determine a COMMERCIAL NAME for such variety under which the seed of the same will be marketed and sold. “COMMERCIAL NAME” means the complete, preferred name of a released variety under which it will be marketed and sold.
 
   18.1.4 The Parties agree that the development of new varieties will not always result in varieties that are commercially acceptable or releasable. Provided all Parties execute their respective obligations under this SCHEDULE in an appropriate and reasonable manner, no one Party shall be liable to the other for any refund or other recompense because no commercially acceptable new variety is produced.
  18.2 BBSRC project: Optimizing the development of the energy grass Miscanthus through manipulation of the flowering time.
    Reference to this project (“BBSRC grant”) is included in EXHIBIT E to the CA.
 
    The RESEARCH AND DEVELOPMENT PLAN in Attachment A hereto refers to certain activities to be conducted by IGER pursuant to the BBSRC grant. The Parties expressly acknowledge and agree that:IN WITNESS THEREOF this SCHEDULE has been executed on the date hereinbefore entered.  
CERES-IGER SCHEDULE 1  
Page 10 of 10  
  (i) the results of such activities shall constitute IGER INTELLECTUAL PROPERTY, and
 
  (ii) IGER may make certain data resulting from such activities publicly available in compliance with the BBSRC grant.
             INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH CERES, INC.          By:  /s/ M. Humphreys  By:  /s/ Richard Flavell
           
Name: Professor Mervyn Humphreys  Name: Richard Flavell, CBE, FRSTitle: Director  Title: Chief Scientific Officer              By:  /s/ Richard Hamilton
           
    Name: Richard Hamilton    Title: President and Chief Executive OfficerAttachment A - RESEARCH AND DEVELOPMENT PLAN   Breeding Project Plan
                                                                                                                                                                                             
  A   B       C     D     E     F    G  H   I    J    K   L  M   N   O   P  Q  R   S   T   U   V    W   X  Y   Z  AA  AB  AC  AD  AE  AF  AG   Ah  1      IGER     Task  Objective Comments         year 1                                                     year 2                                                        year 3                 2      Ceres                                     FTE     Ceres  [***]                IGER  [***]              FTE     Ceres  [***]                IGER  [***]                 FTE     Ceres  [***]   3      CIGER                                       1   2   3    4    5   6   7   8    9   10   11   12    1   2   3    4    5   6   7   8    9   10   11   12    1   2   3    4   4   1            [***]                                                                                                                                                                          5      IGER     [***]                                                                                                                                                                          6 
  
A
  
IGER
     
[***]
     
To capture important [***] to improve productivity and [***] (re [***] for climate change). Particular [***] are geographical including [***] where [***]. [***] can demonstrate Google map showing [***]  
The earliest this could be done in Oct/Nov 20[***]. It may be possible to continue to work with our [***] of 20[***]. Target countries are [***] (incl [***], [***] and [***]. EH would also like to know about ethnobiology. 
This needs to be included in the budget at £30-40K.
                                                                                                                                              7 
  
B
  
IGER
     
[***] 
 
Ensure these can be used without importation of disease outside [***] 
 
[***] will be inspected in Sept [***] by DEFRA. I have contacted DEFRA about [***] import and await a reply. [***] could be [***] in [***] to 1) fulfil [***] requirements 2) make a modest level of multiplication so that [***] can be compared on different sides of the [***].                                                                                                                                                       8 
     
IGER
     
Sample leaf material  
Detailed genetic analysis                                                                                                                                                               
                 from 1 rep, extract DNA, using markers                                                                                                                                                                               send to Ceres                                                                                                                                                                      9      Ceres     SNPmarker analysis  Evaluate material for                                                                                                                                                              
                         markers, send results to                                                                                                                                                                                        IGER                                        [***]                                                       [***]                                                          [***]10
  
C
  
IGER
     
[***] and send subset of about [***] to [***] for further evaluation. Decide which lines Nov 20[***]. Also see [***] sheet. 
 
Characterise morphological and physiological [***] relevant [***] in [***] 
 
This obviously would link to the Trials worksheet. It is practical to start identifying key material in 20[***] - which perhaps should be put [***].                                                                                                                                                       11     Ceres     Evaluate [***] in [***].                                                                                                                                                                       12
     
IGER
     
Identify G X E
 
Analyse if G has a [***] 
Completion may be beyond                                                                                                                                                       
                 interactions and effect in [***] [***] year workplan                                                                                                                                                      
                 identify climatic zones                                                                                                                                                                       13     IGER     Develop supporting          I guess we mean the                                                                                                                                                      
                 
techniques for phenotype          
protocols, which I suggest                                                                                                                                                       
                 
trials
         
we base on EMI. These can be                                                                                                                                                       
                                 
drawn up with statistical                                                                                                                                                      
                                 advice ro test 30 genotypes                                                                                                                                                      
                                 
well in advance of the [***]                                                                                                                                                      
                                 multiplication stage                                                                                                                                                       14  C  IGER     [***]                                                                                                                                                                       15     IGER     Dig samples of [***] key  Test [***] to [***]                                                                                                                                                               
                 Miscanthus genotypes                                                                                                                                                                       
                 from EMI plots, [***]                                                                                                                                                                       and transfer toConfidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
                 [***]                                                                                                                                                                       16     Ceres     [***] in [***] Test [***] and [***] in [***]                                                                                                                                                              17
  
D
  
CIGER JCB
 
WvA and
 
Obtain Commecialization Rights
 
Freedom to commercialize [***] developed in program                                                                                                                                                               18  2            Characterise                                                                                                                                                                                       A) existing and                                                                                                                                                                                       B) new [***] at                                                                                                                                                                      
                 IGER C) selected [***]                                                                                                                                                                                        in [***]                                                                                                                                                                       19
  
A
  
IGER
     
Assess phenotype trial (planted at IGER in April [***]) for morphological and physiological [***] relevant [***]. Include [***], [***] status etc in [***]. 
 
Record important morphometric characters including winter [***], spring [***], [***] to [***] spring [***] and summer [***] (incl [***]), [***]/ [***], [***] and intensity, [***] and [***], [***], [***], [***] and [***], visual assessment of [***]  
Scoring systems need to be transferable. Bar code reading needs to be investigated. 
 
This is the [***] year following [***] so the maturephenotype is ready for the 20[***] season. It should be repeated in 20[***] to check the impact of [***] in [***] 
                                                                                                                                              
     CERES-IGER SCHEDULE 1   April 1, 2007Attachment A - RESEARCH AND DEVELOPMENT PLAN   Breeding Project Plan
                                                                                                                                                                                              
   A   B       C   D   E   F  G H I J K L    M  N  O  P  Q  R  S  T  U  V  W  X    Y  Z  AA  AB  AC  AD  AE  AF  AG  Ah  AI  AJ    Ak  Al  AM  AN AO 20      IGER     Sample leaf material from 1 rep, extract DNA, send to Ceres
 Detailed genetic analysis using markers
 NB One sacc was received as four plants and may not be a clone
                          [***]                                               [***]                                               [***]                      
21      Ceres     SNPmarker analysis  Evaluate material for markers, send results to IGER
                                                                                                                                                               
22   B  IGER     New phenotype trial to be [***] 20[***] based on [***].NB [***] material will consist of [***] plants per [***] derived from [***].
 Characterise morphological and physiological [***] relevant [***] 
 We plan to follow the design of Phenotype Trial [***] above with the [***] at IGER. If [***] through [***] works (we have started this), we may get this trial started in June [***]. However, it is also likely planting will be delayed until May [***]. We could then include the [***] which should have cleared [***]. 
                                                                                                                                                       
23   3             [***] for [***]                                                                                                                                                                        
24      CIGER     Set [***] protocols for [***] analysis
 Method harmonization for future [***] analysis
                                                                                                                                                               
25      IGER     Sample whole plant material harvested at [***], analyze using [***], send [***] to Ceres
 More detailed [***] characterisation will reveal important [***]
 Samples to be taken for 20[***] spring harvest from [***] and [***] (this is earlier than ideal - and should be repeated in 20[***])
 SuperGen funds work on [***] phenotype trial for [***], [***] and [***]. CERES will provide added value to this (eg [***], [***], [***], [***], [***])
                                                                                                                                               
26      Ceres     Obtain [***] and/or [***] Enable review of IGER [***]                                                                                                                                                               
27      Ceres     Review [***] phenotype trial [***] and choose samples to analyze for [***] set
 Choose subset of samples to analyze with [***] from [***] x [***] reps = ~ [***]
 IGER will review as well as part of Supergen project. SuperGen will concentrate on combustion and gasification.
                                                                                                                                                       
28      IGER     Send selected samples to Ceres for [***] analysis
 Develop [***] sets at Ceres and IGER to harmonise [***] analysis
                                                                                                                                                               
29      CIGER     [***] analysis of samples for [***] of [***] models
 Develop models of biomass [***] to harmonise Ceres/IGER [***] analysis
                                                                                                                                                               
30      CIGER     [***] analytical methods 
 Protocol development and harmonisation so that [***] data sent to Ceres can be translated to [***] data as collected by Ceres.
 IGER can perform some [***] based assays for which [***] already exist ([***], [***], and [***] for calculation of [***] and [***]) or those being developed ([***] and [***]) however Ceres may wish to perform additional analyses and there will be a need to standardise protocols and equipment between sites at Aberystwyth and Thousand Oaks
                          [***]                                               [***]                                               [***]                      
31      Ceres     send [***] results from [***] set to IGER
         includes [***] results of the [***] set, the validation data for the [***] and the [***] of the [***] samples in 05 phenotype trial (total [***] x [***])
 Joint publication?                                                                                                                                               
32                 sample whole plant material, analyze using [***], send [***] to Ceres
 More detailed [***] characterisation will reveal important [***] 
                                                                                                                                                               
33      Ceres     Use developed model to determine [***] from [***]. Send results to IGER
 Provide timely detailed information on [***] of phenotype trial [***]
 May need additional samples to ensure accuracy/expand [***] set
                                                                                                                                                       
34      CIGER     Develop database and analytical tools to assist in making [***] 
 To assist [***] and recording of [***] data
 We are currently developing the tools to integrate different types of datasets and to query them.
 CERES and IGER to share inforamtion on this using both ITConfidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
decisions parties.35   4             [***]                                                                                                                                                              36   a  IGER     Plan [***] programme according phenotypic, genotypic and [***] data
 Make useful [***]  Use preliminary database as a decision support tool.                                                                                                                                                       
37      IGER     Plant maintenance and
         We prototyped large                                                                                                                                                       
                  set up including         containers in 20[***]. These                                                                                                                                                        
                  staggering of plant          lead to plants with more                                                                                                                                                       
                  development         [***] - improving the [***].                                                                                                                                                        
     CERES-IGER SCHEDULE 1   April 1, 2007Attachment A - RESEARCH AND DEVELOPMENT PLAN   Breeding Project Plan
                                                                                                                                                                                                   
  A   B        C     D   E     F    G  H  I  J   K   L  M  N  O  P  Q  R  S  T  U  V   W   X  Y  Z  AA  AB  AC  AD  AE  AF  AG  AH   AI  AJ  AK  AL  AM  AN  AO      
38     IGER     Carry out the [***] - a)          
[***] additional [***] for CERES ([***]) Sub-samples of [***] (if available) protected by agreement to be sent to Ceres to inform IGER selection.  (Material from                                                                                                                                                     
                 [***] glasshouses            
CIGER shall not be                                                                                                                                                     
                                    used to create                                                                                                                                                     
                                    CERES material.)                                                                                                                                                    
39     IGER     b) [***] (outside)                                                                                                                                                                             
40     IGER     c) [***] (inside)                                                                                                                                                                             
41     IGER     Development of [***]          a) [***] of [***]. With M.                                                                                                                                                                                             [***] this is easier. With                                                                                                                                                                                             M. [***] we have now                                                                                                                                                                                             modified the [***] on the                                                                                                                                                                                             glass house to follow the                                                                                                                                                                                                [***] - [***].                                                                                                                                                               42     IGER                     b) detached [***]                                                                                                                                                             43     IGER                     c) optimising [***] incl.                                                                                                                                                                                             [***] and [***]                                                                                                                                                             44     IGER                     d) [***] with [***]                                                                                                                                                            
45  b  IGER     Carry out and optimise [***] Increase [***] of [***] from [***] Optimise media and [***].                                                                                                                                                            
46     IGER     Make [***] x [***]  Make [***] [***] with [***] and [***]                                                                                                                                                                                             (JML to help?)                                                                                                                                                             
47     IGER     [***] from [***].  Obtain [***] for selection                                                                                                                                                                     
                         phase. Determine [***]- and                                                                                                                                                                     
                         [***] relationships                                  [***]                                               [***]                                               [***]                           
48  5  IGER     
Test alternative [***]          A step in [***]                                                                                                                                                             
                 systems as proof of                                                                                                                                                                                              principle                                                                                                                                                                             49     IGER     Plan [***] Produce [***] Make [***] in 20[***] using                                                                                                                                                                                             database for [***] etc.                                                                                                                                                                                             Include [***] if possible in                                                                                                                                                                                                20[***].                                                                                                                                                              
50     IGER     Carry out [***] in          The emphasis would be on                                                                                                                                                            
                 [***] chambers         [***] genotypes but we would                                                                                                                                                                                              test several [***] of [***],                                                                                                                                                                                             [***] and [***].                                                                                                                                                             
51     CIGER     Test [***], [***] and         see [***] tab for methodology                                                                                                                                                             
                 [***] characteristics                                                                                                                                                                            
52     CIGER     [***] and/or [***] from Evaluate [***] in IGER and [***]                                                                                                                                                                    
                 relevant [***] to [***]                                                                                                                                                                             
53     CIGER     Assess [***] in field  Determine if [***] is  Field scale phenotypic                                                                                                                                                                                     acceptable  assessments for above [***].                                                                                                                                                            
54  d  IGER     Create [***] Develop methods for large                                                                                                                                                                     
                         scale [***] with [***]                                                                                                                                                                                              advantages                                                                                                                                                                     55     IGER     Harvest [***]                                                                                                                                                                            
56     CIGER     [***] of [***] to [***]  Evaluate [***] in IGER and                                                                                                                                                                                                 [***]                                                                                                                                                                      
57     CIGER     
Assess phenotype in field  Record important                                                                                                                                                                    
                         
morphometric characters as described in 2A i.                                                                                                                                                                    
58     CIGER     Evaluate [***] relative Determine levels of [***],                                                                                                                                                                     
                 to [***] in field  [***] of [***]                                                                                                                                                                    
59  6            Selection from [***] To identify superior                                                                                                                                                                                              genotypes                                                                                                                                                                     
60     IGER     
Raise plants from [***] in Glasshouse Select best on basis of [***]                                                                                                                                                                    
61     IGER     Sample, extract DNA, Use marker analysis to aid [***]-[***] samples x                                                                                                                                                            
                 send to Ceres for marker selection  [***]-[***] markers.                                                                                                                                                                              analysis          Throughput of [***] needs to                                                                                                                                                                                             be confirmed. Include [***]                                                                                                                                                                                             trial, [***] x [***]                                                                                                                                                                                              material and [***] of all                                                                                                                                                                                             [***]. See marker section.                                                                                                                                                            
62     Ceres     SNP marker analysis  evaluate material for                                                                                                                                                                     
                         markers, send results to                                                                                                                                                                                              IGER                                                                                                                                                                     
63     IGER     Transplant to field                                                                                                                                                                             
64     IGER     Raise plants from [***]. Select [***]. [***] MORE [***] TO BE [***].Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
                 Also [***] to [***].                                                                                                                                                                             
65     CIGER     Assess phenotype Recaord important                                                                                                                                                                     
                         morphometric characters                                                                                                                                                                     
                         including winter [***],                                                                                                                                                                     
                         spring [***], [***] to [***]                                                                                                                                                                    
                         spring [***] and summer                                                                                                                                                                     
                         [***] (incl [***]),[***]/                                                                                                                                                                     
                         [***], [***] and intensity,                                                                                                                                                                     
                         [***] and [***], [***],                                                                                                                                                                     
                         [***], [***] and [***],                                                                                                                                                                     
                         visual assessment of [***]                                   [***]                                               [***]                                               [***]                           
     CERES-IGER SCHEDULE 1   April 1, 2007Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     Attachment A - RESEARCH AND DEVELOPMENT PLAN   Breeding Project Plan
                                                                                                                      
  A  B        C   D   E  F G  H  I  J  K   L   M  N  O  P  Q  R  S  T  U  V  W   X   Y  Z  AA  AB  AC  AD  AE  AF  AG  AH  AI   AJ  AK  AL  AM  AN  AO  66     IGER     Sample whole plant More detailed [***]                                                                                                                                                            
                material, analyze using characterisation will reveal                                                                                                                                                                             [***], send [***] to important [***]                                                                                                                                                                            Ceres                                                                                                                                                                     67     IGER     Select, [***] and [***] (or [***]          This depends on the successof the early morphometirc                                                                                                                                                    
                best genotypes for replicated trials.         selection. If selections                                                                                                                                                                    Interesting plants not         after year [***] are                                                                                                                                                                    quite making the grade         reliable reflection of the                                                                                                                                                                    will be transferred to a         mature phenotype, then we                                                                                                                                                                    mass selection          could start this in 20[***]                                                                                                                                                                    reservoir to continue          - making plots.                                                                                                                                                                     montoring for [***].                                                                                                                                                                    68     Ceres     Use developed model to Provide timely detailed                                                                                                                                                                            determine [***] from information on [***]                                                                                                                                                                            [***]. Send results to of [***].                                                                                                                                                                             IGER                                                                                                                                                                     69  7           [***] Trials          NEED TO DETERMINE WHAT IS                                                                                                                                                     
                                DONE OUTSIDE [***] PROGRAM                                                                                                                                                                     Small plot yield                                                                                                                                                                                    assessments in                                                                                                                                                                                     replicated ([***] or                                                                                                                                                                                    [***]) single or                                                                                                                                                                                    multiple rows ([***]) of                                                                                                                                                                                    [***] or [***] plants         Promising lines to be [***].                                                                                                                                                                    per row, depending on To test [***] on an area Connects to [***] and                                                                                                                                                    70     IGER     [***] on [***].  basis and scale up Trialling project schedules                                                                                                                                                    71     IGER     After [***] years, the         I suspect we will need help                                                                                                                                                                    best genotypes will be         from [***] to multiply                                                                                                                                                                    provided to [***] and          promising plants for                                                                                                                                                    
                UK for testing at [***]         agronomic trials since [***]                                                                                                                                                                     locations as part of         is [***] only about [***]                                                                                                                                                                    [***] relevant          [***] after [***] growing                                                                                                                                                                    evaluation.          seasons.                       [***]                                               [***]                                               [***]                       72     IGER     Evaluate green cut of                                                                                                                                                                                    Miscanthus in terms of                                                                                                                                                                                    [***], [***] and [***]                                                                                                                                                                    73     IGER     To investigate [***]         Several suitable [***] were                                                                                                                                                                                    not tested in 20[***]                                                                                                                                                                                    application.                                                                                                                                                     74     IGER     To investigate methods         This is practical issue and                                                                                                                                                                    of preventing [***] at         may be sorted by [***] or                                                                                                                                                                    field borders (applies         more likely by [***]                                                                                                                                                                    to M. [***])                                                                                                                                                                     75  8           Project Management                                                                                                                                                                                                    Telemeetings would be fine                                                                                                                                                                                    every quarter - with an                                                                                                                                                    76              Telemeetings          annual visit.                                                                                                                                                     77              Face to face meetings                                                                                                                                                                    
78              Reporting          based on these project plans                       [***]                                               [***]                                               [***]                       
     CERES-IGER SCHEDULE 1   April 1, 2007Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     Attachment A - RESEARCH AND DEVELOPMENT PLAN   Marker Project Plan
                                                    
       IGER                                          
       CERES           year 1          year 2          year 3     
       CIGER           FTE   Ceres [***]  IGER [***]  FTE FTE  Ceres [***]  IGER [***]  FTE   Ceres [***]  IGER [***]
 1     Marker Development ( Year 1-)    Objectives  Notes   1 2 3 4   5 6 7 8   9 10 11 12   1 2 3 4   5 6 7 8   9 10 11 12   1 2 3 4   5 6 7 8   9 10 11 12 A  
 
Identify target [***] for mapping 
including [***], [***], 
[***], [***], [***], [***], [***], 
[***]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 B  
 
Compare and share candidate gene 
sequences. Use [***] and 
proprietary gene databases to 
predict Miscanthus variants of 
genes of interest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C  
 
Agree on joint list and determine 
long-term strategy including 
complementation of BBSRC funded 
work  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 D  
 
Grow plants of [***] and mapping 
[***]. Take samples from [***]. 
DNA extractions to be made at 
IGER using Autogen and sent to 
Ceres  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
a) [***] Planted April [***]; grow 
out in field  
 
 
 
 
[***]
 
 
 
 
 
[***]
 
 
 
 
 
[***]
 
 
 
 
    
 
[***] planted April [***]; sample, 
extract, send DNA to Ceres  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
b) ~[***] in November [***], timing 
dependent on [***]; grow plants in 
field  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
~[***] in November [***], timing 
dependent on [***]; sample, 
extract, send DNA to Ceres  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
c) [***] mapping [***] individuals, 
for [***]; grow plants in field  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
[***] mapping [***] individuals; 
sample, extract, send DNA to 
Ceres  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
d) [***] ([***]), for [***], [***], 
[***] and [***]; grow plants in field 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
[***] ([***]; [***] + [***] plants); 
sample, extract, send DNA to Ceres  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
e) [***] ([***]), for [***], [***]; 
grow plants in field  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
[***] ([***]; [***]); sample, 
extract, send DNA to Ceres  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 E 
 
DNA to be used at IGER for AFLP 
analysis (a and b above)  
 
determine 
[***] 
diversity 
and [***] 
structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     CERES-IGER SCHEDULE 1   April 1, 2007Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     Attachment A - RESEARCH AND DEVELOPMENT PLAN   Marker Project Plan
                                                    
       IGER                                          
       CERES           year 1          year 2          year 3   
       CIGER           FTE   Ceres [***]  IGER [***]  FTE FTE  Ceres [***]  IGER [***]  FTE   Ceres [***]  IGER [***]
 F  
 
Define primers [[***] to be tested] 
for “[***]” carefully selected and 
agreed genes such that PCR [***] 
can be sequenced and results 
unequivocally interpreted.   
Develop 
markers 
for 
consensus 
genes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 G  
 
Evaluate polymorphisms in selected 
[***]. Assay ~[***] DNA samples 
from [***] in a) c) d) and e) 
supplied by IGER to search for 
SNP polymorphisms in [***] genes 
using primers, PCR and 
Sequencing. Define additional [***] 
(?)primers for genes that show 
insufficient polymorphisms in key 
materials  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
Evaluate polymorphisms in selected 
[***]. Assay ~[***] DNA samples 
from [***] in [***] supplied by 
IGER to search for SNP 
polymorphisms in [***] genes using 
primers, PCR and Sequencing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 H 
 
Compare and share strategies for 
association mapping  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 I  
 
Conduct association mapping with 
field phenotype data for a) Conduct 
association mapping with [***] and 
field phenotype data for b)   
 
 
 
 
[***] 
 
 
 
[***] 
 
 
 
 
 
[***]
 
 
 
 
 
 
 J  
 
DNA to be used at IGER for SSR 
analysis using primers from [***], 
[***] and [***] (BBSRC [***] 
grant) ([***] and [***] from [***] 
and [***])   
integration 
of [***] 
maps
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 K 
 
Construct private and public [***] 
maps and associate marker 
polymorphisms with [***] in [***] 
and mapping [***]. [***]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 L 
 
Review results, write-up in 
confidential reports and non-
confidential papers and devise 
strategies for implentation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2  
 
Marker validation and 
implementation (Year 2-)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A  
 
Phenotype mapping [***] for the 
target [***] selected in 1A (start in 
year [***] to enable early 
morphometric analyses) and grown 
in 1D  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 B  
 
Map [***] and relate to markers 
particularly those derived from 
candidate genes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     CERES-IGER SCHEDULE 1   April 1, 2007Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     Attachment A - RESEARCH AND DEVELOPMENT PLAN   Marker Project Plan
                                                    
       IGER                                          
       CERES           year 1          year 2          year 3   
       CIGER           FTE   Ceres [***]  IGER [***]  FTE FTE  Ceres [***]  IGER [***]  FTE   Ceres [***]  IGER [***]
 3  
 
Develop new mapping [***] of >
[***] plants  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A  
 
Agree on [***] for new mapping 
[***]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 B  
 
Assess results of [***] for target 
[***]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C  
 
Grow and phenotype new mapping 
[***] for agreed [***]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 D  
 
make maps from new [***] from 
mapping [***] d) and e)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4  
 
Use markers ‘routinely’ in the 
[***] programme  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A  
 
Assess relatedness of plants as 
useful [***] in [***] program based 
on correlations with [***], 
conclusions from Items 1-3 and 
[***] data and [***] in field  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 B  
 
IGER to extract DNA from [***] 
of [***] for marker analysis  
 
 
 
 
[***]
 
 
 
 
 
[***]
 
 
 
 
 
[***]
 
 
 
 
 C  
 
Assay all [***] from all [***] for a 
subset of markers ( [***]) based on 
results from Items1-3, [***] 
required and [***] of plants in field. 
Aim is to discover if we can [***] 
many of the [***] early on from 
marker work.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 D  
 
Compare performance of using 
markers on [***] of [***] from the 
[***] programme with [***] where 
no markers are used  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5  
 
Functional analysis of target genes 
which map to [***] (from 
association or QTL mapping)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A  
 
Q-PCR using a range of [***] 
from selected genotypes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 B  
 
[***] of Miscanthus with selected 
target genes which map to [***]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6  
 
Development of BAC libraries 
(BBSRC)  
 
Identification 
of [***] gene 
sequences 
and 
generation of 
a physical 
map  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     CERES-IGER SCHEDULE 1   April 1, 2007Attachment A - RESEARCH AND DEVELOPMENT PLAN  Propagation Project Plan
                                              
   IGER  Consultant      year 1           year 2           year 3    
   Ceres  CIGER       FTE   Ceres [***]   IGER [***]   FTE   Ceres [***]   IGER [***]   FTE Ceres [***]
 Task  Objective  Comment    1 2 3 4   5 6 7 8  9 10 11 12  1 2 3 4  5 6 7 8  9 10 11 12  1 2 3 4  5
1  [***]                               
A
 
Assess [***] for 
[***]  
 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Quantify [***] 
number and size 
by [***] 
individual [***] 
from 
 
Assessing [***] 
and [***] in 
[***] 
 
Investigate 
[***] 
conditions 
to dicipher 
G x E 
impacts on 
[***]   [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
a) in the 
20[***] [***] 
Trial 
at IGER  
Existing range of 
[***] in [***], 
[***] 
 
Mature 20
[***] 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
b) 20[***] 
[***] as [***] 
 
new range of 
[***] in [***], 
[***]  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
c) from 
20[***] [***] 
in 
field / glasshouse 
at IGER  
new range 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
d) on [***] 
([***] and [***] 
from [***] to 
[***])  
[***] 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]           [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
[***] to [***] number of [***] plants 
 
Increase the 
identified 
promising 
genotypes 
for [***]  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]           [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
B
 
A series of field 
relevant 
experiments to 
guide Best 
Management 
Practices  
Demonstrate 
potential of [***]
and create 
protocols. Find 
[***] associated 
with [***]  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
[***] from all 
[***]  
 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Typically [***] 
from each [***] 
which are [***] 
in trays for 
raising [***] for 
field selection 
will be 
monitored. We 
intend to datalog 
[***] (order for 
equipment in 
progress)  
To screen all 
[***] for [***] 
and rate of [***] 
under monitored 
[***] 
 
Year 1 
data will 
be less 
detailed 
than in 
later 
years. 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Greenhouse /CE
experiments to 
investigate [***]
best practice 
 
to determine 
[***] in [***] 
under controlled 
[***] and 
optimise [***]  
depends on 
a PhD 
student 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Test [***] on 
[***] of selected
genotypes 
 
Characteristaion 
of [***] 
conditions to 
stimulate [***] in
different 
genotypes. This 
provides 
information 
about [***] 
where [***] 
could be 
considereds 
(based on [***]). 
 
One can 
test [***] 
over [***] 
days of 
[***] 
genotypes 
(each in 
one lane) 
at [***] 
different 
[***] 
([***] has 
[***] 
wells). 
[***] per 
[***] 
therefore 
we can 
only do this
with 
genotypes 
that 
produce >
[***].   [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Field bed 
preparation 
([***]) 
at [***] (use 
[***] 
as a control)  
scale up to real 
conditions 
including effect 
of [***] & [***] 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Record [***] & 
[***] 
 
relate 
laboratory tests 
to field 
conditions  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Monitoring 
[***] + winter 
[***]  
ensure proper 
quantification of 
conditions  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
     CERES-IGER SCHEDULE 1   April 1, 2007Confidential Treatment Requested and the Redacted Material has been separately filed with the CommissionAttachment A - RESEARCH AND DEVELOPMENT PLAN  Propagation Project Plan
                                              
   IGER  Consultant      year 1           year 2           year 3    
   Ceres  CIGER       FTE   Ceres [***]   IGER [***]   FTE   Ceres [***]   IGER [***]   FTE Ceres [***]
 
Development 
of [***] 
techniques 
 
Precision 
[***] 
considerations.
Optimising 
[***] and 
[***] at field 
scale.  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]           [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
2  [***]         [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Establish [***] 
capacity of 
certain 
genotypes and 
protocols  
Identify [***] 
amenable lines.
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Send lines to 
external 
contractor for 
[***].  
[***] 
promising 
[***] lines 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Send [***] to 
Ceres 
 
Provide [***] 
successfully 
produced in 
[***] 
program for 
additional  
dependent 
on [***] 
success 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
3 
 
[***] 
 
Demonstrate 
potential of 
[***] and 
create 
protocols. 
Explore timing 
of basic 
research to 
inform applied 
work.  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
A Applied [***]         [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
visit global 
[***] experts 
 
benefit from 
expertise and 
tie into the 
project 
([***])  
done 
during 
[***] trip 
to [***] 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
[***] global 
experts visit 
IGER  
benefit from 
expertise 
([***])  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Expert 
Consultancy 
([***]) 
 
provide 
guidance 
for [***] 
projects, 
possibly advise 
student  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
gather 
information to 
develop field 
and glasshouse 
protocols  
 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
assess [***] in 
Miscanthus 
[***] 
characteristics 
of [***] and 
[***] 
 
optimise [***], 
inform [***] 
 
20[***] 
assessment
will be 
include 
[***]. 20
[***]+ 
[***] will 
be [***]   [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
treatments to 
[***], e.g. 
[***]  
optimise [***] 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Glasshouse 
tests of [***] 
growth 
conditions 
 
to predict 
conditions in 
which 
[***] can be 
used  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Field tests of 
[***] 
 
survivorship of
[***] plants 
and G by E 
interactions  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Iterative field 
testing of [***] 
techniques 
 
Evaluate field 
suitability of 
[***] 
techniques  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
B
 
Basic [***] 
Research  
 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Assess [***] 
leading to 
[***] growth 
 
develop 
articicial [***] 
of [***] 
growth and 
[***]  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Assess [***] 
cues leading to 
[***] growth. 
 
develop 
articicial [***] 
of [***] 
growth and 
[***]  
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
4  [***]/[***]         [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
A
 
[***] Lines, 
[***] lines  
 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
 
Desk study of 
state of art in 
industry  
 
 
 
  [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
Discuss with 
PM what couldConfidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
 
be done quickly 
to demonstrate
feasibility       [***] [***] [***] [***]  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
     CERES-IGER SCHEDULE 1   April 1, 2007Attachment B - Budget 
* See page 2  
Page 1  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
             
    2007/8   2008/9   2009/10
No of Months   12.00   12.00   12.00
SALARY   [***]   [***]   [***]NI [***]%   [***]   [***]   [***]super [***]%   [***]   [***]   [***]PAY COSTS   [***]   [***]   [***] OTHER RECURRENT            CONSUMABLES   [***]   [***]   [***]CONSUMABLES MOLECULAR BIO   [***]   [***]   [***]CASUAL & OVERTIME   [***]   [***]   [***]TRAVEL & SUBSISTENCE   [***]   [***]   [***]STUDENTSHIP (PhD)   [***]   [***]   [***]SUB- TOTAL   [***]   [***]   [***] OTHER COSTS            ESTATES COST   [***]   [***]   [***]RECRUITMENT   [***]   [***]   [***]ANALYTICAL CHEMISTRY   [***]   [***]   [***]CONTROLLED ENVIRONMENT   [***]   [***]   [***]BIOINFORMATICS   [***]   [***]   [***]ULTRASTRUCTURE & IMMUNOLOGY   [***]   [***]   [***]MASS SPECTOMETRY   [***]   [***]   [***]SEQUENCING   [***]   [***]   [***]EXTENSION TECHNOLOGIES   [***]   [***]   [***]TRANSFORMATION TECHNOLOGIES   [***]   [***]   [***]SEED STORE   [***]   [***]   [***]ROAD VEHICLES   [***]   [***]   [***]AGRI VEHICLES   [***]   [***]   [***]FARM   [***]   [***]   [***]GLASSHOUSE   [***]   [***]   [***]SUB CONT   [***]   [***]   [***]TOTAL OTHER COSTS   [***]   [***]   [***] OVERHEAD COSTS*            ESTABLISHMENT SERVICES   [***]   [***]   [***]ADMIN SERVICES   [***]   [***]   [***]INSTITUTE & SITE MANAGEMENT   [***]   [***]   [***]FEC NOTIONAL INSURANCE   [***]   [***]   [***]CAPITAL CHARGE   [***]   [***]   [***]DEPARTMENT   [***]   [***]   [***]TOTAL OVERHEAD COSTS   [***]   [***]   [***]TOTAL   [***]   [***]   [***]CERES payment for reasonable perf   [***]   [***]   [***]CERES payment for full completion   [***]   [***]   [***]TOTAL paid by CERES   [***]   [***]   [***]SURPLUS OVER TOC   [***]   [***]   [***]
 
     CERES-IGER SCHEDULE 1   April 1, 2007Attachment B — Budget  
This Budget is agreed upon for contract years 1 through 3. A contract year (“Year”) is April 1 — March 31, starting April 1, 2007. CERES agrees to provide funding for IGER’s RESEARCH PROJECT activities covered by this SCHEDULE in accordance with Article 1.8 of the CA as set forth in the Budget in page 1 of this Attachment B, taking into account what is provided hereinafter. Pay Costs, Other Recurrent and Other Costs are as in the Budget. Overhead Costs will be payable as follows:  
Page 2  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
  -  Each contract year CERES will pay [***]% of the overheads asked, (e.g. of the [***] pounds in Year 1), for the expected reasonable performance in the various aspects of the program Year by Year and especially for all the items listed in the attached document. This [***]% amounts to [***] pounds in contract Year 1.
 
  -  Furthermore, CERES will pay for Year 1 an additional [***]% of the asked overhead ( i.e.[***]% in total of the asked overhead) for full completion of the Year 1 items A and B listed hereinafter. This additional [***]% equals [***] pounds.
 
  -  For Year 2 CERES will pay an additional [***]% of the overhead costs asked for full and successful completion of Year 2 items A and C hereinafter.
 
  -  For Year 3 CERES will pay an additional [***]% of the overhead costs asked for full and successful completion of Year 3 items A, B, C and D listed hereinafter.
 
  -  The MANAGEMENT COMMITTEE will bring forth recommendations to the Parties at the beginning of each Year for the items that IGER should satisfy to obtain extra overheads, outlined in the framework above.
 
  -  Assessment on achievements of the nominated items will be made at the end of each Year by the MANAGEMENT COMMITTEE and recommendations made to the Parties. Upon agreement, CERES will respond to an invoice from IGER as agreed. Should some items in a section not be achieved then the amount paid will be reduced on a pro-rata basis on the number of items in the section.     CERES-IGER SCHEDULE 1   April 1, 2007Attachment B — Budget  
Suggested milestones, for discussion, for full overhead payments  
The Parties agree to finalize this document within thirty (30) days from the commencement date of this SCHEDULE.  
Year 1 (April 1 to March 31):  
A. [***] research to create an economically viable business  
1. [***] and [***] variation affecting [***] amongst available (numbers?) [***] and their behaviour through the season/[***] reported; any clear winners [***]  
2. [***] and [***] variation affecting [***] (numbers?) [***] and early [***] across different [***] and [***] reported; any clear leaders [***] and sent to Ceres  
3. XXX [***] of Miscanthus [***] ([***]?) (good [***]) with Miscanthus [***] made and followed by [***] where necessary. [***] of [***] sent to Ceres by early 20[***].  
4. First [***] of [***] x [***] made based on results from 20[***] field [***] and [***]  
B. [***] to Ceres to help [***] in [***] as early as possible  
1. [***] of latest [***] of [***] from [***] via [***] (how many?) sent into [***] in 20[***] when requested by Ceres  
2. Selected set of promising [***] including [***] lines and [***] trialled to date sent to Ceres in [***] in 20[***] for trial in [***]  
3. Samples of [***] of Year 1 [***] sent to Ceres, including a sample of [***] (Numbers of [***]?)  
4. Approximately [***] from [***] (how many?) occurring in the field in 20[***] believed to be [***]x x [***]x sent to Ceres  
C. Advancing the [***] assisted [***] program as early as possible  
1. DNA from about [***] plant [***] phenotyped in the field since 20[***] and first [***] delivered to Ceres in 20[***].  
2. DNA from about new [***] plant [***] in [***] in 20[***], other [***] and other selected [***] delivered to Ceres in 20[***]  
D. Advancing the [***] program  
1. xxx new [***] of [***] x [***] made based on phenotypes and presumed [***]  
2. xxx [***] of M [***] x other made  
Page 3  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     CERES-IGER SCHEDULE 1   April 1, 2007Attachment B — Budget  
3. [***] phenotype/[***] assessments of material in [***] since 20[***] reported and correlations made with assessments in years 1 and 2 and with [***]  
E. Advancing [***] research  
1. Samples (how many?) and [***] (how many?) sent to Ceres  
F. Enhancing [***]  
1. Additional [***] made and materials brought into [***] in IGER to fill in specific [***] needed for likely commercialization locations  
Year 2 (April 1 to March 31):  
A. [***] research to create an economically viable business  
1. [***]/[***] variation affecting [***] amongst large range of [***] (numbers?) and their behaviour through the season/[***] reported; any clear winners [***]  
2. [***]/[***] variation affecting [***] (numbers?) [***] and early growth across different [***] and [***] reported; any clear leaders [***] and sent to Ceres  
3. XXX [***] of Miscanthus [***] ([***]) (good [***]) with Miscanthus [***] made and followed by [***] where necessary. [***] of [***] sent to Ceres by early 20[***].  
4. Next [***] of [***] x [***] made based on results from 20[***] field [***] and [***]  
5. Synthesis of best practice for [***] of miscanthus based on [***] and [***], [***] and other methods to meet market costs and commercialization in different geographies  
B. [***] to Ceres to help [***] in [***] as early as possible  
1. Approximately [***] from [***] occurring in the field in 20[***] believed to be [***]x x [***]x sent to Ceres  
2. Samples of [***] of Year 2 [***] (numbers?) sent to Ceres, including a sample of [***]  
3. Promising selected genotypes from [***]/[***]/[***] program [***] in [***] and sent to Ceres  
C. Advancing the [***] assisted [***] program as early as possible  
1. DNA from relevant [***] from [***] program, [***] etc delivered to Ceres in 20[***]  
2. Preliminary phenotyping of [***] in field and preliminary [***] made with Ceres  
3. [***] and [***] aligned with [***] and [***] and [***]  
Page 4  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     CERES-IGER SCHEDULE 1   April 1, 2007Attachment B — Budget  
D. Advancing the [***] program  
1. xxx new [***] of [***] x [***] made based on phenotypes, presumed [***], [***] and other characters  
2. xxx new [***] of M [***] x other made  
3. [***] phenotype/[***] assessments of material in [***] since 20[***] reported and correlations made with assessments in previous years and with [***]  
4. Selection and [***] of genotypes for further trialing for potential commercialization based on geography, [***] and [***]  
5. Report on methods to [***] large scale [***] with commercial advantages  
Year 3 (April 1 to March 31):  
A. [***] research to create an economically viable business  
1. [***]/[***] variation affecting [***] amongst available [***] (how many?) and their behaviour through the season/[***] reported; any clear winners [***]  
2. [***]/[***] variation affecting [***] ( how many?) [***] and early [***] across different [***] and [***] reported; any clear leaders [***] and sent to Ceres.  
3. Synthesis of best practice for [***] of miscanthus based on [***] and [***], [***] and other methods to meet market costs and commercialization in different geographies.  
4. XXX [***] of Miscanthus [***] ([***]) (good [***]) with Miscanthus [***] made and followed by [***] where necessary. [***] of [***] sent to Ceres by early 20[***].  
5. Next [***] of [***] x [***] made based on results from 20[***] field [***] and [***]  
B. [***] to Ceres to help [***] in [***] as early as possible  
1. Approximately [***] from [***] occurring in the field in 20[***] believed to be [***]x x [***]x sent to Ceres  
2. Samples of [***] of Year 3 [***] (how many?) sent to Ceres, including a sample of [***]  
3. Promising selected genotypes from [***]/[***] program [***] in [***] and sent to Ceres  
C. Advancing the [***] assisted [***] program as early as possible  
1. DNA from relevant [***] from [***] program, [***] etc delivered to Ceres in 20[***]  
2. Advanced phenotyping of [***] in field and [***] made with Ceres  
D. Advancing the [***] program  
Page 5  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     CERES-IGER SCHEDULE 1   April 1, 2007Attachment B — Budget  
1. xxx new [***] of [***] x [***] made based on phenotypes and presumed [***], [***] and [***] and [***] samples transferred to Ceres  
2. xxx new [***] of M [***] x other made and [***] samples transferred to Ceres  
4. Initial evaluation of [***] in field; report on [***], and commercial feasibility of [***]  
5. Selection and [***] of promising genotypes from all [***] to date for further trialing for potential commercialization based on geography, [***] and [***] and selections transferred to Ceres  
6. Establishment of multisite trial of promising genotypes  
Page 6  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission 
     CERES-IGER SCHEDULE 1   April 1, 2007Attachment C    CERES-IGER SCHEDULE 1   April 1, 2007
  
  
Quarterly Report Format  
Prepared by Date  
1  
     Confidential Project # and nameConcept and Goals  
2  
• Concept           
• Goals           
     Confidential Project # and nameFTEs and Budget Projected vs. Actual  
Dollars  
  
FTEs  
  
3  
• People and activities
     Confidential Project # and nameAction Items and Deliverables for the Period  
4  
                 
    Expected    Actual 
Action Item or Deliverable   Finish    Finish 
                     Confidential Project # and nameKey Milestones or Deliverables for the Period  
5  
• Progress on Key Milestones and Deliverables
 
• Are we on, ahead or behind schedule     Confidential Project # and nameTechnical Highlights  
6  
• 1 or 2 slides covering technical highlights     Confidential Project # and nameResults  
7  
• Several slides summarizing results (if applicable)     Confidential Project # and nameWhat’s Ahead: Key Milestones and Deliverables Next 4 Quarters  
8  
• Quarter 1
 
• Quarter 2
 
• Quarter 3
 
• Quarter 4     Confidential Project # and nameResearch Plan  
9  
• Goal
  — Impact
 
  — Tasks
 
  — Milestones
 
  — Deliverables
• Duplicate this slide as needed to cover each goal for the next period     Confidential Project # and nameTimeline Summary  
  
10  
Time to achieve Milestone 1 2 3 4 5 6 7 8 9 10 11 12  Milestone 1  Milestone 2  Milestone 3  Etc
• Assumptions and risk factors
 
• Use additional slide if necessary
 
• Use red if behind schedule until completed or otherwise resolved
 
• Should be indicated in red as soon as the delay is identified
 
• See issue resolution if behind schedule     Confidential Project # and nameIP  
11  
• Filings during the period           
• Applications in progress           
     Confidential Project # and nameSOPs  
12  
• List SOPS for all Key processes     Confidential Project # and nameIssue Resolution and Decision Making Slides  
These can be used to address new issues or implement corrective action or assist in decision making such as variety release, etc.  
13  
     Confidential Project # and nameIssue Resolution and Decision Making  
 
 
14  
• Issue (e.g. milestone 3 behind schedule)
     Confidential Project # and name 
 
  Actual
 
• What is happening
  Expected
 
• What should be happeningIssue Resolution and Decision Making  
15  
• Issue (e.g. milestone 3 behind schedule)
 
• Possible alternative slide to address new issues
     Confidential Project # and name 
 
Needs  WantsDecision  
16  
• Summary of decision to be made     Confidential Project # and nameOptions  
17  
• Summary of options     Confidential Project # and nameRecommendations  
18  
• What do we need to do to get back on track or address new issue     Confidential Project # and nameResources Required  
19  
     Confidential Project # and namePlan and Schedule  
20  
                 
Action Items   Who     When 
                     Confidential Project # and nameAttachment D 
 
IGER BACKGROUND INTELLECTUAL PROPERTY  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
         
Miscanthus accessions from the following sources:   Number
IGER collection from [***] ([***]), [***] and [***] in 20[***]    approx. [***]             Kew/ADAS (BRL agreement)    -see attached list            [***]    -see attached list            [***]    -see attached list            Other European sources    -see attached list            CERES-IGER SCHEDULE 1        April 1, 2007List of Donated Accessions                                           
AccID Accession  Species  SuppliedBy  PreviousID  Restrictions [***]  Type  [***]  Comments
1  Mb 1  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
2  Mb 2  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
3  Mb 3  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
4  Mb 4  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
5  Mb 5  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
6  Mb 6  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
7  Mb 7  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
8  Mb 8  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
9  Mb 9  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
10  Mb 10  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
11  Mb 11  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
12  Mb 12  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
13  Mb 13  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
14  Mb 14  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
15  Mb 15  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
16  Mb 16  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
17  Mb 17  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
18  Mb 18  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
19  Mb 19  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
20  Mb 20  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
21  Mb 21  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
22  Mb 22  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  No longer retained.
23  Mb 23  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
24  Mb 24  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
25  Mb 25  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
26  Mb 26  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
27  Mb 27  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
28  Mb 28  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
29  Mb 29  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
30  Mb 30  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
31  Mb 31  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
32  Mb 32  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
33  Mb 33  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
34  Mb 34  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
35  Mb 35  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
36  Mb 36  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
37 Mb 37 Miscanthus [***] [***] under MTA [***] [***] [***][***]              38  Mb 38  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
39  Mb 39  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
40  Mb 40  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
41  Mb 41  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
42  Mb 42  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
43  Mb 43  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  No longer retained.
44  Mb 44  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
45  Mb 45  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  No longer retained.
46  Mb 46  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
47  Mb 47  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
48  Mb 48  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
49  Mb 49  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
50  Mb 50  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
51  Mb 51  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
52  Mb 52  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
53  Mb 53  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
54  Mb 54  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
55  Mb 55  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
56  Mb 56  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
57  Mb 57  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
58  Mb 58  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
59  Mb 59  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
60  Mb 60  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
61  Mb 61  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
62  Mb 62  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]    No longer retained.
63  Mb 63  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
64  Mb 64  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
65  Mb 65  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
66  Mb 66  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
67  Mb 67  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
68  Mb 68  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
69  Mb 69  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
70  Mb 70  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
71  Mb 71  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
72  Mb 72  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
73  Mb 73  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
74  Mb 74  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
75  Mb 75  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
76 Mb 76 Miscanthus [***] [***] under MTA [***] [***]Page 1  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
   [***]              77  Mb 77  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
78  Mb 78  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
79  Mb 79  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
80  Mb 80  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
81  Mb 81  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
82  Mb 82  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
83  Mb 83  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
84  Mb 84  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
85  Mb 85  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
86  Mb 86  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
87  Mb 87  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
88  Mb 88  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
89  Mb 89  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
90  Mb 90  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
91  Mb 91  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
92  Mb 92  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
93  Mb 93  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
94  Mb 94  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
95  Mb 95  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
96  Mb 96  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
97  Mb 97  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]List of Donated Accessions                                          98  Mb 98  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
99  Mb 99  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
100  Mb 100  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
101  Mb 101  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
102  Mb 102  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
103  Mb 103  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
104  Mb 104  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
105  Mb 105  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
106  Mb 106  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
107  Mb 107  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
108  Mb 108  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
109  Mb 109  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
110  Mb 110  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
111  Mb 111  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
112  Mb 112  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
113  Mb 113  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
114  Mb 114  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
115  Mb 115  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
116  Mb 116  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
117  Mb 117  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
118  Mb 118  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
119  Mb 119  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
120  Mb 120  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
121  Mb 121  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]    No longer retained.
122  Mb 122  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]    No longer retained.
123  Mb 123  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
124  Mb 124  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
125  Mb 125  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
126  Mb 126  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
127  Mb 127  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
128  Mb 128  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
129  Mb 129  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
130  Mb 130  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
131  Mb 131  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
132  Mb 132  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
133  Mb 133  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
134  Mb 134  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]135  Mb 135  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
136  Mb 136  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
137  Mb 137  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
138  Mb 138  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
139  Mb 139  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
140  Mb 140  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
141  Mb 141  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
142  Mb 142  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
143  Mb 143  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
144  Mb 144  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
145  Mb 145  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
146  Mb 146  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
147  Mb 147  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
148  Mb 148  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
149  Mb 149  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
150  Mb 150  Miscanthus [***]  [***]  [***]  none  [***]  [***]    No longer retained.
151  Mb 151  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
152  Mb 152  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
153  Mb 153  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
154  Mb 154  Miscanthus [***]  [***]  [***]  none  [***]  [***]    No longer retained.
155  Mb 155  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
156  Mb 156  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
157  Mb 157  Miscanthus [***]  [***]  [***]  none  [***]  [***]    No longer retained.
158  Mb 158  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
159  Mb 159  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
160  Mb 160  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
161  Mb 161  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
162  Mb 162  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
163  Mb 163  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
164  Mb 164  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
165  Mb 165  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
166  Mb 166  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
167  Mb 167  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
168  Mb 168  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
169  Mb 169  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
170  Mb 170  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
171  Mb 171  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
172  Mb 172  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
173  Mb 173  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]Page 2  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
174  Mb 174  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
175  Mb 175  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
176  Mb 176  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
177  Mb 177  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
178  Mb 178  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
179  Mb 179  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
180  Mb 180  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
181  Mb 181  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
182  Mb 182  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
183  Mb 183  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
184  Mb 184  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
185  Mb 185  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
186  Mb 186  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
187  Mb 187  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
188  Mb 188  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
189  Mb 189  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
190  Mb 190  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
191  Mb 191  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
192  Mb 192  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
193  Mb 193  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
194  Mb 194  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
195  Mb 195  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]List of Donated Accessions                                          196  Mb 196  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
197  Mb 197  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
198  Mb 198  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
199  Mb 199  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
200  Mb 200  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
201  Mb 201  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
202  Mb 202  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
203  Mb 203  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
204  Mb 204  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
205  Mb 205  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
206  Mb 206  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
207  Mb 207  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
208  Mb 208  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
209  Mb 209  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
210  Mb 210  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
211  Mb 211  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
212  Mb 212  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
213  Mb 213  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
214  Mb 214  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
215  Mb 215  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
216  Mb 216  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
217  Mb 217  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
218  Mb 218  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
219  Mb 219  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
220  Mb 220  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
221  Mb 221  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
222  Mb 222  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
223  Mb 223  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
224  Mb 224  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
225  Mb 225  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
226  Mb 226  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
227  Mb 227  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  No longer retained.
228  Mb 228  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
229  Mb 229  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
230  Mb 230  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
231  Mb 231  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
232  Mb 232  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]233  Mb 233  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
234  Mb 234  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  No longer retained.
235  Mb 235  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
236  Mb 236  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
237  Mb 237  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
238  Mb 238  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
239  Mb 239  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
240  Mb 240  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
241  Mb 241  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
242  Mb 242  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
243  Mb 243  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
244  Mb 244  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
245  Mb 245  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
246  Mb 246  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
247  Mb 247  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
248  Mb 248  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
249  Mb 249  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
250  Mb 250  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
251  Mb 251  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
252  Mb 252  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
253  Mb 253  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
254  Mb 254  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
255  Mb 255  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
256  Mb 256  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
257  Mb 257  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
258  Mb 258  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
259  Mb 259  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
260  Mb 260  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
261  Mb 261  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
262  Mb 262  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
263  Mb 263  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
264  Mb 264  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
265  Mb 265  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
266  Mb 266  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
267  Mb 267  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
268  Mb 268  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
269  Mb 269  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
270  Mb 270  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
271  Mb 271  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]Page 3  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
272  Mb 272  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]  [***]  
273  Mb 273  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
274  Mb 274  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
275  Mb 275  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
276  Mb 276  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
277  Mb 277  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
278  Mb 278  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
279  Mb 279  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
280  Mb 280  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
281  Mb 281  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
282  Mb 282  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
283  Mb 283  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
284  Mb 284  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
285  Mb 285  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
286  Mb 286  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
287  Mb 287  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
288  Mb 288  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
289  Mb 289  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
290  Mb 290  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
291  Mb 291  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
292  Mb 292  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    No longer retained.
293  Mb 293  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]List of Donated Accessions                                          294  Mb 294  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
295  Mb 295  Miscanthus [***]  [***]  [***]  unclear  [***]  [***]     
296  Mb 296  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
297  Mb 297  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
298  Mb 298  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
299  Mb 299  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
300  Mb 300  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
301  Mb 301  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
302  Mb 302  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
303  Mb 303  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
304  Mb 304  Miscanthus [***]  [***]  [***]  none  [***]  [***]    No longer retained.
305  Mb 305  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    Mix of accessions
306  Mb 306  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]    Mix of accessions
307  Mb 307  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
308  Mb 308  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
309  Mb 309  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
310  Mb 310  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
311  Mb 311  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]     
312  Mb 312  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
313  Mb 313  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
314  Mb 314  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
315  Mb 315  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
316  Mb 316  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
317  Mb 317  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
318  Mb 318  Miscanthus [***]  [***]  [***]  none  [***]  [***]  [***]  
319  Mb 319  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
320  Mb 320  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
321  Mb 321  Miscanthus [***]  [***]  [***]  none  [***]  [***]    No longer retained.
322  Mb 322  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]    No longer retained.
323  Mb 323  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
324  Mb 324  Miscanthus [***]  [***]  [***]  under MTA  [***]  [***]     
325  Mb 325  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]  [***]  
326  Mb 326  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]  [***]  
327  Mb 327  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]  [***]  
328  Mb 328  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]  [***]  
329  Mb 329  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]  [***]  
330  Mb 330  Miscanthus [***]  [***]  [***]  no MTA  [***]  [***]  [***]  No longer retained.Page 4  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
331  Mb 331  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
332  Mb 332  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
333  Mb 333  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
334  Mb 334  Miscanthus [***]  [***]  [***]  none  [***]  [***]     
335  Mb 335  Miscanthus [***]  [***]  [***]  none  [***]  [***]Pages where confidential treatment has been requested are stamped ‘Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,’ and the confidential section has been marked as follows: [***].  
AMENDMENT I  
to SCHEDULE 1 between CERES, INC. and INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH dated April 1, 2007 (the “Schedule”).  
Made in two (2) copies.  
Page 1 of 3  
  1. The Parties agree to replace the suggested Year 1 (April 1 to March 31) milestones in Attachment B of the Schedule in their entirety by the Ceres-IGER Milestones — Year 1, as attached hereto. For clarity, no change is made to pages 1 and 2 of such Attachment B. Any changes to the suggested Year 2 and Year 3 milestones will be addressed in separate amendments to the Schedule.
 
  2. The Parties agree that this Amendment I is effective as of January 1, 2008.
 
  3. For the remainder, the Schedule remains unchanged and this Amendment I shall form an integral part thereof.
                 INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH CERES, INC.   
             By: /s/ M Humphreys  By: /s/ Peter Mascia   
 
   
Name: Professor Mervyn Humphreys     
   
Name: Peter Mascia   
 Title: Director     Title: Vice President of Product Development                   By: /s/ Richard Flavell   
       
   
Name: Richard Flavell, CBE, FRS   
       Title: Chief Scientific OfficerCeres-IGER Milestones — Year 1  
Page 2 of 3  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
             
Contract Year           
(April 1 - March 31)  Schedule   Milestone  See key
Year 1   Agronomy  Characterise [***] in the potential for [***] amongst [***] from the [***]   A
           Year 1   Agronomy  Survey of [***] capacity of [***] genotypes taken from the [***] trial during July 20[***].   A           Year 1   Agronomy  Understand [***] affecting [***] across different [***] of [***] different [***].   A           Year 1   [***]  [***] of [***] controlled [***] of Miscanthus [***] ([***]) with Miscanthus [***]. [***] of [***] or [***] to [***] by early 20[***].   A
           Year 1   Agronomy  [***] of [***] (additional to [***] required by DEFRA) [***] of [***] x [***] made based on staggered [***].   D
           Year 1   [***]  [***] of [***] x [***] will be made based on results from 20[***] field [***] and [***].   A           Year 1  
 
[***] 
 
[***] based on outstanding phenotype and [***] geography at [***] from [***] put into [***]. In [***] or [***] or [***] (multiples per [***]) available to put into [***] in 20[***] when requested by Ceres  
B
           Year 1   [***]  [***] promising [***] including [***] lines and [***] trialed to date [***] to [***] in [***] or [***] or [***] for trial in [***] when requested.   B
           Year 1   [***]  Samples of [***] from Year 1 [***] and [***] sent to Ceres. At a minimum [***] + [***] = [***]; more if possible from [***] of [***] x [***] and [***] x [***] and [***] of [***] x [***] ([***]).   B
           Year 1   [***]  [***] to Ceres from M. [***] ([***]) x M. [***] ([***]) in the field in 20[***]; believed to be [***] .   B
           Year 1   Markers  [***]/DNA from [***] plant [***] phenotyped in the field since 20[***] and first [***] delivered to Ceres in 20[***].   C
           Year 1  
 
Markers 
 
[***]/DNA from plant [***] in [***] in 20[***] where material is available, plus other [***] individuals (numbers defined in Marker schedule) and other selected genotypes where material is available delivered to Ceres in 20[***]  
C
           Year 1   [***]  Year 2 and [***] phenotype/[***] assessments of material in [***] trials reported for Ceres to make correlations between assessments and markers   D
           Year 1   Markers  [***] sent to Ceres, samples as requested by Ceres for [***].   E           Year 1   [***]  [***] made in 20[***] and materials brought into [***] in IGER to fill in specific [***] needed for likely [***].   FKEY  
Page 3 of 3  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
A [***] research to create an economically viable business
 
B  [***] to Ceres to help [***] in [***] as early as possible
 
C  Advancing the marker assisted [***] program as early as possible
 
D  Advancing the [***] program
 
E  Advancing [***] research
 
F  Enhancing [***]Pages where confidential treatment has been requested are stamped ‘Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,’ and the confidential section has been marked as follows: [***].  
AMENDMENT II  
to the Collaboration Agreement effective as of April 1, 2007 between the Institute of Grassland and Environmental Research (“IGER”) and Ceres, Inc. (“CERES”), as amended (the “Agreement”) and to SCHEDULE 1 between the Institute of Grassland and Environmental Research (“IGER”) and Ceres, Inc. (“CERES”) and dated April 1, 2007, as amended (“Schedule 1”).  
WHEREAS, the Institute of Grassland and Environmental Research (“IGER”) and CERES entered into the Agreement and Schedule 1 on April 1, 2007;  
WHEREAS, on April 1, 2008 IGER merged with Aberystwyth University Institutes of Biological Sciences and Rural Sciences to form the new Institute of Biological, Environmental and Rural Sciences of Aberystwyth University (“AU”);  
WHEREAS, as a consequence of such merger, the Parties wish to substitute AU in place of IGER as a contract party to the Agreement;  
WHEREAS, AU and CERES wish to amend the Agreement, as set forth hereinafter.  
NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements contained herein and of other good and valuable consideration, the Parties have agreed and do hereby agree as follows:  
Page 1 of 2  
  1. The Parties agree that Aberystwyth University, a Higher Education Establishment registered in the United Kingdom No. RC000641, having an office at Old College, King Street, Aberystwyth SY23 2AX (“AU”) should be substituted as a contract party to the Agreement in place of IGER.
 
  2. The Parties agree to amend Article 14.1 (e) (v) of the Agreement so as to read as follows:
 
     “(v) with thirty (30) days’ written notice to AU if Defra has not assigned to AU, or granted to AU a license reasonably satisfactory to CERES on, the Intellectual Property vested in Defra or the Crown or the Secretary of State pursuant to the DEFRA agreement NF 0426 within three (3) years from the Effective Date (the “Assignment/License”); provided however that Ceres will not unreasonably refuse to extend such three (3) year term by six (6) months if so requested by AU by December 31, 2009.”
 
  3. The Parties agree to add the following clause in Article 6 of Schedule 1:Made in two (2) copies.  
Page 2 of 2  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
     “As long as the assignment or license grant by Defra to AU, and the corresponding grant of a license or sublicense to CERES in compliance with the Agreement, has not occurred, CERES will have the right to withhold [***] percent ([***]%) of the funding payable by CERES to AU pursuant to Attachment B — Budget, attached to Schedule 1 (as this may be amended from time to time). CERES’ rights to withhold such payments will terminate:
  (i) with respect to [***] percent ([***]%) of the funding, as of the date CERES effectively receives a license or sublicense satisfactory to CERES on CERTAIN MISCANTHUS ACCESSIONS (defined in Article 3.2.1 b. of the Agreement) and related information.
 
  (ii) with respect to [***] percent ([***]%) of the funding as of the date CERES effectively receives a license or sublicense satisfactory to CERES on the Intellectual Property vested in Defra or the Crown or the Secretary of State pursuant to the Defra agreement NF0426.”
  4. The Parties agree that this Amendment II is deemed to have become effective as of May 1, 2008.
 
  5. For the remainder, the Agreement and Schedule 1 remain unchanged and this Amendment II shall form an integral part thereof.
              ABERYSTWYTH UNIVERSITY   CERES, INC. By: /s/ S.G.A. Durbin   By: /s/ Richard Flavell Name: S.G.A. Durbin    Name: Richard Flavell, CBE, FRS Title:Director, Risk & Research Finance    Title:Chief Scientific Officer         By: /s/ Richard Hamilton         Name: Richard Hamilton         Title:President and Chief            Executive OfficerPages where confidential treatment has been requested are stamped ‘Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,’ and the confidential section has been marked as follows: [***].  
CONFIDENTIAL  
AMENDMENT III  
to the SCHEDULE 1 between the Institute of Biological, Environmental and Rural Sciences (“IBERS”) of Aberystwyth University and Ceres, Inc. (“CERES”) and dated April 1, 2007, as amended (“Schedule 1”).  
WHEREAS, IBERS and CERES entered into Schedule 1 on April 1, 2007;  
WHEREAS, the initial term of Schedule 1 was for three (3) years;  
WHEREAS, the Parties wish to extend the term of Schedule 1 to cover additional research and development activities;  
WHEREAS, IBERS and CERES further wish to amend Schedule 1, as set forth hereinafter.  
NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements contained herein and of other good and valuable consideration, the Parties have agreed and do hereby agree as follows:  
Richard Flavell (CERES) Jeff Gwyn (CERES) Charlie Rodgers (CERES) Timothy Swaller (CERES)  
Page 1 of 9  
  1. The Parties agree to substitute the RESEARCH AND DEVELOPMENT PLAN referred to in Article 3 of Schedule 1 and attached as Attachment A to Schedule 1 by a new Attachment A/2010 revision, as attached to this Amendment III.
 
  2. The Parties agree to amend Article 5 PHD LEVEL SCIENTIFIC STAFF for CERES staff so as to read as follows:
  3. The Parties agree to substitute the Budget referred to in Article 6 of Schedule 1 and attached as Attachment B to Schedule 1 by a new Attachment B/2010 revision, as attached to this Amendment III.
 
  4. The Parties agree to amend Article 16 Term of Schedule 1 so as to read as follows:
     “Term: Five (5) years provided however, at least one (1) year before the end of the term of this SCHEDULE, the Parties shall decide whether to extend it for one (1) or more years, with appropriate updates to the RESEARCH AND DEVELOPMENTMade in two (2) copies.  
Page 2 of 9  
     PLAN (Attachment A/2010 revision), and FUNDING (Article 6 of this SCHEDULE).”
  5. The Parties agree that this Amendment III is deemed to have become effective as of March 31, 2010.
 
  6. For the remainder, Schedule 1 remains unchanged and this Amendment III shall form an integral part thereof.
              ABERYSTWYTH UNIVERSITY   CERES, INC. By: /s/ E. Reynolds   By: /s/ Jefferson Gwyn Name: Emyr Reynolds    Name: Jefferson Gwyn Title:Head of Research Grants    Title:Vice President of Breeding & Genomics         By: /s/ Richard Flavell         Name: Richard Flavell, CBE, FRS         Title:Chief Scientific OfficerAttachment A/2010 revision  
RESEARCH AND DEVELOPMENT PLAN  
April 1, 2010 — March 31, 2011 workplan  
Page 3 of 9  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
         
Action proposed   Dates Performed  Summary of action taken
1. Supply [***] from the [***] best [***] to CERES partners in [***]   
April 2010 
 
Supplied [***], [***] checked [***] to [***] company as directed by CERES
         2. Supply plants for [***] observation and miniplot trials  
 
April to July 2010 
 
Supplied [***] for the establishment of the following trials [***] 4 ON ([***]) [***] 5 MP (best lines — [***] and [***]) [***] 1 ON (best lines — [***] and [***]) [***] 4 ON [***] 13 MP (best [***] from [***], JKI etc.) [***] A9 ON ([***] survivors, [***], [***]) [***] A 10 ([***] survivors, [***], [***]) [***] A11 RP (small plots of [***])         3. Gather phenotyping data from [***] trials to identify the most promising [***] to be used in [***]  
 
July to November 
 
Best [***] was identified based on autumn [***] scores. [***] ‘Generic high [***] found in [***] at [***] and [***].  Technical enabling A new [***] field nomenclature was developed to ensure clear communication so that each plant or plot in the [***] trials was identified by a UID.   Photographs and data loaded to MSCAN and discussed at the January 2011 quarterly.   Development of the controlled vocabularies for phenotyping fields is ongoing.  [***] data was recorded in [***] and [***] on the [***]  [***] data in Feb 2011 gathered but needs developed of the controlled vocabularies before this can be loaded to MSCAN and analysed.Page 4 of 9  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
         
Action proposed   Dates Performed  Summary of action taken
4. Send [***] of the best selections from [***] and [***] to [***] identified by June 2010  
October 
 
[***] Miscanthus samples for [***] under [***] on behalf of Dr. Charlie Rodgers. The Miscanthus [***] in this package are provided under a research agreement between IBERS and CERES and are restricted to release only to CERES, Inc. They are not [***].         
         6. Develop knowledge of [***] for [***] in a wide range of [***] in order to [***]   
April — Oct 
 
[***] experiments were run in 2010. Discovery of the [***] effect when plants were grown under simulated [***] conditions.
5. Create [***] based on a knowledge of [***] available  All year and ongoing  Table shows number of [***] attempted by [***] types.  
Restricted: a form of [***] where [***] within a [***] has occurred and the plants have been [***] to [***]. The potential [***] contributors can be short listed from the [***] monitoring data. [***]: [***] wise [***] produce two [***] records since [***] contain both [***] and [***] parts. [***]: single [***] [***]: Here the [***] from [***] are registered as [***] ops.  
In 2010 encumbrances ([***] and [***]) stopped us going down the route of [***] M. [***] with the well characterized [***] from [***].  
             
[***] Type   Number   % [***]   Produced >[***]
[***]    [***]  [***]   [***][***]    [***]  [***]   [***][***]    [***]  [***]   [***][***]    [***]  [***]   [***]Total    [***]  [***]   [***]April 1, 2011 — March 31, 2012 workplan  
Page 5 of 9  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
         
Action proposed   Dates Performed  Summary of action taken
7. [***] experiments    April to Oct   A small trial revealed the value of [***] in [***] of [***] M. [***] from [***].         8. Leaf samples from DNA to develop the [***]    Oct   Freeze dried samples sent to CERES from [***]
         9. [***] from 2010 [***] raised for planting in [***] trials    Jan — March   [***] tests identified successful [***]. A tray of each [***] was raised where possible (1 tray = [***] plants)         10. [***] from 2010 [***] sent to CERES    April 2011   From these [***] from [***] with interesting [***] were sent to Charlie.
         11. Reporting  
 
 
 
Powerpoints of July 13 meeting sent  Powerpoints of August 28 meeting sent  Powerpoints of 1 and 2 Nov meeting sent  Document on forward plans (Nov 2010)  Powerpoints of meeting 20-21 Jan 2011
         
milestone   Projected Dates  Summary of planned actions
1. Characterise [***] from the [***] to inform development tracks 1 to 4   
Ongoing 
 
For [***] from the [***] we will perform measurements to collect:
      [***] (when plants are [***] ([***] years from planting) [***] status in autumn [***] (scores and measurements)         2. Development of [***]/ [***] with desirable characters   
Ongoing 
 
Attempt >[***] exploratory [***] between [***] in [***] of the [***] Perform at least [***] with best [***] identified in [***] using the [***] and [***] in 2010 From these [***] of [***] and [***] with interesting [***] to be sent to Charlie.Page 6 of 9  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
         
milestone   Projected Dates  Summary of planned actions
3. Development of [***] (CERES, IBERS)  
 
 
 
Organize [***] phenotype data for use by CERES in collaboration with [***] (on a BBSRC funded flowering grant) and [***] (on the [***]). Monitor [***] planted in 20[***] through collaboration with [***] and the [***]. Supply of further leaf samples as requested for [***] analysis.Page 7 of 9  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
             
milestone   Projected Dates  Summary of planned actions
4. Initiate field evaluation of selected potential new Miscanthus [***] and [***], measure [***] and other key [***].   
April to Aug 2011 
 
Notes [***] and [***] for [***] selections 
 
Putative Trial name [***] 6 ST
      plus [***] controls   [***] 7 MP      [***] blocks          based on best          [***]   [***] 5 CB      [***] blocks          based on best          [***]   [***] 6 CB      [***] blocks          based on best          [***]   [***] 7 CB      [***] blocks          based on best          [***]   [***] 8 CB      [***] testing   [***] 9 ON      miniplots, sue’s          choices   [***] 3 MP      miniplots, sue’s          choices   [***] 25 MP      [***] from          2010 [***]   [***] 26 ST      [***]   [***] 27 CB      [***]   [***] 28 CB      [***]          which are now          in [***]’   [***] 29 ON      Library of [***]          used          in [***] (E.G.          #1 To 5’S)   [***] 30 ON      Selected lines          into [***]   [***] 3 ON      Sue’s MP          selections   [***] 1 MPPage 8 of 9  
Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission  
         
milestone   Projected Dates  Summary of planned actions
5. [***] and [***]  
 
Ongoing 
 
[***] of [***] currently being raised from use in [***] will be supplied to [***].  [***] screens on [***] to be performed and added to MSCAN.         6. [***] experiments        Field experiments with direct sowing using [***].         7. Reporting        Minutes and powerpoints from meetingsAttachment B/2010 revision  
Budget  
CERES shall pay IBERS £[***] (GBP) per year for the implementation of the RESEARCH AND DEVELOPMENT PLAN set forth in Attachment A/2010 revision. Annual payments from CERES to IBERS shall not exceed £[***] (GBP).  
Payment details shall be as set forth in Article 1.8 of the Collaboration Agreement.  
“1.8 Where a SCHEDULE provides that CERES will make a financial contribution to certain RESEARCH PROJECT activities performed by IBERS, unless agreed otherwise in the appropriate SCHEDULE, IBERS will submit invoices after the end of each calendar quarter for the work performed during that quarter. Each such invoice shall reflect only those costs that have been incurred in performance of the RESEARCH PROJECT and shall provide a breakdown of costs similar to the detail set forth in the budget of the related SCHEDULE. CERES will pay all such invoices within thirty (30) days after the invoice date. Payments shall be remitted to:  
Institute of Biological, Environmental and Rural Sciences (“IBERS”) of Aberystwyth University Plas Gogerddan Aberystwyth Ceredigion SY23 3EB United Kingdom”  
Page 9 of 9       Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission.COOPERATION AGREEMENT
 
 
made by and between
 
 
HPIL ENERGYTECH Inc.
 
and
 
GINARES GROUP AG
 
 
January 5, 2015Table of Contents
 
 
 
1. Term........................................................................................................................................... 2
2. Goals And Objectives................................................................................................................ 2
3. Obligations Of The Parties........................................................................................................ 3
4. Confidentiality........................................................................................................................... 3
5. Relation Of The Parties............................................................................................................. 3
6. Closing....................................................................................................................................... 3
7. Representations, Warranties, And Covenants Of GINARES.................................................... 3
8. Representations, Warranties, And Covenants Of HPIL ET...................................................... 4
9. GINARES’s Indemnity.............................................................................................................. 5
10. HPIL ET’s Indemnity............................................................................................................... 5
11. Payment Of Expenses................................................................................................................ 5
12. Approval Of Counsel................................................................................................................. 5
13. Notices....................................................................................................................................... 6
14. Additional Undertakings............................................................................................................ 6
 
15.
Compliance With The Foreign Corrupt Practices Act And Export Control And Antiboycott
Laws...........................................................................................................................................
 
7
16. Arbitration.................................................................................................................................. 7
17. Governing Law.......................................................................................................................... 7
18. Binding Effect............................................................................................................................ 7
19. Counterparts............................................................................................................................... 7
20. No Reliance............................................................................................................................... 8
21. Early Termination...................................................................................................................... 8
22. Captions..................................................................................................................................... 8
23. Entire Agreement....................................................................................................................... 8
 
 
 
 
1COOPERATION AGREEMENT
 
THIS COOPERATION AGREEMENT  (“Agreement”) is signed this 5 th day of January, 2015 (the “Closing Date”), by and
between HPIL ENERGYTECH Inc. , a Nevada (USA) corporation (hereafter “HPIL ET”) and  GINARES GROUP AG, a
private company domiciled in Switzerland (hereafter “GINARES”).
 
R E C I T A L S:
 
The following is a recital of facts underlying this Agreement:
 
A. HPIL ET is focused on investing in both private and public companies in the energy business sector. HPIL ET does not restrict its
potential candidate target companies to any specific geographical location and thus acquires various types of business in the
energy sector. HPIL ET is active with the acquisitions of intellectual properties and technologies in the energy sector.
 
B. HPIL ET is a wholly owned subsidiary of HPIL Holding, a Nevada (USA) corporation and a worldwide diversified investing
holding company. HPIL Holding is a US Public and SEC reporting company.
 
C.  GINARES is an operating international Swiss holding corporation that provides global and independent renewable energy
solutions, in particular related to its NCT technology (Natural Conversion Technology), a catalytic conversion compression to
convert general organic waste (MSW - Municipal Solid Waste) and all kinds of biomass into liquid fuel energy (such as
kerosene and/or diesel) as well as the further production of electricity, that it has an energy efficiency rate and no toxic
chemical byproducts.
 
D. GINARES operates, and has always operated, according to all regulations in force and is fully respectful of the environment.
GINARES periodically evaluates it’s conformity to applicable regulations and obtains the necessary permits, clearances and
certificates. 
 
NOW, THEREFORE, HPIL ET and GINARES (hereafter the “Party” or collectively the “Parties”)  in consideration of and in
reliance upon the representations, warranties, covenants and agreements contained herein,  hereby agree to cooperate together to
expand the GINARES projects and bind themselves to undertake this Agreement under the following terms and conditions:
 
1. Term
 
The term of this Agreement shall be one (1) year unless terminated earlier in accordance with the terms of this Agreement
(the "Term").
 
2. Goals And Objectives
 
The Parties are working cooperatively to develop and cooperate to expand the GINARES projects. The Parties agree to develop a
list of target cooperation projects and common goals, and consequent agreements if required, within six (6) Months of signing this
Agreement.
 
23. Obligations Of The Parties
 
3.1. HPIL ET’s obligations under this Agreement are to:
(i) Follow up on developments regarding GINARES;
(ii) Work with GINARES as appropriate.
 
3.2. GINARES’s obligations under this Agreement are to:
(i) Keep HPIL ET aware of developments regarding GINARES;
(ii) Work with HPIL ET as appropriate.
 
4. Confidentiality
 
Subject to sub-clause below, each Party shall treat as strictly confidential all information received or obtained as a result of
entering into or performing this Agreement. Each Party may disclose information which would otherwise be confidential if and to the
extent:
 
(i) required by the law of any relevant jurisdiction;
(ii) the information has come into the public domain through no fault of that Party; or
(iii) the other Party has given prior written approval to the disclosure, provided that any such information disclosed shall be
disclosed only after consultation with and notice to the other Party.
 
5. Relation Of The Parties
 
The nature of relationship between the Parties is that of two independent contractor's working together to achieve common
goals. There is no payment or compensation contemplated under this Agreement.
 
6. Closing
 
The closing of this Agreement shall take place at the offices of HPIL ET, 7075 Gratiot Road, Suite One, Saginaw, Michigan
48609 (United States of America), or other mutually agreed upon location.
 
7. Representations, Warranties, And Covenants Of  GINARES
 
GINARES hereby represents, warrants, and covenants to HPIL ET that:
 
7.1. Authorization
 
This Agreement constitutes a valid and legally binding obligation of GINARES, enforceable in accordance with its
terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies.
 
 
37.2. Consents
 
To GINARES’s knowledge, no consent, approval, order or authorization of, or registration, qualification, designation,
declaration or filing with, any federal, state or local governmental authority on the part of  GINARES is required in
connection with the consummation of the transactions contemplated by this Agreement.
 
7.3. Compliance With Other Instruments
 
The execution, delivery and performance of this Agreement contemplated hereby will not result in a violation of, or
default under, any instrument, judgment, order, writ, decree or contract known to GINARES, or an event that results in the
creation of any lien, charge or encumbrance upon the Agreement.
 
7.4. Litigation
 
There is no action, suit, proceeding or investigation pending or, to GINARES’s knowledge, currently threatened that
questions the validity of this Agreement, or the right of GINARES to enter into this Agreement.
 
8. Representations, Warranties, And Covenants Of HPIL ET
 
8.1. Authorization
 
This Agreement constitutes a valid and legally binding obligation of HPIL ET, enforceable in accordance with its
terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies.
 
8.2. Consents
 
To HPIL ET’s knowledge, no consent, approval, order or authorization of, or registration, qualification, designation,
declaration or filing with, any federal, state or local governmental authority on the part of HPIL ET is required in connection
with the consummation of the transactions contemplated by this Agreement.
 
8.3. Compliance With Other Instruments
 
The execution, delivery and performance of this Agreement contemplated hereby will not result in a violation of, or
default under, any instrument, judgment, order, writ, decree or contract known to HPIL ET, or an event that results in the
creation of any lien, charge or encumbrance upon the Agreement.
 
8.4. Litigation
 
There is no action, suit, proceeding or investigation pending or, to HPIL ET’s knowledge, currently threatened that
questions the validity of this Agreement, or the right of HPIL ET to enter into this Agreement.
 
 
49. GINARES’s Indemnity
 
9.1. HPIL ET shall indemnify, defend, and hold harmless GINARES  from, against and with respect to any claim, liability,
obligations, loss, damage, assessment, judgment, cost and expense (including, without limitation, reasonable attorneys’ and
accountants’ fees and costs and expenses reasonably incurred in investigating, preparing, defending against or prosecuting
any litigation or claim, action, suit, proceeding or demand) or any kind or character (collectively, “Losses”) arising out of or
in any manner, incident, relating or attributable to: any inaccuracy in any representation or breach of warranty of GINARES
contained in this Agreement and (ii) any failure by HPIL ET to perform or observe, or to have performed or observed in full
any covenant, agreement or condition to be performed or observed by HPIL ET under this Agreement or any of the other
agreements or instruments executed and delivered by HPIL ET on the Closing Date.
 
9.2.  GINARES agrees that the sole and exclusive remedy for money damages related to this Agreement and the
transactions contemplated hereby shall be the rights to indemnification set forth in this Section 9.
 
10. HPIL ET’s Indemnity
 
10.1. GINARES shall indemnify, defend, and hold harmless HPIL ET from, against and with respect to any claim, liability,
obligations, loss, damage, assessment, judgment, cost and expense (including, without limitation, reasonable attorneys’ and
accountants’ fees and costs and expenses reasonably incurred in investigating, preparing, defending against or prosecuting
any litigation or claim, action, suit, proceeding or demand) or any kind or character (collectively, “Losses”) arising out of or
in any manner, incident, relating or attributable to: any inaccuracy in any representation or breach of warranty of HPIL ET
contained in this Agreement and (ii) any failure by GINARES to perform or observe, or to have performed or observed, in
full any covenant, agreement or condition to be performed or observed by GINARES under this Agreement or any of the
other agreements or instruments executed and delivered by GINARES on the Closing Date.
 
10.2.  HPIL ET agrees that the sole and exclusive remedy for money damages relating to this Agreement and the
transactions contemplated hereby shall be the rights to indemnification set forth in this Section 10.
 
11. Payment Of Expenses
 
Each of the Parties shall pay their own expenses associated with this Agreement and the transactions contemplated herein.
 
12. Approval Of Counsel
 
All instruments or documents to be delivered by any Party to this Agreement shall be in  form and content reasonably
satisfactory to the counsel for the Party receiving such instrument or document.
 
513. Notices
 
All notices and other communications required or permitted hereunder shall be in writing and shall be deemed to have been
duly given (a) when delivered in person, (b) five (5) business days after being sent by registered or certified mail, return receipt
requested, postage prepaid, (c) when dispatched by electronic facsimile transmission (with confirmation of successful transmission),
or (d) one (1) business day after having been dispatched by an internationally recognized overnight courier service, in each case to
the appropriate Party at the address or facsimile number specified below:
 
If to HPIL ET:
 
HPIL ENERGYTECH Inc.
Attn.: Louis Bertoli, President and CEO
7075 Gratiot Road, Suite One
Saginaw, Michigan 48609
United States of America
Facsimile No.: 001(248)750-1016
 
with a copy (which shall not constitute notice) to the following e-mail addresses:
info@hpilenergytech.com
 
If to the GINARES:
 
GINARES GROUP AG
Attn.: Peter Zu Sayn-Wittgenstein, President and CEO
Churerstrasse 47
Pfaeffikon 8808
Switzerland
Facsimile No.: +41(55)511-0810
 
with a copy (which shall not constitute notice) to the following e-mail address: 
info@ginares.com
 
Any Party hereto may change its address or facsimile number for the purposes of this Section 13 by giving notice as
provided herein.
 
14. Additional Undertakings
 
The Parties shall hereafter each take those actions and execute and deliver those documents and instruments as shall be
reasonably necessary in order to fulfill the intent and purpose of this Agreement, and shall cooperate in any filing, registration,
investigation or other activity that shall be required or shall occur as a result of or in connection with this transaction.
 
615. Compliance With The Foreign Corrupt Practices Act And Export Control And Antiboycott Laws
 
Neither GINARES or HPIL ET or any representative of  GINARES or HPIL ET in its capacity as such has violated the
Foreign Corrupt Practices Act or the anticorruption laws of any jurisdiction where GINARES or HPIL ET does business. Each of
GINARES and HPIL ET has at all times complied with all legal requirements relating to export control and trade sanctions or
embargoes. Either GINARES or HPIL ET have violated the antiboycott prohibitions contained in 50 U.S.C. Sections 2401 et seq. or
taken any action that can be penalized under Section 999 of the Internal Revenue Code of 1986, as amended.
 
16. Arbitration
 
Any and all disputes or controversies between the Parties arising out of or in connection with this Agreement shall be finally
settled by arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce; provided, a Party may
seek a temporary restraining order, preliminary injunction, or other provisional judicial relief if in its judgment such action is necessary
to avoid irreparable damage or to preserve the status quo. Despite any such action for provisional relief, the Parties will continue to
participate in good faith in the procedures specified in this Section 16.  Each Party shall appoint one arbitrator who shall mutually
appoint a third arbitrator who shall be the sole arbitrator for the proceeding.  The arbitration shall be held, and any award shall be
rendered, in Paris (France), in the English language. The award may include reimbursement of the costs of the arbitration (including,
without limitation, reasonable attorney fees) to the prevailing Party or a portion of such costs as determined by the arbitrator.  An
award of the arbitrator shall be final and binding on the Parties and judgment upon the award rendered by the arbitrator may be
entered by any court having jurisdiction.
 
17. Governing Law
 
This Agreement and its application and interpretation will be governed exclusively by its terms and the laws of the State of
Nevada (USA), and excluding any conflicts of law provisions which would require the application of any law other than Nevada.
 
18. Binding Effect
 
All of the terms and provisions of this Agreement by or for the benefit of the Parties shall be binding upon and inure to the
benefit of their successors, assigns, heirs and personal representatives. The rights and obligations provided by this Agreement shall
not be assignable by any Party. Except as expressly provided herein, nothing herein is intended to confer upon any person, other than
the Parties and their successors, any rights or remedies under or by reason of this Agreement.
 
19. Counterparts
 
This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same Agreement.
 
720. No Reliance
 
No third party is entitled to rely on any of the representations, warranties and agreements contained in this Agreement. The
Parties assume no liability to any third party because of any reliance on the representations, warranties and agreements contained in
this Agreement.
 
21. Early Termination
 
The Parties may terminate its performance of related obligations under this Agreement within thirty (30) days of receipt by
the Party of written termination notice.
 
22. Captions
 
Captions to sections and subsections of this Agreement have been included solely for the sake of convenient reference and
are entirely without substantive effect.
 
23. Entire Agreement
 
This Agreement constitutes the entire agreement among the Parties pertaining to the subject matter hereof and supersedes
all prior and contemporaneous agreements, understandings, negotiations and discussions, whether oral or written, of the Parties and
there are no warranties, representations or other agreements between the Parties in connection with the subject matter hereof
except as set forth specifically herein. No amendment, supplement, modification, waiver or termination of this Agreement shall be
implied or be binding (including, without limitation, any alleged waiver based on a Party’s knowledge of any inaccuracy in any
representation or warranty contained herein) unless in writing and signed by the Party against which such amendment, supplement,
modification, waiver or termination is asserted. No waiver of any of the provisions of this Agreement shall be deemed or shall
constitute a waiver of any other provision hereof (whether or not similar), nor shall such waiver constitute a continuing waiver unless
otherwise expressly therein provided.
 
THIS COOPERATION AGREEMENT has been entered into as of the date first set forth above.
 
GINARES :
 
GINARES GROUP AG, a private company domiciled in
Switzerland.
 
 
 
By: /s/  Peter Zu Sayn-Wittgenstein ​​.   Peter Zu Sayn-
Wittgenstein
As: President and CEO
HPIL ET :
 
HPIL ENERGYTECH Inc., a Nevada (USA)
corporation.
 
 
 
By: /s/ Louis Bertoli ​​.   
Louis Bertoli
As: President and CEO
8Xi’an Zhonghong New Energy Technology Co., Ltd.
 
Boxing County Chengli Gas Supply Co., Ltd.
 
Project Cooperation Agreement
 
July 2013Cooperation Agreement
 
Coke Dry Quenching (CDQ) and CDQ Waste Heat Power Generation Project
 
Party A: Xi’an Zhonghong New Energy Technology Co., Ltd.
Legal Representative: Ku Guohua
 
Xi’an Zhonghong New Energy Technology Co., Ltd. is a subsidiary of Xi’an TCH Energy Technology Co. and is also the third tire subsidiary of
China Recycling Energy Corporation, and it engages in the project operations in China. China Recycling Energy Corporation (the "Company") is a
NASDAQ listing company. Its stock trading symbol is CREG and is a leading industrial waste-to-energy solution provider in China. The Company
is the first in the recycling energy industry with the most completed projects and the widest ranges in the industry. As the direct investor, the
Company provides recycling energy integrated solution covering technology, investment, and operation.
 
Party B: Boxing County Chengli Gas Supply Co., Ltd.
 
Legal Representative: Li Shuxun
 
Boxing County Chengli Gas Supply Co., Ltd. is located in the Industrial Park, Chunhua Town, Boxing County, Shandong Province, which is mainly
engaged in coal coke production and coal chemical industry.
 
After friendly negotiation between two parties, based on the principle of equality and autonomy, Party A and Party B reached following items with
respect to the coke dry quenching (CDQ) and CDQ waste heat power generation project.
 
Item One, Investment Construction Projects
1. Construction of CDQ and CDQ recycling economic projects
Construct CDQ system and CDQ waste heat power generation station as a part of of tamping coke oven with 2 x 60 holes, 5.5 meters and
JNDK55-07 of model at Boxing County Chengli Gas Supply Co., Ltd. The designed total capacity is 25 MW.
 
2. Under the premise of consistent with the CDQ main equipment and main parameter descriptions, Party A will be in charge of layout, technical
performance index and technical specifications of CDQ system and CDQ waste heat power generation system; if there is any difference
between CDQ main equipment and main parameters description, Party B will make the decision. Major equipment and design will be
implemented after Party A obtains Party B’s consent. All requirements, statistics should be scientific, reasonable, and operable.3. Party A is responsible for the investment in the construction and operation of CDQ system and CDQ waste heat power generation system
project, including design of the project, equipment selection, equipment procurement and manufacturing, construction, engineering,
installation, formal power generation.
 
Item Two, Operation of Recycling Project
1. After complete of the project construction, Party A shall be responsible for the operation, maintenance and management of the recycling
project. Party A shall charge Party B energy saving service fee according to the income from CDQ waste heat power generation station.
 
2. Both Parties jointly determine the territorial boundary line of power transmission pursing to technical appendix.
 
3. The operation of CDQ system and CDQ waste heat power generation system includes but is not limited to: equipment maintenance, repair,
and update; Party A will not be responsible for the quality and quantity of the coal coke of CDQ.
 
Item Three, Cost and Operation Target
Party B shall pay Party A energy saving service fee after the construction of CDQ system and CDQ waste heat power generation system are
completed (upon passing evaluation of the ability of connection to the grid for power generation).
 
1. The energy saving service fee is paid in the form of electricity fee.
The calculation basis of energy saving service fee is as follows: average operational time is 8,000 hours per annually; if the annual average
operational time was less than 8,000 hours due to the reasons of Party B, the operational time is calculated as 8,000 hours per year; if the annual
average operational time was less than 8,000 hours due to the reasons by Party A, the operational time is calculated based on the actual
operational hours.
 
2. If the grid-connected electricity price is adjusted since the execution of this agreement, the fee shall be calculated as the energy saving service
fee (stipulated in section 1 of Item III ) plus 85% of the price change/adjustment from the original grid-connected electricity price. The starting
day for the change will be from the date of adjustment by Shandong Provincial Price Department.
 
3. The amount of power generated shall be calculated based on the indicator of electricity meter in the power station.
 
4. The settlement date is the first day of the next month. Deducting the dues of Party A, Party B should pay Party A the energy saving service fee
of the last month before the 15th of each month.5. Payment method: Wire or transfer.
 
6. The policy rebate, award, and preferential treatment shall be shared by both Parties. Each party shares 50% of the policy rebate, award, and
preferential treatment. Both Parties share the expenses incurred in the process of the application for the policy rebate, award, and preferential
treatment.
 
Item Four Starting and End Date for Recycling Project and Term
 
1. The date when Party A completes the construction and installation of CDQ system and CDQ waste heat power generation system and the
power generating system has been in operation and meets the requirements of the design standard for 72 hours. The Parties agree that date
after the recycling project meets the evaluation requirement as the starting date for the recycling project. From that date, Party B shall pay the
service fees monthly according to the power generated and Party B shall also pay for the power generated during the 72 hours testing run
period.
 
2. The cooperation model is BO model.
The expected total project cost is 176 million RMB. For the amount of electricity generated up to 800 million KWH after the project is put into
operation, it shall be charged of the energy saving service fee at 0.40 RMB/KWH. After 800 million KWH, it shall be charged energy saving
service fee with the rate of 0.20 RMB/KWH.
 
The term of the agreement is 20 years, during which if any main equipment of any Party stops operation due to technical problem or at the end
of its life cycle, the agreement shall be automatically terminated. In case of that happens, the Party B will have the full rights to dispose the
system of Party A.
 
Item Five Construction and Construction Period of CDQ System and CDQ waste heat power generation system
 
1. The construction period of the project is 12 months from the execution of technology agreement. If the project was delayed due to Party A,
Party B has right to dispose the equipment on the construction site after two month past due date.
 
2. If the project is stalled due to Party B’s reason (including but not limited its activities that affect daily construction, installation, testing and
safety), the construction period shall be extended accordingly.
 
3. If any party delays the construction without a good reason, which results the construction of the whole project or part of the project cannot be
completed on schedule, the other party has right to terminate wholly or part of the agreement and incurred loss will be assumed by the
breaching party.Item Six Raw Material Consumption of the project of CDQ system and CDQ waste heat power generation system
 
1. All raw materials such as water, electricity consumed in the operation of the project shall be settled based on the party B’s local price. Party A
makes monthly payment. Party B provides pipeline up to designated boundary line on the construction site and then Party A will connect
water lines and electricity lines into the site and assumes related expenses.
 
2. The Parties agree that Party B shall provide steady qualified coal coke production according to the technology agreement which will be used
for CDQ system. Party A guarantees the steady operation of the CDQ and CDQ waste heat power generating systems.
 
3. Party B shall provide effective assistance to the construction and operation management of the recycling project.
 
4. The land for CDQ and CDQ waste heat power generation project shall be provided by Party B to Party A with no charge.
 
Item Seven Meter Confirmation, Management and Maintenance
 
1. The power generation system of Party A has electricity meters. If Party B wants to separately conduct electricity measurement, the meters shall
be provided by Party B and be responsible for the its maintenance and expenses.
 
2. The selection and maintenance of meters shall not affect the normal operation of CDQ and CDQ waste heat power generation project.
 
3. Both Parties have right to examine and verify the electricity meters so as to make sure their accuracy.
 
Item Eight Ownership and Intellectual Property of the Recycling Project
 
1. During the contact period, Party A has the ownership of the CDQ and CDQ waste heat power generation systems. After the termination of the
contact, Party B has the disposition right to the project.
 
2. The intellectual property of the project belongs to Party A. Without written consent of Party A, Party B is not allowed to disclose the
intellectual property to the other third party.Item Nine Quality Assurance
 
1. Party A is responsible for the equipment quality, technical performance, and construction quality. Party B is responsible for the technical
specifications and energy media quality.
 
2. For the CDQ system and waste heat power generation of CDQ system of Party A, Party B shall keep the coking and CDQ process functional,
and provide necessary guidance and assistance. Parties shall fully cooperate to ensure the quality of the project.
 
Item Ten Warrants of Party A
 
Besides responsibilities in this agreement, Party A shall also:
 
1. Keep the power station operating properly and ensure that the electricity supplied to Party B complies with national safety standards.
 
2. Ensure the safety of its employees during construction and operation.
 
3. Provide reliable technical support and guarantee for the project.
 
4. Responsible for the operation of CDQ system and waste heat power generation from CDQ system, and bear operation costs.
 
5. Responsible for the design, equipment procurement, construction, installation, and test and adjustment.
 
Item Eleven Warrants of Party B
 
Besides responsibilities in this agreement, Party B shall also:
 
1. Provide Performance Guarantee Letter  to state that Party B will purchase all electricity generated from the project.
 
2. Responsible for the permits and approvals for operation of the project. Party A is responsible for the permits, inspection and acceptance of the
construction and Party B provides assistance.
 
3. Purchase all generated electricity from the project.
 
4. Cooperate with Party A's due diligence and provide required documents, and ensure that provided documents are true and authentic.
 
5. Provide leveled construction site. For details, refer to the  Technology Attachment .Item Twelve Promises
 
1. Party A and B agree to have long-term cooperation for current and further recycling energy projects. Party A has priority to develop further
recycling energy projects for Party B.
 
2. If the change or update of industrial process or facility of Party B forces Party A to change its system, Party A will use new system cost and
loss for replacement as the new system cost to calculate numbers according to Item Three to continue execute the project.
 
3. From the starting day of the project, Party B must ensure that the coking system works properly and working hours of the CDQ system must be
no less than 8,000 hours/year. Party A must ensure the waste heat power generation system of CDQ working hours no less than 7,200
hours/year.
 
Item Thirteen Liability for Breach of Agreements
 
1. Unless otherwise agreed, either party cannot change or terminate the agreement without written consent of the other party except for force
majeure. Equipment of both parties must work properly.
 
2. Party B shall pay Party A the energy saving service fee at the stipulated time, otherwise:
 
2.1 If Party B fails to pay Party A the energy saving service fee by 15 th of the month and the delay is within 60 days, the daily penalty is 0.05%
of the overdue payment.
 
2.2 If the delay is over 60 days, it is regarded that Party B has no ability to perform its payment obligation. Party A can enforce the
Performance Guarantee by Party B to take all project assets. Party B shall pay the actual energy saving service fees at once and pay Party
A losses.
 
3. If any event affects the ability to its continue operation of the Party A or Party B, such as bankruptcy, going out of business, merging,
transferring, separation or being dissolution, such party must give the other party a written notice within 30 days and provide documentary
evidences. If such party cannot perform the contractual obligation, the other party suffered from loss could claim for compensation.
 
4. If the power plant cannot operate properly due to the shutdown of furnaces, facilities, or valves of Party B and such failure cannot be corrected
upon a written notice from Party A to Party B within two days of occurrence of such event, Party B shall compensate the actual loss of Party A.5. If the facilities and power plant cannot operate properly because of the equipment or human errors of Party A, then upon three consecutive
months of the power generation system cannot reach 65% of its designed capacity, Party A shall compensate actual loss of Party B.
 
6. Party A shall adjust its maintenance time based on the production schedule of Party B. If Party A affects the production of Party B, Party A
shall compensate for the loss.
 
7. Party A cannot transfer or mortgage the CDQ and CDQ power generation systems without the consent of Party B, otherwise it shall be
responsible for the losses.
 
8. The CDQ and CDQ power generation systems shall comply with the national environmental protection standards. If the environment is
polluted during the operation of the power plant, Party A shall bear the liability.
 
9. If the power generation causes upper level power network, each party shall bear their own liabilities based on the determination of the upper
level power network operator.
 
Term Fourteen Force Majeure
 
If the project cannot be completed on schedule or supply power normally due to force majeure, such as war, flood, and earthquake, both parties
shall be partially or fully exempt from their liabilities based on the effects of force majeure. If any party cannot perform the agreement due to force
majeure, the party shall notify the other party immediately, provide the proof within 15 days, and keep the loss to a minimum with reasonable efforts.
 
Term Fifteen Settlement of Disputes
 
Both parties shall settle all disputes through amicable negotiations. If negotiations fail, either party could take a legal action to the local people’s
court where Party A is located.
 
Term Sixteen Agreement, Appendix, and Others
 
1. This agreement shall be signed and sealed by legal representatives or authorized representatives of both parties and take effect from the
effective date.2. After the agreement is signed, Party A shall complete its due diligence and provide Party B with the letter of confirmation. Parties shall sign
Technical Appendix within 90 days after the agreement is signed.
 
3. The Technical Appendix and Performance Guarantee are an integral part of the agreement and have the same legal effect of the agreement.
 
4. The agreement can only be terminated after negotiation and agreement by Party A and B in writing. When the agreement is terminated, Party A
has rights to dispose all assets of the recycling project.
 
5. As for matters not mentioned herein, Party A and Party B shall sign a supplemental agreement through negotiation. The supplemental
agreement has same effect to the agreement. If there is any conflicts, the latest supplemental agreement prevails.
 
The agreement is made in quadruplicate. Each party holds two copies and they have the same legal effect.
 
Party A: Xi’an Zhonghong New Energy Technology Co., Ltd.
(Seal)
 
Representative:
 
Party B: Boxing Cheng Li Gas Supply Co., Ltd.
(Seal)
 
Representative:Exhibit 10.39
English Translation
Jiangsu Telecom Contract No.: JSXCS1200166CC000
Cooperation Agreement on Mobile Game Business
Between
Dazzle Interactive Network Technologies Co., Ltd.
And
Shenzhen iDreamSky Technology Co., Ltd.
Party A: Dazzle Interactive Network Technologies Co., Ltd.
Address: 4F, Han Zhong Hua Mansion, 268 Han Zhong Road, Gu Lou District, Nanjing
Zip code: 210001
Contact person: Chen Xi
Tel:   
Name of account: Dazzle Interactive Network Technologies Co., Ltd
Deposit Bank: China Merchants Bank, Chengbei Sub-branch, Nanjing
A/C:   
Party B: Shenzhen iDreamSky Technology Co., Ltd.
Address: 7F, EVOC Technology Building, No. 31 Gaoxin Central 4th Road, Nanshan District, Shenzhen
Zip code: 518057
Contact person: Chen Zhiyu
Contact Tel:   
Name of account: Shenzhen iDreamSky Technology Co., Ltd.
Deposit Bank: China Merchants Bank Co., Ltd., CMB Shenzhen Sungang Sub-branch
A/C:   
 
 
Page 1 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
In order to provide Party A’s users with better value-added application services and satisfy the growing market demands, the Parties hereto, upon
thorough negotiations based on the principles of equality, mutual benefits, mutual supplementation of advantages, joint development, and fully
leveraging the advantages of the Parties hereto in their respective areas of service, the Parties hereto have agreed as follows in respect of the
cooperation in mobile game services:
Article 1 Contents and Principles of Cooperation
1.1 Party A, as an Internet business provider, and Party B, as a mobile game content provider, will establish a cooperation relationship in the area of
mobile game service.
1.2 The details of the content and application services provided by Party B are: 1) Party B will provide Party A with the mobile games that are
developed by itself and have legitimate intellectual properties, or third party mobile games that are acquired by Party B by way of authorization and
have been granted legitimate right of use; and 2) Party B will provide Party A the software and hardware technical support (and the timely updates
thereof) for game running to secure the stable running of the games.
1.3 Party A shall provide, for a consideration, network resources, portals and such other advertising resources, as well as connection services and
business fee calculation/collection service. Party A will charge relevant information fee from the users of Party B’s mobile game service, and will
share such information fee with Party B as agreed herein.
1.4 Except otherwise agreed between the Parties, Party B will acknowledge and accept the changes in cooperation business and mode proposed by
Party A due to business development, and assist Party A in effecting such changes.
1.5 Resources devoted by Party A: business connection platform, network resources, portals and other advertising channels, etc.
1.6 Resources devoted by Party B: mobile game application system and relevant contents (including, without limitation, copyright, right of portrait
and such other lawful rights), etc.
1.7 Scope of cooperation service: all users of Party A’s interactive platform.
Article 2 Rights and Obligations of Party A
2.1 Party A shall have a preemptive right to carry out mobile game services with Party B on a nationwide basis.
2.2 Party A shall have the right to know and review the business license, relevant qualification certificate, copyright ownership, business permits,
bank account and such other information provided by Party B.
 
Page 2 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
2.3 Party A shall have the right to know the legality of the mobile game information provided by Party B, provided, however, that Party A will not
take any responsibilities arising from any illegal or incorrect information provided by Party B.
2.4 Depending on the business and market development, Party A has the right to formulate or amend the business standards, management
measures, quality and/or service standards, and communicate the same to Party B in an appropriate form for Party B to comply with. At the same
time, these documents will be used by Party A as basis to manage and assess Party B’s business operations. The business standards, management
measures, quality and/or service standards so formulated or amended shall be equally effective as this Agreement.
2.5 Party A shall be responsible for the day-to-day maintenance of the business billing platform, and provide guidance and assistance to Party B in
system connection, debugging and online work to guarantee the stable running of the platform. Party A shall open the network management
system and other interface management tools to Party B to facilitate its checking of the charges to users and relevant status of operation, so as to
ensure that Party B can monitor the fee charge and operation of its games in a convenient, true and valid manner.
2.6 Party A shall have the right to review the content and sources of the games put online by Party B on the platform, and make confirmation on the
business management system in an appropriate form, provided, however, that Party A will not assume any responsibility arising from any illegal
contents provided by Party B.
2.7 According to Management Measures for Cooperation in Mobile Game Business (V1.0), Party A shall have the right to review and assess Party B
and its various business, select the superior and eliminate the inferior based on Party B’s performance in business development, credit points and
breaches, reward Party B’s creative business and supervise Party B’s customer service quality, and may terminate this Agreement with Party B if it
fails to reach Party A’s standards.
 
2.8 Party A shall be responsible for the overall advertising of the cooperation business.
2.9 If Party A is investigated by relevant national authority, consumers’ association or any other organization, or is claimed legal responsibilities,
due to the users’ browsing or use of the contents and application services provided by Party B, Party A may unilaterally terminate this Agreement
by a written notice, and Party B shall bear any direct and indirect losses thus suffered by Party A, including, without limitation:
 
  (1) costs of preliminary input and preparatory work made by Party A for performance of this Agreement;
 
  (2) costs already paid by Party A for performance of this Agreement;
 
  (3) anticipated gains for Party A’s performance of this Agreement;
 
  (4) costs, indemnities or other payables by Party A in relevant litigations incurred for reasons attributable to Party B.
 
Page 3 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
2.10 If Party A receives any complaint or notice alleging that any content provided by Party B is involved in an infringement dispute, Party A may
suspend the connection of Party B’s system, unilaterally terminate this Agreement and suspend the settlement of relevant fees, and notify Party B
to delete or shield such content involving infringement. The business will be resumed upon confirmation by Party A after Party B notifies the
results to Party A.
2.11 Party A shall construct and maintain the business management system, use the business management system to post notice/announcement,
business management measures and relevant policies, and shall inquire, manage and update the information regarding the cooperation. Party A
shall provide Party B with its user name and password on the business management system for Party B to log on.
2.12 Party A shall test the business filed by Party B after approving it, and after the test is passed, provide Party B with a written confirmation or
otherwise confirm with appropriate forms in the business management system. The official launch time of the business will be the time when Party
A officially launches the billing service.
2.13 During the term of cooperation, Party A may suspend its cooperation with Party B if there is user complaint on Party B’s service quality issue,
which has resulted in adverse social impact; in serious cases, Party A may unilaterally terminate this Agreement.
2.14 Party A may, as requested by customers and market orders, review the business contents and prices filed by Party B, and may withhold the
settlement of the information fee incurred by Party B’s discretional change of charges.
2.15 Any complaints made by users with respect to the fee charging activities by Party B (except complaints attributable to Party A), once
discovered, may be immediately notified by Party A in writing to Party B for correction, and Party A may take measures of fee refunding or
suspension of fee charging according to relevant rules and as agreed herein. For complaints which Party B fail to make reasonable explanation,
Party A may require Party B to reduce and exempt information fee of relevant users, and based on the seriousness of situation, require Party B to
take relevant liabilities for breach of contract in accordance with relevant business management measures.
2.16 Party A shall be entitled to supervise the business conduct of Party B, and Party B shall assist Party A to avoid any adverse impact on Party
A’s normal business. If Party B’s businessconduct causes adverse impact on Party A’s normal business in violation of this Agreement, Party A may
terminate this Agreement and Party B shall assume relevant liabilities for breach of contract.
Article 3 Rights and Obligations of Party B
3.1 Party B shall be responsible for content development, platform building and maintenance, marketing and customer service of the cooperation
business.
3.2 Party B guarantees to have the legal permits and qualifications necessary for the performance of the matters hereunder, including, without
limitation, business license with legitimate business scope, qualification for providing contents/application services; Party B shall provide Party A
with true and legitimate business permits for Internet information service and relevant business and such other credentials, creditability certificate,
certificate for legitimacy of copyright sources, adequate after-sale service system, price approval, bank account and such other documents.
 
Page 4 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
3.3 Party B must strictly comply with relevant industry laws, rules and standards promulgated by the State, including, without limitation, the PRC
Telecommunications Regulations, Administrative Measures on Internet Information Service, Interim Provisions on the Administration of Internet
Publishing, Interim Provisions on the Administration of Internet Websites’ Engaging in News Publication Services, and such other laws,
regulations, policies and industry management rules, and shall not distribute and disseminate illegal, unhealthy, reactionary information or
advertisement or such other junk information on the Internet.
3.4 Party B guarantees that it enjoys the intellectual property and civil rights on all the information/application service resources provided by it, has
obtained the license and authorization from relevant right owners, and does not infringe on any person’s copyright, trademark right, patent right,
trade secrets or other intellectual property rights, other property rights, right of portrait or other personal right.
3.5 Party B shall comply with the various rules and requirements in the business standards, management measures, quality and/or service standards
formulated or amended by Party A, which shall be equally binding as this Agreement.
3.6 Party B guarantees that the prices of the various business it provides are in line with the pricing policies of the State, and it will be responsible
for any price complaints made by relevant administrative authority or users.
3.7 Party B may negotiate the mode of cooperation with Party A, and may determine the operation strategy for its mobile game service business,
provided, however that the pricing of its business shall be approved by Party A and filed to relevant authority for record.
3.8 In case of any issues of Party B’s own systems (such as WAP website or game server) that affect Party A’s communications system, Party B
shall submit to the connection control by Party A thereon, and any consequence thus incurred shall be fully taken by Party B itself.
3.9 Party B shall undertake allliabilities arising from the wireless value-added business provided by any third party to the users in any form
whatsoever through Party B’s maintenance interface. Party B shall not transfer the business interface provided by Party A to a third party in any
form whatsoever, and Party A will not be responsible toward any users or third party with respect thereto.
3.10 As required by relevant regulations of the State and as requested by Party A, Party B shall provide relevant qualification certificates when
applying to open and add business, to evidence that it has sufficient qualification, capability and authority to conduct such business. Party B shall
guarantee that such qualification certificates are true and valid, while Party A is not obliged to inspect the authenticity and validity of such
qualification certificates.
 
Page 5 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
3.11 Party B’s conduct of value-added business has to pass necessary technical test. If such business fails to pass the test as required by Party A
for reasons attributable to Party B as of the commencement date of such test period, the application of such business shall be null and void, and
the costs of such technical tests shall be borne by Party B. Party B has to submit a new application for such business if it wishes to continue the
cooperation in this business.
3.12 Party B shall not carry out business testing or provide business to customers at its own discretion without obtaining Party A’s consent.
3.13 Party B shall make available to Party A the network access and authority for business inquiry and cancellation and upon the request of Party
A, may provide such data/reports on user development, user classification, user habits and business outlook forecasts, and will convey to Party A
in time the user files that may be required for management of such business to ensure the real-time update of Party A’s user data room. At the same
time, the Parties confirm that Party A shall have the ownership of the user files, and the user files and information shall belong to Party A’s
confidential information, for which Party B shall take the confidentiality obligation hereunder; Party B shall not use such information for any
purposes other than those agreed herein without authorization, or provide such information to any third party in any manner whatsoever.
3.14 Party B shall resolve any disputes arising from the safety and legality of the information contents or services it provides, and shall guarantee
that the services it provides will not expose Party A’s communications network, value-added business platform or other third party interests to any
significant potential risks. Party B shall assume any losses thus incurred to Party A and/or any third party and appropriately declare its
responsibility in public and eliminate any adverse impact.
3.15 Without Party A’s prior consent, Party B shall not imbed business at mobile terminal or UTK/STK/OTA cards, whether on its own or together
with other mobile terminal companies.
3.16 Party B shall mark the brand of “China Telecom Mobile Game” on the external promotion and advertisement of the cooperation contents of the
Parties; the name of Party A may, but neither the logo of China Telecom nor the customer service number 10000 shall appear at such advertisements.
The contents of the business described by Party B in any media (e.g. newspaper, radio, TV, leaflets, webpages, etc.) shall obtain the prior written
consent of Party A, and Party B shall not post any business content description to which Party A objects.
3.17 When providing services to users, Party B shall not, in any manner including but not limited to coercion, cajole, fraud or cheat, in order to make
users order tailored business and charge fees therefor, or otherwise increase any unnecessary costs to users.
3.18 Party B shall not advertise, or make any statement favorable for, any competitor having the same or similar business scope as Party A in the
services it provides.
 
Page 6 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
3.19 Party B may use its user name and passwords on the business management system to log in, and effect such functions as application for
value-added business, company information maintenance, information exchange between the Parties regarding their cooperation in value-added
business. Party B shall truthfully register/update in time its name, designated bank, account, contact person, customer service and such other
information, and properly keep and maintain any contract information, settlement information, information on handling of complaints and breach of
contract as generated by the business management system. Party B shall take proper care of, and shall not allow any third party to use, its user
name and password for the business management system. Any losses incurred to either Party or users arising from other person’s knowledge of
Party B’s user name and password for reasons attributable to Party B shall be borne by Party B on its own.
 
3.20 Party B shall have the right to obtain the information fee settled by Party A.
3.21 Except otherwise expressly agreed between the parties or agreed by Party A beforehand, Party B shall not transfer any cooperation business to
a third party in any form whatsoever. Any transfer in violation hereof shall be deemed as a breach by Party B, for which Party B shall take relevant
breaching liability and Party A may terminate this Agreement, suspend fee settlement and require Party B to undertake any direct or indirect loss
thus caused.
3.22 In case of subject change of Party B (the change of holding entity of its business license or license for value-added telecommunications
business (ISP Certificate)), Party B shall settle all fees payable to Party A and if there is no pending breach to be resolved, provide the approving
notice on subject change issued by AIC, and may complete the relevant subject change procedures only after approved by Party A.
 
3.23 Party B shall pay performance deposit to Party A on time and in full amount as agreed herein.
Article 4 Standard Business Practices
4.1 Party A shall provide Party B with the interface parameters of WAP gateway, SMS gateway and relevant platform, and assist Party B in business
debugging, testing and opening.
4.2 The boundary to divide the respective areas of maintenance by the Parties shall be the gateway equipment and the interface from
telecommunication business platform to Party B’s equipment. The equipment on the inner side of the interface shall be maintained by Party A’s
maintenance department, and the equipment on the outer side of the interface shall be maintained by Party B. If Party B uses an exclusive line, then
the interface cable and its connectivity shall be in the charge of the applicant for such exclusive line and the other Party shall provide assistance.
4.3 Party B shall be responsible for the building and maintenance of its systems, including all hardware equipment, system debugging, opening, and
system maintenance work relating to the the wireless value-added business under this Agreement and the costs of each of the foregoing .
4.4 Party B shall be responsible for the interconnection of Party B’s systems with the various gateways or servers of Party A and the application,
renting and maintenance of relevant communication circuit, and bear the corresponding costs.
 
Page 7 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
4.5 Party B guarantees that the debugging, connection and system maintenance work of its systems will not be carried out in the busy hours of
Party A’s business, and all work that may have comparative big impact on the users must be done late at night to minimize the impact on the users’
use of wireless value-added business. Party B further guarantees that such work will not impact the normal running of Party A’s network and it will
assume relevant liabilities for malfunctions of Party A’s network system thus incurred.
4.6 Any debugging, connection and system modification work by Party B to its systems must be notified to Party A in advance and obtain Party
A’s confirmation, after which Party B should announce to users via email, advertisement, SMS or other effective manner, so as to minimize the
impact on users.
4.7 Party B shall submit to any adjustment arrangement made by Party A to data traffic in urgent cases for purposes of guaranteeing the normal
stability of the various value-added business.
4.8 Party B guarantees to provide 24 hour non-interrupted system maintenance.
4.9 Party A shall define the scope of effective billing customers of mobile business, and the information fee incurred by invalid user number or the
user number not covered by business will not be settled.
4.10 No fees will be charged to such numbers as provided by Party A that suspend service, that are canceled or recovered from the following
month. In case Party B fails to respond or respond in time, Party A may claim breaching liabilities by Party B and deduct the corresponding amount
at the time of settlement.
4.11 Party B shall make sure that prior to its provision (including marketing and business advertising) of any service to users (including paid service
and free service), it will thoroughly notify the users in a proper form, and ensure that the users are fully aware of, the content, means of provision,
standard fee rate (information fee and communication fee), frequency of transmission, method of use, manner of cancellation, customer service call
number and such other information users need to know for ordering service and make payment for such service. Party B may provide such service
to users only upon obtaining the consent of users in a provable manner, and is prohibited to provide services to users without users’ proper
knowledge. Party B shall not purposefully intercept information, or discretionally send advertising information to users. In case of such breach by
Party B, it shall assmue all liabilities.
4.12 The business operated by Party B shall be confined to the category provided in Article 1 hereof. Any business beyond such scope shall be
subject to an application filed by Party B to Party A via facsimile affixed with official seal, and may be opened and put in practice only after it is
approved by Party A and has successfully passed the test. The application facsimile aforementioned shall specify the reason, expected time for
business opening and business description. If Party B is discovered to have discretionally opened a business that fails to be approved by Party A,
Party A may refuse to settle all the fees and terminate the cooperation.
 
Page 8 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
4.13 Party B must provide users with unified method for inquiries and service cancellation.
4.14 For business that is officially opened after being approved by Party A, Party B may apply for fee rate change at least three months after the
date on which such business is opened. After obtaining the approval from Party A and the official opening of the business, Party B shall
properlynotify the users about such information about the details of fee rate change, the way to cancel the ordered service, customer service call
number of Party B, and post the change notice (which shall last for one month) at a prominent location on Party B’s website; Party B may change
the rate of information fee for the business in close cooperation with a third party information source only after such planned change has been
announced simultaneously at the main advertising media of such third party information source.
4.15 The Parties shall keep records of users’ use of the business for at least 6 months, and shall keep the record of user’s customized business until
more than 6 months after the business is canceled by relevant user.
4.16 The Parties shall act according to the relevant policies promulgated by the competent industry administration authority (if any).
4.17 The Parties confirm to initially adopt such billing modes as payment by month, by time or by length of time for Party B’s users; other more
reasonable billing modes may be additionally adopted upon negotiations between the Parties.
4.18 Party B shall establish a “black list” policy for customer service, based on which Party B will include the users who maliciously owe fees or
customize services into a “black list” for management, and Party B shall well explain such policy to relevant users. Party B shall use technical means
to monitor the extraordinary traffic, and implement monitor alert and restriction on any owed fees that may be produced by large amount of
information fee (over RMB 150/day/user) arising from malicious customization and ordering of services. Party B shall take restrictive measures on
the canceled or recovered user numbers provided by Party A every day, and take restrictive measures on the canceled or empty numbers every
month. In case Party B fails to take measures on such users, or fails to take measures in time, it shall be responsible for all high-value maliciously
owed fees or such other owed fees arising from the using of mobile game services by the users with canceled or suspended number, and Party A
will deduct such amounts from the information fee to be settled.
4.19 Party B shall not discretionally provide inquiry services of detailed bills of information fee to users, which shall be provided by Party A instead.
4.20 Users using services abroad may cancel the mobile game service already ordered, and Party B is obliged to respond and confirm such request
for cancellation in time. When the customer opens such service, Party B has the duty to declare to the users that any international communication
fee incurred due to the customer’s failure to cancel any ordered mobile game service or the customer’s continued use of any mobile game service in
the roaming state will all be borne by users on their own.
 
Page 9 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
Article 5 Customer Service
5.1 Party A will use 4008289289, the technical support hotline of its customer service center as the call center for receiving and handling complaints
and superviing partner services. Party A will be responsible for user inquiries, claims and complaints arising from network communication issues
and billing issues, and Party A’s customer service center will allocate and distribute the complaints on online complaint handling system.
5.2 Party B shall provide standardized and adequate customer service system to deal with the consultation, claims and complaints by users with
respect to the relevant application services or contents it provides. Such system shall include, without limitation:
 
  (1) Customer service call: 24 hours a day, 7 days a week in service, which shall be service numbers starting with 800 or 4008, and shall not
be ordinary in-city number or mobile number;
 
  (2) Platform functions: customer systems having such functions as exchange, automatic call distribution, computer telephony integration,
interactive voice response, manual agent, recording, data base, business preposition, etc.;
 
  (3) Business functions: customer service center will have mainly functions represented by in-calls and manual service, such as information
inquiries, business cancellation, business consulting and complaint handling;
 
  (4) Seat placing: SP’s customer service shall have at least 5 seats and 12 in-call customer service staff;
 
  (5) System performance and business targets: call completion rate by the system: 99% and level of service (call completion rate by manual
service in 20 seconds): 80%;
 
  (6) Email box for complaints.
5.3 Both Parties shall provide customers with multiple convenient means of business ordering inquiry and business cancellation. Party A shall have
the right to use technical and managerial methods to control and manage Party B’s ordering relationship and provide its own means for business
inquiries and cancellation.
5.4 Party B shall be responsible for all kinds of customer inquiries and complaints arising from problems not related to Party A’s network
communication and platform during the cooperation. Party B shall clearly specify and make public the channel and body by which the business
consulting, claims and complaints will be accepted. Party B shall be obliged to visit the online complaint handling system every day and respond to
the complaints within 24 hours.
5.5 The Parties agree that the complaints shall be resolved within 72 hours, and Party B shall provide party A with the list of relevant persons and
their respective details of contact and guarantee smooth communications 24 hours a day.
5.6 The Parties will adopt the “first inquiry responsibility” system for user complaints, which means that the party receiving the user complaint shall
be responsible to coordinate and properly resolve the questions raised by the users, regardless of which Party shall take the final responsibility. If
the issue does involve the other Party, such other Party shall assist Party receiving the complaint ton resolve the issue.
 
Page 10 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
5.7 For the consulting or complaints that can be resolved by Party B only, Party A shall notify Party B by way of work order flow and Party B shall
respond within 24 hours and completely resolve such complaints within 72 hours. If Party B fails to resolve the issue within 72 hours, or if any user
refuses to pay the information fee due to reasons attributable to Party B’s services, Party B shall deduct or exempt relevant fees for such user. If a
fee refund is needed, the relevant amount will be deducted by Party A at the time of settlement with Party B.
5.8 If neither Party is able to judge which Party shall be responsible for the consulting or complaints it receives, it shall contact the other Party
within 1 hour to find out the responsible Party and help the customer to solve the problem as soon as practicable. Neither Party shall shuffle its due
responsibility to other Party.
5.9 For those customer complaints for which neither Party is able to give reasonable explanations, Party B shall deduct or exempt relevant fees for
such user upon the request of Party A. If a fee refund is needed, the relevant amount will be deducted by Party A at the time of settlement with
Party B.
5.10 If any user complaint is caused due to the fact that a service fails to satisfy its advertised quality commitments, then the Party making such
commitments shall be responsible to reply to the users and solve the complained issues, and the other Party shall give necessary assistance.
5.11 If Party B exits this Agreement due to poor management or is unable to continue providing value-added business for other reasons of its own,
Party B shall directly explain to users and handle the after-exit arrangements. Except for the exit according to the exit mechanism provided herein,
Party B shall inform Party A and obtain its consent regarding the cease of value-added business provision three months in advance; Party A shall
timely terminate its service to collect information fee on behalf of Party B, and assist Party B in making explanations and descriptions to users.
5.12 The Parties shall strictly comply with the regulations of Ministry of Information Industry and other relevant authorities, and adopt
“compensation first” principle with respect to user complaints, which means to first refund any amounts in respect of the complaint or objection to
users before finding out which Party shall be responsible. The amounts so refunded shall be deducted from the settlement amounts between the
Parties. If such user complaint is caused by any breach by Party B hereunder, Party B shall undertake relevant breaching liabilities.
Article 6 Performance Bond
6.1 Upon negotiations between the Parties, Party B will pay Party A RMB three thousand (3,000) as performance bond after this Agreement comes
into force.
6.2 If Party A discovers in its spot checks conducted from time to time that any game, software, business, works, content or service provided by
Party B is not in compliance with laws, regulations, industry rules, Party A’s management measures or contractual agreement, Party B shall pay
Party A additional amount of performance bond at RMB5,000 per violation, or RMB10,000 per business, to be payable to by Party B within 10
working days after the results of copyright spot checks are posted.
 
Page 11 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
6.3 If any game, software, business, works, content or service provided by Party B has intellectual property defects or other right defects or other
illegal issues, or Party A or any of its relevant bodies faces accusation, lawsuit, complaint, negative media report, administrative penalty, then Party
A will temporarily withhold the settlement payment during the period when such dispute is pending for at least RMB50,000 per violation (business),
and deduct from the performance bond already paid by Party B; at the same time, Party B shall pay an additional performance bond at an amount
equivalent to the original one, within 10 working days upon the occurrence of the dispute. For the second time of the aforementioned violation, the
amount of performance bond shall be additionally paid at RMB3,000 per time on the basis of the amount previous paid. For the third time of the
aforementioned violation, Party A will withhold the full amount of the performance bond already paid by Party B, and terminate the full-range
business cooperation for one year.
6.4 If Party B fails to properly solve the accusation, lawsuit, complaint, negative media report, administrative penalty and such other dispute, which
has brought goodwill or economic loss to Party A, Party A will withhold all amounts whose settlement has been suspended and full amount of the
performance bond already paid by Party B, and terminate the full-range business cooperation for one year.
6.5 Within two years upon the termination of the cooperation between the Parties, if no legal dispute involving Party B has occurred, Party A will
refund (without interest) the performance bond to Party B within 30 working days upon the day immediately following the 2nd anniversary of the
cooperation termination.
6.6 The correspondent bank account for performance bond:
Account name of Party A: Dazzle Interactive Network Technologies Co., Ltd.
Deposit bank: Shanghai Pudong Development Bank, Business Office of Nanjing Branch
A/C:   
Account name of Party B: Shenzhen iDreamSky Technology Co., Ltd.
Deposit Bank: China Merchants Bank Co., Ltd., CMB Shenzhen Sungang Sub-branch
A/C:   
6.7 This article shall be applied to all agreements executed by and between the Parties.
Article 7 Billing and Settlement
7.1 The prices of information fee shall be formulated by Party B and approved by Party A in principle, provided that Party A may propose advice
regarding fee rate and negotiate such proposal with Party B. any changes to the prices of information fee (including the changes in means of fee
charging) may be implemented formally only after confirmed by Party A. All billing and settlement shall be subject to the provisions of
Management Measures for Cooperation in Mobile Game Business (V1.0).
 
Page 12 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
7.2 The successful charging bill collected on Party A’s billing system shall be used by the Parties as the basis for settlement of information fees; the
business billed by time shall be calculated based on the successful receipt of the business by the customer; business subject to monthly payment
shall be based on customer’s true ordering. Party A shall deduct from the payable information fee, the amount of information fee refused to be paid
by any users due to Party B’s service quality.
7.3 Billing cycle: the statistic cycle of total amount of Party B’s information fee on Party A’s billing system is normally based on calendar month,
starting from 0 o’clock on the 1st day of a calendar month and ending at 24 o’ clock on the last day of such month.
7.4 Mode of distribution: the cooperation may be divided into two categories, content cooperation and channel cooperation, according to the
different rights and responsibilities of the Parties in the cooperation.
 
  7.4.1 Detailed rules for content cooperation settlement
 
7.4.1.1
 
All kinds of communication fee income incurred from the user’s or Party B’s use of communication network shall belong to
Party A in full amount.
7.4.1.2
 
8% (or the actual bad debt rate if such actual rate exceeds 8%) of the receivable information fees in the corresponding month
will be allocated and deducted as the provisions for bad debts.
7.4.1.3
 
Party A will deduct the expenses for fee collection at the percentage provided in the agreement executed with the fee
collection agent (the current sharing percentage of China Telecom is 15%, and the sharing percentage of other fee collection
channels shall be calculated as actually incurred).
7.4.1.4
 
After the bad debt provisions and the part allocated to the fee collection agent are deducted from the total revenue, Party B
will obtain 70% of the remaining revenue (total revenue * (1 – bad debt rate) * (1 – sharing percentage for fee collection
channel) * 70%).
7.4.1.5
 
The Parties shall jointly determine the settlement amount according to system data records and statement provided by Party
A, provided that any expenses incurred by the testing account used by the Parties for business testing shall not be included
in settlement.
7.4.1.6
 
The detailed practices for settlement in content cooperation are set out in Management Measures for Cooperation in Mobile
Game Business (V1.0).
 
Page 13 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
  7.4.2 If Party B agrees to participate in the mode of channel cooperation, details of settlement are listed as follows:
 
7.4.2.1
 
All kinds of communication fee income incurred from the user’s or Party B’s use of communication network shall belong to
Party A in full amount.
7.4.2.2
 
8% (or the actual bad debt rate if such actual rate exceeds 8%) of the receivable information fees in the corresponding month
will be allocated and deducted as the provisions for bad debts.
7.4.2.3
 
Party A will deduct the expenses for fee collection at 15% (or the actual fee collection expense rate if such actual rate exceeds
15%) as provided in the agreement executed with the fee collection agent.
7.4.2.4
 
After the bad debt provisions and the part allocated to the fee collection agent are deducted from the total revenue, Party B will
obtain 40% of the remaining revenue (total revenue * (1 – bad debt rate) * (1 – sharing percentage for fee collection channel) *
40%)
7.4.2.5
 
The Parties shall jointly determine the settlement amount according to system data records and statement provided by Party A,
provided that any expenses incurred by the testing account used by the Parties for business testing shall not be included in
settlement.
7.4.2.6
 
The detailed practices for settlement in content cooperation are set out in Management Measures for Cooperation in Mobile
Game Business (V1.0).
7.5 If Party B agrees to sign off Party A’s access bundle sales or favorable package or such other packaged promotional activities, the fee rate can
be adjusted appropriately upon negotiations between the Parties.
7.5.1 8% (or the actual bad debt rate if such actual rate exceeds 8%) of the receivable information fees of the corresponding month will be allocated
and deducted as the provisions for bad debts.
7.5.2 Party A will deduct the expenses for fee collection at the percentage provided in the agreement executed with the fee collection agent (the
current sharing percentage of China Telecom is 15%, and the sharing percentage of other fee collection channels shall be calculated as actually
incurred).
 
Page 14 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
7.5.3 After the bad debt provisions and the part allocated to the fee collection agent are deducted from the total revenue (total revenue * (1 – bad
debt rate) * (1 – sharing percentage for fee collection channel)), Party A, on the one side, and all content providers participating in such access
bundle sales, favorable package or other packaged promotional activities, on the other side, shall share the income at a ratio of 50%:50% (Party A:
all content providers participating in such business). Party B and all the other content providers participating in such business shall share such
50% of income according to the proportion of the usage of their business to the total usage. The formula for calculation shall be:
(1) If the game package only includes multiple console games:
Based on the amount of downloads of the console games, the sharing percentage among all CSPs in the package shall be calculated as
follows:
Total income of game package * (1 – bad debt rate) * (1 – sharing percentage for fee collection channel) *50% * (number of downloads of
such CSP’s online game/aggregate number of downloads of all console games contained in the game package)
(2) If the game package only includes multiple WAP social online games:
Based on the amount of logons of the online games, the sharing percentage among all CSPs in the package shall be calculated as follows:
Total income of game package * (1 – bad debt rate) * (1 – sharing percentage for fee collection channel) *50% * (logons of such CSP’s online
game/sum of logons of all online games contained in the game package)
The detailed practices are set out in Management Measures for Cooperation in Mobile Game Business (V1.0).
7.6 The Parties shall settle the payment every month, and the initial settlement period shall be the end of the third month, which means that the
information service fee generated in the first month shall be paid to the account of the partner by the end of the third month. When requesting
payment of relevant contract price from Party A, Party B has to:
(1) provide official invoices that are in compliance with the requirements of State tax laws by the 25th of the second month (Party B, instead of
any of its affiliates, shall be the invoice issuer);
(2) provide the payment request confirmed by the Parties; and
(3) pay the performance bond as required in Article 6 hereof.
7.7 The settlement shall be made based on Party A’s data. If there is any discrepancy between the billing data of the Parties, and such discrepancy
reaches over 5% of Party A’s data, Party B may request account reconciliation via CSP management system within 5 working days after the
settlement information is posted, and shall deliver the account statement and invoices confirmed with a stamp to the contact person of Party A by
the 25th of the second month. If Party B fails to make such account reconciliation request within such prescribed period of time, Party A may refuse
to accept and deal with such request. If Party B’s billing data is confirmed as correct after investigation, the relevant account will be adjusted in the
following month. Any CSP’s failure to request account reconciliation in time shall be deemed as the tacit acceptance of the settlement data by such
CSP, and Party A may refuse to accept any further account reconciliation request made by such CSP for the relevant settlement month.
 
Page 15 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
7.8 All business revenue payable to Party B calculated by Party A according to the sharing percentages for different business under cooperation
between the Parties, minus (or plus) other expenses payable (or receivable) by Party B, shall be the revenue to be finally settled to Party B (the
“Settled Information Service Dee”). The aforementioned “other expenses” shall include, without limitation, penalty deducted for breach and co-
location fee. As agreed between the Parties, Party B’s business revenue and other payable expenses may be settled separately and apply different
settlement process.
7.9 Party B shall make timely update of its information of bank account and such other information necessary for payment as registered on the
business management system. If Party B’s failure to update such payment information in time renders Party A’s payment to be rejected by the bank,
or causes other difficulties that prevent Party A from making timely payment, then Party A will postpone such payment till the June or December
closest to the time when Party A learns about the correct bank account of Party B without taking any breaching responsibility for overdue payment.
7.10 Any change of Party B’s corporate name shall be notified to Party A in time via the business management system or other appropriate means.
After such change of Party B’s corporate name, any amounts payable by Party A to Party B, whether incurred before or after such change, shall all
be paid to the bank account with the changed name of Party B. If Party A fails to make the payment on time due to Party B’s failure to properly
complete the name change procedures, Party A will postpone such payment.
7.11 If Party B terminates this Agreement pursuant to its terms, the Parties will settle the information service fee accrued prior to the termination. At
the settlement, the Parties will determine the settlement method, cycle and process and implement the settlement by reference to the rules hereof
regarding the deduction of information service fee or penalty fine in case of breach.
 
7.12 Each Party shall undertake its own due taxes.
7.13 Party A may refuse to settle the information fee incurred by stolen user numbers as proved by public security department or acknowledged by
both parties.
7.14 The abnormal consumption that may be written off with the help of Party B shall be deducted from the Settled Information Service Fee of the
current period after confirmed by the Parties, and Party A shall refund such fee to the relevant users.
7.15 Party B shall be obliged to assist Party A in taking necessary effective steps to reduce the number of abnormal deals.
7.16 Party B shall not make self-consumption and other violations detrimental to Party A’s interests. Such violating acts, once discovered, shall
grant Party A with a right to deduct all settlement amounts of the current month payable to Party B, and Party B will claim breaching responsibility
against Party B according to the extent of impact, including penalty fines, suspension of settlement, suspension of business up to termination of
cooperation.
 
Page 16 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
Article 8 Relevant Undertakings
8.1 Party B undertakes that the games, software, business, works, contents or services it provides are all in compliance with relevant laws, rules and
regulations of the State and are free of any ownership defect, and Party B has executed necessary authorization/license agreement with the right
owner and/or the agent thereof in accordance with applicable requirements.
8.2 Party B will be deemed to have committed a breach hereunder if a third person initiates any legal or administrative proceedings (collectively the
“Infringement Charges”) alleging that Party A or any of its affiliated companies or entities has infringed on the legitimate rights and interests of
such third person (including but not limited to intellectual property rights), or if Party A or any of its affiliated companies or entities is threatened
with administrative penalties. Upon a notice to Party B, Party A shall have the right to freeze Party B’s settlement account, and Party B will take
responsibilities toward such third person and indemnify Party A or any of its affiliated companies or entities for all costs and expenses thus
incurred, including, without limitation, any and all litigation fees, travelling costs, attorney fees, amount of settlement or any compensation
provided in the final sentence. Such costs and expenses incurred may be deducted by Party A directly from the performance deposit or any
unsettled payment under this Agreement or other agreements; any shortfall shall be paid by Party B within 3 working days upon the notice from
Party A. This article shall survive the termination of this Agreement.
8.3 The Parties may negotiate separately the terms regarding the use of Party A’s enterprise name, service brand, business brand, trademark,
markings or logo, etc. in the business hereunder. Party B shall not use any of the foregoing in any form whatsoever without reaching an agreement
with Party A or obtaining Party A’s prior written confirmation; otherwise, an infringement will be constituted. In such case, Party B shall eliminate
the negative impact and compensate Party A for any losses thus caused.
8.4 Party B shall not, in any manner whatsoever, mislead the users into believing that any game, software, business, works, content or service it
provides on its own is provided by Party A or by both Parties.
8.5 Neither Party shall use or imitate the other Party’s business name, trademark, patterns, service logo, symbols, code, model or initials in its
advertisements or in public places without the written permit of such other Party; neither Party shall claim its ownership over such other Party’s
business name, trademark, patterns, service logo, symbols, code, model or initials.
Article 9 Security and Confidentiality
9.1 Party A guarantees the completeness of all information/application service resources it provides, and Party A undertakes not to sell, transfer,
duplicate, lease or hand over any content or app provided by Party B to any third party entity or individual in any form whatsoever (including in
edited, abridged or added version), unless otherwise provided by laws.
 
Page 17 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
9.2 Neither Party shall divulge or disclose this Agreement to any third party without written consent of the other Party.
9.3 Each Party shall have the obligation of confidentiality with respect to any and all information and documents provided by the other Party over
the course of business development and operation, and neither Party may disclose such information to a third party, or use such information for
any purposes other than cooperation project development without the written consent of the other Party (except for the disclosure made in
response to the requirements of laws, regulations or relevant regulators); otherwise, such Party shall assume relevant legal responsibility toward
the other Party; provided, however, that any information that has already been possessed by a Party, has been obtained from a third party through
lawful approaches, or has become publicly available prior to the disclosure shall not belong to the aforementioned confidential information.
9.4 The obligation of confidentiality provided in this article shall survive the termination of this Agreement.
Article 10 Liabilities for Breach of Agreement
10.1 Both Parties shall strictly comply with the terms of this Agreement; a Party’s failure to perform any of its own obligations, undertakings or
covenants, or its violation of any of its statements hereunder, which brings damage to the interests of the other Party or renders the cooperation
business impossible to be continued, shall be operated as a breach, and the breaching Party shall assume the liabilities for breach by indemnifying
the other Party for any loss thus incurred and paying the penalty provided by relevant term hereof. In case of any damage to the other Party’s
reputation, the breaching Party shall also undertake such liabilities as stopping damage, making apologies and restoring reputation.
10.2 In case this Agreement and its appendices is unable to be performed or fully performed due to a breach by a Party, the breaching Party shall
assume the breaching liabilities and the non-breaching Party may terminate the cooperation business, and may further claim legal and economic
responsibility from the breaching party if the breaching Party causes adverse social impact or economic losses to the non-breaching Party. In case
of breach by both Parties, the Parties shall assume their respective due responsibilities according to the actual situation.
10.3 If Party B unilaterally terminates this Agreement, or is penalized with termination of cooperation according to Management Measures for Game
Partner Credit Points, or if Party A terminates this Agreement pursuant to the terms hereof, Party B agrees:
 
  (1) to offer one-month exit grace period during which Party B shall continue to provide services for customers and publish announcement
in respect of the cease of its services at its website;
 
  (2) to pay off penalty fines and performance bond to Party A in full amount; and
 
  (3) that Party A shall have the right not to settle the outstanding and unsettled payments.
 
Page 18 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
10.4 Neither Party shall assume any breaching liability if this Agreement is terminated due to the industry regulation by government (a written
document shall be provided) or other event of force majeure.
10.5 Party A will not be responsible to compensate Party A for any loss arising from the malfunction caused by Party A’s equipment, system or
network and such other non-human caused reasons, but shall be obliged to fix the malfunction as soon as possible.
10.6 Party A will not take any responsibility if the conduct of business agreed herein is impacted when Party A is carrying out necessary
construction or network building.
10.7 If Party A discovers that Party B has violated the Integrity Agreement attached hereto by bribing Party A’s working personnel, Party A may
elect to impose a penalty of RMB10,000 to 100,000, suspend cooperation for 1-3 years or terminate the cooperation depending on the seriousness
of the violation and the consequences thus brought about, and any loss thus incurred to Party A shall be borne by Party B.
10.8 Any of the following acts by Party B shall constitute its breach hereunder, in which case Party A shall have the right to immediately stop the
interface of Party B’s system, suspend settlement, and require Party B to penalty at an amount equivalent to 100% of the total amount of its
receivable information fee of the then-current month or RMB3,000, whichever is higher. Any loss thus incurred to party A shall be fully borne by
Party B. If Party B manages to complete the remedy to the satisfaction of Party A within 10 working days, Party A will resume the interface of Party
B’s system and resume the settlement; if Party B fails to complete the remedy within such 10 working days, or the completed remedy still fails to
reach Party A’s requirements, or Party B has committed three breaches accumulatively, Party A may notify Party B to terminate this Agreement:
 
  (1) Party B’s service has any content that is illegal, in violation of rules, reactionary or against the principle of public order and good social
customs;
 
  (2) Party A has received from different users over 15 (included) justified complaints within one day, or over 50 (included) justified
complaints within 30 days about the same subject;
 
  (3) The user complaints incurred due to reasons attributable to Party B have caused adverse social impact, or have been reported to news
media, administration of telecommunication, AIC or other relevant government agency;
 
  (4) Party B is accused, or causes Party A to be accused of infringement, or Party or Party B is sued by others, penalized or reported by
media for reasons attributable to Party B;
 
Page 19 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
  (5) Party B violates laws, rules or regulations of the sector, or any documents, management measures or policies of telecommunication or
relevant industry authority;
 
  (6) Any hardware, software, business or game provided by Party B in this business is held by Party A to fail to satisfy the business
requirements upon its testing, or is withdrawn by Party B earlier than agreed;
 
  (7) Party B fails to have the relevant qualification, or provide its services beyond the permitted scope of its qualification;
 
  (8) Party B discretionally discloses Party A’s trade secrets, technical files, marketing plan, customer files, cooperation agreement and other
key secrets to any third party;
 
  (9) Party B unilaterally amends, terminates or refuses to perform, this Agreement without justified reason and without first reaching an
agreement with Party A;
 
  (10) Party B fails to obey the business supervision or management of Party A, or fails to remediate as required by Party A;
 
  (11) Party B infringes on the communication secrets or personal privacy of users or other persons; (12) Party B delays or fails to fully
perform its obligations and duties hereunder;
 
  (13) Party B breaches the Undertakings on Network Access Information Safety;
 
  (14) Party B discretionally uses Party A’s name, logo or other relevant information without Party A’s consent, which causes adverse impact
or economic loss to Party A;
 
  (15) Party B’s illegal advertising or practices has resulted in indemnification or negative media reports of Party A;
 
  (16) Party B’s 24-hour customer service call and other relevant information fails to match that existing on the service system, or fails to be
accessed normally, or fails to make response for a long time;
 
 
(17) Party B fails to provide the customer service support as required by this Agreement and business management measures, shuffle
responsibility to others, or fails to respond to any customer claims or complaints transferred by Party A in time as required by its
commitments hereunder or Party A’s management measures;
 
  (18) Party B’s other breach, or acts that are illegal, violating or detrimental to Party A’s interests.
 
Page 20 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
10.9 In case of Party B’s other breach of this Agreement or of Party A’s relevant management rules, Party A may claim breaching liability from Party
B pursuant to thereto, and may terminate this Agreement. At the same time, Party B shall take full responsibilities to compensate any loss incurred
to Party A due to Party B’s such breach.
10.10 Notwithstanding anything herein is provided in contrary, Party A will not be responsible for any loss of expected benefits, goodwill loss, and
data damage or loss arising from acts of Party B hereunder.
10.11 If Party B should pay penalty fines and/or assume compensation liability according to this Agreement or Party A’s relevant management rules,
Party A shall have the right to deduct the relevant amount directly from any settlement payment or performance bond.
Article 11 Force Majeure
11.1 In case this Agreement is unable to be performed or fully performed due to any accident or event of force majeure, neither Party shall
compensate the other Party for any economic loss thus suffered. The Party encountering such event of force majeure shall immediately inform the
circumstances to the other Party in writing and within fifteen days, shall provide the detailed information of the event and a valid document
evidencing the reasons why this Agreement cannot be performed or fully performed or the performance of this Agreement needs to be postponed.
The Parties shall negotiate to decide whether to continue the performance of this Agreement or terminate this Agreement according to the extent of
the effect on the performance hereof.
Article 12 Dispute Resolution
12.1 Any disputes between the Parties arising from the performance of this Agreement shall be resolved through amicable negotiations; in case
such negotiations fail, both Parties agree to submit the dispute to the competent court where Party A is domiciled.
12.2 In case of disputes between the Parties over certain provisions hereof, or when any such dispute is pending for resolution, the Parties shall
continue to implement the other provisions hereof except the disputed provisions.
Article 13 Effectiveness, Amendment and Termination of Agreement
13.1 This Agreement shall come into force as of January 1, 2013 and remain valid for 1 year. As of the effective date hereof, the original cooperation
of mobile game business executed between the Parties shall terminate automatically. Upon the expiry of this Agreement, this Agreement may be
renewed automatically for one year (but can only be renewed once) if neither Party raises objection. Except otherwise agreed between the parties,
the contents of this Agreement shall remain binding throughout the renewed period.
 
Page 21 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
13.2 Throughout the effective term and renewed term hereof, this Agreement may be revised or amended upon mutual consent. The Parties may
execute a supplemental agreement or execute a new agreement to reflect such revision or amendment.
13.3 Any business rules, management measures, quality standards and/or customer service standards formulated by Party A during the term hereof
shall be part of this Agreement, and if such rules, measures and/or standards conflict with the terms hereof, such rules, measures and/or standards
shall prevail, unless the Parties deem it appropriate to apply this Agreement or deem it necessary to execute a separate agreement for such conflicts.
13.4 Any Party who wishes to amend or revise this Agreement must provide a 30-day prior written notice to the other Party, and the Parties shall
negotiate to amend or revise this Agreement in writing.
13.5 During the term hereof, Party A may, depending on the business development and needs of management, evaluate and sort out Party B and its
business according to unified rules. If Party B fails to reach the requirements in Party A’s evaluation, sorting or other business management
measures, Party A may terminate this Agreement.
13.6 Throughout the performance of this Agreement, except otherwise expressly provided herein, neither Party may suspend or terminate the
performance of this Agreement or unilaterally terminate this Agreement without the consent of the other Party.
13.7 Any Party’s failure to perform its obligations or duties hereunder, or serious violation of the provisions hereof, which has made the other Party
unable to operate or normally conduct business cooperation hereunder, shall be deemed that such Party has unilaterally terminated this Agreement.
The non-breaching Party shall have the right to claim compensation from the breaching Party for any economic loss incurred by its breach, and
terminate this Agreement.
13.8 This Agreement shall automatically terminate if Party B:
 
  (1) transfers or leases the numbers, trunk line, digital web address and such other resources acquired from Party A without approval of
Party A;
 
  (2) runs its business beyond the business operation area and business scope provided by its qualification permit;
 
  (3) has no qualification permit issued by the State competent authority but provides the content and category of the business that needs
such qualification permit;
 
  (4) provides fake copyright or qualification;
 
 
(5) fails to pass the assessment of “survival of the fittest” organized by Party A, in which case this Agreement shall be automatically
terminated. If Party B’s receivable information fee of accumulatively 3 months is zero, this Agreement shall be automatically terminated
(except the free games);
 
Page 22 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
  (6) disobeys Party A’s business management or hurts Party A’s interests;
 
  (7) otherwise disobeys the requirements of relevant authority or Party A’s management.
13.9 During the term hereof, any division, merger, dissolution, liquidation, bankruptcy or other events that lead to changes of Party B in the
company nature, qualification and capacity for civil acts shall be notified to Party A in time, and subject to the provisions hereunder about the exit
grace period. If Party B is deprived of the qualification or capacity to provide the wireless value added business hereunder due to its dissolution,
liquidation or bankruptcy, this Agreement shall terminate accordingly. In case of division or merger of Party B, this Agreement shall terminate, and
the successor company (or other entity) to Party B’s wireless value added business hereunder shall re-apply for business opening to Party A, and
timely modify Party B’s enterprise identifier code and other information existing on Party A’s business system or other business management
system.
13.10 In case of any change of Party B’s company information, Party B shall go to the AIC, tax authority, bank or information industry authority to
complete the procedures of company information change, exchange the original certificates for the valid ones, and submit the amended business
license, organization code certificate, tax registration certificate and such other relevant documents and certificates to Party A for verification, the
photocopies of which shall be filed for record.
13.11 If Party B has to terminate this Agreement due to technical or operating difficulties, Party B shall serve an at least 3 month prior written notice
to Party A, and after approved by Party B, offer a one-month exit grace period during which Party B shall continue to provide services for users and
publish announcement in respect of the cease of game services at its website (Web/WAP) or through other channels at least 30 days in advance.
Any loss thus incurred to Party A shall be compensated by Party B.
13.12 During the effective term hereof, if the terms of this Agreement contravene any new fee rate policy or new document published by the
supervisory authority of the Parties, the Parties may negotiate to amend or terminate this Agreement.
Article 14 Miscellaneous
14.1 Any matters not covered herein shall be subject to the relevant business standards, management measures, quality standards and/or customer
service standards, or subject to written supplementary articles agreed by the Parties upon amicable negotiations, which shall be equally binding as
this Agreement.
14.2 If any term hereof becomes invalid at any time but will not fundamentally affect the validity of this Agreement, the other terms hereof shall not
be affected.
 
Page 23 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
14.3 The headings hereof are inserted for reference only. The contents of the terms shall be the basis to determine the rights and obligations of the
Parties.
14.4 Nothing herein shall be deemed or construed as joint venture, partnership or agency relationship between the Parties.
14.5 This Agreement shall be made in four originals, two for each Party, which shall be equally effective.
14.6 Any notices (information) between the Parties arising out of the implementation of this Agreement, or in connection with this Agreement must
be sent to the addresses expressly specified herein in written form, including, without limitation, via facsimile, EMS or other form confirmed by the
Parties. (End of body text)
(The remainder of this page is intentionally left blank.)
 
Page 24 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
[Signature and Stamp Page]
Party A: Dazzle Interactive Network Technologies Co., Ltd.
By authorized representative: Zhang Peng
Signature and stamp:
[Company seal is affixed ]
 
/s/ Zhang Peng  
Date: January 1, 2013  
Party B: Shenzhen iDreamSky Technology Co., Ltd.
By authorized representative: Chen Xiangyu
Signature and stamp:
[Company seal is affixed ]
 
/s/ Chen Xiangyu     Date: January 1, 2013
 
Page 25 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
Appendix 1:
Integrity Agreement
In order to jointly safeguard the company interests of both Parties and cause the parties and their respective working staff to practice in an integral
manner, in accordance with relevant laws and regulations, the Parties agree as follows:
1 The Parties and their respective working staff shall consciously comply with the laws and regulations governing integral practices and prohibited
commercial bribery of the State and government.
2 Party A shall not privately ask for or accept any off-the-book rebates or other money or gifts provided by Party B.
3 Party A’s working staff shall not, in any form whatsoever, ask for or accept from Party B any rebates, money, valuable securities, valuable
properties or other articles; nor shall they reimburse any expenses irrelevant to this project or request personal benefits from Party B.
4 Party A’s working staff shall not attend any treats or entertainment that may affect Party A’s performance of its obligations and duties.
5 Party A’s working staff shall not privately discuss this project with Party B or reach a tacit understanding with Party B, nor disclose any bidding
internal control information or corporate trade secrets.
6 Party A’s working staff shall not seek benefits for his/her family members, relatives or friends in the project by taking advantage of his/her powers
or official capacity.
7 Party B shall not privately offer Party A any off-the-book rebates or other money or gifts.
8 Party B’s working staff shall not, in any name or form whatsoever, provide Party A’s working staff with any rebates, money, valuable securities,
valuable properties or other articles; nor shall they reimburse any expenses irrelevant to this project for Party A’s working staff.
9 Party B shall not invite Party A’s working staff to go trips or other luxury entertainment under the name of discussing business or executing
economic contracts.
10 If either Party discovers any violation hereof by any working staff of the other Party, it shall report such violation to the supervisor or the
disciplinary department of such staff, and the staff so reported shall not retaliate to such Party under any excuses.
 
Page 26 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
11 Liabilities for breach:
If Party A discovers that Party B violates this Agreement, bribes Party A’s working staff, or has committed any commercial bribery being
investigated by judicial authority, Party A shall have the right to suspend the agreement and depending on the actual situation and consequences
thereof, claim compensation from Party B for the economic loss thus incurred to Party A, record such bad acts of Party B, disallow Party B the
access to Party A’s full corporate scope to engage in the various services, supplies, construction and other project cooperation for 1 to 3 years,
Call number for each Party to accept violation reporting:
Party A: 025-86588790
Party B: 0755-86110235
 
Page 27 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
Appendix 2:
Undertakings on Network Access Information Safety
Each of the information source providers connected to the mobile communication network of Dazzle Interactive Network Technologies Co., Ltd.,
CHINANET of China Telecom or relevant business platform (including, without limitation, SMS gateway, WAP gateway, JAVA/BREW download
server, location business server, etc.) shall undertake that:
Article 1 it will comply with the relevant laws, administrative regulations and management rules of the State, and strictly implement the information
safety management rules.
Article 2 it will operate its business according to relevant laws, and provide the service only after obtaining relevant business permits; the business
operation without permit is prohibited.
Article 3 it will not make use of C114 or CHINANET of China Telecom or relevant business platform to (i) engage any illegal or criminal activities
that endanger the national safety or divulge the secrets of the State, (ii) produce, consult, duplicate or disseminate any information that violates the
Constitution or laws, impedes social security, damages national unity or sabotages solidarity among nationalities, or any pornographic or violent
information, or (iii) post any information with any content that:
 
  1 is against the fundamental principles enshrined in the Constitution;
 
  2 compromises State security, divulges State secrets, subverts State power or damages national unity;
 
  3 harms the dignity or interests of the State;
 
  4 instigates hatred and discrimination among nationalities and sabotages solidarity among nationalities;
 
  5 sabotages State religious policy or propagates heretical teachings or feudal superstitions;
 
  6 spreads rumors, disrupts social order or social stability;
 
  7 propagates obscenity, pornographic, gambling, violence, murder and terror and instigates crimes;
 
  8 insults or slanders a third party or infringes upon the lawful rights and interests of a third party;
 
  9 belongs to the thirteen vulgar online contents that violate social ethics and hurt the physical and mental health of youngsters, which
are the contents that:
 
  (a) depict or obscurely depict sex behavior, instigate sex association, or are provocative or insulting;
 
  (b) directly expose and describe the sex organ of human body;
 
  (c) describe sex behavior, sex process or sex manner or contain sexually suggestive or provocative language;
 
  (d) describe or expose the sex organs, or only use very small covering;
 
  (e) depict human body with the entire body or privacy places naked or only covered by limbs;
 
  (f) contain pictures of careless bare, candid shot, privacy place exposure with a nature of infringing personal privacy;
 
  (g) attract clicks with provocative headings;
 
Page 28 of 29Jiangsu Telecom Contract No.: JSXCS1200166CC000
 
  (h) are pornographic, vulgar novels, audios and videos that are prohibited by relevant authority, including the deleted portions of
some movies;
 
  (i) contain illegal social information about one-night stand, wife exchange or SM; (j) pornographic comics;
 
  (k) advertise bloody violence, malicious abuses, or insult others;
 
  (l) contain illegal sex products advertisements and venereal disease treatment advertisements;
 
  (m) maliciously disseminate others’ privacy without permit from others or by using “Internet Mass Hunting”;
 
  10 Otherwise prohibited by laws, administrative regulations, rules or relevant regulations.
Any of the abovementioned illegal or criminal activities and/or posting of any harmful information, once discovered, shall be prevented by
immediate measures and reported to relevant authority in time.
Article 4 any information provided by it will comply with the relevant State laws, administrative regulations, rules or policies governing intellectual
property rights.
Article 5 it shall make sure, during its online testing and pilot running and after the business is officially opened, that the contents of the business it
provides are safe and stable, and will cause damage to C114 or CHINANET of China Telecom or relevant business platform.
Article 6 It shall establish efficient information safety and confidentiality management policies and technical protective measures, and accept the
management, supervision and inspection of relevant competent authority of the relevant business of Dazzle Interactive Network Technologies Co.,
Ltd.
Article 7 in case of any violations of the above, Dazzle Interactive Network Technologies Co., Ltd. may take necessary actions, close relevant
information source access; in case of serious violation, Dazzle Interactive may terminate the cooperation business and claim legal responsibility
from the information source provider. These undertakings will take effect upon executed by the information source provider and be kept in custody
by Dazzle Interactive Network Technologies Co., Ltd.
Information source provider (stamp):
[Company seal is affixed ]
 
Responsible Person
(signature):  
/s/ Chen Xiangyu  
 
Page 29 of 29Exhibit 10.1
COOPERATION AGREEMENT
This Cooperation Agreement (this “ Agreement”), dated as of May 13, 2020, is by and among MG Capital Management Ltd., a Cayman
Islands company limited by shares (“ MG Capital”), Percy Rockdale LLC, a Michigan limited liability company (“Percy Rockdale”), Rio Royal LLC, a
Michigan limited liability company (“Rio Royal”, and together with MG Capital and Percy Rockdale, the “ MG Capital Parties”) and HC2 Holdings,
Inc., a Delaware corporation (the “Company”). Each of the MG Capital Parties and the Company are referred to herein as a “ Party” and collectively,
as the “ Parties.”
RECITALS
WHEREAS, as of the date hereof, the MG Capital Parties may be deemed to beneficially own 2,703,537 shares of the Company’s common
stock, $0.001 par value per share (the “Common Stock”), which represents approximately 5.8% of the Common Stock issued and outstanding on the
date hereof;
WHEREAS, in consideration of the agreements and obligations of the Company, as set forth in this Agreement and subject to the terms
and conditions contained herein, the MG Capital Parties are agreeing (i) to irrevocably withdraw the notice of stockholder nomination of individuals
for election as directors of the Company at the Company’s 2020 Annual Meeting of Stockholders (the “ 2020 Annual Meeting ”) submitted to the
Company on February 13, 2020 (the “Nomination Notice”), and any related materials or notices submitted to the Company in connection therewith
and (ii) to terminate its solicitation of proxies in connection with the 2020 Annual Meeting;
WHEREAS, as of the date hereof, the Company and the MG Capital Parties have determined that it is in their respective best interests to
come to an agreement to modify the composition of the Company’s board of directors (the “ Board”) and as to certain other matters, as provided
herein; and
WHEREAS, the Board and the Nominating and Governance Committee of the Board have selected their 2020 Director Slate (as defined
herein) for the 2020 Annual Meeting.
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound hereby,
agree as follows:
1. Board of Directors.
(a) Appointments.  Simultaneously with the execution and delivery of this Agreement, the Board and its committees shall take such actions
(with such actions deemed to have to occurred substantially simultaneously) as are necessary (i) to increase the size of the Board from six (6) to ten
(10) Directors, and (ii) to appoint each of Kenneth S. Courtis and Michael Gorzynski (the “ MG Capital Designees”) and (iii) to appoint each of
Avram A. Glazer and Shelly Lombard (together with the MG Capital Designees, the “New Directors”) to the Board.
(b) Board Size. From the date of this Agreement through the completion of the 2020 Annual Meeting, the Board will not increase the size
of the Board above ten (10) directors without the unanimous approval of the Board. From the completion of the Company’s 2020 Annual Meeting
through the end of the Standstill Period (as hereinafter defined), the Board will not increase the size of the Board above seven (7) directors without
the unanimous approval of the Board.
(c) Board Chairman Succession . Consistent with the actions previously taken by the Board and the Glazer Agreement, and as of the date
hereof, Mr. Glazer will be appointed as Chairman of the Board, succeeding Mr. Gfeller, who is being replaced as Chairman of the Board effective as
of the date hereof.(d) New Director Information. As a condition to the New Directors’ appointment to the Board and any subsequent nomination for election
as a director at any future Company annual meeting of stockholders, he or she must provide any information required to be disclosed in a proxy
statement or other filing under applicable law, stock exchange rules or listing standards.
(e) Date of the 2020 Annual Meeting.  The Company agrees that it shall hold the 2020 Annual Meeting no later than July 8, 2020 and shall
not cause or permit any delay, postponement or adjournment thereof, except for any adjournment solely due to a lack of quorum under the
Company’s Fourth Amended and Restated By-Laws (the “ By-Laws”).
(f) Slate of Directors for the 2020 Annual Meeting.
(i) The Company agrees that, in connection with the execution and delivery of this Agreement, the Board shall take such actions
as are necessary to (i) reduce the size of the Board from ten (10) to seven (7) Directors, effective as of the 2020 Annual Meeting, and (ii) nominate
each of the New Directors and Wayne Barr, Jr., Warren H. Gfeller and Philip A. Falcone (collectively, the “ 2020 Director Slate ”) for election to the
Board at the 2020 Annual Meeting for a term expiring at the Company’s 2021 Annual Meeting of Stockholders (the “ 2021 Annual Meeting”). The
Board, based on the information provided to it, has determined that each member of the 2020 Director Slate would (i) qualify as an “independent
director” under the applicable rules of the New York Stock Exchange (the “ NYSE”) and the rules and regulations of the U.S. Securities and
Exchange Commission (the “ SEC”) and (ii) satisfy the guidelines and policies with respect to service on the Board applicable to all non-
management directors (other than Mr. Falcone). The Company agrees that, provided that each member of the 2020 Director Slate is able and willing
to serve on the Board, (i) the Board will unanimously recommend that the stockholders of the Company vote to elect each member of the 2020
Director Slate as a director of the Company at the 2020 Annual Meeting, (ii) the Company will use its reasonable best efforts (which will include the
solicitation of proxies) to obtain the election of the 2020 Director Slate at the 2020 Annual Meeting and (iii) the Company will use its best efforts to
resist, discourage and defend against any attempt, solicitation or action by any stockholder of the Company to remove any member of the 2020
Director Slate prior to the 2021 Annual Meeting. For the avoidance of doubt, the Company will be required to use no less than the same level of
efforts and to provide no less than the same level of support as was provided for its director nominees at the 2019 Annual Meeting of Stockholders.
Any of the Company’s current directors that is not standing for election at the 2020 Annual Meeting shall receive the full amount of his or her
quarterly compensation for serving as non-management directors during the second quarter of 2020 (including any quarterly fee awarded and
vesting of any and all equity awards for serving on, or serving as the Chair of, any committee of the Board).
(g) Company Policies and Indemnification.
(i) The Parties acknowledge that each of the MG Capital Designees and each other member of the 2020 Director Slate will be
governed by the same protections and obligations as other non-employee directors of the Company, including, without limitation, confidentiality,
conflicts of interest, related party transactions, fiduciary duties, codes of conduct, trading and disclosure policies, and other governance guidelines
and policies of the Company (collectively, “Company Policies”), and shall have the same rights and benefits as other non-employee directors of the
Company, including without limitation with respect to insurance, indemnification, compensation and fees.
(ii) The Parties acknowledge that to the extent they have not already done so, within three (3) business days of the date hereof,
the Company shall enter into an indemnification agreement with each of the New Directors in the form attached as Exhibit 10.20 to the Company’s
Annual Report on Form 10-K, previously filed with the SEC on March 16, 2020.
2. Additional Agreements .
(a) The MG Capital Parties shall comply, and shall cause each of their Affiliates and Associates (as hereinafter defined) to comply with the
terms of this Agreement and shall be responsible for any breach of this Agreement by any such Affiliate or Associate.
(b) The MG Capital Parties, on behalf of themselves and their Affiliates and Associates, shall irrevocably withdraw their Nomination
Notice and any related materials or notices submitted to the Company in connection therewith and shall agree to terminate any solicitation of
proxies in connection with the 2020 Annual Meeting.
2(c) The MG Capital Parties hereby agree to appear in person (including via permitted remote or virtual attendance) or by proxy at any
annual or special meeting of the Company’s stockholders held during the Standstill Period, and agree that they shall not participate or vote in any
solicitation of written consents of the Company’s stockholders during the Standstill Period (unless expressly requested to do so by the Board), and
that they shall vote all shares of Common Stock beneficially owned by the MG Capital Parties at such meeting or in such consent solicitation, (A) in
favor of all directors nominated by the Board for election and against the removal of any member of the Board, (B) in accordance with the Board’s
recommendation with respect to any “say-on-pay” proposal and (C) in accordance with the Board’s recommendation with respect to any other
Company proposal or stockholder proposal or nomination presented at such meeting or solicitation of consents; provided , however, that in the
event that both Institutional Shareholder Services Inc. (“ ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”) recommend otherwise with respect to
the Company’s “say-on-pay” proposal presented at an annual or special meeting held during the Standstill Period, the MG Capital Parties shall be
permitted to vote in accordance with the recommendation of ISS and Glass Lewis.
(d) The MG Capital Parties agree that the Board or any committee thereof, solely to fulfill the discharge of its fiduciary duties upon the
advice of its legal counsel, may recuse either of Messrs. Courtis or Gorzynski by majority vote of the members of the Board (but excluding the
applicable director), from the portion of any Board or committee meeting at which the Board or any such committee is evaluating and/or taking
action with respect to and after the right of the recused director to be present prior to recusal (A) the exercise of any of the Company’s rights or
enforcement of any of the obligations under this Agreement, and (B) any transaction proposed by, or with, the MG Capital Parties, their Affiliates or
Associates, as long as all other similarly situated directors are similarly recused. The Board or such committee, as applicable, may withhold from
either of Messrs. Courtis or Gorznyski any material distributed to the directors to the extent directly relating to the subject of that recusal.
3. Standstill Provisions .
(a) The standstill period (the “ Standstill Period”) begins on the date of this Agreement and shall extend until thirty (30) days prior to the
deadline for the submission of stockholder nominations for directors for the 2021 Annual Meeting pursuant to the By-Laws. The MG Capital Parties
hereby agree that during the Standstill Period, none of the MG Capital Parties nor any of their Affiliates and Associates will, and they will cause
each of their Affiliates and Associates not to, as applicable, directly or indirectly, alone or in concert with others, in any manner, but expressly
subject, in each case, to the provisions of Section 3(b) below:
(i) fail to comply with all applicable laws and regulatory rules and obtain all applicable regulatory approvals, if and when
acquiring, or offering, seeking or agreeing to acquire, by purchase or otherwise, or directing any third party in the acquisition of, any Common
Stock or any securities convertible or exchangeable into or exercisable for Common Stock (collectively, “ Company Securities”), or rights or options
to acquire any Company Securities, or engaging in any swap instrument or derivative hedging transactions or other derivative agreements of any
nature with respect to Company Securities;
(ii) engage in a “solicitation” of “proxies” (as such terms are defined under the Exchange Act), votes or written consents of
stockholders or security holders with respect to, or from the holders of, the Common Stock (including a “withhold” or similar campaign), for any
purpose, including, without limitation, the election or appointment of individuals to the Board or to approve or vote in favor or against stockholder
proposals, resolutions or motions, or become a “participant” (as such term is defined in Instruction 3 to Item 4 of Schedule 14A promulgated under
the Exchange Act) in any contested “solicitation” of proxies, votes or written consents for any purpose, including, without limitation, the election
or appointment of directors with respect to the Company (as such terms are defined under the Exchange Act) (other than a “solicitation” or acting
as a “participant” in support of the nominees of the Board at any stockholder meeting or providing such encouragement, advice or influence that is
consistent with either the Board’s or Company management’s recommendation in connection with such director nominees or other proposals,
resolutions or motions, pursuant to this Agreement or otherwise);
(iii) form, join or in any way participate in any “ group ” (within the meaning of Section 13(d)(3) of the Exchange Act) with respect
to the shares of the Common Stock (other than a “ group ” that includes all or some of the persons or entities identified on Exhibit A attached
hereto); provided , however, that nothing herein shall limit the ability of an Affiliate, a family member and an estate planning vehicle formed for any
of the foregoing, of the MG Capital Parties to join a “group ” with such parties, as applicable, following the execution of this Agreement;
3(iv) agree, attempt, seek or propose to deposit any shares of Common Stock in any voting trust or similar arrangement or subject
any shares of Common Stock to any arrangement or agreement with respect to the voting of any shares of Common Stock, other than any such
voting trust, arrangement or agreement solely among the MG Capital Parties, and their Affiliates or Associates and otherwise in accordance with
this Agreement;
(v) seek or submit, or knowingly encourage any person or entity to seek or submit, nomination(s) in furtherance of a “contested
solicitation” for the appointment, election or removal of directors with respect to the Company or seek, or knowingly encourage or take any other
action with respect to the appointment, election or removal of any directors, in each case in opposition to the recommendation of the Board;
(vi) (A) present or make to the stockholders of the Company, or knowingly encourage any person to present or make to the
stockholders of the Company, any proposal or other matter for consideration by stockholders at any annual or special meeting of stockholders of
the Company or through action by written consent, (B) make any public offer or proposal to the Company (with or without conditions) with respect
to any merger, tender (or exchange) offer, acquisition, recapitalization, restructuring, disposition or other business combination involving the
Company or any of its significant subsidiaries, or make any such offer privately to the Company, which private offer would reasonably be expected
to require the Company or the Parties to make public disclosure (of any kind), (C) affirmatively solicit a third party to make any public or private
offer or proposal (with or without conditions) with respect to any merger, tender (or exchange) offer, acquisition, recapitalization, restructuring,
disposition or other business combination involving the Company, or encourage, initiate or support any third party in making such an offer or
proposal, (D) publicly comment on any third party proposal regarding any merger, tender (or exchange) offer, acquisition, recapitalization,
restructuring, disposition, or other business combination with respect to the Company or any of its significant subsidiaries by such third party
prior to such proposal becoming public or (E) make any private proposal to the Company that would reasonably be expected to require the
Company or the Parties to make public disclosure (of any kind);
(vii) make any public disclosure, communication, announcement or statement regarding any intent, purpose, plan, or proposal
with respect to (A) controlling, changing or influencing the Board, including, without limitation, any public disclosure, communication,
announcement or statement regarding any intent, purpose, plan, or proposal relating to any change in the number of directors or the filling of any
vacancies on the Board, (B) any material change in the capitalization, dividend policy, share repurchase programs and practices or capital allocation
programs and practices of the Company, (C) relating to any material change in the Company’s management, compensation or corporate structure,
(D) relating to any waiver, amendment or modification to the Company’s Second Amended and Restated Certificate of Incorporation, as amended
(the “Charter”), or to the By-Laws, (E) causing any securities of the Company to be delisted or (F) causing any equity securities of the Company to
become eligible for termination of registration;
(viii) seek, alone or in concert with others, representation on the Board, except as specifically permitted in Section 1;
(ix) subject to Section 3(b) below, advise, knowingly encourage, knowingly support or knowingly influence any person or entity,
in the MG Capital Parties’ capacity as stockholders of the Company, with respect to the voting or disposition of any securities of the Company at
any annual or special meeting of stockholders with respect to the appointment, election or removal of any director(s), except in accordance with
Section 1;
(x) make any request for stockholder list materials or other books and records of the Company in the MG Capital Parties’ capacity
as stockholders of the Company;
(xi) institute, solicit, assist or join, as a party, any litigation, arbitration or other proceeding against or involving the Company or
any of its or their current or former directors or officers (including derivative actions) in order to effect or take any of the actions expressly
prohibited by this Section 3; provided , however, that for the avoidance of doubt the foregoing shall not prevent the MG Capital Parties, and their
Affiliates or Associates from (A) bringing litigation to enforce the provisions of this Agreement, (B) making counterclaims with respect to any
proceeding initiated by, or on behalf of, the Company against the MG Capital Parties, their Affiliates or their Associates, (C) bringing bona fide
commercial disputes that do not relate to the subject matter of this Agreement, (D) complying with a validly issued legal process or (E) exercising
statutory appraisal, dissenters or similar rights under applicable law;
4(xii) make any request or submit any proposal to amend the terms of this Agreement other than through non-public
communications with the Company or the Board that would not be reasonably determined to trigger public disclosure obligations for any Party; or
(xiii) disclose any intention, plan or arrangement inconsistent with the provisions of this Section 2.
(b) Notwithstanding the foregoing, nothing in this Agreement shall prohibit or restrict the MG Capital Parties from: (A) communicating
privately with the Board or any of the Company’s officers regarding any matter in a manner that does not otherwise violate this Section 3, so long
as such communications are not intended to, and would not reasonably be expected to, require any public disclosure of such communications, (B)
communicating privately with stockholders of the Company and others in a manner that does not otherwise violate this Section 3, and (C) taking
any action necessary to comply with any law, rule or regulation or any action required by any governmental or regulatory authority or stock
exchange that has, or may have, jurisdiction over the MG Capital Parties or any of their respective Affiliates or Associates; provided  that a breach
by the MG Capital Parties of this Agreement is not the cause of the applicable requirement. Furthermore, nothing in this Agreement shall be deemed
to restrict in any way the ability of Messrs. Courtis or Gorzynski, each acting in his capacity as a director of the Company, from exercising any of his
rights, powers and privileges as directors, from fulfilling his statutory and fiduciary duties as a director, or otherwise exercising his authority as a
director pursuant to the Charter, the By-Laws and/or any resolution of the Board or a committee thereof.
4. Representations and Warranties of the Company . The Company represents and warrants to the MG Capital Parties as follows: (a) the
Company has the power and authority to execute, deliver and carry out the terms and provisions of this Agreement and to consummate the
transactions contemplated by this Agreement; (b) this Agreement has been duly and validly authorized, executed and delivered by the Company,
constitutes a valid and binding obligation and agreement of the Company and is enforceable against the Company in accordance with its terms,
except as enforcement of this Agreement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance
or similar laws generally affecting the right of creditors and subject to general equity principles; (c) the execution, delivery and performance of this
Agreement by the Company does not and will not (i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to the
Company, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute a
breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment,
acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which the
Company is a party or by which it is bound; and (d) the execution, delivery and performance of this Agreement by the Company does not and will
not violate or conflict with any law, rule, regulation, order, judgment or decree applicable to the Company.
5. Representations and Warranties of the MG Capital Parties . The MG Capital Parties represent and warrant to the Company that, except as
otherwise expressly set forth in, or permitted pursuant to, this Agreement, (a) the authorized signatory or signatories of the MG Capital Parties set
forth on the signature page hereto has the power and authority to execute this Agreement and any other documents or agreements to be entered
into in connection with this Agreement and to bind the MG Capital Parties thereto, (b) this Agreement has been duly authorized, executed and
delivered by the MG Capital Parties, and assuming due execution by each counterparty hereto, is a valid and binding obligation of the Parties,
enforceable against the MG Capital Parties in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general
equity principles, (c) the execution of this Agreement, the consummation of any of the transactions contemplated hereby, and the fulfillment of the
terms hereof, in each case in accordance with the terms hereof, will not conflict with, or result in a breach or violation of the organizational
documents of the MG Capital Parties as currently in effect, (d) the execution, delivery and performance of this Agreement by the MG Capital Parties
does not and will not violate or conflict with any law, rule, regulation, order, judgment or decree applicable to the MG Capital Parties, (e) as of the
date of this Agreement, the MG Capital Parties are deemed to beneficially own 2,703,537 shares of Common Stock, (f) as of the date hereof, and
except as set forth in clause (e) above, the MG Capital Parties do not currently have, and do not currently have any right to acquire any beneficial,
record or derivative interest in any other securities of the Company (or any rights, options or other securities convertible into or exercisable or
exchangeable (whether or not convertible, exercisable or exchangeable immediately or only after the passage of time or the occurrence of a specified
event) for such securities or any obligations measured by the price or value of any securities of the Company or any of its controlled Affiliates,
including any swaps or other derivative arrangements designed to produce economic benefits and risks that correspond to the ownership of shares
of Common Stock or any other securities of the Company, whether or not any of the foregoing would give rise to beneficial ownership (as
determined under Rule 13d-3 promulgated under the Exchange Act), and whether or not to be settled by delivery of shares of Common Stock or any
other class or series of the Company’s stock, payment of cash or by other consideration, and without regard to any short position under any such
contract or arrangement), (g) the MG Capital Parties have not entered into or maintained, and will not enter into or maintain, any economic,
compensatory, pecuniary or other arrangements with any director of the Company for serving as a nominee or director of the Company, (h) no
person other than the MG Capital Parties has any rights with respect to the shares of Common Stock beneficially owned by the MG Capital Parties
and (i) none of the MG Capital Parties or their Affiliates has formed, or has any present intent to form, a group (within the meaning of Section 13(d)
under the Exchange Act) with any person or entity not identified on Exhibit A in relation to the Company or the Common Stock.
56. Mutual Non-Disparagement . Subject to applicable law, each of the Parties covenants and agrees that, during the Standstill Period,
neither Party nor any of its subsidiaries, Affiliates, successors, assigns, principals, partners, members, general partners, officers, key employees or
directors (collectively, “Representatives”), shall in any way, directly or indirectly, in any capacity or manner, whether written or oral, electronically
or otherwise (including, without limitation, in a television, radio, internet, newspaper, magazine interview, or otherwise through the press, media,
analysts or other persons or in any document or report filed with the SEC), publicly disparage, impugn, make ad hominem attacks on or otherwise
defame or slander or make, express, transmit, speak, write, verbalize or otherwise publicly communicate in any way (or cause, further, assist, solicit,
encourage, support or participate in any of the foregoing), any public communication or statement of any kind, whether verbal, in writing,
electronically transferred or otherwise, that might reasonably be construed to be disparage, derogate or impugn, the other Party or such other
Party’s Representatives (including any current officer or director of a Party or a Parties’ subsidiaries who no longer serves in such capacity
following the execution of this Agreement), employees, stockholders (solely in their capacity as stockholders of the applicable Party), or any of
their businesses, products or services, in any manner that would reasonably be expected to damage the business, or reputation of the other Party
or of its Representatives (including former officers and directors), directors (or former directors), employees, stockholders (solely in their capacity
as stockholders of the applicable Party); provided  that, with respect to any litigation, arbitration or other proceeding between the Parties, nothing in
this Section 5  shall prevent either Party from disclosing any facts or circumstances with respect to any such litigation, arbitration or other
proceeding. This Section 5 shall not (i) limit the power of any director of the Company to act in accordance with his or her fiduciary duties or
otherwise in accordance with applicable law and (ii) limit any Party’s ability to comply with any subpoena or other legal process or respond to a
request for information from any governmental authority with jurisdiction over the party from whom information is sought.
7. Public Announcement .
(a) Promptly following the execution of this Agreement, the Company shall issue a joint press release with the MG Capital Parties
substantially in the form attached to this Agreement as Exhibit B (the “Press Release ”), with such modifications, if any, as may be mutually agreed
between the Company and the MG Capital Parties, and (i) the Company shall file a Current Report on Form 8-K, which shall be in form and
substance reasonably acceptable to the Company and the MG Capital Parties (for the avoidance of doubt, nothing herein shall prohibit the
Company from complying with its obligation to file such Current Report by the deadline therefor) and (ii) the MG Capital Parties shall file an
amendment to its Schedule 13D announcing this Agreement and the withdrawal of the 2020 Consent Solicitation, which shall be in form and
substance reasonably acceptable to the Company and the MG Capital Parties (for the avoidance of doubt, nothing herein shall prohibit the MG
Capital Parties from complying with its obligation to file such amendment by the deadline therefor).
(b) Neither the Company, the MG Capital Parties nor any of their respective Affiliates or Associates, will issue a separate press release in
connection with this Agreement, other than as mutually agreed by the Company and the MG Capital Parties.
8. Definitions. For purposes of this Agreement:
(a) the terms “ Affiliate” and “ Associate” shall have the respective meanings set forth in Rule 12b-2 promulgated by the SEC under the
Exchange Act and shall include all persons or entities that at any time during the term of this Agreement become Affiliates or Associates of any
person or entity referred to in this Agreement;
(b) the term “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended; and
(c) the terms “ person” or “ persons” mean any individual, corporation (including not-for-profit), general or limited partnership, limited
liability or unlimited liability company, joint venture, estate, trust, association, organization or other entity of any kind or nature.
9. Notices. All notices, consents, requests, instructions, approvals and other communications provided for herein and all legal process in
regard to this Agreement will be in writing and will be deemed validly given, made or served, if (a) given by email, when sent to the email address
set forth below (as applicable), and receipt of such email is acknowledged, or (b) if given by any other means, when actually received during normal
business hours at the address specified in this Section 9:
6(a) if to the Company:
HC2 Holdings, Inc.
450 Park Avenue, 30th Floor
New York, NY 10022
Attention: Joseph A. Ferraro
Email: jferraro@hc2.com
Telephone: +1-212-235-2691
with copies to:
Skadden, Arps, Slate, Meagher & Flom LLP
One Manhattan West
New York, NY 10001
Attention: Richard J. Grossman
Todd E. Freed
Email: Richard.grossman@skadden.com
Todd.freed@skadden.com
Telephone: +1-212-735-2116
+1-212-735-3714
(b) if to the MG Capital Parties:
MG Capital Management Ltd.
595 Madison Avenue, 29th Floor
New York, NY 10022
Attention: Michael Gorzynski
Email: mike@mgcapitalpartners.com
Telephone: +1-646-274-9610
with a copy to:
Kleinberg, Kaplan, Wolff & Cohen, P.C.
500 Fifth Avenue, 11th Floor
New York, NY 10110
Attention: Christopher P. Davis
Email: cdavis@kkwc.com
Telephone: +1-212-880-9865
10. Expenses. Within five (5) business days following receipt of reasonably satisfactory documentation thereof, the Company will
reimburse the MG Capital Parties for their fees and expenses (including all legal, public relations, proxy advisory and out-of-pocket expenses, the
“Expenses”) incurred in preparation for and in connection with the matters relating to the consent solicitation run by the MG Capital Parties, the
2020 Annual Meeting and the negotiation, execution and effectuation of this Agreement and the transactions contemplated hereby, in an amount
equal to $352,290.25 (the “Initial Reimbursement”). Between the date of the Initial Reimbursement and the date of the 2020 Annual Meeting, the
Company will reimburse the MG Capital Parties for the Expenses in an aggregate amount not exceeding $650,000 (inclusive of the Initial
Reimbursement, the “Cap”), which Expenses shall be reimbursed on a dollar-for-dollar basis at the same time as the Company reimburses its third
party vendors ( e.g., legal counsel, public relations firm, financial advisor and proxy advisory firm)in connection with the MG Capital Parties’
consent solicitation and Nomination Notice; provided  that all Expenses, subject to the Cap, shall be reimbursed no later than the date of the 2020
Annual Meeting.
711. Specific Performance; Remedies; Venue.
(a) Each of the Parties acknowledges and agrees that irreparable injury to the other Party could occur in the event any of the provisions of
this Agreement were not performed in accordance with their specific terms or were otherwise breached and that such injury could not be
adequately compensable by the remedies available at law (including the payment of money damages). It is accordingly agreed that each Party will
be entitled to seek injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this
Agreement, in addition to any other remedy to which they are entitled at law or in equity. FURTHERMORE, THE PARTIES AGREE (1) ANY NON-
BREACHING PARTY WILL BE ENTITLED TO SEEK INJUNCTIVE AND OTHER EQUITABLE RELIEF, WITHOUT PROOF OF ACTUAL
DAMAGES; AND (2) THE BREACHING PARTY AGREES TO WAIVE ANY BONDING REQUIREMENT UNDER ANY APPLICABLE LAW, IN THE
CASE ANY OTHER PARTY SEEKS TO ENFORCE THE TERMS BY WAY OF EQUITABLE RELIEF. THIS AGREEMENT WILL BE GOVERNED IN
ALL RESPECTS, INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF DELAWARE WITHOUT GIVING
EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE.
(b) The Parties (a) irrevocably and unconditionally submit to the personal jurisdiction of the Delaware Court of Chancery (or, only if the
Delaware Court of Chancery declines to accept jurisdiction over a particular matter, the federal or other state courts located in Wilmington,
Delaware), (b) agree that they will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such
courts, (c) agree that any actions or proceedings arising in connection with this Agreement or the transactions contemplated by this Agreement
shall be brought, tried and determined only in such courts, (d) waive any claim of improper venue or any claim that those courts are an
inconvenient forum and (e) agree that they will not bring any action relating to this Agreement or the transactions contemplated hereunder in any
court other than the aforesaid courts. The Parties agree that mailing of process or other papers in connection with any such action or proceeding in
the manner provided in Section 9 or in such other manner as may be permitted by applicable law as sufficient service of process, shall be valid and
sufficient service thereof.
12. Severability. If at any time subsequent to the date hereof, any provision of this Agreement is held by any court of competent
jurisdiction to be illegal, void or unenforceable, such provision will be of no force and effect, but the illegality or unenforceability of such provision
will have no effect upon the legality or enforceability of any other provision of this Agreement.
13. Termination. This Agreement will terminate upon the earlier of: (i) the conclusion of the Standstill Period or (ii) delivery of written notice
by one Party to the other Party of a material breach of this Agreement by the breaching Party that is uncured after ten (10) calendar days of notice
of such breach. Upon such termination, this Agreement shall have no further force and effect. Notwithstanding the foregoing, Sections 9  through
Section 19 hereof shall survive termination of this Agreement, and no termination of this Agreement shall relieve any party of liability for any
breach of this Agreement arising prior to such termination.
14. Counterparts . This Agreement may be executed in two or more counterparts and by scanned computer image (such as .pdf), each of
which will be deemed to be an original copy of this Agreement. For the avoidance of doubt, neither Party shall be bound by any contractual
obligation to the other Party (including by means of any oral agreement) until all counterparts to this Agreement have been duly executed by each
of the Parties and delivered to the other Party (including by means of electronic delivery or facsimile).
15. Affiliates. Each of the Parties agrees that it will cause their or its Affiliates and their respective employees and other representatives to
comply with the terms of this Agreement.
16. No Third-Party Beneficiaries . This Agreement is solely for the benefit of the Company and the MG Capital Parties, and is not
enforceable by any other persons. No Party may assign its rights or delegate its obligations under this Agreement, whether by operation of law or
otherwise, without the prior written consent of the other Party, and any assignment in contravention hereof will be null and void.
17. No Waiver. No failure or delay by any Party in exercising any right or remedy hereunder will operate as a waiver thereof, nor will any
single or partial waiver thereof preclude any other or further exercise thereof or the exercise of any other right or remedy hereunder.
18. Entire Understanding; Amendment . This Agreement contains the entire understanding of the Parties with respect to the subject matter
hereof and supersedes any and all prior and contemporaneous agreements, memoranda, arrangements and understandings, both written and oral,
between the Parties, or any of them, with respect to the subject matter of this Agreement. This Agreement may be amended only by an agreement in
writing executed by each of the Parties.
819. Interpretation and Construction . Each of the Parties acknowledges that they have each been represented by counsel of their choice
throughout all negotiations that have preceded the execution of this Agreement, and that they have executed the same with the advice of said
counsel. Each Party and its counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referred to
herein, and any and all drafts relating thereto exchanged among the Parties will be deemed the work product of all of the Parties and may not be
construed against any Party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require
interpretation of any ambiguities in this Agreement against any Party that drafted or prepared it is of no application and is hereby expressly waived
by each Party, and any controversy over interpretations of this Agreement will be decided without regard to events of drafting or preparation.
Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without
limitation.”
[Signature pages follow ]
9This Agreement has been duly executed and delivered by the duly authorized signatories of the parties as of the date first set forth above.
THE COMPANY:
HC2 Holdings, Inc.
By: /s/ Joseph Ferraro
Name:Joseph Ferraro
Title: Chief Legal Officer
[Signature Page to Cooperation Agreement ]MG CAPITAL PARTIES:
MG Capital Management Ltd.
By:/s/ Michael Gorzynski
Name: Michael Gorzynski
Title: Sole Director
Percy Rockdale LLC
By:/s/ Michael Gorzynski
Name: Michael Gorzynski
Title: Sole Manager
Rio Royal LLC
By:/s/ Michael Gorzynski
Name: Michael Gorzynski
Title: Sole Manager
[Signature Page to Cooperation Agreement ]Exhibit A
MG CAPITAL PARTIES
MG CAPITAL MANAGEMENT LTD.
PERCY ROCKDALE LLC
RIO ROYAL LLCExhibit B
Form of Press ReleaseHC2 HOLDINGS AND MG CAPITAL ANNOUNCE SETTLEMENT
AGREEMENT AND PLAN TO RECONSTITUTE BOARD OF
DIRECTORS
Announces Immediate Appointment of Two New Directors: MG Capital Nominees Kenneth S. Courtis and Michael Gorzynski
Previously Announced Additions Avram A. “Avie” Glazer and Shelly C. Lombard Will Also Begin Serving as Directors Immediately, With Mr.
Glazer to Serve as Chairman of the Board
Recent Collaboration With Stockholders Will Result in More Than 50% of the Board Being Refreshed Following the 2020 Annual Meeting
MG Capital Agrees to Withdraw its Consent Solicitation and Nomination Notice
NEW YORK, May 14, 2020 (GLOBE NEWSWIRE)—HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE: HCHC), a diversified holding company,
and MG Capital Management, Ltd. (together with Percy Rockdale LLC and Rio Royal LLC, “MG Capital”) today announced a settlement agreement
to reconstitute the Board of Directors (the “Board”). The agreement provides for the immediate appointment of four new members – Kenneth S.
Courtis, Avram A. “Avie” Glazer, Michael Gorzynski and Shelly C. Lombard – who will also stand for election on HC2’s seven-member slate at the
Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) to be held on Wednesday, July 8, 2020.
Effective immediately and through the Annual Meeting, the Board will expand from six members to ten members. The Board will be reduced to
seven members following the 2020 Annual Meeting, resulting in more than 50% of the directors being refreshed based on engagement with
stockholders. As part of the settlement agreement, MG Capital has also withdrawn its consent solicitation and nomination for election of directors
at the 2020 Annual Meeting.
The Company had previously announced the nominations of Mr. Glazer and Ms. Lombard for election at the 2020 Annual Meeting as part of the
Board’s ongoing refreshment efforts and commitment to incorporating stockholder feedback and to enhancing value for all stockholders. They will
be appointed immediately along with MG Capital nominees, Mr. Courtis and Mr. Gorzynski, and Mr. Glazer will be appointed Chairman of the Board.
As part of the reconstitution of the Board, three of the current directors – Robert V. Leffler, Jr., Lee S. Hillman and Julie Totman Springer –
announced that they will not stand for re-election at the 2020 Annual Meeting. The Company’s slate of director nominees will include Wayne Barr
Jr., Philip Falcone and Warren H. Gfeller, who will continue to serve as directors and stand for election at the 2020 Annual Meeting alongside the
four newly-appointed directors.
Mr. Gfeller commented: “The Board is pleased to put the consent solicitation behind us and looks forward to working with the new directors. We
are pleased to welcome Avie, Ken, Mike and Shelly to the Board. Additionally, we thank Robert, Lee and Julie for their service and contributions to
HC2. With these additions, we believe HC2 will be positioned to pursue its path of growth and innovation.”Mr. Gorzynski added: “Ken and I want to thank the Board for carrying out HC2’s director refreshment process in a thoughtful manner. We no longer
view ourselves as MG Capital nominees, but rather HC2 directors firmly committed to advocating for stockholders’ best interests in the boardroom.
Our focus now is on working closely with the other directors to enhance stockholder value and seize new opportunities over the long term.”
Under the terms of HC2’s agreements with MG Capital, JDS1, LLC and Lancer Capital LLC, each stockholder has individually agreed to abide by
customary standstill and voting provisions. The agreements will be filed on a Form 8-K with the Securities and Exchange Commission.
Director Biographies:
Kenneth S. Courtis  is a financial executive with more than 30 years of banking, investment management and board service experience. Since
January 2009, Mr. Courtis has served as the Chairman of Starfort Investment Holdings. Previously, he served as Vice Chairman and Managing
Director of Goldman Sachs, and Chief Economist and Investment Strategist of Deutsche Bank Asia. He received an undergraduate degree from
Glendon College in Toronto and an MA in international relations from Sussex University in the United Kingdom. He earned an MBA at the
European Institute of Business Administration and received a Doctorate with honors and high distinction from l’Institut d’etudes politiques, Paris.
Avram A. “Avie” Glazer is the principal of Lancer Capital. In addition, he currently serves as Executive Co-Chairman and Director of Manchester
United Plc (NYSE: MANU). Mr. Glazer served as President and Chief Executive Officer of Zapata Corporation, a U.S. public company between from
March 1995 to July 2009 and Chairman of the board of Zapata Corporation from March 2002 to July 2009. In addition to his professional experience,
Mr. Glazer received a business degree from Washington University in St. Louis and received a law degree from American University, Washington
College of Law.
Michael Gorzynski is the Managing Member of MG Capital, an investment firm focused on complex value-oriented investments. Previously, he
invested in special situations globally at Third Point LLC, a large asset management firm, where he focused on macro, event-driven, distressed, and
private investments across the capital structure. He is an expert in restructurings and in the insurance and banking industries, having participated
in multiple large-scale bank and insurance company restructurings. He began his career at Credit Suisse First Boston in the technology investment
banking group and at Spectrum Equity Investors a private equity fund in Boston. He earned a BA from the University of California, Berkeley, and
received an MBA from Harvard Business School.
Shelly C. Lombard is currently an independent consultant. From 2011 to 2014, she was the Director of High Yield and Distressed Research for
Britton Hill Capital, a broker dealer specializing in high yield bank debt and bonds and value equities. From 2003 to 2010, Ms. Lombard was a high
yield bond analyst covering the automotive industry at Gimme Credit, a subscription bond research firm. From 1992 to 2001, she analyzed, managed,
and was involved in the restructurings of proprietary investments for ING, Chase Manhattan Bank, Barclays Bank, and Credit Lyonnais. Ms.
Lombard began her career at Citibank in the leveraged buyout group. Ms. Lombard has an M.B.A. in finance from Columbia University.
Advisors
Jefferies LLC is serving as financial advisor to HC2, and Skadden, Arps, Slate, Meagher & Flom LLP is serving as its legal advisor.
Kleinberg Kaplan is serving as MG Capital’s legal advisor.About HC2
HC2 Holdings, Inc. is a publicly traded (NYSE: HCHC) diversified holding company, which seeks opportunities to acquire and grow businesses that
can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. HC2 has a diverse array of
operating subsidiaries across multiple reportable segments, including Construction, Energy, Telecommunications, Life Sciences, Broadcasting,
Insurance and Other. HC2’s largest operating subsidiary is DBM Global Inc., a family of companies providing fully integrated structural and steel
construction services. Founded in 1994, HC2 is headquartered in New York, New York. Learn more about HC2 and its portfolio companies at
www.hc2.com.
Cautionary Statement Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This communication, and certain oral statements made by our
representatives from time to time may contain, forward-looking statements. Generally, forward-looking statements include information describing
actions, events, results, strategies and expectations and are generally identifiable by use of the words “believes,” “expects,” “intends,”
“anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might” or “continues” or similar expressions. The forward-looking
statements in this communication include, without limitation, any statements regarding our expectations regarding building stockholder value,
future cash flow, longer-term growth and invested assets, the timing or prospects of any refinancing of HC2’s remaining corporate debt, any
statements regarding HC2’s expectations regarding entering definitive agreements in respect of the potential divestitures of Continental Insurance
and/or DBM Global, reducing HC2’s leverage and related interest expense at the holding company level generally and with the net proceeds of such
divestitures, reducing corporate overhead, growth opportunities at HC2’s Broadcasting and Energy businesses and unlocking value at HC2’s Life
Sciences segment. Such statements are based on the beliefs and assumptions of HC2’s management and the management of HC2’s subsidiaries and
portfolio companies. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees
of performance or results, and the Company’s actual results could differ materially from those expressed or implied in the forward-looking
statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent statements and
reports filed with the SEC, including in our reports on Forms 10-K, 10-Q and 8-K. Such important factors include, without limitation, issues related to
the restatement of our financial statements; the fact that we have historically identified material weaknesses in our internal control over financial
reporting, and any inability to remediate future material weaknesses; capital market conditions, including the ability of HC2 and its subsidiaries to
raise capital; the ability of HC2’s subsidiaries and portfolio companies to generate sufficient net income and cash flows to make upstream cash
distributions; volatility in the trading price of HC2’s common stock; the ability of HC2 and its subsidiaries and portfolio companies to identify any
suitable future acquisition or disposition opportunities; our ability to realize efficiencies, cost savings, income and margin improvements, growth,
economies of scale and other anticipated benefits of strategic transactions; difficulties related to the integration of financial reporting of acquired or
target businesses; difficulties completing pending and future acquisitions and dispositions; activities by activist stockholders, including a proxy
contest, consent solicitation or any unsolicited takeover proposal; effects of litigation, indemnification claims and other contingent liabilities;
changes in regulations and tax laws; the risks and uncertainties associated with, and resulting from, the COVID-19 pandemic; and risks that may
affect the performance of the operating subsidiaries and portfolio companies of the Company. Although HC2 believes its expectations and
assumptions regarding its future operating performance are reasonable, there can be no assurance that the expectations reflected herein will be
achieved. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed
with the SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking
statements made in this communication.
You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to HC2 or persons acting on its
behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date hereof, and
unless legally required, HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.Important Additional Information and Where to Find It
HC2 plans to file a proxy statement (the “2020 Proxy Statement”), together with a proxy card, with the SEC, in connection with the solicitation of
proxies for the 2020 Annual Meeting. STOCKHOLDERS ARE URGED TO READ THE 2020 PROXY STATEMENT (INCLUDING ANY
AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT HC2 FILES WITH THE SEC CAREFULLY
IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
Stockholders will be able to obtain, free of charge, copies of the 2020 Proxy Statement, any amendments or supplements thereto and any other
documents (including a proxy card) when filed by HC2 with the SEC in connection with the 2020 Annual Meeting at the SEC’s website
(http://www.sec.gov ), at HC2’s website ( http://ir.hc2.com) or by contacting Okapi Partners LLC by phone at (877) 629-6355, by email at
info@okapipartners.com  or by mail at 1212 Avenue of the Americas, 24th Floor, New York, New York 10036.
Participants in the Solicitation
HC2, its directors and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies from
stockholders in connection with the 2020 Annual Meeting. Additional information regarding the identity of these potential participants, none of
whom (other than Philip A. Falcone, HC2’s President and Chief Executive Officer, and Avram A. Glazer, the Company’s Chairman of the Board) owns
in excess of one percent (1%) of HC2’s shares, and their direct or indirect interests, by security holdings or otherwise, will be set forth in the 2020
Proxy Statement and other materials to be filed with the SEC in connection with the 2020 Annual Meeting. Information relating to the foregoing can
also be found in HC2’s Amendment No. 1 on Form 10-K (the “Form 10-K/A”), filed with the SEC on April 29, 2020. To the extent holdings of HC2’s
securities by such potential participants (or the identity of such participants) have changed since the information printed in the Form 10-K/A, such
information has been or will be reflected on Statements of Ownership and Change in Ownership on Forms 3 and 4 filed with the SEC.
Contact:
For HC2:
Investor Relations
Garrett Edson
ir@hc2.com
(212) 235-2691
For MG Capital:
Profile
Greg Marose/Charlotte Kiaie, 347-343-2999
gmarose@profileadvisors.com/ckiaie@profileadvisors.comExhibit 10.12
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material
and would likely cause competitive harm to the registrant if publicly disclosed.
Execution Version
COLLABORATION AGREEMENT
This COLLABORATION AGREEMENT (this “Agreement”), effective as of September 13th, 2019 (“Effective Date”), is between Ginkgo Bioworks,
Inc., a Delaware corporation with offices located at 27 Drydock Avenue, 8th floor, Boston, Massachusetts 02210 (“ Ginkgo”), and Berkeley Lights, Inc., a
Delaware corporation with offices located at 5858 Horton Street, Suite 320, Emeryville, California 94608 (“BLI”). Ginkgo and BLI may each be referred to
herein as a “Party” or, collectively, as the “Parties.”
WHEREAS, BLI and Ginkgo are committed to the goal of developing and deploying workflows on the Beacon Platform to accelerate the
engineering of microbial organisms and mammalian cell lines, including by developing new Workflows (as defined below) for use on the Beacon Platform
for the Parties’ mutual benefit (the “Purpose”); and
WHEREAS, in furtherance of the Purpose, BLI and Ginkgo have decided to enter into this Agreement, including mutually agreed upon Workflow
Development Plans, which establish the terms by which Ginkgo and BLI will work together to bring their unique resources and experiences to bear on the
Purpose.
NOW THEREFORE, in consideration of the above premises and the mutual covenants contained herein, the Parties hereby agree as follows:
1. DEFINITIONS
1.1 “Affected Party” has the meaning set forth Section 14.8 (Force Majeure).
1.2 “Affiliate” means with respect to a Party, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or
is under common control with that Party, for so long as such control exists. For purposes of this definition only, “control” and, with correlative meanings,
the terms “controlled by” and “under common control with” means: (a) in the case of Persons that are corporate entities, direct or indirect ownership of
more than fifty percent (50%) of the stock or shares (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction) entitled to vote for the election of directors, or otherwise having the power to control or direct the affairs of such corporate entity;
and (b) in the case of Persons that are non-corporate  entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest or the power
to direct the management and policies of such non-corporate  entity.
1.3 “Agreement” has the meaning set forth in the Preamble.
1.4 “[***]” means [***]. These include [***]. For clarity, [***] does not include [***].
1.5 “Alliance Manager” has the meaning set forth in Section 3.7 (Alliance Managers ).1.6 “Antibody” means a soluble protein derived exclusively from an immunoglobulin protein that includes at least one hyper-variable antigen-
binding region, including any fragment [***] of such protein, but, for clarity, excluding (i) [***] and (ii) [***].
1.7 “Applicable Law” means federal, state, local, national and supra-national  laws, statutes, rules and regulations, including any rules, regulations,
regulatory guidelines or other requirements of Regulatory Authorities, major national securities exchanges or major securities listing organizations, that
may be in effect from time to time during the Term and applicable to a particular activity or country hereunder.
1.8 “Arbitration Notice” has the meaning set forth in Section 14.5.2 (Dispute Resolution ).
1.9 “Beacon Optofluidic Machine Improvement” means any improvement or modification to the Beacon Optofluidic Machine conceived,
developed, generated or reduced to practice during the Term (a) solely by a Party, its Affiliates or Persons acting on behalf of such Party or (b) jointly by,
on one hand, Ginkgo, its Affiliates or Persons acting on behalf of Ginkgo and, on the other hand, BLI, its Affiliates or Persons acting on behalf of BLI, in
each case of clauses (a) and (b) of this Section 1.9 (“Beacon Optofluidic Machine Improvement ” definition ) through the conduct of activities under a
Workflow Development Plan or otherwise arising out of the Parties’ performance of activities under this Agreement.
1.10 “Beacon Optofluidic Machine” means (i) the machine with the Specifications set forth, as of the Effective Date, on Schedule 1.10 (Beacon
Optofluidic Machine ) and (ii) [***] and, with respect to (i)-(ii), any [***] of such machines, developed during the Term by BLI or its Affiliates that [***].
1.11 “Beacon Platform” means, collectively, (a) the Beacon Optofluidic Machine, (b) the OptoSelect Chips, (c) Consumables related to the Beacon
Optofluidic Machine or the OptoSelect Chips and (d) any Software.
1.12 “BLI” has the meaning set forth in the Preamble.
1.13 “BLI Background IP” means any Intellectual Property (a) Controlled by BLI or its Affiliates as of the Effective Date, (b) that comes into the
Control of BLI after the Effective Date other than by means of this Agreement or the activities performed hereunder or (c) developed during the Term by
BLI outside and independently of this Agreement.
1.14 “BLI Indemnitee” has the meaning set forth in Section 12.2 (Indemnification by Ginkgo ).
1.15 “BLI Inventions” has the meaning set forth in Section 8.2.2 (Ownership of Materials and Data - BLI Inventions ).
1.16 “BLI Proprietary Workflow” means any workflow on the Beacon Platform that was developed by or on behalf of BLI prior to the Effective
Date or is developed during the Term in the conduct of activities outside and independent of this Agreement (including, for clarity, outside of any
Workflow Development Plan), in each case whether solely by BLI or jointly by BLI and a Third Party.
Page 2 of 851.17 “BLI Subcontractor” means a Person to whom BLI has subcontracted any of its activities under this Agreement pursuant to Section 2.7
(Subcontracting ).
1.18 “BLI Terms and Conditions” means those terms and conditions set forth in Schedule 1.18 (BLI Terms and Conditions ) and the Product
Warranty, as such may be amended from time to time by BLI, [***].
1.19 “Budget” means, with respect to a Workflow Development Plan, an itemized budget broken down on a [***] and high-level task-by-high-level
task basis [***], that sets forth the following internal and out-of-pocket  costs anticipated to be incurred in the conduct of activities under such Workflow
Development Plan, to the extent applicable and mutually agreed upon by the Parties:
1.19.1 the FAS Support Costs for services provided by any FAS under such Workflow Development Plan;
1.19.2 other FTE Costs for BLI’s personnel in the conduct of activities under, or [***] under, such Workflow Development Plan, including BLI
personnel conducting development of Software for the Workflow under such Workflow Development Plan; provided  that , with respect to the FTE
Costs for BLI’s personnel providing [***] under a Workflow Development Plan, such FTE Costs shall not exceed [***] percent ([***]%) of the
total FTE Costs charged to Ginkgo with respect to any invoice;
1.19.3 the out-of-pocket  development ([***]) costs paid by BLI to Third Parties to purchase finished Consumables that are developed and
designated as a deliverable under a Workflow Development Plan or raw materials necessary to manufacture Consumables that are developed and
designated as a deliverable under a Workflow Development Plan , in each case from such Third Parties for the Beacon Platform, subject to a [***]
percent ([***]%) mark-up;
1.19.4 with respect to any then-existing Consumables (i.e. not Consumables for which development or manufacture is ongoing as described
in Section 1.19.3), an amount equal to the number of units used in the performance of the Workflow Development Plan, multiplied by a price per unit
of Consumables as set forth in Section 5.2.2(b) (Adjustments); and
1.19.5 other out-of-pocket  costs paid by BLI to permitted Third Party subcontractors and vendors attributable to the development of the
Workflow or Hardware under such Workflow Development Plan, [***].
1.20 “Business Day ” means any day, other than a Saturday, Sunday or a day on which commercial banks located in Boston, Massachusetts or San
Francisco, California are authorized or required by Applicable Law or regulation or otherwise to close.
Page 3 of 851.21 “Buy-Down Amount” means, at any given time of a Buy-Down Election, an amount equal to:
1.21.1 if, at such time, [***], [***] ([***]%) of the difference between (a) the Full Purchase Target and (b) the sum of all the Development
Purchases and Production Purchases made or incurred by Ginkgo;
1.21.2 if, at such time, [***], [***] percent ([***]%) of the difference between (a) the Full Purchase Target and (b) the sum of all the
Development Purchases and Production Purchases made or incurred by Ginkgo as of such time;
1.21.3 if, at such time, [***], [***] percent ([***]%) of the difference between (a) the Full Purchase Target and (b) the sum of all the
Development Purchases and Production Purchases made or incurred by Ginkgo as of such time; and
1.21.4 if, at such time, [***], [***].
For illustrative purposes only, Schedule 1.21 (Buy-Down Examples) sets forth a table showing the calculated Buy-Down Amounts assuming [***] and
[***].
1.22 “Buy-Down Election” has the meaning set forth in Section 7.3 (Buy-Down Election ).
1.23 “Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and
December 31; provided  that  the first Calendar Quarter of the Term shall begin on the Effective Date and end on the last day of the then current Calendar
Quarter and the last Calendar Quarter of the Term shall begin on the first day of such Calendar Quarter and end on the last day of the Term.
1.24 “[***]” means [***] that [***], including [***], by [***], whose [***].
1.25 “[***]” means the offering or performance of any services using the Beacon Platform, [***], to [***]:
1.25.1 [***];
1.25.2 [***]; or
1.25.3 [***];
provided  that  in no event shall [***] include the use of the Beacon Platform to (i) [***] or (ii) [***] but, for clarity, are not in any manner or form used as
described in Sections 1.25.1, 1.25.2 or 1.25.3 above.
1.26 “Change in Control” means, with respect to a Person, (a) the acquisition, directly or indirectly, by a Person or “group” (whether in a single
transaction or multiple transactions) of fifty percent (50%) or more of the voting power of such Person or of beneficial ownership of (or the right to
acquire such beneficial ownership) fifty percent (50%) or more of the outstanding
Page 4 of 85equity or convertible securities of such Person (including by tender offer or exchange offer); (b) any merger, consolidation, share exchange, business
combination, recapitalization or similar corporate transaction involving such Person (whether or not including one or more wholly owned subsidiaries of
such Person) or (c) such Person sells or transfers to any Third Party, in one or more related transactions, properties or assets representing all or
substantially all of such Person’s consolidated total assets to which this Agreement relates.
1.27 “Claims” is defined in Section 12.1 (Indemnification by BLI ).
1.28 “Clinical Trial” means a human clinical study conducted on sufficient numbers of human subjects that is designed to (a) establish that a
product is reasonably safe for continued testing, (b) investigate the safety and efficacy of the product for its intended use, and to define warnings,
precautions and adverse reactions that may be associated with the product in the dosage range to be prescribed or (c) support Regulatory Approval of
such product or label expansion of such product. Without limiting the foregoing, Clinical Trial includes any Phase II Clinical Trial or Phase III Clinical Trial
conducted by or on behalf of one or both Parties in connection with this Agreement.
1.29 “Collaboration Data” has the meaning set forth in Section 8.5.1 (Disclosure).
1.30 “Collaboration Intellectual Property” means [***], that is conceived, developed, generated or reduced to practice during the Term (a) solely
by a Party, its Affiliates or Persons acting on behalf of such Party or (b) jointly by, on one hand, Ginkgo, its Affiliates or Persons acting on behalf of
Ginkgo and, on the other hand, BLI, its Affiliates or Persons acting on behalf of BLI, in each case of clauses (a) and (b) of this Section 1.30
(“Collaboration Intellectual Property ” definition ) through the conduct of activities under this Agreement.
1.31 “Collaboration Workflow” means any Workflow on the Beacon Platform that [***] and is (a) developed jointly by the Parties (or on their
behalf) or (b) developed solely by BLI (or on behalf of BLI) for Ginkgo, in each case of clause (a) and (b) of this Section 1.31 (“Collaboration Workflow ”
definition ), pursuant to a Workflow Development Plan. For the avoidance of doubt, Collaboration Workflows shall not include [***].
1.32 “Commercial Services” means any [***] activities conducted by Ginkgo or any sublicensee under the rights granted to Ginkgo by BLI in
Section 9.1.1 (Scope of Grants ) in the Licensed Field (a) under an agreement or arrangement of Ginkgo or any such sublicensee with a Third Party or (b)
for [***] that [***] by Ginkgo, an Affiliate or a Third Party; provided  that , notwithstanding the foregoing, with respect to Third Parties, Workflows may
only be [***] by Ginkgo permitted (under Section 9.1 (Grants to Ginkgo )) sublicensees, but no other Third Parties.
1.33 “Completed Workflow” means any Key Collaboration Workflow that the JRC or the Expert Panel, as applicable, determines has been
Substantially Completed.
1.34 “Confidential Information” has the meaning set forth in Section 10.1 (Confidential Information ).
Page 5 of 851.35 “Conforming Product” means, with respect to a Beacon Optofluidic Machine or Consumable delivered by BLI to Ginkgo under this
Agreement, that such Beacon Optofluidic Machine or Consumable meets the Product Warranty at the time of delivery.
1.36 “Consumables” means those certain OptoSelect Chips and reagents set forth on Schedule 1.36 (Consumables ) or that, during the Term, [***]
for the use of the Beacon Platform and are sold by BLI.
1.37 “Contract Year” means (a) with respect to the first Contract Year, the period of time commencing on the Effective Date and ending on
September 30, 2020 and (b) with respect to each subsequent Contract Year, commencing on October 1 of such Contract Year and continuing for a period
of twelve (12) consecutive calendar months; provided  that the last Contract Year of the Term shall end on the last day of the Term.
1.38 “Control” means, with respect to any item of Intellectual Property or material, the possession (whether by ownership or license, other than by
a license granted pursuant to this Agreement) by a Party or its Affiliates of the ability to grant to the other Party access, ownership, a license or a
sublicense as required herein to such item, without: (a) violating the terms of any agreement or other arrangement with any Third Party in existence as of
the time such Party or its Affiliates would be required hereunder to grant the other Party such access, ownership, license or sublicense; (b) violating any
Applicable Law, or (c) incurring payment obligations by reason of providing access, ownership, a license or a sublicense to the other Party with respect
thereto (unless such other Party agrees in writing to bear such payment obligations [***] to providing access, ownership, a license or a sublicense to
such item by such other Party).
1.39 “Development Purchase Commitment” means, for a given Contract Year, the amount in the column named “Development Purchase
Commitment” in Table 7.2.2 for such Contract Year, as may be amended from time to time under this Agreement.
1.40 “Development Purchases” means, during any period of time, the aggregate amount paid by Ginkgo to BLI for the conduct of activities under
any Workflow Development Plan or otherwise under Section 2.4.2 (Costs under Workflow Development Plan – Payment ) during such period of time.
1.41 “Disclosing Party” is defined in Section 10.1 (Confidential Information ).
1.42 “Discovered Antibody” has the meaning set forth in Section 7.4.2 (Milestone Events ).
1.43 “Dollars” means United States dollars ($).
1.44 “Drug Approval Application” means any New Drug Application (“ NDA”), as defined in the FFDCA, or any corresponding foreign applications
in the Territory, including (a) with respect to the European Union, a Marketing Authorization Application (a “ MAA”) filed with the EMA pursuant to the
Centralized Approval Procedure or with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other
regional or national approval procedure or (b) with respect to Japan, an MAA filed with the PMDA.
Page 6 of 851.45 “Effective Date” has the meaning set forth in the Preamble.
1.46 “EMA” means the European Medicines Agency and any successor agency(ies) or authority having substantially the same function.
1.47 “European Union” or “E.U.” means the economic, scientific and political organization of member states known as the European Union, as its
membership may be altered from time to time, and any successor thereto, except that, for purposes of this Agreement, the E.U. will be deemed to include
[***] the United Kingdom, irrespective of whether any such country leaves the European Union.
1.48 “Excluded Fields” means the use of the Beacon Platform for:
1.48.1 [***];
1.48.2 [***];
1.48.3 [***];
1.48.4 [***];
1.48.5 [***]; and
1.48.6 [***].
1.49 “Expert Panel” has the meaning set forth in Section 3.5.3 (Decision -Making ).
1.50 “Expiration” has the meaning set forth in Section 13.3.1 (General).
1.51 “Extended Force Majeure Event” has the meaning set forth Section 14.8 (Force Majeure).
1.52 “Failure to Supply” has the meaning set forth in Section 5.4.3(a) (Remedial Efforts).
1.53 “FAS” means a BLI Field Application Scientist providing [***] to Ginkgo related to a Workflow Development Plan or a Workflow either (a) at
Ginkgo’s facilities or (b) [***]; provided  that , in the case of clause (b) of this Section 1.50 (“FAS” definition ), such BLI Field Application Scientist must
be specifically dedicated to development of Workflows on at least a part-time basis and identified as such in the Workflow Development Plan under this
Agreement (such identification to include, in the case of part-time FAS, a specified percentage of dedication to Ginkgo [***]).
1.54 “FAS Support Cost” shall mean, with respect to any services provided by one or more FAS(s) to Ginkgo over a specified period of time, the
amount equal to the aggregate of the applicable FAS Support Rates for such services during such period of time.
1.55 “FAS Support Rate” means, with respect to any services provided by a FAS pursuant to this Agreement to Ginkgo, the applicable rate
(dependent on the length of support) for such services set forth in Schedule 5.2.1 (Pricing Schedule ), subject to adjustment as set forth in Section
5.2.2(c) (Adjustments).
Page 7 of 851.56 “FDA” means the United States Food and Drug Administration and any successor agency(ies) or authority having substantially the same
function.
1.57 “FFDCA” means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., as amended from time to time, together with
any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto).
1.58 “Force Majeure Event” has the meaning set forth in Section 14.8 (Force Majeure).
1.59 “FOU License Fee” has the meaning set forth in Section 7.4.1 (License Fees).
1.60 “FTE” means (a) with respect to any full-time employee of BLI, [***], who is [***] dedicated to the development of Workflows under this
Agreement, a total of twelve (12) months of [***] work conducted by such employee or (b) with respect to any full-time employee of BLI that is not [***]
dedicated to the development of Workflows under this Agreement, a full time equivalent effort consisting of a minimum of a total of [***] ([***]) hours
per year of work [***] a Workflow Development Plan by such employee of a Party. In no event shall the work of one (1) employee exceed 1 full FTE.
1.61 “FTE Costs” means, with respect to any given activity or activities over any specified period of time, the number of FTEs conducting such
activity or activities multiplied  by the FTE Rate.
1.62 “FTE Rate” means the rates per annum, listed in Schedule 1.62 (FTE Rate), which rate includes certain allowable allocations and subject to
increase on an annual basis as of January 1 of each year, beginning in 2020, by a factor which reflects the increase, if any, in the Consumer Price Index for
[***], as reported by the U.S. Bureau of Labor Statistics, for January 1 of such year when compared to the comparable statistic for January 1 of the
preceding year. For clarity, if there is no such increase in the CPI-[***], the FTE Rate shall remain the same and shall not decrease.
1.63 “Full Purchase Target” has the meaning set forth in Section 7.2.1 (Purchase Commitments – Generally ).
1.64 “Generalized Workflow” means any Collaboration Workflow or component thereof that is designated as a “Generalized Workflow” by the
Parties in a Workflow Development Plan or, if the Parties have made no designation, is not a Specific Implementation. By way of non-limiting example,
Generalized Workflows would encompass Workflows or components thereof that are not Specific Implementations and are generally directed to and
required to enable:
1.64.1 [***],
1.64.2 [***];
Page 8 of 851.64.3 [***];
1.64.4 [***];
1.64.5 [***]; or
1.64.6 [***].
For the purposes of Section 1.64.3 and Section 1.128, the following examples serve to illustrate the concept of a “[***]” (a) [***] (b) [***] and (c)
[***]
1.65 “Ginkgo” has the meaning set forth in the Preamble.
1.66 “Ginkgo Background IP” means any Intellectual Property provided or otherwise disclosed to BLI under this Agreement or otherwise [***] for
the performance of any activities allocated to BLI under a Workflow Development Plan that is (a) Controlled by Ginkgo or its Affiliates as of the Effective
Date, (b) that comes into the Control of Ginkgo after the Effective Date other than by means of this Agreement or the activities performed hereunder, or
(c) developed during the Term by Ginkgo [***].
1.67 “Ginkgo Excluded Use” has the meaning set forth in Section 9.1.6 (Use in Excluded Fields ).
1.68 “Ginkgo Indemnitee” has the meaning set forth in Section 12.1 (Indemnification by BLI ).
1.69 “Ginkgo Inventions” has the meaning set forth in Section 8.2 (Ownership of Ginkgo Inventions and BLI Inventions ).
1.70 “Ginkgo Licensed IP” has the meaning set forth in Section 9.2 (Grants to BLI).
1.71 “Ginkgo Materials” has the meaning set forth in Section 8.2.1(d) (Ownership of Ginkgo Inventions and BLI Inventions ).
1.72 “Ginkgo Subcontractor” means a Person to whom Ginkgo has subcontracted any of its activities under this Agreement pursuant to Section
2.7 (Subcontracting ).
1.73 “Ginkgo Workflows” means Workflows on the Beacon Platform that are developed by [***]. For clarity, [***].
1.74 “Go/No-Go Criteria” has the meaning set forth in Section 2.2.1(g) (Workflow Development Plans – Generally) .
1.75 “Hardware” means any and all hardware, equipment, devices, tools, apparatus, machinery, and electronics including, but not limited to, the
Beacon Optofluidic Machine, computer and computer-related hardware, servers, networking equipment, interfaces, databases, support equipment, power
supplies, wiring and associated equipment.
Page 9 of 851.76 “Headstart Invention” means any (a) specific part or component of a [***] (other than any [***], including any [***]) or (b) [***] in its
entirety, including [***], in each case, either (i) designated as a “Headstart Invention” in the applicable Workflow Development Plan or (ii) for which
Ginkgo has provided, or is slated to provide, by reference to the applicable category of the Workflow Development Plan(s) as further described in Section
2.2.1(f) and Section 2.2.1(h), Development Purchase funding of greater than [***] percent ([***]%) of the Budget set forth in the applicable Workflow
Development Plan(s). For clarity, in no event shall any improvements, modifications or other changes to the [***], whether [***] based, [***] or [***],
deemed to be a Headstart Invention or be subject to a Headstart Period.
1.77 “[***]” means, [***] and [***] that [***] and (b) [***].
1.78 “Headstart Period” has the meaning set forth in Section 6.1.1 (BLI Standstill ).
1.79 “[***]” means the offering or performance of any [***] services using the Beacon Platform, for commercial sale or otherwise, to [***];
provided  that  in no event shall [***] include (a) use of the Beacon Platform to [***] if the same does not [***] or (b) the [***] outside of the Beacon
Platform.
1.80 “[***]” means the offering or performance of any [***] services using the Beacon Platform, for commercial sale or otherwise, for [***]
applications to the extent specifically related to [***]; provided  that  in no event shall [***] include using the Beacon Platform to [***] if the same does
not [***].
1.81 “Incremental Withholding Taxes” has the meaning set forth in Section 7.6 (Taxes).
1.82 “IND” means an application filed with a Regulatory Authority for authorization to commence Clinical Trials, including: (a) an Investigational
New Drug Application as defined in the FFDCA or any successor application or procedure filed with the FDA; (b) any equivalent of a United States IND
in other countries or regulatory jurisdictions (i.e., clinical trial application); and (c) all supplements, amendments, variations, extensions and renewals
thereof that may be filed with respect to any of the foregoing.
1.83 “Independent Development” has the meaning set forth in Section 8.9 (Specific Implementation Restrictions ).
1.84 “Initial Workflows” has the meaning set forth in Section 2.2.2 (Committed Workflows ).
1.85 “Initiation” or “Initiate” means, with respect to a Clinical Trial, the first dosing of the first human subject or patient in such Clinical Trial.
1.86 “Intellectual Property” means all intellectual and industrial property, and all rights therein and thereto, including registration rights thereto, of
any kind throughout the world, including Patent Rights, Software, ideas, data, inventions, discoveries, algorithms, formulas, compositions,
configurations, specifications, sequences, product applications, formulations, assays, techniques, sketches, drawings, models, works of authorship,
copyrights, recordings, moral
Page 10 of 85rights, mask works, design rights, trademarks, trade names, trade dress, service marks, logos, trade secrets, methods, processes, techniques,
developments, know-how, and all other similar rights, whether or not registered or capable of being registered in any jurisdiction.
1.87 “Intended End of Term” means the later of (a) the seventh (7th) anniversary of the Effective Date and (b) the date determined to be the
“Intended End of Term” under Section 7.2.2(d) (Effects of Tolling).
1.88 “[***]” has the meaning set forth in Section 14.5.2 (Dispute Resolution ).
1.89 “JRC” or “Joint Review Committee” is defined in Section 3.1 (Joint Review Committee ).
1.90 “Key Collaboration Workflow” means a Collaboration Workflow designated as a “Key Collaboration Workflow” by the JRC pursuant to
Section 3.2.11 (JRC Responsibilities ).
1.91 “Key Person” has the meaning set forth in Section 5.4.1(b) (Dedicated FTEs; Key Persons ).
1.92 “Lead Time” means, with respect to a Beacon Optofluidic Machine (including related Hardware and Software), Consumable or Service, the
“Lead Time” for such Beacon Optofluidic Machine, Consumable or Service as set forth in Schedule 1.92 (Lead Time) or as otherwise mutually agreed
upon by the Parties in writing.
1.93 “Licensed Field” means any and all organisms, products, fields and uses other than the Excluded Fields.
1.94 “Licensed Product” means a [***] product within the Licensed Field, including (a) [***] or (b) [***] by such [***] described in clause (a) of
this Section 1.94, in each case of ((a)-(b)), initially produced on the Beacon Platform or, if not initially produced on the Beacon Platform, is later [***]
through use of the Beacon Platform, with respect to each, in the conduct of activities [***] to produce such a product.
1.95 “List Price” means, at any given time and for any Beacon Optofluidic Machine, Consumable or Service, the price for such Optofluidic
Machine, Consumable or Service [***] at such time.
1.96 “Losses ” has the meaning set forth in Section 12.1 (Indemnification by BLI ).
1.97 “MAA” has the meaning set forth in Section 1.44 (“Drug Approval Application ”).
1.98 “[***]” means [***].
1.99 “Maximum Amount” has the meaning set forth in Section 5.3.1 (Issuance).
1.100 “Milestone Event” has the meaning set forth in Section 7.4.2 (Milestone Payments ).
Page 11 of 851.101 “Milestone Payment” has the meaning set forth in Section 7.4.2 (Milestone Payments ).
1.102 “Minimum Cumulative Purchase Commitment” means, with respect to a Contract Year, the amount set forth in the column “Minimum
Cumulative Purchase Commitment” in Table 7.2.2 for such Contract Year, as such Minimum Cumulative Purchase Commitment may be amended from time
to time under this Agreement.
1.103 “NDA” has the meaning set forth in Section 1.44 (“Drug Approval Application ”).
1.104 “OptoSelect Chips” means those BLI microfluidic chips described in Schedule 1.104 (OptoSelect Chips ) and any other BLI chip used on the
Beacon Optofluidic Machine that is developed to execute Workflows.
1.105 “Party” and “Parties” has the meaning set forth in the Preamble.
1.106 “Patent Rights” means any and all (a) issued patents, (b) pending patent applications, including all provisional applications, substitutions,
continuations, continuations-in-part,  divisions and renewals, and all patents granted thereon, (c) patents-of-addition,  reissues, reexaminations and
extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions,
supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) other forms of government-issued  rights substantially
similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing.
1.107 “Performance Service Plan” shall mean the plan set forth in Schedule 1.107 (Performance Service Plan ).
1.108 “Permitted Subcontractor(s)” means, individually or collectively, BLI Subcontractor(s) and Ginkgo Subcontractor(s).
1.109 “Person” means any natural person, corporation, unincorporated organization, partnership, association, joint stock company, joint venture,
limited liability company, trust or government or any agency or administrative or political subdivision of any government, or any other entity.
1.110 “Phase II Clinical Trial” means a Clinical Trial, the principal purpose of which is to make a preliminary determination as to whether a
pharmaceutical product is safe for it intended use and to obtain sufficient information about such product’s efficacy, in a manner that is generally
consistent with 21 CFR § 312.21(b), as amended (or its successor regulation), to permit the design of further Clinical Trials. For clarity, A “Phase II Clinical
Trial” shall include any clinical trial that would or does satisfy the requirements of 21 C.F.R. § 312.21(b) or any comparable regulation outside the United
States whether or not it is designated a Phase II Clinical Trial.
1.111 “Phase III Clinical Trial” means a pivotal Clinical Trial with a defined dose or a set of defined doses of a pharmaceutical product designed to
ascertain efficacy and safety of such product, in a manner that is generally consistent with 21 CFR § 312.21(c), as amended (or its successor regulation),
for the purpose of enabling the preparation and submission of a Drug
Page 12 of 85Approval Application. A “Phase III Clinical Trial” shall include any clinical trial that would or does satisfy requirements of 21 C.F.R. § 312.21(c) or any
comparable regulation outside the United States., whether or not it is designated a Phase III Clinical Trial.
1.112 “PMDA” means Japan’s Pharmaceuticals and Medical Devices Agency and any successor agency(ies) or authority having substantially the
same function.
1.113 “Preamble” means the first, unnumbered paragraph of this Agreement.
1.114 “Product Warranty” means, with respect to any Beacon Optofluidic Machine or Consumable, that (a) the representations, warranties and
covenants of BLI set forth in the applicable BLI Terms and Conditions (including the product warranties therein) are true with respect to such Beacon
Optofluidic Machine or Consumable, (b) with respect to a Beacon Optofluidic Machine, installation and qualification of such Beacon Optofluidic
Machines are in accordance with, and meet the standards of, BLI’s then-existing [***], such standards to be at least as stringent as those set forth in
[***] and (c) BLI does not have knowledge of any defect that would result in a [***] other than those defects [***] or the [***] or any reason that such
Beacon Optofluidic Machine or each Consumable is [***].
1.115 “Production Purchases” means the sum of payments made by Ginkgo to BLI for:
1.115.1 purchases of Beacon Optofluidic Machines together with any associated freight, insurance, customs charges, tariffs or other
transportation charges;
1.115.2 purchases of OptoSelect Chips and other Consumables used by the Beacon Platform outside of a Workflow Development Plan
together with any associated freight, insurance, customs charges, tariffs or other transportation charges;
1.115.3 FAS or other BLI [***] personnel, as requested by Ginkgo, for general support services (including all payments for a Performance
Service Plan), including [***] with respect to activities performed outside of a Workflow Development Plan;
1.115.4 [***];
1.115.5 [***]; and
1.115.6 any other amounts, including for [***] (including for Beacon Optofluidic Machines or any Consumable as applicable, properly
charged and invoiced to Ginkgo and paid by Ginkgo under this Agreement in connection with the supply or provision of goods and services by
BLI, which are not Development Purchases.
1.116 “Purchase Order” has the meaning set forth in Section 5.3.1 (Issuance).
1.117 “Purpose” shall have the meaning set forth in the first WHEREAS clause of this Agreement.
1.118 “Receiving Party” has the meaning set forth in Section 10.1 (Confidential Information ).
Page 13 of 851.119 “Regulatory Approval” means, with respect to a country in the Territory, any and all approvals (including Drug Approval Applications that
have been approved by a Regulatory Authority), licenses, registrations or authorizations of any Regulatory Authority necessary to commercialize a
product in such country[***].
1.120 “Regulatory Authority” means any applicable supra-national,  federal, national, regional, state, provincial or local governmental or regulatory
authority, agency, department, bureau, commission, council or other entities (e.g., the FDA, EMA and PMDA) regulating or otherwise exercising authority
with respect to activities contemplated in this Agreement.
1.121 “Remedial Plan” has the meaning set forth in Section 5.4.3(a) (Remedial Efforts).
1.122 “Responsible Tax Party” has the meaning set forth in Section 7.6 (Taxes).
1.123 “Rolling Forecast” has the meaning set forth in Section 5.1 (Forecasts).
1.124 “Senior Officers ” means, (a) with respect to Ginkgo, [***] and (b) with respect to BLI, [***].
1.125 “Services” means services to be provided by or on behalf of BLI to Ginkgo under this Agreement, including with respect to Beacon Platform
Software development services, installation services, support services and general training services, but excluding those services provided under a
Workflow Development Plan.
1.126 “Service Level Standards” means, with respect to any service at any given time, the standards for the performance of such service most
recently agreed upon by the Parties at such time or if no such standards have been previously agreed upon by the Parties, the standards for the
performance of such service then in effect for BLI’s other [***] customers.
1.127 “Software” means full applications or programs as well as partial applications, programs or sections of software code, whether source code,
object code or other form, in each case incorporated in or otherwise used by the Beacon Optofluidic Machine.
1.128 “Specific Implementation” means any individual component of any Collaboration Workflow that is designated as a “Specific Implementation”
by the Parties in a Workflow Development Plan or, if the Parties have made no designation, (a) is [***] for a particular [***] pursuant to a Workflow
Development Plan or [***]; or (b) incorporates [***] proprietary to Ginkgo that [***], provided  that , to the extent such [***] provided by Ginkgo [***].
1.129 “Specifications” means, (a) with respect to any Beacon Optofluidic Machine (including related Hardware and Software), BLI’s specifications
set forth in Schedule 1.10 (Beacon Optofluidic Machine ), along with any other specifications mutually agreed upon by the Parties in writing, in each case
for such Beacon Optofluidic Machine (including related Hardware and Software) or (b) with respect to any Consumable, the specifications set forth in
Schedule 1.36 (Consumables ), along with any other specifications mutually agreed upon by the Parties in writing, in each case for such Consumable.
Page 14 of 851.130 “Substantially Completed” means, with respect to a Workflow, that such Workflow (a) [***] and (b) is judged by the JRC (or Expert Panel, if
applicable) to be substantially complete based upon [***]. For clarity, [***] will be considered by the JRC (or Expert Panel, if applicable) to be [***] of
substantial completion.
1.131 “Term” has the meaning set forth in Section 13.1 (Term).
1.132 “Territory” means worldwide except for any and all embargoed and sanctioned countries as identified by the U.S. government.
1.133 “Third Party” means any Person other than Ginkgo and its Affiliates and BLI and its Affiliates.
1.134 “United States” or “U.S.” means the United States of America, including its territories and possessions.
1.135 “Upfront Payment” has the meaning set forth in Section 7.1 (Upfront Payment).
1.136 “VAT” has the meaning set forth in Section 7.6 (Taxes).
1.137 “Workflow” means a defined set of tasks performed using the Beacon Platform in a certain order utilizing specific Consumables to [***],
including to load, culture, assay and export cells.
1.138 “Workflow Development Plan(s)” has the meaning set forth in Section 2.2 (Workflow Development Plans ).
1.139 “Working Group” has the meaning set forth in Section 3.8 (Working Groups).
2. DEVELOPMENT
2.1 Collaboration in General. The Parties will undertake this Agreement in furtherance of the Purpose and under the guidance of the JRC pursuant
to Article 3 (Joint Review Committee ). During the Term, each Party will use diligent efforts to implement and perform (itself or through its Permitted
Subcontractors) its respective obligations under and in accordance with (a) this Agreement and (b) each Workflow Development Plan in accordance with
the timelines set forth in such Workflow Development Plan. Each Party will reasonably cooperate with each other in the performance of their
responsibilities under this Agreement and each Workflow Development Plan, including (i) responding to reasonable requests by the other Party
submitted in accordance with this Agreement to provide information reasonably necessary for the performance of such requesting Party’s obligations
under this Agreement (including any Workflow Development Plan) and (ii) causing its personnel, agents and representatives, while at the other Party’s
facility, to abide by the written work rules and facility regulations applicable to such facility as provided in advance by such other Party.
Page 15 of 852.2 Workflow Development Plans.
2.2.1 Generally . Subject to the requirements of Section 2.2.2 (Committed Workflows ), from time to time during the Term, the Parties shall
discuss in good faith entering into work plans setting forth the activities to be undertaken by the Parties to develop a specific Collaboration
Workflow in furtherance of the Purpose (each such work plan that is consistent with the terms of this Agreement and approved by the JRC, and as
may be amended from time to time in accordance with this Agreement, a “Workflow Development Plan”); provided  that  the Parties and the JRC will
manage the pipeline of Collaboration Workflows such that [***]. If the Parties mutually agree that a new Workflow Development Plan should be
undertaken by the Parties in order to further the Purpose, then the Parties shall work together in good faith to prepare an initial draft of the
proposed Workflow Development Plan on commercially reasonable terms. Once the proposed Workflow Development Plan has been drafted, such
proposed Workflow Development Plan will be submitted to the JRC and the JRC shall review such proposed Workflow Development Plan and
either (a) reject the proposed Workflow Development Plan, (b) accept the proposed Workflow Development Plan or (c) amend the proposed
Workflow Development Plan prior to approving such plan. If the JRC approves a proposed Workflow Development Plan, such proposed plan shall
be deemed a “Workflow Development Plan” under this Agreement and attached to this Agreement as an Exhibit (the first approved Workflow
Development Plan to be attached as Exhibit A-1 and subsequently approved Workflow Development Plans to be sequentially numbered as Exhibit
A-2, Exhibit A-3, etc.) and, through such attachment, made a part of this Agreement. BLI hereby acknowledges and agrees that in no event will BLI
perform any work for Ginkgo in connection with this Agreement other than pursuant to a JRC-approved Workflow Development Plan, other than
with respect to BLI providing Ginkgo with any FAS support or other standard service and support pursuant to the terms of this Agreement. At a
minimum, each Workflow Development Plan will include the following information:
(a) defined objective and scope of the relevant Collaboration Workflow;
(b) a detailed description of the work to be performed under such Workflow Development Plan and which components of the
Collaboration Workflow shall be deemed a Generalized Workflow or a Specific Implementation;
(c) a detailed description of each Party’s roles and responsibilities with respect to the work to be performed under such Workflow
Development Plan;
(d) the Budget[***] and the allocation of responsibility between the Parties for the funding of such Budget;
(e) timelines for performing and completing work under such Workflow Development Plan;
Page 16 of 85(f) identification of deliverables to be created by a Party in connection with the work to be performed, including (i) any operating
protocol, Software, Hardware, consumable, Beacon Optofluidic Machine Improvement or Workflow to be created and (ii) categories
(e.g., [***]) of Headstart Inventions (and specific Headstart Inventions) that the JRC reasonably believes, during the drafting of the
Workflow Development Plan, will result from the work to be performed by the Parties under the Workflow Development Plan;
(g) (i) [***] descriptions of one or more go/no-go  criteria, if any, at which time the JRC shall specifically determine whether to
continue work under such Workflow Development Plan (each such criteria, a “ Go/No-Go Criteria”); (ii) [***] metrics associated with
such Collaboration Workflow being Substantially Completed; (iii) additional [***] criteria for the work to be performed and (iv) [***]
criteria for any deliverables to be created, including any Workflows (such criteria with respect to Collaboration Workflows to include
any additional criteria to be used when determining if a Collaboration Workflow has been Substantially Completed); and
(h) (i) the anticipated Development Purchase amounts associated with any Collaboration Workflow that is the subject of such
Workflow Development Plan and (ii) with respect to any Headstart Invention, the anticipated Development Purchase amounts (based
on the Budget) to be paid by Ginkgo for [***] a Headstart Invention and each category of Headstart Inventions set forth in the
applicable Workflow Development Plan.
2.2.2 Committed Workflows . With respect to the Workflow Development Plans to be proposed to the JRC for approval and conducted by the
Parties during the [***] Contract Years, subject to the requirement set forth in Section 7.2.2(b)(i) (Development Purchase Commitments ) that not
less than [***] ([***]%) of the Development Purchases made in the [***] Contract Years be for the development of Workflows for [***], the
Parties agree that such Workflow Development Plans shall focus on yeast and mammalian cells and the [***] ([***]) initial Workflow Development
Plans shall be directed toward the categories of Workflows set forth in Schedule 2.2.2 (Initial Workflow Development Plans ) hereto (collectively,
the “Initial Workflows”). At least [***] ([***]) of the Initial Workflows shall also be deemed to be Key Collaboration Workflows by the JRC
(including as indicated on Schedule 2.2.2 (Initial Workflow Development Plans )). A draft outline of the first [***] ([***]) Workflow Development
Plans for Initial Workflows are attached hereto as Exhibit B. Promptly following the Effective Date and in no event later than [***] ([***]) days after
the Effective Date, the Parties shall finalize the Workflow Development Plans for such first [***] ([***]) Initial Workflows and begin implementation
of such Initial Workflows. Promptly thereafter, the Parties shall develop a Workflow Development Plan for each such Initial Workflow to be
submitted to the JRC for rejection or approval pursuant to Section 2.2.1 (Workflow Development Plans – Generally ).
Page 17 of 852.2.3 Retooling and Development Costs . If, pursuant to Section 3.2.6, the JRC determines that Hardware or Consumables will need to be
developed, retooled or modified in order to create Collaboration Workflows, then Ginkgo and BLI shall discuss and negotiate in good faith the
sharing of the costs associated therewith, which, once mutually agreed by the Parties, will be proposed to the JRC in the form of an amendment to
the applicable Workflow Development Plan pursuant to Section 2.3.2 (Amendments by the Parties ); provided  that  in all events the Intellectual
Property in such developed, retooled or modified Hardware or Consumables will be [***].
2.3 Amendments to Workflow Development Plans .
2.3.1 Amendments Raised by the JRC . The JRC will periodically review (at least once per [***]) each approved Workflow Development Plan
and each Party’s performance thereunder to determine whether amendments are needed with respect to such Workflow Development Plan in order
to more efficiently develop the relevant Workflow, which review will include [***]. If the JRC determines that an amendment is needed with respect
to any approved Workflow Development Plan, then the JRC shall amend and restate the applicable Workflow Development Plan to reflect such
amendment with such amended and restated Workflow Development Plan to replace the previously attached Workflow Development Plan and,
through such attachment and, after signature by each of the Parties, made a part of this Agreement.
2.3.2 Amendments Raised by the Parties . Notwithstanding anything in Section 2.3.1 (Amendments by the JRC ) to the contrary, either Party
may, at any time, propose amendments to a Workflow Development Plan for the JRC’s consideration and such Party shall submit the proposed
amendment to the JRC for consideration. Following submission of a proposed amendment to the JRC, the JRC shall review such proposed
amendment and either (a) reject the proposed amendment to such Workflow Development Plan, (b) accept the proposed amendment to such
Workflow Development Plan or (c) further amend the proposed amendment to such Workflow Development Plan for approval by the JRC. If the JRC
approves a proposed amendment to a Workflow Development Plan, then the JRC shall amend and restate the applicable Workflow Development
Plan to reflect such amendment with such amended and restated Workflow Development Plan to replace the previously attached Workflow
Development Plan and, after signature by each of the Parties, be made a part of this Agreement.
2.4 Costs under Workflow Development Plans .
2.4.1 Reporting. Within [***] ([***]) days following the end of each [***], [***], BLI shall provide a detailed report to Ginkgo setting forth
the activities conducted by BLI [***] during such [***] and the costs for such activities [***]. If Ginkgo disputes any costs set forth in BLI’s
report, it shall so notify BLI in writing within [***] ([***]) days of receiving such report and provide the specific reasons for the dispute and the
Parties will attempt to resolve such dispute in good faith for [***] ([***]) days following such notice. In the event the Parties are unable to resolve
such dispute in such [***] ([***]) day period, then either Party may initiate dispute resolution in accordance with Section 14.5.2 (Dispute
Resolution ) and [***]; provided  that , during the pendency of any such dispute, if
Page 18 of 85[***], [***] and, if any such disputed costs paid by Ginkgo are finally determined, pursuant to Section 14.5.2 (Dispute Resolution ) or by mutual
agreement of the Parties, to not have been owed to BLI at the time of payment, BLI will provide a credit against future purchases made by Ginkgo in
the amount of the overpayment; provided  further that , in the event that there are not sufficient future purchases made by Ginkgo during the Term
to fully so credit, BLI will promptly refund any remaining amount of the overpayment to Ginkgo.
2.4.2 Payment. [***], after generating and delivering a report as set forth in Section 2.4.1 (Reporting ) or at such other time as may be
specified [***], BLI shall issue an invoice to Ginkgo within [***] ([***]) days of Ginkgo receiving such report or, if any costs under BLI’s report
are disputed pursuant to Section 2.4.1 (Reporting ), within [***] ([***]) days of resolution of such dispute, such invoice to be for the amount of
costs owed by Ginkgo, if any, to effect the appropriate cost allocation [***] in such [***]. Notwithstanding anything to the contrary in this
Agreement, in no event shall BLI provide an invoice (a) requesting payment, nor shall Ginkgo be responsible, in any given [***], for any costs
incurred by BLI for any activity in excess of [***] percent ([***]%) of the costs of such activity as set forth in the applicable Workflow
Development Plan’s Budget for such [***] or (b) for any Development work performed outside the Workflow Development Plan. Ginkgo shall pay
all undisputed amounts under an invoice received from BLI under this Section 2.4.2 (Payment) within [***] ([***]) days after receipt of such BLI
invoice, and any overdue payments on undisputed amounts shall be subject to payment of interest pursuant to Section 7.10 (Late Payment ). All
amounts received by BLI in connection with the performance of each Workflow Development Plan shall be non-refundable  except as otherwise set
forth in Section 7.8 (Audits ) and Section 6.1 (Headstart Period ).
2.5 Termination of Workflow Development Plans. A Workflow Development Plan, once approved by the JRC, may be terminated by the JRC,
including, by way of example, if: (a) both Parties provide notice to the JRC requesting such termination or (b) the JRC finds that (i) termination is [***] or
(ii) that [***]. In the event of termination of a Workflow Development Plan under this Section 2.5 (Termination of Workflow Development Plans ), BLI will
cease working on the Workflow Development Plan and [***] cancel orders or stop the work of a Permitted Subcontractor or any other supplier.
Notwithstanding termination of a Workflow Development Plan, Ginkgo shall pay BLI for Ginkgo’s share, if any, of the reasonable costs associated with
[***] incurred in accordance with this Agreement prior to the decision to terminate such Workflow Development Plan to the extent that BLI could not,
after using [***], (A) stop or cancel such or (B) relocate or reassign to any work to be performed for another Person.
2.6 Limitations. Notwithstanding anything to the contrary in this Agreement, neither Party will be required to conduct any activity to develop a
Workflow other than those activities allocated to it in a Workflow Development Plan and no proposed Workflow Development Plan (or, subject to Section
2.3 (Amendments to Workflow Development Plans ), any amendment thereto) shall become binding on the Parties until approved by the JRC.
2.7 Subcontracting . Each Party may only subcontract its activities under this Agreement (including under a Workflow Development Plan) with the
other Party’s consent; provided  that  such consent shall not be necessary if (a) such subcontracting of activities is [***]
Page 19 of 85of such subcontracting Party (e.g. [***]) or (b) [***] (e.g. [***]) in order for a Party to [***]. In any event, prior to any subcontracting by a Party to a
Permitted Subcontractor, the subcontracting Party shall obtain a written undertaking from the Permitted Subcontractor that it will be subject to the
applicable terms and conditions of this Agreement, including the confidentiality provisions of Article 10 (Confidentiality ). Subcontracting will not relieve
a Party of its obligations under this Agreement and each Party will remain directly liable for the acts and omissions of its Permitted Subcontractors. Any
breach of this Agreement by a Permitted Subcontractor will be deemed to be a breach by the Party that subcontracted its activities to such breaching
Permitted Subcontractor.
2.8 Records. Each Party shall, and shall cause its Affiliates and Permitted Subcontractors to, maintain records in sufficient detail for the other Party
to confirm compliance with this Agreement and in good scientific manner appropriate for patent and regulatory purposes under Applicable Law, which
shall [***] properly reflect all activities conducted and results achieved by such Party under this Agreement. Such records shall be retained by such
Party, its Affiliates or Permitted Subcontractors until [***] ([***]) years after the end of the period to which such books and records pertain or for such
longer period as may be required by Applicable Law. Each Party shall have the right, during normal business hours and upon reasonable notice, to
inspect all such records of the other Party, its Affiliates or Permitted Subcontractors. The reviewing Party shall be responsible for all costs of the
inspection but shall have no right to copy or retain records. All disclosed records and the information disclosed therein shall be treated as Confidential
Information in accordance with Article 10 (Confidentiality ).
3. JOINT REVIEW COMMITTEE
3.1 Formation; Chairperson. Within [***] ([***]) days of the Effective Date (or such other date as may be mutually agreed to by the Parties), the
Parties will establish a Joint Review Committee (“JRC”) comprised of two (2) representatives of Ginkgo and two (2) representatives of BLI, each of whom
must have the requisite experience and seniority to enable such Person to make decisions on behalf of the Party it represents with respect to the issues
falling within the jurisdiction of the JRC. Each Party may replace its representatives to the JRC at any time upon prior written notice to the other Party;
provided  that  such replacement representatives must have the experience and seniority required under this Section 3.1 (Formation; Chairperson ). [***]
will select from its representatives the chairperson for the JRC, whose role shall be to call the periodic meetings, and publish meeting minutes. From time
to time during the Term, [***] may change the representative who will serve as chairperson upon written notice to [***].
3.2 JRC Responsibilities. The JRC will have that specific decision-making authority expressly enumerated in this Agreement and will provide
oversight and a forum for discussing all matters arising in connection with this Agreement, including with respect to planning, reviewing and
coordinating the various activities to be undertaken by the Parties pursuant to a Workflow Development Plan. In particular, the JRC will be responsible
for:
3.2.1 rejecting or approving proposed Workflow Development Plans submitted to it by a Party or as amended by the JRC pursuant to Section
2.2.1 (Workflow Development Plans – Generally );
Page 20 of 853.2.2 pursuant to Section 2.2.1 (Workflow Development Plans – Generally ), managing the pipeline of anticipated Collaboration Workflows so
that [***] including in the event a Workflow Development Plan is terminated early by the JRC;
3.2.3 pursuant to Section 2.3.1 (Amendments by the JRC ), periodically reviewing (at least once per [***]) each Workflow Development Plan
and each Party’s performance thereunder in order to determine whether amendments are needed with respect to such Workflow Development Plan
and, if amendments are needed, revising the Workflow Development Plan as necessary;
3.2.4 rejecting, prioritizing, approving or amending proposed amendments to Workflow Development Plans submitted to it by a Party
pursuant to Section 2.3.2 (Amendments by the Parties );
3.2.5 deciding whether [***] are at issue and whether to terminate a Workflow Development Plan as further described in Section 2.5
(Termination of Workflow Development Plans );
3.2.6 in connection with each Workflow Development Plan, determining whether Hardware or Consumables will need to be developed or
retooled in order to create Collaboration Workflows such that the Parties should discuss sharing of the costs associated therewith pursuant to
Section 2.2.3 (Retooling and Development Costs );
3.2.7 in connection with each Workflow Development Plan, designating (a) which components of Workflows are BLI Proprietary Workflows,
which are Generalized Workflows, and which are Specific Implementations and (b) (i) which categories (e.g., [***]) of Headstart Inventions (and
specific Headstart Inventions within such categories) that the JRC reasonably believes, during the drafting of the Workflow Development Plan, will
result from the work to be performed by the Parties under the Workflow Development Plan and (ii) a reasonable estimation of the Development
Purchase funding to be paid by Ginkgo with respect to the development of such categories of Headstart Inventions, which estimation will be set
forth in the Budget for the applicable Workflow Development Plan; provided  that , in no event will failure by the JRC to list (A) specific parts or
components of Generalized Workflows or Collaboration Workflows or (B) Consumables, including OptoSelect Chips, with respect to (A)-(B), as
Headstart Inventions in a Workflow Development Plan be given any significance in determining whether such invention constitutes a Headstart
Invention;
3.2.8 determining whether or not a Collaboration Workflow has been Substantially Completed based on the metrics for such Collaboration
Workflow as set forth in the applicable Workflow Development Plan;
3.2.9 pursuant to Section 7.2.1 (Purchase Commitments – Generally ), determining whether additional development work is necessary in order
to enable Ginkgo to deploy the Beacon Platform as specified in a Workflow Development Plan and if so, then determining how to adjust the
Development Purchase Commitments and Production Purchase Targets for the then-current  and future Contract Years (with the understanding the
JRC has no power to modify the Maximum Amount or the Term);
Page 21 of 853.2.10 upon determination by the JRC or the Expert Panel that a Collaboration Workflow has not been Substantially Completed, discussing if
and how to address the Production Purchase amounts that would have been relevant to such Collaboration Workflow;
3.2.11 designating at least [***] ([***]) Collaboration Workflows as Key Collaboration Workflows within [***] ([***]) years of the Effective
Date and at least [***] ([***]) Collaboration Workflows as Key Collaboration Workflows within [***] ([***]) years of the Effective Date; and
3.2.12 performing such other functions as expressly set forth in this Agreement as being under the purview of the JRC or as the Parties may
mutually agree in writing, except where in conflict with any provision of this Agreement.
3.3 Meetings and Minutes . Unless otherwise mutually agreed to by the Parties, the JRC will meet each [***] by audio or video teleconference and,
at a minimum, [***] each Contract Year in person, with the location for such meetings alternating between Ginkgo and BLI facilities (or such other
locations as are mutually agreed by the Parties). Meetings of the JRC will be effective only if a quorum of the JRC (as defined in Section 3.4 (Procedural
Rules)) is present or participating by videoconferencing. The chairperson of the JRC will be responsible for calling meetings on no less than [***] ([***])
Business Days’ notice, unless exigent circumstances require shorter notice. Each Party will make all proposals for agenda items and will provide all
appropriate information with respect to such proposed items at least [***] ([***]) Business Days in advance of the applicable meeting; provided  that
under exigent circumstances requiring input by the JRC, a Party may provide its agenda items to the other Party within a shorter period of time in advance
of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as the other Party consents to such later addition of
such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably withheld, conditioned or delayed. The JRC
will designate an individual to prepare and circulate for review and approval of the Parties minutes of each meeting [***] ([***]) Business Days after the
meeting. The Parties will agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JRC.
3.4 Procedural Rules. The JRC will have the right to adopt such standing rules as will be necessary for its work, to the extent that such rules are not
inconsistent with this Agreement. A quorum of the JRC will exist whenever there is present at a meeting at least one (1) representative appointed by each
Party. The JRC will take action by consensus of the representatives present at a meeting at which a quorum exists, with each Party having a single vote
irrespective of the number of representatives of such Party in attendance, or by a written resolution signed by at least one representative appointed by
each Party. From time to time during the Term, a Party may invite non-voting  employees (including its Alliance Manager), consultants and other advisors,
experts and specialists to attend meetings of the JRC; provided  that  such attendees (a) will not vote in the decision-making process of the JRC, (b) are
bound by obligations of confidentiality and non-use  that are at least as protective of the Parties as set forth in this Agreement and that restrict use and
disclosure of information learned while attending JRC meetings and (c) can be required to depart the meeting upon the request of the other (non-inviting)
Party, in its sole discretion, due to confidentiality or business reasons.
Page 22 of 853.5 Decision-Making. If the JRC cannot, or does not, reach consensus on an issue at any JRC meeting or within a period of [***] ([***]) Business
Days thereafter (or such other period of time as mutually agreed by the Parties or by consensus of the JRC), then upon the request of either Party, the
disagreement will first be referred to the Senior Officers of the Parties, who will confer in good faith on the resolution of the issue. Any final decision
mutually agreed to by the Senior Officers will be conclusive and binding on the Parties. If the Senior Officers are not able to agree on the resolution of
any such issue within [***] ([***]) days after such issue was first referred to them, then, if such decision is [***], [***] and, for all other decisions, shall
be resolved consistent with the provisions of this Section 3.5 (Decision -Making ):
3.5.1 subject to Section 3.5.3, if the matter concerns (a) [***], including any [***] or (b) the [***], the final decision shall be made by the
Senior Officer of Ginkgo; provided  that , in no event may Ginkgo exercise its final-decision making authority, including in connection with amending
an approved Workflow Development Plan, in any manner that would (i) [***] BLI’s obligations under such Workflow Development Plan, (ii)
obligate or require BLI to increase its spending under such Workflow Development Plan by more than [***] percent ([***]%) of BLI’s spending
obligation under such Workflow Development Plan or (iii) modify the Minimum Cumulative Purchase Commitment or the Full Purchase Target;
3.5.2 subject to Section 3.5.3, if the matter concerns [***], including any [***] ( provided  that  any [***] shall not affect decision-making
authority under this Section 3.5 (Decision -Making )), the final decision shall be made by the Senior Officer of BLI; provided  that , in no event may
BLI exercise its final-decision making authority, including in connection with amending an approved Workflow Development Plan, in any manner
that would (a) [***] Ginkgo’s obligations under such Workflow Development Plan [***] or (b) obligate or require Ginkgo to increase its spending
under such Workflow Development Plan by more than [***] percent ([***]%) of Ginkgo’s spending obligation under such Workflow Development
Plan, or (c) modify the Minimum Cumulative Purchase Commitment or the Full Purchase Target;
3.5.3 if the matter is determining (a) whether [***] or (b) whether [***] (including with respect to [***]), with respect to each, at either Party’s
request, the dispute shall be resolved in an accelerated manner by a panel of three (3) independent Third Parties, each having expertise with respect
to the subject matter of the applicable Workflow Development Plan (such panel, an “ Expert Panel”), subject to the following process: (i) each Party
will engage one independent Third Party expert for the Expert Panel [***] after [***] to serve on the Expert Panel, (ii) within [***] ([***]) days of
any request to refer the matter to an Expert Panel or, if earlier, as promptly as reasonably practicable after each Party’s engagement of its Third Party
Expert, the Parties’ two (2) Third Party experts shall mutually agree on a third (3rd) independent Third Party expert who will serve on such panel and
as chairperson of the panel, (iii) the Expert Panel will reach a decision as to such matter (including whether [***]) as promptly as practicable, which
may include having the JRC or Parties submit information in support of the Expert Panel making a determination,
Page 23 of 85but within no greater than [***] ([***]) days of the third (3 rd) expert being chosen and (iv) [***] the Parties will be bound by the determination of
the Expert Panel. Each Party shall bear its own costs of participating in the proceeding, including the costs incurred by its Third Party expert, and
shall equally share the costs incurred by the third (3 rd) Third Party expert selected jointly by the Parties’ two (2) Third Party Experts, except that,
with respect to [***]. The Expert Panel shall be and is empowered to request additional information or materials from one or both Parties as
reasonably necessary for the Expert Panel to investigate and render a decision, [***]. The Parties shall [***] with all such requests and decisions.
3.6 Limitations on Authority . Each Party will retain the rights, powers and discretion granted to it under this Agreement and, unless expressly
provided in this Agreement, no rights, powers or discretion will be delegated to or vested in the JRC. The JRC will not have the power to accept, amend,
modify, waive or determine compliance with this Agreement; provided  that , for clarity, the JRC may reject, accept or amend proposed Workflow
Development Plans pursuant to Section 2.2.1 (Workflow Development Plans – Generally ) or review, amend or restate an approved Workflow
Development Plan pursuant to Section 2.3 (Amendments to Workflow Development Plans ) or terminate an approved Workflow Development Plan but, for
clarity, in no event may the JRC amend or restate any Workflow Development Plan so it includes work in any Excluded Field. Notwithstanding anything to
the contrary, no decision by the JRC or by a Party within the JRC will: (a) require the other Party to breach any obligation or agreement that such other
Party may have with or to a Third Party [***] or (b) amend, modify, or waive a Party’s compliance with, this Agreement (by way of example, a decision to
[***]), any of which shall require mutual written agreement of the Parties.
3.7 Alliance Managers . Each Party will appoint one employee of such Party who will oversee contact between the Parties for all matters between
meetings of each JRC and will have such other responsibilities as the Parties may agree in writing after the Effective Date (each, an “ Alliance Manager”).
Each Party may replace its Alliance Manager at any time by notice in writing to the other Party. The Alliance Managers will work together to manage and
facilitate the communication between the Parties under this Agreement, including the resolution (in accordance with the terms of this Agreement) of
issues between the Parties that arise in connection with this Agreement.
3.8 Working Groups. From time to time, the JRC may establish and delegate duties to sub-committees  or directed teams (each, a “ Working Group”)
on an “as-needed”  basis to oversee particular projects or activities. Each such Working Group will be constituted and will operate as the JRC determines;
provided  that  each Working Group will have equal representation from each Party, unless otherwise mutually agreed. Working Groups may be established
on an ad hoc basis for purposes of a specific project or on such other basis as the JRC may determine. Each Working Group and its activities will be
subject to the oversight, review and approval of, and will report to, the JRC. In no event will the authority of the Working Group exceed that specified by
the JRC for such Working Group. All decisions of a Working Group will be by consensus. Any disagreement between the designees of Ginkgo and BLI
with respect to a Working Group will be referred to the JRC for resolution.
Page 24 of 853.9 Expenses. Each Party will be responsible for all travel and related costs and expenses for its members and other representatives to attend
meetings of, and otherwise participate in, the JRC or other Working Group.
4. APPLICABILITY OF BLI TERMS AND CONDITIONS.
With respect to Beacon Optofluidic Machines (including related Hardware and Software), Consumables and Services for which Ginkgo has placed a
Purchase Order pursuant to this Agreement, the Parties agree to the BLI Terms and Conditions that apply with respect to Beacon Optofluidic Machines
(including related Hardware and Software), Consumables and Services, unless, notwithstanding anything to the contrary set forth in the BLI Terms and
Conditions (including any language regarding the treatment of additional or different terms set forth therein), a term in such BLI Terms and Conditions is
inconsistent with a term in this Agreement, in which case this Agreement shall control, including as follows:
4.1.1 this Agreement, and not the BLI Terms and Conditions, shall solely set forth the fields in which Ginkgo has and does not have the
ability to use the Beacon Optofluidic Machines (including related Hardware and Software), Consumables and Services for certain purposes (e.g.,
the Excluded Field);
4.1.2 BLI’s liability with respect to any Failure to Supply, penalties for late delivery and obligations with respect to short supply shall be as
set forth in this Agreement, including Section 5.4.3 (Failure to Supply ) of this Agreement;
4.1.3 any right of BLI to use Ginkgo’s data, including Collaboration Data, is solely set forth in this Agreement, including Section 8.5 (Use of
Collaboration Data ) and the BLI Terms and Conditions shall give BLI no right to use any data of Ginkgo or its Affiliates, including Collaboration
Data;
4.1.4 each Party’s indemnification obligations and matters relating to the extent of its liability (e.g. consequential damages waiver) shall solely
be determined under the terms of this Agreement (including Section 11.6 (No Consequential Damages ) and Section 12 (Indemnification;
Insurance ));
4.1.5 any disputes between the Parties related to Beacon Optofluidic Machines (including related Hardware and Software), Consumables,
Services or the activities under this Agreement (including the performance of the Workflow Development Plans) shall be governed by Section 14.5
(Governing Law; Dispute Resolution; Equitable Remedies ) of this Agreement, including disputes as to whether (a) [***], (b) [***] or (c) (i) [***],
(ii) [***] or (iii) [***], and, with respect to each of (a), (b) and (c), which Ginkgo shall be entitled to dispute in writing in good faith irrespective of
whether BLI is given sole or final decision-making authority with respect thereto under the applicable BLI Terms and Conditions;
4.1.6 all payment provisions between the Parties related to the subject matter hereunder shall solely be under this Agreement and not any of
the BLI Terms and Conditions;
Page 25 of 854.1.7 each of the BLI Terms and Conditions shall be freely assignable solely to the applicable assignee in connection with any assignment
permitted under the terms of Section 14.4 (Assignment ) of this Agreement;
4.1.8 no activities by BLI under this Agreement may be terminated or suspended under any of the BLI Terms and Conditions if such
termination or suspension is not permitted under the terms of this Agreement;
4.1.9 Ginkgo may elect, at any time in its sole discretion, to terminate the Software License Agreement that comprises part of the BLI Terms
and Conditions and, upon such termination, Ginkgo’s right to use such underlying Software shall terminate; and
4.1.10 the BLI Terms and Conditions that apply with respect to any Beacon Optofluidic Machines (including related Hardware and Software),
Consumables or Services for which Ginkgo has placed a Purchase Order pursuant to this Agreement shall not terminate absent mutual written
consent of the Parties, unless this Agreement has been terminated early (e.g. prior to its Expiration) in which case such BLI Terms and Conditions
shall survive only for so long and to the extent as Ginkgo continues to have the right to use Beacon Optofluidic Machines or Consumables or
receive Services pursuant to Section 13.3 (Effects of Termination).
5. FORECASTS; ORDERS; SERVICE STANDARDS AND RELATED OBLIGATIONS
5.1 Forecasts of Production Purchases . Within [***] ([***]) days following the Effective Date and on or before the first Business Day of each
[***] thereafter, Ginkgo shall furnish BLI with a rolling forecast of the quantities of Beacon Optofluidic Machines (including related Hardware and
Software) and Consumables (on a Consumable-by-Consumable  basis) that Ginkgo expects to require from BLI under this Agreement during the ensuing
[***] ([***]) month period on a [***] basis (each such forecast, a “ Rolling Forecast”). Subject to the limitations set forth in this Agreement, Ginkgo may,
in its sole discretion, update its estimated requirements of Beacon Optofluidic Machines (including related Hardware and Software) and Consumables in
the next Rolling Forecast delivered; provided  that  (a) the [***] of each Rolling Forecast shall be binding upon the Parties with respect to Beacon
Optofluidic Machines and with respect to Consumables, Ginkgo’s Purchase Orders for Consumables during the [***] may fluctuate by +/- [***] percent
([***]%) of the amount of Consumables set forth in the Rolling Forecast for the [***]; (b) the [***] of each Rolling Forecast shall include binding
amounts forecasted for Beacon Optofluidic Machines and Consumables within (i) [***] percent ([***]%) of the number of units of Beacon Optofluidic
Machines or (ii) [***] percent ([***]%) of the number of units of any Consumable; and (c) the [***] of each Rolling Forecast shall be non-binding,  good
faith estimates of Ginkgo’s demand for Beacon Optofluidic Machines and Consumables. The foregoing, along with any other relevant provisions in this
Agreement, shall be the sole forecasting mechanics for Ginkgo’s requirements of Beacon Optofluidic Machines (including related Hardware and Software)
or Consumables expressly notwithstanding anything to the contrary in the BLI Terms and Conditions with respect to forecasting.
Page 26 of 855.2 Pricing. Notwithstanding anything to the contrary in the BLI Terms and Conditions with respect to pricing for Beacon Optofluidic Machines
(including related Hardware and Software), Consumables or Services, the following shall apply:
5.2.1 General. The pricing as of the Effective Date for Beacon Optofluidic Machines, Consumables and certain services (including Services)
are set forth in Schedule 5.2.1 (Pricing Schedule ). Such pricing shall be adjusted pursuant to this Section 5.2 (Pricing ). For any Consumable or
service not listed in Schedule 5.2.1 (Pricing Schedule ), BLI shall provide the price for such to Ginkgo upon Ginkgo’s request during the Term, such
price to be consistent with this Section 5.2 (Pricing ). BLI represents and warrants that the pricing set forth in Schedule 5.2.1 (Pricing Schedule ) are
BLI’s List Prices for the described Beacon Optofluidic Machines, Consumables and services (including Services) as of the Effective Date. BLI shall
discount List Prices for Ginkgo by [***] percent ([***]%) or such higher amount as agreed by the Parties, and subject to pricing adjustments as
set forth in Section 5.2.2 (Adjustments). For clarity, with respect to Consumables to be purchased under a Workflow Development Plan, Ginkgo will
be responsible for costs for such Consumables as set forth in the Budget for such Workflow Development Plan.
5.2.2 Adjustments. Notwithstanding anything else to the contrary in this Agreement, and [***], with respect to the prices charged by BLI to
Ginkgo under Section 5.3.2 (Purchase Orders – Acceptance and Rejection ):
(a) With respect to any [***], (i) there will be no increases from the per unit pricing set forth in Schedule 5.2.1 (Pricing Schedule ) for
at least the first [***] and (ii) the per unit pricing charged by BLI to Ginkgo at any time shall be no greater than the lowest of the (A)
lowest price per unit charged by BLI or its Affiliates to any similarly situated Third Party customer (i.e. taking into account [***]) for
such unit at any time in the [***] ([***]) months prior to the delivery of the applicable Purchase Order by Ginkgo or (B) the then-
current List Price; provided , however , that  in no event shall BLI be required to charge a price less than the cost of goods sold for
such unit, as determined in accordance with United States generally accepted accounting principles, consistently applied.
(b) With respect to any [***], (i) there will be no increases from the per unit pricing set forth in Schedule 5.2.1 (Pricing Schedule ) for
at least the first [***], (ii) subject to subclause (iii), the per unit pricing charged by BLI to Ginkgo shall be no greater than [***]
percent ([***]%) of the lowest List Price for such unit at any time between the delivery of the applicable Purchase Order by Ginkgo
and delivery of such OptoSelect Chip or Consumable and (iii) the per unit pricing charged by BLI to Ginkgo for such unit that is [***]
shall be no greater than [***] percent ([***]%) of the lowest List Price for such unit.
Page 27 of 85(c) With respect to any [***], there will be no increases from the per unit [***] set forth in Schedule 5.2.1 (Pricing Schedule ) for at
least the [***] and after such [***], BLI may adjust pricing for [***] for a Contract Year within the first [***] ([***]) days of such
Contract Year by written notice to Ginkgo; provided  that  such adjustment [***] for such [***] and in no event will the [***] charged
to Ginkgo for any [***] under this Agreement be higher than the then-current  List Price for the applicable [***].
(d) With respect to any [***], there will be no increases from the rates set forth in Schedule 5.2.1 (Pricing Schedule ), except that, on
an annual basis, upon written notice to Ginkgo, BLI may increase the rates set forth in Schedule 5.2.1 (Pricing Schedule ) by a
percentage [***], not to exceed [***] percent ([***]%) per calendar year.
(e) With respect to any other Beacon Optofluidic Machines, Consumables and services (including Services) not listed on Schedule
5.2.1 (Pricing Schedule ), the per unit pricing charged by BLI to Ginkgo shall be no greater than the then-current  List Price, [***].
5.3 Purchase Orders; Delivery and Payment .
5.3.1 Issuance. Ginkgo shall submit orders for Beacon Optofluidic Machines (including related Hardware and Software), Consumables (on a
Consumable-by-Consumable  basis) and Services pursuant to written purchase orders (each, a “ Purchase Order”) issued to BLI in a form
consistent with this Agreement. Purchase Orders shall be provided by Ginkgo, shall specify (a) the quantity of Beacon Optofluidic Machines
(including related Hardware and Software), Consumables (on a Consumable-by-Consumable  basis) or Services ordered and (b) the requested
delivery date or service date and location. The requested delivery dates or service dates set forth in a Purchase Order shall be no earlier than the
Lead Time for such delivery or service. BLI shall not be obligated to supply in any [***] (i) a quantity of the [***] in excess of the amount
designated in such [***] in the binding portion of the Rolling Forecast or (ii) a quantity of [***] that is greater than [***] percent ([***]%) of the
amount designated for such item or service in such [***] in the binding portion of the Rolling Forecast (such amount, the “ Maximum Amount”);
provided  that  notwithstanding the provisions set forth in this Section 5.3.1 (Issuance) or Section 5.3.2 (Acceptance and Rejection ) to the contrary,
BLI shall use [***] to accept and fulfill Purchase Orders for quantities of [***] in excess of the Maximum Amount in any [***]. The foregoing shall
apply and, along with any applicable provisions of the Agreement, be the exclusive terms and conditions for Ginkgo’s Purchase Orders under this
Agreement, notwithstanding anything to the contrary in the BLI Terms and Conditions with respect to Ginkgo’s orders for or ability to order (and
have orders fulfilled for) [***].
5.3.2 Acceptance and Rejection . BLI shall, by written notice to Ginkgo, accept or, subject to the terms of this Agreement, reject, each
Purchase Order (a) with respect to orders for [***], within [***] ([***]) days of receipt and (b) with respect to
Page 28 of 85orders for [***], within [***] ([***]) days of receipt, with respect to each, by written notice to Ginkgo. Any failure of BLI to accept or reject a
Purchase Order within such [***] day period shall be deemed an acceptance by BLI of such Purchase Order. Any express acceptance of a Purchase
Order by BLI shall confirm the quantity of Beacon Optofluidic Machines (including related Hardware and Software), Consumables (on a
Consumable-by-Consumable  basis) and Services requested to be supplied or performed, the prices, pursuant to Section 5.2 (Pricing ), associated
with such Beacon Optofluidic Machines (including related Hardware and Software), Consumables (on a Consumable-by-Consumable  basis) and
Services and that delivery or performance of such Optofluidic Machines (including related Hardware and Software), Consumables and Services
shall occur [***]; provided  that  (i) BLI shall not have the right to reject, and shall be deemed to have accepted, any Purchase Order meeting the
requirements of this Section 5.3 (Purchase Orders; Delivery and Payment ) and (ii) if any Purchase Order contains quantities in excess of the
Maximum Amount for such month and otherwise meets the requirements of this Section 5.3 (Purchase Orders; Delivery and Payment ), then such
Purchase Order shall be deemed accepted except with respect to such excess quantities and, subject to Section 5.3.1 (Issuance), BLI shall confirm to
Ginkgo within [***] ([***]) days of receipt of such Purchase Order if BLI can supply such excess and if so, such Purchase Order shall be deemed
accepted with respect to such excess quantities as well. The foregoing shall apply notwithstanding anything to the contrary in the BLI Terms and
Conditions with respect to BLI’s ability to accept or reject Ginkgo’s orders for Beacon Optofluidic Machines (including related Hardware and
Software), Consumables or Services.
5.3.3 Delivery and Payment . Notwithstanding anything to the contrary in the BLI Terms and Conditions with respect to the delivery of
Beacon Optofluidic Machines (including related Hardware and Software) or Consumables, the performance of Services and rights and
responsibilities arising in connection with such delivery or performance, the following shall apply:
(a) Machines and Consumables . With respect to Beacon Optofluidic Machines and Consumables for which Ginkgo has placed a
Purchase Order under this Agreement:
(i) such items shall be shipped by BLI (A) [***] or (B) [***], with respect to (A)-(B), to the delivery point set forth on the
Purchase Order; [***];
(ii) a BLI employee will install the Beacon Optofluidic Machines at such delivery point and, within [***] ([***]) Business
Days of installation, will deliver to Ginkgo a completed BLI field service report confirming installation and qualification of the
relevant Beacon Optofluidic Machines in accordance with Schedule 5.3.3 (Qualification Standards );
(iii) title and risk of loss to (A) [***] or (B) [***];
Page 29 of 85(iv) BLI shall invoice Ginkgo for any Beacon Optofluidic Machine or Consumable at a price calculated in accordance with
Section 5.2 (Pricing ) [***];
(v) Ginkgo shall be deemed to have accepted delivery of any Beacon Optofluidic Platform upon [***] unless Ginkgo delivers,
within [***] ([***]) Business Days a written statement detailing the reasons why the item delivered is not a Conforming
Product and, if BLI disputes Ginkgo’s allegation of non-conformance,  the matter shall be resolved pursuant to Section 14.5.2
(Dispute Resolution ); and
(vi) Ginkgo shall pay BLI for all delivered quantities of Conforming Product within [***] ([***]) days from Ginkgo’s [***]
under this Agreement[***].
(b) Services. With respect to Services for which Ginkgo has placed a Purchase Order under this Agreement:
(i) such Services shall be provided at the time and location set forth on an accepted Purchase Order, unless otherwise
mutually agreed by the Parties in writing;
(ii) BLI shall invoice Ginkgo for any Services at a price calculated in accordance with Section 5.2 (Pricing ) [***] except [***],
which shall be paid [***] and the Terms and Conditions except to the extent such conflicts with the terms of this Agreement,
in which case this Agreement shall supersede with respect to the conflicting terms; and
(iii) Ginkgo shall pay BLI for all performed Services that meet the applicable Service Standards within [***] ([***]) days from
receipt of invoice[***].
(c) Payments. All Production Purchase amounts paid by Ginkgo to BLI for Beacon Optofluidic Machines, for Consumables and for
Services are non-creditable  and non-refundable  except as set forth in expressly set forth in this Agreement (including Section 7.8
(Audits )) and the BLI Terms and Conditions.
5.4 Capacity; Failure to Supply .
5.4.1 Personnel . Notwithstanding anything to the contrary in the BLI Terms and Conditions for Services:
(a) Generally. With respect to any [***] in the Term, to [***] continuity of supply with respect to services (including Services)
rendered under this Agreement (including Workflow Development
Page 30 of 85Plans) to Ginkgo, BLI shall [***] employs a sufficient number of personnel so that it [***] satisfy, with respect to the then-current
[***], Ginkgo’s requirements for Services during such [***], as specified in the then-applicable  Rolling Forecast. BLI shall (a) use
qualified personnel in connection with performing Services for Ginkgo and perform such Services in a competent and workmanlike
manner consistent with prevailing industry standards and in material conformance with Applicable Laws, the terms of this Agreement
(which shall include the terms of any Workflow Development Plans) and (b) obtain and maintain all material licenses, permits or
approvals required by Applicable Laws, the terms of this Agreement (which shall include the terms of any approved Workflow
Development Plans) in connection with performing Services for Ginkgo.
(b) Dedicated FTEs; Key Persons . In addition to its obligations set forth in Section 5.4.1(a) (Personnel – Generally ), during the
period beginning [***] ([***]) Business Days after the Effective Date and ending on the [***] ([***]) anniversary of the Effective
Date, BLI shall [***] provide Ginkgo with [***] ([***]) FTEs to work on-site  at Ginkgo to aid in [***]. Following the [***] ([***])
anniversary of the Effective Date, unless otherwise agreed by the Parties, BLI shall provide Ginkgo with [***] to work on-site  at
Ginkgo to aid in [***]. [***] shall designate up to [***] ([***]) BLI employees or personnel as key persons (individually, a “ Key
Person” and collectively, “Key Persons”). [***] to the percentage of any such Key Person’s time that shall be dedicated to activities
performed under this Agreement. No Key Person shall be reassigned, nor shall the time dedicated to activities under this Agreement
be reduced, without [***], but if such Key Person (i) is no longer employed by BLI, (ii) [***] or (iii) [***], with respect to (i)-(iii), then
the Parties shall work together to mutually identify in writing a new employee as a replacement for such Key Person and, upon such
mutual identification, such employee shall be deemed a Key Person for all purposes of this Agreement. For clarity, [***] shall be
[***] if [***], that [***] and [***] or [***]. In the event of a termination of employment at BLI of any Key Person, BLI shall notify
Ginkgo of such circumstance as promptly as practicable. Ginkgo shall have the right, but not the obligation, at any time, to request
that BLI replace such Key Person with another BLI employee reasonably acceptable to Ginkgo. In such event, BLI shall replace such
person [***]. Ginkgo will provide each BLI FTE that is on-site  at Ginkgo with (I) access to Ginkgo’s facility to the extent required to
perform each FTE’s obligations as set forth in each approved Workflow Development Plan and (II) [***].
(c) Conduct on Site . BLI acknowledges and agrees that BLI FTEs (including Key Persons) are not employees or agents of Ginkgo,
that Ginkgo has no responsibility to provide worker’s compensation or other
Page 31 of 85liability coverage, insurance, benefits or, other than as expressly provided in this Agreement, compensation for BLI FTEs. BLI further
acknowledges and agrees that BLI FTEs are acting solely as representatives of BLI during any work performed at Ginkgo’s facilities.
BLI shall (a) comply, and shall cause each BLI FTE to comply, with all Applicable Laws; (b) abide, and shall cause each on-site  BLI
FTE to abide, by [***] guidelines and procedures related to Ginkgo’s facilities and use of its foundries that are [***] (e.g., [***])
made available to BLI or BLI’s FTEs; and (c) cause on-site  BLI FTEs to execute a confidentiality agreement with Ginkgo in the form
attached hereto as Exhibit C. Each BLI FTE will be required to complete training offered by Ginkgo regarding the guidelines and
procedures referred to in Section 5.4.1(b) (Dedicated FTEs; Key Persons ). Without limitation of the foregoing, each BLI FTE shall be
responsible for performing work in such a manner as to [***].
5.4.2 Safety Stock Inventory . At any given time during the Term, to ensure continuity of supply with respect to [***], BLI shall maintain an
inventory of [***] sufficient to fulfill orders by Ginkgo for [***] for the next [***], such amount of [***] to be based on the then-applicable
Rolling Forecast.
5.4.3 Failure to Supply.
(a) Remedial Efforts. If, for any reason, including [***], BLI [***] fails to provide Conforming Product or Service that conforms with
this Agreement and the Service Level Standards for such Service, in each case in accordance with one or more accepted Purchase
Orders for a period of [***] ([***]) consecutive days or more (each, a “ Failure to Supply”), BLI shall notify Ginkgo promptly,
including details of the reasons for the Failure to Supply and BLI’s estimate of when the Failure to Supply shall be corrected. BLI
shall [***] minimize any shortage or delay in delivery of Beacon Optofluidic Machines (including related Hardware and Software),
Consumables or Services to Ginkgo as a result of a Failure to Supply. Within [***] ([***]) days of written notification by BLI to
Ginkgo under this Section 5.4.3(a) (Remedial Efforts) of a Failure to Supply, the Parties shall hold a JRC meeting at which BLI’s
representatives will explain [***] the cause of such Failure to Supply and present BLI’s remedial plan to [***] Beacon Optofluidic
Machines (including related Hardware and Software), Consumables or Services to be supplied to Ginkgo in accordance with this
Agreement and the accepted Purchase Orders, which plan [***] (the “ Remedial Plan”). BLI shall consider [***] in good faith any
reasonable changes proposed by Ginkgo to the Remedial Plan. If the JRC approves the Remedial Plan, BLI will execute such Remedial
Plan [***].
(b) Fees for Late Delivery. [***], the following discounts on the amounts owed by Ginkgo to BLI under an accepted Purchase Order
Page 32 of 85shall be in effect for any [***] not delivered in accordance with this Agreement until after the applicable delivery date set forth in
such Purchase Order: (a) for deliveries made more than [***] ([***]) days and less than [***] ([***]) days after such delivery date, a
[***] percent ([***]%) discount; and (b) for deliveries made after [***] ([***]) days after such delivery date, a [***] percent
([***]%) discount, in each case of clauses (a) through (b), from the price for the Consumable delivered late; provided  that , any
discount shall only apply if the Purchase Order at issue was for a quantity of [***] at or below the binding forecasted quantity
([***]) provided pursuant to Section 5.1 (Forecasts of Production Purchases ). Any discount in effect under this Section 5.4.3(b)
(Fees for Late Delivery ) shall be incorporated under any invoice presented by BLI to Ginkgo; provided  that [***]. For purposes of
counting towards Ginkgo’s Production Purchases and Minimum Cumulative Purchase Commitments under this Agreement, Ginkgo
shall be deemed to have paid any invoice as if no discount for delayed delivery was in effect.
(c) Short Supply . Without limiting anything to the contrary in this Agreement, in the event that any Beacon Optofluidic Machines
(including related Hardware and Software), Consumables or the Services are in short supply, i.e., [***], BLI shall notify Ginkgo in
writing of such circumstances as soon as possible, including the underlying reasons for such shortage, the date such inability is
expected to end and the amount of Beacon Optofluidic Machines (including related Hardware and Software), Consumables or
Services to be allocated to Ginkgo. BLI shall allocate Beacon Optofluidic Machines (including related Hardware and Software),
Consumables and Services in short supply to Ginkgo [***], with such [***] allocation applicable only up to the number of units of
such item set forth in the binding portions of the then-current  Rolling Forecast.
(d) Tolling. Without limiting Ginkgo’s rights under this Agreement or under Applicable Law, in the event of a Failure to Supply, [***]
obligations of Ginkgo that are [***] by such Failure to Supply, including [***], shall be excused by an amount [***] to the Failure to
Supply, which excused amount, in ensuring that such amount is [***] to the Failure to Supply, will include amounts [***] to such
Failure to Supply. In addition, Ginkgo will submit to BLI a good faith proposal with respect to [***], taking into consideration the
[***] that are attributable to such Failure to Supply. BLI shall promptly review such proposal and send written confirmation to
Ginkgo of its [***] or, alternatively, inform Ginkgo in writing of and discuss with Ginkgo [***]. If [***], BLI will [***].
(e) Material Failure to Supply. If for reasons [***], over the course of any consecutive [***] period during the Term, BLI fails to
provide
Page 33 of 85Ginkgo with at least [***] percent ([***]%) of (a) a given [***] or (b) the cumulative total of [***], with respect to each of clauses (a)
and (b), in accordance with accepted Purchase Orders and this Agreement (including, with respect to [***]) over such [***] period,
then, such Failure to Supply shall be deemed a material breach of this Agreement and Ginkgo shall have the right to terminate this
Agreement pursuant to Section 13.2.1 (Material Breach ), subject to BLI’s right to cure such material breach.
6. RESTRICTIONS
6.1 Headstart Period .
6.1.1 BLI Standstill. Unless otherwise expressly agreed to in writing by the Parties, on a Headstart Invention-by-Headstart  Invention basis,
beginning on the date that a Workflow Development Plan is commenced and ending on the earlier of (a) the [***] anniversary of the date on which
[***] under this Agreement or (b) subject to the last sentence of this Section 6.1.1 (BLI Standstill ), if [***], then the [***] anniversary of the date
on which [***] under this Agreement (for each such Headstart Invention, with respect to (a)-(b), the “Headstart Period”): (i) as between the
Parties, Ginkgo will have the sole right to use, practice and exploit such Headstart Invention, and (ii) BLI shall not, and shall cause its Affiliates to
not, directly or indirectly, itself or with or through a Third Party, use, practice or otherwise exploit such Headstart Invention in any way or grant any
right, title or license to any Third Party to use, practice or otherwise exploit such Headstart Invention; provided  that , for clarity, BLI shall retain the
right to use, practice and otherwise exploit such Headstart Invention in accordance with the terms of this Agreement to perform BLI’s obligations
under this Agreement. For further clarity, nothing in this Section 6.1.1 (BLI Standstill ) is intended to prevent a Third Party BLI customer or partner
from using, practicing or otherwise exploiting any independently developed improvement, invention, process or workflow even if similar to a
Headstart Invention as long as BLI and its Affiliates are in compliance with this Section 6.1.1 (BLI Standstill ) [***]. If a Workflow Development
Plan is cancelled under the terms of this Agreement, then the Headstart Period with respect to Headstart Inventions under such Workflow
Development Plan shall be deemed to have immediately accelerated to conclusion, unless Ginkgo (x) identifies in writing one or more Headstart
Inventions under the Workflow Development Plan within [***] ([***]) Business Days of cancellation of the Workflow Development Plan and (y)
[***], in which case such Headstart Invention(s) shall be subject to the applicable Headstart Period under this Section 6.1.1 (BLI Standstill );
provided  that , Ginkgo’s right to identify [***] under clauses (x) and (y) shall not exist if the cancellation of a Workflow Development Plan is [***].
6.1.2 [***]. Notwithstanding anything to the contrary in Section 6.1.1 (BLI Standstill ), on a Headstart Invention-by-Headstart  Invention
basis, BLI may provide written notice to Ginkgo [***] (i.e. [***]), with respect to a Headstart Invention, such notice to specify (a) the applicable
Headstart Invention [***], (b) the [***] and (c) whether BLI would prefer to [***] or, to the extent [***], [***] (which may, [***]); provided  that to
the extent the [***], BLI may only submit such a notice (and [***]) for [***]. Ginkgo
Page 34 of 85shall have [***] ([***]) Business Days following delivery of notice to Ginkgo to [***] by written notice to BLI. If the Parties [***] within [***]
([***]) Business Days of such written notice by Ginkgo, [***]. Following BLI’s delivery of notice to Ginkgo [***], BLI shall [***] (i) if Ginkgo
does not [***] within the [***] ([***]) Business Day period after notice delivery, within [***] ([***]) Business Days following the expiration of
such [***] ([***]) Business Day period and (ii) if Ginkgo does [***] within the [***] ([***]) Business Day period after notice delivery, within
[***] ([***]) Business Days following the [***]. Immediately upon [***] for a Headstart Invention, [***]. For clarity, [***]. For the avoidance of
doubt, following the end of the Headstart Period for a Headstart Invention, Ginkgo shall still have the right to use, practice and exploit such
Headstart Invention under this Agreement.
6.2 Restrictions on the Parties .
6.2.1 Restrictions on BLI. During the Term and for a period of [***] ([***]) months following the Term of this Agreement, other than
pursuant to Sections 13.3.2 (Effects of Termination Based Upon Ginkgo’s Buy -Down Election ) or 13.3.3 (Effects of Termination Based Upon an
Uncured Ginkgo Breach, Insolvency or Force Majeure Event ), BLI shall not, and shall cause its Affiliates not to, directly or indirectly, itself or with
or through a Third Party, develop, configure, customize, license, sell, provide or otherwise give access to the Beacon Platform or any [***] to, [***]
or its Affiliates for any use; provided  that  this restriction shall terminate as set forth in Section 13.3 (Effects of Expiration or Termination) or if
Ginkgo has not satisfied its Minimum Cumulative Purchase Commitments (as such may be adjusted under this Agreement) for a full Contract Year,
including [***] as permitted under Section 7.2.2(a) (Minimum Cumulative Purchase Commitments ) or Section 7.2.2(b)(iii) (Development Purchase
Commitments); provided  that  BLI will provide written notice to Ginkgo within [***] ([***]) days of the end of any Contract Year with respect to
which BLI believes that Ginkgo has not satisfied its Minimum Cumulative Purchase Commitment. Notwithstanding the foregoing, in the event that a
Change in Control of an existing (as of the Effective Date or at any time during the Term) Third Party BLI customer results in such customer being
controlled [***] following the date such Third Party became a BLI customer, BLI shall promptly notify Ginkgo in writing of such Change in Control
(in no event later than [***] ([***]) days after BLI first learns of such Change in Control, [***] (in which case such notice will be provided by BLI
no later than [***] ([***]) days after the earlier of [***] or [***]) and, in such written notice, provide Ginkgo with information regarding [***] and,
if BLI does [***], the [***]. Within [***] ([***]) days of Ginkgo’s receipt of such written notice, Ginkgo will have the option, at its sole discretion,
(a) if [***], to [***] and to [***] and, if Ginkgo makes such election, BLI shall promptly [***] and (i) Ginkgo will [***] (but in no event [***]) and
(ii) in the event [***], Ginkgo and BLI will [***] and (b) if [***], then [***], to (i) [***], (ii) [***] and (iii) [***]. In the event BLI notifies Ginkgo as
aforesaid and Ginkgo fails to make such election within the [***] ([***]) day period, then, in the case of (A) or (B), BLI will not be deemed to be in
breach of this Section 6.2.1 (Restrictions on BLI ) solely on account of a Third Party customer [***]. Nothing in this Section 6.2.1 (Restrictions on
BLI) will require or oblige BLI [***], then [***]. In the event [***], [***] in a manner that (x) [***], (y) [***] or (z) [***]. For clarity, the foregoing
sentence shall not [***]. Except as provided in this Section 6.2.1 (Restrictions on BLI ) and the scope of rights granted to
Page 35 of 85Ginkgo under this Agreement (including under Section 6.1 (Headstart Period ) and Section 9.1 (Licenses to Ginkgo )), nothing in this Agreement
shall otherwise limit, prohibit or preclude BLI from developing, configuring, customizing, licensing, selling or providing the Beacon Platform or
Collaboration Workflows for itself or to a Third Party for any uses or otherwise entering into a business or advisory arrangement with any Third
Party. As used in this Section 6.2.1 (Restrictions on BLI ), “control” has the meaning set forth in Section 1.2 (“Affiliate” definition ). For clarity,
[***].
6.2.2 No Further Restrictions by Ginkgo . During the Term, Ginkgo shall not [***] prohibit (i.e. by [***]), as part of any [***] arrangement
with a Third Party, a Third Party from purchasing a Beacon Platform or other BLI products or services, or otherwise using or utilizing such Beacon
Platforms for [***], including [***]. For clarity, such obligation shall not prohibit or limit Ginkgo from entering into generally exclusive
relationships with Third Parties (e.g., [***]).
7. ECONOMICS
7.1 Upfront Payment. No later than [***] ([***]) days following the Effective Date, Ginkgo will pay to BLI a non-refundable  upfront amount equal
to Ten Million Dollars ($10,000,000) (the “Upfront Payment”). Such amount will be fully creditable against all Development Purchases and Production
Purchases owed by Ginkgo to BLI [***] and will be fully creditable against the Full Purchase Target and, [***], the Minimum Purchase Commitment,
Development Purchase Commitment and Production Purchase Target [***]. [***].
7.2 Purchase Commitments.
7.2.1 Generally. Subject to the terms of this Agreement, during the Term, the Parties’ target is for Ginkgo to make a total of One Hundred Fifty
Million Dollars ($150,000,000) in Development Purchases and Production Purchases from BLI (as amended from time to time under this Agreement
and as more fully set forth in this Section 7.2 (Purchase Commitments ), the “Full Purchase Target”), which Full Purchase Target is divided into
Contract Year purchase commitment targets with respect to Development Purchase Commitment and Production Purchase Targets, as more fully set
forth in Section 7.2.2 (Contract Year Purchase Targets and Commitments ).
7.2.2 Contract Year Purchase Targets and Commitments. Subject to the terms of this Agreement (including the remainder of this Section 7.2.2
(Contract Year Purchase Targets and Commitments )), for each Contract Year, Ginkgo shall [***] make Development Purchases and Production
Purchases from BLI in the amounts set forth in the
Page 36 of 85“Development Purchase Commitment” and “Production Purchase Target” columns respectively in Table 7.2.2 with respect to such Contract Year:
Table 7.2.2
Development
Purchase
Commitment
Production
Purchase
Target
Total
Targeted
Purchase
Minimum
Cumulative
Purchase
Commitment
Contract Year 1 $ [***] $ [***] $ [***] $ [***]
Contract Year 2 $ [***] $ [***] $ [***] $ [***]
Contract Year 3 $ [***] $ [***] $ [***] $ [***]
Contract Year 4 $ [***] $ [***] $ [***] $ [***]
Contract Year 5 $ [***] $ [***] $ [***] $ [***]
Contract Year 6 $ [***] $ [***] $ [***] $ [***]
Contract Year 7 [***] $ [***] $ [***] $ 109,000,000
Total $ [***] $ [***] $150,000,000 N/A
(a) Minimum Cumulative Purchase Commitments. With respect to each Contract Year, by no later than [***], Ginkgo shall have
incurred (including all credits and offsets permitted under this Agreement) at least, in the aggregate since the beginning of the Term,
the Minimum Cumulative Purchase Commitment amount for such Contract Year. The Minimum Cumulative Purchase Commitments for
each of Contract Years [***] are binding commitments. Any amounts paid by Ginkgo to BLI in excess of the Minimum Cumulative
Purchase Commitment amount for a given Contract Year in Contract Years [***], regardless of whether such excess constitutes a
Development Purchase or Production Purchase, will be creditable towards the Minimum Cumulative Purchase Commitment in
subsequent Contract Year(s) until such excess amount has been fully credited. Ginkgo covenants to pay the Minimum Cumulative
Purchase Commitments for each Contract Year by the [***] Business Day after the end of the [***]. If BLI has Substantially
Completed at least [***] ([***]) [***] Workflows within the first [***] ([***]) Contract Years, then the Minimum Cumulative
Purchase Commitment as of the Contract Year (which may include a portion of a full Contract Year) that is the last Contract Year
during the Term pursuant to the terms of this Agreement shall change from $109 million (as currently reflected in Table 7.2.2) to $150
million.
(b) Development Purchase Commitments.
(i) Subject to Section 7.2.2(a) (Minimum Cumulative Purchase Commitments ), unless the Parties otherwise mutually agree in
writing, the Development Purchase Commitment for the [***] Contract Years shall constitute a binding obligation on Ginkgo,
and, subject to Ginkgo exercising its Buy-Down Option pursuant to Section 7.3 (Buy-Down Election ), the Development
Purchase Commitment for the [***] Contract Years shall also constitute binding obligations on Ginkgo. No less than [***]
percent ([***]%) of the Development Purchases made in the [***] Contract Years will be used by the Parties to develop
Workflows for [***].
Page 37 of 85(ii) At any time during a Contract Year, upon written notice to the JRC, Ginkgo may accelerate its Development Purchases in
such Contract Year to include Development Purchases anticipated to be made in upcoming Contract Year(s). Such additional
Development Purchases in excess of the Development Purchase Commitment for such Contract Year will be creditable towards
Ginkgo’s Development Purchases in subsequent Contract Year(s) until such excess amount has been exhausted and will
count towards the Minimum Cumulative Purchase Commitment for the Contract Year in which it is paid, subject to allocation
to subsequent Contract Year(s) as set forth in Section 7.2.2(a) (Minimum Cumulative Purchase Commitments ).
(iii) Notwithstanding anything to the contrary in this Agreement, in the event that Ginkgo’s Development Purchases in a
given Contract Year after [***] are less than the Development Purchase Commitment for such Contract Year, respectively,
Ginkgo shall be able to apply the Development Purchases made in the first [***] of the next Contract Year to satisfy the
previous Contract Year’s Development Purchase Commitment; provided  that  (i) Ginkgo may only be able to satisfy [***]
percent ([***]%) of the relevant Development Purchase Commitment for the previous Contract Year pursuant to this Section
7.2.2(b)(iii) (Development Purchase Commitments ) and (ii) any amount of Development Purchases credited towards satisfying
the previous Contract Year’s Development Purchase Commitment shall not count towards satisfying such targets for the
then-current  Contract Year.
(iv) Notwithstanding anything to the contrary in this Agreement, in the event that a Workflow Development Plan is
terminated prior to completion by the JRC, including (A) [***], (B) [***], (C) [***] or (D) [***], then, subject to Section 3.5.1
(Decision -Making ), the JRC shall, in good faith, discuss and approve [***]; provided , however , that  such [***] ( Term).
(c) Production Purchase Commitments .
(i) Subject to this Section 6.2.2(c) (Production Purchase Commitments ), unless the Parties otherwise mutually agree in writing,
the Production Purchase Target for the [***] shall constitute a binding obligation on Ginkgo and, in partial satisfaction of its
Production Purchase commitment for the
Page 38 of 85[***], Ginkgo shall purchase [***] ([***]) [***] within [***] ([***]) days of the Effective Date, the cost of which, for clarity,
shall be offset by the upfront payment paid by Ginkgo pursuant to Section 7.1 (Upfront Payment). Subject to Ginkgo’s
obligation to satisfy the Minimum Cumulative Purchase Commitment for a Contract Year, with respect to the second [***]
Contract Years), Ginkgo’s Production Purchase Targets for the [***] Contract Years as set forth in Table 7.2.2 are [***], and
the Parties expressly acknowledge and agree that [***].
(ii) At any time during a Contract Year, upon written notice to the JRC, Ginkgo may accelerate its Production Purchases in
such Contract Year to include Production Purchases anticipated to be made in upcoming Contract Year(s). Such additional
Production Purchases in excess of the Production Purchase Target for such Contract Year will be creditable towards Ginkgo’s
Production Purchases in subsequent Contract Year(s) until such excess amount has been exhausted and will count towards
the Minimum Cumulative Purchase Commitment.
(d) Effects of Tolling. Notwithstanding anything to the contrary in this Agreement, Ginkgo’s obligations to satisfy Development
Purchase Commitments and Production Purchase Commitments at all times during the Term (including any Intended End of Term) are
subject to Section 5.4.3(d) (Tolling) and this Section 7.2.2(d) (Effects of Tolling). In the event that, at any time during the Term, there
is a Failure to Supply, then the duration of this Agreement will automatically be extended for additional calendar months (rounded to
the nearest whole calendar month) equal to [***] (the seventh (7 th ) anniversary of the Effective Date plus such additional calendar
months, the “ Intended End of Term”).
7.3 Buy-Down Election. During the Term following the end of the second (2 nd) Contract Year, Ginkgo may elect, upon written notice to BLI, to buy-
down its remaining financial obligations under the Full Purchase Target (the “ Buy-Down Election”) by making a one-time payment to BLI in the amount of
the Buy-Down Amount. In the event Ginkgo notifies BLI of its Buy-Down Election as set forth in this Section 7.3 (Buy-Down Election), then, upon
Ginkgo’s payment of the Buy-Down Amount to BLI within [***] ([***]) days of Ginkgo’s Buy-Down Election, this Agreement shall automatically
terminate, with the applicable effects of termination set forth in Section 13.3.2 (Effects of Termination Based Upon Ginkgo’s Buy -Down Election ).
7.4 Additional Payments .
7.4.1 License Fees. During the Term, and in consideration for the rights granted herein, Ginkgo shall pay field of use license fees (“ FOU
License Fees”) as follows: (a) with respect to any calendar year, no FOU License Fees will be due until [***] and (b) [***] ($[***]) per calendar
year per Beacon Optofluidic Machine [***] up to a
Page 39 of 85maximum of [***] ($[***]) per calendar year per Beacon Optofluidic Machine; provided  that , in no event will the FOU License Fees paid by Ginkgo
for use of a Beacon Optofluidic Machine [***]. FOU License Fees shall be applied to Ginkgo’s use of all Beacon Optofluidic Machines, [***].
Notwithstanding anything to the contrary in this Agreement and without limiting any of Ginkgo’s rights and remedies under Applicable Law and
this Agreement, [***],
7.4.2 Milestone Payments . In the event that Ginkgo uses any of the BLI Proprietary Workflows identified in Exhibit D to conduct Commercial
Services for a Third Party customer and such Commercial Services [***] result in the discovery of an Antibody to be used as the active ingredient
in a therapeutic product for which a Third Party [***] (each such Antibody subject to this Section 7.4.2 (Milestone Payments ), a “Discovered
Antibody”), then, on a Discovered Antibody-by-Discovered  Antibody basis, in the event such Third Party (a) achieves any of the milestone events
noted below in Table 7.4.2 (each, a “Milestone Event”) with respect to a Discovered Antibody and (b) makes a payment to Ginkgo in connection
with such Milestone Event, then Ginkgo will pay BLI [***] percent ([***]%) of such payment received by Ginkgo from such Third Party up to the
amount of the corresponding “Maximum Milestone Payment” for such milestone event set forth below in Table 7.4.2 (each, a “Milestone Payment”.
Notwithstanding anything to the contrary in this Agreement, in no event shall a Discovered Antibody include (x) an Antibody [***] (e.g. [***])
through the conduct of Commercial Services by Ginkgo or (y) an Antibody [***].
Table 7.4.2
Milestone Event
Maximum
Milestone
Payment
[***] $ [***]
[***] $ [***]
[***] $ [***]
[***] $ [***]
Each Milestone Payment shall be payable only once for each and every Discovered Antibody. If any Milestone Event is achieved for any
Discovered Antibody before any of the preceding Milestone Events are achieved for such Discovered Antibody, then all the Milestone Payments
for such unachieved preceding  Milestone Events will be due and payable with the Milestone Payment for the Milestone Event that was achieved.
For example, [***].
7.5 Manner of Payments . Each payment under this Agreement to a Party will be made in Dollars and by electronic transfer in immediately available
funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at such receiving
Party’s election, to such bank account as the receiving Party will designate in writing to the other Party at least [***] ([***]) Business Days before the
payment is due.
7.6 Taxes. It is understood and agreed between the Parties that any payments made by a Party to the other Party under this Agreement are
exclusive of any sales tax, value added tax (if any) or similar tax (“VAT”) upon such payments. Where VAT is properly added to a payment made under
this Agreement, the Party making the payment will pay the amount of VAT only on
Page 40 of 85receipt of a valid tax invoice issued in accordance with the laws and regulations of the country in which the VAT is chargeable. If a Party is required to
deduct or withhold from any payment due hereunder any taxes in the nature of a tax upon or measured by income, then the Parties shall work together to
ensure, subject to this Section 7.6 (Taxes), that the withholding Party is able to comply with its obligations under Applicable Law and that the non-
withholding Party still receives the net amount due to it following payment of such tax by the withholding Party. [***]. The Parties will reasonably
cooperate to provide sufficient documentation to receive any credits available under Applicable Law. Notwithstanding the foregoing, to the extent that,
due to (a) [***], (b) [***], (c) [***], (d) [***] or (e) [***], with respect to each, VAT or other taxes are imposed on payments made by Ginkgo or BLI, as
applicable, to the other Party that were not otherwise applicable (“ Incremental Withholding Taxes”), the Party that took such action resulting in
Incremental Withholding Taxes (together with any subsequent successor or assign, “ Responsible Tax Party”) shall be solely responsible for and shall
solely bear the amount of such Incremental Withholding Taxes. If the other Party receives a refund or tax credit in connection with the Incremental
Withholding Taxes, then such other Party shall promptly pay the Responsible Tax Party an amount equal to the amount of such refund or tax credit.
7.7 Financial and Other Records . Each Party shall, and shall cause its Affiliates to, keep complete and accurate books and records pertaining to its
activities conducted and costs incurred under this Agreement (including each approved Workflow Development Plan), including with respect to Budget
spending, Development Purchases, Production Purchases, FOU License Fees and Milestone Payments, in sufficient detail to calculate all amounts
payable hereunder and to verify compliance with its obligations under this Agreement. Such books and records shall be retained by such Party and its
Affiliates until [***] ([***]) years after the end of the period to which such books and records pertain or for such longer period as may be required by
Applicable Law.
7.8 Audits . At the request of the other Party, each Party will, and will cause its Affiliates to, permit an independent public accounting firm of
nationally recognized standing designated by the other Party and reasonably acceptable to the audited Party, at reasonable times during normal business
hours and upon reasonable notice, to audit the books and records maintained pursuant to Section 7.7 (Financial and Other Records ) solely to confirm
the accuracy of all financial reports, invoices and payments made hereunder or Budget spending under an approved Workflow Development Plan. Such
examinations may not (a) be conducted more than once in any [***] month period (unless a previous audit during such [***] month period revealed an
overpayment (or an underpayment of a Milestone Payment, FOU License Fees, or royalty for Licensed Products) of at least [***] percent ([***]%) of the
amount actually due with respect to such period) or (b) [***]. The accounting firm will execute a reasonable written confidentiality agreement with the
audited Party and will disclose to the auditing Party only such information as is reasonably necessary to provide the auditing Party with information
regarding any actual or potential discrepancies between the amounts actually paid and the amounts payable under this Agreement. The accounting firm’s
report will [***] be delivered to each Party at the same time and will be deemed final [***] ([***]) business days after it is received by both Parties. The
auditing Party shall bear the full cost of any such audit, unless the accounting firm’s report discloses an overpayment (or underpayment) by the auditing
Party of more than [***] percent ([***]%) of the amount due for any Calendar Quarter, in which case the audited Party shall bear the full cost of such
audit. The audited Party shall pay the amount of any overpayment (or underpayment) disclosed in the accounting firm’s report, together with interest
thereon from the date such payment was originally due, within [***] ([***]) days after delivery to the Parties of the accounting firm’s report.
Page 41 of 857.9 Confidentiality. All books and records audited by a Party pursuant to Section 7.8 (Audits ) will be maintained in confidence by such auditing
Party in accordance with Article 10 (Confidentiality ).
7.10 Late Payment. If any payment due is not paid by the due date, BLI may (a) charge interest on any outstanding amount of such payment,
accruing as of the original due date, at an annual rate equal to the rate of prime (as reported in The Wall Street Journal, Eastern U.S. Edition ) plus [***]
percentage points or the maximum rate allowable by Applicable Law, whichever is less.
8. INTELLECTUAL PROPERTY OWNERSHIP; USE OF DATA
8.1 Ownership of Background IP; Efforts to Control . As between the Parties, and subject to the licenses granted under this Agreement, Ginkgo
shall own and retain all rights, title, and interests in, to and under Ginkgo Background IP, and BLI shall own and retain all rights, title, and interests in, to
and under BLI Background IP. With respect to any Intellectual Property developed by BLI or its Affiliates in collaboration or on behalf of a Third Party
during the Term of this Agreement that is [***] for (a) [***] or (b) [***], with respect to each, BLI and its Affiliates shall [***] to [***] that BLI or its
Affiliates Control such Intellectual Property so that BLI may grant a license to Ginkgo with respect to such Intellectual Property as set forth in Section 9.1
(Grants to Ginkgo ).
8.2 Ownership of Ginkgo Inventions and BLI Inventions .
8.2.1 Ginkgo Inventions . Unless otherwise agreed to in writing by the Parties, as between the Parties, Ginkgo shall own:
(a) all biological entities, including all organisms, cells, strains, enzymes and other proteins, nucleic acids and other biomaterials (that
are not BLI-provided biological entities listed in Section 8.2.2(f) (BLI Inventions )) [***], in each case that Ginkgo loads onto the
Beacon Platform or provides to BLI [***];
(b) all [***];
(c) any assays [***];
(d) all chemical entities other than [***], developed, generated, created, used or otherwise exploited in connection with the use of the
Beacon Platform (clauses (a) through (d) of this Section 8.2.1 (Ginkgo Inventions ) collectively, with the exception of [***], the
“Ginkgo Materials”);
(e) all [***];
Page 42 of 85(f) the [***];
(g) the Ginkgo Workflows, with the exception of any BLI Inventions; and
(h) all rights to the Intellectual Property contained or otherwise embodied in the inventions, discoveries, improvements, materials,
chemical entities, Ginkgo Materials, [***], [***], or Ginkgo Workflows, described in clauses (a) through (g) of this Section 8.2.1
(Ginkgo Inventions ) (clauses (a) through (g) collectively, the “ Ginkgo Inventions”).
For clarity, Ginkgo’s ability to use Ginkgo Inventions are subject to the limitations set forth in Section 9.1 (Grants to Ginkgo ).
8.2.2 BLI Inventions. Unless otherwise agreed to in writing by the Parties, as between the Parties, BLI shall own:
(a) all inventions or discoveries [***]related to, or improvements or modifications to, the Beacon Platform that are developed,
generated, created, used or otherwise exploited in connection with the use of the Beacon Platform under a Workflow Development
Plan;
(b) any materials or chemical entities that are not Ginkgo Materials that are developed, generated, created, used or otherwise exploited
in connection with the use of the Beacon Platform under a Workflow Development Plan, with the exception of any materials that are
publicly available for purchase or are otherwise rightfully in the public domain;
(c) all BLI Proprietary Workflows;
(d) Generalized Workflows, with the exception of any Ginkgo Inventions;
(e) all Consumables provided by BLI related to the Beacon Platform and [***], in each case (i) developed, generated, created, used or
otherwise exploited in connection with the use of the Beacon Platform under a Workflow Development Plan and (ii) [***];
(f) although generally not expected during the Term, any [***]; and
(g) all rights to the Intellectual Property contained or otherwise embodied in the inventions, discoveries, improvements, materials,
chemical entities, Beacon Platform or Consumables described in clauses (a) through (f) of this Section 8.2.2 (BLI Inventions )
(collectively, clauses (a) through (f) of this Section 8.2.2 (BLI Inventions ), the “BLI Inventions”).
Page 43 of 858.3 Ownership of Remaining Collaboration Intellectual Property. Subject to Section 8.2 (Ownership of Ginkgo Inventions and BLI Inventions ), as
between the Parties, BLI shall solely own all right, title and interest to all Collaboration Intellectual Property [***].
8.4 Prosecution and Enforcement Rights . Ginkgo shall have the sole and exclusive right, but not the obligation, to protect, seek registration for,
defend and enforce, in its sole and entire discretion, the Ginkgo Inventions. BLI shall have the sole and exclusive right, but not the obligation, to protect,
seek registration for, defend and enforce in its sole and entire discretion, the BLI Inventions and Collaboration Intellectual Property (other than the
Ginkgo Inventions). In no event shall Ginkgo, and Ginkgo shall cause its Affiliates to not, file any patent applications covering (or support existing patent
applications covering) the [***] and, in the event Ginkgo (or its Affiliates) do file one or more of such patent applications, Ginkgo will and hereby does
assign, and shall cause its employees, agents and contractors to assign, to BLI all rights, title and interests in, to and under such patent applications.
Other than as permitted under Section 8.5.2 (Use of Collaboration Data ), in no event shall BLI, and BLI shall cause its Affiliates to not, file any patent
applications covering (or support existing patent applications covering) [***] and, in the event that BLI (or its Affiliates) do file one or more of such
patent applications, BLI will and hereby does assign, and shall cause its employees, agents and contractors to assign, to Ginkgo all rights, title and
interests in, to and under such patent applications.
8.5 Use of Collaboration Data.
8.5.1 Disclosure. With respect to any data or results that are generated in connection with activities under a Workflow Development Plan
(such data and results (but not Collaboration Workflows), “ Collaboration Data”), each Party shall provide the other Party any Collaboration Data in
its possession; provided  that [***] shall provide any such Collaboration Data in its possession to [***] to the extent permitted under obligations
of confidentiality owed by [***] to Third Parties with respect to such Collaboration Data. Notwithstanding the foregoing, [***] shall have the right
to anonymize any Collaboration Data for disclosure to [***] or use by [***] under Section 8.5.2 (Use of Collaboration Data ) and shall be
permitted to remove from such Collaboration Data (a) any Third Party confidential information, (b) the identity of any [***] and (c) proprietary
information regarding [***] Inventions or Intellectual Property Controlled, possessed or owned by [***] or its Affiliates.
8.5.2 Use of Collaboration Data. BLI will have the right to use any Collaboration Data provided to it for disclosure pursuant to Section 8.5.1
(Disclosure) solely for the purposes of (a) [***], (b) [***], (c) [***], and (d) [***]. For clarity, with respect to clause (d) of this Section 8.5.2 (Use of
Collaboration Data ), [***].
8.6 Notification of New Products; [***] .
8.6.1 Access to New Products . During the Term, BLI shall promptly notify Ginkgo of any upcoming or then-current  commercial availability of
any new Beacon Optofluidic Machine or Consumable that, at that time, is not listed in Schedule 1.10 (Beacon Optofluidic Machine ) or Schedule
1.36 (Consumables ) and the Parties shall[***].
Page 44 of 858.6.2 [***]. During the Term, BLI shall provide Ginkgo with [***] (a) [***], (b) [***] and (c) BLI [***], with respect to each, [***] and [***].
As used in this Section, “[***]” means [***].
8.7 Inventor’s Remuneration . Each Party will be solely responsible for any remuneration that may be due to such Party’s inventors under any
applicable inventor remuneration laws.
8.8 [***]. If, at any time during the Term, Ginkgo has purchased from BLI, in the aggregate, [***] ([***]) or more Beacon Optofluidic Machines,
then:
8.8.1 Non-Exclusive [***] License. To ensure that, [***], BLI shall, and hereby does, automatically grant to Ginkgo, as of the date Ginkgo
purchases an aggregate of [***] ([***]) Beacon Optofluidic Machine from BLI, a non-exclusive, non-royalty  bearing and sublicensable (through
multiple tiers) worldwide license in any Intellectual Property Controlled by BLI that is necessary to [***], solely for Ginkgo’s [***] own internal use
so that Ginkgo (or its Affiliates or permitted sublicensees) may [***]. Notwithstanding the foregoing, Ginkgo hereby represents, warrants and
covenants to BLI that, as of the date BLI grants such license to Ginkgo and throughout the Term and thereafter, it shall not, directly or indirectly,
conduct any activities under the rights granted to it in this Section 8.8.1 ([***]) unless and until (a) (i) [***] or (ii) [***], with respect to (i)-(ii), and
such [***] or (b) [***]; provided  that , after the event(s) sufficient to trigger sub-sections  (i) or (ii) of this sentence occur, Ginkgo must provide BLI
with written notice of its intent to conduct activities under rights granted pursuant to this Section 8.8.1 [***]. In the event Ginkgo has the right to
conduct activities under the rights granted to it in this Section 8.8.1 ([***]), Ginkgo shall [***]. BLI shall [***].
8.8.2 [***]. Upon Ginkgo’s written request at any time after [***], BLI shall [***] and will [***] so that [***]. Notwithstanding the
foregoing, Ginkgo hereby represents, warrants and covenants to BLI as of the Effective Date, throughout the Term that it shall not, directly or
indirectly, [***] unless and until (a) (i) [***] or (ii) [***] or (b) [***]; provided  that , after the event(s) sufficient to trigger sub-sections  (i) or (ii) of
this sentence occur, Ginkgo must provide BLI with written notice of its intent to conduct activities under rights granted pursuant to this Section
8.8.2 [***]. In the event Ginkgo has the right to so [***], Ginkgo shall [***].
8.8.3 [***]. Upon Ginkgo’s written request to BLI at any time if (a) there is (i) [***] or (ii) [***], or (b) [***], BLI shall [***] and [***] and
shall [***], including by [***]; provided  further that , if [***] either (A) [***] or (B) [***], then [***]. In the event Ginkgo [***], Ginkgo hereby
represents, warrants and covenants to BLI as of the Effective Date, throughout the Term and thereafter that it shall [***]. BLI shall [***].
8.8.4 Any obligation of Ginkgo to [***] shall be [***].
8.9 Specific Implementation Restrictions. For clarity, this Agreement does not prohibit BLI or its Affiliates, alone or in combination with a Third
Party, from independently developing a Workflow or a part or component thereof; or a derivative, modification, replication or progeny of
Page 45 of 85a biological entity; that is the [***] to a Specific Implementation (each such independently developed item, an “ Independent Development”); provided
that  the Independent Development does not use any [***]; and further provided  that  BLI and its Affiliates do not [***] any [***] to [***] any
Independent Development. Without limiting any other provision of this Agreement or Ginkgo’s rights or remedies under this Agreement or Applicable
Law, any use of [***] by BLI or its Affiliates, alone or in combination with a Third Party to develop a Workflow or a part or component thereof; or a
derivative, modification, replication or progeny of a biological entity that is [***] a Specific Implementation shall be deemed a material breach of this
Agreement by BLI and shall give rise to Ginkgo’s right to terminate this Agreement pursuant to Section 13.2.1 (Material Breach ).
9. LICENSE GRANTS
9.1 Grants to Ginkgo.
9.1.1 Scope of Grants. Subject to the terms and conditions of this Agreement, and in consideration for the payments to BLI under this
Agreement, during the Term, BLI, on behalf of itself and its Affiliates, hereby grants and shall grant to Ginkgo a non-exclusive, sublicensable
(solely in accordance with Section 9.1.4 (Consent to Sublicense )), non-transferable,  non-royalty-bearing  (subject to Section 13.3.2 (Effects of
Termination Based Upon Ginkgo Buy -Down Election )) worldwide license in, to and under (i) BLI Background IP, and (ii) other Intellectual Property
that is Controlled by BLI and that is [***] BLI Inventions, with both of (i) and (ii) being limited to what is necessary for Ginkgo to [***] and (iii) the
Collaboration Intellectual Property solely to:
(a) perform research [***] on biological entities, including organisms, cells and strains (and sub-components  thereof);
(b) (i) design and develop (A) Collaboration Workflows as generally contemplated under a Workflow Development Plan and (B)
Ginkgo Workflows as permitted under this Agreement and (ii) use [***] Workflows to conduct the activities set forth in clause (a)
and clause (c) of this Section 9.1.1 (Scope of Grants );
(c) perform commercial research [***] and other Commercial Services for Third Parties; and
(d) in each case of clauses (a) through (c) of this Section 9.1.1 (Scope of Grants ), the license granted is for activities solely within the
Licensed Field.
9.1.2 License Grant to Exploit [***]. Subject to the terms and conditions of this Agreement, during the Term BLI, on behalf of itself and its
Affiliates, hereby grants and shall grant to Ginkgo a [***] license within the Licensed Field in, to and under any Intellectual Property Controlled by
BLI that is necessary to make, have made, sell, have sold, import or use any [***] to make, have made, sell, have sold, import or use such [***].
Page 46 of 859.1.3 No Consumable License. For clarity and without limiting Section 8.8.1 (Non-Exclusive  Manufacturing License; Covenant ), the licenses
granted to Ginkgo in Section 9.1.1 (Scope of Grants ) and Section 9.1.2 (License Grant to Exploit [***] ) do not include the right to make, have
made, offer to sell or sell Consumables, [***], to or for Third Parties or any Ginkgo Affiliate or Ginkgo Subcontractor that are [***] on the Beacon
Platform [***].
9.1.4 Consent to Sublicense . Ginkgo may grant sublicenses of the license granted to Ginkgo under Section 9.1.1 (Scope of Grants ) and
Section 9.1.2 (License Grant to Exploit [***] ) with the prior written consent of BLI[***]; provided  that  such prior written consent of BLI shall not
be needed for any sublicense granted by Ginkgo to (a) a Permitted Subcontractor of Ginkgo under Section 2.7 (Subcontracting ) to the extent such
sublicense relates to the subcontracted activities, (b) any wholly-owned subsidiary of Ginkgo existing as of the Effective Date or (c) any other
Person, including other Affiliates and any Third Party, under Section 9.1.2 (License Grant to Exploit [***] ) so long as, in the case of this clause
(c), the sublicense [***]. Each sublicense of the license granted to Ginkgo under Section 9.1.1 will (i) be in writing, (ii) be consistent with the terms
and conditions of this Agreement and (iii) require each sublicensee thereunder to comply with all terms of this Agreement applicable to a
sublicensee. Notwithstanding the grant of any sublicense, Ginkgo shall remain [***] liable to BLI for the performance of all of Ginkgo’s obligations
under, and Ginkgo’s compliance with all provisions of, this Agreement.
9.1.5 Responsibility . Ginkgo shall not (and Ginkgo shall ensure that its Affiliates and [***] sublicensees do not) use any Intellectual Property
of BLI’s that is licensed under Section 9.1 (Grants to Ginkgo ), any BLI Confidential Information or any Beacon Platforms that may be transferred to
Ginkgo by BLI under this Agreement, in each case for a purpose other than as expressly permitted under this Agreement.
9.1.6 Use in Excluded Fields. In the event BLI [***] that Ginkgo is using [***] in the Excluded Fields (“ Ginkgo Excluded Use”), BLI shall
send Ginkgo a written notice indicating that it believes Ginkgo is using [***] in an Excluded Field and, within [***] ([***]) Business Days after
Ginkgo’s receipt of BLI’s written notice, Ginkgo shall investigate such claim internally and shall either (a) [***], or (b) [***], and the Parties will
resolve such dispute pursuant to Section 14.5.2 (Dispute Resolution ). If, following the dispute resolution process set forth in Section 14.5.2
(Dispute Resolution ), it is determined that Ginkgo is using [***] in an Excluded Field, then BLI may either (i) [***], (ii) [***] or (iii) [***]; provided
that, following determination that Ginkgo is using [***] in an Excluded Field pursuant to Section 14.5.2 (Dispute Resolution ), if BLI wishes to make
any election under clause (i), (ii) or (iii), it must notify Ginkgo within [***] ([***]) Business Days of such determination. [***].
9.2 Grants to BLI. Subject to the terms and conditions of this Agreement, during the Term, Ginkgo hereby grants and shall grant to BLI:
9.2.1 a [***] and this Section 9.2 (Grants to BLI)), [***] license in, to and under any Intellectual Property (a) Controlled by Ginkgo, (b) used
by Ginkgo in the conduct of a Workflow Development Plan and (c) necessary for BLI to perform its obligations under this Agreement ((a)-(c)
collectively, “Ginkgo Licensed IP”), solely to perform BLI’s obligations under such Workflow Development Plan; and
Page 47 of 859.2.2 after any applicable Headstart Period, with respect to any [***], a [***] license in, to and under any Ginkgo Licensed IP [***]
necessary for the performance of, such [***], to make, have made, offer to sell, sell, have sold, import, use, commercialize or perform such [***] to
or for Third Parties and to license such Third Parties to do the same.
Except as permitted under Sections 9.2.1 and 9.2.2, BLI may not sublicense, assign or otherwise transfer the rights granted to it in this Section 9.2 (Grants
to BLI) without first obtaining the prior written consent of Ginkgo[***]. Each sublicense of any license granted to BLI under this Section 9.2 (Grants to
BLI) will (i) be in writing, (ii) be consistent with the terms and conditions of this Agreement and (iii) require each sublicensee thereunder to comply with
all terms of this Agreement applicable to a sublicensee; provided  that, subject to Section 6.2.1 , such prior written consent of Ginkgo shall not be needed
for any sublicense granted by BLI (a) under Section 9.2.1, to a Permitted Subcontractor of BLI under Section 2.7 (Subcontracting ) to the extent such
sublicense relates to the subcontracted activities, (b) any wholly-owned subsidiary of BLI existing as of the Effective Date, or (c) any other Person,
including other Affiliates and any Third Party, under Section 9.2.2. Notwithstanding the grant of any sublicense, BLI shall remain liable to Ginkgo for the
performance of all of BLI’s obligations under, and BLI’s compliance with, all provisions of, this Agreement. BLI shall not (and BLI shall ensure that any of
its Affiliates and sublicensees do not) use any Intellectual Property or Confidential Information of Ginkgo that is licensed under this Section 9.2 or
otherwise disclosed to BLI under this Agreement for any purpose not expressly permitted under this Agreement. [***].
9.3 No Implied Rights. Except as expressly provided in this Agreement, neither Party will be deemed to have granted the other Party (by implication,
estoppel or otherwise) any right, title, license or other interest in or with respect to any Intellectual Property or information Controlled by such Party.
10. CONFIDENTIALITY
10.1 Confidential Information. Each Party may disclose (“Disclosing Party”) to the other Party (“ Receiving Party”), and Receiving Party may
acquire during the course and conduct of activities under the Agreement, certain non-public  or confidential information of Disclosing Party in connection
with this Agreement. The term “Confidential Information” means all non-public  or confidential information or material in tangible form that one Party
discloses to the other Party hereunder, or proprietary or confidential information disclosed in non-tangible  form that a Disclosing Party identifies to the
Receiving Party as confidential information or that, from the nature of such information, the Receiving Party should reasonably know is the Confidential
Information of the Disclosing Party, including all technical and non-technical  information conveyed from one Party to the other or otherwise accessed or
observed by a Party in any form, electronic data and other proprietary information, data, samples, products, materials, compounds, sequences,
compositions, configurations, methods, formulas, formulations, processes, protocols, specifications, designs, recordings, drawings, sketches, models,
technologies, equipment, information relating to quality assurance or control, laboratory notebooks, techniques, inventions,
Page 48 of 85know-how, apparatuses, formulae, customer lists, pricing information, strategies, business or marketing plans and other information related to the
Disclosing Party’s current, future and proposed products, business, customers, Software or technology. The Parties agree that the terms of this
Agreement will be treated as Confidential Information of each Party. Without limitation of the foregoing, (i) Ginkgo Background IP, Ginkgo Inventions,
Collaboration Data, Specific Implementations, and Ginkgo Workflows will be treated as the Confidential Information of Ginkgo and (ii) BLI Background IP,
BLI Inventions, Generalized Workflows and BLI Proprietary Workflows will be treated as the Confidential Information of BLI. Notwithstanding any other
provisions herein, Confidential Information does not include information that:
10.1.1 was known to Receiving Party or any of its Affiliates prior to the time of disclosure other than under an obligation of confidentiality
with respect to such information;
10.1.2 is at the time of disclosure hereunder or later becomes public knowledge through no fault or omission of Receiving Party or any of its
Affiliates;
10.1.3 is obtained by Receiving Party or any of its Affiliates from a Third Party having the right to disclose such information (e.g. not under
an obligation of confidentiality to the Disclosing Party or its Affiliates) to such Receiving Party or its Affiliates;
10.1.4 has been independently developed by employees, Permitted Subcontractors, consultants or agents of Receiving Party or any of its
Affiliates without the aid, application, or use of or reliance upon Disclosing Party’s Confidential Information, as evidenced by contemporaneous
written records; or
10.1.5 Receiving Party obtains written consent from Disclosing Party to disclose.
Specific aspects or details of Confidential Information will not be deemed to be within the public domain or in the possession of Receiving Party
merely because the Confidential Information is embraced by more general information in the public domain or in the possession of Receiving Party.
Further, any combination of Confidential Information will not be considered in the public domain or in the possession of Receiving Party merely because
individual elements of such Confidential Information are in the public domain or in the possession of Receiving Party unless the combination and its
principles are in the public domain or in the possession of Receiving Party.
10.2 Confidential Treatment. At all times during the Term and for a period of [***] ([***]) years following the end of the Term, or with respect to
trade secrets (with such trade secrets either (i) having been specifically identified in writing to the Receiving Party by the Disclosing Party claiming
ownership of the same or (ii) reasonably distinguishable by its nature or content as a trade secret of the Disclosing Party), until such time that such
information is no longer a trade secret (including pursuant to Sections 10.1.1 - 10.1.5), Receiving Party will, and will cause its Affiliates and its and their
respective officers, directors, employees, Permitted Subcontractors, permitted sublicensees and agents to, keep confidential and not publish or otherwise
disclose to a Third Party and not use for any purpose, any Confidential Information furnished or otherwise made known to it by the Disclosing Party,
except to the extent such disclosure or use is expressly
Page 49 of 85permitted by the terms of this Agreement or is reasonably necessary for the performance of, or the exercise of such Party’s rights under, this Agreement;
provided  that  such parties to which the Confidential Information is disclosed are bound by written obligations of confidentiality at least as stringent as
those set forth in this Agreement. Notwithstanding the foregoing, a Receiving Party will remain liable for any breach of this Article 10 (Confidentiality )
by any party to whom the Receiving Party has disclosed the Disclosing Party’s Confidential Information under this Section 10.2 (Confidential Treatment ).
10.3 Permitted Disclosures . Receiving Party may disclose the Confidential Information of the Disclosing Party in the following instances:
10.3.1 in order to comply with Applicable Law (including any securities law or regulation or the rules of a securities exchange) or with a legal
or administrative proceeding; provided  that  (a) to the extent legally permitted, Receiving Party gives written notice of such required disclosure to
Disclosing Party prior to disclosing such Confidential Information and (b) Disclosing Party shall have the opportunity to take appropriate measures
to assure confidential treatment of such Confidential Information to the extent practicable and consistent with Applicable Law and Receiving Party
agrees to reasonably cooperate with the Disclosing Party in connection with such measures at Disclosing Party’s expense;
10.3.2 in connection with (a) prosecuting or defending litigation or (b) obtaining Regulatory Approval, making other regulatory filings and
communications, and filing, prosecuting, enforcing, and defending patent rights, in each case, in connection with Receiving Party’s rights and
obligations pursuant to this Agreement; provided , however , that , where reasonably possible, Receiving Party will notify Disclosing Party of
Receiving Party’s intent to make any such disclosure sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to
take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed; and
10.3.3 with respect to the terms of this Agreement, after having been reasonably redacted by the Receiving Party, to the extent such
disclosure is reasonably required, to a bona fide potential licensee, investor, investment banker, acquirer, merger partner or other potential financial
partner, and their respective attorneys, professional advisors and agents; provided  that  each such Person to whom such information is to be
disclosed is informed of the confidential nature of such information and has entered into a written agreement with the Party requiring such Person
to keep such information confidential.
10.4 Use of Names. Except as expressly provided herein, neither Party will mention or otherwise use the name, logo or trademark of the other Party
or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, website or marketing and promotional materials, or
other form of publicity, without the prior written approval of such other Party in each instance; [***]. The restrictions imposed by this Section 10.4 (Use
of Name) will not prohibit either Party from making any disclosure identifying the other Party that, in the reasonable opinion of the disclosing Party’s
counsel, is required by Applicable Law; provided  that  such Party will submit the proposed disclosure identifying the other Party in writing to the other
Party as far in advance as reasonably practicable (and in no event less than [***] ([***]) Business Days prior to the anticipated date of disclosure) so as
to provide a reasonable opportunity to comment thereon.
Page 50 of 8510.5 Publicity. Within [***] ([***]) days of the Effective Date (or such other period as mutually agreed to by the Parties), the Parties shall issue a
press release in the form set forth in Schedule 10.5 (Press Release). After such initial press release, neither Party shall issue a press release or public
announcement relating to this Agreement without the prior written approval of the other Party, which approval shall not be unreasonably withheld,
conditioned or delayed, except that a Party may (a) once a press release or other public statement is approved in writing by both Parties, make
subsequent public disclosure of the information contained in such press release or other written statement without the further approval of the other Party
and (b) issue a press release or public announcement, including without limitation, the disclosure of this Agreement (or a summary thereof) in filings, as
required, in the reasonable opinion of the publishing Party’s counsel, by Applicable Law (including by the rules or regulations of the United States
Securities and Exchange Commission or any stock exchange on which the equity interests of such Party or its Affiliates (or any successor entity) are
listed), provided, however, that such Party seeking disclosure will prepare such summary and a proposed redacted version of this Agreement as far in
advance as reasonably practicable (and in no event less than [***] ([***]) Business Days prior to the anticipated date of disclosure) so as to provide a
reasonable opportunity to comment thereon, and the other Party shall within such [***] ([***]) Business Day period, provide its comments, if any, which
may be incorporated, in the reasonable discretion of the Party seeking disclosure.
10.6 Destruction or Return of Confidential Information . Upon the end of the Term, whether in its entirety or with respect to a specific Workflow
Development Plan, Disclosing Party may request in writing to Receiving Party, and Receiving Party will, as requested by Disclosing Party except as and if
necessary for such Receiving Party to exercise surviving rights under this Agreement following such expiration or termination, (a) at the Disclosing
Party’s request, destroy, as soon as reasonably practicable, specific Confidential Information identified by the Disclosing Party in writing to the Receiving
Party that are in Receiving Party’s possession and confirm such destruction in writing to Disclosing Party or (b) deliver to Disclosing Party, as soon as
reasonably practicable, at Disclosing Party’s expense, all copies of such Confidential Information in the possession of Receiving Party; provided  that  the
Receiving Party will be permitted to retain one copy of such Confidential Information for the sole purpose of performing any continuing obligations
hereunder, as required by Applicable Law or for archival purposes. Notwithstanding the foregoing, Receiving Party also will be permitted to retain such
additional copies of or any computer records or files containing such Confidential Information that have been created solely by Receiving Party’s
automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with Receiving Party’s standard archiving and
back-up procedures, but not for any other use or purpose.
11. WARRANTIES AND DISCLAIMER; LIMITATION OF LIABILITY
11.1 Mutual Representations . Each Party hereby represents and warrants to the other Party, as of the Effective Date, as follows:
11.1.1 such Party is a corporation or limited liability company duly organized, validly existing and in good standing under the laws of the state
in which it is incorporated;
Page 51 of 8511.1.2 such Party (a) has the corporate power and authority and legal right to enter into this Agreement, to perform its obligations and to
grant the licenses hereunder and (b) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement
and the performance of its obligations hereunder;
11.1.3 this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal and valid obligation binding
upon such Party and enforceable against it in accordance with its terms;
11.1.4 such Party has the right to grant the rights and licenses granted to the other Party pursuant to this Agreement; and
11.1.5 it has not entered into an agreement with a Third Party, or granted any right or license to any Third Party that conflicts with any of the
rights, obligations or licenses granted to the other Party hereunder.
11.2 Mutual Covenants . Each Party hereby covenants to the other Party, as of the Effective Date, that:
11.2.1 all of its and its Affiliates’ employees who conduct any work under this Agreement will be, during the conduct of all such work, bound
to a written agreement with such Party or its Affiliate to automatically assign all right, title and interest in and to their inventions and discoveries,
whether or not patentable, to such Party as the sole owner thereof;
11.2.2 to the best of its knowledge, without further duty of inquiry, such Party will not
(a) employ or use any contractor or consultant that employs any Person debarred by the FDA (or subject to similar sanction of the
EMA or other Regulatory Authority) or (b) employ any Person that is the subject of an FDA debarment investigation or proceeding
(or similar proceeding of the EMA or other Regulatory Authority), in each of (a)-(b), in the conduct of its activities under this
Agreement;
11.2.3 it will perform or cause to be performed the obligations assigned to it under this Agreement in good scientific manner and in
compliance with all Applicable Laws; and
11.2.4 it shall not, during the Term, enter into an agreement with a Third Party, or grant any right or license to any Third Party relating to any
of the intellectual property rights it Controls, or otherwise encumber such intellectual property rights it Controls, that would conflict with any of the
rights, obligations or licenses granted to the other Party hereunder.
Page 52 of 8511.3 Additional Representations, Warranties and Covenants of BLI . As of the Effective Date, BLI further represents, warrants and, as applicable,
covenants to Ginkgo that:
11.3.1 BLI has, as of the Effective Date, and to its current knowledge will have during the Term, the full right, power and authority to (a) grant
all of the right, title and interest in the licenses and other rights granted or to be granted to Ginkgo under this Agreement and (b) perform its
obligations under this Agreement;
11.3.2 neither BLI nor its Affiliates have granted, and BLI and its Affiliates will not grant, any liens or security interest on any assets,
including Intellectual Property, that would limit the scope of any rights or licenses granted to Ginkgo hereunder;
11.3.3 neither BLI nor its Affiliates have knowledge of or have received any written notice of any claim that any Intellectual Property
Controlled by a Third Party would be infringed or misappropriated by the activities contemplated under this Agreement, including Ginkgo’s use of
the Beacon Platform to perform a general Workflow under this Agreement;
11.3.4 the Beacon Optofluidic Machines (including related Hardware and Software) and Consumables, at the time of delivery to Ginkgo, (a)
shall have been manufactured, stored, shipped and delivered in accordance with Applicable Law and this Agreement; (b) to BLI’s knowledge, [***]
and (c) shall be free from all liens, charges, encumbrances and security interests;
11.3.5 all services, including Services, shall be performed by or on behalf of BLI with requisite care, skill and diligence, by individuals who are
appropriately trained and qualified, and in accordance with Applicable Law and industry standards;
11.3.6 to BLI’s knowledge [***], the use of the Beacon Platform as contemplated under this Agreement, but without any representation or
warranty regarding [***] (a) [***] or (b) [***];
11.3.7 to BLI’s knowledge [***], (a) the use of the Beacon Platform as contemplated under this Agreement and (b) the performance of the
activities Ginkgo is granted the right to conduct under Section 9.1 (Grants to Ginkgo ) (but for both (a) and (b) no representation, warranty or
covenant is given by BLI for Ginkgo Materials, Ginkgo Workflows or for Collaboration Workflows) [***]; and
11.3.8 BLI has independently developed all BLI Background IP or otherwise has a valid right to use and, as applicable, to permit Ginkgo and
its permitted sublicensees to use, the BLI Background IP for all permitted purposes under this Agreement.
11.4 Additional Representations, Warranties and Covenants of Ginkgo . As of the Effective Date, Ginkgo further represents, warrants and, as
applicable, covenants to BLI that:
11.4.1 Ginkgo has, as of the Effective Date, and will have during the Term, the full right, power and authority to (a) grant all of the right, title
and interest in the licenses and other rights granted or to be granted to BLI under this Agreement and (b) perform its obligations under this
Agreement;
Page 53 of 8511.4.2 Ginkgo has independently developed all Ginkgo Background IP or otherwise has a valid right to use, and, as applicable, to permit BLI
and its permitted sublicensees to use, the Ginkgo Background IP for all permitted purposes under this Agreement; and
11.4.3 neither Ginkgo nor its Affiliates have granted, and Ginkgo and its Affiliates will not grant, any liens or security interest on any assets,
including Intellectual Property, that would limit the scope of any rights or licenses granted to BLI hereunder.
11.5 DISCLAIMERS.
11.5.1 EXCEPT AS SPECIFICALLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR
WARRANTIES OF ANY KIND CONCERNING ITS ACTIVITIES UNDER THIS AGREEMENT OR RESULTS OF ANY WORK PLAN AND HEREBY
DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF ITSELF OR THIRD PARTIES,
VALIDITY, ENFORCEABILITY AND SCOPE OF PATENT RIGHTS, VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER ISSUED OR PENDING,
AND THE ABSENCE OF LATENT OR OTHER DEFECTS WHETHER OR NOT DISCOVERABLE.
11.5.2 BEACON PLATFORMS ARE SOLD “FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.” GINKGO
ACKNOWLEDGES THAT (I) BEACON PLATFORMS HAVE NOT BEEN APPROVED, CLEARED OR LICENSED BY THE UNITED STATES FOOD
AND DRUG ADMINISTRATION OR ANY OTHER REGULATORY ENTITY WHETHER FOREIGN OR DOMESTIC FOR ANY SPECIFIC INTENDED
USE, WHETHER RESEARCH, COMMERCIAL, DIAGNOSTIC OR OTHERWISE AND (II) GINKGO MUST ENSURE IT HAS ANY REGULATORY
APPROVALS THAT ARE NECESSARY FOR GINKGO’S INTENDED USES OF BEACON PLATFORMS. GINKGO FURTHER AGREES TO COMPLY
WITH ALL APPLICABLE LAWS AND REGULATIONS WHEN USING, MAINTAINING AND DISPOSING OF BEACON PLATFORMS.
11.6 No Consequential Damages . EXCEPT TO THE EXTENT ARISING (A) FROM A PARTY’S BREACH OF ARTICLE 10 (CONFIDENTIALITY),
(B) [***] (E) FROM A PARTY’S FRAUD, GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OR (F) IN CONNECTION WITH A PARTY’S
INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 12 (INDEMNIFICATION; INSURANCE), IN NO EVENT WILL EITHER PARTY BE LIABLE TO
THE OTHER PARTY FOR ANY LOST PROFITS, INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES OF ANY KIND
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, HOWEVER CAUSED AND ON
Page 54 of 85ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE). THE
LIMITATIONS SET FORTH IN THIS SECTION WILL APPLY EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES,
AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.
11.7 Liability Limit. TO THE GREATEST EXTENT PERMITTED UNDER APPLICABLE LAW, IN NO EVENT WILL A PARTY’S AGGREGATE
LIABILITY (ABOVE AMOUNTS ACTUALLY PAID OR REIMBURSED BY SUCH PARTY’S INSURER (TO THE EXTENT NOT SELF-INSURED)) FOR A
CLAIM ARISING OUT OF OR RELATED TO THIS AGREEMENT UNDER ANY LEGAL OR EQUITABLE THEORY, INCLUDING BREACH OF
CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, AND OTHERWISE EXCEED [***], EXCEPT THAT (A) SUCH LIMITATION
SHALL NOT APPLY TO (I) A PARTY’S BREACH OF ARTICLE 10 (CONFIDENTIALITY), [***], (V) A PARTY’S FRAUD, GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT OR (VI) A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 12 (INDEMNIFICATION; INSURANCE) AND (B)
SUCH LIMITATION ON LIABILITY SHALL NOT INCLUDE ANY AMOUNTS ACCRUED AND ACTUALLY OWED PURSUANT TO THE TERMS OF
THIS AGREEMENT.
12. INDEMNIFICATION; INSURANCE
12.1 Indemnification by BLI. BLI will indemnify, defend and hold Ginkgo and its Affiliates, and its and their officers, directors, employees, licensees,
sublicensees, Permitted Subcontractors and agents (each, a “ Ginkgo Indemnitee”) harmless from and against any and all suits, claims, proceedings and
causes of action brought by a Third Party (collectively, “ Claims”) and all associated damages, liabilities, expenses and losses, including reasonable legal
expenses and reasonable attorneys’ fees (collectively, “ Losses ”), to the extent caused by or arising as a result of (a) the breach by BLI of this Agreement
or material inaccuracy in any representation or warranty made by BLI under this Agreement, (b) the negligence, gross negligence, fraud or willful
misconduct by a BLI Indemnitee in connection with this Agreement, (c) [***], and (d) any Claims by BLI’s employees, Permitted Subcontractors or
agents for worker’s compensation or other liability coverage, insurance, benefits, and other employee-related claims, in each case of clauses (a)-(d) of this
Section 12.1 (Indemnification by BLI ), except to the extent Ginkgo has an obligation to indemnify an BLI Indemnitee in connection with such Claims and
Losses pursuant to Section 12.2 (Indemnification by Ginkgo) .
12.2 Indemnification by Ginkgo. Ginkgo will indemnify, defend and hold BLI and its Affiliates, and its and their officers, directors, employees,
Permitted Subcontractors and agents (each, an “ BLI Indemnitee”) harmless from and against any and all Claims and Losses, to the extent caused by or
arising as a result of (a) the breach by Ginkgo of this Agreement or material inaccuracy in any representation or warranty made by Ginkgo under this
Agreement, (b) the negligence, gross negligence, fraud or willful misconduct by a Ginkgo Indemnitee in connection with this Agreement, (c) [***] and (d)
any Claims by Ginkgo’s employees, Permitted Subcontractors or agents for worker’s compensation or other liability coverage, insurance, benefits, and
other employee-related claims, and (e) the development, manufacture, use, handling, storage, importation, distribution, sale or other commercialization of
Ginkgo Inventions by Ginkgo
Page 55 of 85or its Affiliates, agents, licensees, sublicensees or customers, in each case of clauses (a)-(e) of this Section 12.2 (Indemnification by Ginkgo ) except to
the extent BLI has an obligation to indemnify a Ginkgo Indemnitee in connection with such Claims and Losses pursuant to Section 12.1 (Indemnification
by BLI).
12.3 Procedure. Any Party seeking indemnification under this Article 12 (Indemnification; Insurance ) will promptly notify the indemnifying Party in
writing after the Party seeking indemnification has received notice of any Claim. The Party seeking indemnification will reasonably cooperate with the
indemnifying Party in the defense of any such Claim at the cost of the indemnifying Party. An indemnifying Party will not be obligated to defend,
indemnify and hold harmless the Party seeking indemnification if, and only to the extent, the Party seeking indemnification delays providing notice of a
Claim to the indemnifying Party and the delay in notice substantively prejudices the ability of the indemnifying Party to successfully defend the Claim.
The indemnifying Party may not make any admission on behalf of the Party seeking indemnification [***]. Notwithstanding the foregoing, the Party
seeking indemnification may at any time choose to be represented by its own counsel at its expense (or at the indemnifying Party’s expense if the
indemnifying Party’s defense is inadequate as determined by a reasonableness standard).
12.4 Insurance . Each Party will obtain and carry in full force and effect the minimum insurance requirements set forth below. Such insurance (i) will
be primary insurance with respect to each Party’s own participation under this Agreement and (ii) will be issued by a recognized insurer rated by A.M.
Best “A-VII” (or its equivalent) or better, or an insurer pre-approved  in writing by the other Party.
12.4.1 Types and Minimum Limits. The types of insurance, and minimum limits will be: (i) any insurance policy that is required by any
Applicable Law, including [***] and [***] policies where applicable; and (ii) [***] insurance with a minimum limit of [***] Dollars ($[***]) per
occurrence and [***] Dollars ($[***]) in the aggregate. For clarity, [***].
12.4.2 Certificates of Insurance . Upon request by a Party, the other Party will provide Certificates of Insurance evidencing compliance with
this Section 12.4 (Insurance ). The insurance policies will be under an occurrence form, but if only a claims-made form is available to a Party, then
such Party will continue to maintain such insurance after Expiration or the termination of this Agreement for a period of [***] ([***]) years
following the end of the Term.
13. TERM AND TERMINATION
13.1 Term.
13.1.1 General. This Agreement shall commence on the Effective Date and, unless sooner terminated in accordance with its terms, including
by Ginkgo pursuant to Section 7.3 (Buy-Down Election ) or extended by the mutual written agreement of the Parties, shall continue until the
Intended End of Term (such time period, as may be extended pursuant to this Section 13.3.1 (Term – General), the “Term”); provided  that , if,
Page 56 of 85at the expiration of the Intended End of Term, Ginkgo has paid the Minimum Cumulative Purchase Commitment, but will not have paid to BLI the
Full Purchase Target, then the Term of this Agreement shall automatically extend for an additional [***] ([***]) year period from the date of the
expiration of the then-Intended  End of Term so that, among other things, BLI may potentially receive the benefit of the Full Purchase Target and
Ginkgo may receive the continuing benefit of royalty-free licenses.
13.1.2 Effects of Expiration. Upon Expiration of this Agreement: (i) the licenses granted to BLI from Ginkgo pursuant to Section 9.2 (Grants to
BLI) and the licenses granted to Ginkgo from BLI in Section 9.1.1 (Scope of Grants ) and 9.1.2 (License Grant to Exploit [***] ) shall survive and
become perpetual, irrevocable, and royalty-free, (ii) no royalties shall be payable by Ginkgo on the sale or transfer of a Licensed Product, (iii) the
pricing terms for Beacon Optofluidic Machines, Consumables, and services (including Services) set forth in Section 5.2.2 (Pricing – Adjustments )
shall [***], (iv) the restrictions on BLI set forth in Section 6.2.1 (Restrictions on BLI ) shall survive to the extent set forth therein and (v) [***].
13.2 Termination With Cause.
13.2.1 Material Breach. If either Party commits a material breach of any of its obligations under this Agreement, then the other Party may give
the breaching Party written notice of such material breach. If the breaching Party fails to cure such breach within sixty (60) days after such notice,
then the non-breaching  Party may terminate this Agreement upon written notice to the breaching Party in its entirety. Notwithstanding the
foregoing, if the breaching Party has a bona fide dispute as to whether such breach has occurred or has been cured, it will so notify the non-
breaching  Party in writing and the cure period will be tolled until such dispute is resolved pursuant to Section 14.5.2 (Dispute Resolution ). Upon a
final determination of breach or failure to cure, the breaching Party will have the remainder of the cure period to cure such breach. [***].
13.2.2 Bankruptcy. Each Party will have the right to terminate this Agreement immediately in its entirety by giving written notice of
termination to the other Party, if the other Party files a voluntary petition, or if an involuntary petition is granted in respect of the other Party and
appeal proceedings are not commenced within [***] ([***]) Business Days from the date of such petition under the bankruptcy provisions of
Applicable Law, or the other Party is declared insolvent, undergoes voluntary or involuntary dissolution, or makes an assignment for the benefit of
its creditors, or suffers the appointment of a receiver or trustee over all, or substantially all, of its assets or properties. All rights and licenses under
or to Intellectual Property granted under or pursuant to this Agreement by one Party to the other are, and will otherwise be deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Article 101 (52) of the U.S.
Bankruptcy Code. The Parties agree that each Party will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code
or such similar laws in a jurisdiction outside the United States.
Page 57 of 8513.3 Effects Termination.
13.3.1 General. As of the effective date of any early termination of this Agreement, (a) neither Party shall be relieved of any obligation that
accrued prior to such effective date of termination; (b) except as otherwise expressly provided herein, all rights and obligations of each Party
hereunder will cease and (c) each Party shall return or destroy all Confidential Information of the other Party that is in its possession, subject to and
as more fully set forth in Section 10.6 (Destruction or Return of Confidential Information) . BLI shall fulfill any Production Purchase orders placed
by Ginkgo prior to the effective date of termination and Ginkgo shall pay for such orders pursuant to Section 5.3.3 (Delivery and Payment ). For all
Development Purchases, BLI shall deliver to Ginkgo all works-in-progress  and any report or analysis prepared prior to the effective date of
termination within [***] ([***]) days after the effective date of termination. “ Expiration” of this Agreement occurs only when[***].
13.3.2 Effects of Termination Based Upon Ginkgo’s Buy-Down Election. In the event that termination is the result of Ginkgo exercising the
Buy-Down Election (including payment of the Buy-Down Amount), then, as of the effective date of termination: (a) any and all existing Headstart
Periods shall immediately be deemed to have accelerated to conclusion, (b) the restrictions on BLI set forth in Section 6.2.1 (Restrictions on BLI )
shall terminate; (c) the licenses granted to Ginkgo from BLI in Section 9.1.1 (Scope of Grants ) and 9.1.2 (License Grant to Exploit [***] ) shall
survive and become perpetual and irrevocable; (d) the licenses granted to BLI from Ginkgo pursuant to Section 9.2 (Grants to BLI) shall survive; (e)
any Licensed Products arising from Collaboration Workflows or Ginkgo Workflows developed and used by Ginkgo to good effect prior to the
effective date of termination shall be [***] on any sale or transfer of such Licensed Product, (f) (i) for any Licensed Products arising from
Workflows other than those set forth in subclause (e) of this Section 13.3.2 (Effects of Termination Based on Ginkgo’s Buy -Down Election ), Ginkgo
shall pay [***] and (ii) Ginkgo shall pay [***] for as long as one or more Beacon Optofluidic Machines are in operation at Ginkgo, (g) the pricing
terms for Beacon Optofluidic Machines, Consumables, and services (including Services) shall be consistent with then-current  BLI List Prices, and
(h) Ginkgo shall pay BLI for any amounts due for work performed by BLI under and in accordance with this Agreement prior to the effective date of
termination to the extent that BLI cannot reasonably cancel or reallocate such work.
13.3.3 Effects of Termination Based Upon an Uncured Ginkgo Breach, Insolvency or Extended Force Majeure Event affecting Ginkgo . In the
event that termination is the result of an uncured, material Ginkgo breach of the Agreement under Section 13.2.1 (Material Breach ), for Ginkgo’s
insolvency pursuant to Section 13.2.2 (Bankruptcy ) or for an Extended Force Majeure Event with respect to Ginkgo pursuant to Section 14.8 (Force
Majeure), then, as of the effective date of termination: (a) any and all existing Headstart Periods shall immediately be deemed to have accelerated to
conclusion, (b) the restrictions on BLI set forth in Section 6.2.1 (Restrictions on BLI ) shall immediately deemed to have terminated; (c) the licenses
granted to BLI from Ginkgo pursuant to Section 9.2 (Grants to BLI) shall survive, (d) the licenses granted to Ginkgo under Sections 9.1.1(c) (Grants
to Ginkgo – Commercial License ) and 9.1.2 (License Grant to
Page 58 of 85Exploit [***] ) shall survive, but shall convert immediately into royalty-bearing  licenses as set forth in subclause (e) hereof, (e) Ginkgo shall to pay
to BLI [***]; provided  that  in the event such uncured material breach is [***], Ginkgo, at its election to be made on or before the [***] ([***] th )
day following the effective date of termination (or, if later, within [***] ([***]) days of learning of the relevant royalties for Licensed Products), may
elect, in lieu of royalties, to pay to BLI [***]; (f) the pricing terms for Beacon Optofluidic Machines, Consumables, and services (including
Services) shall be consistent with then-current  BLI List Prices; and (g) Ginkgo shall pay BLI for any amounts due for work performed by BLI under
and in accordance with this Agreement prior to the effective date of termination or materials ordered prior to the effective date of termination to the
extent that BLI cannot reasonably cancel or reallocate such work or materials.
13.3.4 Effects of Termination Based Upon an Uncured BLI Breach or Insolvency . In the event that termination is the result of an uncured
material BLI breach of the Agreement under Section 13.2.1 (Material Breach ) or for BLI’s insolvency pursuant to Section 13.2.2 (Bankruptcy ), then:
(a) Ginkgo’s obligations to pay to BLI the Minimum Cumulative Purchase Commitment under Section 7.2.2(a) (Contract Year Purchase Targets and
Commitments) shall terminate, (b) BLI shall grant royalty-free status on all Licensed Products developed using the Beacon Platform and no
royalties shall be payable by Ginkgo on any sale or transfer of such Licensed Products, (c) Ginkgo’s obligations to pay to BLI the FOU License
Fees pursuant to Section 7.4.1 (License Fees) shall terminate, (d) the licenses granted to Ginkgo from BLI in Section 9.1.1 (Scope of Grants ) and
9.1.2 (License Grant to Exploit [***] ) shall survive [***], (e) the licenses granted to BLI from Ginkgo pursuant to Section 9.2 (Grants to BLI) shall
terminate, except with respect to any sublicenses granted by BLI under Section 9.2.2 for products and processes that were sold, commercialized or
performed by BLI or to or for Third Parties prior to termination, which shall survive and such termination, but only if such sublicenses were granted
in accordance with this Agreement, (f) the pricing terms for Beacon Optofluidic Machines, Consumables, and services (including Services) set forth
in Section 5.2.2 (Pricing – Adjustments ) shall survive for a period of [***] from the effective date of termination, (g) the restrictions on BLI set forth
in Section 6.2.1 (Restrictions on BLI ) shall survive to the extent set forth therein and (h) any and all existing Headstart Periods shall survive for their
duration. If any such uncured, material BLI breach is solely due to BLI’s material failure to perform its supply-related  obligations under this
Agreement, Section 13.4 (Rights in Lieu of Termination for BLI’s Material Breach of Supply Obligations ) may apply in Ginkgo’s sole discretion.
13.3.5 Effects of Termination Based Upon Ginkgo’s Election to Terminate based on a BLI Extended Force Majeure Event. In the event that
termination is elected by Ginkgo based upon an Extended Force Majeure Event with respect to BLI pursuant to Section 13.2.1 (Force Majeure),
then, as of the effective date of termination: (a) any and all existing Headstart Periods shall survive for their duration as if this Agreement had not
been terminated, (b) the restrictions on BLI set forth in Section 6.2.1 (Restrictions on BLI ) shall survive to the extent set forth therein as if this
Agreement had not been terminated; (c) the licenses granted to Ginkgo from BLI in Section 9.1.1 (Scope of Grants ) and 9.1.2 (License Grant to
Exploit [***] ) shall survive and become perpetual, irrevocable and, subject to clause (f) of this Section 13.3.2, royalty-free; (d) the licenses granted
to BLI
Page 59 of 85from Ginkgo pursuant to Section 9.2 (Grants to BLI) shall survive; (e) any Licensed Products arising from Collaboration Workflows or Ginkgo
Workflows developed or used by Ginkgo to good effect prior to the effective date of termination shall be royalty-free and no royalties shall be
payable by Ginkgo on any sale or transfer of such Licensed Product; provided  that , if [***], if [***], then, in order for the sale or transfer of
Licensed Products arising from Collaboration Workflows or Ginkgo Workflows developed or used by Ginkgo to good effect prior to the effective
date of termination to be royalty-free, Ginkgo must pay to BLI [***], but Ginkgo will have [***] ([***]) days following the effective date of
termination to decide whether to make such payment to BLI or to pay royalties for such Licensed Products under subclause (f) of this Section
13.3.5 (Effects of Termination Based Upon Ginkgo’s Election to Terminate based on a BLI Extended Force Majeure Event) , (f) (i) for any Licensed
Products arising from Workflows other than as set forth in subclause (e) of this Section 13.3.5 (Effects of Termination Based Upon Ginkgo’s
Election to Terminate based on a BLI Extended Force Majeure Event) , Ginkgo shall pay [***] and (ii) Ginkgo shall pay [***]; provided that , if
[***], then [***], (g) the pricing terms for Beacon Optofluidic Machines, Consumables, and services (including Services) shall be consistent with
then-current  BLI List Prices and (h) Ginkgo shall pay BLI for any amounts due for work performed by BLI under and in accordance with this
Agreement prior to the effective date of termination to the extent that BLI cannot reasonably cancel or reallocate such work.
13.3.6 Non-Limitation of Remedies. Nothing in this Section 13.3 (Effects of Expiration and Termination ) limits or precludes any other
remedies available to a Party, including for example, the seeking and obtaining of injunctive relief.
13.3.7 Annual Royalty Update . The Parties hereby acknowledge that, if this Agreement is terminated, then, depending on the manner of
termination, Ginkgo may, as more fully set forth in Section 13.3 (Effects of Termination), be required to pay royalties to BLI with respect to Licensed
Product, which royalties will be in line with BLI’s then-standard  commercial terms. In order for Ginkgo to more fully understand the royalty that may
be owed to BLI in the event this Agreement is terminated, on an annual basis, starting at the end of the [***] Contract Year, BLI will provide
Ginkgo, in writing, its then-current  commercial terms with respect to royalties for the Licensed Products.
13.4 Rights in Lieu of Termination for BLI’s Material Breach of Supply Obligations. In the event that Ginkgo has the right to terminate this
Agreement under Section 13.2.1 (Material Breach ) due to a material breach of BLI to perform its supply-related  obligations under this Agreement (for
clarity, this shall not include (a) [***] or (b) [***], Ginkgo may elect by written notice to BLI to, instead of terminating this Agreement, keep this
Agreement and, without limiting any other right or remedy under Applicable Law or this Agreement, to decrease the amount of the Minimum Cumulative
Purchase Commitment for the current and future Contract Years, as well as the Full Purchase Target, in each case in amounts reasonably mutually agreed
upon by the Parties in good faith in accordance with this Section 13.4 (Rights in Lieu of Termination for BLI’s Material Breach of Supply Obligations ).
Following any notice by Ginkgo to BLI under this Section 13.4 (Rights in Lieu of Termination for BLI’s Material Breach of Supply Obligations ), the
Parties shall (i) discuss and implement in good faith a plan to address the supply breach by BLI and shall discuss in good faith potential approaches to
prevent such breach from reoccurring, including a
Page 60 of 85modification to Ginkgo’s forecasts and BLI’s obligation to meet a certain percentage of such forecasts and (ii) discuss and implement reductions to the
Minimum Cumulative Purchase Commitment for the current and future Contract Years, as well as reductions to the Full Purchase Target, which reductions
will be made based on [***].
13.5 Determination of Use of Workflow to Good Effect. In the event the Parties disagree as to whether a Collaboration Workflow or Ginkgo
Workflow has been developed and used by Ginkgo to good effect prior to termination pursuant to Section 13.3.2 (Effects of Termination Based Upon
Ginkgo’s Buy-Down Election ) or Section 13.3.5 (Effects of Termination Based upon Ginkgo’s Election to Terminate based on a BLI Extended Force
Majeure Event) , with respect to each, at either Party’s request, the dispute shall be resolved in an accelerated manner by an Expert Panel subject to the
process and cost allocation set forth in Section 3.5.3.
13.6 Surviving Provisions . In addition to this Section 13.6 (Surviving Provisions), the following Sections and Articles will survive Expiration and
any termination of this Agreement: Article 1 (Definitions ), Section 2.2.3 (Retooling and Development Costs ) (solely with respect to (i) [***] and (ii)
[***]), Section 2.4 (Costs Under Workflow Development Plans ) (solely with respect to costs incurred prior to the end of the Term), Section 2.5
(Termination of Workflow Development Plans ) (solely with respect to the effects of termination of a Workflow Development Plan as set forth therein),
(Termination of Workflow Development Plans ) (solely with respect to the effects of termination of a Workflow Development Plan as set forth therein),
Section 2.8 (Records) (solely for [***] ([***]) years following the end of the Term or for such longer period as required by Applicable Law), Section 3.9
(Expenses ) (solely with respect to expenses incurred prior to the end of the Term), Section 4.1.10 (solely to the extent the BLI Terms and Conditions need
to survive in order to give effect to the surviving terms of this Agreement), Section 6.1 (Headstart Period ) solely to the extent any Headstart Periods
extend beyond the Term) and further subject to each of Section 13.3.2 (Effects of Termination Based Upon Ginkgo’s Buy -Down Election ), Section 13.3.3
(Effects of Termination Based Upon an Uncured Ginkgo Breach, Insolvency or Extended Force Majeure Event affecting Ginkgo ) or Section 13.3.5
(Effects of Termination Based upon Ginkgo’s Election to Terminate based on a BLI Extended Force Majeure Event) , as applicable), Section 6.2.1
(Restrictions on BLI ) (solely for the [***] ([***]) month period following the end of the Term), Section 7.5 (Manner of Payments ) through Section 7.10
(Late Payments ) (solely with respect to any unpaid amounts that accrued prior to the end of the Term or that accrue at any time under Section 7.4.2
(Milestone Payments )), Article 8 (Intellectual Property Ownership; Use of Data ), but excluding Section 8.4 (Prosecution and Enforcement Rights ),
Section 8.5.1 (Disclosure), and Section 8.6 (Notification of New Products; Early Access ), Article 10 (Confidentiality ), Section 11.5 (Disclaimers), Section
11.6 (No Consequential Damages ), Section 11.7 (Liability Limit , Section 12.1 (Indemnification by BLI ) through Section 12.3 (Procedure), Section 13.1.2
(Effects of Expiration ) (solely for Expiration of this Agreement and only for [***] ([***]) years for under clause (iii) thereof), Section 13.3 (Effects of
Termination ) (solely for termination of this Agreement), Section 13.5 (Determination of Use of Workflow to Good Effect ), Section 14.5 (Governing Law;
Dispute Resolution; Equitable Remedies ), Section 14.9 (Further Assurances ) and Section 14.15 (Interpretation ).
14. MISCELLANEOUS
14.1 Notice. Any notice given under this Agreement must be in writing and delivered either to the addresses set forth below in person or via
overnight courier (or to such other addresses
Page 61 of 85of which the Parties may from time to time be notified in writing) and each such notice will be effective upon actual receipt:
If to Ginkgo:
Ginkgo Bioworks, Inc.
27 Drydock Avenue, 8th Floor
Boston, MA 02210
Attn: [***]
With a copy to:
Ginkgo Bioworks, Inc.
27 Drydock Avenue, 8th Floor
Boston, MA 02210
Attn: [***]
with an electronic copy to [***]
With a copy to:
[***]
If to BLI:
Berkeley Lights, Inc.
5858 Horton Street, Suite 320
Emeryville, CA 94608
Attn: [***]
With a copy to:
Berkeley Lights, Inc.
5858 Horton Street, Suite 320
Emeryville, CA 94608
Attn: [***]
With an electronic copy to: [***]
With a copy to:
[***]
Such notice will be deemed to have been given as of the date delivered by hand or on the second business day (at the place of delivery) after
deposit with an internationally recognized overnight delivery service.
14.2 Independent Contractors . It is understood that both Parties hereto are independent contractors and are engaged in the operation of their own
respective businesses, and neither Party is to be considered the agent of the other. Neither Party has any authority to enter into any contracts or assume
any obligations for the other.
Page 62 of 8514.3 Severability. If any provision of this Agreement is held illegal, invalid or unenforceable by a court of competent jurisdiction, such decision will
in no way affect the validity or enforceability of any other provisions, which will remain in full force and effect, and the Agreement will be interpreted as if
such provision were not included in this Agreement; provided  that  the Parties will negotiate in good faith an amendment to this Agreement that replaces
the unenforceable provision with an enforceable provision (to the extent possible) that reflects their initial intent.
14.4 Assignment .
14.4.1 Permitted Assignments . Neither Party may assign or otherwise transfer this Agreement or any rights hereunder, without the prior
written consent of the other Party; provided  that  either Party may assign or otherwise transfer this Agreement or any rights hereunder (a) to a
wholly-owned subsidiary of such Party or (b) in connection with the transfer or sale of all or substantially all of the business or assets of such
Party related to the subject matter of this Agreement, whether by merger, consolidation, divestiture, restructure, sale of stock sale of assets or
otherwise its successor, whether in a merger, sale of stock or sale of assets or any other transaction, in each case (a)-(b), without first obtaining the
prior written consent of the other Party, so long as the non-assigning  Party is notified in writing of such assignment within [***] ([***]) days
following such assignment; provided  further that , in no event may BLI assign this Agreement, in whole or in part, to any Person [***] without first
obtaining Ginkgo’s prior written consent. Any purported assignment of this Agreement by a Party in contradiction to this Section 14.4
(Assignment ) will be void and of no effect.
14.4.2 Transferee. Notwithstanding anything to the contrary set forth herein, if a Party (the “ Assigning Party”) assigns or transfers this
Agreement to a permitted Third Party pursuant to Section 14.4.1 (Permitted Assignments ) (any such Third Party, a “Transferee”), then the
Intellectual Property that was held or developed by such Transferee prior to or after such assignment or transfer (other than Intellectual Property
developed by such Transferee in the course of conducting the Assigning Party’s activities under this Agreement to the extent such Intellectual
Property would have been so included had it been discovered, created, made, developed, conceived or reduced to practice by such Assigning
Party) shall not be deemed to be Intellectual Property Controlled by such Assigning Party, and shall also not be affected or otherwise encumbered
in any manner, including without limitation, by being subject to any rights of or licenses under this Agreement. Furthermore, such Transferee (and
Affiliates of such Transferee: (i) existing immediately prior to such merger, acquisition, assignment or transfer; or (ii) formed on or after such merger,
acquisition, assignment or transfer, which are not controlled by (as defined under the Affiliate definition in Section 1.2 (“Affiliate” definition )) the
Assigning Party) shall be excluded from the Affiliate definition for purposes of determining Intellectual Property that is subject to this Agreement.
Page 63 of 8514.5 Governing Law; Dispute Resolution; Equitable Remedies .
14.5.1 Governing Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Delaware, without regard
to any choice of law provision.
14.5.2 Dispute Resolution . Except with respect to those disputes in which a Party seeks equitable relief pursuant to Section 14.5.3 (Equitable
Remedies) or for which a Party or Person is expressly given final decision-making authority as set forth in Section 3.5 (Decision -Making ), the
Parties, through their Senior Officers, will make a good faith effort to settle any disputes that may arise between them with respect to this
Agreement. If the Parties do not settle the matter within [***] ([***]) days after the delivery by one Party of written notice (the “ Arbitration
Notice”) to the other Party involved, then the Parties will submit the matter to binding arbitration in Wilmington, Delaware. All matters so submitted
to arbitration will be settled by three (3) arbitrators in accordance with the [***], or its successor (the “ [***] Rules”). In the event of a conflict
between [***] Rules and this Agreement, this Agreement shall govern. Each Party will designate an arbitrator and the Parties will cause the
designated arbitrators to mutually agree upon and to designate a third arbitrator who will serve as chairperson; provided , however , that  failing
such agreement within [***] ([***]) days of delivery of the Arbitration Notice, the third (3 rd) arbitrator will be appointed in accordance with [***]
Rules within an additional [***] ([***]) days. The Parties shall arrange for a hearing to occur and be completed within [***] ([***]) days after the
appointment of the third (3 rd) arbitrator, which hearing shall last no longer than [***], unless the arbitral panel believes a longer period is required,
in which case the hearing may last [***]. The Parties will cause the arbitrators to decide the matter to be arbitrated within [***] ([***]) days after
the close of evidence unless the chairperson arbitrator determines, at the request of any Party or on his or her own initiative, that such time period
should be extended, in which case such time period may not be extended beyond an additional [***] ([***]) day period. Each of Ginkgo and BLI
will be permitted to serve one set of document production requests with no more than [***] ([***]) requests; no more than [***] ([***])
interrogatories, including subparts, no more than [***] ([***]) requests for admissions; no more than [***] ([***]) subpoenas to Third Parties;
and no more than [***] ([***]) notices of deposition per side, in each case, unless the arbitral panel directs otherwise. Any documents not in
English that are produced by a Party will be accompanied by a translation into English, which translation will not be binding upon the other Party
or the arbitrators. Each Party covenants and agrees that (a) it will produce documents as required by this Section 14.5.2 (Dispute Resolution ), and
(b) it will make its employees, and will use commercially reasonable efforts to make its former employees, available for depositions and hearing
testimony as requested by the other Party. The final decision of the majority of the arbitrators shall be in writing, in all events follow governing law
and will be furnished to all the Parties in such dispute. Judgment on such decision may be entered in any court having jurisdiction. Such decision
may be used in a court of law only for the purpose of seeking enforcement of the arbitrators’ award. Except as required by Applicable Law or to
enforce an arbitrators’ award, neither Party may disclose the existence, contents or results of an arbitration brought in accordance with this
Agreement, or the evidence produced by its opposing Parties, or any analysis or summaries derived from such evidence. The Parties agree that all
applicable statutes of limitation and
Page 64 of 85time-based defenses (such as estoppel and laches) will be tolled while the procedures set forth in this Section 14.5.2 (Dispute Resolution ) are
pending. The Parties will cooperate in taking any actions necessary to achieve this result. Except as may be determined by the arbitrators, neither
Party shall be penalized for delays resulting from dispute resolution conducted pursuant to this Section 14.5.2 (Dispute Resolution ).
14.5.3 Equitable Remedies; Single Forum. Notwithstanding any other terms of this Agreement, either Party may seek a preliminary injunction
or other provisional equitable relief in any court of competent jurisdiction as permitted by Applicable Law. At all times while any claim, action, suit
or other proceeding between the Parties and/or any of their Affiliates (or among the Parties and/or any of their Affiliates and one or more Third
Parties) arising out of or relating to this Agreement is pending in any court of competent jurisdiction, no dispute that is justiciable and can be
joined to such pending claim, action, suit or other proceeding shall be submitted to arbitration pursuant to Section 14.5.2 (Dispute Resolution )
without both Parties’ mutual consent and, instead, either Party may join such dispute to the pending claim, action, suit or other proceeding by
including such dispute in its pleadings or amending its pleadings. In the event that a motion to amend is required to achieve such joinder, the non-
moving Party shall consent to such motion.
14.6 Entire Agreement; Amendment and Waiver . This Agreement, together with the Exhibits and Schedules attached hereto, sets forth and
constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements,
understandings, promises and representations, whether written or oral, with respect thereto are superseded hereby. This Agreement may not be amended
except by a writing signed by authorized representatives of both Parties. The failure of a Party at any time or times to require performance of any
provision hereof will in no manner affect its rights at a later time to enforce the same. To be valid, a waiver must be in writing and signed by an authorized
representative of the Party having the right that is waived or to whom the obligation to be waived is owed.
14.7 English Language . This Agreement will be written and executed in, and all other communications under or in connection with this Agreement
will be in, the English language. Any translation into any other language will not be an official version thereof, and in the event of any conflict in
interpretation between the English version and such translation, the English version will control.
14.8 Force Majeure. Any delay in the performance of any of the duties or obligations (other than payment obligations) of either Party hereto caused
by a Force Majeure Event (defined below) shall not be considered a breach of this Agreement and the time required for performance shall be extended for
a period equal to the period of such delay. “ Force Majeure Event” shall mean acts of God, acts of the public enemy, war, terrorism, insurrections, riots,
injunctions, embargoes, fires, explosions, floods, or other unforeseeable causes beyond the reasonable control and without the fault or negligence of the
Party who is so prevented or delayed from fulfilling its obligations under this Agreement by such Force Majeure Event (the “ Affected Party”). The
Affected Party shall give prompt written notice to the other Party of such cause and shall take whatever reasonable steps are appropriate in the other
Party’s discretion to relieve the effect of such cause as rapidly as possible. The Party not directly affected by the Force Majeure Event shall have the
right to terminate this Agreement with written notice effective upon receipt if Force
Page 65 of 85Majeure Event continues to prevent performance or compliance in any material respect by the other Party for a period of more than [***] ([***]) days or
should [***] ([***]) Force Majeure Events apply to the performance of such other Party during any [***] (each a “ Extended Force Majeure Event”).
14.9 Further Assurances . Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and
cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary
or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to
better assure and confirm unto such other Party its rights and remedies under this Agreement.
14.10 Third Party Beneficiaries. There are no Third Party beneficiaries under this Agreement, except to the extent a Third Party is indemnified
pursuant to Article 12 (Indemnification; Insurance ); provided  that , in no event will any Third Party entitled to indemnification pursuant to Article 12
(Indemnification; Insurance ) be allowed to enforce the terms thereof against a Party.
14.11 Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United
States or other countries which may be imposed upon the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any
technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner
that at the time of export requires an export license or other governmental approval, without first obtaining the applicable license, approval, or written
consent to do so from the appropriate agency or other governmental entity.
14.12 References. Unless otherwise specified, (a) references in this Agreement to any Article, Section, Exhibit or Schedule will mean references to
such Article, Section, Exhibit or Schedule of this Agreement, (b) references in any Section to any clause are references to such clause of such Section and
(c) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally
executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant
time of reference thereto.
14.13 Attachments . In the event of any inconsistencies between this Agreement and any Exhibits, Schedules or other attachments hereto, the terms
of this Agreement will control, unless the relevant Exhibit, Schedule or other attachment explicitly references its inconsistency with this Agreement and
states that it shall control.
14.14 Non-Solicit. Neither Party will, [***], directly or indirectly with or through any Person, solicit for employment any Person who is an employee
of the other Party; provided , however , that  general solicitation of the public for employment shall not constitute a solicitation hereunder so long as such
general solicitation is not designed to target any such Person. In the event that a Party solicits and then hires an employee of the other Party in violation
of this Section 14.4 (Non-Solicit ), the hiring Party shall, [***], within [***] ([***]) days of such hire, pay the other Party an amount equal to the [***]
cash compensation actually paid to the individual
Page 66 of 85([***]) by the non-hiring Party in the immediately prior calendar year and, further, if the individual solicited and then hired in violation of this is a Key
Person under Section 5.4.1(b) (Dedicated FTEs; Key Persons ), then BLI shall have [***] ([***]) months to identify an employee as the individual to
replace such Key Person and any (a) [***] or (b) [***], in each case (a)-(b), to the extent due to the absence of such Key Person performing a Workflow
Development Plan upon which the Key Person was engaged, shall be deemed waived for that [***] month period.
14.15 Interpretation . All headings are for convenience only and will not affect the meaning of any provision of this Agreement. The Parties
acknowledge that each Party has read and negotiated the language used in this Agreement. Because both Parties participated in negotiating and drafting
this Agreement, no rule of construction will apply to this Agreement which construes ambiguous language in favor of or against either Party by reason of
that Party’s role in drafting this Agreement. Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to
encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words “include,”
“includes” and “including” will be deemed to be followed by the phrase “without limitation,” whether or not so appearing herein, (c) the word “will” will
be construed to have the same meaning and effect as the word “shall,” (d) any reference herein to any Person will be construed to include the Person’s
successors and permitted assigns, (e) the words “herein,” “hereof” and “hereunder,” and words of similar import, will be construed to refer to this
Agreement in its entirety and not to any particular provision hereof, (f) references to any Applicable Law, rule or regulation, or article, section or other
division thereof, will be deemed to include the then-current  amendments thereto or any replacement or successor Applicable Law, rule or regulation
thereof and (g) the term “or” will be interpreted in the inclusive sense commonly associated with the term “and/or.”
14.16 Counterparts . This Agreement may be executed in one or more counterparts, each of which, when executed and delivered by facsimile,
electronic transmission or by mail delivery, will be deemed an original and all of which will constitute one and the same instrument.
[Signature Page Directly Follows ]
Page 67 of 85IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the Effective Date by their respective duly
authorized representatives.
GINKGO BIOWORKS, INC. BERKELEY LIGHTS, INC.
By: /s/ Barry Canton By: /s/ Keith Breinlinger
Name: Barry Canton Name: Keith Breinlinger
Title: CTO Title: CTOSCHEDULE 1.10
Beacon Optofluidic Machine Specifications
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE 1.18
BLI Terms and Conditions
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE 1.21
Buy-Down Examples
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE 1.36
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE 1.62
FTE Rate
$[***] USD per year*
* All FTEs (Hardware, Software, Program Manager, FAS, etc.) will be billed to Ginkgo at this rate. For periods of less than 1 year, billing will be pro-rated
based on time. [***]SCHEDULE 1.92
Lead Time
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE 1.104
OptoSelect Chips
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE 1.107
Performance Service Plan
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE 2.2.2
Initial Workflow Development Plans
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE 5.2.1
Pricing Schedule
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE 5.3.3
Qualification Standards
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)SCHEDULE [***]
1. [***]SCHEDULE 10.5
Draft Press Release – Subject to further changes by Both Parties
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)EXHIBIT A
Workflow Development Plans
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)EXHIBIT B
Outline of First Two (2) Initial Workflow Development Plans
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)EXHIBIT C
GINKGO BIOWORKS, INC.
AGREEMENT CONCERNING RECEIPT OF AND ACCESS TO GINKGO PROPERTY
AND CONFIDENTIAL INFORMATION
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)EXHIBIT D
BLI Proprietary Workflows for Section 7.4.2
Intentionally omitted pursuant to Regulation S-K, Item 601(a)(5)Exhibit 10.1 COOPERATION AGREEMENTBETWEEN THE CITY OF FORT STOCKTON, TEXAS AND STW RESOURCES HOLDING CORP. REGARDING DEVELOPMENT OF WATERWELL(S) IN THE CAPITAN REEF AQUIFER FORMATION
This AGREEMENT regarding development of water well(s) in the Capitan Reef Aquifer Formation (the “AGREEMENT”) is entered into bythe City of Fort Stockton, Texas, a Texas Type A-General Law city (“COFS”) and STW Resources Holding Corp., a Nevada corporation (“STW”),effective as of the last date of signature on the signature pages below. STW and COFS are sometimes individually referred to as a “Party” andcollectively referred to as the “Parties.”
WHEREAS, the City of Fort Stockton, Texas (“COFS”) owns the surface and groundwater rights to several areas of the Capitan ReefAquifer Formation; and
WHEREAS, COFS has an existing Capitan Reef Aquifer (“CRA”) water well located at Section 112 on COFS property, which is currentlydrilled to an approximate depth of 3,500 feet (the “Existing CRA Well”), and also owns property at Section 71; and
WHEREAS, STW desires to attempt to deepen the Existing CRA Well in order to make it a producing water well and/or drill an alternatewell(s) at its own expense, and to lease CRA groundwater rights from Sections 112 and 71 of COFS property; and  WHEREAS, STW and COFS desire to work together for the development of a CRA water supply project within the area that will serve tomeet the future needs of COFS and the municipal and industrial needs within the region.
THE PARTIES HEREBY AGREE AS FOLLOWS:
1.  Leasing of Property and Drilling of Water Well(s). COFS hereby grants, leases and lets unto STW the right to explore for, drill for,produce, utilize, transport, and treat groundwater from the CRA only from beneath the surface of the property more specifically describedin Exhibit “A,” which is attached hereto and fully incorporated into this AGREEMENT (hereinafter collectively referred to as the“Property”). STW is further authorized to drill, deepen, and/or rework at its expense the Existing CRA Well on Section 112 of the Propertyfrom its current depth of approximately 3,500 feet to approximately 4,000 feet, so as to determine the following to be verified by a study tobe performed by a hydrogeologist mutually agreed upon by both Parties (“Post-Well Study”): (a) the gallons per day (“GPD”) of maximumwater capacity of the Existing CRA Well or alternate well, as may be required under Section 5 of the AGREEMENT; and (b) the quality ofthe water to be obtained from the Existing CRA Well or alternate well. The rights granted to STW under this AGREEMENT also include theright of access to the Property to perform the activities authorized herein.  2.  Access and Surface Use. STW agrees to coordinate reasonably with COFS with respect to location of any new wells, roadways, powerinfrastructure, and other improvements that are to be constructed or used on the Property. COFS shall provide STW rent free site leases forthe commercially reasonable amounts of surface area required for CRA pumping and filling stations located on the Property. STW shall payfor or repair all actual damages to roads, fences, or improvements caused by its activities on the Property within sixty (60) days of theoccurrence, and will fill and level all pits, mounds, ruts, and shall restore the surface to as near its original condition as is reasonablypracticable within ninety (90) days after termination of the provisions of this AGREEMENT related only to the Property. Upon terminationof the provisions of this AGREEMENT related to the Property only, STW, or its successors or assigns, shall transfer title of all waterconveyance pipelines from the Property to COFS. STW shall administer and provide all necessary and reasonable insurance to insure itsactivities on the Property in relation to the AGREEMENT and shall list COFS as additional insured.
 
-1-3.  Term.  Subject to the other provisions contained herein, this AGREEMENT shall be for a term of thirty (30) years from the Effective Date,which shall automatically renew from year-to-year thereafter unless terminated by a Party upon sixty (60) days’ written notice after the endof the term. Notwithstanding the 30-year term of this agreement, should STW procure sales agreements with customers for a duration oflonger than 30 years, STW shall be authorized to maintain and service such contract(s) to the extent of the water volume(s) purchased, andthis AGREEMENT shall not terminate during the initial term of any such water supply agreement with a term extending beyond thisAGREEMENT.  4.  Post-Well Study Generally. The Post-Well Study shall provide information on the feasibility of developing a water well field in thatlocation that would produce water from the CRA for: (a) the availability of a minimum 1,200 gallons per minute (“GPM”) per day CRA waterproduction for STW, its successors or assignees, to sell to communities and users within a 500-mile radius outside of COFS (the “PermittedSale Water”) during the Term, with the further requirement that STW would be responsible for the pipelines and pumping facilities requiredto transport the Permitted Sale Water to the intended end-users; and that all such water obtained from the Existing CRA Well containsacceptable levels of Total Dissolved Solids (“TDS”) to meet municipal use standards. If such water does not meet municipal use standardsaccording to the Post-Well Study, STW may either treat the water to municipal use standards or to sell it as-is to industrial end-users.  5.  Replacement CRA Well. If, based on the Post-Well Study of the Existing CRA Well, it is determined that the Existing CRA Well is notsuitable for the purposes of this AGREEMENT, then STW may elect to drill at its expense a second water well (the “Replacement CRAWell”) at a place to be mutually agreed on the Property, with the Existing CRA Well to remain as a monitoring well. After completion of theReplacement CRA Well, a second Post-Well Study will be conducted for the same purposes as that for the Existing CRA Well.  6.  Construction Requirements. STW’s construction of the improvements to the Existing CRA Well, any Replacement CRA Well, and anyadditional production wells shall be pursuant to any recommendation and requirements as may be specified by and agreed upon withCOFS, and the construction shall also be conducted in a manner meeting prevailing industry standards, the Middle Pecos GroundwaterConservation District regulations, Texas Department of Licensing and Regulation (TDLR) regulations, and the Texas Commission onEnvironmental Quality (TCEQ) regulations.  7.  Cooperation Regarding Studies. COFS shall provide to STW any and all documents pertaining to this project, including allhydrogeological studies and any existing Pre-Well Studies for the Existing CRA Well, as well as any similar documents for the ReplacementCRA Well to include:  a.  the best location for the Replacement CRA Well on the Property, considering the spacing with any other wells that might now or in thefuture be located on the Property;  b.  the location on the Property that will best provide data for determining the feasibility of pumping water from the CRA on the Propertyand be the most productive;  c.  documents showing current ownership of the Property including both CRA and surface ownership rights, to demonstrate COFS’ability to lease the land for the Sale of CRA Water Rights to STW, including any documents showing the prior sale or conveyance ofany CRA or water rights from the Property; and  d.  names and addresses of engineers and/or hydrogeologists recommended to perform the Post-Well Study (ies). The Post-Well Study(ies) shall be performed by a hydrogeologist(s) mutually agreed to by both Parties.
 
-2-8.  Post-Well Study Requirements. Any Post-Well Studies shall be paid for by STW and shall include:  a.  a chemical analysis and performance by a qualified certified laboratory mutually approved by the Parties to determine the quality of thewater and its characteristics at that location;  b.  any documents related to the drawdown or recharge rate affecting the producing capacity; and  c.  TDS measurements of CRA water produced by STW.  9.  COFS Responsibilities.   COFS shall perform the following services:  a.  administer and provide all necessary insurance to insure its activities in relation to the AGREEMENT; and  b.  possess or obtain any and all necessary property rights for the activities covered in this AGREEMENT, including both CRA andsurface rights to the Property.  10.  Construction and Post-Well Study Costs.  STW will pay all reasonable and necessary costs to: (a) construct the improvements to theExisting CRA Well or the Replacement CRA Well (including the cost of securing any necessary regulatory approval for the improvementsto the Existing CRA Well and the Replacement CRA Well); (b) obtain the Post-Well Study (ies); and (c) reasonable consulting costs relatedto the negotiation and execution of the AGREEMENT.  11.  STW Termination Rights. STW shall have the right to unilaterally terminate the provisions of this AGREEMENT related only to theProperty, and not proceed further after the completion of any phase of the project and not incur any additional costs. So long as STW isprogressing through the following phases, and subject to the other terms of this AGREEMENT, COFS may not terminate the AGREEMENTduring the:  a.  Pre-well study (ies),  b.  completion of improvements to the Existing CRA Well,  c.  completion of the Replacement CRA Well, if necessary, and  d.  Post-Well Study (ies).  Should COFS unilaterally terminate the provisions of this AGREEMENT related to COFS Property only, with the right to do so beginningon a period beginning no sooner than ninety (90) days following the Post-Well Study (ies), and ending at the one year period following thePost-Well Study (ies), during which STW may exercise its Option to Produce Water, in accordance with Section 15 of this AGREEMENT,COFS shall reimburse STW for 100% of the costs paid by STW up to the point of such termination, pursuant to the AGREEMENT,according to a reasonable accounting schedule of costs prepared by STW and submitted to COFS. Once STW exercises its Option toProduce Water pursuant to Section 15 of this AGREEMENT, and pays COFS its Bonus Payment, in accordance with Section 14(b) of thisAGREEMENT, COFS may no longer unilaterally terminate this AGREEMENT during the Term. If STW terminates the AGREEMENT andCOFS sells water within twenty (20) years from the Effective Date of this AGREEMENT from one or more producing water well(s)developed by STW, STW shall be reimbursed the amount expended for drilling the producing well(s), to be paid from the sale of waterproduced by COFS from the producing well(s). Such reimbursement shall occur based on COFS’ net revenues received from CRA watersales from the producing well(s) in six (6) month increments, which shall begin on the date COFS begins selling CRA water from producingwater well(s), and shall end upon reimbursement in full of the amount STW is owed for drilling any producing well(s).
 
-3-12.  Title of Producing Wells. Title and ownership of the Existing CRA Well, the Replacement CRA Well and any additional wells drilled on theProperty by STW (the “Additional Wells”) shall be transferred to STW by COFS and shall be held by STW; however, upon termination ofthe provisions of this AGREEMENT that relate to COFS Property, STW shall transfer the title(s) back to COFS upon COFS’ reimbursementof STW as necessary under this AGREEMENT.  13.  Uses, Maintenance, Construction and Operation of Wells. STW will construct, maintain, operate, own, and repair (as needed) the ExistingCRA Well, the Replacement CRA Well and any Additional Wells, and in doing so, and in the wells' operation and repair, STW shall:  a.  conduct all work and operations in a businesslike manner consistent with good and economical practices and with due regard for goodland management, damage prevention and environmental protection;  b.  comply with all federal, state, and local laws, regulations and requirements governing the development, production, collection,transportation, and disposal of the water (and any waste or reject water);  c.  allow COFS or its authorized representatives to enter upon the premises at reasonable times to be arranged in advance of entry; and  d.  plug all wells, when abandoned, in accordance with the applicable regulatory requirements of the Middle Pecos GroundwaterConservation District, TDLR, and/or TCEQ.  14.  Obligations Following the Post-Well Study.  a.  For purposes of this section, the Post-Well Study must show that the Existing CRA Well or Replacement CRA Well can produce CRAwater at a minimum of 1,200 GPM or more or a combination of 1,200 GPM from one or more wells on the Property in order for STW toproceed with the obligations set forth in this section (“Critical Criterion”).  b.  Obligations if Post-Well Study shows that the Critical Criterion has been met:  If all necessary regulatory approvals are obtained that allow the production and transport of up to 10 million GPD or the maximumcapacity of the well, for STW’s use or resale, in conjunction with STW exercising its Option to Produce Water under Section 15 ofthis AGREEMENT, STW will pay COFS an upfront Bonus Payment of Five Million and 00/100 Dollars ($5,000,000.00), and STW shallhave the immediate right to develop Additional Wells on the Property, subject to all necessary regulatory approvals, in the eventSTW procures additional water supply contracts that require additional volume of production, the feasibility of which shall be by aPost Well hydrogeological study and report that shows the ability of STW to produce the additional amounts of CRA water. STWshall have the right to the sale of and transport of such additional water produced from Additional Wells. STW shall pay COFS aseventeen percent (17%) royalty of the price STW receives per 1,000 gallons of CRA water produced from the Property andsold.   STW shall also provide to COFS three (3) million GPD of CRA water at no cost to COFS at such time that COFS requestsdelivery of the water for COFS use. Each payment made by STW to COFS will include an accounting statement providing the numberof gallons sold, the price paid by any customer(s), the gross revenues received by STW, and the expenses paid by STW for the sale,treatment, use, and/or delivery of the CRA water. STW shall calculate the amount owed to COFS every one hundred-eighty (180)days (“Accrual Period”), and shall provide required payments to COFS within thirty (30) days after the end of the previous AccrualPeriod.
 
-4-c.  Options if Post-Well Study shows that the Critical Criterion has not been met:  (1)  STW may choose to not pursue the production and transport of the water from the Property. If one or more producing wells aredeveloped by STW and COFS sells the CRA water produced from the well(s), COFS will reimburse STW from the net revenuesCOFS receives up to the point STW has been fully reimbursed for drilling any producing well(s) if such sale occurs within twenty(20) years from the date of this AGREEMENT.  (2)  STW may choose to pursue the production and transport of the water. STW shall have the right to produce and transport the waterupon obtaining all necessary regulatory approvals, and will not seek reimbursement of any of its costs incurred pursuant to theAGREEMENT.  (3)  If regulatory approvals have been granted, but the permit obtained from the Middle Pecos Groundwater Conservation District allowsthe transport of less than the full amount requested for STW's use or sale, then STW may:  i.  elect to produce and transport the water; or  ii.  elect to not produce and transport the water, in which case the conditions of Subsection (c)(1) of this section shall apply.  15.  Option to Produce Water.  a.  STW will have one year from completion of the last of the Post-Well Study (ies) completed on the Existing CRA Well or ReplacementCRA Well to exercise its option to produce and transport the water produced from the CRA on the Property (“Option to Produce”).The AGREEMENT shall thereafter terminate as to both Parties if STW has not exercised its Option to Produce at the expiration of theone-year period unless STW pays as royalty on the first day of each month the sum of Five Hundred and 00/100 Dollars ($500.00) permonth. STW shall have no right to maintain this AGREEMENT through payment of such a royalty for any one period greater thanthree consecutive years.  b.  If, after STW has exercised its option to produce CRA water from the Property, one or more producing wells on the Property arecapable of producing CRA water for sale, but CRA water is not being sold for a consecutive period of 180 days or more, then the leaseshall terminate as to both parties unless STW pays as royalty on the first day of each month after such period of 180 days, the sum ofFive Thousand and 00/100 Dollars ($5,000) per month. STW shall have no right to maintain this AGREEMENT through payment ofsuch a royalty for any one period greater than three (3) consecutive years.  c.  If STW exercises its option to produce and transport the CRA water, STW will construct additional facilities or expand existingfacilities, as necessary, to be able to produce and transport the CRA water for sale. 
 
-5-16.  Payment for Use of COFS Pipeline Easements and COFS Assistance with Project.  a.  STW shall be entitled to use existing COFS easements and right of ways within Pecos County for laying of pipelines necessary forthe delivery of CRA water produced within Pecos County. COFS will assist STW with any negotiations required to procure anyadditional easements and groundwater rights in Pecos County that are necessary for the production and delivery of CRA water.STW shall also be entitled to use and upgrade existing COFS water treatment infrastructure as necessary for the treatment of rawCRA water. STW shall pay COFS a seven percent (7%) royalty of the price STW receives per 1,000 gallons of CRA waterproduced from other properties within Pecos County and sold as consideration for the rights provided by COFS to STW underthis subsection. Such payment shall be made according to the schedule and terms set forth in Section 14(b) of this AGREEMENT.The requirements under this Section 16 shall remain in force and effect despite any termination of those provisions of thisAGREEMENT that apply only to COFS Property. The provisions of this section shall terminate in the event STW is not producingCRA water from other properties in Pecos County for sale due to termination of all such agreements or failure of STW to enter intosuch agreements regarding other properties in Pecos County within ten (10) years from the Effective Date of this AGREEMENT.  b.  COFS shall manage well maintenance and production operations for all CRA water produced within Pecos County under thedirection of STW. STW shall pay COFS for its reasonable costs incurred to manage such well maintenance and productionoperations.  c.  STW shall conduct all necessary storage, holding, and treatment of CRA water produced from the Property and from otherproperties within Pecos County, as set forth in Subsection (a) of this section, within the boundaries of Pecos County.  17.  Authorized Third Party Beneficiary.   STW shall be listed as a third party beneficiary to any contracts to guarantee payment of any of theobligations of this contract between COFS and Pecos County or any other entity or individual.  18.  Venue. This AGREEMENT is controlled by the laws of the State of Texas, and venue for any actions brought to enforce this AGREEMENTshall be brought exclusively in a court of competent jurisdiction in Pecos County, Texas.  19.  Authority. The Parties executing this AGREEMENT represent that they have full and actual authority to sign and to be bound by thisAGREEMENT.  20.  Taxes and Fees. STW shall pay all taxes, fees, assessments, and costs associated with the rights, pumping, and use of the CRA water fromthe Property and other properties in Pecos County. COFS shall bear and pay any ad valorem taxes assessed directly against COFS’ royalty,any federal or state income taxes payable on the royalty and on the other compensation payable to COFS under this AGREEMENT, andtaxes assessed on COFS’ ownership of the surface of the Property and other minerals not conveyed under this AGREEMENT.  21.  Governmental Authority. STW shall be responsible for obtaining any approval required from any applicable governmental authority withjurisdiction over the activities under this AGREEMENT. COFS shall assist STW with any documentation needed to obtain the necessaryapprovals required.
 
-6-22.  Force Majeure. If a Party is rendered unable, wholly or in part, to carry out any of its obligations under the Agreement, other than anobligation to pay money, as a result of Force Majeure, then its obligations shall be suspended, to the extent affected by such ForceMajeure, during the continuance of any inability so caused, provided that notice of the Force Majeure is provided to the other Party assoon as reasonably practicable. The Party claiming the Force Majeure shall use due diligence to resume performance at the earliestpracticable time, and such suspension shall not extend for a period longer than twenty-four (24) months from the date notice of the ForceMajeure is provided without payment as set forth under Section 15(a) of this AGREEMENT by STW, or the option to terminate thisAGREEMENT by STW if COFS is the party asserting the Force Majeure.  23.  Notice of Breach. In the event of default by any Party, a non-defaulting party may give the defaulting party written notice specifying thedefault. If the defaulting party fails to fully cure any monetary default that can be cured by payment within sixty (60) days after receipt ofthe notice, or fails to commence the curing of any default specified in such notice that is other than a monetary default within sixty (60)days from the date of the notice provided, then the non-defaulting party may pursue all legal or equitable remedies against the defaultingparty.  24.  Notices. Service of all notices under this AGREEMENT shall be sufficient when hand- delivered or sent by certified mail to the respectiveaddress set forth below, unless notice is provided by a Party under this section to the other Party indicating a change to the address listedherein. Any such notice mailed to such address shall be effective when hand- delivered, deposited in the United States mail, certified, dulyaddressed, and with postage prepaid or national overnight courier.   STW: STW Resources Attn: Stanley Weiner3424 South County Road 1192Midland, Texas 70706   COFS: City of Fort Stockton Attn: City Manager121 W. 2nd StreetFort Stockton, Texas 79735 25.  Indemnification. The Parties shall indemnify, hold harmless, and defend each other, their heirs, successors, and assigns, from and againstany and all losses, liabilities, damages, costs, attorney’s fees, expenses, causes of action, suits, claims, and judgments of any kindor  character for injury to person or property arising in whole or in part out of the responsibilities set forth in this AGREEMENT, whetherdue to the negligence of a Party or otherwise.  26.  Waiver. The failure on the part of either Party to require performance by the other of any portion of this AGREEMENT shall not be deemeda waiver of, or in any way affect that Party’s rights to enforce such provision.   Any waiver by either Party or any provision of thisAGREEMENT shall not be a waiver of any other provision hereof.  27.  Severability. The invalidity or unenforceability of any provision of this AGREEMENT shall not affect the validity or enforceability of anyother provision of this AGREEMENT. The provisions of Section 16 are severable from the provisions of the AGREEMENT related to theProperty, and shall remain in full force in effect upon termination of the provisions related only to the Property.  28.  Binding Effect. The AGREEMENT shall be binding upon and inure to the benefit of the parties and their respective successors andassigns.
 
-7-29.  No Partnership, Agency, or Third Party Beneficiaries Intended. Nothing in this AGREEMENT will be construed as creating any form ofpartnership or joint venture relationship between the Parties, nor shall any party be authorized to act as an agent for any other party.Nothing in this AGREEMENT shall be construed to confer any right, privilege or benefit on, or to otherwise create any vested right orthird-party beneficiary relationship with any person or entity not a party to the AGREEMENT, unless otherwise provided in thisAGREEMENT.  30.  Authority. Each of the persons signing on behalf of the Parties hereby confirm that they have the authority to execute this AGREEMENTon behalf of the Party indicated by their signature and have the authority to bind such Party hereto.  31.  Further Assurances. STW and COFS shall take all further actions and shall execute and deliver to the other any other document orinstrument which is necessary to fully carry out the transactions evidenced by this AGREEMENT. STW and COFS shall cooperate witheach other and act in good faith to accomplish the purposes of this AGREEMENT.  32.  Compliance with Laws. The Parties agree that each Party will comply with all applicable federal, state, and local laws and any applicableordinances, rules, orders, and regulations of any of the authorities having jurisdiction in carrying out its duties and obligations hereunder.However, nothing contained in this AGREEMENT shall be construed as a waiver of any right to question or contest any law, ordinance,order, rule, or regulation in any forum having jurisdiction.  33.  Entire Agreement. This AGREEMENT contains the entire agreement between the Parties and any agreement not contained herein shall notbe recognized by the parties. The captions used herein are for convenience only and shall not be used to construe this AGREEMENT.  34.  Counterparts. This AGREEMENT may be executed by the parties in any number of counterparts, each of which when so executed anddelivered shall be deemed an original instrument, but all such counterparts together shall constitute but one and the same instrument.
  (Signature Pages Follow)
 
-8-CITY OF FORT STOCKTON:
  CITY OF FORT STOCKTON 
By: _                                        (Printed Name) Title:  Date:                                           
 
  STATE OF TEXAS                                           §COUNTY OF PECOS                                           § 
This instrument was acknowledged before me on the                                                                                         day of, 2014, by Raul B.Rodriguez, City Manager of the City of Fort Stockton.
 
  Notary Public, State of TexasMy Commission Expires                                                                       
 
-9-STW RESOURCES HOLDING CORP.:
  STW Resources Holding Corp. 
  By: _ Stanley T. Weiner 
Title: CEODate:                                           
 
  STATE OF TEXAS                                           §COUNTY OF                                         § 
  This instrument was acknowledged before me on the                                                                                         day of, 2014, by Stanley T.Weiner, CEO of STW Resources Holding Corp.
 
  Notary Public, State of TexasMy Commission ExpiresExhibit 10.34 INTERNET CHANNEL COOPERATION AGREEMENT Contract Number: 181015BD0120 
    
Party A:
 
Beijing Baidu Netcom Science and Technology Co., Ltd.
 
Address:
 
Baidu Building, 10 Shangdi 10 Street, Haidian District, Beijing
 
Contact:
 
HOU Gang
 
Telephone: 010-59927171Fax: 010-59920021 
   
Party B:
 
China Online Housing (Hong Kong) Co., Ltd.
 
Address:
 
8/F, Ideal International Plaza, 58 Beisihuan Xilu, Haidian District, Beijing
 
Contact:Telephone: 010-58951000Fax: 010-58951005 Party C: Beijing Yisheng Leju Information Services Co., Ltd.Legal representative: ZHU XushengAuthorized signatory:Address: 8/F, Ideal International Plaza, 58 Beisihuan Xilu, Haidian District, BeijingContact:Telephone: 010-58951000Fax: 010-58951005 In this Agreement, Party A, Party B and Party C individually a “Party”, collectively the “Parties”. The transaction contemplated to be jointlyconducted by Party A and Party B hereunder is referred to as the “Operation”. WHEREAS: 1. From its formation in January 2000, Party A has been providing search technology services with the mission to provide the public with easyaccess to information. it has completed transformation from a back-office technology provider to an independent search services providerfor the public and is the first operator of competitive ranking in the PRC. The www.baidu.com operated by Party A has grown into thelargest Chinese website and Chinese search engine in the world. 2. Party B is a leading online and offline real estate information and consulting services provider in the PRC. The SINA Leju operated by PartyB is a leading real estate and home furnishing network information network in the PRC, having plentiful and quality database on real estate(including new, used and leased real estate), home and furniture. 3. Party A and Party B through negotiations agree to conduct comprehensive cooperation in real estate and home furnishing informationservices by capitalizing on their respective advantages, including their strategic cooperation on the formation of a real estate and homefurnishing channel by Party A. Both Parties will jointly launch Baidu Leju Real Estate and Home Furnishing Channel for which Party B willbe wholly responsible for its construction. Party B will form a dedicated team and, to the extent permitted by Party A, conduct a whole newdesign of all information, products and data of Party A on real estate, used homes, home and furniture, so as to present the existingservices of Party B to the  1
thcustomers of Party A through the channels of Party A. Meanwhile, Party B will be responsible for all operations of the advertising or anyother businesses in connection with the real estate and home furnishing channel of Party A according to agreement. Party A will usepromotional resources to provide full assistance in Party B’s efforts in customer development and traffic expansion. NOW, THEREFORE, the Parties agree as follows: ARTICLE IDEFINITION AND INTEPRETATION 1.1 Definition Unless otherwise defined in the context, in this Agreement: (a) PRC Laws mean any laws, regulations, rules and regulatory documents in the PRC which are current and will be issued goingforward. (b) Business Secrets mean any technical, financial, commercial or any other information owned and treated as business secretsby one Party and/or its subsidiaries or affiliates, which have the following attributes: (i) It is unknown to the public; (ii) It may generate economic benefit for its owner; (iii) It is practical; and (iv) It is treated as business secrets with appropriate protection measures by its owner. (c) Effective Date means the date of this Agreement. (d) Force Majeure means the occurrence of any acts of God or man-made disasters or accidents during the term of thisAgreement which is unforeseeable or, if foreseeable, unavoidable, or uncontrollable and make it impossible for one Party toperform this Agreement in a whole, including earthquakes, typhoons, floods, fires, wars, strikes, riots, hacker attacks, technicalbreakdown of telecommunication departments, and legal restrictions. (e) Baidu Net/Party A’s Website means the Internet website owned by Party A whose domain name is http://www.baidu.com,through which Party A provides search services to its users. (f) Leju Net/Party B’s Website means the Internet website owned by Party B whose domain name is http://www.leju.com. (g) First Tier Channel on Baidu Net means any of the channels with the headings of news; real estate and home furnishing; tiebar; Zhidao; and entertainment in the product lists of Baidu Net. (h) Second Tier Channel of Baidu Net means any of the channels with the headings of real estate, used homes, and decorationsin the real estate and home furnishing channel of Baidu Net. 2(i) Real Estate and Home Furnishing Channel/Cooperation Channel means a First Tier Channel on Baidu Net jointly constructedby Party A and Party B, whose channel name and domain name is Baidu Leju Real Estate and Home Furnishing Net (the “BaiduLeju”) and leju.baidu.com, respectively. (j) Category means the webpage publishing a certain type of information under each level of the channels on Party A’s Website.The homepage of each channel consists of multiple categories. 1.2 Interpretation (a) Any date in this Agreement means its calendar date. (b) The headings in this Agreement are for convenience only and will not affect the meaning or interpretation of any part of thisAgreement. (c) Singular form of any word include its plural form as required in the context, and vice versa. (d) Any reference to the article, section and paragraph means the article, section and paragraph of this Agreement. ARTICLE IIREPRESENTATIONS AND WARRANTIES 2.1 Legal Status Each Party represents and warrants to the other Parties that as of the date of this Agreement: (a) It is qualified to conduct the transaction contemplated under this Agreement, and such transaction is in line with its scope ofbusiness;  (b) It has the full power to enter into this Agreement and perform its obligations hereunder; (c) Its authorized representative has full authority to sign this Agreement on its behalf (a photocopy of which authorization letterwill be provided upon request of the other Parties); and (d) To its knowledge, it has disclosed all of the documents issued by the local government having jurisdiction over the placewhere it is incorporated or its business address is located which may have material adverse effect upon performance of its obligations under thisAgreement; and it is not a party to any liquidation, dissolution or bankruptcy proceedings. 2.2 Legal Effect (a) As of the date of this Agreement, it is bound by this Agreement. (b) It warrants that none of its execution, delivery and performance of this Agreement or conduct of any transaction contemplatedhereunder is in violation of any PRC laws or any agreement to which it is a party. (c) Prior to the date of this Agreement, it has presented its business license 3which has passed annual inspection for the current year to the other Parties, the sealed copy of which business license will be provided to theother Parties. ARTICLE IIITERM OF THIS AGREEMENT 3.1 Term (a) This Agreement will be effective as of the date of its execution, and term of the Cooperation will be four years from the date onwhich the channel is uploaded. (b) The channel is expected to be uploaded on August 1, 2010. (c) As of the date of this Agreement, both Party A and Party B will cooperate to complete all preparatory work in connection withthe Cooperation channel contemplated under this Agreement, so as to ensure smooth upload of the Cooperation channel. 3.2 Extension Upon expiration of this Agreement, with all conditions being equal, Party B has the preferential right to continue Cooperation with PartyA in respect of the real estate channel. If both Party A and Party B continue their Cooperation, they will negotiate to reach an agreement to thateffect no less than one month prior to the expiration of this Agreement. 3.3 Phases of Cooperation (subject to the actual date of the upload of the channel) Phase I will commence on August 1, 2010 and end on July 31, 2011. Phase II will commence on August 1, 2011 and end on July 31, 2012. Phase III will commence on August 1, 2012 and end on July 31, 2013. Phase IV will commence on August 1, 2013 and end on July 31, 2014. ARTICLE IVCONTENT AND SCOPE OF COOPERATION It is agreed that the Cooperation contemplated under this Agreement will consist of: (i) formation of the Cooperation channel; (ii) advertising operation of the Cooperation channel; (iii) promotion of the Cooperation channel; and (iv) cooperation with any other products. The details of the Cooperation are as follows: 44.1 Formation of the Cooperation Channel (a) During the term of this Agreement, Party B will use the Baidu’s Real Estate and Home Furnishing Channel as the jointly formedchannel of Party A and Party B. Party A grants all-round exclusive rights to Party B to construct, maintain and operate theCooperation channel. As the owner of www.baidu.com, Party A has ownership and control over second tier domain names. PartyA has the right to deprive Party B of the operating rights of the website without any liability if Party B is found in violation of anylaw. Party A is required to receive written consent from Party B prior to its adjustment of any second tier domain names which isunder independent operation of Party B. (b) Party A authorizes Party B to maintain and construct all of the contents under the second tier domain names as follows: (i) Leju.baidu.com (ii) House.baidu.com (iii) Jiaju.baidu.com (iv) Fangyou.baidu.com (v) Esf.baidu.com (vi) Rent.baidu.com (vii) Dichan.baidu.com (viii) Jiancai.baidu.com (c) Party B will be solely responsible for the sponsorship, operation, upgrade, and maintain of Baidu Real Estate and HomeFurnishing Channel, including provision of bottom-level webpage and systems, integration of the data, information andintelligence provided by users relating to real estate and home furnishing on the Cooperation channel, and provide relatedmaintenance and support to end-users. Party B has the discretion to arrange the layout and linkage of the channels, categories,articles and data relating to real estate and home furnishing on the Cooperation channel. (d) The reformed Cooperation channel will still exist as a real estate and home furnishing channel, a First Tier Channel of BaiduWeb, whose domain name is leju.baidu.com. The homepage of the Cooperation channel will be designed to give full presentationof the cooperation between the two Parties. (e) During the term of this Agreement, Party A will add the Cooperation channel to the linkage access to the real estate and homefurnishing in the product list page of Baidu Net (http://www.baidu.com/more/). (f) Party B will be responsible for development of each level of webpage of the Cooperation channel, and has control, approvaland discretion over its design, layout and appearance. It is agreed by both Parties that the homepage of the Cooperation channelwill have a domain name of leju.baidu.com, which may be reformed according to the design and layout of Party B, or remainsconsistent with the overall style of Party A’s Net. If it remains consistent with the style of Party A’s Net, Party B will ensure nomaterial change be made to the brand 5image of Party A or any webpage relating thereto, provided that any design planned by Party B is subject to consent of Party A. (g) Except for the homepage of the Cooperation channel, any other sub-channels, categories and articles within the Cooperationchannel is subject to design and layout of Party B at its sole discretion. Such sub-channels, categories and articles may all usethe domain name of Party B’s Net or Party A’s Net, such as baidu.leju.com\esf or baidu.leju.com\jiaju. (h) The contents, operations, products, services, images, texts and super links of the Cooperation channel will be operated on theserver of Party B. Party B will be solely responsible for the servers, bandwidth and any other facilities necessary for theCooperation channel. Party B has sole control, approval and discretion over the contents, operations, products, services, images,texts and super links in or included in the Cooperation channel, as well as to include which and how to include any existinginformation or services on the Party B’s Net into the Cooperation channel through super links. (i) Party B warrants that none of the articles, contents and web pages of the Cooperation channel is in violation of PRC laws orany international treaty to which the PRC is a signatory, including without limitation any content detrimental to national security,of pornographic, fraudulent, insulting, defamatory, hectoring or harassing nature, infringing upon the copyrights, personal rightsor any other valid rights and interests of any other parties or in breach of any social customs, or any linkage thereto. If Party Areceives any complaint regarding the content of the Cooperation channel, Party B shall resolve such complaint immediately,negotiate with or respond to any review or enquiry from any third party or competent authorities at its own expenses, and beliable for any loss incurred by Party A. (j) To ensure legality of the contents within the Cooperation channel, Party B will make the contact of its customer servicesconspicuously displayed at the homepage of the Cooperation channel, and keep its users of the way to file a complaint uponoccurrence of any tort or law-breaching incidents. Party B will respond to any complaint within a reasonable upon receipt thereof,which response process is subject to approval of Party A. If Party B receives any complaint of any third party regarding the tortor breach of any content in the Cooperation channel which is forwarded from Party A, Party B will delete such content within 24hours or notify Party A of its responsive measures. (k) Party A will cooperate with Party B to handle any agreement relating to cooperation regarding real estate and home furnishingchannel which has not been fully performed by the date of this Agreement. It is agreed that party A will disclose to Party B all ofits agreements regarding Cooperation Channel which are valid as of the date hereof, and Party B reserves the option to agree orwaive its acceptance of such agreement according to its circumstances. If Party B agrees to accept part of such agreements, theconfidentiality and transfer of debts and claims under such agreements will be subject to special agreement of the other partythereto, and Party A will perform the tasks set forth under Section 4.1(k) with reasonable care. (l) Party A hereby agrees to take all actions necessary for cooperation between the client of Cooperation Channel with Party Band the transfer mentioned above, including: (i) Within ten (10) business days upon execution of this Agreement, 6provide to Party B a schedule listing all agreements regarding Cooperation Channel which are valid as of the date hereofas well as a copy of all such agreements; (ii) Within ten (10) business days upon execution of this Agreement, provide to Party B a correct and detailed financialstatement reflecting all accounts receivable and payable, including any payment made by Party A or the client under anyoutstanding agreement with the note whether such payment is for completed or uncompleted services. (iii) Within ten (10) business days upon execution of this Agreement, provide to Party B a client document (including thename, position and the residence of its person in charge) for follow-up and maintenance efforts by Party B; and (iv) Introduce Party B to its clients as the new communicator and the successor of Party A. 4.2 Advertising on the Cooperation Channel (a) Party A agrees that the pricing, specifications and contents of the advertising on the Cooperation Channel is subject to solediscretion of Party B. Party B has absolute and sole control, approval and discretion regarding the advertising operation of theCooperation Channel, may conduct and benefit from legal advertising operations at its sole discretion. (b) Party A will provide to Party B the authorization and any other legal documents necessary for Party B to conduct advertisingoperation on the Cooperation Channel, and provide good-faith support in connection with coordination and promotionnecessary in such advertising operation. (c) Party A will provide assistance to Party B in installing and commissioning advertising management and release system on theCooperation Channel to ensure smooth management of the advertising on the Cooperation Channel by Party B. Party B has solediscretion to use the advertising management and release system of its own or from Party A. (d) Party B will be liable for its advertising operation, and will handle and be held liable for any dispute, complaint or governmentinvestigation or penalty arising from the content or release of its advertising. Party B will be held liable for any loss incurred byParty A as owner of the website resulting from Party B’s conduct. (e) Without prior consent of Party B and during the term of this Agreement, Party A may not release advertising or promotioninformation, or any other information or linkage against law or industrial standards on the Cooperation Channel. (f) Party B has the right to conduct marketing activity in the name of Baidu Leju Real Estate and Home Furnishing Net, providedthat such conduct will not appear as if Party B represents Baidu or Party B and Baidu has any relationship other than thatprovided under this Agreement. (g) Party A represents and warrants that Party B will not be liable for any cost, expense, damage, loss, indemnity, tax, levy, actionor claim regarding any client incurred prior to the date of this Agreement. 74.3 Promotion of the Cooperation Channel (a) During the term of this Agreement, Party A undertakes to promote the key word (including any of the key words relating toreal properties, building material products and home furnishing) involved in the Cooperation Channel. Party A warrants that suchkey word will be promoted on the open search platform of Baidu and preferentially displayed at the left side of the search resultpages, the exact display position of which is subject to separate agreement between the Parties. The search results will link to thereal estate and home furnishing channel under cooperation of the Parties. The key words will be provided to Party B to Party A,and the information included in any of the key words and their search results will be in compliance with laws and regulations, aswell as business rules of Party A, including without limitation user’s experience. Party B agrees that Party A may modify thedisplay of search results out of consideration relating to user experience, provided that such modification will not materiallychange the display, content and position of the search results. Party A will be deemed in breach of this Agreement if it is requiredto modify search results pursuant to laws, regulations, court rulings or other mandatory documents. (b) During the term of this Agreement, Party A undertakes to provide to Party B Baidu network promotion resources equal toRMB10 million for each cooperation period from its commencement. Party A will provide such resources to Party B through aseparate account for promotion of the Cooperation Channel at the discretion of Party B. Party B must use up the resources withinthe period provided under this Agreement and any remaining resources will be cancelled as of the commencement of the nextcooperation period. Additionally, Party A agrees to provide support for Party B’s promotion at Baidu picture search, BaiduZhidao, Baidu Baike, Baidu Search Chart, Hao123 and other Baidu products. Party A will provide assistance for Party B ineffective promotion of search results, the details of which are subject to separate agreement of the Parties. (c) Party A undertakes to provide support for Party B in marketing and promotional efforts, including without limitation jointpromotional activities on Baidu leju Cooperation Channel. 4.4 Cooperation of Other Products (a) During the term of this Agreement, Party A and Party B will conduct cooperation regarding Tieba products, the details ofwhich are subject to supplemental agreement of the Parties. Party A undertakes not to make additional charge from Party Bregarding Tieba products. (b) During the term of this Agreement, Party A and Party B will conduct cooperation regarding Baidu Map products, the details ofwhich are as follows: (i) Party B will provide real estate, home furnishing and life related data required by Party A, and Party A will use itstechnological means to provide display platform for Party B at map.baidu.com, the details of which are subject toseparate agreement of the Parties. (ii) Subject to provision of relevant real estate information to Party A from Party B, Party A will display the real estateinformation, and any of its updates from time to time, provided by Party B on map.baidu.com 8on preferential basis. Party A will deal with any failure to display such information as provided in the precedingsentence immediately upon notice for such effect from Party B in writing. (iii) Party A and Party B have entered into agreement regarding map cooperation prior to this Agreement. Party B has theoption to continue performing such agreement, or terminate such agreement and perform the Cooperation providedhereunder. (c) During the term of this Agreement, Party A agrees to give preferential cooperation to Party B regarding Baidu news products. Cooperation Fee 1. Cooperation Fee The cooperation fee under this Agreement will be RMB200 million, of which RMB160 million will be channel cooperationfee and RMB40 million will be promotion fee for the Cooperation Channel. The cooperation fee will be payable in four installments asfollows  (a) Within 15 business days after the date hereof, Party B will pay RMB50 million to Party A. (b) Within 15 business days after the end of the first cooperation period, Party B will pay another RMB50 million to Party A. (c) Within 15 business days after the end of the second cooperation period, Party B will pay another RMB50 million to Party A. (d) Within 15 business days after the end of the third cooperation period, Party B will pay the remaining RMB50 million to PartyA. 2. Payment of Cooperation Fee The channel cooperation fee provided under this Agreement will be payable by Party B or its designated entity to the followingaccount of Party A at the expense of Party B, which payment could be in foreign currency at equivalent amount. Beneficiary: Beijing Baidu Netcom Science and Technology Co., Ltd. Bank: China Merhcants Bank, Beijing Branch, Beisihuan Sub-branch Account number: 866180198510001 ARTICLE VRIGHTS AND OBLIGATIONS 5.1 Each of the Parties warrants that its execution and performance of this Agreement is in no violation of any third party interests or PRClaws.  5.2 Party B will be responsible for server configuration, bandwidth, operation, maintenance, users and user services management anddevelopment necessary for the Cooperation Channel, as well as any expenses and liabilities arising thereof. 5.3 Party B warrants that any and all information provided or released onto the Cooperation Channel during the Cooperation is in noviolation of PRC laws, general code of  9ethics and intellectual property and/or other legal interests of any third party and, upon occurrence of such violation, Party B will delete theviolating information from the Cooperation Channel, resolve any dispute and be liable for any consequence arising thereof, and indemnify Party Afor any loss incurred by Party A thereof. 5.4 Any delay of service by Party B due to any force majeure will be notified to Party A immediately, and Party B will take prompt measuresto ensure performance of this Agreement; 5.5 Party A allows Party B to conduct any activity in the name of real estate and home furnishing website of Party A’s website withoutviolation of any laws and provisions under this Agreement, provided that such conduct will not appear as if Party B represents Baidu or Party Band Baidu has any relationship other than that provided under this Agreement. 5.6 Party B will be responsible for advertising operation of the real estate channel. Party B has sole discretion to conduct advertisingoperation, and any gains, liabilities, duties, taxes and expenses arising therefrom will be owned or paid by Party B. 5.7 Party B will pay the channel cooperation fee provided under this Agreement. 5.8 Party A will provide to Party B the promotional resources provided under this Agreement, including Baidu network promotionalresources, provide promotional support to Party B, and make promotion of Party B on its website. 5.9 Party B will embed Baidu search bar into the homepage of www.leju.com, and any income thereof will be shared between Party A or anyof its affiliates and Party B on monthly basis, the details of which are subject to separate alliance agreement between Party B and Party A or any ofits affiliates. 5.10 Party C will be severally and jointly liable for any and all obligations of Party B under this Agreement. ARTICLE VI OWNERSHIP Party A maintains its ownership of all rights, entitlements and interests of its websites and trademarks. Party B maintains its ownership of all rights,entitlements and interests of its websites, trademarks, and the information and data on the Cooperation Channel. ARTICLE VIIEXCLUSIVITY During the term of this Agreement, Party B and its affiliates will be the exclusive cooperator of Party A’s real estate and home furnishingcooperation channel. Party B and its affiliates will be the exclusive provider of real estate and home furnishing information, products and data inParty A’s real estate and home furnishing channel. Party A may not make any identical or similar cooperation regarding the real estate and homefurnishing information, products and data in its real estate and home furnishing channel with any competitor of Party B. ARTICLE VIIICONFIDENTIALITY 8.1 Unless with express prior written consent from the other Party (which consent 10may not be withheld without reason), none of the Parties may make any public announcement or statement regarding this Agreement orany relationship with this Agreement. 8.2 Subject to written consent from the other Party, any Party may make press release or any other public presentation regarding thecooperation, cooperation channel and Party B’s participation in the Cooperation Channel contemplated under this Agreement. 8.3 Any Party (the “Receiving Party’) will keep in strict confidence any business secret received by it from the other Party (the “DisclosingParty”) and, without prior written consent of the Disclosing Party, may not disclose such information to any third party or, if it fails to doso, be liable for any loss incurred by the Disclosing Party, unless such information: (a) Has been known to the Receiving Party without any non-disclosure obligation prior to its receipt of the same from theDisclosing Party; (b) Has been known to the public without fault of the Receiving Party; (c) Is legally received from any third party without non-disclosure obligation or use restriction; (d) Is developed independently by the Receiving Party; (e) Is disclosed without prior written consent from the Disclosing Party; and (f) Is disclosed under legal requirements having jurisdiction of the Receiving Party, provided that the Receiving Party will notifythe Disclosing Party with prior written notice permitted under applicable laws and regulations of the exact business secret to bedisclosed so as to enable the Disclosing Party to take effective protective measures. 8.4 The provisions under this Article VIII will have effect during and after the term of this Agreement. ARTICLE IXBREACH LIABILITY 9.1 If any Party fails to perform any of its obligations under this Agreement, the breaching Party will cease its breach of this Agreementimmediately upon receipt of a written notice from the non-breaching Party requesting correction of such breach, and will continue toperform, take corrective measures, or indemnify any loss incurred by the non-breaching Party within ten business days. If the breachingParty continues with such breach or fails to perform any of its obligations, the non-breaching Party may terminate this Agreement withimmediate effect upon written notice to the breaching Party, and hold the breaching Party liable for any loss incurred by the non-breachingParty. 9.2 If each of the Parties is liable for breach of this Agreement, it will be held liable according to the extent of its failure thereof. 11ARTICLE X TERMINATION 10.1 Special Provisions The Parties agree that within three months prior to the 4 anniversary of the date hereof, Party B may conduct comprehensive review ofthe Cooperation contemplated hereunder and may elect to continue performing or terminate this Agreement. If Party B elects to terminatethis Agreement, it will notify Party A in writing and this Agreement will terminate upon receipt of such written notice by Party A. Party Bwill settle any and all cooperation fee regarding the Cooperation Channel outstanding prior to 4 anniversary of the date hereof, andarrange appropriate transfer of all matters relating to the operation and construction of the Cooperation Channel to Party A. Suchtermination will not affect performance of any right and obligation occurred prior thereto. 10.2 This Agreement will terminate if: (a) The Parties decide not to extend it upon its expiry; (b) The non-breaching Party terminates this Agreement pursuant to Article IX; (c) Any of the Parties terminates this Agreement pursuant to Article XI; (d) Any of the Parties declares bankruptcy or is in the process of liquidation or dissolution; (e) Any force majeure event continues for more than 30 days and any of the Parties issues a termination notice pursuant to ArticleXIII of this Agreement and terminates this Agreement on the date of receipt provided under this Agreement; and (f) With agreement of the Parties. If any of the Parties terminates this Agreement unilaterally under any of the above circumstances, this Agreement will terminatedimmediately upon receipt of the termination notice by the other Party. 10.3 If any of the Parties declares bankruptcy or is in the process of liquidation or dissolution, any Party may terminate this Agreementwith immediate effect upon notice to the other Party in writing. Any Party encountering such circumstance will immediately notify theother Party of such circumstance. 10.4 Post-Termination Matters (a) Unless otherwise provided under Section 10.1 of this Agreement, upon early termination of this Agreement, Party A will returnto Party B the channel cooperation fee paid by Party B net part of the payment for the obligations which have been performedunder this Agreement. If this Agreement is early terminated for any fault of Party B, Party B may not claim for any reasonrepayment of any channel cooperation fee paid to Party A. Termination of this Agreement will affect any settlement or paymentobligation outstanding under this Agreement, or any obligation or right accrued prior to such termination. (b) Upon termination of this Agreement, Party B will arrange appropriate transfer of all matters relating to the operation andconstruction of the Cooperation Channel to Party A. (c) Upon termination of this Agreement, Articles VIII, IX and XII will 12
th
thcontinue to have binding effect upon the Parties. ARTICLE XIASSIGNMENT AND WARRANTY OF RIGHTS AND OBLIGATION’S 11.1 Without prior written consent of the other Parties, none of the Parties may assign any or all of its rights and obligations under thisAgreement to any third party. 11.2 In the event of any merger or division involving any of the Parties, all rights and obligations of such Party will be assigned inconjunction with such merger or division, provided that such Party will warrant that the rights and obligations of the other Party underthis Agreement will not be affected. Upon occurrence of any of the above circumstances which could affect performance of thisAgreement, such Party is obligated to notify the other Party of such effect. If such merger or division could make it impossible to performthis Agreement, the Party against which this Agreement will not be performed may terminate this Agreement with a prior written notice tosuch Party. 11.3 Neither Party A or Party B may create any security interest upon any of its rights under this Agreement for any third party claim. 11.4 Any Party involving in any merger will notify the other Party immediately of such merger so that the Parties may reach furtheragreement regarding the assignment of the rights and obligations under this Agreement. ARTICLE XIIGOVERNING LAW AND DISPUTE RESOLUTION 12.1 The execution, effect, interpretation and performance of this Agreement and resolution of any dispute arising from this Agreement willbe governed by PRC Laws. 12.2 Any dispute arising from construction or performance of this Agreement will be firstly resolved through negotiations of the Parties. 12.3 If the Parties fail to resolve the dispute through negotiations, any of the Parties may submit the dispute for resolution by litigation atthe local people’s court having jurisdiction over Party A. ARTICLE XIIIFORCE MAJEURE 13.1 Force Majeure will include without limitation any acts of God, such as earthquakes, fires, and rampant epidemics; governmentauthority factors, such as laws, policies and administrative orders; and any other element subject to legal requirements. 13.2 In the event of any Force Majeure which prevents any of the Parties from performing this Agreement, the Party encountering suchForce Majeure will notify the other Party with details of such Force Majeure as soon as reasonably possible. Any delay or failure toperform this Agreement due to Force Majeure will not operate as breach of this Agreement and ground to make any indemnity, claim orpunishment. Under such circumstance, the Party encountering the Force Majeure will be obligated to perform this Agreement withreasonable measures to the extent practicable and, upon end of the Force Majeure, notify the other Parties of the end of the Force Majeurewithin five days. If the Force Majeure causes this Agreement un-performable, the Parties may negotiate to terminate this Agreementwithout any liability on any Party. Any issue post to such termination will be resolved by the Parties through negotiations. 13ARTICLE XIVSUPPLEMENTAL PROVISIONS 14.1 Any failure or delay to perform any of the rights, powers or privileges under this Agreement will not operate as waiver thereof unlessexpressly made by the waiving Party in writing. Any single or partial exercise of any rights, powers or privileges hereunder by any Partywill not preclude its further exercise of any rights, powers or privileges, unless without express waiver by such Party in writing. 14.2 If any of the provisions under this Agreement is held illegal, invalid or unenforceable under any applicable law, the Parties will modifysuch provision so that this Agreement could be valid, effective and enforceable according to the original intent of the Parties as closely aspossible, and the remainder of this Agreement will remain valid and enforceable. 14.3 Any and all terms of this Agreement may not be changed or amended by any Party. Any matter not provided under this Agreement orany amendment, change or supplement hereto will be subject to supplemental agreement with signature and seal of the authorizedrepresentative of each of the Parties, which supplemental agreement will have the same effect with this Agreement. 14.4 Any matter not provided under this Agreement will be resolved under the PRC Laws. 14.5 This Agreement is made in six counterparts with two for each Party, and each original has the same effect. 14.6 This Agreement is dated April 29, 2010. (NO TEXT BELOW) Party A: /s/ Beijing Baidu Netcom Science and Technology Co., Ltd. Party B: /s/ China Online Housing (Hong Kong) Co., Ltd. Party C: /s/ Beijing Yisheng Leju Information Services Co., Ltd. 14Exhibit 10.2
EXECUTION COPY
***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under
17 C.F.R. Sections 200.80(b)(4) and 240.24b-2
Collaboration Agreement
This Agreement is entered into with effect as of the Effective Date (as defined below)
by and between
F. Hoffmann-La Roche Ltd
with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) 
and
Hoffmann-La Roche Inc.
with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche US”; Roche Basel and Roche US
together referred to as “ Roche”) 
on the one hand
and
Foundation Medicine, Inc.
with an office and place of business at 150 Second Street, Cambridge, Massachusetts 02141  (“FMI”)
on the other hand.Table of Contents
 
1. Definitions   7 
1.1 Affiliate   7 
1.2 Agreement   7 
1.3 Agreement Term   7 
1.4 [...***...] ctDNA [...***...]   7 
1.5 Applicable Law   7 
1.6 Approved Assay   7 
1.7 Background IP   7 
1.8 Business Day   8 
1.9 Calendar Half   8 
1.10 Calendar Quarter   8 
1.11 Calendar Year   8 
1.12 CDx   8 
1.13 CDx Development Program   8 
1.14 CLIA   8 
1.15 Clinical Study   9 
1.16 Commercially Reasonable Efforts   9 
1.17 Confidential Information   9 
1.18 Control   9 
1.19 Cover  10 
1.20 ctDNA  10 
1.21 ctDNA Assay  10 
1.22 ctDNA Platform  10 
1.23 ctDNA Platform Development Program  10 
1.24 ctDNA Working Group  10 
1.25 Data Security Breach  10 
1.26 Effective Date  10 
1.27 Excepted Activities  11 
1.28 Excluded Patent Rights  11 
1.29 FDA  11 
1.30 FDCA  11 
1.31 FMI Background IP Patent Rights  11 
1.32 FMI Decisions  11 
1.33 FMI Development Costs  11 
1.34 FMI Know-How  11 
1.35 FMI Foreground Patent Rights  12 
1.36 FTE  12 
1.37 FTE Rate  12 
1.38 Handle  12 
1.39 HSR  12 
1.40 Immunotherapy Testing Platform Development Program  12 
1.41 Immuno-Platform Working Group  12 
1.42 Initiation  12 
1.43 Insolvency Event  12 
1.44 Invention  13 
1.45 IUO  13 
1.46 JMC  13 
1.47 JOC  13 
1.48 Joint Know-How  13 
1.49 Joint Patent Rights  13 
 
***Confidential Treatment Requested***
- 2 -1.50 JOT  13 
1.51 JRDC  13 
1.52 Know-How  13 
1.53 Molecular Information Platform Program  13 
1.54 Molecular Information Platform Working Group  14 
1.55 Party  14 
1.56 Patent Rights  14 
1.57 Performance Specifications  14 
1.58 Personal Data  14 
1.59 Phase I Study  14 
1.60 Phase II Study  14 
1.61 Phase III Study  14 
1.62 PMA  15 
1.63 Quality Standards  15 
1.64 R&D Plan  15 
1.65 Regulatory Approval  15 
1.66 Regulatory Authority  15 
1.67 Roche Background IP Patent Rights  15 
1.68 Roche Group  15 
1.69 Roche Know-How  15 
1.70 Roche Foreground Patent Rights  15 
1.71 ROW Territory  15 
1.72 RUO  15 
1.73 Study Data  16 
1.74 Sublicensee  16 
1.75 Territory  16 
1.76 Third Party  16 
1.77 US  16 
1.78 US$  16 
1.79 Work Stream  16 
1.80 Additional Definitions  16 
2. Grant of License  18 
2.1 Licenses  18 
2.2 Sublicense  20 
2.3 Right to Subcontract  20 
3. Research and Development Collaboration  20 
3.1 Molecular Information Platform Program  20 
3.2 Immunotherapy Testing Platform Development Program  23 
3.3 ctDNA Platform Development Program  25 
3.4 CDx Development Program  27 
3.5 Samples, Handling and Disposal  29 
3.6 Records; Reports; Audits  30 
4. Diligence  31 
5. Most Favored Customer  31 
6. Governance  31 
6.1 Joint Management Committee  31 
6.2 JRDC  33 
6.3 JOC  34 
6.4 Alliance Director  34 
6.5 Limitations of Authority  34 
6.6 Expenses  35 
6.7 Lifetime  35 
 
- 3 -7. Regulatory   35 
8. Payment   35 
8.1 FTE Funding   35 
8.2 Molecular Information Platform Program Fees   35 
8.3 Immunotherapy Testing Platform Development Budget and Fees   36 
8.4 ctDNA Platform Financial Terms   37 
8.5 CDx Development Financial Terms   38 
8.6 General Terms   38 
8.7 Disclosure of Payments   39 
9. Accounting and reporting   39 
9.1 Timing of Payments   39 
9.2 Late Payment   39 
9.3 Method of Payment   39 
10. Taxes   39 
11. Auditing   40 
11.1 Right to Audit   40 
11.2 Audit Reports   41 
11.3 Over or Underpayment   41 
11.4 Duration of Audit Rights   41 
12. Intellectual Property   41 
12.1 Ownership of Inventions, data and results   41 
12.2 German Statute on Employee’s Inventions   43 
12.3 Prosecution and Maintenance of Patent Rights Claiming FMI Inventions   43 
12.4 Prosecution and Maintenance of Roche Foreground Patent Rights and Joint Patent Rights   44 
12.5 Joint Patent Team   44 
12.6 CREATE Act   44 
12.7 Infringement   44 
12.8 Defense   46 
12.9 Common Interest Disclosures   46 
13. Representations and Warranties   47 
13.1 Mutual Representations and Warranties   47 
13.2 Activities   48 
13.3 Safety Data   48 
13.4 Third Party Patent Rights   48 
13.5 Inventors   48 
13.6 Grants   48 
13.7 Ownership and Validity of Know-How   48 
13.8 Data Protection (Privacy) and Security   48 
13.9 No Other Representations   50 
14. Indemnification   50 
14.1 Indemnification by Roche   50 
14.2 Indemnification by FMI   51 
14.3 Procedure   51 
15. Liability   51 
16. Obligation Not to Disclose Confidential Information   51 
16.1 Non-Use and Non-Disclosure   51 
16.2 Permitted Disclosure &sbsp;52 
16.3 Press Releases   52 
16.4 Publications   52 
16.5 Commercial Considerations   53 
 
- 4 -17. Term and Termination  53 
17.1 Commencement and Term  53 
17.2 Termination  53 
17.2.1 Termination for Breach  53 
17.2.2 Insolvency  53 
17.2.3 Termination by Roche without Cause  54 
17.2.4 Termination by Roche for Frustration of Purpose  54 
17.3 Consequences of Termination  54 
17.3.1 Termination in General  54 
17.3.2 Termination by FMI for Breach by Roche or Roche’s Insolvency; Termination by Roche Without Cause or for Frustration of
Purpose  54 
17.3.3 Termination by Roche for Breach by FMI or FMI Insolvency  56 
17.3.4 Direct License  57 
17.4 Other Obligations  57 
17.5 Survival  57 
18. Bankruptcy  57 
19. Miscellaneous  58 
19.1 Governing Law  58 
19.2 Disputes  58 
19.3 Arbitration  58 
19.4 Assignment  59 
19.5 Debarment and Exclusion  59 
19.6 Independent Contractor  60 
19.7 Unenforceable Provisions and Severability  60 
19.8 Waiver  60 
19.9 Appendices  60 
19.10 Entire Understanding  61 
19.11 Amendments  61 
19.12 Invoices  61 
19.13 Notice  61 
 
- 5 -Collaboration Agreement
WHEREAS, FMI has or is developing platforms for use in genomic testing, including development of a molecular information platform, an
immunotherapy testing platform, a circulating tumor DNA platform, and a companion diagnostics platform; and
WHEREAS, Roche has expertise in the research, development, manufacture and commercialization of pharmaceutical and diagnostic products,
including development of an immunotherapy platform; and
WHEREAS, Roche and FMI want to collaborate on the development of platforms for use in molecular information, immunotherapy, circulating
tumor DNA, companion diagnostics, and  in vitro diagnostic tests and kits; and  
WHEREAS, Roche Holdings, Inc., an Affiliate of Roche, and FMI are concurrently herewith entering into a Transaction Agreement dated as of the
date hereof (as it may be amended from time to time, the “Transaction Agreement”) which provides, among other things, for Roche to acquire a
majority ownership of FMI upon the terms and subject to the conditions set forth in the Transaction Agreement; and  
WHEREAS, in connection therewith, and as an inducement to Roche’s and FMI’s willingness to enter into the Transaction Agreement and to
consummate the transactions contemplated thereby, FMI and Roche agree that Roche will work with FMI in the United States to educate relevant
persons on next generation sequencing and/or comprehensive genomic profiling technology (“ US Education Collaboration Agreement”), Roche
and FMI will collaborate on the commercialization of certain FMI products outside of the United States (“ Ex-US Commercialization Agreement”),
and Roche and FMI may collaborate on development and commercialization of decentralized  in vitro diagnostic (“IVD”) versions of FMI tests
generated by FMI (“IVD Collaboration”), the above mentioned agreements, including the Transaction Agreement, being referred to collectively as
the “Related Agreements”; and 
WHEREAS, FMI and Roche intend that assays and other products generated under this Agreement will be commercialized in accordance with the
Ex-US Commercialization Agreement and that the governance structure under this Agreement will apply to the US Education Collaboration
Agreement and the Ex-US Commercialization Agreement.
 
- 6 -NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as
follows:
 
1. Definitions
As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings:
 
1.1 Affiliate
The term “Affiliate” shall mean any individual, corporation, association or other business entity that directly or indirectly controls, is controlled by,
or is under common control with the Party in question. As used in this definition of “Affiliate,” the term “control” shall mean the direct or indirect
ownership of more than fifty percent (>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the
management of the corporation or other business entity whether through the ownership of voting securities, by contract, resolution, regulation or
otherwise. Anything to the contrary in this paragraph notwithstanding, Chugai Pharmaceutical Co., Ltd, a Japanese corporation (“ Chugai”), shall
not be deemed an Affiliate of Roche unless Roche provides written notice to FMI of its desire to include Chugai as an Affiliate of Roche. Moreover,
FMI and its Affiliates existing as of the Effective Date shall not be deemed Affiliates of Roche and its Affiliates existing as of the Effective Date,
and Roche and its Affiliates existing as of the Effective Date shall not be deemed Affiliates of FMI and its Affiliates existing as of the Effective
Date. Affiliates coming into existence after the Effective Date shall be classified by the Parties as either Roche Affiliates or FMI Affiliates for the
purposes of this Agreement.
 
1.2 Agreement
The term “Agreement” shall mean this document including any and all appendices and amendments to it as may be added and/or amended from
time to time in accordance with the provisions of this Agreement.
 
1.3 Agreement Term
The term “Agreement Term” shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as
provided in Article 17, expiring on the date when all work has been completed or terminated under all R&D Plans.
 
1.4 […***…] ctDNA […***…]
The term “[…***…] ctDNA […***…]” shall mean an analytical validated clinical ctDNA Assay […***…].
 
1.5 Applicable Law
The term “Applicable Law” shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority
(including without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the Agreement Term, in
each case to the extent that the same are applicable to the performance by the Parties of their respective obligations under this Agreement.
 
1.6 Approved Assay
The term “Approved Assay” means any assay or test intended for use in the diagnosis or evaluation of a disease or condition, excluding any IUO,
and with respect to which any necessary Regulatory Approval is received in the relevant country, including PMA approval in the US, if applicable.
 
1.7 Background IP
The term “Background IP” shall mean all intellectual property rights, including Patent Rights and Know-How, Controlled by a Party as of the
Effective Date and all intellectual property rights Controlled by a Party after the Effective Date but arising from activities other than the activities
conducted under this Agreement. Roche Background IP specifically excludes the Excluded Patent Rights and no licenses are granted to FMI under
such Excluded Patent Rights.
 
***Confidential Treatment Requested***
- 7 -1.8 Business Day
The term “Business Day” shall mean 9.00am to 5.00pm local time on a day other than a Saturday, Sunday or bank or other public or federal holiday
in Switzerland, New Jersey or Massachusetts.
 
1.9 Calendar Half
The term “Calendar Half” shall mean each period of six (6) consecutive calendar months, ending June 30 and December 31.
 
1.10 Calendar Quarter
The term “Calendar Quarter” shall mean each period of three (3) consecutive calendar months, ending March 31, June 30, September 30 and
December 31.
 
1.11 Calendar Year
The term “Calendar Year” shall mean the period of time beginning on January 1 and ending December 31, except for the first Calendar Year which
shall begin on the Effective Date and end on December 31.
 
1.12 CDx
The term “CDx” shall mean any Products or Services that require Regulatory Approval, including by any medical device Regulatory Authority,
under the device authorities of the Federal Food, Drug, and Cosmetic Act (or equivalent medical device or  in vitro diagnostic medical device regime
in other countries) for use in connection with a decision to treat, or the specifics of the actual treatment, of person, with a specific product, as more
fully described below:
 
 
(i) identifying a person having a specific disease or condition, or a molecular genotype or phenotype that predisposes a person to
such disease or condition, to support a decision to treat such person with such specific product, whether for prophylactic or
therapeutic purposes;
 
  (ii) defining the prognosis or monitoring the progress of a disease or condition in a person to support a decision to treat, or to
continue to treat, such person with such specific product, whether for prophylactic or therapeutic purposes;
 
  (iii) supporting the selection of a particular therapeutic or prophylactic regimen, wherein at least one (1) potential therapeutic or
prophylactic regimen involves the use of such specific product; and/or
 
  (iv) confirming such specific product’s biological activity and/or optimizing dosing or the scheduled administration of such specific
product.
 
1.13 CDx Development Program
The term “CDx Development Program” shall mean the program for development by FMI of CDx Assays for select Roche products.
 
1.14 CLIA
The term “CLIA” shall mean Clinical Laboratory Improvement Amendments as set forth by the Centers for Medicare & Medicaid Services which
regulates all laboratory testing (except research) performed on humans in the U.S. and is certified by the Division of Laboratory Services, within the
Survey and Certification Group, under the Center for Clinical Standards and Quality.
 
- 8 -1.15 Clinical Study
The term “Clinical Study” shall mean a Phase I Study, Phase II Study, Phase III Study, as applicable.
 
1.16 Commercially Reasonable Efforts
The term “Commercially Reasonable Efforts” shall mean, with respect to the performance of an obligation under this Agreement, such quality and
level of effort as is required to carry out such obligation in a sustained manner, consistent with the efforts Roche or FMI, as applicable, devotes to a
similar obligation in connection with an internally developed product or service that is at the same stage of development or commercialization, as
applicable, in a similar market, with similar market potential, at a similar stage of product life, taking into account the existence of other competitive
products or services in the market place or under development, the proprietary position of the product or service, the regulatory structure involved,
the anticipated profitability of the product or service and other relevant factors. It is understood that such quality and level if effort may change
from time to time based upon changing scientific, business and marketing and return on investment considerations.
 
1.17 Confidential Information
The term “Confidential Information” shall mean any and all information, data or know-how (including Know-How), whether technical or non-
technical, oral or written, that is disclosed by one Party or its Affiliates (“ Disclosing Party”) to the other Party or its Affiliates (“Receiving Party”).
Confidential Information shall not include any information, data or know-how that:
 
  (i) was generally available to the public at the time of disclosure, or information that becomes available to the public after disclosure
by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving Party or its Affiliates,
 
  (ii) can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior to its receipt from
the Disclosing Party,
 
  (iii) is obtained by the Receiving Party at any time lawfully from a Third Party under circumstances permitting its use or disclosure,
 
  (iv) is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than through
knowledge of Confidential Information, or
 
  (v) is approved in writing by the Disclosing Party for release by the Receiving Party.
The terms of this Agreement shall be considered Confidential Information of the Parties.
 
1.18 Control
The term “Control” shall mean (as an adjective or as a verb including conjugations and variations such as “Controls” “Controlled” or
“Controlling”) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such
Patent Rights and/or Know-How as provided herein without violating the terms of any agreement or arrangement between such Party and any
other party, where such ability derives from rights other than an assignment or license granted herein and (b) with respect to proprietary materials,
the possession by a Party of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any
agreement or arrangement between such Party and any other party.
 
- 9 -1.19 Cover
The term “Cover” shall mean (as an adjective or as a verb including conjugations and variations such as “Covered,” “Coverage” or “Covering”)
that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given product would infringe a valid claim under
the Patent Rights. As used in the previous sentence, “valid claim” means, with respect to a particular country a claim in an issued and unexpired
patent that has not lapsed or been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental
agency of competent jurisdiction, unappealable or unappealed within the time allowed fo appeal and that has not been admitted to be invalid or
unenforceable through re-examination, re-issue, disclaimer or otherwise, or lost in an interference proceeding.
 
1.20 ctDNA
The term “ctDNA” shall mean circulating tumor DNA.
 
1.21 ctDNA Assay
The term “ctDNA Assay” shall mean an assay developed on or utilizing FMI’s ctDNA Platform (including instruments and software) for the
detection of genomic alteration in ctDNA, including an RUO, IUO and Approved Assay.
 
1.22 ctDNA Platform
The term “ctDNA Platform” shall mean Products or Services for testing of specimens to identify genomic alterations in ctDNA as a blood-based
liquid biopsy, including FMI instruments, analytical methods, algorithms, procedures, techniques, software or platforms, intended for use in
genomic analysis, and related technologies and any improvements to the foregoing, in each case Controlled by FMI as of the Effective Date or
during the Agreement Term.
 
1.23 ctDNA Platform Development Program
The term “ctDNA Platform Development Program” shall mean the program for development of ctDNA analysis platform by FMI for effective
genomic profiling from liquid biopsy.
 
1.24 ctDNA Working Group
The term “ctDNA Working Group” shall mean the group of persons from both Parties who will handle the day-to-day activities associated with the
ctDNA Platform Development Program a set forth herein.
 
1.25 Data Security Breach
The term “Data Security Breach” means (a) the disclosure or misuse (by any means) of Personal Data; (b) the inadvertent, unauthorized and/or
unlawful processing, access, disclosure, alteration, corruption, transfer, sale or rental, destruction or use of Personal Data; or (c) any other act or
omission that compromises the security, confidentiality, and/or integrity of Personal Data.
 
1.26 Effective Date
The term “Effective Date” shall mean the latest of (a) the date of the last signature of this Agreement, or (b) if a HSR filing is made, the second
Business Day immediately following the earlier of: (i) the date upon which the waiting period under HSR expires or terminates early or (ii) the date
upon which all requests to the Parties by the Federal Trade Commission or the Justice Department, as the case may be, with regard to the
transaction contemplated by this Agreement
 
- 10 -have been satisfactorily met and no objection on the part of the Federal Trade Commission or the Justice Department remains, or (c) the occurrence
of the Acceptance Time (as defined in the Transaction Agreement).
 
1.27 Excepted Activities
The term “Excepted Activities” shall mean […***…].
 
1.28 Excluded Patent Rights
The term “Excluded Patent Rights” shall mean those Patent Rights listed in Appendix 1.28.
 
1.29 FDA
The term “FDA” shall mean the Food and Drug Administration of the United States of America.
 
1.30 FDCA
The term “FDCA” shall mean the Food, Drug and Cosmetics Act.
 
1.31 FMI Background IP Patent Rights
The term “FMI Background IP Patent Rights” means Patent Rights that Cover Background IP that is Controlled by FMI.
 
1.32 FMI Decisions
The term “FMI Decisions” shall mean decisions with respect to any of the following issues that come before the JMC:
 
  (i) […***…].
 
  (ii) […***…].
 
  (iii) […***…].
 
  (iv) […***…].
 
1.33 FMI Development Costs
The term “FMI Development Costs” means all costs reasonably incurred or committed to by FMI to perform its obligations and activities
hereunder, including without limitation, (i) personnel costs equal to the number of FTE’s used to perform such obligations and activities multiplied
by the FTE Rate, (ii) out-of-pocket costs for consultants, materials and services and (iii) facilities costs reasonably allocated to performance of such
obligations and activities, including acquisition, maintenance and operation costs for such facilities.
 
1.34 FMI Know-How
The term “FMI Know-How” shall mean the Know-How that FMI Controls at the Effective Date and during the Agreement Term.
 
***Confidential Treatment Requested***
- 11 -1.35 FMI Foreground Patent Rights
The term “FMI Foreground Patent Rights” shall mean the Patent Rights that FMI Controls and that Cover Inventions conceived of and reduced to
practice after the Effective Date in the performance of the activities under this Agreement, excluding any Joint Patent Rights and any FMI
Background IP Patent Rights.
 
1.36 FTE
The term “FTE” shall mean a full-time equivalent person-year, based upon a total of no less than one thousand eight hundred (1,800) working hours
per year, undertaken in connection with the conduct of research in a Work Stream. In no circumstance can the work of any given person exceed one
(1) FTE.
 
1.37 FTE Rate
The term “FTE Rate” shall mean the amount of […***…], on a fully burdened cost basis, which amount shall be subject to increase following the
[…***…] anniversary of the Effective Date by an amount equal to the increase in the Consumer Price Index as published by the U.S. Department of
Labor, Bureau of Labor Statistics (the “CPI”) between the Effective Date and such date for a new FTE Rate not to exceed […***…] per FTE, and
which such new FTE Rate shall be subject to subsequent increases upon the date of each renewal or extension period comprising the Agreement
Term by an amount equal to the increase in the CPI as of such date.
 
1.38 Handle
The term “Handle” shall mean all activities associated with prosecution and maintenance of a particular patent and patent application(s) derived
from such patent, including preparing, filing, prosecuting and maintaining (including interferences, reissue, re-examination, pre- and post-grant
proceedings, inter-parties reviews, derivation proceedings, applications for patent term adjustment and extensions, supplementary protection
certificates and oppositions and other similar proceedings).
 
1.39 HSR
The term “HSR” shall mean the Hart-Scott-Rodino Antitrust Improvements Act.
 
1.40 Immunotherapy Testing Platform Development Program
The term “Immunotherapy Testing Platform Development Program” shall mean the program for development of an immunotherapy testing platform.
 
1.41 Immuno-Platform Working Group
The term “Immuno-Platform Working Group” shall mean the group of persons from both Parties who will handle the day-to-day activities
associated with the Immunotherapy Testing Platform Development Program.
 
1.42 Initiation
The term “Initiation&1148; shall mean the date that a human is first dosed with the drug in a Clinical Study approved by the respective Regulatory
Authority.
 
1.43 Insolvency Event
The term “Insolvency Event” shall mean circumstances under which a Party (i) has a receiver or similar officer appointed over all or a material part
of its assets or undertaking; (ii) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent
amalgamation or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any
jurisdiction); (iii) enters into
 
***Confidential Treatment Requested***
- 12 -any composition or arrangement with its creditors (other than relating to a solvent restructuring); (iv) ceases to carry on business; (v) is unable to
pay its debts as they become due in the ordinary course of business.
 
1.44 Invention
The term “Invention” shall mean an invention that is made, i.e. conceived and reduced to practice, in performance of activities under this
Agreement. Under this definition, an Invention may be made by solely by individuals having an obligation to assign rights in such invention to
FMI (an “FMI Invention”), solely by individuals having an obligation to assign rights in such invention to Roche (a “Roche Invention”), or jointly
by individuals having an obligation to assign rights in such invention to FMI and individuals having an obligation to assign rights in such
invention to Roche (a “Joint Invention”).
 
1.45 IUO
The term “IUO” shall mean an assay for investigational use only that meets certain clinical and manufacturing standards and which is used in
clinical studies to gather data for submission to a Regulatory Agency in support of an Approved Assay.
 
1.46 JMC
The term “JMC” shall mean the joint management committee described in Article 6.
 
1.47 JOC
The term “JOC” shall mean the joint operating committee as mentioned in Section 6.3 and described in the Ex-US Commercialization Agreement.
 
1.48 Joint Know-How
The term “Joint Know-How” shall mean Know-How that is made jointly by the Parties or their Affiliates or their Sublicensees in performance of
activities carried out pursuant to this Agreement.
 
1.49 Joint Patent Rights
The term “Joint Patent Rights” shall mean all Patent Rights Covering a Joint Invention.
 
1.50 JOT
The term “JOT” shall mean a joint operating team described in Section 6.1.7.
 
1.51 JRDC
The term “JRDC” shall mean the joint research and development committee described in Section 6.2.
 
1.52 Know-How
The term “Know-How” shall mean data, knowledge, algorithms, business rules and information, including manufacturing data, toxicological data,
pharmacological data, preclinical data, formulations, specifications, quality control testing data, which are necessary or useful for the discovery,
manufacture, development or commercialization of Products and Services.
 
1.53 Molecular Information Platform Program
The term “Molecular Information Platform Program” shall mean the program designed to generate insights for certain of Roche’s clinical
development portfolio from FMI’s molecular information platform, comprised of tumor sample genomic analysis, database access, and dedicated
FMI clinical and genomic expertise.
 
- 13 -1.54 Molecular Information Platform Working Group
The term “Molecular Information Platform Working Group” shall mean the group of persons from both Parties who will handle the day-to-day
activities associated with the Molecular Information Platform Program.
 
1.55 Party
The term “Party” shall mean FMI or Roche, as the case may be, and “Parties” shall mean FMI and Roche collectively.
 
1.56 Patent Rights
The term “Patent Rights” shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing
on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination,
renewal, division, continuation or continuation-in-part of any of the foregoing.
 
1.57 Performance Specifications
The term “Performance Specifications” shall mean a set of minimum standards and specifications related to FMI’s supply and delivery of Products
and Services under this Agreement as set forth in the R&D Plans for each Work Stream or Task Orders, including standards with respect to classes
of alterations detected and sequencing sensitivity and specificity (based on tissue requirements); provided, however, the Performance
Specifications for the Molecular Information Platform Program are attached hereto as Exhibit 1.57.
 
1.58 Personal Data
The term “Personal Data” shall mean any information that can be used to identify, locate or contact an individual (a “ Data Subject”), including but
limited to, (a) first name or initial and last name; (b) home or other physical address; (c) telephone number; (d) email address or online identifier
associated with the individual; (e) social security number or other similar identifier; (f) employment financial or health information; or (g) any other
information relating to an individual that is combined with any of the above.
 
1.59 Phase I Study
The term “Phase I Study” shall mean a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. § 312.21(a) (FDCA), as
amended from time to time, and the foreign equivalent thereof.
 
1.60 Phase II Study
The term “Phase II Study” shall mean a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a
preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the
foreign equivalent thereof.
 
1.61 Phase III Study
The term “Phase III Study” shall mean a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe
and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or
condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.
 
- 14 -1.62 PMA
The term “PMA” shall mean a premarket approval application as defined under section 515 of the FDCA.
 
1.63 Quality Standards
The term “Quality Standards” shall mean CLIA or QSR requirements, each as applicable, and other Applicable Laws. If requested by Roche, the
JRDC will establish which such quality standards specifically apply to Products and Services within a given Work Stream.
 
1.64 R&D Plan
The term “R&D Plan” shall mean a plan of research and development for each Work Stream other than the Molecular Information Platform Program.
The initial R&D Plans are attached as Appendix 1.64 and outline the work expected to be performed by FMI for the relevant Work Stream. Such
plans may be updated from time to time as provided in this Agreement.
 
1.65 Regulatory Approval
The term “Regulatory Approval” shall mean any approvals, licenses, registrations, authorizations, or certifications by Regulatory Authority or any
CE markings, necessary for the manufacture, sale or putting into service of a product in a regulatory jurisdiction in the Territory.
 
1.66 Regulatory Authority
The term “Regulatory Authority” shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the
European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity
including the FDA, in each country involved in the granting of Regulatory Approval for a product or service.
 
1.67 Roche Background IP Patent Rights
The term “Roche Background IP Patent Rights” means Patent Rights that Cover Background IP that is Controlled by Roche.
 
1.68 Roche Group
The term “Roche Group” shall mean collectively Roche, its Affiliates and its Sublicensees, excluding FMI and FMI Affiliates.
 
1.69 Roche Know-How
The term “Roche Know-How” shall mean all Know-How that Roche Controls during the Agreement Term.
 
1.70 Roche Foreground Patent Rights
The term “Roche Foreground Patent Rights” shall mean the Patent Rights that Roche Controls (other than through licenses granted under this
Agreement) and that Cover Inventions conceived of and reduced to practice after the Effective Date in the performance of the activities under this
Agreement, excluding any Joint Patent Rights and the Excluded Patent Rights.
 
1.71 ROW Territory
The term “ROW Territory” shall mean […***…].
 
1.72 RUO
The term “RUO” shall mean an assay intended or approved for research use only.
 
***Confidential Treatment Requested***
- 15 -1.73 Study Data
The term “Study Data” shall mean all data related to any Data Subject collected by or transferred to the Roche Group or business partners, in
connection with any services that FMI may provide to Roche.
 
1.74 Sublicensee
The term “Sublicensee” shall mean an entity to which Roche or FMI, as applicable, has licensed rights (through one or multiple tiers), other than
through a Compulsory Sublicense, pursuant to this Agreement.
 
1.75 Territory
The term “Territory” shall mean […***…].
 
1.76 Third Party
The term “Third Party” shall mean a person or entity other than (i) FMI or any of its Affiliates or (ii) a member of the Roche Group.
 
1.77 US
The term “US” shall mean the United States of America and its territories and possessions.
 
1.78 US$
The term “US$” shall mean US dollars.
 
1.79 Work Stream
The term “Work Stream” shall mean each of the Molecular Information Platform Program, Immunotherapy Testing Platform Development Program,
the ctDNA Platform Development Program, and the CDx Development Program.
 
1.80 Additional Definitions
Each of the following definitions is set forth in the Section of this Agreement indicated below:
 
Definition   Section
AAA   19.3
Accounting Period   9.1
Advanced Genomic Analyses   3.1.4
Alliance Director   6.2
Approved Markers   3.4.1
Assessment   10
Bankruptcy Code   18
Binding Orders   3.1.5
Biomarker IP   2.1.2
Breaching Party   17.2.1
CDx Assays   3.4.1
CDx Platform Working Group   3.4.2
Chairperson   6.1.1
Competent Authority Procedures   10
ctDNA Milestone Date   8.4
Create Act   12.6
Database Renewal Term   3.1.9
Database Queries   3.1.8
 
***Confidential Treatment Requested***
- 16 -Definition   Section
Data Subject   1.57
Decision Period   12.5
Disclosing Party   1.17
Ex-US Collaboration Agreement   Whereas Clause
First ctDNA Milestone Date   8.4
FMI CDx IP   12.1.5
FMI-Derived Advanced Genomic Analysis Results   3.1.8
FMI Improvement IP   12.1.2
FMI Invention   1.44
Immuno-Biomarker Discovery Platform   3.2.1
Immuno-Clinical Study Assays   0
Immunotherapy Exclusivity Period   3.2.8
Immunotherapy Testing Platform Development Budget   8.3.1
Genomic Analyses   3.1.4
Indemnified Party   14.3
Indemnifying Party   14.3
Initial Roche ctDNA Assay   8.4
Initiating Party   12.5
Investigational Markers   3.4.1
IVD Collaboration   Whereas Clause
Joint Invention   1.44
Materially Modified   8.3.2(i)
Members   6.1.1
Molecular Information Database   3.1.8
Molecular Information Database Access   3.1.8
Non-Breaching Party   17.2.1
Payment Currency   9.3
Peremptory Notice Period   17.2.1
Products and Services   7
Profiling Renewal Term   3.1.9
Profiling Term   3.1.9
Publishing Notice   16.4
Publishing Party   16.4
Receiving Party   1.17
Related Agreements   Whereas Clause
Reserved Capacity   3.1.4
Reserved Capacity Fees   8.2.1.1
Roche CDx Development IP   12.1.5
Roche ctDNA Sample Results   12.1.4
Roche Immunotherapy Sample Results   12.1.3
Roche Improvement IP   12.1.2
Roche Invention   1.44
Roche-Owned Advanced Genomic Analysis Results   12.1.2
Roche’s Jurisdiction   10
Sample Profiling   3.1.4
 
- 17 -Definition   Section
Sample Results   3.1.6
Second ctDNA Milestone Date   8.4
Settlement   12.5
Signature Identification   3.2.1
Suit Notice   12.5
Task Orders   3.1.3
TPP   6.1.5.2
Transaction Agreement   Whereas Clause
US Education Collaboration Agreement   Whereas Clause
 
2. Grant of License
 
2.1 Licenses
 
  2.1.1 Research and Development Cross License
Each Party grants to the other Party during the time that a Work Stream is in effect, a non-exclusive right and license under Know-How and Patent
Rights, including the Background IP, Controlled by such Party and that are necessary or useful solely to enable the other Party to perform the
activities contemplated under this Agreement; […***…].
 
  2.1.2 Molecular Information Platform Licenses
Roche hereby grants to FMI a non-exclusive, royalty-free, worldwide and perpetual license, sublicensable to FMI’s Affiliates, under any intellectual
property rights arising directly from the Sample Results, or the correlation of the Sample Results to patient data (“ Biomarker IP”) (i) to the extent
such Biomarker IP becomes publicly known, for internal research purposes, (ii) to the extent such Biomarker IP becomes publicly known, to develop,
make, have made, use, offer for sale, sell, import, and commercialize FMI’s Products and Services relating to genomic analysis, and (iii) […***…].
Roche hereby grants to FMI a non-exclusive, royalty-free, worldwide and perpetual license, sublicensable to Affiliates, to use the Roche-Owned
Advanced Genomic Analysis Results to develop, make, have made, use, offer for sale, sell, import and commercialize FMI’s products and services
relating to genomic analysis.
FMI hereby grants to Roche a non-exclusive, royalty-free, worldwide and perpetual license, sublicensable to Roche’s Affiliates under any FMI
Improvements for Roche’s internal research purposes and to develop, make, have made, use, offer for sale, sell, import and commercialize Roche’s
products and services other than diagnostic products and services.
 
  2.1.3 Immunotherapy Testing Platform Licenses
Effective after the Immunotherapy Exclusivity Period, Roche hereby grants to FMI a non-exclusive, royalty-free, worldwide, perpetual, and
sublicensable to Affiliates, license to any intellectual property arising from the Immunotherapy Testing Platform Development Program Controlled
by Roche (excluding Roche Immunotherapy Sample Results) to the extent necessary
 
***Confidential Treatment Requested***
- 18 -for FMI to develop, make, have made, use, offer for sale, sell, import and commercialize the Immuno-Biomarker Discovery Platform, Signature
Identification services, Clinical Study assays, CDx assays, or any other FMI testing or services (including that are part of the Genomic Analysis
Platform).
FMI hereby grants to Roche a non-exclusive, royalty-free, worldwide, perpetual, and sublicensable license to any intellectual property arising from
the Immunotherapy Testing Platform Program Controlled by FMI for internal research purposes and to the extent necessary for Roche to research,
develop, make, have made, use, offer for sale, sell, import and commercialize Roche products other than diagnostic products.
If FMI is unable or unwilling to develop and commercialize an Immuno Clinical Study assay or CDx assay resulting from the Immunotherapy Testing
Platform Development Program in a given country within the Territory as specified in an R&D Plan for any reason other than a breach of this
Agreement by Roche, and on the timeline agreed to in such R&D Plan, then, effective on the end of the timeline specified in such R&D Plan, FMI
hereby grants to Roche a non-exclusive, royalty-free, perpetual, and sublicensable license under any intellectual property invented by FMI arising
from the Immunotherapy Testing Platform Program or the Immunotherapy Testing Platform Development that is necessary for Roche to develop and
commercialize such tests in such country in the Territory.
 
  2.1.4 ctDNA Licenses
FMI hereby grants to Roche (i) an exclusive, royalty-free, sublicensable, worldwide and perpetual license to any intellectual property rights arising
from the ctDNA Development Platform Program that are necessary for Roche to develop, make, have made, use, offer for sale, sell, import and
commercialize Roche products other than diagnostic products (including the use, formulation, methods of treatment, clinical data or other data,
information or results relating to the Roche therapeutic product) solely for use in connection with such activities and such Roche products and (ii)
a non-exclusive, royalty-free, worldwide and perpetual license, with the right to grant sublicenses solely to Roche Affiliates, to any intellectual
property rights arising from the ctDNA Development Platform Program, for internal research purposes.
Roche hereby grants to FMI a non-exclusive, royalty-free, worldwide, perpetual, and sublicensable license to any IP Controlled by Roche and
developed under the ctDNA Platform Development Program (excluding Roche Immunotherapy Sample Results) to the extent necessary for FMI to
research, develop, make, have made, use, offer for sale, sell, import and commercialize the ctDNA Assays.
 
  2.1.5 CDx Development Program
FMI hereby grants to Roche a non-exclusive license under the FMI CDx IP for internal research purposes, and to the extent necessary to research,
develop, make, have made, use, offer for sale, sell, import and commercialize Roche products other than diagnostic products.
If FMI is unwilling or unable to develop and commercialize a CDx Assay for a given country in the Territory as specified in the R&D Plan, and on
the timeline set forth in the relevant R&D Plan, for any reason other than a breach of this Agreement by Roche, then FMI hereby grants to Roche a
non-exclusive, royalty-free, sublicensable, and perpetual license under any intellectual property invented by FMI arising from the CDx
Development Program that is necessary for Roche to develop and commercialize a CDx Assay equivalent in such country in the Territory.
 
- 19 -2.2 Sublicense
Except as otherwise provided herein, where the right to sublicense is granted under this Agreement, the licensee shall have the right to sublicense,
and subcontract (subject to Section 2.3), through multiple tiers. Each sublicense granted hereunder to a Third Party shall be pursuant to a written
agreement. Each sublicense granted hereunder by a Party shall include restrictions on the disclosure of the other Party’s Confidential Information
that are substantially similar to the protections provided herein. Each Party shall be liable for any action or failure to act by a sublicensee under a
sublicense granted by such Party to the extent such action or failure to act on the part of such Party would constitute a breach of this Agreement
by such Party.
 
2.3 Right to Subcontract
Each Party shall have the right to subcontract the work performed under this Agreement in accordance with the applicable R&D Plan. Each such
subcontract with a Third Party shall be pursuant to a written agreement. Each such subcontract by a Party shall include restrictions on the
disclosure of the other Party’s Confidential Information that are substantially similar to the protections provided herein. Each Party shall be liable
for any action or failure to act by a subcontractor under a subcontract entered into by such Party to the extent such action or failure to act on the
part of such Party would constitute a breach of this Agreement by such Party.
 
3. Research and Development Collaboration
 
3.1 Molecular Information Platform Program
 
  3.1.1 Scope
Roche and FMI shall conduct the Molecular Information Platform Program pursuant to this Agreement under the direction of the Molecular
Information Platform Working Group.
 
  3.1.2 Molecular Information Platform Working Group
The Parties shall establish the Molecular Information Platform Working Group within sixty (60) days after the Effective Date to operationalize the
Molecular Information Platform Program. The Molecular Information Platform Working Group’s activities will be overseen by JRDC.
 
  3.1.3 Task Orders
The Parties will conduct the Molecular Information Platform Program in accordance with agreed upon task orders (“ Task Orders”) and in
compliance with Performance Specifications and Quality Standards. Each Task Order will be substantially in the form set forth in Appendix 3.1.3. To
the extent any terms set forth in a Task Order conflict with the terms set forth in this Agreement, the terms of this Agreement shall control.
 
  3.1.4 Sample Profiling and Reserved Capacity
FMI shall provide, and shall reserve capacity to provide, Roche with comprehensive profiling, analysis and reporting (“ Sample Profiling”) of at
least […***…] during the first […***…] immediately following the Effective date, and at least […***…] samples during the next […***…]
 
***Confidential Treatment Requested***
- 20 -(“Reserved Capacity”) using FMI’s platform for molecular genomic profiling of cancer samples (the “Genomic Analysis Platform”). The initial
laboratory and computational biology activities performed on the Samples as part of Sample Profiling are “ Genomic Analyses”. FMI will provide
Sample Profiling in accordance with the Reserved Capacity during the Profiling Term and Profiling Renewal Term, using the then-current versions of
the tests included in its Genomic Analysis Platform. The Sampling Profiles shall be provided in a specified format to be mutually agreed by the
Parties. The JMC will discuss and decide upon the Reserved Capacity commitment for Profiling Renewal Terms, provided that any Reserved
Capacity amount in excess of […***…] that would require FMI to increase its existing capacity will require FMI approval.
Sample Profiling will include advanced genomic analyses, i.e. advanced laboratory and computational biology activities in the field of cancer
genomic sequencing and analysis performed on Samples, including […***…] (collectively, “ Advanced Genomic Analyses”). Sample Profiling
includes Genomic Analyses and Advanced Genomic Analyses.
FMI may adopt modifications to the Performance Specifications without Roche’s consent, so long as such modifications do not result in a material
diminution in the analytical performance of the Genomic Analysis Platform as measured by the metrics set forth in Appendix 1.57 (which such
material diminution would require the prior written consent of Roche). In the event […***…], and such change results in a material diminution in
the analytical performance of the Genomic Analysis Platform as measured by the metrics set forth in Appendix 1.57, Roche may, at its election, and
upon written notice to FMI, terminate each Party’s obligations under Reserved Capacity, including Roche’s obligations under Section 8.2.1.1 to pay
Reserved Capacity Fees and opt out of the price per Sample fees for Sample Profiling otherwise specified in Section 8.2.1.2, in each case, from the
effect of such sequencing platform change. If Roche elects to terminate the Parties’ obligations under Reserved Capacity and opts out of the per
Sample pricing for Sample Profiling specified in Section 8.2.1.2, Sample Profiling shall then be performed, and fees for such Sample Profiling shall
then be charged, on a per Sample basis at FMI’s standard rates or on pricing terms to be mutually agreed in writing by the Parties (or as otherwise
mutually agreed in writing by the Parties).
 
  3.1.5 Forecasting and Binding Orders
Not later than the first Business Day of […***…] during the Profiling Term and Profiling Renewal Terms, Roche will provide FMI with a rolling
forecast of its estimated requirements for Sample Profiling for the following […***…], the rolling forecast for the […***…] of which shall be
deemed to be a binding order for sample volume (including specifications for the number of samples to be run using each of FMI’s different tests)
(“Binding Orders”). Binding Orders will not impact FMI’s commitment to provide services for at least the Reserved Capacity amount, and Roche’s
financial commitment to pay the Reserved Capacity Fee. FMI shall use Commercially Reasonable Efforts to fulfill requests for Sample Profiling
exceeding the Reserved Capacity based on forecasts provided by Roche (each a “ Forecast”) in advance of […***…] as specified below.
 
  3.1.6 Samples, Sample Results, Web-Portal
Roche will provide samples to FMI for Sample Profiling as provided for in Section 3.5. The results of the Sample Profiling (“Sample Results”) shall
be provided by FMI to Roche in a timeframe to be agreed upon by the Parties. A sample report is attached as Appendix 3.1.6.
 
***Confidential Treatment Requested***
- 21 -FMI will set up and utilize a basic web-portal for Roche to access Sample Results and patient reports for Roche Clinical Studies. This web-portal
shall be similar to the portal that FMI provides to its other major pharmaceutical customers.
 
  3.1.7 Clinical Reports
FMI will provide Roche with clinical (e.g., FoundationOne® or FoundationOne® Heme) reports from Sample Profiling on reasonable request, to be
specified in applicable Task Orders, to enable Roche to provide comprehensive information to physicians and patients.
 
  3.1.8 Database Insights
FMI will provide molecular information insights (“Database Insights”) arising from FMI’s database of aggregated clinical genomic analysis results,
which include genomic alterations (base substitutions, insertions and deletions, copy number alterations, and rearrangements) detected by the
Genomic Analysis Platform across FMI’s clinical testing experience in all disease ontologies (the “ Molecular Information Database”), in response
to queries supplied by Roche (“ Database Queries”) or generated by FMI in response to discussions between the Parties about areas of interest for
Roche (e.g., […***…]), utilizing a team of […***…] FMI FTEs with requisite training and experience to generate Database Insights (“Molecular
Information Database Access”).
Database Insights and results of Advanced Genomic Analyses performed against the Molecular Information Database (which, for clarity, does not
include Roche’s Sample Results) (“FMI-Derived Advanced Genomic Analysis Results”) shall be deemed FMI Confidential Information. Roche and
its Affiliates may use the Database Query Results and FMI-Derived Advanced Genomic Analysis Results for all purposes, except that Roche may
not disclose the Database Query Results to Third Parties, other than as necessary for development, approval or commercialization of a therapeutic
or diagnostic product owned or controlled by Roche, or as otherwise consistent with the terms of confidentiality contained in the Definitive
Agreement.
 
  3.1.9 Molecular Information Database Access
As set forth in Section 3.1.8, FMI will provide Roche mediated (indirect through dedicated FMI FTEs) access to the Molecular Information
Database to pose Database Queries and will provide the resulting Database Insights to Roche in a format to be mutually agreed by the Parties. FMI
will also provide Roche with direct access to the Molecular Information Database for Roche to perform Database Queries and generate Database
Insights, when such service is made available to Third Parties by FMI in the ordinary course of business.
 
  3.1.10 Duration and Extension
The term for Sample Profiling set forth in Section 3.1.4 shall commence on the Effective Date and continue for five (5) years thereafter (the
“Profiling Term”). The Profiling Term may be extended at Roche’s option, upon […***…] written notice to FMI as specified in Section 19.13, for
additional three (3) year periods, during any period of time in which Roche is a majority shareholder of FMI (each a “ Profiling Renewal Term”).
The term for Database Insights under Section 3.1.8 shall commence on the Effective Date and continue for five (5) years thereafter (the “ Database
Insights Term”). The Database Insights
 
***Confidential Treatment Requested***
- 22 -Term may be extended at Roche’s option, upon […***…] notice to FMI as specified in Section 19.13, for additional three (3) year periods, during
any period of time in which Roche is a majority shareholder of FMI (each a “Database Renewal Term”).
During any Profiling Renewal Term and/or Database Renewal Term, if FMI increases the fees it charges to Third Parties for Sample Profiling and/or
Database Insights, then FMI will notify Roche of such adjustment(s), and the Parties shall agree upon the fees to be charged to Roche during the
Profiling Renewal Term and/or Database Renewal Term, subject to Article 5, for such Profiling Renewal Term and/or Database Renewal Term prior to
its commencement.
If FMI is unable to provide Roche with the Reserved Capacity, or to provide Roche with deliverables meeting Performance Specifications for the
Sample Profiling or the Database Queries or fails to comply with Quality Standards, then Roche will have the right to terminate the Sample Profiling
and/or Database Insights, as applicable, as set forth in Section 17.3.3, subject to the notice and cure provisions therein.
 
3.2 Immunotherapy Testing Platform Development Program
 
  3.2.1 Scope
Roche and FMI shall conduct the Immunotherapy Testing Platform Development Program pursuant to a mutually agreed R&D Plan under the
direction of the Immuno-Platform Working Group. The purpose of the Immunotherapy Testing Platform Development Program is to develop an
immunotherapy testing platform meeting the specifications set forth by the Immuno-Platform Working Group for profiling of cancer immunotherapy
patients (the “Immuno-Biomarker Discovery Platform”). The Parties hope to further deploy the platform for use in Clinical Study sample profiling
to identify possible signatures for immunotherapy response (“ Signature Identification”). Roche may also, at its option, request that FMI develop
CLIA immunotherapy testing Clinical Study assays for use in selecting or differentiating patients in Roche Clinical Studies in immuno-oncology
(“Immuno-Clinical Study Assays”).
 
  3.2.2 Immuno-Platform Working Group
The Parties shall establish the Immuno-Platform Working Group within sixty (60) days after the Effective Date to operationalize the Immunotherapy
Testing Platform Development. The Immuno-Platform Working Group’s activities will be overseen by JRDC.
The Immuno-Platform Working Group shall serve as a forum for discussion and sharing updates and information between the Parties, but shall have
no decision-making authority. The Immuno-Platform Working Group shall:
 
(i) serve as a forum for discussing the development of the Immuno-Biomarker Discovery Platform and related Products and Services, as well
as Immuno-Clinical Study Assays, if applicable;
 
(ii) serve as a forum for coordinating the Parties’ efforts to carry out the R&D Plan;
 
(iii) periodically monitor progress of activities under the R&D Plan and discuss any obstacles or delays with regard to achieving the timelines
set forth therein;
 
***Confidential Treatment Requested***
- 23 -(iv) discuss the overall strategy, including the submission plans, for obtaining and maintaining Regulatory Approval of any of the Products
and Services developed in the Immunotherapy Testing Platform Development Program; and
 
(v) such other responsibilities as may be assigned to the Immuno-Platform Working Group in or pursuant to this Agreement or as may be
mutually agreed by the Parties in writing.
 
  3.2.3 R&D Plan
The Parties will conduct the Immunotherapy Testing Platform Development Program in accordance with an R&D Plan and in compliance with
Performance Specifications and Quality Standards. Unless decided otherwise by the JMC, the R&D Plan will be updated […***…] by the Immuno-
Platform Working Group, reviewed and recommended for approval by the JRDC and approved by the JMC. The R&D Plan will set forth (i) the scope
of the Immunotherapy Testing Platform Development Program and the FTE resources that will be dedicated to the activities contemplated within the
scope of the Immunotherapy Testing Platform Development Program, including the responsibilities of each Party (ii) an overall timeline and specific
objectives for each year, which objectives will be updated or amended, as appropriate, by the JRDC as research progresses, and (iii) budgets for
such activities. The Parties shall update the R&D Plan no later than […***…] before the first anniversary of the Effective Date. The JRDC shall
review the R&D Plan on an ongoing basis and may amend the R&D Plan. Any such changes shall be reflected in written amendments to the R&D
Plan.
 
  3.2.4 Responsibilities of the Parties
FMI will work with Roche in accordance with the R&D Plan to develop the Immuno-Biomarker Discovery Platform, perform Signature Identification,
and, as requested by Roche, develop Immuno Clinical Study Assays. Except for the contracts listed on Appendix 3.2.4, the Parties will meet and
discuss existing contracts for activities that are Excepted Activities, and enact a plan for winding-down such contracts, where appropriate.
Roche will work with FMI in accordance with the R&D Plan established by the Immuno-Platform Working Group, including by providing relevant
samples and associated data, immuno-oncology expertise, and bioinformatics support, in each case to the extent agreed to in the R&D Plan.
 
  3.2.5 Budget
A budget for the anticipated work for the Immunotherapy Testing Platform Development forms a part of the R&D Plan. Any changes to this budget
shall be reviewed by the JRDC and then submitted to the JMC for approval.
 
  3.2.6 Duration
The initial term of the Immunotherapy Testing Platform Development Program will be five (5) years beginning on the Effective Date.
 
  3.2.7 Extension
Roche shall have the right to extend the Immunotherapy Testing Platform Development Program, upon […***…] written notice to FMI as specified
in Section 19.13, for up to six (6)
 
***Confidential Treatment Requested***
- 24 -additional one (1) year periods, during any period of time in which Roche is a majority shareholder of FMI (each a “ Signature Identification
Renewal Term”), provided, for clarity, that during any Signature Identification Renewal Term, FMI’s obligations under Section 16.1 shall continue
to apply to any signature identified under this Agreement but that exclusivity under Section 3.2.8 shall not apply to the Immuno-Biomarker
Discovery Platform.
 
  3.2.8 Exclusivity
Except for Excepted Activities, for the lesser of (i) […***…] after the Effective Date or (ii) […***…] (the “Immunotherapy Exclusivity Period”),
FMI will work exclusively with Roche with respect to […***…]. Except with regard to Excepted Activities, FMI will not (i) work directly or indirectly
with any Third Party in the field of […***…], (ii) use for the benefit of any Third Party the […***…] or (iii) transfer to or otherwise enable any
Third Party to make use of any data, technology or results from the Immunotherapy Testing Platform Development Program for […***…].
Following the Immunotherapy Exclusivity Period, FMI shall have the right to work with Third Parties in the field of cancer immunotherapy, and to
otherwise commercialize the Immuno-Biomarker Discovery Platform, subject to the Related Agreements.
 
  3.2.9 Excepted Activities
For any Excepted Activities, FMI shall provide copies of proposed publications Roche for review in accordance with Section 16.4.
 
  […***…]
For the first […***…] following commercial launch by FMI of any Immuno Clinical Study Assay(s) created during or derived from the
Immunotherapy Testing Platform Development, Roche and its Affiliates will be entitled to […***…], for the purchase of any such Immuno Clinical
Study Assay(s).
 
3.3 ctDNA Platform Development Program
 
  3.3.1 Scope
Roche and FMI shall conduct the ctDNA Platform Development Program, pursuant to a mutually agreed R&D Plan under the direction of the
ctDNA Working Group. The purpose of the ctDNA Platform Development Program is to develop ctDNA Assays meeting the specifications set forth
in the R&D Plan.
 
  3.3.2 Working Group
The Parties shall establish the ctDNA Working Group within sixty (60) days after the Effective Date to operationalize the ctDNA Platform
Development. The ctDNA Working Group’s activities will be overseen by JRDC.
 
***Confidential Treatment Requested***
- 25 -The ctDNA Working Group shall serve as a forum for discussion and sharing updates and information between the Parties, but shall have no
decision-making authority. The ctDNA Working Group shall:
 
  (i) serve as a forum for discussing the development of the ctDNA Platform and ctDNA Products;
 
  (ii) serve as a forum for coordinating the Parties’ efforts to carry out the R&D Plan;
 
  (iii) periodically monitor progress of activities under the R&D Plan and discuss any obstacles or delays with regard to achieving the
timelines set forth therein;
 
  (iv) discuss the overall strategy, including the submission plans, for obtaining and maintaining Regulatory Approval of any of the
ctDNA Products; and
 
  (v) such other responsibilities as may be assigned to the ctDNA Working Group in or pursuant to this Agreement or as may be
mutually agreed by the Parties in writing.
 
  3.3.3 R&D Plan
FMI will develop the ctDNA Assays, leveraging ongoing efforts, in accordance with the R&D Plan and in compliance with Performance
Specifications and Quality Standards. Unless decided otherwise by the JMC, the R&D Plan will be updated […***…] by the ctDNA Working
Group, reviewed and recommended for approval by the JRDC and approved by the JMC. The R&D Plan will set forth (i) the scope of the ctDNA
Platform Development Program and the FTE resources that will be dedicated to the activities contemplated within the scope of the ctDNA Platform
Development Program, including the responsibilities of each Party (ii) an overall timeline and specific objectives for each year, which objectives will
be updated or amended, as appropriate, by the JRDC as research progresses, and (iii) budgets for such activities. The Parties shall update the R&D
Plan no later than […***…] before the first anniversary of the Effective Date. The JRDC shall review the R&D Plan on an ongoing basis and may
amend the R&D Plan subject to approval of the JMC. Any such changes shall be reflected in written amendments to the R&D Plan.
 
  3.3.4 Responsibilities of the Parties
FMI shall, subject to all terms and conditions of this Agreement, use Commercially Reasonable Efforts to Develop the Initial Roche ctDNA Assay
and the ALK ctDNA Clinical Trial Assay in accordance with the R&D Plan. FMI will work with Roche in accordance with the R&D Plan to develop
ctDNA Assays.
Roche will work with FMI in accordance with the R&D Plan, including by providing relevant Samples and associated data, in each case to the
extent agreed to in the R&D Plan.
Roche assumes no liability for use of the Genomic Analyses obtained from Samples provided under this Agreement, except as and to the extent
arising out of a breach by Roche of this Agreement.
 
- 26 -3.3.5 Budget
FMI will have sole control over, and responsibility for, the budget and funding for the anticipated work for the ctDNA Platform Development under
the R&D Plan.
 
  3.3.6 Duration
The initial term of the ctDNA Platform Development Program will be twelve (12) months.
 
  3.3.7 Extension
The initial term of the ctDNA Platform Development Program may be extended by the mutual agreement of the Parties.
 
  […***…]
For the […***…] following commercial launch by FMI of any ctDNA Assay(s) created during or derived from the ctDNA Platform Development,
Roche and its Affiliates will be entitled to […***…], for the purchase of any such ctDNA Assay(s).
 
  3.3.9 Commercialization
Subject to the Related Agreements, FMI shall have the right to commercialize the ctDNA Assays. The ctDNA Assays may be made commercially
available to any customer, except that FMI shall not disclose to an Third Party the specific content of any ctDNA Assay developed specifically for
Roche for use as a Clinical Study assay.
 
3.4 CDx Development Program
 
  3.4.1 Scope
Roche and FMI shall conduct the CDx Development Program pursuant to a mutually agreed R&D Plan. The activities conducted in connection with
the CDx Development Program will be overseen by the JRDC. The purpose of the CDx Development Program is to develop certain companion
diagnostic tests or assays (the “ CDx Assays”) for use in connection with certain Roche products. Such CDx Assays may include those developed
at Roche’s request in connection with markers that have not yet been approved by the FDA for the particular tumor type/indication for which
Roche is developing the relevant therapeutic (“ Investigational Markers”) and those developed by mutual agreement of the Parties in connection
with markers that are included in one or more assays approved by the FDA for the particular tumor type/indication to indicate use of a Roche
therapeutic (“Approved Markers”).
 
  3.4.2 Working Group
For each CDx Assay under development, the Parties shall establish a working group (the “ CDx Platform Working Group”), to operationalize the
CDx Development. The Parties shall establish the first CDx Platform Working Group within sixty (60) days after the Effective Date. Each CDx
Platform Working Group’s activities will be overseen by JRDC.
 
***Confidential Treatment Requested***
- 27 -The CDx Platform Working Group shall serve as a forum for discussion and sharing updates and information between the Parties, but shall have no
decision-making authority. The CDx Platform Working Group shall:
 
(i) serve as a forum for discussing the development of CDx Assays and related Products and Services;
 
(ii) serve as a forum for coordinating the Parties’ efforts to carry out the R&D Plan;
 
(iii) periodically monitor progress of activities under the R&D Plan and discuss any obstacles or delays with regard to achieving the timelines
set forth therein;
 
(iv) discuss the overall strategy, including the submission plans, for obtaining and maintaining Regulatory Approval of any of the Products
and Services developed in the CDx Development Program; and
 
(v) such other responsibilities as may be assigned to the CDx Platform Working Group in or pursuant to this Agreement or as may be mutually
agreed by the Parties in writing.
 
  3.4.3 R&D Plan
The Parties will conduct the CDx Development Program in accordance with the R&D Plan and in compliance with Performance Specifications and
Quality Standards. Unless decided otherwise by the JMC, the R&D Plan will be updated […***…] by the CDx Platform Working Group, reviewed
and recommended for approval by the JRDC and approved by the JMC. The R&D Plan will set forth (i) the scope of the CDx Development Program
and the resources that will be dedicated to the activities contemplated within the CDx Development Program, including the responsibilities of each
Party (ii) specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JRDC as research progresses, and
(iii) budgets for such activities. The Parties shall prepare a plan for activities to be conducted no later than […***…] before the first anniversary of
the Effective Date. The JMC shall review the R&D Plan on an ongoing basis and may amend the R&D Plan. Any such changes shall be reflected in
written amendments to the R&D Plan.
 
  3.4.4 Responsibilities of the Parties
FMI will provide CDx development and testing services, including, as required by the R&D Plan, providing FDA QSR laboratory capacity to
support such testing. The CDx services will be based on individual CDx R&D Plans for specific Roche assets that will be agreed upon, signed by
the Parties and thereby made a part of this Agreement as Appendices 3.4.4(a), 3.4.4(b) and so on. All CDx services will be performed with
appropriate systems and documentation to support eventual FDA approval of a PMA or 510(k) or, if agreed by the Parties, approval from the
relevant regulatory authorities for an ROW Territory in which FMI will deliver a CDx Assay for Roche therapeutics.
FMI will be responsible for performing the development work for the CDx Assays according to the individual CDx R&D Plans. Unless otherwise
expressly agreed between the Parties, FMI will be responsible for seeking regulatory approval (including PMAs, 510(k)s or equivalent) for the CDx
Assays. FMI will provide Roche with cross-reference letters, and shall otherwise coordinate regulatory submissions and related information, with
Roche.
 
- 28 -Roche is responsible for supplying FMI with the information and materials necessary for each CDx Assay to be developed under the CDx
Development Program in accordance with the R&D Plan. Roche will be solely responsible for seeking regulatory approval for the associated Roche
asset. Roche will provide FMI with cross-reference letters, and shall otherwise coordinate regulatory submissions and related information with FMI.
 
  3.4.5 Budget
Roche and FMI shall agree on a budget for each CDx Assay. The initial budget forms a part of the initial R&D Plan.
 
  3.4.6 Duration
The term of the CDx Development Program shall be five (5) years.
 
  3.4.7 Extension
Roche shall have the right to extend the term of the CDx Development Program, upon […***…] prior written notice to FMI as specified in Section
19.13, for additional three (3) year periods, during any period of time in which Roche is a majority shareholder of FMI.
 
  3.4.8 Continuing Obligations
If work under an individual CDx R&D Plan is initiated during the initial term of the CDx Development Program or an extension thereof, then such
work shall be completed as set forth in the applicable individual CDx R&D Plan after the initial term or extension, as applicable, in accordance with
the terms set forth therein and herein (including with respect to funding obligations).
 
  3.4.9 Commercialization
Subject to the Related Agreements, FMI shall have the right to commercialize the CDx Assays.
 
3.5 Samples, Handling and Disposal
 
  3.5.1 Samples
Roche will provide samples to FMI that meet the FMI specimen requirements attached hereto as Appendix 3.5.1 and in accordance with the
applicable R&D Plan. FMI shall not transfer the Samples or other materials obtained or received in connection with this Agreement, or any
derivatives thereof, to any Third Party without Roche’s prior written approval. FMI shall use the Samples and material obtained or received in
connection with this Agreement solely for the performance of activities permitted under this Agreement in FMI’s laboratories under suitable
containment conditions in accordance with all Applicable Law. FMI shall not analyze the Samples other than as expressly provided for in this
Agreement. FMI may use such Samples in accordance with the applicable R&D Plan without any obligation of compensation to the subjects from
whom such Samples were obtained or any other Third Party for the intellectual property associated with, or any use of, such Samples.
 
***Confidential Treatment Requested***
- 29 -3.5.2 Sample Handling and Disposal
All Samples provided to FMI by or on behalf of Roche shall have been collected or shall be collected, handled, and transferred in compliance with
Applicable Law and any applicable policies of any institutional review board, privacy board, or ethics committee with jurisdiction over the
collection, handling, and transfer of such material or information. Upon termination of the Agreement or the Work Stream requiring the use of the
Samples, or upon completion of those activities requiring use of the Samples, FMI shall promptly return to Roche unused or remaining Samples, or,
at FMI’s option, securely dispose of all unused or remaining Samples and provide Roche with a written notice of such disposal.
Roche has authorization and all consents required for FMI to use the Samples in accordance with the R&D Plans and the Agreement. FMI shall
use, store and handle all Samples in accordance with the R&D Plans and all Applicable Laws. In the event of withdrawal of a subject’s consent,
Roche will promptly notify FMI and FMI will destroy the corresponding unused Samples (as documented by written confirmation) or return such
Samples to Roche for destruction.
 
3.6 Records; Reports; Audits
 
  3.6.1 Progress Reports
At least […***…] during the time a Work Stream remains in effect, unless otherwise agreed by the Parties, FMI shall have the obligation to prepare
and provide to the JRDC a summary presentation on the progress of the work performed by FMI in the course of each Work Stream during the
preceding […***…]. Promptly upon expiry of such Work Stream, other than the Molecular Information Platform Program, FMI shall provide a final
written report summarizing its activities under such Work Stream and the results thereof.
 
  3.6.2 Research Records
Each Party shall maintain records of each Work Stream (or cause such records to be maintained), except Roche shall not have such obligation for
the Molecular Information Platform Program, in sufficient detail and in good scientific manner as will properly reflect all work done and results
achieved by or on behalf of such Party in the performance of such Work Stream. All laboratory notebooks shall be maintained for no less than the
term of any Patent Rights issuing therefrom.
In addition, during the Agreement and for […***…] thereafter, FMI shall maintain all data provided to FMI by Roche, the Genomic Results, the
FMI Advanced Genomic Analysis Results, Database Insights Database Query Results, and documentation necessary to demonstrate FMI’s
compliance with the terms of this Agreement, including computerized records and files, in a secure area reasonably protected from fire, theft and
destruction;  provided, however, that with respect to raw genomic data, FMI shall only be required to retain the original, unprocessed BAM file
generated from its sequencing process and no other raw genomic data or intermediate BAM files created in processing to generate the Results.
 
  3.6.3 Regulatory Inspections and Audit
Roche shall be entitled, upon reasonable notice and during FMI’s regular business hours, to visit FMI’s facility (and those facilities of its
subcontractors), including FMI’s CLIA-compliant
 
***Confidential Treatment Requested***
- 30 -facilities, to audit for quality assurance purposes its facilities, documentation and procedures used in conducting its activities pursuant to this
Agreement. Such audits may be conducted up to […***…] and Roche shall use reasonable effort not to disrupt ongoing operations during such
audits. FMI shall provide Roche with prompt notice of any governmental or regulatory review, audit or inspection of any of its facilities involved in
the development of the Molecular Information Platform, Immunotherapy Testing Platform, ctDNA Platform, or CDx Assays, and all Products and
Services resulting therefrom, and FMI’s CLIA-compliant facilities. FMI shall provide Roche with (a) the results of any such review, audit or
inspection (including a copy of the relevant sections of the report) to the extent such results pertain to any activities under this Agreement; and (b)
the opportunity to provide assistance to FMI in responding to any such review, audit or inspection.
 
4. Diligence
Roche and FMI shall use Commercially Reasonable Efforts to perform their respective activities contemplated by this Agreement.
 
5. Most Favored Customer
FMI agrees that the pricing terms for Products and Services provided by FMI to Roche herein, and services provided under the Molecular
Information Platform Program, are, and will be, at least as favorable as the pricing terms granted by FMI to any existing customer or collaborator for
such (or substantially similar) products or services. If FMI enters into any subsequent agreement with another customer or collaborator which
provides for pricing terms for substantially the same product or services at substantially the same (or a lesser) scale, which pricing terms are more
favorable than those contained herein, then FMI shall notify Roche and Roche will have the right to modify this agreement to provide Roche with
those more favorable pricing terms. […***…].
 
6. Governance
 
6.1 Joint Management Committee
Within sixty (60) days after the Effective Date, the Parties shall establish a JMC to ensure the smooth operation of the arrangements and activities
envisaged under this Agreement.
 
  6.1.1 Members
The JMC shall be composed of six (6) persons (“Members”). Roche and FMI each shall be entitled to appoint three (3) Members with appropriate
seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such
replacement. A Party that replaces a Member shall notify the other Party at least ten (10) days prior to the next scheduled meeting of the JMC. Both
Parties shall use reasonable efforts to keep an appropriate level of continuity in representation. Both Parties may invite a reasonable number of
additional experts and/or advisors to attend part or the whole JMC meeting with prior notification to the JMC. Members may be represented at any
meeting by another person designated by the absent Member. One JMC representative from a Party shall chair (“ Chairperson”) the JMC on a
rotating annual calendar year basis, with the initial chairperson to be from Roche. The JMC will be made up of senior representatives from FMI and
Roche, including alliance directors. The JMC may create and/or dissolve joint teams tasked with oversight of specific programs or projects, subject
to overall governance by the JMC. The role of the alliance directors will be to facilitate communication and collaboration between the Parties.
 
***Confidential Treatment Requested***
- 31 -6.1.2 Responsibilities of the JMC
The JMC shall have the responsibility and authority to:
 
a) approve the R&D Plans;
 
b) establish, disband and set expectations and mandates for JRDC, JOC, JPT and JOTs, if applicable;
 
c) oversee the JRDC, JOC, JPT and JOTs, if applicable;
 
d) provide financial oversight for the Immunotherapy Testing Platform Development Program and the CDx Development Program; and
 
e) attempt to resolve any disputes escalated from the JRDC or JOC.
The JMC shall have no responsibility and authority other than that expressly set forth in this section.
 
  6.1.3 Meetings
The Chairperson or his/her delegate is responsible for sending invitations and agendas for all JMC meetings to all Members at least ten (10) days
before the next scheduled meeting of the JMC. The venue for the meetings shall be agreed by the JMC. The JMC shall hold meetings at least twice
per calendar year, either in person or by tele-/video-conference, and in any case as frequently as the Members of the JMC may agree shall be
necessary, but not more than four times a year. The Alliance Director of each Party may attend the JMC meetings as a permanent participant.
 
  6.1.4 Minutes
The Chairperson is responsible for designating a Member to record in reasonable detail and circulate draft minutes of JMC meetings to all members
of the JMC for comment and review within twenty (20) days after the relevant meeting. The Members of the JMC shall have ten (10) days to provide
comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to all Members of the JMC
within thirty-five (35) days of the relevant meeting. The Chairperson approves the final version of the minutes before its distribution.
 
  6.1.5 Decisions
 
  6.1.5.1 Decision Making Authority
The JMC shall decide matters within its responsibilities set forth in Section 6.1.2.
 
  6.1.5.2 ctDNA Platform
FMI will have final decision-making rights at the JMC with respect to the ctDNA Platform Development, provided that FMI may not change the
timelines agree in Section 8.4, and any change to the Roche specifications (“ TPP”) for a ctDNA Assay specifically requested by Roche as part of
the R&D Plan will require Roche’s prior approval.
 
- 32 -6.1.5.3 Consensus; Good Faith
The Members of the JMC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the
JMC. The Parties shall endeavor to make decisions by consensus with each Party having one (1) vote.
 
  6.1.5.4 Failure to Reach Consensus
If the JMC is unable to decide a matter by consensus, then the escalation procedure in Section 6.1.5.5 shall be applied.
 
  6.1.5.5 Escalation
If the JMC is unable to decide a matter by consensus, then such matter shall be referred to the Chief Executive Officer of FMI or equivalent position
or his/her nominee and the Chief Executive Officer of Roche or equivalent position or his/her nominee for resolution, who together shall use
reasonable and good faith efforts to reach a decision by consensus within […***…] after the date such matter is referred to them. If the Parties still
fail to reach a decision within such […***…]. Any such decision shall constitute a decision of the JMC. Notwithstanding the foregoing, neither
Party may exercise deciding authority (i) to impose resource or financial burdens on the other Party for a Work Stream beyond the scope set forth in
an agreed upon R&D Plan for such Work Stream or Reserved Capacity under the Molecular Information Platform Program, or (ii) that would violate
or amend the terms of this Agreement. The JMC will exist for the Agreement Term.
 
  6.1.6 Information Exchange
FMI and Roche shall exchange the information in relation to its activities under this Agreement through the JMC and FMI and Roche may ask
reasonable questions in relation to the above information and offer advice in relation thereto and Roche shall give due consideration to FMI’s
input. The JMC may determine other routes of information exchange.
 
  6.1.7 Subcommittees and Joint Operational Teams
The JMC has the right to establish sub-committees or JOTs. The JRDC shall be established within thirty (30) days after the JMC is established. The
JOC shall be established as soon as the JMC deems it necessary.
 
6.2 JRDC
The JRDC shall oversee the implementation of the Work Streams and to more generally identify opportunities for value creation in research and
development activities between the Parties. The JDRC shall be composed of an equal number of persons from each Party, each person having
appropriate seniority and functional expertise. Each Party may replace any a person and appoint another person to fill the vacancy arising from
each such replacement. The JRDC will strive to reach consensus on any matters within the committee’s authority with each Party having one (1)
vote. Unresolved dispute at the JRDC will be escalated to the JMC.
 
  6.2.1 Responsibilities of the JRDC
The JRDC shall have the responsibility and authority to:
 
a) recommend the R&D Plans for approval by the JMC;
 
b) review and recommend for approval any revisions to the R&D Plans;
 
***Confidential Treatment Requested***
- 33 -c) review and oversee the execution of the R&D Plans;
 
d) establish timelines and criteria for decision points;
 
e) determine whether criteria have been met, including whether the criteria as to whether milestones or events have been achieved;
 
f) review the efforts of the Parties and allocate those resources for the R&D Plans (including their budgets);
 
g) identify appropriate resources necessary to conduct the R&D Plans;
 
h) oversee the progress of the Work Streams;
 
j) monitor the development costs and manage reimbursement for FMI activities under this Agreement;
 
k) determine for Products and Services Performance Specifications and identify Quality Standards applicable to respective Work Streams;
and
 
l) attempt to resolve any disputes.
The JRDC shall have no responsibility and authority other than that expressly set forth in this section.
 
6.3 JOC
The JOC shall plan and oversee the commercial, co-marketing, educational, and/or promotion activities between the Parties and to serve as a forum
for communicating generally about FMI’s products and strategies for global commercialization, as such activities are further described in the US
Education Collaboration Agreement and the Ex-US Commercialization Agreement. The JOC shall be composed of an equal number of persons from
each Party, each person having appropriate seniority and functional expertise. A description of the roles, responsibilities, and workings of the JOC
are described in the Ex-US Commercialization Agreement. Through the JOC, Roche may share with FMI knowledge and experience related to
countries and markets outside the United States, and will support the design and implementation of a global expansion plan for FMI products. The
JOC will strive to reach consensus on any matters within the committee’s authority, with each Party having one (1) vote. Unresolved disputes at the
JOC will be escalated to the JMC.
 
6.4 Alliance Director
Each Party shall appoint one person to be the point of contact within each Party with responsibility for facilitating communication and collaboration
between the Parties (each, an “ Alliance Director”). The Alliance Directors shall be permanent participants of the JMC meetings (but not members
of the JMC) and may attend JDRC, JOC and JOT meetings as appropriate. The Alliance Directors shall facilitate resolution of potential and pending
issues and potential disputes to enable the JMC to reach consensus and avert escalation of such issues or potential disputes.
 
6.5 Limitations of Authority
No committee, working group or individual shall have the authority to amend or waive any terms of this Agreement.
 
- 34 -6.6 Expenses
Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with the JMC.
 
6.7 Lifetime
The JMC shall exist during the Agreement Term.
 
7. Regulatory
Subject to the Related Agreements, FMI, […***…], shall use Commercially Reasonable Efforts to pursue all regulatory affairs related to its
products and services developed under this Agreement (collectively, “ Products and Services”) in the Territory including the preparation, filing and
maintenance of applications for regulatory approval, as well as any or all governmental approvals required to develop, have developed, make, have
made, use, have used, manufacture, have manufactured, import, have imported, sell and have sold such Products and Services. Subject to the
Related Agreements, FMI shall be responsible for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with
regulatory agencies, for all Products and Services in all countries in the Territory. Subject to the Related Agreements, FMI or its Affiliates shall own
and file in their discretion all regulatory filings and Regulatory Approvals for all Products and Services in all countries of the Territory. FMI shall
supply Roche with a copy of all material communications related to Products and Services to or from the Regulatory Authorities. Upon request of
Roche, FMI shall supply Roche with a copy of all such communications to or from the Regulatory Authorities.
Subject to the Ex-US Commercialization Agreement, FMI, […***…], shall report to appropriate Redulatory Authorities in accordance with local
requirements all adverse events related to use of the Products and Services in the Territory.
 
8. Payment
 
8.1 FTE Funding
Roche will be responsible for funding the FTEs in accordance with the R&D Plans and budgets at the FTE Rate for performance of the research and
other activities for which FMI is responsible under the R&D Plans and for the database queries. Each individual included in the funded FTEs shall
possess a bachelor’s degree or higher in a relevant scientific discipline and shall be experienced in the type of research or other activities to be
performed by such individual under this agreement.
 
8.2 Molecular Information Platform Program Fees
 
  8.2.1 Sample Profiling Fees
 
  8.2.1.1 Reserved Capacity Fees
In consideration for the Reserved Capacity and provision of the Sample Results associated with the Reserved Capacity, and subject to any
reduction resulting from the application of Article 5, Roche shall pay to FMI an amount equal to […***…] for […***…] of the Profiling Term […
***…] for the […***…] of the Profiling Term (“Reserved Capacity Fees”). The Reserved Capacity Fees are paid as follows:
[…***…] equal installments of […***…] payable within […***…] of receipt by Roche of an invoice from FMI, beginning with receipt by Roche of
a first invoice from FMI issued following the Effective Date and followed by […***…] additional invoices at […***…] intervals thereafter.
 
***Confidential Treatment Requested***
- 35 -[…***…] equal installments of […***…] payable within […***…] of receipt by Roche of an invoice from FMI, beginning […***…] of the
Effective Date and followed by […***…] additional invoices at […***…] intervals thereafter.
For renewal terms, the agreed upon Reserved Capacity Fee shall be paid within […***…] of receipt by Roche of an invoice from FMI at […***…]
intervals.
The Reserved Capacity Fee payments shall be […***…] against Roche’s Binding Order for such period, the amount of the Reserved Capacity Fee
being […***…]. Actual Sample Profiling costs, based on delivery of Sample Results during the […***…] to which the Reserved Capacity Fee
applies, shall be […***…]. If actual Sample Profiling exceeds the amount of Sample Profiling paid by the Reserved Capacity Fees, then […***…].
Roche shall pay FMI for […***…]. If a Binding Order causes Roche to […***…]. Fees for Binding Orders shall […***…].
 
  8.2.1.2 Per Sample Profiling Fees
The per Sample Profiling fees (notwithstanding the Reserved Capacity Fee) shall be as follows:
[…***…].
 
  8.2.2 Molecular Information Database Access and Database Queries Fees
For Molecular Information Database Access and performance of Database Queries by FMI, Roche will pay FMI a total of […***…] of the
Database Term, (the “Database Access Fee”), which is comprised of funding for […***…] FTEs, each at the FTE Rate, for performance of such
Database Queries and delivery of Database Insights, and a Database Access Fee of […***…]. Roche shall pay to FMI the Database Access Fee
[…***…] installments of […***…], each payable every […***…] of the Database term and within […***…] after receipt by Roche of an invoice
from FMI.
 
8.3 Immunotherapy Testing Platform Development Budget and Fees
 
  8.3.1 R&D Plan Budget
Roche shall be solely responsible for Roche’s costs under the Immunotherapy Testing Platform Development Budget.
Roche will pay FMI […***…] of FMI Development Cost as agreed in the Immunotherapy Testing Platform Budget for development of the Immuno-
Biomarker Discovery Platform.
Roche will pay […***…] of FMI Development Cost as agreed in the Immunotherapy Testing Platform Budget for Signature Identification.
 
***Confidential Treatment Requested***
- 36 -Such reimbursement of FMI Development Cost shall be paid […***…] in arrears. Each […***…], FMI shall invoice Roche for its share of FMI
Development Cost incurred in the previous […***…]. Invoices shall be payable within […***…] after receipt by Roche of an invoice from FMI.
 
  8.3.2 Payments for Achieving Certain Immunotherapy Testing Platform Development Events
In addition to payment of the Immunotherapy Testing Platform Development Budget as specified above, Roche shall pay FMI:
 
  (i) […***…] on Initiation of the first Roche Clinical Study utilizing a Clinical Study assay, […***…].
 
  (ii) […***…] on Initiation of the first Roche Clinical Study utilizing a Clinical Study assay, […***…].
 
  (iii) […***…] on Initiation of the first Roche Clinical Study utilizing a Clinical Study assay, […***…].
 
  8.3.3 Immuno Clinical Study Assays requested by Roche
Roche will pay […***…] of FMI’s Development Costs for development of Immuno Clinical Study Assays as may be requested by Roche, subject
to an agreed upon budget for such development as provided for in Section 3.2.5.
 
  8.3.4 Immunotherapy CDx Assays
If the Parties chose to develop an Immunotherapy CDx Assay, they the Parties shall agree to Roche paying certain costs and milestones for such
Immunotherapy CDx assay.
 
8.4 ctDNA Platform Financial Terms
FMI will be responsible for all FMI Development Cost for the ctDNA Platform Development. As part of the agreed upon ctDNA R&D Plan, FMI will
provide sample testing performed under such ctDNA R&D Plan at no cost to Roche (other than Roche’s cost in supplying FMI the Samples
specified in the ctDNA R&D Plan).
Roche will pay FMI […***…] if FMI successfully […***…] set forth in the R&D Plan (“Initial Roche ctDNA Assay”) within […***…] from […
***…] (the “First ctDNA Milestone Date”). Payment by Roche shall be made within […***…] after achieving the First ctDNA Milestone Date and
the receipt by Roche of an invoice from FMI.
In addition, Roche will pay FMI […***…] if FMI successfully […***…] as agreed to in the R&D Plan; provided that […***…] (the “Second
ctDNA Milestone Date”). Payment by Roche shall be made within […***…] after achieving the Second ctDNA Milestone Date and the receipt by
Roche of an invoice from FMI.
The Parties may develop additional ctDNA Assays for use as Clinical Study assays, subject to an agreed financial structure for such work under
the R&D Plan. Such additional development work will be conducted, if at all, pursuant to an amendment to this Agreement or a separate written
agreement between the Parties.
 
***Confidential Treatment Requested***
- 37 -8.5 CDx Development Financial Terms
 
  8.5.1 CDx Development Costs
Roche shall pay FMI […***…] of FMI Development Cost for CDx Development of Investigational markers in compliance with the investigational
CDx budget that forms part of the R&D Plan.
FMI shall pay […***…] of the FMI Development Cost for Approved Markers.
Such reimbursement of FMI Development Cost shall be paid […***…] in arrears. Each […***…], FMI shall invoice Roche for its share of the FMI
Development Cost incurred in the […***…]. Invoices shall be payable within […***…] after receipt by Roche of an invoice from FMI.
 
  8.5.2 PMA Event Payments
For each PMA approval corresponding to a Roche product, Roche shall pay FMI […***…], within […***…] after the occurrence of such event
and receipt by Roche of an invoice from FMI.
 
  8.5.3 Commercial Success Event Payments
Roche shall pay FMI the following milestone payments upon achievement of CDx Assay report volumes by tissue type within the first […***…]
after […***…] of the associated CDx Assay as specified below:
 
  (i) CDx Assays Including Investigational/Approved Marker(s) for […***…]:
 
    […***…].
 
  (ii) CDx Assays Including Investigational/Approved Marker(s) for […***…]:
 
    […***…].
Upon achievement of each of the CDx Assay volumes under this Section 8.5.3, FMI shall timely notify Roche and payment shall be made by Roche
within […***…] after achieving the applicable event and the receipt by Roche of an invoice from FMI.
In the event the Parties wish to develop another CDx Assay other than those specified above for […***…] and […***…] pursuant to a CDx R&D
Plan, the Parties shall mutually agree to […***…] milestones and payments for achieving them.
 
8.6 General Terms
All rates and costs set forth herein shall remain firm for the Agreement Term and the services to be performed under each Work Stream, unless
otherwise agreed to in writing, shall be at the FTE Rate. FMI has an affirmative obligation to use Commercially Reasonable Efforts to negotiate
favorable terms for all FMI Development Cost that will be passed through FMI to Roche. FMI shall extend to Roche the benefit of any and all
discounts and savings provided to FMI in connection with FMI Development Cost that will be passed through to Roche. Roche shall […***…],
any amounts in excess of the agreed upon budget.
 
***Confidential Treatment Requested***
- 38 -8.7 Disclosure of Payments
FMI acknowledges that Roche may be obligated to disclose this financial arrangement, including all fees, payments and transfers of value, as may
be advisable or required under Applicable Law, including the US Sunshine Act.
 
9. Accounting and reporting
 
9.1 Timing of Payments
Payments shall be made during the time periods set forth in this Agreement. If not stated explicitly, payments shall be made by Roche within […
***…] after Roche receives an invoice from FMI.
 
9.2 Late Payment
Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by
Applicable Law, at […***…] points above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to
time, calculated on the number of days such payment is overdue.
 
9.3 Method of Payment
All amounts payable hereunder shall be paid in US dollars (the “ Payment Currency”) to account(s) designated by FMI.
 
10. Taxes
FMI shall pay all sales, turnover, income, revenue, value added, and other taxes levied on account of any payments accruing or made to FMI under
this Agreement.
If provision is made in law or regulation of any country for withholding of taxes of any type, levies or other charges with respect to any royalty or
other amounts payable under this Agreement to FMI, then Roche or its relevant Affiliates shall promptly pay such tax, levy or charge for and on
behalf of FMI to the proper governmental authority, and shall promptly furnish FMI with receipt of payment. Roche shall be entitled to deduct any
such tax, levy or charge actually paid from royalty or other payment due FMI or be promptly reimbursed by FMI if no further payments are due
FMI. Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or
similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted.
 
***Confidential Treatment Requested***
- 39 -It is understood between the Parties that the agreed upon and/or applied remunerations and other payments under this Agreement for all
transactions between (a) FMI and (b) Roche are based on arm’s length and good faith considerations. Should such remunerations for products and
services or other payments nevertheless be challenged by any Governmental Authority including any tax authority in the US, or in Switzerland or
other jurisdiction of Roche or its relevant Affiliates (“Roche’s Jurisdiction”):
 
 
(a) FMI and Roche or its relevant Affiliates shall fully co-operate with each other with the objective to convince the challenging
authority that such remunerations for products and services and other payments are appropriate, including providing each other
with copies of third party agreements if necessary to utilize as comparables to support the arm’s length nature of transactions
between FMI and Roche. In the event that the challenging authority is not convinced, the Parties shall request that the tax
authorities in the US and in Roche’s Jurisdiction initiate government-to-government procedures pursuant to the applicable bi-
lateral convention for the avoidance of double taxation or similar treaty or convention (if any) between the US and Roche’s
Jurisdiction (“Competent Authority Procedures”).
 
 
(b) In the event that the US tax authorities determine that such remunerations for products and services or other payments are not
appropriate and levy an assessment on FMI, and such assessment results in a refund (or similar payment or credit) by or from
the tax authorities in Roche’s Jurisdiction to Roche or its relevant Affiliate, then Roche shall pay (or shall ensure that Roche
shall pay) the amount of such refund to FMI. In the event that the tax authorities in Roche’s Jurisdiction determine that such
remunerations for products and services or other payments are not appropriate and levy an assessment on Roche, and such
assessment results in a refund (or similar payment or credit) by or from the US tax authorities to FMI then FMI shall pay (or shall
ensure that FMI shall pay) the amount of such refund to Roche. Each Party shall use its reasonable efforts to obtain such refund
(or similar payment or credit).
 
 
(c) In the event of such an assessment by either tax authority (an “ Assessment”), the Parties agree to making adjustments to the
relevant remunerations for products and services or other payments to levels agreed to by the tax authorities in both the US and
Roche’s Jurisdiction as the result of Competent Authority Procedures.
 
11. Auditing
 
11.1 Right to Audit
Each Party shall keep, and shall require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing all particulars
that may be necessary for the purpose of calculating all payments payable under this Agreement, including, for Roche, the right to audit materials
necessary to ensure compliance with the most favored customer provisions of Article 5. Such books of accounts shall be kept at their principal
place of business. At the expense of the auditing Party, the auditing Party shall have the right to engage an internationally recognized, independent
public accountant reasonably accept able to the other Party to perform, on behalf of such Party an audit of such books and records of the audited
Party and its Affiliates, its licensees and Sublicensees, that are deemed necessary for the period or periods requested by the auditing Party and the
correctness of any financial report or payments made under this Agreement, including with respect to benefits and terms complying with the most
favored
 
- 40 -customer provisions of Article 5. For avoidance of doubt, all audits under this Section shall be conducted solely by an independent public
accountant as described in the foregoing sentence.
Upon timely request and at least […***…] prior written notice from the auditing Party, such audit shall be conducted in the countries specifically
requested by the auditing Party, during regular business hours in such a manner as to not unnecessarily interfere with the audited Party’s normal
business activities, and shall be limited to results in the […***…] prior to audit notification.
Such audit shall not be performed more frequently than […***…] nor more frequently than […***…] with respect to records covering, or
impacting in accordance with Article 5, any specific period of time.
All information, data documents and abstracts herein referred to shall be used only for the purpose of verifying payment obligations, shall be
treated as the audited Party’s Confidential Information subject to the obligations of this Agreement and need neither be retained more than […
***…] after completion of an audit hereof, if an audit has been requested; nor more than […***…] from the end of the […***…] to which each
shall pertain; nor more than […***…] after the date of termination of this Agreement.
 
11.2 Audit Reports
The auditors shall only state factual findings in the audit reports and shall not interpret the agreement. The auditors shall share all draft audit
reports with the auditing Party before the draft report is shared with the audited Party and before the final document is issued. The final audit report
shall be shared with the auditing Party at the same time it is shared with the audited Party.
 
11.3 Over or Underpayment
If the audit reveals an overpayment by Roche, FMI shall reimburse Roche for the amount of the overpayment within […***…]. If the audit reveals
an underpayment by Roche, Roche shall make up such underpayment with the next payment or, if no further payments are owed by Roche, Roche
shall reimburse FMI for the amount of the underpayment within […***…]. The audited Party shall pay for the audit costs if the underpayment of
the audited Party exceeds […***…] of the aggregate amount of royalty payments owed with regard to the period subject of the audit. Section 9.2
shall apply to this Section 11.3.
 
11.4 Duration of Audit Rights
The failure of a Party to request verification of any calculation within the period during which corresponding records must be maintained under this
Article 11 will be deemed to be acceptance of the payments and reports.
 
12. Intellectual Property
 
12.1 Ownership of Inventions, data and results
 
  12.1.1 In General
Except as specifically set forth herein, FMI shall own all FMI Inventions, Roche shall own all Roche Inventions, and FMI and Roche shall jointly
own all Joint Inventions. FMI and Roche each shall require all of its employees to assign all inventions related to Products and Services made by
them to Roche and FMI, as the case may be.
 
***Confidential Treatment Requested***
- 41 -The determination of ownership of Inventions shall be determined in accordance with US inventorship laws as if such Inventions were made in the
US.
Except as otherwise expressly set forth herein, each Party shall retain full ownership and control of, and all rights in, its Background IP and any
improvements or modifications thereto (“Roche Improvement IP” and “FMI Improvement IP” respectively). Roche Improvement IP shall mean any
improvements or modifications to Roche’s Background IP discovered, conceived or reduced to practice after the Effective Date in the performance
of activities under this Agreement. FMI Improvement IP shall mean any improvements or modifications to FMI’s Background IP discovered,
conceived or reduced to practice after the Effective Date in the performance of activities under this Agreement. All materials, information, data and
writings provided to FMI by or on behalf of Roche, in any form whatsoever, which were Controlled by Roche prior to being provided to FMI, shall
remain the property of Roche; FMI shall acquire no right, title or interest in such materials, information, data and writings as the result of its
activities under this Agreement.
Except as specifically set forth herein, this Agreement shall not be construed, by implication, necessity or otherwise as (i) giving any of the Parties
any license, right, title, interest in or ownership to the Confidential Information; (ii) granting any license or right under any intellectual property
rights; or (iii) representing any commitment by either Party to enter into any additional agreement.
 
  12.1.2 For the Molecular Information Platform Program
Subject to the license granted to FMI under Section 2.1.2, Roche shall exclusively own all right title and interest to any information, results, and
intellectual property from any Clinical Study undertaken or supported by Roche, including, without limitation, the Sample Results and information
and results from any Sample Profiling. FMI shall assign to Roche its rights to any intellectual property in or arising from the Sample Results (except
for FMI Improvements).
Except as otherwise set forth herein, FMI shall exclusively own all right, title, and interest to any improvements or modifications to the FMI
Genomic Analysis Platform that arise in connection with the performance of the work under the Molecular Information Platform Program.
Roche shall exclusively own all information, results, and intellectual property from Advanced Genomic Analyses performed on Roche samples
(“Roche-Owned Advanced Genomic Analysis Results”), and any inventions arising from the Roche-Owned Advanced Genomic Analysis Results,
and FMI will assign all rights to any such inventions to Roche (except for FMI Improvements).
 
  12.1.3 For the Immunotherapy Testing Platform Program
Subject to the license granted to FMI under Section 2.1.3, Roche shall exclusively own all data, results, and intellectual property therein arising from
profiling samples provided by Roche to FMI for testing in the Immunotherapy Testing Platform Development (except for FMI Improvements)
(“Roche Immunotherapy Sample Results”), and FMI shall assign to Roche all such intellectual property. FMI shall not disclose Roche
Immunotherapy Sample Results to third parties or use such results in work with Third Parties.
 
- 42 -Roche shall exclusively own, and FMI shall assign to Roche, all intellectual property arising from the Immunotherapy Testing Platform Development
that Covers methods of treatment, stratifying patients, or identifying patients that would benefit from a particular treatment, and all other methods
useful in connection with the therapeutic treatment of a patient.
To the extent third-party intellectual property must be licensed for the Immunotherapy Testing Platform Development, Roche and FMI shall jointly
decide on an appropriate in-licensing strategy and negotiate a fair cost sharing between the Parties in good faith; provided however, that FMI shall
retain the right to take such a license at its own cost on such terms as it shall determine if the Parties cannot reach a timely agreement on how to
proceed.
 
  12.1.4 For the ctDNA Program
Subject to the license granted to FMI under Section 2.1.4, Roche shall exclusively own all data, results, and intellectual property arising from the
profiling of Roche samples in the ctDNA Platform Development Program (“Roche ctDNA Sample Results”). FMI shall not disclose Roche ctDNA
Sample Results to third parties or use such results in work with third parties.
 
  12.1.5 For the CDx Development Program
Subject to the license granted to Roche under Section 2.1.5, FMI shall exclusively own all intellectual property arising from the CDx Development
that Covers the CDx Assays (“ FMI CDx IP”).
Roche shall exclusively own all data, results, and intellectual property arising from analysis of its samples in the relevant CDx Development as well
as all intellectual property arising from the CDx Development Program to the extent that it is reasonably related to or Covers the relevant Roche
product including the use, formulation, and methods of treatment for the relevant Roche product (“ Roche CDx Development IP”).
To the extent third-party intellectual property must be licensed for the Investigational CDx Development or commercialization of the Investigational
CDx Assays, Roche and FMI shall jointly decide on an appropriate in-licensing strategy and negotiate a fair cost sharing between the Parties in
good faith.
 
12.2 German Statute on Employee’s Inventions
In accordance with the German Statute on Employees’ Inventions, each Party agrees to claim the unlimited use of any Invention conceived,
reduced to practice, developed, made or created in the performance of, or as a result of, any Research Program by employees of any German
Affiliates or any other persons acting on behalf of such German Affiliates. For the avoidance of doubt, each Party is responsible for fulfilling the
Affiliates or any other persons acting on behalf of such German Affiliates. For the avoidance of doubt, each Party is responsible for fulfilling the
obligations towards their employees under the German Statute of Employee’s Inventions.
 
12.3 Prosecution and Maintenance of Patent Rights Claiming FMI Inventions
FMI shall, at its own expense and discretion, (i) control and Handle all FMI Foreground Patent Rights, (ii) consult with Roche as to the Handling of
such FMI Foreground Patent Rights, and (iii) furnish to Roche copies of all material documents relevant to any such Handling. FMI shall furnish
such documents and consult with Roche in sufficient time before any action by FMI is due to allow Roche to provide comments thereon, which
comments FMI must consider. At FMI’s
 
- 43 -expense and reasonable request, Roche shall cooperate, in all reasonable ways with the Handling of all FMI Foreground Patent Rights. If FMI
elects not to Handle any FMI Foreground Patent Rights under this Section 12.3, then FMI shall provide at least […***…] prior written notice to
Roche. Thereafter, Roche shall have the right, but not the obligation to Handle any such notified FMI Foreground Patent Rights, at its sole expense
and its sole discretion. Notwithstanding the foregoing, and for clarity, FMI shall have no obligations to Roche under this Section 12.3 in regard to
FMI Foreground Patent Rights relating to the Genomic Analysis Platform or the Molecular Information Database (including, without limitation,
methods, procedures, and algorithms related to or embodied in each) that do not incorporate or rely on the continued use of Roche Confidential
Information.
 
12.4 Prosecution and Maintenance of Roche Foreground Patent Rights and Joint Patent Rights
Roche shall, at its own expense and discretion, control and Handle (including abandon) all Roche Foreground Patent Rights and Joint Patent
Rights. If Roche elects not to Handle any Patent Rights under this Section 12.4, then Roche shall provide at least […***…] prior written notice to
FMI. Thereafter, FMI shall have the right, but not the obligation to Handle any such notified Patent Rights, at its sole expense and its sole
discretion.
 
12.5 Joint Patent Team
Where the Parties need to consult with each other on the Handling of Patent Rights, the Parties shall establish a joint patent team (“ JPT”) and shall
adopt procedures for interacting on patent matters. The JPT shall be subject to the oversight of the JMC. The JPT shall also serve as a forum for
promptly notifying the other Party when an Invention is made by a Party.
 
12.6 CREATE Act
It is the intention of the Parties that this Agreement is a “joint research agreement” as that phrase is defined in Public Law 108-53 (“ Create Act”)
and applied in 35 USC §103(c)(3). If either Party intends to overcome a rejection of a claimed invention within the FMI Foreground Patent Rights or
Roche Foreground Patent Rights pursuant to the provisions of the Create Act, then the Parties, through the JPT, shall work together in good faith
to agree in writing how any rejection should be overcome.
 
12.7 Infringement
Each Party shall promptly provide written notice to the other Party during the Agreement Term of any (i) known infringement or suspected
infringement by a Third Party of any FMI Background Patent Rights, FMI Foreground Patent Rights, Roche Background Patent Rights, Roche
Foreground Patent Rights or Joint Patent Rights, or (ii) known or suspected unauthorized use or misappropriation by a Third Party of any FMI
Background Know-How, FMI Know-How, Roche Background Know-How, Roche Know-How or Joint Know-How, and shall provide the other Party
with all evidence in its possession supporting such infringement or unauthorized use or misappropriation.
Within […***…] after a Party provides or receives such written notice (“ Decision Period”), the Party Handling enforcement of such Patent Right
as set forth in this Section 2.7, in its sole discretion, shall decide whether or not to initiate such suit or action in the Territory and shall notify the
other Party in writing of its decision in writing (“Suit Notice”).
 
***Confidential Treatment Requested***
- 44 -For any FMI Background Patent Right or sole FMI Patent Right, FMI in its sole discretion shall decide whether or not to initiate such suit or action
in the Territory. FMI shall have full discretion as to how it wishes to handle such suit and may reach Settlement under any terms and conditions it
desires and retain all damages, settlement fees or other consideration received in connection therewith. Only if a Settlement could adversely affect
Roche shall the written consent of Roche be required, which consent shall not be unreasonably withheld. The term “adversely affect” in the
previous sentence shall include, among other things, […***…].
For any sole Roche Background Patent Right or Roche Patent Right, Roche, in its sole discretion, shall decide whether or not to initiate such suit or
action in the Territory. Roche shall have full discretion as to how it wishes to handle such suit and may reach Settlement under any terms and
conditions it desires and retain all damages, settlement fees or other consideration received in connection therewith. Only if a Settlement could
adversely affect FMI shall the written consent of FMI be required, which consent shall not be unreasonably withheld.
If for a Joint Patent Right, Roche decides to bring a suit or take action, once Roche provides Suit Notice, Roche may immediately commence such
suit or take such action. In the event that Roche (i) does not in writing advise FMI within the Decision Period that Roche will commence suit or take
action, or (ii) fails to commence suit or take action within a reasonable time after providing Suit Notice, FMI shall thereafter have the right to
commence suit or take action in the Territory and shall provide written notice Roche of any such suit commenced or action taken by FMI.
Upon written request, the Party bringing suit or taking action (“ Initiating Party”) shall keep the other Party informed of the status of any such suit
or action and shall provide the other Party with copies, to the extent the Initiating Party is lawfully permitted to do so, of all material documents or
communications filed in such suit or action. The Initiating Party shall have the sole and exclusive right to select counsel for any such suit or action.
The Initiating Party shall, except as provided below, pay all expenses of the suit or action, including the Initiating Party’s attorneys’ fees and court
costs. Any damages, settlement fees or other consideration received as a result of such suit or action shall be allocated as follows:
 
(a) First, to reimburse the Initiating Party for its costs and, if any remains, to the other Party for any advisory counsel fees and costs; and
 
(b) Second, the balance, if any, shall be allocated […***…].
If the Initiating Party believes it is reasonably necessary or desirable to obtain an effective remedy, upon written request the other Party agrees to
be joined as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation is required as the
result of its being a named party to the suit or action. At the Initiating Party’s written request, the other Party shall offer reasonable assistance to
the Initiating Party in connection therewith at no charge to the Initiating Party except for reimbursement of reasonable out-of-pocket expenses
incurred by the other Party in rendering such assistance. The other Party shall have the right to participate and be represented in any such suit or
action by its own counsel at its own expense.
The Initiating Party may settle, consent judgment or otherwise voluntarily dispose of the suit or action (“ Settlement”) without the written consent
of the other Party but only if such Settlement can be achieved without adversely affecting the other Party (including any of its Patent Rights). If a
Settlement could adversely affect the other Party, then the written consent of the other Party would be required, which consent shall not be
unreasonably withheld.
 
***Confidential Treatment Requested***
- 45 -12.8 Defense
If an action for infringement is commenced against either Party, its licensees or its sublicensees related to such Party’s conduct of a Work Stream
within the scope of an R&D Plan then such Party shall defend such action at its own expense, and the other Party shall assist and cooperate with
such Party, at its own expense, to the extent necessary in the defense of such suit. The defending Party shall have the right to settle the suit or
consent to an adverse judgment thereto, in its sole discretion, so long as such settlement or adverse judgment does not adversely affect the rights
of the other Party and its Affiliates (including any patent rights Controlled by any of them). The defending Party shall assume full responsibility for
the payment of any award for damages, or any amount due pursuant to any settlement entered into by it with such Third Party.
If the manufacture, use, importation, offer for sale or sale of any Products and Services results in any claim, suit or proceeding alleging patent
infringement or trade secret misappropriation against FMI or a member of the Roche Group, then such Party shall promptly notify the other Party
hereto. The Parties shall cooperate with each other in connection with any such claim, suit or proceeding and shall keep each other reasonably
informed of all material developments in connection with any such claim, suit or proceeding.
If a Third Party asserts that Patent Rights owned by or licensed to it are infringed by the development, manufacture, use, importation, offer for sale
or sale of products arising out of this Agreement by a member of the Roche Group, or that its trade secrets were misappropriated in connection with
such activity, then Roche shall have the exclusive right and responsibility to resolve any such claim, whether by obtaining a license from such
Third Party, by defending against such Third Party’s claims or otherwise, and shall be solely responsible for the defense of any such action, any
and all costs incurred in connection with such action (including, without limitation, attorneys’ and expert fees) and all liabilities incurred in
connection therewith. Notwithstanding the above, Roche shall not enter into any settlement of any such claim without the prior written consent of
FMI if such settlement would require FMI to be subject to an injunction or to make any monetary payment to Roche or any Third Party, or admit
any wrongful conduct by FMI or its Affiliates, or would limit or restrict the claims of or admit any invalidity and/or unenforceability of any of the
Patent Rights Controlled by FMI, or have any impact on activities outside the Field.
 
12.9 Common Interest Disclosures
With regard to any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property and/or
technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party
intellectual property rights may affect the conduct of the Work Streams and/or Products and Services, and have a further common legal interest in
defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights
relating to the conduct of the Work Streams and/or Products and Services. Accordingly, the Parties agree that all such information and materials
obtained by FMI and Roche from each other will be used solely for purposes of the Parties’ common legal interests with respect to the conduct of
the Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other
privilege or
 
- 46 -immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or
immunity that may apply to the shared information and materials. Neither Party shall have the authority to waive any privilege or immunity on
behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of
one Party be deemed to apply against any other Party.
 
13. Representations and Warranties
 
13.1 Mutual Representations and Warranties
FMI and Roche each represent and warrant that:
(a) it has all requisite power and authority to enter into and perform its obligations under this Agreement;
(b) it has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement or that would preclude its
personnel from complying with the provisions hereof;
(c) all of its employees, officers and consultants have executed agreements requiring assignment to it of all Inventions made by such individuals
during the course of and as a result of their participation in activities under this Agreement;
(d) the execution, delivery and performance of this Agreement by it and all instruments and documents to be delivered by it hereunder: (i) are within
its corporate power; (ii) have been duly authorized by all necessary or proper corporate action; (iii) are not in contravention of any provision of any
of its formation or governing documents; (iv) to its knowledge, will not violate any law or regulation or any order or decree of any court of
governmental instrumentality; (v) will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which
it is a party or by which it or any of its property is bound, which violation would have an adverse effect on its financial condition or on its ability to
perform its obligations hereunder; and (vi) do not require any filing or registration with, or the consent or approval of, any governmental body,
agency, authority or any other person, which has not been made or obtained previously (other than approvals required under the HSR Act,
Regulatory Approvals required for the sale of Products and filings with Regulatory Authorities required in connection with Products);
(e) there are no claims or investigations (other than with respect to the Parties’ HSR filings), pending or threatened against it or any of its Affiliates,
at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially
adversely affect its ability to perform its obligations hereunder; and
(f) neither it nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of
this Agreement or that would impede the fulfillment of its obligations hereunder.
 
- 47 -13.2 Activities
Each Party will perform all activities under this Agreement (i) in a professional manner, (ii) in conformance with the level or care and skill ordinarily
exercised by other professional institutions in similar circumstances, and (iii) in compliance with Applicable Law.
 
13.3 Safety Data
FMI represents and warrants that FMI has disclosed to Roche and will immediately continue to disclose to Roche any relevant safety data relevant
to the Work Streams and assays being developed thereunder.
 
13.4 Third Party Patent Rights
FMI represents and warrants that FMI has no knowledge of the existence of any patent or patent application owned by or licensed to any Third
Party that could prevent in the Territory the activities contemplated under this Agreement.
 
13.5 Inventors
FMI represents and warrants that FMI has obtained the assignment of, or a license under, the FMI Background Patent Rights necessary to grant
the licenses granted hereunder. FMI shall obtain the assignment of, or a license under, the FMI Foreground Patent Rights necessary to grant the
licenses granted hereunder.
 
13.6 Grants
FMI represents and warrants that, to the best of FMI’s knowledge and belief, FMI has the lawful right to grant Roche and its Affiliates the rights
and licenses described in this Agreement.
 
13.7 Ownership and Validity of Know-How
FMI represents and warrants that FMI’s Know-How is legitimately in the possession of FMI and has not been misappropriated from any Third
Party. FMI has taken reasonable measures to protect the confidentiality of its Know-How.
 
13.8 Data Protection (Privacy) and Security.
 
  13.8.1 Study Data Collection
FMI shall collect and process Study Data in accordance with the provisions of this Agreement and in compliance with Applicable Law with respect
to the processing of Study Data, including but not limited to applicable international, US federal, state and local data protection and data security
laws.
 
  13.8.2 Data Protection
To ensure the privacy and security of the health or medical data, including Study Data or other Personal Data related to this Agreement that FMI
shall create, acquire, receive, maintain, or transmit as a result of entering into the Agreement, FMI shall implement adequate and reasonable
safeguards to prevent the use or disclosure of such information other than as provided for in the Agreement, and to protect the confidentiality,
integrity, and availability of such information. In addition, FMI shall protect all such data, in accordance with applicable international Data
Protection laws and US federal and state laws and regulations.
 
- 48 -13.8.3 Privacy
FMI understands and agrees that the confidentiality, privacy and security requirements contained in this Agreement also apply to any permitted
sub-contractors, temporary employees or other third-parties who receive any health or medical data, including Study Data, or other Personal Data,
as a result of this Agreement. FMI will ensure that all of these parties enter substantially similar confidentiality, privacy and security agreements
with Institution. Copies of such Agreements shall be provided to Roche within seven (7) business days upon written request of Roche.
 
  13.8.4 Training
FMI shall also ensure that its own employees, as well as any permitted subcontractors, temporary employees or other Third Parties who assist FMI
in performing activities under the Agreement, and who have access to any health or medical data, including Study Data or other Personal Data, as a
result of this Agreement receive appropriate privacy and security training, which shall be updated periodically in accordance with applicable laws,
regulations, and industry standard, or as otherwise reasonably requested by Roche.
 
  13.8.5 Processing of Study Data
FMI, its Affiliates and agents shall not collect or process health or medical data, including Study Data or any other Personal Data related to this
Agreement, in a manner that involves the transfer of such Personal Data from one jurisdiction to any other jurisdiction (the EEA constituting a
single jurisdiction for this purpose), without prior written consent of Roche.
 
  13.8.6 Compliance
FMI undertakes to comply with its obligations (if any) under applicable legislation to notify any supervisory authority of its collection and
processing activities under this Agreement and further agrees to take all such steps as Roche may reasonably require from time to time in order to
enable Roche to comply with any notification obligation applicable to Roche.
 
  13.8.7 Data Collection
FMI will ensure that it does not collect any health or medical data, including Study Data, relating to individuals other than the categories of data
specified in the protocol identified in the applicable Task Order and will collect and process Study Data for the sole purpose of the study identified
in the applicable Task Order and not further process such data in any other manner.
 
  13.8.8 Disclosure
FMI will not disclose health or medical data, including Study Data or any other Personal Data related to this Agreement to any Third Party outside
of the requirements of this Agreement without the prior permission in writing of Roche, except where such disclosure is required by any applicable
law, regulation or supervisory authority, in which case the Institution will, wherever possible, notify Roche prior to complying with any such
request for disclosure and shall comply with all reasonable directions of Roche with respect to such disclosure.
 
- 49 -13.8.9 Document Retention
FMI will have appropriate procedures in place for the destruction or purging of any medical or health data, including Study Data and any other
Personal Data, related to this Agreement when the retention time that applies to the data has been reached.
 
  13.8.10 Procedures
FMI shall ensure that it has appropriate procedures in place to fulfill applicable International Data Protection laws and US federal and state or other
legal requirements, should an individual request access to or changes to the health or medical data, including Study Data or any Personal Data
related to this Agreement, maintained by Institution. Institution will notify Roche promptly (and in any event within […***…] after receipt) of any
communication received from a Data Subject relating to the Data Subject a right to access, modify or correct Study Data and to comply with all
instructions of Roche in responding to such communications.
 
  13.8.11 Survival
FMI’s obligations to maintain privacy and security over medical or health data, including Study Data and other Personal Data received pursuant to
this Agreement, will survive the termination or expiration of this Agreement.
 
  13.8.12 Security Breach
At any time during the processing of Persona Data, FMI shall notify Roche immediately (but no later than […***…] from the date) of any Data
Security Breach involving Roche data. FMI shall assist and cooperate with Roche concerning any disclosures to affected parties, government or
regulatory agencies and with any other remedial measures requested by Roche or mandated by Applicable Law.
 
13.9 No Other Representations
EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT AND THE RELATED AGREEMENTS BEING ENTERED INTO BY THE PARTIES AT
THIS TIME, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OF PRODUCTS. IN NO EVENT SHALL EITHER FMI OR ROCHE BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL
OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY.
 
14. Indemnification
 
14.1 Indemnification by Roche
Roche shall indemnify, hold harmless and defend FMI and its directors, officers, employees and agents from and against any and all losses,
expenses, cost of defense (including without
 
***Confidential Treatment Requested***
- 50 -limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts FMI becomes legally
obligated to pay because of any claim or claims against it to the extent that such claim or claims arise out of Roche’s and its Affiliates’ actions or
inactions in connection with activities under this Agreement, except to the extent such losses, expenses, costs and amounts are due to the gross
negligence or willful misconduct or failure to act of FMI.
 
14.2 Indemnification by FMI
FMI shall indemnify, hold harmless and defend Roche and its directors, officers, employees and agents from and against any and all losses,
expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement)
and any amounts Roche becomes legally obligated to pay because of any claim or claims against it to the extent that such claim or claims arise out
of FMI’s and FMI’s Affiliates’ actions or inactions in connection with activities under this Agreement, except to the extent that such losses,
expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of Roche.
 
14.3 Procedure
In the event of a claim by a Third Party against a Party entitled to indemnification under this Agreement (“ Indemnified Party”), the Indemnified
Party shall promptly notify the other Party (“ Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and solely
manage and control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying
Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its choice. The Indemnifying Party shall
not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The
Indemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all liability
relating thereto, unless the Indemnified Party otherwise agrees in writing.
 
15. Liability
THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES NOT
EXPRESSLY SET FORTH HEREIN. FMI AND ROCHE DISCLAIM ALL OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH
RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WITHOUT
LIMITATION, WHETHER THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY, PERFORMANCE,
UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY
PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS.
 
16. Obligation Not to Disclose Confidential Information
 
16.1 Non-Use and Non-Disclosure
During the Agreement Term and for […***…] thereafter, a Receiving Party shall (i) treat Confidential Information provided by Disclosing Party as it
would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information
 
***Confidential Treatment Requested***
- 51 -to Third Parties, without the Disclosing Party’s prior written consent, and (iii) not use such Confidential Information other than for fulfilling its
obligations or exercising its rights under this Agreement. If any Confidential Information is required to be disclosed by the Receiving Party or its
Affiliates to comply with a court or administrative order, the Receiving Party or its Affiliates, prior to making such disclosure, shall furnish as much
notice as is reasonable under the circumstances to the Disclosing Party to enable it to resist such disclosure.
 
16.2 Permitted Disclosure
Notwithstanding the obligation of non-use and non-disclosure set forth in Section 16.1, the Parties recognize the need for certain exceptions to this
obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations.
 
16.3 Press Releases
Following the Effective Date, the Parties will issue a joint press release announcing the existence and selected key terms of this Agreement, in a
form substantially similar to the template attached as Appendix 16.3.
Each Party shall provide the other with a copy of any draft press release related to the activities contemplated by this Agreement at least ten (10)
Business Days prior to its intended publication for such other Party’s review. The reviewing Party may provide the releasing Party with suggested
modification to the draft press release. The releasing Party shall consider, and shall not unreasonably disregard, the reviewing Party’s suggestions
in issuing its press release. Notwithstanding the foregoing, each Party must comply with its obligations under Section 16.1 and 16.5.
 
16.4 Publications
During the Agreement Term, the following restrictions shall apply with respect to disclosure by any Party of Confidential Information in any
publication or presentation. A Party (“ Publishing Party”) shall provide the other Party with a copy of any proposed publication or presentation at
least […***…] prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably
believes are necessary to continue to maintain the Confidential Information disclosed by the other Party to the Publishing Party in accordance with
the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party
notifies (“Publishing Notice”) the Publishing Party in writing, within […***…] after receipt of the copy of the proposed publication or
presentation, that such publication or presentation in its reasonable judgment (i) contains an invention, solely or jointly conceived and/or reduced
to practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (ii) could be expected to have a material
adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party
shall prevent such publication or delay such publication for a mutually agreeable period of time. In the case of inventions, a delay shall be for a
period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event less than […
***…] from the date of the Publishing Notice.
 
***Confidential Treatment Requested***
- 52 -16.5 Commercial Considerations
Nothing in this Agreement shall prevent a Party or its Affiliates from disclosing Confidential Information of the other Party to (i) governmental
agencies to the extent required or desirable to secure government approval for the development, manufacture or sale of a product in the Territory
and (ii) Third Parties acting on behalf of a Party, to the extent reasonably necessary to conduct the activities contemplated by this Agreement
provided that such Third Parties are bound by confidentiality obligations with respect to such information that are no less stringent than those
included in this Agreement.
 
17. Term and Termination
 
17.1 Commencement and Term
This Agreement shall commence upon the Effective Date and continue for the Agreement Term.
 
17.2 Termination
 
  17.2.1 Termination for Breach
A Party (“Non-Breaching Party”) shall have the right to terminate this Agreement on a Work Stream-by-Work Stream basis, or, for Roche, on an
Approved Marker or Investigational Marker basis in the case of the CDx Development Program, in the event the other Party (“ Breaching Party”) is
in material breach of any of its material obligations under the applicable Work Stream (or obligations pertaining to an Approved Marker or
Investigational Marker program). Failure of FMI to comply materially with Performance Specifications or Quality Standards shall be considered a
material breach by FMI. For avoidance of doubt, a Non-Breaching Party shall only be permitted to terminate the Work Stream (or Approved Marker
or Investigational Marker program) to which a material breach of a material obligation relates. The Non-Breaching Party shall provide written notice
to the Breaching Party, which notice shall identify the breach. Except in the event of a breach that, by its nature, is not amenable to cure, in which
case termination may be made effective immediately, the Breaching Party shall have a period of […***…] after such written notice is provided
(“Peremptory Notice Period”) to cure such breach or, absent withdrawal of the Non-Breaching Party’s request for termination, the relevant Work
Stream (or Approved Marker or Investigational Marker program) shall terminate; provided that, if the Breaching Party has a  bona fide dispute as to
whether such breach: (i) occurred, (ii) pertains to a material obligation, or (iii) has been cured, the Breaching Party will so notify the Non-Breaching
Party, the relevant Work Stream (or Approved Marker or Investigational Marker program) shall not terminate and the expiration of the Peremptory
Notice Period shall be tolled until such dispute is resolved pursuant to Section 19.2. If such dispute is resolved by finding that the Non-Breaching
Party is entitled to terminate the relevant Work Stream (or Approved Marker or Investigational Marker program), the Breaching Party may have the
remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent
withdrawal of the Non-Breaching Party’s request for termination, the relevant Work Stream (or Approved Marker or Investigational Marker
program) shall terminate in accordance with the notice from the Non-Breaching Party as of the expiration of the Peremptory Notice Period.
 
  17.2.2 Insolvency
A Party shall have the right to terminate this Agreement, if the other Party incurs an Insolvency Event; provided, however, in the case of any
involuntary bankruptcy proceeding, such right to
 
***Confidential Treatment Requested***
- 53 -terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is
not dismissed within […***…] after the filing thereof.
 
  17.2.3 Termination by Roche without Cause
Roche shall have the right to terminate the Agreement in its entirety, or on a Work Stream-by-Work Stream basis, except for the ctDNA Work
Stream, upon […***…] prior written notice, without cause. With regard to the CDx Development Program, Roche shall also have the right to
terminate, without cause, the development of an Approved Marker and/or an Investigational Marker for inclusion in a CDx Assay, upon […***…]
prior written notice; provided however that this right shall expire with respect to each Approved Marker for inclusion in a particular CDx Assay at
such time as FMI has completed analytical validation for such Approved Marker. With regard to the Molecular Information Platform Program,
Roche shall have the right to terminate without cause either or both of the Sample Profiling or Molecular Information Database Access activities
individually.
 
  17.2.4 Termination by Roche for Frustration of Purpose
Roche shall have the right to terminate the ctDNA Platform Development Program upon […***…] prior written notice for frustration of purpose in
the event that the Clinical Study for which the ctDNA Assay is being developed is canceled.
 
17.3 Consequences of Termination
 
  17.3.1 Termination in General
Upon any termination of the Agreement, a Work Stream (or Approved Marker or Investigational Marker program), or this Agreement under Section
17.2.2, (i) FMI shall promptly return to Roche unused or remaining Samples that were provided for use in a terminated Work Stream (or related to the
relevant Approved Marker or Investigational Marker), or, at Roche’s option, securely dispose of all such unused or remaining Samples and provide
Roche with a written notice of such disposal, (ii) each Party shall wind-down their activities under the Agreement in a manner that is intended to be
expeditious and to mitigate losses arising from non-cancellable expenses and financial commitments to Third Parties, (iii) upon any termination by
Roche under Section 17.2.3, or by FMI under Section 17.2.1 or Section 17.2.2, that includes the Immunotherapy Testing Platform Development Work
Stream, the obligations in Section 3.2.8 shall terminate, (iv) each Party shall continue to Control its own intellectual property, including Patent
Rights and Know-How, and Handle its own Patent Rights, and (v) Joint Patent Rights, if any, shall be handled by Roche subject to the provisions
of Section 12.4 and 12.6, and each Party shall have the right to fully exploit such Joint Patent Rights.
17.3.2 Termination by FMI for Breach by Roche or Roche’s Insolvency; Termination by Roche Without Cause or for Frustration of Purpose
Upon any termination by FMI for breach by Roche under Section 17.2.1, for Roche’s Insolvency under Section 17.2.2, by Roche without cause
under Section 17.2.3, or by Roche for frustration of purpose under Section 17.2.4:
 
  (i) The rights and licenses granted by FMI to Roche hereunder shall terminate for the terminated Agreement, or Work Stream, or
portion of the Work Stream (as applicable, the “Terminated Matter”), on the effective date of termination;
 
***Confidential Treatment Requested***
- 54 -(ii) All licenses granted by Roche to FMI hereunder pertaining to the Terminated Matter become fully paid up, perpetual and
irrevocable;
 
 
(iii) Roche shall retain all licenses granted by FMI to Roche pertaining to intellectual property arising from work on the Terminated
Matter prior to termination, provided, however, FMI shall be under no obligation to Handle any patent or patent application
arising from Terminated Matters and may freely abandon (without offering Roche the right to Handle) or license (but, for clarity,
not exclusively license or assign without Roche’s consent if Roche retains license rights) such patent or patent application.
 
  (iv) Within […***…] after the effective date of termination and receipt by Roche of an invoice from FMI, Roche shall pay to FMI the
following amounts:
 
 
a. In the event of termination of the Molecular Information Platform Program Work Stream, Roche shall pay FMI all […
***…] that would be owed over the remainder of the Agreement Term, or any […***…], plus any applicable
incremental per Sample Profiling Fees for Sample Profiling performed by FMI during the year in which termination
occurs that are […***…];
 
 
b. In the event of termination of the Immunotherapy Testing Platform Development Work Stream, (1) for avoidance of
doubt, Roche shall pay FMI Roche’s share of any FMI Development Costs incurred in connection with the
Immunotherapy Testing Platform Development Work Stream as of the effective date of termination that were not
previously paid by Roche; (2) (A) if the effective date of termination occurs prior to FMI’s completion of the Immuno-
Biomarker Discovery Platform, then Roche will pay FMI for the entirety of the FMI Development Costs FMI incurred in
connection with FMI’s performance of the Immunotherapy Testing Platform Development Work Stream, excluding any
portion that was previously paid by Roche, or (B) if the effective date of termination occurs after FMI’s commencement
of Signature Identification services, then Roche will pay FMI for the entirety of the FMI Development Costs FMI
incurred prior to the effective date of termination in connection with any ongoing performance of Signature
Identification work by FMI, excluding any portion of such FMI Development Costs that was previously paid by Roche
or that is payable by Roche under the foregoing clause (1); and (3) Roche shall pay FMI in accordance with Section
8.3.2 with respect to signatures developed by FMI prior to the effective date of termination.
 
 
c. In the event of termination of the ctDNA Platform Development Program Work Stream, Roche shall have no contractual
payment obligation under this Section 17.3.2; provided, however, that Roche shall be obligated to honor payment
obligations triggered prior to the effective date of termination;
 
 
d. In the event of termination of the CDx Development Program Work Stream: for avoidance of doubt, Roche shall pay any
FMI Development Costs in connection with the development of an Investigational Marker as specified by Section 8.5.1
incurred as of the effective date of termination that were not previously paid by Roche and any non-cancellable
commitments reasonably incurred by FMI in
 
***Confidential Treatment Requested***
- 55 -anticipation of receiving PMA with regard to any Investigational Marker to the extent not re-allocable to FMI’s other
business activities, including without limitation, all accrued amounts under any individual CDx R&D Plan entered into
by the Parties as described in Section 3.4.8 above; (ii) if the effective date of such termination is after FMI has
completed analytical validation of any Investigational Marker for inclusion in a CDx Assay, then Roche shall remain
obligated to pay a fee for each such terminated Investigational Marker equal to […***…] upon PMA approval; and (iii)
the milestone payments specified under Section 8.5.3 shall apply with respect to CDx Assays containing any Approved
Marker and/or Investigational Marker; and
 
  e. In the event of termination of the Agreement in its entirety under 17.2.2, Roche shall pay to FMI all amounts under the
foregoing subsections (a) through (d) (inclusive) as applicable, if such fees become payable.
 
 
(v) FMI shall retain all rights and remedies available to it under law and equity in connection with breach by Roche under Section
17.2.1 or other termination under Section 17.2.2, Section 17.2.3, or 17.2.4, provided, however, that in the case of termination of the
Molecular Information Platform Program under Section 17.2.1 or Section 17.2.3 above, FMI’s exclusive remedy (other than for
breach of confidentiality under Section 16.1) shall be the accelerated payments specified under Section 17.3.2(iv)a.
For avoidance of doubt, in the event FMI terminates the Agreement in its entirety due to Roche’s Insolvency, all Work Streams and other activities
under the Agreement will be deemed to be terminated and all of the applicable effects of termination in this Section 17.3.2 shall apply.
 
  17.3.3 Termination by Roche for Breach by FMI or FMI Insolvency
Upon any termination by Roche for breach by FMI under Section 17.2.1 or FMI’s Insolvency, under Section 17.2.2:
 
  (i) The rights and licenses granted by Roche to FMI under Section 2.1 shall terminate for each terminated Work Stream, on the
effective date of termination, except that the rights granted to FMI under Section 2.1.2 shall survive such termination;
 
  (ii) All licenses granted by FMI to Roche hereunder pertaining to a terminated Work Stream become fully paid up, perpetual and
irrevocable;
 
  (iii) The […***…] under Section 3.2.10 shall survive termination of the Immunotherapy Testing Platform Development Work Stream;
 
  (iv) The […***…] under Section 3.3.9 shall survive termination of the ctDNA Platform Development Program Work Stream;
 
 
(v) Within […***…] after the effective date of termination and receipt by Roche of an accounting from FMI, FMI shall pay to
Roche any unused Reserved Capacity Fees and Database Access Fees previously paid pursuant to Section 8.2.1.1 or any other
unused and pre-paid amounts;
 
***Confidential Treatment Requested***
- 56 -(vi) FMI shall transfer to Roche all FMI Know-How, other than FMI Know-How pertaining to the Molecular Information Platform
Program, necessary for Roche to practice the Terminated Matter, solely for the purposes or practicing the Terminated Matter,
including any necessary algorithms; and
 
  (vii) Roche shall retain all rights and remedies available to it under law and equity in connection with such breach by FMI.
For avoidance of doubt, in the event Roche terminates the Agreement in its entirety due to FMI’s Insolvency, all Work Streams and other activities
under the Agreement will be deemed to be terminated and all of the applicable effects of termination in this Section 17.3.3 shall apply.
 
  17.3.4 Direct License
Irrespective of anything to the contrary in this Agreement, any existing, permitted sublicense granted by a Party under this Agreement (and any
further sublicenses thereunder) shall, upon a termination of the license granted hereunder that pertains to such sublicense, shall terminate;
provided that if the licensee Party so requests in writing, the licensor Party shall negotiate with the relevant sublicensee towards the grant of a
direct license of rights, provided that such sublicensee is not then in breach of its sublicense agreement with the licensee Party.
 
17.4 Other Obligations
Termination of this Agreement by a Party, for any reason, shall not release Roche from any obligation to make payments to FMI that are due and
payable prior to the effective date of termination. Termination of this Agreement by a Party, for any reason, will release Roche from any obligation
to any payments to FMI that would otherwise become due or payable on or after the effective date of termination.
 
17.5 Survival
In addition to any provisions that expressly survive in accordance with Article 17.3, Article 1 (Definitions, to the extent necessary to interpret the
Agreement), Section 3.5.2 (Sample Handling and Disposal, to the extent applicable), Section 10 (Taxes), Section 12.1 (Ownership of Inventions),
Section 12.9 (Common Interest Disclosures), Section 13.8.11 (Survival of Privacy and Security Obligations), Article 14 (Indemnification), Article 16
(Obligation Not to Disclose Confidential Information), Section 17.3 (Consequences of Termination), Section 17.5 (Surival), Section 19.1 (Governing
Law), and Section 19.3 (Arbitration) shall survive any expiration or termination of this Agreement for any reason. Notwithstanding the foregoing,
any provision of this Agreement that is intended by its very nature to survive expiration or termination of this Agreement shall also survive.
 
18. Bankruptcy
All licenses (and to the extent applicable rights) granted under or pursuant to this Agreement by FMI to Roche are, and shall otherwise be deemed
to be, for purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under
Section 101(35A) of the Bankruptcy Code. Unless Roche elects to terminate this Agreement, the Parties agree that Roche, as a licensee or
sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code,
subject to the continued performance of its obligations under this Agreement.
 
- 57 -19. Miscellaneous
 
19.1 Governing Law
This Agreement shall be governed by and construed in accordance with the laws of New York, US, without reference to its conflict of laws
principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention).
 
19.2 Disputes
Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred to the
respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The
designated executive officers are as follows:
 
For FMI: CEO
For
Roche:
Head of Roche Partnering
 
19.3 Arbitration
Should the Parties fail to agree within […***…] after such dispute has first arisen, it shall be finally settled by arbitration in accordance with the
Rules of American Arbitration Association  (“AAA”) as in force at the time when initiating the arbitration. The tribunal shall consist of three
arbitrators. The place of arbitration shall be New York, New York, US. The language to be used shall be English.
 
  19.3.1 Arbitrators
Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the request for arbitration within […***…] of being
requested to do so, or if the respondent should fail to appoint an arbitrator in its answer to the request for arbitration within […***…] of being
requested to do so, the other Party shall request the AAA to make such appointment.
The arbitrators nominated by the Parties shall, within […***…] from the appointment of the arbitrator nominated in the answer to the request for
arbitration, and after consultation with the Parties, agree and appoint a third arbitrator, who will act as a chairman of the Arbitral Tribunal. Should
such procedure not result in an appointment within the […***…] time limit, either Party shall be free to request the AAA to appoint the third
arbitrator.
Where there is more than one claimant and/or more than one respondent, the multiple claimants or respondents shall jointly appoint one arbitrator.
Any Party-appointed arbitrator or the third arbitrator resigns or ceases to be able to act, a replacement shall be appointed in accordance with the
arrangements provided for in this clause.
The language of the arbitration shall be English. Documents submitted in the arbitration (the originals of which are not in English) shall be
submitted together with an English translation.
 
  19.3.2 Decisions; Timing of Decisions
The arbitrators shall render a written opinion setting forth findings of fact and conclusions of law with the reason therefor stated, within no later
than […***…] from the date on which the arbitrators were appointed to the dispute. A transcript of the evidence adduced at the arbitration hearing
shall be made and, upon request, shall be made available to each Party.
 
***Confidential Treatment Requested***
- 58 -The time periods set forth in the AAA Arbitration Rules shall be followed; provided however that the arbitrators may modify such time periods as
reasonably necessary to render a written opinion in accordance with this Section 19.3.2.
The Arbitrator is empowered to award any remedy allowed by law, including money damages, prejudgment interest and attorneys’ fees, and to
grant final, complete, interim, or interlocutory relief, including injunctive relief.
This arbitration agreement does not preclude either Party seeking conservatory or interim measures from any court of competent jurisdiction
including, without limitation, the courts having jurisdiction by reason of either Party’s domicile. Conservatory or interim measures sought by either
Party in any one or more jurisdictions shall not preclude the Arbitral Tribunal granting conservatory or interim measures. Conservatory or interim
measures sought by either Party before the Arbitral Tribunal shall not preclude any court of competent jurisdiction granting conservatory or interim
measures.
In the event that any issue shall arise which is not clearly provided for in this Section 19.3, the matter shall be resolved in accordance with the AAA
Arbitration Rules.
Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard each Party’s
Confidential Information. Except as required by law, neither Party shall make (or instruct the arbitrators to make) any public announcement with
respect to the proceedings or decision of the arbitrators without prior written consent of the other Party. The existence of any dispute submitted to
arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of
such award or as otherwise required by Applicable Law.
Notwithstanding anything to the contrary in this Agreement, any and all issues regarding the scope, construction, validity and/or enforceability of
any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent
Rights in question.
Notwithstanding anything to the contrary in this Agreement, any and all issues regarding a breach or alleged breach of a Party’s obligations under
Article 16 (Obligation Not to Disclose Confidential Information) shall be determined in a court of competent jurisdiction under the laws of New York,
with express exclusion of its conflict of laws principles.
 
19.4 Assignment
Neither Party shall have the right to assign the present Agreement or any part thereof to any Third Party other than Affiliates without the prior
written approval of the other Party.
 
19.5 Debarment and Exclusion
 
  19.5.1 Past Activities
Each Party represents and warrants that it has never been debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R. §312.70 or §812.119,
sanctioned by a Federal Health Care
 
- 59 -Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred,
suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event a Party receives notice
of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the above-referenced statutes, such Party shall immediately
notify the other Party in writing and such other Party shall have the right, but not the obligation, to terminate this Agreement, effective, at such
other Party’s option, immediately or at a specified future date.
 
  19.5.2 Future Activities
Each Party agrees that, to the best of its knowledge, none of its employees or agents conducting activities on its behalf under the Agreement is
currently or will be during the term of this Agreement, debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned
by a Federal Health Care Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid
program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event a
Party learns that any such employee or agent becomes so debarred, sanctioned, suspended, excluded or declared ineligible or is the subject of
proceedings that may result in such debarment, sanction, suspension, exclusion or ineligibility, it will promptly so notify the other Party and will no
longer allow such employee or agent to conduct activities under this Agreement.
 
19.6 Independent Contractor
No employee or representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any
manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all
purposes, and not- withstanding any other provision of this Agreement to the contrary, FMI legal relationship to Roche under this Agreement shall
be that of independent contractor.
 
19.7 Unenforceable Provisions and Severability
If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by
valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this
Agreement will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably
have concluded this Agreement without the unenforceable provisions.
 
19.8 Waiver
The failure by either Party to require strict performance and/or observance of any obligation, term, provision or condition under this Agreement will
neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The
waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach
thereof or of any other obligation, term, provision or condition.
 
19.9 Appendices
All Appendices to this Agreement shall form an integral part to this Agreement.
 
- 60 -19.10 Entire Understanding
This Agreement contains the entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all
prior agreements, understandings and arrangements, whether written or oral.
 
19.11 Amendments
No amendments of the terms and conditions of this Agreement shall be binding upon either Party hereto unless in writing and signed by both
Parties.
 
19.12 Invoices
All invoices that are required or permitted hereunder shall be in writing and sent by FMI to Roche at the following address or other address as
Roche may later provide:
F. Hoffmann-La Roche Ltd
Kreditorenbuchhaltung
4070 Basel
Switzerland
 
19.13 Notice
All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly
confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by
registered or certified mail, postage prepaid, return receipt requested, addressed as follows:
 
if to FMI, to: Foundation Medicine, Inc.
150 Second Street
Cambridge, Massachusetts 02141
Attn: Legal Department
Facsimile No.: +1 617 418 2201
if to Roche, to: F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
4070 Basel
Switzerland
Attn: Legal Department
Facsimile No.: +41 61 688 13 96
and: Hoffmann-La Roche Inc.
150 Clove Road
Suite 8
Little Falls, New Jersey 07424
US
Attn. Corporate Secretary
Facsimile No.: +1 973 890-8433
 
- 61 -or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith.
[Signature Page Follows]
 
- 62 -IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date.
 
Foundation Medicine, Inc.
/s/ Steven J. Kafka
Name: Steven J. Kafka
Title: Chief Operating Officer
 
F. Hoffmann-La Roche Ltd
/s/ Jason Coloma /s/ Stefan Arnold
Name: Jason Coloma Name: Stefan Arnold
Title: Global Head of Venture & Innovation, Roche Partnering Title: Head Legal Pharma
 
Hoffmann-La Roche Inc.
/s/ John P. Parise
Name: John P. Parise
Title: Authorized SignatoryAppendix 1.28
Excluded Patent Rights
[…***…].
 
***Confidential Treatment Requested***
A-1Appendix 1.57
[…***…]
 
***Confidential Treatment Requested***
A-2Appendix 1.64
[…***…]
 
***Confidential Treatment Requested***
A-3Appendix 3.1.3
Form of Task Order
TASK ORDER FOR MOLECULAR INFORMATION PLATFORM AGREEMENT
This [Insert number of Task Order] Task Order is effective as of the last date below (“Task Order # Effective Date.
TASK: [Insert Task Name]
FMI Reference Number: [Insert FMI Reference Number]
 
Roche Contact: [Insert Roche Contact ]
This Task is divided into the following six sections:
 
  A. Task Activities – Description of the Task Activities to be performed.
 
  B. Schedule – Task start date, projected end date and checkpoint dates (if any).
 
  C. Dependencies – Obligations, technology requirements.
 
  D. Deliverables – Identifiable work product resulting from the Task.
 
  E. Fee – Fixed price or time & materials rates and payment schedules.
 
  F. Special Terms – Terms applicable to this specific effort not addressed by this Agreement.
 
A. Task Activities 
[Describe Task Activities to be provided]
 
B. Schedule 
[Describe schedule for Task Activities to be provided and specify the duration of the Task Activities]
 
C. Dependencies 
[Describe dependencies as relating to the Task Activities]
 
D. Deliverables 
[Describe deliverables as relating to the Task Activities]
 
E. Fee 
[Describe payment schedule and form of payment for the Task Activities]
 
F. Special Terms 
[Describe any special terms for the Task Activities]
Signatures of Project ManagersFMI ROCHE
By:   By:  
Name:   Name:  
Title:   Title:  
Date:   Date:  
 
A-5Appendix 3.1.6
[…***…]
 
***Confidential Treatment Requested***
A-6Appendix 3.2.4
Excluded Contracts
[…***…]
 
***Confidential Treatment Requested***
A-7Appendix 3.5.1
FMI Specimen RequirementsAppendix 16.3
Form of Press Release
 
A-9EXHIBIT B 
COOPERATION AGREEMENT
This Agreement dated March 13, 2014 is by and between JANA Partners LLC (“JANA”) and URS Corporation (the “Company”).In consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuableconsideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
1. Representations and Warranties of the Company. The Company represents and warrants to JANA that this Agreementhas been duly authorized, executed and delivered by the Company, and is a valid and binding obligation of the Company, enforceableagainst the Company in accordance with its terms.
2. Representations and Warranties of JANA. JANA represents and warrants to the Company that this Agreement has beenduly authorized, executed and delivered by JANA, and is a valid and binding obligation of JANA, enforceable against JANA inaccordance with its terms. As of the date of this Agreement, JANA beneficially owns 6,745,623 shares of the Company’s commonstock and has voting authority over such shares.
3. Board Nomination and Other Company Matters.
(a) In accordance with the Company’s By­Laws and Delaware law, the Company agrees that, effective as of thenext meeting (the “March Board Meeting”) of the Board of Directors of the Company (the “Board”), which shall be held not laterthan March 27, 2014, and prior to taking any other formal action at such meeting, the Board will:
(1) increase the size of the Board to fourteen (14) members; and
(2) appoint Diane C. Creel, William H. Schumann, III, David N. Siegel and V. Paul Unruh (together, the“JANA Nominees”) (other than in the case of the refusal or inability of any such person to serve, in which case, the Board shallappoint his/her substitute chosen in accordance with Section 3(c)) as Company directors to fill the vacancies created thereby and tohave the same rights of participation in all other matters undertaken at the March Board Meeting as the other Company directors;provided, however, that as a condition to the appointment of each JANA Nominee, such JANA Nominee shall have completed andexecuted the Company’s 2014 Questionnaire for Potential Director Nominees and the Director Nominee Representation andAgreement, provided that such documents have not been amended in any material respect from the versions provided to JANA priorto the date of this Agreement, and have agreed to comply with all policies, codes of conduct, confidentiality obligations and codes ofethics applicable to all of the Company’s directors, including the Company’s Code of Business Conduct, to provide the informationregarding themselves that is required to be disclosed for candidates for directors and directors in a proxy statement under the federalsecurities laws of the United States of America and/or applicable New York Stock Exchange rules and regulations, and to providesuch other customary information as reasonably requested by the Company; and provided, further that any JANA Nominee mayparticipate in the March Board Meeting telephonically if unable to attend in person.
(b) The Company agrees that:(1) the Board will not approve any material new transactions prior to the March Board Meeting;
(2) at the 2014 annual meeting of the Company’s shareholders (the “2014 Annual Meeting”), the Board willnominate the JANA Nominees (other than in the case of the resignation, refusal or inability of any such person to serve, in whichcase, the Board shall nominate his/her substitute chosen in accordance with Section 3(c)), together with the other persons included inthe Company’s slate of nominees for election as director at the 2014 Annual Meeting in accordance with Section 3(d), as directors ofthe Company, in each case with a term expiring at the 2015 annual meeting of the Company’s shareholders (the “2015 AnnualMeeting”);
(3) the Board will recommend that the shareholders of the Company vote to elect the JANA Nominees asdirectors of the Company at the 2014 Annual Meeting;
(4) the Company shall use its reasonable best efforts (which shall include the solicitation of proxies) to obtainthe election of the JANA Nominees at the 2014 Annual Meeting (it being understood that such efforts shall be not less than theefforts used by the Company to obtain the election of any other independent (as determined under Section 303A of the New YorkStock Exchange's Listed Company Manual) director nominee nominated by it to serve as a director on the Board at the 2014 AnnualMeeting); and
(5) two individuals who are Company directors as of the date of this Agreement (other than Martin M.Koffel, or in addition to Mr. Koffel if applicable under Section 4(b) of this Agreement) will not seek re-election to the Board at the2014 Annual Meeting, and the Company shall not seek to fill such vacancies.
(c) The Company agrees that if any of the JANA Nominees resigns as a director or otherwise refuses to or is unableto serve as a director at any time prior to the 2015 Annual Meeting, including as a result of death or disability, JANA shall be entitledto designate a replacement director who shall be independent of JANA, would be considered an independent director of the Companyunder Section 303A of the New York Stock Exchange’s Listed Company Manual, is reasonably acceptable to the Board as areplacement director and has a comparable amount of business experience, although such experience need not be in the sameindustry or industries, and is in equally good standing in all material respects, as the JANA Nominee being replaced. For the avoidanceof doubt, the substitute director shall thereafter be deemed a JANA Nominee for purposes of this Agreement and be entitled to thesame rights and subject to the same requirements under this Agreement applicable to the resigning JANA Nominee prior to his or herresignation, and such person shall be appointed to the Board to serve the unexpired term, if any, of such JANA Nominee.
(d) Other than the JANA Nominees, the Board will only nominate eight (8) individuals for election at the 2014 AnnualMeeting, including Mr. Koffel subject to Section 4(b) of this Agreement.
(e) Promptly following the 2014 Annual Meeting, the Board will decrease the size of the Board to twelve (12)members. Until the 2015 Annual Meeting, the Company shall not increase the size of the Board in excess of twelve (12) members,and shall not decrease the size of the Board if such decrease would require the resignation of one or more of the JANA Nominees.Other than for vacancies filled pursuant to Section 3(c) or arising as a result of a breach of this Agreement by the Company, nothingin this Agreement shall prevent the Company from filling all vacancies in accordance with the By-Laws of the Company.(f) The Company will take appropriate action so that, prior to the 2015 Annual Meeting, its director change of positionpolicy does not require a JANA Nominee to resign by reason of any material change in his or her primary job responsibility or positionheld at the time such JANA Nominee was appointed to the Board.
4. CEO Succession.
(a) At the March Board Meeting, the Company shall appoint two JANA Nominees chosen by JANA to the CEOSuccession Committee of the Board (the “CEO Succession Committee”) and shall appoint such JANA Nominees to any othercommittee currently or in the future designated to review or oversee the selection process for a successor to Mr. Koffel as chiefexecutive officer or substantially similar position (the “New CEO”), and shall not otherwise increase the size of the CEO SuccessionCommittee or any such other committee. In the event of the replacement as set forth in Section 3(c) of any JANA Nomineeappointed to the CEO Succession Committee pursuant to this Section 5, his or her successor shall be promptly appointed to thecommittee seat vacated by such former director to serve until the 2015 Annual Meeting. The CEO Succession Committee and anyother committee currently or in the future designated to review or oversee the selection process for the New CEO shall not take anymaterial action prior to the March Board Meeting.
(b) In order to ensure an orderly transition, Mr. Koffel may in his sole discretion continue (including, for the avoidanceof doubt, after the 2014 Annual Meeting) as the Chief Executive Officer, Chairman of the Board and a director of the Companyduring the selection process for the New CEO until the Board shall appoint the New CEO, which shall not be later than the earlier ofDecember 31, 2014, or Mr. Koffel’s voluntary resignation from such positions; provided that Mr. Koffel will resign as a director ofthe Company and the Chairman of the Board upon the effectiveness of the Board’s appointment of the New CEO; provided, further,that nothing contained herein is intended to modify any employment agreement, equity award, retirement plan or other pre-existingobligation of the Company to Martin Koffel or to impose any additional obligations on Martin Koffel (beyond the obligation to resign asprovided in this Section 4(b)). The Board shall appoint the New CEO as a director of the Company with a term expiring at theCompany’s next annual meeting after his or her appointment.
5. Compensation Committee. At the March Board Meeting, the Company shall appoint one JANA Nominee chosen by JANA(provided that such JANA Nominee must have prior experience serving on the Compensation Committee of a public companyincorporated in the United States and listed for trading on the New York Stock Exchange or NASDAQ) to the CompensationCommittee of the Board (the “Compensation Committee”), and shall not otherwise increase the size of the Compensation Committeeuntil the 2015 Annual Meeting. In the event of the replacement as set forth in Section 3(c) of any JANA Nominee appointed to theCompensation Committee pursuant to this Section 5, his or her successor shall be promptly appointed to the committee seat vacatedby such former director to serve until the 2015 Annual Meeting. The Compensation Committee and any other committee currently orin the future designated to review or oversee compensation shall not take any material action prior to the March Board Meeting.
6. Value Creation Committee and Other Matters.
(a) At the March Board Meeting, the Board shall establish a new committee of the Board (the “Value CreationCommittee”), whose purpose will be to evaluate all options for enhancing shareholder value, including by (i) engaging Bank ofAmerica Merrill Lynch, or if Bank of America Merrill Lynch is unavailable or the Company is unable to reach acceptable terms withMerrill Lynch Bank of America despite using reasonable best efforts to do so, another investment bank mutually agreeable to theCompany and JANA, as promptly as practicable, to review all options for enhancing value, including by conducting a strategic reviewof the Company’s business, operations and capitalstructure; (ii) engaging a cost consultant, mutually agreeable to the Company and JANA, to conduct a cost review commencing withthe completion of the investment banker review described in clause (ii) above; and (iii) reviewing the Company’s managementcompensation structure to enhance alignment with shareholder value creation. There shall be four (4) members of the Value CreationCommittee, two (2) of whom shall be JANA Nominees chosen by JANA, and the Board shall not increase the size of the ValueCreation Committee until the 2015 Annual Meeting, if still in existence at such time. In the event of the replacement as set forth inSection 3(c) of any JANA Nominee appointed to the Value Creation Committee pursuant to this Section 5, his or her successor shallbe promptly appointed to the committee seat vacated by such former director to serve until the 2015 Annual Meeting
(b) The Company hereby agrees that it will not make any acquisitions during the Cooperation Period, except forordinary course acquisitions individually under $10 million (not to exceed $30 million in the aggregate) or acquisitions that a majority ofthe JANA Nominees have recommended.
7. Cooperation.
(a) JANA agrees that, from the date of this Agreement until the earliest of (i) the date that is thirty (30) calendardays prior to any applicable deadline by which a shareholder must give notice to the Company of its intention to nominate a directorfor election at or bring other business before the 2015 Annual Meeting under the Company’s By­Laws and (ii) any material breach ofthis Agreement by the Company (provided that the Company shall have three (3) business days following written notice from JANAof material breach to remedy such material breach if capable of remedy) (such period, the “Cooperation Period”), neither it nor any ofits Affiliates or Associates will in any manner, directly or indirectly, make, or cause to be made, or in any way encourage any otherperson to make or cause to be made, any statement or announcement that relates to and constitutes an ad hominem attack on, orrelates to and otherwise disparages, the Company, any of its officers or directors or any person who has served as an officer ordirector of the Company, including: (i) in any document or report filed with or furnished to the Securities and Exchange Commission(the “SEC”) or any other governmental agency, (ii) in any press release or other publicly available format or (iii) to any journalist ormember of the media (including without limitation, in a television, radio, newspaper or magazine interview), or otherwise; provided,that if the Company makes any material announcement prior to the March Board Meeting, JANA will be permitted to make objectivestatements that solely reflect JANA’s view, as a shareholder, with respect to such announcement.
(b) The Company agrees that, from the date of this Agreement until the earliest of (i) the date that is thirty (30)calendar days prior to any applicable deadline by which a shareholder must give notice to the Company of its intention to nominate adirector for election at or bring other business before the 2015 Annual Meeting under the Company’s By­Laws and (ii) any materialbreach of this Agreement by JANA (provided that JANA shall have three (3) business days following written notice from theCompany of material breach to remedy such material breach if capable of remedy), neither it nor any of its Affiliates or Associateswill in any manner, directly or indirectly make, or cause to be made, or in any way encourage any other person to make or cause to bemade, any statement or announcement that relates to and constitutes an ad hominem attack on, or relates to and otherwise disparages,JANA, any of its members, officers or directors or any person who has served as a member, officer or director of JANA, including:(i) in any document or report filed with or furnished to the SEC or any other governmental agency, (ii) in any press release or otherpublicly available format or (iii) to any journalist or member of the media (including without limitation, in a television, radio, newspaperor magazine interview), or otherwise.(c) The limitations set forth in Sections 7(a) and 7(b) shall not prevent either party from responding to any publicstatement made by the other party of the nature described in Sections 7(a) and 7(b) if such statement by the other party was made inbreach of this Agreement.
(d) During the Cooperation Period, JANA shall cause all shares of the Company’s capital stock (“Shares”)beneficially owned, directly or indirectly, by it, or by any of its Affiliates or Associates (including without limitation all Sharesbeneficially owned as of the respective record dates for the 2014 Annual Meeting and as of the record dates for any special meetingof shareholders) over which it exercises or has voting authority, to be present for quorum purposes and to be voted, at such meetingsor at any adjournments or postponements thereof, in favor of the current members of the Board (including the JANA Nominees) thatwill be up for election at such meetings, and not to submit any proposal for consideration at, or bring any other business before, the2014 Annual Meeting or initiate, encourage or participate in any “withhold” or similar campaign with respect to the election ofdirectors at the 2014 Annual Meeting and shall not permit any of its Affiliates or Associates to do any of the foregoing or publicly orprivately encourage or support any other stockholder to take any such actions.
(e) During the Cooperation Period, JANA will not, and shall cause its Affiliates and Associates to not, directly orindirectly, without the prior written consent of the Company: (i) acquire, seek or propose (publicly or otherwise) to acquire, beneficialownership, directly or indirectly, of any additional Shares or rights or options to acquire any additional Shares if such acquisition wouldcause JANA’s beneficial ownership to exceed 14.9% of the Company’s common stock; (ii) publicly seek or propose to influence orcontrol the management or policies of the Company, seek or propose (publicly or otherwise) to obtain representation on the Board(except as set forth herein), or solicit, or participate in the solicitation of, any proxies or consents with respect to any securities of theCompany, or publicly request permission to do any of the foregoing, or take any action which would, or would reasonably be expectedto, require public disclosure regarding any of the types of matters set forth in this clause (ii); (iii) submit (publicly or otherwise) aproposal for, or offer of (with or without conditions) any extraordinary transaction (including a tender offer, exchange offer, merger,acquisition or consolidation) involving the Company or its securities or assets or take any action which would, or would reasonably beexpected to, require public disclosure regarding any of the types of matters set forth in this clause (iii); (iv) request (publicly orotherwise) a special meeting of the Company’s shareholders or submit, or participate in, any shareholder proposal to the Company orany “shareholder access” proposal that may be adopted by the SEC; or (v) encourage, assist or enter into any discussions,negotiations, arrangements or understandings with any third party with respect to any of the foregoing, or otherwise form, join or inany way participate in a “group” (as defined in Section 13(d)(3) of the Exchange Act) in connection with any of the foregoing. JANAalso agrees not to, and to cause its Affiliates and Associates not to, request during the Cooperation Period that the Company (or itsdirectors, officers, employees or agents), directly or indirectly, amend or waive any provision of this Section (including this sentence),publicly or in a manner that would require public disclosure of such request.
(f) Nothing in this Agreement shall be deemed to limit JANA’s ability to provide its views privately to the Board onany matter or to privately request a waiver of any provision of this Agreement, provided that such actions are not reasonablyexpected to require public disclosure of such actions.
8. Public Announcement and SEC Filing.
(a) JANA and the Company shall announce this Agreement and the material terms hereof including the terms ofSection 6 by means of a joint press release in the form attached hereto as Exhibit A (the “Press Release”) as soon as practicable butin no event later than 9:00 a.m., New York City time, on March 17, 2014.(b) JANA shall promptly prepare and file an amendment (the “13D Amendment”) to its Schedule 13D with respect tothe Company filed with the SEC on February 27, 2014 reporting the entry into this Agreement and amending applicable items toconform to its obligations hereunder. The 13D Amendment shall be consistent with the Press Release and the terms of thisAgreement. JANA shall provide the Company with reasonable opportunity to review and comment upon the 13D Amendment prior tofiling, and shall consider in good faith any changes proposed by the Company necessary to cause such 13D Amendment to complywith this Agreement.
9. Definitions. For purposes of this Agreement:
(a) the terms “Affiliate” and “Associate” shall have the respective meanings set forth in Rule 12b­2 promulgated bythe SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”);
(b) the terms “beneficial owner” and “beneficially own” shall have the same meanings as set forth in Rule 13d­3promulgated by the SEC under the Exchange Act except that a person shall also be deemed to be the beneficial owner of all Shareswhich such person has the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuantto the exercise of any rights in connection with any securities or any agreement, arrangement or understanding (whether or not inwriting), regardless of when such rights may be exercised and whether they are conditional, and all Shares which such person or anyof such person’s Affiliates or Associates has or shares the right to vote or dispose; and
(c) the terms “person” or “persons” shall mean any individual, corporation (including not­for­profit), general or limitedpartnership, limited liability or unlimited liability company, joint venture, estate, trust, association, organization or other entity of any kindor nature.
10. Notices. All notices, consents, requests, instructions, approvals and other communications provided for herein and all legalprocess in regard hereto shall be in writing and shall be deemed validly given, made or served, if (a) given by telecopy and email,when such telecopy is transmitted to the telecopy number set forth below and sent to the email address set forth below and theappropriate confirmation is received or (b) if given by any other means, when actually received during normal business hours at theaddress specified in this Section:
if to the Company: URS Corporation600 Montgomery Street, 26th FloorSan Francisco, California 94111Attention: General CounselFacsimile: (415) 834-1506Email: joseph.masters@urs.com with a copy to: Wachtell, Lipton, Rosen & Katz51 W. 52nd StreetNew York, NY 10019Attention: David E. ShapiroFacsimile: (212) 403-2000Email: DEShapiro@wlrk.comif to JANA: JANA Partners LLC767 Fifth Avenue, 8th FloorNew York, New York 10153Attention: General CounselFacsimile: (212) 455-0901Email: jennifer.fanjiang@janapartners.com with a copy to: Schulte Roth & Zabel919 Third AvenueNew York, NY 10022Attention: Marc WeingartenFacsimile: (212) 593-5955Email: marc.weingarten@srz.com 
11. Specific Performance; Remedies.
(a) In furtherance and not in limitation of Section 11(b), the parties hereto shall be entitled to seek an injunction orinjunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in additionto any other remedy to which they are entitled at law or in equity. FURTHERMORE, EACH OF THE PARTIES HERETO (A)IRREVOCABLY WAIVES THE RIGHT TO TRIAL BY JURY AND (B) AGREES TO WAIVE ANY BONDINGREQUIREMENT UNDER ANY APPLICABLE LAW, IN THE CASE ANY OTHER PARTY SEEKS TO ENFORCE THETERMS BY WAY OF EQUITABLE RELIEF. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS,INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF DELAWAREWITHOUT GIVING EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE.
(b) Notwithstanding any other Section in this Agreement and without limiting any other remedies the Company mayhave in law or equity, in the event that JANA (or any Affiliate or Associate of JANA) fails to perform or otherwise fulfill itsobligations set forth in Section 7 in any material respect, and shall not have remedied such failure or non-fulfillment if capable of beingremedied or fulfilled within three (3) business days following written notice from the Company of such failure or non-fulfillment, theCompany shall not be required to perform or fulfill its obligations set forth in Sections 3, 4, 5 or 7 and the JANA Nominees shall eachpromptly tender their resignation as a member of the Board effective immediately upon its acceptance by the Company. As acondition to nomination and/or appointment to the Board pursuant to this Agreement, each JANA Nominee shall have executed anirrevocable letter agreement with the Company in which each such JANA Nominee shall agree to resign if required in accordancewith the immediately preceding sentence.
12. Severability. If at any time subsequent to the date hereof, any provision of this Agreement shall be held by any court ofcompetent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality orunenforceability of such provision shall have no effect upon the legality or enforceability of any other provision of this Agreement.
13. Termination. This Agreement shall terminate on the expiry of the Cooperation Period.
14. Counterparts. This Agreement may be executed in two (2) or more counterparts which together shall constitute a singleagreement.
15. No Third Party Beneficiaries. This Agreement is solely for the benefit of the parties hereto and is not enforceable by anyother persons.16. No Waiver. No failure or delay by either party in exercising any right or remedy hereunder shall operate as a waiverthereof, nor shall any single or partial waiver thereof preclude any other or further exercise thereof or the exercise of any other rightor remedy hereunder.
17. Entire Understanding. This Agreement contains the entire understanding of the parties with respect to the subject matterhereof and may be amended only by an agreement in writing executed by the parties hereto.
18. Interpretation and Construction.
(a) The Company acknowledges that its Board is bound by the obligations of the Company hereunder.
(b) Each of the parties hereto acknowledges that it has been represented by counsel of its choice throughout allnegotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said counsel.Each party and its counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referredto herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the partiesand may not be construed against any party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decisionthat would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no applicationand is hereby expressly waived by each of the parties hereto, and any controversy over interpretations of this Agreement shall bedecided without regard to events of drafting or preparation.IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly authorized signatories of theparties as of the date hereof.
  
URS CORPORATION   By: /s/ Martin M. KoffelName: Martin M. KoffelTitle: Chairman of the Board and Chief Executive Officer  
JANA PARTNERS LLC   
By: /s/ Barry RosensteinName: Barry RosensteinTitle: Managing PartnerEXHIBIT A
URS CORPORATION ADDS FOUR NEW INDEPENDENT DIRECTORS TO BOARD JANA Partners Agrees to Support All Nominees at 2014 Annual Meeting Board to Establish Value Creation Committee
 
 
SAN FRANCISCO, CA – March [XX], 2014 – URS Corporation (NYSE: URS) today announced that it will add
four new independent directors to its Board of Directors, effective March 27, 2014. These four directors will be on URS’ slate of
directors nominated for election to the Board of Directors at the Company’s 2014 Annual Meeting, along with eight incumbents,
pursuant to an agreement with JANA Partners LLC. The four new directors will be: Diane C. Creel, William H. Schumann, III,
David N. Siegel and V. Paul Unruh. Biographical information on the new directors is provided below.
Current directors [A] and [B] have advised the Company that they do not plan to stand for re-election at the 2014
Annual Meeting. Therefore, from March 27, 2014 until the Annual Meeting, the Board will increase to fourteen members from the
current ten, but will be comprised of twelve directors following the 2014 Annual Meeting.
Under the agreement with JANA, URS will also form a Value Creation Committee of the Board that will evaluate all
options for enhancing shareholder value, including by engaging an investment bank to conduct a strategic review of the
Company’s business segments, operations and capital structure, and reviewing the Company’s management compensation
structure to enhance alignment with shareholder value creation. The Committee will be comprised of four members, two of whom
will be new directors.
Martin M. Koffel, Chairman and Chief Executive Officer of URS, stated: “[A] and [B] are superb directors and have
contributed much to our success, but each has decided for his own reasons not to stand for re-election. I and their fellow board
members look forward to continuing to work with them until the Annual Meeting but will take this opportunity to express our
gratitude for their service, sound counsel and friendship.”
Koffel continued: “With [A]’s and [B]’s decisions to stand down and the expansion of our Board, we are adding four
new, highly qualified independent directors to the Board on March 27 and we will nominate these directors for election at the
2014 Annual Meeting. All are accomplished business leaders with experiencerelevant to the URS enterprise, and we are confident that they will prove to be valuable additions as we continue working to build
value for our stockholders.”
As previously disclosed, the URS Board has been engaged in succession planning for the Company’s Chief Executive
Officer position and has appointed a CEO Succession Committee comprised of independent directors. Two of the new directors
will promptly be appointed to this Committee. One of the new directors will also be appointed to the Compensation Committee.
Said Koffel, “Having led URS for more than 25 years, I had previously communicated to the Board that it was important
to have my successor in place in 2014, and our goal is to do just that. The Board has asked me to remain as Chairman and Chief
Executive Officer until a successor is named, which I expect to do unless circumstances change.”
Barry Rosenstein, Managing Partner of JANA Partners, said, “We have appreciated our constructive dialogue with
Martin Koffel and his team. We share their view that the Company is significantly undervalued, particularly given its strong cash
flows and the valuable work Martin and his team have done over many years to ensure that URS is well-positioned to meet the
needs of its clients. I am confident that the addition of four highly-qualified directors and the formation of the Value Creation
Committee will help unlock this value for all shareholders.” JANA Partners currently owns approximately 9.7 percent of the
Company’s common shares outstanding.
URS’ incumbent directors expected to be nominated for re­election at the 2014 Annual Meeting are: [C]; [D]; [E]; [F];
[G]; [H]; [I]; and [J].
The director nominations will be included in the Company’s 2014 proxy statement and submitted for stockholder
approval at the Company's 2014 Annual Meeting, [to be held on [date]]. The Company expects to file its proxy materials for the
2014 Annual Meeting [in the near future] and encourages stockholders to review the proxy materials when they become available.
The agreement between URS and JANA Partners will be filed on Form 8-K with the Securities and Exchange
Commission. The agreement includes certain standstill restrictions that will be in effect until 30 days prior to the deadline by which
a shareholder must give notice to the Company of its intention to nominate a director at or bring other business before the 2015
Annual Meeting. JANA Partners has committed tovote the shares that it controls in support of URS’ twelve director nominees at the Company’s 2014 Annual Meeting.
Wachtell, Lipton, Rosen & Katz and Cooley LLP are serving as legal advisors to URS.
 
Biographical Information on New Director Nominees
 
Diane Creel, 65
Ms. Diane Creel retired as Chairman, Chief Executive Officer and President of Ecovation, Inc., a subsidiary of Ecolab
Inc. and a waste stream technology company using patented technologies, in September 2008. Ms. Creel had held such positions
since 2003. Previously, Ms. Creel served as Chief Executive Officer and President of Earth Tech, an international consulting
engineering firm, which is now part of AECOM, from 1992 to 2003. Ms. Creel has served on the ATI Board of Directors since
1996 and as Lead Independent Director since the position was established in September 2011. Ms. Creel is also a member of
the Boards of Directors of The Timken Company (since 2012) and Enpro Industries, Inc. (since 2009). She also served on the
Board of Directors of Goodrich Corporation from 1997 to 2012 and Foster Wheeler Ltd. until 2008.
 
William H. Schumann, III, 63
Mr. William H. Schumann, III, has served as the non-executive Chairman of the Board of Directors of Avnet, Inc., a
distributor of electronic components, since November 2012 and has been on the board since 2010. He retired in August 2012 as
Executive Vice President of FMC Technologies, Inc., a provider of technology solutions for the energy industry. He served as
Chief Financial Officer of FMC Technologies from 2001 to 2011 and Chief Financial Officer of FMC Corporation (the
predecessor to FMC Technologies) from 1999 to 2001. Mr. Schumann served on the board of UAP Holdings, an agricultural
chemical distributor, from 2005 to 2008 and Great Lakes Advisors, a registered investment advisor, from 1992 to 2011. Mr.
Schumann has been a director of AMCOL International Corporation, a producer of specialty materials and related products and
services for industrial and consumer markets, since 2012 and McDermott International, Inc., an engineering and construction
company, since 2012.David N. Siegel, 52
David N. Siegel is President & CEO of Frontier Airlines and serves on its board of directors. He was a Director of
Republic Airways, from October 2009 to December 2013, including serving as Lead Independent Director from May 2011 until
January 2012 when he was appointed President & CEO of Frontier, at the time a wholly-owned subsidiary of Republic. Prior to
joining Frontier, Mr. Siegel was Chairman & CEO of XOJET, a private aviation company, controlled by TPG Capital. From June
2004 to May 2008, Mr. Siegel was Chairman and Chief Executive Officer, and from June 2008 to April 2009 Chairman, of
gategroup Holding AG, the world's largest independent airline catering, hospitality and logistics company. Prior to that, Mr. Siegel
served as President, Chief Executive Officer and member of the Board of US Airways Group, Inc., and US Airways, Inc., the
airline operating unit. Prior to US Airways, Mr. Siegel was Chairman and Chief Executive Officer of Avis Rent A Car System,
Inc., a subsidiary of Cendant Corp. Mr. Siegel also spent seven years at Continental Airlines in various senior management roles,
including President of its Continental Express subsidiary. Mr. Siegel is currently a member of the board of directors of gategroup
Holding AG, having served since June 2004.
 
V. Paul Unruh, 65
Mr. V. Paul Unruh retired as vice chairman of Bechtel Group, Inc. in June 2003. During his 25-year tenure he held a
number of management positions including treasurer, controller, and chief financial officer. He also served as president of Bechtel
Enterprises, the finance, development, and ownership arm, from 1997 to 2001. Unruh is also a certified public accountant. Mr.
Unruh is currently a member of the board of directors of Symantec Corporation, a provider of security, backup and availability
solutions, Move, Inc., a provider of real estate media and technology solutions, and Heidrick & Struggles International, Inc., a
provider of executive search and leadership consulting services. He also serves on the boards of two private companies.
URS Corporation (NYSE: URS) is a leading provider of engineering, construction, and technical services for public
agencies and private sector companies around the world. The Company offers a full range of program management; planning,
design and engineering;systems engineering and technical assistance; construction and construction management; operations and maintenance; information
technology; and decommissioning and closure services. URS provides services for federal, oil and gas, infrastructure, power, and
industrial projects and programs. Headquartered in San Francisco, URS Corporation has more than 50,000 employees in a
network of offices in nearly 50 countries (www.urs.com).
 
[add FLS Tag]
 
# # #CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. SUCH
OMITTED PORTIONS, WHICH ARE MARKED WITH BRACKETS [ ] AND AN ASTERISK*, HAVE BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.
Exhibit 10.1
EXECUTION COPY
 
COOPERATION AGREEMENT
 
This AGREEMENT, dated as of June 27, 2017 (this “ Agreement”), is made and entered into by The Meet Group, Inc., a Delaware
corporation (the “ Company”), and each of the persons set forth on the signature page hereto (each, an “ Investor ” and collectively, the “Investors ”
or, with their respective affiliates and associates, the “ Investor Group ”), which presently are or may be deemed to be members of a “group” with
respect to the common stock of the Company, $0.001 par value per share (the “ Common Stock”), pursuant to Rule 13d-5 promulgated by the U.S.
Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the “ Exchange Act”);
 
WHEREAS, the Investor Group is deemed to beneficially own shares of the Common Stock totaling, in the aggregate, 4,425,000 shares of
the Common Stock outstanding as of the date hereof; and
 
WHEREAS, the Company has agreed, at the request of the Investor Group, to cause Jim Parmelee (“ New Director A”) and a person to be
selected from the Director Candidate Pool (as defined herein) (“ New Director B ”) (collectively, the “ New Directors ”) to be appointed to the
Company’s Board of Directors (the “Board”), and to come to an agreement with respect to certain other matters as provided in this Agreement.
 
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally
bound hereby, agree as follows:
 
1. Board Composition Matters . 
 
(a) Appointment of New Director  A . The Company agrees that it shall take all action as is necessary (including, without
limitation, calling a special meeting of the Board to approve all actions contemplated hereby), effective immediately following the execution of this
Agreement, to (i) cause the Board to increase the size of its membership from six (6) to seven (7) members; (ii) accept the resignation of one existing
member of the Board to become effective immediately prior to the appointment of New Director A; and (iii) appoint New Director A to the Board
with a term on the Board expiring at the Company’s 2018 Annual Meeting of Stockholders (the “ 2018 Annual Meeting”) and until his successor is
duly elected and qualified. The Company further agrees that without the unanimous approval of the Board, during the period from the execution of
this Agreement until the expiration of the Standstill Period (as defined below), the size of the Board shall not be increased beyond seven (7 )
members.(i) Identification and Appointment of New Director B. No later than ninety (90) calendar days from the date of execution
of this Agreement (the “ New Director B Appointment Deadline”), the Company shall take the necessary steps to cause the Board to appoint one
of the candidates set forth on Exhibit A (as the same may be supplemented or otherwise amended from time to time by the mutual constent of the
Company and the Investor Group, the “ Director Candidate Pool”) as New Director B with a term on the Board expiring at the 2018 Annual Meeting
and until his or her successor is duly elected and qualified. The Company agrees that, if New Director B is not appointed to the Board prior to the
New Director B Appointment Deadline and none of the candidates included in the Director Candidate Pool are willing to serve on the Board by the
New Director B Appointment Deadline, (1) the Company and Investor Group will discuss in good faith the identification and selection of a
mutually agreed upon substitute person to be added to the Director Candidate Pool following the same process that they would follow pursuant to
Section 1(f) hereof if either of the New Directors, following their appointment to the Board, is unable to serve as a director for any reason, resigns
as a director, or is removed as a director prior to the end of the term of office; and (2) the New Director B Appointment Deadline shall no longer
apply and, in lieu thereof, shall be replaced by the time periods set forth in Section 1(f) hereof.
 
(b) Board’s Review of Qualifications and Determination of Independence . Prior to the execution of this Agreement (i) the
Nominating and Governance Committee of the Board (the “ Nominating Committee”) has reviewed the qualifications of New Director A and each of
the individuals included within the Director Candidate Pool  to serve as members of the Board and has determined that they are so qualified, and (ii)
the Board has determined that each of the New Directors and each of the individuals included within the Director Candidate Pool are
“independent” as defined by the listing standards of NASDAQ .
 
(c) Committees. The Company agrees that, concurrent with the appointment of the New Directors to the Board, the Board shall
take such action as is necessary such that each of the New Directors is appointed to at least one (1) of the three (3) standing committees of the
Board that the Company is required to maintain in accordance with the NASDAQ listing standards; provided  that, with respect to each such
committee appointment, the New Director is and continues to remain eligible to serve as a member of such committee pursuant to applicable law
and the rules of NASDAQ that are applicable to the composition of such committee.
 
(d) Board Policies and Procedures . The Investor Group acknowledges that each of the New Directors shall be required to comply
with all policies, processes, procedures, codes, rules, standards, and guidelines applicable to members of the Board, as in effect from time to time,
including, but not limited to, the Company’s Code of Conduct, and policies on confidentiality, ethics, hedging and pledging of Company securities,
public disclosures, stock trading, and stock ownership, and that each of the New Directors shall be required to strictly preserve the confidentiality
of Company business and information, including the discussion of any matters considered in meetings of the Board whether or not the matters
relate to material non-public information, unless previously publicly disclosed by the Company . Further, the Investor Group acknowledges that the
New Directors will be requested to provide the Company with such information as is reasonably requested by the Company concerning the New
Directors as is required to be disclosed under applicable law or stock exchange regulations, including the completion of the Company’s standard
director and officer questionnaire, in each case as promptly as necessary to enable the timely filing of the Company’s proxy statement and other
periodic reports with the SEC.
 
 
2(e) Rights and Benefits of the New Directors . The Company agrees that each of the New Directors shall receive (i) the same
benefits of director and officer insurance, and any indemnity and exculpation arrangements available generally to the directors on the Board, (ii)
the same compensation for his service as a director as the compensation received by other non-management directors on the Board, and (iii) such
other benefits on the same basis as all other non-management directors on the Board.
 
(f) Replacements. The Company agrees that, during the Standstill Period (as defined below), if any of the New Directors is unable
to serve as a director for any reason, resigns as a director, or is removed as a director prior to the end of the term of office , and at such time the
Investor Group beneficially owns in the aggregate at least three percent (3.0%) of the Company’s then outstanding Common Stock (subject to
adjustment for share issuances, stock splits, reclassifications, combinations and similar actions by the Company that increase the number of
outstanding shares of Common Stock), then the Company and the Investor Group shall work together in good faith to identify and select a
replacement director candidate to be appointed to the Board which shall only be appointed to the Board after having been mutually agreed upon
by both the Company and the Investor Group. Any such mutually agreed upon replacement director candidate shall qualify as “independent”
pursuant to NASDAQ’s listing standards and have the relevant financial and business experience to fill the resulting vacancy. Each of the Investor
Group and the Company shall determine, and inform the other party of its determination, whether any proposed replacement director candidate is
acceptable and meets the foregoing criteria, within ten (10) business days after such party has conducted interview(s) of such proposed
replacement director candidate. Each of the Company and the Investor Group shall use their respective reasonable best efforts to cause any
interview(s) contemplated by this Section 1(f) to be conducted as promptly as practicable, but in any case, assuming reasonable availability of the
proposed replacement director candidate, within ten (10) business days after the receipt of such director candidate’s credentials, including, but not
limited to, a completed copy of the Company’s standard director and officer questionnaire. Upon acceptance of a replacement director candidate
by both the Company and the Investor Group, the Board shall take such actions as to appoint such replacement director candidate to the Board no
later than ten (10) business days after both parties have confirmed in writing that they have mutually agreed upon such candidate. Following the
appointment of any director to replace a New Director in accordance with this Section 1(f), any reference to New Directors herein shall be deemed
to include such replacement director.
 
 
32. Actions by the Investor Group .
 
(a) Voting Agreement.
 
(i) Stockholders Meetings . At each annual and special meeting of stockholders held prior to the expiration of the Standstill
Period (as defined below), each of the Investors agrees to (A) appear at such stockholders’ meeting or otherwise cause all shares of Common
Stock beneficially owned by each Investor and their respective Affiliates and Associates (as defined below) to be counted as present thereat for
purposes of establishing a quorum; (B) vote, or cause to be voted, all shares of Common Stock beneficially owned by each Investor and their
respective Affiliates and Associates on the Company’s proxy card or voting instruction form in favor of each of the nominees for election as
directors nominated by the Board and recommended by the Board (and not in favor of any other nominees to serve on the Board); and, except in
connection with any Opposition Matter (as defined below) or Other Voting Recommendation (as defined below), each of the proposals listed on
the Company’s proxy card or voting instruction form as identified in the Company’s definitive proxy statement or supplement thereto in
accordance with the Board’s recommendations, including in favor of all matters recommended by the Board for stockholder approval and against
all matters which the Board recommends against stockholder approval; provided, however , in the event that Institutional Shareholder Services Inc.
(“ISS”) issues a recommendation with respect to any matter (other than with respect to the election of nominees as directors to the Board or the
removal of directors from the Board) that is different from the recommendation of the Board, each of the Investors shall have the right to vote on
the Company’s proxy card or voting instruction form in accordance with the ISS recommendation (the “ Other Voting Recommendation”); and (C)
not execute any proxy card or voting instruction form in respect of such stockholders’ meeting other than the proxy card and related voting
instruction form being solicited by or on behalf of the Company or the Board. No later than five (5) business days prior to each annual or special
meeting of stockholders held prior to the expiration of the Standstill Period, each Investor shall, and shall cause each of its Associates and
Affiliates to, vote any shares of Common Stock beneficially owned by such Investors in accordance with this Section 2. No Investor nor any of its
Affiliates or Associates nor any person under its direction or control shall take any position, make any statement or take any action inconsistent
with this Section 2(a)(i). For purposes of this Agreement, “ Opposition Matter ” shall mean any of the following transactions but only to the extent
submitted by the Board to the Company’s stockholders for approval: (A) the sale or transfer of all or substantially all of the Company’s assets in
one or a series of transactions; (B) the sale or transfer of a majority of the outstanding shares of the Company’s Common Stock (through a merger,
stock purchase, or otherwise); (C) any merger, consolidation, acquisition of control or other business combination that results in a Change of
Control (as defined below) of the Company; (D) any tender or exchange offer; (E) any dissolution, liquidation, or reorganization; (F) any changes
in the Company’s capital structure (but excluding any proposal regarding the adoption or amendment of equity plans, all of which shall not be
deemed an Opposition Matter for purposes of this Agreement); or (G) any other transactions that would result in a Change of Control of the
Company.
 
(ii) Actions By Written Consent . In connection with any action by written consent that is sought to be taken by any party,
other than the Company or the Board, prior to the expiration of the Standstill Period (as defined below), each of the Investors agrees not to vote
and to take all necessary action, including, without limitation, the execution and completion of any consent revocation card solicited by the
Company or the Board, in accordance with the recommendation of the Board, to cause not to be voted, any of their shares of Common Stock
beneficially owned by each Investor and/or their respective Affiliates and Associates on any consent card related to or affecting the removal,
replacement or election of Board members and solicited by any party, other than the Company or the Board. No Investor nor any of its Affiliates or
Associates nor any person under its direction or control shall take any position, make any statement or take any action inconsistent with this
Section 2(a)(ii).
 
(iii) Special Meeting Demands . In connection with any demand by a stockholder of the Company that the Company call a
special meeting of stockholders, made prior to the expiration of the Standstill Period (as defined below), each of the Investors agrees not to vote
and shall take all necessary action, including, but not limited to, the execution and completion of any consent revocation card solicited by the
Company or the Board in accordance with the recommendation of the Board, to cause not to be voted, any of their shares of Common Stock
beneficially owned by each Investor and/or their respective Affiliates and Associates for any special meeting demand proposed or sought to be
made by any party . No Investor nor any of its Affiliates or Associates nor any person under its direction or control shall take any position, make
any statement or take any action inconsistent with this Section 2(a)(iii).
 
 
43. Standstill.
 
(a) Each Investor agrees that, from the date of this Agreement until the expiration of the Standstill Period (as defined below),
without the prior written consent  of a majority of the Board specifically expressed in a written resolution, neither it nor any of its Related Persons
(as defined herein) will, and it will cause each of its Related Persons not to, directly or indirectly, alone or with others, in any manner:
 
(i) propose or publicly announce or otherwise publicly disclose an intent to propose or enter into or agree to enter into,
singly or with any other person, directly or indirectly, (x) any form of business combination or acquisition or other transaction relating to a material
amount of assets or securities of the Company or any of its subsidiaries, (y) any form of restructuring, recapitalization or similar transaction with
respect to the Company or any of its subsidiaries or (z) any form of tender or exchange offer for the Common Stock, whether or not such
transaction involves a change of control of the Company;
 
(ii) engage in any solicitation of proxies or written consents to vote any voting securities of the Company, or conduct
any non-binding referendum with respect to any voting securities of the Company, or assist or participate in any other way, directly or indirectly, in
any solicitation of proxies or written consents with respect to any voting securities of the Company, or otherwise become a “participant” in a
“solicitation,” as such terms are defined in Instruction 3 of Item 4 of Schedule 14A and Rule 14a-1 of Regulation 14A, respectively, under the
Exchange Act, to vote any securities of the Company in opposition to any recommendation or proposal of the Board;
 
(iii) acquire, offer or propose to acquire, or agree to acquire, directly or indirectly, whether by purchase, tender or
exchange offer, through the acquisition of control of another person, by joining a partnership, limited partnership, syndicate or other group
(including any group of persons that would be treated as a single “person” under Section 13(d) of the Exchange Act), through swap or hedging
transactions or otherwise, any additional securities (including common and preferred equity interests and debt that is convertible into any equity
interests) of the Company or any rights decoupled from the underlying securities of the Company, that would result, or could result, in the Investor
Group owning, in the aggregate (amongst all of the Investors and any Affiliate or Associate thereof), in excess of 10% of the shares of Common
Stock outstanding;
 
(iv) seek to advise, encourage or influence any person with respect to the voting of (or execution of a written consent in
respect of) or disposition of any securities of the Company, other than in a manner in accordance with Section 2;
 
(v) sell, offer or agree to sell directly or indirectly, through swap or hedging transactions or otherwise, any securities
(including common and preferred equity interests and debt that is convertible into any equity interests) of the Company or any rights decoupled
from the underlying securities held by the Investors to any person or entity that would knowingly result in any third party, together with its
Affiliates and Associates, owning, controlling or otherwise having any, beneficial, economic or other ownership interest representing in the
aggregate 5% or more of the shares of Common Stock outstanding at such time;
 
 
5(vi) sell, offer or agree to sell directly or indirectly, through swap or hedging transactions or otherwise, any securities
(including common and preferred equity interests and debt that is convertible into any equity interests) of the Company or any rights decoupled
from the underlying securities held by the Investors to any Affiliate or Associate of the Investors not a party to this Agreement;
 
(vii) except as otherwise set forth in this Agreement, take any action in support of or make any proposal or request that
constitutes: (A) advising, controlling, changing or influencing the Board or management of the Company, including any plans or proposals to
change the number or term of directors or to fill any vacancies on the Board, (B) any material change in the capitalization, stock repurchase
programs and practices or dividend policy of the Company, (C) any other material change in the Company’s management, governance, policies,
strategic direction, business or corporate structure, (D) seeking to have the Company waive or make amendments or modifications to the
Company’s Amended and Restated Certificate of Incorporation or Bylaws, or other actions that may impede or facilitate the acquisition of control
of the Company by any person, (E) causing a class of securities of the Company to be delisted from, or to cease to be authorized to be quoted on,
any securities exchange, or (F) causing a class of securities of the Company to become eligible for termination of registration pursuant to Section
12(g)(4) of the Exchange Act;
 
(viii) call or seek to call, or request the call of, alone or in concert with others, any meeting of stockholders, whether or
not such a meeting is permitted by the Company’s Amended and Restated Certificate of Incorporation or Bylaws, including, but not limited to, a
“town hall meeting;”
 
(ix) seek, alone or in concert with others, representation on the Board, except as expressly permitted by this Agreement;
 
(x) initiate, encourage or participate in any “vote no,” “withhold” or similar campaign;
 
(xi) deposit any Common Stock in any voting trust or subject any Common Stock to any arrangement or agreement with
respect to the voting of any Common Stock (other than any such voting trust, arrangement or agreement solely among the members of the
Investor Group that is otherwise in accordance with this Agreement);
 
(xii) seek, or encourage any person, to submit nominations in furtherance of a “contested solicitation” for the election
or removal of directors with respect to the Company or seek, encourage or take any other action with respect to the election or removal of any
directors of the Company or with respect to the submission of any stockholder proposals (including any submission of stockholder proposals
pursuant to Rule 14a-8 under the Exchange Act);
 
 
6(xiii) form, join or in any other way participate in any “group” (within the meaning of Section 13(d)(3) of the Exchange
Act) with respect to the Common Stock (other than the Investor Group);
 
(xiv) demand a copy of the Company’s list of stockholders or its other books and records, whether pursuant to Section
220 of the Delaware General Corporation Law (the “DGCL”) or pursuant to any other statutory right;
 
(xv) commence, encourage, or support any derivative action in the name of the Company, or any class action against
the Company or any of its officers or directors in order to, directly or indirectly, effect any of the actions expressly prohibited by this Agreement or
cause the Company to amend or waive any of the provisions of this Agreement; provided, however , that for the avoidance of doubt, the foregoing
shall not prevent any Investor from (A) bringing litigation to enforce the provisions of this Agreement, (B) making counterclaims with respect to
any proceeding initiated by, or on behalf of, the Company against an Investor, or (C) exercising statutory dissenters, appraisal or similar rights
under the DGCL; provided, further, that the foregoing shall also not prevent the Investors from responding to or complying with a validly issued
legal process in connection with litigation that it did not initiate, invite, facilitate or encourage, except as otherwise permitted in this Section (3)(a)
(xv);
 
(xvi) disclose publicly or privately, in a manner that could reasonably be expected to become public any intent, purpose,
plan or proposal with respect to the Board, the Company, its management, policies or affairs, any of its securities or assets or this Agreement that
is inconsistent with the provisions of this Agreement; provided, however , that nothing herein shall prohibit the Investor Group from engaging in
private discussions with the Company concerning the Investor Group’s views or suggestions concerning the Company;
 
(xvii) enter into any negotiations, agreements or understandings with any person or entity with respect to any of the
foregoing, or advise, assist, knowingly encourage or seek to persuade any person or entity to take any action or make any statement with respect
to any of the foregoing, or otherwise take or cause any action or make any statement inconsistent with any of the foregoing;
 
(xviii) make any request or submit any proposal to amend the terms of this Agreement other than through non-public
communications with the Company that would not be reasonably determined to trigger public disclosure obligations for any party;
 
(xix) take any action challenging the validity or enforceability of any of the provisions of this Section 3 or publicly
disclose, or cause or facilitate the public disclosure (including, without limitation, the filing of any document with the SEC or any other
governmental agency or any disclosure to any journalist, member of the media or securities analyst) of, any intent, purpose, plan or proposal to
either (A) obtain any waiver or consent under, or any amendment of, any provision of this Agreement, or (B) take any action challenging the
validity or enforceability of any provisions of this Section 3; or
 
(xx) otherwise take, or solicit, cause or encourage others to take, any action inconsistent with the foregoing.
 
 
7(b) Notwithstanding the foregoing, the provisions of this Section 3 shall not limit in any respect the actions of any director of the
Company (including, but not limited to, the New Directors) in their capacity as such, recognizing that such actions are subject to such director’s
fiduciary duties to the Company and its stockholders (it being understood and agreed that neither the Investors nor any of their Affiliates or
Associates shall seek to do indirectly through the New Directors anything that would be prohibited if done by any of the Investors or their
Affiliates and Associates directly). For the avoidance of doubt, no provision in this Section 3 or elsewhere in this Agreement shall prohibit
privately-negotiated transactions in the Common Stock solely between or among the Investors .
 
(c) As of the date of this Agreement, none of the Investors are engaged in any discussions or negotiations with any person, and
do not have any agreements, arrangements, or understandings, written or oral, formal or informal, and whether or not legally enforceable with any
person concerning the acquisition of economic ownership of any securities of the Company, and have no actual and non-public knowledge that
any other stockholders of the Company have any present or future intention of taking any actions that if taken by the Investors would violate any
of the terms of this Agreement. The Investors agree to refrain from taking any actions during the Standstill Period to intentionally encourage other
stockholders of the Company, or any other persons to engage in any of the actions referred to in the previous sentence.
 
(d) As used in this Agreement, the terms “ Affiliate” and “ Associate ” shall have the respective meanings set forth in Rule 12b-2
promulgated by the SEC under the Exchange Act; the terms “beneficial owner” and “beneficial ownership” shall have the same meanings as set
forth in Rule 13d-3 promulgated by the SEC under the Exchange Act; the terms “economic owner” and “economically own” shall have the same
meanings as “beneficial owner” and “beneficially own,” except that a person will also be deemed to economically own and to be the economic
owner of (i) all shares of Common Stock which such person has the right to acquire pursuant to the exercise of any rights in connection with any
securities or any agreement, regardless of when such rights may be exercised and whether they are conditional, and (ii) all shares of Common Stock
in which such person has any economic interest, including, without limitation, pursuant to a cash settled call option or other derivative security,
contract or instrument in any way related to the price of shares of Common Stock; the terms “person” or “persons” shall mean any individual,
corporation (including not-for-profit), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization
or other entity of any kind or nature; and the term “ Related Person ” shall mean, as to any person, any Affiliates or Associates of such person.
 
(e) Notwithstanding anything contained in this Agreement to the contrary:
 
(i) The provisions of Sections 1, 2, and 3 of this Agreement shall automatically terminate upon the occurrence of a
Change of Control transaction (as defined below) involving the Company  if the acquiring or counter-party to the Change of Control transaction
has conditioned the closing of the transaction on the termination of such sections; provided, however,  that the Company shall not directly or
indirectly, propose, seek, encourage or otherwise influence such acquiring or counter-party to the Change of Control transaction to condition the
closing of such transaction on the termination of Sections 1, 2, and 3 of this Agreement; and
 
 
8(ii) For purposes of this Agreement, a “ Change of Control ” transaction shall be deemed to have taken place if (1) any
person is or becomes a beneficial owner, directly or indirectly, of securities of the Company representing more than 50% of the equity interests and
voting power of the Company’s then outstanding equity securities or (2) the Company enters into a stock-for-stock transaction whereby
immediately after the consummation of the transaction the Company’s stockholders retain less than 50% of the equity interests and voting power
of the surviving entity’s then outstanding equity securities.
 
(f) For purposes of this Agreement, “ Standstill Period ” shall mean the period commencing on the date of this Agreement and
ending at 11:59 p.m. Eastern Time on the date of the certification of the vote of stockholders at the 2018 Annual Meeting.
 
4. Expenses. Each of the Company and the Investors shall be responsible for its own fees and expenses incurred in connection with the
negotiation, execution, and effectuation of this Agreement and the transactions contemplated hereby, including, but not limited to attorneys’ fees
incurred in connection with the negotiation and execution of this Agreement and all other activities related to the foregoing.
 
5. Representations and Warranties of the Company . The Company represents and warrants to the Investors that (a) the Company has the
corporate power and authority to execute this Agreement and to bind it thereto, (b) this Agreement has been duly and validly authorized, executed
and delivered by the Company, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the Company
in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles and (c) the execution,
delivery and performance of this Agreement by the Company does not and will not violate or conflict with (i) any law, rule, regulation, order,
judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time
or both could become a default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment,
acceleration or cancellation of, any organizational document, or any material agreement, contract, commitment, understanding or arrangement to
which the Company is a party or by which it is bound.
 
6. Representations and Warranties of the Investors . Each Investor, on behalf of itself, severally represents and warrants to the Company
that (a) as of the date hereof, such Investor beneficially owns, directly or indirectly, only the number of shares of Common Stock as described
opposite its name on Exhibit B and Exhibit B includes all Affiliates and Associates of any Investors that own any securities of the Company
beneficially or of record and reflects all shares of Common Stock in which the Investors have any interest or right to acquire, whether through
derivative securities, voting agreements or otherwise, (b) this Agreement has been duly and validly authorized, executed and delivered by such
Investor, and constitutes a valid and binding obligation and agreement of such Investor, enforceable against such Investor in accordance with its
terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or
similar laws generally affecting the rights of creditors and subject to general equity principles, (c) such Investor has the authority to execute this
Agreement on behalf of itself and the applicable Investor associated with that signatory’s name, and to bind such Investor to the terms hereof, (d)
each of the Investors shall use its commercially reasonable efforts to cause its respective Affiliates and Associates to comply with the terms of
this Agreement and (e) the execution, delivery and performance of this Agreement by such Investor does not and will not violate or conflict with
(i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an event
which with notice or lapse of time or both could become a default) under or pursuant to, or result in the loss of a material benefit under, or give any
right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or
arrangement to which such member is a party or by which it is bound.
 
 
97. Mutual Non-Disparagement .
 
(a) Each Investor agrees that, until the earlier of (i) the expiration of the Standstill Period or (ii) any material breach of this
Agreement by the Company (provided that the Company shall have three (3) business days following written notice from such Investor of any
material breach to remedy such material breach if capable of remedy), neither it nor any of its Affiliates or Associates will, and it will cause each of
its Affiliates and Associates not to, directly or indirectly, publicly make, express, transmit, speak, write, verbalize or otherwise publicly
communicate in any way (or cause, further, assist, solicit, encourage, support or participate in any of the foregoing), any remark, comment,
message, information, declaration, communication or other statement of any kind, whether verbal or in writing, that might reasonably be construed
to be derogatory or critical of, or negative toward, the Company or any of its directors, officers, Affiliates, Associates, subsidiaries, employees,
agents or representatives (collectively, the “ Company Representatives ”), or that reveals, discloses, incorporates, is based upon, discusses,
includes or otherwise involves any confidential or proprietary information of the Company or its subsidiaries or Affiliates or Associates, or to
malign, harm, disparage, defame or damage the reputation or good name of the Company, its business or any of the Company Representatives.
 
(b) The Company hereby agrees that, until the earlier of (i) the expiration of the Standstill Period or (ii) any material breach of this
Agreement by an Investor (provided that such Investor shall have three (3) business days following written notice from the Company of any
material breach to remedy such material breach if capable of remedy), neither it nor any of its Affiliates will, and it will cause each of its Affiliates
not to, directly or indirectly, publicly make, express, transmit, speak, write, verbalize or otherwise publicly communicate in any way (or cause,
further, assist, solicit, encourage, support or participate in any of the foregoing), any remark, comment, message, information, declaration,
communication or other statement of any kind, whether verbal or in writing, that might reasonably be construed to be derogatory or critical of, or
negative toward, the Investors or their Affiliates or Associates or any of their agents or representatives (collectively, the “ Investor Agents ”), or
that reveals, discloses, incorporates, is based upon, discusses, includes or otherwise involves any confidential or proprietary information of any
Investor or its Affiliates or Associates, or to malign, harm, disparage, defame or damage the reputation or good name of any Investor, its business
or any of the Investor Agents.
 
(c) Notwithstanding the foregoing, nothing in this Section 7 or elsewhere in this Agreement shall prohibit any party from making
any statement or disclosure required under the federal securities laws or other applicable laws.
 
(d) The limitations set forth in Section 7(a) and 7(b) shall not prevent any party from responding to any public statement made
by the other party of the nature described in Section 7(a) and 7(b) if such statement by the other party was made in breach of this Agreement.
 
 
108. Public Announcements . Promptly following the execution of this Agreement, the Company and the Investor Group shall issue a
mutually agreeable press release (the “ Mutual Press Release ”), announcing certain terms of this Agreement, substantially in the form attached
hereto as Exhibit C. Prior to the issuance of the Mutual Press Release, neither the Company nor any of the Investors shall issue any press release
or make any public announcement regarding this Agreement or take any action that would require public disclosure thereof without the prior
written consent of the other party. During the Standstill Period, neither the Company nor the Investor Group or any of its Affiliates or Associates
shall make any public announcement or statement that is inconsistent with or contrary to the statements made in the Mutual Press Release, except
as required by law or the rules of any stock exchange (and, in any event, each party will provide the other party, prior to making any such public
announcement or statement, a reasonable opportunity to review and comment on such disclosure, to the extent reasonably practicable under the
circumstances, and each party will consider any comments from the other in good faith) or with the prior written consent of the other party, and
otherwise in accordance with this Agreement.
 
9. SEC Filings. 
 
(a) No later than two (2) business days following the execution of this Agreement, the Company shall file a Current Report on
Form 8-K with the SEC reporting the entry into this Agreement and appending or incorporating by reference this Agreement as an exhibit thereto.
The Company shall provide the Investor Group and its counsel a reasonable opportunity to review and comment on the Form 8-K prior to such
filing, which comments shall be considered in good faith.
 
(b) No later than two (2) business days following the execution of this Agreement, the Investor Group shall file an amendment to
its Schedule 13D with respect to the Company that has been filed with the SEC, reporting the entry into this Agreement, amending applicable items
to conform to their obligations hereunder and appending or incorporating by reference this Agreement as an exhibit thereto. The Investor Group
shall provide the Company and its counsel a reasonable opportunity to review and comment on the Schedule 13D prior to such filing, which
comments shall be considered in good faith.
 
10. Specific Performance. Each of the Investors, on the one hand, and the Company, on the other hand, acknowledges and agrees that
irreparable injury to the other party hereto may occur in the event any of the provisions of this Agreement are not performed in accordance with
their specific terms or are otherwise breached and that such injury would not be adequately compensable in monetary damages. It is accordingly
agreed that the Investors or any Investor, on the one hand, and the Company, on the other hand (the “ Moving Party ”), shall each be entitled to
seek specific enforcement of, and injunctive or other equitable relief to prevent any violation of, the terms hereof, and the other party hereto will
not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other remedy or relief is
available at law or in equity.
 
 
1111. Notice. Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of
this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when
sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); (iii)
upon confirmation of receipt, when sent by email (provided such confirmation is not automatically generated) or (iv) one (1) business day after
deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses
and facsimile numbers for such communications shall be:
 
If to the Company:
 
The Meet Group, Inc.
100 Union Square Drive
New Hope, PA 18938
Fax No.: (215) 862.7825
Email: fred@themeetgroup.com
Attention: Frederic A. Beckley, Esq., General Counsel and Executive Vice President, Business Affairs
 
With copies (which shall not constitute notice) to:
 
Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, N.W.
Washington, DC 20004
Fax No.: (202) 739-3001
Email: keith.gottfried@morganlewis.com
Attention: Keith E. Gottfried, Esq.
 
If to any Investor:
 
Harvest Capital Strategies LLC
600 Montgomery Street, Suite 1700
San Francisco, CA 94111
Fax No.: (415) 869-4433
Email: investments@harvestcaps.com
Attention: Jeffrey B. Osher, Managing Director
 
With copies (which shall not constitute notice) to:
 
Olshan Frome Wolosky LLP
1325 Avenue of the Americas
New York, NY 10019
Fax No.: (212) 451-2222
E-mail: swolosky@olshanlaw.com  
afreedman@olshanlaw.com
Attention: Steve Wolosky, Esq.
Andrew Freedman, Esq.
 
 
1212. Governing Law. This Agreement shall be governed in all respects, including validity, interpretation, and effect, by, and construed in
accordance with, the laws of the State of Delaware executed and to be performed wholly within the State of Delaware, without giving effect to the
choice of law or conflict of law principles thereof or of any other jurisdiction to the extent that such principles would require or permit the
application of the laws of another jurisdiction.
 
13. Jurisdiction. Each of the parties hereto (a) consents to submit itself to the personal jurisdiction of federal or state courts of the State of
Delaware in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (b) agrees that it shall not
bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other than the federal or state courts
of the State of Delaware, and each of the parties irrevocably waives the right to trial by jury, (c) agrees to waive any bonding requirement under
any applicable law, in the case any other party seeks to enforce the terms by way of equitable relief, and (d) irrevocably consents to service of
process by first class certified mail, return receipt requested, postage prepaid, to the address of such party’s principal place of business or as
otherwise provided by applicable law. Each of the parties hereto irrevocably waives, and agrees not to assert, by way of motion, as a defense,
counterclaim or otherwise, in any action, suit or other legal proceeding with respect to this Agreement, (a) any claim that it is not personally
subject to the jurisdiction of the above-named courts for any reason, (b) that it or its property is exempt or immune from jurisdiction of any such
court or from any legal process commenced in such courts (whether through service of notice, attachment before judgment, attachment in aid of
execution of judgment, execution of judgment or otherwise), and (c) to the fullest extent permitted by applicable law, that (i) such action, suit or
other legal proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such action, suit or other legal proceeding is
improper or (iii) this agreement, or the subject matter hereof, may not be enforced in or by such court.
 
14. Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER
THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY
AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF
OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY TO THIS
AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL
ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER
VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE
MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 14.
 
15. Representative.  Each Investor hereby irrevocably appoints Jeffrey B. Osher as its attorney-in-fact and representative (the “ Investor
Group Representative ”), in such Investor’s place and stead, to do any and all things and to execute any and all documents and give and receive
any and all notices or instructions in connection with this Agreement and the transactions contemplated hereby. The Company shall be entitled to
rely, as being binding on each Investor, upon any action taken by the Investor Group Representative or upon any document, notice, instruction or
other writing given or executed by the Investor Group Representative.
 
 
1316. Entire Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with regard to the
subject matter hereof, and supersedes all prior and contemporaneous agreements, understandings and representations, whether oral or written, of
the parties with respect to the subject matter hereof. There are no restrictions, agreements, promises, representations, warranties, covenants or
undertakings, oral or written, between the parties other than those expressly set forth herein.
 
17. Headings.  The section headings contained in this Agreement are for reference purposes only and shall not effect in any way the
meaning or interpretation of this Agreement.
 
18. Waiver. No failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate
as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise
thereof or the exercise of any other right, power or remedy.
 
19. Remedies. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by law or equity.
 
20. Receipt of Adequate Information; No Reliance; Representation by Counsel . Each party acknowledges that it has received adequate
information to enter into this Agreement, that it has had adequate opportunity to make whatever investigation or inquiry it may deem necessary or
desirable in connection with the subject matter of this Agreement prior to the execution hereof, and that it has not relied on any promise,
representation or warranty, express or implied not contained in this Agreement. Each of the parties hereto acknowledges that it has been
represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the
same with the advice of said independent counsel. Each party cooperated and participated in the drafting and preparation of this Agreement and
the documents referred to herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of
the parties and may not be construed against any party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision
that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is
hereby expressly waived by each of the parties hereto, and any controversy over interpretations of this Agreement shall be decided without
regards to events of drafting or preparation. Further, any rule of law or any legal decision that would provide any party with a defense to the
enforcement of the terms of this Agreement against such party shall have no application and is expressly waived. The provisions of this
Agreement shall be interpreted in a reasonable manner to effect the intent of the parties.
 
21. Construction.  When a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement, unless
otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. Whenever the words “include,” “includes” and “including” are used in this Agreement, they shall be deemed to
be followed by the words “without limitation.” The words “hereof, “herein” and “hereunder” and words of similar import when used in this
Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word “will” shall be construed to
have the same meaning as the word “shall.” The words “dates hereof” will refer to the date of this Agreement. The word “or” is not exclusive. The
definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms. Any agreement, instrument, law,
rule or statute defined or referred to herein means, unless otherwise indicated, such agreement, instrument, law, rule or statute as from time to time
amended, modified or supplemented.
 
 
1422. Severability. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other
provisions of this Agreement shall remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or
degree shall remain in full force and effect to the extent not held invalid or unenforceable. The parties further agree to replace such invalid or
unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the purposes of such
invalid or unenforceable provision.
 
23. Amendment. This Agreement may be modified, amended or otherwise changed only in a writing signed by all of the parties hereto, or
in the case of the Investors, the Investor Group Representative, or their respective successors or assigns.
 
24. Successors and Assigns . The terms and conditions of this Agreement shall be binding upon and be enforceable by the parties hereto
and the respective successors, heirs, executors, legal representatives and permitted assigns of the parties, and inure to the benefit of any
successor, heir, executor, legal representative or permitted assign of any of the parties; provided, however , that no party may assign this
Agreement or any rights or obligations hereunder without, with respect to any Investor, the express prior written consent of the Company (with
such consent specifically authorized in a written resolution adopted and approved by the unanimous vote of the entire membership of the Board),
and with respect to the Company, the prior written consent of the Investor Group Representative .
 
25. No Third-Party Beneficiaries. The representations, warranties and agreements of the parties contained herein are intended solely for
the benefit of the party to whom such representations, warranties or agreements are made, and shall confer no rights, benefits, remedies,
obligations, or liabilities hereunder, whether legal or equitable, in any other person or entity, and no other person or entity shall be entitled to rely
thereon.
 
26. Counterparts; Facsimile / PDF Signatures . This Agreement and any amendments hereto may be signed in any number of counterparts,
each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement
shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. In the event that any
signature to this Agreement or any amendment hereto is delivered by facsimile transmission or by e-mail delivery of a portable document format
(.pdf or similar format) data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.
 
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
 
[SIGNATURE PAGE FOLLOWS]
 
 
15[SIGNATURE PAGE TO COOPERATION AGREEMENT]
 
IN WITNESS WHEREOF the parties have duly executed and delivered this Agreement as of the date first above written.
 
 
THE MEET GROUP, INC.
 
 
By: /s/ Frederic Beckley 
Name: Frederic Beckley
Title: General Counsel & EVP Business Affairs
 
HARVEST SMALL CAP PARTNERS MASTER, LTD.
By: Harvest Capital Strategies LLC
Investment Manager
 
By: /s/ Jeffrey B. Osher 
Name: Jeffrey B. Osher
Title: Managing Director
 
HARVEST SMALL CAP PARTNERS, L.P.
By: Harvest Capital Strategies LLC
Investment Manager
 
By: /s/ Jeffrey B. Osher 
Name: Jeffrey B. Osher
Title: Managing Director
 
HARVEST SMALL CAP PARTNERS GP, LLC
By: Harvest Capital Strategies LLC
Investment Manager of the Limited Partner
 
By: /s/ Jeffrey B. Osher 
Name: Jeffrey B. Osher
Title: Managing Director
 
HARVEST CAPITAL STRATEGIES LLC
 
By: /s/ Jeffrey B. Osher 
Name: Jeffrey B. Osher
Title: Managing Director
 
/s/ Jeffrey B. Osher 
JEFFREY B. OSHER
 
 
16CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. SUCH
OMITTED PORTIONS, WHICH ARE MARKED WITH BRACKETS [ ] AND AN ASTERISK*, HAVE BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.
 
 
EXHIBIT A
 
DIRECTOR CANDIDATE POOL
 
[***]
 
 
17EXHIBIT B
 
STOCKHOLDERS, AFFILIATES, AND OWNERSHIP
 
Investor
Shares of Common Stock
Beneficially Owned
  
Harvest Small Cap Partners Master, Ltd.
 
2,763,182
Harvest Small Cap Partners, L.P.
 
1,661,818
 
 
 
 
 
 
 
 
 
 
 
 
Aggregate total beneficially owned by the Investor Group:
 
4,425,000
 
 
18EXHIBIT C
 
FORM OF PRESS RELEASE
 
THE MEET GROUP REACHES AGREEMENT WITH HARVEST CAPITAL
 
Agrees to Appoint Two New Independent Directors to The Meet Group’s Board
 
NEW HOPE, PA, June 27, 2017 - The Meet Group, Inc. (NASDAQ: MEET), a public market leader in the mobile meeting space, today announced
that it has entered into a cooperation agreement with Harvest Capital Strategies LLC and its affiliates, which, in the aggregate, beneficially owns
approximately 6.3% of The Meet Group’s outstanding shares, regarding the composition of The Meet Group’s Board of Directors. Under the terms
of the agreement, The Meet Group has agreed to appoint to its Board two new independent directors: Jim Parmelee, who has agreed to join the
Meet Group Board effective immediately, and a second director mutually acceptable to The Meet Group and Harvest Capital to be identified within
the next ninety days.
 
Spencer G. Rhodes, The Meet Group’s Chairman of the Board, stated, “We are pleased to have reached this cooperation agreement with Harvest
Capital, as we believe this outcome serves the best interests of The Meet Group and its stockholders. We are also pleased to welcome Jim Parmelee
to our Board and look forward to the insights and experience he will bring.”
 
Jeffrey B. Osher, the Managing Director of Harvest Capital, stated, “We have spent considerable time with The Meet Group’s senior management
team and strongly support their strategy of creating a compelling portfolio of mobile meeting apps. Under Geoff Cook’s leadership, The Meet
Group has methodically grown its global platform while delivering consistent profitability and cash flow. We look forward to continuing our
collaboration with The Meet Group’s Board and senior management team as they execute on their long-term growth initiatives and focus on
shareholder value creation.”
 
Pursuant to the cooperation agreement, Harvest Capital has agreed that, until the certification of the shareholder vote at The Meet Group’s 2018
Annual Meeting of Stockholders, it will abide by certain customary standstill provisions.
 
The cooperation agreement between The Meet Group and Harvest Capital will be included as an exhibit to a Current Report on Form 8-K that The
Meet Group will file with the Securities and Exchange Commission.
 
Morgan, Lewis & Bockius LLP served as legal counsel to The Meet Group. Olshan Frome Wolosky LLP served as legal advisor to Harvest Capital.
 
The Meet Group also announced today that it has appointed The Blueshirt Group to lead its investor relations communications and strategy. The
Blueshirt Group is a leading tech-focused investor relations firm that specializes in investor relations, IPO advisory, financial communications,
financial media relations and crisis management.
 
About Jim Parmelee
 
Mr. Parmelee brings over 25 years of technology industry experience. He is currently an advisor to Hamilton Robinson Capital Partners, a middle
market focused private equity firm. Jim was previously a Managing Director in Peak Ten Management LLC, where he was responsible for the firm's
investments in the software, Internet and technology infrastructure verticals. Before Peak Ten, Jim was a Partner in Union Square Advisors, an
M&A advisory firm focused on the technology sector, where he led the firm's global Information Technology infrastructure practice. Jim was
previously a leading data networking and telecom equipment equity research analyst at Credit Suisse First Boston (now Credit Suisse). Jim was
highly ranked by external polls throughout his research career including being named six times to Institutional Investor Magazine's  All America
Research Team.
 
 
19About The Meet Group
The Meet Group (NASDAQ: MEET) is a fast-growing portfolio of mobile apps designed to meet the universal need for human connection. Using
innovative products and sophisticated data science, The Meet Group keeps its approximately 2.8 million mobile daily active users engaged and
originates untold numbers of casual chats, friendships, dates, and marriages. The Meet Group offers advertisers the opportunity to reach
customers on a global scale with hundreds of millions of daily mobile ad impressions. The Meet Group utilizes high user density, economies of
scale, and leading monetization strategies with the goal of maximizing adjusted EBITDA. Our apps - currently MeetMe , Skout , Tagged , and
Hi5  - let users in more than 100 countries chat, share photos, stream live video, and discuss topics of interest, and are available on iPhone, iPad,
and Android  in multiple languages. For more information, please visit themeetgroup.com .
 
MEET Investor Contact:
 
The Blueshirt Group
Allise Furlani
allise@blueshirtgroup.com
 
 
20
® ® ®
®Exhibit 10.1
COOPERATION AGREEMENT
This Cooperation Agreement (“ Agreement”) is entered into as of June 18, 2020, by and between Spôk Holdings, Inc., a Delaware corporation (the
“Company ”), and White Hat Strategic Partners LP, a Delaware limited partnership,  White Hat SP GP LLC, a Delaware limited liability company,
White Hat Capital Partners LP, a Delaware limited partnership, and White Hat Capital Partners GP LLC, a Delaware limited liability company
(collectively, the “ White Hat Parties ”) (each of the Company and the White Hat Parties, a “ Party” to this Agreement, and collectively, the
“Parties”).
RECITALS
WHEREAS, the White Hat Parties have voting power or sole dispositive power or otherwise have beneficial ownership of 319,708 shares (the
“Current Position ”) of the common stock, par value $0.0001 per share, of the Company (the “ Common Stock ”) as of the date of this Agreement;
and
WHEREAS, as of the date of this Agreement, the Company and the White Hat Parties have determined to come to an agreement with respect to
certain matters set forth below; and
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other good
and valuable consideration, the receipt and sufficiency of which are acknowledged, the Parties to this Agreement, intending to be legally bound,
agree as follows:
1. Board Nominations; Certain Information.
(a)Brett Shockley (the “ New Director ”) has provided the Company with responses to a Director and Officer Questionnaire customarily used for
NASDAQ-listed companies and certain biographical information in compliance with Item 401 of Regulation S-K as promulgated by the Securities
and Exchange Commission (the “ SEC”) (collectively, the “ Information”), has executed all documents required to be executed by directors of the
Company, and has cooperated with a background check.
(b) Based on the Information, the Nominating and Governance Committee (the “ Nominating Committee ”) of the Board of Directors (the “ Board ”)
of the Company and the Board have determined that the New Director may serve as an “independent” director of the Company in accordance with
the rules and listing standards of the NASDAQ National Market and applicable rules and regulations of the Securities Exchange Commission (the
“SEC”).
(c)Concurrently with the execution of this Agreement, the Board shall increase the size of the Board by one and appoint the New Director to the
Board to fill the resulting vacancy. Concurrently with the execution of this Agreement, the Board shall also appoint the New Director to the
Nominating Committee.
(d) Concurrently with the execution of this Agreement, the White Hat Parties shall send a letter to the Corporate Secretary and Treasurer of the
Company irrevocably withdrawing (i) the nomination letter they previously sent to the Company on May 26, 2020, and, accordingly, (ii) their
nomination (the “Nominations ”) of three directors for election to the Board at the Company’s 2020 Annual Meeting of Stockholders (including any
adjournments or postponements thereof, the “ 2020 Annual Meeting ”).
(e)The Nominating Committee and the Board shall take all necessary action to nominate Brett Shockley for election to the Board at the 2020 Annual
Meeting, and to recommend his election and to support and solicit proxies in the same manner as the other candidates nominated by the Board in
the Company’s proxy statements for the 2020 Annual Meeting.
(f)Nothing in this Agreement shall be deemed to abridge or limit the fiduciary duties of any member of the Board under Delaware law.
2.Representations of the White Hat Parties . The White Hat Parties represent and warrant to the Company as of the date hereof as follows:
(a)The White Hat Parties are the beneficial owners of 319,708 shares of Common Stock, such shares of Common Stock constitute all of the Common
Stock beneficially owned by the White Hat Parties and the White Hat Parties have no agreements, understandings or undertakings with any third
party to share or delegate disposition or voting control over such shares of Common Stock, or to transfer, hypothecate or lend such shares
Common Stock.
(b) Each of the White Hat Parties has the power and authority to execute and deliver this Agreement. This Agreement (i) has been duly and validly
authorized by each of the White Hat Parties, and constitutes a legal, valid and binding obligation of each of the White Hat Parties, enforceable
against each of the White Hat Parties in accordance with its terms except as may be limited by bankruptcy, insolvency or similar laws affecting
creditors’ rights and general equitable principles, (ii) does not require the approval of any investor in or member of the White Hat Parties and (iii)
does not violate any law, order of any court or any governmental agency or regulation or the charter or any organizational documentExhibit 10.1
of the White Hat Parties, or conflict with, result in a breach of or constitute a default under any agreement or instrument by which the White Hat
Parties or any of their respective assets is bound.
3.Representations of the Company . The Company represents and warrants to the White Hat Parties as of the date hereof that it has the corporate
power and authority to execute and deliver this Agreement. This Agreement (i) has been duly and validly authorized by the Company and
constitutes a legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its terms except as may be
limited by bankruptcy, insolvency or similar laws affecting creditors’ rights and general equitable principles and (ii) does not violate any law, order
of any court or any agency or regulation or the Company’s Certificate of Incorporation or the Bylaws, or conflict with, result in a breach of or
constitute a default under any agreement or instrument by which the Company or any of its assets or the assets of its subsidiaries are bound.
4.Voting Commitments. The White Hat Parties shall appear in person or by proxy for quorum purposes at the 2020 Annual Meeting, including any
adjournment or postponement thereof, to vote all of the shares of Common Stock beneficially owned by the White Hat Parties on the record date (if
the 2020 Annual Meeting is within thirty (30) days of the anniversary of the Company’s 2019 Annual Meeting of Stockholders, such number of
shares shall be no less than 90% of the Current Position) for such meeting (i) in favor of all persons nominated by the Board to serve as directors of
the Company and against any stockholder nominated candidate not endorsed by the Board, (ii) against the stockholder proposal made pursuant to
Rule 14a-8 under the Exchange Act as disclosed to the White Hat Parties prior to the execution of this Agreement, (iii) to ratify the appointment of
the Company’s independent registered public accounting firm, and (iv) in accordance with the Board’s recommendation with respect to the
Company’s “say-on-pay” proposal and new equity compensation plan (collectively, the “ 2020 Proposals ”), provided, that with respect to the
proposals described in clauses (ii) through (iv) of this Section 4 , the White Hat Parties may vote in accordance with the recommendation of
Institutional Shareholders Services to the extent such recommendation differs from the voting commitments set forth herein and provided that the
White Hat Parties do not publicly disclose their vote on such proposals if it differs from the Board’s recommendation; and provided, further, that
White Hat Parties shall have the right to vote the shares of Common Stock beneficially owned by the White Hat Parties in their sole discretion with
respect to all other proposals brought before the 2020 Annual Meeting. The White Hat Parties shall provide written evidence of the votes made in
accordance with the foregoing sentence to the Company no later than ten business days before the 2020 Annual Meeting.
5.Support Period Covenants . Except as otherwise contemplated in this Agreement, at all times during the period commencing on the date hereof
and ending on the date that is thirty (30) days prior to expiration of the advance notice period for the submission by stockholders of director
nominations for consideration at the 2021 Annual Meeting as set forth in the Bylaws, the White Hat Parties shall not, and shall cause the White Hat
Representatives not to, directly or indirectly, in any manner, alone or in concert with others: (a) attempt to call a special meeting of stockholders of
the Company; or (b) make a request for any stockholder list or other Company books and records, whether pursuant to Section 220 of the Delaware
General Corporation Law or otherwise.
6.Press Release . The Parties agree that the Company shall issue a press release and file a Current Report on Form 8-K in substantially the forms
agreed to between the Parties promptly following the execution and delivery of this Agreement by the Parties and shall not make any other public
disclosure relating to this Agreement or the transactions contemplated herein without the prior review and good faith consideration of any
comments made by the White Hat Parties. The White Hat Parties agree that they shall not issue a press release regarding the subject matter of this
Agreement for a period of three (3) months after the date of this Agreement.
7.Miscellaneous .
(a)Specific Enforcement; Special Remedy . Each of the Parties agrees that the other Party would be irreparably injured in the event that any
provision of the Agreement is breached or not performed. Accordingly, it is agreed that each Party shall be entitled to temporary and permanent
injunctive relief with respect to each and any breach or purported repudiation of this Agreement by the other and to specifically enforce strict
adherence to this Agreement and the terms and provisions hereof against the other in any action instituted in a court of competent jurisdiction, in
addition to any other remedy which such aggrieved Party may be entitled to obtain. Moreover, in the event of the breach of any of the provisions
of this Agreement, timeliness in obtaining relief is of the essence.
(b) Amendments; Waiver . Neither this Agreement nor any term hereof may be changed, waived, discharged or terminated orally or in writing
without a writing signed by the Parties. No delay on the part of either Party in exercising any right, power or privilege hereunder shall operate as a
waiver thereof, nor shall any waiver on the part of either Party of any right, power or privilege hereunder operate as a waiver of any other right,
power or privilege hereunder, nor shall any single or partial exercise of any right, power or privilege hereunder, preclude any other or further exercise
thereof or the exercise of any other right, power or privilege hereunder.
(c)Successors and Assigns . This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties.
This Agreement may not be assigned without the prior written consent of the other Party hereto.
(d) No Third Party Beneficiaries. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person or entity,
other than the Parties and their respective successors and assigns, any legal or equitable right, remedy or claim under or in respect of this
Agreement and any conditions and provisions hereof being intended to be and being for theExhibit 10.1
sole and exclusive benefit of the parties hereto and their respective successors and assigns, and for the benefit of no other person or entity.
(e)Counterparts . This Agreement may be executed in any number of counterparts and by the Parties in separate counterparts, each of which when
so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.
(f)Headings . The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.
(g) Governing Law; Choice of Venue.
(i)This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware applicable to agreements made
and to be performed within that state.
(ii)Each Party (A) consents to submit itself to the personal jurisdiction of the Court of Chancery or other federal or state courts of the State of
Delaware in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (B) agrees that it shall not
attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, (C) agrees that it shall not bring any
action relating to this Agreement or the transactions contemplated by this Agreement in any court other than the Court of Chancery or other
federal or state courts of the State of Delaware, and each Party irrevocably waives the right to trial by jury and (D) each Party irrevocably consents
to service of process by a reputable overnight mail delivery service, signature requested, to the address of such Party’s principal place of business
or as otherwise provided by applicable law.
(h) Reimbursement. The Company shall reimburse the White Hat Parties for their out-of-pocket expenses, including the fees and expenses of
counsel, incurred in connection with their engagement with the Company, the Nominations and the negotiation of, and all matters arising under this
Agreement; provided, however, that such reimbursement shall not exceed $55,000.
(i)Severability. If at any time subsequent to the date hereof, any provision of this Agreement shall be held by any court of competent jurisdiction
to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality or unenforceability of such provision shall have
no effect upon the legality or enforceability of any other provision in this Agreement.
(j)Interpretation and Construction . Each of the Parties acknowledges that it has been represented by counsel of its choice throughout all
negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said independent counsel.
Each Party and its counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referred to herein, and
any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed
against any Party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any
ambiguities in this Agreement against any Party that drafted or prepared it is of no application and is hereby expressly waived by each Party, and
any controversy over interpretations of this Agreement shall be decided without regards to events of drafting or preparation.
(k)Entire Agreement. This Agreement contains the entire understanding of the Parties with respect to the subject matter hereof.
(l)Notices. Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this
Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by e-mail to the e-mail address for a Party set forth below; and (iii) one (1) business day after deposit with a nationally recognized overnight
delivery service, in each case properly addressed to the Party to receive the same. The addresses for such communications shall be:Exhibit 10.1
If to the Company or the Board:
Spôk Holdings, Inc.
6850 Versar Center, Suite 420
Springfield, Virginia 22151-4148
Attention: Vince Kelly
Email: vince.kelly@spok.com
with a copy (which shall not constitute notice) to:
Latham & Watkins LLP
555 Eleventh Street, NW
Suite 1000
Washington, D.C. 20004
Attention: William O’Neill and Christopher Drewry
E-mail: William.O'Neill@retiredpartner.lw.com and Christopher.Drewry@lw.com
If to the White Hat Parties:
White Hat Capital Partners LP
150 East 52nd Street
21st Floor
New York, NY 10022
Attention: David Chanley and Mark Quinlan
Email: DChanley@whitehatcp.com  and MQuinlan@whitehatcp.com
with a copy (which shall not constitute notice) to:
Olshan Frome Wolosky LLP
1325 Avenue of the Americas
New York, NY 10019
Attention: Elizabeth Gonzalez-Sussman
E-mail: egonzalez@olshanlaw.com
(m)Termination. Unless earlier terminated as provided in this Agreement, upon the expiration of the Support Period in accordance with Section 4,
this Agreement shall immediately and automatically terminate in its entirety and no Party shall have any further rights or obligations under this
Agreement; provided, however, no Party shall be released from any breach of this Agreement that occurred prior to the termination of this
Agreement.Exhibit 10.1
IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement, or caused the same to be executed by its duly authorized
representative as of the date first above written.
Spōk Holdings, Inc.
By:/s/ Vincent D. Kelly
Name:Vincent D. Kelly
Title:President and Chief Executive OfficerExhibit 10.1
White Hat Strategic Partners LP
By: White Hat SP GP LLC, its General Partner
By:/s/ Mark Quinlan
Name:Mark Quinlan
Title:Managing Member
White Hat SP GP LLC
By:/s/ Mark Quinlan
Name:Mark Quinlan
Title:Managing Member
White Hat Capital Partners LP
By:/s/ Mark Quinlan
Name:Mark Quinlan
Title:Managing Partner
White Hat Capital Partners LP
By:/s/ Mark Quinlan
Name:Mark Quinlan
Title:Managing MemberContract No.: DDCX S DG KC 201812130044
Exhibit 10.5
Collaboration Agreement
This Collaboration Agreement  (hereinafter referred to as this “Agreement") is made and entered into by and between the following parties in
Haidian District, Beijing. This Agreement may be executed in paper form offline or in electronic form through the Didi Chuxing Online Contracting
Platform (website: https://Agreement.didichuxing.com/, hereinafter referred to as the “Contracting Platform”). The Agreement executed offline in
paper form shall become effective upon the completion of the execution by both Parties (hereinafter referred to as the “Effective Date”); and the
Agreement executed online in electronic form shall become effective upon the completion of the execution on the Contracting Platform by both
Parties (hereinafter referred to as the “Effective Date”) recorded by the third-party Online Document Depository.
Party A: Didi Chuxing Technology Co., Ltd.
Legal Representative: Ting Chen
Party B: Hunan Ruixi Financial Leasing Co., Ltd
Legal Representative: Xianglong Li
Party A and Party B shall be individually referred to as a “Party” and collectively as the “Parties”.
Whereas
1. As a company providing third-party e-commerce platform services, and desires to assist the Driver User (hereinafter referred to as the “Driver
User”) registered on the platform to lease vehicles from Party B with the most favorable treatment in the market, so as to reduce the cost of using
vehicles for the Driver User;
2. Party B is an automobile leasing company, with the qualification, resources and ability to carry out the automobile financial leasing business, and
it acknowledges and undertakes to implement the platform rules formulated by Party A;
3. Both Parties hope to clarify the cooperation contents, rights and obligations of each Party And other matters through this Agreement.
NOW, THEREFORE, the Parties hereto agree as follows:
1. Definitions
Unless otherwise stated, the following terms used in this Agreement shall have the following meanings:
1.1 “Platform” refers to the third-party e-commerce platform operated by Party A: Xiaoju Online Ride-Hailing Marketplace.Contract No.: DDCX S DG KC 201812130044
1.2 “Platform Rules” refers to normative documents related to the platform noticed to Party B by Party A by E-mail or other means as well
as the various normative documents published on the platform such as the Regulations on Vehicle Rental Service Business of Xiaoju
Online Ride-hailing Marketplace and Code of Conduct and Risk Notification of Vehicle Service Company .
1.3 “Didi” refers to Party A, Party A’s Affiliates and their respective software and platforms operated by them.
1.4 “Ride-hailing Vehicles” refers to the online car-hailing vehicles.
1.5 “Ride-hailing Service ” refers to the online non-peripatetic car hailing service provided by certain entities through the service
platforms based on Internet technology using qualified vehicles and Driver Users, which integrates supply and demand information.
1.6 “Affiliates” refers to companies that have an affiliated relationship with each other, including, but not limited to, the companies, firms,
corporations or other organizations of such nature established, participated in the establishment, operated, controlled by
shareholders, legal representative, actual controllers or directors, supervisors, etc. and their immediate family members, collateral
relatives within three generations, close relatives, etc.
1.7 “Senior Management” refers to the officers defined in the Company Law of the People’s Republic of China  and the chief executive
officer, chief financial officer, supervisors, etc. in a company.
1.8 “Laws” refers to laws, administrative regulations, local laws and regulations, autonomous regulations and separate regulations
promulgated by the competent authorities, rules and regulations of the Ministries and Commissions of the State Council and local
governments, judicial interpretations, normative documents, etc. in China.
1.9 “Period of Cooperation” refers to the term of validity of this Agreement.
1.10 “Confidential Information” refers to any oral or written materials and information exchanged between the Parties in respect of this
Agreement, including, but not limited to, the following:
1.10.1 The content of this Agreement and its supplemental agreement(s);
1.10.2 The business (including, but not limited to, business decisions, management methods, operating strategies, incentive
strategies, promotional information), operating, financial, technical, product, service information of any party obtained or
received by the other party during the performance of this Agreement or during the term of this Agreement;
1.10.3 The other party’s user profiles, information, etc.;
1.10.4 The processes and results of settlement of any dispute arising from this Agreement
1.11 “Intellectual Property Rights” refers to: (a) patents and patent applications; (b) trademarks, service marks, trade names, trade dress
and domain names, and goodwill exclusively attached thereto; (c) copyrights, including the copyrights of computer software and the
copyrights of the database; (d) secrets and proprietary information, including trade secrets and technical secrets; and (e) any rights
similar to subparagraphs (a)-(d) provided in any law, whether or not any one of the foregoing has been applied for registration or
registered.
1.12 “Personal Injury Compensation” refers to the compensation provided in the Interpretation of the Supreme People’s Court on Several
Issues Concerning the Application of Law in the Trial of Cases on Personal Injury Compensation .Contract No.: DDCX S DG KC 201812130044
1.13 “Xiaoju online Ride-Hailing Marketplace SaaS System ” refers to the operation and management service system for Party B's
vehicles developed by Xiaoju online Ride-Hailing Marketplace. When Party B signs the Vehicle Operation Management Service
Agreement, it shall be deemed to be connected to the SaaS system of Xiaoju online Ride-Hailing Marketplace. Party B is free to
choose the following two types of services: One is the regular free service of Xiaoju online Ride-Hailing Marketplace. One is the
regular value-added charging service of Xiaoju online Ride-Hailing Marketplace.
2. The Cooperation
During the term of cooperation, Party B shall, through the Platform provided by Part A, present to the Driver User the vehicle for rent and
financing and leasing solutions in line with this agreement between Party A and Party B and the Platform Rules. Party B shall provide the
Driver User with long-term and stable rental sources and the most favorable financial leasing scheme, complete the vehicle leasing transactions
with the Driver User through the Platform, and provide the Driver User with high-quality financial leasing services.
3. Rights and Obligations
3.1 Party A’s rights and obligations:
3.1.1 Party A shall maintain and operate the Platform in accordance with the available technology, so that the Platform can
operate normally, and Party B can use the Platform normally and conduct vehicle financial leasing transactions with the
Driver User smoothly.
3.1.2 Party A shall reply to problems encountered by Party B during the registration in and use of the Platform in a timely manner.
3.1.3 Party A is entitled to inspect any information and materials submitted by Party B and the information generated by the use of
the Platform from time to time. In case any problem or question is discovered in the aforesaid information or materials, Party
A is entitled to take the following measures:
3.1.3.1 To request Party B to submit more information or documentary evidence;
3.1.3.2 To request Party B to correct such problem;
3.1.3.3 Removing commodities from the shelves and temporarily shutting down some functions of the Platform
account and other measures considered necessary by Party A.
3.1.4 Party A is entitled to inspect the information released by Party B on the Platform. If the information released by Party B
contains the following information, Party A may, without informing Party B, take restrictive measures such as deleting the
information or removing the commodities from the shelves:
3.1.4.1 Information unrelated to or not intended for a vehicle leasing transaction;Contract No.: DDCX S DG KC 201812130044
3.1.4.2 False information that is misleading or exaggerating the facts or inconsistent with the facts;
3.1.4.3 Information of malicious competition or other information that may disrupt the normal transaction order of the
Platform;
3.1.4.4 Information that violates the Laws or the public interests or may harm the legitimate interests of the Platform
and/or other third parties.
3.1.5 During the cooperation, Party A shall have the right to inquire relevant information of Party B through various channels and
investigate Party B's background. If the investigation results show that Party B has major business risks and other
conditions, Party A shall have the right to unilaterally terminate the cooperation if the assessment suggests that Party A's
reputation is sufficiently affected therefrom.
3.2 Party B’s rights and obligations:
3.2.1 Party B shall be entitled to use the Platform to publish commodities and its own information subject to the compliance with
this Agreement and the Platform Rules and prior approval by Party A.
3.2.2 Party B shall guarantee the authenticity, legality, completeness, accuracy and validity of any materials and information
provided by it to Party A, and guarantee that such materials and information are in compliance with this Agreement and the
Platform Rules during the Period of Cooperation; and shall guarantee the validity and security of the email address,
telephone number, address, postal code, etc., provided by it to Party A, and the successful contact by Party A or the Driver
Users with Party B through the aforementioned contact information. In case such materials or information or contact
information is changed or invalid, Party B shall notify Party A of the changed information or the invalidity at least 3 working
days in advance.
3.2.3 Party B guarantees that the vehicles released and leased on the Platform shall meet the following conditions simultaneously:
3.2.3.1 Obey the requirements of this agreement, Platform Rules, Laws; can drive on the road, and can be used to
engage in online Ride-hailing operation in the place where the leased vehicle is used;
3.2.3.2 The vehicles are passenger cars that meet the Safety Specifications for Power-driven Vehicles Operating on
Roads (GB 7258-2012) and have less than 7 seats, including the driver's seat;
3.2.3.3 No decorations, devices or equipment (except those required by law) have been installed, and there are no
other modifications or additions that may affect the safe operation of the vehicle or endanger the personal and
property safety of the vehicle drivers and passengers;
3.2.3.4 The engine has not been replaced or adjusted in a way different from that of the factory, or the performance has
been substantially modified or installed (except those permitted by local laws and passed the safety inspection
of the traffic administrative department of the public security organ).Contract No.: DDCX S DG KC 201812130044
3.2.3.5 There is no any right defect or ownership dispute. Party B is entitled to lease the vehicle to others in the form
of financial leasing for the operation of online Ride-hailing or other purposes.
3.2.4 Party B shall be obliged to verify the actual use of the leased vehicles, assist and ensure that the Driver User purchases
corresponding insurance according to the actual use of the leased vehicles; if the leased vehicle is used for online Ride-
hailing operation, in case that the provisions of the local Laws on online Ride-hailing insurance are changed within the term
of cooperation or the provisions of the local Laws on online Ride-hailing are officially implemented within the term of
cooperation, Party B shall inform the Driver User within 3 working days after the change of local Laws and regulations on
Ride-hailing or the effective implementation thereof, assist the Driver User and ensure that the insurance of the leased
vehicle shall be changed in accordance with the provisions of local Laws on ride-hailing to make the insurance of the leased
vehicle comply with the provisions of relevant Laws and regulations on Ride-hailing at that time.
3.2.5 If the vehicle released by Party B on the Platform does not comply with the Platform Rules or legal provisions irregularly
updated, Party B shall notify the Platform within 1 working day after the new Platform Rules or new Laws come into force
and remove the vehicle by itself.
3.2.6 When the vehicle leased by Party B is used by the Driver User to provide online Ride-hailing Services  on Didi platform,
Party B shall try its best to cooperate with Party A to conduct investigation and collect evidence and assist Party A to deal
with relevant matters in case of passenger complaints, traffic accidents or complaints received by Party A or reports of Party
B's behaviors in violation of this Agreement or platform rules.
3.2.7 Party B shall ensure a long-term and stable supply of vehicles and give priority to meeting the rental needs of the Driver
User.
3.2.8 Party B shall complete automobile lease transactions with Driver Users through the Platform, and enter into agreements with
Driver Users by using the Financial Leasing Agreement template provided by Party A.
3.2.9 Party B shall truthfully provide Party A with one original copy of the Financial Leasing Agreement  signed by and between
Party B and the Driver User, together with its annexes of Vehicle Handover List  and Financial Leasing Confirmation Letter ,
etc., and shall upload the scanned copy to the Platform within 1 working day after the signing of the Agreement.
3.2.10 Party B shall fulfill its rights and obligations to the Driver User who has signed the Agreement with Party B by means of
strictly following the template of Financial Leasing Agreement and its annex provided by Party A.
3.2.11 Party B is entitled to collect a deposit from the Driver User for the leased vehicle. The amount of the deposit shall be the
same as or lower than the amount of the deposit announced by Party B on the Platform, and the collected deposit shall be
less than RMB20,000 (RMB TWENTY THOUSAND ).Contract No.: DDCX S DG KC 201812130044
3.2.12 Party B shall ensure that the Driver User's down payment, monthly rent, last payment, deposit (fee items shall not exceed the
aforementioned items) are collected only in accordance with the Financial Leasing Agreement , and the overall internal rate
of return (IRR) of the financial leasing scheme shall be kept within 25%.
3.2.13 In the cases that Party B guarantees to sign the Financial Leasing Agreement  with Party A's users, Party B will agree on the
provisions of terminating the Financial Leasing Agreement unilaterally by the Driver User in advance with the Driver User
according to the conditions or better conditions specified in Annex 2 Terms and Conditions for the Driver User to Terminate
Financial Leasing Agreement in Advance , and the relevant provisions shall at least comply with the following agreements:
3.2.13.1 Party B shall clarify the logic and method for calculating the liquidated damages due to the unilateral
termination of the Financial Leasing Agreement  by the Driver User;
3.2.13.2 After signing the agreement with Party B, the Driver User is entitled to terminate the Financial Leasing
Agreement 7 days in advance in the last week (7 natural days) of every three months.
3.2.13.3 In case that the Driver User unilaterally terminates the Financial Leasing Agreement  in advance, he/she does
not need to pay the remaining rent and the last payment;
3.2.13.4 In case that the Driver User unilaterally terminates the Financial Leasing Agreement  in advance, Party B shall
collect the liquidated damages from the Driver User within 30% of the "down payment + total monthly rent +
last payment" stipulated in the Financial Leasing Agreement ; If major maintenance (maintenance fee is
RMB3,000 or above) of the leased vehicle occurs during the lease period, Party B may charge the depreciation
expense of the Driver User's rental of the vehicle in addition to the liquidated damages mentioned above, and
the depreciation expense for each time shall be less than 20% of the current maintenance fee. (Depreciation
expense can only be charged in that the Driver User unilaterally terminates the Agreement in advance without
paying the full amount to buy the vehicle.)
3.2.13.5 Party B shall refund all the monthly rental paid by the Driver User in accordance with the Financial Leasing
Agreement and all the other expenses excluding that paid to the third party (e.g. vehicle purchase tax, insurance
premium, etc.).
3.2.13.6 Party B shall explain the conditions for the termination of the Agreement to the Driver User, fully communicate
to reach consensus, and obtain the signature confirmation from the Driver User.
3.2.13.7 In case that Party B has different conditions for termination of agreement for different types of vehicles, they
shall all conform to the provisions of this agreement, and the written consent of Party A shall be obtained in
advance before they can be applied to the Financial Leasing Agreement  signed with the Driver User.Contract No.: DDCX S DG KC 201812130044
3.2.14 Where a traffic accident or other safety accident occurs in a leased vehicle, Party B shall actively deal with relevant matters
and settle insurance claims. If the Driver User has paid the maintenance fee and personal injury compensation for the leased
vehicle caused by traffic accident or other safety accident, Party B shall pay full insurance premium after deducting the
expenses that the Driver User shall pay to Party B (if any) to the Driver User within 1 working day after receiving the
insurance compensation.
3.2.15 In case that the vehicle leased by Party B to the Driver User is used for the online Ride-Hailing Service, where a traffic
accident or other safety accident occurs when a leased vehicle provides an online Ride-Hailing Service, if passengers or
other subjects in traffic accidents or safety accidents (subjects other than the Driver User who rent vehicles and passengers)
require the Driver User to Compensate For Their Personal Injury, or if the Driver User fails to pay or is unable to pay while
the carriage Agreement losses, or if the passenger requests the Driver User or other subjects to bear the carriage liability of
the online Ride-hailing Service, Party B shall deal with these situations timely, assume the carrier responsibility of leasing
the vehicle which provides online Ride-Hailing S ervice and pay the compensation in time; If it is the Driver User's
responsibility, Party B may recover it from the Driver User.
3.2.16 In case that the Driver User fails to pay the monthly rent in full and on time as stipulated in the Financial Leasing
Agreement, Party B shall deal with it according to the following procedures: a notification shall be sent to the Driver User to
require the Driver User to pay the monthly rent within a reasonable time firstly. If the Driver User refuses to correct and
delays the payment of the monthly rent for more than 30 days, Party B can take reasonable measures to recover the vehicle
or terminate or waive the Financial Leasing Agreement .
3.2.17 Party B guarantees that the Driver User will enjoy the most favorable treatment in accordance with the terms and conditions
stipulated in This Agreement during the Period of Cooperation. In case that the price and other substantive terms offered by
Party B to such entity are more favorable than those enjoyed by the Driver User in any commercial cooperative relationship
signed or formed between Party B and any entity, the Driver User and Party B shall amend the provisions in the Financial
Leasing Agreement  signed by both parties to enable the Driver User to enjoy the same or more favorable provisions as those
enjoyed by such other entities, such modifications shall include but not limit to the modifications of the monthly rent terms.
3.2.18 Party B shall guarantee that after this agreement comes into force, Party B shall sign the Vehicle Operation Management
Service Agreement  on the related platform of Party A (i.e. " Xiaoju online Ride-Hailing Marketplace ") and uniformly access
to the SaaS system of Xiaoju online Ride-Hailing Marketplace, otherwise, Party A is entitled to unilaterally terminate this
agreement.
4. Deposit
4.1 Party B confirms that the deposit paid in accordance with this Agreement is a deposit for the successful cooperation between Party B
and Party A on the vehicle operational leasing business and the vehicle financing leasing business to guarantee that Party B will fulfill
its obligations under this Agreement and the Cooperation Agreement signed by and between Party A and Party B regarding the
vehicle operational leasing business and the Platform Rules and Party B agrees that Party A may deduct reasonable liquidated
damages, overdue fines, compensations, etc. from the deposit when Party B breaches this Agreement, or the above mentioned
Cooperation Agreement  or the Platform Rules . In case that Party A deducts any amount from the deposit, it shall issue a
corresponding receipt to Party B.Contract No.: DDCX S DG KC 201812130044
4.2 During the period of cooperation, Party B shall pay the deposit in accordance with the following rules:
For each payment of RMB 100,000, Party B can list up to 100 vehicles on Party A's platform (for example, if Party B wishes to list 275
vehicles, it shall pay RMB 300,000. A deposit of RMB300,000 permits Party B to list up to 300 (included) vehicles on Party A's
platform.
4.3 Party B shall first pay a deposit of RMB100,000 to Party A within 5 working days after the signing of this Agreement. For list more
products, Party B shall apply to Party A 3 working days in advance and after obtaining the consent of Party A, pay the deposit in full
within 5 working days from the date of receipt of the deposit notice from Party A.
4.4 If Party B shall pay liquidated damages for breach of this Agreement or violation of the platform rules, Party A is entitled to request
Party B to pay the liquidated damages. If Party B refuses or fails to pay, Party A is entitled to deduct the corresponding amount from
the deposit. In this case, Party B shall pay additional deposit equivalent to the liquidated damages when it pays the liquidated
damages. For example, if Party B shall pay liquidated damages as much as RMB N, it shall pay additional RMB N to increase the
deposit paid in accordance with Article 4.2 after it pays the liquidated damages or Party A deducts the liquidated damages from the
deposit.
4.5 If Party B shall increase the deposit in accordance with this Agreement, it shall pay the additional deposit in full within 5 working days
from the date of receipt of Party A's deposit payment notice. If Party B's deposit is deducted in whole or in part due to Party B's
breach of this Agreement or other reasons, Party B shall replenish the deposit within 5 working days from the deduction date of the
deposit as well as pay the additional deposit in full in accordance with Article 4.4.
4.6 If Party B fails to pay, increase or replenish the deposit in accordance with this Agreement, Party A shall have the right to charge a
penalty as much as 1‰ of the unpaid amount for each day. If Party B fails to pay, increase or replenish the deposit in full within 15
days after the expiration of the payment period specified in this Agreement, Party A shall have the right to terminate this Agreement
unilaterally.
4.7 After Party B terminates or rescinds this Agreement, if there is no effective Vehicle Lease Agreement between Party B and a Driver
User (if the operational leasing business is conducted) and there is no dispute on the vehicle lease between Party B and a Driver User,
Party A shall refund the remaining deposit to Party B on a interest-free basis within 30 days after receipt of the deposit receipt
returned by Party B; if there is any effective Vehicle Lease Agreement between Party B and a Driver User or if there is any disputes on
the vehicle lease between Party B and a Driver User, Party A shall refund the remaining deposit to Party B on a interest-free basis
within 30 days after receipt of the deposit receipt returned by Party B after the driver confirms the Vehicle Lease Agreement has been
fulfilled or the dispute has been resolved.Contract No.: DDCX S DG KC 201812130044
5. Taxes
The taxes incurred by the Parties hereto due to the performance of this Agreement shall be borne by the Parties respectively.
6. Intellectual Property Rights
Party A has exclusive rights and interests in all rights, ownership, titles, interests and intellectual property rights arising from or created by the
performance of this Agreement.
7. Confidentiality
7.1 Each party shall maintain the confidentiality of all confidential information and shall not disclose any confidential information to any
third party without the prior written consent of the other party, except for the information which (a) is or will be known by public (not
caused by the disclosure to the public by the receiving party); (b) is required to be disclosed by the applicable law or any securities
exchange rules or regulations; (c) is necessary to be disclosed to the counsels or financial consultants by either party in respect of
the transaction under this Agreement, and such counsels or financial consultants are bound by similar confidentiality obligations
hereunder. Disclosure of any confidential information by an employee or agency employed by either party shall be deemed to be a
disclosure of such confidential information by that party, and the party shall be liable for breach of this Agreement. This provision
shall survive any change or the termination of this Agreement for any reason.
7.2 Without the written consent of Party A, Party B shall not disclose the relevant information of Party A or Party A's Driver Users
obtained by Party B due to this Agreement or the cooperation hereunder to any third parties (including but not limited to disclosing
the cooperation content to any media, website, WeChat Official Account and other promotional channels or making false propaganda
and report), or Party A is entitled to unilaterally cancel the cooperation and pursue Party B's liability for breach of the Agreement
according to the actual loss.
8. Representations and Warranties
8.1 Party A represents and warrants as follows:
8.1.1 Party A is a company duly incorporated and validly existing under the Laws of China;
8.1.2 The execution and performance of this Agreement by Party A is within the scope of its corporate capacity and its business
scope approved by and registered with competent authorities; Party A has taken necessary corporate actions and has been
duly authorized and has obtained the consent and approval from third parties and governmental agencies, and will not be in
violation of any Laws or other restrictions binding upon Party A.
8.1.3 This Agreement constitutes the legal, valid and binding obligations of Party A and may be enforced in accordance with its
terms.Contract No.: DDCX S DG KC 201812130044
8.2 Party B represents and warrants as follows:
8.2.1 Party B is a company duly incorporated and validly existing under the Laws of China;
8.2.2 The registered capital of Party B is more than RMB5 million (FIVE MILLION)
8.2.3 Party B is in good standing and has not been included in the Lists of Enterprises with Abnormal Operations and the List of
Enterprises with Serious Illegal and Dishonest Acts;
8.2.4 Party B's signing and performance of this Agreement is within the permissive scope registered by virtue of its legal
personality (the administrative license for or filing of the business scope has been obtained or completed if required); Party B
has taken necessary corporate actions and has been duly authorized and has obtained the consent and approval from third
parties and governmental agencies, and will not be in violation of any laws or other restrictions binding upon Party B.
8.2.5 This Agreement constitutes the legal, valid and binding obligations of Party B and may be enforced in accordance with its
terms.
9. Termination
9.1 In the following cases, either party may terminate this Agreement immediately by written notice to the other party, and this Agreement
shall terminate as of the date on which such party gives such written notice of termination:
9.1.1 The other party ceases to carry on business or goes into liquidation (other than voluntary liquidation for the purpose of
reorganization or combination of bona fide bankruptcy with prior written consent of such party) or dissolution;
9.1.2 The other party is unable to pay its debts as they become due, or has a receiver, administrative receiver or administrator (or
any similar person provided by the Laws of the place where the company is located or incorporated) appointed for
bankruptcy of all or any part of its property, or will go into any bankruptcy;
9.1.3 Unless otherwise agreed, the other party is in violation of any provision of this Agreement and fails to remedy such violation
within 30 days from the receipt of notice of such violation from such party (if capable of remedy);
9.1.4 The other Party Breaches the Agreement, and such party may terminate this Agreement in accordance with this Agreement
or the Platform Rules.
9.2 In the event of any changes in industry policies, industry restrictions, business strategy adjustments and/or business adjustments,
the Parties shall notify the other Party At least 30 days in advance to terminate this Agreement. This Agreement shall terminate as of
the date of termination specified in the notice of termination. If this Agreement terminates pursuant to this Article, in addition to the
payment of the amount incurred and confirmed under this Agreement to the other Party, the Parties shall not be liable for the
termination of this Agreement, including, but not limited to, payment of late fees, liquidated damages, compensation.
9.3 In the case of a written notice 15 days in advance from either party to the other Party And a payment of the liquidated damages of
RMB10,000 (RMB TEN THOUSAND), this Agreement shall terminate as of the date of termination stated in the notice of termination.Contract No.: DDCX S DG KC 201812130044
9.4 Upon the termination of this Agreement, Party A is not obliged to retain any information on the Platform or provide such information
to Party B; but Party A is entitled to retain Party B’s registration data and Party B’s data in connection with the driver services during
the Period of Cooperation. Upon the termination of the Agreement, in the event of any violation by Party B of this Agreement or the
Platform Rules during the Period of Cooperation is discovered, Party A is still entitled to exercise its rights under this Agreement to
prosecute Party B for such violation
9.5 After the termination of this Agreement, Party B shall strictly perform the Financial Leasing Agreement signed with the Driver User
until the lease expires.
9.6 Upon the termination of this Agreement, Party B shall remove and delete any information or signs related to Didi contained in the
materials in the building, equipment, furnishings inside and outside Party B’s premises and materials published by Party B in any form.
10. Liability for Breach
10.1 The following acts belong to Class I breaches of the Agreement. If Party B has any of the following acts, Party B shall immediately
correct the breach and Party A is entitled to send to Party B a Confirmation Letter on the Breach of the Partner of Xiaoju Online
Ride-Hailing Marketplace
10.1.1 Party B fails to cooperate with Didi’s staff, for example:
10.1.1.1 Party B is in violation of Article 3.1.3.1, and fails to provide more information or documentary evidence as required
by Party A;
10.1.1.2 Party B is in violation of Article 3.2.6, and fails to cooperate with Party A in the investigation and evidence
collection or to assist Party A in handling related matters;
11.1.1.3 Party B fails to affix its seal on the reply letter of the Confirmation Letter on the Breach of the Partner of Xiaoju
Online Ride-hailing Marketplace  or fails to provide Party A with such original sealed letter;
11.1.1.4 Other noncooperation with Didi’s staff by Party B.
10.1.2 Being complained due to the service for more than 3 times by different Driver Users within 1 natural month, including but not
limited to the noncompliance of the requirements for the time limits for telephone invitations and offline interviews (Party B
shall make an invitation by phone within 1 day after a Driver User places an order and conduct an offline interview with the
driver within 7 days), bad service attitude, etc.
10.1.3 Party B is in violation of Article 3.2.2, and fails to notify Party A of any change or invalidity of any material, information,
contact information provided to Party A at least 3 working days prior to such change or invalidity;
10.1.4 Party B is in violation of Article 3.2.9, and fails to upload the scanned copy of the Consulting Service Agreement  to the
Platform within 1 working day from the execution of such Agreement with any Driver User;Contract No.: DDCX S DG KC 201812130044
10.1.5 Party B disseminates any information not published through Didi’s official channels, or disseminates rumors relating to Didi;
10.1.6 Party B conducts other Class A breaches specified in the Platform Rules.
10.2 The following acts constitute Class B breaches. In the event of any breach below by Party B, Party B shall immediately remedy the
breach, and Party A is entitled to request Party B to pay the liquidated damages of an amount from RMB1,000 (RMB ONE
THOUSAND) to RMB 5,000 (RMB FIVE THOUSAND) based on the consequences of the breach, and send the Confirmation Letter
on the Breach of the Partner of Xiaoju Online Ride-hailing Marketplace  to Party B.
10.2.1 In the event of any Class A breach, Party B fails to remedy such breach in a timely manner or within the time limit notified by
Party A, or the Agreement is still breached upon the completion of the remedy;
10.2.2 In the event of three Class A breaches in 12 consecutive calendar months, the third Class A breach shall be regarded as a
Class B breach;
10.2.3 The breach provided in Article 10.1.3 occurs twice in 12 consecutive natural months;
10.2.4 Violating Article 3.2.7 for being complained due to no stock of vehicles for more than 3 times by different Driver Users within
1 natural month;
10.2.5 Listing or leasing on the platform a vehicle that does not meet the requirements of this Agreement or the requirements of the
Platform Rules. For example:
10.2.5.1 Any vehicle listed and leased on the Platform failing to comply with Article 3.2.3;
10.2.5.2 Any vehicle listed and leased on the Platform failing to meet the other requirements of the Platform Rules;
10.2.6 Party B failing to remove any vehicle from the Platform within 1 working day after a recall decision is issued for breach of
Article 3.2.5 or in case that any vehicle is recalled after being listed on the Platform;
10.2.7 Violating Article 3.1.4 for releasing information which is not related to the vehicle lease business or releasing malicious
competition and other information which may disrupt the normal trading order of the Platform, or releasing any information
in violation of the Law or against the public interest or any information which may damage the legitimate interests of the
three parties;
10.2.8 Concealing significant vehicle information (eg, whether a major repair has occurred), or the vehicle information published on
the P latform (eg, service life) and the financial leasing programs (including but not limited to the down payment, monthly
rent, balance payment, value-added services, etc.) being inconsistent with the actual vehicles delivered by the drivers or the
Financial Leasing Agreement;
10.2.9 Being complained due to any failures of Class A vehicles (including but not limited to oil leakage, safety system failure,
power system failure, etc.) listed on the Platform for more than 5 times from different Driver Users;Contract No.: DDCX S DG KC 201812130044
10.2.10 The monthly efficiency indicators failing to meet the standards or the assessment results of the experience indicators failing
to meet the standards (failing to reach 60 points (excluded)) in three consecutive indicator assessments;
10.2.11 Violating Article 3.2.11 for charging a Driver User a deposit of more than RMB20,000 (twenty thousand);
10.2.12 Violating Article 3.2.17 due to not providing the most preferential treatment to a Driver User;
10.2.13 Being in any Class II violations as specified in the Platform Rules.
10.3 The following acts constitute Class C breaches. In the event of any breach below by Party B, Party B shall immediately remedy the
breach, and Party A is entitled to request Party B to pay the liquidated damages of an amount from RMB5,000 (RMB FIVE
THOUSAND) to RMB50,000 (RMB FIFTY THOUSAND) based on the consequences of the breach, and send the Confirmation Letter
on the Breach of the Partner of Xiaoju Online Ride-hailing Marketplace  to Party B.
10.3.1 In the event of any Class B breach, Party B fails to remedy such breach in a timely manner or within the time limit notified by
Party A, or the Agreement is still breached upon the completion of such remedy;
10.3.2 In the event of three Class B breaches in 12 consecutive calendar months, the third Class B breach shall be regarded as a
Class C breach;
10.3.3 Inducing Platform users to transfer the vehicle ownerships to Party B;
10.3.4 Violating Article 3.2.3.3 or 3.2.3.4 for leasing an unqualified vehicle, which later causes a traffic accident or any other safety
accident due to retrofitting or installation of new parts;
10.3.5 Violating Article 3.2.4 for the following reasons: The actual use of a leased vehicle is inconsistent with the purpose as agreed
in the Financial Leasing Agreement , or although the actual use of the leased vehicle is consistent with the purpose as
agreed in the Financial Leasing Agreement , the Driver User is not pursued to buy the corresponding insurance according to
the actual use nature of the leased vehicle and therefore the insurance company refuses to pay for the compensation when
the leased vehicle has a traffic accident or the Driver User is not pursued to buy the insurance meeting the requirements for
the insurance value and type as provided by the law for online vehicle leasing in accordance with Article 3.2.4 and therefore
the compensation amount paid by the insurance company is insufficient to cover the Driver User's liability for tort or carrier
liability in the traffic accident or safety accident.
10.3.6 Violating Article 3.2.8 for inducing the Driver User to carry out a vehicle leasing transaction outside the Platform or sign a
Agreement without using the platform's template of Financial Leasing Agreement;
10.3.7 Violating Article 3.2.10 for failing to perform its obligations to the Driver User in accordance with the Financial Leasing
Agreement signed with the Driver User;
10.3.8 Violating Platform Rules for carrying out misleading propaganda (including but not limited to exaggerating the scale of the
company, making exaggerated advertisement or fictitious promise of service projects, preferential programs, etc., or
misleading the Driver User by use of false facts such as Didi's order precedence);Contract No.: DDCX S DG KC 201812130044
10.3.9 Entering into other agreements with the Driver User in any form other than the P latform's template of Financial Leasing
Agreement; or restricting the rights of the Driver User or increasing the obligations of the driver in any form, without a prior
written notice to Party A and without the written consent of Party A;
10.3.10 Charging the Driver User any fees under any name in any form other than Party A's template of Financial Leasing
Agreement or forcing the Driver User to subscribe any business not related to Didi or forcing Driver Users to make
unreasonable consumption;
10.3.11 Disseminate any information not published by Didi through official channels, or spreading rumors that have a negative
impact on Didi (eg, causing losses to drivers);
10.3.12 Insulting, intimidating, threatening, deceiving, or forcing any Driver User;
10.3.13 Publishing a system that does not comply with or goes against Didi's business policy or the Platform Rules;
10.3.14 Violating Article 3.2.12 for the IRR of the Financial Leasing Program exceeding the upper limit as agreed in this Agreement;
10.3.15 Violating Article 3.2.13;
10.3.16 Violating Article 3.2.14;
10.3.17 Violating Article 3.2.15;
10.3.18 Violating Article 3.2.16;
10.3.19 Party B conducts other Class C breaches specified in the Platform Rules.
10.4 The following acts constitute Class D breaches. In the event of any breach below by Party B, Party B shall immediately remedy the
breach, and Party A is entitled to request Party B to pay the liquidated damages of not less than RMB50,000 (RMB FIFTY
THOUSAND) based on the consequences of the breach, and send the Confirmation Letter on the Breach of the Partner of Xiaoju
Online Ride-hailing Marketplace  to Party B, and terminate the Agreement.
10.4.1 In the event of any Class C breach, Party B fails to remedy such breach in a timely manner or within the time limit notified by
Party A, or this Agreement is still breached upon the completion of such remedy;
10.4.2 In the event of three Class C breaches in 12 consecutive calendar months, the third Class C breach shall be regarded as a
Class D breach;
10.4.3 Party B is in violation of Article 3.2.2 and provides false materials or information to Party A ;
10.4.4 Party B or Party B’s Affiliates use or use in disguised form the company name, trade name, trademark and logo of Party A or
Party A’s Affiliates without the consent of Party A or Party A’s Affiliates or fail to use such names, trademark or logo as
agreed, or Party B uses the company name and logo similar to above trademarks and logo (if Party A or Party A’s Affiliates
considers that the company name or logo used by Party B or Party B’s Affiliates is similar to the trade name or trademark of
Party A or Party A’s Affiliates, Party A may notify Party B and Party B’s Affiliates to change its name. If Party B or Party B’s
Affiliates fail to take measures within 20 days from the receipt of such notice, it shall be deemed as a use of trademark and
logo similar to those of Party A or Party A’s Affiliates).Contract No.: DDCX S DG KC 201812130044
10.4.5 Party B or Party B’s Affiliates conduct illegal or criminal activities relying on the partnership with Didi;
10.4.6 Party B, Party B’s shareholders, legal representatives, Senior Management or Party B’s Affiliates make illegal profits relying
on their relationship with the Didi’s staff (including, but not limited to, relatives, couples, friends);
10.4.7 Party B or Party B’s shareholders, legal representative, Senior Management or Party B’s Affiliates is in violation of the
provisions of the Trust and Integrity and Commercial Anti-Bribery Agreement  between the Parties;
10.4.8 Party B charges any fee against the Driver Users in the name of Didi;
10.4.9 Party B forces the Driver Users to transact any business irrelative to Didi or forces the Driver Users to have unreasonable
consumption, which causes material adverse effects to Didi or causes adverse social effects (including but not limited to
collective complaints, illegal assembly, petitions, march, sit-in or containment of Didi by Driver Users, news media releases);
10.4.10 Party B, Party B’s staff or Party B’s Affiliates are in violation of Article 7 and discloses Party A’s confidential information to
third parties in any form;
10.4.11 In consideration of the fact that Party B may have access to the relevant trade secrets of Didi during the cooperation, Party B
or Party B’s any affiliate cooperates with any entity competitive with Didi (including but not limited to Meituan, CAR,
Yongche, izu, Caocao, Dida) in any form without prior written notice to and confirmation by Didi;
10.4.12 Party B introduces the entities competitive with Didi (including but not limited to Meituan, CAR, Yongche, izu, Caocao, Dida)
to Driver Users, and induces Driver Users to conduct activities directly competing or conflicting with Didi;
10.4.13 Party B instigates and organizes the Driver Users to conduct illegal assembly, petition, march, sit-in or containment of Didi,
etc. in any form, or any collective complaints, illegal assembly, petitions, marches, sit-in or containment of Didi and other
mass disturbances by Driver Users are incurred by the products or services provided by Party B;
10.4.14 Party B disseminates any information not published through Didi’s official channels, or disseminates rumors and causes
material adverse effects to Didi (including but not limited to collective complaints, illegal assembly, petitions, marches, sit-in
or containment of Didi by Driver Users, and News media releases);
10.4.15 Party B maliciously slanders other companies or takes other mean measures to disrupt the market order and conducts unfair
competition:
10.4.15.1Party B disseminates other rumors to maliciously slander other companies;
10.4.15.2Party B dispatches undercover personnel to other companies to disrupt the operation order of other companies and
solicits Driver Users or management personnel of other companies;Contract No.: DDCX S DG KC 201812130044
10.4.15.3Party B conducts other activities of unfair competition which seriously disrupt the market order;
10.4.16 Violating Article 8.2 for failing to meet Party A's requirements for cooperative vehicle leasing companies;
10.4.17 Party B conducts other Class D breaches stipulated in the Platform Rules;
10.5 If Party B has a violation of Article 10.3.5, resulting in the insurance company's refusal to pay or insufficient compensation to pay the
driver's tort liability or carrier's liability in the traffic accident, the claim amount rejected by the insurance company and the
compensation supposed to be paid by the insurance company if the corresponding insurance has been bought shall be borne by
Party B. If Party B fails to bear the above mentioned amount rejected and compensation, resulting in any losses to Party A or its users,
Party B shall compensate Party A for the losses of Party A and Party A shall have the right to terminate this Agreement unilaterally
and shall pursue Party B's liability for breach in accordance with Articles 10.3 and 10.6.
10.6 In the event of any breach of the terms of this Agreement by either party, the breaching party shall remedy such breach within the
time limit notified by the observing party. In the event of any losses incurred to the observing party, in addition to the corresponding
liability for breach under the Agreement, the breaching party shall also be liable for the compensation for such losses (including, but
not limited to, the losses incurred to the counterParty By such breach, the legal costs, notarial fees, appraisal fees, the attorney’s fee,
the travel expenses, etc., arising from the investigation and affixation of the liabilities of the breaching Party By the counterparty) .
Unless any party is in violation of the confidentiality clause, in any case, neither party shall be liable for any indirect, punitive claims,
or claims for losses of commercial profits, or damages for business losses of the company or any third Party Arising from this
Agreement, or for any loss or inaccuracy of data of any form, whether based on Agreement, tort or any other legal principle, even
though the party has been informed of the possibility of such damage.
10.7 If Party B violates this Agreement or the Platform Rules, Party A is entitled to take measures such as suspending the platform
services, permanently stopping the platform services, and/or temporarily or permanently disabling the corresponding functions of the
vehicle service company, and/or removing the products from the platforms.
10.8 In case any act of either party is in violation of several provisions of this Agreement at the same time, the observing party is entitled
to choose one provision as the basis for the investigation and affixation of the liability for breach of the breaching party. In case
several acts of either Party Are in violation of several provisions of this Agreement at the same time, the observing party is entitled to
investigate and affix the liability for breach of the breaching party in accordance with each provision violated.
10.9 In the event of several valid agreements between Party A and Party B, any act of either party is in violation of such agreements
between the Parties at the same time, the observing party is entitled to choose to investigate and affix the liability for breach of the
breaching party in accordance with all provisions of all of such agreements or provisions of part of such agreements.Contract No.: DDCX S DG KC 201812130044
11. Governing Law; Dispute Settlement
11.1 The execution, validation, interpretation, performance, modification and termination of this Agreement and the settlement of disputes
under this Agreement shall be governed by the Laws of China.
11.2 Any dispute arising from the interpretation and performance of the terms of this Agreement shall be settled by the Parties through
negotiation in good faith. If the Parties fail to reach an agreement on the settlement of such dispute within 30 days from the
requirement of such negotiation by either party, such dispute may be submitted to the Beijing Arbitration Commission for arbitration
in accordance with its arbitration rules in force then. The arbitral award shall be final and binding upon the Parties.
11.3 During the settlement of the dispute, the Parties shall continue to fully perform this Agreement, except for the matters in dispute.
12. Notices
12.1 All notices and other communications to either party hereto required or permitted hereunder shall be made in Chinese, by personal
delivery or by registered mail with postage prepaid, commercial courier service or by e-mail to the address of the party specified in this
Agreement. The date on which such notice shall be deemed to have been served upon such party shall be determined as follows:
12.1.1 Notices given by personal delivery, registered mail with postage prepaid or commercial courier service shall be deemed
effectively given on the date of receipt or rejection at the designated address for notices;
12.1.2 Notices given by e-mail shall be deemed effectively given when the mail enters into the addressee’s e-mail address contained
in this article or at the time of the receipt of the system prompt for the failed transaction in the case of the invalidation of
receiver’s e-mail address.
12.2 For the purpose of notices, the contacts and contact information designated by the Parties are as follows:
12.2.1 Party A’s contacts: (Telephone/Mobile number:)
Address:
E-mail:
12.2.2 Party B’s contacts: Xianglong Li (Telephone/Mobile number: 0731-85240273)
Address: Floor 9, Huitong Building, No. 168 Hehua Road, Hehua Street, Furong District, Changsha City, Hunan Province
E-mail: 77128824@qq.com
12.3 In the event of any change to the contacts, address or e-mail address of either party, such party shall notify the other Party At least 3
working days in advance by the means provided in this article. Otherwise, the original address or e-mail address shall still be the valid
address for notices.Contract No.: DDCX S DG KC 201812130044
13. Force Majeure
13.1 “Force Majeure” means an event beyond the reasonable control of the Parties, unforeseeable or even foreseeable, but unavoidable by
the Parties to this Agreement, which prevents, affects or delays the performance by either party of its obligations under this
Agreement in whole or in part. Such event includes, but is not limited to, natural disaster, war, fire, riot, strike, Internet connection
failure, computer system failure, communication failure, computer virus, hacker attack or any other similar events that shall be
considered as events of force majeure in accordance with commercial practices.
13.2 The affected party may temporarily suspend the performance of its obligations under this Agreement until the effects of the event of
force majeure are eliminated. The affected party shall fully notify the other party in writing of the occurrence of such event of force
majeure in a timely manner, notifying the other party of the possible effects of such event on this Agreement, and shall use its best
efforts to eliminate such event and mitigate its adverse effects, and provide the written evidence issued by relevant notary office
within a reasonable period. Upon the fulfillment of the aforesaid obligations, the affected party shall not be liable to the other party for
the breach within the scope of effects of such event of force majeure.
13.3 In case the event of force majeure sustains for more than 20 days, either party is entitled to terminate this Agreement unilaterally by
written notice, and this Agreement shall terminate from the date on which such party gives such written notice of termination.
14. Independent Contractor
Nothing in this Agreement shall be deemed to create any joint venture, partnership, or agency relationship between the Parties. Without the
written consent of the authorized representative of the other party, neither party is entitled to execute any agreement on behalf of the other
party or cause the other party to be bound by any law or borrow money or incur any liability or obligation on behalf of the other party hereto.
Each party shall be solely liable for the actions of its employees and contractors employed for the purposes of the promotional activities.
15. Data and Privacy Protection
The collection, storage and maintenance by either party of the third-party data, personal data or information obtained as a result of the
execution or performance of this Agreement shall comply with all applicable laws, regulations or rules.Contract No.: DDCX S DG KC 201812130044
16. Business Principles
16.1 Party B warrants that it does not give or offer any gift to any employee, agent or representative of Party A, and that there is no other
improper interest transfer (including but not limited to giving material benefits or other non-material benefits in the form of gifting or
lending or at a price significantly higher or lower than the market price) with the aforesaid persons, and it will not offer or grant such
items or carry out improper benefits transfer in the future, in order to obtain any business from Party A, or to affect the aforesaid
persons in the aspects of the terms, conditions or performance of any purchase agreement or order (including but not limited to this
Agreement) between the Parties.
16.2 Party B warrants and undertakes that it will strictly abide by the commercial anti-bribery Laws and regulations in force in China and
provisions for anti-corruption in all applicable Laws and regulations including the Foreign Corrupt Practices Act  (FCPA) of the
United States, and it shall not provide any bribes to any government official, employee of state-owned enterprises or public agency
during the performance of this Agreement. Any violation of this article by Party B shall be considered as a material breach of the this
Agreement, and Party A is entitled to immediately terminate this Agreement and the cooperation relationship between the Parties, and
request Party B to pay the liquidated damages of RMB 50,000 (RMB FIFTY THOUSAND) and indemnify for all losses incurred to
Party A thereby.
16.3 Party A’s e-mail address for receiving the report of any violation of Code of Business Conduct is jubao@didiia.com. In the event of
any violation of its Code of Business Conduct found by Party A, Party B shall cooperate with Party A in the investigation as required
by Party A. If Party B fails to cooperate with Party A in such investigation, it shall be deemed as a material breach by Party B. In such
case, Party A is entitled to immediately terminate the Agreement and the cooperation relationship between the Parties, and request
Party B to pay the liquidated damages of RMB50,000 (RMB FIFTY THOUSAND) and indemnify for all losses incurred to Party A
thereby.
17. Transfer
During the term of this Agreement, neither party may assign, or transfer its rights and obligations under this Agreement in whole or in part,
without the prior written consent of the other party. However, Party A may transfer its rights and obligations under this Agreement to any of its
Affiliates in whole or in part with the written notice to Party B, and Party B irrevocably agrees and permits Party A’s such rights, provided that
Party A shall ensure that such transferee or assignee will comply with relevant laws and regulations, and ensure that Party B is exempt from
any liability and consequences arising from any violation of applicable laws and regulations by such transferee or assignee, and Party A shall
indemnify for the losses incurred to Party B thereby.
18. Severability
If any one or more provisions contained in this Agreement is held to be invalid, illegal or unenforceable in any way in accordance with any law
or regulation, the validity, legality or enforceability of the remaining provisions in this Agreement shall not in any way be affected or impaired.
Such invalid, illegal or unenforceable provision shall be replaced by a valid, legal or enforceable provision that has similar economic effects of
such invalid, illegal or unenforceable provision by the Parties through good faith negotiation to the fullest extent permitted by laws and
expected by the Parties.Contract No.: DDCX S DG KC 201812130044
19. Composition, Modification and Supplement of this Agreement
19.1 All Platform Rules are an integral part of this Agreement. In the event of any inconsistence between the Platform Rules and this
Agreement, the Platform Rules shall prevail. If Party B signs this Agreement and uses the Platform, it shall accept to be bound by
the Platform Rules. Party A is entitled to develop and revise the Platform Rules pursuant to the operation of the Platform. For the
development and revision of the Platform Rules that may affect Party B’s rights and obligations, Party A will notify Party B in writing
via email 10 days prior to the implementation of the new Platform Rules, and Party B shall decide whether to continue to perform this
Agreement within 10 days from the date of receipt of the notice via email. If Party B rejects the new Platform Rules, it shall send a
written application for the termination of this Agreement to Party A within 10 days from the date of receipt of such notice. If Party B
fails to terminate this Agreement or continue to log in and use the Platform within such 10-day period, it shall be deemed to agree to
the new Platform Rules. The new Platform Rules shall become effective as of the effective date specified in the Platform Rules, and
Party B shall strictly abide by the new Platform Rules as of the effective date.
19.2 Except for the Platform Rules, any modification and addition to this Agreement shall be signed by the Parties in writing. The modified
and supplemental agreements signed by the Parties in connection with this Agreement shall be an integral part of this Agreement and
shall have the same legal effect as this Agreement.
20. Limited Liability
20.1 Party A only provides the Platform, and Party B shall select (at its own discretion) the Driver Users to establish the consulting
service relationship. Any dispute or controversy arising from the consulting services between Party B and any Driver User shall be
settled by Party B and the Driver User, and Party A neither shall be liable for such dispute, nor shall be liable for the losses incurred to
Party B and the Driver User during the provision of the consultation service by Party B to the Driver User.
20.2 Party A shall only conduct a formal review for the materials submitted and the information published by Party B. The approval by
Party A shall not represent that Party A acknowledges the authenticity and legality of such material and information. In the event of
any loss incurred to Party A or any third party due to the false materials and information provided by Party B, Party B shall be liable
for compensation and shall be liable to Party A for the breach.
20.3 Party B has fully understood the functions and characteristics of services of the Platform prior to the use of the Platform and agrees
that Party A shall not be liable to Party B for any defect in software, insufficiency of function or any necessary improvement.
20.4 Party B’s use of the Platform and the acquisition of any information by using the Platform are solely at Party B’s independent
judgment and is at Party B’s own risk (including but not limited to the losses caused by damage to Party B’s computer system or
mobile phone system or loss of data.)Contract No.: DDCX S DG KC 201812130044
21. Validation and Term
This Agreement shall enter into force as of the effective date. Unless this Agreement is early terminated in accordance with this Agreement or
other agreements signed by the Parties hereof, the term of the validity of this Agreement shall be one year from the effective date. Party A is
entitled to unilaterally terminate this Agreement within three natural months from the signing date of this Agreement.
22. Miscellaneous
22.1 The online Ride-hailing Service agreements such as the Vehicle Leasing Service Cooperation Agreement , the Management
Consulting Service Agreement , the Consultation Service Cooperation Agreement , and the Corporate Franchising Management
Consulting Service Agreement , the vehicle leasing and consulting service agreements (only limited to the Agreements relevant to
Party A's fast ride business, except for those on general franchise business) shall continue to be valid within the scope of cooperation
before the signing of this Agreement by and between the Parties hereof, and the deposits received by Party A in accordance with
such agreements will temporarily not be refunded. Such agreements shall not be terminated until the end of the cooperation between
the Parties under the agreements, at which time the Parties will conduct friendly negotiations on the termination of these agreements.
22.2 The expressions of “not less than”, “no more than” and “within” in this Agreement, include the given figure; the expressions of “N
working days in advance”, “within N working days”, “N days in advance”, “within N days”, include the Nth working day and the Nth
day.
22.3 This Agreement shall be executed in triplicate of equal legal effect, with two original copies for Party A and one original copy for Party
B.
Annex: Agreement for Didi Chuxing Partners on Honesty & Integrity and Anti-Commercial Bribery
————————— [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]——————
Party A: Didi Chuxing Technology Co., Ltd.
/s/ Didi Chuxing Technology Co., Ltd. [signature authenticated by third party document depository on December 17, 2018]
Party B: Hunan Ruixi Financial Leasing Co., Ltd.
/s/ Hunan Ruixi Financial Leasing Co., Ltd. [signature authenticated by third party document depository on December 17, 2018]Contract No.: DDCX S DG KC 201812130044
Agreement for
Didi Chuxing Partners on Honesty & Integrity and Anti-Commercial Bribery
Party A: Didi Chuxing Technology Co., Ltd.
Party B: Hunan Ruixi Financial Leasing Co., Ltd
[Instruction: this Agreement shall be exclusively used by Didi Chuxing Technology Co., Ltd. to conclude Agreements with external sides.
This Agreement shall be attached to all Agreements signed with external sides as an appendix to guarantee the interests of Contracting parties.]
To build a fair and honest business cooperation ecology, the cooperating Parties hereby make and enter into the honesty & integrity and
anti-commercial bribery agreement binding on both Parties.
To ensure stricter compliance with the provisions of laws and regulations concerning the prohibition of commercial bribery, maintain common
interests, and promote sound development of the Parties' relationship, the Parties hereby agree as follows through friendly negotiation for mutual
compliance:
Article I [Purpose of Contracting]
The Parties shall comply with national laws and regulations on anti-commercial bribery, ensure legal business transactions between the
Parties, and shall never damage either party's interest for the purpose of improper cooperation interest in any illegal or corruptible manner. The
Parties shall strictly comply with this Agreement.
The term commercial bribery used in this Agreement refers to all direct or indirect improper interests in material, service or spiritual forms
given by Party B or its personnel to Party A's employees in order to obtain the opportunity of cooperation with Party A and cooperation benefits.
Article II [Honesty and Integrity Commitments]
(I) Party B undertakes:
1. Not to bribe any employee of Didi Chuxing or family members thereof in any way.
2. To support the honesty and integrity construction of Didi Chuxing and assume the obligation of real-name reporting; if any employee
directly under Party B or involved in the cooperation doesn't refuse or report any bribe demand from the employees of Didi Chuxing or their family
members and meets such demand, it shall be deemed Party B's commitment of bribery.
3. To voluntarily report the connection and interest relationship with the employees of Didi Chuxing.
4. To insist on integrity principle during transactions with Didi Chuxing and at least ensure: all information, documents, materials, data and
relevant written and oral statements provided for Didi Chuxing are true and accurate.Contract No.: DDCX S DG KC 201812130044
5. To strictly comply with the commitments made to Didi Chuxing, Agreements, agreements and memos between the Parties, not to conceal
any information that may impact the interest of Didi Chuxing, and actively cooperate in the audit of Didi Chuxing.
6. To comply with the provisions in the code of conduct for Didi Chuxing partners, cooperation agreements and other policies.
7. To strictly comply with the provisions concerning Didi Chuxing brand management, and without authorization, shall not use 滴滴, DIDI,
Didi Chuxing, DIDI Club, authorized partner and any other easily confusing words.
8. To strictly comply with relevant national laws and regulations, and not to engage in any illegal activity.
9. To strictly manage company employees.
10. To keep practical and realistic, not to communicate any false information internally or to the society, and not to disclose any business
secrets of Didi Chuxing.
11. To comply with national laws, regulations and Didi Chuxing provisions, keep honest in bid & tender or business cooperation course, and
participate in bid or tender activities and business cooperation according to laws and regulations.
Article III [Improper Interest]
Party B, Party B's associated companies or employees and associated persons thereof:
(1) shall not give cash gift, articles, negotiable securities directly or indirectly, or provide improper interest in other disguised forms in the
name of Party B or in personal name to any employee of Party A or associated person (including but not limited to direct relative, collateral relative
within three generations, close relatives by marriage or other persons who are closely related or have interest relationship); including but not
limited to cash, checks, credit card gifts, samples, or other commodities, entertainment tickets, membership cards, or kickback, return commission in
the form of currency or goods, employment or properties, introduction of private business cooperation, and travel, entertainment or personal
service at the cost of Party B.
(2) Introduce business or other activities to Party A, or to any spouse, friend or relative of Party A's employees as required by Party A's
employees.
Article IV [Conflicts of Interest] including but not limited to:
(1) Party B shall not provide loan or financing of any form for Party A's employees and associated persons;
(2) If any of Party B's shareholders, supervisors, managers, senior management personnel (including but not limited to the senior
management, chief executive officer, chief financial officer, and other department managers subject to powers or duties as defined in the Company
Law), cooperation project manager and project members is Party A's employee or its associated person, the aforesaid person shall truthfully and
fully report the same to Party A in writing before cooperation;Contract No.: DDCX S DG KC 201812130044
(3) In the process of cooperation, Party B shall not allow Party A's employees and their direct relative to hold or have a third party to hold
Party B's equities (other than shares held through less than 1% outstanding equities in open securities exchange market, through funds without
actual control right held directly or indirectly, or through trust of which the beneficiary is not any of the aforesaid person or his/her associated
person), or employ Party A's employees and their direct relative (including but not limited to the establishment of formal labor relations, labor
dispatching and outsourcing services, part-time consulting, and other forms). If Party B has employed any relative or other associated person of
Party A's employees (including but not limited to direct relative, collateral relative within three generations, close relatives by marriage or other
persons who are closely related or have interest relationship), Party B shall truthfully and fully report to Party A in written form before Party A and
Party B conclude the cooperation agreement or within three days upon employment.
Article V [Liability for Default]
(1) If Party B commits any violation of the aforesaid agreements, Party A is entitled to unilaterally and completely terminate the Agreement
and cooperation with Party B, and no associated entities of Party A will establish commercial cooperation with Party B at any time and under any
circumstance in the future, including but not limited to Party B and all of its subsidiaries, branches and associated companies (the associated
companies of Party B includes without limitation the companies or other organizations established, participated in, operated, controlled by or
otherwise affiliated with Party B's shareholders, legal person, actual controller or directors, supervisors, and their direct relative, collateral relative
within three generations, close relatives by marriage or other persons who are closely related or have interest relationship); besides, Party B shall
pay liquidated damages to Party A at an amount of RMB 100,000 or 50% of the total amount paid/discharged under the involved order (Agreement),
whichever is higher; if Party B's default causes any loss to Party A that cannot be covered by liquidated damages, Party A will recover
compensations for actual losses from Party B.
(2) Party B shall pay the liquidated damages within 5 working days upon Party A's discovery of any breach, and if the payment is not made in
time, Party A is entitled to directly deduct the same from the Agreement price.
(3) Where any improper interest is provided for any employee of Party A or his/her associated person, whether actively or passively, if Party
B voluntarily provides effective information for Party A actively, Party A will consider based on actual situations whether to continue cooperation
with Party B and/or waive the aforesaid liability for default.
(4) The aforesaid circumstances are at absolute sole discretion of Party A.
(5) Where any violation of the commitments on part of either party or its employee constitutes a crime, either party may report the crime to a
judicial authority, and the persons involved will be prosecuted for criminal offense; the party violating the commitments and its employees, if
causing economic loss to other party, shall provide compensations.
Article VI [Reporting Channels and Reward]
If Party B becomes aware of/suspects any violation of the aforesaid provisions on part of Party A's employees, Party B shall contact the Risk
Control Compliance Department (RCCD) of Party A. If the information provided by the information provider about any commercial bribery is
verified to be true, Party A will reward the information provider depending on the influence extent of the event, and in case of any event producing
significant influence, will give special reward.
Party A has a special email address to accept the complaints from Party B: jubao@didiia.com; complaint hotline: 010-62962880. Party A will
keep all information providers and all materials provided by them strictly confidential.Contract No.: DDCX S DG KC 201812130044
Article VII [Miscellaneous]
This Agreement is an appendix to the Cooperation agreement,  made in two copies, and have equal legal force to the Cooperation
agreement. The issues that are not agreed upon in this Agreement shall be subject to the terms of the Master Agreement.
Party A: Didi Chuxing Technology Co., Ltd.
/s/ Didi Chuxing Technology Co., Ltd. [signature authenticated by third party document depository on December 17, 2018]
Party B: Hunan Ruixi Financial Leasing Co., Ltd.
/s/ Hunan Ruixi Financial Leasing Co., Ltd. [signature authenticated by third party document depository on December 17, 2018]